-DOCSTART- -X- -X- O

10021369 NN NN O
Identification NN NN O
of NN NN O
APC2 NN NN O
, NN NN O
a NN NN O
homologue NN NN O
of NN NN O
the NN NN O
adenomatous NN NN B-Modifier
polyposis NN NN I-Modifier
coli NN NN I-Modifier
tumour NN NN I-Modifier
suppressor NN NN O
. NN NN O

The NN NN O
adenomatous NN NN B-Modifier
polyposis NN NN I-Modifier
coli NN NN I-Modifier
( NN NN I-Modifier
APC NN NN I-Modifier
) NN NN I-Modifier
tumour NN NN I-Modifier
-suppressor NN NN O
protein NN NN O
controls NN NN O
the NN NN O
Wnt NN NN O
signalling NN NN O
pathway NN NN O
by NN NN O
forming NN NN O
a NN NN O
complex NN NN O
with NN NN O
glycogen NN NN O
synthase NN NN O
kinase NN NN O
3beta NN NN O
( NN NN O
GSK-3beta NN NN O
) NN NN O
, NN NN O
axin NN NN O
/ NN NN O
conductin NN NN O
and NN NN O
betacatenin NN NN O
. NN NN O

Complex NN NN O
formation NN NN O
induces NN NN O
the NN NN O
rapid NN NN O
degradation NN NN O
of NN NN O
betacatenin NN NN O
. NN NN O

In NN NN O
colon NN NN B-Modifier
carcinoma NN NN I-Modifier
cells NN NN O
, NN NN O
loss NN NN O
of NN NN O
APC NN NN O
leads NN NN O
to NN NN O
the NN NN O
accumulation NN NN O
of NN NN O
betacatenin NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
, NN NN O
where NN NN O
it NN NN O
binds NN NN O
to NN NN O
and NN NN O
activates NN NN O
the NN NN O
Tcf-4 NN NN O
transcription NN NN O
factor NN NN O
( NN NN O
reviewed NN NN O
in NN NN O
[ NN NN O
1 NN NN O
] NN NN O
[ NN NN O
2 NN NN O
] NN NN O
) NN NN O
. NN NN O

Here NN NN O
, NN NN O
we NN NN O
report NN NN O
the NN NN O
identification NN NN O
and NN NN O
genomic NN NN O
structure NN NN O
of NN NN O
APC NN NN O
homologues NN NN O
. NN NN O

Mammalian NN NN O
APC2 NN NN O
, NN NN O
which NN NN O
closely NN NN O
resembles NN NN O
APC NN NN O
in NN NN O
overall NN NN O
domain NN NN O
structure NN NN O
, NN NN O
was NN NN O
functionally NN NN O
analyzed NN NN O
and NN NN O
shown NN NN O
to NN NN O
contain NN NN O
two NN NN O
SAMP NN NN O
domains NN NN O
, NN NN O
both NN NN O
of NN NN O
which NN NN O
are NN NN O
required NN NN O
for NN NN O
binding NN NN O
to NN NN O
conductin NN NN O
. NN NN O

Like NN NN O
APC NN NN O
, NN NN O
APC2 NN NN O
regulates NN NN O
the NN NN O
formation NN NN O
of NN NN O
active NN NN O
betacatenin-Tcf NN NN O
complexes NN NN O
, NN NN O
as NN NN O
demonstrated NN NN O
using NN NN O
transient NN NN O
transcriptional NN NN O
activation NN NN O
assays NN NN O
in NN NN O
APC NN NN O
- NN NN O
/ NN NN O
- NN NN O
colon NN NN B-Modifier
carcinoma NN NN I-Modifier
cells NN NN O
. NN NN O

Human NN NN O
APC2 NN NN O
maps NN NN O
to NN NN O
chromosome NN NN O
19p13 NN NN O
. NN NN O

3 NN NN O
. NN NN O

APC NN NN O
and NN NN O
APC2 NN NN O
may NN NN O
therefore NN NN O
have NN NN O
comparable NN NN O
functions NN NN O
in NN NN O
development NN NN O
and NN NN O
cancer NN NN B-SpecificDisease
. NN NN O

10051005 NN NN O
A NN NN O
common NN NN O
MSH2 NN NN O
mutation NN NN O
in NN NN O
English NN NN O
and NN NN O
North NN NN O
American NN NN O
HNPCC NN NN B-Modifier
families NN NN O
: NN NN O
origin NN NN O
, NN NN O
phenotypic NN NN O
expression NN NN O
, NN NN O
and NN NN O
sex NN NN O
specific NN NN O
differences NN NN O
in NN NN O
colorectal NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

The NN NN O
frequency NN NN O
, NN NN O
origin NN NN O
, NN NN O
and NN NN O
phenotypic NN NN O
expression NN NN O
of NN NN O
a NN NN O
germline NN NN O
MSH2 NN NN O
gene NN NN O
mutation NN NN O
previously NN NN O
identified NN NN O
in NN NN O
seven NN NN O
kindreds NN NN O
with NN NN O
hereditary NN NN B-SpecificDisease
non-polyposis NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
HNPCC NN NN B-SpecificDisease
) NN NN O
was NN NN O
investigated NN NN O
. NN NN O

The NN NN O
mutation NN NN O
( NN NN O
A NN NN O
-- NN NN O
T NN NN O
at NN NN O
nt943 NN NN O
+ NN NN O
3 NN NN O
) NN NN O
disrupts NN NN O
the NN NN O
3 NN NN O
splice NN NN O
site NN NN O
of NN NN O
exon NN NN O
5 NN NN O
leading NN NN O
to NN NN O
the NN NN O
deletion NN NN O
of NN NN O
this NN NN O
exon NN NN O
from NN NN O
MSH2 NN NN O
mRNA NN NN O
and NN NN O
represents NN NN O
the NN NN O
only NN NN O
frequent NN NN O
MSH2 NN NN O
mutation NN NN O
so NN NN O
far NN NN O
reported NN NN O
. NN NN O

Although NN NN O
this NN NN O
mutation NN NN O
was NN NN O
initially NN NN O
detected NN NN O
in NN NN O
four NN NN O
of NN NN O
33 NN NN O
colorectal NN NN B-Modifier
cancer NN NN I-Modifier
families NN NN O
analysed NN NN O
from NN NN O
eastern NN NN O
England NN NN O
, NN NN O
more NN NN O
extensive NN NN O
analysis NN NN O
has NN NN O
reduced NN NN O
the NN NN O
frequency NN NN O
to NN NN O
four NN NN O
of NN NN O
52 NN NN O
( NN NN O
8 NN NN O
% NN NN O
) NN NN O
English NN NN O
HNPCC NN NN B-Modifier
kindreds NN NN O
analysed NN NN O
. NN NN O

In NN NN O
contrast NN NN O
, NN NN O
the NN NN O
MSH2 NN NN O
mutation NN NN O
was NN NN O
identified NN NN O
in NN NN O
10 NN NN O
of NN NN O
20 NN NN O
( NN NN O
50 NN NN O
% NN NN O
) NN NN O
separately NN NN O
identified NN NN O
colorectal NN NN B-Modifier
families NN NN O
from NN NN O
Newfoundland NN NN O
. NN NN O

To NN NN O
investigate NN NN O
the NN NN O
origin NN NN O
of NN NN O
this NN NN O
mutation NN NN O
in NN NN O
colorectal NN NN B-Modifier
cancer NN NN I-Modifier
families NN NN O
from NN NN O
England NN NN O
( NN NN O
n NN NN O
= NN NN O
4 NN NN O
) NN NN O
, NN NN O
Newfoundland NN NN O
( NN NN O
n NN NN O
= NN NN O
10 NN NN O
) NN NN O
, NN NN O
and NN NN O
the NN NN O
United NN NN O
States NN NN O
( NN NN O
n NN NN O
= NN NN O
3 NN NN O
) NN NN O
, NN NN O
haplotype NN NN O
analysis NN NN O
using NN NN O
microsatellite NN NN O
markers NN NN O
linked NN NN O
to NN NN O
MSH2 NN NN O
was NN NN O
performed NN NN O
. NN NN O

Within NN NN O
the NN NN O
English NN NN O
and NN NN O
US NN NN O
families NN NN O
there NN NN O
was NN NN O
little NN NN O
evidence NN NN O
for NN NN O
a NN NN O
recent NN NN O
common NN NN O
origin NN NN O
of NN NN O
the NN NN O
MSH2 NN NN O
splice NN NN O
site NN NN O
mutation NN NN O
in NN NN O
most NN NN O
families NN NN O
. NN NN O

In NN NN O
contrast NN NN O
, NN NN O
a NN NN O
common NN NN O
haplotype NN NN O
was NN NN O
identified NN NN O
at NN NN O
the NN NN O
two NN NN O
flanking NN NN O
markers NN NN O
( NN NN O
CA5 NN NN O
and NN NN O
D2S288 NN NN O
) NN NN O
in NN NN O
eight NN NN O
of NN NN O
the NN NN O
Newfoundland NN NN O
families NN NN O
. NN NN O

These NN NN O
findings NN NN O
suggested NN NN O
a NN NN O
founder NN NN O
effect NN NN O
within NN NN O
Newfoundland NN NN O
similar NN NN O
to NN NN O
that NN NN O
reported NN NN O
by NN NN O
others NN NN O
for NN NN O
two NN NN O
MLH1 NN NN O
mutations NN NN O
in NN NN O
Finnish NN NN O
HNPCC NN NN B-Modifier
families NN NN O
. NN NN O

We NN NN O
calculated NN NN O
age NN NN O
related NN NN O
risks NN NN O
of NN NN O
all NN NN O
, NN NN O
colorectal NN NN B-CompositeMention
, NN NN I-CompositeMention
endometrial NN NN I-CompositeMention
, NN NN I-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancers NN NN I-CompositeMention
in NN NN O
nt943 NN NN O
+ NN NN O
3 NN NN O
A NN NN O
-- NN NN O
T NN NN O
MSH2 NN NN O
mutation NN NN O
carriers NN NN O
( NN NN O
n NN NN O
= NN NN O
76 NN NN O
) NN NN O
for NN NN O
all NN NN O
patients NN NN O
and NN NN O
for NN NN O
men NN NN O
and NN NN O
women NN NN O
separately NN NN O
. NN NN O

For NN NN O
both NN NN O
sexes NN NN O
combined NN NN O
, NN NN O
the NN NN O
penetrances NN NN O
at NN NN O
age NN NN O
60 NN NN O
years NN NN O
for NN NN O
all NN NN O
cancers NN NN B-DiseaseClass
and NN NN O
for NN NN O
colorectal NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
were NN NN O
0 NN NN O
. NN NN O

86 NN NN O
and NN NN O
0 NN NN O
. NN NN O

57 NN NN O
, NN NN O
respectively NN NN O
. NN NN O

The NN NN O
risk NN NN O
of NN NN O
colorectal NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
was NN NN O
significantly NN NN O
higher NN NN O
( NN NN O
p NN NN O
0 NN NN O
. NN NN O

01 NN NN O
) NN NN O
in NN NN O
males NN NN O
than NN NN O
females NN NN O
( NN NN O
0 NN NN O
. NN NN O

63 NN NN O
v NN NN O
0 NN NN O
. NN NN O

30 NN NN O
and NN NN O
0 NN NN O
. NN NN O

84 NN NN O
v NN NN O
0 NN NN O
. NN NN O

44 NN NN O
at NN NN O
ages NN NN O
50 NN NN O
and NN NN O
60 NN NN O
years NN NN O
, NN NN O
respectively NN NN O
) NN NN O
. NN NN O

For NN NN O
females NN NN O
there NN NN O
was NN NN O
a NN NN O
high NN NN O
risk NN NN O
of NN NN O
endometrial NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
( NN NN O
0 NN NN O
. NN NN O

5 NN NN O
at NN NN O
age NN NN O
60 NN NN O
years NN NN O
) NN NN O
and NN NN O
premenopausal NN NN B-SpecificDisease
ovarian NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
( NN NN O
0 NN NN O
. NN NN O

2 NN NN O
at NN NN O
50 NN NN O
years NN NN O
) NN NN O
. NN NN O

These NN NN O
intersex NN NN O
differences NN NN O
in NN NN O
colorectal NN NN B-Modifier
cancer NN NN I-Modifier
risks NN NN O
have NN NN O
implications NN NN O
for NN NN O
screening NN NN O
programmes NN NN O
and NN NN O
for NN NN O
attempts NN NN O
to NN NN O
identify NN NN O
colorectal NN NN B-Modifier
cancer NN NN I-Modifier
susceptibility NN NN O
modifiers NN NN O
. NN NN O

10051007 NN NN O
Age NN NN O
of NN NN O
onset NN NN O
in NN NN O
Huntington NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
: NN NN O
sex NN NN O
specific NN NN O
influence NN NN O
of NN NN O
apolipoprotein NN NN O
E NN NN O
genotype NN NN O
and NN NN O
normal NN NN O
CAG NN NN O
repeat NN NN O
length NN NN O
. NN NN O

Age NN NN O
of NN NN O
onset NN NN O
( NN NN O
AO NN NN O
) NN NN O
of NN NN O
Huntington NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
HD NN NN B-SpecificDisease
) NN NN O
is NN NN O
known NN NN O
to NN NN O
be NN NN O
correlated NN NN O
with NN NN O
the NN NN O
length NN NN O
of NN NN O
an NN NN O
expanded NN NN O
CAG NN NN O
repeat NN NN O
in NN NN O
the NN NN O
HD NN NN B-Modifier
gene NN NN O
. NN NN O

Apolipoprotein NN NN O
E NN NN O
( NN NN O
APOE NN NN O
) NN NN O
genotype NN NN O
, NN NN O
in NN NN O
turn NN NN O
, NN NN O
is NN NN O
known NN NN O
to NN NN O
influence NN NN O
AO NN NN O
in NN NN O
Alzheimer NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
, NN NN O
rendering NN NN O
the NN NN O
APOE NN NN O
gene NN NN O
a NN NN O
likely NN NN O
candidate NN NN O
to NN NN O
affect NN NN O
AO NN NN O
in NN NN O
other NN NN O
neurological NN NN B-DiseaseClass
diseases NN NN I-DiseaseClass
too NN NN O
. NN NN O

We NN NN O
therefore NN NN O
determined NN NN O
APOE NN NN O
genotype NN NN O
and NN NN O
normal NN NN O
CAG NN NN O
repeat NN NN O
length NN NN O
in NN NN O
the NN NN O
HD NN NN B-Modifier
gene NN NN O
for NN NN O
138 NN NN O
HD NN NN B-Modifier
patients NN NN O
who NN NN O
were NN NN O
previously NN NN O
analysed NN NN O
with NN NN O
respect NN NN O
to NN NN O
CAG NN NN O
repeat NN NN O
length NN NN O
. NN NN O

Genotyping NN NN O
for NN NN O
APOE NN NN O
was NN NN O
performed NN NN O
blind NN NN O
to NN NN O
clinical NN NN O
information NN NN O
. NN NN O

In NN NN O
addition NN NN O
to NN NN O
highlighting NN NN O
the NN NN O
effect NN NN O
of NN NN O
the NN NN O
normal NN NN O
repeat NN NN O
length NN NN O
upon NN NN O
AO NN NN O
in NN NN O
maternally NN NN O
inherited NN NN O
HD NN NN B-SpecificDisease
and NN NN O
in NN NN O
male NN NN O
patients NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
the NN NN O
APOE NN NN O
epsilon2epsilon3 NN NN O
genotype NN NN O
is NN NN O
associated NN NN O
with NN NN O
significantly NN NN O
earlier NN NN O
AO NN NN O
in NN NN O
males NN NN O
than NN NN O
in NN NN O
females NN NN O
. NN NN O

Such NN NN O
a NN NN O
sex NN NN O
difference NN NN O
in NN NN O
AO NN NN O
was NN NN O
not NN NN O
apparent NN NN O
for NN NN O
any NN NN O
of NN NN O
the NN NN O
other NN NN O
APOE NN NN O
genotypes NN NN O
. NN NN O

Our NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
subtle NN NN O
differences NN NN O
in NN NN O
the NN NN O
course NN NN O
of NN NN O
the NN NN O
neurodegeneration NN NN B-DiseaseClass
in NN NN O
HD NN NN B-SpecificDisease
may NN NN O
allow NN NN O
interacting NN NN O
genes NN NN O
to NN NN O
exert NN NN O
gender NN NN O
specific NN NN O
effects NN NN O
upon NN NN O
AO NN NN O
. NN NN O

100562 NN NN O
Familial NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
seventh NN NN I-SpecificDisease
component NN NN I-SpecificDisease
of NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
associated NN NN O
with NN NN O
recurrent NN NN O
bacteremic NN NN B-DiseaseClass
infections NN NN I-DiseaseClass
due NN NN I-DiseaseClass
to NN NN I-DiseaseClass
Neisseria NN NN I-DiseaseClass
. NN NN O

The NN NN O
serum NN NN O
of NN NN O
a NN NN O
29-year NN NN O
old NN NN O
woman NN NN O
with NN NN O
a NN NN O
recent NN NN O
episode NN NN O
of NN NN O
disseminated NN NN B-SpecificDisease
gonococcal NN NN I-SpecificDisease
infection NN NN I-SpecificDisease
and NN NN O
a NN NN O
history NN NN O
of NN NN O
meningococcal NN NN B-SpecificDisease
meningitis NN NN I-SpecificDisease
and NN NN O
arthritis NN NN B-DiseaseClass
as NN NN O
a NN NN O
child NN NN O
was NN NN O
found NN NN O
to NN NN O
lack NN NN O
serum NN NN O
hemolytic NN NN O
complement NN NN O
activity NN NN O
. NN NN O

The NN NN O
seventh NN NN O
component NN NN O
of NN NN O
complement NN NN O
( NN NN O
C7 NN NN O
) NN NN O
was NN NN O
not NN NN O
detected NN NN O
by NN NN O
functional NN NN O
or NN NN O
immunochemical NN NN O
assays NN NN O
, NN NN O
whereas NN NN O
other NN NN O
components NN NN O
were NN NN O
normal NN NN O
by NN NN O
hemolytic NN NN O
and NN NN O
immunochemical NN NN O
assessment NN NN O
. NN NN O

Her NN NN O
fresh NN NN O
serum NN NN O
lacked NN NN O
complement-mediated NN NN O
bactericidal NN NN O
activity NN NN O
against NN NN O
Neisseria NN NN O
gonorrhoeae NN NN O
, NN NN O
but NN NN O
the NN NN O
addition NN NN O
of NN NN O
fresh NN NN O
normal NN NN O
serum NN NN O
or NN NN O
purified NN NN O
C7 NN NN O
restored NN NN O
bactericidal NN NN O
activity NN NN O
as NN NN O
well NN NN O
as NN NN O
hemolytic NN NN O
activity NN NN O
. NN NN O

The NN NN O
absence NN NN B-Modifier
of NN NN I-Modifier
functional NN NN I-Modifier
C7 NN NN I-Modifier
activity NN NN O
could NN NN O
not NN NN O
be NN NN O
accounted NN NN O
for NN NN O
on NN NN O
the NN NN O
basis NN NN O
of NN NN O
an NN NN O
inhibitor NN NN O
. NN NN O

Opsonization NN NN O
and NN NN O
generation NN NN O
of NN NN O
chemotactic NN NN O
activity NN NN O
functioned NN NN O
normally NN NN O
. NN NN O

Complete NN NN B-SpecificDisease
absence NN NN I-SpecificDisease
of NN NN I-SpecificDisease
C7 NN NN I-SpecificDisease
was NN NN O
also NN NN O
found NN NN O
in NN NN O
one NN NN O
sibling NN NN O
who NN NN O
had NN NN O
the NN NN O
clinical NN NN O
syndrome NN NN O
of NN NN O
meningococcal NN NN B-SpecificDisease
meningitis NN NN I-SpecificDisease
and NN NN O
arthritis NN NN B-DiseaseClass
as NN NN O
a NN NN O
child NN NN O
and NN NN O
in NN NN O
this NN NN O
siblings NN NN O
clinically NN NN O
well NN NN O
eight-year-old NN NN O
son NN NN O
. NN NN O

HLA NN NN O
histocompatibility NN NN O
typing NN NN O
of NN NN O
the NN NN O
family NN NN O
members NN NN O
did NN NN O
not NN NN O
demonstrate NN NN O
evidence NN NN O
for NN NN O
genetic NN NN O
linkage NN NN O
of NN NN O
C7 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
with NN NN O
the NN NN O
major NN NN O
histocompatibility NN NN O
loci NN NN O
. NN NN O

This NN NN O
report NN NN O
represents NN NN O
the NN NN O
first NN NN O
cases NN NN O
of NN NN O
C7 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
associated NN NN O
with NN NN O
infectious NN NN O
complications NN NN O
and NN NN O
suggests NN NN O
that NN NN O
bactericidal NN NN O
activity NN NN O
may NN NN O
be NN NN O
important NN NN O
in NN NN O
host NN NN O
defense NN NN O
against NN NN O
bacteremic NN NN B-SpecificDisease
neisseria NN NN I-SpecificDisease
infections NN NN I-SpecificDisease
. NN NN O

10064668 NN NN O
Increased NN NN O
incidence NN NN O
of NN NN O
cancer NN NN B-DiseaseClass
in NN NN O
patients NN NN O
with NN NN O
cartilage-hair NN NN B-SpecificDisease
hypoplasia NN NN I-SpecificDisease
. NN NN O

OBJECTIVE NN NN O
Previous NN NN O
reports NN NN O
have NN NN O
suggested NN NN O
an NN NN O
increased NN NN O
risk NN NN O
of NN NN O
cancer NN NN B-DiseaseClass
among NN NN O
patients NN NN O
with NN NN O
cartilage-hair NN NN B-SpecificDisease
hypoplasia NN NN I-SpecificDisease
( NN NN O
CHH NN NN B-SpecificDisease
) NN NN O
. NN NN O

This NN NN O
study NN NN O
was NN NN O
carried NN NN O
out NN NN O
to NN NN O
further NN NN O
evaluate NN NN O
this NN NN O
risk NN NN O
among NN NN O
patients NN NN O
with NN NN O
CHH NN NN B-SpecificDisease
and NN NN O
their NN NN O
first-degree NN NN O
relatives NN NN O
. NN NN O

STUDY NN NN O
DESIGN NN NN O
One NN NN O
hundred NN NN O
twenty-two NN NN O
patients NN NN O
with NN NN O
CHH NN NN B-SpecificDisease
were NN NN O
identified NN NN O
through NN NN O
2 NN NN O
countrywide NN NN O
epidemiologic NN NN O
surveys NN NN O
in NN NN O
1974 NN NN O
and NN NN O
in NN NN O
1986 NN NN O
. NN NN O

Their NN NN O
parents NN NN O
and NN NN O
nonaffected NN NN O
siblings NN NN O
were NN NN O
identified NN NN O
through NN NN O
the NN NN O
Population NN NN O
Register NN NN O
Center NN NN O
. NN NN O

This NN NN O
cohort NN NN O
underwent NN NN O
follow-up NN NN O
for NN NN O
cancer NN NN B-Modifier
incidence NN NN O
through NN NN O
the NN NN O
Finnish NN NN O
Cancer NN NN O
Registry NN NN O
to NN NN O
the NN NN O
end NN NN O
of NN NN O
1995 NN NN O
. NN NN O

RESULTS NN NN O
A NN NN O
statistically NN NN O
significant NN NN O
excess NN NN O
risk NN NN O
of NN NN O
cancer NN NN B-DiseaseClass
was NN NN O
seen NN NN O
among NN NN O
the NN NN O
patients NN NN O
with NN NN O
CHH NN NN B-SpecificDisease
( NN NN O
standardized NN NN O
incidence NN NN O
ratio NN NN O
6 NN NN O
. NN NN O

9 NN NN O
, NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
2 NN NN O
. NN NN O

3 NN NN O
to NN NN O
16 NN NN O
) NN NN O
, NN NN O
which NN NN O
was NN NN O
mainly NN NN O
attributable NN NN O
to NN NN O
non-Hodgkins NN NN B-SpecificDisease
lymphoma NN NN I-SpecificDisease
( NN NN O
standardized NN NN O
incidence NN NN O
ratio NN NN O
90 NN NN O
, NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
18 NN NN O
to NN NN O
264 NN NN O
) NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
a NN NN O
significant NN NN O
excess NN NN O
risk NN NN O
of NN NN O
basal NN NN B-SpecificDisease
cell NN NN I-SpecificDisease
carcinoma NN NN I-SpecificDisease
was NN NN O
seen NN NN O
( NN NN O
standardized NN NN O
incidence NN NN O
ratio NN NN O
35 NN NN O
, NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
7 NN NN O
. NN NN O

2 NN NN O
to NN NN O
102 NN NN O
) NN NN O
. NN NN O

The NN NN O
cancer NN NN B-Modifier
incidence NN NN O
among NN NN O
the NN NN O
siblings NN NN O
or NN NN O
the NN NN O
parents NN NN O
did NN NN O
not NN NN O
differ NN NN O
from NN NN O
the NN NN O
average NN NN O
cancer NN NN B-Modifier
incidence NN NN O
in NN NN O
the NN NN O
Finnish NN NN O
population NN NN O
. NN NN O

CONCLUSIONS NN NN O
This NN NN O
study NN NN O
confirms NN NN O
an NN NN O
increased NN NN O
risk NN NN O
of NN NN O
cancer NN NN B-DiseaseClass
, NN NN O
especially NN NN O
non-Hodgkins NN NN B-SpecificDisease
lymphoma NN NN I-SpecificDisease
, NN NN O
probably NN NN O
attributable NN NN O
to NN NN O
defective NN NN O
immunity NN NN O
, NN NN O
among NN NN O
patients NN NN O
with NN NN O
CHH NN NN B-SpecificDisease
. NN NN O

10071185 NN NN O
Genotype NN NN O
and NN NN O
phenotype NN NN O
in NN NN O
patients NN NN O
with NN NN O
dihydropyrimidine NN NN B-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

Dihydropyrimidine NN NN B-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
( NN NN I-SpecificDisease
DPD NN NN I-SpecificDisease
) NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
disease NN NN I-DiseaseClass
characterised NN NN O
by NN NN O
thymine-uraciluria NN NN O
in NN NN O
homozygous NN NN O
deficient NN NN O
patients NN NN O
and NN NN O
has NN NN O
been NN NN O
associated NN NN O
with NN NN O
a NN NN O
variable NN NN O
clinical NN NN O
phenotype NN NN O
. NN NN O

In NN NN O
order NN NN O
to NN NN O
understand NN NN O
the NN NN O
genetic NN NN O
and NN NN O
phenotypic NN NN O
basis NN NN O
for NN NN O
DPD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
, NN NN O
we NN NN O
have NN NN O
reviewed NN NN O
17 NN NN O
families NN NN O
presenting NN NN O
22 NN NN O
patients NN NN O
with NN NN O
complete NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
DPD NN NN I-SpecificDisease
. NN NN O

In NN NN O
this NN NN O
group NN NN O
of NN NN O
patients NN NN O
, NN NN O
7 NN NN O
different NN NN O
mutations NN NN O
have NN NN O
been NN NN O
identified NN NN O
, NN NN O
including NN NN O
2 NN NN O
deletions NN NN O
[ NN NN O
295-298delTCAT NN NN O
, NN NN O
1897delC NN NN O
] NN NN O
, NN NN O
1 NN NN O
splice-site NN NN O
mutation NN NN O
[ NN NN O
IVS14 NN NN O
+ NN NN O
1G NN NN O
A NN NN O
) NN NN O
] NN NN O
and NN NN O
4 NN NN O
missense NN NN O
mutations NN NN O
( NN NN O
85T NN NN O
C NN NN O
, NN NN O
703C NN NN O
T NN NN O
, NN NN O
2658G NN NN O
A NN NN O
, NN NN O
2983G NN NN O
T NN NN O
) NN NN O
. NN NN O

Analysis NN NN O
of NN NN O
the NN NN O
prevalence NN NN O
of NN NN O
the NN NN O
various NN NN O
mutations NN NN O
among NN NN O
DPD NN NN B-Modifier
patients NN NN O
has NN NN O
shown NN NN O
that NN NN O
the NN NN O
G NN NN O
-- NN NN O
A NN NN O
point NN NN O
mutation NN NN O
in NN NN O
the NN NN O
invariant NN NN O
splice NN NN O
donor NN NN O
site NN NN O
is NN NN O
by NN NN O
far NN NN O
the NN NN O
most NN NN O
common NN NN O
( NN NN O
52 NN NN O
% NN NN O
) NN NN O
, NN NN O
whereas NN NN O
the NN NN O
other NN NN O
six NN NN O
mutations NN NN O
are NN NN O
less NN NN O
frequently NN NN O
observed NN NN O
. NN NN O

A NN NN O
large NN NN O
phenotypic NN NN O
variability NN NN O
has NN NN O
been NN NN O
observed NN NN O
, NN NN O
with NN NN O
convulsive NN NN B-DiseaseClass
disorders NN NN I-DiseaseClass
, NN NN O
motor NN NN B-DiseaseClass
retardation NN NN I-DiseaseClass
and NN NN O
mental NN NN B-DiseaseClass
retardation NN NN I-DiseaseClass
being NN NN O
the NN NN O
most NN NN O
abundant NN NN O
manifestations NN NN O
. NN NN O

A NN NN O
clear NN NN O
correlation NN NN O
between NN NN O
the NN NN O
genotype NN NN O
and NN NN O
phenotype NN NN O
has NN NN O
not NN NN O
been NN NN O
established NN NN O
. NN NN O

An NN NN O
altered NN NN O
beta-alanine NN NN O
, NN NN O
uracil NN NN O
and NN NN O
thymine NN NN O
homeostasis NN NN O
might NN NN O
underlie NN NN O
the NN NN O
various NN NN O
clinical NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
encountered NN NN O
in NN NN O
patients NN NN O
with NN NN O
DPD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

10071193 NN NN O
Fibroblast NN NN O
growth NN NN O
factor NN NN O
homologous NN NN O
factor NN NN O
2 NN NN O
( NN NN O
FHF2 NN NN O
) NN NN O
: NN NN O
gene NN NN O
structure NN NN O
, NN NN O
expression NN NN O
and NN NN O
mapping NN NN O
to NN NN O
the NN NN O
Borjeson-Forssman-Lehmann NN NN B-Modifier
syndrome NN NN I-Modifier
region NN NN O
in NN NN O
Xq26 NN NN O
delineated NN NN O
by NN NN O
a NN NN O
duplication NN NN O
breakpoint NN NN O
in NN NN O
a NN NN O
BFLS NN NN B-Modifier
-like NN NN O
patient NN NN O
. NN NN O

Borjeson-Forssman-Lehmann NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
BFLS NN NN B-SpecificDisease
) NN NN O
is NN NN O
a NN NN O
syndromal NN NN O
X-linked NN NN B-DiseaseClass
mental NN NN I-DiseaseClass
retardation NN NN I-DiseaseClass
, NN NN O
which NN NN O
maps NN NN O
by NN NN O
linkage NN NN O
to NN NN O
the NN NN O
q26 NN NN O
region NN NN O
of NN NN O
the NN NN O
human NN NN O
X NN NN O
chromosome NN NN O
. NN NN O

We NN NN O
have NN NN O
identified NN NN O
a NN NN O
male NN NN O
patient NN NN O
with NN NN O
BFLS NN NN B-Modifier
-like NN NN O
features NN NN O
and NN NN O
a NN NN O
duplication NN NN O
, NN NN O
46 NN NN O
, NN NN O
Y NN NN O
, NN NN O
dup NN NN O
( NN NN O
X NN NN O
) NN NN O
( NN NN O
q26q28 NN NN O
) NN NN O
, NN NN O
inherited NN NN O
from NN NN O
his NN NN O
phenotypically NN NN O
normal NN NN O
mother NN NN O
. NN NN O

Fluorescence NN NN O
in NN NN O
situ NN NN O
hybridisation NN NN O
using NN NN O
yeast NN NN O
artificial NN NN O
chromosome NN NN O
clones NN NN O
from NN NN O
Xq26 NN NN O
localised NN NN O
the NN NN O
duplication NN NN O
breakpoint NN NN O
to NN NN O
an NN NN O
approximately NN NN O
400-kb NN NN O
interval NN NN O
in NN NN O
the NN NN O
Xq26 NN NN O
. NN NN O

3 NN NN O
region NN NN O
between NN NN O
DXS155 NN NN O
and NN NN O
DXS294 NN NN O
/ NN NN O
DXS730 NN NN O
. NN NN O

Database NN NN O
searches NN NN O
and NN NN O
analysis NN NN O
of NN NN O
available NN NN O
genomic NN NN O
DNA NN NN O
sequence NN NN O
from NN NN O
the NN NN O
region NN NN O
revealed NN NN O
the NN NN O
presence NN NN O
of NN NN O
the NN NN O
fibroblast NN NN O
growth NN NN O
factor NN NN O
homologous NN NN O
factor NN NN O
gene NN NN O
, NN NN O
FHF2 NN NN O
, NN NN O
within NN NN O
the NN NN O
duplication NN NN O
breakpoint NN NN O
interval NN NN O
. NN NN O

The NN NN O
gene NN NN O
structure NN NN O
of NN NN O
FHF2 NN NN O
was NN NN O
determined NN NN O
and NN NN O
two NN NN O
new NN NN O
exons NN NN O
were NN NN O
identified NN NN O
, NN NN O
including NN NN O
a NN NN O
new NN NN O
5 NN NN O
end NN NN O
exon NN NN O
, NN NN O
1B NN NN O
. NN NN O

FHF2 NN NN O
is NN NN O
a NN NN O
large NN NN O
gene NN NN O
extending NN NN O
over NN NN O
approximately NN NN O
200 NN NN O
kb NN NN O
in NN NN O
Xq26 NN NN O
. NN NN O

3 NN NN O
and NN NN O
is NN NN O
composed NN NN O
of NN NN O
at NN NN O
least NN NN O
seven NN NN O
exons NN NN O
. NN NN O

It NN NN O
shows NN NN O
tissue-specific NN NN O
alternative NN NN O
splicing NN NN O
and NN NN O
alternative NN NN O
transcription NN NN O
starts NN NN O
. NN NN O

Northern NN NN O
blot NN NN O
hybridisation NN NN O
showed NN NN O
highest NN NN O
expression NN NN O
in NN NN O
brain NN NN O
and NN NN O
skeletal NN NN O
muscle NN NN O
. NN NN O

The NN NN O
FHF2 NN NN O
gene NN NN O
localisation NN NN O
and NN NN O
tissue-specific NN NN O
expression NN NN O
pattern NN NN O
suggest NN NN O
it NN NN O
to NN NN O
be NN NN O
a NN NN O
candidate NN NN O
gene NN NN O
for NN NN O
familial NN NN O
cases NN NN O
of NN NN O
the NN NN O
BFLS NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
and NN NN O
other NN NN O
syndromal NN NN O
and NN NN O
non-specific NN NN O
forms NN NN O
of NN NN O
X-linked NN NN B-DiseaseClass
mental NN NN I-DiseaseClass
retardation NN NN I-DiseaseClass
mapping NN NN O
to NN NN O
the NN NN O
region NN NN O
. NN NN O

10072428 NN NN O
Germline NN NN O
E-cadherin NN NN O
gene NN NN O
( NN NN O
CDH1 NN NN O
) NN NN O
mutations NN NN O
predispose NN NN O
to NN NN O
familial NN NN B-SpecificDisease
gastric NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
and NN NN O
colorectal NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

Inherited NN NN O
mutations NN NN O
in NN NN O
the NN NN O
E-cadherin NN NN O
gene NN NN O
( NN NN O
CDH1 NN NN O
) NN NN O
were NN NN O
described NN NN O
recently NN NN O
in NN NN O
three NN NN O
Maori NN NN O
kindreds NN NN O
with NN NN O
familial NN NN B-SpecificDisease
gastric NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

Familial NN NN B-SpecificDisease
gastric NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
is NN NN O
genetically NN NN O
heterogeneous NN NN O
and NN NN O
it NN NN O
is NN NN O
not NN NN O
clear NN NN O
what NN NN O
proportion NN NN O
of NN NN O
gastric NN NN B-Modifier
cancer NN NN I-Modifier
susceptibility NN NN O
in NN NN O
non-Maori NN NN O
populations NN NN O
is NN NN O
due NN NN O
to NN NN O
germline NN NN O
CDH1 NN NN O
mutations NN NN O
. NN NN O

Therefore NN NN O
, NN NN O
we NN NN O
screened NN NN O
eight NN NN O
familial NN NN B-Modifier
gastric NN NN I-Modifier
cancer NN NN I-Modifier
kindreds NN NN O
of NN NN O
British NN NN O
and NN NN O
Irish NN NN O
origin NN NN O
for NN NN O
germline NN NN O
CDH1 NN NN O
mutations NN NN O
, NN NN O
by NN NN O
SSCP NN NN O
analysis NN NN O
of NN NN O
all NN NN O
16 NN NN O
exons NN NN O
and NN NN O
flanking NN NN O
sequences NN NN O
. NN NN O

Each NN NN O
family NN NN O
contained NN NN O
( NN NN O
i NN NN O
) NN NN O
two NN NN O
cases NN NN O
of NN NN O
gastric NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
in NN NN O
first NN NN O
degree NN NN O
relatives NN NN O
with NN NN O
one NN NN O
affected NN NN O
before NN NN O
age NN NN O
50 NN NN O
years NN NN O
; NN NN O
or NN NN O
( NN NN O
ii NN NN O
) NN NN O
three NN NN O
or NN NN O
more NN NN O
cases NN NN O
of NN NN O
gastric NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

Novel NN NN O
germline NN NN O
CDH1 NN NN O
mutations NN NN O
( NN NN O
a NN NN O
nonsense NN NN O
and NN NN O
a NN NN O
splice NN NN O
site NN NN O
) NN NN O
were NN NN O
detected NN NN O
in NN NN O
two NN NN O
families NN NN O
( NN NN O
25 NN NN O
% NN NN O
) NN NN O
. NN NN O

Both NN NN O
mutations NN NN O
were NN NN O
predicted NN NN O
to NN NN O
truncate NN NN O
the NN NN O
E-cadherin NN NN O
protein NN NN O
in NN NN O
the NN NN O
signal NN NN O
peptide NN NN O
domain NN NN O
. NN NN O

In NN NN O
one NN NN O
family NN NN O
there NN NN O
was NN NN O
evidence NN NN O
of NN NN O
non-penetrance NN NN O
and NN NN O
susceptibility NN NN O
to NN NN O
both NN NN O
gastric NN NN B-CompositeMention
and NN NN I-CompositeMention
colorectal NN NN I-CompositeMention
cancer NN NN I-CompositeMention
; NN NN O
thus NN NN O
, NN NN O
in NN NN O
addition NN NN O
to NN NN O
six NN NN O
cases NN NN O
of NN NN O
gastric NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
, NN NN O
a NN NN O
CDH1 NN NN O
mutation NN NN O
carrier NN NN O
developed NN NN O
colorectal NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
at NN NN O
age NN NN O
30 NN NN O
years NN NN O
. NN NN O

We NN NN O
have NN NN O
confirmed NN NN O
that NN NN O
germline NN NN O
mutations NN NN O
in NN NN O
the NN NN O
CDH1 NN NN O
gene NN NN O
cause NN NN O
familial NN NN B-SpecificDisease
gastric NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
in NN NN O
non-Maori NN NN O
populations NN NN O
. NN NN O

However NN NN O
, NN NN O
only NN NN O
a NN NN O
minority NN NN O
of NN NN O
familial NN NN O
gastric NN NN B-SpecificDisease
cancers NN NN I-SpecificDisease
can NN NN O
be NN NN O
accounted NN NN O
for NN NN O
by NN NN O
CDH1 NN NN O
mutations NN NN O
. NN NN O

Loss NN NN O
of NN NN O
E-cadherin NN NN O
function NN NN O
has NN NN O
been NN NN O
implicated NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
sporadic NN NN O
colorectal NN NN B-DiseaseClass
and NN NN I-DiseaseClass
other NN NN I-DiseaseClass
cancers NN NN I-DiseaseClass
, NN NN O
and NN NN O
our NN NN O
findings NN NN O
provide NN NN O
evidence NN NN O
that NN NN O
germline NN NN O
CDH1 NN NN O
mutations NN NN O
predispose NN NN O
to NN NN O
early NN NN O
onset NN NN O
colorectal NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

Thus NN NN O
, NN NN O
CDH1 NN NN O
should NN NN O
be NN NN O
investigated NN NN O
as NN NN O
a NN NN O
cause NN NN O
of NN NN O
inherited NN NN O
susceptibility NN NN O
to NN NN O
both NN NN O
gastric NN NN B-CompositeMention
and NN NN I-CompositeMention
colorectal NN NN I-CompositeMention
cancers NN NN I-CompositeMention
. NN NN O

10077614 NN NN O
A NN NN O
zinc NN NN O
finger NN NN O
truncation NN NN O
of NN NN O
murine NN NN O
WT1 NN NN O
results NN NN O
in NN NN O
the NN NN O
characteristic NN NN O
urogenital NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
of NN NN O
Denys-Drash NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

The NN NN O
Wilms NN NN B-Modifier
tumor NN NN I-Modifier
-suppressor NN NN O
gene NN NN O
, NN NN O
WT1 NN NN O
, NN NN O
plays NN NN O
a NN NN O
key NN NN O
role NN NN O
in NN NN O
urogenital NN NN O
development NN NN O
, NN NN O
and NN NN O
WT1 NN NN B-SpecificDisease
dysfunction NN NN I-SpecificDisease
is NN NN O
implicated NN NN O
in NN NN O
both NN NN O
neoplastic NN NN B-Modifier
( NN NN O
Wilms NN NN B-SpecificDisease
tumor NN NN I-SpecificDisease
, NN NN O
mesothelioma NN NN B-SpecificDisease
, NN NN O
leukemias NN NN B-SpecificDisease
, NN NN O
and NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
) NN NN O
and NN NN O
nonneoplastic NN NN B-Modifier
( NN NN O
glomerulosclerosis NN NN B-SpecificDisease
) NN NN O
disease NN NN O
. NN NN O

The NN NN O
analysis NN NN O
of NN NN O
diseases NN NN O
linked NN NN O
specifically NN NN O
with NN NN O
WT1 NN NN O
mutations NN NN O
, NN NN O
such NN NN O
as NN NN O
Denys-Drash NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
DDS NN NN B-SpecificDisease
) NN NN O
, NN NN O
can NN NN O
provide NN NN O
valuable NN NN O
insight NN NN O
concerning NN NN O
the NN NN O
role NN NN O
of NN NN O
WT1 NN NN O
in NN NN O
development NN NN O
and NN NN O
disease NN NN O
. NN NN O

DDS NN NN B-SpecificDisease
is NN NN O
a NN NN O
rare NN NN O
childhood NN NN O
disease NN NN O
characterized NN NN O
by NN NN O
a NN NN O
nephropathy NN NN B-SpecificDisease
involving NN NN O
mesangial NN NN B-SpecificDisease
sclerosis NN NN I-SpecificDisease
, NN NN O
XY NN NN O
pseudohermaphroditism NN NN B-SpecificDisease
, NN NN O
and NN NN O
/ NN NN O
or NN NN O
Wilms NN NN B-SpecificDisease
tumor NN NN I-SpecificDisease
( NN NN O
WT NN NN B-SpecificDisease
) NN NN O
. NN NN O

DDS NN NN B-Modifier
patients NN NN O
are NN NN O
constitutionally NN NN O
heterozygous NN NN O
for NN NN O
exonic NN NN O
point NN NN O
mutations NN NN O
in NN NN O
WT1 NN NN O
, NN NN O
which NN NN O
include NN NN O
mutations NN NN O
predicted NN NN O
to NN NN O
truncate NN NN O
the NN NN O
protein NN NN O
within NN NN O
the NN NN O
C-terminal NN NN O
zinc NN NN O
finger NN NN O
( NN NN O
ZF NN NN O
) NN NN O
region NN NN O
. NN NN O

We NN NN O
report NN NN O
that NN NN O
heterozygosity NN NN O
for NN NN O
a NN NN O
targeted NN NN O
murine NN NN O
Wt1 NN NN O
allele NN NN O
, NN NN O
Wt1 NN NN O
( NN NN O
tmT396 NN NN O
) NN NN O
, NN NN O
which NN NN O
truncates NN NN O
ZF3 NN NN O
at NN NN O
codon NN NN O
396 NN NN O
, NN NN O
induces NN NN O
mesangial NN NN B-SpecificDisease
sclerosis NN NN I-SpecificDisease
characteristic NN NN O
of NN NN O
DDS NN NN B-SpecificDisease
in NN NN O
adult NN NN O
heterozygous NN NN O
and NN NN O
chimeric NN NN O
mice NN NN O
. NN NN O

Male NN NN B-DiseaseClass
genital NN NN I-DiseaseClass
defects NN NN I-DiseaseClass
also NN NN O
were NN NN O
evident NN NN O
and NN NN O
there NN NN O
was NN NN O
a NN NN O
single NN NN O
case NN NN O
of NN NN O
Wilms NN NN B-SpecificDisease
tumor NN NN I-SpecificDisease
in NN NN O
which NN NN O
the NN NN O
transcript NN NN O
of NN NN O
the NN NN O
nontargeted NN NN O
allele NN NN O
showed NN NN O
an NN NN O
exon NN NN O
9 NN NN O
skipping NN NN O
event NN NN O
, NN NN O
implying NN NN O
a NN NN O
causal NN NN O
link NN NN O
between NN NN O
Wt1 NN NN B-SpecificDisease
dysfunction NN NN I-SpecificDisease
and NN NN O
Wilms NN NN B-SpecificDisease
tumorigenesis NN NN I-SpecificDisease
in NN NN O
mice NN NN O
. NN NN O

However NN NN O
, NN NN O
the NN NN O
mutant NN NN O
WT1 NN NN O
( NN NN O
tmT396 NN NN O
) NN NN O
protein NN NN O
accounted NN NN O
for NN NN O
only NN NN O
5 NN NN O
% NN NN O
of NN NN O
WT1 NN NN O
in NN NN O
both NN NN O
heterozygous NN NN O
embryonic NN NN O
stem NN NN O
cells NN NN O
and NN NN O
the NN NN O
WT NN NN B-SpecificDisease
. NN NN O

This NN NN O
has NN NN O
implications NN NN O
regarding NN NN O
the NN NN O
mechanism NN NN O
by NN NN O
which NN NN O
the NN NN O
mutant NN NN O
allele NN NN O
exerts NN NN O
its NN NN O
effect NN NN O
. NN NN O

10077651 NN NN O
Mechanism NN NN O
of NN NN O
increased NN NN O
iron NN NN O
absorption NN NN O
in NN NN O
murine NN NN O
model NN NN O
of NN NN O
hereditary NN NN B-SpecificDisease
hemochromatosis NN NN I-SpecificDisease
: NN NN O
increased NN NN O
duodenal NN NN O
expression NN NN O
of NN NN O
the NN NN O
iron NN NN O
transporter NN NN O
DMT1 NN NN O
. NN NN O

Hereditary NN NN B-SpecificDisease
hemochromatosis NN NN I-SpecificDisease
( NN NN O
HH NN NN B-SpecificDisease
) NN NN O
is NN NN O
a NN NN O
common NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
characterized NN NN O
by NN NN O
tissue NN NN O
iron NN NN O
deposition NN NN O
secondary NN NN O
to NN NN O
excessive NN NN O
dietary NN NN O
iron NN NN O
absorption NN NN O
. NN NN O

We NN NN O
recently NN NN O
reported NN NN O
that NN NN O
HFE NN NN O
, NN NN O
the NN NN O
protein NN NN O
defective NN NN O
in NN NN O
HH NN NN B-SpecificDisease
, NN NN O
was NN NN O
physically NN NN O
associated NN NN O
with NN NN O
the NN NN O
transferrin NN NN O
receptor NN NN O
( NN NN O
TfR NN NN O
) NN NN O
in NN NN O
duodenal NN NN O
crypt NN NN O
cells NN NN O
and NN NN O
proposed NN NN O
that NN NN O
mutations NN NN O
in NN NN O
HFE NN NN O
attenuate NN NN O
the NN NN O
uptake NN NN O
of NN NN O
transferrin-bound NN NN O
iron NN NN O
from NN NN O
plasma NN NN O
by NN NN O
duodenal NN NN O
crypt NN NN O
cells NN NN O
, NN NN O
leading NN NN O
to NN NN O
up-regulation NN NN O
of NN NN O
transporters NN NN O
for NN NN O
dietary NN NN O
iron NN NN O
. NN NN O

Here NN NN O
, NN NN O
we NN NN O
tested NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
HFE- NN NN O
/ NN NN O
- NN NN O
mice NN NN O
have NN NN O
increased NN NN O
duodenal NN NN O
expression NN NN O
of NN NN O
the NN NN O
divalent NN NN O
metal NN NN O
transporter NN NN O
( NN NN O
DMT1 NN NN O
) NN NN O
. NN NN O

By NN NN O
4 NN NN O
weeks NN NN O
of NN NN O
age NN NN O
, NN NN O
the NN NN O
HFE- NN NN O
/ NN NN O
- NN NN O
mice NN NN O
demonstrated NN NN O
iron NN NN O
loading NN NN O
when NN NN O
compared NN NN O
with NN NN O
HFE NN NN O
+ NN NN O
/ NN NN O
+ NN NN O
littermates NN NN O
, NN NN O
with NN NN O
elevated NN NN O
transferrin NN NN O
saturations NN NN O
( NN NN O
68 NN NN O
. NN NN O

4 NN NN O
% NN NN O
vs NN NN O
. NN NN O

49 NN NN O
. NN NN O

8 NN NN O
% NN NN O
) NN NN O
and NN NN O
elevated NN NN O
liver NN NN O
iron NN NN O
concentrations NN NN O
( NN NN O
985 NN NN O
micrograms NN NN O
vs NN NN O
. NN NN O

381 NN NN O
micrograms NN NN O
) NN NN O
. NN NN O

By NN NN O
using NN NN O
Northern NN NN O
blot NN NN O
analyses NN NN O
, NN NN O
we NN NN O
quantitated NN NN O
duodenal NN NN O
expression NN NN O
of NN NN O
both NN NN O
classes NN NN O
of NN NN O
DMT1 NN NN O
transcripts NN NN O
one NN NN O
containing NN NN O
an NN NN O
iron NN NN O
responsive NN NN O
element NN NN O
( NN NN O
IRE NN NN O
) NN NN O
, NN NN O
called NN NN O
DMT1 NN NN O
( NN NN O
IRE NN NN O
) NN NN O
, NN NN O
and NN NN O
one NN NN O
containing NN NN O
no NN NN O
IRE NN NN O
, NN NN O
called NN NN O
DMT1 NN NN O
( NN NN O
non-IRE NN NN O
) NN NN O
. NN NN O

The NN NN O
positive NN NN O
control NN NN O
for NN NN O
DMT1 NN NN O
up-regulation NN NN O
was NN NN O
a NN NN O
murine NN NN O
model NN NN O
of NN NN O
dietary NN NN B-SpecificDisease
iron NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
that NN NN O
demonstrated NN NN O
greatly NN NN O
increased NN NN O
levels NN NN O
of NN NN O
duodenal NN NN O
DMT1 NN NN O
( NN NN O
IRE NN NN O
) NN NN O
mRNA NN NN O
. NN NN O

HFE- NN NN O
/ NN NN O
- NN NN O
mice NN NN O
also NN NN O
demonstrated NN NN O
an NN NN O
increase NN NN O
in NN NN O
duodenal NN NN O
DMT1 NN NN O
( NN NN O
IRE NN NN O
) NN NN O
mRNA NN NN O
( NN NN O
average NN NN O
7 NN NN O
. NN NN O

7-fold NN NN O
) NN NN O
, NN NN O
despite NN NN O
their NN NN O
elevated NN NN O
transferrin NN NN O
saturation NN NN O
and NN NN O
hepatic NN NN O
iron NN NN O
content NN NN O
. NN NN O

Duodenal NN NN O
expression NN NN O
of NN NN O
DMT1 NN NN O
( NN NN O
non-IRE NN NN O
) NN NN O
was NN NN O
not NN NN O
increased NN NN O
, NN NN O
nor NN NN O
was NN NN O
hepatic NN NN O
expression NN NN O
of NN NN O
DMT1 NN NN O
increased NN NN O
. NN NN O

These NN NN O
data NN NN O
support NN NN O
the NN NN O
model NN NN O
for NN NN O
HH NN NN O
in NN NN O
which NN NN O
HFE NN NN O
mutations NN NN O
lead NN NN O
to NN NN O
inappropriately NN NN O
low NN NN O
crypt NN NN O
cell NN NN O
iron NN NN O
, NN NN O
with NN NN O
resultant NN NN O
stabilization NN NN O
of NN NN O
DMT1 NN NN O
( NN NN O
IRE NN NN O
) NN NN O
mRNA NN NN O
, NN NN O
up-regulation NN NN O
of NN NN O
DMT1 NN NN O
, NN NN O
and NN NN O
increased NN NN O
absorption NN NN O
of NN NN O
dietary NN NN O
iron NN NN O
. NN NN O

10078732 NN NN O
Neurophysiologic NN NN O
follow-up NN NN O
of NN NN O
long-term NN NN O
dietary NN NN O
treatment NN NN O
in NN NN O
adult-onset NN NN O
adrenoleukodystrophy NN NN B-SpecificDisease
. NN NN O

OBJECTIVE NN NN O
To NN NN O
monitor NN NN O
the NN NN O
effects NN NN O
of NN NN O
dietary NN NN O
treatment NN NN O
in NN NN O
adult-onset NN NN O
adrenoleukodystrophy NN NN B-SpecificDisease
( NN NN O
ALD NN NN B-SpecificDisease
) NN NN O
by NN NN O
means NN NN O
of NN NN O
somatosensory NN NN O
evoked NN NN O
potentials NN NN O
( NN NN O
SEPs NN NN O
) NN NN O
and NN NN O
motor NN NN O
evoked NN NN O
potentials NN NN O
( NN NN O
MEPs NN NN O
) NN NN O
. NN NN O

BACKGROUND NN NN O
SEPs NN NN O
and NN NN O
MEPs NN NN O
have NN NN O
proved NN NN O
useful NN NN O
in NN NN O
revealing NN NN O
signs NN NN O
of NN NN O
progressively NN NN O
severe NN NN O
, NN NN O
central NN NN O
dying-back NN NN B-SpecificDisease
axonopathy NN NN I-SpecificDisease
in NN NN O
early NN NN O
stages NN NN O
of NN NN O
adult-onset NN NN O
ALD NN NN B-SpecificDisease
. NN NN O

METHODS NN NN O
Eight NN NN O
patients NN NN O
with NN NN O
adult-onset NN NN O
ALD NN NN B-SpecificDisease
underwent NN NN O
clinical NN NN O
examination NN NN O
, NN NN O
brain NN NN O
and NN NN O
spine NN NN O
MRI NN NN O
, NN NN O
and NN NN O
SEP NN NN O
and NN NN O
MEP NN NN O
studies NN NN O
before NN NN O
and NN NN O
after NN NN O
3 NN NN O
years NN NN O
of NN NN O
Lorenzos NN NN O
oil NN NN O
dietary NN NN O
therapy NN NN O
. NN NN O

RESULTS NN NN O
Before NN NN O
treatment NN NN O
, NN NN O
brain NN NN O
MRI NN NN O
was NN NN O
normal NN NN O
in NN NN O
five NN NN O
patients NN NN O
. NN NN O

Three NN NN O
of NN NN O
these NN NN O
patients NN NN O
had NN NN O
pure NN NN O
spinal NN NN B-DiseaseClass
SEP NN NN I-DiseaseClass
abnormalities NN NN I-DiseaseClass
and NN NN O
in NN NN O
the NN NN O
remaining NN NN O
two NN NN O
patients NN NN O
SEPs NN NN O
showed NN NN O
signs NN NN O
of NN NN O
involvement NN NN O
of NN NN O
both NN NN O
the NN NN O
spinal NN NN O
and NN NN O
cerebral NN NN O
somatosensory NN NN O
tracts NN NN O
. NN NN O

After NN NN O
treatment NN NN O
, NN NN O
the NN NN O
three NN NN O
patients NN NN O
with NN NN O
pure NN NN O
spinal NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
showed NN NN O
clinical NN NN O
and NN NN O
neurophysiologic NN NN O
worsening NN NN O
, NN NN O
whereas NN NN O
the NN NN O
two NN NN O
patients NN NN O
with NN NN O
a NN NN O
more NN NN O
advanced NN NN O
stage NN NN O
of NN NN O
disease NN NN O
( NN NN O
exhibited NN NN O
by NN NN O
SEPs NN NN O
) NN NN O
showed NN NN O
substantially NN NN O
unchanged NN NN O
clinical NN NN O
and NN NN O
neurophysiologic NN NN O
features NN NN O
. NN NN O

The NN NN O
patients NN NN O
with NN NN O
abnormal NN NN O
brain NN NN O
MRI NN NN O
at NN NN O
the NN NN O
onset NN NN O
of NN NN O
treatment NN NN O
showed NN NN O
clinical NN NN O
and NN NN O
neurophysiologic NN NN O
worsening NN NN O
. NN NN O

CONCLUSIONS NN NN O
Lorenzos NN NN O
oil NN NN O
therapy NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
patients NN NN O
with NN NN O
evidence NN NN O
of NN NN O
inflammatory NN NN B-DiseaseClass
brain NN NN I-DiseaseClass
lesions NN NN I-DiseaseClass
. NN NN O

Moreover NN NN O
, NN NN O
in NN NN O
patients NN NN O
without NN NN O
clear NN NN O
signs NN NN O
of NN NN O
inflammatory NN NN O
damage NN NN O
, NN NN O
this NN NN O
treatment NN NN O
does NN NN O
not NN NN O
modify NN NN O
significantly NN NN O
the NN NN O
natural NN NN O
course NN NN O
of NN NN O
the NN NN O
disease NN NN O
. NN NN O

However NN NN O
, NN NN O
because NN NN O
effective NN NN O
treatments NN NN O
should NN NN O
begin NN NN O
before NN NN O
the NN NN O
onset NN NN O
of NN NN O
severe NN NN O
neurologic NN NN O
symptoms NN NN O
, NN NN O
SEPs NN NN O
and NN NN O
MEPs NN NN O
should NN NN O
be NN NN O
considered NN NN O
to NN NN O
evaluate NN NN O
the NN NN O
effectiveness NN NN O
of NN NN O
other NN NN O
experimental NN NN O
treatments NN NN O
in NN NN O
the NN NN O
patient NN NN O
with NN NN O
a NN NN O
negative NN NN O
brain NN NN O
MRI NN NN O
. NN NN O

10078749 NN NN O
GCH1 NN NN O
mutation NN NN O
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
adult-onset NN NN O
oromandibular NN NN B-SpecificDisease
dystonia NN NN I-SpecificDisease
. NN NN O

The NN NN O
authors NN NN O
report NN NN O
a NN NN O
mutation NN NN O
in NN NN O
exon NN NN O
5 NN NN O
of NN NN O
GCH1 NN NN O
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
adult-onset NN NN O
oromandibular NN NN B-SpecificDisease
dystonia NN NN I-SpecificDisease
and NN NN O
no NN NN O
obvious NN NN O
family NN NN O
history NN NN O
of NN NN O
dystonia NN NN B-DiseaseClass
. NN NN O

The NN NN O
patient NN NN O
responded NN NN O
positively NN NN O
to NN NN O
treatment NN NN O
with NN NN O
L-dopa NN NN O
. NN NN O

These NN NN O
findings NN NN O
demonstrate NN NN O
that NN NN O
GCH1 NN NN O
mutations NN NN O
must NN NN O
be NN NN O
considered NN NN O
even NN NN O
in NN NN O
patients NN NN O
with NN NN O
dystonic NN NN B-Modifier
symptoms NN NN O
not NN NN O
typical NN NN O
of NN NN O
dopa-responsive NN NN B-SpecificDisease
dystonia NN NN I-SpecificDisease
. NN NN O

10083733 NN NN O
Germline NN NN O
mutations NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
in NN NN O
Korean NN NN O
familial NN NN B-Modifier
adenomatous NN NN I-Modifier
polyposis NN NN I-Modifier
patients NN NN O
. NN NN O

We NN NN O
extensively NN NN O
analyzed NN NN O
genomic NN NN O
DNA NN NN O
and NN NN O
messenger NN NN O
RNA NN NN O
( NN NN O
mRNA NN NN O
) NN NN O
from NN NN O
62 NN NN O
unrelated NN NN O
Korean NN NN O
patients NN NN O
with NN NN O
familial NN NN B-SpecificDisease
adenomatous NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
( NN NN O
FAP NN NN B-SpecificDisease
) NN NN O
for NN NN O
identification NN NN O
of NN NN O
germline NN NN O
adenomatous NN NN B-Modifier
polyposis NN NN I-Modifier
coli NN NN I-Modifier
( NN NN O
APC NN NN B-Modifier
) NN NN O
gene NN NN O
mutations NN NN O
. NN NN O

We NN NN O
adopted NN NN O
both NN NN O
single-strand NN NN O
conformation NN NN O
polymorphism NN NN O
( NN NN O
SSCP NN NN O
) NN NN O
analysis NN NN O
and NN NN O
a NN NN O
method NN NN O
of NN NN O
analysis NN NN O
involving NN NN O
the NN NN O
reverse NN NN O
transcription-polymerase NN NN O
chain NN NN O
reaction NN NN O
( NN NN O
RT-PCR NN NN O
) NN NN O
followed NN NN O
by NN NN O
a NN NN O
protein NN NN O
truncation NN NN O
test NN NN O
( NN NN O
PTT NN NN O
) NN NN O
. NN NN O

DNA NN NN O
sequencing NN NN O
confirmed NN NN O
all NN NN O
alterations NN NN O
represented NN NN O
by NN NN O
aberrant NN NN O
bands NN NN O
. NN NN O

Germline NN NN O
mutations NN NN O
were NN NN O
identified NN NN O
in NN NN O
38 NN NN O
patients NN NN O
( NN NN O
61 NN NN O
% NN NN O
) NN NN O
. NN NN O

Nineteen NN NN O
of NN NN O
the NN NN O
detected NN NN O
mutations NN NN O
were NN NN O
presumed NN NN O
to NN NN O
be NN NN O
novel NN NN O
, NN NN O
thus NN NN O
emphasizing NN NN O
the NN NN O
heterogeneity NN NN O
of NN NN O
the NN NN O
mutational NN NN O
spectrum NN NN O
in NN NN O
Korean NN NN O
FAP NN NN B-Modifier
patients NN NN O
. NN NN O

In NN NN O
the NN NN O
initial NN NN O
48 NN NN O
patients NN NN O
, NN NN O
SSCP NN NN O
analysis NN NN O
was NN NN O
followed NN NN O
by NN NN O
PTT NN NN O
for NN NN O
those NN NN O
patients NN NN O
for NN NN O
whom NN NN O
no NN NN O
detectable NN NN O
mutations NN NN O
were NN NN O
found NN NN O
by NN NN O
SSCP NN NN O
. NN NN O

Using NN NN O
this NN NN O
combined NN NN O
approach NN NN O
, NN NN O
we NN NN O
identified NN NN O
germline NN NN O
APC NN NN B-Modifier
gene NN NN O
mutations NN NN O
in NN NN O
29 NN NN O
of NN NN O
the NN NN O
48 NN NN O
FAP NN NN B-Modifier
patients NN NN O
( NN NN O
60 NN NN O
% NN NN O
) NN NN O
, NN NN O
including NN NN O
6 NN NN O
patients NN NN O
in NN NN O
whom NN NN O
SSCP NN NN O
analysis NN NN O
failed NN NN O
to NN NN O
distinguish NN NN O
the NN NN O
mutant NN NN O
allele NN NN O
. NN NN O

In NN NN O
the NN NN O
14 NN NN O
later NN NN O
patients NN NN O
, NN NN O
we NN NN O
identified NN NN O
truncating NN NN O
mutations NN NN O
in NN NN O
9 NN NN O
patients NN NN O
( NN NN O
64 NN NN O
% NN NN O
) NN NN O
using NN NN O
PTT NN NN O
only NN NN O
. NN NN O

Our NN NN O
results NN NN O
confirm NN NN O
that NN NN O
the NN NN O
mutation NN NN O
detection NN NN O
rate NN NN O
with NN NN O
PTT NN NN O
was NN NN O
superior NN NN O
to NN NN O
that NN NN O
with NN NN O
SSCP NN NN O
, NN NN O
and NN NN O
suggest NN NN O
that NN NN O
PTT NN NN O
would NN NN O
be NN NN O
a NN NN O
more NN NN O
practical NN NN O
screening NN NN O
method NN NN O
to NN NN O
detect NN NN O
germline NN NN O
mutations NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
in NN NN O
FAP NN NN B-Modifier
patients NN NN O
. NN NN O

10083734 NN NN O
Molecular NN NN O
epidemiology NN NN O
of NN NN O
C9 NN NN B-Modifier
deficiency NN NN I-Modifier
heterozygotes NN NN O
with NN NN O
an NN NN O
Arg95Stop NN NN O
mutation NN NN O
of NN NN O
the NN NN O
C9 NN NN O
gene NN NN O
in NN NN O
Japan NN NN O
. NN NN O

Deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
ninth NN NN I-SpecificDisease
component NN NN I-SpecificDisease
of NN NN I-SpecificDisease
human NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
( NN NN O
C9 NN NN O
) NN NN O
is NN NN O
the NN NN O
most NN NN O
common NN NN O
complement NN NN B-DiseaseClass
deficiency NN NN I-DiseaseClass
in NN NN O
Japan NN NN O
, NN NN O
with NN NN O
an NN NN O
incidence NN NN O
of NN NN O
approximately NN NN O
one NN NN O
homozygote NN NN O
in NN NN O
1000 NN NN O
, NN NN O
but NN NN O
is NN NN O
very NN NN O
rare NN NN O
in NN NN O
other NN NN O
countries NN NN O
. NN NN O

Genetic NN NN O
analyses NN NN O
of NN NN O
Japanese NN NN O
C9 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
have NN NN O
shown NN NN O
that NN NN O
a NN NN O
C-to-T NN NN O
transition NN NN O
leading NN NN O
to NN NN O
TGA NN NN O
stop NN NN O
codon NN NN O
for NN NN O
Arg95 NN NN O
in NN NN O
exon NN NN O
4 NN NN O
of NN NN O
the NN NN O
C9 NN NN O
gene NN NN O
( NN NN O
Arg95Stop NN NN O
) NN NN O
is NN NN O
common NN NN O
in NN NN O
Japanese NN NN O
C9 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

To NN NN O
determine NN NN O
the NN NN O
prevalence NN NN O
of NN NN O
heterozygous NN NN O
carriers NN NN O
of NN NN O
the NN NN O
Arg95Stop NN NN O
mutation NN NN O
in NN NN O
a NN NN O
Japanese NN NN O
population NN NN O
, NN NN O
we NN NN O
collected NN NN O
DNA NN NN O
samples NN NN O
from NN NN O
300 NN NN O
individuals NN NN O
in NN NN O
two NN NN O
of NN NN O
the NN NN O
four NN NN O
main NN NN O
islands NN NN O
of NN NN O
Japan NN NN O
. NN NN O

Heterozygote NN NN O
detection NN NN O
was NN NN O
performed NN NN O
with NN NN O
an NN NN O
allele-specific NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
( NN NN O
PCR NN NN O
) NN NN O
system NN NN O
designed NN NN O
to NN NN O
detect NN NN O
exclusively NN NN O
only NN NN O
one NN NN O
of NN NN O
the NN NN O
normal NN NN O
and NN NN O
mutant NN NN O
alleles NN NN O
, NN NN O
followed NN NN O
by NN NN O
confirmation NN NN O
with NN NN O
PCR NN NN O
/ NN NN O
single-strand NN NN O
conformation NN NN O
polymorphism NN NN O
( NN NN O
SSCP NN NN O
) NN NN O
analysis NN NN O
and NN NN O
direct NN NN O
sequencing NN NN O
. NN NN O

Twenty NN NN O
individuals NN NN O
were NN NN O
heterozygous NN NN O
for NN NN O
the NN NN O
Arg95Stop NN NN O
mutation NN NN O
. NN NN O

None NN NN O
was NN NN O
homozygous NN NN O
. NN NN O

The NN NN O
prevalence NN NN O
of NN NN O
carriers NN NN O
of NN NN O
the NN NN O
Arg95Stop NN NN O
mutation NN NN O
was NN NN O
6 NN NN O
. NN NN O

7 NN NN O
% NN NN O
( NN NN O
20 NN NN O
/ NN NN O
300 NN NN O
) NN NN O
. NN NN O

An NN NN O
estimated NN NN O
frequency NN NN O
( NN NN O
0 NN NN O
. NN NN O

12 NN NN O
% NN NN O
) NN NN O
of NN NN O
complete NN NN O
C9 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
due NN NN O
to NN NN O
homozygous NN NN O
Arg95Stop NN NN O
mutation NN NN O
was NN NN O
consistent NN NN O
with NN NN O
frequencies NN NN O
determined NN NN O
by NN NN O
serological NN NN O
studies NN NN O

10085150 NN NN O
The NN NN O
hereditary NN NN B-Modifier
hemochromatosis NN NN I-Modifier
protein NN NN O
, NN NN O
HFE NN NN O
, NN NN O
specifically NN NN O
regulates NN NN O
transferrin-mediated NN NN O
iron NN NN O
uptake NN NN O
in NN NN O
HeLa NN NN O
cells NN NN O
. NN NN O

HFE NN NN O
is NN NN O
the NN NN O
protein NN NN O
product NN NN O
of NN NN O
the NN NN O
gene NN NN O
mutated NN NN O
in NN NN O
the NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
disease NN NN I-DiseaseClass
hereditary NN NN B-SpecificDisease
hemochromatosis NN NN I-SpecificDisease
( NN NN O
Feder NN NN O
, NN NN O
J NN NN O
. NN NN O

N NN NN O
. NN NN O

, NN NN O
Gnirke NN NN O
, NN NN O
A NN NN O
. NN NN O

, NN NN O
Thomas NN NN O
, NN NN O
W NN NN O
. NN NN O

, NN NN O
Tsuchihashi NN NN O
, NN NN O
Z NN NN O
. NN NN O

, NN NN O
Ruddy NN NN O
, NN NN O
D NN NN O
. NN NN O

A NN NN O
. NN NN O

, NN NN O
Basava NN NN O
, NN NN O
A NN NN O
. NN NN O

, NN NN O
Dormishian NN NN O
, NN NN O
F NN NN O
. NN NN O

, NN NN O
Domingo NN NN O
, NN NN O
R NN NN O
. NN NN O

J NN NN O
. NN NN O

, NN NN O
Ellis NN NN O
, NN NN O
M NN NN O
. NN NN O

C NN NN O
. NN NN O

, NN NN O
Fullan NN NN O
, NN NN O
A NN NN O
. NN NN O

, NN NN O
Hinton NN NN O
, NN NN O
L NN NN O
. NN NN O

M NN NN O
. NN NN O

, NN NN O
Jones NN NN O
, NN NN O
N NN NN O
. NN NN O

L NN NN O
. NN NN O

, NN NN O
Kimmel NN NN O
, NN NN O
B NN NN O
. NN NN O

E NN NN O
. NN NN O

, NN NN O
Kronmal NN NN O
, NN NN O
G NN NN O
. NN NN O

S NN NN O
. NN NN O

, NN NN O
Lauer NN NN O
, NN NN O
P NN NN O
. NN NN O

, NN NN O
Lee NN NN O
, NN NN O
V NN NN O
. NN NN O

K NN NN O
. NN NN O

, NN NN O
Loeb NN NN O
, NN NN O
D NN NN O
. NN NN O

B NN NN O
. NN NN O

, NN NN O
Mapa NN NN O
, NN NN O
F NN NN O
. NN NN O

A NN NN O
. NN NN O

, NN NN O
McClelland NN NN O
, NN NN O
E NN NN O
. NN NN O

, NN NN O
Meyer NN NN O
, NN NN O
N NN NN O
. NN NN O

C NN NN O
. NN NN O

, NN NN O
Mintier NN NN O
, NN NN O
G NN NN O
. NN NN O

A NN NN O
. NN NN O

, NN NN O
Moeller NN NN O
, NN NN O
N NN NN O
. NN NN O

, NN NN O
Moore NN NN O
, NN NN O
T NN NN O
. NN NN O

37 NN NN O
, NN NN O
Morikang NN NN O
, NN NN O
E NN NN O
. NN NN O

, NN NN O
Prasss NN NN O
, NN NN O
C NN NN O
. NN NN O

E NN NN O
. NN NN O

, NN NN O
Quintana NN NN O
, NN NN O
L NN NN O
. NN NN O

, NN NN O
Starnes NN NN O
, NN NN O
S NN NN O
. NN NN O

M NN NN O
. NN NN O

, NN NN O
Schatzman NN NN O
, NN NN O
R NN NN O
. NN NN O

C NN NN O
. NN NN O

, NN NN O
Brunke NN NN O
, NN NN O
K NN NN O
. NN NN O

J NN NN O
. NN NN O

, NN NN O
Drayna NN NN O
, NN NN O
D NN NN O
. NN NN O

T NN NN O
. NN NN O

, NN NN O
Risch NN NN O
, NN NN O
N NN NN O
. NN NN O

J NN NN O
. NN NN O

, NN NN O
Bacon NN NN O
, NN NN O
B NN NN O
. NN NN O

R NN NN O
. NN NN O

, NN NN O
and NN NN O
Wolff NN NN O
, NN NN O
R NN NN O
. NN NN O

R NN NN O
. NN NN O

( NN NN O
1996 NN NN O
) NN NN O
Nat NN NN O
. NN NN O

Genet NN NN O
. NN NN O

13 NN NN O
, NN NN O
399-408 NN NN O
) NN NN O
. NN NN O

At NN NN O
the NN NN O
cell NN NN O
surface NN NN O
, NN NN O
HFE NN NN O
complexes NN NN O
with NN NN O
transferrin NN NN O
receptor NN NN O
( NN NN O
TfR NN NN O
) NN NN O
, NN NN O
increasing NN NN O
the NN NN O
dissociation NN NN O
constant NN NN O
of NN NN O
transferrin NN NN O
( NN NN O
Tf NN NN O
) NN NN O
for NN NN O
its NN NN O
receptor NN NN O
10-fold NN NN O
( NN NN O
Gross NN NN O
, NN NN O
C NN NN O
. NN NN O

N NN NN O
. NN NN O

, NN NN O
Irrinki NN NN O
, NN NN O
A NN NN O
. NN NN O

, NN NN O
Feder NN NN O
, NN NN O
J NN NN O
. NN NN O

N NN NN O
. NN NN O

, NN NN O
and NN NN O
Enns NN NN O
, NN NN O
C NN NN O
. NN NN O

A NN NN O
. NN NN O

( NN NN O
1998 NN NN O
) NN NN O
J NN NN O
. NN NN O

Biol NN NN O
. NN NN O

Chem NN NN O
. NN NN O

273 NN NN O
, NN NN O
22068-22074 NN NN O
; NN NN O
Feder NN NN O
, NN NN O
J NN NN O
. NN NN O

N NN NN O
. NN NN O

, NN NN O
Penny NN NN O
, NN NN O
D NN NN O
. NN NN O

M NN NN O
. NN NN O

, NN NN O
Irrinki NN NN O
, NN NN O
A NN NN O
. NN NN O

, NN NN O
Lee NN NN O
, NN NN O
V NN NN O
. NN NN O

K NN NN O
. NN NN O

, NN NN O
Lebron NN NN O
, NN NN O
J NN NN O
. NN NN O

A NN NN O
. NN NN O

, NN NN O
Watson NN NN O
, NN NN O
N NN NN O
. NN NN O

, NN NN O
Tsuchihashi NN NN O
, NN NN O
Z NN NN O
. NN NN O

, NN NN O
Sigal NN NN O
, NN NN O
E NN NN O
. NN NN O

, NN NN O
Bjorkman NN NN O
, NN NN O
P NN NN O
. NN NN O

J NN NN O
. NN NN O

, NN NN O
and NN NN O
Schatzman NN NN O
, NN NN O
R NN NN O
. NN NN O

C NN NN O
. NN NN O

( NN NN O
1998 NN NN O
) NN NN O
Proc NN NN O
. NN NN O

Natl NN NN O
. NN NN O

Acad NN NN O
. NN NN O

Sci NN NN O
. NN NN O

U NN NN O
S NN NN O
A NN NN O
95 NN NN O
, NN NN O
1472-1477 NN NN O
) NN NN O
. NN NN O

HFE NN NN O
does NN NN O
not NN NN O
remain NN NN O
at NN NN O
the NN NN O
cell NN NN O
surface NN NN O
, NN NN O
but NN NN O
traffics NN NN O
with NN NN O
TfR NN NN O
to NN NN O
Tf-positive NN NN O
internal NN NN O
compartments NN NN O
( NN NN O
Gross NN NN O
et NN NN O
al NN NN O
. NN NN O

, NN NN O
1998 NN NN O
) NN NN O
. NN NN O

Using NN NN O
a NN NN O
HeLa NN NN O
cell NN NN O
line NN NN O
in NN NN O
which NN NN O
the NN NN O
expression NN NN O
of NN NN O
HFE NN NN O
is NN NN O
controlled NN NN O
by NN NN O
tetracycline NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
the NN NN O
expression NN NN O
of NN NN O
HFE NN NN O
reduces NN NN O
55Fe NN NN O
uptake NN NN O
from NN NN O
Tf NN NN O
by NN NN O
33 NN NN O
% NN NN O
but NN NN O
does NN NN O
not NN NN O
affect NN NN O
the NN NN O
endocytic NN NN O
or NN NN O
exocytic NN NN O
rates NN NN O
of NN NN O
TfR NN NN O
cycling NN NN O
. NN NN O

Therefore NN NN O
, NN NN O
HFE NN NN O
appears NN NN O
to NN NN O
reduce NN NN O
cellular NN NN O
acquisition NN NN O
of NN NN O
iron NN NN O
from NN NN O
Tf NN NN O
within NN NN O
endocytic NN NN O
compartments NN NN O
. NN NN O

HFE NN NN O
specifically NN NN O
reduces NN NN O
iron NN NN O
uptake NN NN O
from NN NN O
Tf NN NN O
, NN NN O
as NN NN O
non-Tf-mediated NN NN O
iron NN NN O
uptake NN NN O
from NN NN O
Fe-nitrilotriacetic NN NN O
acid NN NN O
is NN NN O
not NN NN O
altered NN NN O
. NN NN O

These NN NN O
results NN NN O
explain NN NN O
the NN NN O
decreased NN NN O
ferritin NN NN O
levels NN NN O
seen NN NN O
in NN NN O
our NN NN O
HeLa NN NN O
cell NN NN O
system NN NN O
and NN NN O
demonstrate NN NN O
the NN NN O
specific NN NN O
control NN NN O
of NN NN O
HFE NN NN O
over NN NN O
the NN NN O
Tf-mediated NN NN O
pathway NN NN O
of NN NN O
iron NN NN O
uptake NN NN O
. NN NN O

These NN NN O
results NN NN O
also NN NN O
have NN NN O
implications NN NN O
for NN NN O
the NN NN O
understanding NN NN O
of NN NN O
cellular NN NN O
iron NN NN O
homeostasis NN NN O
in NN NN O
organs NN NN O
such NN NN O
as NN NN O
the NN NN O
liver NN NN O
, NN NN O
pancreas NN NN O
, NN NN O
heart NN NN O
, NN NN O
and NN NN O
spleen NN NN O
that NN NN O
are NN NN O
iron NN NN O
loaded NN NN O
in NN NN O
hereditary NN NN B-Modifier
hemochromatotic NN NN I-Modifier
individuals NN NN O
lacking NN NN O
functional NN NN O
HFE NN NN O
. NN NN O

10090880 NN NN O
Mutation NN NN O
and NN NN O
haplotype NN NN O
studies NN NN O
of NN NN O
familial NN NN B-SpecificDisease
Mediterranean NN NN I-SpecificDisease
fever NN NN I-SpecificDisease
reveal NN NN O
new NN NN O
ancestral NN NN O
relationships NN NN O
and NN NN O
evidence NN NN O
for NN NN O
a NN NN O
high NN NN O
carrier NN NN O
frequency NN NN O
with NN NN O
reduced NN NN O
penetrance NN NN O
in NN NN O
the NN NN O
Ashkenazi NN NN O
Jewish NN NN O
population NN NN O
. NN NN O

Familial NN NN B-SpecificDisease
Mediterranean NN NN I-SpecificDisease
fever NN NN I-SpecificDisease
( NN NN O
FMF NN NN B-SpecificDisease
) NN NN O
is NN NN O
a NN NN O
recessive NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
characterized NN NN O
by NN NN O
episodes NN NN O
of NN NN O
fever NN NN O
with NN NN O
serositis NN NN B-DiseaseClass
or NN NN O
synovitis NN NN B-DiseaseClass
. NN NN O

The NN NN O
FMF NN NN B-Modifier
gene NN NN O
( NN NN O
MEFV NN NN O
) NN NN O
was NN NN O
cloned NN NN O
recently NN NN O
, NN NN O
and NN NN O
four NN NN O
missense NN NN O
mutations NN NN O
were NN NN O
identified NN NN O
. NN NN O

Here NN NN O
we NN NN O
present NN NN O
data NN NN O
from NN NN O
non-Ashkenazi NN NN O
Jewish NN NN O
and NN NN O
Arab NN NN O
patients NN NN O
in NN NN O
whom NN NN O
we NN NN O
had NN NN O
not NN NN O
originally NN NN O
found NN NN O
mutations NN NN O
and NN NN O
from NN NN O
a NN NN O
new NN NN O
, NN NN O
more NN NN O
ethnically NN NN O
diverse NN NN O
panel NN NN O
. NN NN O

Among NN NN O
90 NN NN O
symptomatic NN NN O
mutation-positive NN NN O
individuals NN NN O
, NN NN O
11 NN NN O
mutations NN NN O
accounted NN NN O
for NN NN O
79 NN NN O
% NN NN O
of NN NN O
carrier NN NN O
chromosomes NN NN O
. NN NN O

Of NN NN O
the NN NN O
two NN NN O
mutations NN NN O
that NN NN O
are NN NN O
novel NN NN O
, NN NN O
one NN NN O
alters NN NN O
the NN NN O
same NN NN O
residue NN NN O
( NN NN O
680 NN NN O
) NN NN O
as NN NN O
a NN NN O
previously NN NN O
known NN NN O
mutation NN NN O
, NN NN O
and NN NN O
the NN NN O
other NN NN O
( NN NN O
P369S NN NN O
) NN NN O
is NN NN O
located NN NN O
in NN NN O
exon NN NN O
3 NN NN O
. NN NN O

Consistent NN NN O
with NN NN O
another NN NN O
recent NN NN O
report NN NN O
, NN NN O
the NN NN O
E148Q NN NN O
mutation NN NN O
was NN NN O
observed NN NN O
in NN NN O
patients NN NN O
of NN NN O
several NN NN O
ethnicities NN NN O
and NN NN O
on NN NN O
multiple NN NN O
microsatellite NN NN O
haplotypes NN NN O
, NN NN O
but NN NN O
haplotype NN NN O
data NN NN O
indicate NN NN O
an NN NN O
ancestral NN NN O
relationships NN NN O
between NN NN O
non-Jewish NN NN O
Italian NN NN O
and NN NN O
Ashkenazi NN NN O
Jewish NN NN O
patients NN NN O
with NN NN O
FMF NN NN B-SpecificDisease
and NN NN O
other NN NN O
affected NN NN O
populations NN NN O
. NN NN O

Among NN NN O
approximately NN NN O
200 NN NN O
anonymous NN NN O
Ashkenazi NN NN O
Jewish NN NN O
DNA NN NN O
samples NN NN O
, NN NN O
the NN NN O
MEFV NN NN O
carrier NN NN O
frequency NN NN O
was NN NN O
21 NN NN O
% NN NN O
, NN NN O
with NN NN O
E148Q NN NN O
the NN NN O
most NN NN O
common NN NN O
mutation NN NN O
. NN NN O

Several NN NN O
lines NN NN O
of NN NN O
evidence NN NN O
indicate NN NN O
reduced NN NN O
penetrance NN NN O
among NN NN O
Ashkenazi NN NN O
Jews NN NN O
, NN NN O
especially NN NN O
for NN NN O
E148Q NN NN O
, NN NN O
P369S NN NN O
, NN NN O
and NN NN O
K695R NN NN O
. NN NN O

Nevertheless NN NN O
, NN NN O
E148Q NN NN O
helps NN NN O
account NN NN O
for NN NN O
recessive NN NN O
inheritance NN NN O
in NN NN O
an NN NN O
Ashkenazi NN NN O
family NN NN O
previously NN NN O
reported NN NN O
as NN NN O
an NN NN O
unusual NN NN O
case NN NN O
of NN NN O
dominantly NN NN O
inherited NN NN O
FMF NN NN B-SpecificDisease
. NN NN O

The NN NN O
presence NN NN O
of NN NN O
three NN NN O
frequent NN NN O
MEFV NN NN O
mutations NN NN O
in NN NN O
multiple NN NN O
Mediterranean NN NN O
populations NN NN O
strongly NN NN O
suggests NN NN O
a NN NN O
heterozygote NN NN O
advantage NN NN O
in NN NN O
this NN NN O
geographic NN NN O
region NN NN O
. NN NN O

10090885 NN NN O
Autoimmune NN NN B-SpecificDisease
lymphoproliferative NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
with NN NN O
defective NN NN O
Fas NN NN O
: NN NN O
genotype NN NN O
influences NN NN O
penetrance NN NN O
. NN NN O

Autoimmune NN NN B-SpecificDisease
lymphoproliferative NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
ALPS NN NN B-SpecificDisease
) NN NN O
is NN NN O
a NN NN O
disorder NN NN B-CompositeMention
of NN NN I-CompositeMention
lymphocyte NN NN I-CompositeMention
homeostasis NN NN I-CompositeMention
and NN NN I-CompositeMention
immunological NN NN I-CompositeMention
tolerance NN NN I-CompositeMention
. NN NN O

Most NN NN O
patients NN NN O
have NN NN O
a NN NN O
heterozygous NN NN O
mutation NN NN O
in NN NN O
the NN NN O
APT1 NN NN O
gene NN NN O
, NN NN O
which NN NN O
encodes NN NN O
Fas NN NN O
( NN NN O
CD95 NN NN O
, NN NN O
APO-1 NN NN O
) NN NN O
, NN NN O
mediator NN NN O
of NN NN O
an NN NN O
apoptotic NN NN O
pathway NN NN O
crucial NN NN O
to NN NN O
lymphocyte NN NN O
homeostasis NN NN O
. NN NN O

Of NN NN O
17 NN NN O
unique NN NN O
APT1 NN NN O
mutations NN NN O
in NN NN O
unrelated NN NN O
ALPS NN NN B-Modifier
probands NN NN O
, NN NN O
12 NN NN O
( NN NN O
71 NN NN O
% NN NN O
) NN NN O
occurred NN NN O
in NN NN O
exons NN NN O
7-9 NN NN O
, NN NN O
which NN NN O
encode NN NN O
the NN NN O
intracellular NN NN O
portion NN NN O
of NN NN O
Fas NN NN O
. NN NN O

In NN NN O
vitro NN NN O
, NN NN O
activated NN NN O
lymphocytes NN NN O
from NN NN O
all NN NN O
17 NN NN O
patients NN NN O
showed NN NN O
apoptotic NN NN O
defects NN NN O
when NN NN O
exposed NN NN O
to NN NN O
an NN NN O
anti-Fas NN NN O
agonist NN NN O
monoclonal NN NN O
antibody NN NN O
. NN NN O

Similar NN NN O
defects NN NN O
were NN NN O
found NN NN O
in NN NN O
a NN NN O
Fas-negative NN NN O
cell NN NN O
line NN NN O
transfected NN NN O
with NN NN O
cDNAs NN NN O
bearing NN NN O
each NN NN O
of NN NN O
the NN NN O
mutations NN NN O
. NN NN O

In NN NN O
cotransfection NN NN O
experiments NN NN O
, NN NN O
Fas NN NN O
constructs NN NN O
with NN NN O
either NN NN O
intra- NN NN O
or NN NN O
extracellular NN NN O
mutations NN NN O
caused NN NN O
dominant NN NN O
inhibition NN NN O
of NN NN O
apoptosis NN NN O
mediated NN NN O
by NN NN O
wild-type NN NN O
Fas NN NN O
. NN NN O

Two NN NN O
missense NN NN O
Fas NN NN O
variants NN NN O
, NN NN O
not NN NN O
restricted NN NN O
to NN NN O
patients NN NN O
with NN NN O
ALPS NN NN B-SpecificDisease
, NN NN O
were NN NN O
identified NN NN O
. NN NN O

Variant NN NN O
A NN NN O
( NN NN O
-1 NN NN O
) NN NN O
T NN NN O
at NN NN O
the NN NN O
Fas NN NN O
signal-sequence NN NN O
cleavage NN NN O
site NN NN O
, NN NN O
which NN NN O
mediates NN NN O
apoptosis NN NN O
less NN NN O
well NN NN O
than NN NN O
wild-type NN NN O
Fas NN NN O
and NN NN O
is NN NN O
partially NN NN O
inhibitory NN NN O
, NN NN O
was NN NN O
present NN NN O
in NN NN O
13 NN NN O
% NN NN O
of NN NN O
African NN NN O
American NN NN O
alleles NN NN O
. NN NN O

Among NN NN O
the NN NN O
ALPS NN NN B-Modifier
-associated NN NN O
Fas NN NN O
mutants NN NN O
, NN NN O
dominant NN NN O
inhibition NN NN O
of NN NN O
apoptosis NN NN O
was NN NN O
much NN NN O
more NN NN O
pronounced NN NN O
in NN NN O
mutants NN NN O
affecting NN NN O
the NN NN O
intracellular NN NN O
, NN NN O
versus NN NN O
extracellular NN NN O
, NN NN O
portion NN NN O
of NN NN O
the NN NN O
Fas NN NN O
receptor NN NN O
. NN NN O

Mutations NN NN O
causing NN NN O
disruption NN NN O
of NN NN O
the NN NN O
intracellular NN NN O
Fas NN NN O
death NN NN O
domain NN NN O
also NN NN O
showed NN NN O
a NN NN O
higher NN NN O
penetrance NN NN O
of NN NN O
ALPS NN NN B-Modifier
phenotype NN NN O
features NN NN O
in NN NN O
mutation-bearing NN NN O
relatives NN NN O
. NN NN O

Significant NN NN O
ALPS NN NN B-Modifier
-related NN NN O
morbidity NN NN O
occurred NN NN O
in NN NN O
44 NN NN O
% NN NN O
of NN NN O
relatives NN NN O
with NN NN O
intracellular NN NN O
mutations NN NN O
, NN NN O
versus NN NN O
0 NN NN O
% NN NN O
of NN NN O
relatives NN NN O
with NN NN O
extracellular NN NN O
mutations NN NN O
. NN NN O

Thus NN NN O
, NN NN O
the NN NN O
location NN NN O
of NN NN O
mutations NN NN O
within NN NN O
APT1 NN NN O
strongly NN NN O
influences NN NN O
the NN NN O
development NN NN O
and NN NN O
the NN NN O
severity NN NN O
of NN NN O
ALPS NN NN B-SpecificDisease
. NN NN O

10090890 NN NN O
Multicentric NN NN O
origin NN NN O
of NN NN O
hemochromatosis NN NN B-Modifier
gene NN NN O
( NN NN O
HFE NN NN O
) NN NN O
mutations NN NN O
. NN NN O

Genetic NN NN B-SpecificDisease
hemochromatosis NN NN I-SpecificDisease
( NN NN O
GH NN NN B-SpecificDisease
) NN NN O
is NN NN O
believed NN NN O
to NN NN O
be NN NN O
a NN NN O
disease NN NN O
restricted NN NN O
to NN NN O
those NN NN O
of NN NN O
European NN NN O
ancestry NN NN O
. NN NN O

In NN NN O
northwestern NN NN O
Europe NN NN O
, NN NN O
80 NN NN O
% NN NN O
of NN NN O
GH NN NN B-Modifier
patients NN NN O
are NN NN O
homozygous NN NN O
for NN NN O
one NN NN O
mutation NN NN O
, NN NN O
the NN NN O
substitution NN NN O
of NN NN O
tyrosine NN NN O
for NN NN O
cysteine NN NN O
at NN NN O
position NN NN O
282 NN NN O
( NN NN O
C282Y NN NN O
) NN NN O
in NN NN O
the NN NN O
unprocessed NN NN O
protein NN NN O
. NN NN O

In NN NN O
a NN NN O
proportion NN NN O
of NN NN O
GH NN NN B-Modifier
patients NN NN O
, NN NN O
two NN NN O
mutations NN NN O
are NN NN O
present NN NN O
, NN NN O
C282Y NN NN O
and NN NN O
H63D NN NN O
. NN NN O

The NN NN O
clinical NN NN O
significance NN NN O
of NN NN O
this NN NN O
second NN NN O
mutation NN NN O
is NN NN O
such NN NN O
that NN NN O
it NN NN O
appears NN NN O
to NN NN O
predispose NN NN O
1 NN NN O
% NN NN O
-2 NN NN O
% NN NN O
of NN NN O
compound NN NN O
heterozygotes NN NN O
to NN NN O
expression NN NN O
of NN NN O
the NN NN O
disease NN NN O
. NN NN O

The NN NN O
distribution NN NN O
of NN NN O
the NN NN O
two NN NN O
mutations NN NN O
differ NN NN O
, NN NN O
C282Y NN NN O
being NN NN O
limited NN NN O
to NN NN O
those NN NN O
of NN NN O
northwestern NN NN O
European NN NN O
ancestry NN NN O
and NN NN O
H63D NN NN O
being NN NN O
found NN NN O
at NN NN O
allele NN NN O
frequencies NN NN O
5 NN NN O
% NN NN O
, NN NN O
in NN NN O
Europe NN NN O
, NN NN O
in NN NN O
countries NN NN O
bordering NN NN O
the NN NN O
Mediterranean NN NN O
, NN NN O
in NN NN O
the NN NN O
Middle NN NN O
East NN NN O
, NN NN O
and NN NN O
in NN NN O
the NN NN O
Indian NN NN O
subcontinent NN NN O
. NN NN O

The NN NN O
C282Y NN NN O
mutation NN NN O
occurs NN NN O
on NN NN O
a NN NN O
haplotype NN NN O
that NN NN O
extends NN NN O
/ NN NN O
= NN NN O
6 NN NN O
Mb NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
this NN NN O
mutation NN NN O
has NN NN O
arisen NN NN O
during NN NN O
the NN NN O
past NN NN O
2 NN NN O
, NN NN O
000 NN NN O
years NN NN O
. NN NN O

The NN NN O
H63D NN NN O
mutation NN NN O
is NN NN O
older NN NN O
and NN NN O
does NN NN O
not NN NN O
occur NN NN O
on NN NN O
such NN NN O
a NN NN O
large NN NN O
extended NN NN O
haplotype NN NN O
, NN NN O
the NN NN O
haplotype NN NN O
in NN NN O
this NN NN O
case NN NN O
extending NN NN O
/ NN NN O
= NN NN O
700 NN NN O
kb NN NN O
. NN NN O

Here NN NN O
we NN NN O
report NN NN O
the NN NN O
finding NN NN O
of NN NN O
the NN NN O
H63D NN NN O
and NN NN O
C282Y NN NN O
mutations NN NN O
on NN NN O
new NN NN O
haplotypes NN NN O
. NN NN O

In NN NN O
Sri NN NN O
Lanka NN NN O
we NN NN O
have NN NN O
found NN NN O
H63D NN NN O
on NN NN O
three NN NN O
new NN NN O
haplotypes NN NN O
and NN NN O
have NN NN O
found NN NN O
C282Y NN NN O
on NN NN O
one NN NN O
new NN NN O
haplotype NN NN O
, NN NN O
demonstrating NN NN O
that NN NN O
these NN NN O
mutations NN NN O
have NN NN O
arisen NN NN O
independently NN NN O
on NN NN O
this NN NN O
island NN NN O
. NN NN O

These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
HFE NN NN O
gene NN NN O
has NN NN O
been NN NN O
the NN NN O
subject NN NN O
of NN NN O
selection NN NN O
pressure NN NN O
. NN NN O

These NN NN O
selection NN NN O
pressures NN NN O
could NN NN O
be NN NN O
due NN NN O
to NN NN O
infectious NN NN B-DiseaseClass
diseases NN NN I-DiseaseClass
, NN NN O
environmental NN NN O
conditions NN NN O
, NN NN O
or NN NN O
other NN NN O
genetic NN NN B-DiseaseClass
disorders NN NN I-DiseaseClass
such NN NN O
as NN NN O
anemia NN NN B-DiseaseClass
. NN NN O

10094552 NN NN O
A NN NN O
retrospective NN NN O
anonymous NN NN O
pilot NN NN O
study NN NN O
in NN NN O
screening NN NN O
newborns NN NN O
for NN NN O
HFE NN NN O
mutations NN NN O
in NN NN O
Scandinavian NN NN O
populations NN NN O
. NN NN O

We NN NN O
have NN NN O
retrospectively NN NN O
analyzed NN NN O
837 NN NN O
random NN NN O
anonymized NN NN O
dried NN NN O
blood NN NN O
spot NN NN O
( NN NN O
DBS NN NN O
) NN NN O
samples NN NN O
from NN NN O
neonatal NN NN O
screening NN NN O
programs NN NN O
in NN NN O
Scandinavia NN NN O
for NN NN O
mutations NN NN O
in NN NN O
HFE NN NN O
, NN NN O
the NN NN O
candidate NN NN O
gene NN NN O
for NN NN O
hemochromatosis NN NN B-SpecificDisease
. NN NN O

We NN NN O
have NN NN O
found NN NN O
C282Y NN NN O
allele NN NN O
frequencies NN NN O
of NN NN O
2 NN NN O
. NN NN O

3 NN NN O
% NN NN O
( NN NN O
+ NN NN O
2 NN NN O
. NN NN O

0 NN NN O
% NN NN O
) NN NN O
( NN NN O
-1 NN NN O
. NN NN O

3 NN NN O
% NN NN O
) NN NN O
in NN NN O
Greenland NN NN O
, NN NN O
4 NN NN O
. NN NN O

5 NN NN O
% NN NN O
+ NN NN O
/ NN NN O
-1 NN NN O
. NN NN O

9 NN NN O
% NN NN O
in NN NN O
Iceland NN NN O
, NN NN O
5 NN NN O
. NN NN O

1 NN NN O
% NN NN O
+ NN NN O
/ NN NN O
-2 NN NN O
. NN NN O

3 NN NN O
% NN NN O
in NN NN O
the NN NN O
Faeroe NN NN O
Islands NN NN O
, NN NN O
and NN NN O
8 NN NN O
. NN NN O

2 NN NN O
% NN NN O
+ NN NN O
/ NN NN O
-2 NN NN O
. NN NN O

7 NN NN O
% NN NN O
in NN NN O
Denmark NN NN O
. NN NN O

The NN NN O
high NN NN O
prevalence NN NN O
of NN NN O
HFE NN NN O
mutations NN NN O
in NN NN O
Denmark NN NN O
suggests NN NN O
that NN NN O
population NN NN O
screening NN NN O
for NN NN O
the NN NN O
C282Y NN NN O
mutation NN NN O
could NN NN O
be NN NN O
highly NN NN O
advantageous NN NN O
in NN NN O
terms NN NN O
of NN NN O
preventive NN NN O
health NN NN O
care NN NN O
. NN NN O

Long-term NN NN O
follow-up NN NN O
evaluation NN NN O
of NN NN O
C282Y NN NN O
homozygotes NN NN O
and NN NN O
H63D NN NN O
/ NN NN O
C282Y NN NN O
compound NN NN O
heterozygotes NN NN O
will NN NN O
give NN NN O
an NN NN O
indication NN NN O
of NN NN O
the NN NN O
penetrance NN NN O
of NN NN O
the NN NN O
mutations NN NN O
. NN NN O

10094559 NN NN O
Identification NN NN O
of NN NN O
the NN NN O
mutation NN NN O
in NN NN O
the NN NN O
alkaptonuria NN NN B-Modifier
mouse NN NN O
model NN NN O
. NN NN O

Alkaptonuria NN NN B-SpecificDisease
( NN NN O
aku NN NN B-SpecificDisease
) NN NN O
, NN NN O
an NN NN O
inborn NN NN B-DiseaseClass
error NN NN I-DiseaseClass
of NN NN I-DiseaseClass
metabolism NN NN I-DiseaseClass
caused NN NN O
by NN NN O
the NN NN O
loss NN NN O
of NN NN O
homogentisate NN NN O
1 NN NN O
, NN NN O
2-dioxygenase NN NN O
( NN NN O
HGD NN NN O
) NN NN O
, NN NN O
has NN NN O
been NN NN O
described NN NN O
in NN NN O
a NN NN O
mouse NN NN O
model NN NN O
created NN NN O
by NN NN O
ethylnitrosourea NN NN O
mutagenesis NN NN O
but NN NN O
the NN NN O
mutation NN NN O
in NN NN O
these NN NN O
mice NN NN O
has NN NN O
not NN NN O
previously NN NN O
been NN NN O
identified NN NN O
. NN NN O

We NN NN O
used NN NN O
RT-PCR NN NN O
to NN NN O
amplify NN NN O
the NN NN O
Hgd NN NN O
cDNA NN NN O
from NN NN O
Hgd NN NN O
( NN NN O
aku NN NN O
) NN NN O
/ NN NN O
Hgd NN NN O
( NN NN O
aku NN NN O
) NN NN O
mice NN NN O
. NN NN O

Two NN NN O
products NN NN O
shorter NN NN O
than NN NN O
the NN NN O
wild-type NN NN O
product NN NN O
were NN NN O
amplified NN NN O
. NN NN O

Restriction NN NN O
mapping NN NN O
and NN NN O
DNA NN NN O
sequencing NN NN O
were NN NN O
then NN NN O
used NN NN O
to NN NN O
identify NN NN O
the NN NN O
Hgd NN NN O
( NN NN O
aku NN NN O
) NN NN O
mouse NN NN O
mutation NN NN O
, NN NN O
found NN NN O
to NN NN O
be NN NN O
a NN NN O
single NN NN O
base NN NN O
change NN NN O
in NN NN O
a NN NN O
splice NN NN O
donor NN NN O
consensus NN NN O
sequence NN NN O
, NN NN O
causing NN NN O
exon NN NN O
skipping NN NN O
and NN NN O
frame-shifted NN NN O
products NN NN O
. NN NN O

This NN NN O
base NN NN O
change NN NN O
allowed NN NN O
us NN NN O
to NN NN O
create NN NN O
a NN NN O
non-radioactive NN NN O
genotyping NN NN O
assay NN NN O
for NN NN O
this NN NN O
allele NN NN O
. NN NN O

10190331 NN NN O
Non-syndromic NN NN B-SpecificDisease
hearing NN NN I-SpecificDisease
loss NN NN I-SpecificDisease
associated NN NN O
with NN NN O
enlarged NN NN B-SpecificDisease
vestibular NN NN I-SpecificDisease
aqueduct NN NN I-SpecificDisease
is NN NN O
caused NN NN O
by NN NN O
PDS NN NN B-Modifier
mutations NN NN O
. NN NN O

Enlarged NN NN B-SpecificDisease
vestibular NN NN I-SpecificDisease
aqueduct NN NN I-SpecificDisease
( NN NN O
EVA NN NN B-SpecificDisease
) NN NN O
, NN NN O
known NN NN O
as NN NN O
the NN NN O
most NN NN O
common NN NN O
form NN NN O
of NN NN O
inner NN NN B-DiseaseClass
ear NN NN I-DiseaseClass
abnormality NN NN I-DiseaseClass
, NN NN O
has NN NN O
recently NN NN O
been NN NN O
of NN NN O
particular NN NN O
genetic NN NN O
interest NN NN O
because NN NN O
this NN NN O
anomaly NN NN O
is NN NN O
inherited NN NN O
in NN NN O
a NN NN O
recessive NN NN O
manner NN NN O
. NN NN O

The NN NN O
locus NN NN O
for NN NN O
non-syndromic NN NN B-SpecificDisease
sensorineural NN NN I-SpecificDisease
hearing NN NN I-SpecificDisease
loss NN NN I-SpecificDisease
with NN NN O
EVA NN NN B-SpecificDisease
has NN NN O
been NN NN O
mapped NN NN O
to NN NN O
the NN NN O
same NN NN O
chromosomal NN NN O
region NN NN O
, NN NN O
7q31 NN NN O
, NN NN O
as NN NN O
the NN NN O
Pendred NN NN B-Modifier
syndrome NN NN I-Modifier
locus NN NN O
. NN NN O

In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
seven NN NN O
mutations NN NN O
in NN NN O
the NN NN O
PDS NN NN B-Modifier
gene NN NN O
( NN NN O
PDS NN NN O
) NN NN O
, NN NN O
the NN NN O
gene NN NN O
responsible NN NN O
for NN NN O
Pendred NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
, NN NN O
have NN NN O
been NN NN O
found NN NN O
in NN NN O
families NN NN O
of NN NN O
non-syndromic NN NN B-SpecificDisease
sensorineural NN NN I-SpecificDisease
hearing NN NN I-SpecificDisease
loss NN NN I-SpecificDisease
with NN NN O
EVA NN NN B-SpecificDisease
. NN NN O

One NN NN O
family NN NN O
is NN NN O
homozygous NN NN O
, NN NN O
three NN NN O
families NN NN O
are NN NN O
compound NN NN O
heterozygotes NN NN O
, NN NN O
and NN NN O
two NN NN O
families NN NN O
are NN NN O
heterozygous NN NN O
but NN NN O
with NN NN O
no NN NN O
other NN NN O
mutation NN NN O
detected NN NN O
. NN NN O

The NN NN O
present NN NN O
results NN NN O
provide NN NN O
evidence NN NN O
that NN NN O
mutations NN NN O
in NN NN O
PDS NN NN O
cause NN NN O
both NN NN O
syndromic NN NN B-CompositeMention
and NN NN I-CompositeMention
non-syndromic NN NN I-CompositeMention
hearing NN NN I-CompositeMention
loss NN NN I-CompositeMention
. NN NN O

. NN NN O

10190819 NN NN O
Mutational NN NN O
analysis NN NN O
and NN NN O
genotype-phenotype NN NN O
correlation NN NN O
of NN NN O
29 NN NN O
unrelated NN NN O
Japanese NN NN O
patients NN NN O
with NN NN O
X-linked NN NN B-SpecificDisease
adrenoleukodystrophy NN NN I-SpecificDisease
. NN NN O

BACKGROUND NN NN O
X-linked NN NN B-SpecificDisease
adrenoleukodystrophy NN NN I-SpecificDisease
( NN NN O
ALD NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
inherited NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
characterized NN NN O
by NN NN O
progressive NN NN O
neurologic NN NN B-SpecificDisease
dysfunction NN NN I-SpecificDisease
, NN NN O
occasionally NN NN O
associated NN NN O
with NN NN O
adrenal NN NN B-DiseaseClass
insufficiency NN NN I-DiseaseClass
. NN NN O

The NN NN O
classic NN NN O
form NN NN O
of NN NN O
ALD NN NN B-SpecificDisease
usually NN NN O
has NN NN O
onset NN NN O
in NN NN O
childhood NN NN O
( NN NN O
childhood NN NN B-SpecificDisease
cerebral NN NN I-SpecificDisease
ALD NN NN I-SpecificDisease
) NN NN O
, NN NN O
with NN NN O
rapid NN NN O
neurologic NN NN B-DiseaseClass
deterioration NN NN I-DiseaseClass
leading NN NN O
to NN NN O
a NN NN O
vegetative NN NN O
state NN NN O
. NN NN O

Adult-onset NN NN O
cerebral NN NN B-SpecificDisease
ALD NN NN I-SpecificDisease
also NN NN O
presents NN NN O
with NN NN O
rapidly NN NN O
progressive NN NN O
neurologic NN NN B-DiseaseClass
dysfunction NN NN I-DiseaseClass
. NN NN O

Milder NN NN O
phenotypes NN NN O
such NN NN O
as NN NN O
adrenomyeloneuropathy NN NN B-SpecificDisease
and NN NN O
Addison NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
only NN NN O
also NN NN O
have NN NN O
been NN NN O
recognized NN NN O
. NN NN O

Despite NN NN O
discovery NN NN O
of NN NN O
the NN NN O
causative NN NN O
gene NN NN O
, NN NN O
a NN NN O
molecular NN NN O
basis NN NN O
for NN NN O
the NN NN O
diverse NN NN O
clinical NN NN O
presentations NN NN O
remains NN NN O
to NN NN O
be NN NN O
elucidated NN NN O
. NN NN O

OBJECTIVES NN NN O
To NN NN O
conduct NN NN O
mutational NN NN O
analyses NN NN O
in NN NN O
29 NN NN O
Japanese NN NN O
patients NN NN O
with NN NN O
ALD NN NN B-SpecificDisease
from NN NN O
29 NN NN O
unrelated NN NN O
families NN NN O
, NN NN O
to NN NN O
obtain NN NN O
knowledge NN NN O
of NN NN O
the NN NN O
spectrum NN NN O
of NN NN O
mutations NN NN O
in NN NN O
this NN NN O
gene NN NN O
, NN NN O
and NN NN O
to NN NN O
study NN NN O
genotype-phenotype NN NN O
correlations NN NN O
in NN NN O
Japanese NN NN O
patients NN NN O
. NN NN O

METHODS NN NN O
The NN NN O
29 NN NN O
patients NN NN O
comprised NN NN O
13 NN NN O
patients NN NN O
with NN NN O
childhood NN NN B-SpecificDisease
cerebral NN NN I-SpecificDisease
ALD NN NN I-SpecificDisease
, NN NN O
11 NN NN O
patients NN NN O
with NN NN O
adult-onset NN NN O
cerebral NN NN B-SpecificDisease
ALD NN NN I-SpecificDisease
, NN NN O
and NN NN O
5 NN NN O
patients NN NN O
with NN NN O
adrenomyeloneuropathy NN NN B-SpecificDisease
. NN NN O

We NN NN O
conducted NN NN O
detailed NN NN O
mutational NN NN O
analyses NN NN O
of NN NN O
29 NN NN O
unrelated NN NN O
Japanese NN NN O
patients NN NN O
with NN NN O
ALD NN NN B-SpecificDisease
by NN NN O
genomic NN NN O
Southern NN NN O
blot NN NN O
analysis NN NN O
and NN NN O
direct NN NN O
nucleotide NN NN O
sequence NN NN O
analysis NN NN O
of NN NN O
reverse NN NN O
transcriptase-polymerase NN NN O
chain NN NN O
reaction NN NN O
products NN NN O
derived NN NN O
from NN NN O
total NN NN O
RNA NN NN O
that NN NN O
was NN NN O
extracted NN NN O
from NN NN O
cultured NN NN O
skin NN NN O
fibroblasts NN NN O
, NN NN O
lymphoblastoid NN NN O
cells NN NN O
, NN NN O
or NN NN O
peripheral NN NN O
blood NN NN O
leukocytes NN NN O
. NN NN O

RESULTS NN NN O
Three NN NN O
patients NN NN O
with NN NN O
adult-onset NN NN O
cerebral NN NN B-SpecificDisease
ALD NN NN I-SpecificDisease
were NN NN O
identified NN NN O
as NN NN O
having NN NN O
large NN NN O
genomic NN NN O
rearrangements NN NN O
. NN NN O

The NN NN O
remaining NN NN O
26 NN NN O
patients NN NN O
were NN NN O
identified NN NN O
as NN NN O
having NN NN O
21 NN NN O
independent NN NN O
mutations NN NN O
, NN NN O
including NN NN O
12 NN NN O
novel NN NN O
mutations NN NN O
resulting NN NN O
in NN NN O
small NN NN O
nucleotide NN NN O
alterations NN NN O
in NN NN O
the NN NN O
ALD NN NN B-Modifier
gene NN NN O
. NN NN O

Eighteen NN NN O
( NN NN O
69 NN NN O
% NN NN O
) NN NN O
of NN NN O
26 NN NN O
mutations NN NN O
were NN NN O
missense NN NN O
mutations NN NN O
. NN NN O

Most NN NN O
missense NN NN O
mutations NN NN O
involved NN NN O
amino NN NN O
acids NN NN O
conserved NN NN O
in NN NN O
homologous NN NN O
gene NN NN O
products NN NN O
, NN NN O
including NN NN O
PMP70 NN NN O
, NN NN O
mALDRP NN NN O
, NN NN O
and NN NN O
Pxa1p NN NN O
. NN NN O

The NN NN O
AG NN NN O
dinucleotide NN NN O
deletion NN NN O
at NN NN O
position NN NN O
1081-1082 NN NN O
, NN NN O
which NN NN O
has NN NN O
been NN NN O
reported NN NN O
previously NN NN O
to NN NN O
be NN NN O
the NN NN O
most NN NN O
common NN NN O
mutation NN NN O
in NN NN O
white NN NN O
patients NN NN O
( NN NN O
12 NN NN O
% NN NN O
-17 NN NN O
% NN NN O
) NN NN O
, NN NN O
was NN NN O
also NN NN O
identified NN NN O
as NN NN O
the NN NN O
most NN NN O
common NN NN O
mutation NN NN O
in NN NN O
Japanese NN NN O
patients NN NN O
( NN NN O
12 NN NN O
% NN NN O
) NN NN O
. NN NN O

All NN NN O
phenotypes NN NN O
were NN NN O
associated NN NN O
with NN NN O
mutations NN NN O
resulting NN NN O
in NN NN O
protein NN NN O
truncation NN NN O
or NN NN O
subtle NN NN O
amino NN NN O
acid NN NN O
changes NN NN O
. NN NN O

There NN NN O
were NN NN O
no NN NN O
differences NN NN O
in NN NN O
phenotypic NN NN O
expressions NN NN O
between NN NN O
missense NN NN O
mutations NN NN O
involving NN NN O
conserved NN NN O
amino NN NN O
acids NN NN O
and NN NN O
those NN NN O
involving NN NN O
nonconserved NN NN O
amino NN NN O
acids NN NN O
. NN NN O

CONCLUSIONS NN NN O
There NN NN O
are NN NN O
no NN NN O
obvious NN NN O
correlations NN NN O
between NN NN O
the NN NN O
phenotypes NN NN O
of NN NN O
patients NN NN O
with NN NN O
ALD NN NN B-SpecificDisease
and NN NN O
their NN NN O
genotypes NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
other NN NN O
genetic NN NN O
or NN NN O
environmental NN NN O
factors NN NN O
modify NN NN O
the NN NN O
phenotypic NN NN O
expressions NN NN O
of NN NN O
ALD NN NN B-SpecificDisease
. NN NN O

. NN NN O

10192393 NN NN O
A NN NN O
common NN NN O
human NN NN O
skin NN NN B-DiseaseClass
tumour NN NN I-DiseaseClass
is NN NN O
caused NN NN O
by NN NN O
activating NN NN O
mutations NN NN O
in NN NN O
beta-catenin NN NN O
. NN NN O

WNT NN NN O
signalling NN NN O
orchestrates NN NN O
a NN NN O
number NN NN O
of NN NN O
developmental NN NN O
programs NN NN O
. NN NN O

In NN NN O
response NN NN O
to NN NN O
this NN NN O
stimulus NN NN O
, NN NN O
cytoplasmic NN NN O
beta-catenin NN NN O
( NN NN O
encoded NN NN O
by NN NN O
CTNNB1 NN NN O
) NN NN O
is NN NN O
stabilized NN NN O
, NN NN O
enabling NN NN O
downstream NN NN O
transcriptional NN NN O
activation NN NN O
by NN NN O
members NN NN O
of NN NN O
the NN NN O
LEF NN NN O
/ NN NN O
TCF NN NN O
family NN NN O
. NN NN O

One NN NN O
of NN NN O
the NN NN O
target NN NN O
genes NN NN O
for NN NN O
beta-catenin NN NN O
/ NN NN O
TCF NN NN O
encodes NN NN O
c-MYC NN NN O
, NN NN O
explaining NN NN O
why NN NN O
constitutive NN NN O
activation NN NN O
of NN NN O
the NN NN O
WNT NN NN O
pathway NN NN O
can NN NN O
lead NN NN O
to NN NN O
cancer NN NN B-DiseaseClass
, NN NN O
particularly NN NN O
in NN NN O
the NN NN O
colon NN NN O
. NN NN O

Most NN NN O
colon NN NN B-DiseaseClass
cancers NN NN I-DiseaseClass
arise NN NN O
from NN NN O
mutations NN NN O
in NN NN O
the NN NN O
gene NN NN O
encoding NN NN O
adenomatous NN NN B-SpecificDisease
polyposis NN NN I-SpecificDisease
coli NN NN I-SpecificDisease
( NN NN O
APC NN NN B-SpecificDisease
) NN NN O
, NN NN O
a NN NN O
protein NN NN O
required NN NN O
for NN NN O
ubiquitin-mediated NN NN O
degradation NN NN O
of NN NN O
beta-catenin NN NN O
, NN NN O
but NN NN O
a NN NN O
small NN NN O
percentage NN NN O
of NN NN O
colon NN NN B-CompositeMention
and NN NN I-CompositeMention
some NN NN I-CompositeMention
other NN NN I-CompositeMention
cancers NN NN I-CompositeMention
harbour NN NN O
beta-catenin-stabilizing NN NN O
mutations NN NN O
. NN NN O

Recently NN NN O
, NN NN O
we NN NN O
discovered NN NN O
that NN NN O
transgenic NN NN O
mice NN NN O
expressing NN NN O
an NN NN O
activated NN NN O
beta-catenin NN NN O
are NN NN O
predisposed NN NN O
to NN NN O
developing NN NN O
skin NN NN B-DiseaseClass
tumours NN NN I-DiseaseClass
resembling NN NN O
pilomatricomas NN NN B-SpecificDisease
. NN NN O

Given NN NN O
that NN NN O
the NN NN O
skin NN NN O
of NN NN O
these NN NN O
adult NN NN O
mice NN NN O
also NN NN O
exhibits NN NN O
signs NN NN O
of NN NN O
de NN NN O
novo NN NN O
hair-follicle NN NN O
morphogenesis NN NN O
, NN NN O
we NN NN O
wondered NN NN O
whether NN NN O
human NN NN O
pilomatricomas NN NN B-SpecificDisease
might NN NN O
originate NN NN O
from NN NN O
hair NN NN O
matrix NN NN O
cells NN NN O
and NN NN O
whether NN NN O
they NN NN O
might NN NN O
possess NN NN O
beta-catenin-stabilizing NN NN O
mutations NN NN O
. NN NN O

Here NN NN O
, NN NN O
we NN NN O
explore NN NN O
the NN NN O
cell NN NN O
origin NN NN O
and NN NN O
aetiology NN NN O
of NN NN O
this NN NN O
common NN NN O
human NN NN O
skin NN NN B-DiseaseClass
tumour NN NN I-DiseaseClass
. NN NN O

We NN NN O
found NN NN O
nuclear NN NN O
LEF-1 NN NN O
in NN NN O
the NN NN O
dividing NN NN O
tumour NN NN B-Modifier
cells NN NN O
, NN NN O
providing NN NN O
biochemical NN NN O
evidence NN NN O
that NN NN O
pilomatricomas NN NN B-SpecificDisease
are NN NN O
derived NN NN O
from NN NN O
hair NN NN O
matrix NN NN O
cells NN NN O
. NN NN O

At NN NN O
least NN NN O
75 NN NN O
% NN NN O
of NN NN O
these NN NN O
tumours NN NN B-DiseaseClass
possess NN NN O
mutations NN NN O
affecting NN NN O
the NN NN O
amino-terminal NN NN O
segment NN NN O
, NN NN O
normally NN NN O
involved NN NN O
in NN NN O
phosphorylation-dependent NN NN O
, NN NN O
ubiquitin-mediated NN NN O
degradation NN NN O
of NN NN O
the NN NN O
protein NN NN O
. NN NN O

This NN NN O
percentage NN NN O
of NN NN O
CTNNB1 NN NN O
mutations NN NN O
is NN NN O
greater NN NN O
than NN NN O
in NN NN O
all NN NN O
other NN NN O
human NN NN O
tumours NN NN B-DiseaseClass
examined NN NN O
thus NN NN O
far NN NN O
, NN NN O
and NN NN O
directly NN NN O
implicates NN NN O
beta-catenin NN NN O
/ NN NN O
LEF NN NN O
misregulation NN NN O
as NN NN O
the NN NN O
major NN NN O
cause NN NN O
of NN NN O
hair NN NN O
matrix NN NN O
cell NN NN O
tumorigenesis NN NN O
in NN NN O
humans NN NN O
. NN NN O

. NN NN O

10192399 NN NN O
The NN NN O
Pendred NN NN B-Modifier
syndrome NN NN I-Modifier
gene NN NN O
encodes NN NN O
a NN NN O
chloride-iodide NN NN O
transport NN NN O
protein NN NN O
. NN NN O

Pendred NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
is NN NN O
the NN NN O
most NN NN O
common NN NN O
form NN NN O
of NN NN O
syndromic NN NN B-DiseaseClass
deafness NN NN I-DiseaseClass
and NN NN O
characterized NN NN O
by NN NN O
congenital NN NN O
sensorineural NN NN B-SpecificDisease
hearing NN NN I-SpecificDisease
loss NN NN I-SpecificDisease
and NN NN O
goitre NN NN B-SpecificDisease
. NN NN O

This NN NN O
disorder NN NN O
was NN NN O
mapped NN NN O
to NN NN O
chromosome NN NN O
7 NN NN O
and NN NN O
the NN NN O
gene NN NN O
causing NN NN O
Pendred NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
PDS NN NN B-SpecificDisease
) NN NN O
was NN NN O
subsequently NN NN O
identified NN NN O
by NN NN O
positional NN NN O
cloning NN NN O
. NN NN O

PDS NN NN O
encodes NN NN O
a NN NN O
putative NN NN O
transmembrane NN NN O
protein NN NN O
designated NN NN O
pendrin NN NN O
. NN NN O

Pendrin NN NN O
is NN NN O
closely NN NN O
related NN NN O
to NN NN O
a NN NN O
family NN NN O
of NN NN O
sulfate NN NN O
transport NN NN O
proteins NN NN O
that NN NN O
includes NN NN O
the NN NN O
rat NN NN O
sulfate-anion NN NN O
transporter NN NN O
( NN NN O
encoded NN NN O
by NN NN O
Sat-1 NN NN O
; NN NN O
29 NN NN O
% NN NN O
amino NN NN O
acid NN NN O
sequence NN NN O
identity NN NN O
) NN NN O
, NN NN O
the NN NN O
human NN NN O
diastrophic NN NN B-Modifier
dysplasia NN NN I-Modifier
sulfate NN NN O
transporter NN NN O
( NN NN O
encoded NN NN O
by NN NN O
DTD NN NN O
; NN NN O
32 NN NN O
% NN NN O
) NN NN O
and NN NN O
the NN NN O
human NN NN O
sulfate NN NN O
transporter NN NN O
downregulated NN NN O
in NN NN O
adenoma NN NN B-DiseaseClass
( NN NN O
encoded NN NN O
by NN NN O
DRA NN NN O
; NN NN O
45 NN NN O
% NN NN O
) NN NN O
. NN NN O

On NN NN O
the NN NN O
basis NN NN O
of NN NN O
this NN NN O
homology NN NN O
and NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
slightly NN NN O
modified NN NN O
sulfate-transporter NN NN O
signature NN NN O
sequence NN NN O
comprising NN NN O
its NN NN O
putative NN NN O
second NN NN O
transmembrane NN NN O
domain NN NN O
, NN NN O
pendrin NN NN O
has NN NN O
been NN NN O
proposed NN NN O
to NN NN O
function NN NN O
as NN NN O
a NN NN O
sulfate NN NN O
transporter NN NN O
. NN NN O

We NN NN O
were NN NN O
unable NN NN O
to NN NN O
detect NN NN O
evidence NN NN O
of NN NN O
sulfate NN NN O
transport NN NN O
following NN NN O
the NN NN O
expression NN NN O
of NN NN O
pendrin NN NN O
in NN NN O
Xenopus NN NN O
laevis NN NN O
oocytes NN NN O
by NN NN O
microinjection NN NN O
of NN NN O
PDS NN NN O
cRNA NN NN O
or NN NN O
in NN NN O
Sf9 NN NN O
cells NN NN O
following NN NN O
infection NN NN O
with NN NN O
PDS-recombinant NN NN O
baculovirus NN NN O
. NN NN O

The NN NN O
rates NN NN O
of NN NN O
transport NN NN O
for NN NN O
iodide NN NN O
and NN NN O
chloride NN NN O
were NN NN O
significantly NN NN O
increased NN NN O
following NN NN O
the NN NN O
expression NN NN O
of NN NN O
pendrin NN NN O
in NN NN O
both NN NN O
cell NN NN O
systems NN NN O
. NN NN O

Our NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
pendrin NN NN O
functions NN NN O
as NN NN O
a NN NN O
transporter NN NN O
of NN NN O
chloride NN NN O
and NN NN O
iodide NN NN O
, NN NN O
but NN NN O
not NN NN O
sulfate NN NN O
, NN NN O
and NN NN O
may NN NN O
provide NN NN O
insight NN NN O
into NN NN O
thyroid NN NN O
physiology NN NN O
and NN NN O
the NN NN O
pathophysiology NN NN O
of NN NN O
Pendred NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

. NN NN O

10194428 NN NN O
HFE NN NN O
mutations NN NN O
analysis NN NN O
in NN NN O
711 NN NN O
hemochromatosis NN NN B-Modifier
probands NN NN O
: NN NN O
evidence NN NN O
for NN NN O
S65C NN NN O
implication NN NN O
in NN NN O
mild NN NN O
form NN NN O
of NN NN O
hemochromatosis NN NN B-SpecificDisease
. NN NN O

Hereditary NN NN B-SpecificDisease
hemochromatosis NN NN I-SpecificDisease
( NN NN O
HH NN NN B-SpecificDisease
) NN NN O
is NN NN O
a NN NN O
common NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
genetic NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
of NN NN O
iron NN NN O
metabolism NN NN O
. NN NN O

The NN NN O
HFE NN NN O
candidate NN NN O
gene NN NN O
encoding NN NN O
an NN NN O
HLA NN NN O
class NN NN O
I-like NN NN O
protein NN NN O
involved NN NN O
in NN NN O
HH NN NN B-SpecificDisease
was NN NN O
identified NN NN O
in NN NN O
1996 NN NN O
. NN NN O

Two NN NN O
missense NN NN O
mutations NN NN O
have NN NN O
been NN NN O
described NN NN O
C282Y NN NN O
, NN NN O
accounting NN NN O
for NN NN O
80 NN NN O
% NN NN O
to NN NN O
90 NN NN O
% NN NN O
of NN NN O
HH NN NN B-Modifier
chromosomes NN NN O
, NN NN O
and NN NN O
H63D NN NN O
, NN NN O
which NN NN O
is NN NN O
associated NN NN O
with NN NN O
a NN NN O
milder NN NN O
form NN NN O
of NN NN O
the NN NN O
disease NN NN O
representing NN NN O
40 NN NN O
% NN NN O
to NN NN O
70 NN NN O
% NN NN O
of NN NN O
non-C282Y NN NN O
HH NN NN B-Modifier
chromosomes NN NN O
. NN NN O

We NN NN O
report NN NN O
here NN NN O
on NN NN O
the NN NN O
analysis NN NN O
of NN NN O
C282Y NN NN O
, NN NN O
H63D NN NN O
, NN NN O
and NN NN O
the NN NN O
193A NN NN O
-- NN NN O
T NN NN O
substitution NN NN O
leading NN NN O
to NN NN O
the NN NN O
S65C NN NN O
missense NN NN O
substitution NN NN O
in NN NN O
a NN NN O
large NN NN O
series NN NN O
of NN NN O
probands NN NN O
and NN NN O
controls NN NN O
. NN NN O

The NN NN O
results NN NN O
confirm NN NN O
that NN NN O
the NN NN O
C282Y NN NN O
substitution NN NN O
was NN NN O
the NN NN O
main NN NN O
mutation NN NN O
involved NN NN O
in NN NN O
hemochromatosis NN NN B-SpecificDisease
, NN NN O
accounting NN NN O
for NN NN O
85 NN NN O
% NN NN O
of NN NN O
carrier NN NN O
chromosomes NN NN O
, NN NN O
whereas NN NN O
the NN NN O
H63D NN NN O
substitution NN NN O
represented NN NN O
39 NN NN O
% NN NN O
of NN NN O
the NN NN O
HH NN NN B-Modifier
chromosomes NN NN O
that NN NN O
did NN NN O
not NN NN O
carry NN NN O
the NN NN O
C282Y NN NN O
mutation NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
our NN NN O
screening NN NN O
showed NN NN O
that NN NN O
the NN NN O
S65C NN NN O
substitution NN NN O
was NN NN O
significantly NN NN O
enriched NN NN O
in NN NN O
probands NN NN O
with NN NN O
at NN NN O
least NN NN O
one NN NN O
chromosome NN NN O
without NN NN O
an NN NN O
assigned NN NN O
mutation NN NN O
. NN NN O

This NN NN O
substitution NN NN O
accounted NN NN O
for NN NN O
7 NN NN O
. NN NN O

8 NN NN O
% NN NN O
of NN NN O
HH NN NN B-Modifier
chromosomes NN NN O
that NN NN O
were NN NN O
neither NN NN O
C282Y NN NN O
nor NN NN O
H63D NN NN O
. NN NN O

This NN NN O
enrichment NN NN O
of NN NN O
S65C NN NN O
among NN NN O
HH NN NN B-Modifier
chromosomes NN NN O
suggests NN NN O
that NN NN O
the NN NN O
S65C NN NN O
substitution NN NN O
is NN NN O
associated NN NN O
with NN NN O
the NN NN O
mild NN NN O
form NN NN O
of NN NN O
hemochromatosis NN NN B-SpecificDisease
. NN NN O

10196379 NN NN O
Germline NN NN O
BRCA1 NN NN O
alterations NN NN O
in NN NN O
a NN NN O
population-based NN NN O
series NN NN O
of NN NN O
ovarian NN NN B-Modifier
cancer NN NN I-Modifier
cases NN NN O
. NN NN O

The NN NN O
objective NN NN O
of NN NN O
this NN NN O
study NN NN O
was NN NN O
to NN NN O
provide NN NN O
more NN NN O
accurate NN NN O
frequency NN NN O
estimates NN NN O
of NN NN O
breast NN NN B-Modifier
cancer NN NN I-Modifier
susceptibility NN NN O
gene NN NN O
1 NN NN O
( NN NN O
BRCA1 NN NN O
) NN NN O
germline NN NN O
alterations NN NN O
in NN NN O
the NN NN O
ovarian NN NN B-Modifier
cancer NN NN I-Modifier
population NN NN O
. NN NN O

To NN NN O
achieve NN NN O
this NN NN O
, NN NN O
we NN NN O
determined NN NN O
the NN NN O
prevalence NN NN O
of NN NN O
BRCA1 NN NN O
alterations NN NN O
in NN NN O
a NN NN O
population-based NN NN O
series NN NN O
of NN NN O
consecutive NN NN O
ovarian NN NN B-Modifier
cancer NN NN I-Modifier
cases NN NN O
. NN NN O

This NN NN O
is NN NN O
the NN NN O
first NN NN O
population-based NN NN O
ovarian NN NN B-Modifier
cancer NN NN I-Modifier
study NN NN O
reporting NN NN O
BRCA1 NN NN O
alterations NN NN O
derived NN NN O
from NN NN O
a NN NN O
comprehensive NN NN O
screen NN NN O
of NN NN O
the NN NN O
entire NN NN O
coding NN NN O
region NN NN O
. NN NN O

One NN NN O
hundred NN NN O
and NN NN O
seven NN NN O
ovarian NN NN B-Modifier
cancer NN NN I-Modifier
cases NN NN O
were NN NN O
analyzed NN NN O
for NN NN O
BRCA1 NN NN O
alterations NN NN O
using NN NN O
the NN NN O
RNase NN NN O
mismatch NN NN O
cleavage NN NN O
assay NN NN O
followed NN NN O
by NN NN O
direct NN NN O
sequencing NN NN O
. NN NN O

Two NN NN O
truncating NN NN O
mutations NN NN O
, NN NN O
962del4 NN NN O
and NN NN O
3600del11 NN NN O
, NN NN O
were NN NN O
identified NN NN O
. NN NN O

Both NN NN O
patients NN NN O
had NN NN O
a NN NN O
family NN NN O
history NN NN O
of NN NN O
breast NN NN B-CompositeMention
or NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
. NN NN O

Several NN NN O
novel NN NN O
as NN NN O
well NN NN O
as NN NN O
previously NN NN O
reported NN NN O
uncharacterized NN NN O
variants NN NN O
were NN NN O
also NN NN O
identified NN NN O
, NN NN O
some NN NN O
of NN NN O
which NN NN O
were NN NN O
associated NN NN O
with NN NN O
a NN NN O
family NN NN O
history NN NN O
of NN NN O
cancer NN NN B-DiseaseClass
. NN NN O

The NN NN O
frequency NN NN O
distribution NN NN O
of NN NN O
common NN NN O
polymorphisms NN NN O
was NN NN O
determined NN NN O
in NN NN O
the NN NN O
91 NN NN O
Caucasian NN NN O
cancer NN NN B-Modifier
cases NN NN O
in NN NN O
this NN NN O
series NN NN O
and NN NN O
24 NN NN O
sister NN NN O
controls NN NN O
using NN NN O
allele-specific NN NN O
amplification NN NN O
. NN NN O

The NN NN O
rare NN NN O
form NN NN O
of NN NN O
the NN NN O
Q356R NN NN O
polymorphism NN NN O
was NN NN O
significantly NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O

03 NN NN O
) NN NN O
associated NN NN O
with NN NN O
a NN NN O
family NN NN O
history NN NN O
of NN NN O
ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
, NN NN O
suggesting NN NN O
that NN NN O
this NN NN O
polymorphism NN NN O
may NN NN O
influence NN NN O
ovarian NN NN B-Modifier
cancer NN NN I-Modifier
risk NN NN O
. NN NN O

In NN NN O
summary NN NN O
, NN NN O
our NN NN O
data NN NN O
suggest NN NN O
a NN NN O
role NN NN O
for NN NN O
some NN NN O
uncharacterized NN NN O
variants NN NN O
and NN NN O
rare NN NN O
forms NN NN O
of NN NN O
polymorphisms NN NN O
in NN NN O
determining NN NN O
ovarian NN NN B-Modifier
cancer NN NN I-Modifier
risk NN NN O
, NN NN O
and NN NN O
highlight NN NN O
the NN NN O
necessity NN NN O
to NN NN O
screen NN NN O
for NN NN O
missense NN NN O
alterations NN NN O
as NN NN O
well NN NN O
as NN NN O
truncating NN NN O
mutations NN NN O
in NN NN O
this NN NN O
population NN NN O
. NN NN O

10196381 NN NN O
Adrenoleukodystrophy-related NN NN O
protein NN NN O
can NN NN O
compensate NN NN O
functionally NN NN O
for NN NN O
adrenoleukodystrophy NN NN B-SpecificDisease
protein NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
( NN NN O
X-ALD NN NN B-SpecificDisease
) NN NN O
: NN NN O
implications NN NN O
for NN NN O
therapy NN NN O
. NN NN O

Inherited NN NN B-DiseaseClass
defects NN NN I-DiseaseClass
in NN NN O
the NN NN O
peroxisomal NN NN O
ATP-binding NN NN O
cassette NN NN O
( NN NN O
ABC NN NN O
) NN NN O
transporter NN NN O
adrenoleukodystrophy NN NN B-Modifier
protein NN NN O
( NN NN O
ALDP NN NN O
) NN NN O
lead NN NN O
to NN NN O
the NN NN O
lethal NN NN O
peroxisomal NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
X-linked NN NN B-SpecificDisease
adrenoleukodystrophy NN NN I-SpecificDisease
( NN NN O
X-ALD NN NN B-SpecificDisease
) NN NN O
, NN NN O
for NN NN O
which NN NN O
no NN NN O
efficient NN NN O
treatment NN NN O
has NN NN O
been NN NN O
established NN NN O
so NN NN O
far NN NN O
. NN NN O

Three NN NN O
other NN NN O
peroxisomal NN NN O
ABC NN NN O
transporters NN NN O
currently NN NN O
are NN NN O
known NN NN O
adrenoleukodystrophy-related NN NN O
protein NN NN O
( NN NN O
ALDRP NN NN O
) NN NN O
, NN NN O
70 NN NN O
kDa NN NN O
peroxisomal NN NN O
membrane NN NN O
protein NN NN O
( NN NN O
PMP70 NN NN O
) NN NN O
and NN NN O
PMP70- NN NN O
related NN NN O
protein NN NN O
. NN NN O

By NN NN O
using NN NN O
transient NN NN O
and NN NN O
stable NN NN O
overexpression NN NN O
of NN NN O
human NN NN O
cDNAs NN NN O
encoding NN NN O
ALDP NN NN O
and NN NN O
its NN NN O
closest NN NN O
relative NN NN O
ALDRP NN NN O
, NN NN O
we NN NN O
could NN NN O
restore NN NN O
the NN NN O
impaired NN NN O
peroxisomal NN NN O
beta-oxidation NN NN O
in NN NN O
fibroblasts NN NN O
of NN NN O
X-ALD NN NN B-Modifier
patients NN NN O
. NN NN O

The NN NN O
pathognomonic NN NN O
accumulation NN NN O
of NN NN O
very NN NN O
long NN NN O
chain NN NN O
fatty NN NN O
acids NN NN O
could NN NN O
also NN NN O
be NN NN O
prevented NN NN O
by NN NN O
overexpression NN NN O
of NN NN O
ALDRP NN NN O
in NN NN O
immortalized NN NN O
X-ALD NN NN O
cells NN NN O
. NN NN O

Immunofluorescence NN NN O
analysis NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
functional NN NN O
replacement NN NN O
of NN NN O
ALDP NN NN O
by NN NN O
ALDRP NN NN O
was NN NN O
not NN NN O
due NN NN O
to NN NN O
stabilization NN NN O
of NN NN O
the NN NN O
mutated NN NN O
ALDP NN NN O
itself NN NN O
. NN NN O

Moreover NN NN O
, NN NN O
we NN NN O
were NN NN O
able NN NN O
to NN NN O
restore NN NN O
the NN NN O
peroxisomal NN NN O
beta-oxidation NN NN O
defect NN NN O
in NN NN O
the NN NN O
liver NN NN O
of NN NN O
ALDP-deficient NN NN O
mice NN NN O
by NN NN O
stimulation NN NN O
of NN NN O
ALDRP NN NN O
and NN NN O
PMP70 NN NN O
gene NN NN O
expression NN NN O
through NN NN O
a NN NN O
dietary NN NN O
treatment NN NN O
with NN NN O
the NN NN O
peroxisome NN NN O
proliferator NN NN O
fenofibrate NN NN O
. NN NN O

These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
a NN NN O
correction NN NN O
of NN NN O
the NN NN O
biochemical NN NN O
defect NN NN O
in NN NN O
X-ALD NN NN B-SpecificDisease
could NN NN O
be NN NN O
possible NN NN O
by NN NN O
drug-induced NN NN O
overexpression NN NN O
or NN NN O
ectopic NN NN O
expression NN NN O
of NN NN O
ALDRP NN NN O
. NN NN O

. NN NN O

10198641 NN NN O
Centrosome NN NN O
amplification NN NN O
and NN NN O
a NN NN O
defective NN NN O
G2-M NN NN O
cell NN NN O
cycle NN NN O
checkpoint NN NN O
induce NN NN O
genetic NN NN O
instability NN NN O
in NN NN O
BRCA1 NN NN O
exon NN NN O
11 NN NN O
isoform-deficient NN NN O
cells NN NN O
. NN NN O

Germline NN NN O
mutations NN NN O
of NN NN O
the NN NN O
Brca1 NN NN O
tumor NN NN B-Modifier
suppressor NN NN O
gene NN NN O
predispose NN NN O
women NN NN O
to NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancers NN NN I-CompositeMention
. NN NN O

To NN NN O
study NN NN O
mechanisms NN NN O
underlying NN NN O
BRCA1-related NN NN O
tumorigenesis NN NN O
, NN NN O
we NN NN O
derived NN NN O
mouse NN NN O
embryonic NN NN O
fibroblast NN NN O
cells NN NN O
carrying NN NN O
a NN NN O
targeted NN NN O
deletion NN NN O
of NN NN O
exon NN NN O
11 NN NN O
of NN NN O
the NN NN O
Brca1 NN NN O
gene NN NN O
. NN NN O

We NN NN O
show NN NN O
that NN NN O
the NN NN O
mutant NN NN O
cells NN NN O
maintain NN NN O
an NN NN O
intact NN NN O
G1-S NN NN O
cell NN NN O
cycle NN NN O
checkpoint NN NN O
and NN NN O
proliferate NN NN O
poorly NN NN O
. NN NN O

However NN NN O
, NN NN O
a NN NN O
defective NN NN O
G2-M NN NN O
checkpoint NN NN O
in NN NN O
these NN NN O
cells NN NN O
is NN NN O
accompanied NN NN O
by NN NN O
extensive NN NN O
chromosomal NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
. NN NN O

Mutant NN NN O
fibroblasts NN NN O
contain NN NN O
multiple NN NN O
, NN NN O
functional NN NN O
centrosomes NN NN O
, NN NN O
which NN NN O
lead NN NN O
to NN NN O
unequal NN NN O
chromosome NN NN O
segregation NN NN O
, NN NN O
abnormal NN NN O
nuclear NN NN O
division NN NN O
, NN NN O
and NN NN O
aneuploidy NN NN B-SpecificDisease
. NN NN O

These NN NN O
data NN NN O
uncover NN NN O
an NN NN O
essential NN NN O
role NN NN O
of NN NN O
BRCA1 NN NN O
in NN NN O
maintaining NN NN O
genetic NN NN O
stability NN NN O
through NN NN O
the NN NN O
regulation NN NN O
of NN NN O
centrosome NN NN O
duplication NN NN O
and NN NN O
the NN NN O
G2-M NN NN O
checkpoint NN NN O
and NN NN O
provide NN NN O
a NN NN O
molecular NN NN O
basis NN NN O
for NN NN O
the NN NN O
role NN NN O
of NN NN O
BRCA1 NN NN O
in NN NN O
tumorigenesis NN NN O
. NN NN O

. NN NN O

10200300 NN NN O
Defective NN NN O
CD95/APO-1/Fas NN NN O
signal NN NN O
complex NN NN O
formation NN NN O
in NN NN O
the NN NN O
human NN NN O
autoimmune NN NN B-SpecificDisease
lymphoproliferative NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
, NN NN I-SpecificDisease
type NN NN I-SpecificDisease
Ia NN NN I-SpecificDisease
. NN NN O

Heterozygous NN NN O
mutations NN NN O
in NN NN O
the NN NN O
CD95 NN NN O
( NN NN O
APO-1 NN NN O
/ NN NN O
Fas NN NN O
) NN NN O
receptor NN NN O
occur NN NN O
in NN NN O
most NN NN O
individuals NN NN O
with NN NN O
autoimmune NN NN B-SpecificDisease
lymphoproliferative NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
ALPS NN NN B-SpecificDisease
) NN NN O
and NN NN O
dominantly NN NN O
interfere NN NN O
with NN NN O
apoptosis NN NN O
by NN NN O
an NN NN O
unknown NN NN O
mechanism NN NN O
. NN NN O

We NN NN O
show NN NN O
that NN NN O
local NN NN O
or NN NN O
global NN NN O
alterations NN NN O
in NN NN O
the NN NN O
structure NN NN O
of NN NN O
the NN NN O
cytoplasmic NN NN O
death NN NN O
domain NN NN O
from NN NN O
nine NN NN O
independent NN NN O
ALPS NN NN B-Modifier
CD95 NN NN O
death-domain NN NN O
mutations NN NN O
result NN NN O
in NN NN O
a NN NN O
failure NN NN O
to NN NN O
bind NN NN O
the NN NN O
FADD NN NN O
/ NN NN O
MORT1 NN NN O
signaling NN NN O
protein NN NN O
. NN NN O

Despite NN NN O
heterozygosity NN NN O
for NN NN O
the NN NN O
abnormal NN NN O
allele NN NN O
, NN NN O
lymphocytes NN NN O
from NN NN O
ALPS NN NN B-Modifier
patients NN NN O
showed NN NN O
markedly NN NN O
decreased NN NN O
FADD NN NN O
association NN NN O
and NN NN O
a NN NN O
loss NN NN O
of NN NN O
caspase NN NN O
recruitment NN NN O
and NN NN O
activation NN NN O
after NN NN O
CD95 NN NN O
crosslinking NN NN O
. NN NN O

These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
intracytoplasmic NN NN O
CD95 NN NN O
mutations NN NN O
in NN NN O
ALPS NN NN B-SpecificDisease
impair NN NN O
apoptosis NN NN O
chiefly NN NN O
by NN NN O
disrupting NN NN O
death-domain NN NN O
interactions NN NN O
with NN NN O
the NN NN O
signaling NN NN O
protein NN NN O
FADD NN NN O
/ NN NN O
MORT1 NN NN O
. NN NN O

. NN NN O

10205262 NN NN O
Analysis NN NN O
of NN NN O
alkaptonuria NN NN B-Modifier
( NN NN O
AKU NN NN B-Modifier
) NN NN O
mutations NN NN O
and NN NN O
polymorphisms NN NN O
reveals NN NN O
that NN NN O
the NN NN O
CCC NN NN O
sequence NN NN O
motif NN NN O
is NN NN O
a NN NN O
mutational NN NN O
hot NN NN O
spot NN NN O
in NN NN O
the NN NN O
homogentisate NN NN O
1,2 NN NN O
dioxygenase NN NN O
gene NN NN O
( NN NN O
HGO NN NN O
) NN NN O
. NN NN O

We NN NN O
recently NN NN O
showed NN NN O
that NN NN O
alkaptonuria NN NN B-SpecificDisease
( NN NN O
AKU NN NN B-SpecificDisease
) NN NN O
is NN NN O
caused NN NN O
by NN NN O
loss-of-function NN NN O
mutations NN NN O
in NN NN O
the NN NN O
homogentisate NN NN O
1 NN NN O
, NN NN O
2 NN NN O
dioxygenase NN NN O
gene NN NN O
( NN NN O
HGO NN NN O
) NN NN O
. NN NN O

Herein NN NN O
we NN NN O
describe NN NN O
haplotype NN NN O
and NN NN O
mutational NN NN O
analyses NN NN O
of NN NN O
HGO NN NN O
in NN NN O
seven NN NN O
new NN NN O
AKU NN NN B-Modifier
pedigrees NN NN O
. NN NN O

These NN NN O
analyses NN NN O
identified NN NN O
two NN NN O
novel NN NN O
single-nucleotide NN NN O
polymorphisms NN NN O
( NN NN O
INV4 NN NN O
+ NN NN O
31A NN NN O
-- NN NN O
G NN NN O
and NN NN O
INV11 NN NN O
+ NN NN O
18A NN NN O
-- NN NN O
G NN NN O
) NN NN O
and NN NN O
six NN NN O
novel NN NN O
AKU NN NN B-Modifier
mutations NN NN O
( NN NN O
INV1-1G NN NN O
-- NN NN O
A NN NN O
, NN NN O
W60G NN NN O
, NN NN O
Y62C NN NN O
, NN NN O
A122D NN NN O
, NN NN O
P230T NN NN O
, NN NN O
and NN NN O
D291E NN NN O
) NN NN O
, NN NN O
which NN NN O
further NN NN O
illustrates NN NN O
the NN NN O
remarkable NN NN O
allelic NN NN O
heterogeneity NN NN O
found NN NN O
in NN NN O
AKU NN NN B-SpecificDisease
. NN NN O

Reexamination NN NN O
of NN NN O
all NN NN O
29 NN NN O
mutations NN NN O
and NN NN O
polymorphisms NN NN O
thus NN NN O
far NN NN O
described NN NN O
in NN NN O
HGO NN NN O
shows NN NN O
that NN NN O
these NN NN O
nucleotide NN NN O
changes NN NN O
are NN NN O
not NN NN O
randomly NN NN O
distributed NN NN O
; NN NN O
the NN NN O
CCC NN NN O
sequence NN NN O
motif NN NN O
and NN NN O
its NN NN O
inverted NN NN O
complement NN NN O
, NN NN O
GGG NN NN O
, NN NN O
are NN NN O
preferentially NN NN O
mutated NN NN O
. NN NN O

These NN NN O
analyses NN NN O
also NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
nucleotide NN NN O
substitutions NN NN O
in NN NN O
HGO NN NN O
do NN NN O
not NN NN O
involve NN NN O
CpG NN NN O
dinucleotides NN NN O
, NN NN O
which NN NN O
illustrates NN NN O
important NN NN O
differences NN NN O
between NN NN O
HGO NN NN O
and NN NN O
other NN NN O
genes NN NN O
for NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
mutation NN NN O
at NN NN O
specific NN NN O
short-sequence NN NN O
motifs NN NN O
. NN NN O

Because NN NN O
the NN NN O
CCC NN NN O
sequence NN NN O
motifs NN NN O
comprise NN NN O
a NN NN O
significant NN NN O
proportion NN NN O
( NN NN O
34 NN NN O
. NN NN O

5 NN NN O
% NN NN O
) NN NN O
of NN NN O
all NN NN O
mutated NN NN O
bases NN NN O
that NN NN O
have NN NN O
been NN NN O
observed NN NN O
in NN NN O
HGO NN NN O
, NN NN O
we NN NN O
conclude NN NN O
that NN NN O
the NN NN O
CCC NN NN O
triplet NN NN O
is NN NN O
a NN NN O
mutational NN NN O
hot NN NN O
spot NN NN O
in NN NN O
HGO NN NN O
. NN NN O

10208645 NN NN O
Pharmacokinetics NN NN O
of NN NN O
chlorpheniramine NN NN O
, NN NN O
phenytoin NN NN O
, NN NN O
glipizide NN NN O
and NN NN O
nifedipine NN NN O
in NN NN O
an NN NN O
individual NN NN O
homozygous NN NN O
for NN NN O
the NN NN O
CYP2C9 NN NN O
* NN NN O
3 NN NN O
allele NN NN O
. NN NN O

Genetic NN NN O
polymorphisms NN NN O
in NN NN O
the NN NN O
cytochrome NN NN O
P450 NN NN O
( NN NN O
CYP NN NN O
) NN NN O
family NN NN O
are NN NN O
widely NN NN O
known NN NN O
to NN NN O
contribute NN NN O
to NN NN O
interindividual NN NN O
differences NN NN O
in NN NN O
the NN NN O
pharmacokinetics NN NN O
of NN NN O
many NN NN O
drugs NN NN O
. NN NN O

Several NN NN O
alleles NN NN O
for NN NN O
the NN NN O
CYP2C9 NN NN O
gene NN NN O
have NN NN O
been NN NN O
reported NN NN O
. NN NN O

Individuals NN NN O
homozygous NN NN O
for NN NN O
the NN NN O
Leu359 NN NN O
variant NN NN O
( NN NN O
CYP2C9 NN NN O
* NN NN O
3 NN NN O
) NN NN O
have NN NN O
been NN NN O
shown NN NN O
to NN NN O
have NN NN O
significantly NN NN O
lower NN NN O
drug NN NN O
clearances NN NN O
compared NN NN O
with NN NN O
Ile359 NN NN O
( NN NN O
CYP2C9 NN NN O
* NN NN O
1 NN NN O
) NN NN O
homozygous NN NN O
individuals NN NN O
. NN NN O

A NN NN O
male NN NN O
Caucasian NN NN O
who NN NN O
participated NN NN O
in NN NN O
six NN NN O
bioavailability NN NN O
studies NN NN O
in NN NN O
our NN NN O
laboratory NN NN O
over NN NN O
a NN NN O
period NN NN O
of NN NN O
several NN NN O
years NN NN O
showed NN NN O
extremely NN NN O
low NN NN O
clearance NN NN O
of NN NN O
two NN NN O
drugs NN NN O
phenytoin NN NN O
and NN NN O
glipizide NN NN O
( NN NN O
both NN NN O
substrates NN NN O
of NN NN O
CYP2C9 NN NN O
) NN NN O
, NN NN O
but NN NN O
not NN NN O
for NN NN O
nifedipine NN NN O
( NN NN O
a NN NN O
CYP3A4 NN NN O
substrate NN NN O
) NN NN O
and NN NN O
chlorpheniramine NN NN O
( NN NN O
a NN NN O
CYP2D6 NN NN O
substrate NN NN O
) NN NN O
. NN NN O

His NN NN O
oral NN NN O
clearance NN NN O
of NN NN O
phenytoin NN NN O
was NN NN O
21 NN NN O
% NN NN O
of NN NN O
the NN NN O
mean NN NN O
of NN NN O
the NN NN O
other NN NN O
11 NN NN O
individuals NN NN O
participating NN NN O
in NN NN O
the NN NN O
study NN NN O
, NN NN O
and NN NN O
his NN NN O
oral NN NN O
clearance NN NN O
of NN NN O
glipizide NN NN O
, NN NN O
a NN NN O
second NN NN O
generation NN NN O
sulfonylurea NN NN O
structurally NN NN O
similar NN NN O
to NN NN O
tolbutamide NN NN O
, NN NN O
was NN NN O
only NN NN O
188 NN NN O
% NN NN O
of NN NN O
the NN NN O
mean NN NN O
of NN NN O
the NN NN O
other NN NN O
10 NN NN O
individuals NN NN O
. NN NN O

However NN NN O
, NN NN O
his NN NN O
oral NN NN O
clearance NN NN O
of NN NN O
nifedipine NN NN O
and NN NN O
chlorpheniramine NN NN O
did NN NN O
not NN NN O
differ NN NN O
from NN NN O
individuals NN NN O
in NN NN O
other NN NN O
studies NN NN O
performed NN NN O
at NN NN O
our NN NN O
laboratories NN NN O
. NN NN O

An NN NN O
additional NN NN O
blood NN NN O
sample NN NN O
was NN NN O
obtained NN NN O
from NN NN O
this NN NN O
individual NN NN O
to NN NN O
determine NN NN O
if NN NN O
he NN NN O
possessed NN NN O
any NN NN O
of NN NN O
the NN NN O
known NN NN O
CYP2C9 NN NN O
or NN NN O
CYP2C19 NN NN O
allelic NN NN O
variants NN NN O
that NN NN O
would NN NN O
account NN NN O
for NN NN O
his NN NN O
poor NN NN O
clearance NN NN O
of NN NN O
the NN NN O
CYP2C9 NN NN O
substrates NN NN O
( NN NN O
phenytoin NN NN O
and NN NN O
glipizide NN NN O
) NN NN O
compared NN NN O
with NN NN O
the NN NN O
CYP3A4 NN NN O
( NN NN O
nifedipine NN NN O
) NN NN O
and NN NN O
CYP2D6 NN NN O
( NN NN O
chlorpheniramine NN NN O
) NN NN O
substrates NN NN O
. NN NN O

The NN NN O
results NN NN O
of NN NN O
the NN NN O
genotype NN NN O
testing NN NN O
showed NN NN O
that NN NN O
this NN NN O
individual NN NN O
was NN NN O
homozygous NN NN O
for NN NN O
the NN NN O
CYP2C9 NN NN O
* NN NN O
3 NN NN O
allele NN NN O
and NN NN O
did NN NN O
not NN NN O
possess NN NN O
any NN NN O
of NN NN O
the NN NN O
known NN NN O
defective NN NN O
CYP2C19 NN NN O
alleles NN NN O
. NN NN O

This NN NN O
study NN NN O
establishes NN NN O
that NN NN O
the NN NN O
Leu359 NN NN O
mutation NN NN O
is NN NN O
responsible NN NN O
for NN NN O
the NN NN O
phenytoin NN NN O
and NN NN O
glipizide NN NN O
/ NN NN O
tolbutamide NN NN O
poor NN NN O
metabolizer NN NN O
phenotype NN NN O
. NN NN O

. NN NN O

10208848 NN NN O
Fabry NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
: NN NN O
identification NN NN O
of NN NN O
novel NN NN O
alpha-galactosidase NN NN O
A NN NN O
mutations NN NN O
and NN NN O
molecular NN NN O
carrier NN NN O
detection NN NN O
by NN NN O
use NN NN O
of NN NN O
fluorescent NN NN O
chemical NN NN O
cleavage NN NN O
of NN NN O
mismatches NN NN O
. NN NN O

Fabry NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
FD NN NN B-SpecificDisease
) NN NN O
( NN NN O
angiokeratoma NN NN B-SpecificDisease
corporis NN NN I-SpecificDisease
diffusum NN NN I-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
X-linked NN NN B-DiseaseClass
inborn NN NN I-DiseaseClass
error NN NN I-DiseaseClass
of NN NN I-DiseaseClass
glycosphingolipid NN NN I-DiseaseClass
metabolism NN NN I-DiseaseClass
caused NN NN O
by NN NN O
defects NN NN O
in NN NN O
the NN NN O
lysosomal NN NN O
alpha-galactosidase NN NN O
A NN NN O
gene NN NN O
( NN NN O
GLA NN NN O
) NN NN O
. NN NN O

The NN NN O
enzymatic NN NN O
defect NN NN O
leads NN NN O
to NN NN O
the NN NN O
systemic NN NN O
accumulation NN NN O
of NN NN O
neutral NN NN O
glycosphingolipids NN NN O
with NN NN O
terminal NN NN O
alpha-galactosyl NN NN O
moieties NN NN O
. NN NN O

Clinically NN NN O
, NN NN O
affected NN NN O
hemizygous NN NN O
males NN NN O
have NN NN O
angiokeratoma NN NN B-SpecificDisease
, NN NN O
severe NN NN B-SpecificDisease
acroparesthesia NN NN I-SpecificDisease
, NN NN O
renal NN NN B-SpecificDisease
failure NN NN I-SpecificDisease
, NN NN O
and NN NN O
vasculopathy NN NN B-CompositeMention
of NN NN I-CompositeMention
the NN NN I-CompositeMention
heart NN NN I-CompositeMention
and NN NN I-CompositeMention
brain NN NN I-CompositeMention
. NN NN O

While NN NN O
demonstration NN NN O
of NN NN O
alpha-galactosidase NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
leukocytes NN NN O
is NN NN O
diagnostic NN NN O
in NN NN O
affected NN NN O
males NN NN O
, NN NN O
enzymatic NN NN O
detection NN NN O
of NN NN O
female NN NN O
carriers NN NN O
is NN NN O
often NN NN O
inconclusive NN NN O
, NN NN O
due NN NN O
to NN NN O
random NN NN O
X-chromosomal NN NN O
inactivation NN NN O
, NN NN O
underlining NN NN O
the NN NN O
need NN NN O
of NN NN O
molecular NN NN O
investigations NN NN O
for NN NN O
accurate NN NN O
genetic NN NN O
counseling NN NN O
. NN NN O

By NN NN O
use NN NN O
of NN NN O
chemical NN NN O
cleavage NN NN O
of NN NN O
mismatches NN NN O
adapted NN NN O
to NN NN O
fluorescence-based NN NN O
detection NN NN O
systems NN NN O
, NN NN O
we NN NN O
have NN NN O
characterized NN NN O
the NN NN O
mutations NN NN O
underlying NN NN O
alpha-Gal NN NN B-SpecificDisease
A NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
16 NN NN O
individuals NN NN O
from NN NN O
six NN NN O
unrelated NN NN O
families NN NN O
with NN NN O
FD NN NN B-SpecificDisease
. NN NN O

The NN NN O
mutational NN NN O
spectrum NN NN O
included NN NN O
five NN NN O
missense NN NN O
mutations NN NN O
( NN NN O
C202W NN NN O
, NN NN O
C223G NN NN O
, NN NN O
N224D NN NN O
, NN NN O
R301Q NN NN O
, NN NN O
and NN NN O
Q327K NN NN O
) NN NN O
and NN NN O
one NN NN O
splice-site NN NN O
mutation NN NN O
[ NN NN O
IVS3 NN NN O
G NN NN O
( NN NN O
-1 NN NN O
) NN NN O
-- NN NN O
C NN NN O
] NN NN O
. NN NN O

Studies NN NN O
at NN NN O
the NN NN O
mRNA NN NN O
level NN NN O
showed NN NN O
that NN NN O
the NN NN O
latter NN NN O
led NN NN O
to NN NN O
altered NN NN O
pre-mRNA NN NN O
splicing NN NN O
with NN NN O
consequent NN NN O
alteration NN NN O
of NN NN O
the NN NN O
mRNA NN NN O
translational NN NN O
reading NN NN O
frame NN NN O
and NN NN O
generation NN NN O
of NN NN O
a NN NN O
premature NN NN O
termination NN NN O
codon NN NN O
of NN NN O
translation NN NN O
. NN NN O

By NN NN O
use NN NN O
of NN NN O
this NN NN O
strategy NN NN O
, NN NN O
carrier NN NN O
status NN NN O
was NN NN O
accurately NN NN O
assessed NN NN O
in NN NN O
all NN NN O
seven NN NN O
at-risk NN NN O
females NN NN O
tested NN NN O
, NN NN O
whereas NN NN O
enzymatic NN NN O
dosages NN NN O
failed NN NN O
to NN NN O
diagnose NN NN O
or NN NN O
exclude NN NN O
heterozygosity NN NN O
. NN NN O

. NN NN O

10210128 NN NN O
Prenatal NN NN O
diagnosis NN NN O
by NN NN O
FISH NN NN O
in NN NN O
a NN NN O
family NN NN O
with NN NN O
Pelizaeus-Merzbacher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
caused NN NN O
by NN NN O
duplication NN NN O
of NN NN O
PLP NN NN O
gene NN NN O
. NN NN O

A NN NN O
diagnosis NN NN O
of NN NN O
Pelizaeus-Merzbacher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
MIM NN NN O
312080 NN NN O
) NN NN O
was NN NN O
made NN NN O
in NN NN O
a NN NN O
young NN NN O
boy NN NN O
. NN NN O

No NN NN O
mutation NN NN O
in NN NN O
the NN NN O
coding NN NN O
region NN NN O
of NN NN O
the NN NN O
proteolipid NN NN O
protein NN NN O
( NN NN O
PLP NN NN O
) NN NN O
gene NN NN O
had NN NN O
been NN NN O
found NN NN O
. NN NN O

The NN NN O
boys NN NN O
maternal NN NN O
aunt NN NN O
came NN NN O
for NN NN O
prenatal NN NN O
diagnosis NN NN O
when NN NN O
16 NN NN O
+ NN NN O
weeks NN NN O
pregnant NN NN O
and NN NN O
carrying NN NN O
a NN NN O
male NN NN O
fetus NN NN O
. NN NN O

Samples NN NN O
were NN NN O
tested NN NN O
for NN NN O
duplication NN NN O
of NN NN O
the NN NN O
PLP NN NN O
gene NN NN O
, NN NN O
by NN NN O
interphase NN NN O
FISH NN NN O
, NN NN O
in NN NN O
lymphocyte NN NN O
preparations NN NN O
from NN NN O
the NN NN O
proband NN NN O
, NN NN O
his NN NN O
aunt NN NN O
and NN NN O
an NN NN O
amniotic NN NN O
fluid NN NN O
cell NN NN O
preparation NN NN O
from NN NN O
the NN NN O
fetus NN NN O
. NN NN O

The NN NN O
proband NN NN O
was NN NN O
found NN NN O
to NN NN O
carry NN NN O
the NN NN O
duplication NN NN O
, NN NN O
thus NN NN O
confirming NN NN O
the NN NN O
diagnosis NN NN O
of NN NN O
Pelizaeus NN NN B-SpecificDisease
Merzbacher NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
, NN NN O
but NN NN O
neither NN NN O
the NN NN O
aunt NN NN O
nor NN NN O
the NN NN O
fetus NN NN O
carried NN NN O
a NN NN O
duplication NN NN O
. NN NN O

. NN NN O

10213492 NN NN O
Dominant NN NN O
negative NN NN O
effect NN NN O
of NN NN O
the NN NN O
APC1309 NN NN O
mutation NN NN O
: NN NN O
a NN NN O
possible NN NN O
explanation NN NN O
for NN NN O
genotype-phenotype NN NN O
correlations NN NN O
in NN NN O
familial NN NN B-SpecificDisease
adenomatous NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
. NN NN O

Inactivation NN NN O
of NN NN O
the NN NN O
adenomatous NN NN B-Modifier
polyposis NN NN I-Modifier
coli NN NN I-Modifier
( NN NN O
APC NN NN B-Modifier
) NN NN O
gene NN NN O
product NN NN O
initiates NN NN O
colorectal NN NN O
tumorigenesis NN NN O
. NN NN O

Patients NN NN O
with NN NN O
familial NN NN B-SpecificDisease
APC NN NN I-SpecificDisease
( NN NN O
FAP NN NN B-SpecificDisease
) NN NN O
carry NN NN O
germ-line NN NN O
mutations NN NN O
in NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
and NN NN O
develop NN NN O
multiple NN NN O
colorectal NN NN B-SpecificDisease
adenomas NN NN I-SpecificDisease
and NN NN O
subsequent NN NN O
carcinomas NN NN B-DiseaseClass
early NN NN O
in NN NN O
life NN NN O
. NN NN O

The NN NN O
severity NN NN O
of NN NN O
the NN NN O
disease NN NN O
correlates NN NN O
with NN NN O
the NN NN O
position NN NN O
of NN NN O
the NN NN O
inherited NN NN O
APC NN NN B-Modifier
mutation NN NN O
( NN NN O
genotype-phenotype NN NN O
correlation NN NN O
) NN NN O
. NN NN O

Together NN NN O
with NN NN O
the NN NN O
fact NN NN O
that NN NN O
both NN NN O
germ-line NN NN O
and NN NN O
sporadic NN NN O
APC NN NN B-Modifier
mutations NN NN O
cluster NN NN O
in NN NN O
the NN NN O
central NN NN O
region NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
, NN NN O
this NN NN O
points NN NN O
to NN NN O
a NN NN O
dominant NN NN O
negative NN NN O
effect NN NN O
of NN NN O
certain NN NN O
APC NN NN B-Modifier
mutants NN NN O
. NN NN O

Loss NN NN O
of NN NN O
APC NN NN B-Modifier
function NN NN O
was NN NN O
recently NN NN O
shown NN NN O
to NN NN O
result NN NN O
in NN NN O
enhanced NN NN O
beta-catenin- NN NN O
/ NN NN O
Tcf-mediated NN NN O
transcription NN NN O
in NN NN O
colon NN NN O
epithelial NN NN O
cells NN NN O
. NN NN O

Here NN NN O
, NN NN O
we NN NN O
provide NN NN O
experimental NN NN O
evidence NN NN O
for NN NN O
a NN NN O
dominant NN NN O
negative NN NN O
effect NN NN O
of NN NN O
APC NN NN B-Modifier
gene NN NN O
products NN NN O
associated NN NN O
with NN NN O
severe NN NN O
polyposis NN NN B-SpecificDisease
. NN NN O

Wild-type NN NN O
APC NN NN B-Modifier
activity NN NN O
in NN NN O
beta-catenin- NN NN O
/ NN NN O
Tcf-mediated NN NN O
transcription NN NN O
was NN NN O
strongly NN NN O
inhibited NN NN O
by NN NN O
a NN NN O
mutant NN NN O
APC NN NN B-Modifier
that NN NN O
is NN NN O
truncated NN NN O
at NN NN O
codon NN NN O
1309 NN NN O
. NN NN O

In NN NN O
contrast NN NN O
, NN NN O
mutant NN NN O
APC NN NN B-Modifier
gene NN NN O
products NN NN O
that NN NN O
are NN NN O
associated NN NN O
with NN NN O
attenuated NN NN B-SpecificDisease
polyposis NN NN I-SpecificDisease
( NN NN O
codon NN NN O
386 NN NN O
or NN NN O
1465 NN NN O
) NN NN O
interfered NN NN O
only NN NN O
weakly NN NN O
with NN NN O
wild-type NN NN O
APC NN NN B-Modifier
activity NN NN O
. NN NN O

These NN NN O
results NN NN O
suggest NN NN O
a NN NN O
molecular NN NN O
explanation NN NN O
for NN NN O
the NN NN O
genotype-phenotype NN NN O
correlation NN NN O
in NN NN O
FAP NN NN B-Modifier
patients NN NN O
and NN NN O
support NN NN O
the NN NN O
idea NN NN O
that NN NN O
colorectal NN NN B-Modifier
tumor NN NN I-Modifier
growth NN NN O
might NN NN O
be NN NN O
, NN NN O
in NN NN O
part NN NN O
, NN NN O
driven NN NN O
by NN NN O
selection NN NN O
for NN NN O
a NN NN O
mutation NN NN O
in NN NN O
the NN NN O
mutation NN NN O
cluster NN NN O
region NN NN O
. NN NN O

. NN NN O

10220405 NN NN O
BRCA1 NN NN O
interacts NN NN O
with NN NN O
components NN NN O
of NN NN O
the NN NN O
histone NN NN O
deacetylase NN NN O
complex NN NN O
. NN NN O

Germ-line NN NN O
mutations NN NN O
in NN NN O
the NN NN O
BRCA1 NN NN O
tumor-suppressor NN NN O
gene NN NN O
are NN NN O
associated NN NN O
with NN NN O
an NN NN O
increased NN NN O
susceptibility NN NN O
to NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
. NN NN O

BRCA1 NN NN O
contains NN NN O
a NN NN O
carboxyl-terminal NN NN O
domain NN NN O
( NN NN O
BRCT NN NN O
) NN NN O
that NN NN O
is NN NN O
shared NN NN O
with NN NN O
several NN NN O
other NN NN O
proteins NN NN O
involved NN NN O
in NN NN O
maintaining NN NN O
genome NN NN O
integrity NN NN O
. NN NN O

In NN NN O
an NN NN O
effort NN NN O
to NN NN O
understand NN NN O
the NN NN O
function NN NN O
of NN NN O
BRCA1 NN NN O
, NN NN O
we NN NN O
sought NN NN O
to NN NN O
isolate NN NN O
proteins NN NN O
that NN NN O
interact NN NN O
with NN NN O
the NN NN O
BRCT NN NN O
domain NN NN O
. NN NN O

Purified NN NN O
BRCT NN NN O
polypeptide NN NN O
was NN NN O
used NN NN O
as NN NN O
a NN NN O
probe NN NN O
to NN NN O
screen NN NN O
a NN NN O
human NN NN O
placenta NN NN O
cDNA NN NN O
expression NN NN O
library NN NN O
by NN NN O
Far NN NN O
Western NN NN O
analysis NN NN O
. NN NN O

Here NN NN O
we NN NN O
report NN NN O
that NN NN O
BRCA1 NN NN O
interacts NN NN O
in NN NN O
vivo NN NN O
and NN NN O
in NN NN O
vitro NN NN O
with NN NN O
the NN NN O
Rb-binding NN NN O
proteins NN NN O
, NN NN O
RbAp46 NN NN O
and NN NN O
RbAp48 NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
with NN NN O
Rb NN NN O
. NN NN O

Moreover NN NN O
, NN NN O
the NN NN O
BRCT NN NN O
domain NN NN O
associates NN NN O
with NN NN O
the NN NN O
histone NN NN O
deacetylases NN NN O
HDAC1 NN NN O
and NN NN O
HDAC2 NN NN O
. NN NN O

These NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
BRCA1 NN NN O
interacts NN NN O
with NN NN O
components NN NN O
of NN NN O
the NN NN O
histone NN NN O
deacetylase NN NN O
complex NN NN O
, NN NN O
and NN NN O
therefore NN NN O
may NN NN O
explain NN NN O
the NN NN O
involvement NN NN O
of NN NN O
BRCA1 NN NN O
in NN NN O
multiple NN NN O
processes NN NN O
such NN NN O
as NN NN O
transcription NN NN O
, NN NN O
DNA NN NN O
repair NN NN O
, NN NN O
and NN NN O
recombination NN NN O
. NN NN O

. NN NN O

102474 NN NN O
Combined NN NN B-CompositeMention
genetic NN NN I-CompositeMention
deficiency NN NN I-CompositeMention
of NN NN I-CompositeMention
C6 NN NN I-CompositeMention
and NN NN I-CompositeMention
C7 NN NN I-CompositeMention
in NN NN O
man NN NN O
. NN NN O

By NN NN O
routine NN NN O
screening NN NN O
of NN NN O
sera NN NN O
, NN NN O
a NN NN O
subject NN NN O
was NN NN O
discovered NN NN O
who NN NN O
showed NN NN O
a NN NN O
sub-total NN NN B-CompositeMention
deficiency NN NN I-CompositeMention
of NN NN I-CompositeMention
C6 NN NN I-CompositeMention
and NN NN I-CompositeMention
C7 NN NN I-CompositeMention
. NN NN O

No NN NN O
clinical NN NN O
disease NN NN O
was NN NN O
associated NN NN O
with NN NN O
this NN NN O
deficiency NN NN O
which NN NN O
was NN NN O
transmitted NN NN O
through NN NN O
the NN NN O
subjects NN NN O
family NN NN O
as NN NN O
a NN NN O
single NN NN O
genetic NN NN O
characteristic NN NN O
, NN NN O
the NN NN O
C6 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
being NN NN O
associated NN NN O
with NN NN O
a NN NN O
silent NN NN O
allele NN NN O
at NN NN O
the NN NN O
structural NN NN O
locus NN NN O
. NN NN O

The NN NN O
propositus NN NN O
was NN NN O
found NN NN O
to NN NN O
have NN NN O
low NN NN O
quantities NN NN O
of NN NN O
an NN NN O
abnormal NN NN O
C6 NN NN O
which NN NN O
was NN NN O
both NN NN O
antigenically NN NN O
deficient NN NN O
and NN NN O
smaller NN NN O
in NN NN O
size NN NN O
than NN NN O
normal NN NN O
C6 NN NN O
( NN NN O
110 NN NN O
, NN NN O
000 NN NN O
daltons NN NN O
compared NN NN O
with NN NN O
140 NN NN O
, NN NN O
000 NN NN O
daltons NN NN O
) NN NN O
and NN NN O
small NN NN O
quantities NN NN O
of NN NN O
apparently NN NN O
normal NN NN O
C7 NN NN O
. NN NN O

It NN NN O
is NN NN O
concluded NN NN O
that NN NN O
the NN NN O
most NN NN O
likely NN NN O
explanation NN NN O
for NN NN O
this NN NN O
defect NN NN O
is NN NN O
that NN NN O
the NN NN O
subject NN NN O
has NN NN O
a NN NN O
structural NN NN O
mutation NN NN O
in NN NN O
his NN NN O
C6 NN NN O
gene NN NN O
which NN NN O
produces NN NN O
hyopsynthesis NN NN O
not NN NN O
only NN NN O
of NN NN O
C6 NN NN O
but NN NN O
also NN NN O
of NN NN O
the NN NN O
closely NN NN O
linked NN NN O
gene NN NN O
for NN NN O
C7 NN NN O
. NN NN O

These NN NN O
findings NN NN O
suggest NN NN O
the NN NN O
possibility NN NN O
that NN NN O
C6 NN NN O
and NN NN O
C7 NN NN O
may NN NN O
function NN NN O
as NN NN O
a NN NN O
single NN NN O
genetic NN NN O
unit NN NN O
and NN NN O
that NN NN O
the NN NN O
primary NN NN O
transcript NN NN O
copied NN NN O
from NN NN O
the NN NN O
genome NN NN O
includes NN NN O
information NN NN O
for NN NN O
both NN NN O
proteins NN NN O
. NN NN O

. NN NN O

10323252 NN NN O
Changes NN NN O
at NN NN O
P183 NN NN O
of NN NN O
emerin NN NN O
weaken NN NN O
its NN NN O
protein-protein NN NN O
interactions NN NN O
resulting NN NN O
in NN NN O
X-linked NN NN B-SpecificDisease
Emery-Dreifuss NN NN I-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
. NN NN O

Emery-Dreifuss NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
EDMD NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
X-linked NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
muscular NN NN I-DiseaseClass
dystrophy NN NN I-DiseaseClass
characterized NN NN O
by NN NN O
early NN NN O
contractures NN NN B-CompositeMention
of NN NN I-CompositeMention
the NN NN I-CompositeMention
elbows NN NN I-CompositeMention
, NN NN I-CompositeMention
Achilles NN NN I-CompositeMention
tendons NN NN I-CompositeMention
and NN NN I-CompositeMention
spine NN NN I-CompositeMention
, NN NN O
slowly NN NN O
progressive NN NN O
muscle NN NN B-DiseaseClass
wasting NN NN I-DiseaseClass
and NN NN O
weakness NN NN B-DiseaseClass
, NN NN O
and NN NN O
cardiomyopathy NN NN B-SpecificDisease
associated NN NN O
with NN NN O
cardiac NN NN B-SpecificDisease
conduction NN NN I-SpecificDisease
defects NN NN I-SpecificDisease
. NN NN O

The NN NN O
emerin NN NN O
gene NN NN O
has NN NN O
been NN NN O
mapped NN NN O
to NN NN O
Xq28 NN NN O
and NN NN O
encodes NN NN O
a NN NN O
34-kDa NN NN O
serine-rich NN NN O
protein NN NN O
, NN NN O
emerin NN NN O
, NN NN O
which NN NN O
has NN NN O
been NN NN O
localized NN NN O
to NN NN O
the NN NN O
nuclear NN NN O
envelope NN NN O
in NN NN O
a NN NN O
wide NN NN O
variety NN NN O
of NN NN O
tissues NN NN O
, NN NN O
including NN NN O
skeletal NN NN O
and NN NN O
cardiac NN NN O
muscle NN NN O
. NN NN O

Mutations NN NN O
spanning NN NN O
the NN NN O
emerin NN NN O
gene NN NN O
have NN NN O
been NN NN O
identified NN NN O
in NN NN O
patients NN NN O
with NN NN O
EDMD NN NN B-SpecificDisease
. NN NN O

We NN NN O
present NN NN O
here NN NN O
the NN NN O
effect NN NN O
, NN NN O
on NN NN O
emerin NN NN O
protein NN NN O
expression NN NN O
, NN NN O
of NN NN O
two NN NN O
missense NN NN O
mutations NN NN O
identified NN NN O
in NN NN O
unrelated NN NN O
EDMD NN NN B-Modifier
patients NN NN O
. NN NN O

These NN NN O
alterations NN NN O
predict NN NN O
the NN NN O
replacement NN NN O
of NN NN O
a NN NN O
proline NN NN O
residue NN NN O
at NN NN O
position NN NN O
183 NN NN O
with NN NN O
either NN NN O
a NN NN O
histidine NN NN O
or NN NN O
a NN NN O
threonine NN NN O
. NN NN O

Biochemical NN NN O
analysis NN NN O
has NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
mobility NN NN O
and NN NN O
expression NN NN O
levels NN NN O
of NN NN O
the NN NN O
mutant NN NN O
forms NN NN O
of NN NN O
emerin NN NN O
are NN NN O
indistinguishable NN NN O
from NN NN O
that NN NN O
of NN NN O
wild-type NN NN O
emerin NN NN O
, NN NN O
but NN NN O
that NN NN O
they NN NN O
have NN NN O
weakened NN NN O
interactions NN NN O
with NN NN O
nuclear NN NN O
lamina NN NN O
components NN NN O
. NN NN O

In NN NN O
comparison NN NN O
with NN NN O
the NN NN O
usual NN NN O
EDMD NN NN B-Modifier
phenotype NN NN O
, NN NN O
patients NN NN O
with NN NN O
P183 NN NN O
missense NN NN O
mutations NN NN O
have NN NN O
a NN NN O
later NN NN O
age NN NN O
at NN NN O
onset NN NN O
of NN NN O
first NN NN O
symptoms NN NN O
, NN NN O
elbow NN NN B-SpecificDisease
contractures NN NN I-SpecificDisease
, NN NN O
ankle NN NN B-SpecificDisease
contractures NN NN I-SpecificDisease
, NN NN O
upper NN NN B-SpecificDisease
limb NN NN I-SpecificDisease
weakness NN NN I-SpecificDisease
and NN NN O
lower NN NN B-SpecificDisease
limb NN NN I-SpecificDisease
weakness NN NN I-SpecificDisease
, NN NN O
but NN NN O
there NN NN O
is NN NN O
no NN NN O
difference NN NN O
for NN NN O
the NN NN O
age NN NN O
at NN NN O
onset NN NN O
of NN NN O
cardiac NN NN B-DiseaseClass
involvement NN NN I-DiseaseClass
. NN NN O

This NN NN O
is NN NN O
the NN NN O
first NN NN O
report NN NN O
of NN NN O
protein NN NN O
studies NN NN O
on NN NN O
patients NN NN O
with NN NN O
missense NN NN O
mutations NN NN O
resulting NN NN O
in NN NN O
the NN NN O
clinical NN NN O
features NN NN O
of NN NN O
EDMD NN NN B-SpecificDisease
. NN NN O

These NN NN O
studies NN NN O
demonstrate NN NN O
the NN NN O
importance NN NN O
of NN NN O
proline NN NN O
183 NN NN O
for NN NN O
the NN NN O
proper NN NN O
structure NN NN O
/ NN NN O
function NN NN O
of NN NN O
emerin NN NN O
. NN NN O

. NN NN O

10323740 NN NN O
Microdeletions NN NN O
at NN NN O
chromosome NN NN O
bands NN NN O
1q32-q41 NN NN O
as NN NN O
a NN NN O
cause NN NN O
of NN NN O
Van NN NN B-SpecificDisease
der NN NN I-SpecificDisease
Woude NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

Van NN NN B-SpecificDisease
der NN NN I-SpecificDisease
Woude NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
VWS NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
dominant NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
comprising NN NN O
cleft NN NN B-SpecificDisease
lip NN NN I-SpecificDisease
and NN NN O
/ NN NN O
or NN NN O
cleft NN NN B-SpecificDisease
palate NN NN I-SpecificDisease
and NN NN O
lip NN NN B-SpecificDisease
pits NN NN I-SpecificDisease
. NN NN O

We NN NN O
reported NN NN O
previously NN NN O
a NN NN O
family NN NN O
whose NN NN O
underlying NN NN O
mutation NN NN O
is NN NN O
a NN NN O
500-800 NN NN O
kb NN NN O
deletion NN NN O
localized NN NN O
to NN NN O
chromosome NN NN O
bands NN NN O
1q32-q41 NN NN O
[ NN NN O
Sander NN NN O
et NN NN O
al NN NN O
. NN NN O

, NN NN O
1994 NN NN O
Hum NN NN O
Mol NN NN O
Genet NN NN O
3 NN NN O
576-578 NN NN O
] NN NN O
. NN NN O

Along NN NN O
with NN NN O
cleft NN NN B-CompositeMention
lip NN NN I-CompositeMention
/ NN NN I-CompositeMention
palate NN NN I-CompositeMention
and NN NN O
lip NN NN B-SpecificDisease
pits NN NN I-SpecificDisease
, NN NN O
affected NN NN O
relatives NN NN O
exhibit NN NN O
developmental NN NN B-DiseaseClass
delays NN NN I-DiseaseClass
, NN NN O
suggesting NN NN O
that NN NN O
the NN NN O
function NN NN O
of NN NN O
a NN NN O
gene NN NN O
nearby NN NN O
may NN NN O
also NN NN O
be NN NN O
disrupted NN NN O
. NN NN O

To NN NN O
further NN NN O
localize NN NN O
the NN NN O
VWS NN NN B-Modifier
gene NN NN O
we NN NN O
searched NN NN O
for NN NN O
other NN NN O
deletions NN NN O
that NN NN O
cause NN NN O
VWS NN NN B-SpecificDisease
. NN NN O

An NN NN O
allele NN NN O
loss NN NN O
assay NN NN O
was NN NN O
performed NN NN O
using NN NN O
a NN NN O
novel NN NN O
highly NN NN O
polymorphic NN NN O
marker NN NN O
, NN NN O
D1S3753 NN NN O
. NN NN O

From NN NN O
a NN NN O
panel NN NN O
of NN NN O
37 NN NN O
unrelated NN NN O
individuals NN NN O
, NN NN O
we NN NN O
detected NN NN O
an NN NN O
allele NN NN O
loss NN NN O
in NN NN O
one NN NN O
family NN NN O
, NN NN O
indicating NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
deletion NN NN O
. NN NN O

In NN NN O
this NN NN O
family NN NN O
, NN NN O
the NN NN O
phenotype NN NN O
in NN NN O
three NN NN O
generations NN NN O
of NN NN O
affected NN NN O
individuals NN NN O
was NN NN O
confined NN NN O
to NN NN O
the NN NN O
cardinal NN NN O
signs NN NN O
of NN NN O
VWS NN NN B-SpecificDisease
. NN NN O

Surprisingly NN NN O
, NN NN O
mapping NN NN O
of NN NN O
the NN NN O
new NN NN O
deletion NN NN O
showed NN NN O
that NN NN O
it NN NN O
extended NN NN O
0 NN NN O
. NN NN O

2-1 NN NN O
Mb NN NN O
beyond NN NN O
the NN NN O
proximal NN NN O
breakpoint NN NN O
for NN NN O
the NN NN O
deletion NN NN O
described NN NN O
previously NN NN O
. NN NN O

No NN NN O
deletions NN NN O
were NN NN O
detected NN NN O
in NN NN O
seven NN NN O
cases NN NN O
of NN NN O
popliteal NN NN B-SpecificDisease
pterygia NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
, NN NN O
76 NN NN O
cases NN NN O
of NN NN O
mixed NN NN O
syndromic NN NN B-CompositeMention
forms NN NN I-CompositeMention
of NN NN I-CompositeMention
cleft NN NN I-CompositeMention
lip NN NN I-CompositeMention
and NN NN I-CompositeMention
palate NN NN I-CompositeMention
, NN NN O
and NN NN O
178 NN NN O
cases NN NN O
of NN NN O
nonsyndromic NN NN B-CompositeMention
cleft NN NN I-CompositeMention
lip NN NN I-CompositeMention
and NN NN I-CompositeMention
palate NN NN I-CompositeMention
. NN NN O

10330348 NN NN O
Splicing NN NN O
defects NN NN O
in NN NN O
the NN NN O
ataxia-telangiectasia NN NN B-Modifier
gene NN NN O
, NN NN O
ATM NN NN O
: NN NN O
underlying NN NN O
mutations NN NN O
and NN NN O
consequences NN NN O
. NN NN O

Mutations NN NN O
resulting NN NN O
in NN NN O
defective NN NN O
splicing NN NN O
constitute NN NN O
a NN NN O
significant NN NN O
proportion NN NN O
( NN NN O
30 NN NN O
/ NN NN O
62 NN NN O
[ NN NN O
48 NN NN O
% NN NN O
] NN NN O
) NN NN O
of NN NN O
a NN NN O
new NN NN O
series NN NN O
of NN NN O
mutations NN NN O
in NN NN O
the NN NN O
ATM NN NN O
gene NN NN O
in NN NN O
patients NN NN O
with NN NN O
ataxia-telangiectasia NN NN B-SpecificDisease
( NN NN O
AT NN NN B-SpecificDisease
) NN NN O
that NN NN O
were NN NN O
detected NN NN O
by NN NN O
the NN NN O
protein-truncation NN NN O
assay NN NN O
followed NN NN O
by NN NN O
sequence NN NN O
analysis NN NN O
of NN NN O
genomic NN NN O
DNA NN NN O
. NN NN O

Fewer NN NN O
than NN NN O
half NN NN O
of NN NN O
the NN NN O
splicing NN NN O
mutations NN NN O
involved NN NN O
the NN NN O
canonical NN NN O
AG NN NN O
splice-acceptor NN NN O
site NN NN O
or NN NN O
GT NN NN O
splice-donor NN NN O
site NN NN O
. NN NN O

A NN NN O
higher NN NN O
percentage NN NN O
of NN NN O
mutations NN NN O
occurred NN NN O
at NN NN O
less NN NN O
stringently NN NN O
conserved NN NN O
sites NN NN O
, NN NN O
including NN NN O
silent NN NN O
mutations NN NN O
of NN NN O
the NN NN O
last NN NN O
nucleotide NN NN O
of NN NN O
exons NN NN O
, NN NN O
mutations NN NN O
in NN NN O
nucleotides NN NN O
other NN NN O
than NN NN O
the NN NN O
conserved NN NN O
AG NN NN O
and NN NN O
GT NN NN O
in NN NN O
the NN NN O
consensus NN NN O
splice NN NN O
sites NN NN O
, NN NN O
and NN NN O
creation NN NN O
of NN NN O
splice-acceptor NN NN O
or NN NN O
splice-donor NN NN O
sites NN NN O
in NN NN O
either NN NN O
introns NN NN O
or NN NN O
exons NN NN O
. NN NN O

These NN NN O
splicing NN NN O
mutations NN NN O
led NN NN O
to NN NN O
a NN NN O
variety NN NN O
of NN NN O
consequences NN NN O
, NN NN O
including NN NN O
exon NN NN O
skipping NN NN O
and NN NN O
, NN NN O
to NN NN O
a NN NN O
lesser NN NN O
degree NN NN O
, NN NN O
intron NN NN O
retention NN NN O
, NN NN O
activation NN NN O
of NN NN O
cryptic NN NN O
splice NN NN O
sites NN NN O
, NN NN O
or NN NN O
creation NN NN O
of NN NN O
new NN NN O
splice NN NN O
sites NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
5 NN NN O
of NN NN O
12 NN NN O
nonsense NN NN O
mutations NN NN O
and NN NN O
1 NN NN O
missense NN NN O
mutation NN NN O
were NN NN O
associated NN NN O
with NN NN O
deletion NN NN O
in NN NN O
the NN NN O
cDNA NN NN O
of NN NN O
the NN NN O
exons NN NN O
in NN NN O
which NN NN O
the NN NN O
mutations NN NN O
occurred NN NN O
. NN NN O

No NN NN O
ATM NN NN O
protein NN NN O
was NN NN O
detected NN NN O
by NN NN O
western NN NN O
blotting NN NN O
in NN NN O
any NN NN O
AT NN NN B-Modifier
cell NN NN O
line NN NN O
in NN NN O
which NN NN O
splicing NN NN O
mutations NN NN O
were NN NN O
identified NN NN O
. NN NN O

Several NN NN O
cases NN NN O
of NN NN O
exon NN NN O
skipping NN NN O
in NN NN O
both NN NN O
normal NN NN O
controls NN NN O
and NN NN O
patients NN NN O
for NN NN O
whom NN NN O
no NN NN O
underlying NN NN O
defect NN NN O
could NN NN O
be NN NN O
found NN NN O
in NN NN O
genomic NN NN O
DNA NN NN O
were NN NN O
also NN NN O
observed NN NN O
, NN NN O
suggesting NN NN O
caution NN NN O
in NN NN O
the NN NN O
interpretation NN NN O
of NN NN O
exon NN NN O
deletions NN NN O
observed NN NN O
in NN NN O
ATM NN NN O
cDNA NN NN O
when NN NN O
there NN NN O
is NN NN O
no NN NN O
accompanying NN NN O
identification NN NN O
of NN NN O
genomic NN NN O
mutations NN NN O
. NN NN O

. NN NN O

10330430 NN NN O
Alpha-cardiac NN NN O
actin NN NN O
is NN NN O
a NN NN O
novel NN NN O
disease NN NN O
gene NN NN O
in NN NN O
familial NN NN B-SpecificDisease
hypertrophic NN NN I-SpecificDisease
cardiomyopathy NN NN I-SpecificDisease
. NN NN O

We NN NN O
identified NN NN O
the NN NN O
alpha-cardiac NN NN O
actin NN NN O
gene NN NN O
( NN NN O
ACTC NN NN O
) NN NN O
as NN NN O
a NN NN O
novel NN NN O
disease NN NN O
gene NN NN O
in NN NN O
a NN NN O
pedigree NN NN O
suffering NN NN O
from NN NN O
familial NN NN B-SpecificDisease
hypertrophic NN NN I-SpecificDisease
cardiomyopathy NN NN I-SpecificDisease
( NN NN O
FHC NN NN B-SpecificDisease
) NN NN O
. NN NN O

Linkage NN NN O
analyses NN NN O
excluded NN NN O
all NN NN O
the NN NN O
previously NN NN O
reported NN NN O
FHC NN NN B-Modifier
loci NN NN O
as NN NN O
possible NN NN O
disease NN NN O
loci NN NN O
in NN NN O
the NN NN O
family NN NN O
studied NN NN O
, NN NN O
with NN NN O
lod NN NN O
scores NN NN O
varying NN NN O
between NN NN O
-2 NN NN O
. NN NN O

5 NN NN O
and NN NN O
-6 NN NN O
. NN NN O

0 NN NN O
0 NN NN O
. NN NN O

Further NN NN O
linkage NN NN O
analyses NN NN O
of NN NN O
plausible NN NN O
candidate NN NN O
genes NN NN O
highly NN NN O
expressed NN NN O
in NN NN O
the NN NN O
adult NN NN O
human NN NN O
heart NN NN O
identified NN NN O
ACTC NN NN O
as NN NN O
the NN NN O
most NN NN O
likely NN NN O
disease NN NN O
gene NN NN O
, NN NN O
showing NN NN O
a NN NN O
maximal NN NN O
lod NN NN O
score NN NN O
of NN NN O
3 NN NN O
. NN NN O

6 NN NN O
6 NN NN O
. NN NN O

Mutation NN NN O
analysis NN NN O
of NN NN O
ACTC NN NN O
revealed NN NN O
an NN NN O
Ala295Ser NN NN O
mutation NN NN O
in NN NN O
exon NN NN O
5 NN NN O
close NN NN O
to NN NN O
2 NN NN O
missense NN NN O
mutations NN NN O
recently NN NN O
described NN NN O
to NN NN O
cause NN NN O
the NN NN O
inherited NN NN O
form NN NN O
of NN NN O
idiopathic NN NN B-SpecificDisease
dilated NN NN I-SpecificDisease
cardiomyopathy NN NN I-SpecificDisease
( NN NN O
IDC NN NN B-SpecificDisease
) NN NN O
. NN NN O

10353787 NN NN O
Overgrowth NN NN B-CompositeMention
of NN NN I-CompositeMention
oral NN NN I-CompositeMention
mucosa NN NN I-CompositeMention
and NN NN I-CompositeMention
facial NN NN I-CompositeMention
skin NN NN I-CompositeMention
, NN NN O
a NN NN O
novel NN NN O
feature NN NN O
of NN NN O
aspartylglucosaminuria NN NN B-SpecificDisease
. NN NN O

Aspartylglucosaminuria NN NN B-SpecificDisease
( NN NN O
AGU NN NN B-SpecificDisease
) NN NN O
is NN NN O
a NN NN O
lysosomal NN NN B-DiseaseClass
storage NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
caused NN NN O
by NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
aspartylglucosaminidase NN NN I-SpecificDisease
( NN NN O
AGA NN NN O
) NN NN O
. NN NN O

The NN NN O
main NN NN O
symptom NN NN O
is NN NN O
progressive NN NN O
mental NN NN B-DiseaseClass
retardation NN NN I-DiseaseClass
. NN NN O

A NN NN O
spectrum NN NN O
of NN NN O
different NN NN O
mutations NN NN O
has NN NN O
been NN NN O
reported NN NN O
in NN NN O
this NN NN O
disease NN NN O
, NN NN O
one NN NN O
missense NN NN O
mutation NN NN O
( NN NN O
Cys163Ser NN NN O
) NN NN O
being NN NN O
responsible NN NN O
for NN NN O
the NN NN O
majority NN NN O
of NN NN O
Finnish NN NN O
cases NN NN O
. NN NN O

We NN NN O
were NN NN O
able NN NN O
to NN NN O
examine NN NN O
66 NN NN O
Finnish NN NN O
AGU NN NN B-Modifier
patients NN NN O
for NN NN O
changes NN NN O
in NN NN O
the NN NN O
oral NN NN O
mucosa NN NN O
and NN NN O
44 NN NN O
of NN NN O
these NN NN O
for NN NN O
changes NN NN O
in NN NN O
facial NN NN O
skin NN NN O
. NN NN O

Biopsy NN NN O
specimens NN NN O
of NN NN O
16 NN NN O
oral NN NN O
lesions NN NN O
, NN NN O
12 NN NN O
of NN NN O
them NN NN O
associated NN NN O
with NN NN O
the NN NN O
teeth NN NN O
, NN NN O
plus NN NN O
two NN NN O
facial NN NN B-DiseaseClass
lesions NN NN I-DiseaseClass
were NN NN O
studied NN NN O
histologically NN NN O
. NN NN O

Immunohistochemical NN NN O
staining NN NN O
for NN NN O
AGA NN NN O
was NN NN O
performed NN NN O
on NN NN O
15 NN NN O
oral NN NN O
specimens NN NN O
. NN NN O

Skin NN NN O
was NN NN O
seborrhoeic NN NN O
in NN NN O
adolescent NN NN O
and NN NN O
adult NN NN O
patients NN NN O
, NN NN O
with NN NN O
erythema NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
facial NN NN I-SpecificDisease
skin NN NN I-SpecificDisease
already NN NN O
common NN NN O
in NN NN O
childhood NN NN O
. NN NN O

Of NN NN O
44 NN NN O
patients NN NN O
, NN NN O
nine NN NN O
( NN NN O
20 NN NN O
% NN NN O
) NN NN O
had NN NN O
facial NN NN B-SpecificDisease
angiofibromas NN NN I-SpecificDisease
, NN NN O
tumours NN NN B-DiseaseClass
primarily NN NN O
occurring NN NN O
in NN NN O
association NN NN O
with NN NN O
tuberous NN NN B-SpecificDisease
sclerosis NN NN I-SpecificDisease
. NN NN O

Oedemic NN NN B-SpecificDisease
buccal NN NN I-SpecificDisease
mucosa NN NN I-SpecificDisease
( NN NN O
leucoedema NN NN B-SpecificDisease
) NN NN O
and NN NN O
gingival NN NN B-SpecificDisease
overgrowths NN NN I-SpecificDisease
were NN NN O
more NN NN O
frequent NN NN O
in NN NN O
AGU NN NN B-Modifier
patients NN NN O
than NN NN O
in NN NN O
controls NN NN O
( NN NN O
p NN NN O
0 NN NN O
. NN NN O

001 NN NN O
) NN NN O
. NN NN O

Of NN NN O
16 NN NN O
oral NN NN B-SpecificDisease
mucosal NN NN I-SpecificDisease
lesions NN NN I-SpecificDisease
studied NN NN O
histologically NN NN O
, NN NN O
15 NN NN O
represented NN NN O
fibroepithelial NN NN B-CompositeMention
or NN NN I-CompositeMention
epithelial NN NN I-CompositeMention
hyperplasias NN NN I-CompositeMention
and NN NN O
were NN NN O
reactive NN NN O
in NN NN O
nature NN NN O
. NN NN O

Cytoplasmic NN NN O
vacuolisation NN NN O
was NN NN O
evident NN NN O
in NN NN O
four NN NN O
. NN NN O

Immunohistochemically NN NN O
, NN NN O
expression NN NN O
of NN NN O
AGA NN NN O
in NN NN O
AGU NN NN B-Modifier
patients NN NN O
mucosal NN NN B-SpecificDisease
lesions NN NN I-SpecificDisease
did NN NN O
not NN NN O
differ NN NN O
from NN NN O
that NN NN O
seen NN NN O
in NN NN O
corresponding NN NN O
lesions NN NN O
of NN NN O
normal NN NN O
subjects NN NN O
. NN NN O

Thus NN NN O
, NN NN O
the NN NN O
high NN NN O
frequency NN NN O
of NN NN O
mucosal NN NN B-SpecificDisease
overgrowth NN NN I-SpecificDisease
in NN NN O
AGU NN NN B-Modifier
patients NN NN O
does NN NN O
not NN NN O
appear NN NN O
to NN NN O
be NN NN O
directly NN NN O
associated NN NN O
with NN NN O
lysosomal NN NN O
storage NN NN O
or NN NN O
with NN NN O
alterations NN NN O
in NN NN O
the NN NN O
level NN NN O
of NN NN O
AGA NN NN O
expression NN NN O
. NN NN O

10364518 NN NN O
Characterization NN NN O
of NN NN O
a NN NN O
germline NN NN O
mosaicism NN NN O
in NN NN O
families NN NN O
with NN NN O
Lowe NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
, NN NN O
and NN NN O
identification NN NN O
of NN NN O
seven NN NN O
novel NN NN O
mutations NN NN O
in NN NN O
the NN NN O
OCRL1 NN NN O
gene NN NN O
. NN NN O

The NN NN O
oculocerebrorenal NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
of NN NN I-SpecificDisease
Lowe NN NN I-SpecificDisease
( NN NN O
OCRL NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
X-linked NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
characterized NN NN O
by NN NN O
major NN NN O
abnormalities NN NN B-CompositeMention
of NN NN I-CompositeMention
eyes NN NN I-CompositeMention
, NN NN I-CompositeMention
nervous NN NN I-CompositeMention
system NN NN I-CompositeMention
, NN NN I-CompositeMention
and NN NN I-CompositeMention
kidneys NN NN I-CompositeMention
. NN NN O

Mutations NN NN O
in NN NN O
the NN NN O
OCRL1 NN NN O
gene NN NN O
have NN NN O
been NN NN O
associated NN NN O
with NN NN O
the NN NN O
disease NN NN O
. NN NN O

OCRL1 NN NN O
encodes NN NN O
a NN NN O
phosphatidylinositol NN NN O
4 NN NN O
, NN NN O
5-biphosphate NN NN O
( NN NN O
PtdIns NN NN O
[ NN NN O
4 NN NN O
, NN NN O
5 NN NN O
] NN NN O
P2 NN NN O
) NN NN O
5-phosphatase NN NN O
. NN NN O

We NN NN O
have NN NN O
examined NN NN O
the NN NN O
OCRL1 NN NN O
gene NN NN O
in NN NN O
eight NN NN O
unrelated NN NN O
patients NN NN O
with NN NN O
OCRL NN NN B-SpecificDisease
and NN NN O
have NN NN O
found NN NN O
seven NN NN O
new NN NN O
mutations NN NN O
and NN NN O
one NN NN O
recurrent NN NN O
in-frame NN NN O
deletion NN NN O
. NN NN O

Among NN NN O
the NN NN O
new NN NN O
mutations NN NN O
, NN NN O
two NN NN O
nonsense NN NN O
mutations NN NN O
( NN NN O
R317X NN NN O
and NN NN O
E558X NN NN O
) NN NN O
and NN NN O
three NN NN O
other NN NN O
frameshift NN NN O
mutations NN NN O
caused NN NN O
premature NN NN O
termination NN NN O
of NN NN O
the NN NN O
protein NN NN O
. NN NN O

A NN NN O
missense NN NN O
mutation NN NN O
, NN NN O
R483G NN NN O
, NN NN O
was NN NN O
located NN NN O
in NN NN O
the NN NN O
highly NN NN O
conserved NN NN O
PtdIns NN NN O
( NN NN O
4 NN NN O
, NN NN O
5 NN NN O
) NN NN O
P2 NN NN O
5-phosphatase NN NN O
domain NN NN O
. NN NN O

Finally NN NN O
, NN NN O
one NN NN O
frameshift NN NN O
mutation NN NN O
, NN NN O
2799delC NN NN O
, NN NN O
modifies NN NN O
the NN NN O
C-terminal NN NN O
part NN NN O
of NN NN O
OCRL1 NN NN O
, NN NN O
with NN NN O
an NN NN O
extension NN NN O
of NN NN O
six NN NN O
amino NN NN O
acids NN NN O
. NN NN O

Altogether NN NN O
, NN NN O
70 NN NN O
% NN NN O
of NN NN O
missense NN NN O
mutations NN NN O
are NN NN O
located NN NN O
in NN NN O
exon NN NN O
15 NN NN O
, NN NN O
and NN NN O
52 NN NN O
% NN NN O
of NN NN O
all NN NN O
mutations NN NN O
cluster NN NN O
in NN NN O
exons NN NN O
11-15 NN NN O
. NN NN O

We NN NN O
also NN NN O
identified NN NN O
two NN NN O
new NN NN O
microsatellite NN NN O
markers NN NN O
for NN NN O
the NN NN O
OCRL1 NN NN O
locus NN NN O
, NN NN O
and NN NN O
we NN NN O
detected NN NN O
a NN NN O
germline NN NN O
mosaicism NN NN O
in NN NN O
one NN NN O
family NN NN O
. NN NN O

This NN NN O
observation NN NN O
has NN NN O
direct NN NN O
implications NN NN O
for NN NN O
genetic NN NN O
counseling NN NN O
of NN NN O
Lowe NN NN B-Modifier
syndrome NN NN I-Modifier
families NN NN O
. NN NN O

. NN NN O

10364520 NN NN O
MEFV-Gene NN NN O
analysis NN NN O
in NN NN O
armenian NN NN O
patients NN NN O
with NN NN O
Familial NN NN B-SpecificDisease
Mediterranean NN NN I-SpecificDisease
fever NN NN I-SpecificDisease
: NN NN O
diagnostic NN NN O
value NN NN O
and NN NN O
unfavorable NN NN O
renal NN NN O
prognosis NN NN O
of NN NN O
the NN NN O
M694V NN NN O
homozygous NN NN O
genotype-genetic NN NN O
and NN NN O
therapeutic NN NN O
implications NN NN O
. NN NN O

Familial NN NN B-SpecificDisease
Mediterranean NN NN I-SpecificDisease
fever NN NN I-SpecificDisease
( NN NN O
FMF NN NN B-SpecificDisease
) NN NN O
is NN NN O
a NN NN O
recessively NN NN B-DiseaseClass
inherited NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
that NN NN O
is NN NN O
common NN NN O
in NN NN O
patients NN NN O
of NN NN O
Armenian NN NN O
ancestry NN NN O
. NN NN O

To NN NN O
date NN NN O
, NN NN O
its NN NN O
diagnosis NN NN O
, NN NN O
which NN NN O
can NN NN O
be NN NN O
made NN NN O
only NN NN O
retrospectively NN NN O
, NN NN O
is NN NN O
one NN NN O
of NN NN O
exclusion NN NN O
, NN NN O
based NN NN O
entirely NN NN O
on NN NN O
nonspecific NN NN O
clinical NN NN O
signs NN NN O
that NN NN O
result NN NN O
from NN NN O
serosal NN NN B-SpecificDisease
inflammation NN NN I-SpecificDisease
and NN NN O
that NN NN O
may NN NN O
lead NN NN O
to NN NN O
unnecessary NN NN O
surgery NN NN O
. NN NN O

Renal NN NN B-SpecificDisease
amyloidosis NN NN I-SpecificDisease
, NN NN O
prevented NN NN O
by NN NN O
colchicine NN NN O
, NN NN O
is NN NN O
the NN NN O
most NN NN O
severe NN NN O
complication NN NN O
of NN NN O
FMF NN NN B-SpecificDisease
, NN NN O
a NN NN O
disorder NN NN O
associated NN NN O
with NN NN O
mutations NN NN O
in NN NN O
the NN NN O
MEFV NN NN O
gene NN NN O
. NN NN O

To NN NN O
evaluate NN NN O
the NN NN O
diagnostic NN NN O
and NN NN O
prognostic NN NN O
value NN NN O
of NN NN O
MEFV-gene NN NN O
analysis NN NN O
, NN NN O
we NN NN O
investigated NN NN O
90 NN NN O
Armenian NN NN O
FMF NN NN B-Modifier
patients NN NN O
from NN NN O
77 NN NN O
unrelated NN NN O
families NN NN O
that NN NN O
were NN NN O
not NN NN O
selected NN NN O
through NN NN O
genetic-linkage NN NN O
analysis NN NN O
. NN NN O

Eight NN NN O
mutations NN NN O
, NN NN O
one NN NN O
of NN NN O
which NN NN O
( NN NN O
R408Q NN NN O
) NN NN O
is NN NN O
new NN NN O
, NN NN O
were NN NN O
found NN NN O
to NN NN O
account NN NN O
for NN NN O
93 NN NN O
% NN NN O
of NN NN O
the NN NN O
163 NN NN O
independent NN NN O
FMF NN NN B-Modifier
alleles NN NN O
, NN NN O
with NN NN O
both NN NN O
FMF NN NN B-Modifier
alleles NN NN O
identified NN NN O
in NN NN O
89 NN NN O
% NN NN O
of NN NN O
the NN NN O
patients NN NN O
. NN NN O

In NN NN O
several NN NN O
instances NN NN O
, NN NN O
family NN NN O
studies NN NN O
provided NN NN O
molecular NN NN O
evidence NN NN O
for NN NN O
pseudodominant NN NN O
transmission NN NN O
and NN NN O
incomplete NN NN O
penetrance NN NN O
of NN NN O
the NN NN O
disease NN NN O
phenotype NN NN O
. NN NN O

The NN NN O
M694V NN NN O
homozygous NN NN O
genotype NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
associated NN NN O
with NN NN O
a NN NN O
higher NN NN O
prevalence NN NN O
of NN NN O
renal NN NN B-SpecificDisease
amyloidosis NN NN I-SpecificDisease
and NN NN O
arthritis NN NN B-SpecificDisease
, NN NN O
compared NN NN O
with NN NN O
other NN NN O
genotypes NN NN O
( NN NN O
P NN NN O
= NN NN O
. NN NN O

0002 NN NN O
and NN NN O
P NN NN O
= NN NN O
. NN NN O

006 NN NN O
, NN NN O
respectively NN NN O
) NN NN O
. NN NN O

The NN NN O
demonstration NN NN O
of NN NN O
both NN NN O
the NN NN O
diagnostic NN NN O
and NN NN O
prognostic NN NN O
value NN NN O
of NN NN O
MEFV NN NN O
analysis NN NN O
and NN NN O
particular NN NN O
modes NN NN O
of NN NN O
inheritance NN NN O
should NN NN O
lead NN NN O
to NN NN O
new NN NN O
ways NN NN O
for NN NN O
management NN NN O
of NN NN O
FMF-including NN NN O
genetic NN NN O
counseling NN NN O
and NN NN O
therapeutic NN NN O
decisions NN NN O
in NN NN O
affected NN NN O
families NN NN O
. NN NN O

10364521 NN NN O
Noninvasive NN NN O
test NN NN O
for NN NN O
fragile NN NN B-SpecificDisease
X NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
, NN NN O
using NN NN O
hair NN NN O
root NN NN O
analysis NN NN O
. NN NN O

Identification NN NN O
of NN NN O
the NN NN O
FMR1 NN NN O
gene NN NN O
and NN NN O
the NN NN O
repeat-amplification NN NN O
mechanism NN NN O
causing NN NN O
fragile NN NN B-SpecificDisease
X NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
led NN NN O
to NN NN O
development NN NN O
of NN NN O
reliable NN NN O
DNA-based NN NN O
diagnostic NN NN O
methods NN NN O
, NN NN O
including NN NN O
Southern NN NN O
blot NN NN O
hybridization NN NN O
and NN NN O
PCR NN NN O
. NN NN O

Both NN NN O
methods NN NN O
are NN NN O
performed NN NN O
on NN NN O
DNA NN NN O
isolated NN NN O
from NN NN O
peripheral NN NN O
blood NN NN O
cells NN NN O
and NN NN O
measure NN NN O
the NN NN O
repeat NN NN O
size NN NN O
in NN NN O
FMR1 NN NN O
. NN NN O

Using NN NN O
an NN NN O
immunocytochemical NN NN O
technique NN NN O
on NN NN O
blood NN NN O
smears NN NN O
, NN NN O
we NN NN O
recently NN NN O
developed NN NN O
a NN NN O
novel NN NN O
test NN NN O
for NN NN O
identification NN NN O
of NN NN O
patients NN NN O
with NN NN O
fragile NN NN B-SpecificDisease
X NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

This NN NN O
method NN NN O
, NN NN O
also NN NN O
called NN NN O
`` NN NN O
antibody NN NN O
test NN NN O
, NN NN O
`` NN NN O
uses NN NN O
monoclonal NN NN O
antibodies NN NN O
against NN NN O
the NN NN O
FMR1 NN NN O
gene NN NN O
product NN NN O
( NN NN O
FMRP NN NN O
) NN NN O
and NN NN O
is NN NN O
based NN NN O
on NN NN O
absence NN NN O
of NN NN O
FMRP NN NN O
in NN NN O
patients NN NN O
cells NN NN O
. NN NN O

Here NN NN O
we NN NN O
describe NN NN O
a NN NN O
new NN NN O
diagnostic NN NN O
test NN NN O
to NN NN O
identify NN NN O
male NN NN O
patients NN NN O
with NN NN O
fragile NN NN B-SpecificDisease
X NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
, NN NN O
on NN NN O
the NN NN O
basis NN NN O
of NN NN O
lack NN NN O
of NN NN O
FMRP NN NN O
in NN NN O
their NN NN O
hair NN NN O
roots NN NN O
. NN NN O

Expression NN NN O
of NN NN O
FMRP NN NN O
in NN NN O
hair NN NN O
roots NN NN O
was NN NN O
studied NN NN O
by NN NN O
use NN NN O
of NN NN O
an NN NN O
FMRP-specific NN NN O
antibody NN NN O
test NN NN O
, NN NN O
and NN NN O
the NN NN O
percentage NN NN O
of NN NN O
FMRP-expressing NN NN O
hair NN NN O
roots NN NN O
in NN NN O
controls NN NN O
and NN NN O
in NN NN O
male NN NN O
fragile NN NN B-Modifier
X NN NN I-Modifier
patients NN NN O
was NN NN O
determined NN NN O
. NN NN O

Control NN NN O
individuals NN NN O
showed NN NN O
clear NN NN O
expression NN NN O
of NN NN O
FMRP NN NN O
in NN NN O
nearly NN NN O
every NN NN O
hair NN NN O
root NN NN O
, NN NN O
whereas NN NN O
male NN NN O
fragile NN NN B-Modifier
X NN NN I-Modifier
patients NN NN O
lacked NN NN O
expression NN NN O
of NN NN O
FMRP NN NN O
in NN NN O
almost NN NN O
all NN NN O
their NN NN O
hair NN NN O
roots NN NN O
. NN NN O

Mentally NN NN B-Modifier
retarded NN NN I-Modifier
female NN NN O
patients NN NN O
with NN NN O
a NN NN O
full NN NN O
mutation NN NN O
showed NN NN O
FMRP NN NN O
expression NN NN O
in NN NN O
only NN NN O
some NN NN O
of NN NN O
their NN NN O
hair NN NN O
roots NN NN O
( NN NN O
55 NN NN O
% NN NN O
) NN NN O
, NN NN O
and NN NN O
no NN NN O
overlap NN NN O
with NN NN O
normal NN NN O
female NN NN O
controls NN NN O
was NN NN O
observed NN NN O
. NN NN O

The NN NN O
advantages NN NN O
of NN NN O
this NN NN O
test NN NN O
are NN NN O
( NN NN O
1 NN NN O
) NN NN O
plucking NN NN O
of NN NN O
hair NN NN O
follicles NN NN O
does NN NN O
no NN NN O
appreciable NN NN O
harm NN NN O
to NN NN O
the NN NN O
mentally NN NN B-Modifier
retarded NN NN I-Modifier
patient NN NN O
, NN NN O
( NN NN O
2 NN NN O
) NN NN O
hairs NN NN O
can NN NN O
be NN NN O
sent NN NN O
in NN NN O
a NN NN O
simple NN NN O
envelope NN NN O
to NN NN O
a NN NN O
diagnostic NN NN O
center NN NN O
, NN NN O
and NN NN O
( NN NN O
3 NN NN O
) NN NN O
the NN NN O
result NN NN O
of NN NN O
the NN NN O
test NN NN O
is NN NN O
available NN NN O
within NN NN O
5 NN NN O
h NN NN O
of NN NN O
plucking NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
this NN NN O
test NN NN O
enabled NN NN O
us NN NN O
to NN NN O
identify NN NN O
two NN NN O
fragile NN NN B-Modifier
X NN NN I-Modifier
patients NN NN O
who NN NN O
did NN NN O
not NN NN O
show NN NN O
the NN NN O
full NN NN O
mutation NN NN O
by NN NN O
analysis NN NN O
of NN NN O
DNA NN NN O
isolated NN NN O
from NN NN O
blood NN NN O
cells NN NN O
. NN NN O

. NN NN O

10364525 NN NN O
In NN NN O
Swedish NN NN O
families NN NN O
with NN NN O
hereditary NN NN B-SpecificDisease
prostate NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
, NN NN O
linkage NN NN O
to NN NN O
the NN NN O
HPC1 NN NN O
locus NN NN O
on NN NN O
chromosome NN NN O
1q24-25 NN NN O
is NN NN O
restricted NN NN O
to NN NN O
families NN NN O
with NN NN O
early-onset NN NN O
prostate NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

Prostate NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
clusters NN NN O
in NN NN O
some NN NN O
families NN NN O
, NN NN O
and NN NN O
an NN NN O
estimated NN NN O
5 NN NN O
% NN NN O
-10 NN NN O
% NN NN O
of NN NN O
all NN NN O
cases NN NN O
are NN NN O
estimated NN NN O
to NN NN O
result NN NN O
from NN NN O
inheritance NN NN O
of NN NN O
prostate NN NN O
cancer-susceptibility NN NN O
genes NN NN O
. NN NN O

We NN NN O
previously NN NN O
reported NN NN O
evidence NN NN O
of NN NN O
linkage NN NN O
to NN NN O
the NN NN O
1q24-25 NN NN O
region NN NN O
( NN NN O
HPC1 NN NN O
) NN NN O
in NN NN O
91 NN NN O
North NN NN O
American NN NN O
and NN NN O
Swedish NN NN O
families NN NN O
each NN NN O
with NN NN O
multiple NN NN O
cases NN NN O
of NN NN O
prostate NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
( NN NN O
Smith NN NN O
et NN NN O
al NN NN O
. NN NN O

1996 NN NN O
) NN NN O
. NN NN O

In NN NN O
the NN NN O
present NN NN O
report NN NN O
we NN NN O
analyze NN NN O
40 NN NN O
( NN NN O
12 NN NN O
original NN NN O
and NN NN O
28 NN NN O
newly NN NN O
identified NN NN O
) NN NN O
Swedish NN NN O
families NN NN O
with NN NN O
hereditary NN NN B-SpecificDisease
prostate NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
( NN NN O
HPC NN NN B-SpecificDisease
) NN NN O
that NN NN O
, NN NN O
on NN NN O
the NN NN O
basis NN NN O
of NN NN O
40 NN NN O
markers NN NN O
spanning NN NN O
a NN NN O
25-cM NN NN O
interval NN NN O
within NN NN O
1q24-25 NN NN O
, NN NN O
have NN NN O
evidence NN NN O
of NN NN O
linkage NN NN O
. NN NN O

In NN NN O
the NN NN O
complete NN NN O
set NN NN O
of NN NN O
families NN NN O
, NN NN O
a NN NN O
maximum NN NN O
two-point NN NN O
LOD NN NN O
score NN NN O
of NN NN O
1 NN NN O
. NN NN O

10 NN NN O
was NN NN O
observed NN NN O
at NN NN O
D1S413 NN NN O
( NN NN O
at NN NN O
a NN NN O
recombination NN NN O
fraction NN NN O
[ NN NN O
theta NN NN O
] NN NN O
of NN NN O
. NN NN O

1 NN NN O
) NN NN O
, NN NN O
with NN NN O
a NN NN O
maximum NN NN O
NPL NN NN O
( NN NN O
nonparametric NN NN O
linkage NN NN O
) NN NN O
Z NN NN O
score NN NN O
of NN NN O
1 NN NN O
. NN NN O

64 NN NN O
at NN NN O
D1S202 NN NN O
( NN NN O
P NN NN O
= NN NN O
. NN NN O

05 NN NN O
) NN NN O
. NN NN O

The NN NN O
evidence NN NN O
of NN NN O
linkage NN NN O
to NN NN O
this NN NN O
region NN NN O
originated NN NN O
almost NN NN O
exclusively NN NN O
from NN NN O
the NN NN O
subset NN NN O
of NN NN O
12 NN NN O
early-onset NN NN O
( NN NN O
age NN NN O
65 NN NN O
years NN NN O
) NN NN O
families NN NN O
, NN NN O
which NN NN O
yielded NN NN O
a NN NN O
maximum NN NN O
LOD NN NN O
score NN NN O
of NN NN O
2 NN NN O
. NN NN O

38 NN NN O
at NN NN O
D1S413 NN NN O
( NN NN O
straight NN NN O
theta NN NN O
= NN NN O
0 NN NN O
) NN NN O
and NN NN O
an NN NN O
NPL NN NN O
Z NN NN O
score NN NN O
of NN NN O
1 NN NN O
. NN NN O

95 NN NN O
at NN NN O
D1S422 NN NN O
( NN NN O
P NN NN O
= NN NN O
. NN NN O

03 NN NN O
) NN NN O
. NN NN O

Estimates NN NN O
from NN NN O
heterogeneity NN NN O
tests NN NN O
suggest NN NN O
that NN NN O
, NN NN O
within NN NN O
Sweden NN NN O
, NN NN O
as NN NN O
many NN NN O
as NN NN O
50 NN NN O
% NN NN O
of NN NN O
early-onset NN NN O
families NN NN O
had NN NN O
evidence NN NN O
of NN NN O
linkage NN NN O
to NN NN O
the NN NN O
HPC1 NN NN O
region NN NN O
. NN NN O

These NN NN O
results NN NN O
are NN NN O
consistent NN NN O
with NN NN O
the NN NN O
hypothesis NN NN O
of NN NN O
linkage NN NN O
to NN NN O
HPC1 NN NN O
in NN NN O
a NN NN O
subset NN NN O
of NN NN O
families NN NN O
with NN NN O
prostate NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
, NN NN O
particularly NN NN O
those NN NN O
with NN NN O
an NN NN O
early NN NN O
age NN NN O
at NN NN O
diagnosis NN NN O
. NN NN O

10366443 NN NN O
Molecular NN NN O
basis NN NN O
of NN NN O
feline NN NN O
beta-glucuronidase NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
: NN NN O
an NN NN O
animal NN NN O
model NN NN O
of NN NN O
mucopolysaccharidosis NN NN B-SpecificDisease
VII NN NN I-SpecificDisease
. NN NN O

A NN NN O
family NN NN O
of NN NN O
domestic NN NN O
cats NN NN O
was NN NN O
found NN NN O
that NN NN O
exhibited NN NN O
clinical NN NN O
and NN NN O
biochemical NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
consistent NN NN O
with NN NN O
mucopolysaccharidosis NN NN B-SpecificDisease
VII NN NN I-SpecificDisease
, NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
lysosomal NN NN I-DiseaseClass
storage NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
caused NN NN O
by NN NN O
beta-glucuronidase NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

beta-Glucuronidase NN NN O
activity NN NN O
was NN NN O
undetectable NN NN O
in NN NN O
affected NN NN O
cat NN NN O
fibroblasts NN NN O
and NN NN O
restored NN NN O
by NN NN O
retroviral NN NN O
gene NN NN O
transfer NN NN O
of NN NN O
rat NN NN O
beta-glucuronidase NN NN O
cDNA NN NN O
. NN NN O

beta-Glucuronidase NN NN O
mRNA NN NN O
was NN NN O
normal NN NN O
in NN NN O
affected NN NN O
cat NN NN O
testis NN NN O
by NN NN O
Northern NN NN O
blot NN NN O
analysis NN NN O
. NN NN O

Normal NN NN O
feline NN NN O
beta-glucuronidase NN NN O
cDNA NN NN O
was NN NN O
cloned NN NN O
and NN NN O
characterized NN NN O
, NN NN O
and NN NN O
amplified NN NN O
from NN NN O
affected NN NN O
cat NN NN O
fibroblasts NN NN O
by NN NN O
reverse NN NN O
transcription NN NN O
coupled NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
. NN NN O

There NN NN O
was NN NN O
a NN NN O
G-to-A NN NN O
transition NN NN O
in NN NN O
the NN NN O
affected NN NN O
cat NN NN O
cDNA NN NN O
that NN NN O
predicted NN NN O
an NN NN O
E351K NN NN O
substitution NN NN O
, NN NN O
destroyed NN NN O
a NN NN O
BssSI NN NN O
site NN NN O
, NN NN O
and NN NN O
eliminated NN NN O
GUSB NN NN O
enzymatic NN NN O
activity NN NN O
in NN NN O
expression NN NN O
studies NN NN O
. NN NN O

Multiple NN NN O
species NN NN O
comparison NN NN O
and NN NN O
the NN NN O
crystal NN NN O
structure NN NN O
of NN NN O
human NN NN O
beta-glucuronidase NN NN O
indicated NN NN O
that NN NN O
E351 NN NN O
is NN NN O
a NN NN O
highly NN NN O
conserved NN NN O
residue NN NN O
most NN NN O
likely NN NN O
essential NN NN O
in NN NN O
maintenance NN NN O
of NN NN O
the NN NN O
enzymes NN NN O
conformation NN NN O
. NN NN O

BssSI NN NN O
digestion NN NN O
of NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
products NN NN O
amplified NN NN O
from NN NN O
genomic NN NN O
DNA NN NN O
indicated NN NN O
that NN NN O
affected NN NN O
cats NN NN O
were NN NN O
homozygous NN NN O
and NN NN O
cats NN NN O
with NN NN O
half-normal NN NN O
beta-glucuronidase NN NN O
activity NN NN O
were NN NN O
heterozygous NN NN O
for NN NN O
the NN NN O
missense NN NN O
mutation NN NN O
. NN NN O

Carriers NN NN O
identified NN NN O
in NN NN O
this NN NN O
manner NN NN O
produced NN NN O
affected NN NN O
kittens NN NN O
in NN NN O
prospective NN NN O
breedings NN NN O
, NN NN O
and NN NN O
a NN NN O
feline NN NN O
MPS NN NN B-Modifier
VII NN NN I-Modifier
breeding NN NN O
colony NN NN O
has NN NN O
been NN NN O
established NN NN O
. NN NN O

. NN NN O

10369860 NN NN O
A NN NN O
common NN NN O
molecular NN NN O
basis NN NN O
for NN NN O
rearrangement NN NN B-DiseaseClass
disorders NN NN I-DiseaseClass
on NN NN O
chromosome NN NN O
22q11 NN NN O
. NN NN O

The NN NN O
chromosome NN NN O
22q11 NN NN O
region NN NN O
is NN NN O
susceptible NN NN O
to NN NN O
rearrangements NN NN O
that NN NN O
are NN NN O
associated NN NN O
with NN NN O
congenital NN NN B-DiseaseClass
anomaly NN NN I-DiseaseClass
disorders NN NN I-DiseaseClass
and NN NN O
malignant NN NN B-DiseaseClass
tumors NN NN I-DiseaseClass
. NN NN O

Three NN NN O
congenital NN NN B-DiseaseClass
anomaly NN NN I-DiseaseClass
disorders NN NN I-DiseaseClass
, NN NN O
cat-eye NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
, NN NN O
der NN NN B-SpecificDisease
( NN NN I-SpecificDisease
) NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
and NN NN O
velo-cardio-facial NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
/ NN NN O
DiGeorge NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
VCFS NN NN B-SpecificDisease
/ NN NN O
DGS NN NN B-SpecificDisease
) NN NN O
are NN NN O
associated NN NN O
with NN NN O
tetrasomy NN NN O
, NN NN O
trisomy NN NN O
or NN NN O
monosomy NN NN O
, NN NN O
respectively NN NN O
, NN NN O
for NN NN O
part NN NN O
of NN NN O
chromosome NN NN O
22q11 NN NN O
. NN NN O

VCFS NN NN B-SpecificDisease
/ NN NN O
DGS NN NN B-SpecificDisease
is NN NN O
the NN NN O
most NN NN O
common NN NN O
syndrome NN NN O
associated NN NN O
with NN NN O
22q11 NN NN O
rearrangements NN NN O
. NN NN O

In NN NN O
order NN NN O
to NN NN O
determine NN NN O
whether NN NN O
there NN NN O
are NN NN O
particular NN NN O
regions NN NN O
on NN NN O
22q11 NN NN O
that NN NN O
are NN NN O
prone NN NN O
to NN NN O
rearrangements NN NN O
, NN NN O
the NN NN O
deletion NN NN O
end-points NN NN O
in NN NN O
a NN NN O
large NN NN O
number NN NN O
of NN NN O
VCFS NN NN B-Modifier
/ NN NN O
DGS NN NN B-Modifier
patients NN NN O
were NN NN O
defined NN NN O
by NN NN O
haplotype NN NN O
analysis NN NN O
. NN NN O

Most NN NN O
VCFS NN NN B-Modifier
/ NN NN O
DGS NN NN B-Modifier
patients NN NN O
have NN NN O
a NN NN O
similar NN NN O
3 NN NN O
Mb NN NN O
deletion NN NN O
, NN NN O
some NN NN O
have NN NN O
a NN NN O
nested NN NN O
distal NN NN O
deletion NN NN O
breakpoint NN NN O
resulting NN NN O
in NN NN O
a NN NN O
1 NN NN O
. NN NN O

5 NN NN O
Mb NN NN O
deletion NN NN O
and NN NN O
a NN NN O
few NN NN O
rare NN NN O
patients NN NN O
have NN NN O
unique NN NN O
deletions NN NN O
or NN NN O
translocations NN NN O
. NN NN O

The NN NN O
high NN NN O
prevalence NN NN O
of NN NN O
the NN NN O
disorder NN NN O
in NN NN O
the NN NN O
population NN NN O
and NN NN O
the NN NN O
fact NN NN O
that NN NN O
most NN NN O
cases NN NN O
occur NN NN O
sporadically NN NN O
suggest NN NN O
that NN NN O
sequences NN NN O
at NN NN O
or NN NN O
near NN NN O
the NN NN O
breakpoints NN NN O
confer NN NN O
susceptibility NN NN O
to NN NN O
chromosome NN NN O
rearrangements NN NN O
. NN NN O

To NN NN O
investigate NN NN O
this NN NN O
hypothesis NN NN O
, NN NN O
we NN NN O
developed NN NN O
hamster-human NN NN O
somatic NN NN O
hybrid NN NN O
cell NN NN O
lines NN NN O
from NN NN O
VCFS NN NN B-Modifier
/ NN NN O
DGS NN NN B-Modifier
patients NN NN O
with NN NN O
all NN NN O
three NN NN O
classes NN NN O
of NN NN O
deletions NN NN O
and NN NN O
we NN NN O
now NN NN O
show NN NN O
that NN NN O
the NN NN O
breakpoints NN NN O
occur NN NN O
within NN NN O
similar NN NN O
low NN NN O
copy NN NN O
repeats NN NN O
, NN NN O
termed NN NN O
LCR22s NN NN O
. NN NN O

To NN NN O
support NN NN O
this NN NN O
idea NN NN O
further NN NN O
, NN NN O
we NN NN O
identified NN NN O
a NN NN O
family NN NN O
that NN NN O
carries NN NN O
an NN NN O
interstitial NN NN O
duplication NN NN O
of NN NN O
the NN NN O
same NN NN O
3 NN NN O
Mb NN NN O
region NN NN O
that NN NN O
is NN NN O
deleted NN NN O
in NN NN O
VCFS NN NN B-Modifier
/ NN NN O
DGS NN NN B-Modifier
patients NN NN O
. NN NN O

We NN NN O
present NN NN O
models NN NN O
to NN NN O
explain NN NN O
how NN NN O
the NN NN O
LCR22s NN NN O
can NN NN O
mediate NN NN O
different NN NN O
homologous NN NN O
recombination NN NN O
events NN NN O
, NN NN O
thereby NN NN O
generating NN NN O
a NN NN O
number NN NN O
of NN NN O
rearrangements NN NN O
that NN NN O
are NN NN O
associated NN NN O
with NN NN O
congenital NN NN B-DiseaseClass
anomaly NN NN I-DiseaseClass
disorders NN NN I-DiseaseClass
. NN NN O

We NN NN O
identified NN NN O
five NN NN O
additional NN NN O
copies NN NN O
of NN NN O
the NN NN O
LCR22 NN NN O
on NN NN O
22q11 NN NN O
that NN NN O
may NN NN O
mediate NN NN O
other NN NN O
rearrangements NN NN O
leading NN NN O
to NN NN O
disease NN NN O
. NN NN O

10369870 NN NN O
Functional NN NN O
consequences NN NN O
of NN NN O
mutations NN NN O
in NN NN O
the NN NN O
early NN NN O
growth NN NN O
response NN NN O
2 NN NN O
gene NN NN O
( NN NN O
EGR2 NN NN O
) NN NN O
correlate NN NN O
with NN NN O
severity NN NN O
of NN NN O
human NN NN O
myelinopathies NN NN B-DiseaseClass
. NN NN O

The NN NN O
early NN NN O
growth NN NN O
response NN NN O
2 NN NN O
gene NN NN O
( NN NN O
EGR2 NN NN O
) NN NN O
is NN NN O
a NN NN O
Cys2His2zinc NN NN O
finger NN NN O
transcription NN NN O
factor NN NN O
which NN NN O
is NN NN O
thought NN NN O
to NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
peripheral NN NN O
nervous NN NN O
system NN NN O
myelination NN NN O
. NN NN O

This NN NN O
idea NN NN O
is NN NN O
based NN NN O
partly NN NN O
on NN NN O
the NN NN O
phenotype NN NN O
of NN NN O
homozygous NN NN O
Krox20 NN NN O
( NN NN O
Egr2 NN NN O
) NN NN O
knockout NN NN O
mice NN NN O
, NN NN O
which NN NN O
display NN NN O
hypomyelination NN NN B-DiseaseClass
of NN NN I-DiseaseClass
the NN NN I-DiseaseClass
PNS NN NN I-DiseaseClass
and NN NN O
a NN NN O
block NN NN O
of NN NN O
Schwann NN NN O
cells NN NN O
at NN NN O
an NN NN O
early NN NN O
stage NN NN O
of NN NN O
differentiation NN NN O
. NN NN O

Mutations NN NN O
in NN NN O
the NN NN O
human NN NN O
EGR2 NN NN O
gene NN NN O
have NN NN O
recently NN NN O
been NN NN O
associated NN NN O
with NN NN O
the NN NN O
inherited NN NN B-DiseaseClass
peripheral NN NN I-DiseaseClass
neuropathies NN NN I-DiseaseClass
Charcot-Marie-Tooth NN NN B-SpecificDisease
type NN NN I-SpecificDisease
1 NN NN I-SpecificDisease
, NN NN O
Dejerine-Sottas NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
and NN NN O
congenital NN NN B-SpecificDisease
hypomyelinating NN NN I-SpecificDisease
neuropathy NN NN I-SpecificDisease
. NN NN O

Three NN NN O
of NN NN O
the NN NN O
four NN NN O
EGR2 NN NN O
mutations NN NN O
are NN NN O
dominant NN NN O
and NN NN O
occur NN NN O
within NN NN O
the NN NN O
zinc NN NN O
finger NN NN O
DNA-binding NN NN O
domain NN NN O
. NN NN O

The NN NN O
fourth NN NN O
mutation NN NN O
is NN NN O
recessive NN NN O
and NN NN O
affects NN NN O
the NN NN O
inhibitory NN NN O
domain NN NN O
( NN NN O
R1 NN NN O
) NN NN O
that NN NN O
binds NN NN O
the NN NN O
NAB NN NN O
transcriptional NN NN O
co-repressors NN NN O
. NN NN O

A NN NN O
combination NN NN O
of NN NN O
DNA-binding NN NN O
assays NN NN O
and NN NN O
transcriptional NN NN O
analysis NN NN O
was NN NN O
used NN NN O
to NN NN O
determine NN NN O
the NN NN O
functional NN NN O
consequences NN NN O
of NN NN O
these NN NN O
mutations NN NN O
. NN NN O

The NN NN O
zinc NN NN O
finger NN NN O
mutations NN NN O
affect NN NN O
DNA NN NN O
binding NN NN O
and NN NN O
the NN NN O
amount NN NN O
of NN NN O
residual NN NN O
binding NN NN O
directly NN NN O
correlates NN NN O
with NN NN O
disease NN NN O
severity NN NN O
. NN NN O

The NN NN O
R1 NN NN O
domain NN NN O
mutation NN NN O
prevents NN NN O
interaction NN NN O
of NN NN O
EGR2 NN NN O
with NN NN O
the NN NN O
NAB NN NN O
co-repressors NN NN O
and NN NN O
thereby NN NN O
increases NN NN O
transcriptional NN NN O
activity NN NN O
. NN NN O

These NN NN O
data NN NN O
provide NN NN O
insight NN NN O
into NN NN O
the NN NN O
possible NN NN O
disease NN NN O
mechanisms NN NN O
underlying NN NN O
EGR2 NN NN O
mutations NN NN O
and NN NN O
the NN NN O
reason NN NN O
for NN NN O
varying NN NN O
severity NN NN O
and NN NN O
differences NN NN O
in NN NN O
inheritance NN NN O
patterns NN NN O
. NN NN O

. NN NN O

10369876 NN NN O
Autosomal NN NN B-SpecificDisease
recessive NN NN I-SpecificDisease
familial NN NN I-SpecificDisease
neurohypophyseal NN NN I-SpecificDisease
diabetes NN NN I-SpecificDisease
insipidus NN NN I-SpecificDisease
with NN NN O
continued NN NN O
secretion NN NN O
of NN NN O
mutant NN NN O
weakly NN NN O
active NN NN O
vasopressin NN NN O
. NN NN O

Familial NN NN B-SpecificDisease
neurohypophyseal NN NN I-SpecificDisease
diabetes NN NN I-SpecificDisease
insipidus NN NN I-SpecificDisease
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
dominant NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
characterized NN NN O
by NN NN O
post-natal NN NN O
development NN NN O
of NN NN O
arginine NN NN B-SpecificDisease
vasopressin NN NN I-SpecificDisease
( NN NN I-SpecificDisease
AVP NN NN I-SpecificDisease
) NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
due NN NN O
to NN NN O
mutations NN NN O
in NN NN O
the NN NN O
AVP NN NN O
gene NN NN O
. NN NN O

All NN NN O
published NN NN O
mutations NN NN O
affect NN NN O
the NN NN O
signal NN NN O
peptide NN NN O
or NN NN O
the NN NN O
neurophysin-II NN NN O
carrier NN NN O
protein NN NN O
and NN NN O
are NN NN O
presumed NN NN O
to NN NN O
interfere NN NN O
with NN NN O
processing NN NN O
of NN NN O
the NN NN O
preprohormone NN NN O
, NN NN O
leading NN NN O
to NN NN O
neuronal NN NN B-DiseaseClass
damage NN NN I-DiseaseClass
. NN NN O

We NN NN O
studied NN NN O
an NN NN O
unusual NN NN O
Palestinian NN NN O
family NN NN O
consisting NN NN O
of NN NN O
asymptomatic NN NN O
first NN NN O
cousin NN NN O
parents NN NN O
and NN NN O
three NN NN O
children NN NN O
affected NN NN O
with NN NN O
neurohypophyseal NN NN B-SpecificDisease
diabetes NN NN I-SpecificDisease
insipidus NN NN I-SpecificDisease
, NN NN O
suggesting NN NN O
autosomal NN NN O
recessive NN NN O
inheritance NN NN O
. NN NN O

All NN NN O
three NN NN O
affected NN NN O
children NN NN O
were NN NN O
homozygous NN NN O
and NN NN O
the NN NN O
parents NN NN O
heterozygous NN NN O
for NN NN O
a NN NN O
single NN NN O
novel NN NN O
mutation NN NN O
( NN NN O
C301- NN NN O
T NN NN O
) NN NN O
in NN NN O
exon NN NN O
1 NN NN O
, NN NN O
replacing NN NN O
Pro7 NN NN O
of NN NN O
mature NN NN O
AVP NN NN O
with NN NN O
Leu NN NN O
( NN NN O
Leu-AVP NN NN O
) NN NN O
. NN NN O

Leu-AVP NN NN O
was NN NN O
a NN NN O
weak NN NN O
agonist NN NN O
with NN NN O
approximately NN NN O
30-fold NN NN O
reduced NN NN O
binding NN NN O
to NN NN O
the NN NN O
human NN NN O
V2 NN NN O
receptor NN NN O
. NN NN O

Measured NN NN O
by NN NN O
radioimmunoassay NN NN O
with NN NN O
a NN NN O
synthetic NN NN O
Leu-AVP NN NN O
standard NN NN O
, NN NN O
serum NN NN O
Leu-AVP NN NN O
levels NN NN O
were NN NN O
elevated NN NN O
in NN NN O
all NN NN O
three NN NN O
children NN NN O
and NN NN O
further NN NN O
increased NN NN O
during NN NN O
water NN NN O
deprivation NN NN O
to NN NN O
as NN NN O
high NN NN O
as NN NN O
30 NN NN O
times NN NN O
normal NN NN O
. NN NN O

The NN NN O
youngest NN NN O
child NN NN O
( NN NN O
2 NN NN O
years NN NN O
old NN NN O
) NN NN O
was NN NN O
only NN NN O
mildly NN NN O
affected NN NN O
but NN NN O
had NN NN O
Leu-AVP NN NN O
levels NN NN O
similar NN NN O
to NN NN O
her NN NN O
severely NN NN O
affected NN NN O
8-year-old NN NN O
brother NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
unknown NN NN O
mechanisms NN NN O
may NN NN O
partially NN NN O
compensate NN NN O
for NN NN O
a NN NN O
deficiency NN NN B-DiseaseClass
of NN NN I-DiseaseClass
active NN NN I-DiseaseClass
AVP NN NN I-DiseaseClass
in NN NN O
very NN NN O
young NN NN O
children NN NN O
. NN NN O

. NN NN O

10377440 NN NN O
X NN NN O
inactivation NN NN O
and NN NN O
somatic NN NN O
cell NN NN O
selection NN NN O
rescue NN NN O
female NN NN O
mice NN NN O
carrying NN NN O
a NN NN O
Piga-null NN NN O
mutation NN NN O
. NN NN O

A NN NN O
somatic NN NN O
mutation NN NN O
in NN NN O
the NN NN O
X NN NN O
linked NN NN O
PIGA NN NN O
gene NN NN O
is NN NN O
responsible NN NN O
for NN NN O
the NN NN O
deficiency NN NN B-DiseaseClass
of NN NN I-DiseaseClass
glycosyl NN NN I-DiseaseClass
phosphatidylinositol NN NN I-DiseaseClass
( NN NN I-DiseaseClass
GPI NN NN I-DiseaseClass
) NN NN I-DiseaseClass
-anchored NN NN I-DiseaseClass
proteins NN NN I-DiseaseClass
on NN NN O
blood NN NN O
cells NN NN O
from NN NN O
patients NN NN O
with NN NN O
paroxysmal NN NN B-SpecificDisease
nocturnal NN NN I-SpecificDisease
hemoglobinuria NN NN I-SpecificDisease
. NN NN O

No NN NN O
inherited NN NN O
form NN NN O
of NN NN O
GPI-anchor NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
has NN NN O
been NN NN O
described NN NN O
. NN NN O

Because NN NN O
conventional NN NN O
Piga NN NN O
gene NN NN O
knockout NN NN O
is NN NN O
associated NN NN O
with NN NN O
high NN NN O
embryonic NN NN B-SpecificDisease
lethality NN NN I-SpecificDisease
in NN NN O
chimeric NN NN O
mice NN NN O
, NN NN O
we NN NN O
used NN NN O
the NN NN O
Cre NN NN O
/ NN NN O
loxP NN NN O
system NN NN O
. NN NN O

We NN NN O
generated NN NN O
mice NN NN O
in NN NN O
which NN NN O
two NN NN O
loxP NN NN O
sites NN NN O
flank NN NN O
part NN NN O
of NN NN O
Piga NN NN O
exon NN NN O
2 NN NN O
. NN NN O

After NN NN O
crossbreeding NN NN O
with NN NN O
female NN NN O
mice NN NN O
of NN NN O
the NN NN O
EIIa-cre NN NN O
strain NN NN O
, NN NN O
the NN NN O
floxed NN NN O
allele NN NN O
undergoes NN NN O
Cre-mediated NN NN O
recombination NN NN O
with NN NN O
high NN NN O
efficiency NN NN O
during NN NN O
early NN NN O
embryonic NN NN O
development NN NN O
. NN NN O

Because NN NN O
of NN NN O
X NN NN O
chromosome NN NN O
inactivation NN NN O
, NN NN O
female NN NN O
offspring NN NN O
are NN NN O
mosaic NN NN O
for NN NN O
cells NN NN O
that NN NN O
express NN NN O
or NN NN O
lack NN NN O
GPI-linked NN NN O
proteins NN NN O
. NN NN O

Analysis NN NN O
of NN NN O
mosaic NN NN O
mice NN NN O
showed NN NN O
that NN NN O
in NN NN O
heart NN NN O
, NN NN O
lung NN NN O
, NN NN O
kidney NN NN O
, NN NN O
brain NN NN O
, NN NN O
and NN NN O
liver NN NN O
, NN NN O
mainly NN NN O
wild-type NN NN O
Piga NN NN O
is NN NN O
active NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
these NN NN O
tissues NN NN O
require NN NN O
GPI-linked NN NN O
proteins NN NN O
. NN NN O

The NN NN O
salient NN NN O
exceptions NN NN O
were NN NN O
spleen NN NN O
, NN NN O
thymus NN NN O
, NN NN O
and NN NN O
red NN NN O
blood NN NN O
cells NN NN O
, NN NN O
which NN NN O
had NN NN O
almost NN NN O
equal NN NN O
numbers NN NN O
of NN NN O
cells NN NN O
expressing NN NN O
the NN NN O
wild-type NN NN O
or NN NN O
the NN NN O
recombined NN NN O
allele NN NN O
, NN NN O
implying NN NN O
that NN NN O
GPI-linked NN NN O
proteins NN NN O
are NN NN O
not NN NN O
essential NN NN O
for NN NN O
the NN NN O
derivation NN NN O
of NN NN O
these NN NN O
tissues NN NN O
. NN NN O

PIGA NN NN O
( NN NN O
- NN NN O
) NN NN O
cells NN NN O
had NN NN O
no NN NN O
growth NN NN O
advantage NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
other NN NN O
factors NN NN O
are NN NN O
needed NN NN O
for NN NN O
their NN NN O
clonal NN NN O
dominance NN NN O
in NN NN O
patients NN NN O
with NN NN O
paroxysmal NN NN B-SpecificDisease
nocturnal NN NN I-SpecificDisease
hemoglobinuria NN NN I-SpecificDisease
. NN NN O

. NN NN O

10381492 NN NN O
The NN NN O
C282Y NN NN O
mutation NN NN O
causing NN NN O
hereditary NN NN B-SpecificDisease
hemochromatosis NN NN I-SpecificDisease
does NN NN O
not NN NN O
produce NN NN O
a NN NN O
null NN NN O
allele NN NN O
. NN NN O

Targeted NN NN O
mutagenesis NN NN O
was NN NN O
used NN NN O
to NN NN O
produce NN NN O
two NN NN O
mutations NN NN O
in NN NN O
the NN NN O
murine NN NN O
hemochromatosis NN NN B-Modifier
gene NN NN O
( NN NN O
Hfe NN NN O
) NN NN O
locus NN NN O
. NN NN O

The NN NN O
first NN NN O
mutation NN NN O
deletes NN NN O
a NN NN O
large NN NN O
portion NN NN O
of NN NN O
the NN NN O
coding NN NN O
sequence NN NN O
, NN NN O
generating NN NN O
a NN NN O
null NN NN O
allele NN NN O
. NN NN O

The NN NN O
second NN NN O
mutation NN NN O
introduces NN NN O
a NN NN O
missense NN NN O
mutation NN NN O
( NN NN O
C282Y NN NN O
) NN NN O
into NN NN O
the NN NN O
Hfe NN NN O
locus NN NN O
, NN NN O
but NN NN O
otherwise NN NN O
leaves NN NN O
the NN NN O
gene NN NN O
intact NN NN O
. NN NN O

This NN NN O
mutation NN NN O
is NN NN O
identical NN NN O
to NN NN O
the NN NN O
disease-causing NN NN O
mutation NN NN O
in NN NN O
patients NN NN O
with NN NN O
hereditary NN NN B-SpecificDisease
hemochromatosis NN NN I-SpecificDisease
. NN NN O

Mice NN NN O
carrying NN NN O
each NN NN O
of NN NN O
the NN NN O
two NN NN O
mutations NN NN O
were NN NN O
bred NN NN O
and NN NN O
analyzed NN NN O
. NN NN O

Homozygosity NN NN O
for NN NN O
either NN NN O
mutation NN NN O
results NN NN O
in NN NN O
postnatal NN NN O
iron NN NN O
loading NN NN O
. NN NN O

The NN NN O
effects NN NN O
of NN NN O
the NN NN O
null NN NN O
mutation NN NN O
are NN NN O
more NN NN O
severe NN NN O
than NN NN O
the NN NN O
effects NN NN O
of NN NN O
the NN NN O
C282Y NN NN O
mutation NN NN O
. NN NN O

Mice NN NN O
heterozygous NN NN O
for NN NN O
either NN NN O
mutation NN NN O
accumulate NN NN O
more NN NN O
iron NN NN O
than NN NN O
normal NN NN O
controls NN NN O
. NN NN O

Interestingly NN NN O
, NN NN O
although NN NN O
liver NN NN O
iron NN NN O
stores NN NN O
are NN NN O
greatly NN NN O
increased NN NN O
, NN NN O
splenic NN NN O
iron NN NN O
is NN NN O
decreased NN NN O
. NN NN O

We NN NN O
conclude NN NN O
that NN NN O
the NN NN O
C282Y NN NN O
mutation NN NN O
does NN NN O
not NN NN O
result NN NN O
in NN NN O
a NN NN O
null NN NN O
allele NN NN O
. NN NN O

. NN NN O

10382909 NN NN O
Genotype-phenotype NN NN O
analysis NN NN O
in NN NN O
X-linked NN NN B-SpecificDisease
Emery-Dreifuss NN NN I-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
and NN NN O
identification NN NN O
of NN NN O
a NN NN O
missense NN NN O
mutation NN NN O
associated NN NN O
with NN NN O
a NN NN O
milder NN NN O
phenotype NN NN O
. NN NN O

Direct NN NN O
sequencing NN NN O
of NN NN O
the NN NN O
emerin NN NN O
gene NN NN O
in NN NN O
22 NN NN O
families NN NN O
with NN NN O
Emery-Dreifuss NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
EMD NN NN B-SpecificDisease
) NN NN O
revealed NN NN O
mutations NN NN O
in NN NN O
21 NN NN O
( NN NN O
95 NN NN O
% NN NN O
) NN NN O
, NN NN O
confirming NN NN O
that NN NN O
emerin NN NN O
mutations NN NN O
can NN NN O
be NN NN O
identified NN NN O
in NN NN O
the NN NN O
majority NN NN O
of NN NN O
families NN NN O
with NN NN O
X-linked NN NN B-SpecificDisease
EMD NN NN I-SpecificDisease
. NN NN O

Most NN NN O
emerin NN NN O
mutations NN NN O
result NN NN O
in NN NN O
absence NN NN O
of NN NN O
the NN NN O
protein NN NN O
. NN NN O

In NN NN O
this NN NN O
study NN NN O
three NN NN O
mutations NN NN O
( NN NN O
a NN NN O
missense NN NN O
mutation NN NN O
Pro183Thr NN NN O
and NN NN O
two NN NN O
in-frame NN NN O
deletions NN NN O
removing NN NN O
residues NN NN O
95-99 NN NN O
and NN NN O
236-241 NN NN O
, NN NN O
respectively NN NN O
) NN NN O
were NN NN O
unusual NN NN O
in NN NN O
being NN NN O
associated NN NN O
with NN NN O
expression NN NN O
of NN NN O
mutant NN NN O
protein NN NN O
. NN NN O

The NN NN O
phenotype NN NN O
in NN NN O
these NN NN O
families NN NN O
was NN NN O
compared NN NN O
in NN NN O
detail NN NN O
with NN NN O
the NN NN O
clinical NN NN O
features NN NN O
in NN NN O
cases NN NN O
with NN NN O
typical NN NN O
null NN NN O
mutations NN NN O
. NN NN O

For NN NN O
the NN NN O
in-frame NN NN O
deletions NN NN O
there NN NN O
were NN NN O
no NN NN O
significant NN NN O
differences NN NN O
. NN NN O

In NN NN O
the NN NN O
family NN NN O
with NN NN O
the NN NN O
missense NN NN O
mutation NN NN O
the NN NN O
phenotype NN NN O
was NN NN O
milder NN NN O
. NN NN O

Age NN NN O
at NN NN O
onset NN NN O
was NN NN O
later NN NN O
for NN NN O
first NN NN O
symptoms NN NN O
and NN NN O
for NN NN O
development NN NN O
of NN NN O
ankle NN NN B-DiseaseClass
contractures NN NN I-DiseaseClass
and NN NN O
muscle NN NN B-DiseaseClass
weakness NN NN I-DiseaseClass
. NN NN O

These NN NN O
findings NN NN O
have NN NN O
diagnostic NN NN O
implications NN NN O
as NN NN O
well NN NN O
as NN NN O
pointing NN NN O
to NN NN O
functionally NN NN O
important NN NN O
regions NN NN O
of NN NN O
the NN NN O
emerin NN NN O
protein NN NN O
. NN NN O

. NN NN O

10382910 NN NN O
Severe NN NN O
clinical NN NN O
expression NN NN O
in NN NN O
X-linked NN NN B-SpecificDisease
Emery-Dreifuss NN NN I-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
. NN NN O

X-linked NN NN B-SpecificDisease
Emery-Dreifuss NN NN I-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
EDMD NN NN B-SpecificDisease
) NN NN O
is NN NN O
a NN NN O
relatively NN NN O
rare NN NN O
benign NN NN B-DiseaseClass
neuromuscular NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
which NN NN O
can NN NN O
vary NN NN O
remarkably NN NN O
in NN NN O
onset NN NN O
, NN NN O
course NN NN O
and NN NN O
severity NN NN O
. NN NN O

In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
a NN NN O
TCTAC NN NN O
deletion NN NN O
spanning NN NN O
the NN NN O
nucleotides NN NN O
631-635 NN NN O
of NN NN O
the NN NN O
emerin NN NN O
gene NN NN O
caused NN NN O
an NN NN O
unusually NN NN O
severe NN NN O
disease NN NN O
phenotype NN NN O
including NN NN O
loss NN NN B-DiseaseClass
of NN NN I-DiseaseClass
ambulation NN NN I-DiseaseClass
and NN NN O
severe NN NN O
muscle NN NN B-DiseaseClass
wasting NN NN I-DiseaseClass
in NN NN O
two NN NN O
affected NN NN O
brothers NN NN O
. NN NN O

The NN NN O
same NN NN O
mutation NN NN O
has NN NN O
been NN NN O
reported NN NN O
previously NN NN O
in NN NN O
an NN NN O
unrelated NN NN O
family NN NN O
showing NN NN O
a NN NN O
significantly NN NN O
milder NN NN O
phenotype NN NN O
. NN NN O

The NN NN O
interfamilial NN NN O
heterogeneity NN NN O
in NN NN O
distribution NN NN O
and NN NN O
in NN NN O
severity NN NN O
of NN NN O
the NN NN O
features NN NN O
in NN NN O
the NN NN O
two NN NN O
families NN NN O
point NN NN O
to NN NN O
environmental NN NN O
or NN NN O
genetic NN NN O
modification NN NN O
as NN NN O
the NN NN O
cause NN NN O
of NN NN O
clinical NN NN O
variability NN NN O
in NN NN O
Emery-Dreifuss NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
. NN NN O

. NN NN O

10398279 NN NN O
Common NN NN O
mutations NN NN O
in NN NN O
BRCA1 NN NN O
and NN NN O
BRCA2 NN NN O
do NN NN O
not NN NN O
contribute NN NN O
to NN NN O
early NN NN O
prostate NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
in NN NN O
Jewish NN NN O
men NN NN O
. NN NN O

BACKGROUND NN NN O
Families NN NN O
with NN NN O
a NN NN O
high NN NN O
incidence NN NN O
of NN NN O
hereditary NN NN B-SpecificDisease
breast NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
, NN NN O
and NN NN O
subsequently NN NN O
shown NN NN O
to NN NN O
have NN NN O
terminating NN NN O
mutations NN NN O
in NN NN O
BRCA1 NN NN O
or NN NN O
BRCA2 NN NN O
, NN NN O
appear NN NN O
to NN NN O
have NN NN O
a NN NN O
higher NN NN O
incidence NN NN O
of NN NN O
prostate NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
among NN NN O
male NN NN O
relatives NN NN O
. NN NN O

We NN NN O
aimed NN NN O
to NN NN O
determine NN NN O
whether NN NN O
the NN NN O
common NN NN O
germline NN NN O
mutations NN NN O
of NN NN O
BRCA1 NN NN O
or NN NN O
BRCA2 NN NN O
in NN NN O
Ashkenazi NN NN O
Jewish NN NN O
men NN NN O
predisposed NN NN O
them NN NN O
to NN NN O
prostate NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

METHODS NN NN O
We NN NN O
examined NN NN O
genomic NN NN O
DNA NN NN O
from NN NN O
83 NN NN O
( NN NN O
for NN NN O
BRCA1 NN NN O
185delAG NN NN O
) NN NN O
or NN NN O
82 NN NN O
( NN NN O
for NN NN O
BRCA2 NN NN O
6174delT NN NN O
) NN NN O
Ashkenazi NN NN O
Jewish NN NN O
prostate NN NN B-Modifier
cancer NN NN I-Modifier
patients NN NN O
, NN NN O
most NN NN O
of NN NN O
whom NN NN O
were NN NN O
treated NN NN O
at NN NN O
a NN NN O
relatively NN NN O
young NN NN O
age NN NN O
, NN NN O
for NN NN O
the NN NN O
most NN NN O
common NN NN O
germline NN NN O
mutation NN NN O
in NN NN O
each NN NN O
gene NN NN O
seen NN NN O
in NN NN O
the NN NN O
Ashkenazi NN NN O
population NN NN O
. NN NN O

RESULTS NN NN O
Our NN NN O
study NN NN O
should NN NN O
have NN NN O
been NN NN O
able NN NN O
to NN NN O
detect NN NN O
a NN NN O
4-5-fold NN NN O
increase NN NN O
in NN NN O
the NN NN O
risk NN NN O
of NN NN O
prostate NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
due NN NN O
to NN NN O
mutation NN NN O
of NN NN O
BRCA1 NN NN O
or NN NN O
BRCA2 NN NN O
. NN NN O

However NN NN O
, NN NN O
only NN NN O
one NN NN O
( NN NN O
1 NN NN O
. NN NN O

15 NN NN O
% NN NN O
; NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
, NN NN O
0-3 NN NN O
. NN NN O

6 NN NN O
% NN NN O
) NN NN O
of NN NN O
the NN NN O
patients NN NN O
was NN NN O
heterozygous NN NN O
for NN NN O
the NN NN O
BRCA1 NN NN O
mutant NN NN O
allele NN NN O
, NN NN O
and NN NN O
only NN NN O
two NN NN O
were NN NN O
heterozygous NN NN O
for NN NN O
the NN NN O
BRCA2 NN NN O
mutation NN NN O
( NN NN O
2 NN NN O
. NN NN O

4 NN NN O
% NN NN O
; NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
, NN NN O
0-6 NN NN O
. NN NN O

2 NN NN O
% NN NN O
) NN NN O
. NN NN O

CONCLUSIONS NN NN O
The NN NN O
incidence NN NN O
of NN NN O
each NN NN O
of NN NN O
the NN NN O
germline NN NN O
mutations NN NN O
in NN NN O
these NN NN O
prostate NN NN B-Modifier
cancer NN NN I-Modifier
patients NN NN O
closely NN NN O
matched NN NN O
their NN NN O
incidence NN NN O
( NN NN O
about NN NN O
1 NN NN O
% NN NN O
) NN NN O
in NN NN O
the NN NN O
general NN NN O
Ashkenazi NN NN O
Jewish NN NN O
population NN NN O
. NN NN O

This NN NN O
suggests NN NN O
that NN NN O
unlike NN NN O
cases NN NN O
of NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancers NN NN I-CompositeMention
, NN NN O
mutations NN NN O
in NN NN O
BRCA1 NN NN O
or NN NN O
BRCA2 NN NN O
do NN NN O
not NN NN O
significantly NN NN O
predispose NN NN O
men NN NN O
to NN NN O
prostate NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease

10398436 NN NN O
Beta-catenin NN NN O
accumulation NN NN O
and NN NN O
mutation NN NN O
of NN NN O
the NN NN O
CTNNB1 NN NN O
gene NN NN O
in NN NN O
hepatoblastoma NN NN B-SpecificDisease
. NN NN O

Hepatoblastoma NN NN B-SpecificDisease
is NN NN O
a NN NN O
rare NN NN O
malignant NN NN B-DiseaseClass
tumor NN NN I-DiseaseClass
of NN NN I-DiseaseClass
the NN NN I-DiseaseClass
liver NN NN I-DiseaseClass
that NN NN O
occurs NN NN O
in NN NN O
children NN NN O
at NN NN O
an NN NN O
average NN NN O
age NN NN O
of NN NN O
2 NN NN O
to NN NN O
3 NN NN O
years NN NN O
. NN NN O

Epidemiologic NN NN O
studies NN NN O
have NN NN O
shown NN NN O
an NN NN O
increased NN NN O
frequency NN NN O
of NN NN O
this NN NN O
tumor NN NN B-Modifier
type NN NN O
in NN NN O
families NN NN O
affected NN NN O
by NN NN O
adenomatous NN NN B-SpecificDisease
polyposis NN NN I-SpecificDisease
coli NN NN I-SpecificDisease
. NN NN O

In NN NN O
addition NN NN O
to NN NN O
the NN NN O
epidemiologic NN NN O
data NN NN O
, NN NN O
molecular NN NN O
genetic NN NN O
studies NN NN O
suggest NN NN O
that NN NN O
inactivation NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
tumor NN NN I-Modifier
suppressor NN NN O
may NN NN O
be NN NN O
involved NN NN O
in NN NN O
hepatoblastoma NN NN B-Modifier
tumorigenesis NN NN O
. NN NN O

A NN NN O
major NN NN O
function NN NN O
of NN NN O
APC NN NN O
is NN NN O
the NN NN O
downregulation NN NN O
of NN NN O
beta-catenin NN NN O
, NN NN O
a NN NN O
transcription-activating NN NN O
protein NN NN O
with NN NN O
oncogenic NN NN O
potential NN NN O
. NN NN O

In NN NN O
an NN NN O
ongoing NN NN O
immunohistochemical NN NN O
study NN NN O
of NN NN O
beta-catenin NN NN O
expression NN NN O
in NN NN O
sporadic NN NN O
cases NN NN O
of NN NN O
tumor NN NN B-Modifier
types NN NN O
that NN NN O
are NN NN O
associated NN NN O
with NN NN O
adenomatous NN NN B-SpecificDisease
polyposis NN NN I-SpecificDisease
coli NN NN I-SpecificDisease
, NN NN O
we NN NN O
observed NN NN O
increased NN NN O
beta-catenin NN NN O
levels NN NN O
in NN NN O
the NN NN O
cytoplasm NN NN O
and NN NN O
in NN NN O
the NN NN O
nuclei NN NN O
of NN NN O
three NN NN O
investigated NN NN O
hepatoblastomas NN NN B-SpecificDisease
. NN NN O

Sequencing NN NN O
of NN NN O
exon NN NN O
3 NN NN O
of NN NN O
the NN NN O
beta-catenin NN NN O
gene NN NN O
( NN NN O
CTNNB1 NN NN O
) NN NN O
revealed NN NN O
an NN NN O
activating NN NN O
mutation NN NN O
in NN NN O
one NN NN O
of NN NN O
the NN NN O
tumor NN NN B-Modifier
samples NN NN O
. NN NN O

Our NN NN O
data NN NN O
indicate NN NN O
for NN NN O
the NN NN O
first NN NN O
time NN NN O
that NN NN O
beta-catenin NN NN O
accumulation NN NN O
may NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
hepatoblastoma NN NN B-SpecificDisease
and NN NN O
that NN NN O
activating NN NN O
mutations NN NN O
of NN NN O
the NN NN O
beta-catenin NN NN O
gene NN NN O
may NN NN O
substitute NN NN O
biallelic NN NN O
APC NN NN O
inactivation NN NN O
in NN NN O
this NN NN O
tumor NN NN B-Modifier
type NN NN O
. NN NN O

Genes NN NN O
Chromosomes NN NN O
Cancer NN NN O
25 NN NN O
399-402 NN NN O
, NN NN O
1999 NN NN O
. NN NN O

. NN NN O

10403837 NN NN O
Decrease NN NN O
in NN NN O
GTP NN NN O
cyclohydrolase NN NN O
I NN NN O
gene NN NN O
expression NN NN O
caused NN NN O
by NN NN O
inactivation NN NN O
of NN NN O
one NN NN O
allele NN NN O
in NN NN O
hereditary NN NN B-SpecificDisease
progressive NN NN I-SpecificDisease
dystonia NN NN I-SpecificDisease
with NN NN O
marked NN NN O
diurnal NN NN O
fluctuation NN NN O
. NN NN O

Hereditary NN NN B-SpecificDisease
progressive NN NN I-SpecificDisease
dystonia NN NN I-SpecificDisease
with NN NN O
marked NN NN O
diurnal NN NN O
fluctuation NN NN O
( NN NN O
HPD NN NN B-SpecificDisease
; NN NN O
dopa-responsive NN NN B-SpecificDisease
dystonia NN NN I-SpecificDisease
, NN NN O
DRD NN NN B-SpecificDisease
) NN NN O
have NN NN O
been NN NN O
recently NN NN O
found NN NN O
to NN NN O
be NN NN O
caused NN NN O
by NN NN O
a NN NN O
genetic NN NN B-DiseaseClass
defect NN NN I-DiseaseClass
in NN NN O
the NN NN O
GTP NN NN O
cyclohydrolase NN NN O
I NN NN O
( NN NN O
GCH1 NN NN O
) NN NN O
gene NN NN O
. NN NN O

In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
quantified NN NN O
the NN NN O
mRNA NN NN O
level NN NN O
of NN NN O
GCH1 NN NN O
in NN NN O
phytohemagglutinin NN NN O
( NN NN O
PHA NN NN O
) NN NN O
-stimulated NN NN O
mononuclear NN NN O
blood NN NN O
cells NN NN O
from NN NN O
one NN NN O
Japanese NN NN O
family NN NN O
that NN NN O
do NN NN O
not NN NN O
have NN NN O
a NN NN O
mutation NN NN O
in NN NN O
the NN NN O
coding NN NN O
region NN NN O
or NN NN O
splice NN NN O
junctions NN NN O
of NN NN O
the NN NN O
gene NN NN O
. NN NN O

The NN NN O
results NN NN O
showed NN NN O
that NN NN O
the NN NN O
amounts NN NN O
of NN NN O
the NN NN O
GCH1 NN NN O
mRNA NN NN O
were NN NN O
decreased NN NN O
to NN NN O
about NN NN O
40 NN NN O
% NN NN O
of NN NN O
the NN NN O
normal NN NN O
level NN NN O
in NN NN O
both NN NN O
patients NN NN O
and NN NN O
carriers NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
we NN NN O
found NN NN O
that NN NN O
the NN NN O
GCH1 NN NN O
mRNA NN NN O
was NN NN O
transcribed NN NN O
from NN NN O
only NN NN O
one NN NN O
allele NN NN O
, NN NN O
indicating NN NN O
that NN NN O
the NN NN O
other NN NN O
allele NN NN O
was NN NN O
in NN NN O
an NN NN O
inactive NN NN O
state NN NN O
. NN NN O

These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
some NN NN O
novel NN NN O
mutations NN NN O
should NN NN O
exist NN NN O
on NN NN O
one NN NN O
of NN NN O
the NN NN O
alleles NN NN O
in NN NN O
some NN NN O
unknown NN NN O
region NN NN O
of NN NN O
the NN NN O
GCH1 NN NN O
gene NN NN O
, NN NN O
and NN NN O
may NN NN O
decrease NN NN O
the NN NN O
GCH1 NN NN O
mRNA NN NN O
causing NN NN O
the NN NN O
HPD NN NN B-Modifier
/ NN NN O
DRD NN NN B-Modifier
symptoms NN NN O
. NN NN O

. NN NN O

10404839 NN NN O
Sulfate NN NN O
transport NN NN O
is NN NN O
not NN NN O
impaired NN NN O
in NN NN O
pendred NN NN B-Modifier
syndrome NN NN I-Modifier
thyrocytes NN NN O
. NN NN O

Pendred NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
is NN NN O
the NN NN O
most NN NN O
common NN NN O
form NN NN O
of NN NN O
syndromic NN NN B-DiseaseClass
deafness NN NN I-DiseaseClass
, NN NN O
characterized NN NN O
by NN NN O
dyshormonogenic NN NN B-SpecificDisease
goiter NN NN I-SpecificDisease
associated NN NN O
with NN NN O
sensory-neural NN NN B-DiseaseClass
deafness NN NN I-DiseaseClass
. NN NN O

The NN NN O
gene NN NN O
responsible NN NN O
for NN NN O
the NN NN O
disease NN NN O
( NN NN O
PDS NN NN B-SpecificDisease
) NN NN O
has NN NN O
been NN NN O
cloned NN NN O
, NN NN O
but NN NN O
its NN NN O
function NN NN O
is NN NN O
as NN NN O
yet NN NN O
unknown NN NN O
and NN NN O
the NN NN O
connection NN NN O
between NN NN O
thyroid NN NN B-DiseaseClass
goiter NN NN I-DiseaseClass
and NN NN O
sensory-neural NN NN B-DiseaseClass
deafness NN NN I-DiseaseClass
remains NN NN O
an NN NN O
enigma NN NN O
. NN NN O

PDS NN NN O
codes NN NN O
for NN NN O
a NN NN O
novel NN NN O
protein NN NN O
, NN NN O
pendrin NN NN O
, NN NN O
which NN NN O
is NN NN O
closely NN NN O
related NN NN O
to NN NN O
a NN NN O
number NN NN O
of NN NN O
sufate NN NN O
transporters NN NN O
. NN NN O

Mechanisms NN NN O
by NN NN O
which NN NN O
abnormal NN NN O
sulfate NN NN O
transport NN NN O
could NN NN O
deleteriously NN NN O
affect NN NN O
iodide NN NN O
organification NN NN O
have NN NN O
been NN NN O
proposed NN NN O
. NN NN O

We NN NN O
tested NN NN O
sulfate NN NN O
transport NN NN O
in NN NN O
thyrocytes NN NN O
obtained NN NN O
from NN NN O
Pendred NN NN B-Modifier
syndrome NN NN I-Modifier
patients NN NN O
and NN NN O
found NN NN O
that NN NN O
it NN NN O
was NN NN O
not NN NN O
defective NN NN O
. NN NN O

This NN NN O
suggests NN NN O
that NN NN O
pendrin NN NN O
in NN NN O
fact NN NN O
may NN NN O
not NN NN O
be NN NN O
a NN NN O
sulfate NN NN O
transporter NN NN O
, NN NN O
and NN NN O
emphasizes NN NN O
the NN NN O
importance NN NN O
of NN NN O
functional NN NN O
studies NN NN O
on NN NN O
this NN NN O
novel NN NN O
protein NN NN O
. NN NN O

. NN NN O

10406661 NN NN O
Small NN NN O
deletions NN NN O
in NN NN O
the NN NN O
type NN NN O
II NN NN O
collagen NN NN O
triple NN NN O
helix NN NN O
produce NN NN O
kniest NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
. NN NN O

Kniest NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
is NN NN O
a NN NN O
moderately NN NN O
severe NN NN O
type NN NN B-DiseaseClass
II NN NN I-DiseaseClass
collagenopathy NN NN I-DiseaseClass
, NN NN O
characterized NN NN O
by NN NN O
short NN NN O
trunk NN NN O
and NN NN O
limbs NN NN O
, NN NN O
kyphoscoliosis NN NN B-DiseaseClass
, NN NN O
midface NN NN B-SpecificDisease
hypoplasia NN NN I-SpecificDisease
, NN NN O
severe NN NN O
myopia NN NN B-DiseaseClass
, NN NN O
and NN NN O
hearing NN NN B-DiseaseClass
loss NN NN I-DiseaseClass
. NN NN O

Mutations NN NN O
in NN NN O
the NN NN O
gene NN NN O
that NN NN O
encodes NN NN O
type NN NN O
II NN NN O
collagen NN NN O
( NN NN O
COL2A1 NN NN O
) NN NN O
, NN NN O
the NN NN O
predominant NN NN O
protein NN NN O
of NN NN O
cartilage NN NN O
, NN NN O
have NN NN O
been NN NN O
identified NN NN O
in NN NN O
a NN NN O
number NN NN O
of NN NN O
individuals NN NN O
with NN NN O
Kniest NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
. NN NN O

All NN NN O
but NN NN O
two NN NN O
of NN NN O
these NN NN O
previously NN NN O
described NN NN O
mutations NN NN O
cause NN NN O
in-frame NN NN O
deletions NN NN O
in NN NN O
type NN NN O
II NN NN O
collagen NN NN O
, NN NN O
either NN NN O
by NN NN O
small NN NN O
deletions NN NN O
in NN NN O
the NN NN O
gene NN NN O
or NN NN O
splice NN NN O
site NN NN O
alterations NN NN O
. NN NN O

Furthermore NN NN O
, NN NN O
all NN NN O
but NN NN O
one NN NN O
of NN NN O
these NN NN O
mutations NN NN O
is NN NN O
located NN NN O
between NN NN O
exons NN NN O
12 NN NN O
and NN NN O
24 NN NN O
in NN NN O
the NN NN O
COL2A1 NN NN O
gene NN NN O
. NN NN O

We NN NN O
used NN NN O
heteroduplex NN NN O
analysis NN NN O
to NN NN O
identify NN NN O
sequence NN NN O
anomalies NN NN O
in NN NN O
five NN NN O
individuals NN NN O
with NN NN O
Kniest NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
. NN NN O

Sequencing NN NN O
of NN NN O
the NN NN O
index NN NN O
patients NN NN O
genomic NN NN O
DNA NN NN O
identified NN NN O
four NN NN O
new NN NN O
dominant NN NN O
mutations NN NN O
in NN NN O
COL2A1 NN NN O
that NN NN O
result NN NN O
in NN NN O
Kniest NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
a NN NN O
21-bp NN NN O
deletion NN NN O
in NN NN O
exon NN NN O
16 NN NN O
, NN NN O
an NN NN O
18-bp NN NN O
deletion NN NN O
in NN NN O
exon NN NN O
19 NN NN O
, NN NN O
and NN NN O
4-bp NN NN O
deletions NN NN O
in NN NN O
the NN NN O
splice NN NN O
donor NN NN O
sites NN NN O
of NN NN O
introns NN NN O
14 NN NN O
and NN NN O
20 NN NN O
. NN NN O

A NN NN O
previously NN NN O
described NN NN O
28-bp NN NN O
deletion NN NN O
at NN NN O
the NN NN O
COL2A1 NN NN O
exon NN NN O
12-intron NN NN O
12 NN NN O
junction NN NN O
, NN NN O
deleting NN NN O
the NN NN O
splice NN NN O
donor NN NN O
site NN NN O
, NN NN O
was NN NN O
identified NN NN O
in NN NN O
the NN NN O
fifth NN NN O
case NN NN O
. NN NN O

The NN NN O
latter NN NN O
three NN NN O
mutations NN NN O
are NN NN O
predicted NN NN O
to NN NN O
result NN NN O
in NN NN O
exon NN NN O
skipping NN NN O
in NN NN O
the NN NN O
mRNA NN NN O
encoded NN NN O
from NN NN O
the NN NN O
mutant NN NN O
allele NN NN O
. NN NN O

These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
Kniest NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
results NN NN O
from NN NN O
shorter NN NN O
type NN NN O
II NN NN O
collagen NN NN O
monomers NN NN O
, NN NN O
and NN NN O
support NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
alteration NN NN O
of NN NN O
a NN NN O
specific NN NN O
COL2A1 NN NN O
domain NN NN O
, NN NN O
which NN NN O
may NN NN O
span NN NN O
from NN NN O
exons NN NN O
12 NN NN O
to NN NN O
24 NN NN O
, NN NN O
leads NN NN O
to NN NN O
the NN NN O
Kniest NN NN B-Modifier
dysplasia NN NN I-Modifier
phenotype NN NN O
. NN NN O

. NN NN O

10408771 NN NN O
Classical NN NN B-SpecificDisease
galactosemia NN NN I-SpecificDisease
and NN NN O
mutations NN NN O
at NN NN O
the NN NN O
galactose-1-phosphate NN NN O
uridyl NN NN O
transferase NN NN O
( NN NN O
GALT NN NN O
) NN NN O
gene NN NN O
. NN NN O

Classical NN NN B-SpecificDisease
galactosemia NN NN I-SpecificDisease
is NN NN O
caused NN NN O
by NN NN O
a NN NN O
deficiency NN NN O
in NN NN O
activity NN NN O
of NN NN O
the NN NN O
enzyme NN NN O
galactose-1-phosphate NN NN O
uridyl NN NN O
transferase NN NN O
( NN NN O
GALT NN NN O
) NN NN O
, NN NN O
which NN NN O
, NN NN O
in NN NN O
turn NN NN O
, NN NN O
is NN NN O
caused NN NN O
by NN NN O
mutations NN NN O
at NN NN O
the NN NN O
GALT NN NN O
gene NN NN O
. NN NN O

The NN NN O
disorder NN NN O
exhibits NN NN O
considerable NN NN O
allelic NN NN O
heterogeneity NN NN O
and NN NN O
, NN NN O
at NN NN O
the NN NN O
end NN NN O
of NN NN O
1998 NN NN O
, NN NN O
more NN NN O
than NN NN O
150 NN NN O
different NN NN O
base NN NN O
changes NN NN O
were NN NN O
recorded NN NN O
in NN NN O
24 NN NN O
different NN NN O
populations NN NN O
and NN NN O
ethnic NN NN O
groups NN NN O
in NN NN O
15 NN NN O
countries NN NN O
worldwide NN NN O
. NN NN O

The NN NN O
mutations NN NN O
most NN NN O
frequently NN NN O
cited NN NN O
are NN NN O
Q188R NN NN O
, NN NN O
K285N NN NN O
, NN NN O
S135L NN NN O
, NN NN O
and NN NN O
N314D NN NN O
. NN NN O

Q188R NN NN O
is NN NN O
the NN NN O
most NN NN O
common NN NN O
mutation NN NN O
in NN NN O
European NN NN O
populations NN NN O
or NN NN O
in NN NN O
those NN NN O
predominantly NN NN O
of NN NN O
European NN NN O
descent NN NN O
. NN NN O

Overall NN NN O
, NN NN O
it NN NN O
accounts NN NN O
for NN NN O
60-70 NN NN O
% NN NN O
of NN NN O
mutant NN NN O
chromosomes NN NN O
, NN NN O
but NN NN O
there NN NN O
are NN NN O
significant NN NN O
differences NN NN O
in NN NN O
its NN NN O
relative NN NN O
frequency NN NN O
in NN NN O
individual NN NN O
populations NN NN O
. NN NN O

Individuals NN NN O
homoallelic NN NN O
for NN NN O
Q188R NN NN O
tend NN NN O
to NN NN O
have NN NN O
a NN NN O
severe NN NN O
phenotype NN NN O
and NN NN O
this NN NN O
is NN NN O
in NN NN O
keeping NN NN O
with NN NN O
the NN NN O
virtually NN NN O
complete NN NN O
loss NN NN O
of NN NN O
enzyme NN NN O
activity NN NN O
observed NN NN O
in NN NN O
in NN NN O
vitro NN NN O
expression NN NN O
systems NN NN O
. NN NN O

Globally NN NN O
, NN NN O
K285N NN NN O
is NN NN O
rarer NN NN O
, NN NN O
but NN NN O
in NN NN O
many NN NN O
European NN NN O
populations NN NN O
it NN NN O
can NN NN O
be NN NN O
found NN NN O
on NN NN O
25-40 NN NN O
% NN NN O
of NN NN O
mutant NN NN O
chromosomes NN NN O
. NN NN O

It NN NN O
is NN NN O
invariably NN NN O
associated NN NN O
with NN NN O
a NN NN O
severe NN NN O
phenotype NN NN O
. NN NN O

S135L NN NN O
is NN NN O
found NN NN O
almost NN NN O
exclusively NN NN O
in NN NN O
African NN NN O
Americans NN NN O
. NN NN O

In NN NN O
vitro NN NN O
expression NN NN O
results NN NN O
are NN NN O
discrepant NN NN O
, NN NN O
but NN NN O
some NN NN O
individuals NN NN O
carrying NN NN O
S135L NN NN O
appear NN NN O
to NN NN O
exhibit NN NN O
GALT NN NN O
activity NN NN O
in NN NN O
some NN NN O
tissues NN NN O
. NN NN O

Duarte NN NN O
1 NN NN O
( NN NN O
or NN NN O
Los NN NN O
Angeles NN NN O
) NN NN O
and NN NN O
Duarte NN NN O
2 NN NN O
( NN NN O
or NN NN O
Duarte NN NN O
) NN NN O
variants NN NN O
carry NN NN O
the NN NN O
same NN NN O
amino NN NN O
acid NN NN O
substitution NN NN O
, NN NN O
N314D NN NN O
, NN NN O
even NN NN O
though NN NN O
D1 NN NN O
is NN NN O
associated NN NN O
with NN NN O
increased NN NN O
erythrocyte NN NN O
GALT NN NN O
activity NN NN O
and NN NN O
D2 NN NN O
with NN NN O
reduced NN NN O
activity NN NN O
. NN NN O

N314D NN NN O
is NN NN O
in NN NN O
linkage NN NN O
disequilibrium NN NN O
with NN NN O
other NN NN O
base NN NN O
changes NN NN O
that NN NN O
differ NN NN O
on NN NN O
the NN NN O
D1 NN NN O
and NN NN O
D2 NN NN O
alleles NN NN O
. NN NN O

N314D NN NN O
does NN NN O
not NN NN O
impair NN NN O
GALT NN NN O
activity NN NN O
in NN NN O
in NN NN O
vitro NN NN O
expression NN NN O
systems NN NN O
. NN NN O

However NN NN O
, NN NN O
there NN NN O
are NN NN O
differences NN NN O
in NN NN O
the NN NN O
abundance NN NN O
of NN NN O
GALT NN NN O
protein NN NN O
in NN NN O
lymphoblastoid NN NN O
cells NN NN O
lines NN NN O
from NN NN O
D2 NN NN O
and NN NN O
D1 NN NN O
individuals NN NN O
. NN NN O

It NN NN O
is NN NN O
unclear NN NN O
whether NN NN O
the NN NN O
specific NN NN O
molecular NN NN O
changes NN NN O
that NN NN O
distinguish NN NN O
the NN NN O
D1 NN NN O
and NN NN O
D2 NN NN O
alleles NN NN O
account NN NN O
for NN NN O
the NN NN O
different NN NN O
activities NN NN O
. NN NN O

The NN NN O
considerable NN NN O
genetic NN NN O
heterogeneity NN NN O
documented NN NN O
to NN NN O
date NN NN O
undoubtedly NN NN O
contributes NN NN O
to NN NN O
the NN NN O
phenotypic NN NN O
heterogeneity NN NN O
that NN NN O
is NN NN O
observed NN NN O
in NN NN O
galactosemia NN NN B-SpecificDisease
. NN NN O

The NN NN O
additional NN NN O
effects NN NN O
of NN NN O
nonallelic NN NN O
variation NN NN O
and NN NN O
other NN NN O
constitutional NN NN O
factors NN NN O
on NN NN O
phenotypic NN NN O
variability NN NN O
remain NN NN O
to NN NN O
be NN NN O
elucidated NN NN O
. NN NN O

. NN NN O

10408776 NN NN O
Mutations NN NN O
of NN NN O
the NN NN O
VHL NN NN B-Modifier
gene NN NN O
in NN NN O
sporadic NN NN B-SpecificDisease
renal NN NN I-SpecificDisease
cell NN NN I-SpecificDisease
carcinoma NN NN I-SpecificDisease
: NN NN O
definition NN NN O
of NN NN O
a NN NN O
risk NN NN O
factor NN NN O
for NN NN O
VHL NN NN B-Modifier
patients NN NN O
to NN NN O
develop NN NN O
an NN NN O
RCC NN NN B-SpecificDisease
. NN NN O

To NN NN O
investigate NN NN O
the NN NN O
nature NN NN O
of NN NN O
somatic NN NN O
von NN NN B-Modifier
Hippel-Lindau NN NN I-Modifier
( NN NN O
VHL NN NN B-Modifier
) NN NN O
mutations NN NN O
, NN NN O
we NN NN O
analyzed NN NN O
173 NN NN O
primary NN NN O
sporadic NN NN O
human NN NN O
renal NN NN B-SpecificDisease
cell NN NN I-SpecificDisease
carcinomas NN NN I-SpecificDisease
for NN NN O
mutations NN NN O
of NN NN O
the NN NN O
VHL NN NN B-Modifier
tumor NN NN I-Modifier
suppressor NN NN O
gene NN NN O
, NN NN O
using NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
( NN NN O
PCR NN NN O
) NN NN O
and NN NN O
single-strand NN NN O
conformational NN NN O
polymorphism NN NN O
analysis NN NN O
( NN NN O
SSCP NN NN O
) NN NN O
of NN NN O
DNA NN NN O
. NN NN O

We NN NN O
detected NN NN O
abnormal NN NN O
SSCP NN NN O
pattern NN NN O
in NN NN O
73 NN NN O
samples NN NN O
. NN NN O

After NN NN O
sequencing NN NN O
, NN NN O
we NN NN O
identified NN NN O
microdeletions NN NN O
in NN NN O
58 NN NN O
% NN NN O
of NN NN O
cases NN NN O
, NN NN O
microinsertions NN NN O
in NN NN O
17 NN NN O
% NN NN O
, NN NN O
nonsense NN NN O
mutations NN NN O
in NN NN O
8 NN NN O
% NN NN O
, NN NN O
and NN NN O
missense NN NN O
mutations NN NN O
in NN NN O
17 NN NN O
% NN NN O
. NN NN O

Among NN NN O
these NN NN O
mutations NN NN O
, NN NN O
50 NN NN O
% NN NN O
correspond NN NN O
to NN NN O
new NN NN O
mutations NN NN O
. NN NN O

VHL NN NN B-Modifier
mutations NN NN O
were NN NN O
found NN NN O
only NN NN O
in NN NN O
the NN NN O
nonpapillary NN NN B-Modifier
renal NN NN I-Modifier
cell NN NN I-Modifier
carcinoma NN NN I-Modifier
( NN NN O
RCC NN NN B-Modifier
) NN NN O
subtype NN NN O
, NN NN O
as NN NN O
previously NN NN O
reported NN NN O
. NN NN O

To NN NN O
compare NN NN O
somatic NN NN O
and NN NN O
germline NN NN O
mutations NN NN O
, NN NN O
we NN NN O
used NN NN O
the NN NN O
VHL NN NN B-Modifier
database NN NN O
, NN NN O
which NN NN O
includes NN NN O
507 NN NN O
mutations NN NN O
. NN NN O

The NN NN O
study NN NN O
of NN NN O
mutational NN NN O
events NN NN O
revealed NN NN O
a NN NN O
significant NN NN O
difference NN NN O
between NN NN O
somatic NN NN O
and NN NN O
germline NN NN O
mutations NN NN O
with NN NN O
mutations NN NN O
leading NN NN O
to NN NN O
truncated NN NN O
proteins NN NN O
observed NN NN O
in NN NN O
78 NN NN O
% NN NN O
of NN NN O
somatic NN NN O
mutations NN NN O
vs NN NN O
only NN NN O
37 NN NN O
% NN NN O
in NN NN O
germline NN NN O
mutations NN NN O
( NN NN O
P NN NN O
0 NN NN O
. NN NN O

001 NN NN O
) NN NN O
. NN NN O

We NN NN O
postulated NN NN O
that NN NN O
a NN NN O
specific NN NN O
pattern NN NN O
of NN NN O
VHL NN NN B-Modifier
mutations NN NN O
is NN NN O
associated NN NN O
with NN NN O
sporadic NN NN B-SpecificDisease
RCC NN NN I-SpecificDisease
. NN NN O

This NN NN O
pattern NN NN O
corresponds NN NN O
to NN NN O
mutations NN NN O
leading NN NN O
mainly NN NN O
to NN NN O
truncated NN NN O
proteins NN NN O
with NN NN O
few NN NN O
specific NN NN O
missense NN NN O
mutations NN NN O
. NN NN O

We NN NN O
then NN NN O
analyzed NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
RCC NN NN B-SpecificDisease
in NN NN O
VHL NN NN B-Modifier
families NN NN O
, NN NN O
based NN NN O
on NN NN O
the NN NN O
nature NN NN O
of NN NN O
mutations NN NN O
. NN NN O

We NN NN O
observed NN NN O
RCC NN NN B-SpecificDisease
in NN NN O
at NN NN O
least NN NN O
one NN NN O
member NN NN O
of NN NN O
the NN NN O
VHL NN NN B-Modifier
families NN NN O
in NN NN O
77 NN NN O
% NN NN O
of NN NN O
cases NN NN O
with NN NN O
mutations NN NN O
leading NN NN O
to NN NN O
truncated NN NN O
proteins NN NN O
versus NN NN O
55 NN NN O
% NN NN O
in NN NN O
cases NN NN O
with NN NN O
missense NN NN O
mutations NN NN O
( NN NN O
P NN NN O
0 NN NN O
. NN NN O

05 NN NN O
) NN NN O
. NN NN O

Thus NN NN O
, NN NN O
mutations NN NN O
resulting NN NN O
in NN NN O
truncated NN NN O
proteins NN NN O
may NN NN O
lead NN NN O
to NN NN O
a NN NN O
higher NN NN O
risk NN NN O
of NN NN O
RCC NN NN B-SpecificDisease
in NN NN O
VHL NN NN B-Modifier
patients NN NN O

10411929 NN NN O
Defective NN NN O
CTLA-4 NN NN O
cycling NN NN O
pathway NN NN O
in NN NN O
Chediak-Higashi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
: NN NN O
a NN NN O
possible NN NN O
mechanism NN NN O
for NN NN O
deregulation NN NN O
of NN NN O
T NN NN O
lymphocyte NN NN O
activation NN NN O
. NN NN O

Cytotoxic NN NN O
T NN NN O
lymphocyte-associated NN NN O
antigen NN NN O
4 NN NN O
( NN NN O
CTLA-4 NN NN O
, NN NN O
also NN NN O
known NN NN O
as NN NN O
CD152 NN NN O
) NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
play NN NN O
a NN NN O
major NN NN O
role NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
T NN NN O
cell NN NN O
activation NN NN O
. NN NN O

Its NN NN O
membrane NN NN O
expression NN NN O
is NN NN O
highly NN NN O
regulated NN NN O
by NN NN O
endocytosis NN NN O
and NN NN O
trafficking NN NN O
through NN NN O
the NN NN O
secretory NN NN O
lysosome NN NN O
pathway NN NN O
. NN NN O

Chediak-Higashi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
CHS NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
inherited NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
caused NN NN O
by NN NN O
mutations NN NN O
in NN NN O
the NN NN O
lysosomal NN NN O
trafficking NN NN O
regulator NN NN O
gene NN NN O
, NN NN O
LYST NN NN O
. NN NN O

It NN NN O
results NN NN O
in NN NN O
defective NN NN O
membrane NN NN O
targeting NN NN O
of NN NN O
the NN NN O
proteins NN NN O
present NN NN O
in NN NN O
secretory NN NN O
lysosomes NN NN O
, NN NN O
and NN NN O
it NN NN O
is NN NN O
associated NN NN O
with NN NN O
a NN NN O
variety NN NN O
of NN NN O
features NN NN O
, NN NN O
including NN NN O
a NN NN O
lymphoproliferative NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
with NN NN O
hemophagocytosis NN NN B-DiseaseClass
. NN NN O

The NN NN O
murine NN NN O
equivalent NN NN O
of NN NN O
CHS NN NN B-SpecificDisease
, NN NN O
beige NN NN O
mice NN NN O
, NN NN O
present NN NN O
similar NN NN O
characteristics NN NN O
but NN NN O
do NN NN O
not NN NN O
develop NN NN O
the NN NN O
lymphoproliferative NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

We NN NN O
show NN NN O
herein NN NN O
that NN NN O
CTLA-4 NN NN O
is NN NN O
present NN NN O
in NN NN O
enlarged NN NN O
, NN NN O
abnormal NN NN O
vesicles NN NN O
in NN NN O
CHS NN NN B-Modifier
T NN NN O
cells NN NN O
and NN NN O
is NN NN O
not NN NN O
properly NN NN O
expressed NN NN O
at NN NN O
the NN NN O
cell NN NN O
surface NN NN O
after NN NN O
T NN NN O
cell NN NN O
activation NN NN O
, NN NN O
whereas NN NN O
its NN NN O
surface NN NN O
expression NN NN O
is NN NN O
not NN NN O
impaired NN NN O
. NN NN O

It NN NN O
is NN NN O
therefore NN NN O
proposed NN NN O
that NN NN O
the NN NN O
defective NN NN O
surface NN NN O
expression NN NN O
of NN NN O
CTLA-4 NN NN O
by NN NN O
CHS NN NN B-Modifier
T NN NN O
cells NN NN O
is NN NN O
involved NN NN O
in NN NN O
the NN NN O
generation NN NN O
of NN NN O
lymphoproliferative NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

This NN NN O
observation NN NN O
may NN NN O
provide NN NN O
insight NN NN O
into NN NN O
the NN NN O
role NN NN O
of NN NN O
CTLA-4 NN NN O
in NN NN O
humans NN NN O
. NN NN O

. NN NN O

10417279 NN NN O
Proteolipoprotein NN NN O
gene NN NN O
analysis NN NN O
in NN NN O
82 NN NN O
patients NN NN O
with NN NN O
sporadic NN NN O
Pelizaeus-Merzbacher NN NN B-SpecificDisease
Disease NN NN I-SpecificDisease
: NN NN O
duplications NN NN O
, NN NN O
the NN NN O
major NN NN O
cause NN NN O
of NN NN O
the NN NN O
disease NN NN O
, NN NN O
originate NN NN O
more NN NN O
frequently NN NN O
in NN NN O
male NN NN O
germ NN NN O
cells NN NN O
, NN NN O
but NN NN O
point NN NN O
mutations NN NN O
do NN NN O
not NN NN O
. NN NN O

The NN NN O
Clinical NN NN O
European NN NN O
Network NN NN O
on NN NN O
Brain NN NN B-DiseaseClass
Dysmyelinating NN NN I-DiseaseClass
Disease NN NN I-DiseaseClass
. NN NN O

Pelizaeus-Merzbacher NN NN B-SpecificDisease
Disease NN NN I-SpecificDisease
( NN NN O
PMD NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
X-linked NN NN B-DiseaseClass
developmental NN NN I-DiseaseClass
defect NN NN I-DiseaseClass
of NN NN I-DiseaseClass
myelination NN NN I-DiseaseClass
affecting NN NN O
the NN NN O
central NN NN O
nervous NN NN O
system NN NN O
and NN NN O
segregating NN NN O
with NN NN O
the NN NN O
proteolipoprotein NN NN O
( NN NN O
PLP NN NN O
) NN NN O
locus NN NN O
. NN NN O

Investigating NN NN O
82 NN NN O
strictly NN NN O
selected NN NN O
sporadic NN NN O
cases NN NN O
of NN NN O
PMD NN NN B-SpecificDisease
, NN NN O
we NN NN O
found NN NN O
PLP NN NN O
mutations NN NN O
in NN NN O
77 NN NN O
% NN NN O
; NN NN O
complete NN NN O
PLP-gene NN NN O
duplications NN NN O
were NN NN O
the NN NN O
most NN NN O
frequent NN NN O
abnormality NN NN O
( NN NN O
62 NN NN O
% NN NN O
) NN NN O
, NN NN O
whereas NN NN O
point NN NN O
mutations NN NN O
in NN NN O
coding NN NN O
or NN NN O
splice-site NN NN O
regions NN NN O
of NN NN O
the NN NN O
gene NN NN O
were NN NN O
involved NN NN O
less NN NN O
frequently NN NN O
( NN NN O
38 NN NN O
% NN NN O
) NN NN O
. NN NN O

We NN NN O
analyzed NN NN O
the NN NN O
maternal NN NN O
status NN NN O
of NN NN O
56 NN NN O
cases NN NN O
to NN NN O
determine NN NN O
the NN NN O
origin NN NN O
of NN NN O
both NN NN O
types NN NN O
of NN NN O
PLP NN NN O
mutation NN NN O
, NN NN O
since NN NN O
this NN NN O
is NN NN O
relevant NN NN O
to NN NN O
genetic NN NN O
counseling NN NN O
. NN NN O

In NN NN O
the NN NN O
22 NN NN O
point NN NN O
mutations NN NN O
, NN NN O
68 NN NN O
% NN NN O
of NN NN O
mothers NN NN O
were NN NN O
heterozygous NN NN O
for NN NN O
the NN NN O
mutation NN NN O
, NN NN O
a NN NN O
value NN NN O
identical NN NN O
to NN NN O
the NN NN O
two-thirds NN NN O
of NN NN O
carrier NN NN O
mothers NN NN O
that NN NN O
would NN NN O
be NN NN O
expected NN NN O
if NN NN O
there NN NN O
were NN NN O
an NN NN O
equal NN NN O
mutation NN NN O
rate NN NN O
in NN NN O
male NN NN O
and NN NN O
female NN NN O
germ NN NN O
cells NN NN O
. NN NN O

In NN NN O
sharp NN NN O
contrast NN NN O
, NN NN O
among NN NN O
the NN NN O
34 NN NN O
duplicated NN NN O
cases NN NN O
, NN NN O
91 NN NN O
% NN NN O
of NN NN O
mothers NN NN O
were NN NN O
carriers NN NN O
, NN NN O
a NN NN O
value NN NN O
significantly NN NN O
( NN NN O
chi2 NN NN O
= NN NN O
9 NN NN O
. NN NN O

20 NN NN O
, NN NN O
P NN NN O
. NN NN O

01 NN NN O
) NN NN O
in NN NN O
favor NN NN O
of NN NN O
a NN NN O
male NN NN O
bias NN NN O
, NN NN O
with NN NN O
an NN NN O
estimation NN NN O
of NN NN O
the NN NN O
male NN NN O
/ NN NN O
female NN NN O
mutation NN NN O
frequency NN NN O
( NN NN O
k NN NN O
) NN NN O
of NN NN O
9 NN NN O
. NN NN O

3 NN NN O
3 NN NN O
. NN NN O

Moreover NN NN O
, NN NN O
we NN NN O
observed NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
de NN NN O
novo NN NN O
mutations NN NN O
between NN NN O
parental NN NN O
and NN NN O
grandparental NN NN O
generations NN NN O
in NN NN O
17 NN NN O
three-generation NN NN O
families NN NN O
, NN NN O
which NN NN O
allowed NN NN O
a NN NN O
direct NN NN O
estimation NN NN O
of NN NN O
the NN NN O
k NN NN O
value NN NN O
( NN NN O
k NN NN O
= NN NN O
11 NN NN O
) NN NN O
. NN NN O

Again NN NN O
, NN NN O
a NN NN O
significant NN NN O
male NN NN O
mutation NN NN O
imbalance NN NN O
was NN NN O
observed NN NN O
only NN NN O
for NN NN O
the NN NN O
duplications NN NN O
. NN NN O

10417280 NN NN O
Chromosome NN NN O
breakage NN NN O
in NN NN O
the NN NN O
Prader-Willi NN NN B-CompositeMention
and NN NN I-CompositeMention
Angelman NN NN I-CompositeMention
syndromes NN NN I-CompositeMention
involves NN NN O
recombination NN NN O
between NN NN O
large NN NN O
, NN NN O
transcribed NN NN O
repeats NN NN O
at NN NN O
proximal NN NN O
and NN NN O
distal NN NN O
breakpoints NN NN O
. NN NN O

Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
PWS NN NN B-SpecificDisease
) NN NN O
and NN NN O
Angelman NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
AS NN NN B-SpecificDisease
) NN NN O
are NN NN O
distinct NN NN O
neurobehavioral NN NN B-DiseaseClass
disorders NN NN I-DiseaseClass
that NN NN O
most NN NN O
often NN NN O
arise NN NN O
from NN NN O
a NN NN O
4-Mb NN NN O
deletion NN NN O
of NN NN O
chromosome NN NN O
15q11-q13 NN NN O
during NN NN O
paternal NN NN O
or NN NN O
maternal NN NN O
gametogenesis NN NN O
, NN NN O
respectively NN NN O
. NN NN O

At NN NN O
a NN NN O
de NN NN O
novo NN NN O
frequency NN NN O
of NN NN O
approximately NN NN O
. NN NN O

67-1 NN NN O
/ NN NN O
10 NN NN O
, NN NN O
000 NN NN O
births NN NN O
, NN NN O
these NN NN O
deletions NN NN O
represent NN NN O
a NN NN O
common NN NN O
structural NN NN O
chromosome NN NN O
change NN NN O
in NN NN O
the NN NN O
human NN NN O
genome NN NN O
. NN NN O

To NN NN O
elucidate NN NN O
the NN NN O
mechanism NN NN O
underlying NN NN O
these NN NN O
events NN NN O
, NN NN O
we NN NN O
characterized NN NN O
the NN NN O
regions NN NN O
that NN NN O
contain NN NN O
two NN NN O
proximal NN NN O
breakpoint NN NN O
clusters NN NN O
and NN NN O
a NN NN O
distal NN NN O
cluster NN NN O
. NN NN O

Novel NN NN O
DNA NN NN O
sequences NN NN O
potentially NN NN O
associated NN NN O
with NN NN O
the NN NN O
breakpoints NN NN O
were NN NN O
positionally NN NN O
cloned NN NN O
from NN NN O
YACs NN NN O
within NN NN O
or NN NN O
near NN NN O
these NN NN O
regions NN NN O
. NN NN O

Analyses NN NN O
of NN NN O
rodent-human NN NN O
somatic-cell NN NN O
hybrids NN NN O
, NN NN O
YAC NN NN O
contigs NN NN O
, NN NN O
and NN NN O
FISH NN NN O
of NN NN O
normal NN NN O
or NN NN O
rearranged NN NN O
chromosomes NN NN O
15 NN NN O
identified NN NN O
duplicated NN NN O
sequences NN NN O
( NN NN O
the NN NN O
END NN NN O
repeats NN NN O
) NN NN O
at NN NN O
or NN NN O
near NN NN O
the NN NN O
breakpoints NN NN O
. NN NN O

The NN NN O
END-repeat NN NN O
units NN NN O
are NN NN O
derived NN NN O
from NN NN O
large NN NN O
genomic NN NN O
duplications NN NN O
of NN NN O
a NN NN O
novel NN NN O
gene NN NN O
( NN NN O
HERC2 NN NN O
) NN NN O
, NN NN O
many NN NN O
copies NN NN O
of NN NN O
which NN NN O
are NN NN O
transcriptionally NN NN O
active NN NN O
in NN NN O
germline NN NN O
tissues NN NN O
. NN NN O

One NN NN O
of NN NN O
five NN NN O
PWS NN NN B-Modifier
/ NN NN O
AS NN NN B-Modifier
patients NN NN O
analyzed NN NN O
to NN NN O
date NN NN O
has NN NN O
an NN NN O
identifiable NN NN O
, NN NN O
rearranged NN NN O
HERC2 NN NN O
transcript NN NN O
derived NN NN O
from NN NN O
the NN NN O
deletion NN NN O
event NN NN O
. NN NN O

We NN NN O
postulate NN NN O
that NN NN O
the NN NN O
END NN NN O
repeats NN NN O
flanking NN NN O
15q11-q13 NN NN O
mediate NN NN O
homologous NN NN O
recombination NN NN O
resulting NN NN O
in NN NN O
deletion NN NN O
. NN NN O

Furthermore NN NN O
, NN NN O
we NN NN O
propose NN NN O
that NN NN O
active NN NN O
transcription NN NN O
of NN NN O
these NN NN O
repeats NN NN O
in NN NN O
male NN NN O
and NN NN O
female NN NN O
germ NN NN O
cells NN NN O
may NN NN O
facilitate NN NN O
the NN NN O
homologous NN NN O
recombination NN NN O
process NN NN O
. NN NN O

10417286 NN NN O
Linkage NN NN O
analysis NN NN O
in NN NN O
a NN NN O
large NN NN O
Brazilian NN NN O
family NN NN O
with NN NN O
van NN NN B-SpecificDisease
der NN NN I-SpecificDisease
Woude NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
suggests NN NN O
the NN NN O
existence NN NN O
of NN NN O
a NN NN O
susceptibility NN NN O
locus NN NN O
for NN NN O
cleft NN NN B-SpecificDisease
palate NN NN I-SpecificDisease
at NN NN O
17p11.2-11.1 NN NN O
. NN NN O

van NN NN B-SpecificDisease
der NN NN I-SpecificDisease
Woude NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
VWS NN NN B-SpecificDisease
) NN NN O
, NN NN O
which NN NN O
has NN NN O
been NN NN O
mapped NN NN O
to NN NN O
1q32-41 NN NN O
, NN NN O
is NN NN O
characterized NN NN O
by NN NN O
pits NN NN B-CompositeMention
and NN NN I-CompositeMention
/ NN NN I-CompositeMention
or NN NN I-CompositeMention
sinuses NN NN I-CompositeMention
of NN NN I-CompositeMention
the NN NN I-CompositeMention
lower NN NN I-CompositeMention
lip NN NN I-CompositeMention
, NN NN O
cleft NN NN B-SpecificDisease
lip NN NN I-SpecificDisease
/ NN NN I-SpecificDisease
palate NN NN I-SpecificDisease
( NN NN O
CL NN NN B-SpecificDisease
/ NN NN I-SpecificDisease
P NN NN I-SpecificDisease
) NN NN O
, NN NN O
cleft NN NN B-SpecificDisease
palate NN NN I-SpecificDisease
( NN NN O
CP NN NN B-SpecificDisease
) NN NN O
, NN NN O
bifid NN NN B-SpecificDisease
uvula NN NN I-SpecificDisease
, NN NN O
and NN NN O
hypodontia NN NN B-SpecificDisease
( NN NN O
H NN NN B-SpecificDisease
) NN NN O
. NN NN O

The NN NN O
expression NN NN O
of NN NN O
VWS NN NN B-SpecificDisease
, NN NN O
which NN NN O
has NN NN O
incomplete NN NN O
penetrance NN NN O
, NN NN O
is NN NN O
highly NN NN O
variable NN NN O
. NN NN O

Both NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
CL NN NN B-SpecificDisease
/ NN NN I-SpecificDisease
P NN NN I-SpecificDisease
and NN NN O
CP NN NN B-SpecificDisease
within NN NN O
the NN NN O
same NN NN O
genealogy NN NN O
and NN NN O
a NN NN O
recurrence NN NN O
risk NN NN O
40 NN NN O
% NN NN O
for NN NN O
CP NN NN B-SpecificDisease
among NN NN O
descendants NN NN O
with NN NN O
VWS NN NN B-SpecificDisease
have NN NN O
suggested NN NN O
that NN NN O
the NN NN O
development NN NN O
of NN NN O
clefts NN NN B-DiseaseClass
in NN NN O
this NN NN O
syndrome NN NN O
is NN NN O
influenced NN NN O
by NN NN O
modifying NN NN O
genes NN NN O
at NN NN O
other NN NN O
loci NN NN O
. NN NN O

To NN NN O
test NN NN O
this NN NN O
hypothesis NN NN O
, NN NN O
we NN NN O
have NN NN O
conducted NN NN O
linkage NN NN O
analysis NN NN O
in NN NN O
a NN NN O
large NN NN O
Brazilian NN NN O
kindred NN NN O
with NN NN O
VWS NN NN B-SpecificDisease
, NN NN O
considering NN NN O
as NN NN O
affected NN NN O
the NN NN O
individuals NN NN O
with NN NN O
CP NN NN B-SpecificDisease
, NN NN O
regardless NN NN O
of NN NN O
whether NN NN O
it NN NN O
is NN NN O
associated NN NN O
with NN NN O
other NN NN O
clinical NN NN O
signs NN NN O
of NN NN O
VWS NN NN B-SpecificDisease
. NN NN O

Our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
a NN NN O
gene NN NN O
at NN NN O
17p11 NN NN O
. NN NN O

2-11 NN NN O
2-11 NN NN O
. NN NN O

1 NN NN O
, NN NN O
together NN NN O
with NN NN O
the NN NN O
VWS NN NN B-Modifier
gene NN NN O
at NN NN O
1p32-41 NN NN O
, NN NN O
enhances NN NN O
the NN NN O
probability NN NN O
of NN NN O
CP NN NN B-SpecificDisease
in NN NN O
an NN NN O
individual NN NN O
carrying NN NN O
the NN NN O
two NN NN O
at-risk NN NN O
genes NN NN O
. NN NN O

If NN NN O
this NN NN O
hypothesis NN NN O
is NN NN O
confirmed NN NN O
in NN NN O
other NN NN O
VWS NN NN B-Modifier
pedigrees NN NN O
, NN NN O
it NN NN O
will NN NN O
represent NN NN O
one NN NN O
of NN NN O
the NN NN O
first NN NN O
examples NN NN O
of NN NN O
a NN NN O
gene NN NN O
, NN NN O
mapped NN NN O
through NN NN O
linkage NN NN O
analysis NN NN O
, NN NN O
which NN NN O
modifies NN NN O
the NN NN O
expression NN NN O
of NN NN O
a NN NN O
major NN NN O
gene NN NN O
. NN NN O

10425038 NN NN O
New NN NN O
mutations NN NN O
, NN NN O
polymorphisms NN NN O
, NN NN O
and NN NN O
rare NN NN O
variants NN NN O
in NN NN O
the NN NN O
ATM NN NN O
gene NN NN O
detected NN NN O
by NN NN O
a NN NN O
novel NN NN O
SSCP NN NN O
strategy NN NN O
. NN NN O

The NN NN O
gene NN NN O
for NN NN O
ataxia-telangiectasia NN NN B-SpecificDisease
, NN NN O
ATM NN NN O
, NN NN O
spans NN NN O
about NN NN O
150 NN NN O
kb NN NN O
of NN NN O
genomic NN NN O
DNA NN NN O
. NN NN O

ATM NN NN O
mutations NN NN O
are NN NN O
found NN NN O
along NN NN O
the NN NN O
entire NN NN O
gene NN NN O
, NN NN O
with NN NN O
no NN NN O
evidence NN NN O
of NN NN O
a NN NN O
mutational NN NN O
hot NN NN O
spot NN NN O
. NN NN O

Using NN NN O
DNA NN NN O
as NN NN O
the NN NN O
starting NN NN O
material NN NN O
, NN NN O
we NN NN O
screened NN NN O
the NN NN O
ATM NN NN O
gene NN NN O
in NN NN O
92 NN NN O
A-T NN NN B-Modifier
patients NN NN O
, NN NN O
using NN NN O
an NN NN O
optimized NN NN O
single-strand NN NN O
conformation NN NN O
polymorphism NN NN O
( NN NN O
SSCP NN NN O
) NN NN O
technique NN NN O
that NN NN O
detected NN NN O
all NN NN O
previously NN NN O
known NN NN O
mutations NN NN O
in NN NN O
the NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
( NN NN O
PCR NN NN O
) NN NN O
segments NN NN O
being NN NN O
analyzed NN NN O
. NN NN O

To NN NN O
expedite NN NN O
screening NN NN O
, NN NN O
we NN NN O
sequentially NN NN O
loaded NN NN O
the NN NN O
SSCP NN NN O
gels NN NN O
with NN NN O
three NN NN O
different NN NN O
sets NN NN O
of NN NN O
PCR NN NN O
products NN NN O
that NN NN O
were NN NN O
pretested NN NN O
to NN NN O
avoid NN NN O
overlapping NN NN O
patterns NN NN O
. NN NN O

Many NN NN O
of NN NN O
the NN NN O
DNA NN NN O
changes NN NN O
we NN NN O
detected NN NN O
were NN NN O
intragenic NN NN O
polymorphisms NN NN O
. NN NN O

Of NN NN O
an NN NN O
expected NN NN O
177 NN NN O
unknown NN NN O
mutations NN NN O
, NN NN O
we NN NN O
detected NN NN O
approximately NN NN O
70 NN NN O
% NN NN O
, NN NN O
mostly NN NN O
protein NN NN O
truncating NN NN O
mutations NN NN O
( NN NN O
that NN NN O
would NN NN O
have NN NN O
been NN NN O
detectable NN NN O
by NN NN O
protein NN NN O
truncation NN NN O
testing NN NN O
if NN NN O
RNA NN NN O
starting NN NN O
material NN NN O
had NN NN O
been NN NN O
available NN NN O
) NN NN O
. NN NN O

Mutations NN NN O
have NN NN O
now NN NN O
been NN NN O
defined NN NN O
for NN NN O
every NN NN O
exon NN NN O
of NN NN O
the NN NN O
ATM NN NN O
gene NN NN O
. NN NN O

Herein NN NN O
, NN NN O
we NN NN O
present NN NN O
35 NN NN O
new NN NN O
mutations NN NN O
and NN NN O
34 NN NN O
new NN NN O
intragenic NN NN O
polymorphisms NN NN O
or NN NN O
rare NN NN O
variants NN NN O
within NN NN O
the NN NN O
ATM NN NN O
gene NN NN O
. NN NN O

This NN NN O
is NN NN O
the NN NN O
most NN NN O
comprehensive NN NN O
compilation NN NN O
of NN NN O
ATM NN NN O
polymorphisms NN NN O
assembled NN NN O
to NN NN O
date NN NN O
. NN NN O

Defining NN NN O
polymorphic NN NN O
sites NN NN O
as NN NN O
well NN NN O
as NN NN O
mutations NN NN O
in NN NN O
the NN NN O
ATM NN NN O
gene NN NN O
will NN NN O
be NN NN O
of NN NN O
great NN NN O
importance NN NN O
in NN NN O
designing NN NN O
automated NN NN O
methods NN NN O
for NN NN O
detecting NN NN O
mutations NN NN O
. NN NN O

. NN NN O

10426139 NN NN O
A NN NN O
novel NN NN O
frameshift NN NN O
mutation NN NN O
in NN NN O
the NN NN O
McLeod NN NN B-Modifier
syndrome NN NN I-Modifier
gene NN NN O
in NN NN O
a NN NN O
Japanese NN NN O
family NN NN O
. NN NN O

We NN NN O
report NN NN O
a NN NN O
novel NN NN O
mutation NN NN O
in NN NN O
the NN NN O
XK NN NN O
gene NN NN O
( NN NN O
XK NN NN O
) NN NN O
in NN NN O
a NN NN O
Japanese NN NN O
patient NN NN O
with NN NN O
McLeod NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

A NN NN O
50-year-old NN NN O
man NN NN O
showed NN NN O
progressive NN NN O
muscular NN NN B-DiseaseClass
atrophy NN NN I-DiseaseClass
, NN NN O
choreic NN NN B-DiseaseClass
movement NN NN I-DiseaseClass
, NN NN O
elevated NN NN O
level NN NN O
of NN NN O
serum NN NN O
creatinine NN NN O
kinase NN NN O
, NN NN O
and NN NN O
acanthocytosis NN NN B-SpecificDisease
. NN NN O

The NN NN O
expression NN NN O
level NN NN O
of NN NN O
all NN NN O
the NN NN O
Kell NN NN O
antigens NN NN O
in NN NN O
erythrocyte NN NN O
was NN NN O
decreased NN NN O
and NN NN O
molecular NN NN O
analysis NN NN O
revealed NN NN O
a NN NN O
single-base NN NN O
( NN NN O
T NN NN O
) NN NN O
deletion NN NN O
at NN NN O
the NN NN O
nucleotide NN NN O
position NN NN O
1095 NN NN O
in NN NN O
XK NN NN O
. NN NN O

This NN NN O
deletion NN NN O
caused NN NN O
a NN NN O
frameshift NN NN O
in NN NN O
translation NN NN O
, NN NN O
leading NN NN O
to NN NN O
a NN NN O
premature NN NN O
stop NN NN O
codon NN NN O
at NN NN O
the NN NN O
amino NN NN O
acid NN NN O
position NN NN O
408 NN NN O
. NN NN O

We NN NN O
conclude NN NN O
this NN NN O
single-base NN NN O
deletion NN NN O
causes NN NN O
defective NN NN O
Kx NN NN O
protein NN NN O
, NN NN O
which NN NN O
is NN NN O
responsible NN NN O
for NN NN O
the NN NN O
McLeod NN NN B-Modifier
phenotype NN NN O
in NN NN O
this NN NN O
patient NN NN O
. NN NN O

. NN NN O

10426999 NN NN O
Association NN NN O
of NN NN O
BRCA1 NN NN O
with NN NN O
the NN NN O
hRad50-hMre11-p95 NN NN O
complex NN NN O
and NN NN O
the NN NN O
DNA NN NN O
damage NN NN O
response NN NN O
. NN NN O

BRCA1 NN NN O
encodes NN NN O
a NN NN O
tumor NN NN B-Modifier
suppressor NN NN O
that NN NN O
is NN NN O
mutated NN NN O
in NN NN O
familial NN NN B-CompositeMention
breast NN NN I-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancers NN NN I-CompositeMention
. NN NN O

Here NN NN O
, NN NN O
it NN NN O
is NN NN O
shown NN NN O
that NN NN O
BRCA1 NN NN O
interacts NN NN O
in NN NN O
vitro NN NN O
and NN NN O
in NN NN O
vivo NN NN O
with NN NN O
hRad50 NN NN O
, NN NN O
which NN NN O
forms NN NN O
a NN NN O
complex NN NN O
with NN NN O
hMre11 NN NN O
and NN NN O
p95 NN NN O
/ NN NN O
nibrin NN NN O
. NN NN O

Upon NN NN O
irradiation NN NN O
, NN NN O
BRCA1 NN NN O
was NN NN O
detected NN NN O
in NN NN O
discrete NN NN O
foci NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
, NN NN O
which NN NN O
colocalize NN NN O
with NN NN O
hRad50 NN NN O
. NN NN O

Formation NN NN O
of NN NN O
irradiation-induced NN NN O
foci NN NN O
positive NN NN O
for NN NN O
BRCA1 NN NN O
, NN NN O
hRad50 NN NN O
, NN NN O
hMre11 NN NN O
, NN NN O
or NN NN O
p95 NN NN O
was NN NN O
dramatically NN NN O
reduced NN NN O
in NN NN O
HCC NN NN O
/ NN NN O
1937 NN NN O
breast NN NN B-Modifier
cancer NN NN I-Modifier
cells NN NN O
carrying NN NN O
a NN NN O
homozygous NN NN O
mutation NN NN O
in NN NN O
BRCA1 NN NN O
but NN NN O
was NN NN O
restored NN NN O
by NN NN O
transfection NN NN O
of NN NN O
wild-type NN NN O
BRCA1 NN NN O
. NN NN O

Ectopic NN NN O
expression NN NN O
of NN NN O
wild-type NN NN O
, NN NN O
but NN NN O
not NN NN O
mutated NN NN O
, NN NN O
BRCA1 NN NN O
in NN NN O
these NN NN O
cells NN NN O
rendered NN NN O
them NN NN O
less NN NN O
sensitive NN NN O
to NN NN O
the NN NN O
DNA NN NN O
damage NN NN O
agent NN NN O
, NN NN O
methyl NN NN O
methanesulfonate NN NN O
. NN NN O

These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
BRCA1 NN NN O
is NN NN O
important NN NN O
for NN NN O
the NN NN O
cellular NN NN O
responses NN NN O
to NN NN O
DNA NN NN O
damage NN NN O
that NN NN O
are NN NN O
mediated NN NN O
by NN NN O
the NN NN O
hRad50-hMre11-p95 NN NN O
complex NN NN O
. NN NN O

. NN NN O

10429004 NN NN O
Relationship NN NN O
among NN NN O
genotype NN NN O
, NN NN O
biochemical NN NN O
phenotype NN NN O
, NN NN O
and NN NN O
cognitive NN NN O
performance NN NN O
in NN NN O
females NN NN O
with NN NN O
phenylalanine NN NN B-SpecificDisease
hydroxylase NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
: NN NN O
report NN NN O
from NN NN O
the NN NN O
Maternal NN NN B-Modifier
Phenylketonuria NN NN I-Modifier
Collaborative NN NN O
Study NN NN O
. NN NN O

OBJECTIVE NN NN O
To NN NN O
examine NN NN O
the NN NN O
relationship NN NN O
of NN NN O
phenylalanine NN NN O
hydroxylase NN NN O
( NN NN O
PAH NN NN O
) NN NN O
genotypes NN NN O
to NN NN O
biochemical NN NN O
phenotype NN NN O
and NN NN O
cognitive NN NN O
development NN NN O
in NN NN O
maternal NN NN B-SpecificDisease
phenylketonuria NN NN I-SpecificDisease
( NN NN O
PKU NN NN B-SpecificDisease
) NN NN O
. NN NN O

METHODOLOGY NN NN O
PAH NN NN O
gene NN NN O
mutations NN NN O
were NN NN O
examined NN NN O
in NN NN O
222 NN NN O
hyperphenylalaninemic NN NN B-Modifier
females NN NN O
enrolled NN NN O
in NN NN O
the NN NN O
Maternal NN NN B-Modifier
PKU NN NN I-Modifier
Collaborative NN NN O
Study NN NN O
( NN NN O
MPKUCS NN NN O
) NN NN O
. NN NN O

A NN NN O
total NN NN O
of NN NN O
84 NN NN O
different NN NN O
mutations NN NN O
were NN NN O
detected NN NN O
, NN NN O
and NN NN O
complete NN NN O
genotype NN NN O
was NN NN O
obtained NN NN O
in NN NN O
199 NN NN O
individuals NN NN O
. NN NN O

Based NN NN O
on NN NN O
previous NN NN O
knowledge NN NN O
about NN NN O
mutation-phenotype NN NN O
associations NN NN O
, NN NN O
78 NN NN O
of NN NN O
the NN NN O
mutations NN NN O
could NN NN O
be NN NN O
assigned NN NN O
to NN NN O
one NN NN O
of NN NN O
four NN NN O
classes NN NN O
of NN NN O
severity NN NN O
( NN NN O
severe NN NN O
PKU NN NN B-SpecificDisease
, NN NN O
moderate NN NN O
PKU NN NN B-SpecificDisease
, NN NN O
mild NN NN O
PKU NN NN B-SpecificDisease
, NN NN O
and NN NN O
mild NN NN B-SpecificDisease
hyperphenylalaninemia NN NN I-SpecificDisease
[ NN NN O
MHP NN NN B-SpecificDisease
] NN NN O
) NN NN O
. NN NN O

Then NN NN O
, NN NN O
189 NN NN O
MPKUCS NN NN O
subjects NN NN O
were NN NN O
grouped NN NN O
according NN NN O
to NN NN O
the NN NN O
various NN NN O
combinations NN NN O
of NN NN O
mutation NN NN O
classifications NN NN O
. NN NN O

The NN NN O
sample NN NN O
sizes NN NN O
were NN NN O
large NN NN O
enough NN NN O
for NN NN O
statistical NN NN O
testing NN NN O
in NN NN O
four NN NN O
groups NN NN O
with NN NN O
at NN NN O
least NN NN O
one NN NN O
mutation NN NN O
that NN NN O
completely NN NN O
abolishes NN NN O
enzyme NN NN O
activity NN NN O
. NN NN O

These NN NN O
patients NN NN O
are NN NN O
considered NN NN O
functionally NN NN O
hemizygous NN NN O
. NN NN O

RESULTS NN NN O
The NN NN O
biochemical NN NN O
phenotype NN NN O
predicted NN NN O
from NN NN O
the NN NN O
genotype NN NN O
in NN NN O
functionally NN NN O
hemizygous NN NN O
patients NN NN O
was NN NN O
related NN NN O
significantly NN NN O
to NN NN O
the NN NN O
assigned NN NN O
phenylalanine NN NN O
level NN NN O
. NN NN O

Cognitive NN NN O
performance NN NN O
( NN NN O
IQ NN NN O
) NN NN O
was NN NN O
also NN NN O
significantly NN NN O
related NN NN O
to NN NN O
genotype NN NN O
. NN NN O

The NN NN O
IQ NN NN O
of NN NN O
PAH-deficient NN NN B-Modifier
mothers NN NN O
with NN NN O
a NN NN O
severe NN NN O
PKU NN NN B-Modifier
mutation NN NN O
in NN NN O
combination NN NN O
with NN NN O
a NN NN O
MHP NN NN B-Modifier
mutation NN NN O
or NN NN O
a NN NN O
mild NN NN O
PKU NN NN B-Modifier
mutation NN NN O
was NN NN O
99 NN NN O
and NN NN O
96 NN NN O
, NN NN O
respectively NN NN O
, NN NN O
whereas NN NN O
the NN NN O
IQ NN NN O
of NN NN O
PKU NN NN B-Modifier
mothers NN NN O
with NN NN O
two NN NN O
severe NN NN O
PKU NN NN B-Modifier
mutations NN NN O
or NN NN O
with NN NN O
one NN NN O
severe NN NN O
and NN NN O
one NN NN O
moderate NN NN O
PKU NN NN B-Modifier
mutation NN NN O
was NN NN O
83 NN NN O
and NN NN O
84 NN NN O
, NN NN O
respectively NN NN O
. NN NN O

Of NN NN O
the NN NN O
patients NN NN O
with NN NN O
PKU NN NN B-SpecificDisease
, NN NN O
92 NN NN O
% NN NN O
had NN NN O
been NN NN O
treated NN NN O
during NN NN O
childhood NN NN O
. NN NN O

Those NN NN O
who NN NN O
were NN NN O
untreated NN NN O
or NN NN O
treated NN NN O
late NN NN O
had NN NN O
lower NN NN O
than NN NN O
average NN NN O
IQ NN NN O
scores NN NN O
for NN NN O
their NN NN O
group NN NN O
of NN NN O
mutation NN NN O
combinations NN NN O
. NN NN O

Females NN NN O
with NN NN O
moderate NN NN O
or NN NN O
mild NN NN O
PKU NN NN B-SpecificDisease
who NN NN O
were NN NN O
treated NN NN O
early NN NN O
and NN NN O
treated NN NN O
for NN NN O
6 NN NN O
years NN NN O
showed NN NN O
IQ NN NN O
scores NN NN O
10 NN NN O
points NN NN O
above NN NN O
average NN NN O
for NN NN O
their NN NN O
group NN NN O
. NN NN O

CONCLUSIONS NN NN O
The NN NN O
reproductive NN NN O
outcome NN NN O
in NN NN O
maternal NN NN B-SpecificDisease
phenylketonuria NN NN I-SpecificDisease
is NN NN O
dependent NN NN O
on NN NN O
prenatal NN NN O
metabolic NN NN O
control NN NN O
and NN NN O
postnatal NN NN O
environmental NN NN O
circumstances NN NN O
. NN NN O

Both NN NN O
factors NN NN O
depend NN NN O
on NN NN O
the NN NN O
intellectual NN NN O
resources NN NN O
of NN NN O
the NN NN O
mother NN NN O
with NN NN O
PKU NN NN B-SpecificDisease
. NN NN O

The NN NN O
significant NN NN O
relationship NN NN O
among NN NN O
genotype NN NN O
, NN NN O
biochemical NN NN O
phenotype NN NN O
, NN NN O
and NN NN O
cognitive NN NN O
performance NN NN O
observed NN NN O
in NN NN O
the NN NN O
present NN NN O
study NN NN O
is NN NN O
of NN NN O
importance NN NN O
for NN NN O
the NN NN O
development NN NN O
of NN NN O
an NN NN O
optimal NN NN O
strategy NN NN O
for NN NN O
future NN NN O
treatment NN NN O
of NN NN O
females NN NN O
with NN NN O
PKU NN NN B-SpecificDisease
who NN NN O
plan NN NN O
pregnancy NN NN O
. NN NN O

. NN NN O

10430841 NN NN O
Spinal NN NN B-SpecificDisease
xanthomatosis NN NN I-SpecificDisease
: NN NN O
a NN NN O
variant NN NN O
of NN NN O
cerebrotendinous NN NN B-DiseaseClass
xanthomatosis NN NN I-DiseaseClass
. NN NN O

We NN NN O
describe NN NN O
seven NN NN O
Dutch NN NN O
patients NN NN O
from NN NN O
six NN NN O
families NN NN O
with NN NN O
a NN NN O
slowly NN NN O
progressive NN NN O
, NN NN O
mainly NN NN O
spinal NN NN B-SpecificDisease
cord NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
that NN NN O
remained NN NN O
for NN NN O
many NN NN O
years NN NN O
the NN NN O
sole NN NN O
expression NN NN O
of NN NN O
cerebrotendinous NN NN B-SpecificDisease
xanthomatosis NN NN I-SpecificDisease
( NN NN O
CTX NN NN B-SpecificDisease
) NN NN O
. NN NN O

MRI NN NN O
demonstrated NN NN O
white NN NN B-DiseaseClass
matter NN NN I-DiseaseClass
abnormalities NN NN I-DiseaseClass
in NN NN O
the NN NN O
lateral NN NN O
and NN NN O
dorsal NN NN O
columns NN NN O
of NN NN O
the NN NN O
spinal NN NN O
cord NN NN O
. NN NN O

Post-mortem NN NN O
examination NN NN O
of NN NN O
one NN NN O
of NN NN O
the NN NN O
patients NN NN O
showed NN NN O
extensive NN NN O
myelin NN NN O
loss NN NN O
in NN NN O
these NN NN O
columns NN NN O
. NN NN O

An NN NN O
array NN NN O
of NN NN O
genotypes NN NN O
was NN NN O
found NN NN O
in NN NN O
these NN NN O
patients NN NN O
. NN NN O

We NN NN O
conclude NN NN O
that NN NN O
spinal NN NN B-SpecificDisease
xanthomatosis NN NN I-SpecificDisease
is NN NN O
a NN NN O
clinical NN NN O
and NN NN O
radiological NN NN O
separate NN NN O
entity NN NN O
of NN NN O
CTX NN NN B-SpecificDisease
that NN NN O
should NN NN O
be NN NN O
included NN NN O
in NN NN O
the NN NN O
differential NN NN O
diagnosis NN NN O
of NN NN O
chronic NN NN B-DiseaseClass
myelopathy NN NN I-DiseaseClass
. NN NN O

. NN NN O

10430930 NN NN O
A NN NN O
transgene NN NN O
insertion NN NN O
creating NN NN O
a NN NN O
heritable NN NN O
chromosome NN NN O
deletion NN NN O
mouse NN NN O
model NN NN O
of NN NN O
Prader-Willi NN NN B-CompositeMention
and NN NN I-CompositeMention
angelman NN NN I-CompositeMention
syndromes NN NN I-CompositeMention
. NN NN O

Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
PWS NN NN B-SpecificDisease
) NN NN O
and NN NN O
Angelman NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
AS NN NN B-SpecificDisease
) NN NN O
result NN NN O
from NN NN O
the NN NN O
loss NN NN O
of NN NN O
function NN NN O
of NN NN O
imprinted NN NN O
genes NN NN O
in NN NN O
human NN NN O
chromosome NN NN O
15q11-q13 NN NN O
. NN NN O

The NN NN O
central NN NN O
part NN NN O
of NN NN O
mouse NN NN O
chromosome NN NN O
7 NN NN O
is NN NN O
homologous NN NN O
to NN NN O
human NN NN O
15q11-q13 NN NN O
, NN NN O
with NN NN O
conservation NN NN O
of NN NN O
both NN NN O
gene NN NN O
order NN NN O
and NN NN O
imprinted NN NN O
features NN NN O
. NN NN O

We NN NN O
report NN NN O
here NN NN O
the NN NN O
characterization NN NN O
of NN NN O
a NN NN O
transgene NN NN O
insertion NN NN O
( NN NN O
Epstein-Barr NN NN O
virus NN NN O
Latent NN NN O
Membrane NN NN O
Protein NN NN O
2A NN NN O
, NN NN O
LMP2A NN NN O
) NN NN O
into NN NN O
mouse NN NN O
chromosome NN NN O
7C NN NN O
, NN NN O
which NN NN O
has NN NN O
resulted NN NN O
in NN NN O
mouse NN NN O
models NN NN O
for NN NN O
PWS NN NN B-SpecificDisease
and NN NN O
AS NN NN B-SpecificDisease
dependent NN NN O
on NN NN O
the NN NN O
sex NN NN O
of NN NN O
the NN NN O
transmitting NN NN O
parent NN NN O
. NN NN O

Epigenotype NN NN O
( NN NN O
allelic NN NN O
expression NN NN O
and NN NN O
DNA NN NN O
methylation NN NN O
) NN NN O
and NN NN O
fluorescence NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
analyses NN NN O
indicate NN NN O
that NN NN O
the NN NN O
transgene-induced NN NN O
mutation NN NN O
has NN NN O
generated NN NN O
a NN NN O
complete NN NN O
deletion NN NN O
of NN NN O
the NN NN O
PWS NN NN B-Modifier
/ NN NN O
AS NN NN B-Modifier
-homologous NN NN O
region NN NN O
but NN NN O
has NN NN O
not NN NN O
deleted NN NN O
flanking NN NN O
loci NN NN O
. NN NN O

Because NN NN O
the NN NN O
intact NN NN O
chromosome NN NN O
7 NN NN O
, NN NN O
opposite NN NN O
the NN NN O
deleted NN NN O
homolog NN NN O
, NN NN O
maintains NN NN O
the NN NN O
correct NN NN O
imprint NN NN O
in NN NN O
somatic NN NN O
cells NN NN O
of NN NN O
PWS NN NN B-Modifier
and NN NN O
AS NN NN B-Modifier
mice NN NN O
and NN NN O
establishes NN NN O
the NN NN O
correct NN NN O
imprint NN NN O
in NN NN O
male NN NN O
and NN NN O
female NN NN O
germ NN NN O
cells NN NN O
of NN NN O
AS NN NN B-Modifier
mice NN NN O
, NN NN O
homologous NN NN O
association NN NN O
and NN NN O
replication NN NN O
asynchrony NN NN O
are NN NN O
not NN NN O
part NN NN O
of NN NN O
the NN NN O
imprinting NN NN O
mechanism NN NN O
. NN NN O

This NN NN O
heritable-deletion NN NN O
mouse NN NN O
model NN NN O
will NN NN O
be NN NN O
particularly NN NN O
useful NN NN O
for NN NN O
the NN NN O
identification NN NN O
of NN NN O
the NN NN O
etiological NN NN O
genes NN NN O
and NN NN O
mechanisms NN NN O
, NN NN O
phenotypic NN NN O
basis NN NN O
, NN NN O
and NN NN O
investigation NN NN O
of NN NN O
therapeutic NN NN O
approaches NN NN O
for NN NN O
PWS NN NN B-SpecificDisease
. NN NN O

. NN NN O

10434119 NN NN O
Linkage NN NN O
analysis NN NN O
of NN NN O
5 NN NN O
novel NN NN O
van NN NN B-Modifier
der NN NN I-Modifier
Woude NN NN I-Modifier
syndrome NN NN I-Modifier
kindreds NN NN O
to NN NN O
1q32-q41 NN NN O
markers NN NN O
further NN NN O
supports NN NN O
locus NN NN O
homogeneity NN NN O
of NN NN O
the NN NN O
disease NN NN O
trait NN NN O
. NN NN O

van NN NN B-SpecificDisease
der NN NN I-SpecificDisease
Woude NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
vWS NN NN B-SpecificDisease
, NN NN O
MIM NN NN O
119300 NN NN O
) NN NN O
is NN NN O
a NN NN O
rare NN NN O
autosomal NN NN B-DiseaseClass
dominant NN NN I-DiseaseClass
clefting NN NN I-DiseaseClass
condition NN NN I-DiseaseClass
with NN NN O
cardinal NN NN O
features NN NN O
of NN NN O
mucous NN NN B-SpecificDisease
cysts NN NN I-SpecificDisease
( NN NN O
lower-lip NN NN B-SpecificDisease
pits NN NN I-SpecificDisease
) NN NN O
and NN NN O
clefts NN NN B-CompositeMention
to NN NN I-CompositeMention
the NN NN I-CompositeMention
lip NN NN I-CompositeMention
and NN NN I-CompositeMention
/ NN NN I-CompositeMention
or NN NN I-CompositeMention
palate NN NN I-CompositeMention
. NN NN O

The NN NN O
vWS NN NN B-Modifier
gene NN NN O
has NN NN O
been NN NN O
assigned NN NN O
to NN NN O
a NN NN O
locus NN NN O
in NN NN O
1q32-q41 NN NN O
by NN NN O
linkage NN NN O
analysis NN NN O
and NN NN O
physical NN NN O
mapping NN NN O
. NN NN O

We NN NN O
have NN NN O
investigated NN NN O
5 NN NN O
novel NN NN O
vWS NN NN B-Modifier
families NN NN O
through NN NN O
probands NN NN O
attended NN NN O
for NN NN O
cleft NN NN B-Modifier
lip NN NN I-Modifier
and NN NN I-Modifier
/ NN NN I-Modifier
or NN NN I-Modifier
palate NN NN I-Modifier
repair NN NN O
at NN NN O
the NN NN O
Department NN NN O
of NN NN O
Maxillofacial NN NN O
Surgery NN NN O
of NN NN O
Hopital NN NN O
Trousseau NN NN O
, NN NN O
Paris NN NN O
, NN NN O
in NN NN O
order NN NN O
to NN NN O
tentatively NN NN O
refine NN NN O
the NN NN O
genetic NN NN O
map NN NN O
of NN NN O
the NN NN O
vWS NN NN B-Modifier
region NN NN O
in NN NN O
1q32-q41 NN NN O
and NN NN O
possibly NN NN O
identify NN NN O
unlinked NN NN O
pedigrees NN NN O
. NN NN O

Linkage NN NN O
analysis NN NN O
was NN NN O
carried NN NN O
out NN NN O
to NN NN O
6 NN NN O
microsatellite NN NN O
markers NN NN O
( NN NN O
D1S249 NN NN O
, NN NN O
D1S425 NN NN O
, NN NN O
D1S491 NN NN O
, NN NN O
D1S205 NN NN O
, NN NN O
D1S414 NN NN O
, NN NN O
D1S425 NN NN O
) NN NN O
, NN NN O
yielding NN NN O
a NN NN O
maximum NN NN O
cumulative NN NN O
LOD NN NN O
score NN NN O
of NN NN O
Z NN NN O
= NN NN O
3 NN NN O
. NN NN O

27 NN NN O
at NN NN O
theta NN NN O
= NN NN O
0 NN NN O
. NN NN O

00 NN NN O
for NN NN O
D1S245 NN NN O
. NN NN O

The NN NN O
innermost NN NN O
four NN NN O
markers NN NN O
were NN NN O
found NN NN O
to NN NN O
be NN NN O
tightly NN NN O
linked NN NN O
to NN NN O
one NN NN O
another NN NN O
, NN NN O
with NN NN O
no NN NN O
evidence NN NN O
for NN NN O
recombination NN NN O
. NN NN O

Our NN NN O
results NN NN O
support NN NN O
linkage NN NN O
of NN NN O
vWS NN NN B-SpecificDisease
within NN NN O
a NN NN O
region NN NN O
of NN NN O
tightly NN NN O
linked NN NN O
markers NN NN O
and NN NN O
do NN NN O
not NN NN O
favour NN NN O
locus NN NN O
heterogeneity NN NN O
of NN NN O
the NN NN O
disease NN NN O
trait NN NN O
. NN NN O

10441329 NN NN O
Null NN NN O
mutation NN NN O
of NN NN O
the NN NN O
murine NN NN O
ATP7B NN NN O
( NN NN O
Wilson NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
) NN NN O
gene NN NN O
results NN NN O
in NN NN O
intracellular NN NN B-DiseaseClass
copper NN NN I-DiseaseClass
accumulation NN NN I-DiseaseClass
and NN NN O
late-onset NN NN B-DiseaseClass
hepatic NN NN I-DiseaseClass
nodular NN NN I-DiseaseClass
transformation NN NN I-DiseaseClass
. NN NN O

The NN NN O
Atp7b NN NN O
protein NN NN O
is NN NN O
a NN NN O
copper-transporting NN NN O
ATPase NN NN O
expressed NN NN O
predominantly NN NN O
in NN NN O
the NN NN O
liver NN NN O
and NN NN O
to NN NN O
a NN NN O
lesser NN NN O
extent NN NN O
in NN NN O
most NN NN O
other NN NN O
tissues NN NN O
. NN NN O

Mutations NN NN O
in NN NN O
the NN NN O
ATP7B NN NN O
gene NN NN O
lead NN NN O
to NN NN O
Wilson NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
, NN NN I-SpecificDisease
a NN NN O
copper NN NN B-DiseaseClass
toxicity NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
characterized NN NN O
by NN NN O
dramatic NN NN O
build-up NN NN O
of NN NN O
intracellular NN NN O
hepatic NN NN O
copper NN NN O
with NN NN O
subsequent NN NN O
hepatic NN NN B-CompositeMention
and NN NN I-CompositeMention
neuro-logical NN NN I-CompositeMention
abnormalities NN NN I-CompositeMention
. NN NN O

Using NN NN O
homologous NN NN O
recombination NN NN O
to NN NN O
disrupt NN NN O
the NN NN O
normal NN NN O
translation NN NN O
of NN NN O
ATP7B NN NN O
, NN NN O
we NN NN O
have NN NN O
generated NN NN O
a NN NN O
strain NN NN O
of NN NN O
mice NN NN O
that NN NN O
are NN NN O
homozygous NN NN O
mutants NN NN O
( NN NN O
null NN NN O
) NN NN O
for NN NN O
the NN NN O
Wilson NN NN B-Modifier
disease NN NN I-Modifier
gene NN NN O
. NN NN O

The NN NN O
ATP7B NN NN O
null NN NN O
mice NN NN O
display NN NN O
a NN NN O
gradual NN NN O
accumulation NN NN O
of NN NN O
hepatic NN NN O
copper NN NN O
that NN NN O
increases NN NN O
to NN NN O
a NN NN O
level NN NN O
60-fold NN NN O
greater NN NN O
than NN NN O
normal NN NN O
by NN NN O
5 NN NN O
months NN NN O
of NN NN O
age NN NN O
. NN NN O

An NN NN O
increase NN NN O
in NN NN O
copper NN NN O
concentration NN NN O
was NN NN O
also NN NN O
observed NN NN O
in NN NN O
the NN NN O
kidney NN NN O
, NN NN O
brain NN NN O
, NN NN O
placenta NN NN O
and NN NN O
lactating NN NN O
mammary NN NN O
glands NN NN O
of NN NN O
homo-zygous NN NN O
mutants NN NN O
, NN NN O
although NN NN O
milk NN NN O
from NN NN O
the NN NN O
mutant NN NN O
glands NN NN O
was NN NN O
copper NN NN B-DiseaseClass
deficient NN NN I-DiseaseClass
. NN NN O

Morphological NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
resembling NN NN O
cirrhosis NN NN B-SpecificDisease
developed NN NN O
in NN NN O
the NN NN O
majority NN NN O
of NN NN O
the NN NN O
livers NN NN O
from NN NN O
homozygous NN NN O
mutants NN NN O
older NN NN O
than NN NN O
7 NN NN O
months NN NN O
of NN NN O
age NN NN O
. NN NN O

Progeny NN NN O
of NN NN O
the NN NN O
homozygous NN NN O
mutant NN NN O
females NN NN O
demonstrated NN NN O
neurological NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
and NN NN O
growth NN NN B-DiseaseClass
retardation NN NN I-DiseaseClass
characteristic NN NN O
of NN NN O
copper NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

Copper NN NN O
concentration NN NN O
in NN NN O
the NN NN O
livers NN NN O
of NN NN O
the NN NN O
newborn NN NN O
homozygous NN NN O
null NN NN O
mutants NN NN O
was NN NN O
decreased NN NN O
dramatically NN NN O
. NN NN O

In NN NN O
summary NN NN O
, NN NN O
inactivation NN NN O
of NN NN O
the NN NN O
murine NN NN O
ATP7B NN NN O
gene NN NN O
produces NN NN O
a NN NN O
form NN NN O
of NN NN O
cirrhotic NN NN B-DiseaseClass
liver NN NN I-DiseaseClass
disease NN NN I-DiseaseClass
that NN NN O
resembles NN NN O
Wilson NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
in NN NN O
humans NN NN O
and NN NN O
the NN NN O
toxic NN NN O
milk NN NN O
phenotype NN NN O
in NN NN O
the NN NN O
mouse NN NN O
. NN NN O

. NN NN O

10441343 NN NN O
French NN NN O
Machado-Joseph NN NN B-Modifier
disease NN NN I-Modifier
patients NN NN O
do NN NN O
not NN NN O
exhibit NN NN O
gametic NN NN O
segregation NN NN O
distortion NN NN O
: NN NN O
a NN NN O
sperm NN NN O
typing NN NN O
analysis NN NN O
. NN NN O

Segregation NN NN O
distortion NN NN O
has NN NN O
been NN NN O
reported NN NN O
to NN NN O
occur NN NN O
in NN NN O
a NN NN O
number NN NN O
of NN NN O
the NN NN O
trinucleotide NN NN B-DiseaseClass
repeat NN NN I-DiseaseClass
disorders NN NN I-DiseaseClass
. NN NN O

On NN NN O
the NN NN O
basis NN NN O
of NN NN O
a NN NN O
sperm NN NN O
typing NN NN O
study NN NN O
performed NN NN O
in NN NN O
patients NN NN O
of NN NN O
Japanese NN NN O
descent NN NN O
with NN NN O
Machado-Joseph NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
MJD NN NN B-SpecificDisease
) NN NN O
, NN NN O
it NN NN O
was NN NN O
reported NN NN O
that NN NN O
disease NN NN O
alleles NN NN O
are NN NN O
preferentially NN NN O
transmitted NN NN O
during NN NN O
meiosis NN NN O
. NN NN O

We NN NN O
performed NN NN O
a NN NN O
sperm NN NN O
typing NN NN O
study NN NN O
of NN NN O
five NN NN O
MJD NN NN B-Modifier
patients NN NN O
of NN NN O
French NN NN O
descent NN NN O
and NN NN O
analysis NN NN O
of NN NN O
the NN NN O
pooled NN NN O
data NN NN O
shows NN NN O
a NN NN O
ratio NN NN O
of NN NN O
mutant NN NN O
to NN NN O
normal NN NN O
alleles NN NN O
of NN NN O
379 NN NN O
436 NN NN O
( NN NN O
46 NN NN O
. NN NN O

5 NN NN O
53 NN NN O
. NN NN O

5 NN NN O
% NN NN O
) NN NN O
, NN NN O
which NN NN O
does NN NN O
not NN NN O
support NN NN O
meiotic NN NN O
segregation NN NN O
distortion NN NN O
. NN NN O

To NN NN O
confirm NN NN O
these NN NN O
results NN NN O
, NN NN O
sperm NN NN O
typing NN NN O
analysis NN NN O
was NN NN O
also NN NN O
performed NN NN O
using NN NN O
a NN NN O
polymorphic NN NN O
marker NN NN O
, NN NN O
D14S1050 NN NN O
, NN NN O
closely NN NN O
linked NN NN O
to NN NN O
the NN NN O
MJD1 NN NN O
gene NN NN O
. NN NN O

Among NN NN O
910 NN NN O
sperm NN NN O
analyzed NN NN O
, NN NN O
the NN NN O
allele NN NN O
linked NN NN O
to NN NN O
the NN NN O
disease NN NN O
chromosome NN NN O
was NN NN O
detected NN NN O
in NN NN O
50 NN NN O
. NN NN O

3 NN NN O
% NN NN O
of NN NN O
the NN NN O
samples NN NN O
and NN NN O
the NN NN O
allele NN NN O
linked NN NN O
to NN NN O
the NN NN O
normal NN NN O
chromosome NN NN O
was NN NN O
found NN NN O
in NN NN O
49 NN NN O
. NN NN O

6 NN NN O
% NN NN O
of NN NN O
the NN NN O
sperm NN NN O
. NN NN O

The NN NN O
difference NN NN O
in NN NN O
frequency NN NN O
of NN NN O
these NN NN O
two NN NN O
alleles NN NN O
is NN NN O
not NN NN O
significant NN NN O
( NN NN O
P NN NN O
= NN NN O
0 NN NN O
. NN NN O

8423 NN NN O
) NN NN O
. NN NN O

Likelihood-based NN NN O
analysis NN NN O
of NN NN O
segregation NN NN O
distortion NN NN O
in NN NN O
the NN NN O
single NN NN O
sperm NN NN O
data NN NN O
using NN NN O
the NN NN O
SPERMSEG NN NN O
program NN NN O
also NN NN O
showed NN NN O
no NN NN O
support NN NN O
for NN NN O
segregation NN NN O
distortion NN NN O
at NN NN O
the NN NN O
gamete NN NN O
level NN NN O
in NN NN O
this NN NN O
patient NN NN O
population NN NN O
. NN NN O

The NN NN O
previous NN NN O
report NN NN O
on NN NN O
the NN NN O
Japanese NN NN O
patients NN NN O
also NN NN O
suggested NN NN O
that NN NN O
disease NN NN O
allele NN NN O
stability NN NN O
may NN NN O
be NN NN O
influenced NN NN O
by NN NN O
a NN NN O
trans NN NN O
effect NN NN O
of NN NN O
an NN NN O
intragenic NN NN O
polymorphism NN NN O
( NN NN O
987 NN NN O
G NN NN O
/ NN NN O
C NN NN O
) NN NN O
in NN NN O
the NN NN O
wild-type NN NN O
allele NN NN O
. NN NN O

All NN NN O
of NN NN O
the NN NN O
French NN NN O
patients NN NN O
were NN NN O
heterozygous NN NN O
for NN NN O
this NN NN O
polymorphism NN NN O
. NN NN O

However NN NN O
, NN NN O
analysis NN NN O
of NN NN O
the NN NN O
variance NN NN O
in NN NN O
repeat NN NN O
number NN NN O
in NN NN O
sperm NN NN O
from NN NN O
the NN NN O
French NN NN O
MJD NN NN B-Modifier
patients NN NN O
overlapped NN NN O
significantly NN NN O
with NN NN O
the NN NN O
variance NN NN O
in NN NN O
repeat NN NN O
number NN NN O
observed NN NN O
in NN NN O
the NN NN O
C NN NN O
/ NN NN O
C NN NN O
homozygous NN NN O
Japanese NN NN O
patients NN NN O
. NN NN O

10441571 NN NN O
Missense NN NN O
mutation NN NN O
in NN NN O
the NN NN O
alternative NN NN O
splice NN NN O
region NN NN O
of NN NN O
the NN NN O
PAX6 NN NN O
gene NN NN O
in NN NN O
eye NN NN B-DiseaseClass
anomalies NN NN I-DiseaseClass
. NN NN O

The NN NN O
PAX6 NN NN O
gene NN NN O
is NN NN O
involved NN NN O
in NN NN O
ocular NN NN O
morphogenesis NN NN O
, NN NN O
and NN NN O
PAX6 NN NN O
mutations NN NN O
have NN NN O
been NN NN O
detected NN NN O
in NN NN O
various NN NN O
types NN NN O
of NN NN O
ocular NN NN B-DiseaseClass
anomalies NN NN I-DiseaseClass
, NN NN O
including NN NN O
aniridia NN NN B-SpecificDisease
, NN NN O
Peters NN NN B-SpecificDisease
anomaly NN NN I-SpecificDisease
, NN NN O
corneal NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
, NN NN O
congenital NN NN B-SpecificDisease
cataract NN NN I-SpecificDisease
, NN NN O
and NN NN O
foveal NN NN B-SpecificDisease
hypoplasia NN NN I-SpecificDisease
. NN NN O

The NN NN O
gene NN NN O
encodes NN NN O
a NN NN O
transcriptional NN NN O
regulator NN NN O
that NN NN O
recognizes NN NN O
target NN NN O
genes NN NN O
through NN NN O
its NN NN O
paired-type NN NN O
DNA-binding NN NN O
domain NN NN O
. NN NN O

The NN NN O
paired NN NN O
domain NN NN O
is NN NN O
composed NN NN O
of NN NN O
two NN NN O
distinct NN NN O
DNA-binding NN NN O
subdomains NN NN O
, NN NN O
the NN NN O
N-terminal NN NN O
subdomain NN NN O
( NN NN O
NTS NN NN O
) NN NN O
and NN NN O
the NN NN O
C-terminal NN NN O
subdomain NN NN O
( NN NN O
CTS NN NN O
) NN NN O
, NN NN O
which NN NN O
bind NN NN O
respective NN NN O
consensus NN NN O
DNA NN NN O
sequences NN NN O
. NN NN O

The NN NN O
human NN NN O
PAX6 NN NN O
gene NN NN O
produces NN NN O
two NN NN O
alternative NN NN O
splice NN NN O
isoforms NN NN O
that NN NN O
have NN NN O
the NN NN O
distinct NN NN O
structure NN NN O
of NN NN O
the NN NN O
paired NN NN O
domain NN NN O
. NN NN O

The NN NN O
insertion NN NN O
, NN NN O
into NN NN O
the NN NN O
NTS NN NN O
, NN NN O
of NN NN O
14 NN NN O
additional NN NN O
amino NN NN O
acids NN NN O
encoded NN NN O
by NN NN O
exon NN NN O
5a NN NN O
abolishes NN NN O
the NN NN O
DNA-binding NN NN O
activity NN NN O
of NN NN O
the NN NN O
NTS NN NN O
and NN NN O
unmasks NN NN O
the NN NN O
DNA-binding NN NN O
ability NN NN O
of NN NN O
the NN NN O
CTS NN NN O
. NN NN O

Thus NN NN O
, NN NN O
exon NN NN O
5a NN NN O
appears NN NN O
to NN NN O
function NN NN O
as NN NN O
a NN NN O
molecular NN NN O
switch NN NN O
that NN NN O
specifies NN NN O
target NN NN O
genes NN NN O
. NN NN O

We NN NN O
ascertained NN NN O
a NN NN O
novel NN NN O
missense NN NN O
mutation NN NN O
in NN NN O
four NN NN O
pedigrees NN NN O
with NN NN O
Peters NN NN B-SpecificDisease
anomaly NN NN I-SpecificDisease
, NN NN O
congenital NN NN B-SpecificDisease
cataract NN NN I-SpecificDisease
, NN NN O
Axenfeldt NN NN B-SpecificDisease
anomaly NN NN I-SpecificDisease
, NN NN O
and NN NN O
/ NN NN O
or NN NN O
foveal NN NN B-SpecificDisease
hypoplasia NN NN I-SpecificDisease
, NN NN O
which NN NN O
, NN NN O
to NN NN O
our NN NN O
knowledge NN NN O
, NN NN O
is NN NN O
the NN NN O
first NN NN O
mutation NN NN O
identified NN NN O
in NN NN O
the NN NN O
splice-variant NN NN O
region NN NN O
. NN NN O

A NN NN O
T NN NN O
-- NN NN O
A NN NN O
transition NN NN O
at NN NN O
the NN NN O
20th NN NN O
nucleotide NN NN O
position NN NN O
of NN NN O
exon NN NN O
5a NN NN O
results NN NN O
in NN NN O
a NN NN O
Val NN NN O
-- NN NN O
Asp NN NN O
( NN NN O
GTC NN NN O
-- NN NN O
GAC NN NN O
) NN NN O
substitution NN NN O
at NN NN O
the NN NN O
7th NN NN O
codon NN NN O
of NN NN O
the NN NN O
alternative NN NN O
splice NN NN O
region NN NN O
. NN NN O

Functional NN NN O
analyses NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
V54D NN NN O
mutation NN NN O
slightly NN NN O
increased NN NN O
NTS NN NN O
binding NN NN O
and NN NN O
decreased NN NN O
CTS NN NN O
transactivation NN NN O
activity NN NN O
to NN NN O
almost NN NN O
half NN NN O
. NN NN O

. NN NN O

10441573 NN NN O
Penetrances NN NN O
of NN NN O
BRCA1 NN NN O
1675delA NN NN O
and NN NN O
1135insA NN NN O
with NN NN O
respect NN NN O
to NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
and NN NN O
ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

For NN NN O
genetic NN NN O
counseling NN NN O
and NN NN O
predictive NN NN O
testing NN NN O
in NN NN O
families NN NN O
with NN NN O
inherited NN NN B-CompositeMention
breast-ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
, NN NN O
penetrances NN NN O
and NN NN O
expressions NN NN O
of NN NN O
the NN NN O
underlying NN NN O
mutations NN NN O
should NN NN O
be NN NN O
known NN NN O
. NN NN O

We NN NN O
have NN NN O
previously NN NN O
reported NN NN O
two NN NN O
BRCA1 NN NN O
founder NN NN O
mutations NN NN O
in NN NN O
the NN NN O
Norwegian NN NN O
population NN NN O
. NN NN O

Index NN NN O
cases NN NN O
for NN NN O
the NN NN O
present NN NN O
study NN NN O
were NN NN O
found NN NN O
two NN NN O
different NN NN O
ways NN NN O
through NN NN O
a NN NN O
series NN NN O
of NN NN O
consecutive NN NN O
ovarian NN NN B-SpecificDisease
cancers NN NN I-SpecificDisease
( NN NN O
n NN NN O
= NN NN O
16 NN NN O
) NN NN O
and NN NN O
through NN NN O
our NN NN O
family NN NN O
cancer NN NN B-Modifier
clinic NN NN O
( NN NN O
n NN NN O
= NN NN O
14 NN NN O
) NN NN O
. NN NN O

Altogether NN NN O
, NN NN O
20 NN NN O
of NN NN O
the NN NN O
patients NN NN O
had NN NN O
BRCA1 NN NN O
1675delA NN NN O
, NN NN O
and NN NN O
10 NN NN O
had NN NN O
1135insA NN NN O
. NN NN O

Their NN NN O
relatives NN NN O
were NN NN O
described NN NN O
with NN NN O
respect NN NN O
to NN NN O
absence NN NN O
/ NN NN O
presence NN NN O
of NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
/ NN NN I-CompositeMention
or NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
. NN NN O

Of NN NN O
133 NN NN O
living NN NN O
female NN NN O
relatives NN NN O
, NN NN O
83 NN NN O
( NN NN O
62 NN NN O
% NN NN O
) NN NN O
were NN NN O
tested NN NN O
for NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
mutation NN NN O
. NN NN O

No NN NN O
difference NN NN O
, NN NN O
in NN NN O
penetrance NN NN O
and NN NN O
expression NN NN O
, NN NN O
between NN NN O
the NN NN O
two NN NN O
mutations NN NN O
were NN NN O
found NN NN O
, NN NN O
whereas NN NN O
differences NN NN O
according NN NN O
to NN NN O
method NN NN O
of NN NN O
ascertainment NN NN O
were NN NN O
seen NN NN O
. NN NN O

The NN NN O
overall NN NN O
findings NN NN O
were NN NN O
that NN NN O
disease NN NN O
started NN NN O
to NN NN O
occur NN NN O
at NN NN O
age NN NN O
30 NN NN O
years NN NN O
and NN NN O
that NN NN O
by NN NN O
age NN NN O
50 NN NN O
years NN NN O
48 NN NN O
% NN NN O
of NN NN O
the NN NN O
mutation-carrying NN NN O
women NN NN O
had NN NN O
experienced NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
/ NN NN I-CompositeMention
or NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
. NN NN O

More NN NN O
ovarian NN NN B-SpecificDisease
cancers NN NN I-SpecificDisease
than NN NN O
breast NN NN B-SpecificDisease
cancers NN NN I-SpecificDisease
were NN NN O
recorded NN NN O
. NN NN O

Both NN NN O
penetrance NN NN O
and NN NN O
expression NN NN O
( NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
vs NN NN O
. NN NN O

ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
) NN NN O
were NN NN O
different NN NN O
from NN NN O
those NN NN O
in NN NN O
reports NN NN O
of NN NN O
the NN NN O
Ashkenazi NN NN O
founder NN NN O
mutations NN NN O
. NN NN O

Whether NN NN O
the NN NN O
reported NN NN O
differences NN NN O
reflect NN NN O
true NN NN O
differences NN NN O
and NN NN O
/ NN NN O
or NN NN O
methodological NN NN O
problems NN NN O
is NN NN O
discussed NN NN O
. NN NN O

An NN NN O
observed NN NN O
excess NN NN O
of NN NN O
mutation NN NN O
carriers NN NN O
could NN NN O
not NN NN O
be NN NN O
accounted NN NN O
for NN NN O
by NN NN O
methodological NN NN O
problems NN NN O
; NN NN O
possible NN NN O
explanations NN NN O
were NN NN O
a NN NN O
`` NN NN O
true NN NN O
`` NN NN O
low NN NN O
penetrance NN NN O
or NN NN O
preferential NN NN O
segregation NN NN O
. NN NN O

. NN NN O

10446987 NN NN O
The NN NN O
dermatofibrosarcoma NN NN B-Modifier
protuberans NN NN I-Modifier
-associated NN NN O
collagen NN NN O
type NN NN O
Ialpha1/platelet-derived NN NN O
growth NN NN O
factor NN NN O
( NN NN O
PDGF NN NN O
) NN NN O
B-chain NN NN O
fusion NN NN O
gene NN NN O
generates NN NN O
a NN NN O
transforming NN NN O
protein NN NN O
that NN NN O
is NN NN O
processed NN NN O
to NN NN O
functional NN NN O
PDGF-BB NN NN O
. NN NN O

Dermatofibrosarcoma NN NN B-SpecificDisease
protuberans NN NN I-SpecificDisease
( NN NN O
DFSP NN NN B-SpecificDisease
) NN NN O
displays NN NN O
chromosomal NN NN O
rearrangements NN NN O
involving NN NN O
chromosome NN NN O
17 NN NN O
and NN NN O
22 NN NN O
, NN NN O
which NN NN O
fuse NN NN O
the NN NN O
collagen NN NN O
type NN NN O
Ialpha1 NN NN O
( NN NN O
COLIA1 NN NN O
) NN NN O
gene NN NN O
to NN NN O
the NN NN O
platelet-derived NN NN O
growth NN NN O
factor NN NN O
( NN NN O
PDGF NN NN O
) NN NN O
B-chain NN NN O
( NN NN O
PDGFB NN NN O
) NN NN O
gene NN NN O
. NN NN O

To NN NN O
characterize NN NN O
the NN NN O
functional NN NN O
and NN NN O
structural NN NN O
properties NN NN O
of NN NN O
the NN NN O
COLIA1 NN NN O
/ NN NN O
PDGFB NN NN O
fusion NN NN O
protein NN NN O
, NN NN O
we NN NN O
generated NN NN O
a NN NN O
stable NN NN O
NIH3T3 NN NN O
cell NN NN O
line NN NN O
that NN NN O
contained NN NN O
a NN NN O
tumor-derived NN NN O
chimeric NN NN O
gene NN NN O
resulting NN NN O
from NN NN O
a NN NN O
COIA1 NN NN O
intron NN NN O
7-PDGFB NN NN O
intron NN NN O
1 NN NN O
fusion NN NN O
. NN NN O

Expression NN NN O
of NN NN O
the NN NN O
fusion NN NN O
protein NN NN O
led NN NN O
to NN NN O
morphological NN NN O
transformation NN NN O
and NN NN O
increased NN NN O
growth NN NN O
rate NN NN O
of NN NN O
these NN NN O
cells NN NN O
. NN NN O

The NN NN O
PDGF NN NN O
receptor NN NN O
kinase NN NN O
inhibitor NN NN O
CGP57148B NN NN O
reversed NN NN O
the NN NN O
transformed NN NN O
phenotype NN NN O
and NN NN O
reduced NN NN O
the NN NN O
growth NN NN O
rate NN NN O
of NN NN O
COLIA1 NN NN O
/ NN NN O
PDGFB-expressing NN NN O
cells NN NN O
but NN NN O
had NN NN O
no NN NN O
effects NN NN O
on NN NN O
control NN NN O
cells NN NN O
. NN NN O

The NN NN O
presence NN NN O
of NN NN O
dimeric NN NN O
COLIA1 NN NN O
/ NN NN O
PDGFB NN NN O
precursors NN NN O
was NN NN O
demonstrated NN NN O
through NN NN O
PDGFB NN NN O
immunoprecipitations NN NN O
of NN NN O
metabolically NN NN O
labeled NN NN O
cells NN NN O
and NN NN O
also NN NN O
by NN NN O
PDGFB NN NN O
immunoprecipitations NN NN O
followed NN NN O
by NN NN O
immunoblotting NN NN O
with NN NN O
COLIA1 NN NN O
antibodies NN NN O
. NN NN O

Pulse-chase NN NN O
studies NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
COLIA1 NN NN O
/ NN NN O
PDGFB NN NN O
precursor NN NN O
was NN NN O
processed NN NN O
to NN NN O
an NN NN O
end NN NN O
product NN NN O
that NN NN O
was NN NN O
indistinguishable NN NN O
from NN NN O
wild-type NN NN O
PDGF-BB NN NN O
. NN NN O

Finally NN NN O
, NN NN O
COLIA1 NN NN O
/ NN NN O
PDGFB-expressing NN NN O
cells NN NN O
generated NN NN O
tumors NN NN B-DiseaseClass
after NN NN O
s NN NN O
. NN NN O

c NN NN O
c NN NN O
. NN NN O

injection NN NN O
into NN NN O
nude NN NN O
mice NN NN O
, NN NN O
and NN NN O
tumor NN NN B-Modifier
growth NN NN O
was NN NN O
reduced NN NN O
by NN NN O
treatment NN NN O
with NN NN O
CGP57148B NN NN O
. NN NN O

We NN NN O
conclude NN NN O
that NN NN O
the NN NN O
COLIA1 NN NN O
/ NN NN O
PDGFB NN NN O
fusion NN NN O
associated NN NN O
with NN NN O
DFSP NN NN B-SpecificDisease
contributes NN NN O
to NN NN O
tumor NN NN B-Modifier
development NN NN O
through NN NN O
ectopic NN NN O
production NN NN O
of NN NN O
PDGF-BB NN NN O
and NN NN O
the NN NN O
formation NN NN O
of NN NN O
an NN NN O
autocrine NN NN O
loop NN NN O
. NN NN O

Our NN NN O
findings NN NN O
, NN NN O
thus NN NN O
, NN NN O
suggest NN NN O
that NN NN O
PDGF NN NN O
receptors NN NN O
could NN NN O
be NN NN O
a NN NN O
target NN NN O
for NN NN O
pharmacological NN NN O
treatment NN NN O
of NN NN O
DFSP NN NN B-SpecificDisease
and NN NN O
giant NN NN B-SpecificDisease
cell NN NN I-SpecificDisease
fibroblastoma NN NN I-SpecificDisease
, NN NN O
e NN NN O
. NN NN O

g NN NN O
. NN NN O

, NN NN O
through NN NN O
the NN NN O
use NN NN O
of NN NN O
PDGF NN NN O
receptor NN NN O
kinase NN NN O
inhibitors NN NN O
such NN NN O
as NN NN O
CGP57148B NN NN O
. NN NN O

10447258 NN NN O
Identification NN NN O
of NN NN O
a NN NN O
common NN NN O
PEX1 NN NN O
mutation NN NN O
in NN NN O
Zellweger NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

The NN NN O
Zellweger NN NN B-DiseaseClass
spectrum NN NN I-DiseaseClass
of NN NN I-DiseaseClass
disease NN NN I-DiseaseClass
, NN NN O
encompassing NN NN O
Zellweger NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
and NN NN O
the NN NN O
progressively NN NN O
milder NN NN O
phenotypes NN NN O
of NN NN O
neonatal NN NN B-SpecificDisease
adrenoleukodystrophy NN NN I-SpecificDisease
and NN NN O
infantile NN NN B-SpecificDisease
Refsum NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
, NN NN O
is NN NN O
due NN NN O
to NN NN O
a NN NN O
failure NN NN O
to NN NN O
form NN NN O
functional NN NN O
peroxisomes NN NN O
. NN NN O

Cell NN NN O
fusion NN NN O
complementation NN NN O
studies NN NN O
demonstrated NN NN O
that NN NN O
these NN NN O
diseases NN NN O
are NN NN O
genetically NN NN O
heterogeneous NN NN O
, NN NN O
with NN NN O
two-thirds NN NN O
of NN NN O
all NN NN O
patients NN NN O
lying NN NN O
within NN NN O
a NN NN O
single NN NN O
complementation NN NN O
group NN NN O
, NN NN O
CG1 NN NN O
. NN NN O

Molecular NN NN O
genetic NN NN O
and NN NN O
cell NN NN O
biology NN NN O
studies NN NN O
have NN NN O
shown NN NN O
that NN NN O
PEX1 NN NN O
is NN NN O
deficient NN NN O
in NN NN O
many NN NN O
CG1 NN NN O
patients NN NN O
. NN NN O

However NN NN O
, NN NN O
previous NN NN O
studies NN NN O
have NN NN O
focused NN NN O
on NN NN O
mildly NN NN O
affected NN NN O
patients NN NN O
and NN NN O
there NN NN O
is NN NN O
still NN NN O
no NN NN O
report NN NN O
of NN NN O
two NN NN O
mutant NN NN O
PEX1 NN NN O
alleles NN NN O
in NN NN O
any NN NN O
Zellweger NN NN B-Modifier
syndrome NN NN I-Modifier
patient NN NN O
. NN NN O

Furthermore NN NN O
, NN NN O
mutations NN NN O
in NN NN O
the NN NN O
PMP70 NN NN O
gene NN NN O
have NN NN O
also NN NN O
been NN NN O
identified NN NN O
in NN NN O
two NN NN O
Zellweger NN NN B-Modifier
syndrome NN NN I-Modifier
patients NN NN O
from NN NN O
CG1 NN NN O
, NN NN O
raising NN NN O
the NN NN O
possibility NN NN O
that NN NN O
CG1 NN NN O
patients NN NN O
may NN NN O
represent NN NN O
a NN NN O
mixture NN NN O
of NN NN O
PEX1-deficient NN NN O
and NN NN O
PMP70-deficient NN NN O
individuals NN NN O
. NN NN O

To NN NN O
address NN NN O
the NN NN O
molecular NN NN O
basis NN NN O
of NN NN O
disease NN NN O
in NN NN O
Zellweger NN NN B-Modifier
syndrome NN NN I-Modifier
patients NN NN O
from NN NN O
CG1 NN NN O
, NN NN O
we NN NN O
examined NN NN O
all NN NN O
24 NN NN O
PEX1 NN NN O
exons NN NN O
in NN NN O
four NN NN O
patients NN NN O
, NN NN O
including NN NN O
both NN NN O
patients NN NN O
that NN NN O
have NN NN O
mutations NN NN O
in NN NN O
PMP70 NN NN O
. NN NN O

PEX1 NN NN O
mutations NN NN O
were NN NN O
detected NN NN O
in NN NN O
all NN NN O
four NN NN O
patients NN NN O
, NN NN O
including NN NN O
a NN NN O
1-bp NN NN O
insertion NN NN O
( NN NN O
c NN NN O
. NN NN O

2097insT NN NN O
) NN NN O
in NN NN O
exon NN NN O
13 NN NN O
that NN NN O
was NN NN O
present NN NN O
in NN NN O
three NN NN O
of NN NN O
the NN NN O
four NN NN O
patients NN NN O
. NN NN O

Subsequent NN NN O
studies NN NN O
demonstrated NN NN O
that NN NN O
this NN NN O
mutation NN NN O
is NN NN O
present NN NN O
in NN NN O
one-half NN NN O
of NN NN O
all NN NN O
CG1 NN NN O
patients NN NN O
and NN NN O
correlates NN NN O
with NN NN O
the NN NN O
Zellweger NN NN B-Modifier
syndrome NN NN I-Modifier
phenotype NN NN O
. NN NN O

As NN NN O
this NN NN O
mutation NN NN O
leads NN NN O
to NN NN O
a NN NN O
loss NN NN O
of NN NN O
protein NN NN O
function NN NN O
its NN NN O
frequency NN NN O
makes NN NN O
it NN NN O
the NN NN O
most NN NN O
common NN NN O
cause NN NN O
of NN NN O
Zellweger NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
, NN NN O
helping NN NN O
to NN NN O
explain NN NN O
the NN NN O
high NN NN O
percentage NN NN O
of NN NN O
patients NN NN O
that NN NN O
belong NN NN O
to NN NN O
CG1 NN NN O
. NN NN O

10447259 NN NN O
Novel NN NN O
mutations NN NN O
in NN NN O
the NN NN O
Wiskott-Aldrich NN NN B-Modifier
syndrome NN NN I-Modifier
protein NN NN O
gene NN NN O
and NN NN O
their NN NN O
effects NN NN O
on NN NN O
transcriptional NN NN O
, NN NN O
translational NN NN O
, NN NN O
and NN NN O
clinical NN NN O
phenotypes NN NN O
. NN NN O

Wiskott-Aldrich NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
WAS NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
X-linked NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
immunodeficiency NN NN I-DiseaseClass
characterized NN NN O
by NN NN O
thrombocytopenia NN NN B-DiseaseClass
, NN NN O
eczema NN NN B-DiseaseClass
, NN NN O
and NN NN O
recurrent NN NN O
infections NN NN O
, NN NN O
and NN NN O
caused NN NN O
by NN NN O
mutations NN NN O
in NN NN O
the NN NN O
WAS NN NN B-Modifier
protein NN NN O
( NN NN O
WASP NN NN O
) NN NN O
gene NN NN O
. NN NN O

WASP NN NN O
contains NN NN O
several NN NN O
functional NN NN O
domains NN NN O
through NN NN O
which NN NN O
it NN NN O
interacts NN NN O
with NN NN O
proteins NN NN O
involved NN NN O
in NN NN O
intracellular NN NN O
signaling NN NN O
and NN NN O
regulation NN NN O
of NN NN O
the NN NN O
actin NN NN O
cytoskeleton NN NN O
. NN NN O

In NN NN O
this NN NN O
report NN NN O
, NN NN O
17 NN NN O
WASP NN NN O
gene NN NN O
mutations NN NN O
were NN NN O
identified NN NN O
, NN NN O
12 NN NN O
of NN NN O
which NN NN O
are NN NN O
novel NN NN O
. NN NN O

DNA NN NN O
of NN NN O
affected NN NN O
males NN NN O
and NN NN O
obligate NN NN O
carriers NN NN O
was NN NN O
PCR NN NN O
amplified NN NN O
and NN NN O
analyzed NN NN O
by NN NN O
SSCA NN NN O
, NN NN O
heteroduplex NN NN O
analysis NN NN O
, NN NN O
and NN NN O
direct NN NN O
sequencing NN NN O
. NN NN O

The NN NN O
effects NN NN O
of NN NN O
the NN NN O
mutations NN NN O
at NN NN O
the NN NN O
mRNA NN NN O
and NN NN O
protein NN NN O
level NN NN O
were NN NN O
ascertained NN NN O
by NN NN O
RT-PCR NN NN O
and NN NN O
Western NN NN O
blot NN NN O
analyses NN NN O
. NN NN O

All NN NN O
missense NN NN O
mutations NN NN O
were NN NN O
located NN NN O
in NN NN O
exons NN NN O
1-4 NN NN O
. NN NN O

Most NN NN O
of NN NN O
the NN NN O
nonsense NN NN O
, NN NN O
frameshift NN NN O
and NN NN O
splice NN NN O
site NN NN O
mutations NN NN O
were NN NN O
found NN NN O
in NN NN O
exons NN NN O
6-11 NN NN O
. NN NN O

Mutations NN NN O
that NN NN O
alter NN NN O
splice NN NN O
sites NN NN O
led NN NN O
to NN NN O
the NN NN O
synthesis NN NN O
of NN NN O
several NN NN O
types NN NN O
of NN NN O
mRNAs NN NN O
, NN NN O
a NN NN O
fraction NN NN O
of NN NN O
which NN NN O
represented NN NN O
the NN NN O
normally NN NN O
spliced NN NN O
product NN NN O
. NN NN O

The NN NN O
presence NN NN O
of NN NN O
normally NN NN O
spliced NN NN O
transcripts NN NN O
was NN NN O
correlated NN NN O
with NN NN O
a NN NN O
milder NN NN O
phenotype NN NN O
. NN NN O

When NN NN O
one NN NN O
such NN NN O
case NN NN O
was NN NN O
studied NN NN O
by NN NN O
Western NN NN O
blotting NN NN O
, NN NN O
reduced NN NN O
amounts NN NN O
of NN NN O
normal-size NN NN O
WASP NN NN O
were NN NN O
present NN NN O
. NN NN O

In NN NN O
other NN NN O
cases NN NN O
as NN NN O
well NN NN O
, NN NN O
a NN NN O
correlation NN NN O
was NN NN O
found NN NN O
between NN NN O
the NN NN O
amount NN NN O
of NN NN O
normal NN NN O
or NN NN O
mutant NN NN O
WASP NN NN O
present NN NN O
and NN NN O
the NN NN O
phenotypes NN NN O
of NN NN O
the NN NN O
affected NN NN O
individuals NN NN O
. NN NN O

No NN NN O
protein NN NN O
was NN NN O
detected NN NN O
in NN NN O
two NN NN O
individuals NN NN O
with NN NN O
severe NN NN O
WAS NN NN B-SpecificDisease
. NN NN O

Reduced NN NN O
levels NN NN O
of NN NN O
a NN NN O
normal-size NN NN O
WASP NN NN O
with NN NN O
a NN NN O
missense NN NN O
mutation NN NN O
were NN NN O
seen NN NN O
in NN NN O
two NN NN O
individuals NN NN O
with NN NN O
XLT NN NN B-SpecificDisease
. NN NN O

It NN NN O
is NN NN O
concluded NN NN O
that NN NN O
mutation NN NN O
analysis NN NN O
at NN NN O
the NN NN O
DNA NN NN O
level NN NN O
is NN NN O
not NN NN O
sufficient NN NN O
for NN NN O
predicting NN NN O
clinical NN NN O
course NN NN O
. NN NN O

Studies NN NN O
at NN NN O
the NN NN O
transcript NN NN O
and NN NN O
protein NN NN O
level NN NN O
are NN NN O
needed NN NN O
for NN NN O
a NN NN O
better NN NN O
assessment NN NN O
. NN NN O

. NN NN O

10449429 NN NN O
Aminoglycoside NN NN O
antibiotics NN NN O
restore NN NN O
dystrophin NN NN O
function NN NN O
to NN NN O
skeletal NN NN O
muscles NN NN O
of NN NN O
mdx NN NN O
mice NN NN O
. NN NN O

Duchenne NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DMD NN NN B-SpecificDisease
) NN NN O
is NN NN O
caused NN NN O
by NN NN O
mutations NN NN O
in NN NN O
the NN NN O
dystrophin NN NN O
gene NN NN O
, NN NN O
leading NN NN O
to NN NN O
the NN NN O
absence NN NN O
of NN NN O
the NN NN O
dystrophin NN NN O
protein NN NN O
in NN NN O
striated NN NN O
muscle NN NN O
. NN NN O

A NN NN O
significant NN NN O
number NN NN O
of NN NN O
these NN NN O
mutations NN NN O
are NN NN O
premature NN NN O
stop NN NN O
codons NN NN O
. NN NN O

On NN NN O
the NN NN O
basis NN NN O
of NN NN O
the NN NN O
observation NN NN O
that NN NN O
aminoglycoside NN NN O
treatment NN NN O
can NN NN O
suppress NN NN O
stop NN NN O
codons NN NN O
in NN NN O
cultured NN NN O
cells NN NN O
, NN NN O
we NN NN O
tested NN NN O
the NN NN O
effect NN NN O
of NN NN O
gentamicin NN NN O
on NN NN O
cultured NN NN O
muscle NN NN O
cells NN NN O
from NN NN O
the NN NN O
mdx NN NN O
mouse NN NN O
- NN NN O
an NN NN O
animal NN NN O
model NN NN O
for NN NN O
DMD NN NN B-SpecificDisease
that NN NN O
possesses NN NN O
a NN NN O
premature NN NN O
stop NN NN O
codon NN NN O
in NN NN O
the NN NN O
dystrophin NN NN O
gene NN NN O
. NN NN O

Exposure NN NN O
of NN NN O
mdx NN NN O
myotubes NN NN O
to NN NN O
gentamicin NN NN O
led NN NN O
to NN NN O
the NN NN O
expression NN NN O
and NN NN O
localization NN NN O
of NN NN O
dystrophin NN NN O
to NN NN O
the NN NN O
cell NN NN O
membrane NN NN O
. NN NN O

We NN NN O
then NN NN O
evaluated NN NN O
the NN NN O
effects NN NN O
of NN NN O
differing NN NN O
dosages NN NN O
of NN NN O
gentamicin NN NN O
on NN NN O
expression NN NN O
and NN NN O
functional NN NN O
protection NN NN O
of NN NN O
the NN NN O
muscles NN NN O
of NN NN O
mdx NN NN O
mice NN NN O
. NN NN O

We NN NN O
identified NN NN O
a NN NN O
treatment NN NN O
regimen NN NN O
that NN NN O
resulted NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
dystrophin NN NN O
in NN NN O
the NN NN O
cell NN NN O
membrane NN NN O
in NN NN O
all NN NN O
striated NN NN O
muscles NN NN O
examined NN NN O
and NN NN O
that NN NN O
provided NN NN O
functional NN NN O
protection NN NN O
against NN NN O
muscular NN NN B-DiseaseClass
injury NN NN I-DiseaseClass
. NN NN O

To NN NN O
our NN NN O
knowledge NN NN O
, NN NN O
our NN NN O
results NN NN O
are NN NN O
the NN NN O
first NN NN O
to NN NN O
demonstrate NN NN O
that NN NN O
aminoglycosides NN NN O
can NN NN O
suppress NN NN O
stop NN NN O
codons NN NN O
not NN NN O
only NN NN O
in NN NN O
vitro NN NN O
but NN NN O
also NN NN O
in NN NN O
vivo NN NN O
. NN NN O

Furthermore NN NN O
, NN NN O
these NN NN O
results NN NN O
raise NN NN O
the NN NN O
possibility NN NN O
of NN NN O
a NN NN O
novel NN NN O
treatment NN NN O
regimen NN NN O
for NN NN O
muscular NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
and NN NN O
other NN NN O
diseases NN NN O
caused NN NN O
by NN NN O
premature NN NN O
stop NN NN O
codon NN NN O
mutations NN NN O
. NN NN O

This NN NN O
treatment NN NN O
could NN NN O
prove NN NN O
effective NN NN O
in NN NN O
up NN NN O
to NN NN O
15 NN NN O
% NN NN O
of NN NN O
patients NN NN O
with NN NN O
DMD NN NN B-SpecificDisease
. NN NN O

. NN NN O

10449794 NN NN O
Loss NN NN O
of NN NN O
the NN NN O
ataxia-telangiectasia NN NN B-Modifier
gene NN NN O
product NN NN O
causes NN NN O
oxidative NN NN O
damage NN NN O
in NN NN O
target NN NN O
organs NN NN O
. NN NN O

Ataxia-telangiectasia NN NN B-SpecificDisease
( NN NN O
A-T NN NN B-SpecificDisease
) NN NN O
is NN NN O
characterized NN NN O
by NN NN O
a NN NN O
markedly NN NN O
increased NN NN O
sensitivity NN NN O
to NN NN O
ionizing NN NN O
radiation NN NN O
, NN NN O
increased NN NN O
incidence NN NN O
of NN NN O
cancer NN NN B-DiseaseClass
, NN NN O
and NN NN O
neurodegeneration NN NN B-DiseaseClass
, NN NN O
especially NN NN O
of NN NN O
the NN NN O
cerebellar NN NN O
Purkinje NN NN O
cells NN NN O
. NN NN O

Ionizing NN NN O
radiation NN NN O
oxidizes NN NN O
macromolecules NN NN O
and NN NN O
causes NN NN O
tissue NN NN O
damage NN NN O
through NN NN O
the NN NN O
generation NN NN O
of NN NN O
reactive NN NN O
oxygen NN NN O
species NN NN O
( NN NN O
ROS NN NN O
) NN NN O
. NN NN O

We NN NN O
therefore NN NN O
hypothesized NN NN O
that NN NN O
A-T NN NN B-SpecificDisease
is NN NN O
due NN NN O
to NN NN O
oxidative NN NN O
damage NN NN O
resulting NN NN O
from NN NN O
loss NN NN O
of NN NN O
function NN NN O
of NN NN O
the NN NN O
A-T NN NN B-Modifier
gene NN NN O
product NN NN O
. NN NN O

To NN NN O
assess NN NN O
this NN NN O
hypothesis NN NN O
, NN NN O
we NN NN O
employed NN NN O
an NN NN O
animal NN NN O
model NN NN O
of NN NN O
A-T NN NN B-SpecificDisease
, NN NN O
the NN NN O
mouse NN NN O
with NN NN O
a NN NN O
disrupted NN NN O
Atm NN NN O
gene NN NN O
. NN NN O

We NN NN O
show NN NN O
that NN NN O
organs NN NN O
which NN NN O
develop NN NN O
pathologic NN NN O
changes NN NN O
in NN NN O
the NN NN O
Atm-deficient NN NN O
mice NN NN O
are NN NN O
targets NN NN O
of NN NN O
oxidative NN NN O
damage NN NN O
, NN NN O
and NN NN O
that NN NN O
cerebellar NN NN O
Purkinje NN NN O
cells NN NN O
are NN NN O
particularly NN NN O
affected NN NN O
. NN NN O

These NN NN O
observations NN NN O
provide NN NN O
a NN NN O
mechanistic NN NN O
basis NN NN O
for NN NN O
the NN NN O
A-T NN NN B-Modifier
phenotype NN NN O
and NN NN O
lay NN NN O
a NN NN O
rational NN NN O
foundation NN NN O
for NN NN O
therapeutic NN NN O
intervention NN NN O
. NN NN O

. NN NN O

10465113 NN NN O
Recessively NN NN O
inherited NN NN O
multiple NN NN B-SpecificDisease
epiphyseal NN NN I-SpecificDisease
dysplasia NN NN I-SpecificDisease
with NN NN O
normal NN NN O
stature NN NN O
, NN NN O
club NN NN B-SpecificDisease
foot NN NN I-SpecificDisease
, NN NN O
and NN NN O
double NN NN B-DiseaseClass
layered NN NN I-DiseaseClass
patella NN NN I-DiseaseClass
caused NN NN O
by NN NN O
a NN NN O
DTDST NN NN O
mutation NN NN O
. NN NN O

We NN NN O
have NN NN O
observed NN NN O
over NN NN O
25 NN NN O
different NN NN O
mutations NN NN O
in NN NN O
the NN NN O
diastrophic NN NN B-Modifier
dysplasia NN NN I-Modifier
sulphate NN NN O
transporter NN NN O
gene NN NN O
( NN NN O
DTDST NN NN O
) NN NN O
in NN NN O
association NN NN O
with NN NN O
the NN NN O
recessive NN NN B-DiseaseClass
disorders NN NN I-DiseaseClass
achondrogenesis NN NN B-SpecificDisease
1B NN NN I-SpecificDisease
, NN NN O
atelosteogenesis NN NN B-SpecificDisease
2 NN NN I-SpecificDisease
, NN NN O
and NN NN O
diastrophic NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
. NN NN O

The NN NN O
c862t NN NN O
( NN NN O
R279W NN NN O
) NN NN O
transition NN NN O
is NN NN O
the NN NN O
most NN NN O
common NN NN O
mutation NN NN O
in NN NN O
non-Finnish NN NN O
patients NN NN O
, NN NN O
but NN NN O
in NN NN O
these NN NN O
disorders NN NN O
it NN NN O
is NN NN O
usually NN NN O
combined NN NN O
with NN NN O
other NN NN O
DTDST NN NN O
mutations NN NN O
. NN NN O

We NN NN O
had NN NN O
not NN NN O
seen NN NN O
a NN NN O
case NN NN O
of NN NN O
homozygosity NN NN O
for NN NN O
c862t NN NN O
( NN NN O
R279W NN NN O
) NN NN O
until NN NN O
we NN NN O
analysed NN NN O
DNA NN NN O
from NN NN O
a NN NN O
36 NN NN O
year NN NN O
old NN NN O
male NN NN O
with NN NN O
tall-normal NN NN O
stature NN NN O
( NN NN O
180 NN NN O
cm NN NN O
) NN NN O
who NN NN O
asked NN NN O
for NN NN O
genetic NN NN O
counselling NN NN O
for NN NN O
suspected NN NN O
multiple NN NN B-SpecificDisease
epiphyseal NN NN I-SpecificDisease
dysplasia NN NN I-SpecificDisease
. NN NN O

He NN NN O
was NN NN O
treated NN NN O
for NN NN O
club NN NN B-SpecificDisease
foot NN NN I-SpecificDisease
and NN NN O
hip NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
at NN NN O
birth NN NN O
. NN NN O

Skeletal NN NN O
changes NN NN O
consistent NN NN O
with NN NN O
multiple NN NN B-SpecificDisease
epiphyseal NN NN I-SpecificDisease
dysplasia NN NN I-SpecificDisease
, NN NN O
with NN NN O
the NN NN O
peculiar NN NN O
finding NN NN O
of NN NN O
a NN NN O
double NN NN B-DiseaseClass
layered NN NN I-DiseaseClass
patella NN NN I-DiseaseClass
, NN NN O
were NN NN O
recognised NN NN O
during NN NN O
childhood NN NN O
. NN NN O

Cleft NN NN B-SpecificDisease
palate NN NN I-SpecificDisease
, NN NN O
swelling NN NN B-DiseaseClass
of NN NN I-DiseaseClass
the NN NN I-DiseaseClass
ear NN NN I-DiseaseClass
pinna NN NN I-DiseaseClass
, NN NN O
and NN NN O
hitch NN NN B-DiseaseClass
hiker NN NN I-DiseaseClass
thumb NN NN I-DiseaseClass
were NN NN O
absent NN NN O
. NN NN O

He NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
homozygous NN NN O
, NN NN O
and NN NN O
both NN NN O
healthy NN NN O
parents NN NN O
heterozygous NN NN O
, NN NN O
for NN NN O
the NN NN O
R279W NN NN O
mutation NN NN O
in NN NN O
DTDST NN NN O
, NN NN O
and NN NN O
his NN NN O
fibroblasts NN NN O
showed NN NN O
a NN NN O
sulphate NN NN O
incorporation NN NN O
defect NN NN O
typical NN NN O
of NN NN O
DTDST NN NN B-SpecificDisease
disorders NN NN I-SpecificDisease
. NN NN O

Counselling NN NN O
was NN NN O
given NN NN O
for NN NN O
a NN NN O
recessive NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
, NN NN O
thereby NN NN O
considerably NN NN O
reducing NN NN O
the NN NN O
probability NN NN O
of NN NN O
affected NN NN O
offspring NN NN O
. NN NN O

Multiple NN NN B-SpecificDisease
epiphyseal NN NN I-SpecificDisease
dysplasia NN NN I-SpecificDisease
is NN NN O
more NN NN O
frequently NN NN O
caused NN NN O
by NN NN O
dominant NN NN O
mutations NN NN O
in NN NN O
the NN NN O
COMP NN NN O
( NN NN O
EDM1 NN NN O
, NN NN O
McKusick NN NN O
132400 NN NN O
) NN NN O
and NN NN O
COL9A2 NN NN O
genes NN NN O
( NN NN O
EDM2 NN NN O
, NN NN O
McKusick NN NN O
600204 NN NN O
) NN NN O
. NN NN O

A NN NN O
few NN NN O
other NN NN O
patients NN NN O
and NN NN O
families NN NN O
with NN NN O
features NN NN O
similar NN NN O
to NN NN O
our NN NN O
proband NN NN O
have NN NN O
been NN NN O
described NN NN O
previously NN NN O
and NN NN O
considered NN NN O
to NN NN O
have NN NN O
autosomal NN NN O
recessive NN NN O
MED NN NN B-SpecificDisease
( NN NN O
EDM4 NN NN O
, NN NN O
McKusick NN NN O
226900 NN NN O
) NN NN O
. NN NN O

This NN NN O
observation NN NN O
confirms NN NN O
the NN NN O
existence NN NN O
of NN NN O
this NN NN O
entity NN NN O
and NN NN O
assigns NN NN O
it NN NN O
to NN NN O
the NN NN O
phenotypic NN NN O
spectrum NN NN O
associated NN NN O
with NN NN O
mutations NN NN O
at NN NN O
the NN NN O
DTDST NN NN O
locus NN NN O
. NN NN O

. NN NN O

10466420 NN NN O
Homozygosity NN NN O
for NN NN O
a NN NN O
novel NN NN O
DTDST NN NN O
mutation NN NN O
in NN NN O
a NN NN O
child NN NN O
with NN NN O
a NN NN O
'broad NN NN O
bone-platyspondylic NN NN O
' NN NN O
variant NN NN O
of NN NN O
diastrophic NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
. NN NN O

Atypical NN NN O
or NN NN O
variant NN NN O
forms NN NN O
of NN NN O
well-known NN NN O
chondrodysplasias NN NN B-DiseaseClass
may NN NN O
pose NN NN O
diagnostic NN NN O
problems NN NN O
. NN NN O

We NN NN O
report NN NN O
on NN NN O
a NN NN O
girl NN NN O
with NN NN O
clinical NN NN O
features NN NN O
suggesting NN NN O
diastrophic NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
but NN NN O
with NN NN O
unusual NN NN O
radiographic NN NN O
features NN NN O
including NN NN O
severe NN NN O
platyspondyly NN NN B-DiseaseClass
, NN NN O
wide NN NN B-DiseaseClass
metaphyses NN NN I-DiseaseClass
, NN NN O
and NN NN O
fibular NN NN B-DiseaseClass
overgrowth NN NN I-DiseaseClass
, NN NN O
which NN NN O
are NN NN O
partially NN NN O
reminiscent NN NN O
of NN NN O
metatropic NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
. NN NN O

The NN NN O
diagnosis NN NN O
was NN NN O
clarified NN NN O
by NN NN O
molecular NN NN O
analysis NN NN O
of NN NN O
the NN NN O
DTDST NN NN O
gene NN NN O
, NN NN O
which NN NN O
revealed NN NN O
homozygosity NN NN O
for NN NN O
a NN NN O
previously NN NN O
undescribed NN NN O
mutation NN NN O
leading NN NN O
to NN NN O
a NN NN O
Q454P NN NN O
substitution NN NN O
in NN NN O
the NN NN O
10th NN NN O
transmembrane NN NN O
domain NN NN O
of NN NN O
the NN NN O
DTDST NN NN O
sulfate NN NN O
transporter NN NN O
. NN NN O

Molecular NN NN O
analysis NN NN O
may NN NN O
be NN NN O
of NN NN O
particular NN NN O
value NN NN O
in NN NN O
such NN NN O
atypical NN NN O
cases NN NN O
. NN NN O

. NN NN O

10470088 NN NN O
The NN NN O
type NN NN O
of NN NN O
somatic NN NN O
mutation NN NN O
at NN NN O
APC NN NN O
in NN NN O
familial NN NN B-SpecificDisease
adenomatous NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
is NN NN O
determined NN NN O
by NN NN O
the NN NN O
site NN NN O
of NN NN O
the NN NN O
germline NN NN O
mutation NN NN O
: NN NN O
a NN NN O
new NN NN O
facet NN NN O
to NN NN O
Knudson NN NN O
's NN NN O
'two-hit NN NN O
' NN NN O
hypothesis NN NN O
. NN NN O

APC NN NN O
is NN NN O
often NN NN O
cited NN NN O
as NN NN O
a NN NN O
prime NN NN O
example NN NN O
of NN NN O
a NN NN O
tumor NN NN B-Modifier
suppressor NN NN O
gene NN NN O
. NN NN O

Truncating NN NN O
germline NN NN O
and NN NN O
somatic NN NN O
mutations NN NN O
( NN NN O
or NN NN O
, NN NN O
infrequently NN NN O
, NN NN O
allelic NN NN O
loss NN NN O
) NN NN O
occur NN NN O
in NN NN O
tumors NN NN B-DiseaseClass
in NN NN O
FAP NN NN B-SpecificDisease
( NN NN O
familial NN NN B-SpecificDisease
adenomatous NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
) NN NN O
. NN NN O

Most NN NN O
sporadic NN NN B-SpecificDisease
colorectal NN NN I-SpecificDisease
cancers NN NN I-SpecificDisease
also NN NN O
have NN NN O
two NN NN O
APC NN NN B-Modifier
mutations NN NN O
. NN NN O

Clues NN NN O
from NN NN O
attenuated NN NN B-Modifier
polyposis NN NN I-Modifier
, NN NN O
missense NN NN O
germline NN NN O
variants NN NN O
with NN NN O
mild NN NN O
disease NN NN O
and NN NN O
the NN NN O
somatic NN NN O
mutation NN NN O
cluster NN NN O
region NN NN O
( NN NN O
codons NN NN O
1 NN NN O
, NN NN O
250-1 NN NN O
, NN NN O
450 NN NN O
) NN NN O
indicate NN NN O
, NN NN O
however NN NN O
, NN NN O
that NN NN O
APC NN NN B-Modifier
mutations NN NN O
might NN NN O
not NN NN O
result NN NN O
in NN NN O
simple NN NN O
loss NN NN O
of NN NN O
protein NN NN O
function NN NN O
. NN NN O

We NN NN O
have NN NN O
found NN NN O
that NN NN O
FAP NN NN B-Modifier
patients NN NN O
with NN NN O
germline NN NN O
APC NN NN B-Modifier
mutations NN NN O
within NN NN O
a NN NN O
small NN NN O
region NN NN O
( NN NN O
codons NN NN O
1 NN NN O
, NN NN O
194-1 NN NN O
, NN NN O
392 NN NN O
at NN NN O
most NN NN O
) NN NN O
mainly NN NN O
show NN NN O
allelic NN NN O
loss NN NN O
in NN NN O
their NN NN O
colorectal NN NN B-SpecificDisease
adenomas NN NN I-SpecificDisease
, NN NN O
in NN NN O
contrast NN NN O
to NN NN O
other NN NN O
FAP NN NN B-Modifier
patients NN NN O
, NN NN O
whose NN NN O
second NN NN O
hits NN NN O
tend NN NN O
to NN NN O
occur NN NN O
by NN NN O
truncating NN NN O
mutations NN NN O
in NN NN O
the NN NN O
mutation NN NN O
cluster NN NN O
region NN NN O
. NN NN O

Our NN NN O
results NN NN O
indicate NN NN O
that NN NN O
different NN NN O
APC NN NN B-Modifier
mutations NN NN O
provide NN NN O
cells NN NN O
with NN NN O
different NN NN O
selective NN NN O
advantages NN NN O
, NN NN O
with NN NN O
mutations NN NN O
close NN NN O
to NN NN O
codon NN NN O
1 NN NN O
, NN NN O
300 NN NN O
providing NN NN O
the NN NN O
greatest NN NN O
advantage NN NN O
. NN NN O

Allelic NN NN O
loss NN NN O
is NN NN O
selected NN NN O
strongly NN NN O
in NN NN O
cells NN NN O
with NN NN O
one NN NN O
mutation NN NN O
near NN NN O
codon NN NN O
1 NN NN O
, NN NN O
300 NN NN O
. NN NN O

A NN NN O
different NN NN O
germline-somatic NN NN O
APC NN NN B-Modifier
mutation NN NN O
association NN NN O
exists NN NN O
in NN NN O
FAP NN NN B-SpecificDisease
desmoids NN NN I-SpecificDisease
. NN NN O

APC NN NN O
is NN NN O
not NN NN O
, NN NN O
therefore NN NN O
, NN NN O
a NN NN O
classical NN NN O
tumor NN NN B-Modifier
suppressor NN NN O
. NN NN O

Our NN NN O
findings NN NN O
also NN NN O
indicate NN NN O
a NN NN O
new NN NN O
mechanism NN NN O
for NN NN O
disease NN NN O
severity NN NN O
if NN NN O
a NN NN O
broader NN NN O
spectrum NN NN O
of NN NN O
mutations NN NN O
is NN NN O
selected NN NN O
in NN NN O
tumors NN NN B-DiseaseClass
, NN NN O
the NN NN O
somatic NN NN O
mutation NN NN O
rate NN NN O
is NN NN O
effectively NN NN O
higher NN NN O
and NN NN O
more NN NN O
tumors NN NN B-DiseaseClass
grow NN NN O
. NN NN O

. NN NN O

10470286 NN NN O
Mxi1 NN NN O
mutations NN NN O
in NN NN O
human NN NN O
neurofibrosarcomas NN NN B-SpecificDisease
. NN NN O

Mxi1 NN NN O
is NN NN O
thought NN NN O
to NN NN O
negatively NN NN O
regulate NN NN O
Myc NN NN O
function NN NN O
and NN NN O
may NN NN O
therefore NN NN O
be NN NN O
a NN NN O
potential NN NN O
tumor NN NN B-Modifier
suppressor NN NN O
gene NN NN O
. NN NN O

Little NN NN O
effort NN NN O
has NN NN O
yet NN NN O
been NN NN O
made NN NN O
to NN NN O
find NN NN O
alterations NN NN O
involving NN NN O
this NN NN O
gene NN NN O
in NN NN O
human NN NN O
solid NN NN B-DiseaseClass
tumors NN NN I-DiseaseClass
. NN NN O

We NN NN O
screened NN NN O
31 NN NN O
human NN NN O
gastric NN NN B-SpecificDisease
cancers NN NN I-SpecificDisease
, NN NN O
7 NN NN O
esophageal NN NN B-SpecificDisease
cancers NN NN I-SpecificDisease
, NN NN O
85 NN NN O
bone NN NN B-CompositeMention
and NN NN I-CompositeMention
soft NN NN I-CompositeMention
tissue NN NN I-CompositeMention
tumors NN NN I-CompositeMention
of NN NN O
various NN NN O
types NN NN O
, NN NN O
including NN NN O
4 NN NN O
neurofibrosarcomas NN NN B-SpecificDisease
. NN NN O

We NN NN O
also NN NN O
examined NN NN O
29 NN NN O
human NN NN O
tumor NN NN B-Modifier
cell NN NN O
lines NN NN O
consisting NN NN O
of NN NN O
12 NN NN O
esophageal NN NN B-SpecificDisease
cancers NN NN I-SpecificDisease
, NN NN O
7 NN NN O
glioma NN NN B-SpecificDisease
/ NN NN O
glioblastomas NN NN B-SpecificDisease
and NN NN O
10 NN NN O
others NN NN O
for NN NN O
Mxi1 NN NN O
mutations NN NN O
in NN NN O
exons NN NN O
1 NN NN O
, NN NN O
2 NN NN O
, NN NN O
4 NN NN O
( NN NN O
HLH NN NN O
domain NN NN O
) NN NN O
, NN NN O
5 NN NN O
and NN NN O
6 NN NN O
. NN NN O

Polymerase NN NN O
chain NN NN O
reaction-single-strand NN NN O
conformation NN NN O
polymorphism NN NN O
( NN NN O
PCR-SSCP NN NN O
) NN NN O
and NN NN O
subsequent NN NN O
sequencing NN NN O
revealed NN NN O
three NN NN O
distinct NN NN O
polymorphisms NN NN O
in NN NN O
the NN NN O
intron-exon NN NN O
boundary NN NN O
upstream NN NN O
from NN NN O
exon NN NN O
6 NN NN O
. NN NN O

We NN NN O
discovered NN NN O
a NN NN O
missense NN NN O
mutation NN NN O
, NN NN O
GCA NN NN O
to NN NN O
GTA NN NN O
( NN NN O
Ala NN NN O
54 NN NN O
Val NN NN O
) NN NN O
, NN NN O
in NN NN O
exon NN NN O
2 NN NN O
in NN NN O
a NN NN O
neurofibrosarcoma NN NN B-Modifier
patient NN NN O
( NN NN O
case NN NN O
1 NN NN O
) NN NN O
, NN NN O
two NN NN O
missense NN NN O
mutations NN NN O
, NN NN O
AAA NN NN O
to NN NN O
CAA NN NN O
( NN NN O
Lys NN NN O
118 NN NN O
Gln NN NN O
) NN NN O
and NN NN O
GAA NN NN O
to NN NN O
GGA NN NN O
( NN NN O
Glu NN NN O
154 NN NN O
Gly NN NN O
) NN NN O
in NN NN O
exon NN NN O
5 NN NN O
of NN NN O
another NN NN O
neurofibrosarcoma NN NN B-Modifier
patient NN NN O
( NN NN O
case NN NN O
2 NN NN O
) NN NN O
, NN NN O
and NN NN O
3 NN NN O
amino NN NN O
acid NN NN O
substitutions NN NN O
, NN NN O
GTG NN NN O
to NN NN O
GCG NN NN O
( NN NN O
Val NN NN O
179 NN NN O
Ala NN NN O
) NN NN O
, NN NN O
GTT NN NN O
to NN NN O
GCT NN NN O
( NN NN O
Val NN NN O
181 NN NN O
Ala NN NN O
) NN NN O
and NN NN O
TTC NN NN O
to NN NN O
CTC NN NN O
( NN NN O
Phe NN NN O
186 NN NN O
Leu NN NN O
) NN NN O
, NN NN O
in NN NN O
a NN NN O
third NN NN O
neurofibrosarcoma NN NN B-Modifier
patient NN NN O
( NN NN O
case NN NN O
3 NN NN O
) NN NN O
. NN NN O

In NN NN O
case NN NN O
3 NN NN O
, NN NN O
loss NN NN O
of NN NN O
heterozygosity NN NN O
was NN NN O
also NN NN O
demonstrated NN NN O
by NN NN O
informative NN NN O
( NN NN O
TTC NN NN O
) NN NN O
3 NN NN O
/ NN NN O
( NN NN O
TTC NN NN O
) NN NN O
2 NN NN O
polymorphism NN NN O
. NN NN O

Our NN NN O
data NN NN O
demonstrate NN NN O
that NN NN O
mutations NN NN O
occur NN NN O
in NN NN O
the NN NN O
Mxi1 NN NN O
gene NN NN O
in NN NN O
neurofibrosarcoma NN NN B-SpecificDisease
. NN NN O

Missense NN NN O
mutations NN NN O
in NN NN O
the NN NN O
functional NN NN O
domain NN NN O
of NN NN O
Mxi1 NN NN O
in NN NN O
these NN NN O
cases NN NN O
may NN NN O
be NN NN O
involved NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
neurofibrosarcoma NN NN B-SpecificDisease
. NN NN O

. NN NN O

10471457 NN NN O
A NN NN O
population-based NN NN O
study NN NN O
of NN NN O
the NN NN O
clinical NN NN O
expression NN NN O
of NN NN O
the NN NN O
hemochromatosis NN NN B-Modifier
gene NN NN O
. NN NN O

BACKGROUND NN NN O
AND NN NN O
METHODS NN NN O
Hereditary NN NN B-SpecificDisease
hemochromatosis NN NN I-SpecificDisease
is NN NN O
associated NN NN O
with NN NN O
homozygosity NN NN O
for NN NN O
the NN NN O
C282Y NN NN O
mutation NN NN O
in NN NN O
the NN NN O
hemochromatosis NN NN B-Modifier
( NN NN O
HFE NN NN O
) NN NN O
gene NN NN O
on NN NN O
chromosome NN NN O
6 NN NN O
, NN NN O
elevated NN NN O
serum NN NN O
transferrin NN NN O
saturation NN NN O
, NN NN O
and NN NN O
excess NN NN B-DiseaseClass
iron NN NN I-DiseaseClass
deposits NN NN I-DiseaseClass
throughout NN NN O
the NN NN O
body NN NN O
. NN NN O

To NN NN O
assess NN NN O
the NN NN O
prevalence NN NN O
and NN NN O
clinical NN NN O
expression NN NN O
of NN NN O
the NN NN O
HFE NN NN O
gene NN NN O
, NN NN O
we NN NN O
conducted NN NN O
a NN NN O
population-based NN NN O
study NN NN O
in NN NN O
Busselton NN NN O
, NN NN O
Australia NN NN O
. NN NN O

In NN NN O
1994 NN NN O
, NN NN O
we NN NN O
obtained NN NN O
blood NN NN O
samples NN NN O
for NN NN O
the NN NN O
determination NN NN O
of NN NN O
serum NN NN O
transferrin NN NN O
saturation NN NN O
and NN NN O
ferritin NN NN O
levels NN NN O
and NN NN O
the NN NN O
presence NN NN O
or NN NN O
absence NN NN O
of NN NN O
the NN NN O
C282Y NN NN O
mutation NN NN O
and NN NN O
the NN NN O
H63D NN NN O
mutation NN NN O
( NN NN O
which NN NN O
may NN NN O
contribute NN NN O
to NN NN O
increased NN NN O
hepatic NN NN O
iron NN NN O
levels NN NN O
) NN NN O
in NN NN O
3011 NN NN O
unrelated NN NN O
white NN NN O
adults NN NN O
. NN NN O

We NN NN O
evaluated NN NN O
all NN NN O
subjects NN NN O
who NN NN O
had NN NN O
persistently NN NN O
elevated NN NN O
transferrin-saturation NN NN O
values NN NN O
( NN NN O
45 NN NN O
percent NN NN O
or NN NN O
higher NN NN O
) NN NN O
or NN NN O
were NN NN O
homozygous NN NN O
for NN NN O
the NN NN O
C282Y NN NN O
mutation NN NN O
. NN NN O

We NN NN O
recommended NN NN O
liver NN NN O
biopsy NN NN O
for NN NN O
subjects NN NN O
with NN NN O
serum NN NN O
ferritin NN NN O
levels NN NN O
of NN NN O
300 NN NN O
ng NN NN O
per NN NN O
milliliter NN NN O
or NN NN O
higher NN NN O
. NN NN O

The NN NN O
subjects NN NN O
were NN NN O
followed NN NN O
for NN NN O
up NN NN O
to NN NN O
four NN NN O
years NN NN O
. NN NN O

RESULTS NN NN O
Sixteen NN NN O
of NN NN O
the NN NN O
subjects NN NN O
( NN NN O
0 NN NN O
. NN NN O

5 NN NN O
percent NN NN O
) NN NN O
were NN NN O
homozygous NN NN O
for NN NN O
the NN NN O
C282Y NN NN O
mutation NN NN O
, NN NN O
and NN NN O
424 NN NN O
( NN NN O
14 NN NN O
. NN NN O

1 NN NN O
percent NN NN O
) NN NN O
were NN NN O
heterozygous NN NN O
. NN NN O

The NN NN O
serum NN NN O
transferrin NN NN O
saturation NN NN O
was NN NN O
45 NN NN O
percent NN NN O
or NN NN O
higher NN NN O
in NN NN O
15 NN NN O
of NN NN O
the NN NN O
16 NN NN O
who NN NN O
were NN NN O
homozygous NN NN O
; NN NN O
in NN NN O
1 NN NN O
subject NN NN O
it NN NN O
was NN NN O
43 NN NN O
percent NN NN O
. NN NN O

Four NN NN O
of NN NN O
the NN NN O
homozygous NN NN O
subjects NN NN O
had NN NN O
previously NN NN O
been NN NN O
given NN NN O
a NN NN O
diagnosis NN NN O
of NN NN O
hemochromatosis NN NN B-SpecificDisease
, NN NN O
and NN NN O
12 NN NN O
had NN NN O
not NN NN O
. NN NN O

Seven NN NN O
of NN NN O
these NN NN O
12 NN NN O
patients NN NN O
had NN NN O
elevated NN NN O
serum NN NN O
ferritin NN NN O
levels NN NN O
in NN NN O
1994 NN NN O
; NN NN O
6 NN NN O
of NN NN O
the NN NN O
7 NN NN O
had NN NN O
further NN NN O
increases NN NN O
in NN NN O
1998 NN NN O
, NN NN O
and NN NN O
1 NN NN O
had NN NN O
a NN NN O
decrease NN NN O
, NN NN O
although NN NN O
the NN NN O
value NN NN O
remained NN NN O
elevated NN NN O
. NN NN O

The NN NN O
serum NN NN O
ferritin NN NN O
levels NN NN O
in NN NN O
the NN NN O
four NN NN O
other NN NN O
homozygous NN NN O
patients NN NN O
remained NN NN O
in NN NN O
the NN NN O
normal NN NN O
range NN NN O
. NN NN O

Eleven NN NN O
of NN NN O
the NN NN O
16 NN NN O
homozygous NN NN O
subjects NN NN O
underwent NN NN O
liver NN NN O
biopsy NN NN O
; NN NN O
3 NN NN O
had NN NN O
hepatic NN NN B-DiseaseClass
fibrosis NN NN I-DiseaseClass
, NN NN O
and NN NN O
1 NN NN O
, NN NN O
who NN NN O
had NN NN O
a NN NN O
history NN NN O
of NN NN O
excessive NN NN B-SpecificDisease
alcohol NN NN I-SpecificDisease
consumption NN NN I-SpecificDisease
, NN NN O
had NN NN O
cirrhosis NN NN B-DiseaseClass
and NN NN O
mild NN NN O
microvesicular NN NN B-SpecificDisease
steatosis NN NN I-SpecificDisease
. NN NN O

Eight NN NN O
of NN NN O
the NN NN O
16 NN NN O
homozygous NN NN O
subjects NN NN O
had NN NN O
clinical NN NN O
findings NN NN O
that NN NN O
were NN NN O
consistent NN NN O
with NN NN O
the NN NN O
presence NN NN O
of NN NN O
hereditary NN NN B-SpecificDisease
hemochromatosis NN NN I-SpecificDisease
, NN NN O
such NN NN O
as NN NN O
hepatomegaly NN NN B-DiseaseClass
, NN NN O
skin NN NN B-DiseaseClass
pigmentation NN NN I-DiseaseClass
, NN NN O
and NN NN O
arthritis NN NN B-DiseaseClass
. NN NN O

CONCLUSIONS NN NN O
In NN NN O
a NN NN O
population NN NN O
of NN NN O
white NN NN O
adults NN NN O
of NN NN O
northern NN NN O
European NN NN O
ancestry NN NN O
, NN NN O
0 NN NN O
. NN NN O

5 NN NN O
percent NN NN O
were NN NN O
homozygous NN NN O
for NN NN O
the NN NN O
C282Y NN NN O
mutation NN NN O
in NN NN O
the NN NN O
HFE NN NN O
gene NN NN O
. NN NN O

However NN NN O
, NN NN O
only NN NN O
half NN NN O
of NN NN O
those NN NN O
who NN NN O
were NN NN O
homozygous NN NN O
had NN NN O
clinical NN NN O
features NN NN O
of NN NN O
hemochromatosis NN NN B-SpecificDisease
, NN NN O
and NN NN O
one NN NN O
quarter NN NN O
had NN NN O
serum NN NN O
ferritin NN NN O
levels NN NN O
that NN NN O
remained NN NN O
normal NN NN O
over NN NN O
a NN NN O
four-year NN NN O
period NN NN O
. NN NN O

10472529 NN NN O
Large NN NN O
heterozygous NN NN O
deletion NN NN O
masquerading NN NN O
as NN NN O
homozygous NN NN O
missense NN NN O
mutation NN NN O
: NN NN O
a NN NN O
pitfall NN NN O
in NN NN O
diagnostic NN NN O
mutation NN NN O
analysis NN NN O
. NN NN O

The NN NN O
clinical NN NN O
use NN NN O
of NN NN O
molecular NN NN O
analyses NN NN O
in NN NN O
recessive NN NN B-DiseaseClass
disorders NN NN I-DiseaseClass
relies NN NN O
on NN NN O
the NN NN O
exact NN NN O
characterization NN NN O
of NN NN O
both NN NN O
mutant NN NN O
alleles NN NN O
in NN NN O
the NN NN O
affected NN NN O
patient NN NN O
. NN NN O

This NN NN O
can NN NN O
be NN NN O
problematic NN NN O
when NN NN O
only NN NN O
part NN NN O
of NN NN O
the NN NN O
gene NN NN O
is NN NN O
examined NN NN O
or NN NN O
when NN NN O
relevant NN NN O
DNA NN NN O
alterations NN NN O
are NN NN O
not NN NN O
recognized NN NN O
by NN NN O
standard NN NN O
methods NN NN O
. NN NN O

We NN NN O
present NN NN O
a NN NN O
child NN NN O
in NN NN O
whom NN NN O
phenylketonuria NN NN B-SpecificDisease
was NN NN O
apparently NN NN O
caused NN NN O
by NN NN O
homozygosity NN NN O
for NN NN O
the NN NN O
mutation NN NN O
E390G NN NN O
in NN NN O
exon NN NN O
11 NN NN O
of NN NN O
the NN NN O
phenylalanine NN NN O
hydroxylase NN NN O
( NN NN O
PAH NN NN O
) NN NN O
gene NN NN O
. NN NN O

However NN NN O
, NN NN O
the NN NN O
clinical NN NN O
severity NN NN O
of NN NN O
the NN NN O
disease NN NN O
was NN NN O
not NN NN O
quite NN NN O
as NN NN O
mild NN NN O
as NN NN O
expected NN NN O
, NN NN O
the NN NN O
mutation NN NN O
was NN NN O
not NN NN O
identified NN NN O
in NN NN O
the NN NN O
father NN NN O
despite NN NN O
confirmed NN NN O
paternity NN NN O
, NN NN O
and NN NN O
the NN NN O
paternal NN NN O
allele NN NN O
showed NN NN O
a NN NN O
highly NN NN O
unusual NN NN O
pattern NN NN O
of NN NN O
polymorphic NN NN O
markers NN NN O
in NN NN O
the NN NN O
PAH NN NN O
gene NN NN O
. NN NN O

Presence NN NN O
of NN NN O
a NN NN O
large NN NN O
deletion NN NN O
involving NN NN O
exons NN NN O
9 NN NN O
, NN NN O
10 NN NN O
and NN NN O
11 NN NN O
of NN NN O
the NN NN O
phenylalanine NN NN O
hydroxylase NN NN O
gene NN NN O
was NN NN O
confirmed NN NN O
by NN NN O
long-range NN NN O
PCR NN NN O
. NN NN O

Diagnostic NN NN O
DNA NN NN O
analyses NN NN O
should NN NN O
include NN NN O
a NN NN O
comprehensive NN NN O
examination NN NN O
of NN NN O
the NN NN O
whole NN NN O
relevant NN NN O
gene NN NN O
in NN NN O
the NN NN O
patient NN NN O
and NN NN O
confirmation NN NN O
of NN NN O
carrier NN NN O
status NN NN O
in NN NN O
both NN NN O
parents NN NN O
. NN NN O

. NN NN O

10480214 NN NN O
Early NN NN O
onset NN NN O
of NN NN O
X-linked NN NN B-SpecificDisease
Emery-Dreifuss NN NN I-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
in NN NN O
a NN NN O
boy NN NN O
with NN NN O
emerin NN NN O
gene NN NN O
deletion NN NN O
. NN NN O

A NN NN O
boy NN NN O
developed NN NN O
contractures NN NN B-DiseaseClass
of NN NN I-DiseaseClass
the NN NN I-DiseaseClass
Achilles NN NN I-DiseaseClass
tendons NN NN I-DiseaseClass
at NN NN O
3 NN NN O
years NN NN O
and NN NN O
of NN NN O
the NN NN O
postcervical NN NN O
muscles NN NN O
at NN NN O
7 NN NN O
years NN NN O
, NN NN O
although NN NN O
neither NN NN O
contractures NN NN B-DiseaseClass
of NN NN I-DiseaseClass
the NN NN I-DiseaseClass
elbows NN NN I-DiseaseClass
nor NN NN O
cardiac NN NN B-DiseaseClass
abnormality NN NN I-DiseaseClass
were NN NN O
recognized NN NN O
by NN NN O
the NN NN O
age NN NN O
of NN NN O
9 NN NN O
years NN NN O
. NN NN O

Muscle NN NN O
computed NN NN O
tomography NN NN O
scanning NN NN O
revealed NN NN O
changes NN NN O
characteristic NN NN O
of NN NN O
muscle NN NN O
involvement NN NN O
. NN NN O

Emerin NN NN O
was NN NN O
not NN NN O
detected NN NN O
in NN NN O
the NN NN O
biopsied NN NN O
muscle NN NN O
, NN NN O
and NN NN O
RT-PCR NN NN O
and NN NN O
PCR-based NN NN O
genomic NN NN O
DNA NN NN O
analyses NN NN O
of NN NN O
the NN NN O
emerin NN NN O
gene NN NN O
demonstrated NN NN O
no NN NN O
amplification NN NN O
product NN NN O
in NN NN O
the NN NN O
patient NN NN O
. NN NN O

These NN NN O
results NN NN O
confirmed NN NN O
the NN NN O
diagnosis NN NN O
of NN NN O
X-linked NN NN B-SpecificDisease
Emery-Dreifuss NN NN I-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
EDMD NN NN B-SpecificDisease
) NN NN O
, NN NN O
and NN NN O
reinforce NN NN O
the NN NN O
necessity NN NN O
of NN NN O
molecular NN NN O
genetic NN NN O
diagnosis NN NN O
of NN NN O
the NN NN O
membrane NN NN O
protein NN NN O
emerin NN NN O
in NN NN O
younger NN NN O
patients NN NN O
with NN NN O
possible NN NN O
EDMD NN NN B-SpecificDisease
before NN NN O
appearance NN NN O
of NN NN O
the NN NN O
typical NN NN O
symptoms NN NN O
, NN NN O
to NN NN O
avoid NN NN O
sudden NN NN B-SpecificDisease
cardiac NN NN I-SpecificDisease
death NN NN I-SpecificDisease
. NN NN O

. NN NN O

10480348 NN NN O
Duchenne/Becker NN NN B-CompositeMention
muscular NN NN I-CompositeMention
dystrophy NN NN I-CompositeMention
: NN NN O
correlation NN NN O
of NN NN O
phenotype NN NN O
by NN NN O
electroretinography NN NN O
with NN NN O
sites NN NN O
of NN NN O
dystrophin NN NN O
mutations NN NN O
. NN NN O

The NN NN O
dark-adapted NN NN O
electroretinogram NN NN O
( NN NN O
ERG NN NN O
) NN NN O
of NN NN O
patients NN NN O
with NN NN O
Duchenne NN NN B-CompositeMention
and NN NN I-CompositeMention
Becker NN NN I-CompositeMention
muscular NN NN I-CompositeMention
dystrophy NN NN I-CompositeMention
( NN NN O
DMD NN NN B-SpecificDisease
/ NN NN O
BMD NN NN B-SpecificDisease
) NN NN O
shows NN NN O
a NN NN O
marked NN NN O
reduction NN NN O
in NN NN O
b-wave NN NN O
amplitude NN NN O
. NN NN O

Genotype-phenotype NN NN O
studies NN NN O
of NN NN O
mouse NN NN O
models NN NN O
for NN NN O
DMD NN NN B-SpecificDisease
show NN NN O
position-specific NN NN O
effects NN NN O
of NN NN O
the NN NN O
mutations NN NN O
upon NN NN O
the NN NN O
phenotype NN NN O
mice NN NN O
with NN NN O
5 NN NN O
defects NN NN O
of NN NN O
dystrophin NN NN O
have NN NN O
normal NN NN O
ERGs NN NN O
, NN NN O
those NN NN O
with NN NN O
defects NN NN O
in NN NN O
the NN NN O
central NN NN O
region NN NN O
have NN NN O
a NN NN O
normal NN NN O
b-wave NN NN O
amplitude NN NN O
associated NN NN O
with NN NN O
prolonged NN NN O
implicit NN NN O
times NN NN O
for NN NN O
both NN NN O
the NN NN O
b-wave NN NN O
and NN NN O
oscillatory NN NN O
potentials NN NN O
, NN NN O
and NN NN O
mice NN NN O
with NN NN O
3 NN NN O
defects NN NN O
have NN NN O
a NN NN O
phenotype NN NN O
similar NN NN O
to NN NN O
that NN NN O
seen NN NN O
in NN NN O
DMD NN NN B-Modifier
/ NN NN O
BMD NN NN B-Modifier
patients NN NN O
. NN NN O

The NN NN O
mouse NN NN O
studies NN NN O
suggest NN NN O
a NN NN O
key NN NN O
role NN NN O
for NN NN O
the NN NN O
carboxyl NN NN O
terminal NN NN O
dystrophin NN NN O
isoform NN NN O
, NN NN O
Dp260 NN NN O
, NN NN O
in NN NN O
retinal NN NN O
electrophysiology NN NN O
. NN NN O

We NN NN O
have NN NN O
undertaken NN NN O
a NN NN O
systematic NN NN O
evaluation NN NN O
of NN NN O
DMD NN NN B-Modifier
/ NN NN O
BMD NN NN B-Modifier
patients NN NN O
through NN NN O
clinical NN NN O
examination NN NN O
and NN NN O
review NN NN O
of NN NN O
the NN NN O
literature NN NN O
in NN NN O
order NN NN O
to NN NN O
determine NN NN O
whether NN NN O
the NN NN O
position-specific NN NN O
effects NN NN O
of NN NN O
mutations NN NN O
noted NN NN O
in NN NN O
the NN NN O
mouse NN NN O
are NN NN O
present NN NN O
in NN NN O
man NN NN O
. NN NN O

We NN NN O
have NN NN O
found NN NN O
that NN NN O
, NN NN O
in NN NN O
man NN NN O
, NN NN O
a NN NN O
wider NN NN O
variation NN NN O
of NN NN O
DMD NN NN B-DiseaseClass
defects NN NN I-DiseaseClass
correlate NN NN O
with NN NN O
reductions NN NN O
in NN NN O
the NN NN O
b-wave NN NN O
amplitude NN NN O
. NN NN O

Individuals NN NN O
with NN NN O
normal NN NN O
ERGs NN NN O
have NN NN O
mutations NN NN O
predominantly NN NN O
located NN NN O
5 NN NN O
of NN NN O
the NN NN O
transcript NN NN O
initiation NN NN O
site NN NN O
of NN NN O
Dp260 NN NN O
. NN NN O

Our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
most NN NN O
important NN NN O
determinant NN NN O
in NN NN O
the NN NN O
ERG NN NN O
b-wave NN NN O
phenotype NN NN O
is NN NN O
the NN NN O
mutation NN NN O
position NN NN O
, NN NN O
rather NN NN O
than NN NN O
muscle NN NN B-Modifier
disease NN NN I-Modifier
severity NN NN O
. NN NN O

Forty-six NN NN O
per NN NN O
cent NN NN O
of NN NN O
patients NN NN O
with NN NN O
mutations NN NN O
5 NN NN O
of NN NN O
the NN NN O
Dp260 NN NN O
transcript NN NN O
start NN NN O
site NN NN O
have NN NN O
abnormal NN NN O
ERGs NN NN O
, NN NN O
as NN NN O
opposed NN NN O
to NN NN O
94 NN NN O
% NN NN O
with NN NN O
more NN NN O
distal NN NN O
mutations NN NN O
. NN NN O

The NN NN O
human NN NN O
genotype-phenotype NN NN O
correlations NN NN O
are NN NN O
consistent NN NN O
with NN NN O
a NN NN O
role NN NN O
for NN NN O
Dp260 NN NN O
in NN NN O
normal NN NN O
retinal NN NN O
electrophysiology NN NN O
and NN NN O
may NN NN O
also NN NN O
reflect NN NN O
the NN NN O
expression NN NN O
of NN NN O
other NN NN O
C-terminal NN NN O
dystrophin NN NN O
isoforms NN NN O
and NN NN O
their NN NN O
contributions NN NN O
to NN NN O
retinal NN NN O
signal NN NN O
transmission NN NN O
. NN NN O

. NN NN O

10484765 NN NN O
Cis NN NN O
and NN NN O
trans NN NN O
effects NN NN O
of NN NN O
the NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
( NN NN O
DM NN NN B-Modifier
) NN NN O
mutation NN NN O
in NN NN O
a NN NN O
cell NN NN O
culture NN NN O
model NN NN O
. NN NN O

The NN NN O
mutation NN NN O
causing NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
has NN NN O
been NN NN O
identified NN NN O
as NN NN O
a NN NN O
CTG NN NN O
expansion NN NN O
in NN NN O
the NN NN O
3-untranslated NN NN O
region NN NN O
( NN NN O
3-UTR NN NN O
) NN NN O
of NN NN O
the NN NN O
DM NN NN B-Modifier
protein NN NN O
kinase NN NN O
gene NN NN O
( NN NN O
DMPK NN NN O
) NN NN O
, NN NN O
but NN NN O
the NN NN O
mechanism NN NN O
( NN NN O
s NN NN O
) NN NN O
of NN NN O
pathogenesis NN NN O
remain NN NN O
unknown NN NN O
. NN NN O

Studies NN NN O
using NN NN O
DM NN NN B-Modifier
patient NN NN O
materials NN NN O
have NN NN O
often NN NN O
produced NN NN O
confusing NN NN O
results NN NN O
. NN NN O

Therefore NN NN O
, NN NN O
to NN NN O
study NN NN O
the NN NN O
effects NN NN O
of NN NN O
the NN NN O
DM NN NN B-Modifier
mutation NN NN O
in NN NN O
a NN NN O
controlled NN NN O
environment NN NN O
, NN NN O
we NN NN O
have NN NN O
established NN NN O
a NN NN O
cell NN NN O
culture NN NN O
model NN NN O
system NN NN O
using NN NN O
C2C12 NN NN O
mouse NN NN O
myoblasts NN NN O
. NN NN O

By NN NN O
expressing NN NN O
chimeric NN NN O
reporter NN NN O
constructs NN NN O
containing NN NN O
a NN NN O
reporter NN NN O
gene NN NN O
fused NN NN O
to NN NN O
a NN NN O
human NN NN O
DMPK NN NN O
3-UTR NN NN O
, NN NN O
we NN NN O
identified NN NN O
both NN NN O
cis NN NN O
and NN NN O
trans NN NN O
effects NN NN O
that NN NN O
are NN NN O
mediated NN NN O
by NN NN O
the NN NN O
DM NN NN B-Modifier
mutation NN NN O
. NN NN O

Our NN NN O
data NN NN O
show NN NN O
that NN NN O
a NN NN O
mutant NN NN O
DMPK NN NN O
3-UTR NN NN O
, NN NN O
with NN NN O
as NN NN O
few NN NN O
as NN NN O
57 NN NN O
CTGs NN NN O
, NN NN O
had NN NN O
a NN NN O
negative NN NN O
cis NN NN O
effect NN NN O
on NN NN O
protein NN NN O
expression NN NN O
and NN NN O
resulted NN NN O
in NN NN O
the NN NN O
aggregation NN NN O
of NN NN O
reporter NN NN O
transcripts NN NN O
into NN NN O
discrete NN NN O
nuclear NN NN O
foci NN NN O
. NN NN O

We NN NN O
determined NN NN O
by NN NN O
deletion NN NN O
analysis NN NN O
that NN NN O
an NN NN O
expanded NN NN O
( NN NN O
CTG NN NN O
) NN NN O
( NN NN O
n NN NN O
) NN NN O
tract NN NN O
alone NN NN O
was NN NN O
sufficient NN NN O
to NN NN O
mediate NN NN O
these NN NN O
cis NN NN O
effects NN NN O
. NN NN O

Furthermore NN NN O
, NN NN O
in NN NN O
contrast NN NN O
to NN NN O
the NN NN O
normal NN NN O
DMPK NN NN O
3-UTR NN NN O
mRNA NN NN O
, NN NN O
a NN NN O
mutant NN NN O
DMPK NN NN O
3-UTR NN NN O
mRNA NN NN O
with NN NN O
( NN NN O
CUG NN NN O
) NN NN O
( NN NN O
200 NN NN O
) NN NN O
selectively NN NN O
inhibited NN NN O
myogenic NN NN O
differentiation NN NN O
of NN NN O
C2C12 NN NN O
myoblasts NN NN O
. NN NN O

Genetic NN NN O
analysis NN NN O
and NN NN O
the NN NN O
Cre- NN NN O
loxP NN NN O
system NN NN O
were NN NN O
used NN NN O
to NN NN O
clearly NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
myoblast NN NN O
fusion NN NN O
defect NN NN O
could NN NN O
be NN NN O
rescued NN NN O
by NN NN O
eliminating NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
mutant NN NN O
DMPK NN NN O
3-UTR NN NN O
transcript NN NN O
. NN NN O

Characterization NN NN O
of NN NN O
spontaneous NN NN O
deletion NN NN O
events NN NN O
mapped NN NN O
the NN NN O
inhibitory NN NN O
effect NN NN O
to NN NN O
the NN NN O
( NN NN O
CTG NN NN O
) NN NN O
( NN NN O
n NN NN O
) NN NN O
expansion NN NN O
and NN NN O
/ NN NN O
or NN NN O
the NN NN O
3 NN NN O
end NN NN O
of NN NN O
the NN NN O
DMPK NN NN O
3-UTR NN NN O
. NN NN O

These NN NN O
results NN NN O
provide NN NN O
evidence NN NN O
that NN NN O
the NN NN O
DM NN NN B-Modifier
mutation NN NN O
acts NN NN O
in NN NN O
cis NN NN O
to NN NN O
reduce NN NN O
protein NN NN O
production NN NN O
( NN NN O
consistent NN NN O
with NN NN O
DMPK NN NN B-SpecificDisease
haploinsufficiency NN NN I-SpecificDisease
) NN NN O
and NN NN O
in NN NN O
trans NN NN O
as NN NN O
a NN NN O
riboregulator NN NN O
to NN NN O
inhibit NN NN O
myogenesis NN NN O
. NN NN O

. NN NN O

10484772 NN NN O
Coats NN NN B-SpecificDisease
' NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
of NN NN O
the NN NN O
retina NN NN O
( NN NN O
unilateral NN NN B-SpecificDisease
retinal NN NN I-SpecificDisease
telangiectasis NN NN I-SpecificDisease
) NN NN O
caused NN NN O
by NN NN O
somatic NN NN O
mutation NN NN O
in NN NN O
the NN NN O
NDP NN NN O
gene NN NN O
: NN NN O
a NN NN O
role NN NN O
for NN NN O
norrin NN NN O
in NN NN O
retinal NN NN O
angiogenesis NN NN O
. NN NN O

Coats NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
is NN NN O
characterized NN NN O
by NN NN O
abnormal NN NN B-DiseaseClass
retinal NN NN I-DiseaseClass
vascular NN NN I-DiseaseClass
development NN NN I-DiseaseClass
( NN NN O
so-called NN NN O
retinal NN NN B-SpecificDisease
telangiectasis NN NN I-SpecificDisease
) NN NN O
which NN NN O
results NN NN O
in NN NN O
massive NN NN O
intraretinal NN NN B-CompositeMention
and NN NN I-CompositeMention
subretinal NN NN I-CompositeMention
lipid NN NN I-CompositeMention
accumulation NN NN I-CompositeMention
( NN NN O
exudative NN NN B-DiseaseClass
retinal NN NN I-DiseaseClass
detachment NN NN I-DiseaseClass
) NN NN O
. NN NN O

The NN NN O
classical NN NN O
form NN NN O
of NN NN O
Coats NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
is NN NN O
almost NN NN O
invariably NN NN O
isolated NN NN O
, NN NN O
unilateral NN NN O
and NN NN O
seen NN NN O
in NN NN O
males NN NN O
. NN NN O

A NN NN O
female NN NN O
with NN NN O
a NN NN O
unilateral NN NN O
variant NN NN O
of NN NN O
Coats NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
gave NN NN O
birth NN NN O
to NN NN O
a NN NN O
son NN NN O
affected NN NN O
by NN NN O
Norrie NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

Both NN NN O
carried NN NN O
a NN NN O
missense NN NN O
mutation NN NN O
within NN NN O
the NN NN O
NDP NN NN O
gene NN NN O
on NN NN O
chromosome NN NN O
Xp11 NN NN O
. NN NN O

2 NN NN O
2 NN NN O
. NN NN O

Subsequently NN NN O
analysis NN NN O
of NN NN O
the NN NN O
retinas NN NN O
of NN NN O
nine NN NN O
enucleated NN NN O
eyes NN NN O
from NN NN O
males NN NN O
with NN NN O
Coats NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
demonstrated NN NN O
in NN NN O
one NN NN O
a NN NN O
somatic NN NN O
mutation NN NN O
in NN NN O
the NN NN O
NDP NN NN O
gene NN NN O
which NN NN O
was NN NN O
not NN NN O
present NN NN O
within NN NN O
non-retinal NN NN O
tissue NN NN O
. NN NN O

We NN NN O
suggest NN NN O
that NN NN O
Coats NN NN B-SpecificDisease
telangiectasis NN NN I-SpecificDisease
is NN NN O
secondary NN NN O
to NN NN O
somatic NN NN O
mutation NN NN O
in NN NN O
the NN NN O
NDP NN NN O
gene NN NN O
which NN NN O
results NN NN O
in NN NN O
a NN NN O
deficiency NN NN B-DiseaseClass
of NN NN I-DiseaseClass
norrin NN NN I-DiseaseClass
( NN NN O
the NN NN O
protein NN NN O
product NN NN O
of NN NN O
the NN NN O
NDP NN NN O
gene NN NN O
) NN NN O
within NN NN O
the NN NN O
developing NN NN O
retina NN NN O
. NN NN O

This NN NN O
supports NN NN O
recent NN NN O
observations NN NN O
that NN NN O
the NN NN O
protein NN NN O
is NN NN O
critical NN NN O
for NN NN O
normal NN NN O
retinal NN NN O
vasculogenesis NN NN O
. NN NN O

10484981 NN NN O
Hereditary NN NN O
TP53 NN NN O
codon NN NN O
292 NN NN O
and NN NN O
somatic NN NN O
P16INK4A NN NN O
codon NN NN O
94 NN NN O
mutations NN NN O
in NN NN O
a NN NN O
Li-Fraumeni NN NN B-Modifier
syndrome NN NN I-Modifier
family NN NN O
. NN NN O

Li-Fraumeni NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
dominant NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
that NN NN O
is NN NN O
characterized NN NN O
by NN NN O
various NN NN O
types NN NN O
of NN NN O
cancer NN NN B-DiseaseClass
in NN NN O
childhood NN NN O
and NN NN O
adult NN NN O
cases NN NN O
. NN NN O

Although NN NN O
hereditary NN NN O
TP53 NN NN O
mutation NN NN O
is NN NN O
very NN NN O
rare NN NN O
in NN NN O
different NN NN O
human NN NN O
cancers NN NN B-DiseaseClass
, NN NN O
it NN NN O
has NN NN O
been NN NN O
frequently NN NN O
reported NN NN O
in NN NN O
Li-Fraumeni NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

On NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
hereditary NN NN O
mutations NN NN O
of NN NN O
TP57KIP2 NN NN O
, NN NN O
P15INK4B NN NN O
, NN NN O
and NN NN O
P16INK4A NN NN O
, NN NN O
which NN NN O
affect NN NN O
the NN NN O
cell NN NN O
cycle NN NN O
similar NN NN O
to NN NN O
TP53 NN NN O
, NN NN O
were NN NN O
observed NN NN O
in NN NN O
some NN NN O
types NN NN O
of NN NN O
cancer NN NN B-DiseaseClass
. NN NN O

In NN NN O
a NN NN O
Turkish NN NN O
family NN NN O
with NN NN O
the NN NN O
diagnosis NN NN O
of NN NN O
Li-Fraumeni NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
, NN NN O
we NN NN O
analyzed NN NN O
the NN NN O
mutation NN NN O
pattern NN NN O
of NN NN O
TP53 NN NN O
, NN NN O
P57KIP2 NN NN O
, NN NN O
P15INK4B NN NN O
, NN NN O
and NN NN O
P16INK4A NN NN O
in NN NN O
the NN NN O
peripheral NN NN O
blood NN NN O
, NN NN O
and NN NN O
loss NN NN O
of NN NN O
heterozygosity NN NN O
( NN NN O
homo NN NN O
/ NN NN O
hemizygous NN NN O
deletion NN NN O
) NN NN O
pattern NN NN O
of NN NN O
TP53 NN NN O
and NN NN O
P15INK4B NN NN O
/ NN NN O
P16INK4A NN NN O
in NN NN O
two NN NN O
tumor NN NN B-Modifier
tissues NN NN O
. NN NN O

The NN NN O
propositus NN NN O
had NN NN O
a NN NN O
seminoma NN NN B-SpecificDisease
, NN NN O
his NN NN O
daughter NN NN O
a NN NN O
medulloblastoma NN NN B-SpecificDisease
, NN NN O
and NN NN O
one NN NN O
of NN NN O
his NN NN O
healthy NN NN O
cousins NN NN O
, NN NN O
a NN NN O
TP53 NN NN O
codon NN NN O
292 NN NN O
missense NN NN O
point NN NN O
mutation NN NN O
( NN NN O
AAA NN NN O
-- NN NN O
ATA NN NN O
; NN NN O
Lys NN NN O
-- NN NN O
Ile NN NN O
) NN NN O
in NN NN O
the NN NN O
peripheral NN NN O
blood NN NN O
cells NN NN O
. NN NN O

Tumor NN NN O
tissue NN NN O
obtained NN NN O
from NN NN O
the NN NN O
propositus NN NN O
with NN NN O
the NN NN O
seminoma NN NN B-SpecificDisease
revealed NN NN O
loss NN NN O
of NN NN O
heterozygosity NN NN O
in NN NN O
the NN NN O
TP53 NN NN O
gene NN NN O
. NN NN O

In NN NN O
the NN NN O
analyses NN NN O
of NN NN O
tumor NN NN B-Modifier
tissues NN NN O
from NN NN O
the NN NN O
propositus NN NN O
and NN NN O
his NN NN O
daughter NN NN O
, NN NN O
a NN NN O
P16INK4A NN NN O
codon NN NN O
94 NN NN O
missense NN NN O
point NN NN O
mutation NN NN O
( NN NN O
GCG NN NN O
-- NN NN O
GAG NN NN O
; NN NN O
Ala NN NN O
-- NN NN O
Glu NN NN O
) NN NN O
was NN NN O
observed NN NN O
with NN NN O
the NN NN O
hereditary NN NN O
TP53 NN NN O
mutation NN NN O
. NN NN O

P16INK4A NN NN O
codon NN NN O
94 NN NN O
mutation NN NN O
observed NN NN O
in NN NN O
our NN NN O
family NN NN O
is NN NN O
a NN NN O
novel NN NN O
mutation NN NN O
in NN NN O
Li-Fraumeni NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

No NN NN O
other NN NN O
gene NN NN O
alteration NN NN O
in NN NN O
TP53 NN NN O
, NN NN O
P57KIP2 NN NN O
, NN NN O
P15INK4B NN NN O
, NN NN O
and NN NN O
P16INK4A NN NN O
was NN NN O
observed NN NN O
. NN NN O

Existence NN NN O
of NN NN O
the NN NN O
P16INK4A NN NN O
mutation NN NN O
and NN NN O
the NN NN O
hereditary NN NN O
TP53 NN NN O
mutation NN NN O
with NN NN O
or NN NN O
without NN NN O
loss NN NN O
of NN NN O
heterozygosity NN NN O
in NN NN O
the NN NN O
TP53 NN NN O
gene NN NN O
( NN NN O
seminoma NN NN B-SpecificDisease
/ NN NN O
medulloblastoma NN NN B-SpecificDisease
) NN NN O
may NN NN O
be NN NN O
evidence NN NN O
for NN NN O
a NN NN O
common NN NN O
mechanism NN NN O
involved NN NN O
in NN NN O
tumorogenesis NN NN B-DiseaseClass
. NN NN O

The NN NN O
gene NN NN O
alterations NN NN O
in NN NN O
TP53 NN NN O
and NN NN O
P16INK4A NN NN O
genes NN NN O
may NN NN O
be NN NN O
used NN NN O
as NN NN O
tumor NN NN B-Modifier
markers NN NN O
in NN NN O
our NN NN O
family NN NN O
. NN NN O

. NN NN O

10487695 NN NN O
A NN NN O
novel NN NN O
mutation NN NN O
in NN NN O
the NN NN O
sodium/iodide NN NN O
symporter NN NN O
gene NN NN O
in NN NN O
the NN NN O
largest NN NN O
family NN NN O
with NN NN O
iodide NN NN B-DiseaseClass
transport NN NN I-DiseaseClass
defect NN NN I-DiseaseClass
. NN NN O

We NN NN O
previously NN NN O
reported NN NN O
nine NN NN O
children NN NN O
with NN NN O
an NN NN O
autosomally NN NN O
recessive NN NN O
form NN NN O
of NN NN O
congenital NN NN B-SpecificDisease
hypothyroidism NN NN I-SpecificDisease
due NN NN O
to NN NN O
an NN NN O
iodide NN NN B-DiseaseClass
transport NN NN I-DiseaseClass
defect NN NN I-DiseaseClass
in NN NN O
a NN NN O
large NN NN O
Hutterite NN NN O
family NN NN O
with NN NN O
extensive NN NN O
consanguinity NN NN O
living NN NN O
in NN NN O
central NN NN O
Canada NN NN O
. NN NN O

Since NN NN O
the NN NN O
original NN NN O
report NN NN O
, NN NN O
we NN NN O
have NN NN O
diagnosed NN NN O
congenital NN NN B-SpecificDisease
hypothyroidism NN NN I-SpecificDisease
by NN NN O
newborn NN NN O
TSH NN NN O
screening NN NN O
in NN NN O
9 NN NN O
additional NN NN O
children NN NN O
from NN NN O
the NN NN O
family NN NN O
. NN NN O

We NN NN O
performed NN NN O
direct NN NN O
sequencing NN NN O
of NN NN O
the NN NN O
PCR NN NN O
products NN NN O
of NN NN O
each NN NN O
NIS NN NN O
( NN NN O
sodium NN NN O
/ NN NN O
iodide NN NN O
symporter NN NN O
) NN NN O
gene NN NN O
exon NN NN O
with NN NN O
flanking NN NN O
introns NN NN O
amplified NN NN O
from NN NN O
genomic NN NN O
DNA NN NN O
extracted NN NN O
from NN NN O
peripheral NN NN O
blood NN NN O
cells NN NN O
of NN NN O
the NN NN O
patients NN NN O
. NN NN O

We NN NN O
identified NN NN O
a NN NN O
novel NN NN O
NIS NN NN O
gene NN NN O
mutation NN NN O
, NN NN O
G395R NN NN O
( NN NN O
Gly395 NN NN O
-- NN NN O
Arg NN NN O
; NN NN O
GGA NN NN O
-- NN NN O
AGA NN NN O
) NN NN O
, NN NN O
in NN NN O
10 NN NN O
patients NN NN O
examined NN NN O
in NN NN O
the NN NN O
present NN NN O
study NN NN O
. NN NN O

All NN NN O
of NN NN O
the NN NN O
parents NN NN O
tested NN NN O
were NN NN O
heterozygous NN NN O
for NN NN O
the NN NN O
mutation NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
the NN NN O
patients NN NN O
were NN NN O
homozygous NN NN O
. NN NN O

The NN NN O
mutation NN NN O
was NN NN O
located NN NN O
in NN NN O
the NN NN O
10th NN NN O
transmembrane NN NN O
helix NN NN O
. NN NN O

Expression NN NN O
experiments NN NN O
by NN NN O
transfection NN NN O
of NN NN O
the NN NN O
mutant NN NN O
NIS NN NN O
complimentary NN NN O
DNA NN NN O
into NN NN O
COS-7 NN NN O
cells NN NN O
showed NN NN O
no NN NN O
perchlorate-sensitive NN NN O
iodide NN NN O
uptake NN NN O
, NN NN O
confirming NN NN O
that NN NN O
the NN NN O
mutation NN NN O
is NN NN O
the NN NN O
direct NN NN O
cause NN NN O
of NN NN O
the NN NN O
iodide NN NN B-DiseaseClass
transport NN NN I-DiseaseClass
defect NN NN I-DiseaseClass
in NN NN O
these NN NN O
patients NN NN O
. NN NN O

A NN NN O
patient NN NN O
who NN NN O
showed NN NN O
an NN NN O
intermediate NN NN O
saliva NN NN O
/ NN NN O
serum NN NN O
technetium NN NN O
ratio NN NN O
( NN NN O
14 NN NN O
. NN NN O

0 NN NN O
; NN NN O
normal NN NN O
, NN NN O
or NN NN O
= NN NN O
20 NN NN O
) NN NN O
and NN NN O
was NN NN O
considered NN NN O
to NN NN O
have NN NN O
a NN NN O
partial NN NN O
or NN NN O
less NN NN O
severe NN NN O
defect NN NN O
in NN NN O
the NN NN O
previous NN NN O
report NN NN O
( NN NN O
IX-24 NN NN O
) NN NN O
did NN NN O
not NN NN O
have NN NN O
a NN NN O
NIS NN NN O
gene NN NN O
mutation NN NN O
. NN NN O

It NN NN O
is NN NN O
now NN NN O
possible NN NN O
to NN NN O
use NN NN O
gene NN NN O
diagnostics NN NN O
of NN NN O
this NN NN O
unique NN NN O
NIS NN NN O
mutation NN NN O
to NN NN O
identify NN NN O
patients NN NN O
with NN NN O
congenital NN NN B-SpecificDisease
hypothyroidism NN NN I-SpecificDisease
due NN NN O
to NN NN O
an NN NN O
iodide NN NN B-DiseaseClass
transport NN NN I-DiseaseClass
defect NN NN I-DiseaseClass
in NN NN O
this NN NN O
family NN NN O
and NN NN O
to NN NN O
determine NN NN O
the NN NN O
carrier NN NN O
state NN NN O
of NN NN O
potential NN NN O
parents NN NN O
for NN NN O
genetic NN NN O
counseling NN NN O
and NN NN O
arranging NN NN O
rapid NN NN O
and NN NN O
early NN NN O
diagnosis NN NN O
of NN NN O
their NN NN O
infants NN NN O
. NN NN O

10487710 NN NN O
Molecular NN NN O
analysis NN NN O
in NN NN O
familial NN NN B-SpecificDisease
neurohypophyseal NN NN I-SpecificDisease
diabetes NN NN I-SpecificDisease
insipidus NN NN I-SpecificDisease
: NN NN O
early NN NN O
diagnosis NN NN O
of NN NN O
an NN NN O
asymptomatic NN NN O
carrier NN NN O
. NN NN O

Familial NN NN B-SpecificDisease
neurohypophyseal NN NN I-SpecificDisease
diabetes NN NN I-SpecificDisease
insipidus NN NN I-SpecificDisease
( NN NN O
FNDI NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
inherited NN NN O
deficiency NN NN B-DiseaseClass
of NN NN I-DiseaseClass
the NN NN I-DiseaseClass
hormone NN NN I-DiseaseClass
arginine NN NN I-DiseaseClass
vasopressin NN NN I-DiseaseClass
( NN NN O
AVP NN NN O
) NN NN O
and NN NN O
is NN NN O
transmitted NN NN O
as NN NN O
an NN NN O
autosomal NN NN O
dominant NN NN O
trait NN NN O
. NN NN O

In NN NN O
the NN NN O
present NN NN O
study NN NN O
we NN NN O
have NN NN O
analyzed NN NN O
the NN NN O
AVP-neurophysin NN NN O
II NN NN O
( NN NN O
AVP-NPII NN NN O
) NN NN O
gene NN NN O
in NN NN O
a NN NN O
Spanish NN NN O
kindred NN NN O
. NN NN O

Studies NN NN O
were NN NN O
performed NN NN O
on NN NN O
seven NN NN O
members NN NN O
( NN NN O
four NN NN O
clinically NN NN O
affected NN NN O
) NN NN O
of NN NN O
the NN NN O
family NN NN O
. NN NN O

Patients NN NN O
were NN NN O
diagnosed NN NN O
at NN NN O
the NN NN O
Hospital NN NN O
Universitario NN NN O
Gregorio NN NN O
Maranon NN NN O
( NN NN O
Madrid NN NN O
, NN NN O
Spain NN NN O
) NN NN O
. NN NN O

The NN NN O
entire NN NN O
coding NN NN O
region NN NN O
of NN NN O
the NN NN O
AVP-NPII NN NN O
gene NN NN O
of NN NN O
all NN NN O
family NN NN O
members NN NN O
was NN NN O
amplified NN NN O
by NN NN O
PCR NN NN O
and NN NN O
sequenced NN NN O
. NN NN O

All NN NN O
affected NN NN O
individuals NN NN O
presented NN NN O
a NN NN O
missense NN NN O
mutation NN NN O
( NN NN O
G1757 NN NN O
-- NN NN O
A NN NN O
) NN NN O
that NN NN O
replaces NN NN O
glycine NN NN O
at NN NN O
position NN NN O
23 NN NN O
with NN NN O
arginine NN NN O
within NN NN O
the NN NN O
NPII NN NN O
domain NN NN O
. NN NN O

The NN NN O
substitution NN NN O
was NN NN O
confirmed NN NN O
by NN NN O
restriction NN NN O
endonuclease NN NN O
analysis NN NN O
and NN NN O
was NN NN O
present NN NN O
in NN NN O
heterozygosis NN NN O
. NN NN O

Additionally NN NN O
, NN NN O
one NN NN O
of NN NN O
the NN NN O
asymptomatic NN NN O
relatives NN NN O
( NN NN O
a NN NN O
girl NN NN O
8 NN NN O
months NN NN O
old NN NN O
at NN NN O
the NN NN O
time NN NN O
of NN NN O
study NN NN O
) NN NN O
was NN NN O
identified NN NN O
as NN NN O
carrier NN NN O
of NN NN O
the NN NN O
same NN NN O
mutation NN NN O
and NN NN O
developed NN NN O
the NN NN O
disease NN NN O
3 NN NN O
months NN NN O
later NN NN O
. NN NN O

The NN NN O
alteration NN NN O
found NN NN O
in NN NN O
the NN NN O
second NN NN O
exon NN NN O
of NN NN O
the NN NN O
gene NN NN O
in NN NN O
this NN NN O
family NN NN O
seems NN NN O
to NN NN O
be NN NN O
responsible NN NN O
for NN NN O
the NN NN O
disease NN NN O
, NN NN O
as NN NN O
all NN NN O
individuals NN NN O
harboring NN NN O
the NN NN O
mutation NN NN O
had NN NN O
been NN NN O
previously NN NN O
diagnosed NN NN O
or NN NN O
have NN NN O
eventually NN NN O
developed NN NN O
FNDI NN NN B-SpecificDisease
. NN NN O

Identification NN NN O
of NN NN O
the NN NN O
molecular NN NN O
defect NN NN O
underlying NN NN O
FNDI NN NN B-SpecificDisease
in NN NN O
affected NN NN O
families NN NN O
is NN NN O
a NN NN O
powerful NN NN O
tool NN NN O
for NN NN O
early NN NN O
asymptomatic NN NN O
diagnosis NN NN O
in NN NN O
infants NN NN O
. NN NN O

. NN NN O

10500204 NN NN O
Deficit NN NN O
of NN NN O
in NN NN O
vivo NN NN O
mitochondrial NN NN O
ATP NN NN O
production NN NN O
in NN NN O
patients NN NN O
with NN NN O
Friedreich NN NN B-SpecificDisease
ataxia NN NN I-SpecificDisease
. NN NN O

Friedreich NN NN B-SpecificDisease
ataxia NN NN I-SpecificDisease
( NN NN O
FRDA NN NN B-SpecificDisease
) NN NN O
, NN NN O
the NN NN O
most NN NN O
common NN NN O
of NN NN O
the NN NN O
inherited NN NN B-DiseaseClass
ataxias NN NN I-DiseaseClass
, NN NN O
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
degenerative NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
, NN NN O
characterized NN NN O
clinically NN NN O
by NN NN O
onset NN NN O
before NN NN O
the NN NN O
age NN NN O
of NN NN O
25 NN NN O
of NN NN O
progressive NN NN B-CompositeMention
gait NN NN I-CompositeMention
and NN NN I-CompositeMention
limb NN NN I-CompositeMention
ataxia NN NN I-CompositeMention
, NN NN O
absence NN NN B-DiseaseClass
of NN NN I-DiseaseClass
deep NN NN I-DiseaseClass
tendon NN NN I-DiseaseClass
reflexes NN NN I-DiseaseClass
, NN NN O
extensor NN NN B-DiseaseClass
plantar NN NN I-DiseaseClass
responses NN NN I-DiseaseClass
, NN NN O
and NN NN O
loss NN NN B-CompositeMention
of NN NN I-CompositeMention
position NN NN I-CompositeMention
and NN NN I-CompositeMention
vibration NN NN I-CompositeMention
sense NN NN I-CompositeMention
in NN NN O
the NN NN O
lower NN NN O
limbs NN NN O
. NN NN O

FRDA NN NN B-SpecificDisease
is NN NN O
caused NN NN O
by NN NN O
a NN NN O
GAA NN NN O
triplet NN NN O
expansion NN NN O
in NN NN O
the NN NN O
first NN NN O
intron NN NN O
of NN NN O
the NN NN O
FRDA NN NN B-Modifier
gene NN NN O
on NN NN O
chromosome NN NN O
9q13 NN NN O
in NN NN O
97 NN NN O
% NN NN O
of NN NN O
patients NN NN O
. NN NN O

The NN NN O
FRDA NN NN B-Modifier
gene NN NN O
encodes NN NN O
a NN NN O
widely NN NN O
expressed NN NN O
210-aa NN NN O
protein NN NN O
, NN NN O
frataxin NN NN O
, NN NN O
which NN NN O
is NN NN O
located NN NN O
in NN NN O
mitochondria NN NN O
and NN NN O
is NN NN O
severely NN NN O
reduced NN NN O
in NN NN O
FRDA NN NN B-Modifier
patients NN NN O
. NN NN O

Frataxin NN NN O
function NN NN O
is NN NN O
still NN NN O
unknown NN NN O
but NN NN O
the NN NN O
knockout NN NN O
of NN NN O
the NN NN O
yeast NN NN O
frataxin NN NN O
homologue NN NN O
gene NN NN O
( NN NN O
YFH1 NN NN O
) NN NN O
showed NN NN O
a NN NN O
severe NN NN O
defect NN NN O
of NN NN O
mitochondrial NN NN O
respiration NN NN O
and NN NN O
loss NN NN O
of NN NN O
mtDNA NN NN O
associated NN NN O
with NN NN O
elevated NN NN O
intramitochondrial NN NN O
iron NN NN O
. NN NN O

Here NN NN O
we NN NN O
report NN NN O
in NN NN O
vivo NN NN O
evidence NN NN O
of NN NN O
impaired NN NN O
mitochondrial NN NN O
respiration NN NN O
in NN NN O
skeletal NN NN O
muscle NN NN O
of NN NN O
FRDA NN NN B-Modifier
patients NN NN O
. NN NN O

Using NN NN O
phosphorus NN NN O
magnetic NN NN O
resonance NN NN O
spectroscopy NN NN O
we NN NN O
demonstrated NN NN O
a NN NN O
maximum NN NN O
rate NN NN O
of NN NN O
muscle NN NN O
mitochondrial NN NN O
ATP NN NN O
production NN NN O
( NN NN O
V NN NN O
( NN NN O
max NN NN O
) NN NN O
) NN NN O
below NN NN O
the NN NN O
normal NN NN O
range NN NN O
in NN NN O
all NN NN O
12 NN NN O
FRDA NN NN B-Modifier
patients NN NN O
and NN NN O
a NN NN O
strong NN NN O
negative NN NN O
correlation NN NN O
between NN NN O
mitochondrial NN NN O
V NN NN O
( NN NN O
max NN NN O
) NN NN O
and NN NN O
the NN NN O
number NN NN O
of NN NN O
GAA NN NN O
repeats NN NN O
in NN NN O
the NN NN O
smaller NN NN O
allele NN NN O
. NN NN O

Our NN NN O
results NN NN O
show NN NN O
that NN NN O
FRDA NN NN B-SpecificDisease
is NN NN O
a NN NN O
nuclear-encoded NN NN O
mitochondrial NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
affecting NN NN O
oxidative NN NN O
phosphorylation NN NN O
and NN NN O
give NN NN O
a NN NN O
rationale NN NN O
for NN NN O
treatments NN NN O
aimed NN NN O
to NN NN O
improve NN NN O
mitochondrial NN NN O
function NN NN O
in NN NN O
this NN NN O
condition NN NN O
. NN NN O

. NN NN O

10502833 NN NN O
Identification NN NN O
of NN NN O
a NN NN O
novel NN NN O
R21X NN NN O
mutation NN NN O
in NN NN O
the NN NN O
liver-type NN NN O
arginase NN NN O
gene NN NN O
( NN NN O
ARG1 NN NN O
) NN NN O
in NN NN O
four NN NN O
Portuguese NN NN O
patients NN NN O
with NN NN O
argininemia NN NN B-SpecificDisease
. NN NN O

Argininemia NN NN B-SpecificDisease
is NN NN O
a NN NN O
rare NN NN O
autossomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
caused NN NN O
by NN NN O
deficiency NN NN B-DiseaseClass
in NN NN I-DiseaseClass
the NN NN I-DiseaseClass
cytosolic NN NN I-DiseaseClass
liver-type NN NN I-DiseaseClass
arginase NN NN I-DiseaseClass
enzyme NN NN I-DiseaseClass
( NN NN O
L-arginine NN NN O
urea-hydrolase NN NN O
; NN NN O
E NN NN O
. NN NN O

C NN NN O
. NN NN O

3 NN NN O
. NN NN O

5 NN NN O
. NN NN O

3 NN NN O
. NN NN O

1 NN NN O
) NN NN O
. NN NN O

In NN NN O
order NN NN O
to NN NN O
investigate NN NN O
the NN NN O
molecular NN NN O
basis NN NN O
for NN NN O
argininemia NN NN B-SpecificDisease
in NN NN O
four NN NN O
unrelated NN NN O
Portuguese NN NN O
patients NN NN O
( NN NN O
two NN NN O
from NN NN O
northern NN NN O
Portugal NN NN O
and NN NN O
two NN NN O
from NN NN O
Madeira NN NN O
Island NN NN O
) NN NN O
we NN NN O
performed NN NN O
a NN NN O
DNA NN NN O
sequence NN NN O
analysis NN NN O
of NN NN O
all NN NN O
the NN NN O
exons NN NN O
and NN NN O
exon NN NN O
/ NN NN O
intron NN NN O
boundaries NN NN O
of NN NN O
the NN NN O
liver-type NN NN O
arginase NN NN O
gene NN NN O
( NN NN O
ARG1 NN NN O
) NN NN O
. NN NN O

All NN NN O
patients NN NN O
were NN NN O
found NN NN O
to NN NN O
be NN NN O
homozygous NN NN O
for NN NN O
a NN NN O
newly NN NN O
identified NN NN O
C NN NN O
- NN NN O
T NN NN O
transition NN NN O
in NN NN O
codon NN NN O
21 NN NN O
( NN NN O
exon NN NN O
2 NN NN O
) NN NN O
substituting NN NN O
arginine NN NN O
for NN NN O
a NN NN O
premature NN NN O
stop NN NN O
codon NN NN O
( NN NN O
R21X NN NN O
CGA NN NN O
to NN NN O
TGA NN NN O
) NN NN O
and NN NN O
generating NN NN O
a NN NN O
NlaIII NN NN O
restriction NN NN O
site NN NN O
. NN NN O

Restriction NN NN O
digestion NN NN O
following NN NN O
PCR NN NN O
amplification NN NN O
of NN NN O
ARG1 NN NN O
exon NN NN O
2 NN NN O
confirmed NN NN O
the NN NN O
presence NN NN O
of NN NN O
the NN NN O
mutation NN NN O
. NN NN O

10519880 NN NN O
Mutation NN NN O
of NN NN O
the NN NN O
sterol NN NN O
27-hydroxylase NN NN O
gene NN NN O
( NN NN O
CYP27 NN NN O
) NN NN O
results NN NN O
in NN NN O
truncation NN NN O
of NN NN O
mRNA NN NN O
expressed NN NN O
in NN NN O
leucocytes NN NN O
in NN NN O
a NN NN O
Japanese NN NN O
family NN NN O
with NN NN O
cerebrotendinous NN NN B-SpecificDisease
xanthomatosis NN NN I-SpecificDisease
. NN NN O

OBJECTIVES NN NN O
A NN NN O
Japanese NN NN O
family NN NN O
with NN NN O
cerebrotendinous NN NN B-SpecificDisease
xanthomatosis NN NN I-SpecificDisease
( NN NN O
CTX NN NN B-SpecificDisease
) NN NN O
was NN NN O
investigated NN NN O
for NN NN O
a NN NN O
sequence NN NN O
alteration NN NN O
in NN NN O
the NN NN O
sterol NN NN O
27-hydroxylase NN NN O
gene NN NN O
( NN NN O
CYP27 NN NN O
) NN NN O
. NN NN O

The NN NN O
expression NN NN O
of NN NN O
CYP27 NN NN O
has NN NN O
been NN NN O
mostly NN NN O
explored NN NN O
using NN NN O
cultured NN NN O
fibroblasts NN NN O
, NN NN O
prompting NN NN O
the NN NN O
examination NN NN O
of NN NN O
the NN NN O
transcripts NN NN O
from NN NN O
blood NN NN O
leucocytes NN NN O
as NN NN O
a NN NN O
simple NN NN O
and NN NN O
rapid NN NN O
technique NN NN O
. NN NN O

METHODS NN NN O
An NN NN O
alteration NN NN O
in NN NN O
CYP27 NN NN O
of NN NN O
the NN NN O
proband NN NN O
was NN NN O
searched NN NN O
for NN NN O
by NN NN O
polymerase NN NN O
chain NN NN O
reaction-single NN NN O
strand NN NN O
conformation NN NN O
polymorphism NN NN O
( NN NN O
PCR-SSCP NN NN O
) NN NN O
analysis NN NN O
and NN NN O
subsequent NN NN O
sequencing NN NN O
. NN NN O

Samples NN NN O
of NN NN O
RNA NN NN O
were NN NN O
subjected NN NN O
to NN NN O
reverse NN NN O
transcription NN NN O
PCR NN NN O
( NN NN O
RT-PCR NN NN O
) NN NN O
and NN NN O
the NN NN O
product NN NN O
of NN NN O
the NN NN O
proband NN NN O
was NN NN O
amplified NN NN O
with NN NN O
nested NN NN O
primers NN NN O
and NN NN O
sequenced NN NN O
. NN NN O

RESULTS NN NN O
A NN NN O
homozygous NN NN O
G NN NN O
to NN NN O
A NN NN O
transition NN NN O
at NN NN O
the NN NN O
5 NN NN O
end NN NN O
of NN NN O
intron NN NN O
7 NN NN O
was NN NN O
detected NN NN O
in NN NN O
the NN NN O
patient NN NN O
. NN NN O

In NN NN O
RT-PCR NN NN O
analysis NN NN O
, NN NN O
only NN NN O
a NN NN O
truncated NN NN O
transcript NN NN O
was NN NN O
detected NN NN O
in NN NN O
the NN NN O
patient NN NN O
, NN NN O
whereas NN NN O
both NN NN O
normal NN NN O
and NN NN O
truncated NN NN O
transcripts NN NN O
were NN NN O
detected NN NN O
in NN NN O
the NN NN O
siblings NN NN O
. NN NN O

The NN NN O
sequencing NN NN O
of NN NN O
the NN NN O
patients NN NN O
cDNA NN NN O
fragment NN NN O
disclosed NN NN O
a NN NN O
direct NN NN O
conjuction NN NN O
of NN NN O
exon NN NN O
6 NN NN O
and NN NN O
exon NN NN O
8 NN NN O
. NN NN O

CONCLUSION NN NN O
The NN NN O
mutation NN NN O
at NN NN O
splice NN NN O
donor NN NN O
site NN NN O
and NN NN O
the NN NN O
truncation NN NN O
of NN NN O
mRNA NN NN O
were NN NN O
identical NN NN O
with NN NN O
those NN NN O
of NN NN O
a NN NN O
recently NN NN O
reported NN NN O
Italian NN NN O
patient NN NN O
, NN NN O
although NN NN O
different NN NN O
in NN NN O
symptomatology NN NN O
. NN NN O

The NN NN O
application NN NN O
of NN NN O
blood NN NN O
leucocytes NN NN O
can NN NN O
be NN NN O
a NN NN O
simple NN NN O
technique NN NN O
on NN NN O
analysing NN NN O
a NN NN O
constructive NN NN O
abnormality NN NN B-SpecificDisease
of NN NN I-SpecificDisease
CYP27 NN NN I-SpecificDisease
mRNA NN NN O
. NN NN O

. NN NN O

10521293 NN NN O
Clinical NN NN O
and NN NN O
molecular NN NN O
genetic NN NN O
analysis NN NN O
of NN NN O
19 NN NN O
Wolfram NN NN B-Modifier
syndrome NN NN I-Modifier
kindreds NN NN O
demonstrating NN NN O
a NN NN O
wide NN NN O
spectrum NN NN O
of NN NN O
mutations NN NN O
in NN NN O
WFS1 NN NN O
. NN NN O

Wolfram NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
neurodegenerative NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
characterized NN NN O
by NN NN O
juvenile-onset NN NN B-SpecificDisease
diabetes NN NN I-SpecificDisease
mellitus NN NN I-SpecificDisease
and NN NN O
progressive NN NN O
optic NN NN B-SpecificDisease
atrophy NN NN I-SpecificDisease
. NN NN O

mtDNA NN NN O
deletions NN NN O
have NN NN O
been NN NN O
described NN NN O
, NN NN O
and NN NN O
a NN NN O
gene NN NN O
( NN NN O
WFS1 NN NN O
) NN NN O
recently NN NN O
has NN NN O
been NN NN O
identified NN NN O
, NN NN O
on NN NN O
chromosome NN NN O
4p16 NN NN O
, NN NN O
encoding NN NN O
a NN NN O
predicted NN NN O
890 NN NN O
amino NN NN O
acid NN NN O
transmembrane NN NN O
protein NN NN O
. NN NN O

Direct NN NN O
DNA NN NN O
sequencing NN NN O
was NN NN O
done NN NN O
to NN NN O
screen NN NN O
the NN NN O
entire NN NN O
coding NN NN O
region NN NN O
of NN NN O
the NN NN O
WFS1 NN NN O
gene NN NN O
in NN NN O
30 NN NN O
patients NN NN O
from NN NN O
19 NN NN O
British NN NN O
kindreds NN NN O
with NN NN O
Wolfram NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

DNA NN NN O
was NN NN O
also NN NN O
screened NN NN O
for NN NN O
structural NN NN O
rearrangements NN NN O
( NN NN O
deletions NN NN O
and NN NN O
duplications NN NN O
) NN NN O
and NN NN O
point NN NN O
mutations NN NN O
in NN NN O
mtDNA NN NN O
. NN NN O

No NN NN O
pathogenic NN NN O
mtDNA NN NN O
mutations NN NN O
were NN NN O
found NN NN O
in NN NN O
our NN NN O
cohort NN NN O
. NN NN O

We NN NN O
identified NN NN O
24 NN NN O
mutations NN NN O
in NN NN O
the NN NN O
WFS1 NN NN O
gene NN NN O
8 NN NN O
nonsense NN NN O
mutations NN NN O
, NN NN O
8 NN NN O
missense NN NN O
mutations NN NN O
, NN NN O
3 NN NN O
in-frame NN NN O
deletions NN NN O
, NN NN O
1 NN NN O
in-frame NN NN O
insertion NN NN O
, NN NN O
and NN NN O
4 NN NN O
frameshift NN NN O
mutations NN NN O
. NN NN O

Of NN NN O
these NN NN O
, NN NN O
23 NN NN O
were NN NN O
novel NN NN O
mutations NN NN O
, NN NN O
and NN NN O
most NN NN O
occurred NN NN O
in NN NN O
exon NN NN O
8 NN NN O
. NN NN O

The NN NN O
majority NN NN O
of NN NN O
patients NN NN O
were NN NN O
compound NN NN O
heterozygotes NN NN O
for NN NN O
two NN NN O
mutations NN NN O
, NN NN O
and NN NN O
there NN NN O
was NN NN O
no NN NN O
common NN NN O
founder NN NN O
mutation NN NN O
. NN NN O

The NN NN O
data NN NN O
were NN NN O
also NN NN O
analyzed NN NN O
for NN NN O
genotype-phenotype NN NN O
relationships NN NN O
. NN NN O

Although NN NN O
some NN NN O
interesting NN NN O
cases NN NN O
were NN NN O
noted NN NN O
, NN NN O
consideration NN NN O
of NN NN O
the NN NN O
small NN NN O
sample NN NN O
size NN NN O
and NN NN O
frequency NN NN O
of NN NN O
each NN NN O
mutation NN NN O
indicated NN NN O
no NN NN O
clear-cut NN NN O
correlations NN NN O
between NN NN O
any NN NN O
of NN NN O
the NN NN O
observed NN NN O
mutations NN NN O
and NN NN O
disease NN NN O
severity NN NN O
. NN NN O

There NN NN O
were NN NN O
no NN NN O
obvious NN NN O
mutation NN NN O
hot NN NN O
spots NN NN O
or NN NN O
clusters NN NN O
. NN NN O

Hence NN NN O
, NN NN O
molecular NN NN O
screening NN NN O
for NN NN O
Wolfram NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
in NN NN O
affected NN NN O
families NN NN O
and NN NN O
for NN NN O
Wolfram NN NN B-Modifier
syndrome NN NN I-Modifier
-carrier NN NN O
status NN NN O
in NN NN O
subjects NN NN O
with NN NN O
psychiatric NN NN B-DiseaseClass
disorders NN NN I-DiseaseClass
or NN NN O
diabetes NN NN B-SpecificDisease
mellitus NN NN I-SpecificDisease
will NN NN O
require NN NN O
complete NN NN O
analysis NN NN O
of NN NN O
exon NN NN O
8 NN NN O
and NN NN O
upstream NN NN O
exons NN NN O
. NN NN O

. NN NN O

10528243 NN NN O
Late-onset NN NN O
familial NN NN B-SpecificDisease
Mediterranean NN NN I-SpecificDisease
fever NN NN I-SpecificDisease
( NN NN O
FMF NN NN B-SpecificDisease
) NN NN O
: NN NN O
a NN NN O
subset NN NN O
with NN NN O
distinct NN NN O
clinical NN NN O
, NN NN O
demographic NN NN O
, NN NN O
and NN NN O
molecular NN NN O
genetic NN NN O
characteristics NN NN O
. NN NN O

To NN NN O
determine NN NN O
the NN NN O
prevalence NN NN O
and NN NN O
characterize NN NN O
demographic NN NN O
, NN NN O
clinical NN NN O
, NN NN O
and NN NN O
genetic NN NN O
features NN NN O
of NN NN O
familial NN NN B-SpecificDisease
Mediterranean NN NN I-SpecificDisease
fever NN NN I-SpecificDisease
( NN NN O
FMF NN NN B-SpecificDisease
) NN NN O
of NN NN O
late NN NN O
onset NN NN O
, NN NN O
all NN NN O
patients NN NN O
experiencing NN NN O
their NN NN O
first NN NN O
FMF NN NN B-Modifier
attack NN NN O
at NN NN O
age NN NN O
40 NN NN O
years NN NN O
or NN NN O
more NN NN O
were NN NN O
identified NN NN O
using NN NN O
the NN NN O
computerized NN NN O
registry NN NN O
of NN NN O
our NN NN O
FMF NN NN B-Modifier
clinic NN NN O
, NN NN O
and NN NN O
then NN NN O
thoroughly NN NN O
interviewed NN NN O
and NN NN O
examined NN NN O
. NN NN O

The NN NN O
control NN NN O
group NN NN O
consisted NN NN O
of NN NN O
40 NN NN O
consecutive NN NN O
FMF NN NN B-Modifier
patients NN NN O
, NN NN O
who NN NN O
arrived NN NN O
at NN NN O
the NN NN O
FMF NN NN B-Modifier
clinic NN NN O
for NN NN O
their NN NN O
regular NN NN O
follow-up NN NN O
visit NN NN O
and NN NN O
were NN NN O
40 NN NN O
years NN NN O
of NN NN O
age NN NN O
or NN NN O
older NN NN O
at NN NN O
the NN NN O
time NN NN O
of NN NN O
the NN NN O
examination NN NN O
. NN NN O

The NN NN O
severity NN NN O
of NN NN O
the NN NN O
disease NN NN O
in NN NN O
patients NN NN O
and NN NN O
controls NN NN O
was NN NN O
determined NN NN O
using NN NN O
a NN NN O
modified NN NN O
score NN NN O
, NN NN O
developed NN NN O
previously NN NN O
. NN NN O

Mutational NN NN O
analysis NN NN O
in NN NN O
the NN NN O
FMF NN NN B-Modifier
gene NN NN O
was NN NN O
performed NN NN O
using NN NN O
a NN NN O
commercial NN NN O
kit NN NN O
. NN NN O

Only NN NN O
20 NN NN O
of NN NN O
4000 NN NN O
( NN NN O
0 NN NN O
. NN NN O

5 NN NN O
% NN NN O
) NN NN O
patients NN NN O
had NN NN O
late-onset NN NN O
FMF NN NN B-SpecificDisease
. NN NN O

These NN NN O
patients NN NN O
were NN NN O
mostly NN NN O
men NN NN O
, NN NN O
of NN NN O
non-North NN NN O
African NN NN O
origin NN NN O
, NN NN O
P NN NN O
0 NN NN O
. NN NN O

05 NN NN O
compared NN NN O
to NN NN O
controls NN NN O
. NN NN O

All NN NN O
had NN NN O
abdominal NN NN O
attacks NN NN O
and NN NN O
in NN NN O
most NN NN O
these NN NN O
were NN NN O
the NN NN O
only NN NN O
manifestation NN NN O
of NN NN O
their NN NN O
disease NN NN O
, NN NN O
P NN NN O
0 NN NN O
. NN NN O

001 NN NN O
001 NN NN O
. NN NN O

None NN NN O
had NN NN O
chronic NN NN O
or NN NN O
prolonged NN NN O
manifestations NN NN O
of NN NN O
FMF NN NN B-SpecificDisease
, NN NN O
for NN NN O
example NN NN O
, NN NN O
amyloidosis NN NN B-SpecificDisease
, NN NN O
chronic NN NN B-SpecificDisease
arthritis NN NN I-SpecificDisease
, NN NN O
or NN NN O
protracted NN NN O
myalgia NN NN B-SpecificDisease
, NN NN O
P NN NN O
0 NN NN O
. NN NN O

001 NN NN O
. NN NN O

The NN NN O
response NN NN O
to NN NN O
treatment NN NN O
was NN NN O
good NN NN O
despite NN NN O
using NN NN O
low NN NN O
colchicine NN NN O
dose NN NN O
, NN NN O
P NN NN O
0 NN NN O
. NN NN O

05 NN NN O
. NN NN O

The NN NN O
overall NN NN O
severity NN NN O
score NN NN O
indicated NN NN O
a NN NN O
mild NN NN O
disease NN NN O
, NN NN O
P NN NN O
0 NN NN O
. NN NN O

001 NN NN O
. NN NN O

Mutational NN NN O
analysis NN NN O
revealed NN NN O
absence NN NN O
of NN NN O
M694V NN NN O
homozygosity NN NN O
, NN NN O
P NN NN O
0 NN NN O
. NN NN O

01 NN NN O
, NN NN O
compared NN NN O
to NN NN O
our NN NN O
regular NN NN O
FMF NN NN B-Modifier
population NN NN O
. NN NN O

We NN NN O
conclude NN NN O
that NN NN O
the NN NN O
onset NN NN O
of NN NN O
FMF NN NN B-SpecificDisease
in NN NN O
a NN NN O
late NN NN O
age NN NN O
defines NN NN O
a NN NN O
milder NN NN O
form NN NN O
of NN NN O
disease NN NN O
with NN NN O
typical NN NN O
clinical NN NN O
, NN NN O
demographic NN NN O
, NN NN O
and NN NN O
molecular NN NN O
genetic NN NN O
characteristics NN NN O

10528853 NN NN O
A NN NN O
highly NN NN O
accurate NN NN O
, NN NN O
low NN NN O
cost NN NN O
test NN NN O
for NN NN O
BRCA1 NN NN O
mutations NN NN O
. NN NN O

The NN NN O
hereditary NN NN B-CompositeMention
breast NN NN I-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
syndrome NN NN I-CompositeMention
is NN NN O
associated NN NN O
with NN NN O
a NN NN O
high NN NN O
frequency NN NN O
of NN NN O
BRCA1 NN NN O
mutations NN NN O
. NN NN O

However NN NN O
, NN NN O
the NN NN O
widespread NN NN O
use NN NN O
of NN NN O
BRCA1 NN NN O
testing NN NN O
has NN NN O
been NN NN O
limited NN NN O
to NN NN O
date NN NN O
by NN NN O
three NN NN O
principal NN NN O
concerns NN NN O
the NN NN O
fear NN NN O
of NN NN O
loss NN NN O
of NN NN O
health NN NN O
and NN NN O
life NN NN O
insurance NN NN O
, NN NN O
the NN NN O
uncertain NN NN O
clinical NN NN O
value NN NN O
of NN NN O
a NN NN O
positive NN NN O
test NN NN O
result NN NN O
, NN NN O
and NN NN O
the NN NN O
current NN NN O
lack NN NN O
of NN NN O
an NN NN O
inexpensive NN NN O
and NN NN O
sensitive NN NN O
screening NN NN O
test NN NN O
for NN NN O
BRCA1 NN NN O
mutations NN NN O
. NN NN O

We NN NN O
have NN NN O
developed NN NN O
an NN NN O
inexpensive NN NN O
system NN NN O
for NN NN O
gene NN NN O
mutational NN NN O
scanning NN NN O
, NN NN O
based NN NN O
on NN NN O
a NN NN O
combination NN NN O
of NN NN O
extensive NN NN O
multiplex NN NN O
PCR NN NN O
amplification NN NN O
and NN NN O
two NN NN O
dimensional NN NN O
electrophoresis NN NN O
. NN NN O

The NN NN O
efficiency NN NN O
of NN NN O
this NN NN O
system NN NN O
, NN NN O
as NN NN O
a NN NN O
screening NN NN O
test NN NN O
for NN NN O
BRCA1 NN NN O
mutations NN NN O
, NN NN O
was NN NN O
evaluated NN NN O
in NN NN O
a NN NN O
panel NN NN O
of NN NN O
60 NN NN O
samples NN NN O
from NN NN O
high NN NN O
risk NN NN O
women NN NN O
, NN NN O
14 NN NN O
of NN NN O
which NN NN O
contained NN NN O
a NN NN O
previously NN NN O
identified NN NN O
mutation NN NN O
in NN NN O
BRCA1 NN NN O
. NN NN O

All NN NN O
14 NN NN O
mutations NN NN O
were NN NN O
identified NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
an NN NN O
additional NN NN O
five NN NN O
that NN NN O
had NN NN O
previously NN NN O
escaped NN NN O
detection NN NN O
. NN NN O

In NN NN O
addition NN NN O
to NN NN O
the NN NN O
19 NN NN O
mutations NN NN O
, NN NN O
a NN NN O
total NN NN O
of NN NN O
15 NN NN O
different NN NN O
polymorphic NN NN O
variants NN NN O
were NN NN O
scored NN NN O
, NN NN O
most NN NN O
of NN NN O
which NN NN O
were NN NN O
recurring NN NN O
. NN NN O

All NN NN O
were NN NN O
confirmed NN NN O
by NN NN O
nucleotide NN NN O
sequencing NN NN O
. NN NN O

The NN NN O
cost NN NN O
of NN NN O
screening NN NN O
per NN NN O
sample NN NN O
was NN NN O
calculated NN NN O
to NN NN O
be NN NN O
approximately NN NN O
US NN NN O
$ NN NN O
70 NN NN O
for NN NN O
the NN NN O
manual NN NN O
technique NN NN O
used NN NN O
in NN NN O
this NN NN O
study NN NN O
, NN NN O
and NN NN O
may NN NN O
be NN NN O
reduced NN NN O
to NN NN O
approximately NN NN O
US NN NN O
$ NN NN O
10 NN NN O
with NN NN O
the NN NN O
introduction NN NN O
of NN NN O
commercially NN NN O
available NN NN O
PCR NN NN O
robotics NN NN O
and NN NN O
fluorescent NN NN O
imaging NN NN O
. NN NN O

Implementation NN NN O
of NN NN O
this NN NN O
method NN NN O
of NN NN O
mutation NN NN O
screening NN NN O
in NN NN O
the NN NN O
research NN NN O
and NN NN O
clinical NN NN O
setting NN NN O
should NN NN O
permit NN NN O
rapid NN NN O
accrual NN NN O
of NN NN O
quantitative NN NN O
data NN NN O
on NN NN O
genotype-phenotype NN NN O
associations NN NN O
for NN NN O
the NN NN O
evaluation NN NN O
of NN NN O
diagnostic NN NN O
testing NN NN O
. NN NN O

. NN NN O

10528860 NN NN O
Maternal NN NN B-SpecificDisease
uniparental NN NN I-SpecificDisease
disomy NN NN I-SpecificDisease
for NN NN I-SpecificDisease
chromosome NN NN I-SpecificDisease
14 NN NN I-SpecificDisease
in NN NN O
a NN NN O
boy NN NN O
with NN NN O
a NN NN O
normal NN NN O
karyotype NN NN O
. NN NN O

We NN NN O
report NN NN O
on NN NN O
a NN NN O
boy NN NN O
with NN NN O
a NN NN O
maternal NN NN B-SpecificDisease
uniparental NN NN I-SpecificDisease
disomy NN NN I-SpecificDisease
for NN NN I-SpecificDisease
chromosome NN NN I-SpecificDisease
14 NN NN I-SpecificDisease
( NN NN O
UPD NN NN B-SpecificDisease
( NN NN O
14 NN NN O
) NN NN O
) NN NN O
. NN NN O

At NN NN O
7 NN NN O
years NN NN O
of NN NN O
age NN NN O
he NN NN O
was NN NN O
referred NN NN O
to NN NN O
us NN NN O
by NN NN O
the NN NN O
paediatrician NN NN O
because NN NN O
of NN NN O
symptoms NN NN O
of NN NN O
Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
PWS NN NN B-SpecificDisease
) NN NN O
. NN NN O

He NN NN O
showed NN NN O
short NN NN B-DiseaseClass
stature NN NN I-DiseaseClass
, NN NN O
obesity NN NN B-SpecificDisease
, NN NN O
mild NN NN O
developmental NN NN B-DiseaseClass
delay NN NN I-DiseaseClass
, NN NN O
cryptorchidism NN NN B-SpecificDisease
, NN NN O
and NN NN O
some NN NN O
mild NN NN O
dysmorphic NN NN O
features NN NN O
. NN NN O

The NN NN O
history NN NN O
further NN NN O
indicated NN NN O
intrauterine NN NN B-DiseaseClass
growth NN NN I-DiseaseClass
retardation NN NN I-DiseaseClass
at NN NN O
the NN NN O
end NN NN O
of NN NN O
the NN NN O
pregnancy NN NN O
. NN NN O

His NN NN O
mother NN NN O
was NN NN O
44 NN NN O
years NN NN O
of NN NN O
age NN NN O
at NN NN O
the NN NN O
time NN NN O
of NN NN O
his NN NN O
birth NN NN O
. NN NN O

After NN NN O
birth NN NN O
he NN NN O
showed NN NN O
hypotonia NN NN B-DiseaseClass
with NN NN O
poor NN NN O
sucking NN NN O
, NN NN O
for NN NN O
which NN NN O
gavage NN NN O
feeding NN NN O
was NN NN O
needed NN NN O
. NN NN O

Motor NN NN O
development NN NN O
was NN NN O
delayed NN NN O
. NN NN O

After NN NN O
1 NN NN O
year NN NN O
he NN NN O
became NN NN O
obese NN NN B-Modifier
despite NN NN O
a NN NN O
normal NN NN O
appetite NN NN O
. NN NN O

Recurrent NN NN O
middle NN NN B-SpecificDisease
ear NN NN I-SpecificDisease
infections NN NN I-SpecificDisease
, NN NN O
a NN NN O
high NN NN O
pain NN NN O
threshold NN NN O
, NN NN O
and NN NN O
a NN NN O
great NN NN O
skill NN NN O
with NN NN O
jigsaw NN NN O
puzzles NN NN O
were NN NN O
reported NN NN O
. NN NN O

There NN NN O
were NN NN O
no NN NN O
behavioural NN NN O
problems NN NN O
or NN NN O
sleep NN NN O
disturbance NN NN O
. NN NN O

Chromosomal NN NN O
analysis NN NN O
was NN NN O
normal NN NN O
( NN NN O
46 NN NN O
, NN NN O
XY NN NN O
) NN NN O
. NN NN O

DNA NN NN O
analysis NN NN O
for NN NN O
Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
showed NN NN O
no NN NN O
abnormalities NN NN O
. NN NN O

Two NN NN O
years NN NN O
later NN NN O
he NN NN O
was NN NN O
re-examined NN NN O
because NN NN O
we NN NN O
thought NN NN O
his NN NN O
features NN NN O
fitted NN NN O
the NN NN O
PWS NN NN B-Modifier
-like NN NN O
phenotype NN NN O
associated NN NN O
with NN NN O
maternal NN NN O
UPD NN NN B-SpecificDisease
( NN NN O
14 NN NN O
) NN NN O
. NN NN O

At NN NN O
that NN NN O
time NN NN O
precocious NN NN O
puberty NN NN O
was NN NN O
evident NN NN O
. NN NN O

DNA NN NN O
analysis NN NN O
showed NN NN O
maternal NN NN B-DiseaseClass
heterodisomy NN NN I-DiseaseClass
for NN NN O
chromosome NN NN O
14 NN NN O
. NN NN O

In NN NN O
all NN NN O
the NN NN O
previously NN NN O
described NN NN O
11 NN NN O
cases NN NN O
with NN NN O
maternal NN NN O
UPD NN NN B-SpecificDisease
( NN NN O
14 NN NN O
) NN NN O
, NN NN O
a NN NN O
Robertsonian NN NN O
translocation NN NN O
involving NN NN O
chromosome NN NN O
14 NN NN O
was NN NN O
detected NN NN O
cytogenetically NN NN O
before NN NN O
DNA NN NN O
analysis NN NN O
. NN NN O

This NN NN O
is NN NN O
the NN NN O
first NN NN O
report NN NN O
of NN NN O
diagnosis NN NN O
of NN NN O
maternal NN NN O
UPD NN NN B-SpecificDisease
( NN NN O
14 NN NN O
) NN NN O
based NN NN O
on NN NN O
clinical NN NN O
features NN NN O
. NN NN O

This NN NN O
finding NN NN O
underlines NN NN O
the NN NN O
importance NN NN O
of NN NN O
DNA NN NN O
analysis NN NN O
for NN NN O
maternal NN NN O
UPD NN NN O
( NN NN O
14 NN NN O
) NN NN O
in NN NN O
patients NN NN O
with NN NN O
a NN NN O
similar NN NN O
PWS NN NN B-Modifier
-like NN NN O
phenotype NN NN O
even NN NN O
without NN NN O
previous NN NN O
identification NN NN O
of NN NN O
a NN NN O
Robertsonian NN NN O
translocation NN NN O
involving NN NN O
chromosome NN NN O
14 NN NN O
. NN NN O

. NN NN O

10533031 NN NN O
Clinical NN NN O
and NN NN O
genetic NN NN O
study NN NN O
of NN NN O
Friedreich NN NN B-SpecificDisease
ataxia NN NN I-SpecificDisease
in NN NN O
an NN NN O
Australian NN NN O
population NN NN O
. NN NN O

Friedreich NN NN B-SpecificDisease
ataxia NN NN I-SpecificDisease
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
caused NN NN O
by NN NN O
mutations NN NN O
in NN NN O
the NN NN O
FRDA NN NN B-Modifier
gene NN NN O
that NN NN O
encodes NN NN O
a NN NN O
210-amino NN NN O
acid NN NN O
protein NN NN O
called NN NN O
frataxin NN NN O
. NN NN O

An NN NN O
expansion NN NN O
of NN NN O
a NN NN O
GAA NN NN O
trinucleotide NN NN O
repeat NN NN O
in NN NN O
intron NN NN O
1 NN NN O
of NN NN O
the NN NN O
gene NN NN O
is NN NN O
present NN NN O
in NN NN O
more NN NN O
than NN NN O
95 NN NN O
% NN NN O
of NN NN O
mutant NN NN O
alleles NN NN O
. NN NN O

Of NN NN O
the NN NN O
83 NN NN O
people NN NN O
we NN NN O
studied NN NN O
who NN NN O
have NN NN O
mutations NN NN O
in NN NN O
FRDA NN NN O
, NN NN O
78 NN NN O
are NN NN O
homozygous NN NN O
for NN NN O
an NN NN O
expanded NN NN O
GAA NN NN O
repeat NN NN O
; NN NN O
the NN NN O
other NN NN O
five NN NN O
patients NN NN O
have NN NN O
an NN NN O
expansion NN NN O
in NN NN O
one NN NN O
allele NN NN O
and NN NN O
a NN NN O
point NN NN O
mutation NN NN O
in NN NN O
the NN NN O
other NN NN O
. NN NN O

Here NN NN O
we NN NN O
present NN NN O
a NN NN O
detailed NN NN O
clinical NN NN O
and NN NN O
genetic NN NN O
study NN NN O
of NN NN O
a NN NN O
subset NN NN O
of NN NN O
51 NN NN O
patients NN NN O
homozygous NN NN O
for NN NN O
an NN NN O
expansion NN NN O
of NN NN O
the NN NN O
GAA NN NN O
repeat NN NN O
. NN NN O

We NN NN O
found NN NN O
a NN NN O
correlation NN NN O
between NN NN O
the NN NN O
size NN NN O
of NN NN O
the NN NN O
smaller NN NN O
of NN NN O
the NN NN O
two NN NN O
expanded NN NN O
alleles NN NN O
and NN NN O
age NN NN O
at NN NN O
onset NN NN O
, NN NN O
age NN NN O
into NN NN O
wheelchair NN NN O
, NN NN O
scoliosis NN NN B-DiseaseClass
, NN NN O
impaired NN NN O
vibration NN NN O
sense NN NN O
, NN NN O
and NN NN O
the NN NN O
presence NN NN O
of NN NN O
foot NN NN B-DiseaseClass
deformity NN NN I-DiseaseClass
. NN NN O

There NN NN O
was NN NN O
no NN NN O
significant NN NN O
correlation NN NN O
between NN NN O
the NN NN O
size NN NN O
of NN NN O
the NN NN O
smaller NN NN O
allele NN NN O
and NN NN O
cardiomyopathy NN NN B-SpecificDisease
, NN NN O
diabetes NN NN B-SpecificDisease
mellitus NN NN I-SpecificDisease
, NN NN O
loss NN NN B-DiseaseClass
of NN NN I-DiseaseClass
proprioception NN NN I-DiseaseClass
, NN NN O
or NN NN O
bladder NN NN B-DiseaseClass
symptoms NN NN I-DiseaseClass
. NN NN O

The NN NN O
larger NN NN O
allele NN NN O
size NN NN O
correlated NN NN O
with NN NN O
bladder NN NN B-DiseaseClass
symptoms NN NN I-DiseaseClass
and NN NN O
the NN NN O
presence NN NN O
of NN NN O
foot NN NN B-DiseaseClass
deformity NN NN I-DiseaseClass
. NN NN O

The NN NN O
duration NN NN O
of NN NN O
disease NN NN O
is NN NN O
correlated NN NN O
with NN NN O
wheelchair NN NN O
use NN NN O
and NN NN O
the NN NN O
presence NN NN O
of NN NN O
diabetes NN NN B-DiseaseClass
, NN NN O
scoliosis NN NN B-DiseaseClass
, NN NN O
bladder NN NN B-DiseaseClass
symptoms NN NN I-DiseaseClass
and NN NN O
impaired NN NN B-DiseaseClass
proprioception NN NN I-DiseaseClass
, NN NN O
and NN NN O
vibration NN NN O
sense NN NN O
but NN NN O
no NN NN O
other NN NN O
complications NN NN O
studied NN NN O
. NN NN O

. NN NN O

10533068 NN NN O
Novel NN NN O
mutations NN NN O
in NN NN O
XLRS1 NN NN O
causing NN NN O
retinoschisis NN NN B-SpecificDisease
, NN NN O
including NN NN O
first NN NN O
evidence NN NN O
of NN NN O
putative NN NN O
leader NN NN O
sequence NN NN O
change NN NN O
. NN NN O

Juvenile NN NN B-SpecificDisease
retinoschisis NN NN I-SpecificDisease
is NN NN O
an NN NN O
X-linked NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
disease NN NN I-DiseaseClass
caused NN NN O
by NN NN O
mutations NN NN O
in NN NN O
the NN NN O
XLRS1 NN NN O
gene NN NN O
. NN NN O

We NN NN O
screened NN NN O
31 NN NN O
new NN NN O
unrelated NN NN O
patients NN NN O
and NN NN O
families NN NN O
for NN NN O
XLRS1 NN NN O
mutations NN NN O
in NN NN O
addition NN NN O
to NN NN O
previously NN NN O
reported NN NN O
mutations NN NN O
for NN NN O
60 NN NN O
of NN NN O
our NN NN O
families NN NN O
( NN NN O
Retinoschisis NN NN B-Modifier
Consortium NN NN O
, NN NN O
Hum NN NN O
Mol NN NN O
Genet NN NN O
1998 NN NN O
; NN NN O
7 NN NN O
1185-1192 NN NN O
) NN NN O
. NN NN O

Twenty-three NN NN O
different NN NN O
mutations NN NN O
including NN NN O
12 NN NN O
novel NN NN O
ones NN NN O
were NN NN O
identified NN NN O
in NN NN O
28 NN NN O
patients NN NN O
. NN NN O

Mutations NN NN O
identified NN NN O
in NN NN O
this NN NN O
study NN NN O
include NN NN O
19 NN NN O
missense NN NN O
mutations NN NN O
, NN NN O
two NN NN O
nonsense NN NN O
mutations NN NN O
, NN NN O
one NN NN O
intragenic NN NN O
deletion NN NN O
, NN NN O
four NN NN O
microdeletions NN NN O
, NN NN O
one NN NN O
insertion NN NN O
, NN NN O
and NN NN O
one NN NN O
intronic NN NN O
sequence NN NN O
substitution NN NN O
that NN NN O
is NN NN O
likely NN NN O
to NN NN O
result NN NN O
in NN NN O
a NN NN O
splice NN NN O
site NN NN O
defect NN NN O
. NN NN O

Two NN NN O
novel NN NN O
mutations NN NN O
, NN NN O
c NN NN O
. NN NN O

38T NN NN O
-- NN NN O
C NN NN O
( NN NN O
L13P NN NN O
) NN NN O
and NN NN O
c NN NN O
. NN NN O

667T NN NN O
-- NN NN O
C NN NN O
( NN NN O
C223R NN NN O
) NN NN O
, NN NN O
respectively NN NN O
, NN NN O
present NN NN O
the NN NN O
first NN NN O
genetic NN NN O
evidence NN NN O
for NN NN O
the NN NN O
functional NN NN O
significance NN NN O
of NN NN O
the NN NN O
putative NN NN O
leader NN NN O
peptide NN NN O
sequence NN NN O
and NN NN O
for NN NN O
the NN NN O
functional NN NN O
significance NN NN O
at NN NN O
the NN NN O
carboxyl NN NN O
terminal NN NN O
of NN NN O
the NN NN O
XLRS1 NN NN O
protein NN NN O
beyond NN NN O
the NN NN O
discoidin NN NN O
domain NN NN O
. NN NN O

Mutations NN NN O
in NN NN O
25 NN NN O
of NN NN O
the NN NN O
families NN NN O
were NN NN O
localized NN NN O
to NN NN O
exons NN NN O
4-6 NN NN O
, NN NN O
emphasizing NN NN O
the NN NN O
critical NN NN O
functional NN NN O
significance NN NN O
of NN NN O
the NN NN O
discoidin NN NN O
domain NN NN O
of NN NN O
the NN NN O
XLRS1 NN NN O
protein NN NN O

10541953 NN NN O
Growth NN NN O
hormone NN NN O
treatment NN NN O
increases NN NN O
CO NN NN O
( NN NN O
2 NN NN O
) NN NN O
response NN NN O
, NN NN O
ventilation NN NN O
and NN NN O
central NN NN O
inspiratory NN NN O
drive NN NN O
in NN NN O
children NN NN O
with NN NN O
Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

We NN NN O
studied NN NN O
whether NN NN O
the NN NN O
beneficial NN NN O
effects NN NN O
of NN NN O
growth NN NN O
hormone NN NN O
( NN NN O
GH NN NN O
) NN NN O
treatment NN NN O
on NN NN O
growth NN NN O
and NN NN O
body NN NN O
composition NN NN O
in NN NN O
PWS NN NN B-SpecificDisease
are NN NN O
accompanied NN NN O
by NN NN O
an NN NN O
improvement NN NN O
in NN NN O
respiratory NN NN O
function NN NN O
. NN NN O

We NN NN O
measured NN NN O
resting NN NN O
ventilation NN NN O
, NN NN O
airway NN NN O
occlusion NN NN O
pressure NN NN O
( NN NN O
P NN NN O
( NN NN O
0 NN NN O
. NN NN O

1 NN NN O
) NN NN O
) NN NN O
and NN NN O
ventilatory NN NN O
response NN NN O
to NN NN O
CO NN NN O
( NN NN O
2 NN NN O
) NN NN O
in NN NN O
nine NN NN O
children NN NN O
, NN NN O
aged NN NN O
7-14 NN NN O
years NN NN O
, NN NN O
before NN NN O
and NN NN O
6-9 NN NN O
months NN NN O
after NN NN O
the NN NN O
start NN NN O
of NN NN O
GH NN NN O
treatment NN NN O
. NN NN O

During NN NN O
GH NN NN O
treatment NN NN O
, NN NN O
resting NN NN O
ventilation NN NN O
increased NN NN O
by NN NN O
26 NN NN O
% NN NN O
, NN NN O
P NN NN O
( NN NN O
0 NN NN O
. NN NN O

1 NN NN O
) NN NN O
by NN NN O
72 NN NN O
% NN NN O
and NN NN O
the NN NN O
response NN NN O
to NN NN O
CO NN NN O
( NN NN O
2 NN NN O
) NN NN O
by NN NN O
65 NN NN O
% NN NN O
( NN NN O
P NN NN O
0 NN NN O
. NN NN O

002 NN NN O
, NN NN O
0 NN NN O
. NN NN O

04 NN NN O
and NN NN O
0 NN NN O
. NN NN O

02 NN NN O
, NN NN O
respectively NN NN O
) NN NN O
. NN NN O

This NN NN O
observed NN NN O
increase NN NN O
in NN NN O
ventilatory NN NN O
output NN NN O
was NN NN O
not NN NN O
correlated NN NN O
to NN NN O
changes NN NN O
in NN NN O
body NN NN O
mass NN NN O
index NN NN O
. NN NN O

CONCLUSION NN NN O
Treatment NN NN O
of NN NN O
children NN NN O
with NN NN O
Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
PWS NN NN B-SpecificDisease
) NN NN O
seems NN NN O
to NN NN O
have NN NN O
a NN NN O
stimulatory NN NN O
effect NN NN O
on NN NN O
central NN NN O
respiratory NN NN O
structures NN NN O
. NN NN O

The NN NN O
observed NN NN O
increase NN NN O
in NN NN O
ventilation NN NN O
and NN NN O
inspiratory NN NN O
drive NN NN O
may NN NN O
contribute NN NN O
to NN NN O
the NN NN O
improved NN NN O
activity NN NN O
level NN NN O
reported NN NN O
by NN NN O
parents NN NN O
of NN NN O
PWS NN NN B-Modifier
children NN NN O
during NN NN O
growth NN NN O
hormone NN NN O
therapy NN NN O

10543403 NN NN O
G130V NN NN O
, NN NN O
a NN NN O
common NN NN O
FRDA NN NN B-Modifier
point NN NN O
mutation NN NN O
, NN NN O
appears NN NN O
to NN NN O
have NN NN O
arisen NN NN O
from NN NN O
a NN NN O
common NN NN O
founder NN NN O
. NN NN O

Friedreich NN NN B-SpecificDisease
ataxia NN NN I-SpecificDisease
( NN NN O
FRDA NN NN B-SpecificDisease
) NN NN O
is NN NN O
the NN NN O
most NN NN O
common NN NN O
inherited NN NN B-DiseaseClass
ataxia NN NN I-DiseaseClass
. NN NN O

About NN NN O
98 NN NN O
% NN NN O
of NN NN O
mutant NN NN O
alleles NN NN O
have NN NN O
an NN NN O
expansion NN NN O
of NN NN O
a NN NN O
GAA NN NN O
trinucleotide NN NN O
repeat NN NN O
in NN NN O
intron NN NN O
1 NN NN O
of NN NN O
the NN NN O
affected NN NN O
gene NN NN O
, NN NN O
FRDA NN NN O
. NN NN O

The NN NN O
other NN NN O
2 NN NN O
% NN NN O
are NN NN O
point NN NN O
mutations NN NN O
. NN NN O

Of NN NN O
the NN NN O
17 NN NN O
point NN NN O
mutations NN NN O
so NN NN O
far NN NN O
described NN NN O
, NN NN O
three NN NN O
appear NN NN O
to NN NN O
be NN NN O
more NN NN O
common NN NN O
. NN NN O

One NN NN O
of NN NN O
these NN NN O
is NN NN O
the NN NN O
G130V NN NN O
mutation NN NN O
in NN NN O
exon NN NN O
4 NN NN O
of NN NN O
FRDA NN NN O
. NN NN O

G130V NN NN O
, NN NN O
when NN NN O
present NN NN O
with NN NN O
an NN NN O
expanded NN NN O
GAA NN NN O
repeat NN NN O
on NN NN O
the NN NN O
other NN NN O
allele NN NN O
, NN NN O
is NN NN O
associated NN NN O
with NN NN O
an NN NN O
atypical NN NN O
FRDA NN NN B-Modifier
phenotype NN NN O
. NN NN O

Haplotype NN NN O
analysis NN NN O
was NN NN O
undertaken NN NN O
on NN NN O
the NN NN O
four NN NN O
families NN NN O
who NN NN O
have NN NN O
been NN NN O
described NN NN O
with NN NN O
this NN NN O
mutation NN NN O
. NN NN O

The NN NN O
results NN NN O
suggest NN NN O
a NN NN O
common NN NN O
founder NN NN O
for NN NN O
this NN NN O
mutation NN NN O
. NN NN O

Although NN NN O
marked NN NN O
differences NN NN O
in NN NN O
extragenic NN NN O
marker NN NN O
haplotypes NN NN O
were NN NN O
seen NN NN O
in NN NN O
one NN NN O
family NN NN O
, NN NN O
similar NN NN O
intragenic NN NN O
haplotyping NN NN O
suggests NN NN O
the NN NN O
same NN NN O
mutation NN NN O
founder NN NN O
for NN NN O
this NN NN O
family NN NN O
with NN NN O
the NN NN O
differences NN NN O
explicable NN NN O
by NN NN O
two NN NN O
recombination NN NN O
events NN NN O
. NN NN O

. NN NN O

10545613 NN NN O
Synergistic NN NN O
effect NN NN O
of NN NN O
histone NN NN O
hyperacetylation NN NN O
and NN NN O
DNA NN NN O
demethylation NN NN O
in NN NN O
the NN NN O
reactivation NN NN O
of NN NN O
the NN NN O
FMR1 NN NN O
gene NN NN O
. NN NN O

Most NN NN O
fragile NN NN B-Modifier
X NN NN I-Modifier
syndrome NN NN I-Modifier
patients NN NN O
have NN NN O
expansion NN NN O
of NN NN O
a NN NN O
( NN NN O
CGG NN NN O
) NN NN O
( NN NN O
n NN NN O
) NN NN O
sequence NN NN O
with NN NN O
200 NN NN O
repeats NN NN O
( NN NN O
full NN NN O
mutation NN NN O
) NN NN O
in NN NN O
the NN NN O
FMR1 NN NN O
gene NN NN O
responsible NN NN O
for NN NN O
this NN NN O
condition NN NN O
. NN NN O

Hypermethylation NN NN O
of NN NN O
the NN NN O
expanded NN NN O
repeat NN NN O
and NN NN O
of NN NN O
the NN NN O
FMR1 NN NN O
promoter NN NN O
is NN NN O
almost NN NN O
always NN NN O
present NN NN O
and NN NN O
apparently NN NN O
suppresses NN NN O
transcription NN NN O
, NN NN O
resulting NN NN O
in NN NN O
absence NN NN O
of NN NN O
the NN NN O
FMR1 NN NN O
protein NN NN O
. NN NN O

We NN NN O
recently NN NN O
showed NN NN O
that NN NN O
transcriptional NN NN O
reactivation NN NN O
of NN NN O
FMR1 NN NN O
full NN NN O
mutations NN NN O
can NN NN O
be NN NN O
achieved NN NN O
by NN NN O
inducing NN NN O
DNA NN NN O
demethylation NN NN O
with NN NN O
5-azadeoxycytidine NN NN O
( NN NN O
5-azadC NN NN O
) NN NN O
. NN NN O

The NN NN O
level NN NN O
of NN NN O
histone NN NN O
acetylation NN NN O
is NN NN O
another NN NN O
important NN NN O
factor NN NN O
in NN NN O
regulating NN NN O
gene NN NN O
expression NN NN O
; NN NN O
therefore NN NN O
, NN NN O
we NN NN O
treated NN NN O
lymphoblastoid NN NN O
cell NN NN O
lines NN NN O
of NN NN O
non-mosaic NN NN O
full NN NN O
mutation NN NN O
patients NN NN O
with NN NN O
three NN NN O
drugs NN NN O
capable NN NN O
of NN NN O
inducing NN NN O
histone NN NN O
hyperacetylation NN NN O
. NN NN O

We NN NN O
observed NN NN O
a NN NN O
consistent NN NN O
, NN NN O
although NN NN O
modest NN NN O
, NN NN O
reactivation NN NN O
of NN NN O
the NN NN O
FMR1 NN NN O
gene NN NN O
with NN NN O
4-phenylbutyrate NN NN O
, NN NN O
sodium NN NN O
butyrate NN NN O
and NN NN O
trichostatin NN NN O
A NN NN O
, NN NN O
as NN NN O
shown NN NN O
by NN NN O
RT-PCR NN NN O
. NN NN O

However NN NN O
, NN NN O
we NN NN O
report NN NN O
that NN NN O
combining NN NN O
these NN NN O
drugs NN NN O
with NN NN O
5-azadC NN NN O
results NN NN O
in NN NN O
a NN NN O
2- NN NN O
to NN NN O
5-fold NN NN O
increase NN NN O
in NN NN O
FMR1 NN NN O
mRNA NN NN O
levels NN NN O
obtained NN NN O
with NN NN O
5-azadC NN NN O
alone NN NN O
, NN NN O
thus NN NN O
showing NN NN O
a NN NN O
marked NN NN O
synergistic NN NN O
effect NN NN O
of NN NN O
histone NN NN O
hyperacetylation NN NN O
and NN NN O
DNA NN NN O
demethylation NN NN O
in NN NN O
the NN NN O
reactivation NN NN O
of NN NN O
FMR1 NN NN O
full NN NN O
mutations NN NN O
. NN NN O

. NN NN O

10554035 NN NN O
Constitutional NN NN O
von NN NN B-Modifier
Hippel-Lindau NN NN I-Modifier
( NN NN O
VHL NN NN B-Modifier
) NN NN O
gene NN NN O
deletions NN NN O
detected NN NN O
in NN NN O
VHL NN NN B-Modifier
families NN NN O
by NN NN O
fluorescence NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
. NN NN O

von NN NN B-SpecificDisease
Hippel-Lindau NN NN I-SpecificDisease
( NN NN I-SpecificDisease
VHL NN NN I-SpecificDisease
) NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
dominantly NN NN I-DiseaseClass
inherited NN NN I-DiseaseClass
cancer NN NN I-DiseaseClass
syndrome NN NN I-DiseaseClass
predisposing NN NN O
to NN NN O
a NN NN O
variety NN NN O
of NN NN O
tumor NN NN B-Modifier
types NN NN O
that NN NN O
include NN NN O
retinal NN NN O
hemangioblastomas NN NN B-DiseaseClass
, NN NN O
hemangioblastomas NN NN B-DiseaseClass
of NN NN O
the NN NN O
central NN NN O
nervous NN NN O
system NN NN O
, NN NN O
renal NN NN B-SpecificDisease
cell NN NN I-SpecificDisease
carcinomas NN NN I-SpecificDisease
, NN NN O
pancreatic NN NN B-CompositeMention
cysts NN NN I-CompositeMention
and NN NN I-CompositeMention
tumors NN NN I-CompositeMention
, NN NN O
pheochromocytomas NN NN B-DiseaseClass
, NN NN O
endolymphatic NN NN B-DiseaseClass
sac NN NN I-DiseaseClass
tumors NN NN I-DiseaseClass
, NN NN O
and NN NN O
epididymal NN NN B-DiseaseClass
cystadenomas NN NN I-DiseaseClass
[ NN NN O
W NN NN O
. NN NN O

M NN NN O
. NN NN O

Linehan NN NN O
et NN NN O
al NN NN O
. NN NN O

, NN NN O
J NN NN O
. NN NN O

Am NN NN O
. NN NN O

Med NN NN O
. NN NN O

Assoc NN NN O
. NN NN O

, NN NN O
273 NN NN O
564-570 NN NN O
, NN NN O
1995 NN NN O
; NN NN O
E NN NN O
. NN NN O

A NN NN O
. NN NN O

Maher NN NN O
and NN NN O
W NN NN O
. NN NN O

G NN NN O
. NN NN O

Kaelin NN NN O
, NN NN O
Jr NN NN O
. NN NN O

, NN NN O
Medicine NN NN O
( NN NN O
Baltimore NN NN O
) NN NN O
, NN NN O
76 NN NN O
381-391 NN NN O
, NN NN O
1997 NN NN O
; NN NN O
W NN NN O
. NN NN O

M NN NN O
. NN NN O

Linehan NN NN O
and NN NN O
R NN NN O
. NN NN O

D NN NN O
. NN NN O

Klausner NN NN O
, NN NN O
In NN NN O
B NN NN O
. NN NN O

Vogelstein NN NN O
and NN NN O
K NN NN O
. NN NN O

Kinzler NN NN O
( NN NN O
eds NN NN O
. NN NN O
) NN NN O

, NN NN O
The NN NN O
Genetic NN NN O
Basis NN NN O
of NN NN O
Human NN NN O
Cancer NN NN O
, NN NN O
pp NN NN O
. NN NN O

455-473 NN NN O
, NN NN O
McGraw-Hill NN NN O
, NN NN O
1998 NN NN O
] NN NN O
. NN NN O

The NN NN O
VHL NN NN B-Modifier
gene NN NN O
was NN NN O
localized NN NN O
to NN NN O
chromosome NN NN O
3p25-26 NN NN O
and NN NN O
cloned NN NN O
[ NN NN O
F NN NN O
. NN NN O

Latif NN NN O
et NN NN O
al NN NN O
. NN NN O

, NN NN O
Science NN NN O
( NN NN O
Washington NN NN O
DC NN NN O
) NN NN O
, NN NN O
260 NN NN O
1317-1320 NN NN O
, NN NN O
1993 NN NN O
] NN NN O
. NN NN O

Germline NN NN O
mutations NN NN O
in NN NN O
the NN NN O
VHL NN NN B-Modifier
gene NN NN O
have NN NN O
been NN NN O
detected NN NN O
in NN NN O
the NN NN O
majority NN NN O
of NN NN O
VHL NN NN B-Modifier
kindreds NN NN O
. NN NN O

The NN NN O
reported NN NN O
frequency NN NN O
of NN NN O
detection NN NN O
of NN NN O
VHL NN NN B-Modifier
germline NN NN O
mutations NN NN O
has NN NN O
varied NN NN O
from NN NN O
39 NN NN O
to NN NN O
80 NN NN O
% NN NN O
( NN NN O
J NN NN O
. NN NN O

M NN NN O
. NN NN O

Whaley NN NN O
et NN NN O
al NN NN O
. NN NN O

, NN NN O
Am NN NN O
. NN NN O

J NN NN O
. NN NN O

Hum NN NN O
. NN NN O

Genet NN NN O
. NN NN O

, NN NN O
55 NN NN O
1092-1102 NN NN O
, NN NN O
1994 NN NN O
; NN NN O
Clinical NN NN O
Research NN NN O
Group NN NN O
for NN NN O
Japan NN NN O
, NN NN O
Hum NN NN O
. NN NN O

Mol NN NN O
. NN NN O

Genet NN NN O
. NN NN O

, NN NN O
4 NN NN O
2233-2237 NN NN O
, NN NN O
1995 NN NN O
; NN NN O
F NN NN O
. NN NN O

Chen NN NN O
et NN NN O
al NN NN O
. NN NN O

, NN NN O
Hum NN NN O
. NN NN O

Mutat NN NN O
. NN NN O

, NN NN O
5 NN NN O
66-75 NN NN O
, NN NN O
1995 NN NN O
; NN NN O
E NN NN O
. NN NN O

R NN NN O
. NN NN O

Maher NN NN O
et NN NN O
al NN NN O
. NN NN O

, NN NN O
J NN NN O
. NN NN O

Med NN NN O
. NN NN O

Genet NN NN O
. NN NN O

, NN NN O
33 NN NN O
328-332 NN NN O
, NN NN O
1996 NN NN O
; NN NN O
B NN NN O
. NN NN O

Zbar NN NN O
, NN NN O
Cancer NN NN O
Surv NN NN O
. NN NN O

, NN NN O
25 NN NN O
219-232 NN NN O
, NN NN O
1995 NN NN O
) NN NN O
. NN NN O

Recently NN NN O
a NN NN O
quantitative NN NN O
Southern NN NN O
blotting NN NN O
procedure NN NN O
was NN NN O
found NN NN O
to NN NN O
improve NN NN O
this NN NN O
frequency NN NN O
( NN NN O
C NN NN O
. NN NN O

Stolle NN NN O
et NN NN O
al NN NN O
. NN NN O

, NN NN O
Hum NN NN O
. NN NN O

Mutat NN NN O
. NN NN O

, NN NN O
12 NN NN O
417-423 NN NN O
, NN NN O
1998 NN NN O
) NN NN O
. NN NN O

In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
we NN NN O
report NN NN O
the NN NN O
use NN NN O
of NN NN O
fluorescence NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
( NN NN O
FISH NN NN O
) NN NN O
as NN NN O
a NN NN O
method NN NN O
to NN NN O
detect NN NN O
and NN NN O
characterize NN NN O
VHL NN NN B-Modifier
germline NN NN O
deletions NN NN O
. NN NN O

We NN NN O
reexamined NN NN O
a NN NN O
group NN NN O
of NN NN O
VHL NN NN B-Modifier
patients NN NN O
shown NN NN O
previously NN NN O
by NN NN O
single-strand NN NN O
conformation NN NN O
and NN NN O
sequencing NN NN O
analysis NN NN O
not NN NN O
to NN NN O
harbor NN NN O
point NN NN O
mutations NN NN O
in NN NN O
the NN NN O
VHL NN NN B-Modifier
locus NN NN O
. NN NN O

We NN NN O
found NN NN O
constitutional NN NN O
deletions NN NN O
in NN NN O
29 NN NN O
of NN NN O
30 NN NN O
VHL NN NN B-Modifier
patients NN NN O
in NN NN O
this NN NN O
group NN NN O
using NN NN O
cosmid NN NN O
and NN NN O
P1 NN NN O
probes NN NN O
that NN NN O
cover NN NN O
the NN NN O
VHL NN NN B-Modifier
locus NN NN O
. NN NN O

We NN NN O
then NN NN O
tested NN NN O
six NN NN O
phenotypically NN NN O
normal NN NN O
offspring NN NN O
from NN NN O
four NN NN O
of NN NN O
these NN NN O
VHL NN NN B-Modifier
families NN NN O
two NN NN O
were NN NN O
found NN NN O
to NN NN O
carry NN NN O
the NN NN O
deletion NN NN O
and NN NN O
the NN NN O
other NN NN O
four NN NN O
were NN NN O
deletion-free NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
germline NN NN O
mosaicism NN NN O
of NN NN O
the NN NN O
VHL NN NN B-Modifier
gene NN NN O
was NN NN O
identified NN NN O
in NN NN O
one NN NN O
family NN NN O
. NN NN O

In NN NN O
sum NN NN O
, NN NN O
FISH NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
a NN NN O
simple NN NN O
and NN NN O
reliable NN NN O
method NN NN O
to NN NN O
detect NN NN O
VHL NN NN B-Modifier
germline NN NN O
deletions NN NN O
and NN NN O
practically NN NN O
useful NN NN O
in NN NN O
cases NN NN O
where NN NN O
other NN NN O
methods NN NN O
of NN NN O
screening NN NN O
have NN NN O
failed NN NN O
to NN NN O
detect NN NN O
a NN NN O
VHL NN NN B-SpecificDisease
gene NN NN I-SpecificDisease
abnormality NN NN I-SpecificDisease

10556283 NN NN O
Spectrum NN NN O
of NN NN O
hSNF5/INI1 NN NN O
somatic NN NN O
mutations NN NN O
in NN NN O
human NN NN O
cancer NN NN B-DiseaseClass
and NN NN O
genotype-phenotype NN NN O
correlations NN NN O
. NN NN O

The NN NN O
hSNF5 NN NN O
/ NN NN O
INI1 NN NN O
gene NN NN O
which NN NN O
encodes NN NN O
a NN NN O
member NN NN O
of NN NN O
the NN NN O
SWI NN NN O
/ NN NN O
SNF NN NN O
chromatin NN NN O
ATP-dependent NN NN O
remodeling NN NN O
complex NN NN O
, NN NN O
is NN NN O
a NN NN O
new NN NN O
tumor NN NN B-Modifier
suppressor NN NN O
gene NN NN O
localized NN NN O
on NN NN O
chromosome NN NN O
22q11 NN NN O
. NN NN O

2 NN NN O
and NN NN O
recently NN NN O
shown NN NN O
to NN NN O
be NN NN O
mutated NN NN O
in NN NN O
malignant NN NN B-DiseaseClass
rhabdoid NN NN I-DiseaseClass
tumors NN NN I-DiseaseClass
. NN NN O

We NN NN O
have NN NN O
searched NN NN O
for NN NN O
hSNF5 NN NN O
/ NN NN O
INI1 NN NN O
mutations NN NN O
in NN NN O
229 NN NN O
tumors NN NN B-DiseaseClass
of NN NN O
various NN NN O
origins NN NN O
using NN NN O
a NN NN O
screening NN NN O
method NN NN O
based NN NN O
on NN NN O
denaturing NN NN O
high-performance NN NN O
liquid NN NN O
chromatography NN NN O
. NN NN O

A NN NN O
total NN NN O
of NN NN O
31 NN NN O
homozygous NN NN O
deletions NN NN O
and NN NN O
36 NN NN O
point NN NN O
alterations NN NN O
were NN NN O
identified NN NN O
. NN NN O

Point NN NN O
mutations NN NN O
were NN NN O
scattered NN NN O
along NN NN O
the NN NN O
coding NN NN O
sequence NN NN O
and NN NN O
included NN NN O
15 NN NN O
nonsense NN NN O
, NN NN O
15 NN NN O
frameshift NN NN O
, NN NN O
three NN NN O
splice NN NN O
site NN NN O
, NN NN O
two NN NN O
missense NN NN O
and NN NN O
one NN NN O
editing NN NN O
mutations NN NN O
. NN NN O

Mutations NN NN O
were NN NN O
retrieved NN NN O
in NN NN O
most NN NN O
rhabdoid NN NN B-DiseaseClass
tumors NN NN I-DiseaseClass
, NN NN O
whatever NN NN O
their NN NN O
sites NN NN O
of NN NN O
occurrence NN NN O
, NN NN O
indicating NN NN O
the NN NN O
common NN NN O
pathogenetic NN NN O
origin NN NN O
of NN NN O
these NN NN O
tumors NN NN B-DiseaseClass
. NN NN O

Recurrent NN NN O
hSNF5 NN NN O
/ NN NN O
INI1 NN NN O
alterations NN NN O
were NN NN O
also NN NN O
observed NN NN O
in NN NN O
choroid NN NN B-SpecificDisease
plexus NN NN I-SpecificDisease
carcinomas NN NN I-SpecificDisease
and NN NN O
in NN NN O
a NN NN O
subset NN NN O
of NN NN O
central NN NN O
primitive NN NN O
neuroectodermal NN NN B-DiseaseClass
tumors NN NN I-DiseaseClass
( NN NN O
cPNETs NN NN O
) NN NN O
and NN NN O
medulloblastomas NN NN B-SpecificDisease
. NN NN O

In NN NN O
contrast NN NN O
, NN NN O
hSNF5 NN NN O
/ NN NN O
INI1 NN NN O
point NN NN O
mutations NN NN O
were NN NN O
not NN NN O
detected NN NN O
in NN NN O
breast NN NN B-SpecificDisease
cancers NN NN I-SpecificDisease
, NN NN O
Wilms NN NN B-SpecificDisease
tumors NN NN I-SpecificDisease
, NN NN O
gliomas NN NN B-SpecificDisease
, NN NN O
ependymomas NN NN B-SpecificDisease
, NN NN O
sarcomas NN NN B-DiseaseClass
and NN NN O
other NN NN O
tumor NN NN B-Modifier
types NN NN O
, NN NN O
even NN NN O
though NN NN O
most NN NN O
analyzed NN NN O
cases NN NN O
harbored NN NN O
loss NN NN O
of NN NN O
heterozygosity NN NN O
at NN NN O
22q11 NN NN O
. NN NN O

2 NN NN O
loci NN NN O
. NN NN O

These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
rhabdoid NN NN B-DiseaseClass
tumors NN NN I-DiseaseClass
, NN NN O
choroid NN NN B-SpecificDisease
plexus NN NN I-SpecificDisease
carcinomas NN NN I-SpecificDisease
and NN NN O
a NN NN O
subset NN NN O
of NN NN O
medulloblastomas NN NN B-SpecificDisease
and NN NN O
cPNETs NN NN O
share NN NN O
common NN NN O
pathways NN NN O
of NN NN O
oncogenesis NN NN O
related NN NN O
to NN NN O
hSNF5 NN NN O
/ NN NN O
INI1 NN NN O
alteration NN NN O
and NN NN O
that NN NN O
hSNF5 NN NN O
/ NN NN O
INI1 NN NN O
mutations NN NN O
define NN NN O
a NN NN O
genetically NN NN O
homogeneous NN NN O
family NN NN O
of NN NN O
highly NN NN O
aggressive NN NN O
cancers NN NN B-DiseaseClass
mainly NN NN O
occurring NN NN O
in NN NN O
young NN NN O
children NN NN O
and NN NN O
frequently NN NN O
, NN NN O
but NN NN O
not NN NN O
always NN NN O
, NN NN O
exhibiting NN NN O
a NN NN O
rhabdoid NN NN B-Modifier
phenotype NN NN O

10556285 NN NN O
Ataxin-3 NN NN O
with NN NN O
an NN NN O
altered NN NN O
conformation NN NN O
that NN NN O
exposes NN NN O
the NN NN O
polyglutamine NN NN O
domain NN NN O
is NN NN O
associated NN NN O
with NN NN O
the NN NN O
nuclear NN NN O
matrix NN NN O
. NN NN O

Spinocerebellar NN NN B-SpecificDisease
ataxia NN NN I-SpecificDisease
type-3 NN NN I-SpecificDisease
or NN NN O
Machado-Joseph NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
SCA3 NN NN B-SpecificDisease
/ NN NN O
MJD NN NN B-SpecificDisease
) NN NN O
is NN NN O
a NN NN O
member NN NN O
of NN NN O
the NN NN O
CAG NN NN B-DiseaseClass
/ NN NN I-DiseaseClass
polyglutamine NN NN I-DiseaseClass
repeat NN NN I-DiseaseClass
disease NN NN I-DiseaseClass
family NN NN O
. NN NN O

In NN NN O
this NN NN O
family NN NN O
of NN NN O
disorders NN NN O
, NN NN O
a NN NN O
normally NN NN O
polymorphic NN NN O
CAG NN NN O
repeat NN NN O
becomes NN NN O
expanded NN NN O
, NN NN O
resulting NN NN O
in NN NN O
expression NN NN O
of NN NN O
an NN NN O
expanded NN NN O
polyglutamine NN NN O
domain NN NN O
in NN NN O
the NN NN O
disease NN NN O
gene NN NN O
product NN NN O
. NN NN O

Experimental NN NN O
models NN NN O
of NN NN O
polyglutamine NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
implicate NN NN O
the NN NN O
nucleus NN NN O
in NN NN O
pathogenesis NN NN O
; NN NN O
however NN NN O
, NN NN O
the NN NN O
link NN NN O
between NN NN O
intranuclear NN NN O
expression NN NN O
of NN NN O
expanded NN NN O
polyglutamine NN NN B-CompositeMention
and NN NN I-CompositeMention
neuronal NN NN I-CompositeMention
dysfunction NN NN I-CompositeMention
remains NN NN O
unclear NN NN O
. NN NN O

Here NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
ataxin-3 NN NN O
, NN NN O
the NN NN O
disease NN NN O
protein NN NN O
in NN NN O
SCA3 NN NN B-SpecificDisease
/ NN NN O
MJD NN NN B-SpecificDisease
, NN NN O
adopts NN NN O
a NN NN O
unique NN NN O
conformation NN NN O
when NN NN O
expressed NN NN O
within NN NN O
the NN NN O
nucleus NN NN O
of NN NN O
transfected NN NN O
cells NN NN O
. NN NN O

The NN NN O
monoclonal NN NN O
antibody NN NN O
1C2 NN NN O
is NN NN O
known NN NN O
preferentially NN NN O
to NN NN O
bind NN NN O
expanded NN NN O
polyglutamine NN NN O
, NN NN O
but NN NN O
we NN NN O
find NN NN O
that NN NN O
it NN NN O
also NN NN O
binds NN NN O
a NN NN O
fragment NN NN O
of NN NN O
ataxin-3 NN NN O
containing NN NN O
a NN NN O
normal NN NN O
glutamine NN NN O
repeat NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
expression NN NN O
of NN NN O
ataxin-3 NN NN O
within NN NN O
the NN NN O
nucleus NN NN O
exposes NN NN O
the NN NN O
glutamine NN NN O
domain NN NN O
of NN NN O
the NN NN O
full-length NN NN O
non-pathological NN NN O
protein NN NN O
, NN NN O
allowing NN NN O
it NN NN O
to NN NN O
bind NN NN O
the NN NN O
monoclonal NN NN O
antibody NN NN O
1C2 NN NN O
. NN NN O

Fractionation NN NN O
and NN NN O
immunochemical NN NN O
experiments NN NN O
indicate NN NN O
that NN NN O
this NN NN O
novel NN NN O
conformation NN NN O
of NN NN O
intranuclear NN NN O
ataxin-3 NN NN O
is NN NN O
not NN NN O
due NN NN O
to NN NN O
proteolysis NN NN O
, NN NN O
suggesting NN NN O
instead NN NN O
that NN NN O
association NN NN O
with NN NN O
nuclear NN NN O
protein NN NN O
( NN NN O
s NN NN O
) NN NN O
alters NN NN O
the NN NN O
structure NN NN O
of NN NN O
full-length NN NN O
ataxin-3 NN NN O
which NN NN O
exposes NN NN O
the NN NN O
polyglutamine NN NN O
domain NN NN O
. NN NN O

This NN NN O
conformationally NN NN O
altered NN NN O
ataxin-3 NN NN O
is NN NN O
bound NN NN O
to NN NN O
the NN NN O
nuclear NN NN O
matrix NN NN O
. NN NN O

The NN NN O
pathological NN NN O
form NN NN O
of NN NN O
ataxin-3 NN NN O
with NN NN O
an NN NN O
expanded NN NN O
polyglutamine NN NN O
domain NN NN O
also NN NN O
associates NN NN O
with NN NN O
the NN NN O
nuclear NN NN O
matrix NN NN O
. NN NN O

These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
an NN NN O
early NN NN O
event NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
SCA3 NN NN B-SpecificDisease
/ NN NN O
MJD NN NN B-SpecificDisease
may NN NN O
be NN NN O
an NN NN O
altered NN NN O
conformation NN NN O
of NN NN O
ataxin-3 NN NN O
within NN NN O
the NN NN O
nucleus NN NN O
that NN NN O
exposes NN NN O
the NN NN O
polyglutamine NN NN O
domain NN NN O
. NN NN O

. NN NN O

10556298 NN NN O
The NN NN O
human NN NN O
MAGEL2 NN NN O
gene NN NN O
and NN NN O
its NN NN O
mouse NN NN O
homologue NN NN O
are NN NN O
paternally NN NN O
expressed NN NN O
and NN NN O
mapped NN NN O
to NN NN O
the NN NN O
Prader-Willi NN NN B-Modifier
region NN NN O
. NN NN O

Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
PWS NN NN B-SpecificDisease
) NN NN O
is NN NN O
a NN NN O
complex NN NN O
neurogenetic NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
. NN NN O

The NN NN O
phenotype NN NN O
is NN NN O
likely NN NN O
to NN NN O
be NN NN O
a NN NN O
contiguous NN NN B-DiseaseClass
gene NN NN I-DiseaseClass
syndrome NN NN I-DiseaseClass
involving NN NN O
genes NN NN O
which NN NN O
are NN NN O
paternally NN NN O
expressed NN NN O
only NN NN O
, NN NN O
located NN NN O
in NN NN O
the NN NN O
human NN NN O
15q11-q13 NN NN O
region NN NN O
. NN NN O

Four NN NN O
mouse NN NN O
models NN NN O
of NN NN O
PWS NN NN B-SpecificDisease
have NN NN O
been NN NN O
reported NN NN O
but NN NN O
these NN NN O
do NN NN O
not NN NN O
definitively NN NN O
allow NN NN O
the NN NN O
delineation NN NN O
of NN NN O
the NN NN O
critical NN NN O
region NN NN O
and NN NN O
the NN NN O
associated NN NN O
genes NN NN O
involved NN NN O
in NN NN O
the NN NN O
aetiology NN NN O
of NN NN O
PWS NN NN B-SpecificDisease
. NN NN O

Moreover NN NN O
, NN NN O
targeted NN NN O
mutagenesis NN NN O
of NN NN O
mouse NN NN O
homologues NN NN O
of NN NN O
the NN NN O
human NN NN O
candidate NN NN O
PWS NN NN B-Modifier
genes NN NN O
does NN NN O
not NN NN O
appear NN NN O
to NN NN O
result NN NN O
in NN NN O
any NN NN O
of NN NN O
the NN NN O
features NN NN O
of NN NN O
PWS NN NN B-SpecificDisease
. NN NN O

Therefore NN NN O
, NN NN O
the NN NN O
isolation NN NN O
of NN NN O
new NN NN O
genes NN NN O
in NN NN O
this NN NN O
region NN NN O
remains NN NN O
crucial NN NN O
for NN NN O
a NN NN O
better NN NN O
understanding NN NN O
of NN NN O
the NN NN O
molecular NN NN O
basis NN NN O
of NN NN O
PWS NN NN B-SpecificDisease
. NN NN O

In NN NN O
this NN NN O
manuscript NN NN O
, NN NN O
we NN NN O
report NN NN O
the NN NN O
characterization NN NN O
of NN NN O
MAGEL2 NN NN O
and NN NN O
its NN NN O
mouse NN NN O
homologue NN NN O
Magel2 NN NN O
. NN NN O

These NN NN O
are NN NN O
located NN NN O
in NN NN O
the NN NN O
human NN NN O
15q11-q13 NN NN O
and NN NN O
mouse NN NN O
7C NN NN O
regions NN NN O
, NN NN O
in NN NN O
close NN NN O
proximity NN NN O
to NN NN O
NDN NN NN O
/ NN NN O
Ndn NN NN O
. NN NN O

By NN NN O
northern NN NN O
blot NN NN O
analysis NN NN O
we NN NN O
did NN NN O
not NN NN O
detect NN NN O
any NN NN O
expression NN NN O
of NN NN O
MAGEL2 NN NN O
/ NN NN O
Magel2 NN NN O
but NN NN O
by NN NN O
RT-PCR NN NN O
analysis NN NN O
, NN NN O
specific NN NN O
expression NN NN O
was NN NN O
detected NN NN O
in NN NN O
fetal NN NN O
and NN NN O
adult NN NN O
brain NN NN O
and NN NN O
in NN NN O
placenta NN NN O
. NN NN O

Both NN NN O
genes NN NN O
are NN NN O
intronless NN NN O
with NN NN O
tandem NN NN O
direct NN NN O
repeat NN NN O
sequences NN NN O
contained NN NN O
within NN NN O
a NN NN O
CpG NN NN O
island NN NN O
in NN NN O
the NN NN O
5-untranscribed NN NN O
region NN NN O
. NN NN O

The NN NN O
transcripts NN NN O
encode NN NN O
putative NN NN O
proteins NN NN O
that NN NN O
are NN NN O
homologous NN NN O
to NN NN O
the NN NN O
MAGE NN NN O
proteins NN NN O
and NN NN O
NDN NN NN O
. NN NN O

Moreover NN NN O
, NN NN O
MAGEL2 NN NN O
/ NN NN O
Magel2 NN NN O
are NN NN O
expressed NN NN O
only NN NN O
from NN NN O
the NN NN O
paternal NN NN O
allele NN NN O
in NN NN O
brain NN NN O
, NN NN O
suggesting NN NN O
a NN NN O
potential NN NN O
role NN NN O
in NN NN O
the NN NN O
aetiology NN NN O
of NN NN O
PWS NN NN B-SpecificDisease
and NN NN O
its NN NN O
mouse NN NN O
model NN NN O
, NN NN O
respectively NN NN O
. NN NN O

. NN NN O

10557309 NN NN O
cDNA NN NN O
microarrays NN NN O
detect NN NN O
activation NN NN O
of NN NN O
a NN NN O
myogenic NN NN O
transcription NN NN O
program NN NN O
by NN NN O
the NN NN O
PAX3-FKHR NN NN O
fusion NN NN O
oncogene NN NN O
. NN NN O

Alveolar NN NN B-SpecificDisease
rhabdomyosarcoma NN NN I-SpecificDisease
is NN NN O
an NN NN O
aggressive NN NN O
pediatric NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
of NN NN I-SpecificDisease
striated NN NN I-SpecificDisease
muscle NN NN I-SpecificDisease
characterized NN NN O
in NN NN O
60 NN NN O
% NN NN O
of NN NN O
cases NN NN O
by NN NN O
a NN NN O
t NN NN O
( NN NN O
2 NN NN O
; NN NN O
13 NN NN O
) NN NN O
( NN NN O
q35 NN NN O
; NN NN O
q14 NN NN O
) NN NN O
. NN NN O

This NN NN O
results NN NN O
in NN NN O
the NN NN O
fusion NN NN O
of NN NN O
PAX3 NN NN O
, NN NN O
a NN NN O
developmental NN NN O
transcription NN NN O
factor NN NN O
required NN NN O
for NN NN O
limb NN NN O
myogenesis NN NN O
, NN NN O
with NN NN O
FKHR NN NN O
, NN NN O
a NN NN O
member NN NN O
of NN NN O
the NN NN O
forkhead NN NN O
family NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
. NN NN O

The NN NN O
resultant NN NN O
PAX3-FKHR NN NN O
gene NN NN O
possesses NN NN O
transforming NN NN O
properties NN NN O
; NN NN O
however NN NN O
, NN NN O
the NN NN O
effects NN NN O
of NN NN O
this NN NN O
chimeric NN NN O
oncogene NN NN O
on NN NN O
gene NN NN O
expression NN NN O
are NN NN O
largely NN NN O
unknown NN NN O
. NN NN O

To NN NN O
investigate NN NN O
the NN NN O
actions NN NN O
of NN NN O
these NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
both NN NN O
Pax3 NN NN O
and NN NN O
PAX3-FKHR NN NN O
were NN NN O
introduced NN NN O
into NN NN O
NIH NN NN O
3T3 NN NN O
cells NN NN O
, NN NN O
and NN NN O
the NN NN O
resultant NN NN O
gene NN NN O
expression NN NN O
changes NN NN O
were NN NN O
analyzed NN NN O
with NN NN O
a NN NN O
murine NN NN O
cDNA NN NN O
microarray NN NN O
containing NN NN O
2 NN NN O
, NN NN O
225 NN NN O
elements NN NN O
. NN NN O

We NN NN O
found NN NN O
that NN NN O
PAX3-FKHR NN NN O
but NN NN O
not NN NN O
PAX3 NN NN O
activated NN NN O
a NN NN O
myogenic NN NN O
transcription NN NN O
program NN NN O
including NN NN O
the NN NN O
induction NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
MyoD NN NN O
, NN NN O
Myogenin NN NN O
, NN NN O
Six1 NN NN O
, NN NN O
and NN NN O
Slug NN NN O
as NN NN O
well NN NN O
as NN NN O
a NN NN O
battery NN NN O
of NN NN O
genes NN NN O
involved NN NN O
in NN NN O
several NN NN O
aspects NN NN O
of NN NN O
muscle NN NN O
function NN NN O
. NN NN O

Notable NN NN O
among NN NN O
this NN NN O
group NN NN O
were NN NN O
the NN NN O
growth NN NN O
factor NN NN O
gene NN NN O
Igf2 NN NN O
and NN NN O
its NN NN O
binding NN NN O
protein NN NN O
Igfbp5 NN NN O
. NN NN O

Relevance NN NN O
of NN NN O
this NN NN O
model NN NN O
was NN NN O
suggested NN NN O
by NN NN O
verification NN NN O
that NN NN O
three NN NN O
of NN NN O
these NN NN O
genes NN NN O
( NN NN O
IGFBP5 NN NN O
, NN NN O
HSIX1 NN NN O
, NN NN O
and NN NN O
Slug NN NN O
) NN NN O
were NN NN O
also NN NN O
expressed NN NN O
in NN NN O
alveolar NN NN B-Modifier
rhabdomyosarcoma NN NN I-Modifier
cell NN NN O
lines NN NN O
. NN NN O

This NN NN O
study NN NN O
utilizes NN NN O
cDNA NN NN O
microarrays NN NN O
to NN NN O
elucidate NN NN O
the NN NN O
pattern NN NN O
of NN NN O
gene NN NN O
expression NN NN O
induced NN NN O
by NN NN O
an NN NN O
oncogenic NN NN O
transcription NN NN O
factor NN NN O
and NN NN O
demonstrates NN NN O
the NN NN O
profound NN NN O
myogenic NN NN O
properties NN NN O
of NN NN O
PAX3-FKHR NN NN O
in NN NN O
NIH NN NN O
3T3 NN NN O
cells NN NN O
. NN NN O

. NN NN O

10557317 NN NN O
Experimental NN NN O
hemochromatosis NN NN B-SpecificDisease
due NN NN O
to NN NN O
MHC NN NN O
class NN NN O
I NN NN O
HFE NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
: NN NN O
immune NN NN O
status NN NN O
and NN NN O
iron NN NN O
metabolism NN NN O
. NN NN O

The NN NN O
puzzling NN NN O
linkage NN NN O
between NN NN O
genetic NN NN O
hemochromatosis NN NN B-SpecificDisease
and NN NN O
histocompatibility NN NN O
loci NN NN O
became NN NN O
even NN NN O
more NN NN O
so NN NN O
when NN NN O
the NN NN O
gene NN NN O
involved NN NN O
, NN NN O
HFE NN NN O
, NN NN O
was NN NN O
identified NN NN O
. NN NN O

Indeed NN NN O
, NN NN O
within NN NN O
the NN NN O
well NN NN O
defined NN NN O
, NN NN O
mainly NN NN O
peptide-binding NN NN O
, NN NN O
MHC NN NN O
class NN NN O
I NN NN O
family NN NN O
of NN NN O
molecules NN NN O
, NN NN O
HFE NN NN O
seems NN NN O
to NN NN O
perform NN NN O
an NN NN O
unusual NN NN O
yet NN NN O
essential NN NN O
function NN NN O
. NN NN O

As NN NN O
yet NN NN O
, NN NN O
our NN NN O
understanding NN NN O
of NN NN O
HFE NN NN O
function NN NN O
in NN NN O
iron NN NN O
homeostasis NN NN O
is NN NN O
only NN NN O
partial NN NN O
; NN NN O
an NN NN O
even NN NN O
more NN NN O
open NN NN O
question NN NN O
is NN NN O
its NN NN O
possible NN NN O
role NN NN O
in NN NN O
the NN NN O
immune NN NN O
system NN NN O
. NN NN O

To NN NN O
advance NN NN O
on NN NN O
both NN NN O
of NN NN O
these NN NN O
avenues NN NN O
, NN NN O
we NN NN O
report NN NN O
the NN NN O
deletion NN NN O
of NN NN O
HFE NN NN O
alpha1 NN NN O
and NN NN O
alpha2 NN NN O
putative NN NN O
ligand NN NN O
binding NN NN O
domains NN NN O
in NN NN O
vivo NN NN O
. NN NN O

HFE-deficient NN NN B-Modifier
animals NN NN O
were NN NN O
analyzed NN NN O
for NN NN O
a NN NN O
comprehensive NN NN O
set NN NN O
of NN NN O
metabolic NN NN O
and NN NN O
immune NN NN O
parameters NN NN O
. NN NN O

Faithfully NN NN O
mimicking NN NN O
human NN NN O
hemochromatosis NN NN B-SpecificDisease
, NN NN O
mice NN NN O
homozygous NN NN O
for NN NN O
this NN NN O
deletion NN NN O
develop NN NN O
iron NN NN O
overload NN NN O
, NN NN O
characterized NN NN O
by NN NN O
a NN NN O
higher NN NN O
plasma NN NN O
iron NN NN O
content NN NN O
and NN NN O
a NN NN O
raised NN NN O
transferrin NN NN O
saturation NN NN O
as NN NN O
well NN NN O
as NN NN O
an NN NN O
elevated NN NN O
hepatic NN NN O
iron NN NN O
load NN NN O
. NN NN O

The NN NN O
primary NN NN O
defect NN NN O
could NN NN O
, NN NN O
indeed NN NN O
, NN NN O
be NN NN O
traced NN NN O
to NN NN O
an NN NN O
augmented NN NN O
duodenal NN NN O
iron NN NN O
absorption NN NN O
. NN NN O

In NN NN O
parallel NN NN O
, NN NN O
measurement NN NN O
of NN NN O
the NN NN O
gut NN NN O
mucosal NN NN O
iron NN NN O
content NN NN O
as NN NN O
well NN NN O
as NN NN O
iron NN NN O
regulatory NN NN O
proteins NN NN O
allows NN NN O
a NN NN O
more NN NN O
informed NN NN O
evaluation NN NN O
of NN NN O
various NN NN O
hypotheses NN NN O
regarding NN NN O
the NN NN O
precise NN NN O
role NN NN O
of NN NN O
HFE NN NN O
in NN NN O
iron NN NN O
homeostasis NN NN O
. NN NN O

Finally NN NN O
, NN NN O
an NN NN O
extensive NN NN O
phenotyping NN NN O
of NN NN O
primary NN NN O
and NN NN O
secondary NN NN O
lymphoid NN NN O
organs NN NN O
including NN NN O
the NN NN O
gut NN NN O
provides NN NN O
no NN NN O
compelling NN NN O
evidence NN NN O
for NN NN O
an NN NN O
obvious NN NN O
immune-linked NN NN O
function NN NN O
for NN NN O
HFE NN NN O
. NN NN O

. NN NN O

1056013 NN NN O
Somatic NN NN O
rearrangement NN NN O
of NN NN O
chromosome NN NN O
14 NN NN O
in NN NN O
human NN NN O
lymphocytes NN NN O
. NN NN O

Ataxia-telangiectasia NN NN B-SpecificDisease
is NN NN O
a NN NN O
rare NN NN O
genetic NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
associated NN NN O
with NN NN O
immune NN NN B-DiseaseClass
deficiency NN NN I-DiseaseClass
, NN NN O
chromosome NN NN B-DiseaseClass
instability NN NN I-DiseaseClass
, NN NN O
and NN NN O
a NN NN O
predisposition NN NN O
to NN NN O
lymphoid NN NN B-SpecificDisease
malignancy NN NN I-SpecificDisease
. NN NN O

We NN NN O
have NN NN O
detected NN NN O
chromosomally NN NN O
anomalous NN NN O
clones NN NN O
of NN NN O
lymphocytes NN NN O
in NN NN O
eight NN NN O
patients NN NN O
with NN NN O
this NN NN O
disorder NN NN O
. NN NN O

Chromosome NN NN O
banding NN NN O
disclosed NN NN O
that NN NN O
the NN NN O
clones NN NN O
are NN NN O
consistently NN NN O
marked NN NN O
by NN NN O
structural NN NN O
rearrangement NN NN O
of NN NN O
the NN NN O
long NN NN O
arm NN NN O
( NN NN O
q NN NN O
) NN NN O
of NN NN O
chromosome NN NN O
14 NN NN O
. NN NN O

A NN NN O
translocation NN NN O
involving NN NN O
14q NN NN O
was NN NN O
found NN NN O
in NN NN O
clones NN NN O
obtained NN NN O
from NN NN O
seven NN NN O
of NN NN O
the NN NN O
eight NN NN O
patients NN NN O
whereas NN NN O
a NN NN O
ring NN NN O
14 NN NN O
chromosome NN NN O
was NN NN O
found NN NN O
in NN NN O
a NN NN O
clone NN NN O
obtained NN NN O
from NN NN O
the NN NN O
other NN NN O
. NN NN O

These NN NN O
findings NN NN O
as NN NN O
well NN NN O
as NN NN O
data NN NN O
obtained NN NN O
by NN NN O
others NN NN O
for NN NN O
patients NN NN O
with NN NN O
ataxia-telangiectasia NN NN B-SpecificDisease
suggest NN NN O
that NN NN O
structural NN NN O
rearrangement NN NN O
of NN NN O
14q NN NN O
is NN NN O
the NN NN O
initial NN NN O
chromosomal NN NN O
change NN NN O
in NN NN O
lymphocyte NN NN O
clones NN NN O
of NN NN O
patients NN NN O
with NN NN O
this NN NN O
disorder NN NN O
. NN NN O

Chromosomes NN NN O
of NN NN O
lymphocytes NN NN O
from NN NN O
one NN NN O
of NN NN O
the NN NN O
patients NN NN O
were NN NN O
studied NN NN O
before NN NN O
and NN NN O
after NN NN O
the NN NN O
onset NN NN O
of NN NN O
chronic NN NN B-SpecificDisease
lymphocytic NN NN I-SpecificDisease
leukemia NN NN I-SpecificDisease
. NN NN O

Before NN NN O
leukemia NN NN B-DiseaseClass
was NN NN O
diagnosed NN NN O
, NN NN O
the NN NN O
patient NN NN O
had NN NN O
a NN NN O
lymphocyte NN NN O
clone NN NN O
with NN NN O
a NN NN O
14q NN NN O
translocation NN NN O
. NN NN O

This NN NN O
clone NN NN O
appears NN NN O
to NN NN O
have NN NN O
given NN NN O
rise NN NN O
to NN NN O
the NN NN O
leukemic NN NN B-Modifier
cells NN NN O
. NN NN O

We NN NN O
hypothesize NN NN O
that NN NN O
structural NN NN O
rearrangement NN NN O
of NN NN O
14q NN NN O
is NN NN O
directly NN NN O
related NN NN O
to NN NN O
abnormal NN NN O
growth NN NN O
of NN NN O
lymphocytes NN NN O
and NN NN O
that NN NN O
it NN NN O
may NN NN O
be NN NN O
a NN NN O
step NN NN O
toward NN NN O
the NN NN O
development NN NN O
of NN NN O
lymphoid NN NN B-SpecificDisease
malignancies NN NN I-SpecificDisease
. NN NN O

Increasing NN NN O
evidence NN NN O
, NN NN O
provided NN NN O
by NN NN O
others NN NN O
, NN NN O
for NN NN O
the NN NN O
nonrandom NN NN O
involvement NN NN O
of NN NN O
14q NN NN O
in NN NN O
African-type NN NN O
Burkitts NN NN B-SpecificDisease
lymphoma NN NN I-SpecificDisease
and NN NN O
other NN NN O
lymphoid NN NN B-DiseaseClass
neoplasms NN NN I-DiseaseClass
further NN NN O
strengthens NN NN O
this NN NN O
hypothesis NN NN O
. NN NN O

. NN NN O

10571943 NN NN O
Exon NN NN O
9 NN NN O
mutations NN NN O
in NN NN O
the NN NN O
WT1 NN NN O
gene NN NN O
, NN NN O
without NN NN O
influencing NN NN O
KTS NN NN O
splice NN NN O
isoforms NN NN O
, NN NN O
are NN NN O
also NN NN O
responsible NN NN O
for NN NN O
Frasier NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

We NN NN O
report NN NN O
new NN NN O
mutations NN NN O
in NN NN O
exon NN NN O
9 NN NN O
of NN NN O
the NN NN O
WT1 NN NN O
gene NN NN O
that NN NN O
did NN NN O
not NN NN O
alter NN NN O
the NN NN O
ratio NN NN O
of NN NN O
+ NN NN O
/ NN NN O
- NN NN O
KTS NN NN O
splice NN NN O
isoforms NN NN O
in NN NN O
two NN NN O
unrelated NN NN O
patients NN NN O
with NN NN O
Frasier NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
FS NN NN B-SpecificDisease
) NN NN O
. NN NN O

The NN NN O
mutation NN NN O
of NN NN O
intron NN NN O
9 NN NN O
inducing NN NN O
defective NN NN O
alternative NN NN O
splicing NN NN O
was NN NN O
reported NN NN O
to NN NN O
be NN NN O
responsible NN NN O
for NN NN O
this NN NN O
syndrome NN NN O
. NN NN O

The NN NN O
mutations NN NN O
found NN NN O
in NN NN O
our NN NN O
cases NN NN O
occurred NN NN O
in NN NN O
the NN NN O
same NN NN O
exon NN NN O
of NN NN O
the NN NN O
WT1 NN NN O
gene NN NN O
as NN NN O
detected NN NN O
in NN NN O
Denys-Drash NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
DDS NN NN B-SpecificDisease
) NN NN O
and NN NN O
could NN NN O
not NN NN O
be NN NN O
explained NN NN O
by NN NN O
the NN NN O
previously NN NN O
proposed NN NN O
mechanism NN NN O
. NN NN O

The NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
two NN NN O
syndromes NN NN O
originate NN NN O
from NN NN O
the NN NN O
same NN NN O
WT1 NN NN B-SpecificDisease
gene NN NN I-SpecificDisease
abnormality NN NN I-SpecificDisease
. NN NN O

From NN NN O
a NN NN O
molecular NN NN O
biological NN NN O
point NN NN O
of NN NN O
view NN NN O
, NN NN O
we NN NN O
concluded NN NN O
that NN NN O
the NN NN O
two NN NN O
diseases NN NN O
were NN NN O
not NN NN O
separable NN NN O
, NN NN O
and NN NN O
that NN NN O
FS NN NN B-SpecificDisease
should NN NN O
be NN NN O
included NN NN O
as NN NN O
an NN NN O
atypical NN NN O
form NN NN O
of NN NN O
DDS NN NN B-SpecificDisease
. NN NN O

. NN NN O

10571950 NN NN O
Splice-site NN NN O
mutation NN NN O
in NN NN O
the NN NN O
PDS NN NN B-Modifier
gene NN NN O
may NN NN O
result NN NN O
in NN NN O
intrafamilial NN NN O
variability NN NN O
for NN NN O
deafness NN NN B-SpecificDisease
in NN NN O
Pendred NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

Pendred NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
is NN NN O
a NN NN O
recessive NN NN B-DiseaseClass
inherited NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
that NN NN O
consists NN NN O
of NN NN O
developmental NN NN O
abnormalities NN NN B-DiseaseClass
of NN NN I-DiseaseClass
the NN NN I-DiseaseClass
cochlea NN NN I-DiseaseClass
, NN NN O
sensorineural NN NN B-SpecificDisease
hearing NN NN I-SpecificDisease
loss NN NN I-SpecificDisease
, NN NN O
and NN NN O
diffuse NN NN B-SpecificDisease
thyroid NN NN I-SpecificDisease
enlargement NN NN I-SpecificDisease
( NN NN O
goiter NN NN B-SpecificDisease
) NN NN O
. NN NN O

This NN NN O
disorder NN NN O
may NN NN O
account NN NN O
for NN NN O
up NN NN O
to NN NN O
10 NN NN O
% NN NN O
of NN NN O
cases NN NN O
of NN NN O
hereditary NN NN B-SpecificDisease
deafness NN NN I-SpecificDisease
. NN NN O

The NN NN O
disease NN NN O
gene NN NN O
( NN NN O
PDS NN NN B-SpecificDisease
) NN NN O
has NN NN O
been NN NN O
mapped NN NN O
to NN NN O
chromosome NN NN O
7q22-q31 NN NN O
, NN NN O
and NN NN O
encodes NN NN O
a NN NN O
chloride-iodide NN NN O
transport NN NN O
protein NN NN O
. NN NN O

We NN NN O
performed NN NN O
mutation NN NN O
analysis NN NN O
of NN NN O
individual NN NN O
exons NN NN O
of NN NN O
the NN NN O
PDS NN NN B-Modifier
gene NN NN O
in NN NN O
one NN NN O
Spanish NN NN O
family NN NN O
that NN NN O
shows NN NN O
intrafamilial NN NN O
variability NN NN O
of NN NN O
the NN NN O
deafness NN NN B-Modifier
phenotype NN NN O
( NN NN O
two NN NN O
patients NN NN O
with NN NN O
profound NN NN O
and NN NN O
one NN NN O
with NN NN O
moderate-severe NN NN O
deafness NN NN B-SpecificDisease
) NN NN O
. NN NN O

We NN NN O
identified NN NN O
a NN NN O
new NN NN O
splice-site NN NN O
mutation NN NN O
affecting NN NN O
intron NN NN O
4 NN NN O
of NN NN O
the NN NN O
PDS NN NN B-Modifier
gene NN NN O
, NN NN O
at NN NN O
nucleotide NN NN O
position NN NN O
639 NN NN O
+ NN NN O
7 NN NN O
. NN NN O

RNA NN NN O
analysis NN NN O
from NN NN O
lymphocytes NN NN O
of NN NN O
the NN NN O
affected NN NN O
patients NN NN O
showed NN NN O
that NN NN O
mutation NN NN O
639 NN NN O
+ NN NN O
7A NN NN O
-- NN NN O
G NN NN O
generates NN NN O
a NN NN O
new NN NN O
donor NN NN O
splice NN NN O
site NN NN O
, NN NN O
leading NN NN O
to NN NN O
an NN NN O
mRNA NN NN O
with NN NN O
an NN NN O
insertion NN NN O
of NN NN O
six NN NN O
nucleotides NN NN O
from NN NN O
intron NN NN O
4 NN NN O
of NN NN O
PDS NN NN O
. NN NN O

Since NN NN O
the NN NN O
newly NN NN O
created NN NN O
donor NN NN O
splice NN NN O
site NN NN O
is NN NN O
likely NN NN O
to NN NN O
compete NN NN O
with NN NN O
the NN NN O
normal NN NN O
one NN NN O
, NN NN O
variations NN NN O
of NN NN O
the NN NN O
levels NN NN O
of NN NN O
normal NN NN O
and NN NN O
aberrant NN NN O
transcripts NN NN O
of NN NN O
the NN NN O
PDS NN NN B-Modifier
gene NN NN O
in NN NN O
the NN NN O
cochlea NN NN O
may NN NN O
explain NN NN O
the NN NN O
variability NN NN O
in NN NN O
the NN NN O
deafness NN NN B-Modifier
presentation NN NN O
. NN NN O

. NN NN O

10577908 NN NN O
The NN NN O
molecular NN NN O
basis NN NN O
of NN NN O
Sjogren-Larsson NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
: NN NN O
mutation NN NN O
analysis NN NN O
of NN NN O
the NN NN O
fatty NN NN O
aldehyde NN NN O
dehydrogenase NN NN O
gene NN NN O
. NN NN O

Sjogren-Larsson NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
SLS NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
characterized NN NN O
by NN NN O
ichthyosis NN NN B-DiseaseClass
, NN NN O
mental NN NN B-DiseaseClass
retardation NN NN I-DiseaseClass
, NN NN O
spasticity NN NN B-DiseaseClass
, NN NN O
and NN NN O
deficient NN NN B-SpecificDisease
activity NN NN I-SpecificDisease
of NN NN I-SpecificDisease
fatty NN NN I-SpecificDisease
aldehyde NN NN I-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
( NN NN O
FALDH NN NN O
) NN NN O
. NN NN O

To NN NN O
define NN NN O
the NN NN O
molecular NN NN O
defects NN NN O
causing NN NN O
SLS NN NN B-SpecificDisease
, NN NN O
we NN NN O
performed NN NN O
mutation NN NN O
analysis NN NN O
of NN NN O
the NN NN O
FALDH NN NN O
gene NN NN O
in NN NN O
probands NN NN O
from NN NN O
63 NN NN O
kindreds NN NN O
with NN NN O
SLS NN NN B-SpecificDisease
. NN NN O

Among NN NN O
these NN NN O
patients NN NN O
, NN NN O
49 NN NN O
different NN NN O
mutations-including NN NN O
10 NN NN O
deletions NN NN O
, NN NN O
2 NN NN O
insertions NN NN O
, NN NN O
22 NN NN O
amino NN NN O
acid NN NN O
substitutions NN NN O
, NN NN O
3 NN NN O
nonsense NN NN O
mutations NN NN O
, NN NN O
9 NN NN O
splice-site NN NN O
defects NN NN O
, NN NN O
and NN NN O
3 NN NN O
complex NN NN O
mutations-were NN NN O
found NN NN O
. NN NN O

All NN NN O
of NN NN O
the NN NN O
patients NN NN O
with NN NN O
SLS NN NN B-SpecificDisease
were NN NN O
found NN NN O
to NN NN O
carry NN NN O
mutations NN NN O
. NN NN O

Nineteen NN NN O
of NN NN O
the NN NN O
missense NN NN O
mutations NN NN O
resulted NN NN O
in NN NN O
a NN NN O
severe NN NN O
reduction NN NN O
of NN NN O
FALDH NN NN O
enzyme NN NN O
catalytic NN NN O
activity NN NN O
when NN NN O
expressed NN NN O
in NN NN O
mammalian NN NN O
cells NN NN O
, NN NN O
but NN NN O
one NN NN O
mutation NN NN O
( NN NN O
798G NN NN O
-- NN NN O
C NN NN O
[ NN NN O
K266N NN NN O
] NN NN O
) NN NN O
seemed NN NN O
to NN NN O
have NN NN O
a NN NN O
greater NN NN O
effect NN NN O
on NN NN O
mRNA NN NN O
stability NN NN O
. NN NN O

The NN NN O
splice-site NN NN O
mutations NN NN O
led NN NN O
to NN NN O
exon NN NN O
skipping NN NN O
or NN NN O
utilization NN NN O
of NN NN O
cryptic NN NN O
acceptor-splice NN NN O
sites NN NN O
. NN NN O

Thirty-seven NN NN O
mutations NN NN O
were NN NN O
private NN NN O
, NN NN O
and NN NN O
12 NN NN O
mutations NN NN O
were NN NN O
seen NN NN O
in NN NN O
two NN NN O
or NN NN O
more NN NN O
probands NN NN O
of NN NN O
European NN NN O
or NN NN O
Middle NN NN O
Eastern NN NN O
descent NN NN O
. NN NN O

Four NN NN O
single-nucleotide NN NN O
polymorphisms NN NN O
( NN NN O
SNPs NN NN O
) NN NN O
were NN NN O
found NN NN O
in NN NN O
the NN NN O
FALDH NN NN O
gene NN NN O
. NN NN O

At NN NN O
least NN NN O
four NN NN O
of NN NN O
the NN NN O
common NN NN O
mutations NN NN O
( NN NN O
551C NN NN O
-- NN NN O
T NN NN O
, NN NN O
682C NN NN O
-- NN NN O
T NN NN O
, NN NN O
733G NN NN O
-- NN NN O
A NN NN O
, NN NN O
and NN NN O
798 NN NN O
+ NN NN O
1delG NN NN O
) NN NN O
were NN NN O
associated NN NN O
with NN NN O
multiple NN NN O
SNP NN NN O
haplotypes NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
these NN NN O
mutations NN NN O
originated NN NN O
independently NN NN O
on NN NN O
more NN NN O
than NN NN O
one NN NN O
occasion NN NN O
or NN NN O
were NN NN O
ancient NN NN O
SLS NN NN B-Modifier
genes NN NN O
that NN NN O
had NN NN O
undergone NN NN O
intragenic NN NN O
recombination NN NN O
. NN NN O

Our NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
SLS NN NN B-SpecificDisease
is NN NN O
caused NN NN O
by NN NN O
a NN NN O
strikingly NN NN O
heterogeneous NN NN O
group NN NN O
of NN NN O
mutations NN NN O
in NN NN O
the NN NN O
FALDH NN NN O
gene NN NN O
and NN NN O
provide NN NN O
a NN NN O
framework NN NN O
for NN NN O
understanding NN NN O
the NN NN O
genetic NN NN O
basis NN NN O
of NN NN O
SLS NN NN B-SpecificDisease
and NN NN O
the NN NN O
development NN NN O
of NN NN O
DNA-based NN NN O
diagnostic NN NN O
tests NN NN O
. NN NN O

. NN NN O

10581027 NN NN O
Loss-of-function NN NN O
mutations NN NN O
in NN NN O
the NN NN O
cathepsin NN NN O
C NN NN O
gene NN NN O
result NN NN O
in NN NN O
periodontal NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
and NN NN O
palmoplantar NN NN B-DiseaseClass
keratosis NN NN I-DiseaseClass
. NN NN O

Papillon-Lefevre NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
, NN NN O
or NN NN O
keratosis NN NN B-DiseaseClass
palmoplantaris NN NN I-DiseaseClass
with NN NN O
periodontopathia NN NN B-SpecificDisease
( NN NN O
PLS NN NN B-SpecificDisease
, NN NN O
MIM NN NN O
245000 NN NN O
) NN NN O
, NN NN O
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
that NN NN O
is NN NN O
mainly NN NN O
ascertained NN NN O
by NN NN O
dentists NN NN O
because NN NN O
of NN NN O
the NN NN O
severe NN NN O
periodontitis NN NN B-SpecificDisease
that NN NN O
afflicts NN NN O
patients NN NN O
. NN NN O

Both NN NN O
the NN NN O
deciduous NN NN O
and NN NN O
permanent NN NN O
dentitions NN NN O
are NN NN O
affected NN NN O
, NN NN O
resulting NN NN O
in NN NN O
premature NN NN O
tooth NN NN B-SpecificDisease
loss NN NN I-SpecificDisease
. NN NN O

Palmoplantar NN NN B-DiseaseClass
keratosis NN NN I-DiseaseClass
, NN NN O
varying NN NN O
from NN NN O
mild NN NN O
psoriasiform NN NN O
scaly NN NN O
skin NN NN O
to NN NN O
overt NN NN O
hyperkeratosis NN NN B-SpecificDisease
, NN NN O
typically NN NN O
develops NN NN O
within NN NN O
the NN NN O
first NN NN O
three NN NN O
years NN NN O
of NN NN O
life NN NN O
. NN NN O

Keratosis NN NN B-SpecificDisease
also NN NN O
affects NN NN O
other NN NN O
sites NN NN O
such NN NN O
as NN NN O
elbows NN NN O
and NN NN O
knees NN NN O
. NN NN O

Most NN NN O
PLS NN NN B-Modifier
patients NN NN O
display NN NN O
both NN NN O
periodontitis NN NN B-SpecificDisease
and NN NN O
hyperkeratosis NN NN B-SpecificDisease
. NN NN O

Some NN NN O
patients NN NN O
have NN NN O
only NN NN O
palmoplantar NN NN B-DiseaseClass
keratosis NN NN I-DiseaseClass
or NN NN O
periodontitis NN NN B-SpecificDisease
, NN NN O
and NN NN O
in NN NN O
rare NN NN O
individuals NN NN O
the NN NN O
periodontitis NN NN B-SpecificDisease
is NN NN O
mild NN NN O
and NN NN O
of NN NN O
late NN NN O
onset NN NN O
. NN NN O

The NN NN O
PLS NN NN O
locus NN NN O
has NN NN O
been NN NN O
mapped NN NN O
to NN NN O
chromosome NN NN O
11q14-q21 NN NN O
( NN NN O
refs NN NN O
7 NN NN O
, NN NN O
8 NN NN O
, NN NN O
9 NN NN O
) NN NN O
. NN NN O

Using NN NN O
homozygosity NN NN O
mapping NN NN O
in NN NN O
eight NN NN O
small NN NN O
consanguineous NN NN O
families NN NN O
, NN NN O
we NN NN O
have NN NN O
narrowed NN NN O
the NN NN O
candidate NN NN O
region NN NN O
to NN NN O
a NN NN O
1 NN NN O
. NN NN O

2-cM NN NN O
interval NN NN O
between NN NN O
D11S4082 NN NN O
and NN NN O
D11S931 NN NN O
. NN NN O

The NN NN O
gene NN NN O
( NN NN O
CTSC NN NN O
) NN NN O
encoding NN NN O
the NN NN O
lysosomal NN NN O
protease NN NN O
cathepsin NN NN O
C NN NN O
( NN NN O
or NN NN O
dipeptidyl NN NN O
aminopeptidase NN NN O
I NN NN O
) NN NN O
lies NN NN O
within NN NN O
this NN NN O
interval NN NN O
. NN NN O

We NN NN O
defined NN NN O
the NN NN O
genomic NN NN O
structure NN NN O
of NN NN O
CTSC NN NN O
and NN NN O
found NN NN O
mutations NN NN O
in NN NN O
all NN NN O
eight NN NN O
families NN NN O
. NN NN O

In NN NN O
two NN NN O
of NN NN O
these NN NN O
families NN NN O
we NN NN O
used NN NN O
a NN NN O
functional NN NN O
assay NN NN O
to NN NN O
demonstrate NN NN O
an NN NN O
almost NN NN O
total NN NN O
loss NN NN O
of NN NN O
cathepsin NN NN O
C NN NN O
activity NN NN O
in NN NN O
PLS NN NN B-Modifier
patients NN NN O
and NN NN O
reduced NN NN O
activity NN NN O
in NN NN O
obligate NN NN O
carriers NN NN O
. NN NN O

10589394 NN NN O
Confirmation NN NN O
of NN NN O
linkage NN NN O
of NN NN O
Van NN NN B-SpecificDisease
der NN NN I-SpecificDisease
Woude NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
to NN NN O
chromosome NN NN O
1q32 NN NN O
: NN NN O
evidence NN NN O
of NN NN O
association NN NN O
with NN NN O
STR NN NN O
alleles NN NN O
suggests NN NN O
possible NN NN O
unique NN NN O
origin NN NN O
of NN NN O
the NN NN O
disease NN NN O
mutation NN NN O
. NN NN O

Van NN NN B-SpecificDisease
der NN NN I-SpecificDisease
Woude NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
VWS NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
dominant NN NN I-DiseaseClass
craniofacial NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
with NN NN O
high NN NN O
penetrance NN NN O
and NN NN O
variable NN NN O
expression NN NN O
. NN NN O

Its NN NN O
clinical NN NN O
features NN NN O
are NN NN O
variably NN NN O
expressed NN NN O
, NN NN O
but NN NN O
include NN NN O
cleft NN NN B-SpecificDisease
lip NN NN I-SpecificDisease
and NN NN O
/ NN NN O
or NN NN O
cleft NN NN B-SpecificDisease
palate NN NN I-SpecificDisease
, NN NN O
lip NN NN B-SpecificDisease
pits NN NN I-SpecificDisease
and NN NN O
hypodontia NN NN B-SpecificDisease
. NN NN O

All NN NN O
VWS NN NN B-Modifier
families NN NN O
studied NN NN O
to NN NN O
date NN NN O
map NN NN O
the NN NN O
disease NN NN O
gene NN NN O
to NN NN O
a NN NN O
2 NN NN O
cM NN NN O
region NN NN O
of NN NN O
chromosome NN NN O
1q32 NN NN O
, NN NN O
with NN NN O
no NN NN O
evidence NN NN O
of NN NN O
locus NN NN O
heterogeneity NN NN O
. NN NN O

The NN NN O
aim NN NN O
of NN NN O
this NN NN O
study NN NN O
is NN NN O
to NN NN O
refine NN NN O
the NN NN O
localization NN NN O
of NN NN O
the NN NN O
VWS NN NN B-Modifier
gene NN NN O
and NN NN O
to NN NN O
further NN NN O
assess NN NN O
possible NN NN O
heterogeneity NN NN O
. NN NN O

We NN NN O
analyzed NN NN O
four NN NN O
multiplex NN NN O
VWS NN NN B-Modifier
families NN NN O
. NN NN O

All NN NN O
available NN NN O
members NN NN O
were NN NN O
clinically NN NN O
assessed NN NN O
and NN NN O
genotyped NN NN O
for NN NN O
19 NN NN O
short NN NN O
tandem NN NN O
repeat NN NN O
markers NN NN O
on NN NN O
chromosome NN NN O
1 NN NN O
in NN NN O
the NN NN O
VWS NN NN B-Modifier
candidate NN NN O
gene NN NN O
region NN NN O
. NN NN O

We NN NN O
performed NN NN O
two-point NN NN O
and NN NN O
multipoint NN NN O
limit NN NN O
of NN NN O
detection NN NN O
( NN NN O
LOD NN NN O
) NN NN O
score NN NN O
analyses NN NN O
using NN NN O
a NN NN O
high NN NN O
penetrance NN NN O
autosomal NN NN O
dominant NN NN O
model NN NN O
. NN NN O

All NN NN O
families NN NN O
showed NN NN O
positive NN NN O
LOD NN NN O
scores NN NN O
without NN NN O
any NN NN O
recombination NN NN O
in NN NN O
the NN NN O
candidate NN NN O
region NN NN O
. NN NN O

The NN NN O
largest NN NN O
two-point NN NN O
LOD NN NN O
score NN NN O
was NN NN O
5 NN NN O
. NN NN O

87 NN NN O
87 NN NN O
. NN NN O

Our NN NN O
assay NN NN O
method NN NN O
for NN NN O
short NN NN O
tandem NN NN O
repeat NN NN O
( NN NN O
STR NN NN O
) NN NN O
markers NN NN O
provided NN NN O
highly NN NN O
accurate NN NN O
size NN NN O
estimation NN NN O
of NN NN O
marker NN NN O
allele NN NN O
fragment NN NN O
sizes NN NN O
, NN NN O
and NN NN O
therefore NN NN O
enabled NN NN O
us NN NN O
to NN NN O
determine NN NN O
the NN NN O
specific NN NN O
alleles NN NN O
segregating NN NN O
with NN NN O
the NN NN O
VWS NN NN B-Modifier
gene NN NN O
in NN NN O
each NN NN O
of NN NN O
our NN NN O
four NN NN O
families NN NN O
. NN NN O

We NN NN O
observed NN NN O
a NN NN O
striking NN NN O
pattern NN NN O
of NN NN O
STR NN NN O
allele NN NN O
sharing NN NN O
at NN NN O
several NN NN O
closely NN NN O
linked NN NN O
loci NN NN O
among NN NN O
our NN NN O
four NN NN O
Caucasian NN NN O
VWS NN NN B-Modifier
families NN NN O
recruited NN NN O
at NN NN O
three NN NN O
different NN NN O
locations NN NN O
in NN NN O
the NN NN O
US NN NN O
. NN NN O

These NN NN O
results NN NN O
suggest NN NN O
the NN NN O
possibility NN NN O
of NN NN O
a NN NN O
unique NN NN O
origin NN NN O
for NN NN O
a NN NN O
mutation NN NN O
responsible NN NN O
for NN NN O
many NN NN O
or NN NN O
most NN NN O
cases NN NN O
of NN NN O
VWS NN NN B-SpecificDisease
. NN NN O

10590055 NN NN O
A NN NN O
point NN NN O
mutation NN NN O
Thr NN NN O
( NN NN O
799 NN NN O
) NN NN O
Met NN NN O
on NN NN O
the NN NN O
alpha NN NN O
( NN NN O
2 NN NN O
) NN NN O
integrin NN NN O
leads NN NN O
to NN NN O
the NN NN O
formation NN NN O
of NN NN O
new NN NN O
human NN NN O
platelet NN NN O
alloantigen NN NN O
Sit NN NN O
( NN NN O
a NN NN O
) NN NN O
and NN NN O
affects NN NN O
collagen-induced NN NN O
aggregation NN NN O
. NN NN O

A NN NN O
new NN NN O
platelet-specific NN NN O
alloantigen NN NN O
, NN NN O
termed NN NN O
Sit NN NN O
( NN NN O
a NN NN O
) NN NN O
, NN NN O
was NN NN O
identified NN NN O
in NN NN O
a NN NN O
severe NN NN O
case NN NN O
of NN NN O
neonatal NN NN B-SpecificDisease
alloimmune NN NN I-SpecificDisease
thrombocytopenia NN NN I-SpecificDisease
. NN NN O

The NN NN O
Sit NN NN O
( NN NN O
a NN NN O
) NN NN O
alloantigen NN NN O
is NN NN O
of NN NN O
low NN NN O
frequency NN NN O
( NN NN O
1 NN NN O
/ NN NN O
400 NN NN O
) NN NN O
in NN NN O
the NN NN O
German NN NN O
population NN NN O
. NN NN O

Immunochemical NN NN O
studies NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
Sit NN NN O
( NN NN O
a NN NN O
) NN NN O
epitopes NN NN O
reside NN NN O
on NN NN O
platelet NN NN O
glycoprotein NN NN O
( NN NN O
GP NN NN O
) NN NN O
Ia NN NN O
. NN NN O

Nucleotide NN NN O
sequence NN NN O
analysis NN NN O
of NN NN O
GPIa NN NN O
cDNA NN NN O
derived NN NN O
from NN NN O
Sit NN NN O
( NN NN O
a NN NN O
) NN NN O
-positive NN NN O
platelets NN NN O
showed NN NN O
C NN NN O
( NN NN O
2531 NN NN O
) NN NN O
-- NN NN O
T NN NN O
( NN NN O
2531 NN NN O
) NN NN O
point NN NN O
mutation NN NN O
, NN NN O
resulting NN NN O
in NN NN O
Thr NN NN O
( NN NN O
799 NN NN O
) NN NN O
Met NN NN O
dimorphism NN NN O
. NN NN O

Analysis NN NN O
of NN NN O
genomic NN NN O
DNA NN NN O
from NN NN O
22 NN NN O
Sit NN NN O
( NN NN O
a NN NN O
) NN NN O
-negative NN NN O
normal NN NN O
individuals NN NN O
showed NN NN O
that NN NN O
the NN NN O
Thr NN NN O
( NN NN O
799 NN NN O
) NN NN O
is NN NN O
encoded NN NN O
by NN NN O
ACG NN NN O
( NN NN O
2532 NN NN O
) NN NN O
( NN NN O
90 NN NN O
. NN NN O

9 NN NN O
% NN NN O
) NN NN O
or NN NN O
ACA NN NN O
( NN NN O
2532 NN NN O
) NN NN O
( NN NN O
9 NN NN O
. NN NN O

1 NN NN O
% NN NN O
) NN NN O
. NN NN O

To NN NN O
establish NN NN O
a NN NN O
DNA NN NN O
typing NN NN O
technique NN NN O
, NN NN O
we NN NN O
elucidated NN NN O
the NN NN O
organization NN NN O
of NN NN O
the NN NN O
GPIa NN NN O
gene NN NN O
adjacent NN NN O
to NN NN O
the NN NN O
polymorphic NN NN O
bases NN NN O
. NN NN O

The NN NN O
introns NN NN O
( NN NN O
421 NN NN O
bp NN NN O
and NN NN O
1 NN NN O
. NN NN O

2 NN NN O
kb NN NN O
) NN NN O
encompass NN NN O
a NN NN O
142-bp NN NN O
exon NN NN O
with NN NN O
the NN NN O
2 NN NN O
polymorphic NN NN O
bases NN NN O
2531 NN NN O
and NN NN O
2532 NN NN O
. NN NN O

Polymerase NN NN O
chain NN NN O
reaction-restriction NN NN O
fragment NN NN O
length NN NN O
polymorphism NN NN O
analysis NN NN O
on NN NN O
DNA NN NN O
derived NN NN O
from NN NN O
100 NN NN O
donors NN NN O
using NN NN O
the NN NN O
restriction NN NN O
enzyme NN NN O
Mae NN NN O
III NN NN O
showed NN NN O
that NN NN O
the NN NN O
Met NN NN O
( NN NN O
799 NN NN O
) NN NN O
form NN NN O
of NN NN O
GPIa NN NN O
is NN NN O
restricted NN NN O
to NN NN O
Sit NN NN O
( NN NN O
a NN NN O
) NN NN O
( NN NN O
+ NN NN O
) NN NN O
phenotype NN NN O
. NN NN O

Analysis NN NN O
of NN NN O
stable NN NN O
Chinese NN NN O
hamster NN NN O
ovary NN NN O
transfectants NN NN O
expressing NN NN O
allele-specific NN NN O
recombinant NN NN O
forms NN NN O
of NN NN O
GPIa NN NN O
showed NN NN O
that NN NN O
anti-Sit NN NN O
( NN NN O
a NN NN O
) NN NN O
exclusively NN NN O
reacted NN NN O
with NN NN O
the NN NN O
Glu NN NN O
( NN NN O
505 NN NN O
) NN NN O
Met NN NN O
( NN NN O
799 NN NN O
) NN NN O
, NN NN O
but NN NN O
not NN NN O
with NN NN O
the NN NN O
Glu NN NN O
( NN NN O
505 NN NN O
) NN NN O
Thr NN NN O
( NN NN O
799 NN NN O
) NN NN O
and NN NN O
the NN NN O
Lys NN NN O
( NN NN O
505 NN NN O
) NN NN O
Thr NN NN O
( NN NN O
799 NN NN O
) NN NN O
isoforms NN NN O
. NN NN O

In NN NN O
contrast NN NN O
, NN NN O
anti-Br NN NN O
( NN NN O
a NN NN O
) NN NN O
( NN NN O
HPA-5b NN NN O
) NN NN O
only NN NN O
recognized NN NN O
the NN NN O
Lys NN NN O
( NN NN O
505 NN NN O
) NN NN O
Thr NN NN O
( NN NN O
799 NN NN O
) NN NN O
form NN NN O
, NN NN O
whereas NN NN O
anti-Br NN NN O
( NN NN O
b NN NN O
) NN NN O
( NN NN O
HPA-5a NN NN O
) NN NN O
reacted NN NN O
with NN NN O
both NN NN O
Glu NN NN O
( NN NN O
505 NN NN O
) NN NN O
Thr NN NN O
( NN NN O
799 NN NN O
) NN NN O
and NN NN O
Glu NN NN O
( NN NN O
505 NN NN O
) NN NN O
Met NN NN O
( NN NN O
799 NN NN O
) NN NN O
isoforms NN NN O
. NN NN O

These NN NN O
results NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
Met NN NN O
( NN NN O
799 NN NN O
) NN NN O
is NN NN O
responsible NN NN O
for NN NN O
formation NN NN O
of NN NN O
the NN NN O
Sit NN NN O
( NN NN O
a NN NN O
) NN NN O
alloantigenic NN NN O
determinants NN NN O
, NN NN O
whereas NN NN O
amino NN NN O
acid NN NN O
505 NN NN O
( NN NN O
Lys NN NN O
or NN NN O
Glu NN NN O
) NN NN O
specifically NN NN O
controls NN NN O
the NN NN O
expression NN NN O
of NN NN O
Br NN NN O
( NN NN O
a NN NN O
) NN NN O
and NN NN O
Br NN NN O
( NN NN O
b NN NN O
) NN NN O
epitopes NN NN O
, NN NN O
respectively NN NN O
. NN NN O

Platelet NN NN O
aggregation NN NN O
responses NN NN O
of NN NN O
Sit NN NN O
( NN NN O
a NN NN O
) NN NN O
( NN NN O
+ NN NN O
) NN NN O
individuals NN NN O
were NN NN O
diminished NN NN O
in NN NN O
response NN NN O
to NN NN O
collagen NN NN O
, NN NN O
indicating NN NN O
that NN NN O
the NN NN O
Thr NN NN O
( NN NN O
799 NN NN O
) NN NN O
Met NN NN O
mutation NN NN O
affects NN NN O
the NN NN O
function NN NN O
of NN NN O
the NN NN O
GPIa NN NN O
/ NN NN O
IIa NN NN O
complex NN NN O

10593994 NN NN O
Mutations NN NN O
of NN NN O
the NN NN O
cathepsin NN NN O
C NN NN O
gene NN NN O
are NN NN O
responsible NN NN O
for NN NN O
Papillon-Lefevre NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

Papillon-Lefevre NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
PLS NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
characterised NN NN O
by NN NN O
palmoplantar NN NN B-SpecificDisease
hyperkeratosis NN NN I-SpecificDisease
and NN NN O
severe NN NN O
early NN NN O
onset NN NN O
periodontitis NN NN B-SpecificDisease
that NN NN O
results NN NN O
in NN NN O
the NN NN O
premature NN NN O
loss NN NN O
of NN NN O
the NN NN O
primary NN NN O
and NN NN O
secondary NN NN O
dentitions NN NN O
. NN NN O

A NN NN O
major NN NN O
gene NN NN O
locus NN NN O
for NN NN O
PLS NN NN B-SpecificDisease
has NN NN O
been NN NN O
mapped NN NN O
to NN NN O
a NN NN O
2 NN NN O
. NN NN O

8 NN NN O
cM NN NN O
interval NN NN O
on NN NN O
chromosome NN NN O
11q14 NN NN O
. NN NN O

Correlation NN NN O
of NN NN O
physical NN NN O
and NN NN O
genetic NN NN O
maps NN NN O
of NN NN O
this NN NN O
interval NN NN O
indicate NN NN O
it NN NN O
includes NN NN O
at NN NN O
least NN NN O
40 NN NN O
ESTs NN NN O
and NN NN O
six NN NN O
known NN NN O
genes NN NN O
including NN NN O
the NN NN O
lysosomal NN NN O
protease NN NN O
cathepsin NN NN O
C NN NN O
gene NN NN O
( NN NN O
CTSC NN NN O
) NN NN O
. NN NN O

The NN NN O
CTSC NN NN O
message NN NN O
is NN NN O
expressed NN NN O
at NN NN O
high NN NN O
levels NN NN O
in NN NN O
a NN NN O
variety NN NN O
of NN NN O
immune NN NN O
cells NN NN O
including NN NN O
polymorphonuclear NN NN O
leucocytes NN NN O
, NN NN O
macrophages NN NN O
, NN NN O
and NN NN O
their NN NN O
precursors NN NN O
. NN NN O

By NN NN O
RT-PCR NN NN O
, NN NN O
we NN NN O
found NN NN O
CTSC NN NN O
is NN NN O
also NN NN O
expressed NN NN O
in NN NN O
epithelial NN NN O
regions NN NN O
commonly NN NN O
affected NN NN O
by NN NN O
PLS NN NN B-SpecificDisease
, NN NN O
including NN NN O
the NN NN O
palms NN NN O
, NN NN O
soles NN NN O
, NN NN O
knees NN NN O
, NN NN O
and NN NN O
oral NN NN O
keratinised NN NN O
gingiva NN NN O
. NN NN O

The NN NN O
4 NN NN O
. NN NN O

7 NN NN O
kb NN NN O
CTSC NN NN O
gene NN NN O
consists NN NN O
of NN NN O
two NN NN O
exons NN NN O
. NN NN O

Sequence NN NN O
analysis NN NN O
of NN NN O
CTSC NN NN O
from NN NN O
subjects NN NN O
affected NN NN O
with NN NN O
PLS NN NN B-SpecificDisease
from NN NN O
five NN NN O
consanguineous NN NN O
Turkish NN NN O
families NN NN O
identified NN NN O
four NN NN O
different NN NN O
mutations NN NN O
. NN NN O

An NN NN O
exon NN NN O
1 NN NN O
nonsense NN NN O
mutation NN NN O
( NN NN O
856C NN NN O
-- NN NN O
T NN NN O
) NN NN O
introduces NN NN O
a NN NN O
premature NN NN O
stop NN NN O
codon NN NN O
at NN NN O
amino NN NN O
acid NN NN O
286 NN NN O
. NN NN O

Three NN NN O
exon NN NN O
2 NN NN O
mutations NN NN O
were NN NN O
identified NN NN O
, NN NN O
including NN NN O
a NN NN O
single NN NN O
nucleotide NN NN O
deletion NN NN O
( NN NN O
2692delA NN NN O
) NN NN O
of NN NN O
codon NN NN O
349 NN NN O
introducing NN NN O
a NN NN O
frameshift NN NN O
and NN NN O
premature NN NN O
termination NN NN O
codon NN NN O
, NN NN O
a NN NN O
2 NN NN O
bp NN NN O
deletion NN NN O
( NN NN O
2673-2674delCT NN NN O
) NN NN O
that NN NN O
results NN NN O
in NN NN O
introduction NN NN O
of NN NN O
a NN NN O
stop NN NN O
codon NN NN O
at NN NN O
amino NN NN O
acid NN NN O
343 NN NN O
, NN NN O
and NN NN O
a NN NN O
G NN NN O
-- NN NN O
A NN NN O
substitution NN NN O
in NN NN O
codon NN NN O
429 NN NN O
( NN NN O
2931G NN NN O
-- NN NN O
A NN NN O
) NN NN O
introducing NN NN O
a NN NN O
premature NN NN O
termination NN NN O
codon NN NN O
. NN NN O

All NN NN O
PLS NN NN B-Modifier
patients NN NN O
were NN NN O
homozygous NN NN O
for NN NN O
cathepsin NN NN O
C NN NN O
mutations NN NN O
inherited NN NN O
from NN NN O
a NN NN O
common NN NN O
ancestor NN NN O
. NN NN O

Parents NN NN O
and NN NN O
sibs NN NN O
heterozygous NN NN O
for NN NN O
cathepsin NN NN O
C NN NN O
mutations NN NN O
do NN NN O
not NN NN O
show NN NN O
either NN NN O
the NN NN O
palmoplantar NN NN B-SpecificDisease
hyperkeratosis NN NN I-SpecificDisease
or NN NN O
severe NN NN O
early NN NN O
onset NN NN O
periodontitis NN NN B-SpecificDisease
characteristic NN NN O
of NN NN O
PLS NN NN B-SpecificDisease
. NN NN O

A NN NN O
more NN NN O
complete NN NN O
understanding NN NN O
of NN NN O
the NN NN O
functional NN NN O
physiology NN NN O
of NN NN O
cathepsin NN NN O
C NN NN O
carries NN NN O
significant NN NN O
implications NN NN O
for NN NN O
understanding NN NN O
normal NN NN O
and NN NN O
abnormal NN NN O
skin NN NN O
development NN NN O
and NN NN O
periodontal NN NN B-Modifier
disease NN NN I-Modifier
susceptibility NN NN O

10594001 NN NN O
Mutational NN NN O
analysis NN NN O
of NN NN O
the NN NN O
HGO NN NN O
gene NN NN O
in NN NN O
Finnish NN NN O
alkaptonuria NN NN B-Modifier
patients NN NN O
. NN NN O

Alkaptonuria NN NN B-SpecificDisease
( NN NN O
AKU NN NN B-SpecificDisease
) NN NN O
, NN NN O
the NN NN O
prototypic NN NN O
inborn NN NN B-DiseaseClass
error NN NN I-DiseaseClass
of NN NN I-DiseaseClass
metabolism NN NN I-DiseaseClass
, NN NN O
has NN NN O
recently NN NN O
been NN NN O
shown NN NN O
to NN NN O
be NN NN O
caused NN NN O
by NN NN O
loss NN NN O
of NN NN O
function NN NN O
mutations NN NN O
in NN NN O
the NN NN O
homogentisate-1 NN NN O
, NN NN O
2-dioxygenase NN NN O
gene NN NN O
( NN NN O
HGO NN NN O
) NN NN O
. NN NN O

So NN NN O
far NN NN O
17 NN NN O
mutations NN NN O
have NN NN O
been NN NN O
characterised NN NN O
in NN NN O
AKU NN NN B-Modifier
patients NN NN O
of NN NN O
different NN NN O
ethnic NN NN O
origin NN NN O
. NN NN O

We NN NN O
describe NN NN O
three NN NN O
novel NN NN O
mutations NN NN O
( NN NN O
R58fs NN NN O
, NN NN O
R330S NN NN O
, NN NN O
and NN NN O
H371R NN NN O
) NN NN O
and NN NN O
one NN NN O
common NN NN O
AKU NN NN B-Modifier
mutation NN NN O
( NN NN O
M368V NN NN O
) NN NN O
, NN NN O
detected NN NN O
by NN NN O
mutational NN NN O
and NN NN O
polymorphism NN NN O
analysis NN NN O
of NN NN O
the NN NN O
HGO NN NN O
gene NN NN O
in NN NN O
five NN NN O
Finnish NN NN O
AKU NN NN B-Modifier
pedigrees NN NN O
. NN NN O

The NN NN O
three NN NN O
novel NN NN O
AKU NN NN B-Modifier
mutations NN NN O
are NN NN O
most NN NN O
likely NN NN O
specific NN NN O
for NN NN O
the NN NN O
Finnish NN NN O
population NN NN O
and NN NN O
have NN NN O
originated NN NN O
recently NN NN O
. NN NN O

. NN NN O

10598803 NN NN O
The NN NN O
identical NN NN O
5 NN NN O
' NN NN O
splice-site NN NN O
acceptor NN NN O
mutation NN NN O
in NN NN O
five NN NN O
attenuated NN NN B-Modifier
APC NN NN I-Modifier
families NN NN O
from NN NN O
Newfoundland NN NN O
demonstrates NN NN O
a NN NN O
founder NN NN O
effect NN NN O
. NN NN O

Inherited NN NN O
mutations NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
predispose NN NN O
carriers NN NN O
to NN NN O
multiple NN NN O
adenomatous NN NN B-CompositeMention
polyps NN NN I-CompositeMention
of NN NN I-CompositeMention
the NN NN I-CompositeMention
colon NN NN I-CompositeMention
and NN NN I-CompositeMention
rectum NN NN I-CompositeMention
and NN NN O
to NN NN O
colorectal NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

Mutations NN NN O
located NN NN O
at NN NN O
the NN NN O
extreme NN NN O
5 NN NN O
end NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
, NN NN O
however NN NN O
, NN NN O
are NN NN O
associated NN NN O
with NN NN O
a NN NN O
less NN NN O
severe NN NN O
disease NN NN O
known NN NN O
as NN NN O
attenuated NN NN B-SpecificDisease
adenomatous NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
coli NN NN I-SpecificDisease
( NN NN O
AAPC NN NN B-SpecificDisease
) NN NN O
. NN NN O

Many NN NN O
individuals NN NN O
with NN NN O
AAPC NN NN B-SpecificDisease
develop NN NN O
relatively NN NN O
few NN NN O
colorectal NN NN B-SpecificDisease
polyps NN NN I-SpecificDisease
but NN NN O
are NN NN O
still NN NN O
at NN NN O
high NN NN O
risk NN NN O
for NN NN O
colorectal NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

We NN NN O
report NN NN O
here NN NN O
the NN NN O
identification NN NN O
of NN NN O
a NN NN O
5 NN NN O
APC NN NN B-Modifier
germline NN NN O
mutation NN NN O
in NN NN O
five NN NN O
separately NN NN O
ascertained NN NN O
AAPC NN NN B-Modifier
families NN NN O
from NN NN O
Newfoundland NN NN O
, NN NN O
Canada NN NN O
. NN NN O

This NN NN O
disease-causing NN NN O
mutation NN NN O
is NN NN O
a NN NN O
single NN NN O
basepair NN NN O
change NN NN O
( NN NN O
G NN NN O
to NN NN O
A NN NN O
) NN NN O
in NN NN O
the NN NN O
splice-acceptor NN NN O
region NN NN O
of NN NN O
APC NN NN B-Modifier
intron NN NN O
3 NN NN O
that NN NN O
creates NN NN O
a NN NN O
mutant NN NN O
RNA NN NN O
without NN NN O
exon NN NN O
4 NN NN O
of NN NN O
APC NN NN O
. NN NN O

The NN NN O
observation NN NN O
of NN NN O
the NN NN O
same NN NN O
APC NN NN B-Modifier
mutation NN NN O
in NN NN O
five NN NN O
families NN NN O
from NN NN O
the NN NN O
same NN NN O
geographic NN NN O
area NN NN O
demonstrates NN NN O
a NN NN O
founder NN NN O
effect NN NN O
. NN NN O

Furthermore NN NN O
, NN NN O
the NN NN O
identification NN NN O
of NN NN O
this NN NN O
germline NN NN O
mutation NN NN O
strengthens NN NN O
the NN NN O
correlation NN NN O
between NN NN O
the NN NN O
5 NN NN O
location NN NN O
of NN NN O
an NN NN O
APC NN NN B-Modifier
disease-causing NN NN O
mutation NN NN O
and NN NN O
the NN NN O
attenuated NN NN B-Modifier
polyposis NN NN I-Modifier
phenotype NN NN O
. NN NN O

. NN NN O

10598815 NN NN O
Alstrom NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
: NN NN O
further NN NN O
evidence NN NN O
for NN NN O
linkage NN NN O
to NN NN O
human NN NN O
chromosome NN NN O
2p13 NN NN O
. NN NN O

Alstrom NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
is NN NN O
a NN NN O
rare NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
characterized NN NN O
by NN NN O
retinal NN NN B-SpecificDisease
degeneration NN NN I-SpecificDisease
, NN NN O
sensorineural NN NN B-SpecificDisease
hearing NN NN I-SpecificDisease
loss NN NN I-SpecificDisease
, NN NN O
early-onset NN NN O
obesity NN NN B-SpecificDisease
, NN NN O
and NN NN O
non-insulin-dependent NN NN B-SpecificDisease
diabetes NN NN I-SpecificDisease
mellitus NN NN I-SpecificDisease
. NN NN O

The NN NN O
gene NN NN O
for NN NN O
Alstrom NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
ALMS1 NN NN O
) NN NN O
has NN NN O
been NN NN O
previously NN NN O
localized NN NN O
to NN NN O
human NN NN O
chromosome NN NN O
2p13 NN NN O
by NN NN O
homozygosity NN NN O
mapping NN NN O
in NN NN O
two NN NN O
distinct NN NN O
isolated NN NN O
populations NN NN O
- NN NN O
French NN NN O
Acadian NN NN O
and NN NN O
North NN NN O
African NN NN O
. NN NN O

Pair-wise NN NN O
analyses NN NN O
resulted NN NN O
in NN NN O
maximum NN NN O
lod NN NN O
( NN NN O
logarithm NN NN O
of NN NN O
the NN NN O
odds NN NN O
ratio NN NN O
) NN NN O
scores NN NN O
of NN NN O
3 NN NN O
. NN NN O

84 NN NN O
and NN NN O
2 NN NN O
. NN NN O

9 NN NN O
, NN NN O
respectively NN NN O
. NN NN O

To NN NN O
confirm NN NN O
these NN NN O
findings NN NN O
, NN NN O
a NN NN O
large NN NN O
linkage NN NN O
study NN NN O
was NN NN O
performed NN NN O
in NN NN O
twelve NN NN O
additional NN NN O
families NN NN O
segregating NN NN O
for NN NN O
Alstrom NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

A NN NN O
maximum NN NN O
two-point NN NN O
lod NN NN O
score NN NN O
of NN NN O
7 NN NN O
. NN NN O

13 NN NN O
( NN NN O
theta NN NN O
= NN NN O
0 NN NN O
. NN NN O

00 NN NN O
) NN NN O
for NN NN O
marker NN NN O
D2S2110 NN NN O
and NN NN O
a NN NN O
maximum NN NN O
cumulative NN NN O
multipoint NN NN O
lod NN NN O
score NN NN O
of NN NN O
9 NN NN O
. NN NN O

16 NN NN O
for NN NN O
marker NN NN O
D2S2110 NN NN O
were NN NN O
observed NN NN O
, NN NN O
further NN NN O
supporting NN NN O
linkage NN NN O
to NN NN O
chromosome NN NN O
2p13 NN NN O
. NN NN O

No NN NN O
evidence NN NN O
of NN NN O
genetic NN NN O
heterogeneity NN NN O
was NN NN O
observed NN NN O
in NN NN O
these NN NN O
families NN NN O
. NN NN O

Meiotic NN NN O
recombination NN NN O
events NN NN O
have NN NN O
localized NN NN O
the NN NN O
critical NN NN O
region NN NN O
containing NN NN O
ALMS1 NN NN O
to NN NN O
a NN NN O
6 NN NN O
. NN NN O

1-cM NN NN O
interval NN NN O
flanked NN NN O
by NN NN O
markers NN NN O
D2S327 NN NN O
and NN NN O
D2S286 NN NN O
. NN NN O

A NN NN O
fine NN NN O
resolution NN NN O
radiation NN NN O
hybrid NN NN O
map NN NN O
of NN NN O
31 NN NN O
genes NN NN O
and NN NN O
markers NN NN O
has NN NN O
been NN NN O
constructed NN NN O
. NN NN O

10602116 NN NN O
Pendred NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
: NN NN O
phenotypic NN NN O
variability NN NN O
in NN NN O
two NN NN O
families NN NN O
carrying NN NN O
the NN NN O
same NN NN O
PDS NN NN B-Modifier
missense NN NN O
mutation NN NN O
. NN NN O

Pendred NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
comprises NN NN O
congenital NN NN B-SpecificDisease
sensorineural NN NN I-SpecificDisease
hearing NN NN I-SpecificDisease
loss NN NN I-SpecificDisease
, NN NN O
thyroid NN NN B-SpecificDisease
goiter NN NN I-SpecificDisease
, NN NN O
and NN NN O
positive NN NN O
perchlorate NN NN O
discharge NN NN O
test NN NN O
. NN NN O

Recently NN NN O
, NN NN O
this NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
was NN NN O
shown NN NN O
to NN NN O
be NN NN O
caused NN NN O
by NN NN O
mutations NN NN O
in NN NN O
the NN NN O
PDS NN NN B-Modifier
gene NN NN O
, NN NN O
which NN NN O
encodes NN NN O
an NN NN O
anion NN NN O
transporter NN NN O
called NN NN O
pendrin NN NN O
. NN NN O

Molecular NN NN O
analysis NN NN O
of NN NN O
the NN NN O
PDS NN NN B-Modifier
gene NN NN O
was NN NN O
performed NN NN O
in NN NN O
two NN NN O
consanguineous NN NN O
large NN NN O
families NN NN O
from NN NN O
Southern NN NN O
Tunisia NN NN O
comprising NN NN O
a NN NN O
total NN NN O
of NN NN O
23 NN NN O
individuals NN NN O
affected NN NN O
with NN NN O
profound NN NN O
congenital NN NN B-SpecificDisease
deafness NN NN I-SpecificDisease
; NN NN O
the NN NN O
same NN NN O
missense NN NN O
mutation NN NN O
, NN NN O
L445W NN NN O
, NN NN O
was NN NN O
identified NN NN O
in NN NN O
all NN NN O
affected NN NN O
individuals NN NN O
. NN NN O

A NN NN O
widened NN NN O
vestibular NN NN B-SpecificDisease
aqueduct NN NN I-SpecificDisease
was NN NN O
found NN NN O
in NN NN O
all NN NN O
patients NN NN O
who NN NN O
underwent NN NN O
computed NN NN O
tomography NN NN O
( NN NN O
CT NN NN O
) NN NN O
scan NN NN O
exploration NN NN O
of NN NN O
the NN NN O
inner NN NN O
ear NN NN O
. NN NN O

In NN NN O
contrast NN NN O
, NN NN O
goiter NN NN B-SpecificDisease
was NN NN O
present NN NN O
in NN NN O
only NN NN O
11 NN NN O
affected NN NN O
individuals NN NN O
, NN NN O
who NN NN O
interestingly NN NN O
had NN NN O
a NN NN O
normal NN NN O
result NN NN O
of NN NN O
the NN NN O
perchlorate NN NN O
discharge NN NN O
test NN NN O
whenever NN NN O
performed NN NN O
. NN NN O

The NN NN O
present NN NN O
results NN NN O
question NN NN O
the NN NN O
sensitivity NN NN O
of NN NN O
the NN NN O
perchlorate NN NN O
test NN NN O
for NN NN O
the NN NN O
diagnosis NN NN O
of NN NN O
Pendred NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
and NN NN O
support NN NN O
the NN NN O
use NN NN O
of NN NN O
a NN NN O
molecular NN NN O
analysis NN NN O
of NN NN O
the NN NN O
PDS NN NN B-Modifier
gene NN NN O
in NN NN O
the NN NN O
assessment NN NN O
of NN NN O
individuals NN NN O
with NN NN O
severe NN NN O
to NN NN O
profound NN NN O
congenital NN NN B-SpecificDisease
hearing NN NN I-SpecificDisease
loss NN NN I-SpecificDisease
associated NN NN O
with NN NN O
inner NN NN B-SpecificDisease
ear NN NN I-SpecificDisease
morphological NN NN I-SpecificDisease
anomaly NN NN I-SpecificDisease
even NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
a NN NN O
thyroid NN NN B-SpecificDisease
goiter NN NN I-SpecificDisease
. NN NN O

. NN NN O

10607954 NN NN O
Knobloch NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
involving NN NN O
midline NN NN B-DiseaseClass
scalp NN NN I-DiseaseClass
defect NN NN I-DiseaseClass
of NN NN I-DiseaseClass
the NN NN I-DiseaseClass
frontal NN NN I-DiseaseClass
region NN NN I-DiseaseClass
. NN NN O

We NN NN O
report NN NN O
on NN NN O
a NN NN O
4-year-old NN NN O
boy NN NN O
with NN NN O
Knobloch NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

He NN NN O
has NN NN O
vitreoretinal NN NN B-SpecificDisease
degeneration NN NN I-SpecificDisease
, NN NN O
high NN NN B-SpecificDisease
myopia NN NN I-SpecificDisease
, NN NN O
cataract NN NN B-SpecificDisease
, NN NN O
telecanthus NN NN B-SpecificDisease
, NN NN O
hypertelorism NN NN B-SpecificDisease
, NN NN O
and NN NN O
a NN NN O
high-arched NN NN B-SpecificDisease
palate NN NN I-SpecificDisease
. NN NN O

He NN NN O
also NN NN O
has NN NN O
a NN NN O
defect NN NN B-DiseaseClass
of NN NN I-DiseaseClass
the NN NN I-DiseaseClass
anterior NN NN I-DiseaseClass
midline NN NN I-DiseaseClass
scalp NN NN I-DiseaseClass
with NN NN O
involvement NN NN O
of NN NN O
the NN NN O
frontal NN NN O
bone NN NN O
as NN NN O
documented NN NN O
by NN NN O
a NN NN O
computed NN NN O
tomography NN NN O
( NN NN O
CT NN NN O
) NN NN O
scan NN NN O
. NN NN O

The NN NN O
brain NN NN O
was NN NN O
normal NN NN O
on NN NN O
CT NN NN O
scan NN NN O
and NN NN O
magnetic NN NN O
resonance NN NN O
imaging NN NN O
. NN NN O

We NN NN O
present NN NN O
a NN NN O
review NN NN O
of NN NN O
the NN NN O
23 NN NN O
published NN NN O
cases NN NN O
with NN NN O
this NN NN O
syndrome NN NN O
. NN NN O

Our NN NN O
patient NN NN O
illustrates NN NN O
the NN NN O
importance NN NN O
of NN NN O
investigating NN NN O
for NN NN O
underlying NN NN O
ocular NN NN O
and NN NN O
central NN NN O
nervous NN NN O
system NN NN O
pathology NN NN O
whenever NN NN O
midline NN NN B-DiseaseClass
scalp NN NN I-DiseaseClass
defects NN NN I-DiseaseClass
are NN NN O
present NN NN O
. NN NN O

. NN NN O

10612394 NN NN O
The NN NN O
DNA NN NN O
double-strand NN NN O
break NN NN O
repair NN NN O
gene NN NN O
hMRE11 NN NN O
is NN NN O
mutated NN NN O
in NN NN O
individuals NN NN O
with NN NN O
an NN NN O
ataxia-telangiectasia-like NN NN B-SpecificDisease
disorder NN NN I-SpecificDisease
. NN NN O

We NN NN O
show NN NN O
that NN NN O
hypomorphic NN NN O
mutations NN NN O
in NN NN O
hMRE11 NN NN O
, NN NN O
but NN NN O
not NN NN O
in NN NN O
ATM NN NN O
, NN NN O
are NN NN O
present NN NN O
in NN NN O
certain NN NN O
individuals NN NN O
with NN NN O
an NN NN O
ataxia-telangiectasia-like NN NN B-SpecificDisease
disorder NN NN I-SpecificDisease
( NN NN O
ATLD NN NN B-SpecificDisease
) NN NN O
. NN NN O

The NN NN O
cellular NN NN O
features NN NN O
resulting NN NN O
from NN NN O
these NN NN O
hMRE11 NN NN O
mutations NN NN O
are NN NN O
similar NN NN O
to NN NN O
those NN NN O
seen NN NN O
in NN NN O
A-T NN NN B-SpecificDisease
as NN NN O
well NN NN O
as NN NN O
NBS NN NN B-SpecificDisease
and NN NN O
include NN NN O
hypersensitivity NN NN O
to NN NN O
ionizing NN NN O
radiation NN NN O
, NN NN O
radioresistant NN NN O
DNA NN NN O
synthesis NN NN O
, NN NN O
and NN NN O
abrogation NN NN O
of NN NN O
ATM-dependent NN NN O
events NN NN O
, NN NN O
such NN NN O
as NN NN O
the NN NN O
activation NN NN O
of NN NN O
Jun NN NN O
kinase NN NN O
following NN NN O
exposure NN NN O
to NN NN O
gamma NN NN O
irradiation NN NN O
. NN NN O

Although NN NN O
the NN NN O
mutant NN NN O
hMre11 NN NN O
proteins NN NN O
retain NN NN O
some NN NN O
ability NN NN O
to NN NN O
interact NN NN O
with NN NN O
hRad50 NN NN O
and NN NN O
Nbs1 NN NN O
, NN NN O
formation NN NN O
of NN NN O
ionizing NN NN O
radiation-induced NN NN O
hMre11 NN NN O
and NN NN O
Nbs1 NN NN O
foci NN NN O
was NN NN O
absent NN NN O
in NN NN O
hMRE11 NN NN O
mutant NN NN O
cells NN NN O
. NN NN O

These NN NN O
data NN NN O
demonstrate NN NN O
that NN NN O
ATM NN NN O
and NN NN O
the NN NN O
hMre11 NN NN O
/ NN NN O
hRad50 NN NN O
/ NN NN O
Nbs1 NN NN O
protein NN NN O
complex NN NN O
act NN NN O
in NN NN O
the NN NN O
same NN NN O
DNA NN NN O
damage NN NN O
response NN NN O
pathway NN NN O
and NN NN O
link NN NN O
hMre11 NN NN O
to NN NN O
the NN NN O
complex NN NN O
pathology NN NN O
of NN NN O
A-T NN NN B-SpecificDisease
. NN NN O

. NN NN O

10615125 NN NN O
Mutations NN NN O
in NN NN O
TNFRSF11A NN NN O
, NN NN O
affecting NN NN O
the NN NN O
signal NN NN O
peptide NN NN O
of NN NN O
RANK NN NN O
, NN NN O
cause NN NN O
familial NN NN B-SpecificDisease
expansile NN NN I-SpecificDisease
osteolysis NN NN I-SpecificDisease
. NN NN O

Familial NN NN B-SpecificDisease
expansile NN NN I-SpecificDisease
osteolysis NN NN I-SpecificDisease
( NN NN O
FEO NN NN B-SpecificDisease
, NN NN O
MIM NN NN O
174810 NN NN O
) NN NN O
is NN NN O
a NN NN O
rare NN NN O
, NN NN O
autosomal NN NN B-DiseaseClass
dominant NN NN I-DiseaseClass
bone NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
characterized NN NN O
by NN NN O
focal NN NN O
areas NN NN O
of NN NN O
increased NN NN B-SpecificDisease
bone NN NN I-SpecificDisease
remodelling NN NN I-SpecificDisease
. NN NN O

The NN NN O
osteolytic NN NN B-SpecificDisease
lesions NN NN I-SpecificDisease
, NN NN O
which NN NN O
develop NN NN O
usually NN NN O
in NN NN O
the NN NN O
long NN NN O
bones NN NN O
during NN NN O
early NN NN O
adulthood NN NN O
, NN NN O
show NN NN O
increased NN NN O
osteoblast NN NN O
and NN NN O
osteoclast NN NN O
activity NN NN O
. NN NN O

Our NN NN O
previous NN NN O
linkage NN NN O
studies NN NN O
mapped NN NN O
the NN NN O
gene NN NN O
responsible NN NN O
for NN NN O
FEO NN NN B-SpecificDisease
to NN NN O
an NN NN O
interval NN NN O
of NN NN O
less NN NN O
than NN NN O
5 NN NN O
cM NN NN O
between NN NN O
D18S64 NN NN O
and NN NN O
D18S51 NN NN O
on NN NN O
chromosome NN NN O
18q21 NN NN O
. NN NN O

2-21 NN NN O
2-21 NN NN O
. NN NN O

3 NN NN O
in NN NN O
a NN NN O
large NN NN O
Northern NN NN O
Irish NN NN O
family NN NN O
. NN NN O

The NN NN O
gene NN NN O
encoding NN NN O
receptor NN NN O
activator NN NN O
of NN NN O
nuclear NN NN O
factor-kappa NN NN O
B NN NN O
( NN NN O
RANK NN NN O
; NN NN O
ref NN NN O
. NN NN O

5 NN NN O
) NN NN O
, NN NN O
TNFRSF11A NN NN O
, NN NN O
maps NN NN O
to NN NN O
this NN NN O
region NN NN O
. NN NN O

RANK NN NN O
is NN NN O
essential NN NN O
in NN NN O
osteoclast NN NN O
formation NN NN O
. NN NN O

We NN NN O
identified NN NN O
two NN NN O
heterozygous NN NN O
insertion NN NN O
mutations NN NN O
in NN NN O
exon NN NN O
1 NN NN O
of NN NN O
TNFRSF11A NN NN O
in NN NN O
affected NN NN O
members NN NN O
of NN NN O
four NN NN O
families NN NN O
with NN NN O
FEO NN NN B-SpecificDisease
or NN NN O
familial NN NN B-SpecificDisease
Paget NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
of NN NN I-SpecificDisease
bone NN NN I-SpecificDisease
( NN NN O
PDB NN NN B-SpecificDisease
) NN NN O
. NN NN O

One NN NN O
was NN NN O
a NN NN O
duplication NN NN O
of NN NN O
18 NN NN O
bases NN NN O
and NN NN O
the NN NN O
other NN NN O
a NN NN O
duplication NN NN O
of NN NN O
27 NN NN O
bases NN NN O
, NN NN O
both NN NN O
of NN NN O
which NN NN O
affected NN NN O
the NN NN O
signal NN NN O
peptide NN NN O
region NN NN O
of NN NN O
the NN NN O
RANK NN NN O
molecule NN NN O
. NN NN O

Expression NN NN O
of NN NN O
recombinant NN NN O
forms NN NN O
of NN NN O
the NN NN O
mutant NN NN O
RANK NN NN O
proteins NN NN O
revealed NN NN O
perturbations NN NN O
in NN NN O
expression NN NN O
levels NN NN O
and NN NN O
lack NN NN O
of NN NN O
normal NN NN O
cleavage NN NN O
of NN NN O
the NN NN O
signal NN NN O
peptide NN NN O
. NN NN O

Both NN NN O
mutations NN NN O
caused NN NN O
an NN NN O
increase NN NN O
in NN NN O
RANK-mediated NN NN O
nuclear NN NN O
factor-kappaB NN NN O
( NN NN O
NF-kappaB NN NN O
) NN NN O
signalling NN NN O
in NN NN O
vitro NN NN O
, NN NN O
consistent NN NN O
with NN NN O
the NN NN O
presence NN NN O
of NN NN O
an NN NN O
activating NN NN O
mutation NN NN O
. NN NN O

10618304 NN NN O
Cardiac NN NN O
Na NN NN O
( NN NN O
+ NN NN O
) NN NN O
channel NN NN O
dysfunction NN NN O
in NN NN O
Brugada NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
is NN NN O
aggravated NN NN O
by NN NN O
beta NN NN O
( NN NN O
1 NN NN O
) NN NN O
-subunit NN NN O
. NN NN O

BACKGROUND NN NN O
Mutations NN NN O
in NN NN O
the NN NN O
gene NN NN O
encoding NN NN O
the NN NN O
human NN NN O
cardiac NN NN O
Na NN NN O
( NN NN O
+ NN NN O
) NN NN O
channel NN NN O
alpha-subunit NN NN O
( NN NN O
hH1 NN NN O
) NN NN O
are NN NN O
responsible NN NN O
for NN NN O
chromosome NN NN O
3-linked NN NN O
congenital NN NN B-SpecificDisease
long-QT NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
LQT3 NN NN B-SpecificDisease
) NN NN O
and NN NN O
idiopathic NN NN B-SpecificDisease
ventricular NN NN I-SpecificDisease
fibrillation NN NN I-SpecificDisease
( NN NN O
IVF NN NN B-SpecificDisease
) NN NN O
. NN NN O

An NN NN O
auxiliary NN NN O
beta NN NN O
( NN NN O
1 NN NN O
) NN NN O
-subunit NN NN O
, NN NN O
widely NN NN O
expressed NN NN O
in NN NN O
excitable NN NN O
tissues NN NN O
, NN NN O
shifts NN NN O
the NN NN O
voltage NN NN O
dependence NN NN O
of NN NN O
steady-state NN NN O
inactivation NN NN O
toward NN NN O
more NN NN O
negative NN NN O
potentials NN NN O
and NN NN O
restores NN NN O
normal NN NN O
gating NN NN O
kinetics NN NN O
of NN NN O
brain NN NN O
and NN NN O
skeletal NN NN O
muscle NN NN O
Na NN NN O
( NN NN O
+ NN NN O
) NN NN O
channels NN NN O
expressed NN NN O
in NN NN O
Xenopus NN NN O
oocytes NN NN O
but NN NN O
has NN NN O
little NN NN O
if NN NN O
any NN NN O
functional NN NN O
effect NN NN O
on NN NN O
the NN NN O
cardiac NN NN O
isoform NN NN O
. NN NN O

Here NN NN O
, NN NN O
we NN NN O
characterize NN NN O
the NN NN O
altered NN NN O
effects NN NN O
of NN NN O
a NN NN O
human NN NN O
beta NN NN O
( NN NN O
1 NN NN O
) NN NN O
-subunit NN NN O
( NN NN O
hbeta NN NN O
( NN NN O
1 NN NN O
) NN NN O
) NN NN O
on NN NN O
the NN NN O
heterologously NN NN O
expressed NN NN O
hH1 NN NN O
mutation NN NN O
( NN NN O
T1620M NN NN O
) NN NN O
previously NN NN O
associated NN NN O
with NN NN O
IVF NN NN B-SpecificDisease
. NN NN O

METHODS NN NN O
AND NN NN O
RESULTS NN NN O
When NN NN O
expressed NN NN O
alone NN NN O
in NN NN O
Xenopus NN NN O
oocytes NN NN O
, NN NN O
T1620M NN NN O
exhibited NN NN O
no NN NN O
persistent NN NN O
currents NN NN O
, NN NN O
in NN NN O
contrast NN NN O
to NN NN O
the NN NN O
LQT3 NN NN B-Modifier
mutant NN NN O
channels NN NN O
, NN NN O
but NN NN O
the NN NN O
midpoint NN NN O
of NN NN O
steady-state NN NN O
inactivation NN NN O
( NN NN O
V NN NN O
( NN NN O
1 NN NN O
/ NN NN O
2 NN NN O
) NN NN O
) NN NN O
was NN NN O
significantly NN NN O
shifted NN NN O
toward NN NN O
more NN NN O
positive NN NN O
potentials NN NN O
than NN NN O
for NN NN O
wild-type NN NN O
hH1 NN NN O
. NN NN O

Coexpression NN NN O
of NN NN O
hbeta NN NN O
( NN NN O
1 NN NN O
) NN NN O
did NN NN O
not NN NN O
significantly NN NN O
alter NN NN O
current NN NN O
decay NN NN O
or NN NN O
recovery NN NN O
from NN NN O
inactivation NN NN O
of NN NN O
wild-type NN NN O
hH1 NN NN O
; NN NN O
however NN NN O
, NN NN O
it NN NN O
further NN NN O
shifted NN NN O
the NN NN O
V NN NN O
( NN NN O
1 NN NN O
/ NN NN O
2 NN NN O
) NN NN O
and NN NN O
accelerated NN NN O
the NN NN O
recovery NN NN O
from NN NN O
inactivation NN NN O
of NN NN O
T1620M NN NN O
. NN NN O

Oocyte NN NN O
macropatch NN NN O
analysis NN NN O
revealed NN NN O
that NN NN O
the NN NN O
activation NN NN O
kinetics NN NN O
of NN NN O
T1620M NN NN O
were NN NN O
normal NN NN O
. NN NN O

CONCLUSIONS NN NN O
It NN NN O
is NN NN O
suggested NN NN O
that NN NN O
coexpression NN NN O
of NN NN O
hbeta NN NN O
( NN NN O
1 NN NN O
) NN NN O
exposes NN NN O
a NN NN O
more NN NN O
severe NN NN O
functional NN NN O
defect NN NN O
that NN NN O
results NN NN O
in NN NN O
a NN NN O
greater NN NN O
overlap NN NN O
in NN NN O
the NN NN O
relationship NN NN O
between NN NN O
channel NN NN O
inactivation NN NN O
and NN NN O
activation NN NN O
( NN NN O
window NN NN O
current NN NN O
) NN NN O
in NN NN O
T1620M NN NN O
, NN NN O
which NN NN O
is NN NN O
proposed NN NN O
to NN NN O
be NN NN O
a NN NN O
potential NN NN O
pathophysiological NN NN O
mechanism NN NN O
of NN NN O
IVF NN NN B-SpecificDisease
in NN NN O
vivo NN NN O
. NN NN O

One NN NN O
possible NN NN O
explanation NN NN O
for NN NN O
our NN NN O
finding NN NN O
is NN NN O
an NN NN O
altered NN NN O
alpha- NN NN O
/ NN NN O
beta NN NN O
( NN NN O
1 NN NN O
) NN NN O
-subunit NN NN O
association NN NN O
in NN NN O
the NN NN O
mutant NN NN O
. NN NN O

. NN NN O

10631148 NN NN O
Meiotic NN NN O
segregation NN NN O
analysis NN NN O
of NN NN O
RB1 NN NN O
alleles NN NN O
in NN NN O
retinoblastoma NN NN B-Modifier
pedigrees NN NN O
by NN NN O
use NN NN O
of NN NN O
single-sperm NN NN O
typing NN NN O
. NN NN O

In NN NN O
hereditary NN NN B-SpecificDisease
retinoblastoma NN NN I-SpecificDisease
, NN NN O
different NN NN O
epidemiological NN NN O
studies NN NN O
have NN NN O
indicated NN NN O
a NN NN O
preferential NN NN O
paternal NN NN O
transmission NN NN O
of NN NN O
mutant NN NN O
retinoblastoma NN NN B-Modifier
alleles NN NN O
to NN NN O
offspring NN NN O
, NN NN O
suggesting NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
a NN NN O
meiotic NN NN O
drive NN NN O
. NN NN O

To NN NN O
investigate NN NN O
this NN NN O
mechanism NN NN O
, NN NN O
we NN NN O
analyzed NN NN O
sperm NN NN O
samples NN NN O
from NN NN O
six NN NN O
individuals NN NN O
from NN NN O
five NN NN O
unrelated NN NN O
families NN NN O
affected NN NN O
with NN NN O
hereditary NN NN B-SpecificDisease
retinoblastoma NN NN I-SpecificDisease
. NN NN O

Single-sperm NN NN O
typing NN NN O
techniques NN NN O
were NN NN O
performed NN NN O
for NN NN O
each NN NN O
sample NN NN O
by NN NN O
study NN NN O
of NN NN O
two NN NN O
informative NN NN O
short NN NN O
tandem NN NN O
repeats NN NN O
located NN NN O
either NN NN O
in NN NN O
or NN NN O
close NN NN O
to NN NN O
the NN NN O
retinoblastoma NN NN B-Modifier
gene NN NN O
( NN NN O
RB1 NN NN O
) NN NN O
. NN NN O

The NN NN O
segregation NN NN O
probability NN NN O
of NN NN O
mutant NN NN O
RB1 NN NN O
alleles NN NN O
in NN NN O
sperm NN NN O
samples NN NN O
was NN NN O
assessed NN NN O
by NN NN O
use NN NN O
of NN NN O
the NN NN O
SPERMSEG NN NN O
program NN NN O
, NN NN O
which NN NN O
includes NN NN O
experimental NN NN O
parameters NN NN O
, NN NN O
recombination NN NN O
fractions NN NN O
between NN NN O
the NN NN O
markers NN NN O
, NN NN O
and NN NN O
segregation NN NN O
parameters NN NN O
. NN NN O

A NN NN O
total NN NN O
of NN NN O
2 NN NN O
, NN NN O
952 NN NN O
single NN NN O
sperm NN NN O
from NN NN O
the NN NN O
six NN NN O
donors NN NN O
were NN NN O
analyzed NN NN O
. NN NN O

We NN NN O
detected NN NN O
a NN NN O
significant NN NN O
segregation NN NN O
distortion NN NN O
in NN NN O
the NN NN O
data NN NN O
as NN NN O
a NN NN O
whole NN NN O
( NN NN O
P NN NN O
= NN NN O
. NN NN O

0099 NN NN O
) NN NN O
and NN NN O
a NN NN O
significant NN NN O
heterogeneity NN NN O
in NN NN O
the NN NN O
segregation NN NN O
rate NN NN O
across NN NN O
donors NN NN O
( NN NN O
. NN NN O

0092 NN NN O
) NN NN O
. NN NN O

Further NN NN O
analysis NN NN O
shows NN NN O
that NN NN O
this NN NN O
result NN NN O
can NN NN O
be NN NN O
explained NN NN O
by NN NN O
segregation NN NN O
distortion NN NN O
in NN NN O
favor NN NN O
of NN NN O
the NN NN O
normal NN NN O
allele NN NN O
in NN NN O
one NN NN O
donor NN NN O
only NN NN O
and NN NN O
that NN NN O
it NN NN O
does NN NN O
not NN NN O
provide NN NN O
evidence NN NN O
of NN NN O
a NN NN O
significant NN NN O
segregation NN NN O
distortion NN NN O
in NN NN O
the NN NN O
other NN NN O
donors NN NN O
. NN NN O

The NN NN O
segregation NN NN O
distortion NN NN O
favoring NN NN O
the NN NN O
mutant NN NN O
RB1 NN NN O
allele NN NN O
does NN NN O
not NN NN O
seem NN NN O
to NN NN O
occur NN NN O
during NN NN O
spermatogenesis NN NN O
, NN NN O
and NN NN O
, NN NN O
thus NN NN O
, NN NN O
meiotic NN NN O
drive NN NN O
may NN NN O
result NN NN O
either NN NN O
from NN NN O
various NN NN O
mechanisms NN NN O
, NN NN O
including NN NN O
a NN NN O
fertilization NN NN O
advantage NN NN O
or NN NN O
a NN NN O
better NN NN O
mobility NN NN O
in NN NN O
sperm NN NN O
bearing NN NN O
a NN NN O
mutant NN NN O
RB1 NN NN O
gene NN NN O
, NN NN O
or NN NN O
from NN NN O
the NN NN O
existence NN NN O
of NN NN O
a NN NN O
defectively NN NN O
imprinted NN NN O
gene NN NN O
located NN NN O
on NN NN O
the NN NN O
human NN NN O
X NN NN O
chromosome NN NN O
. NN NN O

10633128 NN NN O
Friedreich NN NN B-SpecificDisease
ataxia NN NN I-SpecificDisease
: NN NN O
an NN NN O
overview NN NN O
. NN NN O

Friedreich NN NN B-SpecificDisease
ataxia NN NN I-SpecificDisease
, NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
neurodegenerative NN NN I-DiseaseClass
disease NN NN I-DiseaseClass
, NN NN O
is NN NN O
the NN NN O
most NN NN O
common NN NN O
of NN NN O
the NN NN O
inherited NN NN B-SpecificDisease
ataxias NN NN I-SpecificDisease
. NN NN O

The NN NN O
recent NN NN O
discovery NN NN O
of NN NN O
the NN NN O
gene NN NN O
that NN NN O
is NN NN O
mutated NN NN O
in NN NN O
this NN NN O
condition NN NN O
, NN NN O
FRDA NN NN O
, NN NN O
has NN NN O
led NN NN O
to NN NN O
rapid NN NN O
advances NN NN O
in NN NN O
the NN NN O
understanding NN NN O
of NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
Friedreich NN NN B-SpecificDisease
ataxia NN NN I-SpecificDisease
. NN NN O

About NN NN O
98 NN NN O
% NN NN O
of NN NN O
mutant NN NN O
alleles NN NN O
have NN NN O
an NN NN O
expansion NN NN O
of NN NN O
a NN NN O
GAA NN NN O
trinucleotide NN NN O
repeat NN NN O
in NN NN O
intron NN NN O
1 NN NN O
of NN NN O
the NN NN O
gene NN NN O
. NN NN O

This NN NN O
leads NN NN O
to NN NN O
reduced NN NN O
levels NN NN O
of NN NN O
the NN NN O
protein NN NN O
, NN NN O
frataxin NN NN O
. NN NN O

There NN NN O
is NN NN O
mounting NN NN O
evidence NN NN O
to NN NN O
suggest NN NN O
that NN NN O
Friedreich NN NN B-SpecificDisease
ataxia NN NN I-SpecificDisease
is NN NN O
the NN NN O
result NN NN O
of NN NN O
accumulation NN NN O
of NN NN O
iron NN NN O
in NN NN O
mitochondria NN NN O
leading NN NN O
to NN NN O
excess NN NN O
production NN NN O
of NN NN O
free NN NN O
radicals NN NN O
, NN NN O
which NN NN O
then NN NN O
results NN NN O
in NN NN O
cellular NN NN O
damage NN NN O
and NN NN O
death NN NN O
. NN NN O

Currently NN NN O
there NN NN O
is NN NN O
no NN NN O
known NN NN O
treatment NN NN O
that NN NN O
alters NN NN O
the NN NN O
natural NN NN O
course NN NN O
of NN NN O
the NN NN O
disease NN NN O
. NN NN O

The NN NN O
discovery NN NN O
of NN NN O
the NN NN O
FRDA NN NN B-Modifier
gene NN NN O
and NN NN O
its NN NN O
possible NN NN O
function NN NN O
has NN NN O
raised NN NN O
hope NN NN O
that NN NN O
rational NN NN O
therapeutic NN NN O
strategies NN NN O
will NN NN O
be NN NN O
developed NN NN O
. NN NN O

. NN NN O

10636421 NN NN O
X-linked NN NN B-SpecificDisease
retinoschisis NN NN I-SpecificDisease
with NN NN O
point NN NN O
mutations NN NN O
in NN NN O
the NN NN O
XLRS1 NN NN O
gene NN NN O
. NN NN O

BACKGROUND NN NN O
X-linked NN NN B-SpecificDisease
retinoschisis NN NN I-SpecificDisease
( NN NN O
XLRS NN NN B-SpecificDisease
) NN NN O
is NN NN O
a NN NN O
relatively NN NN O
rare NN NN O
vitreoretinal NN NN B-DiseaseClass
dystrophy NN NN I-DiseaseClass
that NN NN O
causes NN NN O
visual NN NN B-SpecificDisease
loss NN NN I-SpecificDisease
in NN NN O
young NN NN O
men NN NN O
. NN NN O

Recently NN NN O
, NN NN O
a NN NN O
gene NN NN O
responsible NN NN O
for NN NN O
this NN NN O
disease NN NN O
, NN NN O
designated NN NN O
XLRS1 NN NN O
, NN NN O
was NN NN O
identified NN NN O
, NN NN O
and NN NN O
several NN NN O
deleterious NN NN O
gene NN NN O
mutations NN NN O
were NN NN O
reported NN NN O
. NN NN O

OBJECTIVE NN NN O
To NN NN O
analyze NN NN O
Japanese NN NN O
patients NN NN O
clinically NN NN O
diagnosed NN NN O
as NN NN O
having NN NN O
XLRS NN NN B-Modifier
formutational NN NN O
changes NN NN O
in NN NN O
the NN NN O
XLRS1 NN NN O
gene NN NN O
. NN NN O

METHODS NN NN O
Ten NN NN O
patients NN NN O
with NN NN O
XLRS NN NN B-SpecificDisease
underwent NN NN O
full NN NN O
ophthalmologic NN NN O
examination NN NN O
, NN NN O
including NN NN O
slitlamp NN NN O
biomicroscopy NN NN O
and NN NN O
dilated NN NN O
funduscopy NN NN O
. NN NN O

Genomic NN NN O
DNA NN NN O
was NN NN O
isolated NN NN O
from NN NN O
leukocytes NN NN O
, NN NN O
and NN NN O
all NN NN O
exons NN NN O
of NN NN O
the NN NN O
XLRS1 NN NN O
gene NN NN O
were NN NN O
amplified NN NN O
by NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
and NN NN O
analyzed NN NN O
using NN NN O
a NN NN O
direct NN NN O
sequencing NN NN O
method NN NN O
. NN NN O

RESULTS NN NN O
Point NN NN O
mutations NN NN O
in NN NN O
the NN NN O
XLRS1 NN NN O
gene NN NN O
were NN NN O
identified NN NN O
in NN NN O
all NN NN O
10 NN NN O
patients NN NN O
. NN NN O

The NN NN O
mutations NN NN O
were NN NN O
identical NN NN O
in NN NN O
each NN NN O
of NN NN O
2 NN NN O
pairs NN NN O
of NN NN O
brothers NN NN O
. NN NN O

Six NN NN O
of NN NN O
the NN NN O
point NN NN O
mutations NN NN O
represented NN NN O
missense NN NN O
mutations NN NN O
, NN NN O
1 NN NN O
was NN NN O
a NN NN O
nonsense NN NN O
mutation NN NN O
, NN NN O
and NN NN O
1 NN NN O
was NN NN O
a NN NN O
frameshift NN NN O
mutation NN NN O
. NN NN O

Five NN NN O
of NN NN O
the NN NN O
mutations NN NN O
are NN NN O
newly NN NN O
reported NN NN O
herein NN NN O
. NN NN O

CONCLUSIONS NN NN O
The NN NN O
discovery NN NN O
of NN NN O
new NN NN O
point NN NN O
mutations NN NN O
in NN NN O
this NN NN O
study NN NN O
increases NN NN O
the NN NN O
available NN NN O
information NN NN O
regarding NN NN O
the NN NN O
spectrum NN NN O
of NN NN O
genetic NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
and NN NN O
clinical NN NN O
manifestations NN NN O
of NN NN O
XLRS NN NN B-SpecificDisease
. NN NN O

However NN NN O
, NN NN O
the NN NN O
limited NN NN O
data NN NN O
failed NN NN O
to NN NN O
reveal NN NN O
a NN NN O
correlation NN NN O
between NN NN O
mutation NN NN O
and NN NN O
disease NN NN O
phenotype NN NN O
. NN NN O

CLINICAL NN NN O
RELEVANCE NN NN O
Identification NN NN O
of NN NN O
mutations NN NN O
in NN NN O
the NN NN O
XLRS1 NN NN O
gene NN NN O
and NN NN O
expanded NN NN O
information NN NN O
on NN NN O
clinical NN NN O
manifestations NN NN O
will NN NN O
facilitate NN NN O
early NN NN O
diagnosis NN NN O
, NN NN O
appropriate NN NN O
early NN NN O
therapy NN NN O
, NN NN O
and NN NN O
genetic NN NN O
counseling NN NN O
regarding NN NN O
the NN NN O
prognosis NN NN O
of NN NN O
XLRS NN NN B-SpecificDisease
. NN NN O

. NN NN O

10639175 NN NN O
Atm NN NN O
and NN NN O
Bax NN NN O
cooperate NN NN O
in NN NN O
ionizing NN NN O
radiation-induced NN NN O
apoptosis NN NN O
in NN NN O
the NN NN O
central NN NN O
nervous NN NN O
system NN NN O
. NN NN O

Ataxia-telangiectasia NN NN B-SpecificDisease
is NN NN O
a NN NN O
hereditary NN NN B-DiseaseClass
multisystemic NN NN I-DiseaseClass
disease NN NN I-DiseaseClass
resulting NN NN O
from NN NN O
mutations NN NN O
of NN NN O
ataxia NN NN B-SpecificDisease
telangiectasia NN NN I-SpecificDisease
, NN NN O
mutated NN NN O
( NN NN O
ATM NN NN O
) NN NN O
and NN NN O
is NN NN O
characterized NN NN O
by NN NN O
neurodegeneration NN NN B-DiseaseClass
, NN NN O
cancer NN NN B-DiseaseClass
, NN NN O
immune NN NN B-DiseaseClass
defects NN NN I-DiseaseClass
, NN NN O
and NN NN O
hypersensitivity NN NN B-DiseaseClass
to NN NN I-DiseaseClass
ionizing NN NN I-DiseaseClass
radiation NN NN I-DiseaseClass
. NN NN O

The NN NN O
molecular NN NN O
details NN NN O
of NN NN O
ATM NN NN O
function NN NN O
in NN NN O
the NN NN O
nervous NN NN O
system NN NN O
are NN NN O
unclear NN NN O
, NN NN O
although NN NN O
the NN NN O
neurological NN NN B-DiseaseClass
lesion NN NN I-DiseaseClass
in NN NN O
ataxia-telangiectasia NN NN B-SpecificDisease
becomes NN NN O
apparent NN NN O
early NN NN O
in NN NN O
life NN NN O
, NN NN O
suggesting NN NN O
a NN NN O
developmental NN NN O
origin NN NN O
. NN NN O

The NN NN O
central NN NN O
nervous NN NN O
system NN NN O
( NN NN O
CNS NN NN O
) NN NN O
of NN NN O
Atm-null NN NN O
mice NN NN O
shows NN NN O
a NN NN O
pronounced NN NN O
defect NN NN O
in NN NN O
apoptosis NN NN O
induced NN NN O
by NN NN O
genotoxic NN NN O
stress NN NN O
, NN NN O
suggesting NN NN O
ATM NN NN O
functions NN NN O
to NN NN O
eliminate NN NN O
neurons NN NN O
with NN NN O
excessive NN NN O
genomic NN NN O
damage NN NN O
. NN NN O

Here NN NN O
, NN NN O
we NN NN O
report NN NN O
that NN NN O
the NN NN O
death NN NN O
effector NN NN O
Bax NN NN O
is NN NN O
required NN NN O
for NN NN O
a NN NN O
large NN NN O
proportion NN NN O
of NN NN O
Atm-dependent NN NN O
apoptosis NN NN O
in NN NN O
the NN NN O
developing NN NN O
CNS NN NN O
after NN NN O
ionizing NN NN O
radiation NN NN O
( NN NN O
IR NN NN O
) NN NN O
. NN NN O

Although NN NN O
many NN NN O
of NN NN O
the NN NN O
same NN NN O
regions NN NN O
of NN NN O
the NN NN O
CNS NN NN O
in NN NN O
both NN NN O
Bax- NN NN O
/ NN NN O
- NN NN O
and NN NN O
Atm- NN NN O
/ NN NN O
- NN NN O
mice NN NN O
were NN NN O
radioresistant NN NN O
, NN NN O
mice NN NN O
nullizygous NN NN O
for NN NN O
both NN NN O
Bax NN NN O
and NN NN O
Atm NN NN O
showed NN NN O
additional NN NN O
reduction NN NN O
in NN NN O
IR-induced NN NN O
apoptosis NN NN O
in NN NN O
the NN NN O
CNS NN NN O
. NN NN O

Therefore NN NN O
, NN NN O
although NN NN O
the NN NN O
major NN NN O
IR-induced NN NN O
apoptotic NN NN O
pathway NN NN O
in NN NN O
the NN NN O
CNS NN NN O
requires NN NN O
Atm NN NN O
and NN NN O
Bax NN NN O
, NN NN O
a NN NN O
p53-dependent NN NN O
collateral NN NN O
pathway NN NN O
exists NN NN O
that NN NN O
has NN NN O
both NN NN O
Atm- NN NN O
and NN NN O
Bax-independent NN NN O
branches NN NN O
. NN NN O

Further NN NN O
, NN NN O
Atm- NN NN O
and NN NN O
Bax-dependent NN NN O
apoptosis NN NN O
in NN NN O
the NN NN O
CNS NN NN O
also NN NN O
required NN NN O
caspase-3 NN NN O
activation NN NN O
. NN NN O

These NN NN O
data NN NN O
implicate NN NN O
Bax NN NN O
and NN NN O
caspase-3 NN NN O
as NN NN O
death NN NN O
effectors NN NN O
in NN NN O
neurodegenerative NN NN O
pathways NN NN O
. NN NN O

. NN NN O

10662807 NN NN O
Haim-Munk NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
and NN NN O
Papillon-Lefevre NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
are NN NN O
allelic NN NN O
mutations NN NN O
in NN NN O
cathepsin NN NN O
C. NN NN O
Of NN NN O
the NN NN O
many NN NN O
palmoplantar NN NN B-DiseaseClass
keratoderma NN NN I-DiseaseClass
( NN NN I-DiseaseClass
PPK NN NN I-DiseaseClass
) NN NN I-DiseaseClass
conditions NN NN I-DiseaseClass
, NN NN O
only NN NN O
Papillon-Lefevre NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
PLS NN NN B-SpecificDisease
) NN NN O
and NN NN O
Haim-Munk NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
HMS NN NN B-SpecificDisease
) NN NN O
are NN NN O
associated NN NN O
with NN NN O
premature NN NN O
periodontal NN NN O
destruction NN NN O
. NN NN O

Although NN NN O
both NN NN O
PLS NN NN B-SpecificDisease
and NN NN O
HMS NN NN B-SpecificDisease
share NN NN O
the NN NN O
cardinal NN NN O
features NN NN O
of NN NN O
PPK NN NN B-DiseaseClass
and NN NN O
severe NN NN O
periodontitis NN NN B-SpecificDisease
, NN NN O
a NN NN O
number NN NN O
of NN NN O
additional NN NN O
findings NN NN O
are NN NN O
reported NN NN O
in NN NN O
HMS NN NN B-SpecificDisease
including NN NN O
arachnodactyly NN NN B-SpecificDisease
, NN NN O
acro-osteolysis NN NN B-SpecificDisease
, NN NN O
atrophic NN NN B-SpecificDisease
changes NN NN I-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
nails NN NN I-SpecificDisease
, NN NN O
and NN NN O
a NN NN O
radiographic NN NN B-SpecificDisease
deformity NN NN I-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
fingers NN NN I-SpecificDisease
. NN NN O

While NN NN O
PLS NN NN B-Modifier
cases NN NN O
have NN NN O
been NN NN O
identified NN NN O
throughout NN NN O
the NN NN O
world NN NN O
, NN NN O
HMS NN NN B-SpecificDisease
has NN NN O
only NN NN O
been NN NN O
described NN NN O
among NN NN O
descendants NN NN O
of NN NN O
a NN NN O
religious NN NN O
isolate NN NN O
originally NN NN O
from NN NN O
Cochin NN NN O
, NN NN O
India NN NN O
. NN NN O

Parental NN NN O
consanguinity NN NN O
is NN NN O
a NN NN O
characteristic NN NN O
of NN NN O
many NN NN O
cases NN NN O
of NN NN O
both NN NN O
conditions NN NN O
. NN NN O

Although NN NN O
autosomal NN NN O
recessive NN NN O
transmission NN NN O
of NN NN O
PLS NN NN B-SpecificDisease
is NN NN O
evident NN NN O
, NN NN O
a NN NN O
more NN NN O
`` NN NN O
complex NN NN O
`` NN NN O
autosomal NN NN O
recessive NN NN O
pattern NN NN O
of NN NN O
inheritance NN NN O
with NN NN O
phenotypic NN NN O
influences NN NN O
from NN NN O
a NN NN O
closely NN NN O
linked NN NN O
modifying NN NN O
locus NN NN O
has NN NN O
been NN NN O
hypothesised NN NN O
for NN NN O
HMS NN NN B-SpecificDisease
. NN NN O

Recently NN NN O
, NN NN O
mutations NN NN O
of NN NN O
the NN NN O
cathepsin NN NN O
C NN NN O
gene NN NN O
have NN NN O
been NN NN O
identified NN NN O
as NN NN O
the NN NN O
underlying NN NN O
genetic NN NN B-DiseaseClass
defect NN NN I-DiseaseClass
in NN NN O
PLS NN NN B-SpecificDisease
. NN NN O

To NN NN O
determine NN NN O
if NN NN O
a NN NN O
cathepsin NN NN O
C NN NN O
mutation NN NN O
is NN NN O
also NN NN O
responsible NN NN O
for NN NN O
HMS NN NN B-SpecificDisease
, NN NN O
we NN NN O
sequenced NN NN O
the NN NN O
gene NN NN O
in NN NN O
affected NN NN O
and NN NN O
unaffected NN NN O
subjects NN NN O
from NN NN O
the NN NN O
Cochin NN NN O
isolate NN NN O
in NN NN O
which NN NN O
both NN NN O
the NN NN O
PLS NN NN B-Modifier
and NN NN O
HMS NN NN B-Modifier
phenotypes NN NN O
appear NN NN O
. NN NN O

Here NN NN O
we NN NN O
report NN NN O
identification NN NN O
of NN NN O
a NN NN O
mutation NN NN O
of NN NN O
cathepsin NN NN O
C NN NN O
( NN NN O
exon NN NN O
6 NN NN O
, NN NN O
2127A NN NN O
-- NN NN O
G NN NN O
) NN NN O
that NN NN O
changes NN NN O
a NN NN O
highly NN NN O
conserved NN NN O
amino NN NN O
acid NN NN O
in NN NN O
the NN NN O
cathepsin NN NN O
C NN NN O
peptide NN NN O
. NN NN O

This NN NN O
mutation NN NN O
segregates NN NN O
with NN NN O
HMS NN NN B-SpecificDisease
in NN NN O
four NN NN O
nuclear NN NN O
families NN NN O
. NN NN O

Additionally NN NN O
, NN NN O
the NN NN O
existence NN NN O
of NN NN O
a NN NN O
shared NN NN O
common NN NN O
haplotype NN NN O
for NN NN O
genetic NN NN O
loci NN NN O
flanking NN NN O
the NN NN O
cathepsin NN NN O
C NN NN O
gene NN NN O
suggests NN NN O
that NN NN O
affected NN NN O
subjects NN NN O
descended NN NN O
from NN NN O
the NN NN O
Cochin NN NN O
isolate NN NN O
are NN NN O
homozygous NN NN O
for NN NN O
a NN NN O
mutation NN NN O
inherited NN NN O
`` NN NN O
identical NN NN O
by NN NN O
descent NN NN O
`` NN NN O
from NN NN O
a NN NN O
common NN NN O
ancestor NN NN O
. NN NN O

This NN NN O
finding NN NN O
supports NN NN O
simple NN NN O
autosomal NN NN O
recessive NN NN O
inheritance NN NN O
for NN NN O
HMS NN NN B-SpecificDisease
in NN NN O
these NN NN O
families NN NN O
. NN NN O

We NN NN O
also NN NN O
report NN NN O
a NN NN O
mutation NN NN O
of NN NN O
the NN NN O
same NN NN O
exon NN NN O
6 NN NN O
CTSC NN NN O
codon NN NN O
( NN NN O
2126C NN NN O
-- NN NN O
T NN NN O
) NN NN O
in NN NN O
a NN NN O
Turkish NN NN O
family NN NN O
with NN NN O
classical NN NN O
PLS NN NN B-SpecificDisease
. NN NN O

These NN NN O
findings NN NN O
provide NN NN O
evidence NN NN O
that NN NN O
PLS NN NN B-SpecificDisease
and NN NN O
HMS NN NN B-SpecificDisease
are NN NN O
allelic NN NN O
variants NN NN O
of NN NN O
cathepsin NN NN O
C NN NN O
gene NN NN O
mutations NN NN O
. NN NN O

. NN NN O

10677309 NN NN O
ATM-heterozygous NN NN O
germline NN NN O
mutations NN NN O
contribute NN NN O
to NN NN O
breast NN NN B-Modifier
cancer NN NN I-Modifier
-susceptibility NN NN O
. NN NN O

Approximately NN NN O
0 NN NN O
. NN NN O

5 NN NN O
% NN NN O
-1 NN NN O
% NN NN O
of NN NN O
the NN NN O
general NN NN O
population NN NN O
has NN NN O
been NN NN O
estimated NN NN O
to NN NN O
be NN NN O
heterozygous NN NN O
for NN NN O
a NN NN O
germline NN NN O
mutation NN NN O
in NN NN O
the NN NN O
ATM NN NN O
gene NN NN O
. NN NN O

Mutations NN NN O
in NN NN O
the NN NN O
ATM NN NN O
gene NN NN O
are NN NN O
responsible NN NN O
for NN NN O
the NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
ataxia-telangiectasia NN NN B-SpecificDisease
( NN NN O
A-T NN NN B-SpecificDisease
) NN NN O
( NN NN O
MIM NN NN O
208900 NN NN O
) NN NN O
. NN NN O

The NN NN O
finding NN NN O
that NN NN O
ATM-heterozygotes NN NN O
have NN NN O
an NN NN O
increased NN NN O
relative NN NN O
risk NN NN O
for NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
was NN NN O
supported NN NN O
by NN NN O
some NN NN O
studies NN NN O
but NN NN O
not NN NN O
confirmed NN NN O
by NN NN O
others NN NN O
. NN NN O

In NN NN O
view NN NN O
of NN NN O
this NN NN O
discrepancy NN NN O
, NN NN O
we NN NN O
examined NN NN O
the NN NN O
frequency NN NN O
of NN NN O
ATM NN NN O
germline NN NN O
mutations NN NN O
in NN NN O
a NN NN O
selected NN NN O
group NN NN O
of NN NN O
Dutch NN NN O
patients NN NN O
with NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

We NN NN O
have NN NN O
analyzed NN NN O
ATM NN NN O
germline NN NN O
mutations NN NN O
in NN NN O
normal NN NN O
blood NN NN O
lymphocytes NN NN O
, NN NN O
using NN NN O
the NN NN O
protein-truncation NN NN O
test NN NN O
followed NN NN O
by NN NN O
genomic-sequence NN NN O
analysis NN NN O
. NN NN O

A NN NN O
high NN NN O
percentage NN NN O
of NN NN O
ATM NN NN O
germline NN NN O
mutations NN NN O
was NN NN O
demonstrated NN NN O
among NN NN O
patients NN NN O
with NN NN O
sporadic NN NN B-SpecificDisease
breast NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

The NN NN O
82 NN NN O
patients NN NN O
included NN NN O
in NN NN O
this NN NN O
study NN NN O
had NN NN O
developed NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
at NN NN O
age NN NN O
45 NN NN O
and NN NN O
had NN NN O
survived NN NN O
/ NN NN O
= NN NN O
5 NN NN O
years NN NN O
( NN NN O
mean NN NN O
15 NN NN O
years NN NN O
) NN NN O
, NN NN O
and NN NN O
in NN NN O
33 NN NN O
( NN NN O
40 NN NN O
% NN NN O
) NN NN O
of NN NN O
the NN NN O
patients NN NN O
a NN NN O
contralateral NN NN B-SpecificDisease
breast NN NN I-SpecificDisease
tumor NN NN I-SpecificDisease
had NN NN O
been NN NN O
diagnosed NN NN O
. NN NN O

Among NN NN O
these NN NN O
patients NN NN O
we NN NN O
identified NN NN O
seven NN NN O
( NN NN O
8 NN NN O
. NN NN O

5 NN NN O
% NN NN O
) NN NN O
ATM NN NN O
germline NN NN O
mutations NN NN O
, NN NN O
of NN NN O
which NN NN O
five NN NN O
are NN NN O
distinct NN NN O
. NN NN O

One NN NN O
splice-site NN NN O
mutation NN NN O
( NN NN O
IVS10-6T NN NN O
-- NN NN O
G NN NN O
) NN NN O
was NN NN O
detected NN NN O
three NN NN O
times NN NN O
in NN NN O
our NN NN O
series NN NN O
. NN NN O

Four NN NN O
heterozygous NN NN O
carriers NN NN O
were NN NN O
patients NN NN O
with NN NN O
bilateral NN NN B-SpecificDisease
breast NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

Our NN NN O
results NN NN O
indicate NN NN O
that NN NN O
the NN NN O
mutations NN NN O
identified NN NN O
in NN NN O
this NN NN O
study NN NN O
are NN NN O
`` NN NN O
A-T NN NN B-Modifier
disease-causing NN NN O
`` NN NN O
mutations NN NN O
that NN NN O
might NN NN O
be NN NN O
associated NN NN O
with NN NN O
an NN NN O
increased NN NN O
risk NN NN O
of NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
in NN NN O
heterozygotes NN NN O
. NN NN O

We NN NN O
conclude NN NN O
that NN NN O
ATM NN NN O
heterozygotes NN NN O
have NN NN O
an NN NN O
approximately NN NN O
ninefold-increased NN NN O
risk NN NN O
of NN NN O
developing NN NN O
a NN NN O
type NN NN O
of NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
characterized NN NN O
by NN NN O
frequent NN NN O
bilateral NN NN O
occurrence NN NN O
, NN NN O
early NN NN O
age NN NN O
at NN NN O
onset NN NN O
, NN NN O
and NN NN O
long-term NN NN O
survival NN NN O
. NN NN O

The NN NN O
specific NN NN O
characteristics NN NN O
of NN NN O
our NN NN O
population NN NN O
of NN NN O
patients NN NN O
may NN NN O
explain NN NN O
why NN NN O
such NN NN O
a NN NN O
high NN NN O
frequency NN NN O
was NN NN O
not NN NN O
found NN NN O
in NN NN O
other NN NN O
series NN NN O
. NN NN O

10698963 NN NN O
Human NN NN O
mutations NN NN O
in NN NN O
glucose NN NN O
6-phosphate NN NN O
dehydrogenase NN NN O
reflect NN NN O
evolutionary NN NN O
history NN NN O
. NN NN O

Glucose NN NN O
6-phosphate NN NN O
dehydrogenase NN NN O
( NN NN O
G6PD NN NN O
) NN NN O
is NN NN O
a NN NN O
cytosolic NN NN O
enzyme NN NN O
encoded NN NN O
by NN NN O
a NN NN O
housekeeping NN NN O
X-linked NN NN O
gene NN NN O
whose NN NN O
main NN NN O
function NN NN O
is NN NN O
to NN NN O
produce NN NN O
NADPH NN NN O
, NN NN O
a NN NN O
key NN NN O
electron NN NN O
donor NN NN O
in NN NN O
the NN NN O
defense NN NN O
against NN NN O
oxidizing NN NN O
agents NN NN O
and NN NN O
in NN NN O
reductive NN NN O
biosynthetic NN NN O
reactions NN NN O
. NN NN O

Inherited NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
is NN NN O
associated NN NN O
with NN NN O
either NN NN O
episodic NN NN B-SpecificDisease
hemolytic NN NN I-SpecificDisease
anemia NN NN I-SpecificDisease
( NN NN O
triggered NN NN O
by NN NN O
fava NN NN O
beans NN NN O
or NN NN O
other NN NN O
agents NN NN O
) NN NN O
or NN NN O
life-long NN NN B-SpecificDisease
hemolytic NN NN I-SpecificDisease
anemia NN NN I-SpecificDisease
. NN NN O

We NN NN O
show NN NN O
here NN NN O
that NN NN O
an NN NN O
evolutionary NN NN O
analysis NN NN O
is NN NN O
a NN NN O
key NN NN O
to NN NN O
understanding NN NN O
the NN NN O
biology NN NN O
of NN NN O
a NN NN O
housekeeping NN NN O
gene NN NN O
. NN NN O

From NN NN O
the NN NN O
alignment NN NN O
of NN NN O
the NN NN O
amino NN NN O
acid NN NN O
( NN NN O
aa NN NN O
) NN NN O
sequence NN NN O
of NN NN O
52 NN NN O
glucose NN NN O
6-phosphate NN NN O
dehydrogenase NN NN O
( NN NN O
G6PD NN NN O
) NN NN O
species NN NN O
from NN NN O
42 NN NN O
different NN NN O
organisms NN NN O
, NN NN O
we NN NN O
found NN NN O
a NN NN O
striking NN NN O
correlation NN NN O
between NN NN O
the NN NN O
aa NN NN O
replacements NN NN O
that NN NN O
cause NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
humans NN NN O
and NN NN O
the NN NN O
sequence NN NN O
conservation NN NN O
of NN NN O
G6PD NN NN O
two-thirds NN NN O
of NN NN O
such NN NN O
replacements NN NN O
are NN NN O
in NN NN O
highly NN NN O
and NN NN O
moderately NN NN O
conserved NN NN O
( NN NN O
50-99 NN NN O
% NN NN O
) NN NN O
aa NN NN O
; NN NN O
relatively NN NN O
few NN NN O
are NN NN O
in NN NN O
fully NN NN O
conserved NN NN O
aa NN NN O
( NN NN O
where NN NN O
they NN NN O
might NN NN O
be NN NN O
lethal NN NN O
) NN NN O
or NN NN O
in NN NN O
poorly NN NN O
conserved NN NN O
aa NN NN O
, NN NN O
where NN NN O
presumably NN NN O
they NN NN O
simply NN NN O
would NN NN O
not NN NN O
cause NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

This NN NN O
is NN NN O
consistent NN NN O
with NN NN O
the NN NN O
notion NN NN O
that NN NN O
all NN NN O
human NN NN O
mutants NN NN O
have NN NN O
residual NN NN O
enzyme NN NN O
activity NN NN O
and NN NN O
that NN NN O
null NN NN O
mutations NN NN O
are NN NN O
lethal NN NN O
at NN NN O
some NN NN O
stage NN NN O
of NN NN O
development NN NN O
. NN NN O

Comparing NN NN O
the NN NN O
distribution NN NN O
of NN NN O
mutations NN NN O
in NN NN O
a NN NN O
human NN NN O
housekeeping NN NN O
gene NN NN O
with NN NN O
evolutionary NN NN O
conservation NN NN O
is NN NN O
a NN NN O
useful NN NN O
tool NN NN O
for NN NN O
pinpointing NN NN O
amino NN NN O
acid NN NN O
residues NN NN O
important NN NN O
for NN NN O
the NN NN O
stability NN NN O
or NN NN O
the NN NN O
function NN NN O
of NN NN O
the NN NN O
corresponding NN NN O
protein NN NN O
. NN NN O

In NN NN O
view NN NN O
of NN NN O
the NN NN O
current NN NN O
explosive NN NN O
increase NN NN O
in NN NN O
full NN NN O
genome NN NN O
sequencing NN NN O
projects NN NN O
, NN NN O
this NN NN O
tool NN NN O
will NN NN O
become NN NN O
rapidly NN NN O
available NN NN O
for NN NN O
numerous NN NN O
other NN NN O
genes NN NN O
. NN NN O

. NN NN O

10699184 NN NN O
Constitutive NN NN O
and NN NN O
regulated NN NN O
modes NN NN O
of NN NN O
splicing NN NN O
produce NN NN O
six NN NN O
major NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
protein NN NN O
kinase NN NN O
( NN NN O
DMPK NN NN O
) NN NN O
isoforms NN NN O
with NN NN O
distinct NN NN O
properties NN NN O
. NN NN O

Myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
is NN NN O
the NN NN O
most NN NN O
prevalent NN NN O
inherited NN NN B-DiseaseClass
neuromuscular NN NN I-DiseaseClass
disease NN NN I-DiseaseClass
in NN NN O
adults NN NN O
. NN NN O

The NN NN O
genetic NN NN B-DiseaseClass
defect NN NN I-DiseaseClass
is NN NN O
a NN NN O
CTG NN NN O
triplet NN NN O
repeat NN NN O
expansion NN NN O
in NN NN O
the NN NN O
3-untranslated NN NN O
region NN NN O
of NN NN O
the NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
protein NN NN O
kinase NN NN O
( NN NN O
DMPK NN NN O
) NN NN O
gene NN NN O
, NN NN O
consisting NN NN O
of NN NN O
15 NN NN O
exons NN NN O
. NN NN O

Using NN NN O
a NN NN O
transgenic NN NN O
DMPK-overexpressor NN NN O
mouse NN NN O
model NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
here NN NN O
that NN NN O
the NN NN O
endogenous NN NN O
mouse NN NN O
DMPK NN NN O
gene NN NN O
and NN NN O
the NN NN O
human NN NN O
DMPK NN NN O
transgene NN NN O
produce NN NN O
six NN NN O
major NN NN O
alternatively NN NN O
spliced NN NN O
mRNAs NN NN O
which NN NN O
have NN NN O
almost NN NN O
identical NN NN O
cell NN NN O
type-dependent NN NN O
distribution NN NN O
frequencies NN NN O
and NN NN O
expression NN NN O
patterns NN NN O
. NN NN O

Use NN NN O
of NN NN O
a NN NN O
cryptic NN NN O
5 NN NN O
splice NN NN O
site NN NN O
in NN NN O
exon NN NN O
8 NN NN O
, NN NN O
which NN NN O
results NN NN O
in NN NN O
absence NN NN O
or NN NN O
presence NN NN O
of NN NN O
15 NN NN O
nucleotides NN NN O
specifying NN NN O
a NN NN O
VSGGG NN NN O
peptide NN NN O
motif NN NN O
, NN NN O
and NN NN O
/ NN NN O
or NN NN O
use NN NN O
of NN NN O
a NN NN O
cryptic NN NN O
3 NN NN O
splice NN NN O
site NN NN O
in NN NN O
exon NN NN O
14 NN NN O
, NN NN O
which NN NN O
leads NN NN O
to NN NN O
a NN NN O
frameshift NN NN O
in NN NN O
the NN NN O
mRNA NN NN O
reading NN NN O
frame NN NN O
, NN NN O
occur NN NN O
as NN NN O
independent NN NN O
stochastic NN NN O
events NN NN O
in NN NN O
all NN NN O
tissues NN NN O
examined NN NN O
. NN NN O

In NN NN O
contrast NN NN O
, NN NN O
the NN NN O
excision NN NN O
of NN NN O
exons NN NN O
13 NN NN O
/ NN NN O
14 NN NN O
that NN NN O
causes NN NN O
a NN NN O
frameshift NN NN O
and NN NN O
creates NN NN O
a NN NN O
C-terminally NN NN O
truncated NN NN O
protein NN NN O
is NN NN O
clearly NN NN O
cell NN NN O
type NN NN O
dependent NN NN O
and NN NN O
occurs NN NN O
predominantly NN NN O
in NN NN O
smooth NN NN O
muscle NN NN O
. NN NN O

We NN NN O
generated NN NN O
all NN NN O
six NN NN O
full-length NN NN O
mouse NN NN O
cDNAs NN NN O
that NN NN O
result NN NN O
from NN NN O
combinations NN NN O
of NN NN O
these NN NN O
three NN NN O
major NN NN O
splicing NN NN O
events NN NN O
and NN NN O
show NN NN O
that NN NN O
their NN NN O
transfection NN NN O
into NN NN O
cells NN NN O
in NN NN O
culture NN NN O
leads NN NN O
to NN NN O
production NN NN O
of NN NN O
four NN NN O
different NN NN O
approximately NN NN O
74 NN NN O
kDa NN NN O
full-length NN NN O
( NN NN O
heart- NN NN O
, NN NN O
skeletal NN NN O
muscle- NN NN O
or NN NN O
brain-specific NN NN O
) NN NN O
and NN NN O
two NN NN O
C-terminally NN NN O
truncated NN NN O
approximately NN NN O
68 NN NN O
kDa NN NN O
( NN NN O
smooth NN NN O
muscle-specific NN NN O
) NN NN O
isoforms NN NN O
. NN NN O

Information NN NN O
on NN NN O
DMPK NN NN O
mRNA NN NN O
and NN NN O
protein NN NN O
isoform NN NN O
expression NN NN O
patterns NN NN O
will NN NN O
be NN NN O
useful NN NN O
for NN NN O
recognizing NN NN O
differential NN NN O
effects NN NN O
of NN NN O
( NN NN O
CTG NN NN O
) NN NN O
( NN NN O
n NN NN O
) NN NN O
expansion NN NN O
in NN NN O
DM NN NN B-Modifier
manifestation NN NN O
. NN NN O

. NN NN O

10706858 NN NN O
Genetic NN NN O
analysis NN NN O
, NN NN O
phenotypic NN NN O
diagnosis NN NN O
, NN NN O
and NN NN O
risk NN NN O
of NN NN O
venous NN NN B-SpecificDisease
thrombosis NN NN I-SpecificDisease
in NN NN O
families NN NN O
with NN NN O
inherited NN NN O
deficiencies NN NN B-SpecificDisease
of NN NN I-SpecificDisease
protein NN NN I-SpecificDisease
S NN NN I-SpecificDisease
. NN NN O

Protein NN NN B-SpecificDisease
S NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
is NN NN O
a NN NN O
recognized NN NN O
risk NN NN O
factor NN NN O
for NN NN O
venous NN NN B-SpecificDisease
thrombosis NN NN I-SpecificDisease
. NN NN O

Of NN NN O
all NN NN O
the NN NN O
inherited NN NN O
thrombophilic NN NN B-DiseaseClass
conditions NN NN I-DiseaseClass
, NN NN O
it NN NN O
remains NN NN O
the NN NN O
most NN NN O
difficult NN NN O
to NN NN O
diagnose NN NN O
because NN NN O
of NN NN O
phenotypic NN NN O
variability NN NN O
, NN NN O
which NN NN O
can NN NN O
lead NN NN O
to NN NN O
inconclusive NN NN O
results NN NN O
. NN NN O

We NN NN O
have NN NN O
overcome NN NN O
this NN NN O
problem NN NN O
by NN NN O
studying NN NN O
a NN NN O
cohort NN NN O
of NN NN O
patients NN NN O
from NN NN O
a NN NN O
single NN NN O
center NN NN O
where NN NN O
the NN NN O
diagnosis NN NN O
was NN NN O
confirmed NN NN O
at NN NN O
the NN NN O
genetic NN NN O
level NN NN O
. NN NN O

Twenty-eight NN NN O
index NN NN O
patients NN NN O
with NN NN O
protein NN NN B-SpecificDisease
S NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
and NN NN O
a NN NN O
PROS1 NN NN B-SpecificDisease
gene NN NN I-SpecificDisease
defect NN NN I-SpecificDisease
were NN NN O
studied NN NN O
, NN NN O
together NN NN O
with NN NN O
109 NN NN O
first-degree NN NN O
relatives NN NN O
. NN NN O

To NN NN O
avoid NN NN O
selection NN NN O
bias NN NN O
, NN NN O
we NN NN O
confined NN NN O
analysis NN NN O
of NN NN O
total NN NN O
and NN NN O
free NN NN O
protein NN NN O
S NN NN O
levels NN NN O
and NN NN O
thrombotic NN NN O
risk NN NN O
to NN NN O
the NN NN O
patients NN NN O
relatives NN NN O
. NN NN O

In NN NN O
this NN NN O
group NN NN O
of NN NN O
relatives NN NN O
, NN NN O
a NN NN O
low NN NN O
free NN NN O
protein NN NN O
S NN NN O
level NN NN O
was NN NN O
the NN NN O
most NN NN O
reliable NN NN O
predictor NN NN O
of NN NN O
a NN NN O
PROS1 NN NN B-SpecificDisease
gene NN NN I-SpecificDisease
defect NN NN I-SpecificDisease
( NN NN O
sensitivity NN NN O
97 NN NN O
. NN NN O

7 NN NN O
% NN NN O
, NN NN O
specificity NN NN O
100 NN NN O
% NN NN O
) NN NN O
. NN NN O

First-degree NN NN O
relatives NN NN O
with NN NN O
a NN NN O
PROS1 NN NN B-SpecificDisease
gene NN NN I-SpecificDisease
defect NN NN I-SpecificDisease
had NN NN O
a NN NN O
5 NN NN O
. NN NN O

0-fold NN NN O
higher NN NN O
risk NN NN O
of NN NN O
thrombosis NN NN B-SpecificDisease
( NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
, NN NN O
1 NN NN O
. NN NN O

5-16 NN NN O
. NN NN O

8 NN NN O
) NN NN O
than NN NN O
those NN NN O
with NN NN O
a NN NN O
normal NN NN O
PROS1 NN NN O
gene NN NN O
and NN NN O
no NN NN O
other NN NN O
recognized NN NN O
thrombophilic NN NN B-SpecificDisease
defect NN NN I-SpecificDisease
. NN NN O

Although NN NN O
pregnancy NN NN O
/ NN NN O
puerperium NN NN O
and NN NN O
immobility NN NN B-SpecificDisease
/ NN NN O
trauma NN NN B-SpecificDisease
were NN NN O
important NN NN O
precipitating NN NN O
factors NN NN O
for NN NN O
thrombosis NN NN B-SpecificDisease
, NN NN O
almost NN NN O
half NN NN O
of NN NN O
the NN NN O
events NN NN O
were NN NN O
spontaneous NN NN O
. NN NN O

Relatives NN NN O
with NN NN O
splice-site NN NN O
or NN NN O
major NN NN O
structural NN NN O
defects NN NN B-SpecificDisease
in NN NN I-SpecificDisease
the NN NN I-SpecificDisease
PROS1 NN NN I-SpecificDisease
gene NN NN I-SpecificDisease
were NN NN O
more NN NN O
likely NN NN O
to NN NN O
have NN NN O
had NN NN O
a NN NN O
thrombotic NN NN O
event NN NN O
and NN NN O
had NN NN O
significantly NN NN O
lower NN NN O
total NN NN O
and NN NN O
free NN NN O
protein NN NN O
S NN NN O
levels NN NN O
than NN NN O
those NN NN O
relatives NN NN O
having NN NN O
missense NN NN O
mutations NN NN O
. NN NN O

We NN NN O
conclude NN NN O
that NN NN O
persons NN NN O
with NN NN O
PROS1 NN NN B-SpecificDisease
gene NN NN I-SpecificDisease
defects NN NN I-SpecificDisease
and NN NN O
protein NN NN B-SpecificDisease
S NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
are NN NN O
at NN NN O
increased NN NN O
risk NN NN O
of NN NN O
thrombosis NN NN B-SpecificDisease
and NN NN O
that NN NN O
free NN NN O
protein NN NN O
S NN NN O
estimation NN NN O
offers NN NN O
the NN NN O
most NN NN O
reliable NN NN O
way NN NN O
of NN NN O
diagnosing NN NN O
the NN NN O
deficiency NN NN O
. NN NN O

( NN NN O
Blood NN NN O
. NN NN O

2000 NN NN O
; NN NN O
95 NN NN O
1935-1941 NN NN O
) NN NN O
. NN NN O

10709732 NN NN O
Autoimmune NN NN B-SpecificDisease
lymphoproliferative NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
ALPS NN NN B-SpecificDisease
) NN NN O
in NN NN O
a NN NN O
child NN NN O
from NN NN O
consanguineous NN NN O
parents NN NN O
: NN NN O
a NN NN O
dominant NN NN O
or NN NN O
recessive NN NN O
disease NN NN O
? NN NN O

Autoimmune NN NN B-SpecificDisease
lymphoproliferative NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
ALPS NN NN B-SpecificDisease
) NN NN O
is NN NN O
characterized NN NN O
by NN NN O
autoimmune NN NN O
features NN NN O
and NN NN O
lymphoproliferations NN NN O
and NN NN O
is NN NN O
generally NN NN O
caused NN NN O
by NN NN O
defective NN NN O
Fas-mediated NN NN O
apoptosis NN NN O
. NN NN O

This NN NN O
report NN NN O
describes NN NN O
a NN NN O
child NN NN O
with NN NN O
clinical NN NN O
features NN NN O
of NN NN O
ALPS NN NN B-SpecificDisease
without NN NN O
detectable NN NN O
Fas NN NN O
expression NN NN O
on NN NN O
freshly NN NN O
isolated NN NN O
blood NN NN O
leukocytes NN NN O
. NN NN O

Detection NN NN O
of NN NN O
FAS NN NN O
transcripts NN NN O
via NN NN O
real-time NN NN O
quantitative NN NN O
PCR NN NN O
made NN NN O
a NN NN O
severe NN NN O
transcriptional NN NN O
defect NN NN O
unlikely NN NN O
. NN NN O

Sequencing NN NN O
of NN NN O
the NN NN O
FAS NN NN O
gene NN NN O
revealed NN NN O
a NN NN O
20-nucleotide NN NN O
duplication NN NN O
in NN NN O
the NN NN O
last NN NN O
exon NN NN O
affecting NN NN O
the NN NN O
cytoplasmic NN NN O
signaling NN NN O
domain NN NN O
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
homozygous NN NN O
for NN NN O
this NN NN O
mutation NN NN O
, NN NN O
whereas NN NN O
the NN NN O
consanguineous NN NN O
parents NN NN O
and NN NN O
the NN NN O
siblings NN NN O
were NN NN O
heterozygous NN NN O
. NN NN O

The NN NN O
patient NN NN O
reported NN NN O
here NN NN O
is NN NN O
a NN NN O
human NN NN O
homologue NN NN O
of NN NN O
the NN NN O
Fas-null NN NN O
mouse NN NN O
, NN NN O
inasmuch NN NN O
as NN NN O
she NN NN O
carries NN NN O
an NN NN O
autosomal NN NN O
homozygous NN NN O
mutation NN NN O
in NN NN O
the NN NN O
FAS NN NN O
gene NN NN O
and NN NN O
she NN NN O
shows NN NN O
the NN NN O
severe NN NN O
and NN NN O
accelerated NN NN O
ALPS NN NN B-Modifier
phenotype NN NN O
. NN NN O

The NN NN O
heterozygous NN NN O
family NN NN O
members NN NN O
did NN NN O
not NN NN O
have NN NN O
the NN NN O
ALPS NN NN B-Modifier
phenotype NN NN O
, NN NN O
indicating NN NN O
that NN NN O
the NN NN O
disease-causing NN NN O
FAS NN NN O
mutation NN NN O
in NN NN O
this NN NN O
family NN NN O
is NN NN O
autosomal NN NN O
recessive NN NN O
. NN NN O

. NN NN O

10712201 NN NN O
Identification NN NN O
of NN NN O
novel NN NN O
imprinted NN NN O
transcripts NN NN O
in NN NN O
the NN NN O
Prader-Willi NN NN B-Modifier
syndrome NN NN I-Modifier
and NN NN O
Angelman NN NN B-Modifier
syndrome NN NN I-Modifier
deletion NN NN O
region NN NN O
: NN NN O
further NN NN O
evidence NN NN O
for NN NN O
regional NN NN O
imprinting NN NN O
control NN NN O
. NN NN O

Deletions NN NN O
and NN NN O
other NN NN O
abnormalities NN NN O
of NN NN O
human NN NN O
chromosome NN NN O
15q11-q13 NN NN O
are NN NN O
associated NN NN O
with NN NN O
two NN NN O
developmental NN NN O
disorders NN NN O
, NN NN O
Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
PWS NN NN B-SpecificDisease
) NN NN O
and NN NN O
Angelman NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
AS NN NN B-SpecificDisease
) NN NN O
. NN NN O

Loss NN NN O
of NN NN O
expression NN NN O
of NN NN O
imprinted NN NN O
, NN NN O
paternally NN NN O
expressed NN NN O
genes NN NN O
has NN NN O
been NN NN O
implicated NN NN O
in NN NN O
PWS NN NN B-SpecificDisease
. NN NN O

However NN NN O
, NN NN O
the NN NN O
number NN NN O
of NN NN O
imprinted NN NN O
genes NN NN O
that NN NN O
contribute NN NN O
to NN NN O
PWS NN NN B-SpecificDisease
, NN NN O
and NN NN O
the NN NN O
range NN NN O
over NN NN O
which NN NN O
the NN NN O
imprinting NN NN O
signal NN NN O
acts NN NN O
to NN NN O
silence NN NN O
one NN NN O
copy NN NN O
of NN NN O
the NN NN O
gene NN NN O
in NN NN O
a NN NN O
parent-of-origin-specific NN NN O
manner NN NN O
, NN NN O
are NN NN O
unknown NN NN O
. NN NN O

To NN NN O
identify NN NN O
additional NN NN O
imprinted NN NN O
genes NN NN O
that NN NN O
could NN NN O
contribute NN NN O
to NN NN O
the NN NN O
PWS NN NN B-Modifier
phenotype NN NN O
and NN NN O
to NN NN O
understand NN NN O
the NN NN O
regional NN NN O
control NN NN O
of NN NN O
imprinting NN NN O
in NN NN O
15q11-q13 NN NN O
, NN NN O
we NN NN O
have NN NN O
constructed NN NN O
an NN NN O
imprinted NN NN O
transcript NN NN O
map NN NN O
of NN NN O
the NN NN O
PWS-AS NN NN O
deletion NN NN O
interval NN NN O
. NN NN O

The NN NN O
imprinting NN NN O
status NN NN O
of NN NN O
22 NN NN O
expressed NN NN O
sequence NN NN O
tags NN NN O
derived NN NN O
from NN NN O
the NN NN O
radiation-hybrid NN NN O
human NN NN O
transcript NN NN O
maps NN NN O
or NN NN O
physical NN NN O
maps NN NN O
was NN NN O
determined NN NN O
in NN NN O
a NN NN O
reverse NN NN O
transcriptase-PCR NN NN O
assay NN NN O
and NN NN O
correlated NN NN O
with NN NN O
the NN NN O
position NN NN O
of NN NN O
the NN NN O
transcripts NN NN O
on NN NN O
the NN NN O
physical NN NN O
map NN NN O
. NN NN O

Seven NN NN O
new NN NN O
paternally NN NN O
expressed NN NN O
transcripts NN NN O
localize NN NN O
to NN NN O
an NN NN O
approximately NN NN O
1 NN NN O
. NN NN O

5-Mb NN NN O
domain NN NN O
surrounding NN NN O
the NN NN O
SNRPN-associated NN NN O
imprinting NN NN O
center NN NN O
, NN NN O
which NN NN O
already NN NN O
includes NN NN O
four NN NN O
imprinted NN NN O
, NN NN O
paternally NN NN O
expressed NN NN O
genes NN NN O
. NN NN O

All NN NN O
other NN NN O
tested NN NN O
new NN NN O
transcripts NN NN O
in NN NN O
the NN NN O
deletion NN NN O
region NN NN O
were NN NN O
expressed NN NN O
from NN NN O
both NN NN O
alleles NN NN O
. NN NN O

A NN NN O
domain NN NN O
of NN NN O
exclusive NN NN O
paternal NN NN O
expression NN NN O
surrounding NN NN O
the NN NN O
imprinting NN NN O
center NN NN O
suggests NN NN O
strong NN NN O
regional NN NN O
control NN NN O
of NN NN O
the NN NN O
imprinting NN NN O
process NN NN O
. NN NN O

This NN NN O
study NN NN O
provides NN NN O
the NN NN O
means NN NN O
for NN NN O
further NN NN O
investigation NN NN O
of NN NN O
additional NN NN O
genes NN NN O
that NN NN O
cause NN NN O
or NN NN O
modify NN NN O
the NN NN O
phenotypes NN NN O
associated NN NN O
with NN NN O
rearrangements NN NN O
of NN NN O
15q11-q13 NN NN O
. NN NN O

10712209 NN NN O
Combined NN NN O
analysis NN NN O
of NN NN O
hereditary NN NN B-Modifier
prostate NN NN I-Modifier
cancer NN NN I-Modifier
linkage NN NN O
to NN NN O
1q24-25 NN NN O
: NN NN O
results NN NN O
from NN NN O
772 NN NN O
hereditary NN NN B-Modifier
prostate NN NN I-Modifier
cancer NN NN I-Modifier
families NN NN O
from NN NN O
the NN NN O
International NN NN O
Consortium NN NN O
for NN NN O
Prostate NN NN B-Modifier
Cancer NN NN I-Modifier
Genetics NN NN O
. NN NN O

A NN NN O
previous NN NN O
linkage NN NN O
study NN NN O
provided NN NN O
evidence NN NN O
for NN NN O
a NN NN O
prostate NN NN B-Modifier
cancer NN NN I-Modifier
-susceptibility NN NN O
locus NN NN O
at NN NN O
1q24-25 NN NN O
. NN NN O

Subsequent NN NN O
reports NN NN O
in NN NN O
additional NN NN O
collections NN NN O
of NN NN O
families NN NN O
have NN NN O
yielded NN NN O
conflicting NN NN O
results NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
evidence NN NN O
for NN NN O
locus NN NN O
heterogeneity NN NN O
has NN NN O
been NN NN O
provided NN NN O
by NN NN O
the NN NN O
identification NN NN O
of NN NN O
other NN NN O
putative NN NN O
hereditary NN NN B-Modifier
prostate NN NN I-Modifier
cancer NN NN I-Modifier
loci NN NN O
on NN NN O
Xq27-28 NN NN O
, NN NN O
1q42-43 NN NN O
, NN NN O
and NN NN O
1p36 NN NN O
. NN NN O

The NN NN O
present NN NN O
study NN NN O
describes NN NN O
a NN NN O
combined NN NN O
analysis NN NN O
for NN NN O
six NN NN O
markers NN NN O
in NN NN O
the NN NN O
1q24-25 NN NN O
region NN NN O
in NN NN O
772 NN NN O
families NN NN O
affected NN NN O
by NN NN O
hereditary NN NN B-SpecificDisease
prostate NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
and NN NN O
ascertained NN NN O
by NN NN O
the NN NN O
members NN NN O
of NN NN O
the NN NN O
International NN NN O
Consortium NN NN O
for NN NN O
Prostate NN NN B-Modifier
Cancer NN NN I-Modifier
Genetics NN NN O
( NN NN O
ICPCG NN NN O
) NN NN O
from NN NN O
North NN NN O
America NN NN O
, NN NN O
Australia NN NN O
, NN NN O
Finland NN NN O
, NN NN O
Norway NN NN O
, NN NN O
Sweden NN NN O
, NN NN O
and NN NN O
the NN NN O
United NN NN O
Kingdom NN NN O
. NN NN O

Overall NN NN O
, NN NN O
there NN NN O
was NN NN O
some NN NN O
evidence NN NN O
for NN NN O
linkage NN NN O
, NN NN O
with NN NN O
a NN NN O
peak NN NN O
parametric NN NN O
multipoint NN NN O
LOD NN NN O
score NN NN O
assuming NN NN O
heterogeneity NN NN O
( NN NN O
HLOD NN NN O
) NN NN O
of NN NN O
1 NN NN O
. NN NN O

40 NN NN O
( NN NN O
P NN NN O
= NN NN O
. NN NN O

01 NN NN O
) NN NN O
at NN NN O
D1S212 NN NN O
. NN NN O

The NN NN O
estimated NN NN O
proportion NN NN O
of NN NN O
families NN NN O
( NN NN O
alpha NN NN O
) NN NN O
linked NN NN O
to NN NN O
the NN NN O
locus NN NN O
was NN NN O
. NN NN O

06 NN NN O
( NN NN O
1-LOD NN NN O
support NN NN O
interval NN NN O
. NN NN O

01- NN NN O
. NN NN O

12 NN NN O
) NN NN O
. NN NN O

This NN NN O
evidence NN NN O
was NN NN O
not NN NN O
observed NN NN O
by NN NN O
a NN NN O
nonparametric NN NN O
approach NN NN O
, NN NN O
presumably NN NN O
because NN NN O
of NN NN O
the NN NN O
extensive NN NN O
heterogeneity NN NN O
. NN NN O

Further NN NN O
parametric NN NN O
analysis NN NN O
revealed NN NN O
a NN NN O
significant NN NN O
effect NN NN O
of NN NN O
the NN NN O
presence NN NN O
of NN NN O
male-to-male NN NN O
disease NN NN O
transmission NN NN O
within NN NN O
the NN NN O
families NN NN O
. NN NN O

In NN NN O
the NN NN O
subset NN NN O
of NN NN O
491 NN NN O
such NN NN O
families NN NN O
, NN NN O
the NN NN O
peak NN NN O
HLOD NN NN O
was NN NN O
2 NN NN O
. NN NN O

In NN NN O
the NN NN O
subset NN NN O
of NN NN O
491 NN NN O
such NN NN O
families NN NN O
, NN NN O
the NN NN O
peak NN NN O
HLOD NN NN O
was NN NN O
2 NN NN O
. NN NN O

56 NN NN O
( NN NN O
P NN NN O
= NN NN O
. NN NN O

0006 NN NN O
) NN NN O
and NN NN O
alpha NN NN O
= NN NN O
. NN NN O

11 NN NN O
( NN NN O
1-LOD NN NN O
support NN NN O
interval NN NN O
. NN NN O

04- NN NN O
. NN NN O

19 NN NN O
) NN NN O
, NN NN O
compared NN NN O
with NN NN O
HLODs NN NN O
of NN NN O
0 NN NN O
in NN NN O
the NN NN O
remaining NN NN O
281 NN NN O
families NN NN O
. NN NN O

Within NN NN O
the NN NN O
families NN NN O
with NN NN O
male-to-male NN NN O
disease NN NN O
transmission NN NN O
, NN NN O
alpha NN NN O
increased NN NN O
with NN NN O
the NN NN O
early NN NN O
mean NN NN O
age NN NN O
at NN NN O
diagnosis NN NN O
( NN NN O
65 NN NN O
years NN NN O
, NN NN O
alpha NN NN O
= NN NN O
. NN NN O

19 NN NN O
, NN NN O
with NN NN O
1-LOD NN NN O
support NN NN O
interval NN NN O
. NN NN O

06- NN NN O
. NN NN O

34 NN NN O
) NN NN O
and NN NN O
the NN NN O
number NN NN O
of NN NN O
affected NN NN O
family NN NN O
members NN NN O
( NN NN O
five NN NN O
or NN NN O
more NN NN O
family NN NN O
members NN NN O
, NN NN O
alpha NN NN O
= NN NN O
. NN NN O

15 NN NN O
, NN NN O
with NN NN O
1-LOD NN NN O
support NN NN O
interval NN NN O
. NN NN O

04- NN NN O
. NN NN O

28 NN NN O
) NN NN O
. NN NN O

The NN NN O
highest NN NN O
value NN NN O
of NN NN O
alpha NN NN O
was NN NN O
observed NN NN O
for NN NN O
the NN NN O
48 NN NN O
families NN NN O
that NN NN O
met NN NN O
all NN NN O
three NN NN O
criteria NN NN O
( NN NN O
peak NN NN O
HLOD NN NN O
= NN NN O
2 NN NN O
. NN NN O

25 NN NN O
, NN NN O
P NN NN O
= NN NN O
. NN NN O

001 NN NN O
, NN NN O
alpha NN NN O
= NN NN O
. NN NN O

29 NN NN O
, NN NN O
with NN NN O
1-LOD NN NN O
support NN NN O
interval NN NN O
. NN NN O

08- NN NN O
. NN NN O

53 NN NN O
) NN NN O
. NN NN O

These NN NN O
results NN NN O
support NN NN O
the NN NN O
finding NN NN O
of NN NN O
a NN NN O
prostate NN NN B-Modifier
cancer NN NN I-Modifier
-susceptibility NN NN O
gene NN NN O
linked NN NN O
to NN NN O
1q24-25 NN NN O
, NN NN O
albeit NN NN O
in NN NN O
a NN NN O
defined NN NN O
subset NN NN O
of NN NN O
prostate NN NN B-Modifier
cancer NN NN I-Modifier
families NN NN O
. NN NN O

Although NN NN O
HPC1 NN NN O
accounts NN NN O
for NN NN O
only NN NN O
a NN NN O
small NN NN O
proportion NN NN O
of NN NN O
all NN NN O
families NN NN O
affected NN NN O
by NN NN O
hereditary NN NN B-SpecificDisease
prostate NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
, NN NN O
it NN NN O
appears NN NN O
to NN NN O
play NN NN O
a NN NN O
more NN NN O
prominent NN NN O
role NN NN O
in NN NN O
the NN NN O
subset NN NN O
of NN NN O
families NN NN O
with NN NN O
several NN NN O
members NN NN O
affected NN NN O
at NN NN O
an NN NN O
early NN NN O
age NN NN O
and NN NN O
with NN NN O
male-to-male NN NN O
disease NN NN O
transmission NN NN O
. NN NN O

10712225 NN NN O
A NN NN O
recurrent NN NN O
expansion NN NN O
of NN NN O
a NN NN O
maternal NN NN O
allele NN NN O
with NN NN O
36 NN NN O
CAG NN NN O
repeats NN NN O
causes NN NN O
Huntington NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
in NN NN O
two NN NN O
sisters NN NN O
. NN NN O

Large NN NN O
intergenerational NN NN O
repeat NN NN O
expansions NN NN O
of NN NN O
the NN NN O
CAG NN NN O
trinucleotide NN NN O
repeat NN NN O
in NN NN O
the NN NN O
HD NN NN B-Modifier
gene NN NN O
have NN NN O
been NN NN O
well NN NN O
documented NN NN O
for NN NN O
the NN NN O
male NN NN O
germline NN NN O
. NN NN O

We NN NN O
describe NN NN O
a NN NN O
recurrent NN NN O
large NN NN O
expansion NN NN O
of NN NN O
a NN NN O
maternal NN NN O
allele NN NN O
with NN NN O
36 NN NN O
CAG NN NN O
repeats NN NN O
( NN NN O
to NN NN O
66 NN NN O
and NN NN O
57 NN NN O
repeats NN NN O
, NN NN O
respectively NN NN O
, NN NN O
in NN NN O
two NN NN O
daughters NN NN O
) NN NN O
associated NN NN O
with NN NN O
onset NN NN O
of NN NN O
Huntington NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
HD NN NN B-SpecificDisease
) NN NN O
in NN NN O
the NN NN O
second NN NN O
and NN NN O
third NN NN O
decade NN NN O
in NN NN O
a NN NN O
family NN NN O
without NN NN O
history NN NN O
of NN NN O
HD NN NN B-SpecificDisease
. NN NN O

Our NN NN O
findings NN NN O
give NN NN O
evidence NN NN O
of NN NN O
a NN NN O
gonadal NN NN O
mosaicism NN NN O
in NN NN O
the NN NN O
unaffected NN NN O
mother NN NN O
. NN NN O

We NN NN O
hypothesize NN NN O
that NN NN O
large NN NN O
expansions NN NN O
also NN NN O
occur NN NN O
in NN NN O
the NN NN O
female NN NN O
germline NN NN O
and NN NN O
that NN NN O
a NN NN O
negative NN NN O
selection NN NN O
of NN NN O
oocytes NN NN O
with NN NN O
long NN NN O
repeats NN NN O
might NN NN O
explain NN NN O
the NN NN O
different NN NN O
instability NN NN O
behavior NN NN O
of NN NN O
the NN NN O
male NN NN O
and NN NN O
the NN NN O
female NN NN O
germlines NN NN O
. NN NN O

. NN NN O

10716718 NN NN O
Abnormal NN NN O
development NN NN O
of NN NN O
Purkinje NN NN O
cells NN NN O
and NN NN O
lymphocytes NN NN O
in NN NN O
Atm NN NN O
mutant NN NN O
mice NN NN O
. NN NN O

Motor NN NN B-DiseaseClass
incoordination NN NN I-DiseaseClass
, NN NN O
immune NN NN B-DiseaseClass
deficiencies NN NN I-DiseaseClass
, NN NN O
and NN NN O
an NN NN O
increased NN NN O
risk NN NN O
of NN NN O
cancer NN NN B-DiseaseClass
are NN NN O
the NN NN O
characteristic NN NN O
features NN NN O
of NN NN O
the NN NN O
hereditary NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
ataxia-telangiectasia NN NN B-SpecificDisease
( NN NN O
A-T NN NN B-SpecificDisease
) NN NN O
, NN NN O
which NN NN O
is NN NN O
caused NN NN O
by NN NN O
mutations NN NN O
in NN NN O
the NN NN O
ATM NN NN O
gene NN NN O
. NN NN O

Through NN NN O
gene NN NN O
targeting NN NN O
, NN NN O
we NN NN O
have NN NN O
generated NN NN O
a NN NN O
line NN NN O
of NN NN O
Atm NN NN O
mutant NN NN O
mice NN NN O
, NN NN O
Atm NN NN O
( NN NN O
y NN NN O
/ NN NN O
y NN NN O
) NN NN O
mice NN NN O
. NN NN O

In NN NN O
contrast NN NN O
to NN NN O
other NN NN O
Atm NN NN O
mutant NN NN O
mice NN NN O
, NN NN O
Atm NN NN O
( NN NN O
y NN NN O
/ NN NN O
y NN NN O
) NN NN O
mice NN NN O
show NN NN O
a NN NN O
lower NN NN O
incidence NN NN O
of NN NN O
thymic NN NN B-SpecificDisease
lymphoma NN NN I-SpecificDisease
and NN NN O
survive NN NN O
beyond NN NN O
a NN NN O
few NN NN O
months NN NN O
of NN NN O
age NN NN O
. NN NN O

Atm NN NN O
( NN NN O
y NN NN O
/ NN NN O
y NN NN O
) NN NN O
mice NN NN O
exhibit NN NN O
deficits NN NN O
in NN NN O
motor NN NN O
learning NN NN O
indicative NN NN O
of NN NN O
cerebellar NN NN B-DiseaseClass
dysfunction NN NN I-DiseaseClass
. NN NN O

Even NN NN O
though NN NN O
we NN NN O
found NN NN O
no NN NN O
gross NN NN O
cerebellar NN NN B-DiseaseClass
degeneration NN NN I-DiseaseClass
in NN NN O
older NN NN O
Atm NN NN O
( NN NN O
y NN NN O
/ NN NN O
y NN NN O
) NN NN O
animals NN NN O
, NN NN O
ectopic NN NN O
and NN NN O
abnormally NN NN O
differentiated NN NN O
Purkinje NN NN O
cells NN NN O
were NN NN O
apparent NN NN O
in NN NN O
mutant NN NN O
mice NN NN O
of NN NN O
all NN NN O
ages NN NN O
. NN NN O

These NN NN O
findings NN NN O
establish NN NN O
that NN NN O
some NN NN O
neuropathological NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
seen NN NN O
in NN NN O
A-T NN NN B-Modifier
patients NN NN O
also NN NN O
are NN NN O
present NN NN O
in NN NN O
Atm NN NN O
mutant NN NN O
mice NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
we NN NN O
report NN NN O
a NN NN O
previously NN NN O
unrecognized NN NN O
effect NN NN O
of NN NN O
Atm NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
on NN NN O
development NN NN O
or NN NN O
maintenance NN NN O
of NN NN O
CD4 NN NN O
( NN NN O
+ NN NN O
) NN NN O
8 NN NN O
( NN NN O
+ NN NN O
) NN NN O
thymocytes NN NN O
. NN NN O

We NN NN O
discuss NN NN O
these NN NN O
findings NN NN O
in NN NN O
the NN NN O
context NN NN O
of NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
abnormal NN NN O
development NN NN O
of NN NN O
Purkinje NN NN O
cells NN NN O
and NN NN O
lymphocytes NN NN O
contributes NN NN O
to NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
A-T NN NN B-SpecificDisease
. NN NN O

. NN NN O

10721669 NN NN O
Novel NN NN O
mutations NN NN O
of NN NN O
the NN NN O
ATP7B NN NN O
gene NN NN O
in NN NN O
Japanese NN NN O
patients NN NN O
with NN NN O
Wilson NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

Wilson NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
WD NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
characterized NN NN O
by NN NN O
copper NN NN O
accumulation NN NN O
in NN NN O
the NN NN O
liver NN NN O
, NN NN O
brain NN NN O
, NN NN O
kidneys NN NN O
, NN NN O
and NN NN O
corneas NN NN O
, NN NN O
and NN NN O
culminating NN NN O
in NN NN O
copper NN NN O
toxication NN NN O
in NN NN O
these NN NN O
organs NN NN O
. NN NN O

In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
analyzed NN NN O
mutations NN NN O
of NN NN O
the NN NN O
responsible NN NN O
gene NN NN O
, NN NN O
ATP7B NN NN O
, NN NN O
in NN NN O
four NN NN O
Japanese NN NN O
patients NN NN O
with NN NN O
WD NN NN B-SpecificDisease
. NN NN O

By NN NN O
direct NN NN O
sequencing NN NN O
, NN NN O
we NN NN O
identified NN NN O
five NN NN O
mutations NN NN O
, NN NN O
of NN NN O
which NN NN O
two NN NN O
were NN NN O
novel NN NN O
, NN NN O
and NN NN O
16 NN NN O
polymorphisms NN NN O
, NN NN O
of NN NN O
which NN NN O
6 NN NN O
were NN NN O
novel NN NN O
. NN NN O

The NN NN O
mutations NN NN O
2871delC NN NN O
and NN NN O
2513delA NN NN O
shift NN NN O
the NN NN O
reading NN NN O
frame NN NN O
so NN NN O
that NN NN O
truncated NN NN O
abnormal NN NN O
protein NN NN O
is NN NN O
expected NN NN O
. NN NN O

In NN NN O
contrast NN NN O
to NN NN O
these NN NN O
mutations NN NN O
found NN NN O
in NN NN O
patients NN NN O
with NN NN O
hepatic-type NN NN O
of NN NN O
early NN NN O
onset NN NN O
, NN NN O
the NN NN O
mutations NN NN O
A874V NN NN O
, NN NN O
R778L NN NN O
, NN NN O
and NN NN O
3892delGTC NN NN O
were NN NN O
either NN NN O
missense NN NN O
mutations NN NN O
or NN NN O
in NN NN O
frame NN NN O
1-amino NN NN O
acid NN NN O
deletion NN NN O
, NN NN O
and NN NN O
occurred NN NN O
in NN NN O
the NN NN O
patients NN NN O
with NN NN O
hepato-neurologic NN NN O
type NN NN O
of NN NN O
late NN NN O
onset NN NN O
. NN NN O

The NN NN O
mutations NN NN O
2871delC NN NN O
and NN NN O
R778L NN NN O
have NN NN O
been NN NN O
previously NN NN O
reported NN NN O
in NN NN O
a NN NN O
relatively NN NN O
large NN NN O
number NN NN O
of NN NN O
Japanese NN NN O
patients NN NN O
. NN NN O

In NN NN O
particular NN NN O
, NN NN O
R778L NN NN O
is NN NN O
known NN NN O
to NN NN O
be NN NN O
more NN NN O
prevalent NN NN O
in NN NN O
Asian NN NN O
countries NN NN O
than NN NN O
in NN NN O
other NN NN O
countries NN NN O
of NN NN O
the NN NN O
world NN NN O
. NN NN O

Our NN NN O
data NN NN O
are NN NN O
compatible NN NN O
with NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
the NN NN O
mutations NN NN O
tend NN NN O
to NN NN O
occur NN NN O
in NN NN O
a NN NN O
population-specific NN NN O
manner NN NN O
. NN NN O

Therefore NN NN O
, NN NN O
the NN NN O
accumulation NN NN O
of NN NN O
the NN NN O
types NN NN O
of NN NN O
mutations NN NN O
in NN NN O
Japanese NN NN O
patients NN NN O
with NN NN O
WD NN NN B-SpecificDisease
will NN NN O
facilitate NN NN O
the NN NN O
fast NN NN O
and NN NN O
effective NN NN O
genetic NN NN O
diagnosis NN NN O
of NN NN O
WD NN NN B-SpecificDisease
in NN NN O
Japanese NN NN O
patients NN NN O
. NN NN O

. NN NN O

10724160 NN NN O
Autoinhibition NN NN O
and NN NN O
activation NN NN O
mechanisms NN NN O
of NN NN O
the NN NN O
Wiskott-Aldrich NN NN B-Modifier
syndrome NN NN I-Modifier
protein NN NN O
. NN NN O

The NN NN O
Rho-family NN NN O
GTPase NN NN O
, NN NN O
Cdc42 NN NN O
, NN NN O
can NN NN O
regulate NN NN O
the NN NN O
actin NN NN O
cytoskeleton NN NN O
through NN NN O
activation NN NN O
of NN NN O
Wiskott-Aldrich NN NN B-Modifier
syndrome NN NN I-Modifier
protein NN NN O
( NN NN O
WASP NN NN O
) NN NN O
family NN NN O
members NN NN O
. NN NN O

Activation NN NN O
relieves NN NN O
an NN NN O
autoinhibitory NN NN O
contact NN NN O
between NN NN O
the NN NN O
GTPase-binding NN NN O
domain NN NN O
and NN NN O
the NN NN O
carboxy-terminal NN NN O
region NN NN O
of NN NN O
WASP NN NN O
proteins NN NN O
. NN NN O

Here NN NN O
we NN NN O
report NN NN O
the NN NN O
autoinhibited NN NN O
structure NN NN O
of NN NN O
the NN NN O
GTPase-binding NN NN O
domain NN NN O
of NN NN O
WASP NN NN O
, NN NN O
which NN NN O
can NN NN O
be NN NN O
induced NN NN O
by NN NN O
the NN NN O
C-terminal NN NN O
region NN NN O
or NN NN O
by NN NN O
organic NN NN O
co-solvents NN NN O
. NN NN O

In NN NN O
the NN NN O
autoinhibited NN NN O
complex NN NN O
, NN NN O
intramolecular NN NN O
interactions NN NN O
with NN NN O
the NN NN O
GTPase-binding NN NN O
domain NN NN O
occlude NN NN O
residues NN NN O
of NN NN O
the NN NN O
C NN NN O
terminus NN NN O
that NN NN O
regulate NN NN O
the NN NN O
Arp2 NN NN O
/ NN NN O
3 NN NN O
actin-nucleating NN NN O
complex NN NN O
. NN NN O

Binding NN NN O
of NN NN O
Cdc42 NN NN O
to NN NN O
the NN NN O
GTPase-binding NN NN O
domain NN NN O
causes NN NN O
a NN NN O
dramatic NN NN O
conformational NN NN O
change NN NN O
, NN NN O
resulting NN NN O
in NN NN O
disruption NN NN O
of NN NN O
the NN NN O
hydrophobic NN NN O
core NN NN O
and NN NN O
release NN NN O
of NN NN O
the NN NN O
C NN NN O
terminus NN NN O
, NN NN O
enabling NN NN O
its NN NN O
interaction NN NN O
with NN NN O
the NN NN O
actin NN NN O
regulatory NN NN O
machinery NN NN O
. NN NN O

These NN NN O
data NN NN O
show NN NN O
that NN NN O
intrinsically NN NN O
unstructured NN NN O
peptides NN NN O
such NN NN O
as NN NN O
the NN NN O
GTPase-binding NN NN O
domain NN NN O
of NN NN O
WASP NN NN O
can NN NN O
be NN NN O
induced NN NN O
into NN NN O
distinct NN NN O
structural NN NN O
and NN NN O
functional NN NN O
states NN NN O
depending NN NN O
on NN NN O
context NN NN O
. NN NN O

. NN NN O

10724175 NN NN O
hCds1-mediated NN NN O
phosphorylation NN NN O
of NN NN O
BRCA1 NN NN O
regulates NN NN O
the NN NN O
DNA NN NN O
damage NN NN O
response NN NN O
. NN NN O

Mutations NN NN O
in NN NN O
the NN NN O
BRCA1 NN NN O
( NN NN O
ref NN NN O
. NN NN O

1 NN NN O
) NN NN O
tumour NN NN B-Modifier
suppressor NN NN O
gene NN NN O
are NN NN O
found NN NN O
in NN NN O
almost NN NN O
all NN NN O
of NN NN O
the NN NN O
families NN NN O
with NN NN O
inherited NN NN B-CompositeMention
breast NN NN I-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancers NN NN I-CompositeMention
and NN NN O
about NN NN O
half NN NN O
of NN NN O
the NN NN O
families NN NN O
with NN NN O
only NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

Although NN NN O
the NN NN O
biochemical NN NN O
function NN NN O
of NN NN O
BRCA1 NN NN O
is NN NN O
not NN NN O
well NN NN O
understood NN NN O
, NN NN O
it NN NN O
is NN NN O
important NN NN O
for NN NN O
DNA NN NN O
damage NN NN O
repair NN NN O
and NN NN O
cell-cycle NN NN O
checkpoint NN NN O
. NN NN O

BRCA1 NN NN O
exists NN NN O
in NN NN O
nuclear NN NN O
foci NN NN O
but NN NN O
is NN NN O
hyperphosphorylated NN NN O
and NN NN O
disperses NN NN O
after NN NN O
DNA NN NN O
damage NN NN O
. NN NN O

It NN NN O
is NN NN O
not NN NN O
known NN NN O
whether NN NN O
BRCA1 NN NN O
phosphorylation NN NN O
and NN NN O
dispersion NN NN O
and NN NN O
its NN NN O
function NN NN O
in NN NN O
DNA NN NN O
damage NN NN O
response NN NN O
are NN NN O
related NN NN O
. NN NN O

In NN NN O
yeast NN NN O
the NN NN O
DNA NN NN O
damage NN NN O
response NN NN O
and NN NN O
the NN NN O
replication-block NN NN O
checkpoint NN NN O
are NN NN O
mediated NN NN O
partly NN NN O
through NN NN O
the NN NN O
Cds1 NN NN O
kinase NN NN O
family NN NN O
. NN NN O

Here NN NN O
we NN NN O
report NN NN O
that NN NN O
the NN NN O
human NN NN O
Cds1 NN NN O
kinase NN NN O
( NN NN O
hCds1 NN NN O
/ NN NN O
Chk2 NN NN O
) NN NN O
regulates NN NN O
BRCA1 NN NN O
function NN NN O
after NN NN O
DNA NN NN O
damage NN NN O
by NN NN O
phosphorylating NN NN O
serine NN NN O
988 NN NN O
of NN NN O
BRCA1 NN NN O
. NN NN O

We NN NN O
show NN NN O
that NN NN O
hCds1 NN NN O
and NN NN O
BRCA1 NN NN O
interact NN NN O
and NN NN O
co-localize NN NN O
within NN NN O
discrete NN NN O
nuclear NN NN O
foci NN NN O
but NN NN O
separate NN NN O
after NN NN O
gamma NN NN O
irradiation NN NN O
. NN NN O

Phosphorylation NN NN O
of NN NN O
BRCA1 NN NN O
at NN NN O
serine NN NN O
988 NN NN O
is NN NN O
required NN NN O
for NN NN O
the NN NN O
release NN NN O
of NN NN O
BRCA1 NN NN O
from NN NN O
hCds1 NN NN O
. NN NN O

This NN NN O
phosphorylation NN NN O
is NN NN O
also NN NN O
important NN NN O
for NN NN O
the NN NN O
ability NN NN O
of NN NN O
BRCA1 NN NN O
to NN NN O
restore NN NN O
survival NN NN O
after NN NN O
DNA NN NN O
damage NN NN O
in NN NN O
the NN NN O
BRCA1-mutated NN NN O
cell NN NN O
line NN NN O
HCC1937 NN NN O
. NN NN O

. NN NN O

10732811 NN NN O
Characterization NN NN O
of NN NN O
the NN NN O
rat NN NN O
spinocerebellar NN NN O
ataxia NN NN O
type NN NN O
3 NN NN O
gene NN NN O
. NN NN O

Machado-Joseph NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
MJD NN NN B-SpecificDisease
) NN NN O
belongs NN NN O
to NN NN O
a NN NN O
group NN NN O
of NN NN O
clinically NN NN O
and NN NN O
genetically NN NN O
heterogeneous NN NN O
neurodegenerative NN NN B-DiseaseClass
disorders NN NN I-DiseaseClass
characterized NN NN O
by NN NN O
progressive NN NN B-SpecificDisease
cerebellar NN NN I-SpecificDisease
ataxia NN NN I-SpecificDisease
. NN NN O

The NN NN O
disease-causing NN NN O
mutation NN NN O
has NN NN O
recently NN NN O
been NN NN O
identified NN NN O
as NN NN O
an NN NN O
unstable NN NN O
and NN NN O
expanded NN NN O
( NN NN O
CAG NN NN O
) NN NN O
n NN NN O
trinucleotide NN NN O
repeat NN NN O
in NN NN O
a NN NN O
novel NN NN O
gene NN NN O
of NN NN O
unknown NN NN O
function NN NN O
. NN NN O

In NN NN O
Caucasians NN NN O
, NN NN O
repeat NN NN O
expansions NN NN O
in NN NN O
the NN NN O
MJD1 NN NN O
gene NN NN O
have NN NN O
also NN NN O
been NN NN O
found NN NN O
in NN NN O
patients NN NN O
with NN NN O
the NN NN O
clinically NN NN O
distinct NN NN O
autosomal NN NN O
dominant NN NN O
spinocerebellar NN NN B-SpecificDisease
ataxia NN NN I-SpecificDisease
type NN NN I-SpecificDisease
3 NN NN I-SpecificDisease
( NN NN O
SCA3 NN NN B-SpecificDisease
) NN NN O
. NN NN O

In NN NN O
order NN NN O
to NN NN O
gain NN NN O
insight NN NN O
into NN NN O
the NN NN O
biology NN NN O
of NN NN O
the NN NN O
MJD1 NN NN O
/ NN NN O
SCA3 NN NN O
gene NN NN O
we NN NN O
cloned NN NN O
the NN NN O
rat NN NN O
homologue NN NN O
and NN NN O
studied NN NN O
its NN NN O
expression NN NN O
. NN NN O

The NN NN O
rat NN NN O
and NN NN O
human NN NN O
ataxin-3 NN NN O
genes NN NN O
are NN NN O
highly NN NN O
homologous NN NN O
with NN NN O
an NN NN O
overall NN NN O
sequence NN NN O
identity NN NN O
of NN NN O
approximately NN NN O
88 NN NN O
% NN NN O
. NN NN O

However NN NN O
, NN NN O
the NN NN O
C-terminal NN NN O
end NN NN O
of NN NN O
the NN NN O
putative NN NN O
protein NN NN O
differs NN NN O
strongly NN NN O
from NN NN O
the NN NN O
published NN NN O
human NN NN O
sequence NN NN O
. NN NN O

The NN NN O
( NN NN O
CAG NN NN O
) NN NN O
n NN NN O
block NN NN O
in NN NN O
the NN NN O
rat NN NN O
cDNA NN NN O
consists NN NN O
of NN NN O
just NN NN O
three NN NN O
interrupted NN NN O
units NN NN O
suggesting NN NN O
that NN NN O
a NN NN O
long NN NN O
polyglutamine NN NN O
stretch NN NN O
is NN NN O
not NN NN O
essential NN NN O
for NN NN O
the NN NN O
normal NN NN O
function NN NN O
of NN NN O
the NN NN O
ataxin-3 NN NN O
protein NN NN O
in NN NN O
rodents NN NN O
. NN NN O

The NN NN O
expression NN NN O
pattern NN NN O
of NN NN O
the NN NN O
SCA3 NN NN O
gene NN NN O
in NN NN O
various NN NN O
rat NN NN O
and NN NN O
human NN NN O
tissues NN NN O
was NN NN O
investigated NN NN O
by NN NN O
Northern NN NN O
blot NN NN O
analyses NN NN O
. NN NN O

The NN NN O
mature NN NN O
transcript NN NN O
is NN NN O
approximately NN NN O
6 NN NN O
kb NN NN O
in NN NN O
length NN NN O
. NN NN O

In NN NN O
rat NN NN O
testis NN NN O
, NN NN O
a NN NN O
smaller NN NN O
transcript NN NN O
of NN NN O
1 NN NN O
. NN NN O

3 NN NN O
kb NN NN O
was NN NN O
identified NN NN O
. NN NN O

Transcription NN NN O
of NN NN O
rsca3 NN NN O
was NN NN O
detected NN NN O
in NN NN O
most NN NN O
rat NN NN O
tissues NN NN O
including NN NN O
brain NN NN O
. NN NN O

Analyzing NN NN O
the NN NN O
expression NN NN O
level NN NN O
of NN NN O
the NN NN O
SCA3 NN NN O
gene NN NN O
in NN NN O
several NN NN O
human NN NN O
brain NN NN O
sections NN NN O
revealed NN NN O
no NN NN O
significant NN NN O
higher NN NN O
mRNA NN NN O
level NN NN O
in NN NN O
regions NN NN O
predominantly NN NN O
affected NN NN O
in NN NN O
MJD NN NN B-SpecificDisease
. NN NN O

Thus NN NN O
additional NN NN O
molecules NN NN O
and NN NN O
/ NN NN O
or NN NN O
regulatory NN NN O
events NN NN O
are NN NN O
necessary NN NN O
to NN NN O
explain NN NN O
the NN NN O
exclusive NN NN O
degeneration NN NN B-DiseaseClass
of NN NN I-DiseaseClass
certain NN NN I-DiseaseClass
brain NN NN I-DiseaseClass
areas NN NN I-DiseaseClass
. NN NN O

10732816 NN NN O
Emerin NN NN B-SpecificDisease
, NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
of NN NN O
which NN NN O
causes NN NN O
Emery-Dreifuss NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
, NN NN O
is NN NN O
localized NN NN O
at NN NN O
the NN NN O
inner NN NN O
nuclear NN NN O
membrane NN NN O
. NN NN O

X-linked NN NN B-SpecificDisease
recessive NN NN I-SpecificDisease
Emery-Dreifuss NN NN I-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
EDMD NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
inherited NN NN B-DiseaseClass
muscle NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
characterized NN NN O
by NN NN O
the NN NN O
clinical NN NN O
triad NN NN O
of NN NN O
progressive NN NN O
wasting NN NN B-SpecificDisease
of NN NN I-SpecificDisease
humero-peroneal NN NN I-SpecificDisease
muscles NN NN I-SpecificDisease
, NN NN O
early NN NN O
contractures NN NN B-CompositeMention
of NN NN I-CompositeMention
the NN NN I-CompositeMention
elbows NN NN I-CompositeMention
, NN NN I-CompositeMention
Achilles NN NN I-CompositeMention
tendons NN NN I-CompositeMention
and NN NN I-CompositeMention
postcervical NN NN I-CompositeMention
muscles NN NN I-CompositeMention
, NN NN O
and NN NN O
cardiac NN NN B-SpecificDisease
conduction NN NN I-SpecificDisease
block NN NN I-SpecificDisease
with NN NN O
a NN NN O
high NN NN O
risk NN NN O
of NN NN O
sudden NN NN B-SpecificDisease
death NN NN I-SpecificDisease
. NN NN O

The NN NN O
gene NN NN O
for NN NN O
EDMD NN NN B-SpecificDisease
on NN NN O
Xq28 NN NN O
encodes NN NN O
a NN NN O
novel NN NN O
protein NN NN O
named NN NN O
emerin NN NN O
that NN NN O
localizes NN NN O
at NN NN O
the NN NN O
nuclear NN NN O
membrane NN NN O
of NN NN O
skeletal NN NN O
, NN NN O
cardiac NN NN O
and NN NN O
smooth NN NN O
muscles NN NN O
and NN NN O
some NN NN O
other NN NN O
non-muscle NN NN O
tissues NN NN O
. NN NN O

To NN NN O
investigate NN NN O
a NN NN O
possible NN NN O
physiological NN NN O
role NN NN O
for NN NN O
emerin NN NN O
, NN NN O
we NN NN O
examined NN NN O
the NN NN O
ultrastructural NN NN O
localization NN NN O
of NN NN O
the NN NN O
protein NN NN O
in NN NN O
human NN NN O
skeletal NN NN O
muscle NN NN O
and NN NN O
HeLa NN NN O
cells NN NN O
, NN NN O
using NN NN O
ultrathin NN NN O
cryosections NN NN O
. NN NN O

We NN NN O
found NN NN O
that NN NN O
the NN NN O
immune-labeled NN NN O
colloidal NN NN O
gold NN NN O
particles NN NN O
were NN NN O
localized NN NN O
on NN NN O
the NN NN O
nucleoplasmic NN NN O
surface NN NN O
of NN NN O
the NN NN O
inner NN NN O
nuclear NN NN O
membrane NN NN O
, NN NN O
but NN NN O
not NN NN O
on NN NN O
the NN NN O
nuclear NN NN O
pore NN NN O
. NN NN O

Emerin NN NN O
stayed NN NN O
on NN NN O
the NN NN O
cytoplasmic NN NN O
surface NN NN O
of NN NN O
the NN NN O
nuclear NN NN O
lamina NN NN O
, NN NN O
even NN NN O
after NN NN O
detergent NN NN O
treatment NN NN O
that NN NN O
solubilizes NN NN O
membrane NN NN O
lipids NN NN O
and NN NN O
washes NN NN O
out NN NN O
membrane NN NN O
proteins NN NN O
. NN NN O

These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
emerin NN NN O
anchors NN NN O
at NN NN O
the NN NN O
inner NN NN O
nuclear NN NN O
membrane NN NN O
through NN NN O
the NN NN O
hydrophobic NN NN O
stretch NN NN O
, NN NN O
and NN NN O
protrudes NN NN O
from NN NN O
the NN NN O
hydrophilic NN NN O
region NN NN O
to NN NN O
the NN NN O
nucleoplasm NN NN O
where NN NN O
it NN NN O
interacts NN NN O
with NN NN O
the NN NN O
nuclear NN NN O
lamina NN NN O
. NN NN O

We NN NN O
speculate NN NN O
that NN NN O
emerin NN NN O
contributes NN NN O
to NN NN O
maintain NN NN O
the NN NN O
nuclear NN NN O
structure NN NN O
and NN NN O
stability NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
nuclear NN NN O
functions NN NN O
, NN NN O
particularly NN NN O
in NN NN O
muscle NN NN O
tissues NN NN O
that NN NN O
have NN NN O
severe NN NN O
stress NN NN O
with NN NN O
rigorous NN NN O
contraction-relaxation NN NN O
movements NN NN O
and NN NN O
calcium NN NN O
flux NN NN O
. NN NN O

. NN NN O

10735274 NN NN O
Locus NN NN O
heterogeneity NN NN O
in NN NN O
Friedreich NN NN B-SpecificDisease
ataxia NN NN I-SpecificDisease
. NN NN O

Friedreich NN NN B-SpecificDisease
ataxia NN NN I-SpecificDisease
( NN NN O
FRDA NN NN B-SpecificDisease
) NN NN O
is NN NN O
the NN NN O
most NN NN O
common NN NN O
form NN NN O
of NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
ataxia NN NN I-DiseaseClass
. NN NN O

The NN NN O
disease NN NN O
locus NN NN O
was NN NN O
assigned NN NN O
to NN NN O
chromosome NN NN O
9 NN NN O
and NN NN O
the NN NN O
disease NN NN O
gene NN NN O
, NN NN O
STM7 NN NN O
/ NN NN O
X25 NN NN O
, NN NN O
has NN NN O
been NN NN O
isolated NN NN O
. NN NN O

To NN NN O
date NN NN O
most NN NN O
data NN NN O
suggest NN NN O
locus NN NN O
homogeneity NN NN O
in NN NN O
FRDA NN NN B-SpecificDisease
. NN NN O

We NN NN O
now NN NN O
provide NN NN O
strong NN NN O
evidence NN NN O
of NN NN O
a NN NN O
second NN NN O
FRDA NN NN B-Modifier
locus NN NN O
. NN NN O

Studying NN NN O
two NN NN O
siblings NN NN O
with NN NN O
FRDA NN NN B-SpecificDisease
from NN NN O
two NN NN O
families NN NN O
we NN NN O
did NN NN O
not NN NN O
detect NN NN O
a NN NN O
mutation NN NN O
in NN NN O
STM7 NN NN O
/ NN NN O
X25 NN NN O
. NN NN O

Haplotype NN NN O
analysis NN NN O
of NN NN O
the NN NN O
STM7 NN NN O
/ NN NN O
X25 NN NN O
region NN NN O
of NN NN O
chromosome NN NN O
9 NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
relevant NN NN O
portion NN NN O
of NN NN O
chromosome NN NN O
9 NN NN O
differs NN NN O
in NN NN O
the NN NN O
patients NN NN O
. NN NN O

Although NN NN O
the NN NN O
patients NN NN O
studied NN NN O
had NN NN O
typical NN NN O
FRDA NN NN B-SpecificDisease
, NN NN O
one NN NN O
sibpair NN NN O
had NN NN O
the NN NN O
uncommon NN NN O
symptom NN NN O
of NN NN O
retained NN NN B-SpecificDisease
tendon NN NN I-SpecificDisease
reflexes NN NN I-SpecificDisease
. NN NN O

In NN NN O
order NN NN O
to NN NN O
investigate NN NN O
whether NN NN O
retained NN NN B-SpecificDisease
tendon NN NN I-SpecificDisease
reflexes NN NN I-SpecificDisease
are NN NN O
characteristic NN NN O
of NN NN O
FRDA NN NN B-SpecificDisease
caused NN NN O
by NN NN O
the NN NN O
second NN NN O
locus NN NN O
, NN NN O
FRDA2 NN NN O
, NN NN O
we NN NN O
studied NN NN O
an NN NN O
unrelated NN NN O
FRDA NN NN B-Modifier
patient NN NN O
with NN NN O
retained NN NN B-SpecificDisease
tendon NN NN I-SpecificDisease
reflexes NN NN I-SpecificDisease
. NN NN O

The NN NN O
observation NN NN O
of NN NN O
typical NN NN O
mutations NN NN O
in NN NN O
STM7 NN NN O
/ NN NN O
X25 NN NN O
( NN NN O
GAA NN NN O
expansions NN NN O
) NN NN O
in NN NN O
this NN NN O
patient NN NN O
demonstrates NN NN O
that NN NN O
the NN NN O
two NN NN O
genetically NN NN O
different NN NN O
forms NN NN O
of NN NN O
FRDA NN NN B-SpecificDisease
can NN NN O
not NN NN O
be NN NN O
distinguished NN NN O
clinically NN NN O
. NN NN O

. NN NN O

10736265 NN NN O
Glycerol NN NN O
as NN NN O
a NN NN O
correlate NN NN O
of NN NN O
impaired NN NN B-SpecificDisease
glucose NN NN I-SpecificDisease
tolerance NN NN I-SpecificDisease
: NN NN O
dissection NN NN O
of NN NN O
a NN NN O
complex NN NN O
system NN NN O
by NN NN O
use NN NN O
of NN NN O
a NN NN O
simple NN NN O
genetic NN NN O
trait NN NN O
. NN NN O

Glycerol NN NN O
kinase NN NN O
( NN NN O
GK NN NN O
) NN NN O
represents NN NN O
the NN NN O
primary NN NN O
entry NN NN O
of NN NN O
glycerol NN NN O
into NN NN O
glucose NN NN O
and NN NN O
triglyceride NN NN O
metabolism NN NN O
. NN NN O

Impaired NN NN B-SpecificDisease
glucose NN NN I-SpecificDisease
tolerance NN NN I-SpecificDisease
( NN NN O
IGT NN NN B-SpecificDisease
) NN NN O
and NN NN O
hypertriglyceridemia NN NN B-SpecificDisease
are NN NN O
associated NN NN O
with NN NN O
an NN NN O
increased NN NN O
risk NN NN O
of NN NN O
diabetes NN NN B-SpecificDisease
mellitus NN NN I-SpecificDisease
and NN NN O
cardiovascular NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

The NN NN O
relationship NN NN O
between NN NN O
glycerol NN NN O
and NN NN O
the NN NN O
risk NN NN O
of NN NN O
IGT NN NN B-SpecificDisease
, NN NN O
however NN NN O
, NN NN O
is NN NN O
poorly NN NN O
understood NN NN O
. NN NN O

We NN NN O
therefore NN NN O
undertook NN NN O
the NN NN O
study NN NN O
of NN NN O
fasting NN NN O
plasma NN NN O
glycerol NN NN O
levels NN NN O
in NN NN O
a NN NN O
cohort NN NN O
of NN NN O
1 NN NN O
, NN NN O
056 NN NN O
unrelated NN NN O
men NN NN O
and NN NN O
women NN NN O
of NN NN O
French-Canadian NN NN O
descent NN NN O
. NN NN O

Family NN NN O
screening NN NN O
in NN NN O
the NN NN O
initial NN NN O
cohort NN NN O
identified NN NN O
18 NN NN O
men NN NN O
from NN NN O
five NN NN O
families NN NN O
with NN NN O
severe NN NN O
hyperglycerolemia NN NN B-SpecificDisease
( NN NN O
values NN NN O
above NN NN O
2 NN NN O
. NN NN O

0 NN NN O
mmol NN NN O
/ NN NN O
liter NN NN O
) NN NN O
and NN NN O
demonstrated NN NN O
an NN NN O
X-linked NN NN O
pattern NN NN O
of NN NN O
inheritance NN NN O
. NN NN O

Linkage NN NN O
analysis NN NN O
of NN NN O
the NN NN O
data NN NN O
from NN NN O
12 NN NN O
microsatellite NN NN O
markers NN NN O
surrounding NN NN O
the NN NN O
Xp21 NN NN O
. NN NN O

3 NN NN O
GK NN NN O
gene NN NN O
resulted NN NN O
in NN NN O
a NN NN O
peak NN NN O
LOD NN NN O
score NN NN O
of NN NN O
3 NN NN O
. NN NN O

46 NN NN O
, NN NN O
centered NN NN O
around NN NN O
marker NN NN O
DXS8039 NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
since NN NN O
all NN NN O
of NN NN O
the NN NN O
families NN NN O
originated NN NN O
in NN NN O
a NN NN O
population NN NN O
with NN NN O
a NN NN O
proven NN NN O
founder NN NN O
effect-the NN NN O
Saguenay NN NN O
Lac-St NN NN O
. NN NN O

-Jean NN NN O
region NN NN O
of NN NN O
Quebec-a NN NN O
common NN NN O
disease NN NN O
haplotype NN NN O
was NN NN O
sought NN NN O
. NN NN O

Indeed NN NN O
, NN NN O
a NN NN O
six-marker NN NN O
haplotype NN NN O
extending NN NN O
over NN NN O
a NN NN O
region NN NN O
of NN NN O
5 NN NN O
. NN NN O

5 NN NN O
cM NN NN O
was NN NN O
observed NN NN O
in NN NN O
all NN NN O
families NN NN O
. NN NN O

Resequencing NN NN O
of NN NN O
the NN NN O
GK NN NN O
gene NN NN O
in NN NN O
family NN NN O
members NN NN O
led NN NN O
to NN NN O
the NN NN O
discovery NN NN O
of NN NN O
a NN NN O
N288D NN NN O
missense NN NN O
mutation NN NN O
in NN NN O
exon NN NN O
10 NN NN O
, NN NN O
which NN NN O
resulted NN NN O
in NN NN O
the NN NN O
substitution NN NN O
of NN NN O
a NN NN O
highly NN NN O
conserved NN NN O
asparagine NN NN O
residue NN NN O
by NN NN O
a NN NN O
negatively NN NN O
charged NN NN O
aspartic NN NN O
acid NN NN O
. NN NN O

10737119 NN NN O
Clinical NN NN O
and NN NN O
molecular NN NN O
genetics NN NN O
of NN NN O
primary NN NN B-DiseaseClass
dystonias NN NN I-DiseaseClass
. NN NN O

Primary NN NN B-DiseaseClass
dystonias NN NN I-DiseaseClass
are NN NN O
movement NN NN B-DiseaseClass
disorders NN NN I-DiseaseClass
with NN NN O
dystonia NN NN B-DiseaseClass
as NN NN O
a NN NN O
major NN NN O
symptom NN NN O
. NN NN O

They NN NN O
are NN NN O
frequently NN NN O
inherited NN NN O
as NN NN O
Mendelian NN NN O
traits NN NN O
. NN NN O

There NN NN O
are NN NN O
at NN NN O
least NN NN O
eight NN NN O
clinically NN NN O
distinct NN NN O
autosomal NN NN O
dominant NN NN O
and NN NN O
two NN NN O
X-linked NN NN O
recessive NN NN O
forms NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
pedigree NN NN O
analyses NN NN O
suggest NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
an NN NN O
autosomal NN NN O
recessive NN NN O
variant NN NN O
. NN NN O

The NN NN O
clinical NN NN O
classification NN NN O
is NN NN O
increasingly NN NN O
being NN NN O
replaced NN NN O
by NN NN O
a NN NN O
genetic NN NN O
one NN NN O
. NN NN O

To NN NN O
date NN NN O
gene NN NN O
loci NN NN O
have NN NN O
been NN NN O
identified NN NN O
in NN NN O
at NN NN O
least NN NN O
six NN NN O
autosomal NN NN O
dominant NN NN O
forms NN NN O
, NN NN O
i NN NN O
. NN NN O

e NN NN O
. NN NN O

, NN NN O
in NN NN O
idiopathic NN NN B-SpecificDisease
torsion NN NN I-SpecificDisease
dystonia NN NN I-SpecificDisease
( NN NN O
9q34 NN NN O
) NN NN O
, NN NN O
focal NN NN B-SpecificDisease
dystonia NN NN I-SpecificDisease
( NN NN O
18p NN NN O
) NN NN O
, NN NN O
adult-onset NN NN O
idiopathic NN NN B-SpecificDisease
torsion NN NN I-SpecificDisease
dystonia NN NN I-SpecificDisease
of NN NN O
mixed NN NN O
type NN NN O
( NN NN O
8p21-q22 NN NN O
) NN NN O
, NN NN O
dopa-responsive NN NN B-SpecificDisease
dystonia NN NN I-SpecificDisease
( NN NN O
14q22 NN NN O
. NN NN O

1-q22 NN NN O
. NN NN O

2 NN NN O
) NN NN O
, NN NN O
and NN NN O
paroxysmal NN NN B-SpecificDisease
dystonic NN NN I-SpecificDisease
choreoathetosis NN NN I-SpecificDisease
( NN NN O
2q25-q33 NN NN O
; NN NN O
1p21-p13 NN NN O
. NN NN O

3 NN NN O
) NN NN O
. NN NN O

Gene NN NN O
loci NN NN O
in NN NN O
the NN NN O
X-linked NN NN O
recessive NN NN O
forms NN NN O
have NN NN O
been NN NN O
assigned NN NN O
to NN NN O
Xq13 NN NN O
. NN NN O

1 NN NN O
in NN NN O
the NN NN O
X-linked NN NN B-SpecificDisease
dystonia NN NN I-SpecificDisease
parkinsonism NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
and NN NN O
to NN NN O
Xq22 NN NN O
in NN NN O
X-linked NN NN B-DiseaseClass
sensorineural NN NN I-DiseaseClass
deafness NN NN I-DiseaseClass
, NN NN O
dystonia NN NN B-DiseaseClass
, NN NN O
and NN NN O
mental NN NN B-DiseaseClass
retardation NN NN I-DiseaseClass
. NN NN O

The NN NN O
disease NN NN O
genes NN NN O
have NN NN O
been NN NN O
identified NN NN O
in NN NN O
two NN NN O
autosomal NN NN O
dominant NN NN O
forms NN NN O
and NN NN O
in NN NN O
one NN NN O
X-linked NN NN O
recessive NN NN O
form NN NN O
. NN NN O

Mutations NN NN O
in NN NN O
a NN NN O
gene NN NN O
coding NN NN O
for NN NN O
an NN NN O
ATP-binding NN NN O
protein NN NN O
were NN NN O
detected NN NN O
in NN NN O
idiopathic NN NN B-SpecificDisease
torsion NN NN I-SpecificDisease
dystonia NN NN I-SpecificDisease
( NN NN O
DYT1 NN NN O
) NN NN O
, NN NN O
and NN NN O
the NN NN O
GTP NN NN O
cyclohydrolase NN NN O
1 NN NN O
gene NN NN O
is NN NN O
mutated NN NN O
in NN NN O
dopa-responsive NN NN B-SpecificDisease
dystonia NN NN I-SpecificDisease
( NN NN O
DYT5 NN NN O
) NN NN O
. NN NN O

In NN NN O
sensorineural NN NN B-DiseaseClass
deafness NN NN I-DiseaseClass
, NN NN O
dystonia NN NN B-DiseaseClass
, NN NN O
and NN NN O
mental NN NN B-DiseaseClass
retardation NN NN I-DiseaseClass
, NN NN O
mutations NN NN O
were NN NN O
found NN NN O
in NN NN O
the NN NN O
gene NN NN O
DDP NN NN O
coding NN NN O
for NN NN O
a NN NN O
polypeptide NN NN O
of NN NN O
unknown NN NN O
function NN NN O
. NN NN O

This NN NN O
article NN NN O
reviews NN NN O
the NN NN O
clinical NN NN O
and NN NN O
molecular NN NN O
genetics NN NN O
of NN NN O
primary NN NN B-DiseaseClass
dystonias NN NN I-DiseaseClass
, NN NN O
critically NN NN O
discusses NN NN O
present NN NN O
findings NN NN O
, NN NN O
and NN NN O
proposes NN NN O
referring NN NN O
to NN NN O
the NN NN O
known NN NN O
forms NN NN O
, NN NN O
most NN NN O
of NN NN O
which NN NN O
can NN NN O
be NN NN O
distinguished NN NN O
by NN NN O
genetic NN NN O
criteria NN NN O
, NN NN O
as NN NN O
dystonias NN NN B-CompositeMention
1-12 NN NN I-CompositeMention
. NN NN O

10737980 NN NN O
Determination NN NN O
of NN NN O
30 NN NN O
X-linked NN NN B-Modifier
adrenoleukodystrophy NN NN I-Modifier
mutations NN NN O
, NN NN O
including NN NN O
15 NN NN O
not NN NN O
previously NN NN O
described NN NN O
. NN NN O

X-linked NN NN B-SpecificDisease
Adrenoleukodystrophy NN NN I-SpecificDisease
( NN NN O
X-ALD NN NN B-SpecificDisease
) NN NN O
is NN NN O
the NN NN O
most NN NN O
frequent NN NN O
peroxisomal NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
. NN NN O

It NN NN O
mainly NN NN O
involves NN NN O
the NN NN O
nervous NN NN O
system NN NN O
white NN NN O
matter NN NN O
, NN NN O
adrenal NN NN O
cortex NN NN O
and NN NN O
testes NN NN O
. NN NN O

Several NN NN O
distinct NN NN O
clinical NN NN O
phenotypes NN NN O
are NN NN O
known NN NN O
. NN NN O

The NN NN O
principal NN NN O
biochemical NN NN B-DiseaseClass
abnormality NN NN I-DiseaseClass
is NN NN O
the NN NN O
accumulation NN NN O
of NN NN O
saturated NN NN O
very-long-chain NN NN O
fatty NN NN O
acids NN NN O
( NN NN O
VLCFAs NN NN O
C22 NN NN O
0 NN NN O
, NN NN O
mainly NN NN O
C26 NN NN O
0 NN NN O
) NN NN O
, NN NN O
which NN NN O
is NN NN O
due NN NN O
to NN NN O
impaired NN NN O
capacity NN NN O
for NN NN O
beta-oxidation NN NN O
in NN NN O
peroxisomes NN NN O
. NN NN O

Diagnosis NN NN O
is NN NN O
usually NN NN O
based NN NN O
on NN NN O
the NN NN O
VLCFA NN NN O
levels NN NN O
in NN NN O
plasma NN NN O
or NN NN O
cultured NN NN O
skin NN NN O
fibroblasts NN NN O
in NN NN O
both NN NN O
patients NN NN O
and NN NN O
carriers NN NN O
. NN NN O

In NN NN O
0 NN NN O
. NN NN O

1 NN NN O
% NN NN O
of NN NN O
affected NN NN O
males NN NN O
, NN NN O
however NN NN O
, NN NN O
the NN NN O
plasma NN NN O
C26 NN NN O
0 NN NN O
level NN NN O
is NN NN O
borderline NN NN O
normal NN NN O
, NN NN O
and NN NN O
15 NN NN O
% NN NN O
of NN NN O
obligate NN NN O
female NN NN O
carriers NN NN O
have NN NN O
normal NN NN O
results NN NN O
. NN NN O

Effective NN NN O
mutation NN NN O
detection NN NN O
in NN NN O
these NN NN O
families NN NN O
is NN NN O
therefore NN NN O
fundamental NN NN O
to NN NN O
unambiguously NN NN O
determine NN NN O
the NN NN O
genetic NN NN O
status NN NN O
of NN NN O
each NN NN O
individual NN NN O
at NN NN O
risk NN NN O
. NN NN O

Of NN NN O
particular NN NN O
concern NN NN O
are NN NN O
female NN NN O
members NN NN O
of NN NN O
kindreds NN NN O
segregating NN NN O
X-ALD NN NN B-Modifier
mutations NN NN O
, NN NN O
because NN NN O
normal NN NN O
VLCFA NN NN O
levels NN NN O
do NN NN O
not NN NN O
guarantee NN NN O
lack NN NN O
of NN NN O
carrier NN NN O
status NN NN O
. NN NN O

We NN NN O
describe NN NN O
a NN NN O
fast NN NN O
method NN NN O
for NN NN O
detection NN NN O
of NN NN O
X-ALD NN NN B-Modifier
mutations NN NN O
. NN NN O

The NN NN O
method NN NN O
is NN NN O
based NN NN O
on NN NN O
SSCP NN NN O
analysis NN NN O
of NN NN O
nested NN NN O
PCR NN NN O
fragments NN NN O
followed NN NN O
by NN NN O
sequence-determination NN NN O
reactions NN NN O
. NN NN O

Using NN NN O
this NN NN O
methodology NN NN O
we NN NN O
have NN NN O
found NN NN O
X-ALD NN NN B-Modifier
mutations NN NN O
in NN NN O
30 NN NN O
kindreds NN NN O
, NN NN O
including NN NN O
15 NN NN O
not NN NN O
previously NN NN O
reported NN NN O
. NN NN O

10737981 NN NN O
beta-galactosidase NN NN O
gene NN NN O
mutations NN NN O
affecting NN NN O
the NN NN O
lysosomal NN NN O
enzyme NN NN O
and NN NN O
the NN NN O
elastin-binding NN NN O
protein NN NN O
in NN NN O
GM1-gangliosidosis NN NN B-Modifier
patients NN NN O
with NN NN O
cardiac NN NN B-SpecificDisease
involvement NN NN I-SpecificDisease
. NN NN O

GM1-gangliosidosis NN NN B-SpecificDisease
is NN NN O
a NN NN O
lysosomal NN NN B-DiseaseClass
storage NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
caused NN NN O
by NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
acid NN NN I-SpecificDisease
beta-galactosidase NN NN I-SpecificDisease
( NN NN O
GLB1 NN NN O
) NN NN O
. NN NN O

We NN NN O
report NN NN O
five NN NN O
new NN NN O
beta-galactosidase NN NN O
gene NN NN O
mutations NN NN O
in NN NN O
nine NN NN O
Italian NN NN O
patients NN NN O
and NN NN O
one NN NN O
fetus NN NN O
, NN NN O
segregating NN NN O
in NN NN O
seven NN NN O
unrelated NN NN O
families NN NN O
. NN NN O

Six NN NN O
of NN NN O
the NN NN O
eight NN NN O
patients NN NN O
with NN NN O
the NN NN O
infantile NN NN O
, NN NN O
severe NN NN O
form NN NN O
of NN NN O
the NN NN O
disease NN NN O
presented NN NN O
cardiac NN NN B-DiseaseClass
involvement NN NN I-DiseaseClass
, NN NN O
a NN NN O
feature NN NN O
rarely NN NN O
associated NN NN O
with NN NN O
GM1-gangliosidosis NN NN B-SpecificDisease
. NN NN O

Molecular NN NN O
analysis NN NN O
of NN NN O
the NN NN O
patients NN NN O
RNA NN NN O
and NN NN O
DNA NN NN O
identified NN NN O
two NN NN O
new NN NN O
RNA NN NN O
splicing NN NN O
defects NN NN O
, NN NN O
three NN NN O
new NN NN O
and NN NN O
three NN NN O
previously NN NN O
described NN NN O
amino NN NN O
acid NN NN O
substitutions NN NN O
. NN NN O

Interestingly NN NN O
, NN NN O
all NN NN O
patients NN NN O
with NN NN O
cardiac NN NN B-DiseaseClass
involvement NN NN I-DiseaseClass
were NN NN O
homozygous NN NN O
for NN NN O
one NN NN O
of NN NN O
these NN NN O
mutations NN NN O
R59H NN NN O
, NN NN O
Y591C NN NN O
, NN NN O
Y591N NN NN O
, NN NN O
or NN NN O
IVS14-2A NN NN O
G NN NN O
. NN NN O

In NN NN O
contrast NN NN O
, NN NN O
all NN NN O
other NN NN O
patients NN NN O
were NN NN O
compound NN NN O
heterozygous NN NN O
for NN NN O
one NN NN O
of NN NN O
the NN NN O
following NN NN O
mutations NN NN O
R201H NN NN O
, NN NN O
R482H NN NN O
, NN NN O
G579D NN NN O
, NN NN O
IVS8 NN NN O
+ NN NN O
2T NN NN O
C NN NN O
. NN NN O

Although NN NN O
we NN NN O
could NN NN O
not NN NN O
directly NN NN O
correlate NN NN O
the NN NN O
presence NN NN O
of NN NN O
cardiac NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
with NN NN O
specific NN NN O
genetic NN NN B-DiseaseClass
lesions NN NN I-DiseaseClass
, NN NN O
the NN NN O
mutations NN NN O
identified NN NN O
in NN NN O
patients NN NN O
with NN NN O
cardiomyopathy NN NN B-DiseaseClass
fell NN NN O
in NN NN O
the NN NN O
GLB1 NN NN O
cDNA NN NN O
region NN NN O
common NN NN O
to NN NN O
the NN NN O
lysosomal NN NN O
enzyme NN NN O
and NN NN O
the NN NN O
Hbeta-Gal-related NN NN O
protein NN NN O
, NN NN O
also NN NN O
known NN NN O
as NN NN O
the NN NN O
elastin NN NN O
binding NN NN O
protein NN NN O
( NN NN O
EBP NN NN O
) NN NN O
. NN NN O

Consequently NN NN O
, NN NN O
both NN NN O
molecules NN NN O
are NN NN O
affected NN NN O
by NN NN O
the NN NN O
mutations NN NN O
, NN NN O
and NN NN O
they NN NN O
may NN NN O
contribute NN NN O
differently NN NN O
to NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
specific NN NN O
clinical NN NN O
manifestations NN NN O
. NN NN O

. NN NN O

10742101 NN NN O
In NN NN O
vivo NN NN O
modulation NN NN O
of NN NN O
Hmgic NN NN O
reduces NN NN O
obesity NN NN B-SpecificDisease
. NN NN O

The NN NN O
HMGI NN NN O
family NN NN O
of NN NN O
proteins NN NN O
consists NN NN O
of NN NN O
three NN NN O
members NN NN O
, NN NN O
HMGIC NN NN O
, NN NN O
HMGI NN NN O
and NN NN O
HMGI NN NN O
( NN NN O
Y NN NN O
) NN NN O
, NN NN O
that NN NN O
function NN NN O
as NN NN O
architectural NN NN O
factors NN NN O
and NN NN O
are NN NN O
essential NN NN O
components NN NN O
of NN NN O
the NN NN O
enhancesome NN NN O
. NN NN O

HMGIC NN NN O
is NN NN O
predominantly NN NN O
expressed NN NN O
in NN NN O
proliferating NN NN O
, NN NN O
undifferentiated NN NN O
mesenchymal NN NN O
cells NN NN O
and NN NN O
is NN NN O
not NN NN O
detected NN NN O
in NN NN O
adult NN NN O
tissues NN NN O
. NN NN O

It NN NN O
is NN NN O
disrupted NN NN O
and NN NN O
misexpressed NN NN O
in NN NN O
a NN NN O
number NN NN O
of NN NN O
mesenchymal NN NN B-Modifier
tumour NN NN I-Modifier
cell NN NN O
types NN NN O
, NN NN O
including NN NN O
fat-cell NN NN B-DiseaseClass
tumours NN NN I-DiseaseClass
( NN NN O
lipomas NN NN B-DiseaseClass
) NN NN O
. NN NN O

In NN NN O
addition NN NN O
Hmgic- NN NN O
/ NN NN O
- NN NN O
mice NN NN O
have NN NN O
a NN NN O
deficiency NN NN O
in NN NN O
fat NN NN O
tissue NN NN O
. NN NN O

To NN NN O
study NN NN O
its NN NN O
role NN NN O
in NN NN O
adipogenesis NN NN O
and NN NN O
obesity NN NN B-SpecificDisease
, NN NN O
we NN NN O
examined NN NN O
Hmgic NN NN O
expression NN NN O
in NN NN O
the NN NN O
adipose NN NN O
tissue NN NN O
of NN NN O
adult NN NN O
, NN NN O
obese NN NN B-Modifier
mice NN NN O
. NN NN O

Mice NN NN O
with NN NN O
a NN NN O
partial NN NN B-CompositeMention
or NN NN I-CompositeMention
complete NN NN I-CompositeMention
deficiency NN NN I-CompositeMention
of NN NN I-CompositeMention
Hmgic NN NN I-CompositeMention
resisted NN NN O
diet-induced NN NN O
obesity NN NN B-SpecificDisease
. NN NN O

Disruption NN NN O
of NN NN O
Hmgic NN NN O
caused NN NN O
a NN NN O
reduction NN NN O
in NN NN O
the NN NN O
obesity NN NN B-SpecificDisease
induced NN NN O
by NN NN O
leptin NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
( NN NN O
Lepob NN NN O
/ NN NN O
Lepob NN NN O
) NN NN O
in NN NN O
a NN NN O
gene-dose-dependent NN NN O
manner NN NN O
. NN NN O

Our NN NN O
studies NN NN O
implicate NN NN O
a NN NN O
role NN NN O
for NN NN O
HMGIC NN NN O
in NN NN O
fat-cell NN NN O
proliferation NN NN O
, NN NN O
indicating NN NN O
that NN NN O
it NN NN O
may NN NN O
be NN NN O
an NN NN O
adipose-specific NN NN O
target NN NN O
for NN NN O
the NN NN O
treatment NN NN O
of NN NN O
obesity NN NN B-SpecificDisease
. NN NN O

. NN NN O

10746568 NN NN O
Molecular NN NN O
analysis NN NN O
of NN NN O
the NN NN O
genotype-phenotype NN NN O
relationship NN NN O
in NN NN O
factor NN NN B-SpecificDisease
X NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

Factor NN NN B-SpecificDisease
X NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
is NN NN O
a NN NN O
rare NN NN O
haemorrhagic NN NN B-DiseaseClass
condition NN NN I-DiseaseClass
, NN NN O
normally NN NN O
inherited NN NN O
as NN NN O
an NN NN O
autosomal NN NN O
recessive NN NN O
trait NN NN O
, NN NN O
in NN NN O
which NN NN O
a NN NN O
variable NN NN O
clinical NN NN O
presentation NN NN O
correlates NN NN O
poorly NN NN O
with NN NN O
laboratory NN NN O
phenotype NN NN O
. NN NN O

The NN NN O
factor NN NN O
X NN NN O
( NN NN O
F10 NN NN O
) NN NN O
genes NN NN O
of NN NN O
14 NN NN O
unrelated NN NN O
individuals NN NN O
with NN NN O
factor NN NN B-SpecificDisease
X NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
( NN NN O
12 NN NN O
familial NN NN O
and NN NN O
two NN NN O
sporadic NN NN O
cases NN NN O
) NN NN O
were NN NN O
sequenced NN NN O
yielding NN NN O
a NN NN O
total NN NN O
of NN NN O
13 NN NN O
novel NN NN O
mutations NN NN O
. NN NN O

Family NN NN O
studies NN NN O
were NN NN O
performed NN NN O
in NN NN O
order NN NN O
to NN NN O
distinguish NN NN O
the NN NN O
contributions NN NN O
of NN NN O
individual NN NN O
mutant NN NN O
F10 NN NN O
alleles NN NN O
to NN NN O
the NN NN O
clinical NN NN O
and NN NN O
laboratory NN NN O
phenotypes NN NN O
. NN NN O

Missense NN NN O
mutations NN NN O
were NN NN O
studied NN NN O
by NN NN O
means NN NN O
of NN NN O
molecular NN NN O
modelling NN NN O
, NN NN O
whereas NN NN O
single NN NN O
basepair NN NN O
substitutions NN NN O
in NN NN O
splice NN NN O
sites NN NN O
and NN NN O
the NN NN O
5 NN NN O
flanking NN NN O
region NN NN O
were NN NN O
examined NN NN O
by NN NN O
in NN NN O
vitro NN NN O
splicing NN NN O
assay NN NN O
and NN NN O
luciferase NN NN O
reporter NN NN O
gene NN NN O
assay NN NN O
respectively NN NN O
. NN NN O

The NN NN O
deletion NN NN O
allele NN NN O
of NN NN O
a NN NN O
novel NN NN O
hexanucleotide NN NN O
insertion NN NN O
/ NN NN O
deletion NN NN O
polymorphism NN NN O
in NN NN O
the NN NN O
F10 NN NN O
gene NN NN O
promoter NN NN O
region NN NN O
was NN NN O
shown NN NN O
by NN NN O
reporter NN NN O
gene NN NN O
assay NN NN O
, NN NN O
to NN NN O
reduce NN NN O
promoter NN NN O
activity NN NN O
by NN NN O
approximately NN NN O
20 NN NN O
% NN NN O
. NN NN O

One NN NN O
family NN NN O
manifesting NN NN O
an NN NN O
autosomal NN NN O
dominant NN NN O
pattern NN NN O
of NN NN O
inheritance NN NN O
possessed NN NN O
three NN NN O
clinically NN NN O
affected NN NN O
members NN NN O
who NN NN O
were NN NN O
heterozygous NN NN O
for NN NN O
a NN NN O
splice-site NN NN O
mutation NN NN O
that NN NN O
was NN NN O
predicted NN NN O
to NN NN O
lead NN NN O
to NN NN O
the NN NN O
production NN NN O
of NN NN O
a NN NN O
truncated NN NN O
protein NN NN O
product NN NN O
. NN NN O

A NN NN O
model NN NN O
which NN NN O
accounts NN NN O
for NN NN O
the NN NN O
dominant NN NN O
negative NN NN O
effect NN NN O
of NN NN O
this NN NN O
lesion NN NN O
is NN NN O
presented NN NN O
. NN NN O

Variation NN NN O
in NN NN O
the NN NN O
antigen NN NN O
level NN NN O
of NN NN O
heterozygous NN NN O
relatives NN NN O
of NN NN O
probands NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
significantly NN NN O
higher NN NN O
between NN NN O
families NN NN O
than NN NN O
within NN NN O
families NN NN O
, NN NN O
consistent NN NN O
with NN NN O
the NN NN O
view NN NN O
that NN NN O
the NN NN O
nature NN NN O
of NN NN O
the NN NN O
F10 NN NN O
lesion NN NN O
( NN NN O
s NN NN O
) NN NN O
segregating NN NN O
in NN NN O
a NN NN O
given NN NN O
family NN NN O
is NN NN O
a NN NN O
prime NN NN O
determinant NN NN O
of NN NN O
the NN NN O
laboratory NN NN O
phenotype NN NN O
. NN NN O

By NN NN O
contrast NN NN O
, NN NN O
no NN NN O
such NN NN O
relationship NN NN O
could NN NN O
be NN NN O
discerned NN NN O
between NN NN O
laboratory NN NN O
phenotype NN NN O
and NN NN O
polymorphism NN NN O
genotype NN NN O
. NN NN O

. NN NN O

10747931 NN NN O
Transgenic NN NN O
mice NN NN O
expressing NN NN O
a NN NN O
truncated NN NN O
form NN NN O
of NN NN O
the NN NN O
high NN NN O
mobility NN NN O
group NN NN O
I-C NN NN O
protein NN NN O
develop NN NN O
adiposity NN NN O
and NN NN O
an NN NN O
abnormally NN NN O
high NN NN O
prevalence NN NN O
of NN NN O
lipomas NN NN B-DiseaseClass
. NN NN O

Chromosomal NN NN O
translocations NN NN O
in NN NN O
human NN NN O
lipomas NN NN B-DiseaseClass
frequently NN NN O
create NN NN O
fusion NN NN O
transcripts NN NN O
encoding NN NN O
high NN NN O
mobility NN NN O
group NN NN O
( NN NN O
HMG NN NN O
) NN NN O
I-C NN NN O
DNA-binding NN NN O
domains NN NN O
and NN NN O
C-terminal NN NN O
sequences NN NN O
from NN NN O
different NN NN O
presumed NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
suggesting NN NN O
a NN NN O
potential NN NN O
role NN NN O
for NN NN O
HMG NN NN O
I-C NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
lipomas NN NN B-DiseaseClass
. NN NN O

To NN NN O
evaluate NN NN O
the NN NN O
role NN NN O
of NN NN O
the NN NN O
HMG NN NN O
I-C NN NN O
component NN NN O
, NN NN O
the NN NN O
three NN NN O
DNA-binding NN NN O
domains NN NN O
of NN NN O
HMG NN NN O
I-C NN NN O
have NN NN O
now NN NN O
been NN NN O
expressed NN NN O
in NN NN O
transgenic NN NN O
mice NN NN O
. NN NN O

Despite NN NN O
the NN NN O
ubiquitous NN NN O
expression NN NN O
of NN NN O
the NN NN O
truncated NN NN O
HMG NN NN O
I-C NN NN O
protein NN NN O
, NN NN O
the NN NN O
transgenic NN NN O
mice NN NN O
develop NN NN O
a NN NN O
selective NN NN O
abundance NN NN O
of NN NN O
fat NN NN O
tissue NN NN O
early NN NN O
in NN NN O
life NN NN O
, NN NN O
show NN NN O
marked NN NN O
adipose NN NN B-SpecificDisease
tissue NN NN I-SpecificDisease
inflammation NN NN I-SpecificDisease
, NN NN O
and NN NN O
have NN NN O
an NN NN O
abnormally NN NN O
high NN NN O
incidence NN NN O
of NN NN O
lipomas NN NN B-DiseaseClass
. NN NN O

These NN NN O
findings NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
DNA-binding NN NN O
domains NN NN O
of NN NN O
HMG NN NN O
I-C NN NN O
, NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
a NN NN O
C-terminal NN NN O
fusion NN NN O
partner NN NN O
, NN NN O
are NN NN O
sufficient NN NN O
to NN NN O
perturb NN NN O
adipogenesis NN NN O
and NN NN O
predispose NN NN O
to NN NN O
lipomas NN NN B-DiseaseClass
. NN NN O

We NN NN O
provide NN NN O
data NN NN O
supporting NN NN O
the NN NN O
central NN NN O
utility NN NN O
of NN NN O
this NN NN O
animal NN NN O
model NN NN O
as NN NN O
a NN NN O
tool NN NN O
to NN NN O
understand NN NN O
the NN NN O
molecular NN NN O
mechanisms NN NN O
underlying NN NN O
the NN NN O
development NN NN O
of NN NN O
one NN NN O
of NN NN O
the NN NN O
most NN NN O
common NN NN O
kind NN NN O
of NN NN O
human NN NN O
benign NN NN B-DiseaseClass
tumors NN NN I-DiseaseClass
. NN NN O

. NN NN O

10766245 NN NN O
ATM NN NN O
phosphorylates NN NN O
p95/nbs1 NN NN O
in NN NN O
an NN NN O
S-phase NN NN O
checkpoint NN NN O
pathway NN NN O
. NN NN O

The NN NN O
rare NN NN B-DiseaseClass
diseases NN NN I-DiseaseClass
ataxia-telangiectasia NN NN B-SpecificDisease
( NN NN O
AT NN NN B-SpecificDisease
) NN NN O
, NN NN O
caused NN NN O
by NN NN O
mutations NN NN O
in NN NN O
the NN NN O
ATM NN NN O
gene NN NN O
, NN NN O
and NN NN O
Nijmegen NN NN B-SpecificDisease
breakage NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
NBS NN NN B-SpecificDisease
) NN NN O
, NN NN O
with NN NN O
mutations NN NN O
in NN NN O
the NN NN O
p95 NN NN O
/ NN NN O
nbs1 NN NN O
gene NN NN O
, NN NN O
share NN NN O
a NN NN O
variety NN NN O
of NN NN O
phenotypic NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
such NN NN O
as NN NN O
chromosomal NN NN B-DiseaseClass
instability NN NN I-DiseaseClass
, NN NN O
radiation NN NN O
sensitivity NN NN O
and NN NN O
defects NN NN O
in NN NN O
cell-cycle NN NN O
checkpoints NN NN O
in NN NN O
response NN NN O
to NN NN O
ionizing NN NN O
radiation NN NN O
. NN NN O

The NN NN O
ATM NN NN O
gene NN NN O
encodes NN NN O
a NN NN O
protein NN NN O
kinase NN NN O
that NN NN O
is NN NN O
activated NN NN O
by NN NN O
ionizing NN NN O
radiation NN NN O
or NN NN O
radiomimetic NN NN O
drugs NN NN O
, NN NN O
whereas NN NN O
p95 NN NN O
/ NN NN O
nbs1 NN NN O
is NN NN O
part NN NN O
of NN NN O
a NN NN O
protein NN NN O
complex NN NN O
that NN NN O
is NN NN O
involved NN NN O
in NN NN O
responses NN NN O
to NN NN O
DNA NN NN O
double-strand NN NN O
breaks NN NN O
. NN NN O

Here NN NN O
, NN NN O
because NN NN O
of NN NN O
the NN NN O
similarities NN NN O
between NN NN O
AT NN NN B-SpecificDisease
and NN NN O
NBS NN NN B-SpecificDisease
, NN NN O
we NN NN O
evaluated NN NN O
the NN NN O
functional NN NN O
interactions NN NN O
between NN NN O
ATM NN NN O
and NN NN O
p95 NN NN O
/ NN NN O
nbs1 NN NN O
. NN NN O

Activation NN NN O
of NN NN O
the NN NN O
ATM NN NN O
kinase NN NN O
by NN NN O
ionizing NN NN O
radiation NN NN O
and NN NN O
induction NN NN O
of NN NN O
ATM-dependent NN NN O
responses NN NN O
in NN NN O
NBS NN NN B-Modifier
cells NN NN O
indicated NN NN O
that NN NN O
p95 NN NN O
/ NN NN O
nbs1 NN NN O
may NN NN O
not NN NN O
be NN NN O
required NN NN O
for NN NN O
signalling NN NN O
to NN NN O
ATM NN NN O
after NN NN O
ionizing NN NN O
radiation NN NN O
. NN NN O

However NN NN O
, NN NN O
p95 NN NN O
/ NN NN O
nbs1 NN NN O
was NN NN O
phosphorylated NN NN O
on NN NN O
serine NN NN O
343 NN NN O
in NN NN O
an NN NN O
ATM-dependent NN NN O
manner NN NN O
in NN NN O
vitro NN NN O
and NN NN O
in NN NN O
vivo NN NN O
after NN NN O
ionizing NN NN O
radiation NN NN O
. NN NN O

A NN NN O
p95 NN NN O
/ NN NN O
nbs1 NN NN O
construct NN NN O
mutated NN NN O
at NN NN O
the NN NN O
ATM NN NN O
phosphorylation NN NN O
site NN NN O
abrogated NN NN O
an NN NN O
S-phase NN NN O
checkpoint NN NN O
induced NN NN O
by NN NN O
ionizing NN NN O
radiation NN NN O
in NN NN O
normal NN NN O
cells NN NN O
and NN NN O
failed NN NN O
to NN NN O
compensate NN NN O
for NN NN O
this NN NN O
functional NN NN O
deficiency NN NN O
in NN NN O
NBS NN NN B-Modifier
cells NN NN O
. NN NN O

These NN NN O
observations NN NN O
link NN NN O
ATM NN NN O
and NN NN O
p95 NN NN O
/ NN NN O
nbs1 NN NN O
in NN NN O
a NN NN O
common NN NN O
signalling NN NN O
pathway NN NN O
and NN NN O
provide NN NN O
an NN NN O
explanation NN NN O
for NN NN O
phenotypic NN NN O
similarities NN NN O
in NN NN O
these NN NN O
two NN NN O
diseases NN NN O
. NN NN O

. NN NN O

10767313 NN NN O
Understanding NN NN O
the NN NN O
molecular NN NN O
basis NN NN O
of NN NN O
fragile NN NN B-SpecificDisease
X NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

Fragile NN NN B-SpecificDisease
X NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
, NN NN O
a NN NN O
common NN NN O
form NN NN O
of NN NN O
inherited NN NN B-DiseaseClass
mental NN NN I-DiseaseClass
retardation NN NN I-DiseaseClass
, NN NN O
is NN NN O
mainly NN NN O
caused NN NN O
by NN NN O
massive NN NN O
expansion NN NN O
of NN NN O
CGG NN NN O
triplet NN NN O
repeats NN NN O
located NN NN O
in NN NN O
the NN NN O
5-untranslated NN NN O
region NN NN O
of NN NN O
the NN NN O
fragile NN NN B-Modifier
X NN NN I-Modifier
mental NN NN I-Modifier
retardation NN NN I-Modifier
-1 NN NN O
( NN NN O
FMR1 NN NN O
) NN NN O
gene NN NN O
. NN NN O

In NN NN O
patients NN NN O
with NN NN O
fragile NN NN B-SpecificDisease
X NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
, NN NN O
the NN NN O
expanded NN NN O
CGG NN NN O
triplet NN NN O
repeats NN NN O
are NN NN O
hypermethylated NN NN O
and NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
FMR1 NN NN O
gene NN NN O
is NN NN O
repressed NN NN O
, NN NN O
which NN NN O
leads NN NN O
to NN NN O
the NN NN O
absence NN NN O
of NN NN O
FMR1 NN NN O
protein NN NN O
( NN NN O
FMRP NN NN O
) NN NN O
and NN NN O
subsequent NN NN O
mental NN NN B-DiseaseClass
retardation NN NN I-DiseaseClass
. NN NN O

FMRP NN NN O
is NN NN O
an NN NN O
RNA-binding NN NN O
protein NN NN O
that NN NN O
shuttles NN NN O
between NN NN O
the NN NN O
nucleus NN NN O
and NN NN O
cytoplasm NN NN O
. NN NN O

This NN NN O
protein NN NN O
has NN NN O
been NN NN O
implicated NN NN O
in NN NN O
protein NN NN O
translation NN NN O
as NN NN O
it NN NN O
is NN NN O
found NN NN O
associated NN NN O
with NN NN O
polyribosomes NN NN O
and NN NN O
the NN NN O
rough NN NN O
endoplasmic NN NN O
reticulum NN NN O
. NN NN O

We NN NN O
discuss NN NN O
here NN NN O
the NN NN O
recent NN NN O
progress NN NN O
made NN NN O
towards NN NN O
understanding NN NN O
the NN NN O
molecular NN NN O
mechanism NN NN O
of NN NN O
CGG NN NN O
repeat NN NN O
expansion NN NN O
and NN NN O
physiological NN NN O
function NN NN O
( NN NN O
s NN NN O
) NN NN O
of NN NN O
FMRP NN NN O
. NN NN O

These NN NN O
studies NN NN O
will NN NN O
not NN NN O
only NN NN O
help NN NN O
to NN NN O
illuminate NN NN O
the NN NN O
molecular NN NN O
basis NN NN O
of NN NN O
the NN NN O
general NN NN O
class NN NN O
of NN NN O
human NN NN O
diseases NN NN O
with NN NN O
trinucleotide NN NN O
repeat NN NN O
expansion NN NN O
but NN NN O
also NN NN O
provide NN NN O
an NN NN O
avenue NN NN O
to NN NN O
understand NN NN O
aspects NN NN O
of NN NN O
human NN NN O
cognition NN NN O
and NN NN O
intelligence NN NN O
. NN NN O

. NN NN O

10767326 NN NN O
Haploinsufficiency NN NN B-CompositeMention
of NN NN I-CompositeMention
the NN NN I-CompositeMention
transcription NN NN I-CompositeMention
factors NN NN I-CompositeMention
FOXC1 NN NN I-CompositeMention
and NN NN I-CompositeMention
FOXC2 NN NN I-CompositeMention
results NN NN O
in NN NN O
aberrant NN NN O
ocular NN NN O
development NN NN O
. NN NN O

Anterior NN NN B-DiseaseClass
segment NN NN I-DiseaseClass
developmental NN NN I-DiseaseClass
disorders NN NN I-DiseaseClass
, NN NN O
including NN NN O
Axenfeld-Rieger NN NN B-SpecificDisease
anomaly NN NN I-SpecificDisease
( NN NN O
ARA NN NN B-SpecificDisease
) NN NN O
, NN NN O
variably NN NN O
associate NN NN O
with NN NN O
harmfully NN NN O
elevated NN NN O
intraocular NN NN O
pressure NN NN O
( NN NN O
IOP NN NN O
) NN NN O
, NN NN O
which NN NN O
causes NN NN O
glaucoma NN NN B-SpecificDisease
. NN NN O

Clinically NN NN O
observed NN NN O
dysgenesis NN NN O
does NN NN O
not NN NN O
correlate NN NN O
with NN NN O
IOP NN NN O
, NN NN O
however NN NN O
, NN NN O
and NN NN O
the NN NN O
etiology NN NN O
of NN NN O
glaucoma NN NN B-Modifier
development NN NN O
is NN NN O
not NN NN O
understood NN NN O
. NN NN O

The NN NN O
forkhead NN NN O
transcription NN NN O
factor NN NN O
genes NN NN O
Foxc1 NN NN O
( NN NN O
formerly NN NN O
Mf1 NN NN O
) NN NN O
and NN NN O
Foxc2 NN NN O
( NN NN O
formerly NN NN O
Mfh1 NN NN O
) NN NN O
are NN NN O
expressed NN NN O
in NN NN O
the NN NN O
mesenchyme NN NN O
from NN NN O
which NN NN O
the NN NN O
ocular NN NN O
drainage NN NN O
structures NN NN O
derive NN NN O
. NN NN O

Mutations NN NN O
in NN NN O
the NN NN O
human NN NN O
homolog NN NN O
of NN NN O
Foxc1 NN NN O
, NN NN O
FKHL7 NN NN O
, NN NN O
cause NN NN O
dominant NN NN O
anterior NN NN B-DiseaseClass
segment NN NN I-DiseaseClass
defects NN NN I-DiseaseClass
and NN NN O
glaucoma NN NN B-SpecificDisease
in NN NN O
various NN NN O
families NN NN O
. NN NN O

We NN NN O
show NN NN O
that NN NN O
Foxc1 NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
) NN NN O
mice NN NN O
have NN NN O
anterior NN NN B-DiseaseClass
segment NN NN I-DiseaseClass
abnormalities NN NN I-DiseaseClass
similar NN NN O
to NN NN O
those NN NN O
reported NN NN O
in NN NN O
human NN NN O
patients NN NN O
. NN NN O

These NN NN O
abnormalities NN NN O
include NN NN O
small NN NN O
or NN NN O
absent NN NN O
Schlemms NN NN O
canal NN NN O
, NN NN O
aberrantly NN NN O
developed NN NN O
trabecular NN NN O
meshwork NN NN O
, NN NN O
iris NN NN B-SpecificDisease
hypoplasia NN NN I-SpecificDisease
, NN NN O
severely NN NN O
eccentric NN NN O
pupils NN NN O
and NN NN O
displaced NN NN O
Schwalbes NN NN O
line NN NN O
. NN NN O

The NN NN O
penetrance NN NN O
of NN NN O
clinically NN NN O
obvious NN NN O
abnormalities NN NN O
varies NN NN O
with NN NN O
genetic NN NN O
background NN NN O
. NN NN O

In NN NN O
some NN NN O
affected NN NN O
eyes NN NN O
, NN NN O
collagen NN NN O
bundles NN NN O
were NN NN O
half NN NN O
normal NN NN O
diameter NN NN O
, NN NN O
or NN NN O
collagen NN NN O
and NN NN O
elastic NN NN O
tissue NN NN O
were NN NN O
very NN NN O
sparse NN NN O
. NN NN O

Thus NN NN O
, NN NN O
abnormalities NN NN O
in NN NN O
extracellular NN NN O
matrix NN NN O
synthesis NN NN O
or NN NN O
organization NN NN O
may NN NN O
contribute NN NN O
to NN NN O
development NN NN O
of NN NN O
the NN NN O
ocular NN NN O
phenotypes NN NN O
. NN NN O

Despite NN NN O
the NN NN O
abnormalities NN NN O
in NN NN O
ocular NN NN O
drainage NN NN O
structures NN NN O
in NN NN O
Foxc1 NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
) NN NN O
mice NN NN O
, NN NN O
IOP NN NN O
was NN NN O
normal NN NN O
in NN NN O
almost NN NN O
all NN NN O
mice NN NN O
analyzed NN NN O
, NN NN O
on NN NN O
all NN NN O
genetic NN NN O
backgrounds NN NN O
and NN NN O
at NN NN O
all NN NN O
ages NN NN O
. NN NN O

Similar NN NN O
abnormalities NN NN O
were NN NN O
found NN NN O
in NN NN O
Foxc2 NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
) NN NN O
mice NN NN O
, NN NN O
but NN NN O
no NN NN O
disease-associated NN NN O
mutations NN NN O
were NN NN O
identified NN NN O
in NN NN O
the NN NN O
human NN NN O
homolog NN NN O
FKHL14 NN NN O
in NN NN O
32 NN NN O
ARA NN NN B-Modifier
patients NN NN O
. NN NN O

Foxc1 NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
) NN NN O
and NN NN O
Foxc2 NN NN O
( NN NN O
+ NN NN O
/ NN NN O
- NN NN O
) NN NN O
mice NN NN O
are NN NN O
useful NN NN O
models NN NN O
for NN NN O
studying NN NN O
anterior NN NN O
segment NN NN O
development NN NN O
and NN NN O
its NN NN O
anomalies NN NN O
, NN NN O
and NN NN O
may NN NN O
allow NN NN O
identification NN NN O
of NN NN O
genes NN NN O
that NN NN O
interact NN NN O
with NN NN O
Foxc1 NN NN O
and NN NN O
Foxc2 NN NN O
( NN NN O
or NN NN O
FKHL7 NN NN O
and NN NN O
FKHL14 NN NN O
) NN NN O
to NN NN O
produce NN NN O
a NN NN O
phenotype NN NN O
with NN NN O
elevated NN NN O
IOP NN NN O
and NN NN O
glaucoma NN NN B-SpecificDisease
. NN NN O

. NN NN O

10767339 NN NN O
( NN NN O
Over NN NN O
) NN NN O
correction NN NN O
of NN NN O
FMR1 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
with NN NN O
YAC NN NN O
transgenics NN NN O
: NN NN O
behavioral NN NN O
and NN NN O
physical NN NN O
features NN NN O
. NN NN O

Fragile NN NN B-SpecificDisease
X NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
is NN NN O
a NN NN O
common NN NN O
cause NN NN O
of NN NN O
mental NN NN B-DiseaseClass
retardation NN NN I-DiseaseClass
involving NN NN O
loss NN NN O
of NN NN O
expression NN NN O
of NN NN O
the NN NN O
FMR1 NN NN O
gene NN NN O
. NN NN O

The NN NN O
role NN NN O
of NN NN O
FMR1 NN NN O
remains NN NN O
undetermined NN NN O
but NN NN O
the NN NN O
protein NN NN O
appears NN NN O
to NN NN O
be NN NN O
involved NN NN O
in NN NN O
RNA NN NN O
metabolism NN NN O
. NN NN O

Fmr1 NN NN O
knockout NN NN O
mice NN NN O
exhibit NN NN O
a NN NN O
phenotype NN NN O
with NN NN O
some NN NN O
similarities NN NN O
to NN NN O
humans NN NN O
, NN NN O
such NN NN O
as NN NN O
macroorchidism NN NN B-SpecificDisease
and NN NN O
behavioral NN NN O
abnormalities NN NN O
. NN NN O

As NN NN O
a NN NN O
step NN NN O
toward NN NN O
understanding NN NN O
the NN NN O
function NN NN O
of NN NN O
FMR1 NN NN O
and NN NN O
the NN NN O
determination NN NN O
of NN NN O
the NN NN O
potential NN NN O
for NN NN O
therapeutic NN NN O
approaches NN NN O
to NN NN O
fragile NN NN B-SpecificDisease
X NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
, NN NN O
yeast NN NN O
artificial NN NN O
chromosome NN NN O
( NN NN O
YAC NN NN O
) NN NN O
transgenic NN NN O
mice NN NN O
were NN NN O
generated NN NN O
in NN NN O
order NN NN O
to NN NN O
determine NN NN O
whether NN NN O
the NN NN O
Fmr1 NN NN O
knockout NN NN O
mouse NN NN O
phenotype NN NN O
could NN NN O
be NN NN O
rescued NN NN O
. NN NN O

Several NN NN O
transgenic NN NN O
lines NN NN O
were NN NN O
generated NN NN O
that NN NN O
carried NN NN O
the NN NN O
entire NN NN O
FMR1 NN NN O
locus NN NN O
with NN NN O
extensive NN NN O
amounts NN NN O
of NN NN O
flanking NN NN O
sequence NN NN O
. NN NN O

We NN NN O
observed NN NN O
that NN NN O
the NN NN O
YAC NN NN O
transgene NN NN O
supported NN NN O
production NN NN O
of NN NN O
the NN NN O
human NN NN O
protein NN NN O
( NN NN O
FMRP NN NN O
) NN NN O
which NN NN O
was NN NN O
present NN NN O
at NN NN O
levels NN NN O
10 NN NN O
to NN NN O
15 NN NN O
times NN NN O
that NN NN O
of NN NN O
endogenous NN NN O
protein NN NN O
and NN NN O
was NN NN O
expressed NN NN O
in NN NN O
a NN NN O
cell- NN NN O
and NN NN O
tissue-specific NN NN O
manner NN NN O
. NN NN O

Macro-orchidism NN NN O
was NN NN O
absent NN NN O
in NN NN O
knockout NN NN O
mice NN NN O
carrying NN NN O
the NN NN O
YAC NN NN O
transgene NN NN O
indicating NN NN O
functional NN NN O
rescue NN NN O
by NN NN O
the NN NN O
human NN NN O
protein NN NN O
. NN NN O

Given NN NN O
the NN NN O
complex NN NN O
behavioral NN NN O
phenotype NN NN O
in NN NN O
fragile NN NN B-Modifier
X NN NN I-Modifier
patients NN NN O
and NN NN O
the NN NN O
mild NN NN O
phenotype NN NN O
previously NN NN O
reported NN NN O
for NN NN O
the NN NN O
Fmr1 NN NN O
knockout NN NN O
mouse NN NN O
, NN NN O
we NN NN O
performed NN NN O
a NN NN O
more NN NN O
thorough NN NN O
evaluation NN NN O
of NN NN O
the NN NN O
Fmr1 NN NN O
knockout NN NN O
phenotype NN NN O
using NN NN O
additional NN NN O
behavioral NN NN O
assays NN NN O
that NN NN O
had NN NN O
not NN NN O
previously NN NN O
been NN NN O
reported NN NN O
for NN NN O
this NN NN O
animal NN NN O
model NN NN O
. NN NN O

The NN NN O
mouse NN NN O
displayed NN NN O
reduced NN NN O
anxiety NN NN B-Modifier
-related NN NN O
responses NN NN O
with NN NN O
increased NN NN O
exploratory NN NN O
behavior NN NN O
. NN NN O

FMR1 NN NN O
YAC NN NN O
transgenic NN NN O
mice NN NN O
overexpressing NN NN O
the NN NN O
human NN NN O
protein NN NN O
did NN NN O
produce NN NN O
opposing NN NN O
behavioral NN NN O
responses NN NN O
and NN NN O
additional NN NN O
abnormal NN NN O
behaviors NN NN O
were NN NN O
also NN NN O
observed NN NN O
. NN NN O

These NN NN O
findings NN NN O
have NN NN O
significant NN NN O
implications NN NN O
for NN NN O
gene NN NN O
therapy NN NN O
for NN NN O
fragile NN NN B-SpecificDisease
X NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
since NN NN O
overexpression NN NN O
of NN NN O
the NN NN O
gene NN NN O
may NN NN O
harbor NN NN O
its NN NN O
own NN NN O
phenotype NN NN O
. NN NN O

. NN NN O

10767343 NN NN O
Transgenic NN NN O
mice NN NN O
carrying NN NN O
large NN NN O
human NN NN O
genomic NN NN O
sequences NN NN O
with NN NN O
expanded NN NN O
CTG NN NN O
repeat NN NN O
mimic NN NN O
closely NN NN O
the NN NN O
DM NN NN B-Modifier
CTG NN NN O
repeat NN NN O
intergenerational NN NN O
and NN NN O
somatic NN NN O
instability NN NN O
. NN NN O

Myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
is NN NN O
caused NN NN O
by NN NN O
a NN NN O
CTG NN NN O
repeat NN NN O
expansion NN NN O
in NN NN O
the NN NN O
3UTR NN NN O
of NN NN O
the NN NN O
DM NN NN B-Modifier
protein NN NN O
kinase NN NN O
( NN NN O
DMPK NN NN O
) NN NN O
gene NN NN O
. NN NN O

A NN NN O
very NN NN O
high NN NN O
level NN NN O
of NN NN O
instability NN NN O
is NN NN O
observed NN NN O
through NN NN O
successive NN NN O
generations NN NN O
and NN NN O
the NN NN O
size NN NN O
of NN NN O
the NN NN O
repeat NN NN O
is NN NN O
generally NN NN O
correlated NN NN O
with NN NN O
the NN NN O
severity NN NN O
of NN NN O
the NN NN O
disease NN NN O
and NN NN O
with NN NN O
age NN NN O
at NN NN O
onset NN NN O
. NN NN O

Furthermore NN NN O
, NN NN O
tissues NN NN O
from NN NN O
DM NN NN B-Modifier
patients NN NN O
exhibit NN NN O
somatic NN NN O
mosaicism NN NN O
that NN NN O
increases NN NN O
with NN NN O
age NN NN O
. NN NN O

We NN NN O
generated NN NN O
transgenic NN NN O
mice NN NN O
carrying NN NN O
large NN NN O
human NN NN O
genomic NN NN O
sequences NN NN O
with NN NN O
20 NN NN O
, NN NN O
55 NN NN O
or NN NN O
300 NN NN O
CTG NN NN O
, NN NN O
cloned NN NN O
from NN NN O
patients NN NN O
from NN NN O
the NN NN O
same NN NN O
affected NN NN O
DM NN NN B-Modifier
family NN NN O
. NN NN O

Using NN NN O
large NN NN O
human NN NN O
flanking NN NN O
sequences NN NN O
and NN NN O
a NN NN O
large NN NN O
amplification NN NN O
, NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
intergenerational NN NN O
CTG NN NN O
repeat NN NN O
instability NN NN O
is NN NN O
reproduced NN NN O
in NN NN O
mice NN NN O
, NN NN O
with NN NN O
a NN NN O
strong NN NN O
bias NN NN O
towards NN NN O
expansions NN NN O
and NN NN O
with NN NN O
the NN NN O
same NN NN O
sex- NN NN O
and NN NN O
size-dependent NN NN O
characteristics NN NN O
as NN NN O
in NN NN O
humans NN NN O
. NN NN O

Moreover NN NN O
, NN NN O
a NN NN O
high NN NN O
level NN NN O
of NN NN O
instability NN NN O
, NN NN O
increasing NN NN O
with NN NN O
age NN NN O
, NN NN O
can NN NN O
be NN NN O
observed NN NN O
in NN NN O
tissues NN NN O
and NN NN O
in NN NN O
sperm NN NN O
. NN NN O

Although NN NN O
we NN NN O
did NN NN O
not NN NN O
observe NN NN O
dramatic NN NN O
expansions NN NN O
( NN NN O
or NN NN O
big NN NN O
jumps NN NN O
over NN NN O
several NN NN O
hundred NN NN O
CTG NN NN O
repeats NN NN O
) NN NN O
as NN NN O
in NN NN O
congenital NN NN O
forms NN NN O
of NN NN O
DM NN NN B-SpecificDisease
, NN NN O
our NN NN O
model NN NN O
carrying NN NN O
300 NN NN O
CTG NN NN O
is NN NN O
the NN NN O
first NN NN O
to NN NN O
show NN NN O
instability NN NN O
so NN NN O
close NN NN O
to NN NN O
the NN NN O
human NN NN O
DM NN NN B-Modifier
situation NN NN O
. NN NN O

Our NN NN O
three NN NN O
models NN NN O
carrying NN NN O
different NN NN O
sizes NN NN O
of NN NN O
CTG NN NN O
repeat NN NN O
provide NN NN O
insight NN NN O
on NN NN O
the NN NN O
different NN NN O
factors NN NN O
modulating NN NN O
the NN NN O
CTG NN NN O
repeat NN NN O
instability NN NN O
. NN NN O

. NN NN O

10767347 NN NN O
Inactivation NN NN O
of NN NN O
the NN NN O
Friedreich NN NN B-Modifier
ataxia NN NN I-Modifier
mouse NN NN O
gene NN NN O
leads NN NN O
to NN NN O
early NN NN O
embryonic NN NN B-SpecificDisease
lethality NN NN I-SpecificDisease
without NN NN O
iron NN NN O
accumulation NN NN O
. NN NN O

Friedreich NN NN B-SpecificDisease
ataxia NN NN I-SpecificDisease
( NN NN O
FRDA NN NN B-SpecificDisease
) NN NN O
, NN NN O
the NN NN O
most NN NN O
common NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
ataxia NN NN I-DiseaseClass
, NN NN O
is NN NN O
caused NN NN O
in NN NN O
almost NN NN O
all NN NN O
cases NN NN O
by NN NN O
homozygous NN NN O
intronic NN NN O
expansions NN NN O
resulting NN NN O
in NN NN O
the NN NN O
loss NN NN O
of NN NN O
frataxin NN NN O
, NN NN O
a NN NN O
mitochondrial NN NN O
protein NN NN O
conserved NN NN O
through NN NN O
evolution NN NN O
, NN NN O
and NN NN O
involved NN NN O
in NN NN O
mitochondrial NN NN O
iron NN NN O
homeostasis NN NN O
. NN NN O

Yeast NN NN O
knockout NN NN O
models NN NN O
, NN NN O
and NN NN O
histological NN NN O
and NN NN O
biochemical NN NN O
data NN NN O
from NN NN O
patient NN NN O
heart NN NN O
biopsies NN NN O
or NN NN O
autopsies NN NN O
indicate NN NN O
that NN NN O
the NN NN O
frataxin NN NN O
defect NN NN O
causes NN NN O
a NN NN O
specific NN NN O
iron-sulfur NN NN B-SpecificDisease
protein NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
and NN NN O
mitochondrial NN NN O
iron NN NN O
accumulation NN NN O
leading NN NN O
to NN NN O
the NN NN O
pathological NN NN O
changes NN NN O
. NN NN O

Affected NN NN O
human NN NN O
tissues NN NN O
are NN NN O
rarely NN NN O
available NN NN O
to NN NN O
further NN NN O
examine NN NN O
this NN NN O
hypothesis NN NN O
. NN NN O

To NN NN O
study NN NN O
the NN NN O
mechanism NN NN O
of NN NN O
the NN NN O
disease NN NN O
, NN NN O
we NN NN O
generated NN NN O
a NN NN O
mouse NN NN O
model NN NN O
by NN NN O
deletion NN NN O
of NN NN O
exon NN NN O
4 NN NN O
leading NN NN O
to NN NN O
inactivation NN NN O
of NN NN O
the NN NN O
Frda NN NN B-Modifier
gene NN NN O
product NN NN O
. NN NN O

We NN NN O
show NN NN O
that NN NN O
homozygous NN NN O
deletions NN NN O
cause NN NN O
embryonic NN NN B-SpecificDisease
lethality NN NN I-SpecificDisease
a NN NN O
few NN NN O
days NN NN O
after NN NN O
implantation NN NN O
, NN NN O
demonstrating NN NN O
an NN NN O
important NN NN O
role NN NN O
for NN NN O
frataxin NN NN O
during NN NN O
early NN NN O
development NN NN O
. NN NN O

These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
milder NN NN O
phenotype NN NN O
in NN NN O
humans NN NN O
is NN NN O
due NN NN O
to NN NN O
residual NN NN O
frataxin NN NN O
expression NN NN O
associated NN NN O
with NN NN O
the NN NN O
expansion NN NN O
mutations NN NN O
. NN NN O

Surprisingly NN NN O
, NN NN O
in NN NN O
the NN NN O
frataxin NN NN O
knockout NN NN O
mouse NN NN O
, NN NN O
no NN NN O
iron NN NN O
accumulation NN NN O
was NN NN O
observed NN NN O
during NN NN O
embryonic NN NN O
resorption NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
cell NN NN O
death NN NN O
could NN NN O
be NN NN O
due NN NN O
to NN NN O
a NN NN O
mechanism NN NN O
independent NN NN O
of NN NN O
iron NN NN O
accumulation NN NN O
. NN NN O

. NN NN O

10777718 NN NN O
Gaucher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
: NN NN O
the NN NN O
origins NN NN O
of NN NN O
the NN NN O
Ashkenazi NN NN O
Jewish NN NN O
N370S NN NN O
and NN NN O
84GG NN NN O
acid NN NN O
beta-glucosidase NN NN O
mutations NN NN O
. NN NN O

Type NN NN O
1 NN NN O
Gaucher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
GD NN NN B-SpecificDisease
) NN NN O
, NN NN O
a NN NN O
non-neuronopathic NN NN O
lysosomal NN NN B-DiseaseClass
storage NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
, NN NN O
results NN NN O
from NN NN O
the NN NN O
deficient NN NN O
activity NN NN O
of NN NN O
acid NN NN O
beta-glucosidase NN NN O
( NN NN O
GBA NN NN O
) NN NN O
. NN NN O

Type NN NN O
1 NN NN O
disease NN NN O
is NN NN O
panethnic NN NN O
but NN NN O
is NN NN O
more NN NN O
prevalent NN NN O
in NN NN O
individuals NN NN O
of NN NN O
Ashkenazi NN NN O
Jewish NN NN O
( NN NN O
AJ NN NN O
) NN NN O
descent NN NN O
. NN NN O

Of NN NN O
the NN NN O
causative NN NN O
GBA NN NN O
mutations NN NN O
, NN NN O
N370S NN NN O
is NN NN O
particularly NN NN O
frequent NN NN O
in NN NN O
the NN NN O
AJ NN NN O
population NN NN O
, NN NN O
( NN NN O
q NN NN O
approximately NN NN O
. NN NN O

03 NN NN O
) NN NN O
, NN NN O
whereas NN NN O
the NN NN O
84GG NN NN O
insertion NN NN O
( NN NN O
q NN NN O
approximately NN NN O
. NN NN O

003 NN NN O
) NN NN O
occurs NN NN O
exclusively NN NN O
in NN NN O
the NN NN O
Ashkenazim NN NN O
. NN NN O

To NN NN O
investigate NN NN O
the NN NN O
genetic NN NN O
history NN NN O
of NN NN O
these NN NN O
mutations NN NN O
in NN NN O
the NN NN O
AJ NN NN O
population NN NN O
, NN NN O
short NN NN O
tandem NN NN O
repeat NN NN O
( NN NN O
STR NN NN O
) NN NN O
markers NN NN O
were NN NN O
used NN NN O
to NN NN O
map NN NN O
a NN NN O
9 NN NN O
. NN NN O

3-cM NN NN O
region NN NN O
containing NN NN O
the NN NN O
GBA NN NN O
locus NN NN O
and NN NN O
to NN NN O
genotype NN NN O
261 NN NN O
AJ NN NN O
N370S NN NN O
chromosomes NN NN O
, NN NN O
60 NN NN O
European NN NN O
non-Jewish NN NN O
N370S NN NN O
chromosomes NN NN O
, NN NN O
and NN NN O
62 NN NN O
AJ NN NN O
84GG NN NN O
chromosomes NN NN O
. NN NN O

A NN NN O
highly NN NN O
conserved NN NN O
haplotype NN NN O
at NN NN O
four NN NN O
markers NN NN O
flanking NN NN O
GBA NN NN O
( NN NN O
PKLR NN NN O
, NN NN O
D1S1595 NN NN O
, NN NN O
D1S2721 NN NN O
, NN NN O
and NN NN O
D1S2777 NN NN O
) NN NN O
was NN NN O
observed NN NN O
on NN NN O
both NN NN O
the NN NN O
AJ NN NN O
chromosomes NN NN O
and NN NN O
the NN NN O
non-Jewish NN NN O
N370S NN NN O
chromosomes NN NN O
, NN NN O
suggesting NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
a NN NN O
founder NN NN O
common NN NN O
to NN NN O
both NN NN O
populations NN NN O
. NN NN O

Of NN NN O
note NN NN O
, NN NN O
the NN NN O
presence NN NN O
of NN NN O
different NN NN O
divergent NN NN O
haplotypes NN NN O
suggested NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
de NN NN O
novo NN NN O
, NN NN O
recurrent NN NN O
N370S NN NN O
mutations NN NN O
. NN NN O

In NN NN O
contrast NN NN O
, NN NN O
a NN NN O
different NN NN O
conserved NN NN O
haplotype NN NN O
at NN NN O
these NN NN O
markers NN NN O
was NN NN O
identified NN NN O
on NN NN O
the NN NN O
84GG NN NN O
chromosomes NN NN O
, NN NN O
which NN NN O
was NN NN O
unique NN NN O
to NN NN O
the NN NN O
AJ NN NN O
population NN NN O
. NN NN O

On NN NN O
the NN NN O
basis NN NN O
of NN NN O
the NN NN O
linkage NN NN O
disequilibrium NN NN O
( NN NN O
LD NN NN O
) NN NN O
delta NN NN O
values NN NN O
, NN NN O
the NN NN O
non-Jewish NN NN O
European NN NN O
N370S NN NN O
chromosomes NN NN O
had NN NN O
greater NN NN O
haplotype NN NN O
diversity NN NN O
and NN NN O
less NN NN O
LD NN NN O
at NN NN O
the NN NN O
markers NN NN O
flanking NN NN O
the NN NN O
conserved NN NN O
haplotype NN NN O
than NN NN O
did NN NN O
the NN NN O
AJ NN NN O
N370S NN NN O
chromosomes NN NN O
. NN NN O

This NN NN O
finding NN NN O
is NN NN O
consistent NN NN O
with NN NN O
the NN NN O
presence NN NN O
of NN NN O
the NN NN O
N370S NN NN O
mutation NN NN O
in NN NN O
the NN NN O
non-Jewish NN NN O
European NN NN O
population NN NN O
prior NN NN O
to NN NN O
the NN NN O
founding NN NN O
of NN NN O
the NN NN O
AJ NN NN O
population NN NN O
. NN NN O

Coalescence NN NN O
analyses NN NN O
for NN NN O
the NN NN O
N370S NN NN O
and NN NN O
84GG NN NN O
mutations NN NN O
estimated NN NN O
similar NN NN O
coalescence NN NN O
times NN NN O
, NN NN O
of NN NN O
48 NN NN O
and NN NN O
55.5 NN NN O
generations NN NN O
ago NN NN O
, NN NN O
respectively NN NN O
. NN NN O

The NN NN O
results NN NN O
of NN NN O
these NN NN O
studies NN NN O
are NN NN O
consistent NN NN O
with NN NN O
a NN NN O
significant NN NN O
bottleneck NN NN O
occurring NN NN O
in NN NN O
the NN NN O
AJ NN NN O
population NN NN O
during NN NN O
the NN NN O
first NN NN O
millennium NN NN O
, NN NN O
when NN NN O
the NN NN O
population NN NN O
became NN NN O
established NN NN O
in NN NN O
Europe NN NN O
. NN NN O

107868 NN NN O
HLA NN NN O
B27 NN NN O
and NN NN O
the NN NN O
genetics NN NN O
of NN NN O
ankylosing NN NN B-SpecificDisease
spondylitis NN NN I-SpecificDisease
. NN NN O

One NN NN O
hundred NN NN O
and NN NN O
twenty-eight NN NN O
of NN NN O
145 NN NN O
patients NN NN O
with NN NN O
ankylosing NN NN B-SpecificDisease
spondylitis NN NN I-SpecificDisease
( NN NN O
AS NN NN B-SpecificDisease
) NN NN O
were NN NN O
found NN NN O
to NN NN O
be NN NN O
HLA NN NN O
B27 NN NN O
positive NN NN O
. NN NN O

Five NN NN O
patients NN NN O
had NN NN O
evidence NN NN O
of NN NN O
a NN NN O
sero-negative NN NN O
peripheral NN NN B-SpecificDisease
arthritis NN NN I-SpecificDisease
resembling NN NN O
peripheral NN NN B-SpecificDisease
psoriatic NN NN I-SpecificDisease
arthritis NN NN I-SpecificDisease
and NN NN O
3 NN NN O
of NN NN O
these NN NN O
were NN NN O
B27 NN NN O
negative NN NN O
. NN NN O

One NN NN O
further NN NN O
B27 NN NN O
negative NN NN O
patients NN NN O
had NN NN O
a NN NN O
sister NN NN O
with NN NN O
ankylosing NN NN B-SpecificDisease
spondylitis NN NN I-SpecificDisease
and NN NN O
ulcerative NN NN B-SpecificDisease
colitis NN NN I-SpecificDisease
and NN NN O
a NN NN O
mother NN NN O
with NN NN O
ulcerative NN NN B-SpecificDisease
colitis NN NN I-SpecificDisease
. NN NN O

There NN NN O
was NN NN O
evidence NN NN O
of NN NN O
a NN NN O
somewhat NN NN O
later NN NN O
age NN NN O
of NN NN O
onset NN NN O
of NN NN O
symptoms NN NN O
in NN NN O
B27 NN NN O
negative NN NN O
patients NN NN O
. NN NN O

These NN NN O
findings NN NN O
are NN NN O
interpreted NN NN O
as NN NN O
suggesting NN NN O
some NN NN O
degree NN NN O
of NN NN O
clinical NN NN O
and NN NN O
genetic NN NN O
heterogeneity NN NN O
in NN NN O
ankylosing NN NN B-SpecificDisease
spondylitis NN NN I-SpecificDisease
with NN NN O
genes NN NN O
for NN NN O
psoriasis NN NN B-SpecificDisease
and NN NN O
inflammatory NN NN B-SpecificDisease
bowel NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
being NN NN O
important NN NN O
in NN NN O
some NN NN O
individuals NN NN O
, NN NN O
particularly NN NN O
those NN NN O
who NN NN O
are NN NN O
B27 NN NN O
negative NN NN O
. NN NN O

Twenty-five NN NN O
first-degree NN NN O
relatives NN NN O
with NN NN O
ankylosing NN NN B-SpecificDisease
spondylitis NN NN I-SpecificDisease
were NN NN O
all NN NN O
B27 NN NN O
positive NN NN O
. NN NN O

The NN NN O
only NN NN O
instance NN NN O
of NN NN O
disassociation NN NN O
of NN NN O
B27 NN NN O
and NN NN O
spondylitis NN NN B-SpecificDisease
in NN NN O
a NN NN O
family NN NN O
was NN NN O
where NN NN O
the NN NN O
proband NN NN O
had NN NN O
ulcerative NN NN B-SpecificDisease
colitis NN NN I-SpecificDisease
as NN NN O
well NN NN O
as NN NN O
spondylitis NN NN B-SpecificDisease
. NN NN O

Of NN NN O
13 NN NN O
B27 NN NN O
positive NN NN O
fathers NN NN O
3 NN NN O
could NN NN O
be NN NN O
diagnosed NN NN O
as NN NN O
having NN NN O
definite NN NN O
ankylosing NN NN B-SpecificDisease
spondylitis NN NN I-SpecificDisease
( NN NN O
23 NN NN O
% NN NN O
) NN NN O
. NN NN O

These NN NN O
findings NN NN O
are NN NN O
thought NN NN O
to NN NN O
provide NN NN O
evidence NN NN O
against NN NN O
the NN NN O
concept NN NN O
that NN NN O
the NN NN O
gene NN NN O
for NN NN O
ankylosing NN NN B-SpecificDisease
spondylitis NN NN I-SpecificDisease
is NN NN O
not NN NN O
B27 NN NN O
but NN NN O
a NN NN O
closely NN NN O
linked NN NN O
gene NN NN O
and NN NN O
favour NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
an NN NN O
environmental NN NN O
event NN NN O
affecting NN NN O
approximately NN NN O
one-fifth NN NN O
of NN NN O
B27 NN NN O
positive NN NN O
males NN NN O
to NN NN O
result NN NN O
in NN NN O
disease NN NN O
. NN NN O

. NN NN O

10788334 NN NN O
Founder NN NN O
mutations NN NN O
in NN NN O
the NN NN O
BRCA1 NN NN O
gene NN NN O
in NN NN O
Polish NN NN O
families NN NN O
with NN NN O
breast-ovarian NN NN B-CompositeMention
cancer NN NN I-CompositeMention
. NN NN O

We NN NN O
have NN NN O
undertaken NN NN O
a NN NN O
hospital-based NN NN O
study NN NN O
, NN NN O
to NN NN O
identify NN NN O
possible NN NN O
BRCA1 NN NN O
and NN NN O
BRCA2 NN NN O
founder NN NN O
mutations NN NN O
in NN NN O
the NN NN O
Polish NN NN O
population NN NN O
. NN NN O

The NN NN O
study NN NN O
group NN NN O
consisted NN NN O
of NN NN O
66 NN NN O
Polish NN NN O
families NN NN O
with NN NN O
cancer NN NN B-DiseaseClass
who NN NN O
have NN NN O
at NN NN O
least NN NN O
three NN NN O
related NN NN O
females NN NN O
affected NN NN O
with NN NN O
breast NN NN B-CompositeMention
or NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
and NN NN O
who NN NN O
had NN NN O
cancer NN NN B-DiseaseClass
diagnosed NN NN O
, NN NN O
in NN NN O
at NN NN O
least NN NN O
one NN NN O
of NN NN O
the NN NN O
three NN NN O
affected NN NN O
females NN NN O
, NN NN O
at NN NN O
age NN NN O
50 NN NN O
years NN NN O
. NN NN O

A NN NN O
total NN NN O
of NN NN O
26 NN NN O
families NN NN O
had NN NN O
both NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancers NN NN I-CompositeMention
, NN NN O
4 NN NN O
families NN NN O
had NN NN O
ovarian NN NN B-SpecificDisease
cancers NN NN I-SpecificDisease
only NN NN O
, NN NN O
and NN NN O
36 NN NN O
families NN NN O
had NN NN O
breast NN NN B-SpecificDisease
cancers NN NN I-SpecificDisease
only NN NN O
. NN NN O

Genomic NN NN O
DNA NN NN O
was NN NN O
prepared NN NN O
from NN NN O
the NN NN O
peripheral NN NN O
blood NN NN O
leukocytes NN NN O
of NN NN O
at NN NN O
least NN NN O
one NN NN O
affected NN NN O
woman NN NN O
from NN NN O
each NN NN O
family NN NN O
. NN NN O

The NN NN O
entire NN NN O
coding NN NN O
region NN NN O
of NN NN O
BRCA1 NN NN O
and NN NN O
BRCA2 NN NN O
was NN NN O
screened NN NN O
for NN NN O
the NN NN O
presence NN NN O
of NN NN O
germline NN NN O
mutations NN NN O
, NN NN O
by NN NN O
use NN NN O
of NN NN O
SSCP NN NN O
followed NN NN O
by NN NN O
direct NN NN O
sequencing NN NN O
of NN NN O
observed NN NN O
variants NN NN O
. NN NN O

Mutations NN NN O
were NN NN O
found NN NN O
in NN NN O
35 NN NN O
( NN NN O
53 NN NN O
% NN NN O
) NN NN O
of NN NN O
the NN NN O
66 NN NN O
families NN NN O
studied NN NN O
. NN NN O

All NN NN O
but NN NN O
one NN NN O
of NN NN O
the NN NN O
mutations NN NN O
were NN NN O
detected NN NN O
within NN NN O
the NN NN O
BRCA1 NN NN O
gene NN NN O
. NN NN O

BRCA1 NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
were NN NN O
identified NN NN O
in NN NN O
all NN NN O
four NN NN O
families NN NN O
with NN NN O
ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
only NN NN O
, NN NN O
in NN NN O
67 NN NN O
% NN NN O
of NN NN O
27 NN NN O
families NN NN O
with NN NN O
both NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
, NN NN O
and NN NN O
in NN NN O
34 NN NN O
% NN NN O
of NN NN O
35 NN NN O
families NN NN O
with NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
only NN NN O
. NN NN O

The NN NN O
single NN NN O
family NN NN O
with NN NN O
a NN NN O
BRCA2 NN NN O
mutation NN NN O
had NN NN O
the NN NN O
breast-ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

Seven NN NN O
distinct NN NN O
mutations NN NN O
were NN NN O
identified NN NN O
; NN NN O
five NN NN O
of NN NN O
these NN NN O
occurred NN NN O
in NN NN O
two NN NN O
or NN NN O
more NN NN O
families NN NN O
. NN NN O

In NN NN O
total NN NN O
, NN NN O
recurrent NN NN O
mutations NN NN O
were NN NN O
found NN NN O
in NN NN O
33 NN NN O
( NN NN O
94 NN NN O
% NN NN O
) NN NN O
of NN NN O
the NN NN O
35 NN NN O
families NN NN O
with NN NN O
detected NN NN O
mutations NN NN O
. NN NN O

Three NN NN O
BRCA1 NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
- NN NN O
5382insC NN NN O
, NN NN O
C61G NN NN O
, NN NN O
and NN NN O
4153delA NN NN O
- NN NN O
accounted NN NN O
for NN NN O
51 NN NN O
% NN NN O
, NN NN O
20 NN NN O
% NN NN O
, NN NN O
and NN NN O
11 NN NN O
% NN NN O
of NN NN O
the NN NN O
identified NN NN O
mutations NN NN O
, NN NN O
respectively NN NN O
. NN NN O

. NN NN O

10790204 NN NN O
Molecular NN NN O
basis NN NN O
of NN NN O
very NN NN B-SpecificDisease
long NN NN I-SpecificDisease
chain NN NN I-SpecificDisease
acyl-CoA NN NN I-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
three NN NN O
Israeli NN NN O
patients NN NN O
: NN NN O
identification NN NN O
of NN NN O
a NN NN O
complex NN NN O
mutant NN NN O
allele NN NN O
with NN NN O
P65L NN NN O
and NN NN O
K247Q NN NN O
mutations NN NN O
, NN NN O
the NN NN O
former NN NN O
being NN NN O
an NN NN O
exonic NN NN O
mutation NN NN O
causing NN NN O
exon NN NN O
3 NN NN O
skipping NN NN O
. NN NN O

Very NN NN B-SpecificDisease
long NN NN I-SpecificDisease
chain NN NN I-SpecificDisease
acyl-CoA NN NN I-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
( NN NN I-SpecificDisease
VLCAD NN NN I-SpecificDisease
) NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
is NN NN O
a NN NN O
life-threatening NN NN O
disorder NN NN O
of NN NN O
mitochondrial NN NN O
fatty NN NN O
acid NN NN O
beta-oxidation NN NN O
. NN NN O

We NN NN O
identified NN NN O
four NN NN O
novel NN NN O
mutations NN NN O
in NN NN O
three NN NN O
unrelated NN NN O
patients NN NN O
. NN NN O

All NN NN O
patients NN NN O
had NN NN O
the NN NN O
severe NN NN O
childhood NN NN O
form NN NN O
of NN NN O
VLCAD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
with NN NN O
early NN NN O
onset NN NN O
and NN NN O
high NN NN O
mortality NN NN O
. NN NN O

Immunoblot NN NN O
analysis NN NN O
revealed NN NN O
that NN NN O
VLCAD NN NN O
protein NN NN O
was NN NN O
undetectable NN NN O
in NN NN O
patients NN NN O
2 NN NN O
and NN NN O
3 NN NN O
, NN NN O
whereas NN NN O
normal-size NN NN O
VLCAD NN NN O
protein NN NN O
and NN NN O
an NN NN O
aberrant NN NN O
form NN NN O
of NN NN O
VLCAD NN NN O
( NN NN O
4kDa NN NN O
smaller NN NN O
) NN NN O
were NN NN O
detected NN NN O
in NN NN O
patient NN NN O
1 NN NN O
. NN NN O

As NN NN O
expected NN NN O
, NN NN O
null NN NN O
mutations NN NN O
were NN NN O
found NN NN O
in NN NN O
patients NN NN O
2 NN NN O
and NN NN O
3 NN NN O
patient NN NN O
2 NN NN O
is NN NN O
homozygous NN NN O
for NN NN O
a NN NN O
frameshift NN NN O
mutation NN NN O
, NN NN O
del NN NN O
4 NN NN O
bp NN NN O
at NN NN O
798-801 NN NN O
, NN NN O
and NN NN O
patient NN NN O
3 NN NN O
is NN NN O
homozygous NN NN O
for NN NN O
a NN NN O
nonsense NN NN O
mutation NN NN O
65C NN NN O
A NN NN O
( NN NN O
S22X NN NN O
) NN NN O
. NN NN O

Patient NN NN O
1 NN NN O
was NN NN O
homozygous NN NN O
for NN NN O
a NN NN O
complex NN NN O
mutant NN NN O
allele NN NN O
containing NN NN O
two NN NN O
alterations NN NN O
, NN NN O
including NN NN O
a NN NN O
194C NN NN O
T NN NN O
transition NN NN O
( NN NN O
P65L NN NN O
) NN NN O
and NN NN O
739A NN NN O
C NN NN O
transversion NN NN O
( NN NN O
K247Q NN NN O
) NN NN O
; NN NN O
in NN NN O
the NN NN O
case NN NN O
of NN NN O
P65L NN NN O
, NN NN O
the NN NN O
amino NN NN O
acid NN NN O
change NN NN O
does NN NN O
not NN NN O
reduce NN NN O
enzyme NN NN O
activity NN NN O
. NN NN O

However NN NN O
, NN NN O
the NN NN O
nucleotide NN NN O
change NN NN O
resulted NN NN O
in NN NN O
exon NN NN O
3 NN NN O
skipping NN NN O
, NN NN O
whereas NN NN O
the NN NN O
latter NN NN O
K247Q NN NN O
mutation NN NN O
had NN NN O
a NN NN O
drastic NN NN O
effect NN NN O
on NN NN O
enzyme NN NN O
activity NN NN O
. NN NN O

We NN NN O
verified NN NN O
these NN NN O
events NN NN O
by NN NN O
in NN NN O
vivo NN NN O
splicing NN NN O
experiments NN NN O
and NN NN O
transient NN NN O
expression NN NN O
analysis NN NN O
of NN NN O
mutant NN NN O
cDNAs NN NN O
. NN NN O

The NN NN O
P65L NN NN O
mutation NN NN O
locates NN NN O
11 NN NN O
bases NN NN O
upstream NN NN O
of NN NN O
a NN NN O
splice NN NN O
donor NN NN O
site NN NN O
of NN NN O
intron NN NN O
3 NN NN O
. NN NN O

This NN NN O
is NN NN O
an NN NN O
example NN NN O
of NN NN O
an NN NN O
exonic NN NN O
mutation NN NN O
which NN NN O
affects NN NN O
exon-splicing NN NN O
. NN NN O

. NN NN O

10797418 NN NN O
Submicroscopic NN NN O
deletion NN NN O
in NN NN O
cousins NN NN O
with NN NN O
Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
causes NN NN O
a NN NN O
grandmatrilineal NN NN O
inheritance NN NN O
pattern NN NN O
: NN NN O
effects NN NN O
of NN NN O
imprinting NN NN O
. NN NN O

The NN NN O
Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
PWS NN NN B-SpecificDisease
) NN NN O
critical NN NN O
region NN NN O
on NN NN O
15q11-q13 NN NN O
is NN NN O
subject NN NN O
to NN NN O
imprinting NN NN O
. NN NN O

PWS NN NN B-SpecificDisease
becomes NN NN O
apparent NN NN O
when NN NN O
genes NN NN O
on NN NN O
the NN NN O
paternally NN NN O
inherited NN NN O
chromosome NN NN O
are NN NN O
not NN NN O
expressed NN NN O
. NN NN O

Familial NN NN B-SpecificDisease
PWS NN NN I-SpecificDisease
is NN NN O
rare NN NN O
. NN NN O

We NN NN O
report NN NN O
on NN NN O
a NN NN O
family NN NN O
in NN NN O
which NN NN O
a NN NN O
male NN NN O
and NN NN O
a NN NN O
female NN NN O
paternal NN NN O
first NN NN O
cousin NN NN O
both NN NN O
have NN NN O
PWS NN NN B-SpecificDisease
with NN NN O
cytogenetically NN NN O
normal NN NN O
karyotypes NN NN O
. NN NN O

Fluorescence NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
( NN NN O
FISH NN NN O
) NN NN O
analysis NN NN O
shows NN NN O
a NN NN O
submicroscopic NN NN O
deletion NN NN O
of NN NN O
SNRPN NN NN O
, NN NN O
but NN NN O
not NN NN O
the NN NN O
closely NN NN O
associated NN NN O
loci NN NN O
D15S10 NN NN O
, NN NN O
D15S11 NN NN O
, NN NN O
D15S63 NN NN O
, NN NN O
and NN NN O
GABRB3 NN NN O
. NN NN O

The NN NN O
cousins NN NN O
fathers NN NN O
and NN NN O
two NN NN O
paternal NN NN O
aunts NN NN O
have NN NN O
the NN NN O
same NN NN O
deletion NN NN O
and NN NN O
are NN NN O
clinically NN NN O
normal NN NN O
. NN NN O

The NN NN O
grandmother NN NN O
of NN NN O
the NN NN O
cousins NN NN O
is NN NN O
deceased NN NN O
and NN NN O
not NN NN O
available NN NN O
for NN NN O
study NN NN O
, NN NN O
and NN NN O
their NN NN O
grandfather NN NN O
is NN NN O
not NN NN O
deleted NN NN O
for NN NN O
SNRPN NN NN O
. NN NN O

DNA NN NN O
methylation NN NN O
analysis NN NN O
of NN NN O
D15S63 NN NN O
is NN NN O
consistent NN NN O
with NN NN O
an NN NN O
abnormality NN NN O
of NN NN O
the NN NN O
imprinting NN NN O
center NN NN O
associated NN NN O
with NN NN O
PWS NN NN B-SpecificDisease
. NN NN O
`` NN NN O

Grandmatrilineal NN NN O
`` NN NN O
inheritance NN NN O
occurs NN NN O
when NN NN O
a NN NN O
woman NN NN O
with NN NN O
deletion NN NN O
of NN NN O
an NN NN O
imprinted NN NN O
, NN NN O
paternally NN NN O
expressed NN NN O
gene NN NN O
is NN NN O
at NN NN O
risk NN NN O
of NN NN O
having NN NN O
affected NN NN O
grandchildren NN NN O
through NN NN O
her NN NN O
sons NN NN O
. NN NN O

In NN NN O
this NN NN O
case NN NN O
, NN NN O
PWS NN NN B-SpecificDisease
does NN NN O
not NN NN O
become NN NN O
evident NN NN O
as NN NN O
long NN NN O
as NN NN O
the NN NN O
deletion NN NN O
is NN NN O
passed NN NN O
through NN NN O
the NN NN O
matrilineal NN NN O
line NN NN O
. NN NN O

This NN NN O
represents NN NN O
a NN NN O
unique NN NN O
inheritance NN NN O
pattern NN NN O
due NN NN O
to NN NN O
imprinting NN NN O
. NN NN O

. NN NN O

10798358 NN NN O
Human NN NN O
glycine NN NN O
decarboxylase NN NN O
gene NN NN O
( NN NN O
GLDC NN NN O
) NN NN O
and NN NN O
its NN NN O
highly NN NN O
conserved NN NN O
processed NN NN O
pseudogene NN NN O
( NN NN O
psiGLDC NN NN O
) NN NN O
: NN NN O
their NN NN O
structure NN NN O
and NN NN O
expression NN NN O
, NN NN O
and NN NN O
the NN NN O
identification NN NN O
of NN NN O
a NN NN O
large NN NN O
deletion NN NN O
in NN NN O
a NN NN O
family NN NN O
with NN NN O
nonketotic NN NN B-SpecificDisease
hyperglycinemia NN NN I-SpecificDisease
. NN NN O

Mutations NN NN O
in NN NN O
the NN NN O
glycine NN NN O
decarboxylase NN NN O
gene NN NN O
( NN NN O
GLDC NN NN O
) NN NN O
cause NN NN O
nonketotic NN NN B-SpecificDisease
hyperglycinemia NN NN I-SpecificDisease
( NN NN O
NKH NN NN B-SpecificDisease
) NN NN O
, NN NN O
an NN NN O
in-born NN NN B-DiseaseClass
error NN NN I-DiseaseClass
of NN NN I-DiseaseClass
metabolism NN NN I-DiseaseClass
characterized NN NN O
by NN NN O
severe NN NN O
neurological NN NN B-DiseaseClass
disturbance NN NN I-DiseaseClass
. NN NN O

We NN NN O
have NN NN O
determined NN NN O
the NN NN O
structure NN NN O
of NN NN O
GLDC NN NN O
and NN NN O
of NN NN O
its NN NN O
pseudogene NN NN O
( NN NN O
psiGLDC NN NN O
) NN NN O
and NN NN O
studied NN NN O
their NN NN O
expression NN NN O
for NN NN O
a NN NN O
molecular NN NN O
analysis NN NN O
of NN NN O
NKH NN NN B-SpecificDisease
. NN NN O

The NN NN O
GLDC NN NN O
gene NN NN O
spans NN NN O
at NN NN O
least NN NN O
135 NN NN O
kb NN NN O
and NN NN O
consists NN NN O
of NN NN O
25 NN NN O
exons NN NN O
. NN NN O

All NN NN O
donor NN NN O
and NN NN O
acceptor NN NN O
sites NN NN O
adhere NN NN O
to NN NN O
the NN NN O
canonical NN NN O
GT-AG NN NN O
rule NN NN O
, NN NN O
except NN NN O
for NN NN O
the NN NN O
donor NN NN O
site NN NN O
of NN NN O
intron NN NN O
21 NN NN O
, NN NN O
where NN NN O
a NN NN O
variant NN NN O
form NN NN O
GC NN NN O
is NN NN O
used NN NN O
instead NN NN O
of NN NN O
GT NN NN O
. NN NN O

The NN NN O
transcription NN NN O
initiation NN NN O
site NN NN O
has NN NN O
been NN NN O
assigned NN NN O
to NN NN O
a NN NN O
residue NN NN O
163 NN NN O
bp NN NN O
upstream NN NN O
from NN NN O
the NN NN O
translation NN NN O
initiation NN NN O
triplet NN NN O
by NN NN O
primer NN NN O
extension NN NN O
analysis NN NN O
. NN NN O

The NN NN O
psiGLDC NN NN O
gene NN NN O
has NN NN O
no NN NN O
intron NN NN O
and NN NN O
shares NN NN O
97 NN NN O
. NN NN O

5 NN NN O
% NN NN O
homology NN NN O
with NN NN O
the NN NN O
coding NN NN O
region NN NN O
of NN NN O
functional NN NN O
GLDC NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
psiGLDC NN NN O
is NN NN O
a NN NN O
processed NN NN O
pseudogene NN NN O
that NN NN O
arose NN NN O
from NN NN O
the NN NN O
GLDC NN NN O
transcript NN NN O
about NN NN O
4-8 NN NN O
million NN NN O
years NN NN O
ago NN NN O
. NN NN O

RNA NN NN O
blotting NN NN O
analysis NN NN O
has NN NN O
revealed NN NN O
that NN NN O
GLDC NN NN O
is NN NN O
expressed NN NN O
in NN NN O
human NN NN O
liver NN NN O
, NN NN O
kidney NN NN O
, NN NN O
brain NN NN O
, NN NN O
and NN NN O
placenta NN NN O
. NN NN O

We NN NN O
have NN NN O
also NN NN O
examined NN NN O
a NN NN O
patient NN NN O
with NN NN O
NKH NN NN B-SpecificDisease
with NN NN O
no NN NN O
detectable NN NN O
GLDC NN NN O
mRNA NN NN O
in NN NN O
his NN NN O
lymphoblasts NN NN O
. NN NN O

Exons NN NN O
1-3 NN NN O
of NN NN O
the NN NN O
functional NN NN O
GLDC NN NN O
gene NN NN O
from NN NN O
this NN NN O
patient NN NN O
are NN NN O
not NN NN O
amplified NN NN O
by NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
( NN NN O
PCR NN NN O
) NN NN O
, NN NN O
whereas NN NN O
those NN NN O
from NN NN O
control NN NN O
subjects NN NN O
are NN NN O
. NN NN O

These NN NN O
results NN NN O
suggest NN NN O
a NN NN O
large NN NN O
homozygous NN NN O
deletion NN NN O
( NN NN O
at NN NN O
least NN NN O
30 NN NN O
kb NN NN O
) NN NN O
in NN NN O
the NN NN O
patient NN NN O
. NN NN O

Furthermore NN NN O
, NN NN O
we NN NN O
have NN NN O
devised NN NN O
a NN NN O
semi-quantitative NN NN O
PCR NN NN O
to NN NN O
estimate NN NN O
the NN NN O
number NN NN O
of NN NN O
GLDC NN NN O
alleles NN NN O
by NN NN O
using NN NN O
psiGLDC NN NN O
as NN NN O
an NN NN O
internal NN NN O
control NN NN O
and NN NN O
have NN NN O
confirmed NN NN O
the NN NN O
homozygosity NN NN O
and NN NN O
heterozygosity NN NN O
of NN NN O
the NN NN O
deletion NN NN O
in NN NN O
the NN NN O
patient NN NN O
and NN NN O
his NN NN O
parents NN NN O
, NN NN O
respectively NN NN O
. NN NN O

Structural NN NN O
information NN NN O
of NN NN O
GLDC NN NN O
and NN NN O
psiGLDC NN NN O
should NN NN O
facilitate NN NN O
the NN NN O
molecular NN NN O
analysis NN NN O
of NN NN O
NKH NN NN B-SpecificDisease
. NN NN O

10802660 NN NN O
De NN NN O
novo NN NN O
deletions NN NN O
of NN NN O
SNRPN NN NN O
exon NN NN O
1 NN NN O
in NN NN O
early NN NN O
human NN NN O
and NN NN O
mouse NN NN O
embryos NN NN O
result NN NN O
in NN NN O
a NN NN O
paternal NN NN O
to NN NN O
maternal NN NN O
imprint NN NN O
switch NN NN O
. NN NN O

Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
PWS NN NN B-SpecificDisease
) NN NN O
is NN NN O
a NN NN O
neurogenetic NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
characterized NN NN O
by NN NN O
infantile NN NN B-SpecificDisease
hypotonia NN NN I-SpecificDisease
, NN NN O
gonadal NN NN B-SpecificDisease
hypoplasia NN NN I-SpecificDisease
, NN NN O
obsessive NN NN O
behaviour NN NN O
and NN NN O
neonatal NN NN O
feeding NN NN O
difficulties NN NN O
followed NN NN O
by NN NN O
hyperphagia NN NN B-SpecificDisease
, NN NN O
leading NN NN O
to NN NN O
profound NN NN O
obesity NN NN B-SpecificDisease
. NN NN O

PWS NN NN B-SpecificDisease
is NN NN O
due NN NN O
to NN NN O
a NN NN O
lack NN NN O
of NN NN O
paternal NN NN O
genetic NN NN O
information NN NN O
at NN NN O
15q11-q13 NN NN O
( NN NN O
ref NN NN O
. NN NN O

2 NN NN O
) NN NN O
. NN NN O

Five NN NN O
imprinted NN NN O
, NN NN O
paternally NN NN O
expressed NN NN O
genes NN NN O
map NN NN O
to NN NN O
the NN NN O
PWS NN NN B-Modifier
region NN NN O
, NN NN O
MKRN3 NN NN O
( NN NN O
ref NN NN O
. NN NN O

3 NN NN O
) NN NN O
, NN NN O
NDN NN NN O
( NN NN O
ref NN NN O
. NN NN O

4 NN NN O
) NN NN O
, NN NN O
NDNL1 NN NN O
( NN NN O
ref NN NN O
. NN NN O

5 NN NN O
) NN NN O
, NN NN O
SNRPN NN NN O
( NN NN O
refs NN NN O
6-8 NN NN O
) NN NN O
and NN NN O
IPW NN NN O
( NN NN O
ref NN NN O
. NN NN O

9 NN NN O
) NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
two NN NN O
poorly NN NN O
characterized NN NN O
framents NN NN O
designated NN NN O
PAR-1 NN NN O
and NN NN O
PAR-5 NN NN O
( NN NN O
ref NN NN O
. NN NN O

10 NN NN O
) NN NN O
. NN NN O

Imprinting NN NN O
of NN NN O
this NN NN O
region NN NN O
involves NN NN O
a NN NN O
bipartite NN NN O
imprinting NN NN O
centre NN NN O
( NN NN O
IC NN NN O
) NN NN O
, NN NN O
which NN NN O
overlaps NN NN O
SNRPN NN NN O
( NN NN O
refs NN NN O
10 NN NN O
, NN NN O
11 NN NN O
) NN NN O
. NN NN O

Deletion NN NN O
of NN NN O
the NN NN O
SNRPN NN NN O
promoter NN NN O
/ NN NN O
exon NN NN O
1 NN NN O
region NN NN O
( NN NN O
the NN NN O
PWS NN NN B-Modifier
IC NN NN O
element NN NN O
) NN NN O
appears NN NN O
to NN NN O
impair NN NN O
the NN NN O
establishment NN NN O
of NN NN O
the NN NN O
paternal NN NN O
imprint NN NN O
in NN NN O
the NN NN O
male NN NN O
germ NN NN O
line NN NN O
and NN NN O
leads NN NN O
to NN NN O
PWS NN NN B-SpecificDisease
. NN NN O

Here NN NN O
we NN NN O
report NN NN O
a NN NN O
PWS NN NN B-Modifier
family NN NN O
in NN NN O
which NN NN O
the NN NN O
father NN NN O
is NN NN O
mosaic NN NN O
for NN NN O
an NN NN O
IC NN NN O
deletion NN NN O
on NN NN O
his NN NN O
paternal NN NN O
chromosome NN NN O
. NN NN O

The NN NN O
deletion NN NN O
chromosome NN NN O
has NN NN O
acquired NN NN O
a NN NN O
maternal NN NN O
methylation NN NN O
imprint NN NN O
in NN NN O
his NN NN O
somatic NN NN O
cells NN NN O
. NN NN O

We NN NN O
have NN NN O
made NN NN O
identical NN NN O
findings NN NN O
in NN NN O
chimaeric NN NN O
mice NN NN O
generated NN NN O
from NN NN O
two NN NN O
independent NN NN O
embryonic NN NN O
stem NN NN O
( NN NN O
ES NN NN O
) NN NN O
cell NN NN O
lines NN NN O
harbouring NN NN O
a NN NN O
similar NN NN O
deletion NN NN O
. NN NN O

Our NN NN O
studies NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
PWS NN NN B-Modifier
IC NN NN O
element NN NN O
is NN NN O
not NN NN O
only NN NN O
required NN NN O
for NN NN O
the NN NN O
establishment NN NN O
of NN NN O
the NN NN O
paternal NN NN O
imprint NN NN O
, NN NN O
but NN NN O
also NN NN O
for NN NN O
its NN NN O
postzygotic NN NN O
maintenance NN NN O
. NN NN O

. NN NN O

10802667 NN NN O
Mice NN NN O
deficient NN NN B-SpecificDisease
in NN NN I-SpecificDisease
Six5 NN NN I-SpecificDisease
develop NN NN O
cataracts NN NN B-SpecificDisease
: NN NN O
implications NN NN O
for NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
. NN NN O

Expansion NN NN O
of NN NN O
a NN NN O
CTG NN NN O
trinucleotide NN NN O
repeat NN NN O
in NN NN O
the NN NN O
3 NN NN O
UTR NN NN O
of NN NN O
the NN NN O
gene NN NN O
DMPK NN NN O
at NN NN O
the NN NN O
DM1 NN NN O
locus NN NN O
on NN NN O
chromosome NN NN O
19 NN NN O
causes NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
, NN NN O
a NN NN O
dominantly NN NN B-DiseaseClass
inherited NN NN I-DiseaseClass
disease NN NN I-DiseaseClass
characterized NN NN O
by NN NN O
skeletal NN NN O
muscle NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
and NN NN O
myotonia NN NN B-DiseaseClass
, NN NN O
cataracts NN NN B-SpecificDisease
and NN NN O
cardiac NN NN B-DiseaseClass
conduction NN NN I-DiseaseClass
defects NN NN I-DiseaseClass
. NN NN O

Targeted NN NN O
deletion NN NN O
of NN NN O
Dm15 NN NN O
, NN NN O
the NN NN O
mouse NN NN O
orthologue NN NN O
of NN NN O
human NN NN O
DMPK NN NN O
, NN NN O
produced NN NN O
mice NN NN O
with NN NN O
a NN NN O
mild NN NN O
myopathy NN NN B-DiseaseClass
and NN NN O
cardiac NN NN B-DiseaseClass
conduction NN NN I-DiseaseClass
abnormalities NN NN I-DiseaseClass
, NN NN O
but NN NN O
without NN NN O
other NN NN O
features NN NN O
of NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
, NN NN O
such NN NN O
as NN NN O
myotonia NN NN B-DiseaseClass
and NN NN O
cataracts NN NN B-SpecificDisease
. NN NN O

We NN NN O
, NN NN O
and NN NN O
others NN NN O
, NN NN O
have NN NN O
demonstrated NN NN O
that NN NN O
repeat NN NN O
expansion NN NN O
decreases NN NN O
expression NN NN O
of NN NN O
the NN NN O
adjacent NN NN O
gene NN NN O
SIX5 NN NN O
( NN NN O
refs NN NN O
7 NN NN O
, NN NN O
8 NN NN O
) NN NN O
, NN NN O
which NN NN O
encodes NN NN O
a NN NN O
homeodomain NN NN O
transcription NN NN O
factor NN NN O
. NN NN O

To NN NN O
determine NN NN O
whether NN NN O
SIX5 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
contributes NN NN O
to NN NN O
the NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
phenotype NN NN O
, NN NN O
we NN NN O
disrupted NN NN O
mouse NN NN O
Six5 NN NN O
by NN NN O
replacing NN NN O
the NN NN O
first NN NN O
exon NN NN O
with NN NN O
a NN NN O
beta-galactosidase NN NN O
reporter NN NN O
. NN NN O

Six5-mutant NN NN O
mice NN NN O
showed NN NN O
reporter NN NN O
expression NN NN O
in NN NN O
multiple NN NN O
tissues NN NN O
, NN NN O
including NN NN O
the NN NN O
developing NN NN O
lens NN NN O
. NN NN O

Homozygous NN NN O
mutant NN NN O
mice NN NN O
had NN NN O
no NN NN O
apparent NN NN O
abnormalities NN NN B-DiseaseClass
of NN NN I-DiseaseClass
skeletal NN NN I-DiseaseClass
muscle NN NN I-DiseaseClass
function NN NN I-DiseaseClass
, NN NN O
but NN NN O
developed NN NN O
lenticular NN NN B-SpecificDisease
opacities NN NN I-SpecificDisease
at NN NN O
a NN NN O
higher NN NN O
rate NN NN O
than NN NN O
controls NN NN O
. NN NN O

Our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
SIX5 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
contributes NN NN O
to NN NN O
the NN NN O
cataract NN NN B-Modifier
phenotype NN NN O
in NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
, NN NN O
and NN NN O
that NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
represents NN NN O
a NN NN O
multigenic NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
. NN NN O

. NN NN O

10802668 NN NN O
Heterozygous NN NN O
loss NN NN O
of NN NN O
Six5 NN NN O
in NN NN O
mice NN NN O
is NN NN O
sufficient NN NN O
to NN NN O
cause NN NN O
ocular NN NN O
cataracts NN NN B-SpecificDisease
. NN NN O

Myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
dominant NN NN I-DiseaseClass
disorde NN NN I-DiseaseClass
r NN NN O
characterized NN NN O
by NN NN O
skeletal NN NN O
muscle NN NN B-SpecificDisease
wasting NN NN I-SpecificDisease
, NN NN O
myotonia NN NN B-DiseaseClass
, NN NN O
cardiac NN NN B-DiseaseClass
arrhythmia NN NN I-DiseaseClass
, NN NN O
hyperinsulinaemia NN NN B-SpecificDisease
, NN NN O
mental NN NN B-DiseaseClass
retardation NN NN I-DiseaseClass
and NN NN O
ocular NN NN O
cataracts NN NN B-SpecificDisease
. NN NN O

The NN NN O
genetic NN NN B-DiseaseClass
defect NN NN I-DiseaseClass
in NN NN O
DM NN NN B-SpecificDisease
is NN NN O
a NN NN O
CTG NN NN O
repeat NN NN O
expansion NN NN O
located NN NN O
in NN NN O
the NN NN O
3 NN NN O
untranslated NN NN O
region NN NN O
of NN NN O
DMPK NN NN O
and NN NN O
5 NN NN O
of NN NN O
a NN NN O
homeodomain-encoding NN NN O
gene NN NN O
, NN NN O
SIX5 NN NN O
( NN NN O
formerly NN NN O
DMAHP NN NN O
; NN NN O
refs NN NN O
2-5 NN NN O
) NN NN O
. NN NN O

There NN NN O
are NN NN O
three NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
CTG NN NN O
expansion NN NN O
can NN NN O
result NN NN O
in NN NN O
DM NN NN B-SpecificDisease
. NN NN O

First NN NN O
, NN NN O
repeat NN NN O
expansion NN NN O
may NN NN O
alter NN NN O
the NN NN O
processing NN NN O
or NN NN O
transport NN NN O
of NN NN O
the NN NN O
mutant NN NN O
DMPK NN NN O
mRNA NN NN O
and NN NN O
consequently NN NN O
reduce NN NN O
DMPK NN NN O
levels NN NN O
. NN NN O

Second NN NN O
, NN NN O
CTG NN NN O
expansion NN NN O
may NN NN O
establish NN NN O
a NN NN O
region NN NN O
of NN NN O
heterochromatin NN NN O
3 NN NN O
of NN NN O
the NN NN O
repeat NN NN O
sequence NN NN O
and NN NN O
decrease NN NN O
SIX5 NN NN O
transcription NN NN O
. NN NN O

Third NN NN O
, NN NN O
toxic NN NN O
effects NN NN O
of NN NN O
the NN NN O
repeat NN NN O
expansion NN NN O
may NN NN O
be NN NN O
intrinsic NN NN O
to NN NN O
the NN NN O
repeated NN NN O
elements NN NN O
at NN NN O
the NN NN O
level NN NN O
of NN NN O
DNA NN NN O
or NN NN O
RNA NN NN O
( NN NN O
refs NN NN O
10 NN NN O
, NN NN O
11 NN NN O
) NN NN O
. NN NN O

Previous NN NN O
studies NN NN O
have NN NN O
demonstrated NN NN O
that NN NN O
a NN NN O
dose-dependent NN NN O
loss NN NN O
of NN NN O
Dm15 NN NN O
( NN NN O
the NN NN O
mouse NN NN O
DMPK NN NN O
homologue NN NN O
) NN NN O
in NN NN O
mice NN NN O
produces NN NN O
a NN NN O
partial NN NN O
DM NN NN B-Modifier
phenotype NN NN O
characterized NN NN O
by NN NN O
decreased NN NN O
development NN NN O
of NN NN O
skeletal NN NN O
muscle NN NN O
force NN NN O
and NN NN O
cardiac NN NN B-DiseaseClass
conduction NN NN I-DiseaseClass
disorders NN NN I-DiseaseClass
. NN NN O

To NN NN O
test NN NN O
the NN NN O
role NN NN O
of NN NN O
Six5 NN NN O
loss NN NN O
in NN NN O
DM NN NN B-SpecificDisease
, NN NN O
we NN NN O
have NN NN O
analysed NN NN O
a NN NN O
strain NN NN O
of NN NN O
mice NN NN O
in NN NN O
which NN NN O
Six5 NN NN O
was NN NN O
deleted NN NN O
. NN NN O

Our NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
rate NN NN O
and NN NN O
severity NN NN O
of NN NN O
cataract NN NN B-Modifier
formation NN NN O
is NN NN O
inversely NN NN O
related NN NN O
to NN NN O
Six5 NN NN O
dosage NN NN O
and NN NN O
is NN NN O
temporally NN NN O
progressive NN NN O
. NN NN O

Six5 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
and NN NN O
Six5- NN NN O
/ NN NN O
- NN NN O
mice NN NN O
show NN NN O
increased NN NN O
steady-state NN NN O
levels NN NN O
of NN NN O
the NN NN O
Na NN NN O
+ NN NN O
/ NN NN O
K NN NN O
+ NN NN O
-ATPase NN NN O
alpha-1 NN NN O
subunit NN NN O
and NN NN O
decreased NN NN O
Dm15 NN NN O
mRNA NN NN O
levels NN NN O
. NN NN O

Thus NN NN O
, NN NN O
altered NN NN O
ion NN NN O
homeostasis NN NN O
within NN NN O
the NN NN O
lens NN NN O
may NN NN O
contribute NN NN O
to NN NN O
cataract NN NN B-Modifier
formation NN NN O
. NN NN O

As NN NN O
ocular NN NN O
cataracts NN NN B-SpecificDisease
are NN NN O
a NN NN O
characteristic NN NN O
feature NN NN O
of NN NN O
DM NN NN B-SpecificDisease
, NN NN O
these NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
decreased NN NN O
SIX5 NN NN O
transcription NN NN O
is NN NN O
important NN NN O
in NN NN O
the NN NN O
aetiology NN NN O
of NN NN O
DM NN NN B-SpecificDisease
. NN NN O

Our NN NN O
data NN NN O
support NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
DM NN NN B-SpecificDisease
is NN NN O
a NN NN O
contiguous NN NN O
gene NN NN O
syndrome NN NN O
associated NN NN O
with NN NN O
the NN NN O
partial NN NN O
loss NN NN O
of NN NN O
both NN NN O
DMPK NN NN O
and NN NN O
SIX5 NN NN O
. NN NN O

. NN NN O

10802669 NN NN O
ATM-dependent NN NN O
phosphorylation NN NN O
of NN NN O
nibrin NN NN O
in NN NN O
response NN NN O
to NN NN O
radiation NN NN O
exposure NN NN O
. NN NN O

Mutations NN NN O
in NN NN O
the NN NN O
gene NN NN O
ATM NN NN O
are NN NN O
responsible NN NN O
for NN NN O
the NN NN O
genetic NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
ataxia-telangiectasia NN NN B-SpecificDisease
( NN NN O
A-T NN NN B-SpecificDisease
) NN NN O
, NN NN O
which NN NN O
is NN NN O
characterized NN NN O
by NN NN O
cerebellar NN NN B-DiseaseClass
dysfunction NN NN I-DiseaseClass
, NN NN O
radiosensitivity NN NN O
, NN NN O
chromosomal NN NN O
instability NN NN O
and NN NN O
cancer NN NN B-Modifier
predisposition NN NN O
. NN NN O

Both NN NN O
the NN NN O
A-T NN NN B-Modifier
phenotype NN NN O
and NN NN O
the NN NN O
similarity NN NN O
of NN NN O
the NN NN O
ATM NN NN O
protein NN NN O
to NN NN O
other NN NN O
DNA-damage NN NN O
sensors NN NN O
suggests NN NN O
a NN NN O
role NN NN O
for NN NN O
ATM NN NN O
in NN NN O
biochemical NN NN O
pathways NN NN O
involved NN NN O
in NN NN O
the NN NN O
recognition NN NN O
, NN NN O
signalling NN NN O
and NN NN O
repair NN NN O
of NN NN O
DNA NN NN O
double-strand NN NN O
breaks NN NN O
( NN NN O
DSBs NN NN O
) NN NN O
. NN NN O

There NN NN O
are NN NN O
strong NN NN O
parallels NN NN O
between NN NN O
the NN NN O
pattern NN NN O
of NN NN O
radiosensitivity NN NN O
, NN NN O
chromosomal NN NN O
instability NN NN O
and NN NN O
cancer NN NN B-Modifier
predisposition NN NN O
in NN NN O
A-T NN NN B-SpecificDisease
patients NN NN O
and NN NN O
that NN NN O
in NN NN O
patients NN NN O
with NN NN O
Nijmegen NN NN B-SpecificDisease
breakage NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
NBS NN NN B-SpecificDisease
) NN NN O
. NN NN O

The NN NN O
protein NN NN O
defective NN NN O
in NN NN O
NBS NN NN B-SpecificDisease
, NN NN O
nibrin NN NN O
( NN NN O
encoded NN NN O
by NN NN O
NBS1 NN NN O
) NN NN O
, NN NN O
forms NN NN O
a NN NN O
complex NN NN O
with NN NN O
MRE11 NN NN O
and NN NN O
RAD50 NN NN O
( NN NN O
refs NN NN O
1 NN NN O
, NN NN O
2 NN NN O
) NN NN O
. NN NN O

This NN NN O
complex NN NN O
localizes NN NN O
to NN NN O
DSBs NN NN O
within NN NN O
30 NN NN O
minutes NN NN O
after NN NN O
cellular NN NN O
exposure NN NN O
to NN NN O
ionizing NN NN O
radiation NN NN O
( NN NN O
IR NN NN O
) NN NN O
and NN NN O
is NN NN O
observed NN NN O
in NN NN O
brightly NN NN O
staining NN NN O
nuclear NN NN O
foci NN NN O
after NN NN O
a NN NN O
longer NN NN O
period NN NN O
of NN NN O
time NN NN O
. NN NN O

The NN NN O
overlap NN NN O
between NN NN O
clinical NN NN O
and NN NN O
cellular NN NN O
phenotypes NN NN O
in NN NN O
A-T NN NN B-SpecificDisease
and NN NN O
NBS NN NN B-SpecificDisease
suggests NN NN O
that NN NN O
ATM NN NN O
and NN NN O
nibrin NN NN O
may NN NN O
function NN NN O
in NN NN O
the NN NN O
same NN NN O
biochemical NN NN O
pathway NN NN O
. NN NN O

Here NN NN O
we NN NN O
demonstrate NN NN O
that NN NN O
nibrin NN NN O
is NN NN O
phosphorylated NN NN O
within NN NN O
one NN NN O
hour NN NN O
of NN NN O
treatment NN NN O
of NN NN O
cells NN NN O
with NN NN O
IR NN NN O
. NN NN O

This NN NN O
response NN NN O
is NN NN O
abrogated NN NN O
in NN NN O
A-T NN NN B-Modifier
cells NN NN O
that NN NN O
either NN NN O
do NN NN O
not NN NN O
express NN NN O
ATM NN NN O
protein NN NN O
or NN NN O
express NN NN O
near NN NN O
full-length NN NN O
mutant NN NN O
protein NN NN O
. NN NN O

We NN NN O
also NN NN O
show NN NN O
that NN NN O
ATM NN NN O
physically NN NN O
interacts NN NN O
with NN NN O
and NN NN O
phosphorylates NN NN O
nibrin NN NN O
on NN NN O
serine NN NN O
343 NN NN O
both NN NN O
in NN NN O
vivo NN NN O
and NN NN O
in NN NN O
vitro NN NN O
. NN NN O

Phosphorylation NN NN O
of NN NN O
this NN NN O
site NN NN O
appears NN NN O
to NN NN O
be NN NN O
functionally NN NN O
important NN NN O
because NN NN O
mutated NN NN O
nibrin NN NN O
( NN NN O
S343A NN NN O
) NN NN O
does NN NN O
not NN NN O
completely NN NN O
complement NN NN O
radiosensitivity NN NN O
in NN NN O
NBS NN NN B-Modifier
cells NN NN O
. NN NN O

ATM NN NN O
phosphorylation NN NN O
of NN NN O
nibrin NN NN O
does NN NN O
not NN NN O
affect NN NN O
nibrin-MRE11-RAD50 NN NN O
association NN NN O
as NN NN O
revealed NN NN O
by NN NN O
radiation-induced NN NN O
foci NN NN O
formation NN NN O
. NN NN O

Our NN NN O
data NN NN O
provide NN NN O
a NN NN O
biochemical NN NN O
explanation NN NN O
for NN NN O
the NN NN O
similarity NN NN O
in NN NN O
phenotype NN NN O
between NN NN O
A-T NN NN B-SpecificDisease
and NN NN O
NBS NN NN B-SpecificDisease
. NN NN O

. NN NN O

10807385 NN NN O
Clinicopathologic NN NN O
features NN NN O
of NN NN O
BRCA-linked NN NN B-CompositeMention
and NN NN I-CompositeMention
sporadic NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
. NN NN O

CONTEXT NN NN O
Most NN NN O
hereditary NN NN B-SpecificDisease
ovarian NN NN I-SpecificDisease
cancers NN NN I-SpecificDisease
are NN NN O
associated NN NN O
with NN NN O
germline NN NN O
mutations NN NN O
in NN NN O
BRCA1 NN NN O
or NN NN O
BRCA2 NN NN O
. NN NN O

Attempts NN NN O
to NN NN O
define NN NN O
the NN NN O
clinical NN NN O
significance NN NN O
of NN NN O
BRCA NN NN O
mutation NN NN O
status NN NN O
in NN NN O
ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
have NN NN O
produced NN NN O
conflicting NN NN O
results NN NN O
, NN NN O
especially NN NN O
regarding NN NN O
survival NN NN O
. NN NN O

OBJECTIVE NN NN O
To NN NN O
determine NN NN O
whether NN NN O
hereditary NN NN B-SpecificDisease
ovarian NN NN I-SpecificDisease
cancers NN NN I-SpecificDisease
have NN NN O
distinct NN NN O
clinical NN NN O
and NN NN O
pathological NN NN O
features NN NN O
compared NN NN O
with NN NN O
sporadic NN NN B-SpecificDisease
( NN NN I-SpecificDisease
nonhereditary NN NN I-SpecificDisease
) NN NN I-SpecificDisease
ovarian NN NN I-SpecificDisease
cancers NN NN I-SpecificDisease
. NN NN O

DESIGN NN NN O
AND NN NN O
SETTING NN NN O
Retrospective NN NN O
cohort NN NN O
study NN NN O
of NN NN O
a NN NN O
consecutive NN NN O
series NN NN O
of NN NN O
933 NN NN O
ovarian NN NN B-SpecificDisease
cancers NN NN I-SpecificDisease
diagnosed NN NN O
and NN NN O
treated NN NN O
at NN NN O
our NN NN O
institution NN NN O
, NN NN O
which NN NN O
is NN NN O
a NN NN O
comprehensive NN NN O
cancer NN NN B-Modifier
center NN NN O
as NN NN O
designated NN NN O
by NN NN O
the NN NN O
National NN NN O
Cancer NN NN B-Modifier
Institute NN NN O
, NN NN O
over NN NN O
a NN NN O
12-year NN NN O
period NN NN O
( NN NN O
December NN NN O
1986 NN NN O
to NN NN O
August NN NN O
1998 NN NN O
) NN NN O
. NN NN O

PATIENTS NN NN O
The NN NN O
study NN NN O
was NN NN O
restricted NN NN O
to NN NN O
patients NN NN O
of NN NN O
Jewish NN NN O
origin NN NN O
because NN NN O
of NN NN O
the NN NN O
ease NN NN O
of NN NN O
BRCA1 NN NN O
and NN NN O
BRCA2 NN NN O
genotyping NN NN O
in NN NN O
this NN NN O
ethnic NN NN O
group NN NN O
. NN NN O

From NN NN O
the NN NN O
189 NN NN O
patients NN NN O
who NN NN O
identified NN NN O
themselves NN NN O
as NN NN O
Jewish NN NN O
, NN NN O
88 NN NN O
hereditary NN NN O
cases NN NN O
were NN NN O
identified NN NN O
with NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
germline NN NN O
founder NN NN O
mutation NN NN O
in NN NN O
BRCA1 NN NN O
or NN NN O
BRCA2 NN NN O
. NN NN O

The NN NN O
remaining NN NN O
101 NN NN O
cases NN NN O
from NN NN O
the NN NN O
same NN NN O
series NN NN O
not NN NN O
associated NN NN O
with NN NN O
a NN NN O
BRCA NN NN O
mutation NN NN O
and NN NN O
2 NN NN O
additional NN NN O
groups NN NN O
( NN NN O
Gynecologic NN NN O
Oncology NN NN O
Group NN NN O
protocols NN NN O
52 NN NN O
and NN NN O
111 NN NN O
) NN NN O
with NN NN O
ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
from NN NN O
clinical NN NN O
trials NN NN O
( NN NN O
for NN NN O
the NN NN O
survival NN NN O
analysis NN NN O
) NN NN O
were NN NN O
included NN NN O
for NN NN O
comparison NN NN O
. NN NN O

MAIN NN NN O
OUTCOME NN NN O
MEASURES NN NN O
Age NN NN O
at NN NN O
diagnosis NN NN O
, NN NN O
surgical NN NN O
stage NN NN O
, NN NN O
histologic NN NN O
cell NN NN O
type NN NN O
and NN NN O
grade NN NN O
, NN NN O
and NN NN O
surgical NN NN O
outcome NN NN O
; NN NN O
and NN NN O
response NN NN O
to NN NN O
chemotherapy NN NN O
and NN NN O
survival NN NN O
for NN NN O
advanced-stage NN NN O
( NN NN O
II NN NN O
and NN NN O
IV NN NN O
) NN NN O
cases NN NN O
. NN NN O

RESULTS NN NN O
Hereditary NN NN B-DiseaseClass
cancers NN NN I-DiseaseClass
were NN NN O
rarely NN NN O
diagnosed NN NN O
before NN NN O
age NN NN O
40 NN NN O
years NN NN O
and NN NN O
were NN NN O
common NN NN O
after NN NN O
age NN NN O
60 NN NN O
years NN NN O
, NN NN O
with NN NN O
mean NN NN O
age NN NN O
at NN NN O
diagnosis NN NN O
being NN NN O
significantly NN NN O
younger NN NN O
for NN NN O
BRCA1- NN NN O
vs NN NN O
BRCA2-linked NN NN O
patients NN NN O
( NN NN O
54 NN NN O
vs NN NN O
62 NN NN O
years NN NN O
; NN NN O
P NN NN O
= NN NN O
. NN NN O

04 NN NN O
) NN NN O
. NN NN O

Histology NN NN O
, NN NN O
grade NN NN O
, NN NN O
stage NN NN O
, NN NN O
and NN NN O
success NN NN O
of NN NN O
cytoreductive NN NN O
surgery NN NN O
were NN NN O
similar NN NN O
for NN NN O
hereditary NN NN O
and NN NN O
sporadic NN NN O
cases NN NN O
. NN NN O

The NN NN O
hereditary NN NN O
group NN NN O
had NN NN O
a NN NN O
longer NN NN O
disease-free NN NN O
interval NN NN O
following NN NN O
primary NN NN O
chemotherapy NN NN O
in NN NN O
comparison NN NN O
with NN NN O
the NN NN O
nonhereditary NN NN O
group NN NN O
, NN NN O
with NN NN O
a NN NN O
median NN NN O
time NN NN O
to NN NN O
recurrence NN NN O
of NN NN O
14 NN NN O
months NN NN O
and NN NN O
7 NN NN O
months NN NN O
, NN NN O
respectively NN NN O
( NN NN O
P NN NN O
. NN NN O

001 NN NN O
) NN NN O
. NN NN O

Those NN NN O
with NN NN O
hereditary NN NN B-DiseaseClass
cancers NN NN I-DiseaseClass
had NN NN O
improved NN NN O
survival NN NN O
compared NN NN O
with NN NN O
the NN NN O
nonhereditary NN NN O
group NN NN O
( NN NN O
P NN NN O
= NN NN O
. NN NN O

004 NN NN O
) NN NN O
. NN NN O

For NN NN O
stage NN NN B-DiseaseClass
III NN NN I-DiseaseClass
cancers NN NN I-DiseaseClass
, NN NN O
BRCA NN NN O
mutation NN NN O
status NN NN O
was NN NN O
an NN NN O
independent NN NN O
prognostic NN NN O
variable NN NN O
( NN NN O
P NN NN O
= NN NN O
. NN NN O

03 NN NN O
) NN NN O
. NN NN O

CONCLUSIONS NN NN O
Although NN NN O
BRCA-associated NN NN B-SpecificDisease
hereditary NN NN I-SpecificDisease
ovarian NN NN I-SpecificDisease
cancers NN NN I-SpecificDisease
in NN NN O
this NN NN O
population NN NN O
have NN NN O
surgical NN NN O
and NN NN O
pathological NN NN O
characteristics NN NN O
similar NN NN O
to NN NN O
those NN NN O
of NN NN O
sporadic NN NN B-DiseaseClass
cancers NN NN I-DiseaseClass
, NN NN O
advanced-stage NN NN B-Modifier
hereditary NN NN I-Modifier
cancer NN NN I-Modifier
patients NN NN O
survive NN NN O
longer NN NN O
than NN NN O
nonhereditary NN NN B-Modifier
cancer NN NN I-Modifier
patients NN NN O
. NN NN O

Age NN NN O
penetrance NN NN O
is NN NN O
greater NN NN O
for NN NN O
BRCA1-linked NN NN B-CompositeMention
than NN NN I-CompositeMention
for NN NN I-CompositeMention
BRCA2-linked NN NN I-CompositeMention
cancers NN NN I-CompositeMention
in NN NN O
this NN NN O
population NN NN O
. NN NN O

10807793 NN NN O
The NN NN O
gene NN NN O
for NN NN O
familial NN NN B-SpecificDisease
Mediterranean NN NN I-SpecificDisease
fever NN NN I-SpecificDisease
, NN NN O
MEFV NN NN O
, NN NN O
is NN NN O
expressed NN NN O
in NN NN O
early NN NN O
leukocyte NN NN O
development NN NN O
and NN NN O
is NN NN O
regulated NN NN O
in NN NN O
response NN NN O
to NN NN O
inflammatory NN NN O
mediators NN NN O
. NN NN O

Familial NN NN B-SpecificDisease
Mediterranean NN NN I-SpecificDisease
fever NN NN I-SpecificDisease
( NN NN O
FMF NN NN B-SpecificDisease
) NN NN O
is NN NN O
a NN NN O
recessive NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
characterized NN NN O
by NN NN O
episodes NN NN O
of NN NN O
fever NN NN B-DiseaseClass
and NN NN O
neutrophil-mediated NN NN B-SpecificDisease
serosal NN NN I-SpecificDisease
inflammation NN NN I-SpecificDisease
. NN NN O

We NN NN O
recently NN NN O
identified NN NN O
the NN NN O
gene NN NN O
causing NN NN O
FMF NN NN B-SpecificDisease
, NN NN O
designated NN NN O
MEFV NN NN O
, NN NN O
and NN NN O
found NN NN O
it NN NN O
to NN NN O
be NN NN O
expressed NN NN O
in NN NN O
mature NN NN O
neutrophils NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
it NN NN O
functions NN NN O
as NN NN O
an NN NN O
inflammatory NN NN O
regulator NN NN O
. NN NN O

To NN NN O
facilitate NN NN O
our NN NN O
understanding NN NN O
of NN NN O
the NN NN O
normal NN NN O
function NN NN O
of NN NN O
MEFV NN NN O
, NN NN O
we NN NN O
extended NN NN O
our NN NN O
previous NN NN O
studies NN NN O
. NN NN O

MEFV NN NN O
messenger NN NN O
RNA NN NN O
was NN NN O
detected NN NN O
by NN NN O
reverse NN NN O
transcriptase-polymerase NN NN O
chain NN NN O
reaction NN NN O
in NN NN O
bone NN NN O
marrow NN NN O
leukocytes NN NN O
, NN NN O
with NN NN O
differential NN NN O
expression NN NN O
observed NN NN O
among NN NN O
cells NN NN O
by NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
. NN NN O

CD34 NN NN O
hematopoietic NN NN O
stem-cell NN NN O
cultures NN NN O
induced NN NN O
toward NN NN O
the NN NN O
granulocytic NN NN O
lineage NN NN O
expressed NN NN O
MEFV NN NN O
at NN NN O
the NN NN O
myelocyte NN NN O
stage NN NN O
, NN NN O
concurrently NN NN O
with NN NN O
lineage NN NN O
commitment NN NN O
. NN NN O

The NN NN O
prepromyelocytic NN NN O
cell NN NN O
line NN NN O
HL60 NN NN O
expressed NN NN O
MEFV NN NN O
only NN NN O
at NN NN O
granulocytic NN NN O
and NN NN O
monocytic NN NN O
differentiation NN NN O
. NN NN O

MEFV NN NN O
was NN NN O
also NN NN O
expressed NN NN O
in NN NN O
the NN NN O
monocytic NN NN O
cell NN NN O
lines NN NN O
U937 NN NN O
and NN NN O
THP-1 NN NN O
. NN NN O

Among NN NN O
peripheral NN NN O
blood NN NN O
leukocytes NN NN O
, NN NN O
MEFV NN NN O
expression NN NN O
was NN NN O
detected NN NN O
in NN NN O
neutrophils NN NN O
, NN NN O
eosinophils NN NN O
, NN NN O
and NN NN O
to NN NN O
varying NN NN O
degrees NN NN O
, NN NN O
monocytes NN NN O
. NN NN O

Consistent NN NN O
with NN NN O
the NN NN O
tissue NN NN O
specificity NN NN O
of NN NN O
expression NN NN O
, NN NN O
complete NN NN O
sequencing NN NN O
and NN NN O
analysis NN NN O
of NN NN O
upstream NN NN O
regulatory NN NN O
regions NN NN O
of NN NN O
MEFV NN NN O
revealed NN NN O
homology NN NN O
to NN NN O
myeloid-specific NN NN O
promoters NN NN O
and NN NN O
to NN NN O
more NN NN O
broadly NN NN O
expressed NN NN O
inflammatory NN NN O
promoter NN NN O
elements NN NN O
. NN NN O

In NN NN O
vitro NN NN O
stimulation NN NN O
of NN NN O
monocytes NN NN O
with NN NN O
the NN NN O
proinflammatory NN NN O
agents NN NN O
interferon NN NN O
( NN NN O
IFN NN NN O
) NN NN O
gamma NN NN O
, NN NN O
tumor NN NN B-Modifier
necrosis NN NN O
factor NN NN O
, NN NN O
and NN NN O
lipopolysaccharide NN NN O
induced NN NN O
MEFV NN NN O
expression NN NN O
, NN NN O
whereas NN NN O
the NN NN O
antiinflammatory NN NN O
cytokines NN NN O
interleukin NN NN O
( NN NN O
IL NN NN O
) NN NN O
4 NN NN O
, NN NN O
IL-10 NN NN O
, NN NN O
and NN NN O
transforming NN NN O
growth NN NN O
factor NN NN O
beta NN NN O
inhibited NN NN O
such NN NN O
expression NN NN O
. NN NN O

Induction NN NN O
by NN NN O
IFN-gamma NN NN O
occurred NN NN O
rapidly NN NN O
and NN NN O
was NN NN O
resistant NN NN O
to NN NN O
cycloheximide NN NN O
. NN NN O

IFN-alpha NN NN O
also NN NN O
induced NN NN O
MEFV NN NN O
expression NN NN O
. NN NN O

In NN NN O
granulocytes NN NN O
, NN NN O
MEFV NN NN O
was NN NN O
up-regulated NN NN O
by NN NN O
IFN-gamma NN NN O
and NN NN O
the NN NN O
combination NN NN O
of NN NN O
IFN-alpha NN NN O
and NN NN O
colchicine NN NN O
. NN NN O

These NN NN O
results NN NN O
refine NN NN O
understanding NN NN O
of NN NN O
MEFV NN NN O
by NN NN O
placing NN NN O
the NN NN O
gene NN NN O
in NN NN O
the NN NN O
myelomonocytic-specific NN NN O
proinflammatory NN NN O
pathway NN NN O
and NN NN O
identifying NN NN O
it NN NN O
as NN NN O
an NN NN O
IFN-gamma NN NN O
immediate NN NN O
early NN NN O
gene NN NN O
. NN NN O

. NN NN O

10814710 NN NN O
Biochemical NN NN O
and NN NN O
structural NN NN O
analysis NN NN O
of NN NN O
missense NN NN O
mutations NN NN O
in NN NN O
N-acetylgalactosamine-6-sulfate NN NN O
sulfatase NN NN O
causing NN NN O
mucopolysaccharidosis NN NN B-Modifier
IVA NN NN I-Modifier
phenotypes NN NN O
. NN NN O

Mucopolysaccharidosis NN NN B-SpecificDisease
IVA NN NN I-SpecificDisease
( NN NN O
MPS NN NN B-SpecificDisease
IVA NN NN I-SpecificDisease
; NN NN O
OMIM NN NN O
# NN NN O
253000 NN NN O
) NN NN O
, NN NN O
a NN NN O
lysosomal NN NN B-DiseaseClass
storage NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
caused NN NN O
by NN NN O
a NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
N NN NN I-SpecificDisease
-acetylgalactosamine-6-sulfate NN NN I-SpecificDisease
sulfatase NN NN I-SpecificDisease
( NN NN O
GALNS NN NN O
) NN NN O
, NN NN O
has NN NN O
variable NN NN O
clinical NN NN O
phenotypes NN NN O
. NN NN O

To NN NN O
date NN NN O
we NN NN O
have NN NN O
identified NN NN O
65 NN NN O
missense NN NN O
mutations NN NN O
in NN NN O
the NN NN O
GALNS NN NN O
gene NN NN O
from NN NN O
MPS NN NN B-Modifier
IVA NN NN I-Modifier
patients NN NN O
, NN NN O
but NN NN O
the NN NN O
correlation NN NN O
between NN NN O
genotype NN NN O
and NN NN O
phenotype NN NN O
has NN NN O
remained NN NN O
unclear NN NN O
. NN NN O

We NN NN O
studied NN NN O
17 NN NN O
missense NN NN O
mutations NN NN O
using NN NN O
biochemical NN NN O
approaches NN NN O
and NN NN O
32 NN NN O
missense NN NN O
mutations NN NN O
, NN NN O
using NN NN O
structural NN NN O
analyses NN NN O
. NN NN O

Fifteen NN NN O
missense NN NN O
mutations NN NN O
and NN NN O
two NN NN O
newly NN NN O
engineered NN NN O
active NN NN O
site NN NN O
mutations NN NN O
( NN NN O
C79S NN NN O
, NN NN O
C79T NN NN O
) NN NN O
were NN NN O
characterized NN NN O
by NN NN O
transient NN NN O
expression NN NN O
analysis NN NN O
. NN NN O

Mutant NN NN O
proteins NN NN O
, NN NN O
except NN NN O
for NN NN O
C79S NN NN O
and NN NN O
C79T NN NN O
, NN NN O
were NN NN O
destabilized NN NN O
and NN NN O
detected NN NN O
as NN NN O
insoluble NN NN O
precursor NN NN O
forms NN NN O
while NN NN O
the NN NN O
C79S NN NN O
and NN NN O
C79T NN NN O
mutants NN NN O
were NN NN O
of NN NN O
a NN NN O
soluble NN NN O
mature NN NN O
size NN NN O
. NN NN O

Mutants NN NN O
found NN NN O
in NN NN O
the NN NN O
severe NN NN O
phenotype NN NN O
had NN NN O
no NN NN O
activity NN NN O
. NN NN O

Mutants NN NN O
found NN NN O
in NN NN O
the NN NN O
mild NN NN O
phenotype NN NN O
had NN NN O
a NN NN O
considerable NN NN O
residual NN NN O
activity NN NN O
( NN NN O
1 NN NN O
. NN NN O

3-13 NN NN O
. NN NN O

3 NN NN O
% NN NN O
of NN NN O
wild-type NN NN O
GALNS NN NN O
activity NN NN O
) NN NN O
. NN NN O

Sulfatases NN NN O
, NN NN O
including NN NN O
GALNS NN NN O
, NN NN O
are NN NN O
members NN NN O
of NN NN O
a NN NN O
highly NN NN O
conserved NN NN O
gene NN NN O
family NN NN O
sharing NN NN O
an NN NN O
extensive NN NN O
sequence NN NN O
homology NN NN O
. NN NN O

Thus NN NN O
, NN NN O
a NN NN O
tertiary NN NN O
structural NN NN O
model NN NN O
of NN NN O
human NN NN O
GALNS NN NN O
was NN NN O
constructed NN NN O
from NN NN O
the NN NN O
X-ray NN NN O
crystal NN NN O
structure NN NN O
of NN NN O
N NN NN O
-acetylgalacto-samine-4-sulfatase NN NN O
and NN NN O
arylsulfatase NN NN O
A NN NN O
, NN NN O
using NN NN O
homology NN NN O
modeling NN NN O
, NN NN O
and NN NN O
32 NN NN O
missense NN NN O
mutations NN NN O
were NN NN O
investigated NN NN O
. NN NN O

Consequently NN NN O
, NN NN O
we NN NN O
propose NN NN O
that NN NN O
there NN NN O
are NN NN O
at NN NN O
least NN NN O
three NN NN O
different NN NN O
reasons NN NN O
for NN NN O
the NN NN O
severe NN NN O
phenotype NN NN O
( NN NN O
i NN NN O
) NN NN O
destruction NN NN O
of NN NN O
the NN NN O
hydrophobic NN NN O
core NN NN O
or NN NN O
modification NN NN O
of NN NN O
the NN NN O
packing NN NN O
; NN NN O
( NN NN O
ii NN NN O
) NN NN O
removal NN NN O
of NN NN O
a NN NN O
salt NN NN O
bridge NN NN O
to NN NN O
destabilize NN NN O
the NN NN O
entire NN NN O
conformation NN NN O
; NN NN O
( NN NN O
iii NN NN O
) NN NN O
modification NN NN O
of NN NN O
the NN NN O
active NN NN O
site NN NN O
. NN NN O

In NN NN O
contrast NN NN O
, NN NN O
mild NN NN O
mutations NN NN O
were NN NN O
mostly NN NN O
located NN NN O
on NN NN O
the NN NN O
surface NN NN O
of NN NN O
the NN NN O
GALNS NN NN O
protein NN NN O
. NN NN O

These NN NN O
studies NN NN O
shed NN NN O
further NN NN O
light NN NN O
on NN NN O
the NN NN O
genotype-phenotype NN NN O
correlation NN NN O
of NN NN O
MPS NN NN B-SpecificDisease
IVA NN NN I-SpecificDisease
and NN NN O
structure-function NN NN O
relationship NN NN O
in NN NN O
the NN NN O
sulfatase NN NN O
family NN NN O
. NN NN O

10817650 NN NN O
Mutations NN NN O
at NN NN O
the NN NN O
ataxia-telangiectasia NN NN B-Modifier
locus NN NN O
and NN NN O
clinical NN NN O
phenotypes NN NN O
of NN NN O
A-T NN NN B-Modifier
patients NN NN O
. NN NN O

Mutations NN NN O
at NN NN O
the NN NN O
ataxia-telangiectasia NN NN B-Modifier
( NN NN O
A-T NN NN B-Modifier
) NN NN O
locus NN NN O
on NN NN O
chromosome NN NN O
band NN NN O
11q22 NN NN O
cause NN NN O
a NN NN O
distinctive NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
syndrome NN NN I-DiseaseClass
in NN NN O
homozygotes NN NN O
and NN NN O
predispose NN NN O
heterozygotes NN NN O
to NN NN O
cancer NN NN B-DiseaseClass
, NN NN O
ischemic NN NN B-SpecificDisease
heart NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
, NN NN O
and NN NN O
early NN NN O
mortality NN NN O
. NN NN O

PCR NN NN O
amplification NN NN O
from NN NN O
genomic NN NN O
DNA NN NN O
and NN NN O
automated NN NN O
sequencing NN NN O
of NN NN O
the NN NN O
entire NN NN O
coding NN NN O
region NN NN O
( NN NN O
66 NN NN O
exons NN NN O
) NN NN O
and NN NN O
splice NN NN O
junctions NN NN O
detected NN NN O
77 NN NN O
mutations NN NN O
( NN NN O
85 NN NN O
% NN NN O
) NN NN O
in NN NN O
90 NN NN O
A-T NN NN B-Modifier
chromosomes NN NN O
. NN NN O

Heteroduplex NN NN O
analysis NN NN O
detected NN NN O
another NN NN O
42 NN NN O
mutations NN NN O
at NN NN O
the NN NN O
A-T NN NN B-Modifier
locus NN NN O
. NN NN O

Out NN NN O
of NN NN O
a NN NN O
total NN NN O
of NN NN O
71 NN NN O
unique NN NN O
mutations NN NN O
, NN NN O
50 NN NN O
were NN NN O
found NN NN O
only NN NN O
in NN NN O
a NN NN O
single NN NN O
family NN NN O
, NN NN O
and NN NN O
51 NN NN O
had NN NN O
not NN NN O
been NN NN O
reported NN NN O
previously NN NN O
. NN NN O

Most NN NN O
( NN NN O
58 NN NN O
/ NN NN O
71 NN NN O
, NN NN O
82 NN NN O
% NN NN O
) NN NN O
mutations NN NN O
were NN NN O
frameshift NN NN O
and NN NN O
nonsense NN NN O
mutations NN NN O
that NN NN O
are NN NN O
predicted NN NN O
to NN NN O
cause NN NN O
truncation NN NN O
of NN NN O
the NN NN O
A-T NN NN B-Modifier
protein NN NN O
; NN NN O
the NN NN O
less NN NN O
common NN NN O
mutation NN NN O
types NN NN O
were NN NN O
missense NN NN O
( NN NN O
9 NN NN O
/ NN NN O
71 NN NN O
, NN NN O
13 NN NN O
% NN NN O
) NN NN O
, NN NN O
splicing NN NN O
( NN NN O
3 NN NN O
/ NN NN O
71 NN NN O
, NN NN O
4 NN NN O
% NN NN O
) NN NN O
and NN NN O
one NN NN O
in-frame NN NN O
deletion NN NN O
, NN NN O
2546 NN NN O
3 NN NN O
( NN NN O
1 NN NN O
/ NN NN O
71 NN NN O
, NN NN O
1 NN NN O
% NN NN O
) NN NN O
. NN NN O

The NN NN O
mean NN NN O
survival NN NN O
and NN NN O
height NN NN O
distribution NN NN O
of NN NN O
134 NN NN O
A-T NN NN B-Modifier
patients NN NN O
correlated NN NN O
significantly NN NN O
with NN NN O
the NN NN O
specific NN NN O
mutations NN NN O
present NN NN O
in NN NN O
the NN NN O
patients NN NN O
. NN NN O

Patients NN NN O
homozygous NN NN O
for NN NN O
a NN NN O
single NN NN O
truncating NN NN O
mutation NN NN O
, NN NN O
typically NN NN O
near NN NN O
the NN NN O
N-terminal NN NN O
end NN NN O
of NN NN O
the NN NN O
gene NN NN O
, NN NN O
or NN NN O
heterozygous NN NN O
for NN NN O
the NN NN O
in-frame NN NN O
deletion NN NN O
2546 NN NN O
3 NN NN O
, NN NN O
were NN NN O
shorter NN NN O
and NN NN O
had NN NN O
significantly NN NN O
shorter NN NN O
survival NN NN O
than NN NN O
those NN NN O
heterozygous NN NN O
for NN NN O
a NN NN O
splice NN NN O
site NN NN O
or NN NN O
missense NN NN O
mutation NN NN O
, NN NN O
or NN NN O
heterozygous NN NN O
for NN NN O
two NN NN O
truncating NN NN O
mutations NN NN O
. NN NN O

Alterations NN NN O
of NN NN O
the NN NN O
length NN NN O
or NN NN O
amino NN NN O
acid NN NN O
composition NN NN O
of NN NN O
the NN NN O
A-T NN NN B-Modifier
gene NN NN O
product NN NN O
affect NN NN O
the NN NN O
A-T NN NN B-Modifier
clinical NN NN O
phenotype NN NN O
in NN NN O
different NN NN O
ways NN NN O
. NN NN O

Mutation NN NN O
analysis NN NN O
at NN NN O
the NN NN O
A-T NN NN B-Modifier
locus NN NN O
may NN NN O
help NN NN O
estimate NN NN O
the NN NN O
prognosis NN NN O
of NN NN O
A-T NN NN B-Modifier
patients NN NN O
. NN NN O

. NN NN O

10818206 NN NN O
Isolation NN NN O
, NN NN O
genomic NN NN O
organization NN NN O
, NN NN O
and NN NN O
expression NN NN O
analysis NN NN O
of NN NN O
the NN NN O
mouse NN NN O
and NN NN O
rat NN NN O
homologs NN NN O
of NN NN O
MEFV NN NN O
, NN NN O
the NN NN O
gene NN NN O
for NN NN O
familial NN NN B-SpecificDisease
mediterranean NN NN I-SpecificDisease
fever NN NN I-SpecificDisease
. NN NN O

Familial NN NN B-SpecificDisease
Mediterranean NN NN I-SpecificDisease
fever NN NN I-SpecificDisease
( NN NN O
FMF NN NN B-SpecificDisease
) NN NN O
is NN NN O
a NN NN O
recessive NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
characterized NN NN O
by NN NN O
episodes NN NN O
of NN NN O
fever NN NN B-DiseaseClass
with NN NN O
serositis NN NN B-SpecificDisease
or NN NN O
synovitis NN NN B-SpecificDisease
. NN NN O

Recently NN NN O
the NN NN O
FMF NN NN B-Modifier
gene NN NN O
( NN NN O
MEFV NN NN O
) NN NN O
was NN NN O
cloned NN NN O
; NN NN O
the NN NN O
protein NN NN O
product NN NN O
, NN NN O
pyrin NN NN O
/ NN NN O
marenostrin NN NN O
, NN NN O
is NN NN O
thought NN NN O
to NN NN O
regulate NN NN O
inflammation NN NN O
in NN NN O
myeloid NN NN O
cells NN NN O
. NN NN O

In NN NN O
this NN NN O
manuscript NN NN O
we NN NN O
report NN NN O
the NN NN O
mouse NN NN O
and NN NN O
rat NN NN O
homologs NN NN O
of NN NN O
MEFV NN NN O
. NN NN O

The NN NN O
murine NN NN O
gene NN NN O
contains NN NN O
ten NN NN O
exons NN NN O
with NN NN O
a NN NN O
coding NN NN O
sequence NN NN O
of NN NN O
2304 NN NN O
bp NN NN O
, NN NN O
while NN NN O
the NN NN O
rat NN NN O
homolog NN NN O
has NN NN O
nine NN NN O
exons NN NN O
with NN NN O
a NN NN O
coding NN NN O
sequence NN NN O
of NN NN O
2253 NN NN O
bp NN NN O
. NN NN O

A NN NN O
considerable NN NN O
amino NN NN O
acid NN NN O
sequence NN NN O
homology NN NN O
was NN NN O
observed NN NN O
between NN NN O
the NN NN O
mouse NN NN O
and NN NN O
human NN NN O
( NN NN O
47 NN NN O
. NN NN O

6 NN NN O
% NN NN O
identity NN NN O
and NN NN O
65 NN NN O
. NN NN O

5 NN NN O
% NN NN O
similarity NN NN O
) NN NN O
and NN NN O
between NN NN O
the NN NN O
mouse NN NN O
and NN NN O
rat NN NN O
genes NN NN O
( NN NN O
73 NN NN O
. NN NN O

5 NN NN O
% NN NN O
identity NN NN O
and NN NN O
82 NN NN O
. NN NN O

1 NN NN O
% NN NN O
similarity NN NN O
) NN NN O
. NN NN O

The NN NN O
predicted NN NN O
rodent NN NN O
proteins NN NN O
have NN NN O
several NN NN O
important NN NN O
domains NN NN O
and NN NN O
signals NN NN O
found NN NN O
in NN NN O
human NN NN O
pyrin NN NN O
, NN NN O
including NN NN O
a NN NN O
B-box NN NN O
zinc NN NN O
finger NN NN O
domain NN NN O
, NN NN O
Robbins-Dingwall NN NN O
nuclear NN NN O
localization NN NN O
signal NN NN O
, NN NN O
and NN NN O
coiled-coil NN NN O
domain NN NN O
. NN NN O

However NN NN O
, NN NN O
perhaps NN NN O
because NN NN O
of NN NN O
an NN NN O
ancient NN NN O
frame-shift NN NN O
mutation NN NN O
, NN NN O
neither NN NN O
the NN NN O
mouse NN NN O
nor NN NN O
the NN NN O
rat NN NN O
protein NN NN O
has NN NN O
an NN NN O
intact NN NN O
C-terminal NN NN O
B30 NN NN O
. NN NN O

2 NN NN O
domain NN NN O
, NN NN O
in NN NN O
which NN NN O
most NN NN O
FMF NN NN B-Modifier
-associated NN NN O
mutations NN NN O
have NN NN O
been NN NN O
found NN NN O
in NN NN O
human NN NN O
MEFV NN NN O
. NN NN O

Nevertheless NN NN O
, NN NN O
like NN NN O
the NN NN O
human NN NN O
gene NN NN O
, NN NN O
mouse NN NN O
Mefv NN NN O
is NN NN O
expressed NN NN O
in NN NN O
peripheral NN NN O
blood NN NN O
granulocytes NN NN O
but NN NN O
not NN NN O
lymphocytes NN NN O
. NN NN O

Consistent NN NN O
with NN NN O
its NN NN O
expression NN NN O
in NN NN O
granulocytes NN NN O
, NN NN O
Mefv NN NN O
was NN NN O
detected NN NN O
at NN NN O
high NN NN O
levels NN NN O
in NN NN O
the NN NN O
primary NN NN O
follicles NN NN O
and NN NN O
marginal NN NN O
zones NN NN O
of NN NN O
the NN NN O
splenic NN NN O
white NN NN O
pulp NN NN O
. NN NN O

Mefv NN NN O
is NN NN O
localized NN NN O
on NN NN O
mouse NN NN O
Chromosome NN NN O
( NN NN O
Chr NN NN O
) NN NN O
16 NN NN O
, NN NN O
region NN NN O
A3-B1 NN NN O
, NN NN O
extending NN NN O
a NN NN O
region NN NN O
of NN NN O
synteny NN NN O
with NN NN O
human NN NN O
Chr NN NN O
16p13 NN NN O
. NN NN O

3 NN NN O
. NN NN O

Development NN NN O
of NN NN O
knockout NN NN O
and NN NN O
knockin NN NN O
mouse NN NN O
models NN NN O
may NN NN O
provide NN NN O
further NN NN O
insights NN NN O
into NN NN O
the NN NN O
functional NN NN O
evolution NN NN O
of NN NN O
this NN NN O
gene NN NN O
. NN NN O

10827108 NN NN O
Additional NN NN O
copies NN NN O
of NN NN O
the NN NN O
proteolipid NN NN O
protein NN NN O
gene NN NN O
causing NN NN O
Pelizaeus-Merzbacher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
arise NN NN O
by NN NN O
separate NN NN O
integration NN NN O
into NN NN O
the NN NN O
X NN NN O
chromosome NN NN O
. NN NN O

The NN NN O
proteolipid NN NN O
protein NN NN O
gene NN NN O
( NN NN O
PLP NN NN O
) NN NN O
is NN NN O
normally NN NN O
present NN NN O
at NN NN O
chromosome NN NN O
Xq22 NN NN O
. NN NN O

Mutations NN NN O
and NN NN O
duplications NN NN O
of NN NN O
this NN NN O
gene NN NN O
are NN NN O
associated NN NN O
with NN NN O
Pelizaeus-Merzbacher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
PMD NN NN B-SpecificDisease
) NN NN O
. NN NN O

Here NN NN O
we NN NN O
describe NN NN O
two NN NN O
new NN NN O
families NN NN O
in NN NN O
which NN NN O
males NN NN O
affected NN NN O
with NN NN O
PMD NN NN B-SpecificDisease
were NN NN O
found NN NN O
to NN NN O
have NN NN O
a NN NN O
copy NN NN O
of NN NN O
PLP NN NN O
on NN NN O
the NN NN O
short NN NN O
arm NN NN O
of NN NN O
the NN NN O
X NN NN O
chromosome NN NN O
, NN NN O
in NN NN O
addition NN NN O
to NN NN O
a NN NN O
normal NN NN O
copy NN NN O
on NN NN O
Xq22 NN NN O
. NN NN O

In NN NN O
the NN NN O
first NN NN O
family NN NN O
, NN NN O
the NN NN O
extra NN NN O
copy NN NN O
was NN NN O
first NN NN O
detected NN NN O
by NN NN O
the NN NN O
presence NN NN O
of NN NN O
heterozygosity NN NN O
of NN NN O
the NN NN O
AhaII NN NN O
dimorphism NN NN O
within NN NN O
the NN NN O
PLP NN NN O
gene NN NN O
. NN NN O

The NN NN O
results NN NN O
of NN NN O
FISH NN NN O
analysis NN NN O
showed NN NN O
an NN NN O
additional NN NN O
copy NN NN O
of NN NN O
PLP NN NN O
in NN NN O
Xp22 NN NN O
. NN NN O

1 NN NN O
, NN NN O
although NN NN O
no NN NN O
chromosomal NN NN O
rearrangements NN NN O
could NN NN O
be NN NN O
detected NN NN O
by NN NN O
standard NN NN O
karyotype NN NN O
analysis NN NN O
. NN NN O

Another NN NN O
three NN NN O
affected NN NN O
males NN NN O
from NN NN O
the NN NN O
family NN NN O
had NN NN O
similar NN NN O
findings NN NN O
. NN NN O

In NN NN O
a NN NN O
second NN NN O
unrelated NN NN O
family NN NN O
with NN NN O
signs NN NN O
of NN NN O
PMD NN NN B-SpecificDisease
, NN NN O
cytogenetic NN NN O
analysis NN NN O
showed NN NN O
a NN NN O
pericentric NN NN O
inversion NN NN O
of NN NN O
the NN NN O
X NN NN O
chromosome NN NN O
. NN NN O

In NN NN O
the NN NN O
inv NN NN O
( NN NN O
X NN NN O
) NN NN O
carried NN NN O
by NN NN O
several NN NN O
affected NN NN O
family NN NN O
members NN NN O
, NN NN O
FISH NN NN O
showed NN NN O
PLP NN NN O
signals NN NN O
at NN NN O
Xp11 NN NN O
. NN NN O

4 NN NN O
and NN NN O
Xq22 NN NN O
. NN NN O

A NN NN O
third NN NN O
family NN NN O
has NN NN O
previously NN NN O
been NN NN O
reported NN NN O
, NN NN O
in NN NN O
which NN NN O
affected NN NN O
members NN NN O
had NN NN O
an NN NN O
extra NN NN O
copy NN NN O
of NN NN O
the NN NN O
PLP NN NN O
gene NN NN O
detected NN NN O
at NN NN O
Xq26 NN NN O
in NN NN O
a NN NN O
chromosome NN NN O
with NN NN O
an NN NN O
otherwise NN NN O
normal NN NN O
banding NN NN O
pattern NN NN O
. NN NN O

The NN NN O
identification NN NN O
of NN NN O
three NN NN O
separate NN NN O
families NN NN O
in NN NN O
which NN NN O
PLP NN NN O
is NN NN O
duplicated NN NN O
at NN NN O
a NN NN O
noncontiguous NN NN O
site NN NN O
suggests NN NN O
that NN NN O
such NN NN O
duplications NN NN O
could NN NN O
be NN NN O
a NN NN O
relatively NN NN O
common NN NN O
but NN NN O
previously NN NN O
undetected NN NN O
cause NN NN O
of NN NN O
genetic NN NN B-DiseaseClass
disorders NN NN I-DiseaseClass
. NN NN O

10827109 NN NN O
The NN NN O
exon NN NN O
13 NN NN O
duplication NN NN O
in NN NN O
the NN NN O
BRCA1 NN NN O
gene NN NN O
is NN NN O
a NN NN O
founder NN NN O
mutation NN NN O
present NN NN O
in NN NN O
geographically NN NN O
diverse NN NN O
populations NN NN O
. NN NN O

The NN NN O
BRCA1 NN NN O
Exon NN NN O
13 NN NN O
Duplication NN NN O
Screening NN NN O
Group NN NN O
. NN NN O

Recently NN NN O
, NN NN O
a NN NN O
6-kb NN NN O
duplication NN NN O
of NN NN O
exon NN NN O
13 NN NN O
, NN NN O
which NN NN O
creates NN NN O
a NN NN O
frameshift NN NN O
in NN NN O
the NN NN O
coding NN NN O
sequence NN NN O
of NN NN O
the NN NN O
BRCA1 NN NN O
gene NN NN O
, NN NN O
has NN NN O
been NN NN O
described NN NN O
in NN NN O
three NN NN O
unrelated NN NN O
U NN NN O
. NN NN O

S NN NN O
S NN NN O
. NN NN O

families NN NN O
of NN NN O
European NN NN O
ancestry NN NN O
and NN NN O
in NN NN O
one NN NN O
Portuguese NN NN O
family NN NN O
. NN NN O

Here NN NN O
, NN NN O
our NN NN O
goal NN NN O
was NN NN O
to NN NN O
estimate NN NN O
the NN NN O
frequency NN NN O
and NN NN O
geographic NN NN O
diversity NN NN O
of NN NN O
carriers NN NN O
of NN NN O
this NN NN O
duplication NN NN O
. NN NN O

To NN NN O
do NN NN O
this NN NN O
, NN NN O
a NN NN O
collaborative NN NN O
screening NN NN O
study NN NN O
was NN NN O
set NN NN O
up NN NN O
that NN NN O
involved NN NN O
39 NN NN O
institutions NN NN O
from NN NN O
19 NN NN O
countries NN NN O
and NN NN O
included NN NN O
3 NN NN O
, NN NN O
580 NN NN O
unrelated NN NN O
individuals NN NN O
with NN NN O
a NN NN O
family NN NN O
history NN NN O
of NN NN O
the NN NN O
disease NN NN O
and NN NN O
934 NN NN O
early-onset NN NN O
breast NN NN B-Modifier
and NN NN I-Modifier
/ NN NN I-Modifier
or NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
cases NN NN O
. NN NN O

A NN NN O
total NN NN O
of NN NN O
11 NN NN O
additional NN NN O
families NN NN O
carrying NN NN O
this NN NN O
mutation NN NN O
were NN NN O
identified NN NN O
in NN NN O
Australia NN NN O
( NN NN O
1 NN NN O
) NN NN O
, NN NN O
Belgium NN NN O
( NN NN O
1 NN NN O
) NN NN O
, NN NN O
Canada NN NN O
( NN NN O
1 NN NN O
) NN NN O
, NN NN O
Great NN NN O
Britain NN NN O
( NN NN O
6 NN NN O
) NN NN O
, NN NN O
and NN NN O
the NN NN O
United NN NN O
States NN NN O
( NN NN O
2 NN NN O
) NN NN O
. NN NN O

Haplotyping NN NN O
showed NN NN O
that NN NN O
they NN NN O
are NN NN O
likely NN NN O
to NN NN O
derive NN NN O
from NN NN O
a NN NN O
common NN NN O
ancestor NN NN O
, NN NN O
possibly NN NN O
of NN NN O
northern NN NN O
British NN NN O
origin NN NN O
. NN NN O

Our NN NN O
results NN NN O
demonstrate NN NN O
that NN NN O
it NN NN O
is NN NN O
strongly NN NN O
advisable NN NN O
, NN NN O
for NN NN O
laboratories NN NN O
carrying NN NN O
out NN NN O
screening NN NN O
either NN NN O
in NN NN O
English-speaking NN NN O
countries NN NN O
or NN NN O
in NN NN O
countries NN NN O
with NN NN O
historical NN NN O
links NN NN O
with NN NN O
Britain NN NN O
, NN NN O
to NN NN O
include NN NN O
within NN NN O
their NN NN O
BRCA1 NN NN O
screening NN NN O
protocols NN NN O
the NN NN O
polymerase NN NN O
chain NN NN O
reaction-based NN NN O
assay NN NN O
described NN NN O
in NN NN O
this NN NN O
report NN NN O
. NN NN O

10830910 NN NN O
Genotype-phenotype NN NN O
correlations NN NN O
in NN NN O
families NN NN O
with NN NN O
deletions NN NN O
in NN NN O
the NN NN O
von NN NN B-Modifier
Hippel-Lindau NN NN I-Modifier
( NN NN O
VHL NN NN B-Modifier
) NN NN O
gene NN NN O
. NN NN O

Von NN NN B-SpecificDisease
Hippel-Lindau NN NN I-SpecificDisease
( NN NN I-SpecificDisease
VHL NN NN I-SpecificDisease
) NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
is NN NN O
a NN NN O
hereditary NN NN B-DiseaseClass
tumor NN NN I-DiseaseClass
syndrome NN NN I-DiseaseClass
characterized NN NN O
by NN NN O
predisposition NN NN O
for NN NN O
bilateral NN NN B-CompositeMention
and NN NN I-CompositeMention
multi-centric NN NN I-CompositeMention
hemangioblastoma NN NN I-CompositeMention
in NN NN O
the NN NN O
retina NN NN O
and NN NN O
central NN NN O
nervous NN NN O
system NN NN O
, NN NN O
pheochromocytoma NN NN B-SpecificDisease
, NN NN O
renal NN NN B-SpecificDisease
cell NN NN I-SpecificDisease
carcinoma NN NN I-SpecificDisease
, NN NN O
and NN NN O
cysts NN NN B-CompositeMention
in NN NN I-CompositeMention
the NN NN I-CompositeMention
kidney NN NN I-CompositeMention
, NN NN I-CompositeMention
pancreas NN NN I-CompositeMention
, NN NN I-CompositeMention
and NN NN I-CompositeMention
epididymis NN NN I-CompositeMention
. NN NN O

We NN NN O
describe NN NN O
five NN NN O
families NN NN O
for NN NN O
which NN NN O
direct NN NN O
sequencing NN NN O
of NN NN O
the NN NN O
coding NN NN O
region NN NN O
of NN NN O
the NN NN O
VHL NN NN B-Modifier
gene NN NN O
had NN NN O
failed NN NN O
to NN NN O
identify NN NN O
the NN NN O
family-specific NN NN O
mutation NN NN O
. NN NN O

Further NN NN O
molecular NN NN O
analysis NN NN O
revealed NN NN O
deletions NN NN O
involving NN NN O
the NN NN O
VHL NN NN B-Modifier
gene NN NN O
in NN NN O
each NN NN O
of NN NN O
these NN NN O
families NN NN O
. NN NN O

In NN NN O
four NN NN O
families NN NN O
, NN NN O
partial NN NN O
deletions NN NN O
of NN NN O
one NN NN O
or NN NN O
more NN NN O
exons NN NN O
were NN NN O
detected NN NN O
by NN NN O
Southern NN NN O
blot NN NN O
analysis NN NN O
. NN NN O

In NN NN O
the NN NN O
fifth NN NN O
family NN NN O
, NN NN O
FISH NN NN O
analysis NN NN O
demonstrated NN NN O
the NN NN O
deletion NN NN O
of NN NN O
the NN NN O
entire NN NN O
VHL NN NN B-Modifier
gene NN NN O
. NN NN O

Our NN NN O
results NN NN O
show NN NN O
that NN NN O
( NN NN O
quantitative NN NN O
) NN NN O
Southern NN NN O
blot NN NN O
analysis NN NN O
is NN NN O
a NN NN O
sensitive NN NN O
method NN NN O
for NN NN O
detecting NN NN O
germline NN NN O
deletions NN NN O
of NN NN O
the NN NN O
VHL NN NN B-Modifier
gene NN NN O
and NN NN O
should NN NN O
be NN NN O
implemented NN NN O
in NN NN O
routine NN NN O
DNA NN NN O
diagnosis NN NN O
for NN NN O
VHL NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

Our NN NN O
data NN NN O
support NN NN O
the NN NN O
previously NN NN O
established NN NN O
observation NN NN O
that NN NN O
families NN NN O
with NN NN O
a NN NN O
germline NN NN O
deletion NN NN O
have NN NN O
a NN NN O
low NN NN O
risk NN NN O
for NN NN O
pheochromocytoma NN NN B-SpecificDisease
. NN NN O

Further NN NN O
unraveling NN NN O
of NN NN O
genotype-phenotype NN NN O
correlations NN NN O
in NN NN O
VHL NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
has NN NN O
revealed NN NN O
that NN NN O
families NN NN O
with NN NN O
a NN NN O
full NN NN O
or NN NN O
partial NN NN O
deletion NN NN O
of NN NN O
the NN NN O
VHL NN NN B-Modifier
gene NN NN O
exhibit NN NN O
a NN NN O
phenotype NN NN O
with NN NN O
a NN NN O
preponderance NN NN O
of NN NN O
central NN NN B-SpecificDisease
nervous NN NN I-SpecificDisease
system NN NN I-SpecificDisease
hemangioblastoma NN NN I-SpecificDisease
. NN NN O

. NN NN O

10830915 NN NN O
Age NN NN O
of NN NN O
the NN NN O
intronic NN NN O
GAA NN NN O
triplet NN NN O
repeat NN NN O
expansion NN NN O
mutation NN NN O
in NN NN O
Friedreich NN NN B-SpecificDisease
ataxia NN NN I-SpecificDisease
. NN NN O

Friedreich NN NN B-SpecificDisease
ataxia NN NN I-SpecificDisease
( NN NN O
FRDA NN NN B-SpecificDisease
) NN NN O
, NN NN O
the NN NN O
most NN NN O
frequently NN NN O
inherited NN NN B-DiseaseClass
ataxia NN NN I-DiseaseClass
, NN NN O
is NN NN O
due NN NN O
in NN NN O
the NN NN O
vast NN NN O
majority NN NN O
of NN NN O
cases NN NN O
to NN NN O
a NN NN O
large NN NN O
expansion NN NN O
of NN NN O
an NN NN O
intronic NN NN O
GAA NN NN O
repeat NN NN O
. NN NN O

Using NN NN O
linkage NN NN O
disequilibrium NN NN O
analysis NN NN O
based NN NN O
on NN NN O
haplotype NN NN O
data NN NN O
of NN NN O
seven NN NN O
polymorphic NN NN O
markers NN NN O
close NN NN O
to NN NN O
the NN NN O
frataxin NN NN O
gene NN NN O
, NN NN O
the NN NN O
age NN NN O
of NN NN O
FRDA NN NN B-Modifier
founding NN NN O
mutational NN NN O
event NN NN O
( NN NN O
s NN NN O
) NN NN O
is NN NN O
estimated NN NN O
to NN NN O
be NN NN O
at NN NN O
least NN NN O
682 NN NN O
+ NN NN O
/ NN NN O
-203 NN NN O
generations NN NN O
( NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
564-801 NN NN O
g NN NN O
) NN NN O
, NN NN O
a NN NN O
dating NN NN O
which NN NN O
is NN NN O
consistent NN NN O
with NN NN O
little NN NN O
or NN NN O
no NN NN O
negative NN NN O
selection NN NN O
and NN NN O
provides NN NN O
further NN NN O
evidence NN NN O
for NN NN O
an NN NN O
ancient NN NN O
spread NN NN O
of NN NN O
a NN NN O
pre-mutation NN NN O
( NN NN O
at-risk NN NN O
alleles NN NN O
) NN NN O
in NN NN O
western NN NN O
Europe NN NN O
. NN NN O

. NN NN O

10839544 NN NN O
Functional NN NN O
link NN NN O
between NN NN O
ataxia-telangiectasia NN NN B-Modifier
and NN NN O
Nijmegen NN NN B-Modifier
breakage NN NN I-Modifier
syndrome NN NN I-Modifier
gene NN NN O
products NN NN O
. NN NN O

Ataxia-telangiectasia NN NN B-SpecificDisease
( NN NN O
A-T NN NN B-SpecificDisease
) NN NN O
and NN NN O
Nijmegen NN NN B-SpecificDisease
breakage NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
NBS NN NN B-SpecificDisease
) NN NN O
are NN NN O
recessive NN NN B-DiseaseClass
genetic NN NN I-DiseaseClass
disorders NN NN I-DiseaseClass
with NN NN O
susceptibility NN NN O
to NN NN O
cancer NN NN B-DiseaseClass
and NN NN O
similar NN NN O
cellular NN NN O
phenotypes NN NN O
. NN NN O

The NN NN O
protein NN NN O
product NN NN O
of NN NN O
the NN NN O
gene NN NN O
responsible NN NN O
for NN NN O
A-T NN NN B-SpecificDisease
, NN NN O
designated NN NN O
ATM NN NN O
, NN NN O
is NN NN O
a NN NN O
member NN NN O
of NN NN O
a NN NN O
family NN NN O
of NN NN O
kinases NN NN O
characterized NN NN O
by NN NN O
a NN NN O
carboxy-terminal NN NN O
phosphatidylinositol NN NN O
3-kinase-like NN NN O
domain NN NN O
. NN NN O

The NN NN O
NBS1 NN NN O
protein NN NN O
is NN NN O
specifically NN NN O
mutated NN NN O
in NN NN O
patients NN NN O
with NN NN O
Nijmegen NN NN B-SpecificDisease
breakage NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
and NN NN O
forms NN NN O
a NN NN O
complex NN NN O
with NN NN O
the NN NN O
DNA NN NN O
repair NN NN O
proteins NN NN O
Rad50 NN NN O
and NN NN O
Mrel1 NN NN O
. NN NN O

Here NN NN O
we NN NN O
show NN NN O
that NN NN O
phosphorylation NN NN O
of NN NN O
NBS1 NN NN O
, NN NN O
induced NN NN O
by NN NN O
ionizing NN NN O
radiation NN NN O
, NN NN O
requires NN NN O
catalytically NN NN O
active NN NN O
ATM NN NN O
. NN NN O

Complexes NN NN O
containing NN NN O
ATM NN NN O
and NN NN O
NBS1 NN NN O
exist NN NN O
in NN NN O
vivo NN NN O
in NN NN O
both NN NN O
untreated NN NN O
cells NN NN O
and NN NN O
cells NN NN O
treated NN NN O
with NN NN O
ionizing NN NN O
radiation NN NN O
. NN NN O

We NN NN O
have NN NN O
identified NN NN O
two NN NN O
residues NN NN O
of NN NN O
NBS1 NN NN O
, NN NN O
Ser NN NN O
278 NN NN O
and NN NN O
Ser NN NN O
343 NN NN O
that NN NN O
are NN NN O
phosphorylated NN NN O
in NN NN O
vitro NN NN O
by NN NN O
ATM NN NN O
and NN NN O
whose NN NN O
modification NN NN O
in NN NN O
vivo NN NN O
is NN NN O
essential NN NN O
for NN NN O
the NN NN O
cellular NN NN O
response NN NN O
to NN NN O
DNA NN NN O
damage NN NN O
. NN NN O

This NN NN O
response NN NN O
includes NN NN O
S-phase NN NN O
checkpoint NN NN O
activation NN NN O
, NN NN O
formation NN NN O
of NN NN O
the NN NN O
NBS1 NN NN O
/ NN NN O
Mrel1 NN NN O
/ NN NN O
Rad50 NN NN O
nuclear NN NN O
foci NN NN O
and NN NN O
rescue NN NN O
of NN NN O
hypersensitivity NN NN B-DiseaseClass
to NN NN I-DiseaseClass
ionizing NN NN I-DiseaseClass
radiation NN NN I-DiseaseClass
. NN NN O

Together NN NN O
, NN NN O
these NN NN O
results NN NN O
demonstrate NN NN O
a NN NN O
biochemical NN NN O
link NN NN O
between NN NN O
cell-cycle NN NN O
checkpoints NN NN O
activated NN NN O
by NN NN O
DNA NN NN O
damage NN NN O
and NN NN O
DNA NN NN O
repair NN NN O
in NN NN O
two NN NN O
genetic NN NN B-DiseaseClass
diseases NN NN I-DiseaseClass
with NN NN O
overlapping NN NN O
phenotypes NN NN O
. NN NN O

. NN NN O

10842298 NN NN O
Homozygosity NN NN O
mapping NN NN O
in NN NN O
a NN NN O
family NN NN O
with NN NN O
microcephaly NN NN B-DiseaseClass
, NN NN O
mental NN NN B-DiseaseClass
retardation NN NN I-DiseaseClass
, NN NN O
and NN NN O
short NN NN B-DiseaseClass
stature NN NN I-DiseaseClass
to NN NN O
a NN NN O
Cohen NN NN B-Modifier
syndrome NN NN I-Modifier
region NN NN O
on NN NN O
8q21.3-8q22.1 NN NN O
: NN NN O
redefining NN NN O
a NN NN O
clinical NN NN O
entity NN NN O
. NN NN O

A NN NN O
syndrome NN NN O
of NN NN O
microcephaly NN NN B-DiseaseClass
, NN NN O
progressive NN NN O
postnatal NN NN B-DiseaseClass
growth NN NN I-DiseaseClass
deficiency NN NN I-DiseaseClass
, NN NN O
and NN NN O
mental NN NN B-DiseaseClass
retardation NN NN I-DiseaseClass
was NN NN O
observed NN NN O
in NN NN O
two NN NN O
brothers NN NN O
and NN NN O
their NN NN O
cousin NN NN O
from NN NN O
a NN NN O
multiply NN NN O
consanguineous NN NN O
kindred NN NN O
of NN NN O
Lebanese NN NN O
descent NN NN O
. NN NN O

Hypotonia NN NN B-DiseaseClass
, NN NN O
chorioretinal NN NN B-DiseaseClass
dystrophy NN NN I-DiseaseClass
, NN NN O
and NN NN O
myopia NN NN B-DiseaseClass
were NN NN O
also NN NN O
identified NN NN O
. NN NN O

The NN NN O
severity NN NN O
of NN NN O
the NN NN O
condition NN NN O
varied NN NN O
among NN NN O
the NN NN O
closely NN NN O
related NN NN O
patients NN NN O
. NN NN O

Because NN NN O
of NN NN O
absence NN NN O
of NN NN O
a NN NN O
distinctive NN NN O
facial NN NN O
appearance NN NN O
, NN NN O
the NN NN O
degree NN NN O
of NN NN O
mental NN NN B-DiseaseClass
retardation NN NN I-DiseaseClass
, NN NN O
and NN NN O
short NN NN B-DiseaseClass
stature NN NN I-DiseaseClass
, NN NN O
the NN NN O
initially NN NN O
considered NN NN O
clinical NN NN O
diagnosis NN NN O
of NN NN O
Cohen NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
was NN NN O
withdrawn NN NN O
and NN NN O
a NN NN O
novel NN NN O
genetic NN NN O
entity NN NN O
was NN NN O
assumed NN NN O
. NN NN O

Homozygosity NN NN O
mapping NN NN O
in NN NN O
this NN NN O
family NN NN O
assigned NN NN O
the NN NN O
gene NN NN O
to NN NN O
a NN NN O
26 NN NN O
. NN NN O

8-cM NN NN O
region NN NN O
on NN NN O
the NN NN O
chromosome NN NN O
band NN NN O
8q21 NN NN O
. NN NN O

3 NN NN O
-22 NN NN O
. NN NN O

1 NN NN O
, NN NN O
between NN NN O
the NN NN O
microsatellites NN NN O
at NN NN O
D8S270 NN NN O
and NN NN O
D8S514 NN NN O
. NN NN O

The NN NN O
maximum NN NN O
two-point NN NN O
LOD NN NN O
score NN NN O
was NN NN O
found NN NN O
for NN NN O
marker NN NN O
at NN NN O
D8S267 NN NN O
( NN NN O
Zmax NN NN O
= NN NN O
3 NN NN O
. NN NN O

. NN NN O

237 NN NN O
at NN NN O
Omax NN NN O
= NN NN O
0 NN NN O
. NN NN O

00 NN NN O
) NN NN O
. NN NN O

Intriguingly NN NN O
enough NN NN O
, NN NN O
the NN NN O
identified NN NN O
gene NN NN O
region NN NN O
overlaps NN NN O
the NN NN O
refined NN NN O
gene NN NN O
region NN NN O
for NN NN O
Cohen NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
COH1 NN NN O
) NN NN O
[ NN NN O
Kolehmainen NN NN O
et NN NN O
al NN NN O
. NN NN O

, NN NN O
1997 NN NN O
Euro NN NN O
J NN NN O
Hum NN NN O
Genet NN NN O
5 NN NN O
206-213 NN NN O
] NN NN O
. NN NN O

This NN NN O
fact NN NN O
encourages NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
the NN NN O
described NN NN O
kindred NN NN O
segregates NN NN O
for NN NN O
a NN NN O
variant NN NN O
of NN NN O
Cohen NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
and NN NN O
suggests NN NN O
a NN NN O
redefinition NN NN O
of NN NN O
its NN NN O
phenotype NN NN O

10861282 NN NN O
Polymorphisms NN NN O
of NN NN O
the NN NN O
CYP2D6 NN NN O
gene NN NN O
increase NN NN O
susceptibility NN NN O
to NN NN O
ankylosing NN NN B-SpecificDisease
spondylitis NN NN I-SpecificDisease
. NN NN O

Ankylosing NN NN B-SpecificDisease
spondylitis NN NN I-SpecificDisease
( NN NN O
AS NN NN B-SpecificDisease
) NN NN O
is NN NN O
a NN NN O
common NN NN O
and NN NN O
highly NN NN O
familial NN NN O
rheumatic NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
. NN NN O

The NN NN O
sibling NN NN O
recurrence NN NN O
risk NN NN O
ratio NN NN O
for NN NN O
the NN NN O
disease NN NN O
is NN NN O
63 NN NN O
and NN NN O
heritability NN NN O
assessed NN NN O
in NN NN O
twins NN NN O
90 NN NN O
% NN NN O
. NN NN O

Although NN NN O
MHC NN NN O
genes NN NN O
, NN NN O
including NN NN O
HLA-B27 NN NN O
, NN NN O
contribute NN NN O
only NN NN O
20-50 NN NN O
% NN NN O
of NN NN O
the NN NN O
genetic NN NN O
risk NN NN O
for NN NN O
the NN NN O
disease NN NN O
, NN NN O
no NN NN O
non-MHC NN NN O
gene NN NN O
has NN NN O
yet NN NN O
been NN NN O
convincingly NN NN O
demonstrated NN NN O
to NN NN O
influence NN NN O
either NN NN O
susceptibility NN NN O
to NN NN O
the NN NN O
disease NN NN O
or NN NN O
its NN NN O
phenotypic NN NN O
expression NN NN O
. NN NN O

Previous NN NN O
linkage NN NN O
and NN NN O
association NN NN O
studies NN NN O
have NN NN O
suggested NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
susceptibility NN NN O
gene NN NN O
for NN NN O
AS NN NN B-SpecificDisease
close NN NN O
to NN NN O
, NN NN O
or NN NN O
within NN NN O
, NN NN O
the NN NN O
cytochrome NN NN O
P450 NN NN O
2D6 NN NN O
gene NN NN O
( NN NN O
CYP2D6 NN NN O
, NN NN O
debrisoquine NN NN O
hydroxylase NN NN O
) NN NN O
located NN NN O
at NN NN O
chromosome NN NN O
22q13 NN NN O
. NN NN O

1 NN NN O
1 NN NN O
. NN NN O

We NN NN O
performed NN NN O
a NN NN O
linkage NN NN O
study NN NN O
of NN NN O
chromosome NN NN O
22 NN NN O
in NN NN O
200 NN NN O
families NN NN O
with NN NN O
AS NN NN B-Modifier
affected NN NN O
sibling-pairs NN NN O
. NN NN O

Association NN NN O
of NN NN O
alleles NN NN O
of NN NN O
the NN NN O
CYP2D6 NN NN O
gene NN NN O
was NN NN O
examined NN NN O
by NN NN O
both NN NN O
case-control NN NN O
and NN NN O
within-family NN NN O
means NN NN O
. NN NN O

For NN NN O
case-control NN NN O
studies NN NN O
, NN NN O
617 NN NN O
unrelated NN NN O
individuals NN NN O
with NN NN O
AS NN NN B-SpecificDisease
( NN NN O
361 NN NN O
probands NN NN O
from NN NN O
sibling-pair NN NN O
and NN NN O
parent-case NN NN O
trio NN NN O
families NN NN O
and NN NN O
256 NN NN O
unrelated NN NN O
non-familial NN NN O
sporadic NN NN O
cases NN NN O
) NN NN O
and NN NN O
402 NN NN O
healthy NN NN O
ethnically NN NN O
matched NN NN O
controls NN NN O
were NN NN O
employed NN NN O
. NN NN O

For NN NN O
within-family NN NN O
association NN NN O
studies NN NN O
, NN NN O
361 NN NN O
families NN NN O
including NN NN O
161 NN NN O
parent-case NN NN O
trios NN NN O
and NN NN O
200 NN NN O
affected NN NN O
sibling-pair NN NN O
families NN NN O
were NN NN O
employed NN NN O
. NN NN O

Homozygosity NN NN O
for NN NN O
poor NN NN O
metabolizer NN NN O
alleles NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
associated NN NN O
with NN NN O
AS NN NN B-SpecificDisease
. NN NN O

Heterozygosity NN NN O
for NN NN O
the NN NN O
most NN NN O
frequent NN NN O
poor NN NN O
metabolizer NN NN O
allele NN NN O
( NN NN O
CYP2D6 NN NN O
* NN NN O
4 NN NN O
) NN NN O
was NN NN O
not NN NN O
associated NN NN O
with NN NN O
increased NN NN O
susceptibility NN NN O
to NN NN O
AS NN NN B-SpecificDisease
. NN NN O

Significant NN NN O
within-family NN NN O
association NN NN O
of NN NN O
CYP2D6 NN NN O
* NN NN O
4 NN NN O
alleles NN NN O
and NN NN O
AS NN NN B-SpecificDisease
was NN NN O
demonstrated NN NN O
. NN NN O

Weak NN NN O
linkage NN NN O
was NN NN O
also NN NN O
demonstrated NN NN O
between NN NN O
CYP2D6 NN NN O
and NN NN O
AS NN NN B-SpecificDisease
. NN NN O

We NN NN O
postulate NN NN O
that NN NN O
altered NN NN O
metabolism NN NN O
of NN NN O
a NN NN O
natural NN NN O
toxin NN NN O
or NN NN O
antigen NN NN O
by NN NN O
the NN NN O
CYP2D6 NN NN O
gene NN NN O
may NN NN O
increase NN NN O
susceptibility NN NN O
to NN NN O
AS NN NN B-SpecificDisease
. NN NN O

10861298 NN NN O
Functional NN NN O
differences NN NN O
of NN NN O
the NN NN O
PDS NN NN B-Modifier
gene NN NN O
product NN NN O
are NN NN O
associated NN NN O
with NN NN O
phenotypic NN NN O
variation NN NN O
in NN NN O
patients NN NN O
with NN NN O
Pendred NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
and NN NN O
non-syndromic NN NN B-SpecificDisease
hearing NN NN I-SpecificDisease
loss NN NN I-SpecificDisease
( NN NN O
DFNB4 NN NN B-SpecificDisease
) NN NN O
. NN NN O

The NN NN O
PDS NN NN B-Modifier
gene NN NN O
encodes NN NN O
a NN NN O
transmembrane NN NN O
protein NN NN O
, NN NN O
known NN NN O
as NN NN O
pendrin NN NN O
, NN NN O
which NN NN O
functions NN NN O
as NN NN O
a NN NN O
transporter NN NN O
of NN NN O
iodide NN NN O
and NN NN O
chloride NN NN O
. NN NN O

Mutations NN NN O
in NN NN O
this NN NN O
gene NN NN O
are NN NN O
responsible NN NN O
for NN NN O
Pendred NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
and NN NN O
autosomal NN NN B-SpecificDisease
recessive NN NN I-SpecificDisease
non-syndromic NN NN I-SpecificDisease
hearing NN NN I-SpecificDisease
loss NN NN I-SpecificDisease
at NN NN O
the NN NN O
DFNB4 NN NN B-Modifier
locus NN NN O
on NN NN O
chromosome NN NN O
7q31 NN NN O
. NN NN O

A NN NN O
screen NN NN O
of NN NN O
20 NN NN O
individuals NN NN O
from NN NN O
the NN NN O
midwestern NN NN O
USA NN NN O
with NN NN O
non-syndromic NN NN B-SpecificDisease
hearing NN NN I-SpecificDisease
loss NN NN I-SpecificDisease
and NN NN O
dilated NN NN O
vestibular NN NN O
aqueducts NN NN O
identified NN NN O
three NN NN O
people NN NN O
( NN NN O
15 NN NN O
% NN NN O
) NN NN O
with NN NN O
PDS NN NN B-Modifier
mutations NN NN O
. NN NN O

To NN NN O
determine NN NN O
whether NN NN O
PDS NN NN B-Modifier
mutations NN NN O
in NN NN O
individuals NN NN O
with NN NN O
Pendred NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
differ NN NN O
functionally NN NN O
from NN NN O
PDS NN NN B-Modifier
mutations NN NN O
in NN NN O
individuals NN NN O
with NN NN O
non-syndromic NN NN B-SpecificDisease
hearing NN NN I-SpecificDisease
loss NN NN I-SpecificDisease
, NN NN O
we NN NN O
compared NN NN O
three NN NN O
common NN NN O
Pendred NN NN B-Modifier
syndrome NN NN I-Modifier
allele NN NN O
variants NN NN O
( NN NN O
L236P NN NN O
, NN NN O
T416P NN NN O
and NN NN O
E384G NN NN O
) NN NN O
, NN NN O
with NN NN O
three NN NN O
PDS NN NN B-Modifier
mutations NN NN O
reported NN NN O
only NN NN O
in NN NN O
individuals NN NN O
with NN NN O
non-syndromic NN NN B-SpecificDisease
hearing NN NN I-SpecificDisease
loss NN NN I-SpecificDisease
( NN NN O
V480D NN NN O
, NN NN O
V653A NN NN O
and NN NN O
I490L NN NN O
/ NN NN O
G497S NN NN O
) NN NN O
. NN NN O

The NN NN O
mutations NN NN O
associated NN NN O
with NN NN O
Pendred NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
have NN NN O
complete NN NN O
loss NN NN O
of NN NN O
pendrin-induced NN NN O
chloride NN NN O
and NN NN O
iodide NN NN O
transport NN NN O
, NN NN O
while NN NN O
alleles NN NN O
unique NN NN O
to NN NN O
people NN NN O
with NN NN O
DFNB4 NN NN B-SpecificDisease
are NN NN O
able NN NN O
to NN NN O
transport NN NN O
both NN NN O
iodide NN NN O
and NN NN O
chloride NN NN O
, NN NN O
albeit NN NN O
at NN NN O
a NN NN O
much NN NN O
lower NN NN O
level NN NN O
than NN NN O
wild-type NN NN O
pendrin NN NN O
. NN NN O

We NN NN O
hypothesize NN NN O
that NN NN O
this NN NN O
residual NN NN O
level NN NN O
of NN NN O
anion NN NN O
transport NN NN O
is NN NN O
sufficient NN NN O
to NN NN O
eliminate NN NN O
or NN NN O
postpone NN NN O
the NN NN O
onset NN NN O
of NN NN O
goiter NN NN B-DiseaseClass
in NN NN O
individuals NN NN O
with NN NN O
DFNB4 NN NN B-SpecificDisease
. NN NN O

We NN NN O
propose NN NN O
a NN NN O
model NN NN O
for NN NN O
pendrin NN NN O
function NN NN O
in NN NN O
the NN NN O
thyroid NN NN O
in NN NN O
which NN NN O
pendrin NN NN O
transports NN NN O
iodide NN NN O
across NN NN O
the NN NN O
apical NN NN O
membrane NN NN O
of NN NN O
the NN NN O
thyrocyte NN NN O
into NN NN O
the NN NN O
colloid NN NN O
space NN NN O
. NN NN O

. NN NN O

10874302 NN NN O
The NN NN O
human NN NN O
factor NN NN O
IX NN NN O
gene NN NN O
as NN NN O
germline NN NN O
mutagen NN NN O
test NN NN O
: NN NN O
samples NN NN O
from NN NN O
Mainland NN NN O
China NN NN O
have NN NN O
the NN NN O
putatively NN NN O
endogenous NN NN O
pattern NN NN O
of NN NN O
mutation NN NN O
. NN NN O

Germline NN NN O
mutations NN NN O
are NN NN O
the NN NN O
major NN NN O
source NN NN O
of NN NN O
genetic NN NN O
variation NN NN O
that NN NN O
allows NN NN O
a NN NN O
species NN NN O
to NN NN O
evolve NN NN O
over NN NN O
time NN NN O
but NN NN O
at NN NN O
the NN NN O
cost NN NN O
of NN NN O
Mendelian NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
and NN NN O
genetic NN NN O
predisposition NN NN O
to NN NN O
multifactorial NN NN B-DiseaseClass
diseases NN NN I-DiseaseClass
. NN NN O

Previous NN NN O
analyses NN NN O
have NN NN O
revealed NN NN O
that NN NN O
the NN NN O
pattern NN NN O
of NN NN O
germline NN NN O
mutations NN NN O
in NN NN O
the NN NN O
factor NN NN O
IX NN NN O
gene NN NN O
( NN NN O
F9 NN NN O
) NN NN O
is NN NN O
similar NN NN O
among NN NN O
a NN NN O
variety NN NN O
of NN NN O
ethnically NN NN O
and NN NN O
geographically NN NN O
diverse NN NN O
populations NN NN O
and NN NN O
compatible NN NN O
with NN NN O
the NN NN O
ancient NN NN O
pattern NN NN O
that NN NN O
has NN NN O
shaped NN NN O
the NN NN O
mammalian NN NN O
genome NN NN O
. NN NN O

Here NN NN O
, NN NN O
we NN NN O
compare NN NN O
the NN NN O
pattern NN NN O
of NN NN O
germline NN NN O
mutation NN NN O
in NN NN O
a NN NN O
population NN NN O
of NN NN O
hemophilia NN NN B-Modifier
B NN NN I-Modifier
patients NN NN O
from NN NN O
Mainland NN NN O
China NN NN O
( NN NN O
n NN NN O
= NN NN O
66 NN NN O
) NN NN O
to NN NN O
that NN NN O
in NN NN O
U NN NN O
. NN NN O

S NN NN O
. NN NN O

Caucasians NN NN O
, NN NN O
Blacks NN NN O
, NN NN O
and NN NN O
Mexican NN NN O
Hispanics NN NN O
and NN NN O
stratify NN NN O
by NN NN O
disease NN NN O
severity NN NN O
and NN NN O
ethnicity NN NN O
. NN NN O

The NN NN O
similar NN NN O
pattern NN NN O
of NN NN O
germline NN NN O
mutation NN NN O
in NN NN O
all NN NN O
ethnic NN NN O
groups NN NN O
studied NN NN O
to NN NN O
date NN NN O
provides NN NN O
additional NN NN O
data NN NN O
compatible NN NN O
with NN NN O
the NN NN O
inference NN NN O
that NN NN O
endogenous NN NN O
processes NN NN O
predominate NN NN O
in NN NN O
germline NN NN O
mutations NN NN O
. NN NN O

10875918 NN NN O
Fas NN NN O
preassociation NN NN O
required NN NN O
for NN NN O
apoptosis NN NN O
signaling NN NN O
and NN NN O
dominant NN NN O
inhibition NN NN O
by NN NN O
pathogenic NN NN O
mutations NN NN O
. NN NN O

Heterozygous NN NN O
mutations NN NN O
encoding NN NN O
abnormal NN NN O
forms NN NN O
of NN NN O
the NN NN O
death NN NN O
receptor NN NN O
Fas NN NN O
dominantly NN NN O
interfere NN NN O
with NN NN O
Fas-induced NN NN O
lymphocyte NN NN O
apoptosis NN NN O
in NN NN O
human NN NN O
autoimmune NN NN B-SpecificDisease
lymphoproliferative NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

This NN NN O
effect NN NN O
, NN NN O
rather NN NN O
than NN NN O
depending NN NN O
on NN NN O
ligand-induced NN NN O
receptor NN NN O
oligomerization NN NN O
, NN NN O
was NN NN O
found NN NN O
to NN NN O
stem NN NN O
from NN NN O
ligand- NN NN O
independent NN NN O
interaction NN NN O
of NN NN O
wild-type NN NN O
and NN NN O
mutant NN NN O
Fas NN NN O
receptors NN NN O
through NN NN O
a NN NN O
specific NN NN O
region NN NN O
in NN NN O
the NN NN O
extracellular NN NN O
domain NN NN O
. NN NN O

Preassociated NN NN O
Fas NN NN O
complexes NN NN O
were NN NN O
found NN NN O
in NN NN O
living NN NN O
cells NN NN O
by NN NN O
means NN NN O
of NN NN O
fluorescence NN NN O
resonance NN NN O
energy NN NN O
transfer NN NN O
between NN NN O
variants NN NN O
of NN NN O
green NN NN O
fluorescent NN NN O
protein NN NN O
. NN NN O

These NN NN O
results NN NN O
show NN NN O
that NN NN O
formation NN NN O
of NN NN O
preassociated NN NN O
receptor NN NN O
complexes NN NN O
is NN NN O
necessary NN NN O
for NN NN O
Fas NN NN O
signaling NN NN O
and NN NN O
dominant NN NN O
interference NN NN O
in NN NN O
human NN NN O
disease NN NN O
. NN NN O

. NN NN O

10878391 NN NN O
Determination NN NN O
of NN NN O
carrier NN NN O
status NN NN O
for NN NN O
the NN NN O
Wiskott-Aldrich NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
by NN NN O
flow NN NN O
cytometric NN NN O
analysis NN NN O
of NN NN O
Wiskott-Aldrich NN NN B-Modifier
syndrome NN NN I-Modifier
protein NN NN O
expression NN NN O
in NN NN O
peripheral NN NN O
blood NN NN O
mononuclear NN NN O
cells NN NN O
. NN NN O

The NN NN O
Wiskott-Aldrich NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
WAS NN NN B-SpecificDisease
) NN NN O
is NN NN O
caused NN NN O
by NN NN O
defects NN NN O
in NN NN O
the NN NN O
WAS NN NN B-Modifier
protein NN NN O
( NN NN O
WASP NN NN O
) NN NN O
gene NN NN O
on NN NN O
the NN NN O
X NN NN O
chromosome NN NN O
. NN NN O

Previous NN NN O
study NN NN O
disclosed NN NN O
that NN NN O
flow NN NN O
cytometric NN NN O
analysis NN NN O
of NN NN O
intracellular NN NN O
WASP NN NN O
expression NN NN O
( NN NN O
FCM-WASP NN NN O
analysis NN NN O
) NN NN O
in NN NN O
lymphocytes NN NN O
was NN NN O
useful NN NN O
for NN NN O
the NN NN O
diagnosis NN NN O
of NN NN O
WAS NN NN B-Modifier
patients NN NN O
. NN NN O

Lymphocytes NN NN O
from NN NN O
all NN NN O
WAS NN NN B-Modifier
patients NN NN O
showed NN NN O
WASPdim NN NN O
instead NN NN O
of NN NN O
WASPbright NN NN O
. NN NN O

Here NN NN O
we NN NN O
report NN NN O
that NN NN O
FCM-WASP NN NN O
analysis NN NN O
in NN NN O
monocytes NN NN O
could NN NN O
be NN NN O
a NN NN O
useful NN NN O
tool NN NN O
for NN NN O
the NN NN O
WAS NN NN B-Modifier
carrier NN NN O
diagnosis NN NN O
. NN NN O

Monocytes NN NN O
from NN NN O
all NN NN O
nine NN NN O
WAS NN NN B-Modifier
carriers NN NN O
showed NN NN O
varied NN NN O
population NN NN O
of NN NN O
WASPdim NN NN O
together NN NN O
with NN NN O
WASPbright NN NN O
. NN NN O

None NN NN O
of NN NN O
control NN NN O
individuals NN NN O
possessed NN NN O
the NN NN O
WASPdim NN NN O
population NN NN O
. NN NN O

In NN NN O
contrast NN NN O
, NN NN O
lymphocytes NN NN O
from NN NN O
all NN NN O
the NN NN O
carriers NN NN O
except NN NN O
two NN NN O
lacked NN NN O
the NN NN O
WASPdim NN NN O
population NN NN O
. NN NN O

The NN NN O
difference NN NN O
of NN NN O
the NN NN O
WASPdim NN NN O
population NN NN O
in NN NN O
monocytes NN NN O
and NN NN O
lymphocytes NN NN O
observed NN NN O
in NN NN O
WAS NN NN B-Modifier
carriers NN NN O
suggests NN NN O
that NN NN O
WASP NN NN O
plays NN NN O
a NN NN O
more NN NN O
critical NN NN O
role NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
lymphocytes NN NN O
than NN NN O
in NN NN O
that NN NN O
of NN NN O
monocytes NN NN O
. NN NN O

The NN NN O
present NN NN O
studies NN NN O
suggest NN NN O
that NN NN O
a NN NN O
skewed NN NN O
X-chromosomal NN NN O
inactivation NN NN O
pattern NN NN O
observed NN NN O
in NN NN O
WAS NN NN B-Modifier
carrier NN NN O
peripheral NN NN O
blood NN NN O
cells NN NN O
is NN NN O
not NN NN O
fixed NN NN O
at NN NN O
the NN NN O
hemopoietic NN NN O
stem NN NN O
cell NN NN O
level NN NN O
but NN NN O
progresses NN NN O
after NN NN O
the NN NN O
lineage NN NN O
commitment NN NN O
. NN NN O

. NN NN O

10888879 NN NN O
Restoration NN NN O
of NN NN O
photoreceptor NN NN O
ultrastructure NN NN O
and NN NN O
function NN NN O
in NN NN O
retinal NN NN B-Modifier
degeneration NN NN I-Modifier
slow NN NN O
mice NN NN O
by NN NN O
gene NN NN O
therapy NN NN O
. NN NN O

The NN NN O
gene NN NN O
Prph2 NN NN O
encodes NN NN O
a NN NN O
photoreceptor-specific NN NN O
membrane NN NN O
glycoprotein NN NN O
, NN NN O
peripherin-2 NN NN O
( NN NN O
also NN NN O
known NN NN O
as NN NN O
peripherin NN NN O
/ NN NN O
rds NN NN O
) NN NN O
, NN NN O
which NN NN O
is NN NN O
inserted NN NN O
into NN NN O
the NN NN O
rims NN NN O
of NN NN O
photoreceptor NN NN O
outer NN NN O
segment NN NN O
discs NN NN O
in NN NN O
a NN NN O
complex NN NN O
with NN NN O
rom-1 NN NN O
( NN NN O
ref NN NN O
. NN NN O

2 NN NN O
) NN NN O
. NN NN O

The NN NN O
complex NN NN O
is NN NN O
necessary NN NN O
for NN NN O
the NN NN O
stabilization NN NN O
of NN NN O
the NN NN O
discs NN NN O
, NN NN O
which NN NN O
are NN NN O
renewed NN NN O
constantly NN NN O
throughout NN NN O
life NN NN O
, NN NN O
and NN NN O
which NN NN O
contain NN NN O
the NN NN O
visual NN NN O
pigments NN NN O
necessary NN NN O
for NN NN O
photon NN NN O
capture NN NN O
. NN NN O

Mutations NN NN O
in NN NN O
Prph2 NN NN O
have NN NN O
been NN NN O
shown NN NN O
to NN NN O
result NN NN O
in NN NN O
a NN NN O
variety NN NN O
of NN NN O
photoreceptor NN NN B-DiseaseClass
dystrophies NN NN I-DiseaseClass
, NN NN O
including NN NN O
autosomal NN NN B-SpecificDisease
dominant NN NN I-SpecificDisease
retinitis NN NN I-SpecificDisease
pigmentosa NN NN I-SpecificDisease
and NN NN O
macular NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
. NN NN O

A NN NN O
common NN NN O
feature NN NN O
of NN NN O
these NN NN O
diseases NN NN O
is NN NN O
the NN NN O
loss NN NN O
of NN NN O
photoreceptor NN NN O
function NN NN O
, NN NN O
also NN NN O
seen NN NN O
in NN NN O
the NN NN O
retinal NN NN B-Modifier
degeneration NN NN I-Modifier
slow NN NN O
( NN NN O
rds NN NN O
or NN NN O
Prph2 NN NN O
Rd2 NN NN O
/ NN NN O
Rd2 NN NN O
) NN NN O
mouse NN NN O
, NN NN O
which NN NN O
is NN NN O
homozygous NN NN O
for NN NN O
a NN NN O
null NN NN O
mutation NN NN O
in NN NN O
Prph2 NN NN O
. NN NN O

It NN NN O
is NN NN O
characterized NN NN O
by NN NN O
a NN NN O
complete NN NN O
failure NN NN O
to NN NN O
develop NN NN O
photoreceptor NN NN O
discs NN NN O
and NN NN O
outer NN NN O
segments NN NN O
, NN NN O
downregulation NN NN O
of NN NN O
rhodopsin NN NN O
and NN NN O
apoptotic NN NN O
loss NN NN O
of NN NN O
photoreceptor NN NN O
cells NN NN O
. NN NN O

The NN NN O
electroretinograms NN NN O
( NN NN O
ERGs NN NN O
) NN NN O
of NN NN O
Prph2Rd2 NN NN O
/ NN NN O
Rd2 NN NN O
mice NN NN O
have NN NN O
greatly NN NN O
diminished NN NN O
a-wave NN NN O
and NN NN O
b-wave NN NN O
amplitudes NN NN O
, NN NN O
which NN NN O
decline NN NN O
to NN NN O
virtually NN NN O
undetectable NN NN O
concentrations NN NN O
by NN NN O
two NN NN O
months NN NN O
. NN NN O

Subretinal NN NN O
injection NN NN O
of NN NN O
recombinant NN NN O
adeno-associated NN NN O
virus NN NN O
( NN NN O
AAV NN NN O
) NN NN O
encoding NN NN O
a NN NN O
Prph2 NN NN O
transgene NN NN O
results NN NN O
in NN NN O
stable NN NN O
generation NN NN O
of NN NN O
outer NN NN O
segment NN NN O
structures NN NN O
and NN NN O
formation NN NN O
of NN NN O
new NN NN O
stacks NN NN O
of NN NN O
discs NN NN O
containing NN NN O
both NN NN O
perpherin-2 NN NN O
and NN NN O
rhodopsin NN NN O
, NN NN O
which NN NN O
in NN NN O
many NN NN O
cases NN NN O
are NN NN O
morphologically NN NN O
similar NN NN O
to NN NN O
normal NN NN O
outer NN NN O
segments NN NN O
. NN NN O

Moreover NN NN O
, NN NN O
the NN NN O
re-establishment NN NN O
of NN NN O
the NN NN O
structural NN NN O
integrity NN NN O
of NN NN O
the NN NN O
photoreceptor NN NN O
layer NN NN O
also NN NN O
results NN NN O
in NN NN O
electrophysiological NN NN O
correction NN NN O
. NN NN O

These NN NN O
studies NN NN O
demonstrate NN NN O
for NN NN O
the NN NN O
first NN NN O
time NN NN O
that NN NN O
a NN NN O
complex NN NN O
ultrastructural NN NN O
cell NN NN O
defect NN NN O
can NN NN O
be NN NN O
corrected NN NN O
both NN NN O
morphologically NN NN O
and NN NN O
functionally NN NN O
by NN NN O
in NN NN O
vivo NN NN O
gene NN NN O
transfer NN NN O
. NN NN O

. NN NN O

10891444 NN NN O
Mutations NN NN O
in NN NN O
the NN NN O
fibrinogen NN NN O
aalpha NN NN O
gene NN NN O
account NN NN O
for NN NN O
the NN NN O
majority NN NN O
of NN NN O
cases NN NN O
of NN NN O
congenital NN NN B-SpecificDisease
afibrinogenemia NN NN I-SpecificDisease
. NN NN O

Congenital NN NN B-SpecificDisease
afibrinogenemia NN NN I-SpecificDisease
is NN NN O
a NN NN O
rare NN NN O
, NN NN O
autosomal NN NN B-DiseaseClass
, NN NN I-DiseaseClass
recessive NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
characterized NN NN O
by NN NN O
the NN NN O
complete NN NN O
absence NN NN O
of NN NN O
detectable NN NN O
fibrinogen NN NN O
. NN NN O

We NN NN O
previously NN NN O
identified NN NN O
the NN NN O
first NN NN O
causative NN NN O
mutations NN NN O
in NN NN O
a NN NN O
nonconsanguineous NN NN O
Swiss NN NN O
family NN NN O
; NN NN O
the NN NN O
4 NN NN O
affected NN NN O
persons NN NN O
have NN NN O
homozygous NN NN O
deletions NN NN O
of NN NN O
approximately NN NN O
11 NN NN O
kb NN NN O
of NN NN O
the NN NN O
fibrinogen NN NN O
alpha NN NN O
( NN NN O
FGA NN NN O
) NN NN O
gene NN NN O
. NN NN O

Haplotype NN NN O
data NN NN O
implied NN NN O
that NN NN O
these NN NN O
deletions NN NN O
occurred NN NN O
on NN NN O
distinct NN NN O
ancestral NN NN O
chromosomes NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
this NN NN O
region NN NN O
may NN NN O
be NN NN O
susceptible NN NN O
to NN NN O
deletion NN NN O
by NN NN O
a NN NN O
common NN NN O
mechanism NN NN O
. NN NN O

We NN NN O
subsequently NN NN O
showed NN NN O
that NN NN O
all NN NN O
the NN NN O
deletions NN NN O
were NN NN O
identical NN NN O
to NN NN O
the NN NN O
base NN NN O
pair NN NN O
and NN NN O
probably NN NN O
resulted NN NN O
from NN NN O
a NN NN O
nonhomologous NN NN O
recombination NN NN O
mediated NN NN O
by NN NN O
7-bp NN NN O
direct NN NN O
repeats NN NN O
. NN NN O

In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
have NN NN O
collected NN NN O
data NN NN O
on NN NN O
13 NN NN O
additional NN NN O
unrelated NN NN O
patients NN NN O
to NN NN O
identify NN NN O
the NN NN O
causative NN NN O
mutations NN NN O
and NN NN O
to NN NN O
determine NN NN O
the NN NN O
prevalence NN NN O
of NN NN O
the NN NN O
11-kb NN NN O
deletion NN NN O
. NN NN O

A NN NN O
common NN NN O
recurrent NN NN O
mutation NN NN O
, NN NN O
at NN NN O
the NN NN O
donor NN NN O
splice NN NN O
site NN NN O
of NN NN O
FGA NN NN O
intron NN NN O
4 NN NN O
( NN NN O
IVS4 NN NN O
+ NN NN O
1 NN NN O
G NN NN O
T NN NN O
) NN NN O
, NN NN O
accounted NN NN O
for NN NN O
14 NN NN O
of NN NN O
the NN NN O
26 NN NN O
( NN NN O
54 NN NN O
% NN NN O
) NN NN O
alleles NN NN O
. NN NN O

One NN NN O
patient NN NN O
was NN NN O
heterozygous NN NN O
for NN NN O
the NN NN O
previously NN NN O
identified NN NN O
deletion NN NN O
. NN NN O

Three NN NN O
more NN NN O
frameshift NN NN O
mutations NN NN O
, NN NN O
2 NN NN O
nonsense NN NN O
mutations NN NN O
, NN NN O
and NN NN O
a NN NN O
second NN NN O
splice NN NN O
site NN NN O
mutation NN NN O
were NN NN O
also NN NN O
identified NN NN O
. NN NN O

Consequently NN NN O
, NN NN O
86 NN NN O
% NN NN O
of NN NN O
afibrinogenemia NN NN B-Modifier
alleles NN NN O
analyzed NN NN O
to NN NN O
date NN NN O
have NN NN O
truncating NN NN O
mutations NN NN O
of NN NN O
FGA NN NN O
, NN NN O
though NN NN O
mutations NN NN O
in NN NN O
all NN NN O
3 NN NN O
fibrinogen NN NN O
genes NN NN O
, NN NN O
FGG NN NN O
, NN NN O
FGA NN NN O
, NN NN O
and NN NN O
FGB NN NN O
, NN NN O
might NN NN O
be NN NN O
predicted NN NN O
to NN NN O
cause NN NN O
congenital NN NN B-SpecificDisease
afibrinogenemia NN NN I-SpecificDisease
. NN NN O

. NN NN O

10911990 NN NN O
Myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
: NN NN O
the NN NN O
role NN NN O
of NN NN O
the NN NN O
CUG NN NN O
triplet NN NN O
repeats NN NN O
in NN NN O
splicing NN NN O
of NN NN O
a NN NN O
novel NN NN O
DMPK NN NN O
exon NN NN O
and NN NN O
altered NN NN O
cytoplasmic NN NN O
DMPK NN NN O
mRNA NN NN O
isoform NN NN O
ratios NN NN O
. NN NN O

The NN NN O
mechanism NN NN O
by NN NN O
which NN NN O
( NN NN O
CTG NN NN O
) NN NN O
n NN NN O
expansion NN NN O
in NN NN O
the NN NN O
3 NN NN O
UTR NN NN O
of NN NN O
the NN NN O
DMPK NN NN O
gene NN NN O
causes NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
is NN NN O
unknown NN NN O
. NN NN O

We NN NN O
identified NN NN O
four NN NN O
RNA NN NN O
splicing NN NN O
factors NN NN O
-- NN NN O
hnRNP NN NN O
C NN NN O
, NN NN O
U2AF NN NN O
( NN NN O
U2 NN NN O
auxiliary NN NN O
factor NN NN O
) NN NN O
, NN NN O
PTB NN NN O
( NN NN O
polypyrimidine NN NN O
tract NN NN O
binding NN NN O
protein NN NN O
) NN NN O
, NN NN O
and NN NN O
PSF NN NN O
( NN NN O
PTB NN NN O
associated NN NN O
splicing NN NN O
factor NN NN O
) NN NN O
-- NN NN O
that NN NN O
bind NN NN O
to NN NN O
two NN NN O
short NN NN O
regions NN NN O
3 NN NN O
of NN NN O
the NN NN O
( NN NN O
CUG NN NN O
) NN NN O
n NN NN O
, NN NN O
and NN NN O
found NN NN O
a NN NN O
novel NN NN O
3 NN NN O
DMPK NN NN O
exon NN NN O
resulting NN NN O
in NN NN O
an NN NN O
mRNA NN NN O
lacking NN NN O
the NN NN O
repeats NN NN O
. NN NN O

We NN NN O
propose NN NN O
that NN NN O
the NN NN O
( NN NN O
CUG NN NN O
) NN NN O
n NN NN O
is NN NN O
an NN NN O
essential NN NN O
cis NN NN O
acting NN NN O
element NN NN O
for NN NN O
this NN NN O
splicing NN NN O
event NN NN O
. NN NN O

In NN NN O
contrast NN NN O
to NN NN O
( NN NN O
CUG NN NN O
) NN NN O
n NN NN O
containing NN NN O
mRNAs NN NN O
, NN NN O
the NN NN O
novel NN NN O
isoform NN NN O
is NN NN O
not NN NN O
retained NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
in NN NN O
DM NN NN B-Modifier
cells NN NN O
, NN NN O
resulting NN NN O
in NN NN O
imbalances NN NN O
in NN NN O
relative NN NN O
levels NN NN O
of NN NN O
cytoplasmic NN NN O
DMPK NN NN O
mRNA NN NN O
isoforms NN NN O
and NN NN O
a NN NN O
new NN NN O
dominant NN NN O
effect NN NN O
of NN NN O
the NN NN O
mutation NN NN O
on NN NN O
DMPK NN NN O
. NN NN O

. NN NN O

10915770 NN NN O
Expression NN NN O
and NN NN O
imprinting NN NN O
of NN NN O
MAGEL2 NN NN O
suggest NN NN O
a NN NN O
role NN NN O
in NN NN O
Prader-willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
and NN NN O
the NN NN O
homologous NN NN O
murine NN NN O
imprinting NN NN O
phenotype NN NN O
. NN NN O

Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
PWS NN NN B-SpecificDisease
) NN NN O
is NN NN O
caused NN NN O
by NN NN O
the NN NN O
loss NN NN O
of NN NN O
expression NN NN O
of NN NN O
imprinted NN NN O
genes NN NN O
in NN NN O
chromosome NN NN O
15q11-q13 NN NN O
. NN NN O

Affected NN NN O
individuals NN NN O
exhibit NN NN O
neonatal NN NN B-SpecificDisease
hypotonia NN NN I-SpecificDisease
, NN NN O
developmental NN NN B-DiseaseClass
delay NN NN I-DiseaseClass
and NN NN O
childhood-onset NN NN B-DiseaseClass
obesity NN NN I-DiseaseClass
. NN NN O

Necdin NN NN O
, NN NN O
a NN NN O
protein NN NN O
implicated NN NN O
in NN NN O
the NN NN O
terminal NN NN O
differentiation NN NN O
of NN NN O
neurons NN NN O
, NN NN O
is NN NN O
the NN NN O
only NN NN O
PWS NN NN B-Modifier
candidate NN NN O
gene NN NN O
to NN NN O
reduce NN NN O
viability NN NN O
when NN NN O
disrupted NN NN O
in NN NN O
a NN NN O
mouse NN NN O
model NN NN O
. NN NN O

In NN NN O
this NN NN O
study NN NN O
, NN NN O
we NN NN O
have NN NN O
characterized NN NN O
MAGEL2 NN NN O
( NN NN O
also NN NN O
known NN NN O
as NN NN O
NDNL1 NN NN O
) NN NN O
, NN NN O
a NN NN O
gene NN NN O
with NN NN O
51 NN NN O
% NN NN O
amino NN NN O
acid NN NN O
sequence NN NN O
similarity NN NN O
to NN NN O
necdin NN NN O
and NN NN O
located NN NN O
41 NN NN O
kb NN NN O
distal NN NN O
to NN NN O
NDN NN NN O
in NN NN O
the NN NN O
PWS NN NN B-Modifier
deletion NN NN O
region NN NN O
. NN NN O

MAGEL2 NN NN O
is NN NN O
expressed NN NN O
predominantly NN NN O
in NN NN O
brain NN NN O
, NN NN O
the NN NN O
primary NN NN O
tissue NN NN O
affected NN NN O
in NN NN O
PWS NN NN B-SpecificDisease
and NN NN O
in NN NN O
several NN NN O
fetal NN NN O
tissues NN NN O
as NN NN O
shown NN NN O
by NN NN O
northern NN NN O
blot NN NN O
analysis NN NN O
. NN NN O

MAGEL2 NN NN O
is NN NN O
imprinted NN NN O
with NN NN O
monoallelic NN NN O
expression NN NN O
in NN NN O
control NN NN O
brain NN NN O
, NN NN O
and NN NN O
paternal-only NN NN O
expression NN NN O
in NN NN O
the NN NN O
central NN NN O
nervous NN NN O
system NN NN O
as NN NN O
demonstrated NN NN O
by NN NN O
its NN NN O
lack NN NN O
of NN NN O
expression NN NN O
in NN NN O
brain NN NN O
from NN NN O
a NN NN O
PWS NN NN B-Modifier
-affected NN NN O
individual NN NN O
. NN NN O

The NN NN O
orthologous NN NN O
mouse NN NN O
gene NN NN O
( NN NN O
Magel2 NN NN O
) NN NN O
is NN NN O
located NN NN O
within NN NN O
150 NN NN O
kb NN NN O
of NN NN O
NDN NN NN O
, NN NN O
is NN NN O
imprinted NN NN O
with NN NN O
paternal-only NN NN O
expression NN NN O
and NN NN O
is NN NN O
expressed NN NN O
predominantly NN NN O
in NN NN O
late NN NN O
developmental NN NN O
stages NN NN O
and NN NN O
adult NN NN O
brain NN NN O
as NN NN O
shown NN NN O
by NN NN O
northern NN NN O
blotting NN NN O
, NN NN O
RT-PCR NN NN O
and NN NN O
whole-mount NN NN O
RNA NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
. NN NN O

Magel2 NN NN O
distribution NN NN O
partially NN NN O
overlaps NN NN O
that NN NN O
of NN NN O
NDN NN NN O
, NN NN O
with NN NN O
strong NN NN O
expression NN NN O
being NN NN O
detected NN NN O
in NN NN O
the NN NN O
central NN NN O
nervous NN NN O
system NN NN O
in NN NN O
mid-gestation NN NN O
mouse NN NN O
embryos NN NN O
by NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
. NN NN O

We NN NN O
hypothesize NN NN O
that NN NN O
, NN NN O
although NN NN O
loss NN NN O
of NN NN O
necdin NN NN O
expression NN NN O
may NN NN O
be NN NN O
important NN NN O
in NN NN O
the NN NN O
neonatal NN NN O
presentation NN NN O
of NN NN O
PWS NN NN B-SpecificDisease
, NN NN O
loss NN NN O
of NN NN O
MAGEL2 NN NN O
may NN NN O
be NN NN O
critical NN NN O
to NN NN O
abnormalities NN NN B-DiseaseClass
in NN NN I-DiseaseClass
brain NN NN I-DiseaseClass
development NN NN I-DiseaseClass
and NN NN O
dysmorphic NN NN B-DiseaseClass
features NN NN I-DiseaseClass
in NN NN O
individuals NN NN O
with NN NN O
PWS NN NN B-SpecificDisease
. NN NN O

. NN NN O

10915776 NN NN O
Retinoschisin NN NN O
, NN NN O
the NN NN O
X-linked NN NN B-Modifier
retinoschisis NN NN I-Modifier
protein NN NN O
, NN NN O
is NN NN O
a NN NN O
secreted NN NN O
photoreceptor NN NN O
protein NN NN O
, NN NN O
and NN NN O
is NN NN O
expressed NN NN O
and NN NN O
released NN NN O
by NN NN O
Weri-Rb1 NN NN O
cells NN NN O
. NN NN O

X-linked NN NN B-SpecificDisease
retinoschisis NN NN I-SpecificDisease
is NN NN O
characterized NN NN O
by NN NN O
microcystic-like NN NN O
changes NN NN O
of NN NN O
the NN NN O
macular NN NN O
region NN NN O
and NN NN O
schisis NN NN O
within NN NN O
the NN NN O
inner NN NN O
retinal NN NN O
layers NN NN O
, NN NN O
leading NN NN O
to NN NN O
visual NN NN B-DiseaseClass
deterioration NN NN I-DiseaseClass
in NN NN O
males NN NN O
. NN NN O

Many NN NN O
missense NN NN O
and NN NN O
protein-truncating NN NN O
mutations NN NN O
of NN NN O
the NN NN O
causative NN NN O
gene NN NN O
RS1 NN NN O
have NN NN O
now NN NN O
been NN NN O
identified NN NN O
and NN NN O
are NN NN O
thought NN NN O
to NN NN O
be NN NN O
inactivating NN NN O
. NN NN O

RS1 NN NN O
encodes NN NN O
a NN NN O
224 NN NN O
amino NN NN O
acid NN NN O
protein NN NN O
, NN NN O
retinoschisin NN NN O
, NN NN O
which NN NN O
contains NN NN O
a NN NN O
discoidin NN NN O
domain NN NN O
but NN NN O
is NN NN O
of NN NN O
unknown NN NN O
function NN NN O
. NN NN O

We NN NN O
have NN NN O
generated NN NN O
a NN NN O
polyclonal NN NN O
antibody NN NN O
against NN NN O
a NN NN O
peptide NN NN O
from NN NN O
a NN NN O
unique NN NN O
region NN NN O
within NN NN O
retinoschisin NN NN O
, NN NN O
which NN NN O
detects NN NN O
a NN NN O
protein NN NN O
of NN NN O
approximately NN NN O
28 NN NN O
kDa NN NN O
in NN NN O
retinal NN NN O
samples NN NN O
reduced NN NN O
with NN NN O
dithiothreitol NN NN O
, NN NN O
but NN NN O
multimers NN NN O
sized NN NN O
40 NN NN O
kDa NN NN O
under NN NN O
non-reducing NN NN O
conditions NN NN O
. NN NN O

A NN NN O
screen NN NN O
of NN NN O
human NN NN O
tissues NN NN O
with NN NN O
this NN NN O
antibody NN NN O
reveals NN NN O
retinoschisin NN NN O
to NN NN O
be NN NN O
retina NN NN O
specific NN NN O
and NN NN O
the NN NN O
antibody NN NN O
detects NN NN O
a NN NN O
protein NN NN O
of NN NN O
similar NN NN O
size NN NN O
in NN NN O
bovine NN NN O
and NN NN O
murine NN NN O
retinae NN NN O
. NN NN O

We NN NN O
investigated NN NN O
the NN NN O
expression NN NN O
pattern NN NN O
in NN NN O
the NN NN O
retina NN NN O
of NN NN O
both NN NN O
RS1 NN NN O
mRNA NN NN O
( NN NN O
using NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
with NN NN O
riboprobes NN NN O
) NN NN O
and NN NN O
retinoschisin NN NN O
( NN NN O
using NN NN O
immunohistochemistry NN NN O
) NN NN O
. NN NN O

The NN NN O
antisense NN NN O
riboprobe NN NN O
detected NN NN O
RS1 NN NN O
mRNA NN NN O
only NN NN O
in NN NN O
the NN NN O
photoreceptor NN NN O
layer NN NN O
but NN NN O
the NN NN O
protein NN NN O
product NN NN O
of NN NN O
the NN NN O
gene NN NN O
was NN NN O
present NN NN O
both NN NN O
in NN NN O
the NN NN O
photoreceptors NN NN O
and NN NN O
within NN NN O
the NN NN O
inner NN NN O
portions NN NN O
of NN NN O
the NN NN O
retina NN NN O
. NN NN O

Furthermore NN NN O
, NN NN O
differentiated NN NN O
retinoblastoma NN NN B-Modifier
cells NN NN O
( NN NN O
Weri-Rb1 NN NN O
cells NN NN O
) NN NN O
were NN NN O
found NN NN O
to NN NN O
express NN NN O
RS1 NN NN O
mRNA NN NN O
and NN NN O
to NN NN O
release NN NN O
retinoschisin NN NN O
. NN NN O

These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
retinoschisin NN NN O
is NN NN O
released NN NN O
by NN NN O
photo-receptors NN NN O
and NN NN O
has NN NN O
functions NN NN O
within NN NN O
the NN NN O
inner NN NN O
retinal NN NN O
layers NN NN O
. NN NN O

Thus NN NN O
, NN NN O
X-linked NN NN B-SpecificDisease
retinoschisis NN NN I-SpecificDisease
is NN NN O
caused NN NN O
by NN NN O
abnormalities NN NN O
in NN NN O
a NN NN O
putative NN NN O
secreted NN NN O
photoreceptor NN NN O
protein NN NN O
and NN NN O
is NN NN O
the NN NN O
first NN NN O
example NN NN O
of NN NN O
a NN NN O
secreted NN NN O
photo-receptor NN NN O
protein NN NN O
associated NN NN O
with NN NN O
a NN NN O
retinal NN NN B-DiseaseClass
dystrophy NN NN I-DiseaseClass
. NN NN O

. NN NN O

10923035 NN NN O
Study NN NN O
of NN NN O
the NN NN O
voltage-gated NN NN O
sodium NN NN O
channel NN NN O
beta NN NN O
1 NN NN O
subunit NN NN O
gene NN NN O
( NN NN O
SCN1B NN NN O
) NN NN O
in NN NN O
the NN NN O
benign NN NN B-SpecificDisease
familial NN NN I-SpecificDisease
infantile NN NN I-SpecificDisease
convulsions NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
BFIC NN NN B-SpecificDisease
) NN NN O
. NN NN O

Benign NN NN B-SpecificDisease
familial NN NN I-SpecificDisease
infantile NN NN I-SpecificDisease
convulsions NN NN I-SpecificDisease
( NN NN O
BFIC NN NN B-SpecificDisease
) NN NN O
is NN NN O
a NN NN O
rare NN NN O
autosomal NN NN B-DiseaseClass
dominant NN NN I-DiseaseClass
epilepsy NN NN I-DiseaseClass
syndrome NN NN I-DiseaseClass
. NN NN O

This NN NN O
syndrome NN NN O
has NN NN O
been NN NN O
recently NN NN O
described NN NN O
in NN NN O
Italian NN NN O
and NN NN O
French NN NN O
pedigrees NN NN O
. NN NN O

Patients NN NN O
present NN NN O
with NN NN O
partial NN NN O
, NN NN O
then NN NN O
generalized NN NN O
seizures NN NN O
, NN NN O
with NN NN O
onset NN NN O
at NN NN O
age NN NN O
three NN NN O
months NN NN O
. NN NN O

The NN NN O
seizures NN NN O
usually NN NN O
spontaneously NN NN O
cease NN NN O
after NN NN O
one NN NN O
year NN NN O
without NN NN O
treatment NN NN O
, NN NN O
leaving NN NN O
no NN NN O
neurological NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
. NN NN O

We NN NN O
have NN NN O
mapped NN NN O
BFIC NN NN B-SpecificDisease
to NN NN O
chromosome NN NN O
19q NN NN O
in NN NN O
five NN NN O
Italian NN NN O
pedigrees NN NN O
. NN NN O

The NN NN O
sodium NN NN O
channel NN NN O
beta1 NN NN O
subunit NN NN O
gene NN NN O
( NN NN O
SCN1B NN NN O
) NN NN O
maps NN NN O
to NN NN O
this NN NN O
candidate NN NN O
region NN NN O
and NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
be NN NN O
involved NN NN O
in NN NN O
one NN NN O
Australian NN NN O
pedigree NN NN O
with NN NN O
generalized NN NN B-SpecificDisease
epilepsy NN NN I-SpecificDisease
and NN NN I-SpecificDisease
febrile NN NN I-SpecificDisease
seizures NN NN I-SpecificDisease
`` NN NN I-SpecificDisease
plus NN NN I-SpecificDisease
`` NN NN I-SpecificDisease
( NN NN O
GEFS NN NN B-SpecificDisease
+ NN NN I-SpecificDisease
) NN NN O
. NN NN O

In NN NN O
this NN NN O
family NN NN O
, NN NN O
a NN NN O
missense NN NN O
mutation NN NN O
in NN NN O
SCN1B NN NN O
cosegregates NN NN O
with NN NN O
the NN NN O
GEFS NN NN B-Modifier
+ NN NN I-Modifier
phenotype NN NN O
. NN NN O

BFIC NN NN B-SpecificDisease
and NN NN O
GEFS NN NN B-SpecificDisease
+ NN NN I-SpecificDisease
have NN NN O
clinical NN NN O
features NN NN O
in NN NN O
common NN NN O
, NN NN O
therefore NN NN O
SCN1B NN NN O
is NN NN O
a NN NN O
candidate NN NN O
gene NN NN O
for NN NN O
BFIC NN NN B-SpecificDisease
. NN NN O

We NN NN O
studied NN NN O
SCN1B NN NN O
exons NN NN O
1 NN NN O
, NN NN O
2 NN NN O
, NN NN O
3 NN NN O
, NN NN O
4 NN NN O
, NN NN O
and NN NN O
5 NN NN O
, NN NN O
using NN NN O
four NN NN O
SSCP NN NN O
methods NN NN O
in NN NN O
10 NN NN O
Caucasian NN NN O
BFIC NN NN B-Modifier
probands NN NN O
of NN NN O
Western NN NN O
Europe NN NN O
. NN NN O

We NN NN O
found NN NN O
no NN NN O
exon NN NN O
variants NN NN O
. NN NN O

One NN NN O
variant NN NN O
was NN NN O
identified NN NN O
in NN NN O
intron NN NN O
5 NN NN O
( NN NN O
IVS5-10C NN NN O
G NN NN O
) NN NN O
, NN NN O
which NN NN O
did NN NN O
not NN NN O
segregate NN NN O
with NN NN O
BFIC NN NN B-SpecificDisease
and NN NN O
was NN NN O
observed NN NN O
in NN NN O
9 NN NN O
. NN NN O

2 NN NN O
% NN NN O
controls NN NN O
. NN NN O

A NN NN O
second NN NN O
variant NN NN O
in NN NN O
intron NN NN O
5 NN NN O
was NN NN O
identified NN NN O
( NN NN O
IVS5 NN NN O
+ NN NN O
30G NN NN O
A NN NN O
) NN NN O
. NN NN O

It NN NN O
was NN NN O
rare NN NN O
, NN NN O
as NN NN O
not NN NN O
observed NN NN O
in NN NN O
controls NN NN O
, NN NN O
but NN NN O
not NN NN O
segregating NN NN O
with NN NN O
the NN NN O
BFIC NN NN B-Modifier
phenotype NN NN O
. NN NN O

10924409 NN NN O
Inactivation NN NN O
of NN NN O
germline NN NN O
mutant NN NN O
APC NN NN B-Modifier
alleles NN NN O
by NN NN O
attenuated NN NN O
somatic NN NN O
mutations NN NN O
: NN NN O
a NN NN O
molecular NN NN O
genetic NN NN O
mechanism NN NN O
for NN NN O
attenuated NN NN B-SpecificDisease
familial NN NN I-SpecificDisease
adenomatous NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
. NN NN O

Germline NN NN O
mutations NN NN O
of NN NN O
the NN NN O
adenomatous NN NN B-Modifier
polyposis NN NN I-Modifier
coli NN NN I-Modifier
( NN NN I-Modifier
APC NN NN I-Modifier
) NN NN I-Modifier
tumor NN NN I-Modifier
-suppressor NN NN O
gene NN NN O
result NN NN O
in NN NN O
familial NN NN B-SpecificDisease
adenomatous NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
( NN NN O
FAP NN NN B-SpecificDisease
) NN NN O
. NN NN O

Patients NN NN O
with NN NN O
FAP NN NN B-SpecificDisease
typically NN NN O
develop NN NN O
hundreds NN NN O
to NN NN O
thousands NN NN O
of NN NN O
benign NN NN B-SpecificDisease
colorectal NN NN I-SpecificDisease
tumors NN NN I-SpecificDisease
and NN NN O
early-onset NN NN O
colorectal NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

A NN NN O
subset NN NN O
of NN NN O
germline NN NN O
APC NN NN B-Modifier
mutations NN NN O
results NN NN O
in NN NN O
an NN NN O
attenuated NN NN B-Modifier
FAP NN NN I-Modifier
( NN NN O
AFAP NN NN B-Modifier
) NN NN O
phenotype NN NN O
, NN NN O
in NN NN O
which NN NN O
patients NN NN O
develop NN NN O
fewer NN NN O
tumors NN NN B-DiseaseClass
and NN NN O
develop NN NN O
them NN NN O
at NN NN O
an NN NN O
older NN NN O
age NN NN O
. NN NN O

Although NN NN O
a NN NN O
genotype-phenotype NN NN O
correlation NN NN O
between NN NN O
the NN NN O
locations NN NN O
of NN NN O
APC NN NN B-Modifier
germline NN NN O
mutations NN NN O
and NN NN O
the NN NN O
development NN NN O
of NN NN O
AFAP NN NN B-SpecificDisease
has NN NN O
been NN NN O
well NN NN O
documented NN NN O
, NN NN O
the NN NN O
mechanism NN NN O
for NN NN O
AFAP NN NN B-SpecificDisease
has NN NN O
not NN NN O
been NN NN O
well NN NN O
defined NN NN O
. NN NN O

We NN NN O
investigated NN NN O
the NN NN O
mechanism NN NN O
for NN NN O
AFAP NN NN B-SpecificDisease
in NN NN O
patients NN NN O
carrying NN NN O
a NN NN O
mutant NN NN O
APC NN NN B-Modifier
allele NN NN O
( NN NN O
APC NN NN O
( NN NN O
AS9 NN NN O
) NN NN O
) NN NN O
that NN NN O
has NN NN O
a NN NN O
mutation NN NN O
in NN NN O
the NN NN O
alternatively NN NN O
spliced NN NN O
region NN NN O
of NN NN O
exon NN NN O
9 NN NN O
. NN NN O

APC NN NN O
( NN NN O
AS9 NN NN O
) NN NN O
was NN NN O
found NN NN O
to NN NN O
down-regulate NN NN O
beta-catenin-regulated NN NN O
transcription NN NN O
, NN NN O
the NN NN O
major NN NN O
tumor NN NN B-Modifier
-suppressor NN NN O
function NN NN O
of NN NN O
APC NN NN O
, NN NN O
as NN NN O
did NN NN O
the NN NN O
wild-type NN NN O
APC NN NN O
. NN NN O

Mutation NN NN O
analysis NN NN O
showed NN NN O
that NN NN O
both NN NN O
APC NN NN O
( NN NN O
AS9 NN NN O
) NN NN O
and NN NN O
the NN NN O
wild-type NN NN O
APC NN NN B-Modifier
alleles NN NN O
were NN NN O
somatically NN NN O
mutated NN NN O
in NN NN O
most NN NN O
colorectal NN NN B-SpecificDisease
tumors NN NN I-SpecificDisease
from NN NN O
these NN NN O
patients NN NN O
. NN NN O

Functional NN NN O
analysis NN NN O
showed NN NN O
that NN NN O
4666insA NN NN O
, NN NN O
a NN NN O
common NN NN O
somatic NN NN O
mutation NN NN O
in NN NN O
APC NN NN O
( NN NN O
AS9 NN NN O
) NN NN O
in NN NN O
these NN NN O
tumors NN NN B-DiseaseClass
, NN NN O
did NN NN O
not NN NN O
inactivate NN NN O
the NN NN O
wild-type NN NN O
APC NN NN O
. NN NN O

Our NN NN O
results NN NN O
indicate NN NN O
that NN NN O
carriers NN NN O
of NN NN O
APC NN NN O
( NN NN O
AS9 NN NN O
) NN NN O
develop NN NN O
fewer NN NN O
colorectal NN NN B-SpecificDisease
tumors NN NN I-SpecificDisease
than NN NN O
do NN NN O
typical NN NN O
patients NN NN O
with NN NN O
FAP NN NN B-SpecificDisease
because NN NN O
somatic NN NN O
inactivation NN NN O
of NN NN O
both NN NN O
APC NN NN B-Modifier
alleles NN NN O
is NN NN O
necessary NN NN O
for NN NN O
colorectal NN NN O
tumorigenesis NN NN O
. NN NN O

However NN NN O
, NN NN O
these NN NN O
patients NN NN O
develop NN NN O
colorectal NN NN B-SpecificDisease
tumors NN NN I-SpecificDisease
more NN NN O
frequently NN NN O
than NN NN O
does NN NN O
the NN NN O
general NN NN O
population NN NN O
because NN NN O
APC NN NN O
( NN NN O
AS9 NN NN O
) NN NN O
is NN NN O
inactivated NN NN O
by NN NN O
mutations NN NN O
that NN NN O
do NN NN O
not NN NN O
inactivate NN NN O
the NN NN O
wild-type NN NN O
APC NN NN O
. NN NN O

. NN NN O

10930361 NN NN O
Iron-dependent NN NN O
self-assembly NN NN O
of NN NN O
recombinant NN NN O
yeast NN NN O
frataxin NN NN O
: NN NN O
implications NN NN O
for NN NN O
Friedreich NN NN B-SpecificDisease
ataxia NN NN I-SpecificDisease
. NN NN O

Frataxin NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
is NN NN O
the NN NN O
primary NN NN O
cause NN NN O
of NN NN O
Friedreich NN NN B-SpecificDisease
ataxia NN NN I-SpecificDisease
( NN NN O
FRDA NN NN B-SpecificDisease
) NN NN O
, NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
cardiodegenerative NN NN I-DiseaseClass
and NN NN I-DiseaseClass
neurodegenerative NN NN I-DiseaseClass
disease NN NN I-DiseaseClass
. NN NN O

Frataxin NN NN O
is NN NN O
a NN NN O
nuclear-encoded NN NN O
mitochondrial NN NN O
protein NN NN O
that NN NN O
is NN NN O
widely NN NN O
conserved NN NN O
among NN NN O
eukaryotes NN NN O
. NN NN O

Genetic NN NN O
inactivation NN NN O
of NN NN O
the NN NN O
yeast NN NN O
frataxin NN NN O
homologue NN NN O
( NN NN O
Yfh1p NN NN O
) NN NN O
results NN NN O
in NN NN O
mitochondrial NN NN O
iron NN NN O
accumulation NN NN O
and NN NN O
hypersensitivity NN NN O
to NN NN O
oxidative NN NN O
stress NN NN O
. NN NN O

Increased NN NN O
iron NN NN O
deposition NN NN O
and NN NN O
evidence NN NN O
of NN NN O
oxidative NN NN O
damage NN NN O
have NN NN O
also NN NN O
been NN NN O
observed NN NN O
in NN NN O
cardiac NN NN O
tissue NN NN O
and NN NN O
cultured NN NN O
fibroblasts NN NN O
from NN NN O
patients NN NN O
with NN NN O
FRDA NN NN B-SpecificDisease
. NN NN O

These NN NN O
findings NN NN O
indicate NN NN O
that NN NN O
frataxin NN NN O
is NN NN O
essential NN NN O
for NN NN O
mitochondrial NN NN O
iron NN NN O
homeostasis NN NN O
and NN NN O
protection NN NN O
from NN NN O
iron-induced NN NN O
formation NN NN O
of NN NN O
free NN NN O
radicals NN NN O
. NN NN O

The NN NN O
functional NN NN O
mechanism NN NN O
of NN NN O
frataxin NN NN O
, NN NN O
however NN NN O
, NN NN O
is NN NN O
still NN NN O
unknown NN NN O
. NN NN O

We NN NN O
have NN NN O
expressed NN NN O
the NN NN O
mature NN NN O
form NN NN O
of NN NN O
Yfh1p NN NN O
( NN NN O
mYfh1p NN NN O
) NN NN O
in NN NN O
Escherichia NN NN O
coli NN NN O
and NN NN O
have NN NN O
analyzed NN NN O
its NN NN O
function NN NN O
in NN NN O
vitro NN NN O
. NN NN O

Isolated NN NN O
mYfh1p NN NN O
is NN NN O
a NN NN O
soluble NN NN O
monomer NN NN O
( NN NN O
13 NN NN O
, NN NN O
783 NN NN O
Da NN NN O
) NN NN O
that NN NN O
contains NN NN O
no NN NN O
iron NN NN O
and NN NN O
shows NN NN O
no NN NN O
significant NN NN O
tendency NN NN O
to NN NN O
self-associate NN NN O
. NN NN O

Aerobic NN NN O
addition NN NN O
of NN NN O
ferrous NN NN O
iron NN NN O
to NN NN O
mYfh1p NN NN O
results NN NN O
in NN NN O
assembly NN NN O
of NN NN O
regular NN NN O
spherical NN NN O
multimers NN NN O
with NN NN O
a NN NN O
molecular NN NN O
mass NN NN O
of NN NN O
approximately NN NN O
1 NN NN O
. NN NN O

1 NN NN O
MDa NN NN O
( NN NN O
megadaltons NN NN O
) NN NN O
and NN NN O
a NN NN O
diameter NN NN O
of NN NN O
13 NN NN O
+ NN NN O
/ NN NN O
-2 NN NN O
nm NN NN O
. NN NN O

Each NN NN O
multimer NN NN O
consists NN NN O
of NN NN O
approximately NN NN O
60 NN NN O
subunits NN NN O
and NN NN O
can NN NN O
sequester NN NN O
3 NN NN O
, NN NN O
000 NN NN O
atoms NN NN O
of NN NN O
iron NN NN O
. NN NN O

Titration NN NN O
of NN NN O
mYfh1p NN NN O
with NN NN O
increasing NN NN O
iron NN NN O
concentrations NN NN O
supports NN NN O
a NN NN O
stepwise NN NN O
mechanism NN NN O
of NN NN O
multimer NN NN O
assembly NN NN O
. NN NN O

Sequential NN NN O
addition NN NN O
of NN NN O
an NN NN O
iron NN NN O
chelator NN NN O
and NN NN O
a NN NN O
reducing NN NN O
agent NN NN O
results NN NN O
in NN NN O
quantitative NN NN O
iron NN NN O
release NN NN O
with NN NN O
concomitant NN NN O
disassembly NN NN O
of NN NN O
the NN NN O
multimer NN NN O
, NN NN O
indicating NN NN O
that NN NN O
mYfh1p NN NN O
sequesters NN NN O
iron NN NN O
in NN NN O
an NN NN O
available NN NN O
form NN NN O
. NN NN O

In NN NN O
yeast NN NN O
mitochondria NN NN O
, NN NN O
native NN NN O
mYfh1p NN NN O
exists NN NN O
as NN NN O
monomer NN NN O
and NN NN O
a NN NN O
higher-order NN NN O
species NN NN O
with NN NN O
a NN NN O
molecular NN NN O
weight NN NN O
600 NN NN O
, NN NN O
000 NN NN O
. NN NN O

After NN NN O
addition NN NN O
of NN NN O
( NN NN O
55 NN NN O
) NN NN O
Fe NN NN O
to NN NN O
the NN NN O
medium NN NN O
, NN NN O
immunoprecipitates NN NN O
of NN NN O
this NN NN O
species NN NN O
contain NN NN O
16 NN NN O
atoms NN NN O
of NN NN O
( NN NN O
55 NN NN O
) NN NN O
Fe NN NN O
per NN NN O
molecule NN NN O
of NN NN O
mYfh1p NN NN O
. NN NN O

We NN NN O
propose NN NN O
that NN NN O
iron-dependent NN NN O
self-assembly NN NN O
of NN NN O
recombinant NN NN O
mYfh1p NN NN O
reflects NN NN O
a NN NN O
physiological NN NN O
role NN NN O
for NN NN O
frataxin NN NN O
in NN NN O
mitochondrial NN NN O
iron NN NN O
sequestration NN NN O
and NN NN O
bioavailability NN NN O
. NN NN O

. NN NN O

10930571 NN NN O
A NN NN O
mutation NN NN O
in NN NN O
the NN NN O
pleckstrin NN NN O
homology NN NN O
( NN NN O
PH NN NN O
) NN NN O
domain NN NN O
of NN NN O
the NN NN O
FGD1 NN NN O
gene NN NN O
in NN NN O
an NN NN O
Italian NN NN O
family NN NN O
with NN NN O
faciogenital NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
( NN NN O
Aarskog-Scott NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
) NN NN O
. NN NN O

Aarskog-Scott NN NN B-SpecificDisease
Syndrome NN NN I-SpecificDisease
( NN NN O
AAS NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
X-linked NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
characterised NN NN O
by NN NN O
short NN NN B-DiseaseClass
stature NN NN I-DiseaseClass
and NN NN O
multiple NN NN O
facial NN NN B-CompositeMention
, NN NN I-CompositeMention
limb NN NN I-CompositeMention
and NN NN I-CompositeMention
genital NN NN I-CompositeMention
abnormalities NN NN I-CompositeMention
. NN NN O

A NN NN O
gene NN NN O
, NN NN O
FGD1 NN NN O
, NN NN O
altered NN NN O
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
AAS NN NN B-Modifier
phenotype NN NN O
, NN NN O
has NN NN O
been NN NN O
identified NN NN O
and NN NN O
found NN NN O
to NN NN O
encode NN NN O
a NN NN O
protein NN NN O
with NN NN O
homology NN NN O
to NN NN O
Rho NN NN O
/ NN NN O
Rac NN NN O
guanine NN NN O
nucleotide NN NN O
exchange NN NN O
factors NN NN O
( NN NN O
Rho NN NN O
/ NN NN O
Rac NN NN O
GEF NN NN O
) NN NN O
. NN NN O

However NN NN O
, NN NN O
since NN NN O
this NN NN O
original NN NN O
report NN NN O
on NN NN O
identification NN NN O
of NN NN O
a NN NN O
mutated NN NN O
FGD1 NN NN O
gene NN NN O
in NN NN O
an NN NN O
AAS NN NN B-Modifier
patient NN NN O
, NN NN O
no NN NN O
additional NN NN O
mutations NN NN O
in NN NN O
the NN NN O
FGD1 NN NN O
gene NN NN O
have NN NN O
been NN NN O
described NN NN O
. NN NN O

We NN NN O
analysed NN NN O
13 NN NN O
independent NN NN O
patients NN NN O
with NN NN O
clinical NN NN O
diagnosis NN NN O
of NN NN O
AAS NN NN B-SpecificDisease
. NN NN O

One NN NN O
patient NN NN O
presented NN NN O
a NN NN O
mutation NN NN O
that NN NN O
results NN NN O
in NN NN O
a NN NN O
nucleotide NN NN O
change NN NN O
in NN NN O
exon NN NN O
10 NN NN O
of NN NN O
the NN NN O
FGD1 NN NN O
gene NN NN O
( NN NN O
G2559 NN NN O
A NN NN O
) NN NN O
substituting NN NN O
a NN NN O
Gln NN NN O
for NN NN O
Arg NN NN O
in NN NN O
position NN NN O
610 NN NN O
. NN NN O

The NN NN O
mutation NN NN O
was NN NN O
found NN NN O
to NN NN O
segregate NN NN O
with NN NN O
the NN NN O
AAS NN NN B-Modifier
phenotype NN NN O
in NN NN O
affected NN NN O
males NN NN O
and NN NN O
carrier NN NN O
females NN NN O
in NN NN O
the NN NN O
family NN NN O
of NN NN O
this NN NN O
patient NN NN O
. NN NN O

Interestingly NN NN O
, NN NN O
Arg-610 NN NN O
is NN NN O
located NN NN O
within NN NN O
one NN NN O
of NN NN O
the NN NN O
two NN NN O
pleckstrin NN NN O
homology NN NN O
( NN NN O
PH NN NN O
) NN NN O
domains NN NN O
of NN NN O
the NN NN O
FGD1 NN NN O
gene NN NN O
and NN NN O
it NN NN O
corresponds NN NN O
to NN NN O
a NN NN O
highly NN NN O
conserved NN NN O
residue NN NN O
which NN NN O
has NN NN O
been NN NN O
involved NN NN O
in NN NN O
InsP NN NN O
binding NN NN O
in NN NN O
PH NN NN O
domains NN NN O
of NN NN O
other NN NN O
proteins NN NN O
. NN NN O

The NN NN O
same NN NN O
residue NN NN O
is NN NN O
often NN NN O
mutated NN NN O
in NN NN O
the NN NN O
Brutons NN NN O
tyrosine NN NN O
kinase NN NN O
( NN NN O
Btk NN NN O
) NN NN O
gene NN NN O
in NN NN O
patients NN NN O
with NN NN O
an NN NN O
X-linked NN NN B-SpecificDisease
agammaglobulinemia NN NN I-SpecificDisease
. NN NN O

The NN NN O
Arg610Gln NN NN O
mutation NN NN O
represents NN NN O
the NN NN O
first NN NN O
case NN NN O
of NN NN O
a NN NN O
mutation NN NN O
in NN NN O
the NN NN O
PH NN NN O
domain NN NN O
of NN NN O
the NN NN O
FGD1 NN NN O
gene NN NN O
and NN NN O
additional NN NN O
evidence NN NN O
that NN NN O
mutations NN NN O
in NN NN O
PH NN NN O
domains NN NN O
can NN NN O
be NN NN O
associated NN NN O
to NN NN O
human NN NN O
diseases NN NN O
. NN NN O

. NN NN O

10932179 NN NN O
Amino-terminal NN NN O
fragments NN NN O
of NN NN O
mutant NN NN O
huntingtin NN NN O
show NN NN O
selective NN NN O
accumulation NN NN O
in NN NN O
striatal NN NN O
neurons NN NN O
and NN NN O
synaptic NN NN O
toxicity NN NN O
. NN NN O

Huntington NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
HD NN NN B-SpecificDisease
) NN NN O
is NN NN O
caused NN NN O
by NN NN O
expansion NN NN O
of NN NN O
a NN NN O
glutamine NN NN O
repeat NN NN O
in NN NN O
the NN NN O
amino-terminal NN NN O
region NN NN O
of NN NN O
huntingtin NN NN O
. NN NN O

Despite NN NN O
its NN NN O
widespread NN NN O
expression NN NN O
, NN NN O
mutant NN NN O
huntingtin NN NN O
induces NN NN O
selective NN NN O
neuronal NN NN O
loss NN NN O
in NN NN O
striatal NN NN O
neurons NN NN O
. NN NN O

Here NN NN O
we NN NN O
report NN NN O
that NN NN O
, NN NN O
in NN NN O
mutant NN NN O
mice NN NN O
expressing NN NN O
HD NN NN B-Modifier
repeats NN NN O
, NN NN O
the NN NN O
production NN NN O
and NN NN O
aggregation NN NN O
of NN NN O
N-terminal NN NN O
huntingtin NN NN O
fragments NN NN O
preferentially NN NN O
occur NN NN O
in NN NN O
HD NN NN B-Modifier
-affected NN NN O
neurons NN NN O
and NN NN O
their NN NN O
processes NN NN O
and NN NN O
axonal NN NN O
terminals NN NN O
. NN NN O

N-terminal NN NN O
fragments NN NN O
of NN NN O
mutant NN NN O
huntingtin NN NN O
form NN NN O
aggregates NN NN O
and NN NN O
induce NN NN O
neuritic NN NN B-DiseaseClass
degeneration NN NN I-DiseaseClass
in NN NN O
cultured NN NN O
striatal NN NN O
neurons NN NN O
. NN NN O

N-terminal NN NN O
mutant NN NN O
huntingtin NN NN O
also NN NN O
binds NN NN O
to NN NN O
synaptic NN NN O
vesicles NN NN O
and NN NN O
inhibits NN NN O
their NN NN O
glutamate NN NN O
uptake NN NN O
in NN NN O
vitro NN NN O
. NN NN O

The NN NN O
specific NN NN O
processing NN NN O
and NN NN O
accumulation NN NN O
of NN NN O
toxic NN NN O
fragments NN NN O
of NN NN O
N-terminal NN NN O
huntingtin NN NN O
in NN NN O
HD NN NN B-Modifier
-affected NN NN O
striatal NN NN O
neurons NN NN O
, NN NN O
especially NN NN O
in NN NN O
their NN NN O
neuronal NN NN O
processes NN NN O
and NN NN O
axonal NN NN O
terminals NN NN O
, NN NN O
may NN NN O
contribute NN NN O
to NN NN O
the NN NN O
selective NN NN O
neuropathology NN NN O
of NN NN O
HD NN NN B-SpecificDisease
. NN NN O

. NN NN O

10943845 NN NN O
BRCA1 NN NN O
is NN NN O
associated NN NN O
with NN NN O
a NN NN O
human NN NN O
SWI/SNF-related NN NN O
complex NN NN O
: NN NN O
linking NN NN O
chromatin NN NN O
remodeling NN NN O
to NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

Germline NN NN O
mutations NN NN O
in NN NN O
the NN NN O
tumor NN NN B-Modifier
suppressor NN NN O
gene NN NN O
, NN NN O
BRCA1 NN NN O
, NN NN O
predispose NN NN O
individuals NN NN O
to NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancers NN NN I-CompositeMention
. NN NN O

Using NN NN O
a NN NN O
combination NN NN O
of NN NN O
affinity- NN NN O
and NN NN O
conventional NN NN O
chromatographic NN NN O
techniques NN NN O
, NN NN O
we NN NN O
have NN NN O
isolated NN NN O
a NN NN O
predominant NN NN O
form NN NN O
of NN NN O
a NN NN O
multiprotein NN NN O
BRCA1-containing NN NN O
complex NN NN O
from NN NN O
human NN NN O
cells NN NN O
displaying NN NN O
chromatin-remodeling NN NN O
activity NN NN O
. NN NN O

Mass NN NN O
spectrometric NN NN O
sequencing NN NN O
of NN NN O
components NN NN O
of NN NN O
this NN NN O
complex NN NN O
indicated NN NN O
that NN NN O
BRCA1 NN NN O
is NN NN O
associated NN NN O
with NN NN O
a NN NN O
SWI NN NN O
/ NN NN O
SNF-related NN NN O
complex NN NN O
. NN NN O

We NN NN O
show NN NN O
that NN NN O
BRCA1 NN NN O
can NN NN O
directly NN NN O
interact NN NN O
with NN NN O
the NN NN O
BRG1 NN NN O
subunit NN NN O
of NN NN O
the NN NN O
SWI NN NN O
/ NN NN O
SNF NN NN O
complex NN NN O
. NN NN O

Moreover NN NN O
, NN NN O
p53-mediated NN NN O
stimulation NN NN O
of NN NN O
transcription NN NN O
by NN NN O
BRCA1 NN NN O
was NN NN O
completely NN NN O
abrogated NN NN O
by NN NN O
either NN NN O
a NN NN O
dominant-negative NN NN O
mutant NN NN O
of NN NN O
BRG1 NN NN O
or NN NN O
the NN NN O
cancer-causing NN NN B-Modifier
deletion NN NN O
in NN NN O
exon NN NN O
11 NN NN O
of NN NN O
BRCA1 NN NN O
. NN NN O

These NN NN O
findings NN NN O
reveal NN NN O
a NN NN O
direct NN NN O
function NN NN O
for NN NN O
BRCA1 NN NN O
in NN NN O
transcriptional NN NN O
control NN NN O
through NN NN O
modulation NN NN O
of NN NN O
chromatin NN NN O
structure NN NN O
. NN NN O

. NN NN O

10947987 NN NN O
Asef NN NN O
, NN NN O
a NN NN O
link NN NN O
between NN NN O
the NN NN O
tumor NN NN B-Modifier
suppressor NN NN O
APC NN NN O
and NN NN O
G-protein NN NN O
signaling NN NN O
. NN NN O

The NN NN O
adenomatous NN NN B-Modifier
polyposis NN NN I-Modifier
coli NN NN I-Modifier
gene NN NN O
( NN NN O
APC NN NN O
) NN NN O
is NN NN O
mutated NN NN O
in NN NN O
familial NN NN B-SpecificDisease
adenomatous NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
and NN NN O
in NN NN O
sporadic NN NN O
colorectal NN NN B-SpecificDisease
tumors NN NN I-SpecificDisease
. NN NN O

Here NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
product NN NN O
is NN NN O
shown NN NN O
to NN NN O
bind NN NN O
through NN NN O
its NN NN O
armadillo NN NN O
repeat NN NN O
domain NN NN O
to NN NN O
a NN NN O
Rac-specific NN NN O
guanine NN NN O
nucleotide NN NN O
exchange NN NN O
factor NN NN O
( NN NN O
GEF NN NN O
) NN NN O
, NN NN O
termed NN NN O
Asef NN NN O
. NN NN O

Endogenous NN NN O
APC NN NN O
colocalized NN NN O
with NN NN O
Asef NN NN O
in NN NN O
mouse NN NN O
colon NN NN O
epithelial NN NN O
cells NN NN O
and NN NN O
neuronal NN NN O
cells NN NN O
. NN NN O

Furthermore NN NN O
, NN NN O
APC NN NN O
enhanced NN NN O
the NN NN O
GEF NN NN O
activity NN NN O
of NN NN O
Asef NN NN O
and NN NN O
stimulated NN NN O
Asef-mediated NN NN O
cell NN NN O
flattening NN NN O
, NN NN O
membrane NN NN O
ruffling NN NN O
, NN NN O
and NN NN O
lamellipodia NN NN O
formation NN NN O
in NN NN O
MDCK NN NN O
cells NN NN O
. NN NN O

These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
APC-Asef NN NN O
complex NN NN O
may NN NN O
regulate NN NN O
the NN NN O
actin NN NN O
cytoskeletal NN NN O
network NN NN O
, NN NN O
cell NN NN O
morphology NN NN O
and NN NN O
migration NN NN O
, NN NN O
and NN NN O
neuronal NN NN O
function NN NN O
. NN NN O

. NN NN O

10958786 NN NN O
Function NN NN O
of NN NN O
an NN NN O
axonal NN NN O
chemoattractant NN NN O
modulated NN NN O
by NN NN O
metalloprotease NN NN O
activity NN NN O
. NN NN O

The NN NN O
axonal NN NN O
chemoattractant NN NN O
netrin-1 NN NN O
guides NN NN O
spinal NN NN O
commissural NN NN O
axons NN NN O
by NN NN O
activating NN NN O
its NN NN O
receptor NN NN O
DCC NN NN O
( NN NN O
Deleted NN NN O
in NN NN O
Colorectal NN NN B-SpecificDisease
Cancer NN NN I-SpecificDisease
) NN NN O
. NN NN O

We NN NN O
have NN NN O
found NN NN O
that NN NN O
chemical NN NN O
inhibitors NN NN O
of NN NN O
metalloproteases NN NN O
potentiate NN NN O
netrin-mediated NN NN O
axon NN NN O
outgrowth NN NN O
in NN NN O
vitro NN NN O
. NN NN O

We NN NN O
have NN NN O
also NN NN O
found NN NN O
that NN NN O
DCC NN NN O
is NN NN O
a NN NN O
substrate NN NN O
for NN NN O
metalloprotease-dependent NN NN O
ectodomain NN NN O
shedding NN NN O
, NN NN O
and NN NN O
that NN NN O
the NN NN O
inhibitors NN NN O
block NN NN O
proteolytic NN NN O
processing NN NN O
of NN NN O
DCC NN NN O
and NN NN O
cause NN NN O
an NN NN O
increase NN NN O
in NN NN O
DCC NN NN O
protein NN NN O
levels NN NN O
on NN NN O
axons NN NN O
within NN NN O
spinal NN NN O
cord NN NN O
explants NN NN O
. NN NN O

Thus NN NN O
, NN NN O
potentiation NN NN O
of NN NN O
netrin NN NN O
activity NN NN O
by NN NN O
inhibitors NN NN O
may NN NN O
result NN NN O
from NN NN O
stabilization NN NN O
of NN NN O
DCC NN NN O
on NN NN O
the NN NN O
axons NN NN O
, NN NN O
and NN NN O
proteolytic NN NN O
activity NN NN O
may NN NN O
regulate NN NN O
axon NN NN O
migration NN NN O
by NN NN O
controlling NN NN O
the NN NN O
number NN NN O
of NN NN O
functional NN NN O
extracellular NN NN O
axon NN NN O
guidance NN NN O
receptors NN NN O
. NN NN O

. NN NN O

10976074 NN NN O
Myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
in NN NN O
transgenic NN NN O
mice NN NN O
expressing NN NN O
an NN NN O
expanded NN NN O
CUG NN NN O
repeat NN NN O
. NN NN O

Myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
, NN NN O
the NN NN O
most NN NN O
common NN NN O
form NN NN O
of NN NN O
muscular NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
in NN NN O
adult NN NN O
humans NN NN O
, NN NN O
results NN NN O
from NN NN O
expansion NN NN O
of NN NN O
a NN NN O
CTG NN NN O
repeat NN NN O
in NN NN O
the NN NN O
3 NN NN O
untranslated NN NN O
region NN NN O
of NN NN O
the NN NN O
DMPK NN NN O
gene NN NN O
. NN NN O

The NN NN O
mutant NN NN O
DMPK NN NN O
messenger NN NN O
RNA NN NN O
( NN NN O
mRNA NN NN O
) NN NN O
contains NN NN O
an NN NN O
expanded NN NN O
CUG NN NN O
repeat NN NN O
and NN NN O
is NN NN O
retained NN NN O
in NN NN O
the NN NN O
nucleus NN NN O
. NN NN O

We NN NN O
have NN NN O
expressed NN NN O
an NN NN O
untranslated NN NN O
CUG NN NN O
repeat NN NN O
in NN NN O
an NN NN O
unrelated NN NN O
mRNA NN NN O
in NN NN O
transgenic NN NN O
mice NN NN O
. NN NN O

Mice NN NN O
that NN NN O
expressed NN NN O
expanded NN NN O
CUG NN NN O
repeats NN NN O
developed NN NN O
myotonia NN NN B-DiseaseClass
and NN NN O
myopathy NN NN B-DiseaseClass
, NN NN O
whereas NN NN O
mice NN NN O
expressing NN NN O
a NN NN O
nonexpanded NN NN O
repeat NN NN O
did NN NN O
not NN NN O
. NN NN O

Thus NN NN O
, NN NN O
transcripts NN NN O
with NN NN O
expanded NN NN O
CUG NN NN O
repeats NN NN O
are NN NN O
sufficient NN NN O
to NN NN O
generate NN NN O
a NN NN O
DM NN NN B-Modifier
phenotype NN NN O
. NN NN O

This NN NN O
result NN NN O
supports NN NN O
a NN NN O
role NN NN O
for NN NN O
RNA NN NN O
gain NN NN O
of NN NN O
function NN NN O
in NN NN O
disease NN NN O
pathogenesis NN NN O
. NN NN O

. NN NN O

10982189 NN NN O
Genomic NN NN O
rearrangements NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
tumor NN NN I-Modifier
-suppressor NN NN O
gene NN NN O
in NN NN O
familial NN NN B-SpecificDisease
adenomatous NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
. NN NN O

Germline NN NN O
mutations NN NN O
of NN NN O
the NN NN O
adenomatous NN NN B-Modifier
polyposis NN NN I-Modifier
coli NN NN I-Modifier
( NN NN I-Modifier
APC NN NN I-Modifier
) NN NN I-Modifier
tumor NN NN I-Modifier
-suppressor NN NN O
gene NN NN O
result NN NN O
in NN NN O
the NN NN O
hereditary NN NN B-SpecificDisease
colorectal NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
familial NN NN B-SpecificDisease
adenomatous NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
( NN NN O
FAP NN NN B-SpecificDisease
) NN NN O
. NN NN O

Almost NN NN O
all NN NN O
APC NN NN B-Modifier
mutations NN NN O
that NN NN O
have NN NN O
been NN NN O
identified NN NN O
are NN NN O
single-nucleotide NN NN O
alterations NN NN O
, NN NN O
small NN NN O
insertions NN NN O
, NN NN O
or NN NN O
small NN NN O
deletions NN NN O
that NN NN O
would NN NN O
truncate NN NN O
the NN NN O
protein NN NN O
product NN NN O
of NN NN O
the NN NN O
gene NN NN O
. NN NN O

No NN NN O
well-characterized NN NN O
intragenic NN NN O
rearrangement NN NN O
of NN NN O
APC NN NN O
has NN NN O
been NN NN O
described NN NN O
, NN NN O
and NN NN O
the NN NN O
prevalence NN NN O
of NN NN O
this NN NN O
type NN NN O
of NN NN O
mutation NN NN O
in NN NN O
FAP NN NN B-Modifier
patients NN NN O
is NN NN O
not NN NN O
clear NN NN O
. NN NN O

We NN NN O
screened NN NN O
49 NN NN O
potential NN NN O
FAP NN NN B-Modifier
families NN NN O
and NN NN O
identified NN NN O
26 NN NN O
different NN NN O
germline NN NN O
APC NN NN B-Modifier
mutations NN NN O
in NN NN O
30 NN NN O
families NN NN O
. NN NN O

Four NN NN O
of NN NN O
these NN NN O
mutations NN NN O
were NN NN O
genomic NN NN O
rearrangements NN NN O
resulting NN NN O
from NN NN O
homologous NN NN O
and NN NN O
nonhomologous NN NN O
recombinations NN NN O
mediated NN NN O
by NN NN O
Alu NN NN O
elements NN NN O
. NN NN O

Two NN NN O
of NN NN O
these NN NN O
four NN NN O
rearrangements NN NN O
were NN NN O
complex NN NN O
, NN NN O
involving NN NN O
deletion NN NN O
and NN NN O
insertion NN NN O
of NN NN O
nucleotides NN NN O
. NN NN O

Of NN NN O
these NN NN O
four NN NN O
rearrangements NN NN O
, NN NN O
one NN NN O
resulted NN NN O
in NN NN O
the NN NN O
deletion NN NN O
of NN NN O
exons NN NN O
11 NN NN O
and NN NN O
12 NN NN O
and NN NN O
two NN NN O
others NN NN O
resulted NN NN O
in NN NN O
either NN NN O
complete NN NN O
or NN NN O
partial NN NN O
deletion NN NN O
of NN NN O
exon NN NN O
14 NN NN O
. NN NN O

The NN NN O
fourth NN NN O
rearrangement NN NN O
grossly NN NN O
altered NN NN O
the NN NN O
sequence NN NN O
within NN NN O
intron NN NN O
14 NN NN O
. NN NN O

Although NN NN O
this NN NN O
rearrangement NN NN O
did NN NN O
not NN NN O
affect NN NN O
any NN NN O
coding NN NN O
sequence NN NN O
of NN NN O
APC NN NN O
at NN NN O
the NN NN O
genomic NN NN O
DNA NN NN O
level NN NN O
, NN NN O
it NN NN O
caused NN NN O
inappropriate NN NN O
splicing NN NN O
of NN NN O
exon NN NN O
14 NN NN O
. NN NN O

These NN NN O
rearrangements NN NN O
were NN NN O
initially NN NN O
revealed NN NN O
by NN NN O
analyzing NN NN O
cDNAs NN NN O
and NN NN O
could NN NN O
not NN NN O
have NN NN O
been NN NN O
identified NN NN O
by NN NN O
using NN NN O
mutation NN NN O
detection NN NN O
methods NN NN O
that NN NN O
screened NN NN O
each NN NN O
exon NN NN O
individually NN NN O
. NN NN O

The NN NN O
identification NN NN O
of NN NN O
a NN NN O
rearrangement NN NN O
that NN NN O
did NN NN O
not NN NN O
alter NN NN O
any NN NN O
coding NN NN O
exons NN NN O
yet NN NN O
affected NN NN O
the NN NN O
splicing NN NN O
further NN NN O
underscores NN NN O
the NN NN O
importance NN NN O
of NN NN O
using NN NN O
cDNA NN NN O
for NN NN O
mutation NN NN O
analysis NN NN O
. NN NN O

The NN NN O
identification NN NN O
of NN NN O
four NN NN O
genomic NN NN O
rearrangements NN NN O
among NN NN O
30 NN NN O
mutations NN NN O
suggests NN NN O
that NN NN O
genomic NN NN O
rearrangements NN NN O
are NN NN O
frequent NN NN O
germline NN NN O
APC NN NN B-Modifier
mutations NN NN O
. NN NN O

. NN NN O

10987655 NN NN O
Detection NN NN O
of NN NN O
a NN NN O
novel NN NN O
missense NN NN O
mutation NN NN O
and NN NN O
second NN NN O
recurrent NN NN O
mutation NN NN O
in NN NN O
the NN NN O
CACNA1A NN NN O
gene NN NN O
in NN NN O
individuals NN NN O
with NN NN O
EA-2 NN NN B-SpecificDisease
and NN NN O
FHM NN NN B-SpecificDisease
. NN NN O

Mutations NN NN O
in NN NN O
the NN NN O
brain NN NN O
specific NN NN O
P NN NN O
/ NN NN O
Q NN NN O
type NN NN O
Ca2 NN NN O
+ NN NN O
channel NN NN O
alpha1 NN NN O
subunit NN NN O
gene NN NN O
, NN NN O
CACNA1A NN NN O
, NN NN O
have NN NN O
been NN NN O
identified NN NN O
in NN NN O
three NN NN O
clinically NN NN O
distinct NN NN O
disorders NN NN O
, NN NN O
viz NN NN O
. NN NN O

episodic NN NN B-SpecificDisease
ataxia NN NN I-SpecificDisease
type NN NN I-SpecificDisease
2 NN NN I-SpecificDisease
( NN NN O
EA-2 NN NN B-SpecificDisease
) NN NN O
, NN NN O
familial NN NN B-SpecificDisease
hemiplegic NN NN I-SpecificDisease
migraine NN NN I-SpecificDisease
( NN NN O
FHM NN NN B-SpecificDisease
) NN NN O
and NN NN O
spinocerebellar NN NN B-SpecificDisease
ataxia NN NN I-SpecificDisease
6 NN NN I-SpecificDisease
( NN NN O
SCA6 NN NN B-SpecificDisease
) NN NN O
. NN NN O

For NN NN O
individuals NN NN O
with NN NN O
EA-2 NN NN B-SpecificDisease
, NN NN O
the NN NN O
mutations NN NN O
described NN NN O
thus NN NN O
far NN NN O
are NN NN O
presumed NN NN O
to NN NN O
result NN NN O
in NN NN O
a NN NN O
truncated NN NN O
protein NN NN O
product NN NN O
. NN NN O

Several NN NN O
different NN NN O
missense NN NN O
mutations NN NN O
have NN NN O
been NN NN O
identified NN NN O
in NN NN O
patients NN NN O
with NN NN O
FHM NN NN B-SpecificDisease
. NN NN O

At NN NN O
least NN NN O
two NN NN O
of NN NN O
these NN NN O
mutations NN NN O
have NN NN O
been NN NN O
identified NN NN O
on NN NN O
two NN NN O
different NN NN O
chromosome NN NN O
19p13 NN NN O
haplotypes NN NN O
and NN NN O
thus NN NN O
represent NN NN O
recurrent NN NN O
mutations NN NN O
. NN NN O

In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
we NN NN O
have NN NN O
screened NN NN O
several NN NN O
individuals NN NN O
for NN NN O
mutations NN NN O
in NN NN O
all NN NN O
47 NN NN O
exons NN NN O
in NN NN O
the NN NN O
CACNA1A NN NN O
gene NN NN O
by NN NN O
single-strand NN NN O
conformation NN NN O
analysis NN NN O
. NN NN O

We NN NN O
have NN NN O
characterised NN NN O
a NN NN O
novel NN NN O
missense NN NN O
mutation NN NN O
, NN NN O
G5260A NN NN O
, NN NN O
in NN NN O
exon NN NN O
32 NN NN O
in NN NN O
a NN NN O
family NN NN O
segregating NN NN O
for NN NN O
EA-2 NN NN B-SpecificDisease
. NN NN O

The NN NN O
consequence NN NN O
of NN NN O
this NN NN O
mutation NN NN O
is NN NN O
an NN NN O
amino NN NN O
acid NN NN O
substitution NN NN O
at NN NN O
a NN NN O
highly NN NN O
conserved NN NN O
position NN NN O
within NN NN O
the NN NN O
CACNA1A NN NN O
gene NN NN O
. NN NN O

This NN NN O
represents NN NN O
the NN NN O
first NN NN O
point NN NN O
mutation NN NN O
not NN NN O
resulting NN NN O
in NN NN O
a NN NN O
proposed NN NN O
truncated NN NN O
protein NN NN O
. NN NN O

Furthermore NN NN O
, NN NN O
this NN NN O
mutation NN NN O
has NN NN O
been NN NN O
detected NN NN O
in NN NN O
a NN NN O
family NN NN O
member NN NN O
with NN NN O
mild NN NN O
clinical NN NN O
signs NN NN O
including NN NN O
only NN NN O
migraine NN NN B-SpecificDisease
. NN NN O

Additionally NN NN O
, NN NN O
a NN NN O
second NN NN O
previously NN NN O
identified NN NN O
recurrent NN NN O
muta NN NN O
tion NN NN O
, NN NN O
C2272T NN NN O
, NN NN O
in NN NN O
exon NN NN O
16 NN NN O
has NN NN O
been NN NN O
discovered NN NN O
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
FHM NN NN B-SpecificDisease
. NN NN O

. NN NN O

1127526 NN NN O
Analbuminemia NN NN B-SpecificDisease
in NN NN O
a NN NN O
neonate NN NN O
. NN NN O

A NN NN O
small-for-gestational-age NN NN O
infant NN NN O
, NN NN O
found NN NN O
to NN NN O
have NN NN O
analbuminemia NN NN B-SpecificDisease
in NN NN O
the NN NN O
neonatal NN NN O
period NN NN O
, NN NN O
is NN NN O
reported NN NN O
and NN NN O
the NN NN O
twelve NN NN O
cases NN NN O
recorded NN NN O
in NN NN O
the NN NN O
world NN NN O
literature NN NN O
are NN NN O
reviewed NN NN O
. NN NN O

Patients NN NN O
lacking NN NN O
this NN NN O
serum NN NN O
protein NN NN O
are NN NN O
essentially NN NN O
asymptomatic NN NN O
, NN NN O
apart NN NN O
from NN NN O
minimal NN NN O
ankle NN NN B-DiseaseClass
edema NN NN I-DiseaseClass
and NN NN O
ease NN NN B-DiseaseClass
of NN NN I-DiseaseClass
fatigue NN NN I-DiseaseClass
. NN NN O

Apparent NN NN O
compensatory NN NN O
mechanisms NN NN O
which NN NN O
come NN NN O
into NN NN O
play NN NN O
when NN NN O
serum NN NN O
albumin NN NN O
is NN NN O
low NN NN O
include NN NN O
prolonged NN NN O
half-life NN NN O
of NN NN O
albumin NN NN O
and NN NN O
transferrin NN NN O
, NN NN O
an NN NN O
increase NN NN O
in NN NN O
serum NN NN O
globulins NN NN O
, NN NN O
beta NN NN O
lipoprotein NN NN O
, NN NN O
and NN NN O
glycoproteins NN NN O
, NN NN O
arterial NN NN B-DiseaseClass
hypotension NN NN I-DiseaseClass
with NN NN O
reduced NN NN O
capillary NN NN O
hydrostatic NN NN O
pressure NN NN O
, NN NN O
and NN NN O
the NN NN O
ability NN NN O
to NN NN O
respond NN NN O
with NN NN O
rapid NN NN O
sodium NN NN O
and NN NN O
chloride NN NN O
diuresis NN NN O
in NN NN O
response NN NN O
to NN NN O
small NN NN O
volume NN NN O
changes NN NN O
. NN NN O

Examination NN NN O
of NN NN O
plasma NN NN O
amino NN NN O
acids NN NN O
, NN NN O
an NN NN O
investigation NN NN O
not NN NN O
previously NN NN O
reported NN NN O
, NN NN O
revealed NN NN O
an NN NN O
extremely NN NN O
low NN NN O
plasma NN NN O
tryptophan NN NN O
level NN NN O
, NN NN O
a NN NN O
finding NN NN O
which NN NN O
may NN NN O
be NN NN O
important NN NN O
in NN NN O
view NN NN O
of NN NN O
the NN NN O
role NN NN O
of NN NN O
tryptophan NN NN O
in NN NN O
albumin NN NN O
synthesis NN NN O
. NN NN O

. NN NN O

1146783 NN NN O
Histidinemia NN NN B-SpecificDisease
. NN NN O

Classical NN NN O
and NN NN O
atypical NN NN O
form NN NN O
in NN NN O
siblings NN NN O
. NN NN O

Two NN NN O
brothers NN NN O
, NN NN O
6 NN NN O
and NN NN O
13 NN NN O
years NN NN O
old NN NN O
, NN NN O
had NN NN O
histidinemia NN NN B-SpecificDisease
. NN NN O

On NN NN O
the NN NN O
basis NN NN O
of NN NN O
clinical NN NN O
and NN NN O
biochemical NN NN O
observations NN NN O
, NN NN O
the NN NN O
younger NN NN O
boy NN NN O
was NN NN O
considered NN NN O
to NN NN O
have NN NN O
a NN NN O
classical NN NN O
type NN NN O
of NN NN O
the NN NN O
disease NN NN O
, NN NN O
while NN NN O
the NN NN O
older NN NN O
boy NN NN O
had NN NN O
an NN NN O
atypical NN NN O
form NN NN O
characterized NN NN O
by NN NN O
partial NN NN O
impairment NN NN O
of NN NN O
the NN NN O
skin NN NN O
histidase NN NN O
activity NN NN O
and NN NN O
a NN NN O
moderately NN NN O
prolonged NN NN O
half-life NN NN O
of NN NN O
blood NN NN O
histidine NN NN O
. NN NN O

The NN NN O
mother NN NN O
is NN NN O
a NN NN O
heterozygous NN NN O
carrier NN NN O
, NN NN O
while NN NN O
the NN NN O
father NN NN O
and NN NN O
sister NN NN O
seem NN NN O
to NN NN O
be NN NN O
normal NN NN O
. NN NN O

. NN NN O

116187 NN NN O
Carrier NN NN O
detection NN NN O
of NN NN O
pyruvate NN NN B-SpecificDisease
carboxylase NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
fibroblasts NN NN O
and NN NN O
lymphocytes NN NN O
. NN NN O

Pyruvate NN NN O
carboxylase NN NN O
( NN NN O
E NN NN O
. NN NN O

C NN NN O
. NN NN O

6 NN NN O
. NN NN O

4 NN NN O
. NN NN O

1 NN NN O
. NN NN O

1 NN NN O
) NN NN O
activity NN NN O
was NN NN O
determined NN NN O
in NN NN O
the NN NN O
circulating NN NN O
peripheral NN NN O
lymphocytes NN NN O
and NN NN O
cultured NN NN O
skin NN NN O
fibroblasts NN NN O
from NN NN O
the NN NN O
family NN NN O
of NN NN O
a NN NN O
patient NN NN O
with NN NN O
hepatic NN NN O
, NN NN O
cerebral NN NN O
, NN NN O
renal NN NN O
cortical NN NN O
, NN NN O
leukocyte NN NN O
, NN NN O
and NN NN O
fibroblast NN NN O
pyruvate NN NN B-SpecificDisease
carboxylase NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
( NN NN O
PC NN NN B-SpecificDisease
Portland NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
) NN NN O
. NN NN O

Lymphocyte NN NN O
activities NN NN O
were NN NN O
mother NN NN O
, NN NN O
33 NN NN O
-- NN NN O
39 NN NN O
% NN NN O
; NN NN O
father NN NN O
, NN NN O
11 NN NN O
-- NN NN O
29 NN NN O
% NN NN O
; NN NN O
brother NN NN O
, NN NN O
82 NN NN O
-- NN NN O
103 NN NN O
% NN NN O
; NN NN O
and NN NN O
sister NN NN O
, NN NN O
38 NN NN O
-- NN NN O
48 NN NN O
% NN NN O
of NN NN O
the NN NN O
lowest NN NN O
normal NN NN O
. NN NN O

Fibroblasts NN NN O
from NN NN O
the NN NN O
patients NN NN O
mother NN NN O
and NN NN O
father NN NN O
had NN NN O
42 NN NN O
and NN NN O
34 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
, NN NN O
of NN NN O
the NN NN O
activity NN NN O
of NN NN O
the NN NN O
lowest NN NN O
normal NN NN O
. NN NN O

These NN NN O
data NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
disease NN NN O
is NN NN O
inherited NN NN O
in NN NN O
an NN NN O
autosomal NN NN O
recessive NN NN O
manner NN NN O
and NN NN O
that NN NN O
lymphocytes NN NN O
and NN NN O
fibroblasts NN NN O
can NN NN O
be NN NN O
used NN NN O
to NN NN O
detect NN NN O
carriers NN NN O
. NN NN O

Neither NN NN O
pyruvate NN NN O
carboxylase NN NN O
nor NN NN O
mitochondrial NN NN O
PEPCK NN NN O
activity NN NN O
in NN NN O
lymphocytes NN NN O
was NN NN O
increased NN NN O
by NN NN O
a NN NN O
21-hr NN NN O
fast NN NN O
. NN NN O

1201235 NN NN O
Glucose-6-phosphate NN NN O
dehydrogenase NN NN O
variants NN NN O
from NN NN O
Italian NN NN O
subjects NN NN O
associated NN NN O
with NN NN O
severe NN NN B-SpecificDisease
neonatal NN NN I-SpecificDisease
jaundice NN NN I-SpecificDisease
. NN NN O

Screening NN NN O
for NN NN O
the NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
was NN NN O
carried NN NN O
out NN NN O
at NN NN O
the NN NN O
Maternity NN NN O
Division NN NN O
of NN NN O
the NN NN O
Galliera NN NN O
Hospital NN NN O
in NN NN O
Genoa NN NN O
, NN NN O
Italy NN NN O
. NN NN O

Two NN NN O
groups NN NN O
of NN NN O
subjects NN NN O
with NN NN O
hyperbilirubinaemia NN NN B-DiseaseClass
of NN NN O
non-immunological NN NN O
origin NN NN O
were NN NN O
examined NN NN O
( NN NN O
a NN NN O
) NN NN O
302 NN NN O
newborn NN NN O
babies NN NN O
of NN NN O
Sardinian NN NN O
extraction NN NN O
( NN NN O
on NN NN O
cord NN NN O
blood NN NN O
) NN NN O
and NN NN O
( NN NN O
b NN NN O
) NN NN O
201 NN NN O
newborn NN NN O
babies NN NN O
of NN NN O
south NN NN O
Italian NN NN O
ancestry NN NN O
( NN NN O
on NN NN O
peripheral NN NN O
blood NN NN O
) NN NN O
. NN NN O

Among NN NN O
503 NN NN O
subjects NN NN O
, NN NN O
43 NN NN O
showed NN NN O
an NN NN O
enzyme NN NN O
deficiency NN NN O
; NN NN O
in NN NN O
39 NN NN O
the NN NN O
defect NN NN O
was NN NN O
of NN NN O
the NN NN O
Mediterranean NN NN O
type NN NN O
. NN NN O

In NN NN O
one NN NN O
case NN NN O
, NN NN O
previously NN NN O
described NN NN O
, NN NN O
the NN NN O
enzyme NN NN O
was NN NN O
of NN NN O
the NN NN O
A- NN NN O
type NN NN O
. NN NN O

In NN NN O
the NN NN O
remaining NN NN O
cases NN NN O
three NN NN O
different NN NN O
variants NN NN O
were NN NN O
identified NN NN O
. NN NN O

In NN NN O
the NN NN O
present NN NN O
work NN NN O
these NN NN O
three NN NN O
cases NN NN O
, NN NN O
each NN NN O
with NN NN O
severe NN NN B-SpecificDisease
neonatal NN NN I-SpecificDisease
jaundice NN NN I-SpecificDisease
, NN NN O
are NN NN O
reported NN NN O
. NN NN O

Their NN NN O
parents NN NN O
originated NN NN O
from NN NN O
Calabria NN NN O
, NN NN O
from NN NN O
Sardinia NN NN O
and NN NN O
from NN NN O
Sicily NN NN O
. NN NN O

The NN NN O
abnormal NN NN O
enzymes NN NN O
are NN NN O
respectively NN NN O
designated NN NN O
as NN NN O
GdDcbrousse-like NN NN O
, NN NN O
GdGallura NN NN O
and NN NN O
GdAgrigento NN NN O
. NN NN O

. NN NN O

1222588 NN NN O
Cytogenetic NN NN O
investigations NN NN O
in NN NN O
families NN NN O
with NN NN O
ataxia-telangiectasia NN NN B-SpecificDisease
. NN NN O

Chromosomal NN NN O
studies NN NN O
were NN NN O
performed NN NN O
on NN NN O
peripheral NN NN O
blood NN NN O
lymphocytes NN NN O
and NN NN O
cultured NN NN O
skin NN NN O
fibroblasts NN NN O
from NN NN O
five NN NN O
Israeli-Moroccan NN NN O
families NN NN O
with NN NN O
ataxia-telangiectasia NN NN B-SpecificDisease
. NN NN O

A NN NN O
total NN NN O
of NN NN O
24 NN NN O
individuals NN NN O
, NN NN O
including NN NN O
seven NN NN O
propositi NN NN O
, NN NN O
was NN NN O
investigated NN NN O
. NN NN O

Among NN NN O
the NN NN O
probands NN NN O
, NN NN O
significantly NN NN O
elevated NN NN O
rates NN NN O
of NN NN O
chromosome NN NN O
damage NN NN O
were NN NN O
observed NN NN O
in NN NN O
both NN NN O
blood NN NN O
and NN NN O
skin NN NN O
. NN NN O

Skin NN NN O
fibroblasts NN NN O
of NN NN O
affected NN NN O
individuals NN NN O
showed NN NN O
several NN NN O
orders NN NN O
of NN NN O
magnitude NN NN O
more NN NN O
chromosome NN NN O
breakage NN NN O
than NN NN O
lymphocytes NN NN O
. NN NN O

Increased NN NN O
rates NN NN O
of NN NN O
chromosome NN NN O
damage NN NN O
were NN NN O
also NN NN O
observed NN NN O
in NN NN O
the NN NN O
fibroblasts NN NN O
of NN NN O
some NN NN O
phenotypically NN NN O
normal NN NN O
family NN NN O
members NN NN O
( NN NN O
obligate NN NN O
heterozygotes NN NN O
and NN NN O
sibs NN NN O
) NN NN O
when NN NN O
compared NN NN O
to NN NN O
normal NN NN O
controls NN NN O
. NN NN O

An NN NN O
apparent NN NN O
abnormal NN NN O
clone NN NN O
of NN NN O
cells NN NN O
, NN NN O
possessing NN NN O
a NN NN O
large NN NN O
acrocentric NN NN O
marker NN NN O
chromosome NN NN O
( NN NN O
14q NN NN O
+ NN NN O
) NN NN O
, NN NN O
was NN NN O
observed NN NN O
in NN NN O
varying NN NN O
proportions NN NN O
among NN NN O
cells NN NN O
of NN NN O
all NN NN O
the NN NN O
propositi NN NN O
( NN NN O
2-5 NN NN O
% NN NN O
of NN NN O
lymphocytes NN NN O
; NN NN O
1-9 NN NN O
% NN NN O
of NN NN O
fibroblasts NN NN O
) NN NN O
. NN NN O

. NN NN O

122435 NN NN O
Prenatal NN NN O
diagnosis NN NN O
of NN NN O
Wolman NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

Two NN NN O
pregnancies NN NN O
at NN NN O
risk NN NN O
for NN NN O
Wolman NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
were NN NN O
monitored NN NN O
by NN NN O
assay NN NN O
and NN NN O
electrophoresis NN NN O
of NN NN O
acid NN NN O
lipase NN NN O
in NN NN O
cultured NN NN O
amniotic-fluid NN NN O
cells NN NN O
. NN NN O

Cells NN NN O
from NN NN O
patient NN NN O
1 NN NN O
had NN NN O
5 NN NN O
% NN NN O
of NN NN O
control NN NN O
levels NN NN O
of NN NN O
acid NN NN O
lipase NN NN O
, NN NN O
using NN NN O
14C-triolein NN NN O
as NN NN O
substrate NN NN O
; NN NN O
however NN NN O
, NN NN O
when NN NN O
artificial NN NN O
substrates NN NN O
( NN NN O
esters NN NN O
of NN NN O
4-methylumbelliferone NN NN O
and NN NN O
p-nitrophenol NN NN O
) NN NN O
were NN NN O
used NN NN O
to NN NN O
measure NN NN O
acid NN NN O
lipase NN NN O
, NN NN O
these NN NN O
cells NN NN O
had NN NN O
30 NN NN O
% NN NN O
of NN NN O
control NN NN O
levels NN NN O
. NN NN O

Electrophoresis NN NN O
of NN NN O
cell NN NN O
extracts NN NN O
revealed NN NN O
the NN NN O
absence NN NN O
of NN NN O
the NN NN O
A NN NN O
form NN NN O
of NN NN O
acid NN NN O
lipase NN NN O
, NN NN O
consistent NN NN O
with NN NN O
the NN NN O
diagnosis NN NN O
of NN NN O
Wolman NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

Analysis NN NN O
of NN NN O
fetal NN NN O
tissues NN NN O
following NN NN O
prostaglandin NN NN O
termination NN NN O
of NN NN O
this NN NN O
pregnancy NN NN O
confirmed NN NN O
the NN NN O
diagnosis NN NN O
. NN NN O

Assay NN NN O
of NN NN O
fetal-skin NN NN O
fibroblasts NN NN O
with NN NN O
14C-triolein NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
with NN NN O
artificial NN NN O
substrates NN NN O
, NN NN O
showed NN NN O
marked NN NN O
deficiency NN NN O
of NN NN O
acid NN NN O
lipase NN NN O
activity NN NN O
. NN NN O

Electrophoresis NN NN O
of NN NN O
fetal-tissue NN NN O
extracts NN NN O
also NN NN O
demonstrated NN NN O
the NN NN O
absence NN NN O
of NN NN O
the NN NN O
A NN NN O
form NN NN O
of NN NN O
acid NN NN O
lipase NN NN O
. NN NN O

Amniotic-fluid NN NN O
cells NN NN O
from NN NN O
patient NN NN O
2 NN NN O
showed NN NN O
normal NN NN O
levels NN NN O
of NN NN O
acid NN NN O
lipase NN NN O
with NN NN O
all NN NN O
substrates NN NN O
tested NN NN O
; NN NN O
the NN NN O
electrophoretic NN NN O
pattern NN NN O
of NN NN O
acid NN NN O
lipase NN NN O
was NN NN O
normal NN NN O
. NN NN O

The NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
prenatal NN NN O
diagnosis NN NN O
of NN NN O
Wolman NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
be NN NN O
made NN NN O
using NN NN O
the NN NN O
radioassay NN NN O
of NN NN O
acid NN NN O
lipase NN NN O
and NN NN O
/ NN NN O
or NN NN O
electrophoresis NN NN O
. NN NN O

. NN NN O

1248000 NN NN O
Malignant NN NN B-DiseaseClass
neoplasms NN NN I-DiseaseClass
in NN NN O
the NN NN O
families NN NN O
of NN NN O
patients NN NN O
with NN NN O
ataxia-telangiectasia NN NN B-SpecificDisease
. NN NN O

Ataxia-telangiectasia NN NN B-SpecificDisease
( NN NN O
A-T NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
syndrome NN NN I-DiseaseClass
associated NN NN O
with NN NN O
a NN NN O
greatly NN NN O
increased NN NN O
incidence NN NN O
of NN NN O
malignant NN NN B-DiseaseClass
neoplasms NN NN I-DiseaseClass
in NN NN O
homozygous NN NN O
affected NN NN O
individuals NN NN O
. NN NN O

Heterozygotes NN NN O
for NN NN O
the NN NN O
gene NN NN O
for NN NN O
A-T NN NN B-SpecificDisease
are NN NN O
thought NN NN O
to NN NN O
comprise NN NN O
about NN NN O
1 NN NN O
% NN NN O
of NN NN O
the NN NN O
general NN NN O
population NN NN O
and NN NN O
, NN NN O
therefore NN NN O
, NN NN O
it NN NN O
is NN NN O
important NN NN O
to NN NN O
know NN NN O
whether NN NN O
this NN NN O
gene NN NN O
also NN NN O
predisposes NN NN O
the NN NN O
heterozygous NN NN O
carrier NN NN O
to NN NN O
cancers NN NN B-DiseaseClass
. NN NN O

Heterozygous NN NN O
carriers NN NN O
of NN NN O
this NN NN O
gene NN NN O
are NN NN O
common NN NN O
among NN NN O
the NN NN O
close NN NN O
relatives NN NN O
of NN NN O
patients NN NN O
with NN NN O
A-T NN NN B-SpecificDisease
, NN NN O
although NN NN O
individual NN NN O
carriers NN NN O
can NN NN O
not NN NN O
be NN NN O
identified NN NN O
by NN NN O
any NN NN O
clinical NN NN O
criterion NN NN O
or NN NN O
laboratory NN NN O
test NN NN O
. NN NN O

For NN NN O
this NN NN O
reason NN NN O
, NN NN O
we NN NN O
compared NN NN O
the NN NN O
incidence NN NN O
of NN NN O
death NN NN O
from NN NN O
malignant NN NN B-DiseaseClass
neoplasms NN NN I-DiseaseClass
in NN NN O
2 NN NN O
families NN NN O
of NN NN O
patients NN NN O
with NN NN O
A-T NN NN B-SpecificDisease
to NN NN O
that NN NN O
expected NN NN O
in NN NN O
a NN NN O
random NN NN O
sample NN NN O
of NN NN O
the NN NN O
general NN NN O
population NN NN O
. NN NN O

There NN NN O
were NN NN O
59 NN NN O
deaths NN NN O
from NN NN O
malignant NN NN B-DiseaseClass
neoplasms NN NN I-DiseaseClass
in NN NN O
relatives NN NN O
dying NN NN O
before NN NN O
age NN NN O
75 NN NN O
, NN NN O
compared NN NN O
to NN NN O
42 NN NN O
. NN NN O

6 NN NN O
expected NN NN O
( NN NN O
p NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O

02 NN NN O
) NN NN O
. NN NN O

For NN NN O
A-T NN NN B-Modifier
heterozygotes NN NN O
younger NN NN O
than NN NN O
age NN NN O
45 NN NN O
, NN NN O
the NN NN O
risk NN NN O
of NN NN O
dying NN NN O
from NN NN O
a NN NN O
malignant NN NN B-DiseaseClass
neoplasm NN NN I-DiseaseClass
was NN NN O
estimated NN NN O
to NN NN O
be NN NN O
greater NN NN O
than NN NN O
5 NN NN O
times NN NN O
the NN NN O
risk NN NN O
for NN NN O
the NN NN O
general NN NN O
population NN NN O
. NN NN O

A-T NN NN B-Modifier
heterozygotes NN NN O
may NN NN O
comprise NN NN O
more NN NN O
than NN NN O
5 NN NN O
% NN NN O
of NN NN O
all NN NN O
persons NN NN O
dying NN NN O
from NN NN O
a NN NN O
cancer NN NN B-DiseaseClass
before NN NN O
age NN NN O
45 NN NN O
. NN NN O

The NN NN O
incidence NN NN O
of NN NN O
ovarian NN NN B-CompositeMention
, NN NN I-CompositeMention
gastric NN NN I-CompositeMention
, NN NN I-CompositeMention
and NN NN I-CompositeMention
biliary NN NN I-CompositeMention
system NN NN I-CompositeMention
carcinomas NN NN I-CompositeMention
and NN NN O
of NN NN O
leukemia NN NN B-DiseaseClass
and NN NN O
lymphoma NN NN B-DiseaseClass
was NN NN O
increased NN NN O
in NN NN O
these NN NN O
A-T NN NN B-Modifier
families NN NN O
. NN NN O

Other NN NN O
neoplasms NN NN B-DiseaseClass
that NN NN O
may NN NN O
be NN NN O
associated NN NN O
with NN NN O
this NN NN O
gene NN NN O
in NN NN O
heterozygotes NN NN O
include NN NN O
pancreatic NN NN B-CompositeMention
, NN NN I-CompositeMention
basal NN NN I-CompositeMention
cell NN NN I-CompositeMention
, NN NN I-CompositeMention
colonic NN NN I-CompositeMention
, NN NN I-CompositeMention
breast NN NN I-CompositeMention
, NN NN I-CompositeMention
and NN NN I-CompositeMention
cervical NN NN I-CompositeMention
carcinomas NN NN I-CompositeMention
. NN NN O

126380 NN NN O
Striking NN NN O
prevalence NN NN O
of NN NN O
ankylosing NN NN B-SpecificDisease
spondylitis NN NN I-SpecificDisease
in NN NN O
`` NN NN O
healthy NN NN O
'' NN NN O
w27 NN NN O
positive NN NN O
males NN NN O
and NN NN O
females NN NN O
. NN NN O

Ankylosing NN NN B-SpecificDisease
spondylitis NN NN I-SpecificDisease
is NN NN O
diagnosed NN NN O
once NN NN O
or NN NN O
twice NN NN O
in NN NN O
each NN NN O
1000 NN NN O
males NN NN O
and NN NN O
one NN NN O
tenth NN NN O
as NN NN O
frequently NN NN O
in NN NN O
females NN NN O
, NN NN O
but NN NN O
the NN NN O
true NN NN O
prevalence NN NN O
is NN NN O
unknown NN NN O
. NN NN O

Indentification NN NN O
of NN NN O
genetic NN NN O
marker NN NN O
, NN NN O
HL-A NN NN O
W27 NN NN O
, NN NN O
for NN NN O
susceptible NN NN O
persons NN NN O
has NN NN O
provided NN NN O
a NN NN O
tool NN NN O
facilitating NN NN O
epidemiologic NN NN O
studies NN NN O
and NN NN O
allowing NN NN O
identification NN NN O
of NN NN O
`` NN NN O
control NN NN O
`` NN NN O
populations NN NN O
without NN NN O
the NN NN O
marker NN NN O
. NN NN O

Evaluation NN NN O
by NN NN O
postal NN NN O
questionnaires NN NN O
, NN NN O
and NN NN O
pelvic NN NN O
radiography NN NN O
of NN NN O
78 NN NN O
HL-A NN NN O
27W-positive NN NN O
blood NN NN O
donors NN NN O
selected NN NN O
from NN NN O
a NN NN O
group NN NN O
of NN NN O
apparently NN NN O
healthy NN NN O
subjects NN NN O
revealed NN NN O
14 NN NN O
who NN NN O
satisfied NN NN O
the NN NN O
criteria NN NN O
for NN NN O
definite NN NN O
ankylosing NN NN B-SpecificDisease
spondylitis NN NN I-SpecificDisease
. NN NN O

The NN NN O
prevalence NN NN O
was NN NN O
similar NN NN O
in NN NN O
both NN NN O
sexes NN NN O
. NN NN O

One NN NN O
hundred NN NN O
and NN NN O
twenty-six NN NN O
W27-negative NN NN O
controls NN NN O
matched NN NN O
for NN NN O
race NN NN O
, NN NN O
sex NN NN O
, NN NN O
and NN NN O
age NN NN O
failed NN NN O
to NN NN O
yield NN NN O
a NN NN O
single NN NN O
case NN NN O
. NN NN O

For NN NN O
a NN NN O
person NN NN O
of NN NN O
either NN NN O
sex NN NN O
with NN NN O
HL-A NN NN O
W27 NN NN O
, NN NN O
there NN NN O
appears NN NN O
to NN NN O
be NN NN O
about NN NN O
a NN NN O
20 NN NN O
per NN NN O
cent NN NN O
chance NN NN O
that NN NN O
ankylosing NN NN B-SpecificDisease
spondylitis NN NN I-SpecificDisease
will NN NN O
develop NN NN O
, NN NN O
suggesting NN NN O
a NN NN O
prevalence NN NN O
of NN NN O
10 NN NN O
to NN NN O
15 NN NN O
per NN NN O
thousand NN NN O
. NN NN O

Hitherto NN NN O
accepted NN NN O
figures NN NN O
may NN NN O
underestimate NN NN O
the NN NN O
frequency NN NN O
by NN NN O
a NN NN O
factor NN NN O
of NN NN O
10 NN NN O
to NN NN O
20 NN NN O
. NN NN O

. NN NN O

1269174 NN NN O
Analbuminemia NN NN B-SpecificDisease
in NN NN O
an NN NN O
American NN NN O
Indian NN NN O
girl NN NN O
. NN NN O

Analbuminemia NN NN B-SpecificDisease
was NN NN O
fortuitously NN NN O
detected NN NN O
in NN NN O
a NN NN O
nonedematous NN NN O
12-year-old NN NN O
American NN NN O
Indian NN NN O
girl NN NN O
with NN NN O
atopic NN NN B-SpecificDisease
dermatitis NN NN I-SpecificDisease
, NN NN O
mild NN NN O
bronchial NN NN B-SpecificDisease
asthma NN NN I-SpecificDisease
, NN NN O
a NN NN O
mild NN NN O
seizure NN NN B-SpecificDisease
disorder NN NN I-SpecificDisease
, NN NN O
and NN NN O
hyperlipoproteinemia NN NN B-SpecificDisease
with NN NN O
a NN NN O
corneal NN NN B-SpecificDisease
arcus NN NN I-SpecificDisease
. NN NN O

Immunologic NN NN O
methods NN NN O
revealed NN NN O
trace NN NN O
amounts NN NN O
( NN NN O
17 NN NN O
mg NN NN O
/ NN NN O
100 NN NN O
ml NN NN O
) NN NN O
of NN NN O
apparently NN NN O
normal NN NN O
serum NN NN O
albumin NN NN O
. NN NN O

The NN NN O
patients NN NN O
parents NN NN O
were NN NN O
remotely NN NN O
related NN NN O
. NN NN O

The NN NN O
pedigree NN NN O
and NN NN O
clinical NN NN O
findings NN NN O
were NN NN O
compatible NN NN O
with NN NN O
autosomal NN NN O
recessive NN NN O
transmission NN NN O
of NN NN O
analbuminemia NN NN B-SpecificDisease
. NN NN O

Heterozygotes NN NN O
had NN NN O
subnormal NN NN O
levels NN NN O
of NN NN O
serum NN NN O
albumin NN NN O
. NN NN O

The NN NN O
Gc-locus NN NN O
is NN NN O
closely NN NN O
linked NN NN O
to NN NN O
the NN NN O
structural NN NN O
albumin NN NN O
locus NN NN O
. NN NN O

Gc-protein NN NN O
levels NN NN O
were NN NN O
normal NN NN O
in NN NN O
the NN NN O
patient NN NN O
and NN NN O
together NN NN O
with NN NN O
normal NN NN O
chromosomal NN NN O
banding NN NN O
studies NN NN O
make NN NN O
it NN NN O
unlikely NN NN O
that NN NN O
a NN NN O
chromosomal NN NN O
deletion NN NN O
caused NN NN O
analbuminemia NN NN B-SpecificDisease
. NN NN O

Gc-types NN NN O
in NN NN O
the NN NN O
family NN NN O
were NN NN O
compatible NN NN O
with NN NN O
, NN NN O
but NN NN O
did NN NN O
not NN NN O
prove NN NN O
, NN NN O
linkage NN NN O
of NN NN O
analbuminemia NN NN B-SpecificDisease
to NN NN O
the NN NN O
Gc-locus NN NN O
. NN NN O

These NN NN O
findings NN NN O
suggest NN NN O
a NN NN O
`` NN NN O
thalassemia NN NN B-Modifier
`` NN NN O
-like NN NN O
mutation NN NN O
for NN NN O
this NN NN O
disorder NN NN O
. NN NN O

. NN NN O

1279971 NN NN O
Deletion NN NN O
of NN NN O
the NN NN O
KIT NN NN O
and NN NN O
PDGFRA NN NN O
genes NN NN O
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
piebaldism NN NN B-SpecificDisease
. NN NN O

We NN NN O
have NN NN O
previously NN NN O
shown NN NN O
that NN NN O
human NN NN O
piebaldism NN NN B-SpecificDisease
results NN NN O
from NN NN O
mutations NN NN O
of NN NN O
the NN NN O
KIT NN NN O
gene NN NN O
, NN NN O
which NN NN O
encodes NN NN O
the NN NN O
receptor NN NN O
for NN NN O
the NN NN O
mast NN NN O
/ NN NN O
stem NN NN O
cell NN NN O
growth NN NN O
factor NN NN O
and NN NN O
is NN NN O
located NN NN O
in NN NN O
chromosome NN NN O
segment NN NN O
4q12 NN NN O
. NN NN O

Using NN NN O
DNA NN NN O
of NN NN O
a NN NN O
patient NN NN O
with NN NN O
piebaldism NN NN B-SpecificDisease
, NN NN O
mental NN NN B-DiseaseClass
retardation NN NN I-DiseaseClass
, NN NN O
and NN NN O
multiple NN NN B-DiseaseClass
congenital NN NN I-DiseaseClass
anomalies NN NN I-DiseaseClass
associated NN NN O
with NN NN O
a NN NN O
46 NN NN O
, NN NN O
XY NN NN O
, NN NN O
del NN NN O
( NN NN O
4 NN NN O
) NN NN O
( NN NN O
q12q21 NN NN O
. NN NN O

1 NN NN O
) NN NN O
karyotype NN NN O
, NN NN O
we NN NN O
carried NN NN O
out NN NN O
quantitative NN NN O
Southern NN NN O
blot NN NN O
hybridization NN NN O
analyses NN NN O
of NN NN O
the NN NN O
KIT NN NN O
gene NN NN O
and NN NN O
the NN NN O
adjacent NN NN O
PDGFRA NN NN O
( NN NN O
platelet-derived NN NN O
growth NN NN O
factor NN NN O
receptor NN NN O
alpha NN NN O
subunit NN NN O
) NN NN O
genes NN NN O
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
hemizygous NN NN O
for NN NN O
both NN NN O
the NN NN O
KIT NN NN O
and NN NN O
PDGFRA NN NN O
genes NN NN O
, NN NN O
indicating NN NN O
that NN NN O
both NN NN O
of NN NN O
these NN NN O
genes NN NN O
are NN NN O
included NN NN O
within NN NN O
the NN NN O
deleted NN NN O
region NN NN O
. NN NN O

Therefore NN NN O
, NN NN O
deletion NN NN O
of NN NN O
the NN NN O
KIT NN NN O
and NN NN O
PDGFRA NN NN O
genes NN NN O
may NN NN O
account NN NN O
for NN NN O
the NN NN O
piebald NN NN B-Modifier
phenotype NN NN O
in NN NN O
this NN NN O
patient NN NN O
. NN NN O

1282899 NN NN O
A NN NN O
germ NN NN O
line NN NN O
mutation NN NN O
within NN NN O
the NN NN O
coding NN NN O
sequence NN NN O
for NN NN O
the NN NN O
putative NN NN O
5-phosphoribosyl-1-pyrophosphate NN NN O
binding NN NN O
site NN NN O
of NN NN O
hypoxanthine-guanine NN NN O
phosphoribosyltransferase NN NN O
( NN NN O
HPRT NN NN O
) NN NN O
in NN NN O
a NN NN O
Lesch-Nyhan NN NN B-Modifier
patient NN NN O
: NN NN O
missense NN NN O
mutations NN NN O
within NN NN O
a NN NN O
functionally NN NN O
important NN NN O
region NN NN O
probably NN NN O
cause NN NN O
disease NN NN O
. NN NN O

Lesch-Nyhan NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
caused NN NN O
by NN NN O
a NN NN O
complete NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
of NN NN I-SpecificDisease
hypoxanthine NN NN I-SpecificDisease
guanine NN NN I-SpecificDisease
phosphoribosyltransferase NN NN I-SpecificDisease
( NN NN O
HPRT NN NN O
) NN NN O
is NN NN O
the NN NN O
result NN NN O
of NN NN O
a NN NN O
heterogeneous NN NN O
group NN NN O
of NN NN O
germ NN NN O
line NN NN O
mutations NN NN O
. NN NN O

Identification NN NN O
of NN NN O
each NN NN O
mutant NN NN O
gene NN NN O
provides NN NN O
valuable NN NN O
information NN NN O
as NN NN O
to NN NN O
the NN NN O
type NN NN O
of NN NN O
mutation NN NN O
that NN NN O
occurs NN NN O
spontaneously NN NN O
. NN NN O

We NN NN O
report NN NN O
here NN NN O
a NN NN O
newly NN NN O
identified NN NN O
HPRT NN NN O
mutation NN NN O
in NN NN O
a NN NN O
Japanese NN NN O
patient NN NN O
with NN NN O
Lesch-Nyhan NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

This NN NN O
gene NN NN O
, NN NN O
designated NN NN O
HPRT NN NN O
Tokyo NN NN O
, NN NN O
had NN NN O
a NN NN O
single NN NN O
nucleotide NN NN O
change NN NN O
from NN NN O
G NN NN O
to NN NN O
A NN NN O
, NN NN O
as NN NN O
identified NN NN O
by NN NN O
sequencing NN NN O
cDNA NN NN O
amplified NN NN O
by NN NN O
the NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
. NN NN O

Allele NN NN O
specific NN NN O
oligonucleotide NN NN O
hybridization NN NN O
analysis NN NN O
using NN NN O
amplified NN NN O
genomic NN NN O
DNA NN NN O
showed NN NN O
that NN NN O
the NN NN O
mutant NN NN O
gene NN NN O
was NN NN O
transmitted NN NN O
from NN NN O
the NN NN O
maternal NN NN O
germ NN NN O
line NN NN O
. NN NN O

This NN NN O
mutation NN NN O
would NN NN O
lead NN NN O
to NN NN O
an NN NN O
amino NN NN O
acid NN NN O
substitution NN NN O
of NN NN O
Asp NN NN O
for NN NN O
Gly NN NN O
at NN NN O
the NN NN O
amino NN NN O
acid NN NN O
position NN NN O
140 NN NN O
located NN NN O
within NN NN O
the NN NN O
putative NN NN O
5-phosphoribosyl-1-pyrophosphate NN NN O
( NN NN O
PRPP NN NN O
) NN NN O
binding NN NN O
region NN NN O
. NN NN O

Missense NN NN O
mutations NN NN O
in NN NN O
human NN NN O
HPRT NN NN B-Modifier
deficient NN NN I-Modifier
patients NN NN O
thus NN NN O
far NN NN O
reported NN NN O
tend NN NN O
to NN NN O
accumulate NN NN O
in NN NN O
this NN NN O
functionally NN NN O
active NN NN O
region NN NN O
. NN NN O

However NN NN O
, NN NN O
a NN NN O
comparison NN NN O
of NN NN O
the NN NN O
data NN NN O
suggested NN NN O
that NN NN O
both NN NN O
missense NN NN O
and NN NN O
synonymous NN NN O
mutations NN NN O
can NN NN O
occur NN NN O
at NN NN O
any NN NN O
coding NN NN O
sequence NN NN O
of NN NN O
the NN NN O
human NN NN O
germ NN NN O
line NN NN O
HPRT NN NN O
gene NN NN O
, NN NN O
but NN NN O
that NN NN O
a NN NN O
limited NN NN O
percentage NN NN O
of NN NN O
all NN NN O
the NN NN O
missense NN NN O
mutations NN NN O
cause NN NN O
disease NN NN O
. NN NN O

The NN NN O
probability NN NN O
that NN NN O
a NN NN O
mutation NN NN O
will NN NN O
cause NN NN O
disease NN NN O
tends NN NN O
to NN NN O
be NN NN O
higher NN NN O
when NN NN O
the NN NN O
missense NN NN O
mutation NN NN O
is NN NN O
within NN NN O
a NN NN O
functionally NN NN O
important NN NN O
sequence NN NN O
. NN NN O

. NN NN O

1301146 NN NN O
Characterisation NN NN O
of NN NN O
a NN NN O
new NN NN O
rare NN NN O
fragile NN NN O
site NN NN O
easily NN NN O
confused NN NN O
with NN NN O
the NN NN O
fragile NN NN B-SpecificDisease
X NN NN I-SpecificDisease
. NN NN O

A NN NN O
new NN NN O
fragile NN NN O
site NN NN O
( NN NN O
FRAXE NN NN O
) NN NN O
in NN NN O
Xq28 NN NN O
is NN NN O
described NN NN O
. NN NN O

It NN NN O
appears NN NN O
to NN NN O
be NN NN O
a NN NN O
typical NN NN O
folate NN NN O
sensitive NN NN O
fragile NN NN O
site NN NN O
. NN NN O

The NN NN O
fragile NN NN O
site NN NN O
is NN NN O
not NN NN O
associated NN NN O
with NN NN O
mental NN NN B-DiseaseClass
retardation NN NN I-DiseaseClass
, NN NN O
it NN NN O
does NN NN O
not NN NN O
give NN NN O
abnormal NN NN O
results NN NN O
when NN NN O
subjected NN NN O
to NN NN O
Southern NN NN O
analysis NN NN O
with NN NN O
probe NN NN O
pfxa3 NN NN O
which NN NN O
detects NN NN O
the NN NN O
unstable NN NN O
DNA NN NN O
sequence NN NN O
characteristic NN NN O
of NN NN O
fragile NN NN B-SpecificDisease
X NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

In NN NN O
situ NN NN O
hybridization NN NN O
mapping NN NN O
locates NN NN O
the NN NN O
fragile NN NN O
site NN NN O
between NN NN O
150 NN NN O
kb NN NN O
and NN NN O
600 NN NN O
kb NN NN O
distal NN NN O
to NN NN O
FRAXA NN NN O
. NN NN O

The NN NN O
distinction NN NN O
between NN NN O
the NN NN O
two NN NN O
fragile NN NN O
sites NN NN O
is NN NN O
important NN NN O
clinically NN NN O
since NN NN O
cytogenetic NN NN O
detection NN NN O
of NN NN O
FRAXE NN NN O
, NN NN O
without NN NN O
molecular NN NN O
analysis NN NN O
, NN NN O
could NN NN O
result NN NN O
in NN NN O
misdiagnosis NN NN O
of NN NN O
fragile NN NN B-SpecificDisease
X NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

. NN NN O

1301161 NN NN O
The NN NN O
Norrie NN NN B-Modifier
disease NN NN I-Modifier
gene NN NN O
maps NN NN O
to NN NN O
a NN NN O
150 NN NN O
kb NN NN O
region NN NN O
on NN NN O
chromosome NN NN O
Xp11.3 NN NN O
. NN NN O

Norrie NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
is NN NN O
a NN NN O
human NN NN O
X-linked NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
of NN NN O
unknown NN NN O
etiology NN NN O
characterized NN NN O
by NN NN O
congenital NN NN B-SpecificDisease
blindness NN NN I-SpecificDisease
, NN NN O
sensory NN NN B-SpecificDisease
neural NN NN I-SpecificDisease
deafness NN NN I-SpecificDisease
and NN NN O
mental NN NN B-DiseaseClass
retardation NN NN I-DiseaseClass
. NN NN O

This NN NN O
disease NN NN O
gene NN NN O
was NN NN O
previously NN NN O
linked NN NN O
to NN NN O
the NN NN O
DXS7 NN NN O
( NN NN O
L1 NN NN O
. NN NN O

28 NN NN O
) NN NN O
locus NN NN O
and NN NN O
the NN NN O
MAO NN NN O
genes NN NN O
in NN NN O
band NN NN O
Xp11 NN NN O
. NN NN O

3 NN NN O
3 NN NN O
. NN NN O

We NN NN O
report NN NN O
here NN NN O
fine NN NN O
physical NN NN O
mapping NN NN O
of NN NN O
the NN NN O
obligate NN NN O
region NN NN O
containing NN NN O
the NN NN O
Norrie NN NN B-Modifier
disease NN NN I-Modifier
gene NN NN O
( NN NN O
NDP NN NN O
) NN NN O
defined NN NN O
by NN NN O
a NN NN O
recombination NN NN O
and NN NN O
by NN NN O
the NN NN O
smallest NN NN O
submicroscopic NN NN O
chromosomal NN NN O
deletion NN NN O
associated NN NN O
with NN NN O
Norrie NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
identified NN NN O
to NN NN O
date NN NN O
. NN NN O

Analysis NN NN O
, NN NN O
using NN NN O
in NN NN O
addition NN NN O
two NN NN O
overlapping NN NN O
YAC NN NN O
clones NN NN O
from NN NN O
this NN NN O
region NN NN O
, NN NN O
allowed NN NN O
orientation NN NN O
of NN NN O
the NN NN O
MAOA NN NN O
and NN NN O
MAOB NN NN O
genes NN NN O
in NN NN O
a NN NN O
5-3-3-5 NN NN O
configuration NN NN O
. NN NN O

A NN NN O
recombination NN NN O
event NN NN O
between NN NN O
a NN NN O
( NN NN O
GT NN NN O
) NN NN O
n NN NN O
polymorphism NN NN O
in NN NN O
intron NN NN O
2 NN NN O
of NN NN O
the NN NN O
MAOB NN NN O
gene NN NN O
and NN NN O
the NN NN O
NDP NN NN O
locus NN NN O
, NN NN O
in NN NN O
a NN NN O
family NN NN O
previously NN NN O
reported NN NN O
to NN NN O
have NN NN O
a NN NN O
recombination NN NN O
between NN NN O
DXS7 NN NN O
and NN NN O
NDP NN NN O
, NN NN O
delineates NN NN O
a NN NN O
flanking NN NN O
marker NN NN O
telomeric NN NN O
to NN NN O
this NN NN O
disease NN NN O
gene NN NN O
. NN NN O

An NN NN O
anonymous NN NN O
DNA NN NN O
probe NN NN O
, NN NN O
dc12 NN NN O
, NN NN O
present NN NN O
in NN NN O
one NN NN O
of NN NN O
the NN NN O
YACs NN NN O
and NN NN O
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
a NN NN O
submicroscopic NN NN O
deletion NN NN O
which NN NN O
includes NN NN O
MAOA NN NN O
and NN NN O
MAOB NN NN O
but NN NN O
not NN NN O
L1 NN NN O
. NN NN O

28 NN NN O
, NN NN O
serves NN NN O
as NN NN O
a NN NN O
flanking NN NN O
marker NN NN O
centromeric NN NN O
to NN NN O
the NN NN O
disease NN NN O
gene NN NN O
. NN NN O

An NN NN O
Alu-PCR NN NN O
fragment NN NN O
from NN NN O
the NN NN O
right NN NN O
arm NN NN O
of NN NN O
the NN NN O
MAO NN NN O
YAC NN NN O
( NN NN O
YMAO NN NN O
. NN NN O

AluR NN NN O
) NN NN O
is NN NN O
not NN NN O
deleted NN NN O
in NN NN O
this NN NN O
patient NN NN O
and NN NN O
also NN NN O
delineates NN NN O
the NN NN O
centromeric NN NN O
extent NN NN O
of NN NN O
the NN NN O
obligate NN NN O
disease NN NN O
region NN NN O
. NN NN O

The NN NN O
apparent NN NN O
order NN NN O
of NN NN O
these NN NN O
loci NN NN O
is NN NN O
telomere NN NN O
. NN NN O

DXS7-MAOA-MAOB-NDP-dc12-YMAO NN NN O
DXS7-MAOA-MAOB-NDP-dc12-YMAO NN NN O
. NN NN O

AluR NN NN O
. NN NN O

centromere NN NN O
. NN NN O

Together NN NN O
these NN NN O
data NN NN O
define NN NN O
the NN NN O
obligate NN NN O
region NN NN O
containing NN NN O
the NN NN O
NDP NN NN O
gene NN NN O
to NN NN O
a NN NN O
chromosomal NN NN O
segment NN NN O
less NN NN O
than NN NN O
150 NN NN O
kb NN NN O
. NN NN O

1301187 NN NN O
Molecular NN NN O
basis NN NN O
of NN NN O
phenylketonuria NN NN B-SpecificDisease
and NN NN O
related NN NN O
hyperphenylalaninemias NN NN B-DiseaseClass
: NN NN O
mutations NN NN O
and NN NN O
polymorphisms NN NN O
in NN NN O
the NN NN O
human NN NN O
phenylalanine NN NN O
hydroxylase NN NN O
gene NN NN O
. NN NN O

Mutations NN NN O
in NN NN O
the NN NN O
human NN NN O
phenylalanine NN NN O
hydroxylase NN NN O
gene NN NN O
producing NN NN O
phenylketonuria NN NN B-SpecificDisease
or NN NN O
hyperphenylalaninemia NN NN B-DiseaseClass
have NN NN O
now NN NN O
been NN NN O
identified NN NN O
in NN NN O
many NN NN O
patients NN NN O
from NN NN O
various NN NN O
ethnic NN NN O
groups NN NN O
. NN NN O

These NN NN O
mutations NN NN O
all NN NN O
exhibit NN NN O
a NN NN O
high NN NN O
degree NN NN O
of NN NN O
association NN NN O
with NN NN O
specific NN NN O
restriction NN NN O
fragment-length NN NN O
polymorphism NN NN O
haplotypes NN NN O
at NN NN O
the NN NN O
PAH NN NN O
locus NN NN O
. NN NN O

About NN NN O
50 NN NN O
of NN NN O
these NN NN O
mutations NN NN O
are NN NN O
single-base NN NN O
substitutions NN NN O
, NN NN O
including NN NN O
six NN NN O
nonsense NN NN O
mutations NN NN O
and NN NN O
eight NN NN O
splicing NN NN O
mutations NN NN O
, NN NN O
with NN NN O
the NN NN O
remainder NN NN O
being NN NN O
missense NN NN O
mutations NN NN O
. NN NN O

One NN NN O
splicing NN NN O
mutation NN NN O
results NN NN O
in NN NN O
a NN NN O
3 NN NN O
amino NN NN O
acid NN NN O
in-frame NN NN O
insertion NN NN O
. NN NN O

Two NN NN O
or NN NN O
3 NN NN O
large NN NN O
deletions NN NN O
, NN NN O
2 NN NN O
single NN NN O
codon NN NN O
deletions NN NN O
, NN NN O
and NN NN O
2 NN NN O
single NN NN O
base NN NN O
deletions NN NN O
have NN NN O
been NN NN O
found NN NN O
. NN NN O

Twelve NN NN O
of NN NN O
the NN NN O
missense NN NN O
mutations NN NN O
apparently NN NN O
result NN NN O
from NN NN O
the NN NN O
methylation NN NN O
and NN NN O
subsequent NN NN O
deamination NN NN O
of NN NN O
highly NN NN O
mutagenic NN NN O
CpG NN NN O
dinucleotides NN NN O
. NN NN O

Recurrent NN NN O
mutation NN NN O
has NN NN O
been NN NN O
observed NN NN O
at NN NN O
several NN NN O
of NN NN O
these NN NN O
sites NN NN O
, NN NN O
producing NN NN O
associations NN NN O
with NN NN O
different NN NN O
haplotypes NN NN O
in NN NN O
different NN NN O
populations NN NN O
. NN NN O

About NN NN O
half NN NN O
of NN NN O
all NN NN O
missense NN NN O
mutations NN NN O
have NN NN O
been NN NN O
examined NN NN O
by NN NN O
in NN NN O
vitro NN NN O
expression NN NN O
analysis NN NN O
, NN NN O
and NN NN O
a NN NN O
significant NN NN O
correlation NN NN O
has NN NN O
been NN NN O
observed NN NN O
between NN NN O
residual NN NN O
PAH NN NN O
activity NN NN O
and NN NN O
disease NN NN O
phenotype NN NN O
. NN NN O

Since NN NN O
continuing NN NN O
advances NN NN O
in NN NN O
molecular NN NN O
methodologies NN NN O
have NN NN O
dramatically NN NN O
accelerated NN NN O
the NN NN O
rate NN NN O
in NN NN O
which NN NN O
new NN NN O
mutations NN NN O
are NN NN O
being NN NN O
identified NN NN O
and NN NN O
characterized NN NN O
, NN NN O
this NN NN O
register NN NN O
of NN NN O
mutations NN NN O
will NN NN O
be NN NN O
updated NN NN O
periodically NN NN O
. NN NN O

. NN NN O

1301189 NN NN O
A NN NN O
glycine250 NN NN O
-- NN NN O
aspartate NN NN O
substitution NN NN O
in NN NN O
the NN NN O
alpha-subunit NN NN O
of NN NN O
hexosaminidase NN NN O
A NN NN O
causes NN NN O
juvenile-onset NN NN O
Tay-Sachs NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
in NN NN O
a NN NN O
Lebanese-Canadian NN NN O
family NN NN O
. NN NN O

The NN NN O
mutation NN NN O
causing NN NN O
juvenile NN NN O
Tay-Sachs NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
TSD NN NN B-SpecificDisease
) NN NN O
in NN NN O
two NN NN O
sibs NN NN O
of NN NN O
Lebanese-Maronite NN NN O
origin NN NN O
is NN NN O
described NN NN O
. NN NN O

An NN NN O
mRNA-containing NN NN O
extract NN NN O
of NN NN O
cultured NN NN O
fibroblasts NN NN O
obtained NN NN O
from NN NN O
one NN NN O
of NN NN O
the NN NN O
probands NN NN O
was NN NN O
used NN NN O
as NN NN O
a NN NN O
template NN NN O
to NN NN O
amplify NN NN O
the NN NN O
coding NN NN O
sequence NN NN O
of NN NN O
the NN NN O
hexosaminidase NN NN O
A NN NN O
( NN NN O
Hex NN NN O
A NN NN O
) NN NN O
alpha-subunit NN NN O
. NN NN O

Sequencing NN NN O
of NN NN O
amplified NN NN O
cDNA NN NN O
fragments NN NN O
revealed NN NN O
a NN NN O
single NN NN O
alteration NN NN O
, NN NN O
guanine NN NN O
to NN NN O
adenine NN NN O
at NN NN O
nt NN NN O
749 NN NN O
creating NN NN O
a NN NN O
G250D NN NN O
mutation NN NN O
. NN NN O

The NN NN O
mutation NN NN O
introduces NN NN O
a NN NN O
new NN NN O
recognition NN NN O
site NN NN O
for NN NN O
the NN NN O
restriction NN NN O
enzyme NN NN O
Eco NN NN O
RV NN NN O
, NN NN O
permitting NN NN O
identification NN NN O
of NN NN O
heterozygotes NN NN O
for NN NN O
this NN NN O
allele NN NN O
following NN NN O
PCR NN NN O
amplification NN NN O
and NN NN O
Eco NN NN O
RV NN NN O
digestion NN NN O
of NN NN O
exon NN NN O
7 NN NN O
sequences NN NN O
from NN NN O
genomic NN NN O
DNA NN NN O
templates NN NN O
. NN NN O

In NN NN O
order NN NN O
to NN NN O
test NN NN O
the NN NN O
effect NN NN O
of NN NN O
this NN NN O
substitution NN NN O
, NN NN O
an NN NN O
in NN NN O
vitro NN NN O
mutagenized NN NN O
cDNA NN NN O
construct NN NN O
was NN NN O
introduced NN NN O
into NN NN O
a NN NN O
mammalian NN NN O
expression NN NN O
vector NN NN O
and NN NN O
transfected NN NN O
into NN NN O
monkey NN NN O
Cos-1 NN NN O
cells NN NN O
separately NN NN O
or NN NN O
along NN NN O
with NN NN O
a NN NN O
beta-cDNA NN NN O
expression NN NN O
vector NN NN O
. NN NN O

When NN NN O
the NN NN O
mutant NN NN O
alpha-cDNA NN NN O
was NN NN O
the NN NN O
only NN NN O
gene NN NN O
introduced NN NN O
into NN NN O
COS NN NN O
cells NN NN O
no NN NN O
enzymatic NN NN O
activity NN NN O
above NN NN O
endogenous NN NN O
COS NN NN O
cell NN NN O
activity NN NN O
was NN NN O
detected NN NN O
. NN NN O

Cotransfection NN NN O
of NN NN O
normal NN NN O
alpha-cDNA NN NN O
and NN NN O
beta-cDNA NN NN O
followed NN NN O
by NN NN O
immunoprecipitation NN NN O
of NN NN O
human NN NN O
Hex NN NN O
A NN NN O
resulted NN NN O
in NN NN O
20-fold NN NN O
increase NN NN O
in NN NN O
the NN NN O
ratio NN NN O
between NN NN O
positive NN NN O
and NN NN O
negative NN NN O
( NN NN O
mock NN NN O
transfection NN NN O
) NN NN O
control NN NN O
values NN NN O
. NN NN O

This NN NN O
allowed NN NN O
the NN NN O
detection NN NN O
of NN NN O
some NN NN O
residual NN NN O
activity NN NN O
( NN NN O
12 NN NN O
% NN NN O
of NN NN O
the NN NN O
positive NN NN O
control NN NN O
) NN NN O
when NN NN O
the NN NN O
mutant NN NN O
alpha-cDNA NN NN O
replaced NN NN O
its NN NN O
wild-type NN NN O
counterpart NN NN O
. NN NN O

The NN NN O
predicted NN NN O
protein NN NN O
environment NN NN O
in NN NN O
which NN NN O
the NN NN O
mutation NN NN O
occurs NN NN O
is NN NN O
compared NN NN O
to NN NN O
that NN NN O
of NN NN O
the NN NN O
adult-onset NN NN O
Tay-Sachs NN NN B-Modifier
disease NN NN I-Modifier
mutation NN NN O
caused NN NN O
by NN NN O
a NN NN O
Gly269 NN NN O
-- NN NN O
Ser NN NN O
substitution NN NN O
in NN NN O
exon NN NN O
7 NN NN O
. NN NN O

( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
. NN NN O

1301190 NN NN O
Novel NN NN O
Tay-Sachs NN NN B-Modifier
disease NN NN I-Modifier
mutations NN NN O
from NN NN O
China NN NN O
. NN NN O

We NN NN O
describe NN NN O
three NN NN O
HEXA NN NN O
mutations NN NN O
associated NN NN O
with NN NN O
infantile NN NN O
Tay-Sachs NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
TSD NN NN B-SpecificDisease
) NN NN O
in NN NN O
three NN NN O
unrelated NN NN O
nonconsanguineous NN NN O
Chinese NN NN O
families NN NN O
. NN NN O

Novel NN NN O
mutations NN NN O
were NN NN O
found NN NN O
in NN NN O
two NN NN O
of NN NN O
these NN NN O
families NN NN O
. NN NN O

The NN NN O
third NN NN O
is NN NN O
a NN NN O
previously NN NN O
reported NN NN O
mutation NN NN O
( NN NN O
G NN NN O
-- NN NN O
A NN NN O
transition NN NN O
at NN NN O
nt NN NN O
1444 NN NN O
) NN NN O
( NN NN O
Nakano NN NN O
et NN NN O
al NN NN O
. NN NN O

, NN NN O
1988 NN NN O
) NN NN O
. NN NN O

Direct NN NN O
sequencing NN NN O
of NN NN O
PCR NN NN O
products NN NN O
identified NN NN O
a NN NN O
novel NN NN O
insertion NN NN O
of NN NN O
an NN NN O
A NN NN O
after NN NN O
nt NN NN O
547 NN NN O
in NN NN O
family NN NN O
1 NN NN O
. NN NN O

This NN NN O
change NN NN O
generates NN NN O
an NN NN O
early NN NN O
termination NN NN O
codon NN NN O
6 NN NN O
bp NN NN O
downstream NN NN O
from NN NN O
the NN NN O
insertion NN NN O
site NN NN O
. NN NN O

Allele-specific NN NN O
oligonucleotide NN NN O
hybridization NN NN O
confirmed NN NN O
homozygosity NN NN O
in NN NN O
the NN NN O
proband NN NN O
. NN NN O

Single NN NN O
strand NN NN O
conformational NN NN O
polymorphism NN NN O
analysis NN NN O
and NN NN O
direct NN NN O
sequencing NN NN O
of NN NN O
amplified NN NN O
exon NN NN O
13 NN NN O
revealed NN NN O
a NN NN O
T NN NN O
-- NN NN O
C NN NN O
transition NN NN O
at NN NN O
nt NN NN O
1453 NN NN O
with NN NN O
the NN NN O
corresponding NN NN O
amino NN NN O
acid NN NN O
substitution NN NN O
W485R NN NN O
in NN NN O
the NN NN O
second NN NN O
family NN NN O
. NN NN O

This NN NN O
mutation NN NN O
creates NN NN O
an NN NN O
Fnu4HI NN NN O
restriction NN NN O
site NN NN O
. NN NN O

The NN NN O
proband NN NN O
is NN NN O
homozygous NN NN O
for NN NN O
this NN NN O
allele NN NN O
. NN NN O

When NN NN O
the NN NN O
site-specific NN NN O
mutagenized NN NN O
alpha NN NN O
cDNA NN NN O
carrying NN NN O
the NN NN O
T NN NN O
-- NN NN O
C NN NN O
transition NN NN O
at NN NN O
nt NN NN O
1453 NN NN O
was NN NN O
expressed NN NN O
in NN NN O
COS NN NN O
1 NN NN O
cells NN NN O
hexosaminidase NN NN O
S NN NN O
activity NN NN O
was NN NN O
not NN NN O
detectable NN NN O
above NN NN O
background NN NN O
. NN NN O

A NN NN O
G NN NN O
-- NN NN O
A NN NN O
transition NN NN O
at NN NN O
nt NN NN O
1444 NN NN O
( NN NN O
exon NN NN O
13 NN NN O
) NN NN O
corresponding NN NN O
to NN NN O
the NN NN O
E482K NN NN O
substitution NN NN O
was NN NN O
found NN NN O
in NN NN O
the NN NN O
third NN NN O
family NN NN O
. NN NN O

This NN NN O
mutation NN NN O
occurs NN NN O
at NN NN O
a NN NN O
CpG NN NN O
dinucleotide NN NN O
. NN NN O

It NN NN O
has NN NN O
been NN NN O
reported NN NN O
in NN NN O
an NN NN O
Italian NN NN O
TSD NN NN B-Modifier
proband NN NN O
and NN NN O
causes NN NN O
defective NN NN O
intracellular NN NN O
transport NN NN O
of NN NN O
the NN NN O
alpha-subunit NN NN O
from NN NN O
the NN NN O
rough NN NN O
endoplasmic NN NN O
reticulum NN NN O
to NN NN O
the NN NN O
Golgi NN NN O
apparatus NN NN O
. NN NN O

1301200 NN NN O
Two NN NN O
missense NN NN O
mutations NN NN O
causing NN NN O
mild NN NN O
hyperphenylalaninemia NN NN B-DiseaseClass
associated NN NN O
with NN NN O
DNA NN NN O
haplotype NN NN O
12 NN NN O
. NN NN O

The NN NN O
genetic NN NN B-DiseaseClass
defects NN NN I-DiseaseClass
responsible NN NN O
for NN NN O
most NN NN O
phenylketonuria NN NN B-SpecificDisease
( NN NN O
PKU NN NN B-SpecificDisease
) NN NN O
and NN NN O
hyperphenylalaninemia NN NN B-DiseaseClass
( NN NN O
HPA NN NN B-DiseaseClass
) NN NN O
cases NN NN O
are NN NN O
located NN NN O
in NN NN O
the NN NN O
phenylalanine NN NN O
hydroxylase NN NN O
( NN NN O
PAH NN NN O
) NN NN O
gene NN NN O
. NN NN O

Approximately NN NN O
50-60 NN NN O
mutations NN NN O
have NN NN O
been NN NN O
reported NN NN O
in NN NN O
Caucasians NN NN O
and NN NN O
are NN NN O
reflected NN NN O
in NN NN O
a NN NN O
wide NN NN O
range NN NN O
of NN NN O
clinical NN NN O
severities NN NN O
. NN NN O

Most NN NN O
mutations NN NN O
are NN NN O
linked NN NN O
to NN NN O
specific NN NN O
haplotypes NN NN O
, NN NN O
as NN NN O
defined NN NN O
by NN NN O
eight NN NN O
polymorphic NN NN O
restriction NN NN O
sites NN NN O
in NN NN O
the NN NN O
PAH NN NN O
gene NN NN O
. NN NN O

We NN NN O
hypothesized NN NN O
that NN NN O
there NN NN O
is NN NN O
at NN NN O
least NN NN O
one NN NN O
mild NN NN O
mutation NN NN O
linked NN NN O
to NN NN O
haplotype NN NN O
12 NN NN O
in NN NN O
the NN NN O
Swedish NN NN O
PKU NN NN B-Modifier
/ NN NN O
HPA NN NN B-Modifier
population NN NN O
, NN NN O
since NN NN O
7 NN NN O
of NN NN O
8 NN NN O
patients NN NN O
carrying NN NN O
haplotype NN NN O
12 NN NN O
had NN NN O
mild NN NN O
HPA NN NN B-DiseaseClass
. NN NN O

Sequence NN NN O
analysis NN NN O
revealed NN NN O
a NN NN O
C-to-G NN NN O
transversion NN NN O
at NN NN O
the NN NN O
second NN NN O
base NN NN O
of NN NN O
codon NN NN O
322 NN NN O
, NN NN O
resulting NN NN O
in NN NN O
a NN NN O
substitution NN NN O
of NN NN O
glycine NN NN O
for NN NN O
alanine NN NN O
, NN NN O
in NN NN O
four NN NN O
mutant NN NN O
haplotype NN NN O
12 NN NN O
genes NN NN O
, NN NN O
and NN NN O
a NN NN O
G-to-A NN NN O
transition NN NN O
at NN NN O
the NN NN O
second NN NN O
base NN NN O
of NN NN O
codon NN NN O
408 NN NN O
, NN NN O
resulting NN NN O
in NN NN O
a NN NN O
substitution NN NN O
of NN NN O
glutamine NN NN O
for NN NN O
arginine NN NN O
, NN NN O
in NN NN O
another NN NN O
three NN NN O
mutant NN NN O
haplotype NN NN O
12 NN NN O
genes NN NN O
. NN NN O

These NN NN O
mutations NN NN O
segregated NN NN O
with NN NN O
mutant NN NN O
haplotype NN NN O
12 NN NN O
alleles NN NN O
in NN NN O
nuclear NN NN O
families NN NN O
but NN NN O
were NN NN O
not NN NN O
present NN NN O
on NN NN O
normal NN NN O
or NN NN O
other NN NN O
mutant NN NN O
alleles NN NN O
. NN NN O

Both NN NN O
mutations NN NN O
were NN NN O
tested NN NN O
in NN NN O
a NN NN O
eukaryotic NN NN O
expression NN NN O
system NN NN O
in NN NN O
which NN NN O
enzyme NN NN O
activities NN NN O
of NN NN O
different NN NN O
mutant NN NN O
PAH NN NN O
enzymes NN NN O
reflect NN NN O
the NN NN O
relative NN NN O
severities NN NN O
of NN NN O
the NN NN O
mutations NN NN O
, NN NN O
although NN NN O
these NN NN O
in NN NN O
vitro NN NN O
activities NN NN O
can NN NN O
not NN NN O
be NN NN O
translated NN NN O
directly NN NN O
into NN NN O
in NN NN O
vivo NN NN O
hepatic NN NN O
activities NN NN O
. NN NN O

The NN NN O
A322G NN NN O
mutant NN NN O
PAH NN NN O
had NN NN O
about NN NN O
75 NN NN O
% NN NN O
and NN NN O
the NN NN O
R408Q NN NN O
mutant NN NN O
PAH NN NN O
about NN NN O
55 NN NN O
% NN NN O
of NN NN O
the NN NN O
wild-type NN NN O
PAH NN NN O
enzyme NN NN O
activity NN NN O
. NN NN O

These NN NN O
in NN NN O
vitro NN NN O
activities NN NN O
are NN NN O
the NN NN O
highest NN NN O
reported NN NN O
for NN NN O
mutant NN NN O
PAH NN NN O
enzymes NN NN O
produced NN NN O
in NN NN O
the NN NN O
same NN NN O
expression NN NN O
system NN NN O
. NN NN O

( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
. NN NN O

1301201 NN NN O
In NN NN O
vitro NN NN O
and NN NN O
in NN NN O
vivo NN NN O
correlations NN NN O
for NN NN O
I65T NN NN O
and NN NN O
M1V NN NN O
mutations NN NN O
at NN NN O
the NN NN O
phenylalanine NN NN O
hydroxylase NN NN O
locus NN NN O
. NN NN O

Mutations NN NN O
at NN NN O
the NN NN O
phenylalanine NN NN O
hydroxylase NN NN O
( NN NN O
PAH NN NN O
) NN NN O
locus NN NN O
are NN NN O
the NN NN O
major NN NN O
cause NN NN O
of NN NN O
hyperphenylalaninemia NN NN B-DiseaseClass
. NN NN O

We NN NN O
have NN NN O
previously NN NN O
described NN NN O
four NN NN O
mutations NN NN O
( NN NN O
M1V NN NN O
, NN NN O
IVS12nt1 NN NN O
, NN NN O
R408W NN NN O
, NN NN O
and NN NN O
S349P NN NN O
) NN NN O
at NN NN O
the NN NN O
PAH NN NN O
locus NN NN O
in NN NN O
French NN NN O
Canadians NN NN O
with NN NN O
ancestry NN NN O
in NN NN O
eastern NN NN O
Quebec NN NN O
. NN NN O

Here NN NN O
we NN NN O
report NN NN O
( NN NN O
1 NN NN O
) NN NN O
identification NN NN O
of NN NN O
another NN NN O
mutation NN NN O
, NN NN O
on NN NN O
a NN NN O
haplotype NN NN O
9 NN NN O
chromosome NN NN O
, NN NN O
which NN NN O
converts NN NN O
codon NN NN O
65 NN NN O
from NN NN O
isoleucine NN NN O
( NN NN O
ATT NN NN O
) NN NN O
to NN NN O
threonine NN NN O
( NN NN O
ACT NN NN O
) NN NN O
, NN NN O
( NN NN O
2 NN NN O
) NN NN O
expression NN NN O
analysis NN NN O
of NN NN O
the NN NN O
I65T NN NN O
mutation NN NN O
in NN NN O
COS NN NN O
cells NN NN O
demonstrating NN NN O
75 NN NN O
% NN NN O
loss NN NN O
of NN NN O
both NN NN O
immunoreactive NN NN O
protein NN NN O
and NN NN O
enzyme NN NN O
activity NN NN O
, NN NN O
and NN NN O
( NN NN O
3 NN NN O
) NN NN O
expression NN NN O
analysis NN NN O
of NN NN O
the NN NN O
most NN NN O
prevalent NN NN O
PKU NN NN B-Modifier
allele NN NN O
( NN NN O
M1V NN NN O
) NN NN O
in NN NN O
eastern NN NN O
Quebec NN NN O
, NN NN O
showing NN NN O
nondetectable NN NN O
levels NN NN O
of NN NN O
PAH NN NN O
protein NN NN O
and NN NN O
activity NN NN O
, NN NN O
a NN NN O
finding NN NN O
compatible NN NN O
with NN NN O
a NN NN O
mutation NN NN O
in NN NN O
the NN NN O
translation NN NN O
initiation NN NN O
codon NN NN O
. NN NN O

Homozygosity NN NN O
for NN NN O
M1V NN NN O
and NN NN O
codominant NN NN O
inheritance NN NN O
of NN NN O
I65T NN NN O
/ NN NN O
R408W NN NN O
were NN NN O
both NN NN O
associated NN NN O
with NN NN O
classical NN NN B-SpecificDisease
phenylketonuria NN NN I-SpecificDisease
. NN NN O

. NN NN O

1301937 NN NN O
Molecular NN NN O
basis NN NN O
of NN NN O
hexosaminidase NN NN B-SpecificDisease
A NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
and NN NN O
pseudodeficiency NN NN O
in NN NN O
the NN NN O
Berks NN NN O
County NN NN O
Pennsylvania NN NN O
Dutch NN NN O
. NN NN O

Following NN NN O
the NN NN O
birth NN NN O
of NN NN O
two NN NN O
infants NN NN O
with NN NN O
Tay-Sachs NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
TSD NN NN B-SpecificDisease
) NN NN O
, NN NN O
a NN NN O
non-Jewish NN NN O
, NN NN O
Pennsylvania NN NN O
Dutch NN NN O
kindred NN NN O
was NN NN O
screened NN NN O
for NN NN O
TSD NN NN B-Modifier
carriers NN NN O
using NN NN O
the NN NN O
biochemical NN NN O
assay NN NN O
. NN NN O

A NN NN O
high NN NN O
frequency NN NN O
of NN NN O
individuals NN NN O
who NN NN O
appeared NN NN O
to NN NN O
be NN NN O
TSD NN NN B-Modifier
heterozygotes NN NN O
was NN NN O
detected NN NN O
( NN NN O
Kelly NN NN O
et NN NN O
al NN NN O
. NN NN O

, NN NN O
1975 NN NN O
) NN NN O
. NN NN O

Clinical NN NN O
and NN NN O
biochemical NN NN O
evidence NN NN O
suggested NN NN O
that NN NN O
the NN NN O
increased NN NN O
carrier NN NN O
frequency NN NN O
was NN NN O
due NN NN O
to NN NN O
at NN NN O
least NN NN O
two NN NN O
altered NN NN O
alleles NN NN O
for NN NN O
the NN NN O
hexosaminidase NN NN O
A NN NN O
alpha-subunit NN NN O
. NN NN O

We NN NN O
now NN NN O
report NN NN O
two NN NN O
mutant NN NN O
alleles NN NN O
in NN NN O
this NN NN O
Pennsylvania NN NN O
Dutch NN NN O
kindred NN NN O
, NN NN O
and NN NN O
one NN NN O
polymorphism NN NN O
. NN NN O

One NN NN O
allele NN NN O
, NN NN O
reported NN NN O
originally NN NN O
in NN NN O
a NN NN O
French NN NN O
TSD NN NN B-Modifier
patient NN NN O
( NN NN O
Akli NN NN O
et NN NN O
al NN NN O
. NN NN O

, NN NN O
1991 NN NN O
) NN NN O
, NN NN O
is NN NN O
a NN NN O
GT NN NN O
-- NN NN O
AT NN NN O
transition NN NN O
at NN NN O
the NN NN O
donor NN NN O
splice-site NN NN O
of NN NN O
intron NN NN O
9 NN NN O
. NN NN O

The NN NN O
second NN NN O
, NN NN O
a NN NN O
C NN NN O
-- NN NN O
T NN NN O
transition NN NN O
at NN NN O
nucleotide NN NN O
739 NN NN O
( NN NN O
Arg247Trp NN NN O
) NN NN O
, NN NN O
has NN NN O
been NN NN O
shown NN NN O
by NN NN O
Triggs-Raine NN NN O
et NN NN O
al NN NN O
. NN NN O

( NN NN O
1992 NN NN O
) NN NN O
to NN NN O
be NN NN O
a NN NN O
clinically NN NN O
benign NN NN O
`` NN NN O
pseudodeficient NN NN O
`` NN NN O
allele NN NN O
associated NN NN O
with NN NN O
reduced NN NN O
enzyme NN NN O
activity NN NN O
against NN NN O
artificial NN NN O
substrate NN NN O
. NN NN O

Finally NN NN O
, NN NN O
a NN NN O
polymorphism NN NN O
[ NN NN O
G NN NN O
-- NN NN O
A NN NN O
( NN NN O
759 NN NN O
) NN NN O
] NN NN O
, NN NN O
which NN NN O
leaves NN NN O
valine NN NN O
at NN NN O
codon NN NN O
253 NN NN O
unchanged NN NN O
, NN NN O
is NN NN O
described NN NN O
. NN NN O

1301938 NN NN O
A NN NN O
mutation NN NN O
common NN NN O
in NN NN O
non-Jewish NN NN O
Tay-Sachs NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
: NN NN O
frequency NN NN O
and NN NN O
RNA NN NN O
studies NN NN O
. NN NN O

Tay-Sachs NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
TSD NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
genetic NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
resulting NN NN O
from NN NN O
mutation NN NN O
of NN NN O
the NN NN O
HEXA NN NN O
gene NN NN O
encoding NN NN O
the NN NN O
alpha-subunit NN NN O
of NN NN O
the NN NN O
lysosomal NN NN O
enzyme NN NN O
, NN NN O
beta-N-acetylhexosaminidase NN NN O
A NN NN O
( NN NN O
Hex NN NN O
A NN NN O
) NN NN O
. NN NN O

We NN NN O
have NN NN O
discovered NN NN O
that NN NN O
a NN NN O
Tay-Sachs NN NN B-Modifier
mutation NN NN O
, NN NN O
IVS-9 NN NN O
+ NN NN O
1 NN NN O
G NN NN O
-- NN NN O
A NN NN O
, NN NN O
first NN NN O
detected NN NN O
by NN NN O
Akli NN NN O
et NN NN O
al NN NN O
. NN NN O

( NN NN O
Genomics NN NN O
11 NN NN O
124-134 NN NN O
, NN NN O
1991 NN NN O
) NN NN O
, NN NN O
is NN NN O
a NN NN O
common NN NN O
disease NN NN O
allele NN NN O
in NN NN O
non-Jewish NN NN O
Caucasians NN NN O
( NN NN O
10 NN NN O
/ NN NN O
58 NN NN O
alleles NN NN O
examined NN NN O
) NN NN O
. NN NN O

A NN NN O
PCR-based NN NN O
diagnostic NN NN O
test NN NN O
, NN NN O
which NN NN O
detects NN NN O
an NN NN O
NlaIII NN NN O
site NN NN O
generated NN NN O
by NN NN O
the NN NN O
mutation NN NN O
, NN NN O
revealed NN NN O
a NN NN O
frequency NN NN O
among NN NN O
enzyme-defined NN NN O
carriers NN NN O
of NN NN O
9 NN NN O
/ NN NN O
64 NN NN O
( NN NN O
14 NN NN O
% NN NN O
) NN NN O
. NN NN O

Most NN NN O
of NN NN O
those NN NN O
carrying NN NN O
the NN NN O
allele NN NN O
trace NN NN O
their NN NN O
origins NN NN O
to NN NN O
the NN NN O
United NN NN O
Kingdom NN NN O
, NN NN O
Ireland NN NN O
, NN NN O
or NN NN O
Western NN NN O
Europe NN NN O
. NN NN O

It NN NN O
was NN NN O
not NN NN O
identified NN NN O
among NN NN O
12 NN NN O
Black NN NN O
American NN NN O
TSD NN NN B-Modifier
alleles NN NN O
or NN NN O
in NN NN O
any NN NN O
of NN NN O
18 NN NN O
Ashkenazi NN NN O
Jewish NN NN O
, NN NN O
enzyme-defined NN NN O
carriers NN NN O
who NN NN O
did NN NN O
not NN NN O
carry NN NN O
any NN NN O
of NN NN O
the NN NN O
mutations NN NN O
common NN NN O
to NN NN O
this NN NN O
population NN NN O
. NN NN O

No NN NN O
normally NN NN O
spliced NN NN O
RNA NN NN O
was NN NN O
detected NN NN O
in NN NN O
PCR NN NN O
products NN NN O
generated NN NN O
from NN NN O
reverse NN NN O
transcription NN NN O
of NN NN O
RNA NN NN O
carrying NN NN O
the NN NN O
IVS-9 NN NN O
mutation NN NN O
. NN NN O

Instead NN NN O
, NN NN O
the NN NN O
low NN NN O
levels NN NN O
of NN NN O
mRNA NN NN O
from NN NN O
this NN NN O
allele NN NN O
were NN NN O
comprised NN NN O
of NN NN O
aberrant NN NN O
species NN NN O
resulting NN NN O
from NN NN O
the NN NN O
use NN NN O
of NN NN O
either NN NN O
of NN NN O
two NN NN O
cryptic NN NN O
donor NN NN O
sites NN NN O
, NN NN O
one NN NN O
truncating NN NN O
exon NN NN O
9 NN NN O
and NN NN O
the NN NN O
other NN NN O
within NN NN O
IVS-9 NN NN O
, NN NN O
spliced NN NN O
to NN NN O
exon NN NN O
10 NN NN O
. NN NN O

Numerous NN NN O
additional NN NN O
splice NN NN O
products NN NN O
were NN NN O
detected NN NN O
, NN NN O
most NN NN O
involving NN NN O
skipping NN NN O
of NN NN O
one NN NN O
or NN NN O
more NN NN O
surrounding NN NN O
exons NN NN O
. NN NN O

Together NN NN O
with NN NN O
a NN NN O
recently NN NN O
identified NN NN O
allele NN NN O
responsible NN NN O
for NN NN O
Hex NN NN O
A NN NN O
pseudodeficiency NN NN O
( NN NN O
Triggs-Raine NN NN O
et NN NN O
al NN NN O
. NN NN O

Am NN NN O
J NN NN O
Hum NN NN O
Genet NN NN O
, NN NN O
1992 NN NN O
) NN NN O
, NN NN O
these NN NN O
two NN NN O
alleles NN NN O
accounted NN NN O
for NN NN O
almost NN NN O
50 NN NN O
% NN NN O
( NN NN O
29 NN NN O
/ NN NN O
64 NN NN O
) NN NN O
of NN NN O
TSD NN NN B-Modifier
or NN NN O
carrier NN NN O
alleles NN NN O
ascertained NN NN O
by NN NN O
enzyme NN NN O
screening NN NN O
tests NN NN O
in NN NN O
non-Jewish NN NN O
Caucasians NN NN O
. NN NN O

. NN NN O

1302003 NN NN O
Aberrant NN NN O
splicing NN NN O
of NN NN O
the NN NN O
CHM NN NN B-Modifier
gene NN NN O
is NN NN O
a NN NN O
significant NN NN O
cause NN NN O
of NN NN O
choroideremia NN NN B-SpecificDisease
. NN NN O

Choroideremia NN NN B-SpecificDisease
( NN NN O
CHM NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
X-linked NN NN B-DiseaseClass
progressive NN NN I-DiseaseClass
degeneration NN NN I-DiseaseClass
of NN NN I-DiseaseClass
the NN NN I-DiseaseClass
choroid NN NN I-DiseaseClass
and NN NN I-DiseaseClass
retina NN NN I-DiseaseClass
. NN NN O

12 NN NN O
% NN NN O
of NN NN O
unrelated NN NN O
male NN NN O
patients NN NN O
carry NN NN O
deletions NN NN O
of NN NN O
the NN NN O
partially NN NN O
cloned NN NN O
CHM NN NN B-Modifier
gene NN NN O
. NN NN O

In NN NN O
Finland NN NN O
, NN NN O
there NN NN O
are NN NN O
more NN NN O
than NN NN O
120 NN NN O
living NN NN O
CHM NN NN B-Modifier
patients NN NN O
belonging NN NN O
to NN NN O
eight NN NN O
apparently NN NN O
unrelated NN NN O
pedigrees NN NN O
. NN NN O

Molecular NN NN O
deletions NN NN O
involving NN NN O
the NN NN O
CHM NN NN B-Modifier
gene NN NN O
have NN NN O
been NN NN O
detected NN NN O
in NN NN O
three NN NN O
families NN NN O
. NN NN O

We NN NN O
have NN NN O
screened NN NN O
the NN NN O
remaining NN NN O
five NN NN O
families NN NN O
for NN NN O
point NN NN O
mutations NN NN O
. NN NN O

In NN NN O
one NN NN O
large NN NN O
family NN NN O
a NN NN O
single NN NN O
nucleotide NN NN O
( NN NN O
T NN NN O
) NN NN O
insertion NN NN O
into NN NN O
the NN NN O
donor NN NN O
splice NN NN O
site NN NN O
of NN NN O
exon NN NN O
C NN NN O
leads NN NN O
to NN NN O
two NN NN O
aberrantly NN NN O
spliced NN NN O
mRNAs NN NN O
both NN NN O
producing NN NN O
a NN NN O
premature NN NN O
stop NN NN O
codon NN NN O
. NN NN O

The NN NN O
mutation NN NN O
can NN NN O
be NN NN O
assayed NN NN O
easily NN NN O
by NN NN O
amplification NN NN O
and NN NN O
digestion NN NN O
with NN NN O
Msel NN NN O
. NN NN O

Our NN NN O
findings NN NN O
provide NN NN O
additional NN NN O
evidence NN NN O
for NN NN O
the NN NN O
pathogenetic NN NN O
role NN NN O
of NN NN O
CHM NN NN B-Modifier
mutations NN NN O
and NN NN O
provide NN NN O
a NN NN O
diagnostic NN NN O
tool NN NN O
for NN NN O
one NN NN O
fifth NN NN O
of NN NN O
the NN NN O
worlds NN NN O
known NN NN O
CHM NN NN B-Modifier
patients NN NN O
. NN NN O

. NN NN O

1302008 NN NN O
Germline NN NN O
intronic NN NN O
and NN NN O
exonic NN NN O
mutations NN NN O
in NN NN O
the NN NN O
Wilms NN NN B-Modifier
' NN NN I-Modifier
tumour NN NN I-Modifier
gene NN NN O
( NN NN O
WT1 NN NN O
) NN NN O
affecting NN NN O
urogenital NN NN O
development NN NN O
. NN NN O

Denys-Drash NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
is NN NN O
a NN NN O
rare NN NN O
human NN NN O
developmental NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
affecting NN NN O
the NN NN O
urogenital NN NN O
system NN NN O
and NN NN O
leading NN NN O
to NN NN O
renal NN NN B-DiseaseClass
failure NN NN I-DiseaseClass
, NN NN O
intersex NN NN B-DiseaseClass
disorders NN NN I-DiseaseClass
and NN NN O
Wilms NN NN B-SpecificDisease
tumour NN NN I-SpecificDisease
. NN NN O

In NN NN O
this NN NN O
report NN NN O
, NN NN O
four NN NN O
individuals NN NN O
with NN NN O
this NN NN O
syndrome NN NN O
are NN NN O
described NN NN O
carrying NN NN O
germline NN NN O
point NN NN O
mutations NN NN O
in NN NN O
the NN NN O
Wilms NN NN B-Modifier
tumour NN NN I-Modifier
suppressor NN NN O
gene NN NN O
, NN NN O
WT1 NN NN O
. NN NN O

Three NN NN O
of NN NN O
these NN NN O
mutations NN NN O
were NN NN O
in NN NN O
the NN NN O
zinc NN NN O
finger NN NN O
domains NN NN O
of NN NN O
WT1 NN NN O
. NN NN O

The NN NN O
fourth NN NN O
occurred NN NN O
within NN NN O
intron NN NN O
9 NN NN O
, NN NN O
preventing NN NN O
splicing NN NN O
at NN NN O
one NN NN O
of NN NN O
the NN NN O
alternatively NN NN O
chosen NN NN O
splice NN NN O
donor NN NN O
sites NN NN O
of NN NN O
exon NN NN O
9 NN NN O
when NN NN O
assayed NN NN O
in NN NN O
vitro NN NN O
. NN NN O

These NN NN O
results NN NN O
provide NN NN O
genetic NN NN O
evidence NN NN O
for NN NN O
distinct NN NN O
functional NN NN O
roles NN NN O
of NN NN O
the NN NN O
WT1 NN NN O
isoforms NN NN O
in NN NN O
urogenital NN NN O
development NN NN O
. NN NN O

. NN NN O

1302022 NN NN O
Characterization NN NN O
of NN NN O
the NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
region NN NN O
predicts NN NN O
multiple NN NN O
protein NN NN O
isoform-encoding NN NN O
mRNAs NN NN O
. NN NN O

The NN NN O
mutation NN NN O
underlying NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
has NN NN O
been NN NN O
identified NN NN O
as NN NN O
an NN NN O
expansion NN NN O
of NN NN O
a NN NN O
polymorphic NN NN O
CTG-repeat NN NN O
in NN NN O
a NN NN O
gene NN NN O
encoding NN NN O
protein NN NN O
kinase NN NN O
activity NN NN O
. NN NN O

Brain NN NN O
and NN NN O
heart NN NN O
transcripts NN NN O
of NN NN O
the NN NN O
DM-kinase NN NN O
( NN NN O
DMR-B15 NN NN O
) NN NN O
gene NN NN O
are NN NN O
subject NN NN O
to NN NN O
alternative NN NN O
RNA NN NN O
splicing NN NN O
in NN NN O
both NN NN O
human NN NN O
and NN NN O
mouse NN NN O
. NN NN O

The NN NN O
unstable NN NN O
[ NN NN O
CTG NN NN O
] NN NN O
5-30 NN NN O
motif NN NN O
is NN NN O
found NN NN O
uniquely NN NN O
in NN NN O
humans NN NN O
, NN NN O
although NN NN O
the NN NN O
flanking NN NN O
nucleotides NN NN O
are NN NN O
also NN NN O
present NN NN O
in NN NN O
mouse NN NN O
. NN NN O

Characterization NN NN O
of NN NN O
the NN NN O
DM NN NN B-Modifier
region NN NN O
of NN NN O
both NN NN O
species NN NN O
reveals NN NN O
another NN NN O
active NN NN O
gene NN NN O
( NN NN O
DMR-N9 NN NN O
) NN NN O
in NN NN O
close NN NN O
proximity NN NN O
to NN NN O
the NN NN O
kinase NN NN O
gene NN NN O
. NN NN O

DMR-N9 NN NN O
transcripts NN NN O
, NN NN O
mainly NN NN O
expressed NN NN O
in NN NN O
brain NN NN O
and NN NN O
testis NN NN O
, NN NN O
possess NN NN O
a NN NN O
single NN NN O
, NN NN O
large NN NN O
open NN NN O
reading NN NN O
frame NN NN O
, NN NN O
but NN NN O
the NN NN O
function NN NN O
of NN NN O
its NN NN O
protein NN NN O
product NN NN O
is NN NN O
unknown NN NN O
. NN NN O

Clinical NN NN O
manifestation NN NN O
of NN NN O
DM NN NN B-SpecificDisease
may NN NN O
be NN NN O
caused NN NN O
by NN NN O
the NN NN O
expanded NN NN O
CTG-repeat NN NN O
compromising NN NN O
the NN NN O
( NN NN O
alternative NN NN O
) NN NN O
expression NN NN O
of NN NN O
DM-kinase NN NN O
or NN NN O
DMR-N9 NN NN O
proteins NN NN O
. NN NN O

. NN NN O

1302032 NN NN O
Fragile NN NN B-SpecificDisease
X NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
without NN NN O
CCG NN NN O
amplification NN NN O
has NN NN O
an NN NN O
FMR1 NN NN O
deletion NN NN O
. NN NN O

We NN NN O
describe NN NN O
a NN NN O
patient NN NN O
with NN NN O
typical NN NN O
clinical NN NN O
features NN NN O
of NN NN O
the NN NN O
fragile NN NN B-SpecificDisease
X NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
, NN NN O
but NN NN O
without NN NN O
cytogenetic NN NN O
expression NN NN O
of NN NN O
the NN NN O
fragile NN NN B-SpecificDisease
X NN NN I-SpecificDisease
or NN NN O
an NN NN O
amplified NN NN O
CCG NN NN O
trinucleotide NN NN O
repeat NN NN O
fragment NN NN O
. NN NN O

The NN NN O
patient NN NN O
has NN NN O
a NN NN O
previously NN NN O
uncharacterized NN NN O
submicroscopic NN NN O
deletion NN NN O
encompassing NN NN O
the NN NN O
CCG NN NN O
repeat NN NN O
, NN NN O
the NN NN O
entire NN NN O
FMR1 NN NN O
gene NN NN O
and NN NN O
about NN NN O
2 NN NN O
. NN NN O

5 NN NN O
megabases NN NN O
of NN NN O
flanking NN NN O
sequences NN NN O
. NN NN O

This NN NN O
finding NN NN O
confirms NN NN O
that NN NN O
the NN NN O
fragile NN NN B-Modifier
X NN NN I-Modifier
phenotype NN NN O
can NN NN O
exist NN NN O
, NN NN O
without NN NN O
amplification NN NN O
of NN NN O
the NN NN O
CCG NN NN O
repeat NN NN O
or NN NN O
cytogenetic NN NN O
expression NN NN O
of NN NN O
the NN NN O
fragile NN NN B-SpecificDisease
X NN NN I-SpecificDisease
, NN NN O
and NN NN O
that NN NN O
fragile NN NN B-SpecificDisease
X NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
is NN NN O
a NN NN O
genetically NN NN O
homogeneous NN NN O
disorder NN NN O
involving NN NN O
FMR1 NN NN O
. NN NN O

We NN NN O
also NN NN O
found NN NN O
random NN NN O
X-inactivation NN NN O
in NN NN O
the NN NN O
mother NN NN O
of NN NN O
the NN NN O
patient NN NN O
who NN NN O
was NN NN O
shown NN NN O
to NN NN O
be NN NN O
a NN NN O
carrier NN NN O
of NN NN O
this NN NN O
deletion NN NN O
. NN NN O

1303170 NN NN O
Cloning NN NN O
of NN NN O
the NN NN O
Huntington NN NN B-Modifier
disease NN NN I-Modifier
region NN NN O
in NN NN O
yeast NN NN O
artificial NN NN O
chromosomes NN NN O
. NN NN O

The NN NN O
gene NN NN O
responsible NN NN O
for NN NN O
Huntington NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
has NN NN O
been NN NN O
localized NN NN O
to NN NN O
a NN NN O
2 NN NN O
. NN NN O

5 NN NN O
million NN NN O
base NN NN O
pair NN NN O
( NN NN O
Mb NN NN O
) NN NN O
region NN NN O
between NN NN O
the NN NN O
loci NN NN O
D4S10 NN NN O
and NN NN O
D4S168 NN NN O
on NN NN O
the NN NN O
short NN NN O
arm NN NN O
of NN NN O
chromosome NN NN O
4 NN NN O
. NN NN O

As NN NN O
part NN NN O
of NN NN O
a NN NN O
strategy NN NN O
to NN NN O
clone NN NN O
the NN NN O
HD NN NN B-Modifier
gene NN NN O
on NN NN O
the NN NN O
basis NN NN O
of NN NN O
its NN NN O
chromosomal NN NN O
location NN NN O
, NN NN O
we NN NN O
isolated NN NN O
genomic NN NN O
DNA NN NN O
from NN NN O
the NN NN O
HD NN NN B-Modifier
region NN NN O
as NN NN O
a NN NN O
set NN NN O
of NN NN O
overlapping NN NN O
yeast NN NN O
artificial NN NN O
chromosome NN NN O
( NN NN O
YAC NN NN O
) NN NN O
clones NN NN O
. NN NN O

Twenty-eight NN NN O
YAC NN NN O
clones NN NN O
were NN NN O
identified NN NN O
by NN NN O
screening NN NN O
human NN NN O
YAC NN NN O
libraries NN NN O
with NN NN O
twelve NN NN O
PCR-based NN NN O
sequence-tagged NN NN O
sites NN NN O
( NN NN O
STSs NN NN O
) NN NN O
from NN NN O
the NN NN O
region NN NN O
. NN NN O

We NN NN O
assembled NN NN O
the NN NN O
YAC NN NN O
clones NN NN O
into NN NN O
overlapping NN NN O
sets NN NN O
by NN NN O
hybridizing NN NN O
them NN NN O
to NN NN O
a NN NN O
large NN NN O
number NN NN O
of NN NN O
DNA NN NN O
probes NN NN O
from NN NN O
the NN NN O
HD NN NN B-Modifier
region NN NN O
, NN NN O
including NN NN O
the NN NN O
STSs NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
we NN NN O
isolated NN NN O
the NN NN O
ends NN NN O
of NN NN O
the NN NN O
human NN NN O
DNA NN NN O
inserts NN NN O
of NN NN O
most NN NN O
of NN NN O
the NN NN O
YAC NN NN O
clones NN NN O
to NN NN O
assist NN NN O
in NN NN O
the NN NN O
construction NN NN O
of NN NN O
the NN NN O
contig NN NN O
. NN NN O

Although NN NN O
almost NN NN O
half NN NN O
of NN NN O
the NN NN O
YACs NN NN O
appear NN NN O
to NN NN O
contain NN NN O
chimeric NN NN O
inserts NN NN O
and NN NN O
several NN NN O
contain NN NN O
internal NN NN O
deletions NN NN O
or NN NN O
other NN NN O
rearrangements NN NN O
, NN NN O
we NN NN O
were NN NN O
able NN NN O
to NN NN O
obtain NN NN O
over NN NN O
2 NN NN O
. NN NN O

2 NN NN O
Mb NN NN O
of NN NN O
the NN NN O
HD NN NN B-Modifier
region NN NN O
in NN NN O
YACs NN NN O
, NN NN O
including NN NN O
one NN NN O
continuous NN NN O
segment NN NN O
of NN NN O
2 NN NN O
. NN NN O

0 NN NN O
Mb NN NN O
covering NN NN O
the NN NN O
region NN NN O
that NN NN O
most NN NN O
likely NN NN O
contains NN NN O
the NN NN O
HD NN NN B-Modifier
gene NN NN O
. NN NN O

Ten NN NN O
of NN NN O
the NN NN O
twenty NN NN O
eight NN NN O
YAC NN NN O
clones NN NN O
comprise NN NN O
a NN NN O
minimal NN NN O
set NN NN O
spanning NN NN O
the NN NN O
2 NN NN O
. NN NN O

2 NN NN O
Mb NN NN O
. NN NN O

These NN NN O
clones NN NN O
provide NN NN O
reagents NN NN O
for NN NN O
the NN NN O
complete NN NN O
characterization NN NN O
of NN NN O
this NN NN O
region NN NN O
of NN NN O
the NN NN O
genome NN NN O
and NN NN O
for NN NN O
the NN NN O
eventual NN NN O
isolation NN NN O
of NN NN O
the NN NN O
HD NN NN B-Modifier
gene NN NN O
. NN NN O

1303171 NN NN O
Characterization NN NN O
of NN NN O
a NN NN O
YAC NN NN O
containing NN NN O
part NN NN O
or NN NN O
all NN NN O
of NN NN O
the NN NN O
Norrie NN NN B-Modifier
disease NN NN I-Modifier
locus NN NN O
. NN NN O

It NN NN O
has NN NN O
been NN NN O
shown NN NN O
from NN NN O
pulsed-field NN NN O
gel NN NN O
electrophoresis NN NN O
( NN NN O
PFGE NN NN O
) NN NN O
that NN NN O
the NN NN O
monoamine NN NN O
oxidase NN NN O
genes NN NN O
A NN NN O
and NN NN O
B NN NN O
( NN NN O
MAOA NN NN O
& NN NN O
MAOB NN NN O
) NN NN O
and NN NN O
DXS7 NN NN O
loci NN NN O
are NN NN O
physically NN NN O
very NN NN O
close NN NN O
. NN NN O

We NN NN O
have NN NN O
therefore NN NN O
extended NN NN O
studies NN NN O
on NN NN O
their NN NN O
relationship NN NN O
through NN NN O
the NN NN O
characterisation NN NN O
of NN NN O
a NN NN O
650 NN NN O
kb NN NN O
YAC NN NN O
isolated NN NN O
using NN NN O
L1 NN NN O
. NN NN O

28 NN NN O
( NN NN O
recognising NN NN O
the NN NN O
DXS7 NN NN O
locus NN NN O
) NN NN O
as NN NN O
a NN NN O
probe NN NN O
. NN NN O

Restriction NN NN O
mapping NN NN O
of NN NN O
the NN NN O
YAC NN NN O
indicates NN NN O
that NN NN O
it NN NN O
contains NN NN O
both NN NN O
MAOA NN NN O
and NN NN O
MAOB NN NN O
genes NN NN O
in NN NN O
addition NN NN O
to NN NN O
the NN NN O
DXS7 NN NN O
locus NN NN O
. NN NN O

The NN NN O
map NN NN O
derived NN NN O
from NN NN O
the NN NN O
YL1 NN NN O
. NN NN O

28-YAC NN NN O
is NN NN O
compatible NN NN O
both NN NN O
with NN NN O
the NN NN O
map NN NN O
from NN NN O
an NN NN O
independently NN NN O
derived NN NN O
YAC NN NN O
carrying NN NN O
MAOA NN NN O
and NN NN O
B NN NN O
genes NN NN O
and NN NN O
with NN NN O
the NN NN O
long NN NN O
range NN NN O
genomic NN NN O
map NN NN O
for NN NN O
the NN NN O
region NN NN O
. NN NN O

A NN NN O
series NN NN O
of NN NN O
subclones NN NN O
prepared NN NN O
from NN NN O
a NN NN O
phage NN NN O
library NN NN O
( NN NN O
lambda NN NN O
DASH NN NN O
II NN NN O
) NN NN O
of NN NN O
the NN NN O
YAC NN NN O
have NN NN O
been NN NN O
characterised NN NN O
and NN NN O
have NN NN O
been NN NN O
employed NN NN O
to NN NN O
determine NN NN O
the NN NN O
end NN NN O
point NN NN O
of NN NN O
the NN NN O
deletion NN NN O
of NN NN O
a NN NN O
Norrie NN NN B-Modifier
disease NN NN I-Modifier
( NN NN O
NDP NN NN B-Modifier
) NN NN O
patient NN NN O
who NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
lack NN NN O
both NN NN O
DXS7 NN NN O
and NN NN O
MAO NN NN O
coding NN NN O
sequences NN NN O
. NN NN O

The NN NN O
pattern NN NN O
of NN NN O
retention NN NN O
of NN NN O
subclones NN NN O
in NN NN O
the NN NN O
deletion NN NN O
patient NN NN O
place NN NN O
the NN NN O
end NN NN O
point NN NN O
of NN NN O
the NN NN O
deletion NN NN O
within NN NN O
30-130 NN NN O
kb NN NN O
of NN NN O
the NN NN O
proximal NN NN O
end NN NN O
of NN NN O
the NN NN O
YAC NN NN O
. NN NN O

By NN NN O
combining NN NN O
the NN NN O
data NN NN O
with NN NN O
established NN NN O
recombination NN NN O
analysis NN NN O
, NN NN O
we NN NN O
provide NN NN O
evidence NN NN O
that NN NN O
all NN NN O
or NN NN O
part NN NN O
of NN NN O
the NN NN O
NDP NN NN O
lies NN NN O
in NN NN O
the NN NN O
interval NN NN O
of NN NN O
approximately NN NN O
250kb NN NN O
within NN NN O
the NN NN O
YAC NN NN O
. NN NN O

1303173 NN NN O
Both NN NN O
mutations NN NN O
in NN NN O
G6PD NN NN O
A- NN NN O
are NN NN O
necessary NN NN O
to NN NN O
produce NN NN O
the NN NN O
G6PD NN NN B-Modifier
deficient NN NN I-Modifier
phenotype NN NN O
. NN NN O

The NN NN O
high NN NN O
prevalence NN NN O
of NN NN O
glucose NN NN B-SpecificDisease
6-phosphate NN NN I-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
( NN NN I-SpecificDisease
G6PD NN NN I-SpecificDisease
) NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
African NN NN O
populations NN NN O
is NN NN O
due NN NN O
almost NN NN O
entirely NN NN O
to NN NN O
the NN NN O
enzyme NN NN O
variant NN NN O
A- NN NN O
, NN NN O
which NN NN O
differs NN NN O
from NN NN O
the NN NN O
wild-type NN NN O
G6PD NN NN O
B NN NN O
by NN NN O
two NN NN O
amino NN NN O
acid NN NN O
replacements NN NN O
, NN NN O
68 NN NN O
Val NN NN O
-- NN NN O
Met NN NN O
and NN NN O
126 NN NN O
Asn NN NN O
-- NN NN O
Asp NN NN O
. NN NN O

The NN NN O
non-deficient NN NN O
polymorphic NN NN O
variant NN NN O
G6PD NN NN O
A NN NN O
contains NN NN O
only NN NN O
the NN NN O
mutation NN NN O
126 NN NN O
Asn NN NN O
-- NN NN O
Asp NN NN O
. NN NN O

The NN NN O
frequencies NN NN O
of NN NN O
the NN NN O
G6PD NN NN O
A NN NN O
and NN NN O
of NN NN O
the NN NN O
G6PD NN NN O
A- NN NN O
genes NN NN O
in NN NN O
parts NN NN O
of NN NN O
Africa NN NN O
are NN NN O
both NN NN O
about NN NN O
0 NN NN O
. NN NN O

2 NN NN O
. NN NN O

The NN NN O
68 NN NN O
Val NN NN O
-- NN NN O
Met NN NN O
mutation NN NN O
has NN NN O
not NN NN O
been NN NN O
found NN NN O
in NN NN O
a NN NN O
B NN NN O
background NN NN O
. NN NN O

This NN NN O
could NN NN O
be NN NN O
because NN NN O
the NN NN O
68 NN NN O
Val NN NN O
-- NN NN O
Met NN NN O
mutation NN NN O
happened NN NN O
to NN NN O
arise NN NN O
in NN NN O
an NN NN O
A NN NN O
gene NN NN O
in NN NN O
the NN NN O
first NN NN O
instance NN NN O
, NN NN O
or NN NN O
because NN NN O
the NN NN O
68 NN NN O
Val NN NN O
-- NN NN O
Met NN NN O
mutation NN NN O
alone NN NN O
is NN NN O
not NN NN O
sufficient NN NN O
to NN NN O
cause NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

We NN NN O
have NN NN O
approached NN NN O
this NN NN O
question NN NN O
by NN NN O
producing NN NN O
G6PD NN NN O
B NN NN O
, NN NN O
A NN NN O
, NN NN O
A- NN NN O
, NN NN O
and NN NN O
G6PD NN NN O
68 NN NN O
Val NN NN O
-- NN NN O
Met NN NN O
in NN NN O
a NN NN O
bacterial NN NN O
expression NN NN O
system NN NN O
and NN NN O
analysing NN NN O
their NN NN O
biochemical NN NN O
properties NN NN O
. NN NN O

With NN NN O
each NN NN O
single NN NN O
mutation NN NN O
we NN NN O
found NN NN O
a NN NN O
slight NN NN O
decrease NN NN O
in NN NN O
both NN NN O
the NN NN O
specific NN NN O
activity NN NN O
and NN NN O
the NN NN O
yield NN NN O
of NN NN O
enzyme NN NN O
when NN NN O
compared NN NN O
to NN NN O
G6PD NN NN O
B NN NN O
. NN NN O

When NN NN O
both NN NN O
mutations NN NN O
were NN NN O
introduced NN NN O
together NN NN O
, NN NN O
there NN NN O
was NN NN O
a NN NN O
roughly NN NN O
additive NN NN O
effect NN NN O
on NN NN O
specific NN NN O
activity NN NN O
, NN NN O
but NN NN O
a NN NN O
much NN NN O
more NN NN O
drastic NN NN O
effect NN NN O
on NN NN O
enzyme NN NN O
yield NN NN O
( NN NN O
4 NN NN O
% NN NN O
of NN NN O
normal NN NN O
) NN NN O
. NN NN O

This NN NN O
synergistic NN NN O
effect NN NN O
was NN NN O
also NN NN O
demonstrated NN NN O
on NN NN O
thermal NN NN O
stability NN NN O
, NN NN O
especially NN NN O
at NN NN O
low NN NN O
NADP NN NN O
concentrations NN NN O
. NN NN O

Comparable NN NN O
results NN NN O
were NN NN O
produced NN NN O
when NN NN O
the NN NN O
replacement NN NN O
119 NN NN O
Gln NN NN O
-- NN NN O
Glu NN NN O
was NN NN O
studied NN NN O
instead NN NN O
of NN NN O
126 NN NN O
Asn NN NN O
-- NN NN O
Asp NN NN O
. NN NN O

We NN NN O
infer NN NN O
that NN NN O
the NN NN O
coexistence NN NN O
of NN NN O
the NN NN O
two NN NN O
mutations NN NN O
is NN NN O
responsible NN NN O
for NN NN O
enzyme NN NN O
deficiency NN NN B-SpecificDisease
in NN NN I-SpecificDisease
G6PD NN NN I-SpecificDisease
A- NN NN O
because NN NN O
they NN NN O
act NN NN O
synergistically NN NN O
in NN NN O
causing NN NN O
instability NN NN O
of NN NN O
the NN NN O
enzyme NN NN O
. NN NN O

1303277 NN NN O
Small NN NN O
nuclear NN NN O
ribonucleoprotein NN NN O
polypeptide NN NN O
N NN NN O
( NN NN O
SNRPN NN NN O
) NN NN O
, NN NN O
an NN NN O
expressed NN NN O
gene NN NN O
in NN NN O
the NN NN O
Prader-Willi NN NN B-Modifier
syndrome NN NN I-Modifier
critical NN NN O
region NN NN O
. NN NN O

Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
PWS NN NN B-SpecificDisease
) NN NN O
is NN NN O
associated NN NN O
with NN NN O
paternally NN NN O
derived NN NN O
chromosomal NN NN O
deletions NN NN O
in NN NN O
region NN NN O
15q11-13 NN NN O
or NN NN O
with NN NN O
maternal NN NN B-SpecificDisease
disomy NN NN I-SpecificDisease
for NN NN I-SpecificDisease
chromosome NN NN I-SpecificDisease
15 NN NN I-SpecificDisease
. NN NN O

Therefore NN NN O
, NN NN O
loss NN NN O
of NN NN O
the NN NN O
expressed NN NN O
paternal NN NN O
alleles NN NN O
of NN NN O
maternally NN NN O
imprinted NN NN O
genes NN NN O
must NN NN O
be NN NN O
responsible NN NN O
for NN NN O
the NN NN O
PWS NN NN B-Modifier
phenotype NN NN O
. NN NN O

We NN NN O
have NN NN O
mapped NN NN O
the NN NN O
gene NN NN O
encoding NN NN O
the NN NN O
small NN NN O
nuclear NN NN O
RNA NN NN O
associated NN NN O
polypeptide NN NN O
SmN NN NN O
( NN NN O
SNRPN NN NN O
) NN NN O
to NN NN O
human NN NN O
chromosome NN NN O
15q12 NN NN O
and NN NN O
a NN NN O
processed NN NN O
pseudogene NN NN O
SNRPNP1 NN NN O
to NN NN O
chromosome NN NN O
region NN NN O
6pter-p21 NN NN O
. NN NN O

Furthermore NN NN O
, NN NN O
SNRPN NN NN O
was NN NN O
mapped NN NN O
to NN NN O
the NN NN O
minimal NN NN O
deletion NN NN O
interval NN NN O
that NN NN O
is NN NN O
critical NN NN O
for NN NN O
PWS NN NN B-SpecificDisease
. NN NN O

The NN NN O
fact NN NN O
that NN NN O
the NN NN O
mouse NN NN O
Snrpn NN NN O
gene NN NN O
is NN NN O
maternally NN NN O
imprinted NN NN O
in NN NN O
brain NN NN O
suggests NN NN O
that NN NN O
loss NN NN O
of NN NN O
the NN NN O
paternally NN NN O
derived NN NN O
SNRPN NN NN O
allele NN NN O
may NN NN O
be NN NN O
involved NN NN O
in NN NN O
the NN NN O
PWS NN NN B-Modifier
phenotype NN NN O
. NN NN O

. NN NN O

1307230 NN NN O
The NN NN O
presence NN NN O
of NN NN O
two NN NN O
different NN NN O
infantile NN NN O
Tay-Sachs NN NN B-Modifier
disease NN NN I-Modifier
mutations NN NN O
in NN NN O
a NN NN O
Cajun NN NN O
population NN NN O
. NN NN O

A NN NN O
study NN NN O
was NN NN O
undertaken NN NN O
to NN NN O
characterize NN NN O
the NN NN O
mutation NN NN O
( NN NN O
s NN NN O
) NN NN O
responsible NN NN O
for NN NN O
Tay-Sachs NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
TSD NN NN B-SpecificDisease
) NN NN O
in NN NN O
a NN NN O
Cajun NN NN O
population NN NN O
in NN NN O
southwest NN NN O
Louisiana NN NN O
and NN NN O
to NN NN O
identify NN NN O
the NN NN O
origins NN NN O
of NN NN O
these NN NN O
mutations NN NN O
. NN NN O

Eleven NN NN O
of NN NN O
12 NN NN O
infantile NN NN O
TSD NN NN B-Modifier
alleles NN NN O
examined NN NN O
in NN NN O
six NN NN O
families NN NN O
had NN NN O
the NN NN O
beta-hexosaminidase NN NN O
A NN NN O
( NN NN O
Hex NN NN O
A NN NN O
) NN NN O
alpha-subunit NN NN O
exon NN NN O
11 NN NN O
insertion NN NN O
mutation NN NN O
that NN NN O
is NN NN O
present NN NN O
in NN NN O
approximately NN NN O
70 NN NN O
% NN NN O
of NN NN O
Ashkenazi NN NN O
Jewish NN NN O
TSD NN NN B-Modifier
heterozygotes NN NN O
. NN NN O

The NN NN O
mutation NN NN O
in NN NN O
the NN NN O
remaining NN NN O
allele NN NN O
was NN NN O
a NN NN O
single-base NN NN O
transition NN NN O
in NN NN O
the NN NN O
donor NN NN O
splice NN NN O
site NN NN O
of NN NN O
the NN NN O
alpha-subunit NN NN O
intron NN NN O
9 NN NN O
. NN NN O

To NN NN O
determine NN NN O
the NN NN O
origins NN NN O
of NN NN O
these NN NN O
two NN NN O
mutations NN NN O
in NN NN O
the NN NN O
Cajun NN NN O
population NN NN O
, NN NN O
the NN NN O
TSD NN NN B-Modifier
carrier NN NN O
status NN NN O
was NN NN O
enzymatically NN NN O
determined NN NN O
for NN NN O
90 NN NN O
members NN NN O
of NN NN O
four NN NN O
of NN NN O
the NN NN O
six NN NN O
families NN NN O
, NN NN O
and NN NN O
extensive NN NN O
pedigrees NN NN O
were NN NN O
constructed NN NN O
for NN NN O
all NN NN O
carriers NN NN O
. NN NN O

A NN NN O
single NN NN O
ancestral NN NN O
couple NN NN O
from NN NN O
France NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
common NN NN O
to NN NN O
most NN NN O
of NN NN O
the NN NN O
carriers NN NN O
of NN NN O
the NN NN O
exon NN NN O
11 NN NN O
insertion NN NN O
. NN NN O

Pedigree NN NN O
data NN NN O
suggest NN NN O
that NN NN O
this NN NN O
mutation NN NN O
has NN NN O
been NN NN O
in NN NN O
the NN NN O
Cajun NN NN O
population NN NN O
since NN NN O
its NN NN O
founding NN NN O
over NN NN O
2 NN NN O
centuries NN NN O
ago NN NN O
and NN NN O
that NN NN O
it NN NN O
may NN NN O
be NN NN O
widely NN NN O
distributed NN NN O
within NN NN O
the NN NN O
population NN NN O
. NN NN O

In NN NN O
contrast NN NN O
, NN NN O
the NN NN O
intron NN NN O
9 NN NN O
mutation NN NN O
apparently NN NN O
was NN NN O
introduced NN NN O
within NN NN O
the NN NN O
last NN NN O
century NN NN O
and NN NN O
probably NN NN O
is NN NN O
limited NN NN O
to NN NN O
a NN NN O
few NN NN O
Louisiana NN NN O
families NN NN O
. NN NN O

. NN NN O

1307245 NN NN O
Mutations NN NN O
in NN NN O
the NN NN O
candidate NN NN O
gene NN NN O
for NN NN O
Norrie NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

Recently NN NN O
, NN NN O
we NN NN O
and NN NN O
others NN NN O
have NN NN O
isolated NN NN O
a NN NN O
candidate NN NN O
gene NN NN O
for NN NN O
X NN NN B-SpecificDisease
linked NN NN I-SpecificDisease
Norrie NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
ND NN NN B-SpecificDisease
) NN NN O
which NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
deleted NN NN O
or NN NN O
disrupted NN NN O
in NN NN O
several NN NN O
patients NN NN O
. NN NN O

As NN NN O
a NN NN O
prerequisite NN NN O
for NN NN O
the NN NN O
identification NN NN O
of NN NN O
point NN NN O
mutations NN NN O
in NN NN O
the NN NN O
ND NN NN B-Modifier
gene NN NN O
we NN NN O
have NN NN O
established NN NN O
the NN NN O
exon-intron NN NN O
structure NN NN O
of NN NN O
this NN NN O
gene NN NN O
. NN NN O

In NN NN O
17 NN NN O
unrelated NN NN O
patients NN NN O
and NN NN O
15 NN NN O
controls NN NN O
, NN NN O
PCR NN NN O
products NN NN O
derived NN NN O
from NN NN O
the NN NN O
promoter NN NN O
region NN NN O
, NN NN O
exons NN NN O
1 NN NN O
and NN NN O
2 NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
coding NN NN O
part NN NN O
of NN NN O
exon NN NN O
3 NN NN O
were NN NN O
analysed NN NN O
with NN NN O
the NN NN O
single NN NN O
strand NN NN O
conformation NN NN O
polymorphism NN NN O
( NN NN O
SSCP NN NN O
) NN NN O
technique NN NN O
. NN NN O

In NN NN O
12 NN NN O
patients NN NN O
altered NN NN O
PCR NN NN O
fragments NN NN O
were NN NN O
detected NN NN O
which NN NN O
were NN NN O
studied NN NN O
in NN NN O
detail NN NN O
by NN NN O
direct NN NN O
sequencing NN NN O
. NN NN O

Eleven NN NN O
different NN NN O
mutations NN NN O
were NN NN O
found NN NN O
, NN NN O
and NN NN O
all NN NN O
but NN NN O
one NN NN O
are NN NN O
likely NN NN O
to NN NN O
give NN NN O
rise NN NN O
to NN NN O
significant NN NN O
structural NN NN O
changes NN NN O
in NN NN O
the NN NN O
predicted NN NN O
protein NN NN O
. NN NN O

These NN NN O
findings NN NN O
, NN NN O
and NN NN O
the NN NN O
absence NN NN O
of NN NN O
functionally NN NN O
relevant NN NN O
base NN NN O
changes NN NN O
in NN NN O
healthy NN NN O
controls NN NN O
, NN NN O
emphasize NN NN O
the NN NN O
causal NN NN O
role NN NN O
of NN NN O
this NN NN O
candidate NN NN O
gene NN NN O
in NN NN O
Norrie NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
and NN NN O
pave NN NN O
the NN NN O
way NN NN O
for NN NN O
reliable NN NN O
diagnosis NN NN O
and NN NN O
carrier NN NN O
detection NN NN O
. NN NN O

. NN NN O

1307253 NN NN O
Detection NN NN O
of NN NN O
a NN NN O
nonsense NN NN O
mutation NN NN O
in NN NN O
the NN NN O
dystrophin NN NN O
gene NN NN O
by NN NN O
multiple NN NN O
SSCP NN NN O
. NN NN O

A NN NN O
combination NN NN O
of NN NN O
multiplex NN NN O
PCR NN NN O
with NN NN O
the NN NN O
single NN NN O
strand NN NN O
conformation NN NN O
polymorphism NN NN O
( NN NN O
SSCP NN NN O
) NN NN O
technique NN NN O
was NN NN O
employed NN NN O
to NN NN O
screen NN NN O
for NN NN O
point NN NN O
mutations NN NN O
in NN NN O
the NN NN O
human NN NN O
dystrophin NN NN O
gene NN NN O
. NN NN O

Co-amplification NN NN O
of NN NN O
11 NN NN O
exons NN NN O
from NN NN O
genomic NN NN O
DNA NN NN O
of NN NN O
Duchenne NN NN B-Modifier
and NN NN I-Modifier
Becker NN NN I-Modifier
muscular NN NN I-Modifier
dystrophy NN NN I-Modifier
( NN NN O
DMD NN NN B-Modifier
/ NN NN O
BMD NN NN B-Modifier
) NN NN O
patients NN NN O
with NN NN O
no NN NN O
deletion NN NN O
or NN NN O
duplication NN NN O
was NN NN O
performed NN NN O
and NN NN O
the NN NN O
samples NN NN O
subjected NN NN O
to NN NN O
multiple NN NN O
SSCP NN NN O
analysis NN NN O
. NN NN O

We NN NN O
report NN NN O
the NN NN O
case NN NN O
of NN NN O
a NN NN O
nonsense NN NN O
mutation NN NN O
in NN NN O
a NN NN O
Duchenne NN NN B-Modifier
patient NN NN O
identified NN NN O
by NN NN O
this NN NN O
approach NN NN O
. NN NN O

The NN NN O
mutation NN NN O
introduces NN NN O
a NN NN O
termination NN NN O
codon NN NN O
within NN NN O
exon NN NN O
8 NN NN O
of NN NN O
the NN NN O
dystrophin NN NN O
gene NN NN O
. NN NN O

It NN NN O
is NN NN O
predicted NN NN O
to NN NN O
cause NN NN O
a NN NN O
very NN NN O
premature NN NN O
translational NN NN O
termination NN NN O
accounting NN NN O
for NN NN O
the NN NN O
severe NN NN O
phenotype NN NN O
observed NN NN O
. NN NN O

The NN NN O
patient NN NN O
inherited NN NN O
this NN NN O
mutation NN NN O
from NN NN O
his NN NN O
mother NN NN O
. NN NN O

In NN NN O
addition NN NN O
the NN NN O
analysis NN NN O
revealed NN NN O
5 NN NN O
polymorphisms NN NN O
useful NN NN O
for NN NN O
internal NN NN O
control NN NN O
. NN NN O

. NN NN O

1311721 NN NN O
Proliferation-related NN NN O
expression NN NN O
of NN NN O
p19/nm23 NN NN O
nucleoside NN NN O
diphosphate NN NN O
kinase NN NN O
. NN NN O

High NN NN O
level NN NN O
expression NN NN O
of NN NN O
the NN NN O
nm23-H1 NN NN O
gene NN NN O
, NN NN O
which NN NN O
encodes NN NN O
for NN NN O
a NN NN O
nucleoside NN NN O
diphosphate NN NN O
kinase NN NN O
, NN NN O
has NN NN O
been NN NN O
found NN NN O
to NN NN O
correlate NN NN O
with NN NN O
diminished NN NN O
metastasis NN NN O
in NN NN O
some NN NN O
tumors NN NN B-DiseaseClass
but NN NN O
not NN NN O
in NN NN O
others NN NN O
. NN NN O

We NN NN O
have NN NN O
previously NN NN O
identified NN NN O
the NN NN O
protein NN NN O
product NN NN O
of NN NN O
the NN NN O
nm23-H1 NN NN O
gene NN NN O
in NN NN O
two-dimensional NN NN O
electrophoretic NN NN O
gels NN NN O
and NN NN O
have NN NN O
designated NN NN O
it NN NN O
p19 NN NN O
/ NN NN O
nm23 NN NN O
. NN NN O

In NN NN O
neuroblastoma NN NN B-SpecificDisease
, NN NN O
higher NN NN O
levels NN NN O
of NN NN O
p19 NN NN O
/ NN NN O
nm23 NN NN O
, NN NN O
which NN NN O
are NN NN O
associated NN NN O
with NN NN O
amplification NN NN O
of NN NN O
the NN NN O
N-myc NN NN O
oncogene NN NN O
, NN NN O
large NN NN O
tumor NN NN B-Modifier
mass NN NN O
, NN NN O
and NN NN O
metastasis NN NN O
, NN NN O
were NN NN O
observed NN NN O
in NN NN O
advanced NN NN O
stage NN NN O
tumors NN NN B-DiseaseClass
compared NN NN O
with NN NN O
limited NN NN O
stage NN NN O
disease NN NN O
. NN NN O

Because NN NN O
of NN NN O
the NN NN O
variable NN NN O
expression NN NN O
of NN NN O
nm23-H1 NN NN O
in NN NN O
different NN NN O
tumors NN NN B-DiseaseClass
, NN NN O
we NN NN O
have NN NN O
investigated NN NN O
the NN NN O
relationship NN NN O
between NN NN O
amounts NN NN O
of NN NN O
the NN NN O
protein NN NN O
and NN NN O
cell NN NN O
proliferation NN NN O
. NN NN O

The NN NN O
levels NN NN O
of NN NN O
p19 NN NN O
/ NN NN O
nm23 NN NN O
were NN NN O
compared NN NN O
between NN NN O
resting NN NN O
and NN NN O
mitotically NN NN O
stimulated NN NN O
normal NN NN O
human NN NN O
PBLs NN NN O
and NN NN O
in NN NN O
leukemia NN NN B-Modifier
cells NN NN O
. NN NN O

The NN NN O
amount NN NN O
of NN NN O
p19 NN NN O
/ NN NN O
nm23 NN NN O
increased NN NN O
in NN NN O
normal NN NN O
lymphocytes NN NN O
in NN NN O
response NN NN O
to NN NN O
mitotic NN NN O
stimulation NN NN O
and NN NN O
paralleled NN NN O
the NN NN O
increase NN NN O
in NN NN O
DNA NN NN O
synthesis NN NN O
. NN NN O

In NN NN O
leukemia NN NN B-Modifier
cells NN NN O
obtained NN NN O
from NN NN O
patients NN NN O
with NN NN O
different NN NN O
subtypes NN NN O
of NN NN O
acute NN NN B-SpecificDisease
leukemia NN NN I-SpecificDisease
, NN NN O
p19 NN NN O
/ NN NN O
nm23 NN NN O
levels NN NN O
were NN NN O
also NN NN O
increased NN NN O
relative NN NN O
to NN NN O
resting NN NN O
normal NN NN O
lymphocytes NN NN O
. NN NN O

Treatment NN NN O
of NN NN O
mitotically NN NN O
stimulated NN NN O
lymphocytes NN NN O
with NN NN O
cyclosporin NN NN O
, NN NN O
which NN NN O
inhibits NN NN O
proliferation NN NN O
, NN NN O
blocked NN NN O
the NN NN O
increase NN NN O
in NN NN O
p19 NN NN O
/ NN NN O
nm23 NN NN O
; NN NN O
treatment NN NN O
of NN NN O
the NN NN O
leukemia NN NN B-Modifier
cell NN NN O
line NN NN O
HL-60 NN NN O
with NN NN O
dimethylsulfoxide NN NN O
, NN NN O
which NN NN O
induces NN NN O
terminal NN NN O
differentiation NN NN O
, NN NN O
resulted NN NN O
in NN NN O
diminished NN NN O
levels NN NN O
of NN NN O
p19 NN NN O
/ NN NN O
nm23 NN NN O
. NN NN O

Our NN NN O
data NN NN O
therefore NN NN O
provide NN NN O
evidence NN NN O
that NN NN O
nm23-H1 NN NN O
expression NN NN O
is NN NN O
related NN NN O
to NN NN O
cell NN NN O
proliferative NN NN O
activity NN NN O
. NN NN O

. NN NN O

1313112 NN NN O
An NN NN O
intrachromosomal NN NN O
insertion NN NN O
causing NN NN O
5q22 NN NN O
deletion NN NN O
and NN NN O
familial NN NN B-SpecificDisease
adenomatous NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
coli NN NN I-SpecificDisease
in NN NN O
two NN NN O
generations NN NN O
. NN NN O

We NN NN O
report NN NN O
familial NN NN B-SpecificDisease
adenomatous NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
coli NN NN I-SpecificDisease
( NN NN O
FAPC NN NN B-SpecificDisease
) NN NN O
with NN NN O
epidermoid NN NN B-SpecificDisease
cysts NN NN I-SpecificDisease
, NN NN O
osteomata NN NN B-SpecificDisease
, NN NN O
and NN NN O
areas NN NN O
of NN NN O
congenital NN NN B-SpecificDisease
hypertrophy NN NN I-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
retinal NN NN I-SpecificDisease
pigment NN NN I-SpecificDisease
epithelium NN NN I-SpecificDisease
( NN NN O
CHRPEs NN NN B-SpecificDisease
) NN NN O
in NN NN O
a NN NN O
male NN NN O
patient NN NN O
and NN NN O
his NN NN O
maternal NN NN O
aunt NN NN O
, NN NN O
both NN NN O
of NN NN O
whom NN NN O
suffered NN NN O
a NN NN O
mild NN NN O
to NN NN O
moderate NN NN O
degree NN NN O
of NN NN O
mental NN NN B-DiseaseClass
handicap NN NN I-DiseaseClass
. NN NN O

Both NN NN O
had NN NN O
an NN NN O
interstitial NN NN O
deletion NN NN O
of NN NN O
the NN NN O
long NN NN O
arm NN NN O
of NN NN O
chromosome NN NN O
5 NN NN O
( NN NN O
del NN NN O
( NN NN O
5 NN NN O
) NN NN O
( NN NN O
q22q23 NN NN O
. NN NN O

2 NN NN O
) NN NN O
) NN NN O
. NN NN O

Two NN NN O
other NN NN O
normal NN NN O
family NN NN O
members NN NN O
had NN NN O
the NN NN O
underlying NN NN O
direct NN NN O
insertion NN NN O
of NN NN O
chromosome NN NN O
5 NN NN O
( NN NN O
dir NN NN O
ins NN NN O
( NN NN O
5 NN NN O
) NN NN O
( NN NN O
q31 NN NN O
. NN NN O

3q22q23 NN NN O
3q22q23 NN NN O
. NN NN O

2 NN NN O
) NN NN O
) NN NN O
. NN NN O

Molecular NN NN O
genetic NN NN O
and NN NN O
fluorescent NN NN O
hybridisation NN NN O
studies NN NN O
have NN NN O
shown NN NN O
that NN NN O
loci NN NN O
D5S37 NN NN O
and NN NN O
D5S98 NN NN O
are NN NN O
outside NN NN O
the NN NN O
deletion NN NN O
whereas NN NN O
loci NN NN O
detected NN NN O
by NN NN O
probes NN NN O
EF5 NN NN O
. NN NN O

44 NN NN O
and NN NN O
YN5 NN NN O
. NN NN O

48 NN NN O
are NN NN O
lost NN NN O
. NN NN O

As NN NN O
expected NN NN O
, NN NN O
the NN NN O
molecular NN NN O
analyses NN NN O
indicate NN NN O
loss NN NN O
of NN NN O
one NN NN O
allele NN NN O
at NN NN O
the NN NN O
MCC NN NN O
and NN NN O
APC NN NN B-Modifier
loci NN NN O
. NN NN O

The NN NN O
APC NN NN B-Modifier
gene NN NN O
is NN NN O
located NN NN O
within NN NN O
band NN NN O
5q22 NN NN O
. NN NN O

Familial NN NN O
direct NN NN O
insertions NN NN O
should NN NN O
be NN NN O
considered NN NN O
as NN NN O
a NN NN O
cause NN NN O
of NN NN O
recurrent NN NN O
microdeletion NN NN O
syndromes NN NN O
. NN NN O

1315306 NN NN O
Chromosome NN NN O
mapping NN NN O
of NN NN O
the NN NN O
rod NN NN O
photoreceptor NN NN O
cGMP NN NN O
phosphodiesterase NN NN O
beta-subunit NN NN O
gene NN NN O
in NN NN O
mouse NN NN O
and NN NN O
human NN NN O
: NN NN O
tight NN NN O
linkage NN NN O
to NN NN O
the NN NN O
Huntington NN NN B-Modifier
disease NN NN I-Modifier
region NN NN O
( NN NN O
4p16.3 NN NN O
) NN NN O
. NN NN O

The NN NN O
retinal NN NN B-Modifier
degeneration NN NN I-Modifier
mouse NN NN O
( NN NN O
gene NN NN O
symbol NN NN O
, NN NN O
rd NN NN O
) NN NN O
is NN NN O
an NN NN O
animal NN NN O
model NN NN O
for NN NN O
certain NN NN O
forms NN NN O
of NN NN O
human NN NN O
hereditary NN NN B-DiseaseClass
retinopathies NN NN I-DiseaseClass
. NN NN O

Recent NN NN O
findings NN NN O
of NN NN O
a NN NN O
nonsense NN NN O
mutation NN NN O
in NN NN O
the NN NN O
rd NN NN O
mouse NN NN O
PDE NN NN O
beta-subunit NN NN O
gene NN NN O
( NN NN O
Pdeb NN NN O
) NN NN O
prompted NN NN O
us NN NN O
to NN NN O
investigate NN NN O
the NN NN O
chromosome NN NN O
locations NN NN O
of NN NN O
the NN NN O
mouse NN NN O
and NN NN O
human NN NN O
genes NN NN O
. NN NN O

We NN NN O
have NN NN O
utilized NN NN O
backcross NN NN O
analysis NN NN O
in NN NN O
mice NN NN O
to NN NN O
verify NN NN O
and NN NN O
define NN NN O
more NN NN O
precisely NN NN O
the NN NN O
location NN NN O
of NN NN O
the NN NN O
Pdeb NN NN O
locus NN NN O
6 NN NN O
. NN NN O

1 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
2 NN NN O
. NN NN O

3 NN NN O
cM NN NN O
distal NN NN O
of NN NN O
Mgsa NN NN O
on NN NN O
mouse NN NN O
chromosome NN NN O
5 NN NN O
. NN NN O

We NN NN O
have NN NN O
determined NN NN O
that NN NN O
the NN NN O
human NN NN O
gene NN NN O
( NN NN O
PDEB NN NN O
) NN NN O
maps NN NN O
to NN NN O
4p16 NN NN O
. NN NN O

3 NN NN O
, NN NN O
very NN NN O
close NN NN O
to NN NN O
the NN NN O
Huntington NN NN B-Modifier
disease NN NN I-Modifier
( NN NN O
HD NN NN B-Modifier
) NN NN O
region NN NN O
. NN NN O

Analysis NN NN O
of NN NN O
the NN NN O
comparative NN NN O
map NN NN O
for NN NN O
mice NN NN O
and NN NN O
humans NN NN O
shows NN NN O
that NN NN O
the NN NN O
mouse NN NN O
homologue NN NN O
of NN NN O
the NN NN O
HD NN NN B-Modifier
gene NN NN O
will NN NN O
reside NN NN O
on NN NN O
chromosome NN NN O
5 NN NN O
. NN NN O

Linkage NN NN O
of NN NN O
the NN NN O
mouse NN NN O
Pdeb NN NN O
locus NN NN O
with NN NN O
other NN NN O
homologues NN NN O
in NN NN O
the NN NN O
human NN NN O
4p16 NN NN O
. NN NN O

3 NN NN O
region NN NN O
is NN NN O
maintained NN NN O
but NN NN O
gene NN NN O
order NN NN O
is NN NN O
not NN NN O
, NN NN O
suggesting NN NN O
at NN NN O
least NN NN O
three NN NN O
possible NN NN O
sites NN NN O
for NN NN O
the NN NN O
corresponding NN NN O
mouse NN NN O
HD NN NN B-Modifier
gene NN NN O
. NN NN O

1316718 NN NN O
Coincident NN NN O
Kaposi NN NN B-SpecificDisease
sarcoma NN NN I-SpecificDisease
and NN NN O
T-cell NN NN B-SpecificDisease
lymphoma NN NN I-SpecificDisease
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
the NN NN O
Wiskott-Aldrich NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

A NN NN O
24 NN NN O
year NN NN O
old NN NN O
male NN NN O
with NN NN O
a NN NN O
history NN NN O
of NN NN O
eczema NN NN B-DiseaseClass
, NN NN O
recurrent NN NN O
mild NN NN O
infections NN NN O
, NN NN O
and NN NN O
thrombocytopenia NN NN B-SpecificDisease
consistent NN NN O
with NN NN O
the NN NN O
Wiskott-Aldrich NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
WAS NN NN B-SpecificDisease
) NN NN O
presented NN NN O
with NN NN O
a NN NN O
mediastinal NN NN O
mass NN NN O
, NN NN O
generalized NN NN O
lymphadenopathy NN NN B-SpecificDisease
, NN NN O
splenomegaly NN NN B-SpecificDisease
, NN NN O
and NN NN O
severe NN NN O
thrombocytopenia NN NN B-SpecificDisease
. NN NN O

Studies NN NN O
of NN NN O
immune NN NN O
function NN NN O
including NN NN O
immunoglobulin NN NN O
levels NN NN O
and NN NN O
T-cell NN NN O
subsets NN NN O
were NN NN O
normal NN NN O
. NN NN O

Furthermore NN NN O
, NN NN O
his NN NN O
T NN NN O
lymphocytes NN NN O
proliferated NN NN O
normally NN NN O
in NN NN O
response NN NN O
to NN NN O
phytohemagglutinin NN NN O
, NN NN O
concanavalin NN NN O
A NN NN O
, NN NN O
and NN NN O
the NN NN O
combination NN NN O
of NN NN O
neuraminidase NN NN O
/ NN NN O
galactose NN NN O
oxidase NN NN O
. NN NN O

However NN NN O
, NN NN O
their NN NN O
proliferative NN NN O
responses NN NN O
to NN NN O
anti-CD43 NN NN O
antibody NN NN O
and NN NN O
periodate NN NN O
were NN NN O
diminished NN NN O
, NN NN O
consistent NN NN O
with NN NN O
the NN NN O
clinical NN NN O
diagnosis NN NN O
of NN NN O
WAS NN NN B-SpecificDisease
. NN NN O

An NN NN O
initial NN NN O
inguinal NN NN O
lymph NN NN O
node NN NN O
biopsy NN NN O
surprisingly NN NN O
revealed NN NN O
Kaposi NN NN B-SpecificDisease
sarcoma NN NN I-SpecificDisease
. NN NN O

However NN NN O
, NN NN O
following NN NN O
splenectomy NN NN O
to NN NN O
increase NN NN O
the NN NN O
platelet NN NN O
count NN NN O
, NN NN O
biopsy NN NN O
of NN NN O
the NN NN O
mediastinal NN NN O
mass NN NN O
revealed NN NN O
T-cell NN NN B-SpecificDisease
large NN NN I-SpecificDisease
cell NN NN I-SpecificDisease
lymphoma NN NN I-SpecificDisease
. NN NN O

Studies NN NN O
of NN NN O
biopsied NN NN O
tissue NN NN O
for NN NN O
the NN NN O
presence NN NN O
of NN NN O
Epstein-Barr NN NN B-SpecificDisease
virus NN NN I-SpecificDisease
and NN NN O
cytomegalovirus NN NN B-SpecificDisease
were NN NN O
negative NN NN O
, NN NN O
as NN NN O
were NN NN O
studies NN NN O
of NN NN O
blood NN NN O
, NN NN O
including NN NN O
the NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
, NN NN O
for NN NN O
the NN NN O
presence NN NN O
of NN NN O
the NN NN O
human NN NN B-SpecificDisease
immunodeficiency NN NN I-SpecificDisease
virus NN NN I-SpecificDisease
( NN NN O
HIV NN NN B-SpecificDisease
) NN NN O
. NN NN O

This NN NN O
is NN NN O
the NN NN O
first NN NN O
report NN NN O
of NN NN O
Kaposi NN NN B-SpecificDisease
sarcoma NN NN I-SpecificDisease
arising NN NN O
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
a NN NN O
congenital NN NN B-DiseaseClass
immunodeficiency NN NN I-DiseaseClass
syndrome NN NN I-DiseaseClass
. NN NN O

Although NN NN O
Kaposi NN NN B-SpecificDisease
sarcoma NN NN I-SpecificDisease
can NN NN O
arise NN NN O
in NN NN O
the NN NN O
face NN NN O
of NN NN O
the NN NN O
severe NN NN O
immunosuppression NN NN O
that NN NN O
follows NN NN O
allograft NN NN O
transplantation NN NN O
and NN NN O
in NN NN O
patients NN NN O
infected NN NN O
with NN NN O
HIV NN NN B-SpecificDisease
, NN NN O
we NN NN O
postulate NN NN O
that NN NN O
longevity NN NN O
in NN NN O
the NN NN O
face NN NN O
of NN NN O
mild NN NN O
immunosuppression NN NN O
was NN NN O
the NN NN O
major NN NN O
factor NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
Kaposi NN NN B-SpecificDisease
sarcoma NN NN I-SpecificDisease
in NN NN O
this NN NN O
patient NN NN O
. NN NN O

. NN NN O

1317264 NN NN O
The NN NN O
APC NN NN B-Modifier
gene NN NN O
, NN NN O
responsible NN NN O
for NN NN O
familial NN NN B-SpecificDisease
adenomatous NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
, NN NN O
is NN NN O
mutated NN NN O
in NN NN O
human NN NN O
gastric NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

Although NN NN O
gastric NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
is NN NN O
the NN NN O
most NN NN O
common NN NN O
cancer NN NN B-DiseaseClass
in NN NN O
the NN NN O
world NN NN O
, NN NN O
genetic NN NN O
changes NN NN O
during NN NN O
its NN NN O
carcinogenesis NN NN O
are NN NN O
not NN NN O
well NN NN O
understood NN NN O
. NN NN O

Since NN NN O
some NN NN O
gastric NN NN B-SpecificDisease
cancers NN NN I-SpecificDisease
are NN NN O
considered NN NN O
to NN NN O
originate NN NN O
from NN NN O
the NN NN O
intestinal NN NN O
metaplasia NN NN O
, NN NN O
it NN NN O
is NN NN O
likely NN NN O
that NN NN O
the NN NN O
adenomatous NN NN B-Modifier
polyposis NN NN I-Modifier
coli NN NN I-Modifier
( NN NN O
APC NN NN B-Modifier
) NN NN O
gene NN NN O
, NN NN O
the NN NN O
mutation NN NN O
of NN NN O
which NN NN O
causes NN NN O
adenomatous NN NN B-SpecificDisease
polyps NN NN I-SpecificDisease
in NN NN I-SpecificDisease
the NN NN I-SpecificDisease
colon NN NN I-SpecificDisease
, NN NN O
is NN NN O
associated NN NN O
with NN NN O
carcinogenesis NN NN O
of NN NN O
gastric NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

Based NN NN O
on NN NN O
this NN NN O
idea NN NN O
, NN NN O
DNAs NN NN O
isolated NN NN O
from NN NN O
gastric NN NN B-SpecificDisease
cancers NN NN I-SpecificDisease
were NN NN O
examined NN NN O
by NN NN O
means NN NN O
of NN NN O
a NN NN O
RNase NN NN O
protection NN NN O
analysis NN NN O
coupled NN NN O
with NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
followed NN NN O
by NN NN O
sequencing NN NN O
of NN NN O
the NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
products NN NN O
. NN NN O

By NN NN O
screening NN NN O
nearly NN NN O
one-half NN NN O
of NN NN O
the NN NN O
coding NN NN O
region NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
in NN NN O
44 NN NN O
tumors NN NN B-DiseaseClass
, NN NN O
somatic NN NN O
mutations NN NN O
were NN NN O
detected NN NN O
in NN NN O
three NN NN O
tumors NN NN B-DiseaseClass
a NN NN O
missense NN NN O
mutation NN NN O
, NN NN O
a NN NN O
nonsense NN NN O
mutation NN NN O
, NN NN O
and NN NN O
a NN NN O
5-base NN NN O
pair NN NN O
deletion NN NN O
resulting NN NN O
in NN NN O
a NN NN O
frame NN NN O
shift NN NN O
which NN NN O
causes NN NN O
truncation NN NN O
of NN NN O
the NN NN O
gene NN NN O
product NN NN O
. NN NN O

These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
mutation NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
also NN NN O
plays NN NN O
an NN NN O
important NN NN O
role NN NN O
during NN NN O
the NN NN O
carcinogenesis NN NN O
of NN NN O
at NN NN O
least NN NN O
some NN NN O
gastric NN NN B-SpecificDisease
cancers NN NN I-SpecificDisease
. NN NN O

. NN NN O

1319059 NN NN O
A NN NN O
71-kilodalton NN NN O
protein NN NN O
is NN NN O
a NN NN O
major NN NN O
product NN NN O
of NN NN O
the NN NN O
Duchenne NN NN B-Modifier
muscular NN NN I-Modifier
dystrophy NN NN I-Modifier
gene NN NN O
in NN NN O
brain NN NN O
and NN NN O
other NN NN O
nonmuscle NN NN O
tissues NN NN O
. NN NN O

The NN NN O
known NN NN O
Duchenne NN NN B-Modifier
muscular NN NN I-Modifier
dystrophy NN NN I-Modifier
( NN NN O
DMD NN NN B-Modifier
) NN NN O
gene NN NN O
products NN NN O
, NN NN O
the NN NN O
muscle- NN NN O
and NN NN O
brain-type NN NN O
dystrophin NN NN O
isoforms NN NN O
, NN NN O
are NN NN O
427-kDa NN NN O
proteins NN NN O
translated NN NN O
from NN NN O
14-kilobase NN NN O
( NN NN O
kb NN NN O
) NN NN O
mRNAs NN NN O
. NN NN O

Recently NN NN O
we NN NN O
described NN NN O
a NN NN O
6 NN NN O
. NN NN O

5-kb NN NN O
mRNA NN NN O
that NN NN O
also NN NN O
is NN NN O
transcribed NN NN O
from NN NN O
the NN NN O
DMD NN NN B-Modifier
gene NN NN O
. NN NN O

Cloning NN NN O
and NN NN O
in NN NN O
vitro NN NN O
transcription NN NN O
and NN NN O
translation NN NN O
of NN NN O
the NN NN O
entire NN NN O
coding NN NN O
region NN NN O
show NN NN O
that NN NN O
the NN NN O
6 NN NN O
. NN NN O

5-kb NN NN O
mRNA NN NN O
encodes NN NN O
a NN NN O
70 NN NN O
. NN NN O

8-kDa NN NN O
protein NN NN O
that NN NN O
is NN NN O
a NN NN O
major NN NN O
product NN NN O
of NN NN O
the NN NN O
DMD NN NN B-Modifier
gene NN NN O
. NN NN O

It NN NN O
contains NN NN O
the NN NN O
C-terminal NN NN O
and NN NN O
the NN NN O
cysteine-rich NN NN O
domains NN NN O
of NN NN O
dystrophin NN NN O
, NN NN O
seven NN NN O
additional NN NN O
amino NN NN O
acids NN NN O
at NN NN O
the NN NN O
N NN NN O
terminus NN NN O
, NN NN O
and NN NN O
some NN NN O
modifications NN NN O
formed NN NN O
by NN NN O
alternative NN NN O
splicing NN NN O
in NN NN O
the NN NN O
C-terminal NN NN O
domain NN NN O
. NN NN O

It NN NN O
lacks NN NN O
the NN NN O
entire NN NN O
large NN NN O
domain NN NN O
of NN NN O
spectrin-like NN NN O
repeats NN NN O
and NN NN O
the NN NN O
actin-binding NN NN O
N-terminal NN NN O
domain NN NN O
of NN NN O
dystrophin NN NN O
. NN NN O

This NN NN O
protein NN NN O
is NN NN O
the NN NN O
major NN NN O
DMD NN NN B-Modifier
gene NN NN O
product NN NN O
in NN NN O
brain NN NN O
and NN NN O
other NN NN O
nonmuscle NN NN O
tissues NN NN O
but NN NN O
is NN NN O
undetectable NN NN O
in NN NN O
skeletal NN NN O
muscle NN NN O
extracts NN NN O
. NN NN O

1319838 NN NN O
Correlation NN NN O
between NN NN O
the NN NN O
location NN NN O
of NN NN O
germ-line NN NN O
mutations NN NN O
in NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
and NN NN O
the NN NN O
number NN NN O
of NN NN O
colorectal NN NN B-SpecificDisease
polyps NN NN I-SpecificDisease
in NN NN O
familial NN NN B-Modifier
adenomatous NN NN I-Modifier
polyposis NN NN I-Modifier
patients NN NN O
. NN NN O

Recently NN NN O
we NN NN O
have NN NN O
isolated NN NN O
the NN NN O
adenomatous NN NN B-Modifier
polyposis NN NN I-Modifier
coli NN NN I-Modifier
( NN NN O
APC NN NN B-Modifier
) NN NN O
gene NN NN O
which NN NN O
causes NN NN O
familial NN NN B-SpecificDisease
adenomatous NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
( NN NN O
FAP NN NN B-SpecificDisease
) NN NN O
, NN NN O
and NN NN O
its NN NN O
germ-line NN NN O
mutations NN NN O
in NN NN O
a NN NN O
substantial NN NN O
number NN NN O
of NN NN O
FAP NN NN B-Modifier
patients NN NN O
have NN NN O
been NN NN O
identified NN NN O
. NN NN O

On NN NN O
the NN NN O
basis NN NN O
of NN NN O
this NN NN O
information NN NN O
, NN NN O
we NN NN O
compared NN NN O
the NN NN O
location NN NN O
of NN NN O
germ-line NN NN O
mutations NN NN O
in NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
in NN NN O
22 NN NN O
unrelated NN NN O
patients NN NN O
( NN NN O
12 NN NN O
of NN NN O
whom NN NN O
have NN NN O
been NN NN O
reported NN NN O
previously NN NN O
) NN NN O
with NN NN O
the NN NN O
number NN NN O
of NN NN O
colorectal NN NN B-SpecificDisease
polyps NN NN I-SpecificDisease
developed NN NN O
in NN NN O
FAP NN NN B-Modifier
patients NN NN O
; NN NN O
17 NN NN O
were NN NN O
sparse NN NN O
types NN NN O
and NN NN O
five NN NN O
were NN NN O
profuse NN NN O
types NN NN O
. NN NN O

All NN NN O
but NN NN O
one NN NN O
of NN NN O
the NN NN O
mutations NN NN O
were NN NN O
considered NN NN O
to NN NN O
cause NN NN O
truncation NN NN O
of NN NN O
the NN NN O
gene NN NN O
product NN NN O
by NN NN O
frame-shift NN NN O
due NN NN O
to NN NN O
deletion NN NN O
( NN NN O
14 NN NN O
cases NN NN O
) NN NN O
or NN NN O
nonsense NN NN O
mutation NN NN O
( NN NN O
seven NN NN O
cases NN NN O
) NN NN O
. NN NN O

The NN NN O
location NN NN O
of NN NN O
the NN NN O
germ-line NN NN O
mutations NN NN O
seems NN NN O
to NN NN O
correlate NN NN O
with NN NN O
the NN NN O
two NN NN O
clinical NN NN O
types NN NN O
; NN NN O
germ-line NN NN O
mutations NN NN O
in NN NN O
five NN NN O
FAP NN NN B-Modifier
patients NN NN O
with NN NN O
profuse NN NN O
polyps NN NN B-DiseaseClass
were NN NN O
observed NN NN O
between NN NN O
codon NN NN O
1250 NN NN O
and NN NN O
codon NN NN O
1464 NN NN O
, NN NN O
whereas NN NN O
mutations NN NN O
in NN NN O
17 NN NN O
FAP NN NN B-Modifier
patients NN NN O
with NN NN O
fewer NN NN O
polyps NN NN B-DiseaseClass
were NN NN O
observed NN NN O
in NN NN O
the NN NN O
other NN NN O
regions NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
. NN NN O

The NN NN O
result NN NN O
suggests NN NN O
that NN NN O
the NN NN O
number NN NN O
of NN NN O
colorectal NN NN B-SpecificDisease
polyps NN NN I-SpecificDisease
in NN NN O
FAP NN NN B-Modifier
patients NN NN O
may NN NN O
be NN NN O
associated NN NN O
with NN NN O
a NN NN O
difference NN NN O
in NN NN O
the NN NN O
stability NN NN O
or NN NN O
biological NN NN O
function NN NN O
of NN NN O
the NN NN O
truncated NN NN O
APC NN NN B-Modifier
protein NN NN O
. NN NN O

. NN NN O

1322637 NN NN O
Identification NN NN O
and NN NN O
rapid NN NN O
detection NN NN O
of NN NN O
three NN NN O
Tay-Sachs NN NN B-Modifier
mutations NN NN O
in NN NN O
the NN NN O
Moroccan NN NN O
Jewish NN NN O
population NN NN O
. NN NN O

Infantile NN NN O
Tay-Sachs NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
TSD NN NN B-SpecificDisease
) NN NN O
is NN NN O
caused NN NN O
by NN NN O
mutations NN NN O
in NN NN O
the NN NN O
HEXA NN NN O
gene NN NN O
that NN NN O
result NN NN O
in NN NN O
the NN NN O
complete NN NN O
absence NN NN O
of NN NN O
beta-hexosaminidase NN NN O
A NN NN O
activity NN NN O
. NN NN O

It NN NN O
is NN NN O
well NN NN O
known NN NN O
that NN NN O
an NN NN O
elevated NN NN O
frequency NN NN O
of NN NN O
TSD NN NN B-Modifier
mutations NN NN O
exists NN NN O
among NN NN O
Ashkenazi NN NN O
Jews NN NN O
. NN NN O

More NN NN O
recently NN NN O
it NN NN O
has NN NN O
become NN NN O
apparent NN NN O
that NN NN O
elevated NN NN O
carrier NN NN O
frequencies NN NN O
for NN NN O
TSD NN NN B-SpecificDisease
also NN NN O
occur NN NN O
in NN NN O
several NN NN O
other NN NN O
ethnic NN NN O
groups NN NN O
, NN NN O
including NN NN O
Moroccan NN NN O
Jews NN NN O
, NN NN O
a NN NN O
subgroup NN NN O
of NN NN O
Sephardic NN NN O
Jews NN NN O
. NN NN O

Elsewhere NN NN O
we NN NN O
reported NN NN O
an NN NN O
in-frame NN NN O
deletion NN NN O
of NN NN O
one NN NN O
of NN NN O
the NN NN O
two NN NN O
adjacent NN NN O
phenylalanine NN NN O
codons NN NN O
at NN NN O
position NN NN O
304 NN NN O
or NN NN O
305 NN NN O
( NN NN O
delta NN NN O
F304 NN NN O
/ NN NN O
305 NN NN O
) NN NN O
in NN NN O
one NN NN O
HEXA NN NN O
allele NN NN O
of NN NN O
a NN NN O
Moroccan NN NN O
Jewish NN NN O
TSD NN NN B-Modifier
patient NN NN O
and NN NN O
in NN NN O
three NN NN O
obligate NN NN O
carriers NN NN O
from NN NN O
six NN NN O
unrelated NN NN O
Moroccan NN NN O
Jewish NN NN O
families NN NN O
. NN NN O

We NN NN O
have NN NN O
now NN NN O
identified NN NN O
two NN NN O
additional NN NN O
mutations NN NN O
within NN NN O
exon NN NN O
5 NN NN O
of NN NN O
the NN NN O
HEXA NN NN O
gene NN NN O
that NN NN O
account NN NN O
for NN NN O
the NN NN O
remaining NN NN O
TSD NN NN B-Modifier
alleles NN NN O
in NN NN O
the NN NN O
patient NN NN O
and NN NN O
carriers NN NN O
. NN NN O

One NN NN O
of NN NN O
the NN NN O
mutations NN NN O
is NN NN O
a NN NN O
novel NN NN O
C-to-G NN NN O
transversion NN NN O
, NN NN O
resulting NN NN O
in NN NN O
a NN NN O
replacement NN NN O
of NN NN O
Tyr180 NN NN O
by NN NN O
a NN NN O
stop NN NN O
codon NN NN O
. NN NN O

The NN NN O
other NN NN O
mutation NN NN O
is NN NN O
a NN NN O
G-to-A NN NN O
transition NN NN O
resulting NN NN O
in NN NN O
an NN NN O
Arg170-to-Gln NN NN O
substitution NN NN O
. NN NN O

This NN NN O
mutation NN NN O
is NN NN O
at NN NN O
a NN NN O
CpG NN NN O
site NN NN O
in NN NN O
a NN NN O
Japanese NN NN O
infant NN NN O
with NN NN O
Tay-Sachs NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
and NN NN O
was NN NN O
described NN NN O
elsewhere NN NN O
. NN NN O

Analysis NN NN O
of NN NN O
nine NN NN O
obligate NN NN O
carriers NN NN O
from NN NN O
seven NN NN O
unrelated NN NN O
families NN NN O
showed NN NN O
that NN NN O
four NN NN O
harbor NN NN O
the NN NN O
delta NN NN O
F304 NN NN O
/ NN NN O
305 NN NN O
mutation NN NN O
, NN NN O
two NN NN O
the NN NN O
Arg170 NN NN O
-- NN NN O
-- NN NN O
Gln NN NN O
mutation NN NN O
, NN NN O
and NN NN O
one NN NN O
the NN NN O
Tyr180 NN NN O
-- NN NN O
-- NN NN O
Stop NN NN O
mutation NN NN O
. NN NN O

We NN NN O
also NN NN O
have NN NN O
developed NN NN O
rapid NN NN O
, NN NN O
nonradioactive NN NN O
assays NN NN O
for NN NN O
the NN NN O
detection NN NN O
of NN NN O
each NN NN O
mutation NN NN O
, NN NN O
which NN NN O
should NN NN O
be NN NN O
helpful NN NN O
for NN NN O
carrier NN NN O
screening NN NN O
. NN NN O

. NN NN O

1323345 NN NN O
Molecular NN NN O
characterization NN NN O
of NN NN O
glucose-6-phosphate NN NN B-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
( NN NN I-SpecificDisease
G6PD NN NN I-SpecificDisease
) NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
by NN NN O
natural NN NN O
and NN NN O
amplification NN NN O
created NN NN O
restriction NN NN O
sites NN NN O
: NN NN O
five NN NN O
mutations NN NN O
account NN NN O
for NN NN O
most NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
cases NN NN O
in NN NN O
Taiwan NN NN O
. NN NN O

We NN NN O
have NN NN O
developed NN NN O
a NN NN O
rapid NN NN O
and NN NN O
simple NN NN O
method NN NN O
to NN NN O
diagnose NN NN O
the NN NN O
molecular NN NN O
defects NN NN O
of NN NN O
glucose-6-phosphate NN NN B-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
( NN NN I-SpecificDisease
G6PD NN NN I-SpecificDisease
) NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
Chinese NN NN O
in NN NN O
Taiwan NN NN O
. NN NN O

This NN NN O
method NN NN O
involves NN NN O
the NN NN O
selective NN NN O
amplification NN NN O
of NN NN O
a NN NN O
DNA NN NN O
fragment NN NN O
from NN NN O
human NN NN O
G6PD NN NN O
gene NN NN O
with NN NN O
specific NN NN O
oligonucleotide NN NN O
primers NN NN O
followed NN NN O
by NN NN O
digestion NN NN O
with NN NN O
restriction NN NN O
enzymes NN NN O
that NN NN O
recognize NN NN O
artificially NN NN O
created NN NN O
or NN NN O
naturally NN NN O
occurring NN NN O
restriction NN NN O
sites NN NN O
. NN NN O

Ninety-four NN NN O
Chinese NN NN O
males NN NN O
with NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
were NN NN O
studied NN NN O
. NN NN O

The NN NN O
results NN NN O
show NN NN O
that NN NN O
50 NN NN O
% NN NN O
( NN NN O
47 NN NN O
of NN NN O
94 NN NN O
) NN NN O
were NN NN O
G NN NN O
to NN NN O
T NN NN O
mutation NN NN O
at NN NN O
nucleotide NN NN O
( NN NN O
nt NN NN O
) NN NN O
1376 NN NN O
, NN NN O
21 NN NN O
. NN NN O

3 NN NN O
% NN NN O
( NN NN O
20 NN NN O
of NN NN O
94 NN NN O
) NN NN O
were NN NN O
G NN NN O
to NN NN O
A NN NN O
mutation NN NN O
at NN NN O
nt NN NN O
1388 NN NN O
, NN NN O
7 NN NN O
. NN NN O

4 NN NN O
% NN NN O
( NN NN O
7 NN NN O
of NN NN O
94 NN NN O
) NN NN O
were NN NN O
A NN NN O
to NN NN O
G NN NN O
mutation NN NN O
at NN NN O
nt NN NN O
493 NN NN O
, NN NN O
7 NN NN O
. NN NN O

4 NN NN O
% NN NN O
( NN NN O
7 NN NN O
of NN NN O
94 NN NN O
) NN NN O
were NN NN O
A NN NN O
to NN NN O
G NN NN O
mutation NN NN O
at NN NN O
nt NN NN O
95 NN NN O
, NN NN O
4 NN NN O
. NN NN O

2 NN NN O
% NN NN O
( NN NN O
4 NN NN O
of NN NN O
94 NN NN O
) NN NN O
were NN NN O
C NN NN O
to NN NN O
T NN NN O
mutation NN NN O
at NN NN O
nt NN NN O
1024 NN NN O
, NN NN O
1 NN NN O
. NN NN O

1 NN NN O
% NN NN O
( NN NN O
1 NN NN O
of NN NN O
94 NN NN O
) NN NN O
was NN NN O
G NN NN O
to NN NN O
T NN NN O
mutation NN NN O
at NN NN O
nt NN NN O
392 NN NN O
, NN NN O
and NN NN O
1 NN NN O
. NN NN O

1 NN NN O
% NN NN O
( NN NN O
1 NN NN O
of NN NN O
94 NN NN O
) NN NN O
was NN NN O
G NN NN O
to NN NN O
A NN NN O
mutation NN NN O
at NN NN O
nt NN NN O
487 NN NN O
. NN NN O

These NN NN O
results NN NN O
show NN NN O
that NN NN O
the NN NN O
former NN NN O
five NN NN O
mutations NN NN O
account NN NN O
for NN NN O
more NN NN O
than NN NN O
90 NN NN O
% NN NN O
of NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
cases NN NN O
in NN NN O
Taiwan NN NN O
. NN NN O

Aside NN NN O
from NN NN O
showing NN NN O
that NN NN O
G NN NN O
to NN NN O
T NN NN O
change NN NN O
at NN NN O
nt NN NN O
1376 NN NN O
is NN NN O
the NN NN O
most NN NN O
common NN NN O
mutation NN NN O
, NN NN O
our NN NN O
research NN NN O
indicates NN NN O
that NN NN O
nt NN NN O
493 NN NN O
mutation NN NN O
is NN NN O
a NN NN O
frequent NN NN O
mutation NN NN O
among NN NN O
Chinese NN NN O
in NN NN O
Taiwan NN NN O
. NN NN O

We NN NN O
compared NN NN O
G6PD NN NN O
activity NN NN O
among NN NN O
different NN NN O
mutations NN NN O
, NN NN O
without NN NN O
discovering NN NN O
significant NN NN O
differences NN NN O
between NN NN O
them NN NN O
. NN NN O

1324223 NN NN O
Eight NN NN O
novel NN NN O
inactivating NN NN O
germ NN NN O
line NN NN O
mutations NN NN O
at NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
identified NN NN O
by NN NN O
denaturing NN NN O
gradient NN NN O
gel NN NN O
electrophoresis NN NN O
. NN NN O

Familial NN NN B-SpecificDisease
adenomatous NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
( NN NN O
FAP NN NN B-SpecificDisease
) NN NN O
is NN NN O
a NN NN O
dominantly NN NN O
inherited NN NN O
condition NN NN O
predisposing NN NN O
to NN NN O
colorectal NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

The NN NN O
recent NN NN O
isolation NN NN O
of NN NN O
the NN NN O
responsible NN NN O
gene NN NN O
( NN NN O
adenomatous NN NN B-SpecificDisease
polyposis NN NN I-SpecificDisease
coli NN NN I-SpecificDisease
or NN NN O
APC NN NN B-SpecificDisease
) NN NN O
has NN NN O
facilitated NN NN O
the NN NN O
search NN NN O
for NN NN O
germ NN NN O
line NN NN O
mutations NN NN O
in NN NN O
affected NN NN O
individuals NN NN O
. NN NN O

Previous NN NN O
authors NN NN O
have NN NN O
used NN NN O
the NN NN O
RNase NN NN O
protection NN NN O
assay NN NN O
and NN NN O
the NN NN O
single-strand NN NN O
conformation NN NN O
polymorphisms NN NN O
procedure NN NN O
to NN NN O
screen NN NN O
for NN NN O
mutations NN NN O
. NN NN O

In NN NN O
this NN NN O
study NN NN O
we NN NN O
used NN NN O
denaturing NN NN O
gradient NN NN O
gel NN NN O
electrophoresis NN NN O
( NN NN O
DGGE NN NN O
) NN NN O
. NN NN O

DGGE NN NN O
analysis NN NN O
of NN NN O
10 NN NN O
APC NN NN B-Modifier
exons NN NN O
( NN NN O
4 NN NN O
, NN NN O
5 NN NN O
, NN NN O
7 NN NN O
, NN NN O
8 NN NN O
, NN NN O
9 NN NN O
, NN NN O
10 NN NN O
, NN NN O
12 NN NN O
, NN NN O
13 NN NN O
, NN NN O
14 NN NN O
, NN NN O
and NN NN O
part NN NN O
of NN NN O
15 NN NN O
) NN NN O
in NN NN O
33 NN NN O
unrelated NN NN O
Dutch NN NN O
FAP NN NN B-Modifier
patients NN NN O
has NN NN O
led NN NN O
to NN NN O
the NN NN O
identification NN NN O
of NN NN O
eight NN NN O
novel NN NN O
germ NN NN O
line NN NN O
mutations NN NN O
resulting NN NN O
in NN NN O
stop NN NN O
codons NN NN O
or NN NN O
frameshifts NN NN O
. NN NN O

The NN NN O
results NN NN O
reported NN NN O
here NN NN O
indicate NN NN O
that NN NN O
( NN NN O
1 NN NN O
) NN NN O
familial NN NN B-SpecificDisease
adenomatous NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
is NN NN O
caused NN NN O
by NN NN O
an NN NN O
extremely NN NN O
heterogeneous NN NN O
spectrum NN NN O
of NN NN O
point NN NN O
mutations NN NN O
; NN NN O
( NN NN O
2 NN NN O
) NN NN O
all NN NN O
the NN NN O
mutations NN NN O
found NN NN O
in NN NN O
this NN NN O
study NN NN O
are NN NN O
chain NN NN O
terminating NN NN O
; NN NN O
and NN NN O
( NN NN O
3 NN NN O
) NN NN O
DGGE NN NN O
represents NN NN O
a NN NN O
rapid NN NN O
and NN NN O
sensitive NN NN O
technique NN NN O
for NN NN O
the NN NN O
detection NN NN O
of NN NN O
mutations NN NN O
in NN NN O
the NN NN O
unusually NN NN O
large NN NN O
APC NN NN B-Modifier
gene NN NN O
. NN NN O

An NN NN O
extension NN NN O
of NN NN O
the NN NN O
DGGE NN NN O
analysis NN NN O
to NN NN O
the NN NN O
entire NN NN O
coding NN NN O
region NN NN O
in NN NN O
a NN NN O
sufficient NN NN O
number NN NN O
of NN NN O
clinically NN NN O
well-characterized NN NN O
, NN NN O
unrelated NN NN O
patients NN NN O
will NN NN O
facilitate NN NN O
the NN NN O
establishment NN NN O
of NN NN O
genotype-phenotype NN NN O
correlations NN NN O
. NN NN O

On NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
an NN NN O
extremely NN NN O
heterogeneous NN NN O
spectrum NN NN O
of NN NN O
mutations NN NN O
spread NN NN O
throughout NN NN O
the NN NN O
entire NN NN O
length NN NN O
of NN NN O
the NN NN O
large NN NN O
APC NN NN B-Modifier
gene NN NN O
among NN NN O
the NN NN O
FAP NN NN B-Modifier
patients NN NN O
indicates NN NN O
that NN NN O
this NN NN O
approach NN NN O
may NN NN O
not NN NN O
be NN NN O
useful NN NN O
as NN NN O
a NN NN O
rapid NN NN O
presymptomatic NN NN O
diagnostic NN NN O
procedure NN NN O
in NN NN O
a NN NN O
routine NN NN O
laboratory NN NN O
. NN NN O

Nevertheless NN NN O
, NN NN O
the NN NN O
above NN NN O
DGGE NN NN O
approach NN NN O
has NN NN O
incidentally NN NN O
led NN NN O
to NN NN O
the NN NN O
identification NN NN O
of NN NN O
a NN NN O
common NN NN O
polymorphism NN NN O
in NN NN O
exon NN NN O
13 NN NN O
. NN NN O

Such NN NN O
intragenic NN NN O
polymorphisms NN NN O
offer NN NN O
a NN NN O
practical NN NN O
approach NN NN O
to NN NN O
a NN NN O
more NN NN O
rapid NN NN O
procedure NN NN O
for NN NN O
presymptomatic NN NN O
diagnosis NN NN O
of NN NN O
FAP NN NN B-SpecificDisease
by NN NN O
linkage NN NN O
analysis NN NN O
in NN NN O
informative NN NN O
families NN NN O
. NN NN O

. NN NN O

1325652 NN NN O
Yeast NN NN O
artificial NN NN O
chromosomes NN NN O
for NN NN O
the NN NN O
molecular NN NN O
analysis NN NN O
of NN NN O
the NN NN O
familial NN NN B-Modifier
polyposis NN NN I-Modifier
APC NN NN I-Modifier
gene NN NN O
region NN NN O
. NN NN O

Two NN NN O
yeast NN NN O
artificial NN NN O
chromosomes NN NN O
( NN NN O
YACs NN NN O
) NN NN O
spanning NN NN O
a NN NN O
total NN NN O
distance NN NN O
of NN NN O
1 NN NN O
. NN NN O

1 NN NN O
megabase NN NN O
pairs NN NN O
of NN NN O
DNA NN NN O
around NN NN O
the NN NN O
MCC NN NN O
( NN NN O
for NN NN O
mutated NN NN O
in NN NN O
colorectal NN NN B-SpecificDisease
carcinoma NN NN I-SpecificDisease
) NN NN O
and NN NN O
APC NN NN B-Modifier
( NN NN O
for NN NN O
adenomatous NN NN B-Modifier
polyposis NN NN I-Modifier
coli NN NN I-Modifier
) NN NN O
genes NN NN O
at NN NN O
5q21 NN NN O
have NN NN O
been NN NN O
isolated NN NN O
and NN NN O
characterized NN NN O
. NN NN O

Starting NN NN O
from NN NN O
the NN NN O
MCC NN NN O
gene NN NN O
, NN NN O
a NN NN O
strategy NN NN O
was NN NN O
undertaken NN NN O
to NN NN O
identify NN NN O
constitutional NN NN O
submicroscopic NN NN O
deletions NN NN O
in NN NN O
familial NN NN B-Modifier
adenomatous NN NN I-Modifier
polyposis NN NN I-Modifier
patients NN NN O
that NN NN O
might NN NN O
considerably NN NN O
narrow NN NN O
down NN NN O
the NN NN O
position NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
. NN NN O

To NN NN O
this NN NN O
end NN NN O
, NN NN O
YACs NN NN O
identified NN NN O
by NN NN O
the NN NN O
MCC NN NN O
gene NN NN O
were NN NN O
screened NN NN O
across NN NN O
a NN NN O
chromosome NN NN O
5-specific NN NN O
cosmid NN NN O
library NN NN O
to NN NN O
provide NN NN O
a NN NN O
source NN NN O
of NN NN O
DNA NN NN O
probes NN NN O
for NN NN O
genomic NN NN O
scanning NN NN O
. NN NN O

The NN NN O
cosmids NN NN O
isolated NN NN O
from NN NN O
these NN NN O
experiments NN NN O
were NN NN O
used NN NN O
to NN NN O
screen NN NN O
a NN NN O
panel NN NN O
of NN NN O
somatic NN NN O
cell NN NN O
hybrids NN NN O
containing NN NN O
chromosome NN NN O
5 NN NN O
segregated NN NN O
from NN NN O
patients NN NN O
suspected NN NN O
to NN NN O
carry NN NN O
putative NN NN O
interstitial NN NN O
deletions NN NN O
. NN NN O

This NN NN O
screening NN NN O
approach NN NN O
led NN NN O
to NN NN O
the NN NN O
confirmation NN NN O
of NN NN O
a NN NN O
small NN NN O
heterozygous NN NN O
deletion NN NN O
in NN NN O
a NN NN O
polyposis NN NN B-Modifier
patient NN NN O
that NN NN O
overlaps NN NN O
one NN NN O
of NN NN O
the NN NN O
two NN NN O
isolated NN NN O
YACs NN NN O
. NN NN O

This NN NN O
YAC NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
contain NN NN O
the NN NN O
entire NN NN O
APC NN NN B-Modifier
gene NN NN O
, NN NN O
in NN NN O
addition NN NN O
to NN NN O
a NN NN O
significant NN NN O
portion NN NN O
of NN NN O
DNA NN NN O
flanking NN NN O
the NN NN O
5 NN NN O
end NN NN O
of NN NN O
the NN NN O
gene NN NN O
, NN NN O
and NN NN O
should NN NN O
therefore NN NN O
prove NN NN O
a NN NN O
valuable NN NN O
resource NN NN O
for NN NN O
functional NN NN O
studies NN NN O
by NN NN O
transfer NN NN O
to NN NN O
colorectal NN NN B-Modifier
tumor NN NN I-Modifier
-derived NN NN O
cell NN NN O
lines NN NN O
. NN NN O

1327525 NN NN O
Inherited NN NN O
WT1 NN NN O
mutation NN NN O
in NN NN O
Denys-Drash NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

Patients NN NN O
with NN NN O
the NN NN O
Denys-Drash NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
Wilms NN NN B-SpecificDisease
tumor NN NN I-SpecificDisease
, NN NN O
genital NN NN B-DiseaseClass
anomalies NN NN I-DiseaseClass
, NN NN O
and NN NN O
nephropathy NN NN B-SpecificDisease
) NN NN O
have NN NN O
been NN NN O
demonstrated NN NN O
to NN NN O
carry NN NN O
de NN NN O
novo NN NN O
constitutional NN NN O
mutations NN NN O
in NN NN O
WT1 NN NN O
, NN NN O
the NN NN O
Wilms NN NN B-Modifier
tumor NN NN I-Modifier
gene NN NN O
at NN NN O
chromosome NN NN O
11p13 NN NN O
. NN NN O

We NN NN O
report NN NN O
three NN NN O
new NN NN O
cases NN NN O
, NN NN O
two NN NN O
carrying NN NN O
a NN NN O
previously NN NN O
described NN NN O
WT1 NN NN O
exon NN NN O
9 NN NN O
mutation NN NN O
and NN NN O
one NN NN O
with NN NN O
a NN NN O
novel NN NN O
WT1 NN NN O
exon NN NN O
8 NN NN O
mutation NN NN O
. NN NN O

However NN NN O
, NN NN O
unlike NN NN O
patients NN NN O
in NN NN O
previous NN NN O
reports NN NN O
, NN NN O
one NN NN O
of NN NN O
our NN NN O
three NN NN O
patients NN NN O
inherited NN NN O
the NN NN O
affected NN NN O
allele NN NN O
from NN NN O
his NN NN O
phenotypically NN NN O
unaffected NN NN O
father NN NN O
. NN NN O

This NN NN O
observation NN NN O
indicates NN NN O
that NN NN O
the NN NN O
WT1 NN NN O
exon NN NN O
9 NN NN O
mutation NN NN O
affecting NN NN O
394Arg NN NN O
demonstrated NN NN O
in NN NN O
over NN NN O
one-half NN NN O
of NN NN O
the NN NN O
patients NN NN O
with NN NN O
the NN NN O
Denys-Drash NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
may NN NN O
exhibit NN NN O
incomplete NN NN O
penetrance NN NN O
. NN NN O

Consequently NN NN O
, NN NN O
familial NN NN O
studies NN NN O
in NN NN O
patients NN NN O
affected NN NN O
by NN NN O
this NN NN O
syndrome NN NN O
are NN NN O
recommended NN NN O
. NN NN O

. NN NN O

1334370 NN NN O
Submicroscopic NN NN O
deletions NN NN O
at NN NN O
the NN NN O
WAGR NN NN B-Modifier
locus NN NN O
, NN NN O
revealed NN NN O
by NN NN O
nonradioactive NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
. NN NN O

Fluorescence NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
( NN NN O
FISH NN NN O
) NN NN O
with NN NN O
biotin-labeled NN NN O
probes NN NN O
mapping NN NN O
to NN NN O
11p13 NN NN O
has NN NN O
been NN NN O
used NN NN O
for NN NN O
the NN NN O
molecular NN NN O
analysis NN NN O
of NN NN O
deletions NN NN O
of NN NN O
the NN NN O
WAGR NN NN B-Modifier
( NN NN O
Wilms NN NN B-Modifier
tumor NN NN I-Modifier
, NN NN O
aniridia NN NN B-Modifier
, NN NN O
genitourinary NN NN B-Modifier
abnormalities NN NN I-Modifier
, NN NN O
and NN NN O
mental NN NN B-Modifier
retardation NN NN I-Modifier
) NN NN O
locus NN NN O
. NN NN O

We NN NN O
have NN NN O
detected NN NN O
a NN NN O
submicroscopic NN NN O
11p13 NN NN O
deletion NN NN O
in NN NN O
a NN NN O
child NN NN O
with NN NN O
inherited NN NN O
aniridia NN NN B-SpecificDisease
who NN NN O
subsequently NN NN O
presented NN NN O
with NN NN O
Wilms NN NN B-SpecificDisease
tumor NN NN I-SpecificDisease
in NN NN O
a NN NN O
horseshoe NN NN O
kidney NN NN O
, NN NN O
only NN NN O
revealed NN NN O
at NN NN O
surgery NN NN O
. NN NN O

The NN NN O
mother NN NN O
, NN NN O
who NN NN O
has NN NN O
aniridia NN NN B-SpecificDisease
, NN NN O
was NN NN O
also NN NN O
found NN NN O
to NN NN O
carry NN NN O
a NN NN O
deletion NN NN O
including NN NN O
both NN NN O
the NN NN O
aniridia NN NN B-Modifier
candidate NN NN O
gene NN NN O
( NN NN O
AN2 NN NN O
) NN NN O
and NN NN O
the NN NN O
Wilms NN NN B-Modifier
tumor NN NN I-Modifier
predisposition NN NN O
gene NN NN O
( NN NN O
WT1 NN NN O
) NN NN O
. NN NN O

This NN NN O
is NN NN O
therefore NN NN O
a NN NN O
rare NN NN O
case NN NN O
of NN NN O
an NN NN O
inherited NN NN O
WAGR NN NN B-Modifier
deletion NN NN O
. NN NN O

Wilms NN NN B-SpecificDisease
tumor NN NN I-SpecificDisease
has NN NN O
so NN NN O
far NN NN O
only NN NN O
been NN NN O
associated NN NN O
with NN NN O
sporadic NN NN O
de NN NN O
novo NN NN O
aniridia NN NN B-Modifier
cases NN NN O
. NN NN O

We NN NN O
have NN NN O
shown NN NN O
that NN NN O
a NN NN O
cosmid NN NN O
probe NN NN O
for NN NN O
a NN NN O
candidate NN NN O
aniridia NN NN B-Modifier
gene NN NN O
, NN NN O
homologous NN NN O
to NN NN O
the NN NN O
mouse NN NN O
Pax-6 NN NN O
gene NN NN O
, NN NN O
is NN NN O
deleted NN NN O
in NN NN O
cell NN NN O
lines NN NN O
from NN NN O
aniridia NN NN B-Modifier
patients NN NN O
with NN NN O
previously NN NN O
characterized NN NN O
deletions NN NN O
at NN NN O
11p13 NN NN O
, NN NN O
while NN NN O
another NN NN O
cosmid NN NN O
marker NN NN O
mapping NN NN O
between NN NN O
two NN NN O
aniridia NN NN B-Modifier
-associated NN NN O
translocation NN NN O
breakpoints NN NN O
( NN NN O
and NN NN O
hence NN NN O
a NN NN O
second NN NN O
candidate NN NN O
marker NN NN O
) NN NN O
is NN NN O
present NN NN O
on NN NN O
both NN NN O
chromosomes NN NN O
. NN NN O

These NN NN O
results NN NN O
support NN NN O
the NN NN O
Pax-6 NN NN O
homologue NN NN O
as NN NN O
a NN NN O
strong NN NN O
candidate NN NN O
for NN NN O
the NN NN O
AN2 NN NN O
gene NN NN O
. NN NN O

FISH NN NN O
with NN NN O
cosmid NN NN O
probes NN NN O
has NN NN O
proved NN NN O
to NN NN O
be NN NN O
a NN NN O
fast NN NN O
and NN NN O
reliable NN NN O
technique NN NN O
for NN NN O
the NN NN O
molecular NN NN O
analysis NN NN O
of NN NN O
deletions NN NN O
. NN NN O

It NN NN O
can NN NN O
be NN NN O
used NN NN O
with NN NN O
limited NN NN O
amounts NN NN O
of NN NN O
material NN NN O
and NN NN O
has NN NN O
strong NN NN O
potential NN NN O
for NN NN O
clinical NN NN O
applications NN NN O
. NN NN O

. NN NN O

133535 NN NN O
Linkage NN NN O
of NN NN O
gene NN NN O
for NN NN O
C2 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
and NN NN O
the NN NN O
major NN NN O
histocompatibility NN NN O
complex NN NN O
MHC NN NN O
in NN NN O
man NN NN O
. NN NN O

Family NN NN O
study NN NN O
of NN NN O
a NN NN O
further NN NN O
case NN NN O
. NN NN O

Close NN NN O
linkage NN NN O
between NN NN O
HL-A NN NN O
and NN NN O
C2 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
was NN NN O
first NN NN O
reported NN NN O
by NN NN O
FU NN NN O
and NN NN O
co-workers NN NN O
in NN NN O
1974 NN NN O
. NN NN O

We NN NN O
present NN NN O
here NN NN O
a NN NN O
pedigree NN NN O
of NN NN O
a NN NN O
31-year-old NN NN O
C2-deficient NN NN B-Modifier
individual NN NN O
with NN NN O
clinical NN NN O
manifestations NN NN O
of NN NN O
Hodgkins NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

The NN NN O
following NN NN O
markers NN NN O
were NN NN O
tested NN NN O
C2 NN NN O
levels NN NN O
, NN NN O
factor NN NN O
B NN NN O
polymorphism NN NN O
, NN NN O
blood NN NN O
groups NN NN O
, NN NN O
and NN NN O
enzyme NN NN O
typing NN NN O
. NN NN O

In NN NN O
addition NN NN O
to NN NN O
close NN NN O
linkage NN NN O
between NN NN O
HL-A NN NN O
and NN NN O
C2 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
, NN NN O
both NN NN O
parents NN NN O
were NN NN O
heterozygous NN NN O
for NN NN O
Bf NN NN O
( NN NN O
HL-A NN NN O
linked NN NN O
, NN NN O
electrophoretic NN NN O
variation NN NN O
of NN NN O
B NN NN O
) NN NN O
. NN NN O

The NN NN O
two NN NN O
HL-A NN NN O
haplotypes NN NN O
closely NN NN O
linked NN NN O
to NN NN O
C2 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
are NN NN O
different NN NN O
2 NN NN O
, NN NN O
W18 NN NN O
and NN NN O
W24 NN NN O
, NN NN O
W18 NN NN O
. NN NN O

They NN NN O
share NN NN O
, NN NN O
however NN NN O
, NN NN O
the NN NN O
SD2 NN NN O
antigen NN NN O
W18 NN NN O
and NN NN O
the NN NN O
LD NN NN O
type NN NN O
7a NN NN O
. NN NN O

. NN NN O

1338764 NN NN O
Screening NN NN O
for NN NN O
germ-line NN NN O
mutations NN NN O
in NN NN O
familial NN NN B-Modifier
adenomatous NN NN I-Modifier
polyposis NN NN I-Modifier
patients NN NN O
: NN NN O
61 NN NN O
new NN NN O
patients NN NN O
and NN NN O
a NN NN O
summary NN NN O
of NN NN O
150 NN NN O
unrelated NN NN O
patients NN NN O
. NN NN O

We NN NN O
report NN NN O
here NN NN O
the NN NN O
result NN NN O
of NN NN O
a NN NN O
screening NN NN O
for NN NN O
germ-line NN NN O
mutations NN NN O
in NN NN O
the NN NN O
adenomatous NN NN B-Modifier
polyposis NN NN I-Modifier
coli NN NN I-Modifier
( NN NN O
APC NN NN B-Modifier
) NN NN O
gene NN NN O
in NN NN O
61 NN NN O
new NN NN O
familial NN NN B-Modifier
adenomatous NN NN I-Modifier
polyposis NN NN I-Modifier
( NN NN O
FAP NN NN B-Modifier
) NN NN O
patients NN NN O
as NN NN O
well NN NN O
as NN NN O
a NN NN O
summary NN NN O
of NN NN O
the NN NN O
results NN NN O
of NN NN O
150 NN NN O
patients NN NN O
. NN NN O

Examination NN NN O
of NN NN O
the NN NN O
entire NN NN O
coding NN NN O
region NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
, NN NN O
based NN NN O
on NN NN O
a NN NN O
ribonuclease NN NN O
protection NN NN O
assay NN NN O
coupled NN NN O
with NN NN O
the NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
( NN NN O
PCR NN NN O
) NN NN O
, NN NN O
disclosed NN NN O
mutations NN NN O
that NN NN O
were NN NN O
considered NN NN O
to NN NN O
cause NN NN O
significant NN NN O
defects NN NN O
in NN NN O
the NN NN O
APC NN NN B-Modifier
product NN NN O
in NN NN O
97 NN NN O
of NN NN O
150 NN NN O
unrelated NN NN O
FAP NN NN B-Modifier
patients NN NN O
. NN NN O

Our NN NN O
findings NN NN O
revealed NN NN O
the NN NN O
following NN NN O
characteristics NN NN O
of NN NN O
the NN NN O
germ-line NN NN O
mutations NN NN O
of NN NN O
APC NN NN O
1 NN NN O
) NN NN O
the NN NN O
great NN NN O
majority NN NN O
of NN NN O
the NN NN O
mutations NN NN O
were NN NN O
found NN NN O
to NN NN O
truncate NN NN O
the NN NN O
APC NN NN B-Modifier
product NN NN O
; NN NN O
2 NN NN O
) NN NN O
almost NN NN O
all NN NN O
of NN NN O
the NN NN O
mutations NN NN O
were NN NN O
located NN NN O
within NN NN O
the NN NN O
first NN NN O
half NN NN O
of NN NN O
the NN NN O
coding NN NN O
region NN NN O
; NN NN O
3 NN NN O
) NN NN O
no NN NN O
correlation NN NN O
was NN NN O
observed NN NN O
between NN NN O
the NN NN O
locations NN NN O
of NN NN O
germ-line NN NN O
mutations NN NN O
and NN NN O
extracolonic NN NN O
manifestations NN NN O
in NN NN O
FAP NN NN B-Modifier
patients NN NN O
; NN NN O
4 NN NN O
) NN NN O
more NN NN O
than NN NN O
80 NN NN O
% NN NN O
of NN NN O
base NN NN O
substitutions NN NN O
in NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
were NN NN O
from NN NN O
cytosine NN NN O
to NN NN O
other NN NN O
nucleotides NN NN O
, NN NN O
nearly NN NN O
one-third NN NN O
of NN NN O
which NN NN O
occurred NN NN O
at NN NN O
the NN NN O
GpG NN NN O
site NN NN O
. NN NN O

Our NN NN O
results NN NN O
provide NN NN O
information NN NN O
helpful NN NN O
to NN NN O
an NN NN O
understanding NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
and NN NN O
will NN NN O
also NN NN O
contribute NN NN O
to NN NN O
presymptomatic NN NN O
diagnosis NN NN O
of NN NN O
members NN NN O
in NN NN O
FAP NN NN B-Modifier
families NN NN O
. NN NN O

. NN NN O

1338904 NN NN O
Somatic NN NN O
mutations NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
in NN NN O
colorectal NN NN B-DiseaseClass
tumors NN NN I-DiseaseClass
: NN NN O
mutation NN NN O
cluster NN NN O
region NN NN O
in NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
. NN NN O

We NN NN O
examined NN NN O
somatic NN NN O
mutations NN NN O
of NN NN O
the NN NN O
adenomatous NN NN B-Modifier
polyposis NN NN I-Modifier
coli NN NN I-Modifier
( NN NN O
APC NN NN B-Modifier
) NN NN O
gene NN NN O
in NN NN O
63 NN NN O
colorectal NN NN B-DiseaseClass
tumors NN NN I-DiseaseClass
( NN NN O
16 NN NN O
adenomas NN NN B-DiseaseClass
and NN NN O
47 NN NN O
carcinomas NN NN B-DiseaseClass
) NN NN O
developed NN NN O
in NN NN O
familial NN NN B-Modifier
adenomatous NN NN I-Modifier
polyposis NN NN I-Modifier
( NN NN O
FAP NN NN B-Modifier
) NN NN O
and NN NN O
non-FAP NN NN O
patients NN NN O
. NN NN O

In NN NN O
addition NN NN O
to NN NN O
loss NN NN O
of NN NN O
heterozygosity NN NN O
( NN NN O
LOH NN NN O
) NN NN O
at NN NN O
the NN NN O
APC NN NN B-Modifier
locus NN NN O
in NN NN O
30 NN NN O
tumors NN NN B-DiseaseClass
, NN NN O
43 NN NN O
other NN NN O
somatic NN NN O
mutations NN NN O
were NN NN O
detected NN NN O
. NN NN O

Twenty-one NN NN O
of NN NN O
them NN NN O
were NN NN O
point NN NN O
mutations NN NN O
; NN NN O
16 NN NN O
nonsense NN NN O
and NN NN O
two NN NN O
missense NN NN O
mutations NN NN O
, NN NN O
and NN NN O
three NN NN O
occurred NN NN O
in NN NN O
introns NN NN O
at NN NN O
the NN NN O
splicing NN NN O
site NN NN O
. NN NN O

Twenty-two NN NN O
tumors NN NN B-DiseaseClass
had NN NN O
frameshift NN NN O
mutations NN NN O
due NN NN O
to NN NN O
deletion NN NN O
or NN NN O
insertion NN NN O
; NN NN O
nineteen NN NN O
of NN NN O
them NN NN O
were NN NN O
deletions NN NN O
of NN NN O
one NN NN O
to NN NN O
31 NN NN O
bp NN NN O
and NN NN O
three NN NN O
were NN NN O
a NN NN O
1-bp NN NN O
insertion NN NN O
. NN NN O

One NN NN O
tumor NN NN B-DiseaseClass
had NN NN O
a NN NN O
1-bp NN NN O
deletion NN NN O
in NN NN O
an NN NN O
intron NN NN O
near NN NN O
the NN NN O
splicing NN NN O
site NN NN O
. NN NN O

Hence NN NN O
, NN NN O
41 NN NN O
( NN NN O
95 NN NN O
% NN NN O
) NN NN O
of NN NN O
43 NN NN O
mutations NN NN O
resulted NN NN O
in NN NN O
truncation NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
protein NN NN O
. NN NN O

Over NN NN O
60 NN NN O
% NN NN O
of NN NN O
the NN NN O
somatic NN NN O
mutations NN NN O
in NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
were NN NN O
clustered NN NN O
within NN NN O
a NN NN O
small NN NN O
region NN NN O
of NN NN O
exon NN NN O
15 NN NN O
, NN NN O
designated NN NN O
as NN NN O
MCR NN NN O
( NN NN O
mutation NN NN O
cluster NN NN O
region NN NN O
) NN NN O
, NN NN O
which NN NN O
accounted NN NN O
for NN NN O
less NN NN O
than NN NN O
10 NN NN O
% NN NN O
of NN NN O
the NN NN O
coding NN NN O
region NN NN O
. NN NN O

Combining NN NN O
these NN NN O
data NN NN O
and NN NN O
the NN NN O
results NN NN O
of NN NN O
LOH NN NN O
, NN NN O
more NN NN O
than NN NN O
80 NN NN O
% NN NN O
of NN NN O
tumors NN NN B-DiseaseClass
( NN NN O
14 NN NN O
adenomas NN NN B-DiseaseClass
and NN NN O
39 NN NN O
carcinomas NN NN B-DiseaseClass
) NN NN O
had NN NN O
at NN NN O
least NN NN O
one NN NN O
mutation NN NN O
in NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
, NN NN O
of NN NN O
which NN NN O
more NN NN O
than NN NN O
60 NN NN O
% NN NN O
( NN NN O
9 NN NN O
adenomas NN NN B-DiseaseClass
and NN NN O
23 NN NN O
carcinomas NN NN B-DiseaseClass
) NN NN O
had NN NN O
two NN NN O
mutations NN NN O
. NN NN O

These NN NN O
results NN NN O
strongly NN NN O
suggest NN NN O
that NN NN O
somatic NN NN O
mutations NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
are NN NN O
associated NN NN O
with NN NN O
development NN NN O
of NN NN O
a NN NN O
great NN NN O
majority NN NN O
of NN NN O
colorectal NN NN B-DiseaseClass
tumors NN NN I-DiseaseClass
. NN NN O

. NN NN O

1338906 NN NN O
Constitutional NN NN O
mutations NN NN O
in NN NN O
the NN NN O
WT1 NN NN O
gene NN NN O
in NN NN O
patients NN NN O
with NN NN O
Denys-Drash NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

The NN NN O
Denys-Drash NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
is NN NN O
characterised NN NN O
by NN NN O
a NN NN O
typical NN NN O
nephropathy NN NN B-DiseaseClass
, NN NN O
genital NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
and NN NN O
also NN NN O
predisposes NN NN O
to NN NN O
the NN NN O
development NN NN O
of NN NN O
Wilms NN NN B-SpecificDisease
tumor NN NN I-SpecificDisease
. NN NN O

These NN NN O
patients NN NN O
eventually NN NN O
go NN NN O
into NN NN O
end NN NN O
stage NN NN O
renal NN NN B-SpecificDisease
failure NN NN I-SpecificDisease
. NN NN O

A NN NN O
candidate NN NN O
Wilms NN NN B-Modifier
tumor NN NN I-Modifier
gene NN NN O
, NN NN O
WT1 NN NN O
, NN NN O
from NN NN O
the NN NN O
11p13 NN NN O
chromosome NN NN O
region NN NN O
has NN NN O
recently NN NN O
been NN NN O
cloned NN NN O
. NN NN O

We NN NN O
have NN NN O
analysed NN NN O
the NN NN O
DNA NN NN O
sequence NN NN O
in NN NN O
constitutional NN NN O
cells NN NN O
from NN NN O
eight NN NN O
patients NN NN O
and NN NN O
have NN NN O
shown NN NN O
heterozygous NN NN O
mutations NN NN O
in NN NN O
six NN NN O
of NN NN O
them NN NN O
. NN NN O

Four NN NN O
of NN NN O
the NN NN O
mutations NN NN O
were NN NN O
in NN NN O
exon NN NN O
9 NN NN O
, NN NN O
all NN NN O
resulting NN NN O
in NN NN O
missense NN NN O
mutations NN NN O
. NN NN O

Three NN NN O
were NN NN O
at NN NN O
nucleotide NN NN O
position NN NN O
1180 NN NN O
resulting NN NN O
in NN NN O
an NN NN O
arg NN NN O
trp NN NN O
amino NN NN O
acid NN NN O
change NN NN O
. NN NN O

The NN NN O
other NN NN O
was NN NN O
at NN NN O
position NN NN O
1186 NN NN O
converting NN NN O
an NN NN O
asp NN NN O
asn NN NN O
in NN NN O
the NN NN O
predicted NN NN O
resultant NN NN O
protein NN NN O
. NN NN O

One NN NN O
patient NN NN O
had NN NN O
a NN NN O
missense NN NN O
mutation NN NN O
in NN NN O
exon NN NN O
8 NN NN O
, NN NN O
converting NN NN O
an NN NN O
arg NN NN O
his NN NN O
. NN NN O

A NN NN O
single NN NN O
base NN NN O
pair NN NN O
insertion NN NN O
at NN NN O
nucleotide NN NN O
position NN NN O
821 NN NN O
in NN NN O
exon NN NN O
6 NN NN O
resulted NN NN O
in NN NN O
the NN NN O
generation NN NN O
of NN NN O
a NN NN O
premature NN NN O
stop NN NN O
codon NN NN O
in NN NN O
the NN NN O
last NN NN O
patient NN NN O
. NN NN O

We NN NN O
were NN NN O
unable NN NN O
to NN NN O
find NN NN O
a NN NN O
mutation NN NN O
in NN NN O
one NN NN O
patient NN NN O
despite NN NN O
complete NN NN O
sequencing NN NN O
of NN NN O
the NN NN O
genomic NN NN O
sequence NN NN O
of NN NN O
the NN NN O
gene NN NN O
. NN NN O

The NN NN O
last NN NN O
patient NN NN O
carried NN NN O
a NN NN O
constitutional NN NN O
deletion NN NN O
of NN NN O
the NN NN O
11p13 NN NN O
region NN NN O
and NN NN O
no NN NN O
additional NN NN O
mutation NN NN O
was NN NN O
found NN NN O
. NN NN O

There NN NN O
was NN NN O
no NN NN O
obvious NN NN O
correlation NN NN O
between NN NN O
the NN NN O
type NN NN O
of NN NN O
mutation NN NN O
and NN NN O
phenotypic NN NN O
expression NN NN O
. NN NN O

These NN NN O
results NN NN O
further NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
WT1 NN NN O
gene NN NN O
is NN NN O
important NN NN O
in NN NN O
both NN NN O
the NN NN O
development NN NN O
of NN NN O
the NN NN O
kidney NN NN O
and NN NN O
the NN NN O
genito-urinary NN NN O
system NN NN O
. NN NN O

. NN NN O

1345170 NN NN O
Linkage NN NN O
disequilibrium NN NN O
mapping NN NN O
in NN NN O
isolated NN NN O
founder NN NN O
populations NN NN O
: NN NN O
diastrophic NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
in NN NN O
Finland NN NN O
. NN NN O

Linkage NN NN O
disequilibrium NN NN O
mapping NN NN O
in NN NN O
isolated NN NN O
populations NN NN O
provides NN NN O
a NN NN O
powerful NN NN O
tool NN NN O
for NN NN O
fine NN NN O
structure NN NN O
localization NN NN O
of NN NN O
disease NN NN O
genes NN NN O
. NN NN O

Here NN NN O
, NN NN O
Luria NN NN O
and NN NN O
Delbrucks NN NN O
classical NN NN O
methods NN NN O
for NN NN O
analysing NN NN O
bacterial NN NN O
cultures NN NN O
are NN NN O
adapted NN NN O
to NN NN O
the NN NN O
study NN NN O
of NN NN O
human NN NN O
isolated NN NN O
founder NN NN O
populations NN NN O
in NN NN O
order NN NN O
to NN NN O
estimate NN NN O
( NN NN O
i NN NN O
) NN NN O
the NN NN O
recombination NN NN O
fraction NN NN O
between NN NN O
a NN NN O
disease NN NN O
locus NN NN O
and NN NN O
a NN NN O
marker NN NN O
; NN NN O
( NN NN O
ii NN NN O
) NN NN O
the NN NN O
expected NN NN O
degree NN NN O
of NN NN O
allelic NN NN O
homogeneity NN NN O
in NN NN O
a NN NN O
population NN NN O
; NN NN O
and NN NN O
( NN NN O
iii NN NN O
) NN NN O
the NN NN O
mutation NN NN O
rate NN NN O
of NN NN O
marker NN NN O
loci NN NN O
. NN NN O

Using NN NN O
these NN NN O
methods NN NN O
, NN NN O
we NN NN O
report NN NN O
striking NN NN O
linkage NN NN O
disequilibrium NN NN O
for NN NN O
diastrophic NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
( NN NN O
DTD NN NN B-SpecificDisease
) NN NN O
in NN NN O
Finland NN NN O
indicating NN NN O
that NN NN O
the NN NN O
DTD NN NN B-Modifier
gene NN NN O
should NN NN O
lie NN NN O
within NN NN O
0 NN NN O
. NN NN O

06 NN NN O
centimorgans NN NN O
( NN NN O
or NN NN O
about NN NN O
60 NN NN O
kilobases NN NN O
) NN NN O
of NN NN O
the NN NN O
CSF1R NN NN O
gene NN NN O
. NN NN O

Predictions NN NN O
about NN NN O
allelic NN NN O
homogeneity NN NN O
in NN NN O
Finland NN NN O
and NN NN O
mutation NN NN O
rates NN NN O
in NN NN O
simple NN NN O
sequence NN NN O
repeats NN NN O
are NN NN O
confirmed NN NN O
by NN NN O
independent NN NN O
observations NN NN O
. NN NN O

1346773 NN NN O
The NN NN O
Wiskott-Aldrich NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
: NN NN O
refinement NN NN O
of NN NN O
the NN NN O
localization NN NN O
on NN NN O
Xp NN NN O
and NN NN O
identification NN NN O
of NN NN O
another NN NN O
closely NN NN O
linked NN NN O
marker NN NN O
locus NN NN O
, NN NN O
OATL1 NN NN O
. NN NN O

The NN NN O
Wiskott-Aldrich NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
WAS NN NN B-SpecificDisease
) NN NN O
has NN NN O
previously NN NN O
been NN NN O
mapped NN NN O
to NN NN O
the NN NN O
proximal NN NN O
short NN NN O
arm NN NN O
of NN NN O
the NN NN O
X NN NN O
chromosome NN NN O
between NN NN O
the NN NN O
DXS14 NN NN O
and NN NN O
DXS7 NN NN O
loci NN NN O
. NN NN O

In NN NN O
this NN NN O
study NN NN O
, NN NN O
further NN NN O
segregation NN NN O
analysis NN NN O
has NN NN O
been NN NN O
performed NN NN O
using NN NN O
a NN NN O
newly NN NN O
identified NN NN O
WAS NN NN B-Modifier
family NN NN O
as NN NN O
well NN NN O
as NN NN O
an NN NN O
additional NN NN O
marker NN NN O
probe NN NN O
, NN NN O
HOATL1 NN NN O
. NN NN O

The NN NN O
results NN NN O
indicate NN NN O
close NN NN O
linkage NN NN O
between NN NN O
the NN NN O
WAS NN NN B-SpecificDisease
and NN NN O
OATL1 NN NN O
loci NN NN O
( NN NN O
Z NN NN O
= NN NN O
6 NN NN O
. NN NN O

08 NN NN O
at NN NN O
theta NN NN O
= NN NN O
0 NN NN O
. NN NN O

00 NN NN O
) NN NN O
and NN NN O
localize NN NN O
the NN NN O
TIMP NN NN O
, NN NN O
OATL1 NN NN O
, NN NN O
DXS255 NN NN O
, NN NN O
and NN NN O
WAS NN NN B-Modifier
loci NN NN O
distal NN NN O
to NN NN O
DXS146 NN NN O
and NN NN O
the NN NN O
OATL1 NN NN O
and NN NN O
WAS NN NN B-Modifier
loci NN NN O
proximal NN NN O
to NN NN O
TIMP NN NN O
. NN NN O

These NN NN O
linkage NN NN O
data NN NN O
narrow NN NN O
the NN NN O
boundaries NN NN O
within NN NN O
which NN NN O
the NN NN O
WAS NN NN B-Modifier
locus NN NN O
maps NN NN O
to NN NN O
the NN NN O
chromosomal NN NN O
region NN NN O
bracketed NN NN O
by NN NN O
TIMP NN NN O
and NN NN O
DXS146 NN NN O
and NN NN O
support NN NN O
the NN NN O
loci NN NN O
order NN NN O
Xpter-DXS7-TIMP- NN NN O
( NN NN O
OATL1 NN NN O
, NN NN O
WAS NN NN O
, NN NN O
DXS255 NN NN O
) NN NN O
-DXS146 NN NN O
. NN NN O

1346924 NN NN O
Detection NN NN O
of NN NN O
an NN NN O
unstable NN NN O
fragment NN NN O
of NN NN O
DNA NN NN O
specific NN NN O
to NN NN O
individuals NN NN O
with NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
. NN NN O

Myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
is NN NN O
the NN NN O
most NN NN O
common NN NN O
form NN NN O
of NN NN O
adult NN NN O
muscular NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
, NN NN O
with NN NN O
a NN NN O
prevalence NN NN O
of NN NN O
2-14 NN NN O
per NN NN O
100 NN NN O
, NN NN O
000 NN NN O
individuals NN NN O
. NN NN O

The NN NN O
disease NN NN O
is NN NN O
characterized NN NN O
by NN NN O
progressive NN NN O
muscle NN NN B-DiseaseClass
weakness NN NN I-DiseaseClass
and NN NN O
sustained NN NN B-DiseaseClass
muscle NN NN I-DiseaseClass
contraction NN NN I-DiseaseClass
, NN NN O
often NN NN O
with NN NN O
a NN NN O
wide NN NN O
range NN NN O
of NN NN O
accompanying NN NN O
symptoms NN NN O
. NN NN O

The NN NN O
age NN NN O
at NN NN O
onset NN NN O
and NN NN O
severity NN NN O
of NN NN O
the NN NN O
disease NN NN O
show NN NN O
extreme NN NN O
variation NN NN O
, NN NN O
both NN NN O
within NN NN O
and NN NN O
between NN NN O
families NN NN O
. NN NN O

Despite NN NN O
its NN NN O
clinical NN NN O
variability NN NN O
, NN NN O
this NN NN O
dominant NN NN O
condition NN NN O
segregates NN NN O
as NN NN O
a NN NN O
single NN NN O
locus NN NN O
at NN NN O
chromosome NN NN O
19q13 NN NN O
. NN NN O

3 NN NN O
in NN NN O
every NN NN O
population NN NN O
studied NN NN O
. NN NN O

It NN NN O
is NN NN O
flanked NN NN O
by NN NN O
the NN NN O
tightly NN NN O
linked NN NN O
genetic NN NN O
markers NN NN O
ERCC1 NN NN O
proximally NN NN O
and NN NN O
D19S51 NN NN O
distally NN NN O
; NN NN O
these NN NN O
define NN NN O
the NN NN O
DM NN NN B-Modifier
critical NN NN O
region NN NN O
. NN NN O

We NN NN O
report NN NN O
the NN NN O
isolation NN NN O
of NN NN O
an NN NN O
expressed NN NN O
sequence NN NN O
from NN NN O
this NN NN O
region NN NN O
which NN NN O
detects NN NN O
a NN NN O
DNA NN NN O
fragment NN NN O
that NN NN O
is NN NN O
larger NN NN O
in NN NN O
affected NN NN O
individuals NN NN O
than NN NN O
in NN NN O
normal NN NN O
siblings NN NN O
or NN NN O
unaffected NN NN O
controls NN NN O
. NN NN O

The NN NN O
size NN NN O
of NN NN O
this NN NN O
fragment NN NN O
varies NN NN O
between NN NN O
affected NN NN O
siblings NN NN O
, NN NN O
and NN NN O
increases NN NN O
in NN NN O
size NN NN O
through NN NN O
generations NN NN O
in NN NN O
parallel NN NN O
with NN NN O
increasing NN NN O
severity NN NN O
of NN NN O
the NN NN O
disease NN NN O
. NN NN O

We NN NN O
postulate NN NN O
that NN NN O
this NN NN O
unstable NN NN O
DNA NN NN O
sequence NN NN O
is NN NN O
the NN NN O
molecular NN NN O
feature NN NN O
that NN NN O
underlies NN NN O
DM NN NN B-SpecificDisease
. NN NN O

1347968 NN NN O
Common NN NN O
sequence NN NN O
motifs NN NN O
at NN NN O
the NN NN O
rearrangement NN NN O
sites NN NN O
of NN NN O
a NN NN O
constitutional NN NN O
X/autosome NN NN O
translocation NN NN O
and NN NN O
associated NN NN O
deletion NN NN O
. NN NN O

Reciprocal NN NN O
chromosome NN NN O
translocations NN NN O
are NN NN O
common NN NN O
de NN NN O
novo NN NN O
rearrangements NN NN O
that NN NN O
occur NN NN O
randomly NN NN O
throughout NN NN O
the NN NN O
human NN NN O
genome NN NN O
. NN NN O

To NN NN O
learn NN NN O
about NN NN O
causative NN NN O
mechanisms NN NN O
, NN NN O
we NN NN O
have NN NN O
cloned NN NN O
and NN NN O
sequenced NN NN O
the NN NN O
breakpoints NN NN O
of NN NN O
a NN NN O
cytologically NN NN O
balanced NN NN O
constitutional NN NN O
reciprocal NN NN O
translocation NN NN O
, NN NN O
t NN NN O
( NN NN O
X NN NN O
; NN NN O
4 NN NN O
) NN NN O
( NN NN O
p21 NN NN O
. NN NN O

2 NN NN O
; NN NN O
q31 NN NN O
. NN NN O

22 NN NN O
) NN NN O
, NN NN O
present NN NN O
in NN NN O
a NN NN O
girl NN NN O
with NN NN O
Duchenne NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DMD NN NN B-SpecificDisease
) NN NN O
. NN NN O

Physical NN NN O
mapping NN NN O
of NN NN O
the NN NN O
derivative NN NN O
chromosomes NN NN O
, NN NN O
after NN NN O
their NN NN O
separation NN NN O
in NN NN O
somatic NN NN O
cell NN NN O
hybrids NN NN O
, NN NN O
reveals NN NN O
that NN NN O
the NN NN O
translocation NN NN O
disrupts NN NN O
the NN NN O
DMD NN NN B-Modifier
gene NN NN O
in NN NN O
Xp21 NN NN O
within NN NN O
the NN NN O
18-kb NN NN O
intron NN NN O
16 NN NN O
. NN NN O

Restriction NN NN O
mapping NN NN O
and NN NN O
sequencing NN NN O
of NN NN O
clones NN NN O
that NN NN O
span NN NN O
both NN NN O
translocation NN NN O
breakpoints NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
corresponding NN NN O
normal NN NN O
regions NN NN O
indicate NN NN O
the NN NN O
loss NN NN O
of NN NN O
approximately NN NN O
5 NN NN O
kb NN NN O
in NN NN O
the NN NN O
formation NN NN O
of NN NN O
the NN NN O
derivative NN NN O
X NN NN O
chromosome NN NN O
, NN NN O
with NN NN O
4-6 NN NN O
bp NN NN O
deleted NN NN O
from NN NN O
chromosome NN NN O
4 NN NN O
. NN NN O

RFLP NN NN O
and NN NN O
Southern NN NN O
analyses NN NN O
indicate NN NN O
that NN NN O
the NN NN O
de NN NN O
novo NN NN O
translocation NN NN O
is NN NN O
a NN NN O
paternal NN NN O
origin NN NN O
and NN NN O
that NN NN O
the NN NN O
fathers NN NN O
X NN NN O
chromosome NN NN O
contains NN NN O
the NN NN O
DNA NN NN O
that NN NN O
is NN NN O
deleted NN NN O
in NN NN O
the NN NN O
derivative NN NN O
X NN NN O
. NN NN O

Most NN NN O
likely NN NN O
, NN NN O
deletion NN NN O
and NN NN O
translation NN NN O
arose NN NN O
simultaneously NN NN O
from NN NN O
a NN NN O
complex NN NN O
rearrangement NN NN O
event NN NN O
that NN NN O
involves NN NN O
three NN NN O
chromosomal NN NN O
breakpoints NN NN O
. NN NN O

Short NN NN O
regions NN NN O
of NN NN O
sequence NN NN O
homology NN NN O
were NN NN O
present NN NN O
at NN NN O
the NN NN O
three NN NN O
sites NN NN O
. NN NN O

A NN NN O
5-bp NN NN O
sequence NN NN O
, NN NN O
GGAAT NN NN O
, NN NN O
found NN NN O
exactly NN NN O
at NN NN O
the NN NN O
translocation NN NN O
breakpoints NN NN O
on NN NN O
both NN NN O
normal NN NN O
chromosomes NN NN O
X NN NN O
and NN NN O
4 NN NN O
, NN NN O
has NN NN O
been NN NN O
preserved NN NN O
only NN NN O
on NN NN O
the NN NN O
der NN NN O
( NN NN O
4 NN NN O
) NN NN O
chromosome NN NN O
. NN NN O

It NN NN O
is NN NN O
likely NN NN O
that NN NN O
the NN NN O
X-derived NN NN O
sequence NN NN O
GGAATCA NN NN O
has NN NN O
been NN NN O
lost NN NN O
in NN NN O
the NN NN O
formation NN NN O
of NN NN O
the NN NN O
der NN NN O
( NN NN O
X NN NN O
) NN NN O
chromosome NN NN O
, NN NN O
as NN NN O
it NN NN O
matches NN NN O
an NN NN O
inverted NN NN O
GAATCA NN NN O
sequence NN NN O
present NN NN O
on NN NN O
the NN NN O
opposite NN NN O
strand NN NN O
exactly NN NN O
at NN NN O
the NN NN O
other NN NN O
end NN NN O
of NN NN O
the NN NN O
deleted NN NN O
5-kb NN NN O
fragment NN NN O
. NN NN O

1349199 NN NN O
A NN NN O
genetic NN NN O
etiology NN NN O
for NN NN O
DiGeorge NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
: NN NN O
consistent NN NN O
deletions NN NN O
and NN NN O
microdeletions NN NN O
of NN NN O
22q11 NN NN O
. NN NN O

DiGeorge NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
DGS NN NN B-SpecificDisease
) NN NN O
, NN NN O
a NN NN O
developmental NN NN O
field NN NN O
defect NN NN O
of NN NN O
the NN NN O
third NN NN O
and NN NN O
fourth NN NN O
pharyngeal NN NN O
pouches NN NN O
, NN NN O
is NN NN O
characterized NN NN O
by NN NN O
aplasia NN NN B-CompositeMention
or NN NN I-CompositeMention
hypoplasia NN NN I-CompositeMention
of NN NN I-CompositeMention
the NN NN I-CompositeMention
thymus NN NN I-CompositeMention
and NN NN I-CompositeMention
parathyroid NN NN I-CompositeMention
glands NN NN I-CompositeMention
and NN NN O
by NN NN O
conotruncal NN NN B-SpecificDisease
cardiac NN NN I-SpecificDisease
malformations NN NN I-SpecificDisease
. NN NN O

Cytogenetic NN NN O
studies NN NN O
support NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
DGS NN NN B-Modifier
critical NN NN O
region NN NN O
in NN NN O
band NN NN O
22q11 NN NN O
. NN NN O

In NN NN O
the NN NN O
present NN NN O
study NN NN O
, NN NN O
we NN NN O
report NN NN O
the NN NN O
results NN NN O
of NN NN O
clinical NN NN O
, NN NN O
cytogenetic NN NN O
, NN NN O
and NN NN O
molecular NN NN O
studies NN NN O
of NN NN O
14 NN NN O
patients NN NN O
with NN NN O
DGS NN NN B-SpecificDisease
. NN NN O

Chromosome NN NN O
analysis NN NN O
, NN NN O
utilizing NN NN O
high-resolution NN NN O
banding NN NN O
techniques NN NN O
, NN NN O
detected NN NN O
interstitial NN NN O
deletions NN NN O
in NN NN O
five NN NN O
probands NN NN O
and NN NN O
was NN NN O
inconclusive NN NN O
for NN NN O
a NN NN O
deletion NN NN O
in NN NN O
three NN NN O
probands NN NN O
. NN NN O

The NN NN O
remaining NN NN O
six NN NN O
patients NN NN O
had NN NN O
normal NN NN O
karyotypes NN NN O
. NN NN O

In NN NN O
contrast NN NN O
, NN NN O
molecular NN NN O
analysis NN NN O
detected NN NN O
DNA NN NN O
deletions NN NN O
in NN NN O
all NN NN O
14 NN NN O
probands NN NN O
. NN NN O

Two NN NN O
of NN NN O
10 NN NN O
loci NN NN O
tested NN NN O
, NN NN O
D22S75 NN NN O
and NN NN O
D22S259 NN NN O
, NN NN O
are NN NN O
deleted NN NN O
in NN NN O
all NN NN O
14 NN NN O
patients NN NN O
. NN NN O

A NN NN O
third NN NN O
locus NN NN O
, NN NN O
D22S66 NN NN O
, NN NN O
is NN NN O
deleted NN NN O
in NN NN O
the NN NN O
eight NN NN O
DGS NN NN B-Modifier
probands NN NN O
tested NN NN O
. NN NN O

Physical NN NN O
mapping NN NN O
using NN NN O
somatic NN NN O
cell NN NN O
hybrids NN NN O
places NN NN O
D22S66 NN NN O
between NN NN O
D22S75 NN NN O
and NN NN O
D22S259 NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
it NN NN O
should NN NN O
be NN NN O
deleted NN NN O
in NN NN O
the NN NN O
remaining NN NN O
six NN NN O
cases NN NN O
. NN NN O

Parent-of-origin NN NN O
studies NN NN O
were NN NN O
performed NN NN O
in NN NN O
five NN NN O
families NN NN O
. NN NN O

Four NN NN O
probands NN NN O
failed NN NN O
to NN NN O
inherit NN NN O
a NN NN O
maternal NN NN O
allele NN NN O
, NN NN O
and NN NN O
one NN NN O
failed NN NN O
to NN NN O
inherit NN NN O
a NN NN O
paternal NN NN O
allele NN NN O
. NN NN O

On NN NN O
the NN NN O
basis NN NN O
of NN NN O
these NN NN O
families NN NN O
, NN NN O
and NN NN O
of NN NN O
six NN NN O
maternally NN NN O
and NN NN O
five NN NN O
paternally NN NN O
derived NN NN O
unbalanced-translocation NN NN O
DGS NN NN B-Modifier
probands NN NN O
in NN NN O
the NN NN O
literature NN NN O
, NN NN O
parent NN NN O
of NN NN O
origin NN NN O
or NN NN O
imprinting NN NN O
does NN NN O
not NN NN O
appear NN NN O
to NN NN O
play NN NN O
an NN NN O
important NN NN O
role NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
DGS NN NN B-SpecificDisease
. NN NN O

Deletion NN NN O
of NN NN O
the NN NN O
same NN NN O
three NN NN O
loci NN NN O
in NN NN O
all NN NN O
14 NN NN O
DGS NN NN B-Modifier
probands NN NN O
begins NN NN O
to NN NN O
delineate NN NN O
the NN NN O
region NN NN O
of NN NN O
chromosome NN NN O
22 NN NN O
critical NN NN O
for NN NN O
DGS NN NN B-SpecificDisease
and NN NN O
confirms NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
submicroscopic NN NN O
deletions NN NN O
of NN NN O
22q11 NN NN O
are NN NN O
etiologic NN NN O
in NN NN O
the NN NN O
vast NN NN O
majority NN NN O
of NN NN O
cases NN NN O
. NN NN O

. NN NN O

1351034 NN NN O
Loss NN NN O
of NN NN O
normal NN NN O
allele NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
in NN NN O
an NN NN O
adrenocortical NN NN B-SpecificDisease
carcinoma NN NN I-SpecificDisease
from NN NN O
a NN NN O
patient NN NN O
with NN NN O
familial NN NN B-SpecificDisease
adenomatous NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
. NN NN O

Endocrine NN NN B-DiseaseClass
neoplasms NN NN I-DiseaseClass
have NN NN O
been NN NN O
reported NN NN O
occasionally NN NN O
in NN NN O
patients NN NN O
with NN NN O
familial NN NN B-SpecificDisease
adenomatous NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
( NN NN O
FAP NN NN B-SpecificDisease
) NN NN O
. NN NN O

An NN NN O
adrenocorotical NN NN B-SpecificDisease
carcinoma NN NN I-SpecificDisease
was NN NN O
studied NN NN O
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
a NN NN O
family NN NN O
history NN NN O
of NN NN O
FAP NN NN B-SpecificDisease
. NN NN O

Loss NN NN O
of NN NN O
heterozygosity NN NN O
( NN NN O
LOH NN NN O
) NN NN O
in NN NN O
the NN NN O
region NN NN O
close NN NN O
to NN NN O
the NN NN O
adenomatous NN NN B-Modifier
polyposis NN NN I-Modifier
coli NN NN I-Modifier
( NN NN O
APC NN NN B-Modifier
) NN NN O
gene NN NN O
was NN NN O
detected NN NN O
in NN NN O
this NN NN O
carcinoma NN NN B-DiseaseClass
, NN NN O
and NN NN O
evidence NN NN O
was NN NN O
obtained NN NN O
that NN NN O
there NN NN O
was NN NN O
a NN NN O
loss NN NN O
of NN NN O
the NN NN O
normal NN NN O
allele NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
. NN NN O

This NN NN O
is NN NN O
the NN NN O
first NN NN O
demonstration NN NN O
of NN NN O
LOH NN NN O
at NN NN O
the NN NN O
APC NN NN B-Modifier
locus NN NN O
in NN NN O
adrenocortical NN NN B-SpecificDisease
tumors NN NN I-SpecificDisease
. NN NN O

The NN NN O
present NN NN O
results NN NN O
and NN NN O
our NN NN O
previous NN NN O
data NN NN O
on NN NN O
LOH NN NN O
in NN NN O
a NN NN O
recurring NN NN O
desmoid NN NN B-SpecificDisease
tumor NN NN I-SpecificDisease
suggest NN NN O
that NN NN O
the NN NN O
heterozygous NN NN O
mutant NN NN O
/ NN NN O
wild-type NN NN O
condition NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
may NN NN O
give NN NN O
rise NN NN O
to NN NN O
benign NN NN B-DiseaseClass
tumors NN NN I-DiseaseClass
, NN NN O
and NN NN O
that NN NN O
functional NN NN O
loss NN NN O
of NN NN O
this NN NN O
gene NN NN O
leads NN NN O
to NN NN O
development NN NN O
of NN NN O
tumors NN NN B-DiseaseClass
not NN NN O
only NN NN O
in NN NN O
the NN NN O
colon NN NN O
but NN NN O
also NN NN O
in NN NN O
other NN NN O
various NN NN O
parts NN NN O
of NN NN O
the NN NN O
body NN NN O
in NN NN O
FAP NN NN B-Modifier
patients NN NN O
. NN NN O

. NN NN O

1352883 NN NN O
Oncogenic NN NN O
point NN NN O
mutations NN NN O
in NN NN O
exon NN NN O
20 NN NN O
of NN NN O
the NN NN O
RB1 NN NN O
gene NN NN O
in NN NN O
families NN NN O
showing NN NN O
incomplete NN NN O
penetrance NN NN O
and NN NN O
mild NN NN O
expression NN NN O
of NN NN O
the NN NN O
retinoblastoma NN NN B-Modifier
phenotype NN NN O
. NN NN O

The NN NN O
retinoblastoma NN NN B-Modifier
-predisposition NN NN O
gene NN NN O
, NN NN O
RB1 NN NN O
, NN NN O
segregates NN NN O
as NN NN O
an NN NN O
autosomal NN NN O
dominant NN NN O
trait NN NN O
with NN NN O
high NN NN O
( NN NN O
90 NN NN O
% NN NN O
) NN NN O
penetrance NN NN O
. NN NN O

Certain NN NN O
families NN NN O
, NN NN O
however NN NN O
, NN NN O
show NN NN O
an NN NN O
unusual NN NN O
low-penetrance NN NN O
phenotype NN NN O
with NN NN O
many NN NN O
individuals NN NN O
being NN NN O
unaffected NN NN O
, NN NN O
unilaterally NN NN O
affected NN NN O
, NN NN O
or NN NN O
with NN NN O
evidence NN NN O
of NN NN O
spontaneously NN NN O
regressed NN NN O
tumors NN NN B-DiseaseClass
. NN NN O

We NN NN O
have NN NN O
used NN NN O
single-strand NN NN O
conformation NN NN O
polymorphism NN NN O
analysis NN NN O
and NN NN O
PCR NN NN O
sequencing NN NN O
to NN NN O
study NN NN O
two NN NN O
such NN NN O
families NN NN O
. NN NN O

Mutations NN NN O
were NN NN O
found NN NN O
in NN NN O
exon NN NN O
20 NN NN O
of NN NN O
RB1 NN NN O
in NN NN O
both NN NN O
cases NN NN O
. NN NN O

In NN NN O
one NN NN O
family NN NN O
a NN NN O
C NN NN O
-- NN NN O
-- NN NN O
T NN NN O
transition NN NN O
in NN NN O
codon NN NN O
661 NN NN O
converts NN NN O
an NN NN O
arginine NN NN O
( NN NN O
CGG NN NN O
) NN NN O
to NN NN O
a NN NN O
tryptophan NN NN O
( NN NN O
TGG NN NN O
) NN NN O
codon NN NN O
. NN NN O

In NN NN O
this NN NN O
family NN NN O
, NN NN O
incomplete NN NN O
penetrance NN NN O
and NN NN O
mild NN NN O
phenotypic NN NN O
expression NN NN O
were NN NN O
observed NN NN O
in NN NN O
virtually NN NN O
all NN NN O
patients NN NN O
, NN NN O
possibly NN NN O
indicating NN NN O
that NN NN O
single NN NN O
amino NN NN O
acid NN NN O
changes NN NN O
may NN NN O
modify NN NN O
protein NN NN O
structure NN NN O
/ NN NN O
function NN NN O
such NN NN O
that NN NN O
tumorigenesis NN NN O
is NN NN O
not NN NN O
inevitable NN NN O
. NN NN O

In NN NN O
the NN NN O
second NN NN O
family NN NN O
the NN NN O
mutation NN NN O
in NN NN O
codon NN NN O
675 NN NN O
is NN NN O
a NN NN O
G NN NN O
-- NN NN O
-- NN NN O
T NN NN O
transversion NN NN O
that NN NN O
converts NN NN O
a NN NN O
glutamine NN NN O
( NN NN O
GAA NN NN O
) NN NN O
to NN NN O
a NN NN O
stop NN NN O
( NN NN O
TAA NN NN O
) NN NN O
codon NN NN O
. NN NN O

However NN NN O
, NN NN O
this NN NN O
mutation NN NN O
also NN NN O
occurs NN NN O
near NN NN O
a NN NN O
potential NN NN O
cryptic NN NN O
splice NN NN O
acceptor NN NN O
site NN NN O
, NN NN O
raising NN NN O
the NN NN O
possibility NN NN O
of NN NN O
alternative NN NN O
splicing NN NN O
resulting NN NN O
in NN NN O
a NN NN O
less NN NN O
severely NN NN O
disrupted NN NN O
protein NN NN O
. NN NN O

. NN NN O

1353340 NN NN O
Late-onset NN NN O
metachromatic NN NN B-SpecificDisease
leukodystrophy NN NN I-SpecificDisease
: NN NN O
molecular NN NN O
pathology NN NN O
in NN NN O
two NN NN O
siblings NN NN O
. NN NN O

We NN NN O
report NN NN O
on NN NN O
a NN NN O
new NN NN O
allele NN NN O
at NN NN O
the NN NN O
arylsulfatase NN NN O
A NN NN O
( NN NN O
ARSA NN NN O
) NN NN O
locus NN NN O
causing NN NN O
late-onset NN NN O
metachromatic NN NN B-SpecificDisease
leukodystrophy NN NN I-SpecificDisease
( NN NN O
MLD NN NN B-SpecificDisease
) NN NN O
. NN NN O

In NN NN O
that NN NN O
allele NN NN O
arginine84 NN NN O
, NN NN O
a NN NN O
residue NN NN O
that NN NN O
is NN NN O
highly NN NN O
conserved NN NN O
in NN NN O
the NN NN O
arylsulfatase NN NN O
gene NN NN O
family NN NN O
, NN NN O
is NN NN O
replaced NN NN O
by NN NN O
glutamine NN NN O
. NN NN O

In NN NN O
contrast NN NN O
to NN NN O
alleles NN NN O
that NN NN O
cause NN NN O
early-onset NN NN O
MLD NN NN B-SpecificDisease
, NN NN O
the NN NN O
arginine84 NN NN O
to NN NN O
glutamine NN NN O
substitution NN NN O
is NN NN O
associated NN NN O
with NN NN O
some NN NN O
residual NN NN O
ARSA NN NN O
activity NN NN O
. NN NN O

A NN NN O
comparison NN NN O
of NN NN O
genotypes NN NN O
, NN NN O
ARSA NN NN O
activities NN NN O
, NN NN O
and NN NN O
clinical NN NN O
data NN NN O
on NN NN O
4 NN NN O
individuals NN NN O
carrying NN NN O
the NN NN O
allele NN NN O
of NN NN O
81 NN NN O
patients NN NN O
with NN NN O
MLD NN NN B-Modifier
examined NN NN O
, NN NN O
further NN NN O
validates NN NN O
the NN NN O
concept NN NN O
that NN NN O
different NN NN O
degrees NN NN O
of NN NN O
residual NN NN O
ARSA NN NN O
activity NN NN O
are NN NN O
the NN NN O
basis NN NN O
of NN NN O
phenotypical NN NN O
variation NN NN O
in NN NN O
MLD NN NN B-SpecificDisease
. NN NN O

. NN NN O

1357962 NN NN O
Trisomy NN NN B-SpecificDisease
15 NN NN I-SpecificDisease
with NN NN O
loss NN NN O
of NN NN O
the NN NN O
paternal NN NN O
15 NN NN O
as NN NN O
a NN NN O
cause NN NN O
of NN NN O
Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
due NN NN O
to NN NN O
maternal NN NN B-SpecificDisease
disomy NN NN I-SpecificDisease
. NN NN O

Uniparental NN NN B-SpecificDisease
disomy NN NN I-SpecificDisease
has NN NN O
recently NN NN O
been NN NN O
recognized NN NN O
to NN NN O
cause NN NN O
human NN NN O
disorders NN NN O
, NN NN O
including NN NN O
Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
PWS NN NN B-SpecificDisease
) NN NN O
. NN NN O

We NN NN O
describe NN NN O
a NN NN O
particularly NN NN O
instructive NN NN O
case NN NN O
which NN NN O
raises NN NN O
important NN NN O
issues NN NN O
concerning NN NN O
the NN NN O
mechanisms NN NN O
producing NN NN O
uniparental NN NN B-SpecificDisease
disomy NN NN I-SpecificDisease
and NN NN O
whose NN NN O
evaluation NN NN O
provides NN NN O
evidence NN NN O
that NN NN O
trisomy NN NN O
may NN NN O
precede NN NN O
uniparental NN NN B-SpecificDisease
disomy NN NN I-SpecificDisease
in NN NN O
a NN NN O
fetus NN NN O
. NN NN O

Chorionic NN NN O
villus NN NN O
sampling NN NN O
performed NN NN O
for NN NN O
advanced NN NN O
maternal NN NN O
age NN NN O
revealed NN NN O
trisomy NN NN B-SpecificDisease
15 NN NN I-SpecificDisease
in NN NN O
all NN NN O
direct NN NN O
and NN NN O
cultured NN NN O
cells NN NN O
, NN NN O
though NN NN O
the NN NN O
fetus NN NN O
appeared NN NN O
normal NN NN O
. NN NN O

Chromosome NN NN O
analysis NN NN O
of NN NN O
amniocytes NN NN O
obtained NN NN O
at NN NN O
15 NN NN O
wk NN NN O
was NN NN O
normal NN NN O
in NN NN O
over NN NN O
100 NN NN O
cells NN NN O
studied NN NN O
. NN NN O

The NN NN O
child NN NN O
was NN NN O
hypotonic NN NN B-SpecificDisease
at NN NN O
birth NN NN O
, NN NN O
and NN NN O
high-resolution NN NN O
banding NN NN O
failed NN NN O
to NN NN O
reveal NN NN O
the NN NN O
deletion NN NN O
of NN NN O
15q11-13 NN NN O
, NN NN O
a NN NN O
deletion NN NN O
which NN NN O
is NN NN O
found NN NN O
in NN NN O
50 NN NN O
% NN NN O
-70 NN NN O
% NN NN O
of NN NN O
patients NN NN O
with NN NN O
PWS NN NN B-SpecificDisease
. NN NN O

Over NN NN O
time NN NN O
, NN NN O
typical NN NN O
features NN NN O
of NN NN O
PWS NN NN B-SpecificDisease
developed NN NN O
. NN NN O

Molecular NN NN O
genetic NN NN O
analysis NN NN O
using NN NN O
probes NN NN O
for NN NN O
chromosome NN NN O
15 NN NN O
revealed NN NN O
maternal NN NN O
disomy NN NN O
. NN NN O

Maternal NN NN O
nondisjunction NN NN O
with NN NN O
fertilization NN NN O
of NN NN O
a NN NN O
disomic NN NN O
egg NN NN O
by NN NN O
a NN NN O
normal NN NN O
sperm NN NN O
, NN NN O
followed NN NN O
by NN NN O
loss NN NN O
of NN NN O
the NN NN O
paternal NN NN O
15 NN NN O
, NN NN O
is NN NN O
a NN NN O
likely NN NN O
cause NN NN O
of NN NN O
confined NN NN O
placental NN NN O
mosaicism NN NN O
and NN NN O
uniparental NN NN B-SpecificDisease
disomy NN NN I-SpecificDisease
in NN NN O
this NN NN O
case NN NN O
of NN NN O
PWS NN NN B-SpecificDisease
, NN NN O
and NN NN O
advanced NN NN O
maternal NN NN O
age NN NN O
may NN NN O
be NN NN O
a NN NN O
predisposing NN NN O
factor NN NN O
. NN NN O

. NN NN O

1358807 NN NN O
Genetic NN NN O
heterogeneity NN NN O
in NN NN O
X-linked NN NN B-SpecificDisease
amelogenesis NN NN I-SpecificDisease
imperfecta NN NN I-SpecificDisease
. NN NN O

The NN NN O
AMELX NN NN O
gene NN NN O
located NN NN O
at NN NN O
Xp22 NN NN O
. NN NN O

1-p22 NN NN O
1-p22 NN NN O
. NN NN O

3 NN NN O
encodes NN NN O
for NN NN O
the NN NN O
enamel NN NN O
protein NN NN O
amelogenin NN NN O
and NN NN O
has NN NN O
been NN NN O
implicated NN NN O
as NN NN O
the NN NN O
gene NN NN O
responsible NN NN O
for NN NN O
the NN NN O
inherited NN NN B-DiseaseClass
dental NN NN I-DiseaseClass
abnormality NN NN I-DiseaseClass
X-linked NN NN B-SpecificDisease
amelogenesis NN NN I-SpecificDisease
imperfecta NN NN I-SpecificDisease
( NN NN O
XAI NN NN B-SpecificDisease
) NN NN O
. NN NN O

Three NN NN O
families NN NN O
with NN NN O
XAI NN NN B-SpecificDisease
have NN NN O
been NN NN O
investigated NN NN O
using NN NN O
polymorphic NN NN O
DNA NN NN O
markers NN NN O
flanking NN NN O
the NN NN O
position NN NN O
of NN NN O
AMELX NN NN O
. NN NN O

Using NN NN O
two-point NN NN O
linkage NN NN O
analysis NN NN O
, NN NN O
linkage NN NN O
was NN NN O
established NN NN O
between NN NN O
XAI NN NN B-SpecificDisease
and NN NN O
several NN NN O
of NN NN O
these NN NN O
markers NN NN O
in NN NN O
two NN NN O
families NN NN O
, NN NN O
with NN NN O
a NN NN O
combined NN NN O
lod NN NN O
score NN NN O
of NN NN O
6 NN NN O
. NN NN O

05 NN NN O
for NN NN O
DXS16 NN NN O
at NN NN O
theta NN NN O
= NN NN O
0 NN NN O
. NN NN O

04 NN NN O
04 NN NN O
. NN NN O

This NN NN O
supports NN NN O
the NN NN O
involvement NN NN O
of NN NN O
AMELX NN NN O
, NN NN O
located NN NN O
close NN NN O
to NN NN O
DXS16 NN NN O
, NN NN O
in NN NN O
the NN NN O
XAI NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
process NN NN O
( NN NN O
AIH1 NN NN O
) NN NN O
in NN NN O
those NN NN O
families NN NN O
. NN NN O

Using NN NN O
multipoint NN NN O
linkage NN NN O
analysis NN NN O
, NN NN O
the NN NN O
combined NN NN O
maximum NN NN O
lod NN NN O
score NN NN O
for NN NN O
these NN NN O
two NN NN O
families NN NN O
was NN NN O
7 NN NN O
. NN NN O

30 NN NN O
for NN NN O
a NN NN O
location NN NN O
of NN NN O
AIH1 NN NN O
at NN NN O
2 NN NN O
cM NN NN O
distal NN NN O
to NN NN O
DXS16 NN NN O
. NN NN O

The NN NN O
support NN NN O
interval NN NN O
around NN NN O
this NN NN O
location NN NN O
extended NN NN O
about NN NN O
8 NN NN O
cM NN NN O
proximal NN NN O
to NN NN O
DXS92 NN NN O
, NN NN O
and NN NN O
the NN NN O
AIH1 NN NN O
location NN NN O
could NN NN O
not NN NN O
be NN NN O
precisely NN NN O
defined NN NN O
by NN NN O
multipoint NN NN O
mapping NN NN O
. NN NN O

Study NN NN O
of NN NN O
recombination NN NN O
events NN NN O
indicated NN NN O
that NN NN O
AIH1 NN NN O
lies NN NN O
in NN NN O
the NN NN O
interval NN NN O
between NN NN O
DXS143 NN NN O
and NN NN O
DXS85 NN NN O
. NN NN O

There NN NN O
was NN NN O
significant NN NN O
evidence NN NN O
against NN NN O
linkage NN NN O
to NN NN O
this NN NN O
region NN NN O
in NN NN O
the NN NN O
third NN NN O
family NN NN O
, NN NN O
indicating NN NN O
locus NN NN O
heterogeneity NN NN O
in NN NN O
XAI NN NN B-SpecificDisease
. NN NN O

Further NN NN O
analysis NN NN O
with NN NN O
markers NN NN O
on NN NN O
the NN NN O
long NN NN O
arm NN NN O
of NN NN O
the NN NN O
X NN NN O
chromosome NN NN O
showed NN NN O
evidence NN NN O
of NN NN O
linkage NN NN O
to NN NN O
DXS144E NN NN O
and NN NN O
F9 NN NN O
with NN NN O
no NN NN O
recombination NN NN O
with NN NN O
either NN NN O
of NN NN O
these NN NN O
markers NN NN O
. NN NN O

Two-point NN NN O
analysis NN NN O
gave NN NN O
a NN NN O
peak NN NN O
lod NN NN O
score NN NN O
at NN NN O
DXS144E NN NN O
with NN NN O
a NN NN O
maximum NN NN O
lod NN NN O
score NN NN O
of NN NN O
2 NN NN O
. NN NN O

83 NN NN O
at NN NN O
theta NN NN O
= NN NN O
0 NN NN O
, NN NN O
with NN NN O
a NN NN O
peak NN NN O
lod NN NN O
score NN NN O
in NN NN O
multipoint NN NN O
linkage NN NN O
analysis NN NN O
of NN NN O
2 NN NN O
. NN NN O

84 NN NN O
at NN NN O
theta NN NN O
= NN NN O
0 NN NN O
. NN NN O

The NN NN O
support NN NN O
interval NN NN O
extended NN NN O
9 NN NN O
cM NN NN O
proximal NN NN O
to NN NN O
DXS144E NN NN O
and NN NN O
14 NN NN O
cM NN NN O
distal NN NN O
to NN NN O
F9 NN NN O
. NN NN O

( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O
. NN NN O

1361100 NN NN O
Multiple NN NN O
origins NN NN O
for NN NN O
phenylketonuria NN NN B-SpecificDisease
in NN NN O
Europe NN NN O
. NN NN O

Phenylketonuria NN NN B-SpecificDisease
( NN NN O
PKU NN NN B-SpecificDisease
) NN NN O
, NN NN O
a NN NN O
disorder NN NN B-DiseaseClass
of NN NN I-DiseaseClass
amino NN NN I-DiseaseClass
acid NN NN I-DiseaseClass
metabolism NN NN I-DiseaseClass
prevalent NN NN O
among NN NN O
Caucasians NN NN O
and NN NN O
other NN NN O
ethnic NN NN O
groups NN NN O
, NN NN O
is NN NN O
caused NN NN O
primarily NN NN O
by NN NN O
a NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
hepatic NN NN I-SpecificDisease
enzyme NN NN I-SpecificDisease
phenylalanine NN NN I-SpecificDisease
hydroxylase NN NN I-SpecificDisease
( NN NN O
PAH NN NN O
) NN NN O
. NN NN O

PKU NN NN B-SpecificDisease
is NN NN O
a NN NN O
highly NN NN O
heterogeneous NN NN O
disorder NN NN O
, NN NN O
with NN NN O
more NN NN O
than NN NN O
60 NN NN O
molecular NN NN B-DiseaseClass
lesions NN NN I-DiseaseClass
identified NN NN O
in NN NN O
the NN NN O
PAH NN NN O
gene NN NN O
. NN NN O

The NN NN O
haplotype NN NN O
associations NN NN O
, NN NN O
relative NN NN O
frequencies NN NN O
, NN NN O
and NN NN O
distributions NN NN O
of NN NN O
five NN NN O
prevalent NN NN O
PAH NN NN O
mutations NN NN O
( NN NN O
R158Q NN NN O
, NN NN O
R261Q NN NN O
, NN NN O
IVS10nt546 NN NN O
, NN NN O
R408W NN NN O
, NN NN O
and NN NN O
IVS12n1 NN NN O
) NN NN O
were NN NN O
established NN NN O
in NN NN O
a NN NN O
comprehensive NN NN O
European NN NN O
sample NN NN O
population NN NN O
and NN NN O
subsequently NN NN O
were NN NN O
examined NN NN O
to NN NN O
determine NN NN O
the NN NN O
potential NN NN O
roles NN NN O
of NN NN O
several NN NN O
genetic NN NN O
mechanisms NN NN O
in NN NN O
explaining NN NN O
the NN NN O
present NN NN O
distribution NN NN O
of NN NN O
the NN NN O
major NN NN O
PKU NN NN B-Modifier
alleles NN NN O
. NN NN O

Each NN NN O
of NN NN O
these NN NN O
five NN NN O
mutations NN NN O
was NN NN O
strongly NN NN O
associated NN NN O
with NN NN O
only NN NN O
one NN NN O
of NN NN O
the NN NN O
more NN NN O
than NN NN O
70 NN NN O
chromosomal NN NN O
haplotypes NN NN O
defined NN NN O
by NN NN O
eight NN NN O
RFLPs NN NN O
in NN NN O
or NN NN O
near NN NN O
the NN NN O
PAH NN NN O
gene NN NN O
. NN NN O

These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
each NN NN O
of NN NN O
these NN NN O
mutations NN NN O
arose NN NN O
through NN NN O
a NN NN O
single NN NN O
founding NN NN O
event NN NN O
that NN NN O
occurred NN NN O
within NN NN O
time NN NN O
periods NN NN O
ranging NN NN O
from NN NN O
several NN NN O
hundred NN NN O
to NN NN O
several NN NN O
thousand NN NN O
years NN NN O
ago NN NN O
. NN NN O

From NN NN O
the NN NN O
significant NN NN O
differences NN NN O
observed NN NN O
in NN NN O
the NN NN O
relative NN NN O
frequencies NN NN O
and NN NN O
distributions NN NN O
of NN NN O
these NN NN O
five NN NN O
alleles NN NN O
throughout NN NN O
Europe NN NN O
, NN NN O
four NN NN O
of NN NN O
these NN NN O
putative NN NN O
founding NN NN O
events NN NN O
could NN NN O
be NN NN O
localized NN NN O
to NN NN O
specific NN NN O
ethnic NN NN O
subgroups NN NN O
. NN NN O

Together NN NN O
, NN NN O
these NN NN O
data NN NN O
suggest NN NN O
that NN NN O
there NN NN O
were NN NN O
multiple NN NN O
, NN NN O
geographically NN NN O
and NN NN O
ethnically NN NN O
distinct NN NN O
origins NN NN O
for NN NN O
PKU NN NN B-SpecificDisease
within NN NN O
the NN NN O
European NN NN O
population NN NN O
. NN NN O

. NN NN O

1361318 NN NN O
Complement NN NN B-SpecificDisease
factor NN NN I-SpecificDisease
2 NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
: NN NN O
a NN NN O
clinical NN NN O
and NN NN O
serological NN NN O
family NN NN O
study NN NN O
. NN NN O

Inherited NN NN B-DiseaseClass
complement NN NN I-DiseaseClass
deficiencies NN NN I-DiseaseClass
are NN NN O
associated NN NN O
with NN NN O
a NN NN O
variety NN NN O
of NN NN O
connective NN NN O
tissue NN NN O
diseases NN NN O
. NN NN O

A NN NN O
family NN NN O
with NN NN O
inherited NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
of NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
factor NN NN I-SpecificDisease
2 NN NN I-SpecificDisease
( NN NN O
C2 NN NN O
) NN NN O
is NN NN O
described NN NN O
in NN NN O
which NN NN O
two NN NN O
family NN NN O
members NN NN O
with NN NN O
homozygous NN NN O
C2 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
developed NN NN O
cutaneous NN NN B-SpecificDisease
vasculitis NN NN I-SpecificDisease
and NN NN O
sicca NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

The NN NN O
other NN NN O
family NN NN O
members NN NN O
had NN NN O
heterozygous NN NN O
C2 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
and NN NN O
each NN NN O
member NN NN O
had NN NN O
the NN NN O
HLA-A25 NN NN O
, NN NN O
B18 NN NN O
, NN NN O
DR2 NN NN O
( NN NN O
w15 NN NN O
) NN NN O
haplotype NN NN O
. NN NN O

The NN NN O
mother NN NN O
had NN NN O
seropositive NN NN B-SpecificDisease
rheumatoid NN NN I-SpecificDisease
arthritis NN NN I-SpecificDisease
. NN NN O

Further NN NN O
studies NN NN O
showed NN NN O
the NN NN O
presence NN NN O
of NN NN O
cryoglobulins NN NN O
, NN NN O
antibodies NN NN O
against NN NN O
endothelial NN NN O
cells NN NN O
, NN NN O
and NN NN O
anticardiolipin NN NN O
antibodies NN NN O
. NN NN O

. NN NN O

1376553 NN NN O
New NN NN O
variant NN NN O
in NN NN O
exon NN NN O
3 NN NN O
of NN NN O
the NN NN O
proteolipid NN NN O
protein NN NN O
( NN NN O
PLP NN NN O
) NN NN O
gene NN NN O
in NN NN O
a NN NN O
family NN NN O
with NN NN O
Pelizaeus-Merzbacher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

A NN NN O
C NN NN O
-- NN NN O
greater NN NN O
than NN NN O
G NN NN O
transversion NN NN O
has NN NN O
been NN NN O
found NN NN O
in NN NN O
exon NN NN O
3 NN NN O
of NN NN O
the NN NN O
PLP NN NN O
gene NN NN O
of NN NN O
affected NN NN O
males NN NN O
and NN NN O
their NN NN O
mother NN NN O
in NN NN O
a NN NN O
single NN NN O
sibship NN NN O
with NN NN O
Pelizaeus-merzbacher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
PMD NN NN B-SpecificDisease
) NN NN O
. NN NN O

The NN NN O
transversion NN NN O
should NN NN O
not NN NN O
result NN NN O
in NN NN O
an NN NN O
amino NN NN O
acid NN NN O
change NN NN O
in NN NN O
the NN NN O
protein NN NN O
but NN NN O
it NN NN O
does NN NN O
result NN NN O
in NN NN O
the NN NN O
loss NN NN O
of NN NN O
a NN NN O
HaeIII NN NN O
restriction NN NN O
endonuclease NN NN O
cleavage NN NN O
site NN NN O
. NN NN O

It NN NN O
is NN NN O
concordant NN NN O
with NN NN O
the NN NN O
disease NN NN O
in NN NN O
this NN NN O
family NN NN O
. NN NN O

One-hundred-ten NN NN O
unrelated NN NN O
X NN NN O
chromosomes NN NN O
are NN NN O
negative NN NN O
for NN NN O
this NN NN O
mutation NN NN O
. NN NN O

No NN NN O
other NN NN O
sequence NN NN O
defect NN NN O
was NN NN O
found NN NN O
in NN NN O
the NN NN O
PLP NN NN O
exons NN NN O
of NN NN O
the NN NN O
affected NN NN O
males NN NN O
. NN NN O

The NN NN O
cause NN NN O
of NN NN O
disease NN NN O
in NN NN O
this NN NN O
family NN NN O
remains NN NN O
unknown NN NN O
, NN NN O
but NN NN O
the NN NN O
association NN NN O
between NN NN O
this NN NN O
rare NN NN O
mutation NN NN O
and NN NN O
PMD NN NN B-SpecificDisease
is NN NN O
intriguing NN NN O
. NN NN O

The NN NN O
mutation NN NN O
can NN NN O
serve NN NN O
as NN NN O
a NN NN O
marker NN NN O
for NN NN O
following NN NN O
segregation NN NN O
of NN NN O
the NN NN O
PLP NN NN O
gene NN NN O
. NN NN O

. NN NN O

1380672 NN NN O
Uncoupling NN NN O
of NN NN O
hypomyelination NN NN B-SpecificDisease
and NN NN O
glial NN NN B-SpecificDisease
cell NN NN I-SpecificDisease
death NN NN I-SpecificDisease
by NN NN O
a NN NN O
mutation NN NN O
in NN NN O
the NN NN O
proteolipid NN NN O
protein NN NN O
gene NN NN O
. NN NN O

Proteolipid NN NN O
protein NN NN O
( NN NN O
PLP NN NN O
; NN NN O
M NN NN O
( NN NN O
r NN NN O
) NN NN O
30 NN NN O
, NN NN O
000 NN NN O
) NN NN O
is NN NN O
a NN NN O
highly NN NN O
conserved NN NN O
major NN NN O
polytopic NN NN O
membrane NN NN O
protein NN NN O
in NN NN O
myelin NN NN O
but NN NN O
its NN NN O
cellular NN NN O
function NN NN O
remains NN NN O
obscure NN NN O
. NN NN O

Neurological NN NN O
mutant NN NN O
mice NN NN O
can NN NN O
often NN NN O
provide NN NN O
model NN NN O
systems NN NN O
for NN NN O
human NN NN O
genetic NN NN B-DiseaseClass
disorders NN NN I-DiseaseClass
. NN NN O

Mutations NN NN O
of NN NN O
the NN NN O
X-chromosome-linked NN NN O
PLP NN NN O
gene NN NN O
are NN NN O
lethal NN NN O
, NN NN O
identified NN NN O
first NN NN O
in NN NN O
the NN NN O
jimpy NN NN O
mouse NN NN O
and NN NN O
subsequently NN NN O
in NN NN O
patients NN NN O
with NN NN O
Pelizaeus-Merzbacher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

The NN NN O
unexplained NN NN O
phenotype NN NN O
of NN NN O
these NN NN O
mutations NN NN O
includes NN NN O
degeneration NN NN B-CompositeMention
and NN NN I-CompositeMention
premature NN NN I-CompositeMention
cell NN NN I-CompositeMention
death NN NN I-CompositeMention
of NN NN I-CompositeMention
oligodendrocytes NN NN I-CompositeMention
with NN NN O
associated NN NN O
hypomyelination NN NN B-SpecificDisease
. NN NN O

Here NN NN O
we NN NN O
show NN NN O
that NN NN O
a NN NN O
new NN NN O
mouse NN NN O
mutant NN NN O
rumpshaker NN NN O
is NN NN O
defined NN NN O
by NN NN O
the NN NN O
amino-acid NN NN O
substitution NN NN O
Ile-to-Thr NN NN O
at NN NN O
residue NN NN O
186 NN NN O
in NN NN O
a NN NN O
membrane-embedded NN NN O
domain NN NN O
of NN NN O
PLP NN NN O
. NN NN O

Surprisingly NN NN O
, NN NN O
rumpshaker NN NN O
mice NN NN O
, NN NN O
although NN NN O
myelin-deficient NN NN B-SpecificDisease
, NN NN O
have NN NN O
normal NN NN O
longevity NN NN O
and NN NN O
a NN NN O
full NN NN O
complement NN NN O
of NN NN O
morphologically NN NN O
normal NN NN O
oligodendrocytes NN NN O
. NN NN O

Hypomyelination NN NN B-SpecificDisease
can NN NN O
thus NN NN O
be NN NN O
genetically NN NN O
separated NN NN O
from NN NN O
the NN NN O
PLP-dependent NN NN O
oligodendrocyte NN NN B-SpecificDisease
degeneration NN NN I-SpecificDisease
. NN NN O

We NN NN O
suggest NN NN O
that NN NN O
PLP NN NN O
has NN NN O
a NN NN O
vital NN NN O
function NN NN O
in NN NN O
glial NN NN O
cell NN NN O
development NN NN O
, NN NN O
distinct NN NN O
from NN NN O
its NN NN O
later NN NN O
role NN NN O
in NN NN O
myelin NN NN O
assembly NN NN O
, NN NN O
and NN NN O
that NN NN O
this NN NN O
dichotomy NN NN O
of NN NN O
action NN NN O
may NN NN O
explain NN NN O
the NN NN O
clinical NN NN O
spectrum NN NN O
of NN NN O
Pelizaeus-Merzbacher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

. NN NN O

1384323 NN NN O
A NN NN O
pseudodeficiency NN NN O
allele NN NN O
common NN NN O
in NN NN O
non-Jewish NN NN O
Tay-Sachs NN NN B-Modifier
carriers NN NN O
: NN NN O
implications NN NN O
for NN NN O
carrier NN NN O
screening NN NN O
. NN NN O

Deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
beta-hexosaminidase NN NN I-SpecificDisease
A NN NN I-SpecificDisease
( NN NN O
Hex NN NN O
A NN NN O
) NN NN O
activity NN NN O
typically NN NN O
results NN NN O
in NN NN O
Tay-Sachs NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

However NN NN O
, NN NN O
healthy NN NN O
subjects NN NN O
found NN NN O
to NN NN O
be NN NN O
deficient NN NN B-SpecificDisease
in NN NN I-SpecificDisease
Hex NN NN I-SpecificDisease
A NN NN I-SpecificDisease
activity NN NN O
( NN NN O
i NN NN O
. NN NN O

e NN NN O
. NN NN O

, NN NN O
pseudodeficient NN NN O
) NN NN O
by NN NN O
means NN NN O
of NN NN O
in NN NN O
vitro NN NN O
biochemical NN NN O
tests NN NN O
have NN NN O
been NN NN O
described NN NN O
. NN NN O

We NN NN O
analyzed NN NN O
the NN NN O
HEXA NN NN O
gene NN NN O
of NN NN O
one NN NN O
pseudodeficient NN NN O
subject NN NN O
and NN NN O
identified NN NN O
both NN NN O
a NN NN O
C739-to-T NN NN O
substitution NN NN O
that NN NN O
changes NN NN O
Arg247 NN NN O
-- NN NN O
-- NN NN O
Trp NN NN O
on NN NN O
one NN NN O
allele NN NN O
and NN NN O
a NN NN O
previously NN NN O
identified NN NN O
Tay-Sachs NN NN B-Modifier
disease NN NN I-Modifier
mutation NN NN O
on NN NN O
the NN NN O
second NN NN O
allele NN NN O
. NN NN O

Six NN NN O
additional NN NN O
pseudodeficient NN NN O
subjects NN NN O
were NN NN O
found NN NN O
to NN NN O
have NN NN O
the NN NN O
C739-to-T NN NN O
mutation NN NN O
. NN NN O

This NN NN O
allele NN NN O
accounted NN NN O
for NN NN O
32 NN NN O
% NN NN O
( NN NN O
20 NN NN O
/ NN NN O
62 NN NN O
) NN NN O
of NN NN O
non-Jewish NN NN O
enzyme-defined NN NN O
Tay-Sachs NN NN B-Modifier
disease NN NN I-Modifier
carriers NN NN O
but NN NN O
for NN NN O
none NN NN O
of NN NN O
36 NN NN O
Jewish NN NN O
enzyme-defined NN NN O
carriers NN NN O
who NN NN O
did NN NN O
not NN NN O
have NN NN O
one NN NN O
of NN NN O
three NN NN O
known NN NN O
mutations NN NN O
common NN NN O
to NN NN O
this NN NN O
group NN NN O
. NN NN O

The NN NN O
C739-to-T NN NN O
allele NN NN O
, NN NN O
together NN NN O
with NN NN O
a NN NN O
`` NN NN O
true NN NN O
`` NN NN O
Tay-Sachs NN NN B-Modifier
disease NN NN I-Modifier
allele NN NN O
, NN NN O
causes NN NN O
Hex NN NN O
A NN NN O
pseudodeficiency NN NN O
. NN NN O

Given NN NN O
both NN NN O
the NN NN O
large NN NN O
proportion NN NN O
of NN NN O
non-Jewish NN NN O
carriers NN NN O
with NN NN O
this NN NN O
allele NN NN O
and NN NN O
that NN NN O
standard NN NN O
biochemical NN NN O
screening NN NN O
can NN NN O
not NN NN O
differentiate NN NN O
between NN NN O
heterozygotes NN NN O
for NN NN O
the NN NN O
C739-to-T NN NN O
mutations NN NN O
and NN NN O
Tay-Sachs NN NN B-Modifier
disease NN NN I-Modifier
carriers NN NN O
, NN NN O
DNA NN NN O
testing NN NN O
for NN NN O
this NN NN O
mutation NN NN O
in NN NN O
at-risk NN NN O
couples NN NN O
is NN NN O
essential NN NN O
. NN NN O

1384324 NN NN O
Pelizaeus-Merzbacher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
: NN NN O
detection NN NN O
of NN NN O
mutations NN NN O
Thr181 NN NN O
-- NN NN O
-- NN NN O
Pro NN NN O
and NN NN O
Leu223 NN NN O
-- NN NN O
-- NN NN O
Pro NN NN O
in NN NN O
the NN NN O
proteolipid NN NN O
protein NN NN O
gene NN NN O
, NN NN O
and NN NN O
prenatal NN NN O
diagnosis NN NN O
. NN NN O

A NN NN O
family NN NN O
with NN NN O
an NN NN O
apparent NN NN O
history NN NN O
of NN NN O
X-linked NN NN O
Pelizaeus-Merzbacher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
presented NN NN O
for NN NN O
genetic NN NN O
counseling NN NN O
, NN NN O
requesting NN NN O
carrier NN NN O
detection NN NN O
and NN NN O
prenatal NN NN O
diagnosis NN NN O
. NN NN O

RFLP NN NN O
analysis NN NN O
using NN NN O
the NN NN O
proteolipid NN NN O
protein NN NN O
( NN NN O
PLP NN NN O
) NN NN O
gene NN NN O
probe NN NN O
was NN NN O
uninformative NN NN O
in NN NN O
this NN NN O
family NN NN O
. NN NN O

A NN NN O
prenatal NN NN O
diagnosis NN NN O
on NN NN O
a NN NN O
chorionic NN NN O
villus NN NN O
sample NN NN O
( NN NN O
CVS NN NN O
) NN NN O
was NN NN O
carried NN NN O
out NN NN O
using NN NN O
single-strand NN NN O
conformation NN NN O
polymorphism NN NN O
( NN NN O
SSCP NN NN O
) NN NN O
analysis NN NN O
of NN NN O
a NN NN O
variant NN NN O
in NN NN O
exon NN NN O
4 NN NN O
of NN NN O
the NN NN O
PLP NN NN O
gene NN NN O
. NN NN O

The NN NN O
fetus NN NN O
was NN NN O
predicted NN NN O
to NN NN O
be NN NN O
unaffected NN NN O
. NN NN O

Sequencing NN NN O
of NN NN O
the NN NN O
exon NN NN O
from NN NN O
the NN NN O
CVS NN NN O
, NN NN O
the NN NN O
predicted-carrier NN NN O
mother NN NN O
, NN NN O
and NN NN O
the NN NN O
obligate-carrier NN NN O
grandmother NN NN O
revealed NN NN O
an NN NN O
A-to-C NN NN O
change NN NN O
at NN NN O
nucleotide NN NN O
541 NN NN O
in NN NN O
the NN NN O
two NN NN O
women NN NN O
but NN NN O
not NN NN O
in NN NN O
the NN NN O
fetus NN NN O
. NN NN O

As NN NN O
this NN NN O
change NN NN O
results NN NN O
in NN NN O
a NN NN O
Thr-to-Pro NN NN O
change NN NN O
at NN NN O
amino NN NN O
acid NN NN O
181 NN NN O
in NN NN O
a NN NN O
region NN NN O
of NN NN O
the NN NN O
gene NN NN O
predicted NN NN O
to NN NN O
be NN NN O
part NN NN O
of NN NN O
a NN NN O
transmembrane NN NN O
segment NN NN O
, NN NN O
it NN NN O
was NN NN O
concluded NN NN O
that NN NN O
this NN NN O
was NN NN O
the NN NN O
mutation NN NN O
causing NN NN O
the NN NN O
disease NN NN O
in NN NN O
this NN NN O
family NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
in NN NN O
a NN NN O
second NN NN O
family NN NN O
, NN NN O
an NN NN O
exon NN NN O
5 NN NN O
variant NN NN O
band NN NN O
pattern NN NN O
on NN NN O
SSCP NN NN O
analysis NN NN O
was NN NN O
shown NN NN O
by NN NN O
sequencing NN NN O
to NN NN O
be NN NN O
due NN NN O
to NN NN O
a NN NN O
T-to-C NN NN O
change NN NN O
at NN NN O
nucleotide NN NN O
668 NN NN O
. NN NN O

This NN NN O
results NN NN O
in NN NN O
a NN NN O
Leu-to-Pro NN NN O
change NN NN O
in NN NN O
a NN NN O
carrier NN NN O
mother NN NN O
and NN NN O
in NN NN O
her NN NN O
two NN NN O
affected NN NN O
sons NN NN O
. NN NN O

These NN NN O
results NN NN O
provide NN NN O
further NN NN O
examples NN NN O
of NN NN O
mutations NN NN O
in NN NN O
PLP NN NN O
that NN NN O
cause NN NN O
Pelizaeus-Merzbacher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
and NN NN O
illustrate NN NN O
the NN NN O
value NN NN O
of NN NN O
SSCP NN NN O
in NN NN O
genetic NN NN O
analysis NN NN O
. NN NN O

. NN NN O

1409710 NN NN O
von NN NN B-SpecificDisease
Willebrand NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
type NN NN I-SpecificDisease
B NN NN I-SpecificDisease
: NN NN O
a NN NN O
missense NN NN O
mutation NN NN O
selectively NN NN O
abolishes NN NN O
ristocetin-induced NN NN O
von NN NN B-Modifier
Willebrand NN NN I-Modifier
factor NN NN O
binding NN NN O
to NN NN O
platelet NN NN O
glycoprotein NN NN O
Ib NN NN O
. NN NN O

von NN NN B-Modifier
Willebrand NN NN I-Modifier
factor NN NN O
( NN NN O
vWF NN NN O
) NN NN O
is NN NN O
a NN NN O
multimeric NN NN O
glycoprotein NN NN O
that NN NN O
mediates NN NN O
the NN NN O
adhesion NN NN O
of NN NN O
platelets NN NN O
to NN NN O
the NN NN O
subendothelium NN NN O
by NN NN O
binding NN NN O
to NN NN O
platelet NN NN O
glycoprotein NN NN O
Ib NN NN O
. NN NN O

For NN NN O
human NN NN O
vWF NN NN O
, NN NN O
this NN NN O
interaction NN NN O
can NN NN O
be NN NN O
induced NN NN O
in NN NN O
vitro NN NN O
by NN NN O
the NN NN O
antibiotic NN NN O
ristocetin NN NN O
or NN NN O
the NN NN O
snake NN NN O
venom NN NN O
protein NN NN O
botrocetin NN NN O
. NN NN O

A NN NN O
missense NN NN O
mutation NN NN O
, NN NN O
Gly-561 NN NN O
-- NN NN O
Ser NN NN O
, NN NN O
was NN NN O
identified NN NN O
within NN NN O
the NN NN O
proposed NN NN O
glycoprotein NN NN O
Ib NN NN O
binding NN NN O
domain NN NN O
of NN NN O
vWF NN NN O
in NN NN O
the NN NN O
proband NN NN O
with NN NN O
von NN NN B-SpecificDisease
Willebrand NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
type NN NN I-SpecificDisease
B NN NN I-SpecificDisease
, NN NN O
a NN NN O
unique NN NN O
variant NN NN O
characterized NN NN O
by NN NN O
no NN NN O
ristocetin-induced NN NN O
, NN NN O
but NN NN O
normal NN NN O
botrocetin-induced NN NN O
, NN NN O
binding NN NN O
to NN NN O
glycoprotein NN NN O
Ib NN NN O
. NN NN O

The NN NN O
corresponding NN NN O
mutant NN NN O
recombinant NN NN O
protein NN NN O
, NN NN O
rvWF NN NN O
( NN NN O
G561S NN NN O
) NN NN O
, NN NN O
formed NN NN O
normal NN NN O
multimers NN NN O
and NN NN O
exhibited NN NN O
the NN NN O
same NN NN O
functional NN NN O
defect NN NN O
as NN NN O
the NN NN O
patients NN NN O
plasma NN NN O
vWF NN NN O
, NN NN O
confirming NN NN O
that NN NN O
this NN NN O
mutation NN NN O
causes NN NN O
von NN NN B-SpecificDisease
Willebrand NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
type NN NN I-SpecificDisease
B NN NN I-SpecificDisease
. NN NN O

These NN NN O
data NN NN O
show NN NN O
that NN NN O
botrocetin NN NN O
and NN NN O
ristocetin NN NN O
cofactor NN NN O
activities NN NN O
of NN NN O
vWF NN NN O
can NN NN O
be NN NN O
dissociated NN NN O
by NN NN O
a NN NN O
point NN NN O
mutation NN NN O
and NN NN O
confirm NN NN O
that NN NN O
these NN NN O
mediators NN NN O
promote NN NN O
vWF NN NN O
binding NN NN O
to NN NN O
platelets NN NN O
by NN NN O
different NN NN O
mechanisms NN NN O
. NN NN O

The NN NN O
normal NN NN O
botrocetin-induced NN NN O
binding NN NN O
and NN NN O
the NN NN O
defective NN NN O
ristocetin-induced NN NN O
binding NN NN O
of NN NN O
rvWF NN NN O
( NN NN O
G561S NN NN O
) NN NN O
suggest NN NN O
that NN NN O
the NN NN O
primary NN NN O
defect NN NN O
in NN NN O
von NN NN B-SpecificDisease
Willebrand NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
type NN NN I-SpecificDisease
B NN NN I-SpecificDisease
may NN NN O
be NN NN O
a NN NN O
failure NN NN O
of NN NN O
normal NN NN O
allosteric NN NN O
regulation NN NN O
of NN NN O
the NN NN O
glycoprotein NN NN O
Ib NN NN O
binding NN NN O
function NN NN O
of NN NN O
vWF NN NN O
. NN NN O

. NN NN O

1424237 NN NN O
Typical NN NN O
and NN NN O
partial NN NN O
cat NN NN B-SpecificDisease
eye NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
: NN NN O
identification NN NN O
of NN NN O
the NN NN O
marker NN NN O
chromosome NN NN O
by NN NN O
FISH NN NN O
. NN NN O

Three NN NN O
children NN NN O
are NN NN O
reported NN NN O
with NN NN O
typical NN NN O
cat NN NN B-SpecificDisease
eye NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
CES NN NN B-SpecificDisease
) NN NN O
and NN NN O
three NN NN O
more NN NN O
children NN NN O
with NN NN O
partial NN NN O
CES NN NN B-SpecificDisease
because NN NN O
of NN NN O
absence NN NN O
of NN NN O
coloboma NN NN O
, NN NN O
in NN NN O
which NN NN O
the NN NN O
supernumerary NN NN O
marker NN NN O
chromosome NN NN O
was NN NN O
studied NN NN O
by NN NN O
FISH NN NN O
. NN NN O

Using NN NN O
a NN NN O
genomic NN NN O
library NN NN O
, NN NN O
and NN NN O
also NN NN O
a NN NN O
centromeric NN NN O
and NN NN O
particularly NN NN O
a NN NN O
cosmid NN NN O
probe NN NN O
of NN NN O
22q11 NN NN O
, NN NN O
partial NN NN O
tetrasomy NN NN B-DiseaseClass
was NN NN O
shown NN NN O
in NN NN O
all NN NN O
cases NN NN O
. NN NN O

. NN NN O

144081 NN NN O
[ NN NN O
Genetic NN NN O
heterogeneity NN NN O
of NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
: NN NN O
mutant NN NN O
alleles NN NN O
of NN NN O
G6PD NN NN O
in NN NN O
the NN NN O
Shekii NN NN O
district NN NN O
of NN NN O
Azerbaijan NN NN O
] NN NN O
Examination NN NN O
on NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
349 NN NN O
patients NN NN O
of NN NN O
Shekii NN NN O
district NN NN O
hospital NN NN O
( NN NN O
Azerbaijan NN NN O
) NN NN O
revealed NN NN O
16 NN NN O
hemi- NN NN O
, NN NN O
4 NN NN O
homo- NN NN O
and NN NN O
9 NN NN O
heterozygotic NN NN O
carriers NN NN O
of NN NN O
the NN NN O
defect NN NN O
. NN NN O

Gd- NN NN O
frequency NN NN O
, NN NN O
calculated NN NN O
from NN NN O
the NN NN O
data NN NN O
obtained NN NN O
( NN NN O
7 NN NN O
. NN NN O

7 NN NN O
% NN NN O
) NN NN O
, NN NN O
may NN NN O
be NN NN O
compared NN NN O
to NN NN O
neighbouring NN NN O
regions NN NN O
frequencies NN NN O
( NN NN O
6-30 NN NN O
% NN NN O
) NN NN O
. NN NN O

Carriers NN NN O
of NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
are NN NN O
residents NN NN O
of NN NN O
11 NN NN O
villages NN NN O
located NN NN O
in NN NN O
Alasani-Aphtalan NN NN O
valley NN NN O
, NN NN O
highly NN NN O
endemic NN NN O
with NN NN O
malaria NN NN B-SpecificDisease
in NN NN O
the NN NN O
past NN NN O
; NN NN O
nearly NN NN O
all NN NN O
marriages NN NN O
are NN NN O
endogamic NN NN O
. NN NN O

Physico-chemical NN NN O
and NN NN O
kinetic NN NN O
study NN NN O
of NN NN O
10 NN NN O
mutant NN NN O
forms NN NN O
of NN NN O
G6PD NN NN O
, NN NN O
according NN NN O
to NN NN O
WHO NN NN O
program NN NN O
, NN NN O
led NN NN O
to NN NN O
identification NN NN O
of NN NN O
5 NN NN O
variants NN NN O
of NN NN O
the NN NN O
II NN NN O
class NN NN O
( NN NN O
Shekii NN NN O
, NN NN O
Bideiz NN NN O
, NN NN O
Shirin-Bulakh NN NN O
, NN NN O
Okhut NN NN O
I NN NN O
and NN NN O
Zakataly NN NN O
) NN NN O
and NN NN O
2 NN NN O
variants NN NN O
of NN NN O
the NN NN O
III NN NN O
class NN NN O
( NN NN O
Okhut NN NN O
II NN NN O
and NN NN O
Martinique-like NN NN O
) NN NN O
. NN NN O

Resemblance NN NN O
of NN NN O
the NN NN O
majority NN NN O
of NN NN O
variants NN NN O
in NN NN O
electrophoretic NN NN O
mobility NN NN O
and NN NN O
the NN NN O
level NN NN O
of NN NN O
erythrocyte NN NN O
enzyme NN NN O
activity NN NN O
permit NN NN O
to NN NN O
suggest NN NN O
the NN NN O
existence NN NN O
of NN NN O
a NN NN O
common NN NN O
parental NN NN O
mutant NN NN O
G6PD NN NN O
allele NN NN O
distributed NN NN O
in NN NN O
this NN NN O
area NN NN O
. NN NN O

1468459 NN NN O
Craniofrontonasal NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
. NN NN O

We NN NN O
report NN NN O
on NN NN O
nine NN NN O
patients NN NN O
with NN NN O
craniofrontonasal NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
( NN NN O
CFND NN NN B-SpecificDisease
) NN NN O
. NN NN O

Seven NN NN O
classical NN NN O
cases NN NN O
had NN NN O
facial NN NN O
features NN NN O
suggestive NN NN O
of NN NN O
frontonasal NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
and NN NN O
coronal NN NN B-SpecificDisease
craniosynostosis NN NN I-SpecificDisease
. NN NN O

Extracranial NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
such NN NN O
as NN NN O
brittle NN NN B-SpecificDisease
nails NN NN I-SpecificDisease
with NN NN I-SpecificDisease
prominent NN NN I-SpecificDisease
longitudinal NN NN I-SpecificDisease
grooves NN NN I-SpecificDisease
or NN NN O
syndactyly NN NN B-CompositeMention
of NN NN I-CompositeMention
fingers NN NN I-CompositeMention
and NN NN I-CompositeMention
toes NN NN I-CompositeMention
were NN NN O
observed NN NN O
in NN NN O
individual NN NN O
patients NN NN O
. NN NN O

In NN NN O
two NN NN O
families NN NN O
the NN NN O
father NN NN O
of NN NN O
classical NN NN O
cases NN NN O
showed NN NN O
a NN NN O
milder NN NN O
pattern NN NN O
of NN NN O
abnormalities NN NN O
, NN NN O
consistent NN NN O
with NN NN O
the NN NN O
diagnosis NN NN O
. NN NN O

We NN NN O
present NN NN O
a NN NN O
2- NN NN O
to NN NN O
13-year NN NN O
follow-up NN NN O
on NN NN O
our NN NN O
patients NN NN O
. NN NN O

Hypotonia NN NN B-SpecificDisease
and NN NN O
laxity NN NN B-SpecificDisease
of NN NN I-SpecificDisease
joints NN NN I-SpecificDisease
are NN NN O
common NN NN O
and NN NN O
may NN NN O
necessitate NN NN O
supportive NN NN O
measures NN NN O
. NN NN O

Mild NN NN O
developmental NN NN B-DiseaseClass
delay NN NN I-DiseaseClass
was NN NN O
noted NN NN O
in NN NN O
three NN NN O
out NN NN O
of NN NN O
six NN NN O
classical NN NN O
cases NN NN O
studied NN NN O
in NN NN O
detail NN NN O
. NN NN O

Unlike NN NN O
almost NN NN O
all NN NN O
other NN NN O
X-linked NN NN B-DiseaseClass
disorders NN NN I-DiseaseClass
, NN NN O
clinical NN NN O
expression NN NN O
in NN NN O
CFND NN NN B-SpecificDisease
is NN NN O
generally NN NN O
much NN NN O
more NN NN O
severe NN NN O
in NN NN O
females NN NN O
than NN NN O
in NN NN O
males NN NN O
. NN NN O

In NN NN O
contrast NN NN O
to NN NN O
previous NN NN O
reports NN NN O
of NN NN O
this NN NN O
condition NN NN O
, NN NN O
one NN NN O
of NN NN O
our NN NN O
severely NN NN O
affected NN NN O
cases NN NN O
is NN NN O
a NN NN O
male NN NN O
. NN NN O

. NN NN O

1483696 NN NN O
The NN NN O
intron NN NN O
7 NN NN O
donor NN NN O
splice NN NN O
site NN NN O
transition NN NN O
: NN NN O
a NN NN O
second NN NN O
Tay-Sachs NN NN B-Modifier
disease NN NN I-Modifier
mutation NN NN O
in NN NN O
French NN NN O
Canada NN NN O
. NN NN O

Mutations NN NN O
at NN NN O
the NN NN O
hexosaminidase NN NN O
A NN NN O
( NN NN O
HEXA NN NN O
) NN NN O
gene NN NN O
which NN NN O
cause NN NN O
Tay-Sachs NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
TSD NN NN B-SpecificDisease
) NN NN O
have NN NN O
elevated NN NN O
frequency NN NN O
in NN NN O
the NN NN O
Ashkenazi NN NN O
Jewish NN NN O
and NN NN O
French-Canadian NN NN O
populations NN NN O
. NN NN O

We NN NN O
report NN NN O
a NN NN O
novel NN NN O
TSD NN NN B-Modifier
allele NN NN O
in NN NN O
the NN NN O
French-Canadian NN NN O
population NN NN O
associated NN NN O
with NN NN O
the NN NN O
infantile NN NN O
form NN NN O
of NN NN O
the NN NN O
disease NN NN O
. NN NN O

The NN NN O
mutation NN NN O
, NN NN O
a NN NN O
G NN NN O
-- NN NN O
A NN NN O
transition NN NN O
at NN NN O
the NN NN O
+ NN NN O
1 NN NN O
position NN NN O
of NN NN O
intron NN NN O
7 NN NN O
, NN NN O
abolishes NN NN O
the NN NN O
donor NN NN O
splice NN NN O
site NN NN O
. NN NN O

Cultured NN NN O
human NN NN O
fibroblasts NN NN O
from NN NN O
a NN NN O
compound NN NN O
heterozygote NN NN O
for NN NN O
this NN NN O
transition NN NN O
( NN NN O
and NN NN O
for NN NN O
a NN NN O
deletion NN NN O
mutation NN NN O
) NN NN O
produce NN NN O
no NN NN O
detectable NN NN O
HEXA NN NN O
mRNA NN NN O
. NN NN O

The NN NN O
intron NN NN O
7 NN NN O
+ NN NN O
1 NN NN O
mutation NN NN O
occurs NN NN O
in NN NN O
the NN NN O
base NN NN O
adjacent NN NN O
to NN NN O
the NN NN O
site NN NN O
of NN NN O
the NN NN O
adult-onset NN NN O
TSD NN NN B-Modifier
mutation NN NN O
( NN NN O
G805A NN NN O
) NN NN O
. NN NN O

In NN NN O
both NN NN O
mutations NN NN O
a NN NN O
restriction NN NN O
site NN NN O
for NN NN O
the NN NN O
endonuclease NN NN O
EcoRII NN NN O
is NN NN O
abolished NN NN O
. NN NN O

Unambiguous NN NN O
diagnosis NN NN O
, NN NN O
therefore NN NN O
, NN NN O
requires NN NN O
allele-specific NN NN O
oligonucleotide NN NN O
hybridization NN NN O
to NN NN O
distinguish NN NN O
between NN NN O
these NN NN O
two NN NN O
mutant NN NN O
alleles NN NN O
. NN NN O

The NN NN O
intron NN NN O
7 NN NN O
+ NN NN O
1 NN NN O
mutation NN NN O
has NN NN O
been NN NN O
detected NN NN O
in NN NN O
three NN NN O
unrelated NN NN O
families NN NN O
. NN NN O

Obligate NN NN O
heterozygotes NN NN O
for NN NN O
the NN NN O
intron NN NN O
7 NN NN O
+ NN NN O
1 NN NN O
mutation NN NN O
were NN NN O
born NN NN O
in NN NN O
the NN NN O
Saguenay-Lac-St-Jean NN NN O
region NN NN O
of NN NN O
Quebec NN NN O
. NN NN O

The NN NN O
most NN NN O
recent NN NN O
ancestors NN NN O
common NN NN O
to NN NN O
obligate NN NN O
carriers NN NN O
of NN NN O
this NN NN O
mutation NN NN O
were NN NN O
from NN NN O
the NN NN O
Charlevoix NN NN O
region NN NN O
of NN NN O
the NN NN O
province NN NN O
of NN NN O
Quebec NN NN O
. NN NN O

This NN NN O
mutation NN NN O
thus NN NN O
has NN NN O
a NN NN O
different NN NN O
geographic NN NN O
centre NN NN O
of NN NN O
diffusion NN NN O
and NN NN O
is NN NN O
probably NN NN O
less NN NN O
common NN NN O
than NN NN O
the NN NN O
exon NN NN O
1 NN NN O
deletion NN NN O
TSD NN NN B-Modifier
mutation NN NN O
in NN NN O
French NN NN O
Canadians NN NN O
. NN NN O

Neither NN NN O
mutation NN NN O
has NN NN O
been NN NN O
detected NN NN O
in NN NN O
France NN NN O
, NN NN O
the NN NN O
ancestral NN NN O
homeland NN NN O
of NN NN O
French NN NN O
Canada NN NN O
. NN NN O

. NN NN O

1505217 NN NN O
Assignment NN NN O
of NN NN O
the NN NN O
aspartylglucosaminidase NN NN O
gene NN NN O
( NN NN O
AGA NN NN O
) NN NN O
to NN NN O
4q33 NN NN O
-- NN NN O
-- NN NN O
q35 NN NN O
based NN NN O
on NN NN O
decreased NN NN O
activity NN NN O
in NN NN O
a NN NN O
girl NN NN O
with NN NN O
a NN NN O
46 NN NN O
, NN NN O
XX NN NN O
, NN NN O
del NN NN O
( NN NN O
4 NN NN O
) NN NN O
( NN NN O
q33 NN NN O
) NN NN O
karyotype NN NN O
. NN NN O

Aspartylglucosaminuria NN NN B-SpecificDisease
( NN NN O
AGU NN NN B-SpecificDisease
) NN NN O
is NN NN O
a NN NN O
recessive NN NN O
autosomally NN NN O
inherited NN NN O
lysosomal NN NN B-DiseaseClass
storage NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
due NN NN O
to NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
enzyme NN NN I-SpecificDisease
aspartylglucosaminidase NN NN I-SpecificDisease
( NN NN O
AGA NN NN O
) NN NN O
. NN NN O

The NN NN O
structural NN NN O
gene NN NN O
for NN NN O
this NN NN O
human NN NN O
enzyme NN NN O
( NN NN O
AGA NN NN O
) NN NN O
has NN NN O
been NN NN O
assigned NN NN O
to NN NN O
the NN NN O
region NN NN O
4q21 NN NN O
-- NN NN O
-- NN NN O
qter NN NN O
. NN NN O

We NN NN O
determined NN NN O
the NN NN O
AGA NN NN O
activity NN NN O
in NN NN O
cultured NN NN O
fibroblasts NN NN O
of NN NN O
a NN NN O
girl NN NN O
with NN NN O
a NN NN O
46 NN NN O
, NN NN O
XX NN NN O
, NN NN O
del NN NN O
( NN NN O
4 NN NN O
) NN NN O
( NN NN O
q33 NN NN O
) NN NN O
karyotype NN NN O
. NN NN O

The NN NN O
results NN NN O
indicate NN NN O
that NN NN O
the NN NN O
girl NN NN O
is NN NN O
a NN NN O
hemizygote NN NN O
for NN NN O
AGA NN NN O
, NN NN O
permitting NN NN O
the NN NN O
assignment NN NN O
of NN NN O
human NN NN O
AGA NN NN O
to NN NN O
the NN NN O
region NN NN O
4q33 NN NN O
-- NN NN O
-- NN NN O
qter NN NN O
. NN NN O

. NN NN O

1505982 NN NN O
Resolution NN NN O
of NN NN O
the NN NN O
two NN NN O
loci NN NN O
for NN NN O
autosomal NN NN O
dominant NN NN O
aniridia NN NN B-SpecificDisease
, NN NN O
AN1 NN NN O
and NN NN O
AN2 NN NN O
, NN NN O
to NN NN O
a NN NN O
single NN NN O
locus NN NN O
on NN NN O
chromosome NN NN O
11p13 NN NN O
. NN NN O

Two NN NN O
distinct NN NN O
loci NN NN O
have NN NN O
been NN NN O
proposed NN NN O
for NN NN O
aniridia NN NN B-SpecificDisease
; NN NN O
AN1 NN NN O
for NN NN O
autosomal NN NN O
dominant NN NN O
aniridia NN NN B-SpecificDisease
on NN NN O
chromosome NN NN O
2p NN NN O
and NN NN O
AN2 NN NN O
for NN NN O
the NN NN O
aniridia NN NN B-SpecificDisease
in NN NN O
the NN NN O
WAGR NN NN B-SpecificDisease
contiguous NN NN I-SpecificDisease
gene NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
on NN NN O
chromosome NN NN O
11p13 NN NN O
. NN NN O

In NN NN O
this NN NN O
report NN NN O
, NN NN O
the NN NN O
kindred NN NN O
segregating NN NN O
for NN NN O
autosomal NN NN O
dominant NN NN O
aniridia NN NN B-SpecificDisease
, NN NN O
which NN NN O
suggested NN NN O
linkage NN NN O
to NN NN O
acid NN NN O
phosphatase-1 NN NN O
( NN NN O
ACP1 NN NN O
) NN NN O
and NN NN O
led NN NN O
to NN NN O
the NN NN O
assignment NN NN O
of NN NN O
the NN NN O
AN1 NN NN O
locus NN NN O
on NN NN O
chromosome NN NN O
2p NN NN O
, NN NN O
has NN NN O
been NN NN O
updated NN NN O
and NN NN O
expanded NN NN O
. NN NN O

Linkage NN NN O
analysis NN NN O
between NN NN O
the NN NN O
aniridia NN NN B-SpecificDisease
phenotype NN NN O
and NN NN O
ACP1 NN NN O
does NN NN O
not NN NN O
support NN NN O
the NN NN O
original NN NN O
linkage NN NN O
results NN NN O
, NN NN O
excluding NN NN O
linkage NN NN O
up NN NN O
to NN NN O
theta NN NN O
= NN NN O
0 NN NN O
. NN NN O

17 NN NN O
with NN NN O
Z NN NN O
= NN NN O
-2 NN NN O
. NN NN O

Tests NN NN O
for NN NN O
linkage NN NN O
to NN NN O
other NN NN O
chromosome NN NN O
2p NN NN O
markers NN NN O
. NN NN O

APOB NN NN O
, NN NN O
D2S71 NN NN O
, NN NN O
D2S5 NN NN O
, NN NN O
and NN NN O
D2S1 NN NN O
, NN NN O
also NN NN O
excluded NN NN O
linkage NN NN O
to NN NN O
aniridia NN NN B-SpecificDisease
. NN NN O

Markers NN NN O
that NN NN O
have NN NN O
been NN NN O
isolated NN NN O
from NN NN O
the NN NN O
chromosome NN NN O
11p13 NN NN O
region NN NN O
were NN NN O
then NN NN O
analyzed NN NN O
in NN NN O
this NN NN O
aniridia NN NN B-Modifier
family NN NN O
. NN NN O

Two NN NN O
RFLPs NN NN O
at NN NN O
the NN NN O
D11S323 NN NN O
locus NN NN O
give NN NN O
significant NN NN O
evidence NN NN O
for NN NN O
linkage NN NN O
. NN NN O

The NN NN O
PvuII NN NN O
polymorphism NN NN O
detected NN NN O
by NN NN O
probe NN NN O
p5S1 NN NN O
. NN NN O

6 NN NN O
detects NN NN O
no NN NN O
recombinants NN NN O
, NN NN O
with NN NN O
a NN NN O
maximum NN NN O
lod NN NN O
score NN NN O
of NN NN O
Z NN NN O
= NN NN O
6 NN NN O
. NN NN O

97 NN NN O
at NN NN O
theta NN NN O
= NN NN O
0 NN NN O
. NN NN O

00 NN NN O
00 NN NN O
. NN NN O

The NN NN O
HaeIII NN NN O
polymorphism NN NN O
detected NN NN O
by NN NN O
the NN NN O
probe NN NN O
p5BE1 NN NN O
. NN NN O

2 NN NN O
gives NN NN O
a NN NN O
maximum NN NN O
lod NN NN O
score NN NN O
of NN NN O
Z NN NN O
= NN NN O
2 NN NN O
. NN NN O

57 NN NN O
at NN NN O
theta NN NN O
= NN NN O
0 NN NN O
. NN NN O

00 NN NN O
00 NN NN O
. NN NN O

Locus NN NN O
D11S325 NN NN O
gives NN NN O
a NN NN O
lod NN NN O
score NN NN O
of NN NN O
Z NN NN O
= NN NN O
1 NN NN O
. NN NN O

53 NN NN O
at NN NN O
theta NN NN O
= NN NN O
0 NN NN O
. NN NN O

00 NN NN O
00 NN NN O
. NN NN O

These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
a NN NN O
locus NN NN O
for NN NN O
aniridia NN NN B-SpecificDisease
( NN NN O
AN1 NN NN O
) NN NN O
on NN NN O
chromosome NN NN O
2p NN NN O
has NN NN O
been NN NN O
misassigned NN NN O
and NN NN O
that NN NN O
this NN NN O
autosomal NN NN O
dominant NN NN O
aniridia NN NN B-Modifier
family NN NN O
is NN NN O
segregating NN NN O
for NN NN O
an NN NN O
aniridia NN NN B-Modifier
mutation NN NN O
linked NN NN O
to NN NN O
markers NN NN O
in NN NN O
the NN NN O
11p13 NN NN O
region NN NN O
. NN NN O

1517503 NN NN O
Fatal NN NN O
pyoderma NN NN B-SpecificDisease
gangrenosum NN NN I-SpecificDisease
in NN NN O
association NN NN O
with NN NN O
C7 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

Although NN NN O
pyoderma NN NN B-SpecificDisease
gangrenosum NN NN I-SpecificDisease
( NN NN O
PG NN NN B-SpecificDisease
) NN NN O
is NN NN O
often NN NN O
associated NN NN O
with NN NN O
systemic NN NN B-DiseaseClass
diseases NN NN I-DiseaseClass
, NN NN O
it NN NN O
has NN NN O
not NN NN O
been NN NN O
reported NN NN O
in NN NN O
association NN NN O
with NN NN O
congenital NN NN B-DiseaseClass
complement NN NN I-DiseaseClass
deficiencies NN NN I-DiseaseClass
. NN NN O

We NN NN O
describe NN NN O
an NN NN O
aggressive NN NN O
and NN NN O
ultimately NN NN O
fatal NN NN O
case NN NN O
of NN NN O
PG NN NN B-SpecificDisease
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
a NN NN O
congenital NN NN O
C7 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

Deficiencies NN NN B-SpecificDisease
of NN NN I-SpecificDisease
C7 NN NN I-SpecificDisease
can NN NN O
be NN NN O
associated NN NN O
with NN NN O
decreased NN NN O
neutrophil NN NN O
chemotaxis NN NN O
, NN NN O
phagocytosis NN NN O
, NN NN O
and NN NN O
opsonization NN NN O
, NN NN O
similar NN NN O
to NN NN O
the NN NN O
immunologic NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
described NN NN O
in NN NN O
patients NN NN O
with NN NN O
PG NN NN B-SpecificDisease
. NN NN O

Our NN NN O
patients NN NN O
decreased NN NN O
complement NN NN O
level NN NN O
, NN NN O
if NN NN O
not NN NN O
directly NN NN O
related NN NN O
to NN NN O
the NN NN O
development NN NN O
of NN NN O
PG NN NN B-SpecificDisease
, NN NN O
may NN NN O
have NN NN O
contributed NN NN O
to NN NN O
the NN NN O
aggressive NN NN O
nature NN NN O
of NN NN O
her NN NN O
disease NN NN O
. NN NN O

. NN NN O

1562739 NN NN O
Diverse NN NN O
point NN NN O
mutations NN NN O
result NN NN O
in NN NN O
glucose-6-phosphate NN NN O
dehydrogenase NN NN O
( NN NN O
G6PD NN NN O
) NN NN O
polymorphism NN NN O
in NN NN O
Taiwan NN NN O
. NN NN O


1 NN NN O
. NN NN O

49 NN NN O
) NN NN O
deficiency NN NN O
is NN NN O
the NN NN O
most NN NN O
common NN NN O
human NN NN O
enzymopathy NN NN B-DiseaseClass
, NN NN O
affecting NN NN O
more NN NN O
than NN NN O
200 NN NN O
million NN NN O
people NN NN O
worldwide NN NN O
. NN NN O

Although NN NN O
greater NN NN O
than NN NN O
400 NN NN O
variants NN NN O
have NN NN O
been NN NN O
described NN NN O
based NN NN O
on NN NN O
clinical NN NN O
and NN NN O
biochemical NN NN O
criteria NN NN O
, NN NN O
little NN NN O
is NN NN O
known NN NN O
about NN NN O
the NN NN O
molecular NN NN O
basis NN NN O
of NN NN O
these NN NN O
G6PD NN NN B-SpecificDisease
deficiencies NN NN I-SpecificDisease
. NN NN O

Recently NN NN O
, NN NN O
the NN NN O
gene NN NN O
that NN NN O
encodes NN NN O
human NN NN O
G6PD NN NN O
has NN NN O
been NN NN O
cloned NN NN O
and NN NN O
sequenced NN NN O
, NN NN O
which NN NN O
enables NN NN O
us NN NN O
to NN NN O
examine NN NN O
directly NN NN O
the NN NN O
heterogeneity NN NN O
of NN NN O
G6PD NN NN O
at NN NN O
the NN NN O
DNA NN NN O
level NN NN O
. NN NN O

During NN NN O
the NN NN O
past NN NN O
10 NN NN O
years NN NN O
, NN NN O
we NN NN O
examined NN NN O
the NN NN O
G6PD NN NN O
activity NN NN O
in NN NN O
21 NN NN O
, NN NN O
271 NN NN O
newborn NN NN O
Chinese NN NN O
infants NN NN O
( NN NN O
11 NN NN O
, NN NN O
400 NN NN O
males NN NN O
and NN NN O
9 NN NN O
, NN NN O
871 NN NN O
females NN NN O
) NN NN O
and NN NN O
identified NN NN O
314 NN NN O
( NN NN O
2 NN NN O
. NN NN O

8 NN NN O
% NN NN O
) NN NN O
males NN NN O
and NN NN O
246 NN NN O
( NN NN O
2 NN NN O
. NN NN O

5 NN NN O
% NN NN O
) NN NN O
females NN NN O
having NN NN O
low NN NN O
G6PD NN NN O
activity NN NN O
. NN NN O

The NN NN O
G6PD NN NN O
gene NN NN O
from NN NN O
10 NN NN O
randomly NN NN O
selected NN NN O
affected NN NN O
individuals NN NN O
and NN NN O
their NN NN O
relatives NN NN O
was NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
( NN NN O
PCR NN NN O
) NN NN O
amplified NN NN O
, NN NN O
subcloned NN NN O
, NN NN O
and NN NN O
sequenced NN NN O
. NN NN O

Our NN NN O
results NN NN O
indicate NN NN O
that NN NN O
at NN NN O
least NN NN O
four NN NN O
types NN NN O
of NN NN O
mutation NN NN O
are NN NN O
responsible NN NN O
for NN NN O
the NN NN O
G6PD NN NN O
polymorphism NN NN O
in NN NN O
Taiwan NN NN O
. NN NN O

The NN NN O
first NN NN O
type NN NN O
of NN NN O
mutation NN NN O
( NN NN O
487 NN NN O
G NN NN O
-- NN NN O
-- NN NN O
A NN NN O
) NN NN O
was NN NN O
found NN NN O
in NN NN O
an NN NN O
affected NN NN O
Chinese NN NN O
with NN NN O
a NN NN O
G NN NN O
to NN NN O
A NN NN O
change NN NN O
at NN NN O
nucleotide NN NN O
487 NN NN O
, NN NN O
which NN NN O
results NN NN O
in NN NN O
a NN NN O
( NN NN O
163 NN NN O
) NN NN O
Gly NN NN O
to NN NN O
Ser NN NN O
substitution NN NN O
. NN NN O

The NN NN O
second NN NN O
type NN NN O
of NN NN O
mutation NN NN O
( NN NN O
493 NN NN O
A NN NN O
-- NN NN O
-- NN NN O
G NN NN O
) NN NN O
is NN NN O
a NN NN O
novel NN NN O
mutation NN NN O
that NN NN O
has NN NN O
not NN NN O
been NN NN O
reported NN NN O
in NN NN O
any NN NN O
other NN NN O
ethnic NN NN O
group NN NN O
and NN NN O
was NN NN O
identified NN NN O
in NN NN O
two NN NN O
affected NN NN O
Chinese NN NN O
. NN NN O

This NN NN O
mutation NN NN O
causes NN NN O
an NN NN O
A NN NN O
to NN NN O
G NN NN O
change NN NN O
at NN NN O
nucleotide NN NN O
position NN NN O
493 NN NN O
, NN NN O
producing NN NN O
an NN NN O
( NN NN O
165 NN NN O
) NN NN O
Asn NN NN O
to NN NN O
Asp NN NN O
substitution NN NN O
. NN NN O

Interestingly NN NN O
, NN NN O
the NN NN O
487 NN NN O
G NN NN O
-- NN NN O
-- NN NN O
A NN NN O
and NN NN O
493 NN NN O
A NN NN O
-- NN NN O
-- NN NN O
G NN NN O
mutations NN NN O
create NN NN O
Alu NN NN O
I NN NN O
and NN NN O
Ava NN NN O
II NN NN O
recognition NN NN O
sites NN NN O
, NN NN O
respectively NN NN O
, NN NN O
which NN NN O
enabled NN NN O
us NN NN O
to NN NN O
rapidly NN NN O
detect NN NN O
these NN NN O
two NN NN O
mutations NN NN O
by NN NN O
PCR NN NN O
/ NN NN O
restriction NN NN O
enzyme NN NN O
( NN NN O
RE NN NN O
) NN NN O
digestion NN NN O
method NN NN O
. NN NN O

The NN NN O
third NN NN O
mutation NN NN O
( NN NN O
1376 NN NN O
G NN NN O
-- NN NN O
-- NN NN O
T NN NN O
) NN NN O
was NN NN O
found NN NN O
in NN NN O
four NN NN O
affected NN NN O
Chinese NN NN O
. NN NN O

This NN NN O
mutation NN NN O
causes NN NN O
a NN NN O
G NN NN O
to NN NN O
T NN NN O
change NN NN O
at NN NN O
nucleotide NN NN O
position NN NN O
1376 NN NN O
that NN NN O
results NN NN O
in NN NN O
an NN NN O
( NN NN O
459 NN NN O
) NN NN O
Arg NN NN O
to NN NN O
Leu NN NN O
substitution NN NN O
. NN NN O

The NN NN O
1376 NN NN O
G NN NN O
-- NN NN O
-- NN NN O
T NN NN O
mutation NN NN O
seems NN NN O
to NN NN O
be NN NN O
the NN NN O
dominant NN NN O
allele NN NN O
that NN NN O
causes NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
Taiwan NN NN O
. NN NN O

Finally NN NN O
, NN NN O
two NN NN O
affected NN NN O
Chinese NN NN O
were NN NN O
identified NN NN O
as NN NN O
having NN NN O
the NN NN O
fourth NN NN O
mutation NN NN O
( NN NN O
1388 NN NN O
G NN NN O
-- NN NN O
-- NN NN O
A NN NN O
) NN NN O
. NN NN O

This NN NN O
mutation NN NN O
causes NN NN O
a NN NN O
G NN NN O
to NN NN O
A NN NN O
change NN NN O
at NN NN O
nucleotide NN NN O
1388 NN NN O
that NN NN O
produces NN NN O
an NN NN O
( NN NN O
463 NN NN O
) NN NN O
Arg NN NN O
to NN NN O
His NN NN O
substitution NN NN O
. NN NN O

Our NN NN O
studies NN NN O
provide NN NN O
the NN NN O
direct NN NN O
proof NN NN O
of NN NN O
the NN NN O
genetic NN NN O
heterogeneity NN NN O
of NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
the NN NN O
Chinese NN NN O
populations NN NN O
of NN NN O
Taiwan NN NN O
and NN NN O
the NN NN O
PCR NN NN O
/ NN NN O
RE NN NN O
digestion NN NN O
method NN NN O
is NN NN O
suitable NN NN O
for NN NN O
simultaneous NN NN O
detection NN NN O
of NN NN O
the NN NN O
487 NN NN O
G NN NN O
-- NN NN O
-- NN NN O
A NN NN O
and NN NN O
493 NN NN O
A NN NN O
-- NN NN O
-- NN NN O
G NN NN O
mutations NN NN O
. NN NN O

1577476 NN NN O
An NN NN O
error NN NN O
in NN NN O
dystrophin NN NN O
mRNA NN NN O
processing NN NN O
in NN NN O
golden NN NN B-SpecificDisease
retriever NN NN I-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
, NN NN O
an NN NN O
animal NN NN O
homologue NN NN O
of NN NN O
Duchenne NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
. NN NN O

Golden NN NN B-SpecificDisease
retriever NN NN I-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
GRMD NN NN B-SpecificDisease
) NN NN O
is NN NN O
a NN NN O
spontaneous NN NN O
, NN NN O
X-linked NN NN O
, NN NN O
progressively NN NN O
fatal NN NN O
disease NN NN O
of NN NN O
dogs NN NN O
and NN NN O
is NN NN O
also NN NN O
a NN NN O
homologue NN NN O
of NN NN O
Duchenne NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DMD NN NN B-SpecificDisease
) NN NN O
. NN NN O

Two-thirds NN NN O
of NN NN O
DMD NN NN B-Modifier
patients NN NN O
carry NN NN O
detectable NN NN O
deletions NN NN O
in NN NN O
their NN NN O
dystrophin NN NN O
gene NN NN O
. NN NN O

The NN NN O
defect NN NN O
underlying NN NN O
the NN NN O
remaining NN NN O
one-third NN NN O
of NN NN O
DMD NN NN B-Modifier
patients NN NN O
is NN NN O
undetermined NN NN O
. NN NN O

Analysis NN NN O
of NN NN O
the NN NN O
canine NN NN O
dystrophin NN NN O
gene NN NN O
in NN NN O
normal NN NN O
and NN NN O
GRMD NN NN B-Modifier
dogs NN NN O
has NN NN O
failed NN NN O
to NN NN O
demonstrate NN NN O
any NN NN O
detectable NN NN O
loss NN NN O
of NN NN O
exons NN NN O
. NN NN O

Here NN NN O
, NN NN O
we NN NN O
have NN NN O
demonstrated NN NN O
a NN NN O
RNA NN NN O
processing NN NN O
error NN NN O
in NN NN O
GRMD NN NN B-SpecificDisease
that NN NN O
results NN NN O
from NN NN O
a NN NN O
single NN NN O
base NN NN O
change NN NN O
in NN NN O
the NN NN O
3 NN NN O
consensus NN NN O
splice NN NN O
site NN NN O
of NN NN O
intron NN NN O
6 NN NN O
. NN NN O

The NN NN O
seventh NN NN O
exon NN NN O
is NN NN O
then NN NN O
skipped NN NN O
, NN NN O
which NN NN O
predicts NN NN O
a NN NN O
termination NN NN O
of NN NN O
the NN NN O
dystrophin NN NN O
reading NN NN O
frame NN NN O
within NN NN O
its NN NN O
N-terminal NN NN O
domain NN NN O
in NN NN O
exon NN NN O
8 NN NN O
. NN NN O

This NN NN O
is NN NN O
the NN NN O
first NN NN O
example NN NN O
of NN NN O
dystrophin NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
caused NN NN O
by NN NN O
a NN NN O
splice-site NN NN O
mutation NN NN O
. NN NN O

. NN NN O

1577763 NN NN O
Type NN NN B-SpecificDisease
I NN NN I-SpecificDisease
human NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
C2 NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

A NN NN O
28-base NN NN O
pair NN NN O
gene NN NN O
deletion NN NN O
causes NN NN O
skipping NN NN O
of NN NN O
exon NN NN O
6 NN NN O
during NN NN O
RNA NN NN O
splicing NN NN O
. NN NN O

Two NN NN O
variants NN NN O
of NN NN O
a NN NN O
genetic NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
protein NN NN I-SpecificDisease
C2 NN NN I-SpecificDisease
( NN NN O
C2D NN NN O
) NN NN O
have NN NN O
been NN NN O
previously NN NN O
identified NN NN O
. NN NN O

No NN NN O
C2 NN NN O
protein NN NN O
translation NN NN O
is NN NN O
detected NN NN O
in NN NN O
type NN NN O
I NN NN O
deficiency NN NN O
, NN NN O
while NN NN O
type NN NN O
II NN NN O
deficiency NN NN O
is NN NN O
characterized NN NN O
by NN NN O
a NN NN O
selective NN NN O
block NN NN O
in NN NN O
C2 NN NN O
secretion NN NN O
. NN NN O

Type NN NN B-SpecificDisease
I NN NN I-SpecificDisease
C2 NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
was NN NN O
described NN NN O
in NN NN O
a NN NN O
family NN NN O
in NN NN O
which NN NN O
the NN NN O
C2 NN NN O
null NN NN O
allele NN NN O
( NN NN O
C2Q0 NN NN O
) NN NN O
is NN NN O
associated NN NN O
with NN NN O
the NN NN O
major NN NN O
histocompatibility NN NN O
haplotype NN NN O
/ NN NN O
complotype NN NN O
HLA-A25 NN NN O
, NN NN O
B18 NN NN O
, NN NN O
C2Q0 NN NN O
, NN NN O
BfS NN NN O
, NN NN O
C4A4 NN NN O
, NN NN O
C4B2 NN NN O
, NN NN O
Drw2 NN NN O
; NN NN O
this NN NN O
extended NN NN O
haplotype NN NN O
occurs NN NN O
in NN NN O
over NN NN O
90 NN NN O
% NN NN O
of NN NN O
C2-deficient NN NN B-Modifier
individuals NN NN O
( NN NN O
common NN NN O
complotype NN NN O
/ NN NN O
haplotype NN NN O
) NN NN O
. NN NN O

To NN NN O
determine NN NN O
the NN NN O
molecular NN NN O
basis NN NN O
of NN NN O
type NN NN B-SpecificDisease
I NN NN I-SpecificDisease
C2 NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
, NN NN O
the NN NN O
C2 NN NN O
gene NN NN O
and NN NN O
cDNA NN NN O
were NN NN O
characterized NN NN O
from NN NN O
a NN NN O
homozygous NN NN O
type NN NN B-Modifier
I NN NN I-Modifier
C2-deficient NN NN I-Modifier
individual NN NN O
with NN NN O
the NN NN O
common NN NN O
associated NN NN O
haplotype NN NN O
/ NN NN O
complotype NN NN O
. NN NN O

We NN NN O
found NN NN O
a NN NN O
28-base NN NN O
pair NN NN O
deletion NN NN O
in NN NN O
the NN NN O
type NN NN O
I NN NN O
C2Q0 NN NN O
gene NN NN O
, NN NN O
beginning NN NN O
9 NN NN O
base NN NN O
pairs NN NN O
upstream NN NN O
of NN NN O
the NN NN O
3-end NN NN O
of NN NN O
exon NN NN O
6 NN NN O
, NN NN O
that NN NN O
generates NN NN O
a NN NN O
C2 NN NN O
transcript NN NN O
with NN NN O
a NN NN O
complete NN NN O
deletion NN NN O
of NN NN O
exon NN NN O
6 NN NN O
( NN NN O
134 NN NN O
base NN NN O
pair NN NN O
) NN NN O
and NN NN O
a NN NN O
premature NN NN O
termination NN NN O
codon NN NN O
. NN NN O

In NN NN O
studies NN NN O
of NN NN O
eight NN NN O
kindred NN NN O
, NN NN O
the NN NN O
28-base NN NN O
pair NN NN O
deletion NN NN O
was NN NN O
observed NN NN O
in NN NN O
all NN NN O
C2Q0 NN NN O
alleles NN NN O
associated NN NN O
with NN NN O
the NN NN O
common NN NN O
type NN NN O
I NN NN O
deficient NN NN O
complotype NN NN O
/ NN NN O
haplotype NN NN O
; NN NN O
this NN NN O
deletion NN NN O
was NN NN O
not NN NN O
present NN NN O
in NN NN O
normal NN NN O
C2 NN NN O
nor NN NN O
in NN NN O
type NN NN B-Modifier
II NN NN I-Modifier
C2-deficient NN NN I-Modifier
genes NN NN O
. NN NN O

These NN NN O
data NN NN O
demonstrate NN NN O
that NN NN O
1 NN NN O
) NN NN O
type NN NN B-SpecificDisease
I NN NN I-SpecificDisease
human NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
C2 NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
is NN NN O
caused NN NN O
by NN NN O
a NN NN O
28-base NN NN O
pair NN NN O
genomic NN NN O
deletion NN NN O
that NN NN O
causes NN NN O
skipping NN NN O
of NN NN O
exon NN NN O
6 NN NN O
during NN NN O
RNA NN NN O
splicing NN NN O
, NN NN O
resulting NN NN O
in NN NN O
generation NN NN O
of NN NN O
a NN NN O
premature NN NN O
termination NN NN O
codon NN NN O
, NN NN O
2 NN NN O
) NN NN O
the NN NN O
28-base NN NN O
pair NN NN O
deletion NN NN O
in NN NN O
the NN NN O
type NN NN O
I NN NN O
C2Q0 NN NN O
gene NN NN O
is NN NN O
strongly NN NN O
associated NN NN O
with NN NN O
the NN NN O
HLA NN NN O
haplotype NN NN O
/ NN NN O
complotype NN NN O
A25 NN NN O
, NN NN O
B18 NN NN O
, NN NN O
C2Q0 NN NN O
, NN NN O
BfS NN NN O
, NN NN O
C4A4 NN NN O
, NN NN O
C4B2 NN NN O
, NN NN O
Drw2 NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
all NN NN O
C2-deficient NN NN B-Modifier
individuals NN NN O
with NN NN O
this NN NN O
haplotype NN NN O
/ NN NN O
complotype NN NN O
will NN NN O
harbor NN NN O
the NN NN O
28-base NN NN O
pair NN NN O
C2 NN NN O
gene NN NN O
deletion NN NN O
, NN NN O
and NN NN O
3 NN NN O
) NN NN O
type NN NN B-SpecificDisease
II NN NN I-SpecificDisease
C2 NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
is NN NN O
caused NN NN O
by NN NN O
a NN NN O
different NN NN O
, NN NN O
as NN NN O
yet NN NN O
uncharacterized NN NN O
, NN NN O
molecular NN NN O
genetic NN NN B-DiseaseClass
defect NN NN I-DiseaseClass
. NN NN O

. NN NN O

1610789 NN NN O
Molecular NN NN O
characterization NN NN O
of NN NN O
two NN NN O
galactosemia NN NN B-Modifier
mutations NN NN O
and NN NN O
one NN NN O
polymorphism NN NN O
: NN NN O
implications NN NN O
for NN NN O
structure-function NN NN O
analysis NN NN O
of NN NN O
human NN NN O
galactose-1-phosphate NN NN O
uridyltransferase NN NN O
. NN NN O

We NN NN O
report NN NN O
here NN NN O
the NN NN O
molecular NN NN O
characterization NN NN O
of NN NN O
two NN NN O
galactosemia NN NN B-Modifier
mutations NN NN O
, NN NN O
L74P NN NN O
and NN NN O
F171S NN NN O
, NN NN O
and NN NN O
one NN NN O
polymorphism NN NN O
, NN NN O
S135L NN NN O
, NN NN O
in NN NN O
human NN NN O
galactose-1-phosphate NN NN O
uridyltransferase NN NN O
( NN NN O
GALT NN NN O
) NN NN O
. NN NN O

Both NN NN O
galactosemia NN NN B-Modifier
mutations NN NN O
result NN NN O
in NN NN O
reduced NN NN O
enzymatic NN NN O
activity NN NN O
when NN NN O
reconstructed NN NN O
in NN NN O
the NN NN O
cDNA NN NN O
and NN NN O
overexpressed NN NN O
. NN NN O

The NN NN O
polymorphism NN NN O
, NN NN O
in NN NN O
contrast NN NN O
, NN NN O
has NN NN O
near NN NN O
normal NN NN O
activity NN NN O
. NN NN O

Both NN NN O
mutations NN NN O
affect NN NN O
evolutionarily NN NN O
conserved NN NN O
residues NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
they NN NN O
are NN NN O
functionally NN NN O
important NN NN O
, NN NN O
while NN NN O
the NN NN O
polymorphism NN NN O
occurs NN NN O
in NN NN O
a NN NN O
nonconserved NN NN O
domain NN NN O
which NN NN O
is NN NN O
presumably NN NN O
not NN NN O
critical NN NN O
for NN NN O
enzymatic NN NN O
function NN NN O
. NN NN O

The NN NN O
F171S NN NN O
mutation NN NN O
is NN NN O
close NN NN O
to NN NN O
the NN NN O
putative NN NN O
active-site NN NN O
nucleophile NN NN O
. NN NN O

Our NN NN O
data NN NN O
further NN NN O
support NN NN O
the NN NN O
notion NN NN O
of NN NN O
molecular NN NN O
heterogeneity NN NN O
of NN NN O
galactosemia NN NN B-SpecificDisease
and NN NN O
suggest NN NN O
that NN NN O
galactosemia NN NN B-Modifier
mutations NN NN O
and NN NN O
GALT NN NN O
polymorphisms NN NN O
may NN NN O
be NN NN O
useful NN NN O
tools NN NN O
in NN NN O
highlighting NN NN O
different NN NN O
functional NN NN O
domains NN NN O
in NN NN O
human NN NN O
GALT NN NN O
. NN NN O

. NN NN O

161677 NN NN O
Linkage NN NN O
relationship NN NN O
of NN NN O
C2 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
, NN NN O
HLA NN NN O
and NN NN O
glyoxalase NN NN O
I NN NN O
loci NN NN O
. NN NN O

Immunogenetic NN NN O
analysis NN NN O
of NN NN O
a NN NN O
homozygous NN NN O
C2-deficient NN NN B-Modifier
individual NN NN O
and NN NN O
family NN NN O
members NN NN O
demonstrated NN NN O
linkage NN NN O
of NN NN O
HLA-A25 NN NN O
, NN NN O
B18 NN NN O
and NN NN O
C2o NN NN O
. NN NN O

HLA-D NN NN O
typing NN NN O
showed NN NN O
that NN NN O
5 NN NN O
members NN NN O
typed NN NN O
with NN NN O
homozygous NN NN O
Dw2 NN NN O
typing NN NN O
cells NN NN O
from NN NN O
an NN NN O
individual NN NN O
with NN NN O
C2 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
but NN NN O
not NN NN O
with NN NN O
Dw2 NN NN O
typing NN NN O
cells NN NN O
from NN NN O
2 NN NN O
individuals NN NN O
with NN NN O
normal NN NN O
C2 NN NN O
. NN NN O

The NN NN O
homozygous NN NN O
C2-deficient NN NN B-Modifier
propositus NN NN O
and NN NN O
brother NN NN O
were NN NN O
HLA-A NN NN O
and NN NN O
B NN NN O
homozygous NN NN O
but NN NN O
heterozygous NN NN O
at NN NN O
the NN NN O
HLA-D NN NN O
and NN NN O
glyoxalase NN NN O
I NN NN O
loci NN NN O
. NN NN O

Therefore NN NN O
, NN NN O
in NN NN O
this NN NN O
family NN NN O
, NN NN O
the NN NN O
C2o NN NN O
gene NN NN O
is NN NN O
linked NN NN O
with NN NN O
two NN NN O
distinct NN NN O
haplotypes NN NN O
HLA-A25 NN NN O
, NN NN O
B18 NN NN O
, NN NN O
Dw2 NN NN O
, NN NN O
GLO1 NN NN O
and NN NN O
HLA-A25 NN NN O
, NN NN O
B18 NN NN O
, NN NN O
D NN NN O
unknown NN NN O
, NN NN O
GL02 NN NN O
. NN NN O

These NN NN O
results NN NN O
could NN NN O
be NN NN O
explained NN NN O
by NN NN O
an NN NN O
ancestral NN NN O
recombinant NN NN O
event NN NN O
, NN NN O
which NN NN O
occurred NN NN O
between NN NN O
the NN NN O
C2o NN NN O
locus NN NN O
and NN NN O
HLA-D NN NN O
locus NN NN O
in NN NN O
which NN NN O
C2o NN NN O
segregated NN NN O
with NN NN O
HLA-B NN NN O
. NN NN O

This NN NN O
would NN NN O
suggest NN NN O
that NN NN O
the NN NN O
locus NN NN O
for NN NN O
the NN NN O
C2o NN NN O
gene NN NN O
maps NN NN O
between NN NN O
HLA-B NN NN O
and NN NN O
HLA-D NN NN O
on NN NN O
the NN NN O
sixth NN NN O
chromosome NN NN O
. NN NN O

. NN NN O

1655284 NN NN O
Germline NN NN O
mutations NN NN O
in NN NN O
the NN NN O
Wilms NN NN B-Modifier
' NN NN I-Modifier
tumor NN NN I-Modifier
suppressor NN NN O
gene NN NN O
are NN NN O
associated NN NN O
with NN NN O
abnormal NN NN O
urogenital NN NN O
development NN NN O
in NN NN O
Denys-Drash NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

Denys-Drash NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
is NN NN O
a NN NN O
rare NN NN O
human NN NN O
condition NN NN O
in NN NN O
which NN NN O
severe NN NN O
urogenital NN NN B-DiseaseClass
aberrations NN NN I-DiseaseClass
result NN NN O
in NN NN O
renal NN NN B-SpecificDisease
failure NN NN I-SpecificDisease
, NN NN O
pseudohermaphroditism NN NN B-SpecificDisease
, NN NN O
and NN NN O
Wilms NN NN B-SpecificDisease
tumor NN NN I-SpecificDisease
( NN NN O
nephroblastoma NN NN B-SpecificDisease
) NN NN O
. NN NN O

To NN NN O
investigate NN NN O
its NN NN O
possible NN NN O
role NN NN O
, NN NN O
we NN NN O
have NN NN O
analyzed NN NN O
the NN NN O
coding NN NN O
exons NN NN O
of NN NN O
the NN NN O
Wilms NN NN B-Modifier
tumor NN NN I-Modifier
suppressor NN NN O
gene NN NN O
( NN NN O
WT1 NN NN O
) NN NN O
for NN NN O
germline NN NN O
mutations NN NN O
. NN NN O

In NN NN O
ten NN NN O
independent NN NN O
cases NN NN O
of NN NN O
Denys-Drash NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
, NN NN O
point NN NN O
mutations NN NN O
in NN NN O
the NN NN O
zinc NN NN O
finger NN NN O
domains NN NN O
of NN NN O
one NN NN O
WT1 NN NN O
gene NN NN O
copy NN NN O
were NN NN O
found NN NN O
. NN NN O

Nine NN NN O
of NN NN O
these NN NN O
mutations NN NN O
are NN NN O
found NN NN O
within NN NN O
exon NN NN O
9 NN NN O
( NN NN O
zinc NN NN O
finger NN NN O
III NN NN O
) NN NN O
; NN NN O
the NN NN O
remaining NN NN O
mutation NN NN O
is NN NN O
in NN NN O
exon NN NN O
8 NN NN O
( NN NN O
zinc NN NN O
finger NN NN O
II NN NN O
) NN NN O
. NN NN O

These NN NN O
mutations NN NN O
directly NN NN O
affect NN NN O
DNA NN NN O
sequence NN NN O
recognition NN NN O
. NN NN O

In NN NN O
two NN NN O
families NN NN O
analyzed NN NN O
, NN NN O
the NN NN O
mutations NN NN O
were NN NN O
shown NN NN O
to NN NN O
arise NN NN O
de NN NN O
novo NN NN O
. NN NN O

Wilms NN NN B-SpecificDisease
tumors NN NN I-SpecificDisease
from NN NN O
three NN NN O
individuals NN NN O
and NN NN O
one NN NN O
juvenile NN NN O
granulosa NN NN O
cell NN NN O
tumor NN NN B-DiseaseClass
demonstrate NN NN O
reduction NN NN O
to NN NN O
homozygosity NN NN O
for NN NN O
the NN NN O
mutated NN NN O
WT1 NN NN O
allele NN NN O
. NN NN O

Our NN NN O
results NN NN O
provide NN NN O
evidence NN NN O
of NN NN O
a NN NN O
direct NN NN O
role NN NN O
for NN NN O
WT1 NN NN O
in NN NN O
Denys-Drash NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
and NN NN O
thus NN NN O
urogenital NN NN O
system NN NN O
development NN NN O
. NN NN O

. NN NN O

1671851 NN NN O
Linkage NN NN O
analysis NN NN O
in NN NN O
X-linked NN NN B-SpecificDisease
adrenoleukodystrophy NN NN I-SpecificDisease
and NN NN O
application NN NN O
in NN NN O
post- NN NN O
and NN NN O
prenatal NN NN O
diagnosis NN NN O
. NN NN O

We NN NN O
have NN NN O
performed NN NN O
linkage NN NN O
analysis NN NN O
with NN NN O
the NN NN O
DNA NN NN O
markers NN NN O
DXS52 NN NN O
and NN NN O
the NN NN O
clotting NN NN O
factor NN NN O
VIII NN NN O
gene NN NN O
( NN NN O
F8C NN NN O
) NN NN O
, NN NN O
in NN NN O
several NN NN O
large NN NN O
families NN NN O
with NN NN O
X-linked NN NN B-SpecificDisease
adrenoleukodystrophy NN NN I-SpecificDisease
( NN NN O
ALD NN NN B-SpecificDisease
) NN NN O
. NN NN O

The NN NN O
tight NN NN O
linkage NN NN O
to NN NN O
DXS52 NN NN O
could NN NN O
be NN NN O
extended NN NN O
giving NN NN O
a NN NN O
maximal NN NN O
LOD NN NN O
score NN NN O
of NN NN O
22 NN NN O
. NN NN O

5 NN NN O
at NN NN O
1 NN NN O
cM NN NN O
. NN NN O

F8C NN NN O
was NN NN O
also NN NN O
tightly NN NN O
linked NN NN O
to NN NN O
ALD NN NN B-SpecificDisease
with NN NN O
a NN NN O
maximal NN NN O
LOD NN NN O
score NN NN O
of NN NN O
7 NN NN O
. NN NN O

8 NN NN O
without NN NN O
recombination NN NN O
. NN NN O

Multipoint NN NN O
linkage NN NN O
analysis NN NN O
with NN NN O
the NN NN O
markers NN NN O
DXS304 NN NN O
, NN NN O
DXS52 NN NN O
, NN NN O
and NN NN O
F8C NN NN O
indicated NN NN O
that NN NN O
both NN NN O
the NN NN O
gene NN NN O
for NN NN O
ALD NN NN B-SpecificDisease
and NN NN O
for NN NN O
F8C NN NN O
are NN NN O
distal NN NN O
to NN NN O
DXS52 NN NN O
. NN NN O

In NN NN O
four NN NN O
patients NN NN O
with NN NN O
ALD NN NN B-SpecificDisease
, NN NN O
no NN NN O
major NN NN O
structural NN NN O
rearrangement NN NN O
in NN NN O
the NN NN O
Xqter NN NN O
region NN NN O
was NN NN O
observed NN NN O
; NN NN O
in NN NN O
particular NN NN O
, NN NN O
there NN NN O
were NN NN O
no NN NN O
abnormalities NN NN B-DiseaseClass
in NN NN I-DiseaseClass
the NN NN I-DiseaseClass
vision NN NN I-DiseaseClass
blindness NN NN I-DiseaseClass
genes NN NN I-DiseaseClass
. NN NN O

DNA NN NN O
analysis NN NN O
appeared NN NN O
to NN NN O
be NN NN O
of NN NN O
use NN NN O
in NN NN O
determination NN NN O
of NN NN O
the NN NN O
carrier NN NN O
status NN NN O
of NN NN O
females NN NN O
at NN NN O
risk NN NN O
, NN NN O
for NN NN O
the NN NN O
determination NN NN O
of NN NN O
the NN NN O
origin NN NN O
of NN NN O
the NN NN O
mutation NN NN O
in NN NN O
a NN NN O
particular NN NN O
family NN NN O
, NN NN O
and NN NN O
for NN NN O
prenatal NN NN O
diagnosis NN NN O
. NN NN O

1671881 NN NN O
Two NN NN O
distinct NN NN O
mutations NN NN O
at NN NN O
a NN NN O
single NN NN O
BamHI NN NN O
site NN NN O
in NN NN O
phenylketonuria NN NN B-SpecificDisease
. NN NN O

Classical NN NN B-SpecificDisease
phenylketonuria NN NN I-SpecificDisease
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
disease NN NN I-DiseaseClass
caused NN NN O
by NN NN O
a NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
hepatic NN NN I-SpecificDisease
phenylalanine NN NN I-SpecificDisease
hydroxylase NN NN I-SpecificDisease
( NN NN O
PAH NN NN O
) NN NN O
. NN NN O

The NN NN O
abolition NN NN O
of NN NN O
an NN NN O
invariant NN NN O
BamHI NN NN O
site NN NN O
located NN NN O
in NN NN O
the NN NN O
coding NN NN O
sequence NN NN O
of NN NN O
the NN NN O
PAH NN NN O
gene NN NN O
( NN NN O
exon NN NN O
7 NN NN O
) NN NN O
led NN NN O
to NN NN O
the NN NN O
recognition NN NN O
of NN NN O
two NN NN O
new NN NN O
point NN NN O
mutations NN NN O
at NN NN O
codon NN NN O
272 NN NN O
and NN NN O
273 NN NN O
( NN NN O
272gly NN NN O
-- NN NN O
-- NN NN O
stop NN NN O
and NN NN O
273ser NN NN O
-- NN NN O
-- NN NN O
phe NN NN O
, NN NN O
respectively NN NN O
) NN NN O
. NN NN O

Both NN NN O
mutations NN NN O
were NN NN O
detected NN NN O
in NN NN O
north NN NN O
eastern NN NN O
France NN NN O
or NN NN O
Belgium NN NN O
and NN NN O
occurred NN NN O
on NN NN O
the NN NN O
background NN NN O
of NN NN O
RFLP NN NN O
haplotype NN NN O
7 NN NN O
alleles NN NN O
. NN NN O

The NN NN O
present NN NN O
study NN NN O
supports NN NN O
the NN NN O
view NN NN O
that NN NN O
the NN NN O
clinical NN NN O
heterogeneity NN NN O
in NN NN O
PKU NN NN B-SpecificDisease
is NN NN O
accounted NN NN O
for NN NN O
by NN NN O
the NN NN O
large NN NN O
variety NN NN O
of NN NN O
mutant NN NN O
genotypes NN NN O
associated NN NN O
with NN NN O
PAH NN NN B-SpecificDisease
deficiencies NN NN I-SpecificDisease
. NN NN O

. NN NN O

1673289 NN NN O
A NN NN O
detailed NN NN O
multipoint NN NN O
map NN NN O
of NN NN O
human NN NN O
chromosome NN NN O
4 NN NN O
provides NN NN O
evidence NN NN O
for NN NN O
linkage NN NN O
heterogeneity NN NN O
and NN NN O
position-specific NN NN O
recombination NN NN O
rates NN NN O
. NN NN O

Utilizing NN NN O
the NN NN O
CEPH NN NN O
reference NN NN O
panel NN NN O
and NN NN O
genotypic NN NN O
data NN NN O
for NN NN O
53 NN NN O
markers NN NN O
, NN NN O
we NN NN O
have NN NN O
constructed NN NN O
a NN NN O
20-locus NN NN O
multipoint NN NN O
genetic NN NN O
map NN NN O
of NN NN O
human NN NN O
chromosome NN NN O
4 NN NN O
. NN NN O

New NN NN O
RFLPs NN NN O
are NN NN O
reported NN NN O
for NN NN O
four NN NN O
loci NN NN O
. NN NN O

The NN NN O
map NN NN O
integrates NN NN O
a NN NN O
high-resolution NN NN O
genetic NN NN O
map NN NN O
of NN NN O
4p16 NN NN O
into NN NN O
a NN NN O
continuous NN NN O
map NN NN O
extending NN NN O
to NN NN O
4q31 NN NN O
and NN NN O
an NN NN O
unlinked NN NN O
cluster NN NN O
of NN NN O
three NN NN O
loci NN NN O
at NN NN O
4q35 NN NN O
. NN NN O

The NN NN O
20 NN NN O
linked NN NN O
markers NN NN O
form NN NN O
a NN NN O
continuous NN NN O
linkage NN NN O
group NN NN O
of NN NN O
152 NN NN O
cM NN NN O
in NN NN O
males NN NN O
and NN NN O
202 NN NN O
cM NN NN O
in NN NN O
females NN NN O
. NN NN O

Likely NN NN O
genetic NN NN O
locations NN NN O
are NN NN O
provided NN NN O
for NN NN O
25 NN NN O
polymorphic NN NN O
anonymous NN NN O
sequences NN NN O
and NN NN O
28 NN NN O
gene-specific NN NN O
RFLPs NN NN O
. NN NN O

The NN NN O
map NN NN O
was NN NN O
constructed NN NN O
employing NN NN O
the NN NN O
LINKAGE NN NN O
and NN NN O
CRIMAP NN NN O
computational NN NN O
methodologies NN NN O
to NN NN O
build NN NN O
the NN NN O
multipoint NN NN O
map NN NN O
via NN NN O
a NN NN O
stepwise NN NN O
algorithm NN NN O
. NN NN O

A NN NN O
detailed NN NN O
10-point NN NN O
map NN NN O
of NN NN O
the NN NN O
4p16 NN NN O
region NN NN O
constructed NN NN O
from NN NN O
the NN NN O
CEPH NN NN O
panel NN NN O
provides NN NN O
evidence NN NN O
for NN NN O
heterogeneity NN NN O
in NN NN O
the NN NN O
linkage NN NN O
maps NN NN O
constructed NN NN O
from NN NN O
families NN NN O
segregating NN NN O
for NN NN O
Huntington NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
HD NN NN B-SpecificDisease
) NN NN O
. NN NN O

It NN NN O
additionally NN NN O
provides NN NN O
evidence NN NN O
for NN NN O
position-specific NN NN O
recombination NN NN O
frequencies NN NN O
in NN NN O
the NN NN O
telomeric NN NN O
region NN NN O
of NN NN O
4p NN NN O
. NN NN O

. NN NN O

1676565 NN NN O
Carrier NN NN O
detection NN NN O
and NN NN O
prenatal NN NN O
diagnosis NN NN O
of NN NN O
Pelizaeus-Merzbacher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
using NN NN O
a NN NN O
combination NN NN O
of NN NN O
anonymous NN NN O
DNA NN NN O
polymorphisms NN NN O
and NN NN O
the NN NN O
proteolipid NN NN O
protein NN NN O
( NN NN O
PLP NN NN O
) NN NN O
gene NN NN O
cDNA NN NN O
. NN NN O

We NN NN O
report NN NN O
carrier NN NN O
identification NN NN O
and NN NN O
a NN NN O
prenatal NN NN O
diagnosis NN NN O
using NN NN O
DNA NN NN O
polymorphisms NN NN O
in NN NN O
2 NN NN O
families NN NN O
with NN NN O
X-linked NN NN B-SpecificDisease
Pelizaeus-Merzbacher NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
PMD NN NN B-SpecificDisease
) NN NN O
. NN NN O

In NN NN O
both NN NN O
families NN NN O
, NN NN O
the NN NN O
proteolipid NN NN O
protein NN NN O
( NN NN O
PLP NN NN O
) NN NN O
gene NN NN O
in NN NN O
the NN NN O
single NN NN O
affected NN NN O
male NN NN O
could NN NN O
be NN NN O
traced NN NN O
back NN NN O
to NN NN O
his NN NN O
unaffected NN NN O
maternal NN NN O
grandfather NN NN O
. NN NN O

Therefore NN NN O
, NN NN O
each NN NN O
family NN NN O
contains NN NN O
a NN NN O
new NN NN O
mutation NN NN O
. NN NN O

In NN NN O
the NN NN O
case NN NN O
of NN NN O
the NN NN O
prenatal NN NN O
diagnosis NN NN O
, NN NN O
the NN NN O
fetus NN NN O
was NN NN O
shown NN NN O
by NN NN O
cytogenetic NN NN O
analysis NN NN O
to NN NN O
be NN NN O
a NN NN O
female NN NN O
, NN NN O
who NN NN O
we NN NN O
predict NN NN O
will NN NN O
be NN NN O
a NN NN O
noncarrier NN NN O
of NN NN O
PMD NN NN B-SpecificDisease
based NN NN O
on NN NN O
her NN NN O
genotype NN NN O
with NN NN O
the NN NN O
PLP NN NN O
intragenic NN NN O
polymorphism NN NN O
. NN NN O

. NN NN O

1678319 NN NN O
Identification NN NN O
of NN NN O
deletion NN NN O
mutations NN NN O
and NN NN O
three NN NN O
new NN NN O
genes NN NN O
at NN NN O
the NN NN O
familial NN NN B-Modifier
polyposis NN NN I-Modifier
locus NN NN O
. NN NN O

Small NN NN O
( NN NN O
100-260 NN NN O
kb NN NN O
) NN NN O
, NN NN O
nested NN NN O
deletions NN NN O
were NN NN O
characterized NN NN O
in NN NN O
DNA NN NN O
from NN NN O
two NN NN O
unrelated NN NN O
patients NN NN O
with NN NN O
familial NN NN B-SpecificDisease
adenomatous NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
coli NN NN I-SpecificDisease
( NN NN O
APC NN NN B-SpecificDisease
) NN NN O
. NN NN O

Three NN NN O
candidate NN NN O
genes NN NN O
located NN NN O
within NN NN O
the NN NN O
deleted NN NN O
region NN NN O
were NN NN O
ascertained NN NN O
and NN NN O
a NN NN O
previous NN NN O
candidate NN NN O
gene NN NN O
, NN NN O
MCC NN NN O
, NN NN O
was NN NN O
shown NN NN O
to NN NN O
be NN NN O
located NN NN O
outside NN NN O
the NN NN O
deleted NN NN O
region NN NN O
. NN NN O

One NN NN O
of NN NN O
the NN NN O
new NN NN O
genes NN NN O
contained NN NN O
sequence NN NN O
identical NN NN O
to NN NN O
SRP19 NN NN O
, NN NN O
the NN NN O
gene NN NN O
coding NN NN O
for NN NN O
the NN NN O
19 NN NN O
kd NN NN O
component NN NN O
of NN NN O
the NN NN O
ribosomal NN NN O
signal NN NN O
recognition NN NN O
particle NN NN O
. NN NN O

The NN NN O
second NN NN O
, NN NN O
provisionally NN NN O
designated NN NN O
DP1 NN NN O
( NN NN O
deleted NN NN O
in NN NN O
polyposis NN NN O
1 NN NN O
) NN NN O
, NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
transcribed NN NN O
in NN NN O
the NN NN O
same NN NN O
orientation NN NN O
as NN NN O
MCC NN NN O
. NN NN O

Two NN NN O
other NN NN O
cDNAs NN NN O
, NN NN O
DP2 NN NN O
and NN NN O
DP3 NN NN O
, NN NN O
were NN NN O
found NN NN O
to NN NN O
overlap NN NN O
, NN NN O
forming NN NN O
a NN NN O
single NN NN O
gene NN NN O
, NN NN O
DP2 NN NN O
. NN NN O

5 NN NN O
, NN NN O
that NN NN O
is NN NN O
transcribed NN NN O
in NN NN O
the NN NN O
same NN NN O
orientation NN NN O
as NN NN O
SRP19 NN NN O
. NN NN O

1679035 NN NN O
Exclusion NN NN O
of NN NN O
linkage NN NN O
between NN NN O
familial NN NN B-SpecificDisease
Mediterranean NN NN I-SpecificDisease
fever NN NN I-SpecificDisease
and NN NN O
the NN NN O
human NN NN O
serum NN NN O
amyloid NN NN O
A NN NN O
( NN NN O
SAA NN NN O
) NN NN O
gene NN NN O
cluster NN NN O
. NN NN O

We NN NN O
studied NN NN O
the NN NN O
relationship NN NN O
between NN NN O
the NN NN O
autosomal NN NN O
recessive NN NN O
trait NN NN O
familial NN NN B-SpecificDisease
Mediterranean NN NN I-SpecificDisease
fever NN NN I-SpecificDisease
( NN NN O
FMF NN NN B-SpecificDisease
) NN NN O
and NN NN O
the NN NN O
serum NN NN O
amyloid NN NN O
A NN NN O
( NN NN O
SAA NN NN O
) NN NN O
genes NN NN O
by NN NN O
comparing NN NN O
alleles NN NN O
of NN NN O
a NN NN O
highly NN NN O
polymorphic NN NN O
dinucleotide NN NN O
repeat NN NN O
and NN NN O
a NN NN O
conventional NN NN O
restriction NN NN O
fragment NN NN O
length NN NN O
polymorphism NN NN O
( NN NN O
RFLP NN NN O
) NN NN O
in NN NN O
the NN NN O
SAA NN NN O
gene NN NN O
cluster NN NN O
in NN NN O
Israeli NN NN O
FMF NN NN B-Modifier
kindreds NN NN O
. NN NN O

By NN NN O
haplotype NN NN O
analysis NN NN O
, NN NN O
our NN NN O
data NN NN O
indicate NN NN O
a NN NN O
minimum NN NN O
crossover NN NN O
frequency NN NN O
of NN NN O
22 NN NN O
% NN NN O
between NN NN O
the NN NN O
SAA NN NN O
gene NN NN O
marker NN NN O
and NN NN O
FMF NN NN B-SpecificDisease
. NN NN O

By NN NN O
conventional NN NN O
linkage NN NN O
analysis NN NN O
this NN NN O
eliminates NN NN O
a NN NN O
minimum NN NN O
of NN NN O
10 NN NN O
. NN NN O

4 NN NN O
cM NN NN O
including NN NN O
and NN NN O
surrounding NN NN O
the NN NN O
SAA NN NN O
gene NN NN O
cluster NN NN O
as NN NN O
the NN NN O
site NN NN O
of NN NN O
the NN NN O
FMF NN NN B-Modifier
mutation NN NN O
although NN NN O
SAA NN NN O
proteins NN NN O
are NN NN O
prominent NN NN O
physiologic NN NN O
markers NN NN O
of NN NN O
the NN NN O
acute NN NN O
attacks NN NN O
. NN NN O

1682919 NN NN O
PRAD1 NN NN O
, NN NN O
a NN NN O
candidate NN NN O
BCL1 NN NN O
oncogene NN NN O
: NN NN O
mapping NN NN O
and NN NN O
expression NN NN O
in NN NN O
centrocytic NN NN B-DiseaseClass
lymphoma NN NN I-DiseaseClass
. NN NN O

Rearrangement NN NN O
of NN NN O
the NN NN O
BCL1 NN NN O
( NN NN O
B-cell NN NN O
lymphoma NN NN O
1 NN NN O
) NN NN O
region NN NN O
on NN NN O
chromosome NN NN O
11q13 NN NN O
appears NN NN O
to NN NN O
be NN NN O
highly NN NN O
characteristic NN NN O
of NN NN O
centrocytic NN NN B-DiseaseClass
lymphoma NN NN I-DiseaseClass
and NN NN O
also NN NN O
is NN NN O
found NN NN O
infrequently NN NN O
in NN NN O
other NN NN O
B-cell NN NN B-SpecificDisease
neoplasms NN NN I-SpecificDisease
. NN NN O

Rearrangement NN NN O
is NN NN O
thought NN NN O
to NN NN O
deregulate NN NN O
a NN NN O
nearby NN NN O
protooncogene NN NN O
, NN NN O
but NN NN O
transcribed NN NN O
sequences NN NN O
in NN NN O
the NN NN O
immediate NN NN O
vicinity NN NN O
of NN NN O
BCL1 NN NN O
breakpoints NN NN O
had NN NN O
not NN NN O
been NN NN O
identified NN NN O
. NN NN O

PRAD1 NN NN O
, NN NN O
previously NN NN O
designated NN NN O
D11S287E NN NN O
, NN NN O
was NN NN O
identified NN NN O
on NN NN O
11q13 NN NN O
as NN NN O
a NN NN O
chromosomal NN NN O
breakpoint NN NN O
region NN NN O
rearranged NN NN O
with NN NN O
the NN NN O
parathyroid NN NN O
hormone NN NN O
gene NN NN O
in NN NN O
a NN NN O
subset NN NN O
of NN NN O
parathyroid NN NN B-DiseaseClass
adenomas NN NN I-DiseaseClass
; NN NN O
this NN NN O
highly NN NN O
conserved NN NN O
putative NN NN O
oncogene NN NN O
, NN NN O
which NN NN O
encodes NN NN O
a NN NN O
novel NN NN O
cyclin NN NN O
, NN NN O
has NN NN O
been NN NN O
linked NN NN O
to NN NN O
BCL1 NN NN O
and NN NN O
implicated NN NN O
also NN NN O
in NN NN O
subsets NN NN O
of NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
squamous NN NN I-CompositeMention
cell NN NN I-CompositeMention
neoplasms NN NN I-CompositeMention
with NN NN O
11q13 NN NN O
amplification NN NN O
. NN NN O

We NN NN O
report NN NN O
pulsed-field NN NN O
gel NN NN O
electrophoresis NN NN O
data NN NN O
showing NN NN O
BCL1 NN NN O
and NN NN O
PRAD1 NN NN O
to NN NN O
be NN NN O
no NN NN O
more NN NN O
than NN NN O
130 NN NN O
kilobases NN NN O
apart NN NN O
. NN NN O

PRAD1 NN NN O
mRNA NN NN O
is NN NN O
abundantly NN NN O
expressed NN NN O
in NN NN O
seven NN NN O
of NN NN O
seven NN NN O
centrocytic NN NN B-DiseaseClass
lymphomas NN NN I-DiseaseClass
( NN NN O
Kiel NN NN O
classification NN NN O
) NN NN O
, NN NN O
in NN NN O
contrast NN NN O
to NN NN O
13 NN NN O
closely NN NN O
related NN NN O
but NN NN O
noncentrocytic NN NN B-DiseaseClass
lymphomas NN NN I-DiseaseClass
. NN NN O

Three NN NN O
of NN NN O
the NN NN O
seven NN NN O
centrocytic NN NN B-DiseaseClass
lymphomas NN NN I-DiseaseClass
had NN NN O
detectable NN NN O
BCL1 NN NN O
DNA NN NN O
rearrangement NN NN O
. NN NN O

Also NN NN O
, NN NN O
two NN NN O
unusual NN NN O
cases NN NN O
of NN NN O
CLL NN NN O
with NN NN O
BCL1 NN NN O
rearrangement NN NN O
overexpressed NN NN O
PRAD1 NN NN O
, NN NN O
in NN NN O
contrast NN NN O
to NN NN O
five NN NN O
CLL NN NN O
controls NN NN O
. NN NN O

Thus NN NN O
, NN NN O
PRAD1 NN NN O
is NN NN O
an NN NN O
excellent NN NN O
candidate NN NN O
`` NN NN O
BCL1 NN NN O
oncogene NN NN O
. NN NN O
`` NN NN O

Its NN NN O
overexpression NN NN O
may NN NN O
be NN NN O
a NN NN O
key NN NN O
consequence NN NN O
of NN NN O
rearrangement NN NN O
of NN NN O
the NN NN O
BCL1 NN NN O
vicinity NN NN O
in NN NN O
B-cell NN NN B-SpecificDisease
neoplasms NN NN I-SpecificDisease
and NN NN O
a NN NN O
unifying NN NN O
pathogenetic NN NN O
feature NN NN O
in NN NN O
centrocytic NN NN B-DiseaseClass
lymphoma NN NN I-DiseaseClass
. NN NN O

1684088 NN NN O
Two NN NN O
new NN NN O
arylsulfatase NN NN O
A NN NN O
( NN NN O
ARSA NN NN O
) NN NN O
mutations NN NN O
in NN NN O
a NN NN O
juvenile NN NN O
metachromatic NN NN B-Modifier
leukodystrophy NN NN I-Modifier
( NN NN O
MLD NN NN B-Modifier
) NN NN O
patient NN NN O
. NN NN O

Fragments NN NN O
of NN NN O
the NN NN O
arylsulfatase NN NN O
A NN NN O
( NN NN O
ARSA NN NN O
) NN NN O
gene NN NN O
from NN NN O
a NN NN O
patient NN NN O
with NN NN O
juvenile-onset NN NN O
metachromatic NN NN B-SpecificDisease
leukodystrophy NN NN I-SpecificDisease
( NN NN O
MLD NN NN B-SpecificDisease
) NN NN O
were NN NN O
amplified NN NN O
by NN NN O
PCR NN NN O
and NN NN O
ligated NN NN O
into NN NN O
MP13 NN NN O
cloning NN NN O
vectors NN NN O
. NN NN O

Clones NN NN O
hybridizing NN NN O
with NN NN O
cDNA NN NN O
for NN NN O
human NN NN O
ARSA NN NN O
were NN NN O
selected NN NN O
, NN NN O
examined NN NN O
for NN NN O
appropriate NN NN O
size NN NN O
inserts NN NN O
, NN NN O
and NN NN O
used NN NN O
to NN NN O
prepare NN NN O
single-stranded NN NN O
phage NN NN O
DNA NN NN O
. NN NN O

Examination NN NN O
of NN NN O
the NN NN O
entire NN NN O
coding NN NN O
and NN NN O
most NN NN O
of NN NN O
the NN NN O
intronic NN NN O
sequence NN NN O
revealed NN NN O
two NN NN O
putative NN NN O
disease-related NN NN O
mutations NN NN O
. NN NN O

One NN NN O
, NN NN O
a NN NN O
point NN NN O
mutation NN NN O
in NN NN O
exon NN NN O
3 NN NN O
, NN NN O
resulted NN NN O
in NN NN O
the NN NN O
substitution NN NN O
of NN NN O
isoleucine NN NN O
by NN NN O
serine NN NN O
. NN NN O

Introduction NN NN O
of NN NN O
this NN NN O
alteration NN NN O
into NN NN O
the NN NN O
normal NN NN O
ARSA NN NN O
cDNA NN NN O
sequence NN NN O
resulted NN NN O
in NN NN O
a NN NN O
substantial NN NN O
decrease NN NN O
in NN NN O
ARSA NN NN O
activity NN NN O
on NN NN O
transient NN NN O
expression NN NN O
in NN NN O
cultured NN NN O
baby NN NN O
hamster NN NN O
kidney NN NN O
cells NN NN O
. NN NN O

About NN NN O
5 NN NN O
% NN NN O
of NN NN O
the NN NN O
control NN NN O
expression NN NN O
was NN NN O
observed NN NN O
, NN NN O
suggesting NN NN O
a NN NN O
small NN NN O
residual NN NN O
activity NN NN O
in NN NN O
the NN NN O
mutated NN NN O
ARSA NN NN O
. NN NN O

The NN NN O
second NN NN O
mutation NN NN O
, NN NN O
a NN NN O
G-to-A NN NN O
transition NN NN O
, NN NN O
occurred NN NN O
in NN NN O
the NN NN O
other NN NN O
allele NN NN O
and NN NN O
resulted NN NN O
in NN NN O
an NN NN O
altered NN NN O
splice-recognition NN NN O
sequence NN NN O
between NN NN O
exon NN NN O
7 NN NN O
and NN NN O
the NN NN O
following NN NN O
intron NN NN O
. NN NN O

The NN NN O
mutation NN NN O
also NN NN O
resulted NN NN O
in NN NN O
the NN NN O
loss NN NN O
of NN NN O
a NN NN O
restriction NN NN O
site NN NN O
. NN NN O

Apparently NN NN O
normal NN NN O
levels NN NN O
of NN NN O
mRNA NN NN O
were NN NN O
generated NN NN O
from NN NN O
this NN NN O
allele NN NN O
, NN NN O
but NN NN O
no NN NN O
ARSA NN NN O
activity NN NN O
or NN NN O
immuno-cross-reactive NN NN O
material NN NN O
could NN NN O
be NN NN O
detected NN NN O
. NN NN O

A NN NN O
collection NN NN O
of NN NN O
DNA NN NN O
samples NN NN O
from NN NN O
known NN NN O
or NN NN O
suspected NN NN O
MLD NN NN B-Modifier
patients NN NN O
, NN NN O
members NN NN O
of NN NN O
their NN NN O
families NN NN O
, NN NN O
and NN NN O
normal NN NN O
controls NN NN O
was NN NN O
screened NN NN O
for NN NN O
these NN NN O
mutations NN NN O
. NN NN O

Four NN NN O
additional NN NN O
individuals NN NN O
carrying NN NN O
each NN NN O
of NN NN O
the NN NN O
mutations NN NN O
were NN NN O
found NN NN O
among NN NN O
the NN NN O
nearly NN NN O
100 NN NN O
MLD NN NN B-Modifier
patients NN NN O
in NN NN O
the NN NN O
sample NN NN O
. NN NN O

Gene NN NN O
segregation NN NN O
in NN NN O
the NN NN O
original NN NN O
patients NN NN O
family NN NN O
was NN NN O
consistent NN NN O
with NN NN O
available NN NN O
clinical NN NN O
and NN NN O
biochemical NN NN O
data NN NN O
. NN NN O

No NN NN O
individuals NN NN O
homozygous NN NN O
for NN NN O
either NN NN O
of NN NN O
these NN NN O
two NN NN O
mutations NN NN O
were NN NN O
identified NN NN O
. NN NN O

However NN NN O
, NN NN O
combinations NN NN O
with NN NN O
other NN NN O
MLD NN NN B-Modifier
mutations NN NN O
suggest NN NN O
that NN NN O
the NN NN O
point NN NN O
mutation NN NN O
in NN NN O
exon NN NN O
3 NN NN O
does NN NN O
result NN NN O
in NN NN O
some NN NN O
residual NN NN O
enzyme NN NN O
activity NN NN O
and NN NN O
is NN NN O
associated NN NN O
with NN NN O
late-onset NN NN O
forms NN NN O
of NN NN O
the NN NN O
disease NN NN O
. NN NN O

The NN NN O
splice-site NN NN O
mutation NN NN O
following NN NN O
exon NN NN O
7 NN NN O
produces NN NN O
late-infantile NN NN O
MLD NN NN B-SpecificDisease
when NN NN O
combined NN NN O
with NN NN O
other NN NN O
enzyme-null NN NN O
mutations NN NN O
, NN NN O
implying NN NN O
that NN NN O
it NN NN O
is NN NN O
completely NN NN O
silent NN NN O
enzymatically NN NN O
. NN NN O

. NN NN O

1684569 NN NN O
Analysis NN NN O
of NN NN O
X-chromosome NN NN O
inactivation NN NN O
and NN NN O
presumptive NN NN O
expression NN NN O
of NN NN O
the NN NN O
Wiskott-Aldrich NN NN B-Modifier
syndrome NN NN I-Modifier
( NN NN O
WAS NN NN B-Modifier
) NN NN O
gene NN NN O
in NN NN O
hematopoietic NN NN O
cell NN NN O
lineages NN NN O
of NN NN O
a NN NN O
thrombocytopenic NN NN O
carrier NN NN O
female NN NN O
of NN NN O
WAS NN NN B-SpecificDisease
. NN NN O

We NN NN O
report NN NN O
on NN NN O
a NN NN O
thrombocytopenic NN NN B-Modifier
female NN NN O
belonging NN NN O
to NN NN O
a NN NN O
pedigree NN NN O
with NN NN O
the NN NN O
Wiskott-Aldrich NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
WAS NN NN B-SpecificDisease
) NN NN O
. NN NN O

Restriction NN NN O
fragment NN NN O
length NN NN O
polymorphism NN NN O
( NN NN O
RFLP NN NN O
) NN NN O
analysis NN NN O
with NN NN O
probe NN NN O
M27 NN NN O
beta NN NN O
, NN NN O
closely NN NN O
linked NN NN O
to NN NN O
the NN NN O
WAS NN NN B-Modifier
gene NN NN O
, NN NN O
demonstrated NN NN O
that NN NN O
she NN NN O
is NN NN O
a NN NN O
carrier NN NN O
of NN NN O
WAS NN NN B-SpecificDisease
. NN NN O

Both NN NN O
small-sized NN NN O
and NN NN O
normal-sized NN NN O
platelets NN NN O
were NN NN O
present NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
, NN NN O
unlike NN NN O
the NN NN O
vast NN NN O
majority NN NN O
of NN NN O
WAS NN NN B-Modifier
carriers NN NN O
, NN NN O
she NN NN O
does NN NN O
not NN NN O
manifest NN NN O
nonrandom NN NN O
X-chromosome NN NN O
inactivation NN NN O
in NN NN O
the NN NN O
thrombopoietic NN NN O
cell NN NN O
lineage NN NN O
. NN NN O

Study NN NN O
of NN NN O
X-chromosome NN NN O
inactivation NN NN O
by NN NN O
means NN NN O
of NN NN O
RFLP NN NN O
and NN NN O
methylation NN NN O
analysis NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
pattern NN NN O
of NN NN O
X-chromosome NN NN O
inactivation NN NN O
was NN NN O
nonrandom NN NN O
in NN NN O
T NN NN O
lymphocytes NN NN O
, NN NN O
but NN NN O
random NN NN O
in NN NN O
granulocytes NN NN O
. NN NN O

While NN NN O
this NN NN O
is NN NN O
the NN NN O
first NN NN O
complete NN NN O
report NN NN O
on NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
thrombocytopenia NN NN B-SpecificDisease
in NN NN O
a NN NN O
carrier NN NN O
female NN NN O
of NN NN O
WAS NN NN B-SpecificDisease
as NN NN O
the NN NN O
result NN NN O
of NN NN O
atypical NN NN O
lyonization NN NN O
, NN NN O
it NN NN O
also NN NN O
suggests NN NN O
that NN NN O
expression NN NN O
of NN NN O
the NN NN O
WAS NN NN B-Modifier
gene NN NN O
occurs NN NN O
at NN NN O
( NN NN O
or NN NN O
extends NN NN O
up NN NN O
to NN NN O
) NN NN O
a NN NN O
later NN NN O
stage NN NN O
than NN NN O
the NN NN O
multipotent NN NN O
stem NN NN O
cell NN NN O
along NN NN O
the NN NN O
hematopoietic NN NN O
differentiation NN NN O
pathway NN NN O
. NN NN O

. NN NN O

1707231 NN NN O
A NN NN O
new NN NN O
mutation NN NN O
in NN NN O
the NN NN O
proteolipid NN NN O
protein NN NN O
( NN NN O
PLP NN NN O
) NN NN O
gene NN NN O
in NN NN O
a NN NN O
German NN NN O
family NN NN O
with NN NN O
Pelizaeus-Merzbacher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

A NN NN O
C-to-T NN NN O
transition NN NN O
in NN NN O
exon NN NN O
4 NN NN O
of NN NN O
the NN NN O
PLP NN NN O
gene NN NN O
was NN NN O
found NN NN O
in NN NN O
2 NN NN O
affected NN NN O
males NN NN O
and NN NN O
two NN NN O
obligate NN NN O
carriers NN NN O
in NN NN O
a NN NN O
German NN NN O
family NN NN O
with NN NN O
Pelizaeus-Merzbacher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

The NN NN O
mutation NN NN O
, NN NN O
which NN NN O
causes NN NN O
loss NN NN O
of NN NN O
an NN NN O
HphI NN NN O
site NN NN O
and NN NN O
changes NN NN O
amino NN NN O
acid NN NN O
155 NN NN O
from NN NN O
threonine NN NN O
to NN NN O
isoleucine NN NN O
, NN NN O
was NN NN O
absent NN NN O
from NN NN O
108 NN NN O
normal NN NN O
chromosomes NN NN O
. NN NN O

There NN NN O
are NN NN O
5 NN NN O
concordances NN NN O
and NN NN O
1 NN NN O
discrepancy NN NN O
between NN NN O
these NN NN O
results NN NN O
and NN NN O
those NN NN O
obtained NN NN O
by NN NN O
magnetic NN NN O
resonance NN NN O
imaging NN NN O
in NN NN O
this NN NN O
family NN NN O
. NN NN O

. NN NN O

1709636 NN NN O
A NN NN O
3-base NN NN O
pair NN NN O
in-frame NN NN O
deletion NN NN O
of NN NN O
the NN NN O
phenylalanine NN NN O
hydroxylase NN NN O
gene NN NN O
results NN NN O
in NN NN O
a NN NN O
kinetic NN NN O
variant NN NN O
of NN NN O
phenylketonuria NN NN B-SpecificDisease
. NN NN O

Phenylketonuria NN NN B-SpecificDisease
( NN NN O
PKU NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
disease NN NN I-DiseaseClass
due NN NN O
to NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
a NN NN I-SpecificDisease
hepatic NN NN I-SpecificDisease
enzyme NN NN I-SpecificDisease
, NN NN I-SpecificDisease
phenylalanine NN NN I-SpecificDisease
hydroxylase NN NN I-SpecificDisease
( NN NN O
PAH NN NN O
) NN NN O
. NN NN O

The NN NN O
absence NN NN O
of NN NN O
PAH NN NN O
activity NN NN O
results NN NN O
in NN NN O
typical NN NN O
PKU NN NN B-SpecificDisease
while NN NN O
persistence NN NN O
of NN NN O
a NN NN O
residual NN NN O
enzyme NN NN O
activity NN NN O
gives NN NN O
rise NN NN O
to NN NN O
variant NN NN O
forms NN NN O
of NN NN O
the NN NN O
disease NN NN O
. NN NN O

We NN NN O
report NN NN O
here NN NN O
a NN NN O
3-base NN NN O
pair NN NN O
in-frame NN NN O
deletion NN NN O
of NN NN O
the NN NN O
PAH NN NN O
gene NN NN O
( NN NN O
delta NN NN O
194 NN NN O
) NN NN O
in NN NN O
a NN NN O
mild NN NN O
variant NN NN O
, NN NN O
with NN NN O
markedly NN NN O
reduced NN NN O
affinity NN NN O
of NN NN O
the NN NN O
enzyme NN NN O
for NN NN O
phenylalanine NN NN O
( NN NN O
Km NN NN O
= NN NN O
160 NN NN O
nM NN NN O
) NN NN O
, NN NN O
and NN NN O
we NN NN O
provide NN NN O
functional NN NN O
evidence NN NN O
for NN NN O
responsibility NN NN O
of NN NN O
the NN NN O
deletion NN NN O
in NN NN O
the NN NN O
mutant NN NN O
phenotype NN NN O
. NN NN O

Since NN NN O
the NN NN O
deletion NN NN O
was NN NN O
located NN NN O
in NN NN O
the NN NN O
third NN NN O
exon NN NN O
of NN NN O
the NN NN O
gene NN NN O
, NN NN O
which NN NN O
presents NN NN O
no NN NN O
homology NN NN O
with NN NN O
other NN NN O
hydroxylases NN NN O
, NN NN O
we NN NN O
suggest NN NN O
that NN NN O
exon NN NN O
3 NN NN O
is NN NN O
involved NN NN O
in NN NN O
the NN NN O
specificity NN NN O
of NN NN O
the NN NN O
enzyme NN NN O
for NN NN O
phenylalanine NN NN O
. NN NN O

Finally NN NN O
, NN NN O
since NN NN O
none NN NN O
of NN NN O
the NN NN O
98 NN NN O
PKU NN NN B-Modifier
patients NN NN O
tested NN NN O
were NN NN O
found NN NN O
to NN NN O
carry NN NN O
this NN NN O
particular NN NN O
deletion NN NN O
, NN NN O
our NN NN O
study NN NN O
suggests NN NN O
that NN NN O
this NN NN O
molecular NN NN O
event NN NN O
probably NN NN O
occurred NN NN O
recently NN NN O
on NN NN O
the NN NN O
background NN NN O
of NN NN O
a NN NN O
haplotype NN NN O
2 NN NN O
gene NN NN O
in NN NN O
Portugal NN NN O
. NN NN O

. NN NN O

1717985 NN NN O
Mutation NN NN O
of NN NN O
the NN NN O
KIT NN NN O
( NN NN O
mast/stem NN NN O
cell NN NN O
growth NN NN O
factor NN NN O
receptor NN NN O
) NN NN O
protooncogene NN NN O
in NN NN O
human NN NN O
piebaldism NN NN B-SpecificDisease
. NN NN O

Piebaldism NN NN B-SpecificDisease
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
dominant NN NN I-DiseaseClass
genetic NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
characterized NN NN O
by NN NN O
cogenital NN NN O
patches NN NN O
of NN NN O
skin NN NN O
and NN NN O
hair NN NN O
from NN NN O
which NN NN O
melanocytes NN NN O
are NN NN O
completely NN NN O
absent NN NN O
. NN NN O

A NN NN O
similar NN NN O
disorder NN NN O
of NN NN O
mouse NN NN O
, NN NN O
dominant NN NN O
white NN NN O
spotting NN NN O
( NN NN O
W NN NN O
) NN NN O
, NN NN O
results NN NN O
from NN NN O
mutations NN NN O
of NN NN O
the NN NN O
c-Kit NN NN O
protooncogene NN NN O
, NN NN O
which NN NN O
encodes NN NN O
and NN NN O
receptor NN NN O
for NN NN O
mast NN NN O
/ NN NN O
stem NN NN O
cell NN NN O
growth NN NN O
factor NN NN O
. NN NN O

We NN NN O
identified NN NN O
a NN NN O
KIT NN NN O
gene NN NN O
mutation NN NN O
in NN NN O
a NN NN O
proband NN NN O
with NN NN O
classic NN NN O
autosomal NN NN O
dominant NN NN O
piebaldism NN NN B-SpecificDisease
. NN NN O

This NN NN O
mutation NN NN O
results NN NN O
in NN NN O
a NN NN O
Gly NN NN O
-- NN NN O
-- NN NN O
Arg NN NN O
substitution NN NN O
at NN NN O
codon NN NN O
664 NN NN O
, NN NN O
within NN NN O
the NN NN O
tyrosine NN NN O
kinase NN NN O
domain NN NN O
. NN NN O

This NN NN O
substitution NN NN O
was NN NN O
not NN NN O
seen NN NN O
in NN NN O
any NN NN O
normal NN NN O
individuals NN NN O
and NN NN O
was NN NN O
completely NN NN O
linked NN NN O
to NN NN O
the NN NN O
piebald NN NN B-Modifier
phenotype NN NN O
in NN NN O
the NN NN O
probands NN NN O
family NN NN O
. NN NN O

Piebaldism NN NN B-SpecificDisease
in NN NN O
this NN NN O
family NN NN O
thus NN NN O
appears NN NN O
to NN NN O
be NN NN O
the NN NN O
human NN NN O
homologue NN NN O
to NN NN O
dominant NN NN O
white NN NN O
spotting NN NN O
( NN NN O
W NN NN O
) NN NN O
of NN NN O
the NN NN O
mouse NN NN O
. NN NN O

. NN NN O

1731805 NN NN O
Genetic NN NN O
analysis NN NN O
of NN NN O
a NN NN O
Japanese NN NN O
family NN NN O
with NN NN O
normotriglyceridemic NN NN B-SpecificDisease
abetalipoproteinemia NN NN I-SpecificDisease
indicates NN NN O
a NN NN O
lack NN NN O
of NN NN O
linkage NN NN O
to NN NN O
the NN NN O
apolipoprotein NN NN O
B NN NN O
gene NN NN O
. NN NN O

Normotriglyceridemic NN NN B-SpecificDisease
abetalipoproteinemia NN NN I-SpecificDisease
is NN NN O
a NN NN O
rare NN NN O
familial NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
characterized NN NN O
by NN NN O
an NN NN O
isolated NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
apoB-100 NN NN I-SpecificDisease
. NN NN O

We NN NN O
have NN NN O
previously NN NN O
reported NN NN O
a NN NN O
patient NN NN O
with NN NN O
this NN NN O
disease NN NN O
, NN NN O
who NN NN O
had NN NN O
normal NN NN O
apoB-48 NN NN O
but NN NN O
no NN NN O
apoB-100 NN NN O
. NN NN O

To NN NN O
elucidate NN NN O
the NN NN O
genetic NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
in NN NN O
this NN NN O
family NN NN O
, NN NN O
we NN NN O
studied NN NN O
the NN NN O
linkage NN NN O
of NN NN O
apoB NN NN O
gene NN NN O
using NN NN O
three NN NN O
genetic NN NN O
markers NN NN O
. NN NN O

The NN NN O
proband NN NN O
and NN NN O
her NN NN O
affected NN NN O
brother NN NN O
showed NN NN O
completely NN NN O
different NN NN O
apoB NN NN O
gene NN NN O
alleles NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
the NN NN O
apoB NN NN O
gene NN NN O
itself NN NN O
is NN NN O
not NN NN O
related NN NN O
to NN NN O
this NN NN O
disorder NN NN O
in NN NN O
this NN NN O
family NN NN O
. NN NN O

By NN NN O
contrast NN NN O
, NN NN O
an NN NN O
American NN NN O
case NN NN O
had NN NN O
a NN NN O
point NN NN O
substitution NN NN O
in NN NN O
the NN NN O
apoB NN NN O
gene NN NN O
generating NN NN O
an NN NN O
in-frame NN NN O
stop NN NN O
codon NN NN O
. NN NN O

These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
this NN NN O
disorder NN NN O
can NN NN O
be NN NN O
caused NN NN O
by NN NN O
defect NN NN O
( NN NN O
s NN NN O
) NN NN O
of NN NN O
either NN NN O
an NN NN O
apoB NN NN O
gene NN NN O
or NN NN O
other NN NN O
genes NN NN O
. NN NN O

. NN NN O

1733838 NN NN O
Localisation NN NN O
of NN NN O
the NN NN O
gene NN NN O
for NN NN O
Norrie NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
to NN NN O
between NN NN O
DXS7 NN NN O
and NN NN O
DXS426 NN NN O
on NN NN O
Xp NN NN O
. NN NN O

A NN NN O
highly NN NN O
informative NN NN O
microsatellite NN NN O
marker NN NN O
, NN NN O
DXS426 NN NN O
, NN NN O
which NN NN O
maps NN NN O
proximal NN NN O
to NN NN O
DXS7 NN NN O
in NN NN O
the NN NN O
interval NN NN O
Xp11 NN NN O
. NN NN O

4-Xp11 NN NN O
4-Xp11 NN NN O
. NN NN O

23 NN NN O
, NN NN O
has NN NN O
been NN NN O
used NN NN O
to NN NN O
refine NN NN O
further NN NN O
the NN NN O
localisation NN NN O
of NN NN O
the NN NN O
gene NN NN O
for NN NN O
Norrie NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
NDP NN NN B-SpecificDisease
) NN NN O
. NN NN O

The NN NN O
results NN NN O
from NN NN O
a NN NN O
multiply NN NN O
informative NN NN O
crossover NN NN O
localize NN NN O
the NN NN O
NDP NN NN B-Modifier
gene NN NN O
proximal NN NN O
to NN NN O
DXS7 NN NN O
. NN NN O

In NN NN O
conjunction NN NN O
with NN NN O
information NN NN O
from NN NN O
2 NN NN O
NDP NN NN B-Modifier
patients NN NN O
who NN NN O
have NN NN O
a NN NN O
deletion NN NN O
for NN NN O
DXS7 NN NN O
but NN NN O
not NN NN O
for NN NN O
DSX426 NN NN O
, NN NN O
our NN NN O
data NN NN O
indicate NN NN O
that NN NN O
the NN NN O
NDP NN NN B-Modifier
gene NN NN O
lies NN NN O
between NN NN O
DXS7 NN NN O
and NN NN O
DXS426 NN NN O
on NN NN O
proximal NN NN O
Xp NN NN O
. NN NN O

1769645 NN NN O
Aberrant NN NN O
splicing NN NN O
of NN NN O
phenylalanine NN NN O
hydroxylase NN NN O
mRNA NN NN O
: NN NN O
the NN NN O
major NN NN O
cause NN NN O
for NN NN O
phenylketonuria NN NN B-SpecificDisease
in NN NN O
parts NN NN O
of NN NN O
southern NN NN O
Europe NN NN O
. NN NN O

We NN NN O
report NN NN O
a NN NN O
mutation NN NN O
within NN NN O
the NN NN O
phenylalanine NN NN O
hydroxylase NN NN O
( NN NN O
PAH NN NN O
) NN NN O
gene NN NN O
that NN NN O
causes NN NN O
aberrant NN NN O
splicing NN NN O
of NN NN O
the NN NN O
mRNA NN NN O
and NN NN O
that NN NN O
is NN NN O
in NN NN O
tight NN NN O
association NN NN O
with NN NN O
chromosomal NN NN O
haplotypes NN NN O
6 NN NN O
, NN NN O
10 NN NN O
, NN NN O
and NN NN O
36 NN NN O
. NN NN O

Because NN NN O
of NN NN O
the NN NN O
high NN NN O
frequency NN NN O
of NN NN O
these NN NN O
particular NN NN O
haplotypes NN NN O
in NN NN O
Bulgaria NN NN O
, NN NN O
Italy NN NN O
, NN NN O
and NN NN O
Turkey NN NN O
, NN NN O
it NN NN O
appears NN NN O
to NN NN O
be NN NN O
one NN NN O
of NN NN O
the NN NN O
more NN NN O
frequent NN NN O
defects NN NN O
in NN NN O
the NN NN O
PAH NN NN O
gene NN NN O
causing NN NN O
classical NN NN O
phenylketonuria NN NN B-SpecificDisease
in NN NN O
this NN NN O
part NN NN O
of NN NN O
Europe NN NN O
. NN NN O

The NN NN O
mutation NN NN O
is NN NN O
a NN NN O
G NN NN O
to NN NN O
A NN NN O
transition NN NN O
at NN NN O
position NN NN O
546 NN NN O
in NN NN O
intron NN NN O
10 NN NN O
of NN NN O
the NN NN O
PAH NN NN O
gene NN NN O
, NN NN O
11 NN NN O
bp NN NN O
upstream NN NN O
from NN NN O
the NN NN O
intron NN NN O
10 NN NN O
/ NN NN O
exon NN NN O
11 NN NN O
boundary NN NN O
. NN NN O

It NN NN O
activates NN NN O
a NN NN O
cryptic NN NN O
splice NN NN O
site NN NN O
and NN NN O
results NN NN O
in NN NN O
an NN NN O
in-frame NN NN O
insertion NN NN O
of NN NN O
9 NN NN O
nucleotides NN NN O
between NN NN O
exon NN NN O
10 NN NN O
and NN NN O
exon NN NN O
11 NN NN O
of NN NN O
the NN NN O
processed NN NN O
mRNA NN NN O
. NN NN O

Normal NN NN O
amounts NN NN O
of NN NN O
liver NN NN O
PAH NN NN O
protein NN NN O
are NN NN O
present NN NN O
in NN NN O
homozygous NN NN O
patients NN NN O
, NN NN O
but NN NN O
no NN NN O
catalytic NN NN O
activity NN NN O
can NN NN O
be NN NN O
detected NN NN O
. NN NN O

This NN NN O
loss NN NN O
of NN NN O
enzyme NN NN O
activity NN NN O
is NN NN O
probably NN NN O
caused NN NN O
by NN NN O
conformational NN NN O
changes NN NN O
resulting NN NN O
from NN NN O
the NN NN O
insertion NN NN O
of NN NN O
three NN NN O
additional NN NN O
amino NN NN O
acids NN NN O
( NN NN O
Gly-Leu-Gln NN NN O
) NN NN O
between NN NN O
the NN NN O
normal NN NN O
sequences NN NN O
encoded NN NN O
by NN NN O
exon NN NN O
10 NN NN O
and NN NN O
exon NN NN O
11 NN NN O
. NN NN O

. NN NN O

1776638 NN NN O
Gardner NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
in NN NN O
a NN NN O
boy NN NN O
with NN NN O
interstitial NN NN O
deletion NN NN O
of NN NN O
the NN NN O
long NN NN O
arm NN NN O
of NN NN O
chromosome NN NN O
5 NN NN O
. NN NN O

We NN NN O
described NN NN O
a NN NN O
15-year-old NN NN O
boy NN NN O
with NN NN O
Gardner NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
GS NN NN B-SpecificDisease
) NN NN O
, NN NN O
mental NN NN B-DiseaseClass
retardation NN NN I-DiseaseClass
, NN NN O
and NN NN O
craniofacial NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
. NN NN O

High-resolution NN NN O
banding NN NN O
analysis NN NN O
showed NN NN O
an NN NN O
interstitial NN NN O
deletion NN NN O
of NN NN O
the NN NN O
long NN NN O
arm NN NN O
of NN NN O
chromosome NN NN O
5 NN NN O
( NN NN O
q22 NN NN O
. NN NN O

1 NN NN O
-- NN NN O
-- NN NN O
q31 NN NN O
1 NN NN O
-- NN NN O
-- NN NN O
q31 NN NN O
. NN NN O

1 NN NN O
) NN NN O
. NN NN O

The NN NN O
breakpoints NN NN O
in NN NN O
the NN NN O
present NN NN O
case NN NN O
and NN NN O
in NN NN O
3 NN NN O
previously NN NN O
reported NN NN O
5q- NN NN O
patients NN NN O
with NN NN O
adenomatous NN NN B-SpecificDisease
polyposis NN NN I-SpecificDisease
coli NN NN I-SpecificDisease
suggest NN NN O
that NN NN O
the NN NN O
gene NN NN O
responsible NN NN O
for NN NN O
GS NN NN B-SpecificDisease
/ NN NN O
or NN NN O
familial NN NN B-SpecificDisease
polyposis NN NN I-SpecificDisease
coli NN NN I-SpecificDisease
( NN NN O
FPC NN NN B-SpecificDisease
) NN NN O
is NN NN O
in NN NN O
the NN NN O
5q22 NN NN O
region NN NN O
, NN NN O
a NN NN O
result NN NN O
consistent NN NN O
with NN NN O
the NN NN O
findings NN NN O
of NN NN O
linkage NN NN O
studies NN NN O

1831007 NN NN O
Huntington NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
and NN NN O
childhood-onset NN NN O
Tourette NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

A NN NN O
40-year-old NN NN O
man NN NN O
with NN NN O
childhood-onset NN NN O
Tourette NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
TS NN NN B-SpecificDisease
) NN NN O
developed NN NN O
Huntington NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
HD NN NN B-SpecificDisease
) NN NN O
. NN NN O

We NN NN O
believe NN NN O
this NN NN O
to NN NN O
be NN NN O
the NN NN O
first NN NN O
reported NN NN O
case NN NN O
of NN NN O
childhood-onset NN NN O
TS NN NN B-SpecificDisease
with NN NN O
adult NN NN O
onset NN NN O
HD NN NN B-SpecificDisease
. NN NN O

Discovery NN NN O
of NN NN O
other NN NN O
cases NN NN O
with NN NN O
both NN NN O
disorders NN NN O
may NN NN O
provide NN NN O
clues NN NN O
to NN NN O
the NN NN O
pathophysiology NN NN O
of NN NN O
both NN NN O
conditions NN NN O
. NN NN O

. NN NN O

1833974 NN NN O
Sequence NN NN O
of NN NN O
DNA NN NN O
flanking NN NN O
the NN NN O
exons NN NN O
of NN NN O
the NN NN O
HEXA NN NN O
gene NN NN O
, NN NN O
and NN NN O
identification NN NN O
of NN NN O
mutations NN NN O
in NN NN O
Tay-Sachs NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

The NN NN O
rapid NN NN O
identification NN NN O
of NN NN O
mutations NN NN O
causing NN NN O
Tay-Sachs NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
requires NN NN O
the NN NN O
capacity NN NN O
to NN NN O
readily NN NN O
screen NN NN O
the NN NN O
regions NN NN O
of NN NN O
the NN NN O
HEXA NN NN O
gene NN NN O
most NN NN O
likely NN NN O
to NN NN O
be NN NN O
affected NN NN O
by NN NN O
mutation NN NN O
. NN NN O

We NN NN O
have NN NN O
sequenced NN NN O
the NN NN O
portions NN NN O
of NN NN O
the NN NN O
introns NN NN O
flanking NN NN O
each NN NN O
of NN NN O
the NN NN O
14 NN NN O
HEXA NN NN O
exons NN NN O
in NN NN O
order NN NN O
to NN NN O
specify NN NN O
oligonucleotide NN NN O
primers NN NN O
for NN NN O
the NN NN O
PCR-dependent NN NN O
amplification NN NN O
of NN NN O
each NN NN O
exon NN NN O
and NN NN O
splice-junction NN NN O
sequence NN NN O
. NN NN O

The NN NN O
amplified NN NN O
products NN NN O
were NN NN O
analyzed NN NN O
, NN NN O
by NN NN O
electrophoresis NN NN O
in NN NN O
nondenaturing NN NN O
polyacrylamide NN NN O
gels NN NN O
, NN NN O
for NN NN O
the NN NN O
presence NN NN O
of NN NN O
either NN NN O
heteroduplexes NN NN O
, NN NN O
derived NN NN O
from NN NN O
the NN NN O
annealing NN NN O
of NN NN O
normal NN NN O
and NN NN O
mutant NN NN O
DNA NN NN O
strands NN NN O
, NN NN O
or NN NN O
single-strand NN NN O
conformational NN NN O
polymorphisms NN NN O
( NN NN O
SSCP NN NN O
) NN NN O
, NN NN O
derived NN NN O
from NN NN O
the NN NN O
renaturation NN NN O
of NN NN O
single-stranded NN NN O
DNA NN NN O
. NN NN O

Five NN NN O
novel NN NN O
mutations NN NN O
from NN NN O
Tay-Sachs NN NN B-Modifier
disease NN NN I-Modifier
patients NN NN O
were NN NN O
detected NN NN O
a NN NN O
5-bp NN NN O
deletion NN NN O
of NN NN O
TCTCC NN NN O
in NN NN O
IVS-9 NN NN O
; NN NN O
a NN NN O
2-bp NN NN O
deletion NN NN O
of NN NN O
TG NN NN O
in NN NN O
exon NN NN O
5 NN NN O
; NN NN O
G78 NN NN O
to NN NN O
A NN NN O
, NN NN O
giving NN NN O
a NN NN O
stop NN NN O
codon NN NN O
in NN NN O
exon NN NN O
1 NN NN O
; NN NN O
G533 NN NN O
to NN NN O
T NN NN O
in NN NN O
exon NN NN O
5 NN NN O
, NN NN O
producing NN NN O
the NN NN O
third NN NN O
amino NN NN O
acid NN NN O
substitution NN NN O
detected NN NN O
at NN NN O
this NN NN O
site NN NN O
; NN NN O
and NN NN O
G NN NN O
to NN NN O
C NN NN O
at NN NN O
position NN NN O
1 NN NN O
of NN NN O
IVS-2 NN NN O
, NN NN O
expected NN NN O
to NN NN O
produce NN NN O
abnormal NN NN O
splicing NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
two NN NN O
mutations NN NN O
, NN NN O
( NN NN O
G1496 NN NN O
to NN NN O
A NN NN O
in NN NN O
exon NN NN O
13 NN NN O
and NN NN O
a NN NN O
4-bp NN NN O
insertion NN NN O
in NN NN O
exon NN NN O
11 NN NN O
) NN NN O
that NN NN O
have NN NN O
previously NN NN O
been NN NN O
reported NN NN O
were NN NN O
identified NN NN O
. NN NN O

. NN NN O

1897530 NN NN O
Molecular NN NN O
characterization NN NN O
of NN NN O
two NN NN O
galactosemia NN NN B-Modifier
mutations NN NN O
: NN NN O
correlation NN NN O
of NN NN O
mutations NN NN O
with NN NN O
highly NN NN O
conserved NN NN O
domains NN NN O
in NN NN O
galactose-1-phosphate NN NN O
uridyl NN NN O
transferase NN NN O
. NN NN O

Galactosemia NN NN B-SpecificDisease
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
of NN NN I-DiseaseClass
human NN NN I-DiseaseClass
galactose NN NN I-DiseaseClass
metabolism NN NN I-DiseaseClass
caused NN NN O
by NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
enzyme NN NN I-SpecificDisease
galactose-1-phosphate NN NN I-SpecificDisease
uridyl NN NN I-SpecificDisease
transferase NN NN I-SpecificDisease
( NN NN O
GALT NN NN O
) NN NN O
. NN NN O

The NN NN O
molecular NN NN O
basis NN NN O
of NN NN O
this NN NN O
disorder NN NN O
is NN NN O
at NN NN O
present NN NN O
not NN NN O
well NN NN O
understood NN NN O
. NN NN O

We NN NN O
report NN NN O
here NN NN O
two NN NN O
missense NN NN O
mutations NN NN O
which NN NN O
result NN NN O
in NN NN O
low NN NN O
or NN NN O
undetectable NN NN O
enzymatic NN NN O
activity NN NN O
. NN NN O

First NN NN O
, NN NN O
we NN NN O
identified NN NN O
at NN NN O
nucleotide NN NN O
591 NN NN O
a NN NN O
transition NN NN O
which NN NN O
substitutes NN NN O
glutamine NN NN O
188 NN NN O
by NN NN O
arginine NN NN O
. NN NN O

The NN NN O
mutated NN NN O
glutamine NN NN O
is NN NN O
not NN NN O
only NN NN O
highly NN NN O
conserved NN NN O
in NN NN O
evolution NN NN O
( NN NN O
conserved NN NN O
also NN NN O
in NN NN O
Escherichia NN NN O
coli NN NN O
and NN NN O
Saccharomyces NN NN O
cerevisiae NN NN O
) NN NN O
, NN NN O
but NN NN O
is NN NN O
also NN NN O
two NN NN O
amino NN NN O
acid NN NN O
residues NN NN O
downstream NN NN O
from NN NN O
the NN NN O
active NN NN O
site NN NN O
histidine-proline-histidine NN NN O
triad NN NN O
and NN NN O
results NN NN O
in NN NN O
about NN NN O
10 NN NN O
% NN NN O
of NN NN O
normal NN NN O
enzymatic NN NN O
activity NN NN O
. NN NN O

The NN NN O
arginine NN NN O
188 NN NN O
mutation NN NN O
is NN NN O
the NN NN O
most NN NN O
common NN NN O
galactosemia NN NN B-Modifier
mutation NN NN O
characterized NN NN O
to NN NN O
date NN NN O
. NN NN O

It NN NN O
accounts NN NN O
for NN NN O
one-fourth NN NN O
of NN NN O
the NN NN O
galactosemia NN NN B-Modifier
alleles NN NN O
studied NN NN O
. NN NN O

Second NN NN O
, NN NN O
we NN NN O
report NN NN O
the NN NN O
substitution NN NN O
of NN NN O
arginine NN NN O
333 NN NN O
by NN NN O
tryptophan NN NN O
, NN NN O
caused NN NN O
by NN NN O
a NN NN O
transition NN NN O
at NN NN O
nucleotide NN NN O
1025 NN NN O
. NN NN O

The NN NN O
area NN NN O
surrounding NN NN O
this NN NN O
missense NN NN O
mutation NN NN O
is NN NN O
the NN NN O
most NN NN O
highly NN NN O
conserved NN NN O
domain NN NN O
in NN NN O
the NN NN O
homologous NN NN O
enzymes NN NN O
from NN NN O
E NN NN O
. NN NN O

coli NN NN O
, NN NN O
yeast NN NN O
, NN NN O
and NN NN O
humans NN NN O
, NN NN O
and NN NN O
this NN NN O
mutation NN NN O
results NN NN O
in NN NN O
undetectable NN NN O
enzymatic NN NN O
activity NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
this NN NN O
is NN NN O
a NN NN O
severe NN NN O
mutation NN NN O
. NN NN O

This NN NN O
second NN NN O
mutation NN NN O
appears NN NN O
to NN NN O
be NN NN O
rare NN NN O
, NN NN O
since NN NN O
it NN NN O
was NN NN O
found NN NN O
only NN NN O
in NN NN O
the NN NN O
patient NN NN O
we NN NN O
sequenced NN NN O
. NN NN O

Our NN NN O
data NN NN O
provide NN NN O
further NN NN O
evidence NN NN O
for NN NN O
the NN NN O
heterogeneity NN NN O
of NN NN O
galactosemia NN NN B-SpecificDisease
at NN NN O
the NN NN O
molecular NN NN O
level NN NN O
, NN NN O
heterogeneity NN NN O
which NN NN O
might NN NN O
be NN NN O
related NN NN O
to NN NN O
the NN NN O
variable NN NN O
clinical NN NN O
outcome NN NN O
observed NN NN O
in NN NN O
this NN NN O
disorder NN NN O
. NN NN O

. NN NN O

1937471 NN NN O
Hypoxanthine-guanine NN NN B-SpecificDisease
phosphoribosyltransferase NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
: NN NN O
analysis NN NN O
of NN NN O
HPRT NN NN O
mutations NN NN O
by NN NN O
direct NN NN O
sequencing NN NN O
and NN NN O
allele-specific NN NN O
amplification NN NN O
. NN NN O

The NN NN O
Lesch-Nyhan NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
is NN NN O
a NN NN O
severe NN NN O
X NN NN B-DiseaseClass
chromosome-linked NN NN I-DiseaseClass
human NN NN I-DiseaseClass
disease NN NN I-DiseaseClass
caused NN NN O
by NN NN O
a NN NN O
virtual NN NN O
absence NN NN B-SpecificDisease
of NN NN I-SpecificDisease
hypoxanthine-guanine NN NN I-SpecificDisease
phosphoribosyltransferase NN NN I-SpecificDisease
( NN NN I-SpecificDisease
HPRT NN NN I-SpecificDisease
) NN NN I-SpecificDisease
activity NN NN I-SpecificDisease
. NN NN O

A NN NN O
partial NN NN O
deficiency NN NN O
in NN NN O
the NN NN O
activity NN NN O
of NN NN O
this NN NN O
enzyme NN NN O
can NN NN O
result NN NN O
in NN NN O
gouty NN NN B-SpecificDisease
arthritis NN NN I-SpecificDisease
. NN NN O

To NN NN O
determine NN NN O
the NN NN O
genetic NN NN O
basis NN NN O
for NN NN O
reduction NN NN O
or NN NN O
loss NN NN O
of NN NN O
enzyme NN NN O
activity NN NN O
, NN NN O
we NN NN O
have NN NN O
amplified NN NN O
and NN NN O
sequenced NN NN O
the NN NN O
coding NN NN O
region NN NN O
of NN NN O
HPRT NN NN O
cDNA NN NN O
from NN NN O
four NN NN O
patients NN NN O
one NN NN O
with NN NN O
Lesch-Nyhan NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
HPRTPerth NN NN O
) NN NN O
and NN NN O
three NN NN O
with NN NN O
partial NN NN B-DiseaseClass
deficiencies NN NN I-DiseaseClass
of NN NN I-DiseaseClass
HPRT NN NN I-DiseaseClass
activity NN NN I-DiseaseClass
, NN NN O
which NN NN O
have NN NN O
been NN NN O
designated NN NN O
HPRTUrangan NN NN O
, NN NN O
HPRTSwan NN NN O
and NN NN O
HPRTToowong NN NN O
. NN NN O

In NN NN O
all NN NN O
four NN NN O
patients NN NN O
, NN NN O
the NN NN O
only NN NN O
mutation NN NN O
identified NN NN O
was NN NN O
a NN NN O
single NN NN O
base NN NN O
substitution NN NN O
in NN NN O
exons NN NN O
2 NN NN O
or NN NN O
3 NN NN O
of NN NN O
the NN NN O
coding NN NN O
region NN NN O
, NN NN O
which NN NN O
in NN NN O
each NN NN O
case NN NN O
predicts NN NN O
a NN NN O
single NN NN O
amino NN NN O
acid NN NN O
substitution NN NN O
in NN NN O
the NN NN O
translated NN NN O
protein NN NN O
. NN NN O

Each NN NN O
base NN NN O
change NN NN O
was NN NN O
confirmed NN NN O
by NN NN O
allele-specific NN NN O
amplification NN NN O
of NN NN O
the NN NN O
patients NN NN O
genomic NN NN O
DNA NN NN O
. NN NN O

It NN NN O
is NN NN O
interesting NN NN O
to NN NN O
note NN NN O
that NN NN O
the NN NN O
mutation NN NN O
found NN NN O
for NN NN O
HPRTPerth NN NN O
is NN NN O
identical NN NN O
to NN NN O
that NN NN O
reported NN NN O
for NN NN O
HPRTFlint NN NN O
. NN NN O

It NN NN O
appears NN NN O
that NN NN O
the NN NN O
two NN NN O
mutations NN NN O
are NN NN O
de NN NN O
novo NN NN O
events NN NN O
. NN NN O

. NN NN O

1939657 NN NN O
Molecular NN NN O
and NN NN O
metabolic NN NN O
basis NN NN O
for NN NN O
the NN NN O
metabolic NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
normotriglyceridemic NN NN B-SpecificDisease
abetalipoproteinemia NN NN I-SpecificDisease
. NN NN O

We NN NN O
have NN NN O
previously NN NN O
described NN NN O
a NN NN O
disorder NN NN O
, NN NN O
normotriglyceridemic NN NN B-SpecificDisease
abetalipoproteinemia NN NN I-SpecificDisease
, NN NN O
that NN NN O
is NN NN O
characterized NN NN O
by NN NN O
the NN NN O
virtual NN NN O
absence NN NN O
of NN NN O
plasma NN NN O
low NN NN O
density NN NN O
lipoproteins NN NN O
and NN NN O
complete NN NN O
absence NN NN O
of NN NN O
apoB-100 NN NN O
, NN NN O
but NN NN O
with NN NN O
apparently NN NN O
normal NN NN O
secretion NN NN O
of NN NN O
triglyceride-rich NN NN O
lipoproteins NN NN O
containing NN NN O
apoB-48 NN NN O
. NN NN O

The NN NN O
patients NN NN O
plasma NN NN O
lipoproteins NN NN O
were NN NN O
shown NN NN O
on NN NN O
polyacrylamide NN NN O
gels NN NN O
and NN NN O
by NN NN O
antibody NN NN O
mapping NN NN O
to NN NN O
have NN NN O
a NN NN O
new NN NN O
truncated NN NN O
apoB NN NN O
variant NN NN O
, NN NN O
apoB-50 NN NN O
, NN NN O
circulating NN NN O
along NN NN O
with NN NN O
her NN NN O
apoB-48 NN NN O
. NN NN O

We NN NN O
have NN NN O
found NN NN O
this NN NN O
individual NN NN O
to NN NN O
be NN NN O
homozygous NN NN O
for NN NN O
a NN NN O
single NN NN O
C-to-T NN NN O
nucleotide NN NN O
substitution NN NN O
at NN NN O
apoB NN NN O
codon NN NN O
2252 NN NN O
, NN NN O
which NN NN O
produces NN NN O
a NN NN O
premature NN NN O
in-frame NN NN O
stop NN NN O
codon NN NN O
. NN NN O

Thus NN NN O
, NN NN O
this NN NN O
is NN NN O
a NN NN O
rare NN NN O
example NN NN O
of NN NN O
homozygous NN NN B-SpecificDisease
hypobetalipoproteinemia NN NN I-SpecificDisease
. NN NN O

Electron NN NN O
photomicrographs NN NN O
revealed NN NN O
that NN NN O
the NN NN O
diameters NN NN O
of NN NN O
particles NN NN O
in NN NN O
the NN NN O
d NN NN O
less NN NN O
than NN NN O
1 NN NN O
. NN NN O

006 NN NN O
g NN NN O
/ NN NN O
ml NN NN O
lipoprotein NN NN O
fraction NN NN O
, NN NN O
in NN NN O
both NN NN O
the NN NN O
postprandial NN NN O
and NN NN O
postabsorptive NN NN O
state NN NN O
, NN NN O
are NN NN O
bimodally NN NN O
distributed NN NN O
. NN NN O

The NN NN O
molar NN NN O
ratio NN NN O
of NN NN O
apoE NN NN O
to NN NN O
apoB NN NN O
in NN NN O
these NN NN O
particles NN NN O
is NN NN O
3 NN NN O
. NN NN O

5 NN NN O
1 NN NN O
, NN NN O
similar NN NN O
to NN NN O
normal NN NN O
VLDL NN NN O
. NN NN O

The NN NN O
plasma NN NN O
LDL NN NN O
interval NN NN O
contains NN NN O
both NN NN O
spherical NN NN O
and NN NN O
cuboidal NN NN O
particles NN NN O
. NN NN O

Autologous NN NN O
reinfusion NN NN O
of NN NN O
labeled NN NN O
d NN NN O
less NN NN O
than NN NN O
1 NN NN O
. NN NN O

006 NN NN O
g NN NN O
/ NN NN O
ml NN NN O
lipoproteins NN NN O
showed NN NN O
exponential NN NN O
disappearance NN NN O
from NN NN O
plasma NN NN O
, NN NN O
with NN NN O
an NN NN O
apparent NN NN O
half-removal NN NN O
time NN NN O
of NN NN O
50 NN NN O
min NN NN O
, NN NN O
somewhat NN NN O
slower NN NN O
than NN NN O
for NN NN O
normal NN NN O
chylomicrons NN NN O
but NN NN O
within NN NN O
the NN NN O
normal NN NN O
range NN NN O
for NN NN O
VLDL NN NN O
. NN NN O

The NN NN O
calculated NN NN O
production NN NN O
rate NN NN O
for NN NN O
apoB NN NN O
was NN NN O
within NN NN O
the NN NN O
normal NN NN O
range NN NN O
in NN NN O
this NN NN O
subject NN NN O
. NN NN O

1968617 NN NN O
A NN NN O
single NN NN O
origin NN NN O
of NN NN O
phenylketonuria NN NN B-SpecificDisease
in NN NN O
Yemenite NN NN O
Jews NN NN O
. NN NN O

Phenylketonuria NN NN B-SpecificDisease
( NN NN O
PKU NN NN B-SpecificDisease
) NN NN O
is NN NN O
a NN NN O
metabolic NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
caused NN NN O
by NN NN O
recessive NN NN O
mutations NN NN O
of NN NN O
the NN NN O
gene NN NN O
encoding NN NN O
the NN NN O
hepatic NN NN O
enzyme NN NN O
phenylalanine NN NN O
hydroxylase NN NN O
( NN NN O
PAH NN NN O
) NN NN O
. NN NN O

The NN NN O
incidence NN NN O
of NN NN O
PKU NN NN B-SpecificDisease
varies NN NN O
widely NN NN O
across NN NN O
different NN NN O
geographic NN NN O
areas NN NN O
, NN NN O
and NN NN O
is NN NN O
highest NN NN O
( NN NN O
about NN NN O
1 NN NN O
in NN NN O
5 NN NN O
, NN NN O
000 NN NN O
live NN NN O
births NN NN O
) NN NN O
in NN NN O
Ireland NN NN O
and NN NN O
western NN NN O
Scotland NN NN O
, NN NN O
and NN NN O
among NN NN O
Yemenite NN NN O
Jews NN NN O
. NN NN O

A NN NN O
limited NN NN O
number NN NN O
of NN NN O
point NN NN O
mutations NN NN O
account NN NN O
for NN NN O
most NN NN O
of NN NN O
the NN NN O
PKU NN NN B-Modifier
cases NN NN O
in NN NN O
the NN NN O
European NN NN O
population NN NN O
. NN NN O

Here NN NN O
we NN NN O
report NN NN O
that NN NN O
a NN NN O
single NN NN O
molecular NN NN O
defect NN NN O
-- NN NN O
a NN NN O
deletion NN NN O
spanning NN NN O
the NN NN O
third NN NN O
exon NN NN O
of NN NN O
the NN NN O
PAH NN NN O
gene NN NN O
-- NN NN O
is NN NN O
responsible NN NN O
for NN NN O
all NN NN O
the NN NN O
PKU NN NN B-Modifier
cases NN NN O
among NN NN O
the NN NN O
Yemenite NN NN O
Jews NN NN O
. NN NN O

Examination NN NN O
of NN NN O
a NN NN O
random NN NN O
sample NN NN O
of NN NN O
Yemenite NN NN O
Jews NN NN O
using NN NN O
a NN NN O
molecular NN NN O
probe NN NN O
that NN NN O
detects NN NN O
the NN NN O
carriers NN NN O
of NN NN O
this NN NN O
deletion NN NN O
indicated NN NN O
a NN NN O
high NN NN O
frequency NN NN O
of NN NN O
the NN NN O
defective NN NN O
gene NN NN O
in NN NN O
this NN NN O
community NN NN O
. NN NN O

Although NN NN O
the NN NN O
deleted NN NN O
PAH NN NN O
gene NN NN O
was NN NN O
traced NN NN O
to NN NN O
25 NN NN O
different NN NN O
locations NN NN O
throughout NN NN O
Yemen NN NN O
, NN NN O
family NN NN O
histories NN NN O
and NN NN O
official NN NN O
documents NN NN O
of NN NN O
the NN NN O
Yemenite NN NN O
Jewish NN NN O
community NN NN O
showed NN NN O
that NN NN O
the NN NN O
common NN NN O
ancestor NN NN O
of NN NN O
all NN NN O
the NN NN O
carriers NN NN O
of NN NN O
this NN NN O
genetic NN NN B-DiseaseClass
defect NN NN I-DiseaseClass
lived NN NN O
in NN NN O
Sana NN NN O
, NN NN O
the NN NN O
capital NN NN O
of NN NN O
Yemen NN NN O
, NN NN O
before NN NN O
the NN NN O
eighteenth NN NN O
century NN NN O
. NN NN O

. NN NN O

1973404 NN NN O
Linkage NN NN O
of NN NN O
aspartylglucosaminuria NN NN B-SpecificDisease
( NN NN O
AGU NN NN B-SpecificDisease
) NN NN O
to NN NN O
marker NN NN O
loci NN NN O
on NN NN O
the NN NN O
long NN NN O
arm NN NN O
of NN NN O
chromosome NN NN O
4 NN NN O
. NN NN O

Aspartylglucosaminuria NN NN B-SpecificDisease
( NN NN O
AGU NN NN B-SpecificDisease
) NN NN O
is NN NN O
caused NN NN O
by NN NN O
deficient NN NN O
activity NN NN O
of NN NN O
the NN NN O
enzyme NN NN O
aspartylglucosaminidase NN NN O
( NN NN O
AGA NN NN O
) NN NN O
. NN NN O

The NN NN O
structural NN NN O
gene NN NN O
for NN NN O
AGA NN NN O
has NN NN O
been NN NN O
assigned NN NN O
to NN NN O
the NN NN O
region NN NN O
4q21-qter NN NN O
of NN NN O
chromosome NN NN O
4 NN NN O
. NN NN O

We NN NN O
have NN NN O
studied NN NN O
the NN NN O
map NN NN O
position NN NN O
of NN NN O
the NN NN O
AGU NN NN O
locus NN NN O
in NN NN O
relation NN NN O
to NN NN O
other NN NN O
marker NN NN O
loci NN NN O
on NN NN O
the NN NN O
long NN NN O
arm NN NN O
of NN NN O
chromosome NN NN O
4 NN NN O
using NN NN O
linkage NN NN O
analyses NN NN O
. NN NN O

Restriction NN NN O
fragment NN NN O
length NN NN O
polymorphism NN NN O
alleles NN NN O
for NN NN O
the NN NN O
ADH2 NN NN O
, NN NN O
ADH3 NN NN O
, NN NN O
EGF NN NN O
, NN NN O
FG NN NN O
alpha NN NN O
and NN NN O
FG NN NN O
beta NN NN O
loci NN NN O
and NN NN O
blood NN NN O
group NN NN O
antigens NN NN O
for NN NN O
the NN NN O
MNS NN NN O
locus NN NN O
were NN NN O
determined NN NN O
in NN NN O
a NN NN O
panel NN NN O
of NN NN O
12 NN NN O
Finnish NN NN O
AGU NN NN B-Modifier
families NN NN O
. NN NN O

The NN NN O
heterozygous NN NN O
family NN NN O
members NN NN O
were NN NN O
identified NN NN O
by NN NN O
reduced NN NN O
activity NN NN O
of NN NN O
AGA NN NN O
in NN NN O
lymphocytes NN NN O
. NN NN O

Linkage NN NN O
studies NN NN O
were NN NN O
performed NN NN O
using NN NN O
both NN NN O
pairwise NN NN O
and NN NN O
multipoint NN NN O
analyses NN NN O
. NN NN O

Loose NN NN O
linkage NN NN O
of NN NN O
the NN NN O
AGU NN NN B-Modifier
locus NN NN O
to NN NN O
the NN NN O
FG NN NN O
and NN NN O
MNS NN NN O
loci NN NN O
was NN NN O
observed NN NN O
( NN NN O
z NN NN O
= NN NN O
1 NN NN O
. NN NN O

16 NN NN O
, NN NN O
z NN NN O
= NN NN O
1 NN NN O
. NN NN O

39 NN NN O
, NN NN O
respectively NN NN O
) NN NN O
. NN NN O

Multipoint NN NN O
analysis NN NN O
to NN NN O
the NN NN O
fixed NN NN O
map NN NN O
[ NN NN O
ADH- NN NN O
( NN NN O
0 NN NN O
. NN NN O

03 NN NN O
) NN NN O
-EGF- NN NN O
( NN NN O
0 NN NN O
. NN NN O

35 NN NN O
) NN NN O
-FG- NN NN O
( NN NN O
0 NN NN O
. NN NN O

11 NN NN O
) NN NN O
-MNS NN NN O
] NN NN O
suggests NN NN O
that NN NN O
the NN NN O
location NN NN O
of NN NN O
the NN NN O
AGU NN NN O
locus NN NN O
is NN NN O
0 NN NN O
. NN NN O

05-0 NN NN O
. NN NN O

30 NN NN O
recombination NN NN O
units NN NN O
distal NN NN O
to NN NN O
MNS NN NN O
( NN NN O
z NN NN O
= NN NN O
3 NN NN O
. NN NN O

03 NN NN O
) NN NN O
. NN NN O

The NN NN O
order NN NN O
cen-ADH-EGF-FG-MNS-AGU NN NN O
is NN NN O
35 NN NN O
times NN NN O
more NN NN O
likely NN NN O
than NN NN O
the NN NN O
next NN NN O
best NN NN O
order NN NN O
cen-ADH-EGF-AGU-FG-MNS NN NN O
. NN NN O

1975560 NN NN O
Linkage NN NN O
relationships NN NN O
of NN NN O
the NN NN O
apolipoprotein NN NN O
C1 NN NN O
gene NN NN O
and NN NN O
a NN NN O
cytochrome NN NN O
P450 NN NN O
gene NN NN O
( NN NN O
CYP2A NN NN O
) NN NN O
to NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
. NN NN O

We NN NN O
have NN NN O
studied NN NN O
the NN NN O
genetic NN NN O
linkage NN NN O
of NN NN O
two NN NN O
markers NN NN O
, NN NN O
the NN NN O
apolipoprotein NN NN O
C1 NN NN O
( NN NN O
APOC1 NN NN O
) NN NN O
gene NN NN O
and NN NN O
a NN NN O
cytochrome NN NN O
P450 NN NN O
( NN NN O
CYP2A NN NN O
) NN NN O
gene NN NN O
, NN NN O
in NN NN O
relation NN NN O
to NN NN O
the NN NN O
gene NN NN O
for NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
. NN NN O

A NN NN O
peak NN NN O
lod NN NN O
score NN NN O
of NN NN O
9 NN NN O
. NN NN O

29 NN NN O
at NN NN O
2 NN NN O
cM NN NN O
was NN NN O
observed NN NN O
for NN NN O
APOC1-DM NN NN O
, NN NN O
with NN NN O
a NN NN O
lod NN NN O
score NN NN O
of NN NN O
8 NN NN O
. NN NN O

55 NN NN O
at NN NN O
4 NN NN O
cM NN NN O
for NN NN O
CYP2A-DM NN NN O
. NN NN O

These NN NN O
two NN NN O
markers NN NN O
also NN NN O
show NN NN O
close NN NN O
linkage NN NN O
to NN NN O
each NN NN O
other NN NN O
( NN NN O
theta NN NN O
max NN NN O
= NN NN O
0 NN NN O
. NN NN O

05 NN NN O
, NN NN O
Zmax NN NN O
= NN NN O
9 NN NN O
. NN NN O

09 NN NN O
) NN NN O
. NN NN O

From NN NN O
examination NN NN O
of NN NN O
the NN NN O
genotypes NN NN O
of NN NN O
the NN NN O
recombinant NN NN O
individuals NN NN O
, NN NN O
CYP2A NN NN O
appears NN NN O
to NN NN O
map NN NN O
proximal NN NN O
to NN NN O
DM NN NN O
because NN NN O
in NN NN O
one NN NN O
recombinant NN NN O
individual NN NN O
CYP2A NN NN O
, NN NN O
APOC2 NN NN O
and NN NN O
CKMM NN NN O
had NN NN O
all NN NN O
recombined NN NN O
with NN NN O
DM NN NN O
. NN NN O

Evidence NN NN O
from NN NN O
another NN NN O
CYP2A-DM NN NN O
recombinant NN NN O
individual NN NN O
places NN NN O
CYP2A NN NN O
proximal NN NN O
to NN NN O
APOC2 NN NN O
and NN NN O
CKMM NN NN O
. NN NN O

Localisation NN NN O
of NN NN O
CYP2A NN NN O
on NN NN O
a NN NN O
panel NN NN O
of NN NN O
somatic NN NN O
cell NN NN O
hybrids NN NN O
also NN NN O
suggests NN NN O
that NN NN O
it NN NN O
is NN NN O
proximal NN NN O
to NN NN O
DM NN NN O
and NN NN O
APOC2 NN NN O
/ NN NN O
C1 NN NN O
/ NN NN O
E NN NN O
gene NN NN O
cluster NN NN O
. NN NN O

1978564 NN NN O
Genetic NN NN O
linkage NN NN O
map NN NN O
of NN NN O
six NN NN O
polymorphic NN NN O
DNA NN NN O
markers NN NN O
around NN NN O
the NN NN O
gene NN NN O
for NN NN O
familial NN NN B-SpecificDisease
adenomatous NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
on NN NN O
chromosome NN NN O
5 NN NN O
. NN NN O

A NN NN O
genetic NN NN O
linkage NN NN O
map NN NN O
of NN NN O
six NN NN O
polymorphic NN NN O
DNA NN NN O
markers NN NN O
close NN NN O
to NN NN O
the NN NN O
gene NN NN O
( NN NN O
APC NN NN O
) NN NN O
for NN NN O
familial NN NN B-SpecificDisease
adenomatous NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
( NN NN O
FAP NN NN B-SpecificDisease
) NN NN O
on NN NN O
chromosome NN NN O
5q NN NN O
is NN NN O
reported NN NN O
. NN NN O

One NN NN O
hundred NN NN O
fifty-five NN NN O
typed NN NN O
members NN NN O
of NN NN O
nine NN NN O
FAP NN NN B-Modifier
kindred NN NN O
provided NN NN O
more NN NN O
than NN NN O
90 NN NN O
meioses NN NN O
for NN NN O
linkage NN NN O
analysis NN NN O
. NN NN O

A NN NN O
number NN NN O
of NN NN O
crucial NN NN O
recombination NN NN O
events NN NN O
have NN NN O
been NN NN O
identified NN NN O
which NN NN O
are NN NN O
informative NN NN O
at NN NN O
three NN NN O
or NN NN O
more NN NN O
loci NN NN O
, NN NN O
allowing NN NN O
confident NN NN O
ordering NN NN O
of NN NN O
parts NN NN O
of NN NN O
the NN NN O
map NN NN O
. NN NN O

There NN NN O
was NN NN O
no NN NN O
evidence NN NN O
of NN NN O
genetic NN NN O
heterogeneity NN NN O
, NN NN O
with NN NN O
all NN NN O
families NN NN O
showing NN NN O
linkage NN NN O
of NN NN O
at NN NN O
least NN NN O
one NN NN O
chromosome NN NN O
5 NN NN O
marker NN NN O
to NN NN O
the NN NN O
gene NN NN O
. NN NN O

Recombination NN NN O
data NN NN O
and NN NN O
two-point NN NN O
linkage NN NN O
analysis NN NN O
support NN NN O
a NN NN O
locus NN NN O
order NN NN O
of NN NN O
centromere-pi NN NN O
227-C11P11-ECB27-L5 NN NN O
. NN NN O

62-APC-EF5 NN NN O
62-APC-EF5 NN NN O
. NN NN O

44-YN5 NN NN O
44-YN5 NN NN O
. NN NN O

48-telomer NN NN O
e NN NN O
, NN NN O
although NN NN O
EF5 NN NN O
. NN NN O

44 NN NN O
could NN NN O
lie NN NN O
in NN NN O
the NN NN O
interval NN NN O
L5 NN NN O
. NN NN O

62-APC NN NN O
or NN NN O
ECB27-L5 NN NN O
. NN NN O

62 NN NN O
. NN NN O

No NN NN O
recombinants NN NN O
were NN NN O
identified NN NN O
between NN NN O
APC NN NN O
and NN NN O
either NN NN O
EF5 NN NN O
. NN NN O

44 NN NN O
or NN NN O
YN5 NN NN O
. NN NN O

48 NN NN O
, NN NN O
but NN NN O
published NN NN O
deletion NN NN O
mapping NN NN O
in NN NN O
colorectal NN NN B-SpecificDisease
carcinomas NN NN I-SpecificDisease
and NN NN O
linkage NN NN O
analysis NN NN O
in NN NN O
FAP NN NN B-SpecificDisease
suggest NN NN O
that NN NN O
YN5 NN NN O
. NN NN O

48 NN NN O
is NN NN O
1-3 NN NN O
cM NN NN O
from NN NN O
APC NN NN O
. NN NN O

The NN NN O
present NN NN O
study NN NN O
suggests NN NN O
that NN NN O
YN5 NN NN O
. NN NN O

48 NN NN O
and NN NN O
L5 NN NN O
. NN NN O

62 NN NN O
delineate NN NN O
a NN NN O
small NN NN O
region NN NN O
of NN NN O
chromosome NN NN O
5 NN NN O
within NN NN O
which NN NN O
the NN NN O
EF5 NN NN O
. NN NN O

44 NN NN O
locus NN NN O
lies NN NN O
very NN NN O
close NN NN O
to NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
. NN NN O

These NN NN O
data NN NN O
not NN NN O
only NN NN O
allow NN NN O
use NN NN O
of NN NN O
flanking NN NN O
markers NN NN O
for NN NN O
presymptomatic NN NN O
diagnosis NN NN O
of NN NN O
FAP NN NN B-SpecificDisease
but NN NN O
also NN NN O
provide NN NN O
a NN NN O
high-density NN NN O
map NN NN O
of NN NN O
the NN NN O
region NN NN O
for NN NN O
isolation NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
itself NN NN O
and NN NN O
for NN NN O
further NN NN O
assessment NN NN O
of NN NN O
the NN NN O
role NN NN O
of NN NN O
chromosome NN NN O
5 NN NN O
deletions NN NN O
in NN NN O
the NN NN O
biology NN NN O
of NN NN O
sporadic NN NN O
colorectal NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

1981994 NN NN O
Serum NN NN O
amyloid NN NN O
A NN NN O
and NN NN O
P NN NN O
protein NN NN O
genes NN NN O
in NN NN O
familial NN NN B-SpecificDisease
Mediterranean NN NN I-SpecificDisease
fever NN NN I-SpecificDisease
. NN NN O

Two NN NN O
recent NN NN O
studies NN NN O
have NN NN O
suggested NN NN O
the NN NN O
involvement NN NN O
of NN NN O
serum NN NN O
amyloid NN NN O
A NN NN O
( NN NN O
SAA NN NN O
) NN NN O
and NN NN O
P NN NN O
( NN NN O
APCS NN NN O
) NN NN O
genes NN NN O
in NN NN O
familial NN NN B-SpecificDisease
Mediterranean NN NN I-SpecificDisease
fever NN NN I-SpecificDisease
( NN NN O
MEF NN NN B-SpecificDisease
) NN NN O
. NN NN O

To NN NN O
test NN NN O
the NN NN O
role NN NN O
of NN NN O
SAA NN NN O
and NN NN O
APCS NN NN O
in NN NN O
MEF NN NN B-SpecificDisease
and NN NN O
MEF-amyloidosis NN NN B-SpecificDisease
, NN NN O
we NN NN O
studied NN NN O
17 NN NN O
informative NN NN O
families NN NN O
( NN NN O
15 NN NN O
Armenians NN NN O
, NN NN O
2 NN NN O
non-Ashkenazi NN NN O
Jews NN NN O
) NN NN O
and NN NN O
8 NN NN O
MEF NN NN B-Modifier
patients NN NN O
with NN NN O
amyloidosis NN NN B-DiseaseClass
using NN NN O
a NN NN O
candidate NN NN O
gene NN NN O
approach NN NN O
. NN NN O

No NN NN O
evidence NN NN O
for NN NN O
any NN NN O
MEF NN NN B-Modifier
-associated NN NN O
polymorphism NN NN O
was NN NN O
found NN NN O
in NN NN O
any NN NN O
of NN NN O
the NN NN O
41 NN NN O
Armenian NN NN O
and NN NN O
Jewish NN NN O
MEF NN NN B-Modifier
patients NN NN O
tested NN NN O
. NN NN O

Our NN NN O
family NN NN O
studies NN NN O
allowed NN NN O
us NN NN O
to NN NN O
rule NN NN O
out NN NN O
tight NN NN O
linkage NN NN O
between NN NN O
SAA NN NN O
and NN NN O
MEF NN NN B-SpecificDisease
( NN NN O
lod NN NN O
score NN NN O
= NN NN O
-2 NN NN O
. NN NN O

16 NN NN O
, NN NN O
theta NN NN O
less NN NN O
than NN NN O
or NN NN O
equal NN NN O
to NN NN O
0 NN NN O
. NN NN O

06 NN NN O
) NN NN O
. NN NN O

For NN NN O
APCS NN NN O
we NN NN O
found NN NN O
that NN NN O
the NN NN O
allele NN NN O
frequency NN NN O
in NN NN O
the NN NN O
MEF-amyloidosis NN NN B-Modifier
patients NN NN O
was NN NN O
similar NN NN O
to NN NN O
that NN NN O
in NN NN O
18 NN NN O
unrelated NN NN O
MEF NN NN B-Modifier
patients NN NN O
without NN NN O
amyloidosis NN NN B-DiseaseClass
and NN NN O
their NN NN O
33 NN NN O
healthy NN NN O
parents NN NN O
. NN NN O

1999339 NN NN O
Some NN NN O
Mexican NN NN O
glucose-6-phosphate NN NN O
dehydrogenase NN NN O
variants NN NN O
revisited NN NN O
. NN NN O

Glucose-6-phosphate NN NN B-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
( NN NN I-SpecificDisease
G6PD NN NN I-SpecificDisease
) NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
appears NN NN O
to NN NN O
be NN NN O
fairly NN NN O
common NN NN O
in NN NN O
Mexico NN NN O
. NN NN O

We NN NN O
have NN NN O
now NN NN O
examined NN NN O
the NN NN O
DNA NN NN O
of NN NN O
three NN NN O
previously NN NN O
reported NN NN O
electrophoretically NN NN O
fast NN NN O
Mexican NN NN O
G6PD NN NN O
variants NN NN O
, NN NN O
-G6PD NN NN O
Distrito NN NN O
Federal NN NN O
, NN NN O
G6PD NN NN O
Tepic NN NN O
, NN NN O
and NN NN O
G6PD NN NN O
Castilla NN NN O
. NN NN O

All NN NN O
three NN NN O
of NN NN O
these NN NN O
variants NN NN O
, NN NN O
believed NN NN O
on NN NN O
the NN NN O
basis NN NN O
of NN NN O
biochemical NN NN O
characterization NN NN O
and NN NN O
population NN NN O
origin NN NN O
to NN NN O
be NN NN O
unique NN NN O
, NN NN O
have NN NN O
the NN NN O
G NN NN O
-- NN NN O
-- NN NN O
A NN NN O
transition NN NN O
at NN NN O
nucleotide NN NN O
202 NN NN O
and NN NN O
the NN NN O
A NN NN O
-- NN NN O
-- NN NN O
G NN NN O
transition NN NN O
at NN NN O
nucleotide NN NN O
376 NN NN O
, NN NN O
mutations NN NN O
that NN NN O
we NN NN O
now NN NN O
recognize NN NN O
to NN NN O
be NN NN O
characteristic NN NN O
of NN NN O
G6PD NN NN O
A- NN NN O
. NN NN O

Two NN NN O
other NN NN O
Mexican NN NN O
males NN NN O
with NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
were NN NN O
found NN NN O
to NN NN O
have NN NN O
the NN NN O
same NN NN O
mutation NN NN O
. NN NN O

All NN NN O
five NN NN O
have NN NN O
the NN NN O
( NN NN O
NlaIII NN NN O
/ NN NN O
FokI NN NN O
/ NN NN O
PvuII NN NN O
/ NN NN O
PstI NN NN O
) NN NN O
haplotype NN NN O
characteristic NN NN O
of NN NN O
G6PD NN NN O
A NN NN O
-in NN NN O
Africa NN NN O
. NN NN O

Since NN NN O
the NN NN O
PvuII NN NN O
+ NN NN O
genotype NN NN O
seems NN NN O
to NN NN O
be NN NN O
rare NN NN O
in NN NN O
Europe NN NN O
, NN NN O
we NN NN O
conclude NN NN O
that NN NN O
all NN NN O
of NN NN O
these NN NN O
G6PD NN NN O
A NN NN O
- NN NN O
genes NN NN O
had NN NN O
their NN NN O
ancient NN NN O
origin NN NN O
in NN NN O
Africa NN NN O
, NN NN O
although NN NN O
in NN NN O
many NN NN O
of NN NN O
the NN NN O
Mexican NN NN O
patients NN NN O
with NN NN O
G6PD NN NN O
A NN NN O
-202A NN NN O
/ NN NN O
376G NN NN O
the NN NN O
gene NN NN O
may NN NN O
have NN NN O
been NN NN O
imported NN NN O
more NN NN O
recently NN NN O
from NN NN O
Spain NN NN O
, NN NN O
where NN NN O
this NN NN O
variant NN NN O
, NN NN O
formerly NN NN O
known NN NN O
as NN NN O
G6PD NN NN O
Betica NN NN O
, NN NN O
is NN NN O
also NN NN O
prevalent NN NN O
. NN NN O

. NN NN O

1999552 NN NN O
Hereditary NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
C5 NN NN I-SpecificDisease
in NN NN O
association NN NN O
with NN NN O
discoid NN NN B-SpecificDisease
lupus NN NN I-SpecificDisease
erythematosus NN NN I-SpecificDisease
. NN NN O

A NN NN O
29-year-old NN NN O
woman NN NN O
with NN NN O
discoid NN NN B-SpecificDisease
lupus NN NN I-SpecificDisease
erythematosus NN NN I-SpecificDisease
had NN NN O
undetectable NN NN O
classic NN NN O
pathway NN NN O
complement NN NN O
activity NN NN O
. NN NN O

Hypocomplementemia NN NN B-DiseaseClass
was NN NN O
due NN NN O
to NN NN O
selective NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
C5 NN NN I-SpecificDisease
. NN NN O

One NN NN O
of NN NN O
her NN NN O
children NN NN O
was NN NN O
also NN NN O
deficient NN NN O
. NN NN O

To NN NN O
our NN NN O
knowledge NN NN O
this NN NN O
is NN NN O
the NN NN O
first NN NN O
documented NN NN O
case NN NN O
of NN NN O
an NN NN O
association NN NN O
between NN NN O
discoid NN NN B-SpecificDisease
lupus NN NN I-SpecificDisease
erythematosus NN NN I-SpecificDisease
and NN NN O
C5 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

. NN NN O

2006152 NN NN O
Founder NN NN O
effect NN NN O
of NN NN O
a NN NN O
prevalent NN NN O
phenylketonuria NN NN B-Modifier
mutation NN NN O
in NN NN O
the NN NN O
Oriental NN NN O
population NN NN O
. NN NN O

A NN NN O
missense NN NN O
mutation NN NN O
has NN NN O
been NN NN O
identified NN NN O
in NN NN O
the NN NN O
human NN NN O
phenylalanine NN NN O
hydroxylase NN NN O
[ NN NN O
PAH NN NN O
; NN NN O
phenylalanine NN NN O
4-monooxygenase NN NN O
; NN NN O
L-phenylalanine NN NN O
, NN NN O
tetrahydrobiopterin NN NN O
oxygen NN NN O
oxidoreductase NN NN O
( NN NN O
4-hydroxylating NN NN O
) NN NN O
, NN NN O
EC NN NN O
1 NN NN O
. NN NN O

14 NN NN O
. NN NN O

16 NN NN O
. NN NN O

1 NN NN O
] NN NN O
gene NN NN O
in NN NN O
a NN NN O
Chinese NN NN O
patient NN NN O
with NN NN O
classic NN NN O
phenylketonuria NN NN B-SpecificDisease
( NN NN O
PKU NN NN B-SpecificDisease
) NN NN O
. NN NN O

A NN NN O
G-to-C NN NN O
transition NN NN O
at NN NN O
the NN NN O
second NN NN O
base NN NN O
of NN NN O
codon NN NN O
413 NN NN O
in NN NN O
exon NN NN O
12 NN NN O
of NN NN O
the NN NN O
gene NN NN O
results NN NN O
in NN NN O
the NN NN O
substitution NN NN O
of NN NN O
Pro413 NN NN O
for NN NN O
Arg413 NN NN O
in NN NN O
the NN NN O
mutant NN NN O
protein NN NN O
. NN NN O

This NN NN O
mutation NN NN O
( NN NN O
R413P NN NN O
) NN NN O
results NN NN O
in NN NN O
negligible NN NN O
enzymatic NN NN O
activity NN NN O
when NN NN O
expressed NN NN O
in NN NN O
heterologous NN NN O
mammalian NN NN O
cells NN NN O
and NN NN O
is NN NN O
compatible NN NN O
with NN NN O
a NN NN O
classic NN NN O
PKU NN NN B-Modifier
phenotype NN NN O
in NN NN O
the NN NN O
patient NN NN O
. NN NN O

Population NN NN O
genetic NN NN O
studies NN NN O
reveal NN NN O
that NN NN O
this NN NN O
mutation NN NN O
is NN NN O
tightly NN NN O
linked NN NN O
to NN NN O
restriction NN NN O
fragment NN NN O
length NN NN O
polymorphism NN NN O
haplotype NN NN O
4 NN NN O
, NN NN O
which NN NN O
is NN NN O
the NN NN O
predominant NN NN O
haplotype NN NN O
of NN NN O
the NN NN O
PAH NN NN O
locus NN NN O
in NN NN O
the NN NN O
Oriental NN NN O
population NN NN O
. NN NN O

It NN NN O
accounts NN NN O
for NN NN O
13 NN NN O
. NN NN O

8 NN NN O
% NN NN O
of NN NN O
northern NN NN O
Chinese NN NN O
and NN NN O
27 NN NN O
% NN NN O
of NN NN O
Japanese NN NN O
PKU NN NN B-Modifier
alleles NN NN O
, NN NN O
but NN NN O
it NN NN O
is NN NN O
rare NN NN O
in NN NN O
southern NN NN O
Chinese NN NN O
( NN NN O
2 NN NN O
. NN NN O

2 NN NN O
% NN NN O
) NN NN O
and NN NN O
is NN NN O
absent NN NN O
in NN NN O
the NN NN O
Caucasian NN NN O
population NN NN O
. NN NN O

The NN NN O
data NN NN O
demonstrate NN NN O
unambiguously NN NN O
that NN NN O
the NN NN O
mutation NN NN O
occurred NN NN O
after NN NN O
racial NN NN O
divergence NN NN O
of NN NN O
Orientals NN NN O
and NN NN O
Caucasians NN NN O
and NN NN O
suggest NN NN O
that NN NN O
the NN NN O
allele NN NN O
has NN NN O
spread NN NN O
throughout NN NN O
the NN NN O
Orient NN NN O
by NN NN O
a NN NN O
founder NN NN O
effect NN NN O
. NN NN O

Previous NN NN O
protein NN NN O
polymorphism NN NN O
studies NN NN O
in NN NN O
eastern NN NN O
Asia NN NN O
have NN NN O
led NN NN O
to NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
`` NN NN O
northern NN NN O
Mongoloids NN NN O
`` NN NN O
represented NN NN O
a NN NN O
founding NN NN O
population NN NN O
in NN NN O
Asia NN NN O
. NN NN O

Our NN NN O
results NN NN O
are NN NN O
compatible NN NN O
with NN NN O
this NN NN O
hypothesis NN NN O
in NN NN O
that NN NN O
the NN NN O
PKU NN NN B-Modifier
mutation NN NN O
might NN NN O
have NN NN O
occurred NN NN O
in NN NN O
northern NN NN O
Mongoloids NN NN O
and NN NN O
subsequently NN NN O
spread NN NN O
to NN NN O
the NN NN O
Chinese NN NN O
and NN NN O
Japanese NN NN O
populations NN NN O
. NN NN O

2008213 NN NN O
Glucose/galactose NN NN B-SpecificDisease
malabsorption NN NN I-SpecificDisease
caused NN NN O
by NN NN O
a NN NN O
defect NN NN O
in NN NN O
the NN NN O
Na+/glucose NN NN O
cotransporter NN NN O
. NN NN O

Glucose NN NN B-SpecificDisease
/ NN NN I-SpecificDisease
galactose NN NN I-SpecificDisease
malabsorption NN NN I-SpecificDisease
( NN NN O
GGM NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
disease NN NN I-DiseaseClass
manifesting NN NN O
within NN NN O
the NN NN O
first NN NN O
weeks NN NN O
of NN NN O
life NN NN O
and NN NN O
characterized NN NN O
by NN NN O
a NN NN O
selective NN NN O
failure NN NN O
to NN NN O
absorb NN NN O
dietary NN NN O
glucose NN NN O
and NN NN O
galactose NN NN O
from NN NN O
the NN NN O
intestine NN NN O
. NN NN O

The NN NN O
consequent NN NN O
severe NN NN O
diarrhoea NN NN B-SpecificDisease
and NN NN O
dehydration NN NN B-SpecificDisease
are NN NN O
usually NN NN O
fatal NN NN O
unless NN NN O
these NN NN O
sugars NN NN O
are NN NN O
eliminated NN NN O
from NN NN O
the NN NN O
diet NN NN O
. NN NN O

Intestinal NN NN O
biopsies NN NN O
of NN NN O
GGM NN NN B-Modifier
patients NN NN O
have NN NN O
revealed NN NN O
a NN NN O
specific NN NN O
defect NN NN O
in NN NN O
Na NN NN O
( NN NN O
+ NN NN O
) NN NN O
-dependent NN NN O
absorption NN NN O
of NN NN O
glucose NN NN O
in NN NN O
the NN NN O
brush NN NN O
border NN NN O
. NN NN O

Normal NN NN O
glucose NN NN O
absorption NN NN O
is NN NN O
mediated NN NN O
by NN NN O
the NN NN O
Na NN NN O
+ NN NN O
/ NN NN O
glucose NN NN O
cotransporter NN NN O
in NN NN O
the NN NN O
brush NN NN O
border NN NN O
membrane NN NN O
of NN NN O
the NN NN O
intestinal NN NN O
epithelium NN NN O
. NN NN O

Cellular NN NN O
influx NN NN O
is NN NN O
driven NN NN O
by NN NN O
the NN NN O
transmembrane NN NN O
Na NN NN O
+ NN NN O
electrochemical NN NN O
potential NN NN O
gradient NN NN O
; NN NN O
thereafter NN NN O
the NN NN O
sugar NN NN O
moves NN NN O
to NN NN O
the NN NN O
blood NN NN O
across NN NN O
the NN NN O
basolateral NN NN O
membrane NN NN O
via NN NN O
the NN NN O
facilitated NN NN O
glucose NN NN O
carrier NN NN O
. NN NN O

We NN NN O
have NN NN O
previously NN NN O
cloned NN NN O
and NN NN O
sequenced NN NN O
a NN NN O
Na NN NN O
+ NN NN O
/ NN NN O
glucose NN NN O
cotransporter NN NN O
from NN NN O
normal NN NN O
human NN NN O
ileum NN NN O
and NN NN O
shown NN NN O
that NN NN O
this NN NN O
gene NN NN O
, NN NN O
SGLT1 NN NN O
, NN NN O
resides NN NN O
on NN NN O
the NN NN O
distal NN NN O
q NN NN O
arm NN NN O
of NN NN O
chromosome NN NN O
22 NN NN O
. NN NN O

We NN NN O
have NN NN O
now NN NN O
amplified NN NN O
SGLT1 NN NN O
complementary NN NN O
DNA NN NN O
and NN NN O
genomic NN NN O
DNA NN NN O
from NN NN O
members NN NN O
of NN NN O
a NN NN O
family NN NN O
affected NN NN O
with NN NN O
GGM NN NN B-SpecificDisease
by NN NN O
the NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
. NN NN O

Sequence NN NN O
analysis NN NN O
of NN NN O
the NN NN O
amplified NN NN O
products NN NN O
has NN NN O
revealed NN NN O
a NN NN O
single NN NN O
missense NN NN O
mutation NN NN O
in NN NN O
SGLT1 NN NN O
which NN NN O
cosegregates NN NN O
with NN NN O
the NN NN O
GGM NN NN B-Modifier
phenotype NN NN O
and NN NN O
results NN NN O
in NN NN O
a NN NN O
complete NN NN O
loss NN NN O
of NN NN O
Na NN NN O
( NN NN O
+ NN NN O
) NN NN O
-dependent NN NN O
glucose NN NN O
transport NN NN O
in NN NN O
Xenopus NN NN O
oocytes NN NN O
injected NN NN O
with NN NN O
this NN NN O
complementary NN NN O
RNA NN NN O
. NN NN O

. NN NN O

2016095 NN NN O
A NN NN O
de NN NN O
novo NN NN O
unbalanced NN NN O
reciprocal NN NN O
translocation NN NN O
identified NN NN O
as NN NN O
paternal NN NN O
in NN NN O
origin NN NN O
in NN NN O
the NN NN O
Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

Interstitial NN NN O
cytogenetic NN NN O
deletions NN NN O
involving NN NN O
the NN NN O
paternally NN NN O
derived NN NN O
chromosome NN NN O
15q11-13 NN NN O
have NN NN O
been NN NN O
described NN NN O
in NN NN O
patients NN NN O
with NN NN O
the NN NN O
Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
PWS NN NN B-SpecificDisease
) NN NN O
. NN NN O

We NN NN O
report NN NN O
a NN NN O
child NN NN O
with NN NN O
PWS NN NN B-SpecificDisease
and NN NN O
a NN NN O
de NN NN O
novo NN NN O
unbalanced NN NN O
karyotype NN NN O
-45 NN NN O
, NN NN O
XY NN NN O
, NN NN O
-9 NN NN O
, NN NN O
-15 NN NN O
, NN NN O
+ NN NN O
der NN NN O
( NN NN O
9 NN NN O
) NN NN O
t NN NN O
( NN NN O
9 NN NN O
; NN NN O
15 NN NN O
) NN NN O
( NN NN O
q34 NN NN O
; NN NN O
q13 NN NN O
) NN NN O
. NN NN O

Molecular NN NN O
studies NN NN O
with NN NN O
the NN NN O
DNA NN NN O
probe NN NN O
pML34 NN NN O
confirmed NN NN O
that NN NN O
only NN NN O
a NN NN O
single NN NN O
Prader NN NN B-Modifier
Willi NN NN I-Modifier
critical NN NN O
region NN NN O
( NN NN O
PWCR NN NN O
15q11 NN NN O
. NN NN O

2-q12 NN NN O
) NN NN O
copy NN NN O
was NN NN O
present NN NN O
. NN NN O

Hybridisation NN NN O
of NN NN O
patient NN NN O
and NN NN O
parental NN NN O
DNA NN NN O
with NN NN O
the NN NN O
multi-allelic NN NN O
probe NN NN O
CMW1 NN NN O
, NN NN O
which NN NN O
maps NN NN O
to NN NN O
pter-15q13 NN NN O
, NN NN O
showed NN NN O
that NN NN O
the NN NN O
chromosome NN NN O
involved NN NN O
in NN NN O
the NN NN O
translocation NN NN O
was NN NN O
paternal NN NN O
in NN NN O
origin NN NN O
. NN NN O

This NN NN O
is NN NN O
the NN NN O
first NN NN O
example NN NN O
of NN NN O
a NN NN O
paternally-derived NN NN O
PWCR NN NN O
allele NN NN O
loss NN NN O
caused NN NN O
by NN NN O
an NN NN O
unbalanced NN NN O
translocation NN NN O
that NN NN O
has NN NN O
arisen NN NN O
de NN NN O
novo NN NN O
. NN NN O

2037285 NN NN O
Localisation NN NN O
of NN NN O
the NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
locus NN NN O
to NN NN O
19q13.2-19q13.3 NN NN O
and NN NN O
its NN NN O
relationship NN NN O
to NN NN O
twelve NN NN O
polymorphic NN NN O
loci NN NN O
on NN NN O
19q NN NN O
. NN NN O

The NN NN O
order NN NN O
of NN NN O
fourteen NN NN O
polymorphic NN NN O
markers NN NN O
localised NN NN O
to NN NN O
the NN NN O
long NN NN O
arm NN NN O
of NN NN O
human NN NN O
chromosome NN NN O
19 NN NN O
has NN NN O
been NN NN O
established NN NN O
by NN NN O
multipoint NN NN O
mapping NN NN O
in NN NN O
a NN NN O
set NN NN O
of NN NN O
40 NN NN O
CEPH NN NN O
( NN NN O
Centre NN NN O
dEtude NN NN O
de NN NN O
Polymorphisme NN NN O
Humain NN NN O
, NN NN O
Paris NN NN O
) NN NN O
reference NN NN O
families NN NN O
. NN NN O

We NN NN O
report NN NN O
here NN NN O
the NN NN O
linkage NN NN O
relationship NN NN O
of NN NN O
the NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
( NN NN O
DM NN NN B-Modifier
) NN NN O
locus NN NN O
to NN NN O
twelve NN NN O
of NN NN O
these NN NN O
markers NN NN O
as NN NN O
studied NN NN O
in NN NN O
45 NN NN O
families NN NN O
with NN NN O
DM NN NN B-SpecificDisease
. NN NN O

The NN NN O
resulting NN NN O
genetic NN NN O
map NN NN O
is NN NN O
supported NN NN O
by NN NN O
the NN NN O
localisation NN NN O
of NN NN O
the NN NN O
DNA NN NN O
markers NN NN O
in NN NN O
a NN NN O
panel NN NN O
of NN NN O
somatic NN NN O
cell NN NN O
hybrids NN NN O
. NN NN O

Ten NN NN O
of NN NN O
the NN NN O
twelve NN NN O
markers NN NN O
have NN NN O
been NN NN O
shown NN NN O
to NN NN O
be NN NN O
proximal NN NN O
to NN NN O
the NN NN O
DM NN NN B-Modifier
gene NN NN O
and NN NN O
two NN NN O
, NN NN O
PRKCG NN NN O
and NN NN O
D19S22 NN NN O
, NN NN O
distal NN NN O
but NN NN O
at NN NN O
distances NN NN O
of NN NN O
approximately NN NN O
25 NN NN O
cM NN NN O
and NN NN O
15 NN NN O
cM NN NN O
, NN NN O
respectively NN NN O
. NN NN O

The NN NN O
closest NN NN O
proximal NN NN O
markers NN NN O
are NN NN O
APOC2 NN NN O
( NN NN O
apolipoprotein NN NN O
C-II NN NN O
) NN NN O
and NN NN O
CKM NN NN O
( NN NN O
creatine NN NN O
kinase NN NN O
, NN NN O
muscle NN NN O
) NN NN O
approximately NN NN O
3 NN NN O
cM NN NN O
and NN NN O
2 NN NN O
cM NN NN O
from NN NN O
the NN NN O
DM NN NN B-Modifier
gene NN NN O
respectively NN NN O
, NN NN O
in NN NN O
the NN NN O
order NN NN O
APOC2-CKM-DM NN NN O
. NN NN O

The NN NN O
distance NN NN O
between NN NN O
APOC2 NN NN O
, NN NN O
CKM NN NN O
and NN NN O
DM NN NN B-SpecificDisease
( NN NN O
of NN NN O
the NN NN O
order NN NN O
of NN NN O
2 NN NN O
million NN NN O
base NN NN O
pairs NN NN O
) NN NN O
and NN NN O
their NN NN O
known NN NN O
orientation NN NN O
should NN NN O
permit NN NN O
directional NN NN O
chromosome NN NN O
walking NN NN O
and NN NN O
jumping NN NN O
. NN NN O

The NN NN O
data NN NN O
presented NN NN O
here NN NN O
should NN NN O
enable NN NN O
us NN NN O
to NN NN O
determine NN NN O
whether NN NN O
or NN NN O
not NN NN O
new NN NN O
markers NN NN O
are NN NN O
distal NN NN O
to NN NN O
APOC2 NN NN O
/ NN NN O
CKM NN NN O
and NN NN O
thus NN NN O
potentially NN NN O
flank NN NN O
the NN NN O
DM NN NN B-Modifier
gene NN NN O
. NN NN O

. NN NN O

2055114 NN NN O
Localization NN NN O
of NN NN O
histidase NN NN O
to NN NN O
human NN NN O
chromosome NN NN O
region NN NN O
12q22 NN NN O
-- NN NN O
-- NN NN O
q24.1 NN NN O
and NN NN O
mouse NN NN O
chromosome NN NN O
region NN NN O
10C2 NN NN O
-- NN NN O
-- NN NN O
D1 NN NN O
. NN NN O

The NN NN O
human NN NN O
gene NN NN O
for NN NN O
histidase NN NN O
( NN NN O
histidine NN NN O
ammonia-lyase NN NN O
; NN NN O
HAL NN NN O
) NN NN O
, NN NN O
the NN NN O
enzyme NN NN O
deficient NN NN O
in NN NN O
histidinemia NN NN B-SpecificDisease
, NN NN O
was NN NN O
assigned NN NN O
to NN NN O
human NN NN O
chromosome NN NN O
12 NN NN O
by NN NN O
Southern NN NN O
blot NN NN O
analysis NN NN O
of NN NN O
human NN NN O
X NN NN O
mouse NN NN O
somatic NN NN O
cell NN NN O
hybrid NN NN O
DNA NN NN O
. NN NN O

The NN NN O
gene NN NN O
was NN NN O
sublocalized NN NN O
to NN NN O
region NN NN O
12q22 NN NN O
-- NN NN O
-- NN NN O
q24 NN NN O
. NN NN O

1 NN NN O
by NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
, NN NN O
using NN NN O
a NN NN O
human NN NN O
histidase NN NN O
cDNA NN NN O
. NN NN O

The NN NN O
homologous NN NN O
locus NN NN O
in NN NN O
the NN NN O
mouse NN NN O
( NN NN O
Hal NN NN O
) NN NN O
was NN NN O
mapped NN NN O
to NN NN O
region NN NN O
10C2 NN NN O
-- NN NN O
-- NN NN O
D1 NN NN O
by NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
, NN NN O
using NN NN O
a NN NN O
cell NN NN O
line NN NN O
from NN NN O
a NN NN O
mouse NN NN O
homozygous NN NN O
for NN NN O
a NN NN O
1 NN NN O
. NN NN O

10 NN NN O
Robertsonian NN NN O
translocation NN NN O
. NN NN O

These NN NN O
assignments NN NN O
extend NN NN O
the NN NN O
conserved NN NN O
syntenic NN NN O
region NN NN O
between NN NN O
human NN NN O
chromosome NN NN O
12 NN NN O
and NN NN O
mouse NN NN O
chromosome NN NN O
10 NN NN O
that NN NN O
includes NN NN O
the NN NN O
genes NN NN O
for NN NN O
phenylalanine NN NN O
hydroxylase NN NN O
, NN NN O
gamma NN NN O
interferon NN NN O
, NN NN O
peptidase NN NN O
, NN NN O
and NN NN O
citrate NN NN O
synthase NN NN O
. NN NN O

The NN NN O
localization NN NN O
of NN NN O
histidase NN NN O
to NN NN O
mouse NN NN O
chromosome NN NN O
10 NN NN O
suggests NN NN O
that NN NN O
the NN NN O
histidase NN NN O
regulatory NN NN O
locus NN NN O
( NN NN O
Hsd NN NN O
) NN NN O
and NN NN O
the NN NN O
histidinemia NN NN O
mutation NN NN O
( NN NN O
his NN NN O
) NN NN O
, NN NN O
which NN NN O
are NN NN O
both NN NN O
known NN NN O
to NN NN O
be NN NN O
on NN NN O
chromosome NN NN O
10 NN NN O
, NN NN O
may NN NN O
be NN NN O
alleles NN NN O
of NN NN O
the NN NN O
histidase NN NN O
structural NN NN O
gene NN NN O
locus NN NN O
. NN NN O

2071157 NN NN O
Determination NN NN O
of NN NN O
the NN NN O
mutations NN NN O
responsible NN NN O
for NN NN O
the NN NN O
Lesch-Nyhan NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
in NN NN O
17 NN NN O
subjects NN NN O
. NN NN O

Hypoxanthine NN NN O
-- NN NN O
guanine NN NN O
phosphoribosyltransferase NN NN O
( NN NN O
HPRT NN NN O
) NN NN O
is NN NN O
a NN NN O
purine NN NN O
salvage NN NN O
enzyme NN NN O
that NN NN O
catalyzes NN NN O
the NN NN O
conversion NN NN O
of NN NN O
hypoxanthine NN NN O
to NN NN O
inosine NN NN O
monophosphate NN NN O
and NN NN O
guanine NN NN O
to NN NN O
guanosine NN NN O
monophosphate NN NN O
. NN NN O

Previous NN NN O
studies NN NN O
of NN NN O
mutant NN NN O
HPRT NN NN O
proteins NN NN O
analyzed NN NN O
at NN NN O
the NN NN O
molecular NN NN O
level NN NN O
have NN NN O
shown NN NN O
a NN NN O
significant NN NN O
heterogeneity NN NN O
. NN NN O

This NN NN O
investigation NN NN O
further NN NN O
verifies NN NN O
this NN NN O
heterogeneity NN NN O
and NN NN O
identifies NN NN O
insertions NN NN O
, NN NN O
deletions NN NN O
, NN NN O
and NN NN O
point NN NN O
mutations NN NN O
. NN NN O

The NN NN O
direct NN NN O
sequencing NN NN O
of NN NN O
the NN NN O
polymerase NN NN O
chain NN NN O
reaction-amplified NN NN O
product NN NN O
of NN NN O
reverse-transcribed NN NN O
HPRT NN NN O
mRNA NN NN O
enabled NN NN O
the NN NN O
rapid NN NN O
identification NN NN O
of NN NN O
the NN NN O
mutations NN NN O
found NN NN O
in NN NN O
17 NN NN O
previously NN NN O
uncharacterized NN NN O
cell NN NN O
lines NN NN O
derived NN NN O
from NN NN O
patients NN NN O
with NN NN O
the NN NN O
Lesch-Nyhan NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

. NN NN O

2161209 NN NN O
Linkage NN NN O
of NN NN O
DNA NN NN O
markers NN NN O
at NN NN O
Xq28 NN NN O
to NN NN O
adrenoleukodystrophy NN NN B-SpecificDisease
and NN NN O
adrenomyeloneuropathy NN NN B-SpecificDisease
present NN NN O
within NN NN O
the NN NN O
same NN NN O
family NN NN O
. NN NN O

We NN NN O
present NN NN O
a NN NN O
large NN NN O
kindred NN NN O
that NN NN O
contained NN NN O
patients NN NN O
with NN NN O
either NN NN O
adrenoleukodystrophy NN NN B-SpecificDisease
( NN NN O
ALD NN NN B-SpecificDisease
) NN NN O
or NN NN O
adrenomyeloneuropathy NN NN B-SpecificDisease
( NN NN O
AMN NN NN B-SpecificDisease
) NN NN O
. NN NN O

The NN NN O
pedigree NN NN O
clearly NN NN O
supported NN NN O
the NN NN O
X-linked NN NN O
mode NN NN O
of NN NN O
inheritance NN NN O
of NN NN O
the NN NN O
nonneonatal NN NN O
form NN NN O
of NN NN O
ALD NN NN B-SpecificDisease
/ NN NN O
AMN NN NN B-SpecificDisease
. NN NN O

Analysis NN NN O
with NN NN O
DNA NN NN O
markers NN NN O
at NN NN O
Xq28 NN NN O
suggested NN NN O
segregation NN NN O
of NN NN O
both NN NN O
ALD NN NN B-SpecificDisease
and NN NN O
AMN NN NN B-SpecificDisease
with NN NN O
an NN NN O
identical NN NN O
haplotype NN NN O
. NN NN O

This NN NN O
indicated NN NN O
that NN NN O
nonneonatal NN NN O
ALD NN NN B-SpecificDisease
and NN NN O
AMN NN NN B-SpecificDisease
are NN NN O
caused NN NN O
by NN NN O
a NN NN O
mutation NN NN O
in NN NN O
the NN NN O
same NN NN O
gene NN NN O
at NN NN O
Xq28 NN NN O
. NN NN O

It NN NN O
showed NN NN O
, NN NN O
furthermore NN NN O
, NN NN O
that NN NN O
phenotypic NN NN O
differences NN NN O
between NN NN O
ALD NN NN B-SpecificDisease
and NN NN O
AMN NN NN B-SpecificDisease
are NN NN O
not NN NN O
necessarily NN NN O
the NN NN O
consequence NN NN O
of NN NN O
allelic NN NN O
heterogeneity NN NN O
due NN NN O
to NN NN O
different NN NN O
mutations NN NN O
within NN NN O
the NN NN O
same NN NN O
gene NN NN O
. NN NN O

The NN NN O
maximal NN NN O
lod NN NN O
score NN NN O
for NN NN O
linkage NN NN O
of NN NN O
the NN NN O
ALD NN NN B-Modifier
/ NN NN O
AMN NN NN B-Modifier
gene NN NN O
and NN NN O
the NN NN O
multiallelic NN NN O
anonymous NN NN O
DNA NN NN O
marker NN NN O
at NN NN O
DXS52 NN NN O
was NN NN O
3 NN NN O
. NN NN O

0 NN NN O
at NN NN O
a NN NN O
recombination NN NN O
fraction NN NN O
of NN NN O
0 NN NN O
. NN NN O

00 NN NN O
. NN NN O

This NN NN O
made NN NN O
a NN NN O
prenatal NN NN O
or NN NN O
presymptomatic NN NN O
diagnosis NN NN O
and NN NN O
heterozygote NN NN O
detection NN NN O
by NN NN O
DNA NN NN O
analysis NN NN O
with NN NN O
this NN NN O
marker NN NN O
reliable NN NN O
. NN NN O

2180286 NN NN O
Skewed NN NN O
X NN NN O
inactivation NN NN O
in NN NN O
a NN NN O
female NN NN O
MZ NN NN O
twin NN NN O
results NN NN O
in NN NN O
Duchenne NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
. NN NN O

One NN NN O
of NN NN O
female NN NN O
MZ NN NN O
twins NN NN O
presented NN NN O
with NN NN O
muscular NN NN B-DiseaseClass
dystrophy NN NN I-DiseaseClass
. NN NN O

Physical NN NN O
examination NN NN O
, NN NN O
creatine NN NN O
phosphokinase NN NN O
levels NN NN O
, NN NN O
and NN NN O
muscle NN NN O
biopsy NN NN O
were NN NN O
consistent NN NN O
with NN NN O
Duchenne NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DMD NN NN B-SpecificDisease
) NN NN O
. NN NN O

However NN NN O
, NN NN O
because NN NN O
of NN NN O
her NN NN O
sex NN NN O
she NN NN O
was NN NN O
diagnosed NN NN O
as NN NN O
having NN NN O
limb-girdle NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
. NN NN O

With NN NN O
cDNA NN NN O
probes NN NN O
to NN NN O
the NN NN O
DMD NN NN B-Modifier
gene NN NN O
, NN NN O
a NN NN O
gene NN NN O
deletion NN NN O
was NN NN O
detected NN NN O
in NN NN O
the NN NN O
twins NN NN O
and NN NN O
their NN NN O
mother NN NN O
. NN NN O

The NN NN O
de NN NN O
novo NN NN O
mutation NN NN O
which NN NN O
arose NN NN O
in NN NN O
the NN NN O
mother NN NN O
was NN NN O
shown NN NN O
by NN NN O
novel NN NN O
junction NN NN O
fragments NN NN O
generated NN NN O
by NN NN O
HindIII NN NN O
, NN NN O
PstI NN NN O
, NN NN O
or NN NN O
TaqI NN NN O
when NN NN O
probed NN NN O
with NN NN O
cDNA8 NN NN O
. NN NN O

Additional NN NN O
evidence NN NN O
of NN NN O
a NN NN O
large NN NN O
gene NN NN O
deletion NN NN O
was NN NN O
given NN NN O
by NN NN O
novel NN NN O
SfiI NN NN O
junction NN NN O
fragments NN NN O
detected NN NN O
by NN NN O
probes NN NN O
p20 NN NN O
, NN NN O
J-Bir NN NN O
, NN NN O
and NN NN O
J-66 NN NN O
on NN NN O
pulsed-field NN NN O
gel NN NN O
electrophoresis NN NN O
( NN NN O
PFGE NN NN O
) NN NN O
. NN NN O

Immunoblot NN NN O
analysis NN NN O
of NN NN O
muscle NN NN O
from NN NN O
the NN NN O
affected NN NN O
twin NN NN O
showed NN NN O
dystrophin NN NN O
of NN NN O
normal NN NN O
size NN NN O
but NN NN O
of NN NN O
reduced NN NN O
amount NN NN O
. NN NN O

Immunofluorescent NN NN O
visualization NN NN O
of NN NN O
dystrophin NN NN O
revealed NN NN O
foci NN NN O
of NN NN O
dystrophin-positive NN NN O
fibers NN NN O
adjacent NN NN O
to NN NN O
foci NN NN O
of NN NN O
dystrophin-negative NN NN O
fibers NN NN O
. NN NN O

These NN NN O
data NN NN O
indicate NN NN O
that NN NN O
the NN NN O
affected NN NN O
twin NN NN O
is NN NN O
a NN NN O
manifesting NN NN O
carrier NN NN O
of NN NN O
an NN NN O
abnormal NN NN O
DMD NN NN B-Modifier
gene NN NN O
, NN NN O
her NN NN O
myopathy NN NN B-DiseaseClass
being NN NN O
a NN NN O
direct NN NN O
result NN NN O
of NN NN O
underexpression NN NN O
of NN NN O
dystrophin NN NN O
. NN NN O

Cytogenetic NN NN O
analysis NN NN O
revealed NN NN O
normal NN NN O
karyotypes NN NN O
, NN NN O
eliminating NN NN O
the NN NN O
possibility NN NN O
of NN NN O
a NN NN O
translocation NN NN O
affecting NN NN O
DMD NN NN B-Modifier
gene NN NN O
function NN NN O
. NN NN O

Both NN NN O
linkage NN NN O
analysis NN NN O
and NN NN O
DNA NN NN O
fingerprint NN NN O
analysis NN NN O
revealed NN NN O
that NN NN O
each NN NN O
twin NN NN O
has NN NN O
two NN NN O
different NN NN O
X NN NN O
chromosomes NN NN O
, NN NN O
eliminating NN NN O
the NN NN O
possibility NN NN O
of NN NN O
uniparental NN NN B-SpecificDisease
disomy NN NN I-SpecificDisease
as NN NN O
a NN NN O
mechanism NN NN O
for NN NN O
DMD NN NN B-Modifier
expression NN NN O
. NN NN O

On NN NN O
the NN NN O
basis NN NN O
of NN NN O
methylation NN NN O
differences NN NN O
of NN NN O
the NN NN O
paternal NN NN O
and NN NN O
maternal NN NN O
X NN NN O
chromosomes NN NN O
in NN NN O
these NN NN O
MZ NN NN O
twins NN NN O
, NN NN O
we NN NN O
propose NN NN O
uneven NN NN O
lyonization NN NN O
( NN NN O
X NN NN O
chromosome NN NN O
inactivation NN NN O
) NN NN O
as NN NN O
the NN NN O
underlying NN NN O
mechanism NN NN O
for NN NN O
disease NN NN O
expression NN NN O
in NN NN O
the NN NN O
affected NN NN O
female NN NN O
. NN NN O

. NN NN O

218453 NN NN O
Adrenoleukodystrophy NN NN B-SpecificDisease
and NN NN O
adrenomyeloneuropathy NN NN B-SpecificDisease
associated NN NN O
with NN NN O
partial NN NN O
adrenal NN NN B-DiseaseClass
insufficiency NN NN I-DiseaseClass
in NN NN O
three NN NN O
generations NN NN O
of NN NN O
a NN NN O
kindred NN NN O
. NN NN O

Four NN NN O
cases NN NN O
of NN NN O
adrenoleukodystrophy NN NN B-SpecificDisease
( NN NN O
ALD NN NN B-SpecificDisease
) NN NN O
and NN NN O
one NN NN O
case NN NN O
of NN NN O
adrenomyeloneuropathy NN NN B-SpecificDisease
( NN NN O
AMN NN NN B-SpecificDisease
) NN NN O
have NN NN O
developed NN NN O
in NN NN O
a NN NN O
kindred NN NN O
over NN NN O
three NN NN O
generations NN NN O
demonstrating NN NN O
that NN NN O
AMN NN NN B-SpecificDisease
is NN NN O
a NN NN O
clinical NN NN O
variant NN NN O
of NN NN O
ALD NN NN B-SpecificDisease
. NN NN O

Pituitary-adrenal NN NN O
function NN NN O
studies NN NN O
were NN NN O
performed NN NN O
in NN NN O
10 NN NN O
family NN NN O
members NN NN O
, NN NN O
including NN NN O
two NN NN O
affected NN NN O
males NN NN O
and NN NN O
four NN NN O
females NN NN O
identified NN NN O
as NN NN O
carriers NN NN O
of NN NN O
ALD NN NN B-SpecificDisease
/ NN NN O
AMN NN NN B-SpecificDisease
. NN NN O

No NN NN O
pituitary-adrenal NN NN B-DiseaseClass
abnormality NN NN I-DiseaseClass
was NN NN O
found NN NN O
in NN NN O
the NN NN O
carriers NN NN O
. NN NN O

However NN NN O
, NN NN O
basal NN NN O
morning NN NN O
plasma NN NN O
adrenocorticotropic NN NN O
hormone NN NN O
( NN NN O
ACTH NN NN O
) NN NN O
levels NN NN O
were NN NN O
markedly NN NN O
elevated NN NN O
in NN NN O
the NN NN O
two NN NN O
males NN NN O
with NN NN O
ALD NN NN B-SpecificDisease
and NN NN O
AMN NN NN B-SpecificDisease
, NN NN O
despite NN NN O
the NN NN O
fact NN NN O
that NN NN O
they NN NN O
had NN NN O
no NN NN O
clinical NN NN O
signs NN NN O
of NN NN O
adrenal NN NN B-DiseaseClass
insufficiency NN NN I-DiseaseClass
and NN NN O
that NN NN O
morning NN NN O
plasma NN NN O
cortisol NN NN O
levels NN NN O
and NN NN O
their NN NN O
response NN NN O
to NN NN O
maximal NN NN O
exogenous NN NN O
ACTH NN NN O
stimulation NN NN O
appeared NN NN O
to NN NN O
be NN NN O
normal NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
the NN NN O
integrated NN NN O
24-hour NN NN O
response NN NN O
to NN NN O
the NN NN O
administration NN NN O
were NN NN O
also NN NN O
subnormal NN NN O
in NN NN O
these NN NN O
two NN NN O
cases NN NN O
. NN NN O

Thus NN NN O
, NN NN O
people NN NN O
with NN NN O
ALD NN NN B-SpecificDisease
and NN NN O
AMN NN NN B-SpecificDisease
may NN NN O
have NN NN O
subclinical NN NN O
partial NN NN O
adrenocrotical NN NN B-DiseaseClass
insufficiency NN NN I-DiseaseClass
. NN NN O

No NN NN O
other NN NN O
endocrinologic NN NN B-DiseaseClass
dysfunction NN NN I-DiseaseClass
was NN NN O
identified NN NN O
. NN NN O

. NN NN O

2209091 NN NN O
Regional NN NN O
localisation NN NN O
of NN NN O
the NN NN O
Friedreich NN NN B-Modifier
ataxia NN NN I-Modifier
locus NN NN O
to NN NN O
human NN NN O
chromosome NN NN O
9q13 NN NN O
-- NN NN O
-- NN NN O
q21.1 NN NN O
. NN NN O

We NN NN O
have NN NN O
previously NN NN O
assigned NN NN O
the NN NN O
Friedreich NN NN B-Modifier
ataxia NN NN I-Modifier
locus NN NN O
( NN NN O
FRDA NN NN O
) NN NN O
to NN NN O
chromosome NN NN O
9 NN NN O
; NN NN O
the NN NN O
current NN NN O
maximal NN NN O
lod NN NN O
score NN NN O
between NN NN O
FRDA NN NN O
and NN NN O
MCT112 NN NN O
( NN NN O
D9S15 NN NN O
) NN NN O
is NN NN O
greater NN NN O
than NN NN O
50 NN NN O
at NN NN O
a NN NN O
recombination NN NN O
fraction NN NN O
of NN NN O
theta NN NN O
= NN NN O
0 NN NN O
. NN NN O

The NN NN O
physical NN NN O
assignment NN NN O
of NN NN O
the NN NN O
locus NN NN O
defined NN NN O
by NN NN O
MCT112 NN NN O
, NN NN O
and NN NN O
hence NN NN O
FRDA NN NN O
, NN NN O
has NN NN O
not NN NN O
been NN NN O
determined NN NN O
, NN NN O
although NN NN O
linkage NN NN O
analysis NN NN O
of NN NN O
MCT112 NN NN O
with NN NN O
other NN NN O
chromosome NN NN O
9 NN NN O
markers NN NN O
inferred NN NN O
a NN NN O
location NN NN O
close NN NN O
to NN NN O
the NN NN O
centromere NN NN O
. NN NN O

We NN NN O
have NN NN O
used NN NN O
in NN NN O
situ NN NN O
hybridisation NN NN O
with NN NN O
MCT112 NN NN O
, NN NN O
a NN NN O
corresponding NN NN O
cosmid NN NN O
MJ1 NN NN O
, NN NN O
and NN NN O
DR47 NN NN O
( NN NN O
D9S5 NN NN O
) NN NN O
, NN NN O
coupled NN NN O
with NN NN O
mapping NN NN O
studies NN NN O
on NN NN O
hybrid NN NN O
cell NN NN O
panels NN NN O
, NN NN O
to NN NN O
define NN NN O
more NN NN O
precisely NN NN O
the NN NN O
location NN NN O
of NN NN O
the NN NN O
disease NN NN O
locus NN NN O
. NN NN O

The NN NN O
in NN NN O
situ NN NN O
location NN NN O
of NN NN O
all NN NN O
three NN NN O
probes NN NN O
is NN NN O
9q13 NN NN O
-- NN NN O
-- NN NN O
q21 NN NN O
. NN NN O

1 NN NN O
, NN NN O
distal NN NN O
to NN NN O
the NN NN O
variable NN NN O
heterochromatin NN NN O
region NN NN O
. NN NN O

Physical NN NN O
assignment NN NN O
of NN NN O
FRDA NN NN O
will NN NN O
allow NN NN O
us NN NN O
to NN NN O
identify NN NN O
hybrid NN NN O
cell NN NN O
lines NN NN O
containing NN NN O
the NN NN O
mutated NN NN O
gene NN NN O
. NN NN O

2215607 NN NN O
Increased NN NN O
high-density NN NN O
lipoprotein NN NN O
levels NN NN O
caused NN NN O
by NN NN O
a NN NN O
common NN NN O
cholesteryl-ester NN NN O
transfer NN NN O
protein NN NN O
gene NN NN O
mutation NN NN O
. NN NN O

BACKGROUND NN NN O
AND NN NN O
METHODS NN NN O
. NN NN O

The NN NN O
plasma NN NN O
cholesteryl-ester NN NN O
transfer NN NN O
protein NN NN O
( NN NN O
CETP NN NN O
) NN NN O
catalyzes NN NN O
the NN NN O
transfer NN NN O
of NN NN O
cholesteryl NN NN O
esters NN NN O
from NN NN O
high-density NN NN O
lipoprotein NN NN O
( NN NN O
HDL NN NN O
) NN NN O
to NN NN O
other NN NN O
lipoproteins NN NN O
. NN NN O

We NN NN O
recently NN NN O
described NN NN O
a NN NN O
Japanese NN NN O
family NN NN O
with NN NN O
increased NN NN O
HDL NN NN O
levels NN NN O
and NN NN O
CETP NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
due NN NN O
to NN NN O
a NN NN O
splicing NN NN O
defect NN NN O
of NN NN O
the NN NN O
CETP NN NN O
gene NN NN O
. NN NN O

To NN NN O
assess NN NN O
the NN NN O
frequency NN NN O
and NN NN O
phenotype NN NN O
of NN NN O
this NN NN O
condition NN NN O
, NN NN O
we NN NN O
screened NN NN O
11 NN NN O
additional NN NN O
families NN NN O
with NN NN O
high NN NN O
HDL NN NN O
levels NN NN O
by NN NN O
means NN NN O
of NN NN O
a NN NN O
radioimmunoassay NN NN O
for NN NN O
CETP NN NN O
and NN NN O
DNA NN NN O
analysis NN NN O
. NN NN O

RESULTS NN NN O
. NN NN O

We NN NN O
found NN NN O
the NN NN O
same NN NN O
CETP NN NN O
gene NN NN O
mutation NN NN O
in NN NN O
four NN NN O
families NN NN O
from NN NN O
three NN NN O
different NN NN O
regions NN NN O
of NN NN O
Japan NN NN O
. NN NN O

Analysis NN NN O
of NN NN O
restriction-fragment-length NN NN O
polymorphisms NN NN O
of NN NN O
the NN NN O
mutant NN NN O
CETP NN NN O
allele NN NN O
showed NN NN O
that NN NN O
all NN NN O
probands NN NN O
were NN NN O
homozygous NN NN O
for NN NN O
the NN NN O
identical NN NN O
haplotype NN NN O
. NN NN O

Family NN NN O
members NN NN O
homozygous NN NN O
for NN NN O
CETP NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
( NN NN O
n NN NN O
= NN NN O
10 NN NN O
) NN NN O
had NN NN O
moderate NN NN O
hypercholesterolemia NN NN B-SpecificDisease
( NN NN O
mean NN NN O
total NN NN O
cholesterol NN NN O
level NN NN O
[ NN NN O
+ NN NN O
/ NN NN O
- NN NN O
SD NN NN O
] NN NN O
, NN NN O
7 NN NN O
. NN NN O

01 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O

83 NN NN O
mmol NN NN O
per NN NN O
liter NN NN O
) NN NN O
, NN NN O
markedly NN NN O
increased NN NN O
levels NN NN O
of NN NN O
HDL NN NN O
cholesterol NN NN O
( NN NN O
4 NN NN O
. NN NN O

24 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
1 NN NN O
. NN NN O

01 NN NN O
mmol NN NN O
per NN NN O
liter NN NN O
) NN NN O
and NN NN O
apolipoprotein NN NN O
A-I NN NN O
, NN NN O
and NN NN O
decreased NN NN O
levels NN NN O
of NN NN O
low-density NN NN O
lipoprotein NN NN O
cholesterol NN NN O
( NN NN O
1 NN NN O
. NN NN O

99 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O

80 NN NN O
mmol NN NN O
per NN NN O
liter NN NN O
) NN NN O
and NN NN O
apolipoprotein NN NN O
B NN NN O
. NN NN O

Members NN NN O
heterozygous NN NN O
for NN NN O
the NN NN O
deficiency NN NN O
( NN NN O
n NN NN O
= NN NN O
20 NN NN O
) NN NN O
, NN NN O
whose NN NN O
CETP NN NN O
levels NN NN O
were NN NN O
in NN NN O
the NN NN O
lower NN NN O
part NN NN O
of NN NN O
the NN NN O
normal NN NN O
range NN NN O
, NN NN O
had NN NN O
moderately NN NN O
increased NN NN O
levels NN NN O
of NN NN O
HDL NN NN O
cholesterol NN NN O
and NN NN O
apolipoprotein NN NN O
A-I NN NN O
and NN NN O
an NN NN O
increased NN NN O
ratio NN NN O
of NN NN O
HDL NN NN O
subclass NN NN O
2 NN NN O
to NN NN O
HDL NN NN O
subclass NN NN O
3 NN NN O
, NN NN O
as NN NN O
compared NN NN O
with NN NN O
unaffected NN NN O
family NN NN O
members NN NN O
( NN NN O
1 NN NN O
. NN NN O

5 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O

8 NN NN O
vs NN NN O
. NN NN O

0 NN NN O
. NN NN O

7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O

4 NN NN O
) NN NN O
. NN NN O

CETP NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
was NN NN O
not NN NN O
found NN NN O
in NN NN O
six NN NN O
unrelated NN NN O
subjects NN NN O
with NN NN O
elevated NN NN O
HDL NN NN O
cholesterol NN NN O
levels NN NN O
who NN NN O
were NN NN O
from NN NN O
different NN NN O
parts NN NN O
of NN NN O
the NN NN O
United NN NN O
States NN NN O
. NN NN O

CONCLUSIONS NN NN O
. NN NN O

CETP NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
appears NN NN O
to NN NN O
be NN NN O
a NN NN O
frequent NN NN O
cause NN NN O
of NN NN O
increased NN NN O
HDL NN NN O
levels NN NN O
in NN NN O
the NN NN O
population NN NN O
of NN NN O
Japan NN NN O
, NN NN O
possibly NN NN O
because NN NN O
of NN NN O
a NN NN O
founder NN NN O
effect NN NN O
. NN NN O

The NN NN O
results NN NN O
that NN NN O
we NN NN O
observed NN NN O
in NN NN O
heterozygotes NN NN O
suggest NN NN O
that NN NN O
CETP NN NN O
normally NN NN O
plays NN NN O
a NN NN O
part NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
levels NN NN O
of NN NN O
HDL NN NN O
subclass NN NN O
2 NN NN O
. NN NN O

There NN NN O
was NN NN O
no NN NN O
evidence NN NN O
of NN NN O
premature NN NN B-SpecificDisease
atherosclerosis NN NN I-SpecificDisease
in NN NN O
the NN NN O
families NN NN O
with NN NN O
CETP NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

In NN NN O
fact NN NN O
, NN NN O
the NN NN O
lipoprotein NN NN O
profile NN NN O
of NN NN O
persons NN NN O
with NN NN O
CETP NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
is NN NN O
potentially NN NN O
antiatherogenic NN NN O
and NN NN O
may NN NN O
be NN NN O
associated NN NN O
with NN NN O
an NN NN O
increased NN NN O
life NN NN O
span NN NN O
. NN NN O

2220826 NN NN O
Further NN NN O
mapping NN NN O
of NN NN O
an NN NN O
ataxia-telangiectasia NN NN B-Modifier
locus NN NN O
to NN NN O
the NN NN O
chromosome NN NN O
11q23 NN NN O
region NN NN O
. NN NN O

We NN NN O
recently NN NN O
mapped NN NN O
the NN NN O
gene NN NN O
for NN NN O
ataxia-telangiectasia NN NN B-Modifier
group NN NN O
A NN NN O
( NN NN O
ATA NN NN O
) NN NN O
to NN NN O
chromosome NN NN O
11q22-23 NN NN O
by NN NN O
linkage NN NN O
analysis NN NN O
, NN NN O
using NN NN O
the NN NN O
genetic NN NN O
markers NN NN O
THY1 NN NN O
and NN NN O
pYNB3 NN NN O
. NN NN O

12 NN NN O
( NN NN O
D11S144 NN NN O
) NN NN O
. NN NN O

The NN NN O
most NN NN O
likely NN NN O
order NN NN O
was NN NN O
cent-AT-S144-THY1 NN NN O
. NN NN O

The NN NN O
present NN NN O
paper NN NN O
describes NN NN O
further NN NN O
mapping NN NN O
of NN NN O
the NN NN O
AT NN NN B-Modifier
locus NN NN O
by NN NN O
means NN NN O
of NN NN O
a NN NN O
panel NN NN O
of NN NN O
10 NN NN O
markers NN NN O
that NN NN O
span NN NN O
approximately NN NN O
60 NN NN O
cM NN NN O
in NN NN O
the NN NN O
11q22-23 NN NN O
region NN NN O
centered NN NN O
around NN NN O
S144 NN NN O
and NN NN O
THY1 NN NN O
. NN NN O

Location NN NN O
scores NN NN O
indicate NN NN O
that NN NN O
three NN NN O
contiguous NN NN O
subsegments NN NN O
within NN NN O
the NN NN O
[ NN NN O
S144-THY1 NN NN O
] NN NN O
segment NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
three NN NN O
contiguous NN NN O
segments NN NN O
telomeric NN NN O
to NN NN O
THY1 NN NN O
, NN NN O
are NN NN O
each NN NN O
unlikely NN NN O
to NN NN O
contain NN NN O
the NN NN O
AT NN NN B-Modifier
locus NN NN O
, NN NN O
while NN NN O
the NN NN O
more NN NN O
centromeric NN NN O
[ NN NN O
STMY-S144 NN NN O
] NN NN O
segment NN NN O
is NN NN O
most NN NN O
likely NN NN O
to NN NN O
contain NN NN O
the NN NN O
AT NN NN B-Modifier
locus NN NN O
. NN NN O

These NN NN O
data NN NN O
, NN NN O
together NN NN O
with NN NN O
recent NN NN O
refinements NN NN O
in NN NN O
the NN NN O
linkage NN NN O
and NN NN O
physical NN NN O
maps NN NN O
of NN NN O
11q22-23 NN NN O
, NN NN O
place NN NN O
the NN NN O
AT NN NN B-Modifier
locus NN NN O
at NN NN O
11q23 NN NN O
. NN NN O

2241452 NN NN O
Recurrent NN NN O
meningitis NN NN B-SpecificDisease
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
congenital NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
C9 NN NN I-SpecificDisease
component NN NN I-SpecificDisease
of NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
. NN NN O

First NN NN O
case NN NN O
of NN NN O
C9 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
Europe NN NN O
. NN NN O

We NN NN O
describe NN NN O
the NN NN O
first NN NN O
cases NN NN O
, NN NN O
to NN NN O
our NN NN O
knowledge NN NN O
, NN NN O
of NN NN O
C9 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
Europe NN NN O
that NN NN O
were NN NN O
detected NN NN O
in NN NN O
a NN NN O
Swiss NN NN O
family NN NN O
, NN NN O
of NN NN O
which NN NN O
two NN NN O
members NN NN O
-- NN NN O
one NN NN O
with NN NN O
a NN NN O
complete NN NN O
deficiency NN NN O
and NN NN O
the NN NN O
other NN NN O
with NN NN O
approximately NN NN O
half-normal NN NN O
C9 NN NN O
levels NN NN O
-- NN NN O
experienced NN NN O
bacterial NN NN B-SpecificDisease
meningitis NN NN I-SpecificDisease
. NN NN O

The NN NN O
index NN NN O
patient NN NN O
, NN NN O
a NN NN O
56-year-old NN NN O
white NN NN O
man NN NN O
with NN NN O
a NN NN O
history NN NN O
of NN NN O
purulent NN NN B-SpecificDisease
meningitis NN NN I-SpecificDisease
at NN NN O
the NN NN O
age NN NN O
of NN NN O
23 NN NN O
years NN NN O
, NN NN O
presented NN NN O
with NN NN O
an NN NN O
acute NN NN B-SpecificDisease
meningococcal NN NN I-SpecificDisease
meningitis NN NN I-SpecificDisease
. NN NN O

No NN NN O
impairment NN NN B-DiseaseClass
of NN NN I-DiseaseClass
cellular NN NN I-DiseaseClass
immunity NN NN I-DiseaseClass
or NN NN O
immunoglobulin NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
could NN NN O
be NN NN O
found NN NN O
. NN NN O

Complement NN NN O
assays NN NN O
showed NN NN O
a NN NN O
complete NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
C9 NN NN I-SpecificDisease
component NN NN I-SpecificDisease
, NN NN O
while NN NN O
the NN NN O
other NN NN O
individual NN NN O
component NN NN O
levels NN NN O
were NN NN O
normal NN NN O
and NN NN O
the NN NN O
hemolytic NN NN O
activity NN NN O
( NN NN O
measured NN NN O
using NN NN O
the NN NN O
CH50 NN NN O
assay NN NN O
) NN NN O
was NN NN O
only NN NN O
slightly NN NN O
reduced NN NN O
. NN NN O

A NN NN O
family NN NN O
study NN NN O
revealed NN NN O
complete NN NN B-SpecificDisease
C9 NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
the NN NN O
patients NN NN O
healthy NN NN O
brother NN NN O
and NN NN O
half-normal NN NN O
C9 NN NN O
concentrations NN NN O
in NN NN O
his NN NN O
sister NN NN O
, NN NN O
his NN NN O
son NN NN O
( NN NN O
who NN NN O
also NN NN O
had NN NN O
experienced NN NN O
an NN NN O
episode NN NN O
of NN NN O
bacterial NN NN B-SpecificDisease
meningitis NN NN I-SpecificDisease
) NN NN O
, NN NN O
and NN NN O
his NN NN O
niece NN NN O
, NN NN O
consistent NN NN O
with NN NN O
an NN NN O
inherited NN NN O
C9 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

This NN NN O
first NN NN O
case NN NN O
of NN NN O
recurrent NN NN B-SpecificDisease
meningitis NN NN I-SpecificDisease
in NN NN O
a NN NN O
white NN NN O
patient NN NN O
with NN NN O
complete NN NN B-SpecificDisease
C9 NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
suggests NN NN O
that NN NN O
this NN NN O
complement NN NN B-DiseaseClass
defect NN NN I-DiseaseClass
may NN NN O
also NN NN O
be NN NN O
a NN NN O
risk NN NN O
factor NN NN O
for NN NN O
bacterial NN NN B-DiseaseClass
, NN NN I-DiseaseClass
especially NN NN I-DiseaseClass
neisserial NN NN I-DiseaseClass
, NN NN I-DiseaseClass
infections NN NN I-DiseaseClass
. NN NN O

. NN NN O

2253937 NN NN O
Detection NN NN O
of NN NN O
98 NN NN O
% NN NN O
of NN NN O
DMD NN NN B-Modifier
/ NN NN O
BMD NN NN B-Modifier
gene NN NN O
deletions NN NN O
by NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
. NN NN O

We NN NN O
describe NN NN O
oligonucleotide NN NN O
primer NN NN O
sequences NN NN O
that NN NN O
can NN NN O
be NN NN O
used NN NN O
to NN NN O
amplify NN NN O
eight NN NN O
exons NN NN O
plus NN NN O
the NN NN O
muscle NN NN O
promoter NN NN O
of NN NN O
the NN NN O
dystrophin NN NN O
gene NN NN O
in NN NN O
a NN NN O
single NN NN O
multiplex NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
( NN NN O
PCR NN NN O
) NN NN O
. NN NN O

When NN NN O
used NN NN O
in NN NN O
conjunction NN NN O
with NN NN O
an NN NN O
existing NN NN O
primer NN NN O
set NN NN O
, NN NN O
these NN NN O
two NN NN O
multiplex NN NN O
reactions NN NN O
detect NN NN O
about NN NN O
98 NN NN O
% NN NN O
of NN NN O
deletions NN NN O
in NN NN O
patients NN NN O
with NN NN O
Duchenne NN NN B-CompositeMention
or NN NN I-CompositeMention
Becker NN NN I-CompositeMention
muscular NN NN I-CompositeMention
dystrophy NN NN I-CompositeMention
( NN NN O
DMD NN NN B-SpecificDisease
, NN NN O
BMD NN NN B-SpecificDisease
) NN NN O
. NN NN O

Furthermore NN NN O
, NN NN O
these NN NN O
primers NN NN O
amplify NN NN O
most NN NN O
of NN NN O
the NN NN O
exons NN NN O
in NN NN O
the NN NN O
deletion NN NN O
prone NN NN O
`` NN NN O
hot NN NN O
spot NN NN O
`` NN NN O
region NN NN O
around NN NN O
exons NN NN O
44 NN NN O
to NN NN O
53 NN NN O
, NN NN O
allowing NN NN O
determination NN NN O
of NN NN O
deletion NN NN O
endpoints NN NN O
and NN NN O
prediction NN NN O
of NN NN O
mutational NN NN O
effects NN NN O
on NN NN O
the NN NN O
translational NN NN O
reading NN NN O
frame NN NN O
. NN NN O

Thus NN NN O
, NN NN O
use NN NN O
of NN NN O
these NN NN O
PCR-based NN NN O
assays NN NN O
will NN NN O
allow NN NN O
deletion NN NN O
detection NN NN O
and NN NN O
prenatal NN NN O
diagnosis NN NN O
for NN NN O
most NN NN O
DMD NN NN B-Modifier
/ NN NN O
BMD NN NN B-Modifier
patients NN NN O
in NN NN O
a NN NN O
fraction NN NN O
of NN NN O
the NN NN O
time NN NN O
required NN NN O
for NN NN O
Southern NN NN O
blot NN NN O
analysis NN NN O
. NN NN O

. NN NN O

2253938 NN NN O
Genetic NN NN O
heterogeneity NN NN O
at NN NN O
the NN NN O
glucose-6-phosphate NN NN O
dehydrogenase NN NN O
locus NN NN O
in NN NN O
southern NN NN O
Italy NN NN O
: NN NN O
a NN NN O
study NN NN O
on NN NN O
a NN NN O
population NN NN O
from NN NN O
the NN NN O
Matera NN NN O
district NN NN O
. NN NN O

Glucose-6-phosphate NN NN O
dehydrogenase NN NN O
( NN NN O
G6PD NN NN O
) NN NN O
has NN NN O
been NN NN O
analyzed NN NN O
by NN NN O
gel NN NN O
electrophoresis NN NN O
and NN NN O
by NN NN O
quantitative NN NN O
assay NN NN O
in NN NN O
an NN NN O
unselected NN NN O
sample NN NN O
of NN NN O
1524 NN NN O
schoolboys NN NN O
from NN NN O
the NN NN O
province NN NN O
of NN NN O
Matera NN NN O
( NN NN O
Lucania NN NN O
) NN NN O
in NN NN O
southern NN NN O
Italy NN NN O
. NN NN O

We NN NN O
have NN NN O
identified NN NN O
43 NN NN O
subjects NN NN O
with NN NN O
a NN NN O
G6PD NN NN O
variant NN NN O
. NN NN O

Of NN NN O
these NN NN O
, NN NN O
31 NN NN O
had NN NN O
severe NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
, NN NN O
nine NN NN O
had NN NN O
mild NN NN O
to NN NN O
moderate NN NN O
deficiency NN NN O
, NN NN O
and NN NN O
three NN NN O
had NN NN O
a NN NN O
non-deficient NN NN O
electrophoretic NN NN O
variant NN NN O
. NN NN O

The NN NN O
overall NN NN O
rate NN NN O
of NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
was NN NN O
2 NN NN O
. NN NN O

6 NN NN O
% NN NN O
. NN NN O

The NN NN O
frequency NN NN O
of NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
, NN NN O
ranging NN NN O
from NN NN O
7 NN NN O
. NN NN O

2 NN NN O
% NN NN O
on NN NN O
the NN NN O
Ionian NN NN O
Coast NN NN O
to NN NN O
zero NN NN O
on NN NN O
the NN NN O
eastern NN NN O
side NN NN O
of NN NN O
the NN NN O
Lucanian NN NN O
Apennines NN NN O
, NN NN O
appears NN NN O
to NN NN O
be NN NN O
inversely NN NN O
related NN NN O
to NN NN O
the NN NN O
distance NN NN O
of NN NN O
each NN NN O
town NN NN O
examined NN NN O
from NN NN O
the NN NN O
Ionian NN NN O
Coast NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
this NN NN O
geographic NN NN O
distribution NN NN O
may NN NN O
reflect NN NN O
, NN NN O
at NN NN O
least NN NN O
in NN NN O
part NN NN O
, NN NN O
gene NN NN O
flow NN NN O
from NN NN O
Greek NN NN O
settlers NN NN O
. NN NN O

Biochemical NN NN O
characterization NN NN O
has NN NN O
shown NN NN O
that NN NN O
most NN NN O
of NN NN O
the NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
this NN NN O
population NN NN O
is NN NN O
accounted NN NN O
for NN NN O
by NN NN O
G6PD NN NN O
Mediterranean NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
we NN NN O
have NN NN O
found NN NN O
several NN NN O
examples NN NN O
of NN NN O
two NN NN O
other NN NN O
known NN NN O
polymorphic NN NN O
variants NN NN O
( NN NN O
G6PD NN NN O
Cagliari NN NN O
and NN NN O
G6PD NN NN O
A- NN NN O
) NN NN O
; NN NN O
three NN NN O
new NN NN O
polymorphic NN NN O
variants NN NN O
, NN NN O
G6PD NN NN O
Metaponto NN NN O
( NN NN O
class NN NN O
III NN NN O
) NN NN O
, NN NN O
G6PD NN NN O
Montalbano NN NN O
( NN NN O
class NN NN O
III NN NN O
) NN NN O
, NN NN O
and NN NN O
G6PD NN NN O
Pisticci NN NN O
( NN NN O
class NN NN O
IV NN NN O
) NN NN O
; NN NN O
and NN NN O
two NN NN O
sporadic NN NN O
variants NN NN O
, NN NN O
G6PD NN NN O
Tursi NN NN O
( NN NN O
class NN NN O
III NN NN O
) NN NN O
and NN NN O
G6PD NN NN O
Ferrandina NN NN O
( NN NN O
class NN NN O
II NN NN O
) NN NN O
. NN NN O

These NN NN O
data NN NN O
provide NN NN O
further NN NN O
evidence NN NN O
for NN NN O
the NN NN O
marked NN NN O
genetic NN NN O
heterogeneity NN NN O
of NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
within NN NN O
a NN NN O
relatively NN NN O
narrow NN NN O
geographic NN NN O
area NN NN O
and NN NN O
they NN NN O
prove NN NN O
the NN NN O
presence NN NN O
in NN NN O
the NN NN O
Italian NN NN O
peninsula NN NN O
of NN NN O
a NN NN O
gene NN NN O
( NN NN O
GdA- NN NN O
) NN NN O
regarded NN NN O
as NN NN O
characteristically NN NN O
African NN NN O
. NN NN O

2303408 NN NN O
Deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
murine NN NN I-SpecificDisease
fifth NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
component NN NN I-SpecificDisease
( NN NN I-SpecificDisease
C5 NN NN I-SpecificDisease
) NN NN I-SpecificDisease
. NN NN O

A NN NN O
2-base NN NN O
pair NN NN O
gene NN NN O
deletion NN NN O
in NN NN O
a NN NN O
5'-exon NN NN O
. NN NN O

To NN NN O
ascertain NN NN O
the NN NN O
molecular NN NN O
mechanism NN NN O
that NN NN O
causes NN NN O
murine NN NN O
C5 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
, NN NN O
genomic NN NN O
and NN NN O
cDNA NN NN O
libraries NN NN O
were NN NN O
constructed NN NN O
from NN NN O
mouse NN NN O
liver NN NN O
DNA NN NN O
and NN NN O
mRNA NN NN O
employing NN NN O
the NN NN O
congenic NN NN O
strains NN NN O
B10 NN NN O
. NN NN O

D2 NN NN O
/ NN NN O
nSnJ NN NN O
and NN NN O
B10 NN NN O
. NN NN O

D2 NN NN O
/ NN NN O
oSnJ NN NN O
that NN NN O
are NN NN O
sufficient NN NN O
and NN NN O
deficient NN NN B-SpecificDisease
for NN NN I-SpecificDisease
C5 NN NN I-SpecificDisease
, NN NN O
respectively NN NN O
. NN NN O

Genomic NN NN O
fragments NN NN O
were NN NN O
isolated NN NN O
which NN NN O
correspond NN NN O
to NN NN O
PvuII NN NN O
and NN NN O
HindIII NN NN O
restriction NN NN O
fragment NN NN O
length NN NN O
polymorphisms NN NN O
associated NN NN O
with NN NN O
C5 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

Sequence NN NN O
analyses NN NN O
demonstrated NN NN O
that NN NN O
each NN NN O
of NN NN O
these NN NN O
polymorphisms NN NN O
resulted NN NN O
from NN NN O
single NN NN O
base NN NN O
pair NN NN O
substitutions NN NN O
and NN NN O
that NN NN O
neither NN NN O
substitution NN NN O
would NN NN O
probably NN NN O
cause NN NN O
or NN NN O
contribute NN NN O
to NN NN O
the NN NN O
C5 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

Sequence NN NN O
analyses NN NN O
of NN NN O
C5 NN NN O
sufficient NN NN O
and NN NN O
deficient NN NN O
cDNAs NN NN O
revealed NN NN O
a NN NN O
2 NN NN O
base-pair NN NN O
deletion NN NN O
in NN NN O
the NN NN O
deficient NN NN O
cDNAs NN NN O
. NN NN O

The NN NN O
`` NN NN O
TA NN NN O
`` NN NN O
deletion NN NN O
was NN NN O
located NN NN O
near NN NN O
the NN NN O
5 NN NN O
end NN NN O
of NN NN O
the NN NN O
cDNA NN NN O
. NN NN O

This NN NN O
deletion NN NN O
shifts NN NN O
the NN NN O
reading NN NN O
frame NN NN O
of NN NN O
the NN NN O
C5 NN NN O
mRNA NN NN O
so NN NN O
that NN NN O
the NN NN O
termination NN NN O
codon NN NN O
UGA NN NN O
is NN NN O
present NN NN O
4 NN NN O
base NN NN O
pairs NN NN O
downstream NN NN O
from NN NN O
the NN NN O
deletion NN NN O
. NN NN O

Genomic NN NN O
DNA NN NN O
was NN NN O
amplified NN NN O
and NN NN O
sequenced NN NN O
corresponding NN NN O
to NN NN O
the NN NN O
area NN NN O
surrounding NN NN O
the NN NN O
2-base NN NN O
pair NN NN O
deletion NN NN O
. NN NN O

Six NN NN O
C5-deficient NN NN B-Modifier
strains NN NN O
, NN NN O
A NN NN O
/ NN NN O
HeJ NN NN O
, NN NN O
AKR NN NN O
/ NN NN O
J NN NN O
, NN NN O
DBA NN NN O
/ NN NN O
2J NN NN O
, NN NN O
NZB NN NN O
/ NN NN O
B1NJ NN NN O
, NN NN O
SWR NN NN O
/ NN NN O
J NN NN O
, NN NN O
and NN NN O
B10 NN NN O
. NN NN O

D2 NN NN O
/ NN NN O
oSnJ NN NN O
, NN NN O
and NN NN O
four NN NN O
C5-sufficient NN NN O
strains NN NN O
, NN NN O
Balb NN NN O
/ NN NN O
CJ NN NN O
, NN NN O
C57Bl NN NN O
/ NN NN O
6J NN NN O
, NN NN O
DBA NN NN O
/ NN NN O
1J NN NN O
, NN NN O
and NN NN O
B10 NN NN O
. NN NN O

D2 NN NN O
/ NN NN O
nSnJ NN NN O
, NN NN O
were NN NN O
analyzed NN NN O
. NN NN O

The NN NN O
sequencing NN NN O
data NN NN O
revealed NN NN O
that NN NN O
the NN NN O
2 NN NN O
base NN NN O
pairs NN NN O
were NN NN O
deleted NN NN O
from NN NN O
the NN NN O
C5 NN NN O
gene NN NN O
of NN NN O
each NN NN O
deficient NN NN O
mouse NN NN O
tested NN NN O
but NN NN O
not NN NN O
from NN NN O
the NN NN O
C5 NN NN O
gene NN NN O
of NN NN O
any NN NN O
sufficient NN NN O
mouse NN NN O
. NN NN O

These NN NN O
data NN NN O
demonstrate NN NN O
that NN NN O
1 NN NN O
) NN NN O
there NN NN O
is NN NN O
an NN NN O
identical NN NN O
2-base NN NN O
pair NN NN O
deletion NN NN O
in NN NN O
an NN NN O
exon NN NN O
of NN NN O
the NN NN O
C5 NN NN O
gene NN NN O
in NN NN O
several NN NN O
different NN NN O
C5-deficient NN NN B-Modifier
mouse NN NN O
strains NN NN O
; NN NN O
2 NN NN O
) NN NN O
the NN NN O
mRNA NN NN O
transcribed NN NN O
from NN NN O
the NN NN O
C5D NN NN O
gene NN NN O
retains NN NN O
this NN NN O
deletion NN NN O
; NN NN O
and NN NN O
3 NN NN O
) NN NN O
this NN NN O
mutation NN NN O
should NN NN O
result NN NN O
in NN NN O
C5 NN NN B-SpecificDisease
protein NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

2309142 NN NN O
Molecular NN NN O
genetics NN NN O
of NN NN O
PKU NN NN B-SpecificDisease
in NN NN O
eastern NN NN O
Europe NN NN O
: NN NN O
a NN NN O
nonsense NN NN O
mutation NN NN O
associated NN NN O
with NN NN O
haplotype NN NN O
4 NN NN O
of NN NN O
the NN NN O
phenylalanine NN NN O
hydroxylase NN NN O
gene NN NN O
. NN NN O

Phenylketonuria NN NN B-SpecificDisease
( NN NN O
PKU NN NN B-SpecificDisease
) NN NN O
is NN NN O
a NN NN O
genetic NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
secondary NN NN O
to NN NN O
a NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
hepatic NN NN I-SpecificDisease
phenylalanine NN NN I-SpecificDisease
hydroxylase NN NN I-SpecificDisease
( NN NN O
PAH NN NN O
) NN NN O
. NN NN O

Several NN NN O
mutations NN NN O
in NN NN O
the NN NN O
PAH NN NN O
gene NN NN O
have NN NN O
recently NN NN O
been NN NN O
reported NN NN O
, NN NN O
and NN NN O
linkage NN NN O
disequilibrium NN NN O
was NN NN O
observed NN NN O
between NN NN O
RFLP NN NN O
haplotypes NN NN O
and NN NN O
specific NN NN O
mutations NN NN O
. NN NN O

A NN NN O
new NN NN O
molecular NN NN B-DiseaseClass
lesion NN NN I-DiseaseClass
has NN NN O
been NN NN O
identified NN NN O
in NN NN O
exon NN NN O
7 NN NN O
of NN NN O
the NN NN O
PAH NN NN O
gene NN NN O
in NN NN O
a NN NN O
Hungarian NN NN O
PKU NN NN B-Modifier
patient NN NN O
by NN NN O
direct NN NN O
sequencing NN NN O
of NN NN O
PCR-amplified NN NN O
DNA NN NN O
. NN NN O

The NN NN O
C-to-T NN NN O
transition NN NN O
causes NN NN O
the NN NN O
substitution NN NN O
of NN NN O
Arg243 NN NN O
to NN NN O
a NN NN O
termination NN NN O
codon NN NN O
, NN NN O
and NN NN O
the NN NN O
mutant NN NN O
allele NN NN O
is NN NN O
associated NN NN O
with NN NN O
haplotype NN NN O
4 NN NN O
of NN NN O
the NN NN O
PAH NN NN O
gene NN NN O
. NN NN O

The NN NN O
mutation NN NN O
is NN NN O
present NN NN O
in NN NN O
two NN NN O
of NN NN O
nine NN NN O
mutant NN NN O
haplotype NN NN O
4 NN NN O
alleles NN NN O
among NN NN O
Eastern NN NN O
Europeans NN NN O
and NN NN O
is NN NN O
not NN NN O
present NN NN O
among NN NN O
Western NN NN O
Europeans NN NN O
and NN NN O
Asians NN NN O
. NN NN O

The NN NN O
rarity NN NN O
of NN NN O
this NN NN O
mutant NN NN O
allele NN NN O
and NN NN O
its NN NN O
restricted NN NN O
geographic NN NN O
distribution NN NN O
suggest NN NN O
that NN NN O
the NN NN O
mutational NN NN O
event NN NN O
occurred NN NN O
recently NN NN O
on NN NN O
a NN NN O
normal NN NN O
haplotype NN NN O
4 NN NN O
background NN NN O
in NN NN O
Eastern NN NN O
Europe NN NN O
. NN NN O

. NN NN O

2309698 NN NN O
The NN NN O
red-green NN NN O
visual NN NN O
pigment NN NN O
gene NN NN O
region NN NN O
in NN NN O
adrenoleukodystrophy NN NN B-SpecificDisease
. NN NN O

Although NN NN O
recent NN NN O
data NN NN O
established NN NN O
that NN NN O
a NN NN O
specific NN NN O
very-long-chain NN NN O
fatty NN NN O
acyl-CoA NN NN O
synthetase NN NN O
is NN NN O
defective NN NN O
in NN NN O
X-linked NN NN B-SpecificDisease
adrenoleukodystrophy NN NN I-SpecificDisease
( NN NN O
ALD NN NN B-SpecificDisease
) NN NN O
, NN NN O
the NN NN O
ALD NN NN B-Modifier
gene NN NN O
is NN NN O
still NN NN O
unidentified NN NN O
. NN NN O

The NN NN O
ALD NN NN B-Modifier
locus NN NN O
has NN NN O
been NN NN O
mapped NN NN O
to NN NN O
Xq28 NN NN O
, NN NN O
like NN NN O
the NN NN O
red NN NN O
and NN NN O
green NN NN O
color NN NN O
pigment NN NN O
genes NN NN O
. NN NN O

Abnormal NN NN B-DiseaseClass
color NN NN I-DiseaseClass
vision NN NN I-DiseaseClass
has NN NN O
been NN NN O
observed NN NN O
in NN NN O
12 NN NN O
of NN NN O
27 NN NN O
patients NN NN O
with NN NN O
adrenomyeloneuropathy NN NN B-SpecificDisease
( NN NN O
AMN NN NN B-SpecificDisease
) NN NN O
, NN NN O
a NN NN O
milder NN NN O
form NN NN O
of NN NN O
ALD NN NN B-SpecificDisease
. NN NN O

Furthermore NN NN O
, NN NN O
rearrangements NN NN O
of NN NN O
the NN NN O
color NN NN O
vision NN NN O
gene NN NN O
cluster NN NN O
were NN NN O
found NN NN O
in NN NN O
four NN NN O
of NN NN O
eight NN NN O
ALD NN NN B-Modifier
kindreds NN NN O
. NN NN O

This NN NN O
led NN NN O
us NN NN O
to NN NN O
propose NN NN O
that NN NN O
a NN NN O
single NN NN O
DNA NN NN O
rearrangement NN NN O
could NN NN O
underlie NN NN O
both NN NN O
ALD NN NN B-SpecificDisease
and NN NN O
abnormal NN NN B-SpecificDisease
color NN NN I-SpecificDisease
vision NN NN I-SpecificDisease
in NN NN O
these NN NN O
patients NN NN O
. NN NN O

Study NN NN O
of NN NN O
34 NN NN O
French NN NN O
ALD NN NN B-Modifier
patients NN NN O
failed NN NN O
to NN NN O
reveal NN NN O
a NN NN O
higher NN NN O
than NN NN O
expected NN NN O
frequency NN NN O
of NN NN O
green NN NN O
/ NN NN O
red NN NN O
visual NN NN O
pigment NN NN O
rearrangements NN NN O
3 NN NN O
to NN NN O
the NN NN O
red NN NN O
/ NN NN O
green NN NN O
color NN NN O
vision NN NN O
gene NN NN O
complex NN NN O
. NN NN O

The NN NN O
previous NN NN O
report NN NN O
of NN NN O
such NN NN O
rearrangements NN NN O
was NN NN O
based NN NN O
on NN NN O
small NN NN O
numbers NN NN O
and NN NN O
lack NN NN O
of NN NN O
knowledge NN NN O
that NN NN O
the NN NN O
frequency NN NN O
of NN NN O
`` NN NN O
abnormal NN NN O
`` NN NN O
color NN NN O
vision NN NN O
arrays NN NN O
on NN NN O
molecular NN NN O
analysis NN NN O
was NN NN O
twice NN NN O
as NN NN O
high NN NN O
as NN NN O
expected NN NN O
on NN NN O
the NN NN O
basis NN NN O
of NN NN O
the NN NN O
frequency NN NN O
of NN NN O
phenotypic NN NN B-SpecificDisease
color NN NN I-SpecificDisease
vision NN NN I-SpecificDisease
defects NN NN I-SpecificDisease
. NN NN O

The NN NN O
red NN NN O
/ NN NN O
green NN NN O
color NN NN O
pigment NN NN O
( NN NN O
R NN NN O
/ NN NN O
GCP NN NN O
) NN NN O
region NN NN O
was NN NN O
studied NN NN O
by NN NN O
pulsed-field NN NN O
gel NN NN O
electrophoresis NN NN O
in NN NN O
14 NN NN O
of NN NN O
these NN NN O
patients NN NN O
, NN NN O
and NN NN O
we NN NN O
did NN NN O
not NN NN O
find NN NN O
any NN NN O
fragment NN NN O
size NN NN O
difference NN NN O
between NN NN O
the NN NN O
patients NN NN O
and NN NN O
normal NN NN O
individuals NN NN O
who NN NN O
have NN NN O
the NN NN O
same NN NN O
number NN NN O
of NN NN O
pigment NN NN O
genes NN NN O
. NN NN O

The NN NN O
R NN NN O
/ NN NN O
GCP NN NN O
region NN NN O
was NN NN O
also NN NN O
analyzed NN NN O
in NN NN O
29 NN NN O
French NN NN O
and NN NN O
seven NN NN O
North NN NN O
American NN NN O
ALD NN NN B-Modifier
patients NN NN O
by NN NN O
using NN NN O
six NN NN O
genomic NN NN O
DNA NN NN O
probes NN NN O
, NN NN O
isolated NN NN O
from NN NN O
a NN NN O
cosmid NN NN O
walk NN NN O
, NN NN O
that NN NN O
flank NN NN O
the NN NN O
color NN NN O
vision NN NN O
genes NN NN O
. NN NN O

No NN NN O
deletions NN NN O
were NN NN O
found NN NN O
with NN NN O
probes NN NN O
that NN NN O
lie NN NN O
3 NN NN O
of NN NN O
the NN NN O
green NN NN O
pigment NN NN O
genes NN NN O
. NN NN O

One NN NN O
of NN NN O
the NN NN O
eight NN NN O
previously NN NN O
reported NN NN O
ALD NN NN B-Modifier
individuals NN NN O
has NN NN O
a NN NN O
long NN NN O
deletion NN NN O
5 NN NN O
of NN NN O
the NN NN O
red NN NN O
pigment NN NN O
gene NN NN O
, NN NN O
a NN NN O
deletion NN NN O
causing NN NN O
blue NN NN O
cone NN NN O
monochromacy NN NN O
. NN NN O

This NN NN O
finding NN NN O
and NN NN O
the NN NN O
previous NN NN O
findings NN NN O
of NN NN O
a NN NN O
45 NN NN O
% NN NN O
frequency NN NN O
of NN NN O
phenotypic NN NN O
color NN NN O
vision NN NN O
defects NN NN O
in NN NN O
patients NN NN O
with NN NN O
AMN NN NN B-SpecificDisease
may NN NN O
suggest NN NN O
that NN NN O
the NN NN O
ALD NN NN B-Modifier
/ NN NN O
AMN NN NN B-Modifier
gene NN NN O
lies NN NN O
5 NN NN O
to NN NN O
the NN NN O
red NN NN O
pigment NN NN O
gene NN NN O
and NN NN O
that NN NN O
the NN NN O
frequent NN NN O
phenotypic NN NN O
color NN NN B-DiseaseClass
vision NN NN I-DiseaseClass
anomalies NN NN I-DiseaseClass
owe NN NN O
their NN NN O
origin NN NN O
to NN NN O
deleted NN NN O
DNA NN NN O
that NN NN O
includes NN NN O
regulatory NN NN O
genes NN NN O
for NN NN O
color NN NN O
vision NN NN O
. NN NN O

It NN NN O
is NN NN O
possible NN NN O
, NN NN O
however NN NN O
, NN NN O
that NN NN O
phenotypic NN NN O
color NN NN B-DiseaseClass
vision NN NN I-DiseaseClass
anomalies NN NN I-DiseaseClass
in NN NN O
AMN NN NN B-SpecificDisease
may NN NN O
be NN NN O
phenocopies NN NN O
secondary NN NN O
to NN NN O
retinal NN NN O
or NN NN O
neural NN NN O
involvement NN NN O
by NN NN O
the NN NN O
disease NN NN O
. NN NN O

The NN NN O
single NN NN O
case NN NN O
of NN NN O
blue NN NN O
cone NN NN O
monochromacy NN NN O
may NN NN O
therefore NN NN O
be NN NN O
a NN NN O
fortuitous NN NN O
coincidence NN NN O
of NN NN O
two NN NN O
diseases NN NN O
. NN NN O

. NN NN O

2310692 NN NN O
Paroxysmal NN NN B-SpecificDisease
nocturnal NN NN I-SpecificDisease
haemoglobinuria NN NN I-SpecificDisease
with NN NN O
coexisting NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
ninth NN NN I-SpecificDisease
component NN NN I-SpecificDisease
of NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
: NN NN O
lack NN NN O
of NN NN O
massive NN NN O
haemolytic NN NN B-SpecificDisease
attack NN NN I-SpecificDisease
. NN NN O

A NN NN O
47-year-old NN NN O
woman NN NN O
with NN NN O
paroxysmal NN NN B-SpecificDisease
nocturnal NN NN I-SpecificDisease
haemoglobinuria NN NN I-SpecificDisease
( NN NN O
PNH NN NN B-SpecificDisease
) NN NN O
was NN NN O
found NN NN O
to NN NN O
have NN NN O
an NN NN O
inherited NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN I-SpecificDisease
the NN NN I-SpecificDisease
ninth NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
component NN NN I-SpecificDisease
( NN NN O
C9 NN NN O
) NN NN O
. NN NN O

In NN NN O
complement-sensitivity NN NN O
lysis NN NN O
tests NN NN O
, NN NN O
80 NN NN O
% NN NN O
of NN NN O
her NN NN O
erythrocytes NN NN O
were NN NN O
markedly NN NN O
complement-sensitive NN NN O
( NN NN O
PNH-III NN NN O
) NN NN O
. NN NN O

Laser NN NN O
cytofluorimetry NN NN O
with NN NN O
a NN NN O
monoclonal NN NN O
antibody NN NN O
against NN NN O
decay-accelerating NN NN O
factor NN NN O
( NN NN O
DAF NN NN O
) NN NN O
revealed NN NN O
that NN NN O
95 NN NN O
% NN NN O
of NN NN O
her NN NN O
erythrocytes NN NN O
were NN NN O
DAF-negative NN NN O
. NN NN O

Surprisingly NN NN O
, NN NN O
she NN NN O
has NN NN O
suffered NN NN O
only NN NN O
mild NN NN O
haemolysis NN NN B-SpecificDisease
and NN NN O
has NN NN O
never NN NN O
experienced NN NN O
massive NN NN O
spontaneous NN NN O
haemolysis NN NN B-SpecificDisease
. NN NN O

Gross NN NN O
haemoglobinuria NN NN B-SpecificDisease
and NN NN O
jaundice NN NN B-SpecificDisease
occurred NN NN O
only NN NN O
after NN NN O
receiving NN NN O
postoperative NN NN O
transfusion NN NN O
of NN NN O
whole NN NN O
blood NN NN O
. NN NN O

In NN NN O
her NN NN O
serum NN NN O
, NN NN O
C9 NN NN O
was NN NN O
not NN NN O
detectable NN NN O
either NN NN O
by NN NN O
immunological NN NN O
or NN NN O
by NN NN O
functional NN NN O
assays NN NN O
. NN NN O

Both NN NN O
the NN NN O
Ham NN NN O
test NN NN O
and NN NN O
the NN NN O
sugar NN NN O
water NN NN O
test NN NN O
using NN NN O
normal NN NN O
human NN NN O
serum NN NN O
or NN NN O
plasma NN NN O
yielded NN NN O
marked NN NN O
haemolysis NN NN O
of NN NN O
the NN NN O
patients NN NN O
erythrocytes NN NN O
. NN NN O

When NN NN O
the NN NN O
patients NN NN O
serum NN NN O
or NN NN O
plasma NN NN O
was NN NN O
used NN NN O
, NN NN O
only NN NN O
a NN NN O
trace NN NN O
of NN NN O
lysis NN NN O
was NN NN O
detected NN NN O
. NN NN O

Addition NN NN O
of NN NN O
purified NN NN O
human NN NN O
C9 NN NN O
to NN NN O
her NN NN O
plasma NN NN O
fully NN NN O
restored NN NN O
haemolysis NN NN O
. NN NN O

These NN NN O
observations NN NN O
indicated NN NN O
that NN NN O
C9 NN NN O
may NN NN O
play NN NN O
a NN NN O
critical NN NN O
role NN NN O
in NN NN O
haemolytic NN NN B-DiseaseClass
attacks NN NN I-DiseaseClass
in NN NN O
patients NN NN O
with NN NN O
PNH NN NN B-SpecificDisease
and NN NN O
that NN NN O
characteristic NN NN O
haemolysis NN NN B-SpecificDisease
in NN NN O
PNH NN NN B-SpecificDisease
may NN NN O
be NN NN O
tempered NN NN O
by NN NN O
coexisting NN NN O
C9 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

. NN NN O

2316519 NN NN O
Duplicational NN NN O
mutation NN NN O
at NN NN O
the NN NN O
Duchenne NN NN B-Modifier
muscular NN NN I-Modifier
dystrophy NN NN I-Modifier
locus NN NN O
: NN NN O
its NN NN O
frequency NN NN O
, NN NN O
distribution NN NN O
, NN NN O
origin NN NN O
, NN NN O
and NN NN O
phenotypegenotype NN NN O
correlation NN NN O
. NN NN O

Partial NN NN O
gene NN NN O
deletion NN NN O
is NN NN O
the NN NN O
major NN NN O
cause NN NN O
of NN NN O
mutation NN NN O
leading NN NN O
to NN NN O
Duchenne NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DMD NN NN B-SpecificDisease
) NN NN O
and NN NN O
Becker NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
BMD NN NN B-SpecificDisease
) NN NN O
. NN NN O

Partial NN NN O
gene NN NN O
duplication NN NN O
has NN NN O
also NN NN O
been NN NN O
recognized NN NN O
in NN NN O
a NN NN O
few NN NN O
cases NN NN O
. NN NN O

We NN NN O
have NN NN O
conducted NN NN O
a NN NN O
survey NN NN O
for NN NN O
duplication NN NN O
in NN NN O
72 NN NN O
unrelated NN NN O
nondeletion NN NN O
patients NN NN O
, NN NN O
analyzed NN NN O
by NN NN O
Southern NN NN O
blot NN NN O
hybridization NN NN O
with NN NN O
clones NN NN O
representing NN NN O
the NN NN O
entire NN NN O
DMD NN NN B-Modifier
cDNA NN NN O
. NN NN O

With NN NN O
careful NN NN O
quantitative NN NN O
analysis NN NN O
of NN NN O
hybridization NN NN O
band NN NN O
intensity NN NN O
, NN NN O
10 NN NN O
cases NN NN O
were NN NN O
found NN NN O
to NN NN O
carry NN NN O
a NN NN O
duplication NN NN O
of NN NN O
part NN NN O
of NN NN O
the NN NN O
gene NN NN O
, NN NN O
a NN NN O
frequency NN NN O
of NN NN O
14 NN NN O
% NN NN O
for NN NN O
nondeletion NN NN O
cases NN NN O
( NN NN O
10 NN NN O
/ NN NN O
72 NN NN O
) NN NN O
, NN NN O
or NN NN O
6 NN NN O
% NN NN O
for NN NN O
all NN NN O
cases NN NN O
( NN NN O
10 NN NN O
/ NN NN O
181 NN NN O
) NN NN O
. NN NN O

The NN NN O
extent NN NN O
of NN NN O
these NN NN O
duplications NN NN O
has NN NN O
been NN NN O
characterized NN NN O
according NN NN O
to NN NN O
the NN NN O
published NN NN O
exon-containing NN NN O
HindIII NN NN O
fragment NN NN O
map NN NN O
, NN NN O
and NN NN O
in NN NN O
six NN NN O
of NN NN O
the NN NN O
10 NN NN O
duplications NN NN O
a NN NN O
novel NN NN O
restriction NN NN O
fragment NN NN O
that NN NN O
spanned NN NN O
the NN NN O
duplication NN NN O
junction NN NN O
was NN NN O
detected NN NN O
. NN NN O

The NN NN O
resulting NN NN O
translational NN NN O
reading NN NN O
frame NN NN O
of NN NN O
mRNA NN NN O
has NN NN O
been NN NN O
predicted NN NN O
for NN NN O
nine NN NN O
duplications NN NN O
. NN NN O

A NN NN O
shift NN NN O
of NN NN O
the NN NN O
reading NN NN O
frame NN NN O
was NN NN O
predicted NN NN O
in NN NN O
four NN NN O
of NN NN O
the NN NN O
six NN NN O
DMD NN NN B-Modifier
cases NN NN O
and NN NN O
in NN NN O
one NN NN O
of NN NN O
the NN NN O
two NN NN O
intermediate NN NN O
cases NN NN O
, NN NN O
while NN NN O
the NN NN O
reading NN NN O
frame NN NN O
remained NN NN O
uninterrupted NN NN O
in NN NN O
both NN NN O
BMD NN NN B-Modifier
cases NN NN O
. NN NN O

RFLP NN NN O
and NN NN O
quantitative NN NN O
Southern NN NN O
blot NN NN O
analyses NN NN O
revealed NN NN O
a NN NN O
grandpaternal NN NN O
origin NN NN O
of NN NN O
duplication NN NN O
in NN NN O
four NN NN O
families NN NN O
and NN NN O
grandmaternal NN NN O
origin NN NN O
in NN NN O
one NN NN O
family NN NN O
. NN NN O

In NN NN O
all NN NN O
five NN NN O
families NN NN O
, NN NN O
the NN NN O
duplication NN NN O
was NN NN O
found NN NN O
to NN NN O
originate NN NN O
from NN NN O
a NN NN O
single NN NN O
X NN NN O
chromosome NN NN O
. NN NN O

Unequal NN NN O
sister-chromatid NN NN O
exchange NN NN O
is NN NN O
proposed NN NN O
to NN NN O
be NN NN O
the NN NN O
mechanism NN NN O
for NN NN O
the NN NN O
formation NN NN O
of NN NN O
these NN NN O
duplications NN NN O
. NN NN O

. NN NN O

23402 NN NN O
Glucose NN NN O
6-phosphate NN NN O
dehydrogenase NN NN O
variants NN NN O
: NN NN O
Gd NN NN O
( NN NN O
+ NN NN O
) NN NN O
Alexandra NN NN O
associated NN NN O
with NN NN O
neonatal NN NN B-SpecificDisease
jaundice NN NN I-SpecificDisease
and NN NN O
Gd NN NN O
( NN NN O
- NN NN O
) NN NN O
Camperdown NN NN O
in NN NN O
a NN NN O
young NN NN O
man NN NN O
with NN NN O
lamellar NN NN B-SpecificDisease
cataracts NN NN I-SpecificDisease
. NN NN O

Two NN NN O
male NN NN O
subjects NN NN O
are NN NN O
described NN NN O
, NN NN O
with NN NN O
unusual NN NN O
clinical NN NN O
presentations NN NN O
and NN NN O
with NN NN O
hitherto NN NN O
undescribed NN NN O
G6PD NN NN O
variants NN NN O
. NN NN O

The NN NN O
first NN NN O
, NN NN O
of NN NN O
Italian NN NN O
extraction NN NN O
, NN NN O
suffered NN NN O
from NN NN O
severe NN NN O
neonatal NN NN B-SpecificDisease
jaundice NN NN I-SpecificDisease
following NN NN O
maternal NN NN O
ingestion NN NN O
of NN NN O
fresh NN NN O
broad NN NN O
beans NN NN O
( NN NN O
Vicia NN NN O
fava NN NN O
) NN NN O
both NN NN O
prenatally NN NN O
and NN NN O
postnatally NN NN O
the NN NN O
expression NN NN O
of NN NN O
the NN NN O
enzymatic NN NN O
defect NN NN O
was NN NN O
much NN NN O
more NN NN O
severe NN NN O
in NN NN O
the NN NN O
neonatal NN NN O
period NN NN O
than NN NN O
on NN NN O
retesting NN NN O
in NN NN O
adolescence NN NN O
, NN NN O
when NN NN O
biochemical NN NN O
characterization NN NN O
showed NN NN O
unique NN NN O
features NN NN O
which NN NN O
justify NN NN O
designation NN NN O
as NN NN O
a NN NN O
new NN NN O
variant NN NN O
Gd NN NN O
( NN NN O
+ NN NN O
) NN NN O
Alexandra NN NN O
. NN NN O

The NN NN O
second NN NN O
patient NN NN O
, NN NN O
a NN NN O
boy NN NN O
of NN NN O
Maltese NN NN O
extraction NN NN O
who NN NN O
was NN NN O
found NN NN O
to NN NN O
have NN NN O
bilateral NN NN B-SpecificDisease
lamellar NN NN I-SpecificDisease
cataracts NN NN I-SpecificDisease
at NN NN O
the NN NN O
age NN NN O
of NN NN O
4 NN NN O
years NN NN O
, NN NN O
was NN NN O
identified NN NN O
as NN NN O
G6PD NN NN B-SpecificDisease
deficient NN NN I-SpecificDisease
only NN NN O
as NN NN O
a NN NN O
result NN NN O
of NN NN O
a NN NN O
survey NN NN O
of NN NN O
children NN NN O
of NN NN O
Mediterranean NN NN O
origin NN NN O
with NN NN O
unexplained NN NN O
cataract NN NN B-Modifier
formation NN NN O
; NN NN O
he NN NN O
has NN NN O
approximately NN NN O
15 NN NN O
% NN NN O
of NN NN O
normal NN NN O
enzyme NN NN O
activity NN NN O
, NN NN O
with NN NN O
another NN NN O
unique NN NN O
combination NN NN O
of NN NN O
biochemical NN NN O
characteristics NN NN O
which NN NN O
has NN NN O
led NN NN O
to NN NN O
its NN NN O
designation NN NN O
as NN NN O
Gd NN NN O
( NN NN O
- NN NN O
) NN NN O
Camperdown NN NN O
. NN NN O

Although NN NN O
this NN NN O
association NN NN O
may NN NN O
be NN NN O
coincidental NN NN O
, NN NN O
it NN NN O
prompts NN NN O
further NN NN O
attention NN NN O
to NN NN O
the NN NN O
possibility NN NN O
that NN NN O
under NN NN O
certain NN NN O
circumstances NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
may NN NN O
favor NN NN O
cataract NN NN B-Modifier
formation NN NN O
. NN NN O

The NN NN O
two NN NN O
cases NN NN O
illustrate NN NN O
the NN NN O
value NN NN O
of NN NN O
characterization NN NN O
of NN NN O
the NN NN O
mutant NN NN O
enzyme NN NN O
whenever NN NN O
unexpected NN NN O
clinical NN NN O
or NN NN O
laboratory NN NN O
results NN NN O
are NN NN O
obtained NN NN O
. NN NN O

. NN NN O

2352258 NN NN O
Statistical NN NN O
analysis NN NN O
of NN NN O
the NN NN O
two NN NN O
stage NN NN O
mutation NN NN O
model NN NN O
in NN NN O
von NN NN B-SpecificDisease
Hippel-Lindau NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
, NN NN O
and NN NN O
in NN NN O
sporadic NN NN B-SpecificDisease
cerebellar NN NN I-SpecificDisease
haemangioblastoma NN NN I-SpecificDisease
and NN NN O
renal NN NN B-SpecificDisease
cell NN NN I-SpecificDisease
carcinoma NN NN I-SpecificDisease
. NN NN O

Analysis NN NN O
of NN NN O
the NN NN O
age NN NN O
incidence NN NN O
curves NN NN O
for NN NN O
unilateral NN NN B-CompositeMention
and NN NN I-CompositeMention
bilateral NN NN I-CompositeMention
retinoblastoma NN NN I-CompositeMention
led NN NN O
Knudson NN NN O
to NN NN O
propose NN NN O
that NN NN O
hereditary NN NN B-DiseaseClass
tumours NN NN I-DiseaseClass
may NN NN O
arise NN NN O
by NN NN O
a NN NN O
single NN NN O
event NN NN O
and NN NN O
sporadic NN NN B-DiseaseClass
tumours NN NN I-DiseaseClass
by NN NN O
a NN NN O
two NN NN O
stage NN NN O
mutation NN NN O
process NN NN O
. NN NN O

It NN NN O
has NN NN O
been NN NN O
suggested NN NN O
recently NN NN O
that NN NN O
sporadic NN NN B-SpecificDisease
renal NN NN I-SpecificDisease
cell NN NN I-SpecificDisease
carcinoma NN NN I-SpecificDisease
may NN NN O
arise NN NN O
from NN NN O
a NN NN O
two NN NN O
stage NN NN O
mutation NN NN O
process NN NN O
. NN NN O

We NN NN O
analysed NN NN O
the NN NN O
age NN NN O
incidence NN NN O
curves NN NN O
for NN NN O
symptomatic NN NN O
renal NN NN B-SpecificDisease
cell NN NN I-SpecificDisease
carcinoma NN NN I-SpecificDisease
( NN NN O
n NN NN O
= NN NN O
26 NN NN O
) NN NN O
and NN NN O
cerebellar NN NN B-SpecificDisease
haemangioblastoma NN NN I-SpecificDisease
( NN NN O
n NN NN O
= NN NN O
68 NN NN O
) NN NN O
in NN NN O
109 NN NN O
patients NN NN O
with NN NN O
von NN NN B-SpecificDisease
Hippel-Lindau NN NN I-SpecificDisease
( NN NN I-SpecificDisease
VHL NN NN I-SpecificDisease
) NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
, NN NN O
and NN NN O
compared NN NN O
them NN NN O
to NN NN O
104 NN NN O
patients NN NN O
with NN NN O
sporadic NN NN B-SpecificDisease
renal NN NN I-SpecificDisease
cell NN NN I-SpecificDisease
carcinoma NN NN I-SpecificDisease
and NN NN O
43 NN NN O
patients NN NN O
with NN NN O
sporadic NN NN B-SpecificDisease
cerebellar NN NN I-SpecificDisease
haemangioblastoma NN NN I-SpecificDisease
. NN NN O

The NN NN O
age NN NN O
incidence NN NN O
curves NN NN O
for NN NN O
renal NN NN B-SpecificDisease
cell NN NN I-SpecificDisease
carcinoma NN NN I-SpecificDisease
and NN NN O
cerebellar NN NN B-SpecificDisease
haemangioblastoma NN NN I-SpecificDisease
in NN NN O
VHL NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
were NN NN O
compatible NN NN O
with NN NN O
a NN NN O
single NN NN O
mutation NN NN O
model NN NN O
, NN NN O
whereas NN NN O
the NN NN O
age NN NN O
incidence NN NN O
curves NN NN O
for NN NN O
sporadic NN NN B-SpecificDisease
renal NN NN I-SpecificDisease
cell NN NN I-SpecificDisease
carcinoma NN NN I-SpecificDisease
and NN NN O
cerebellar NN NN B-SpecificDisease
haemangioblastoma NN NN I-SpecificDisease
suggested NN NN O
a NN NN O
two NN NN O
stage NN NN O
mutation NN NN O
process NN NN O
. NN NN O

These NN NN O
data NN NN O
are NN NN O
compatible NN NN O
with NN NN O
the NN NN O
VHL NN NN B-Modifier
gene NN NN O
functioning NN NN O
as NN NN O
a NN NN O
recessive NN NN O
tumour NN NN B-Modifier
suppressor NN NN O
gene NN NN O
. NN NN O

Sporadic NN NN B-SpecificDisease
cerebellar NN NN I-SpecificDisease
haemangioblastoma NN NN I-SpecificDisease
and NN NN O
some NN NN O
renal NN NN B-SpecificDisease
cell NN NN I-SpecificDisease
carcinoma NN NN I-SpecificDisease
may NN NN O
arise NN NN O
from NN NN O
somatic NN NN O
mutations NN NN O
inactivating NN NN O
both NN NN O
alleles NN NN O
at NN NN O
the NN NN O
VHL NN NN B-Modifier
locus NN NN O
. NN NN O

. NN NN O

2355960 NN NN O
Screening NN NN O
for NN NN O
carriers NN NN O
of NN NN O
Tay-Sachs NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
among NN NN O
Ashkenazi NN NN O
Jews NN NN O
. NN NN O

A NN NN O
comparison NN NN O
of NN NN O
DNA-based NN NN O
and NN NN O
enzyme-based NN NN O
tests NN NN O
. NN NN O

BACKGROUND NN NN O
AND NN NN O
METHODS NN NN O
. NN NN O

The NN NN O
prevention NN NN O
of NN NN O
Tay-Sachs NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
GM2 NN NN B-SpecificDisease
gangliosidosis NN NN I-SpecificDisease
, NN NN I-SpecificDisease
type NN NN I-SpecificDisease
1 NN NN I-SpecificDisease
) NN NN O
depends NN NN O
on NN NN O
the NN NN O
identification NN NN O
of NN NN O
carriers NN NN O
of NN NN O
the NN NN O
gene NN NN O
for NN NN O
this NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
. NN NN O

We NN NN O
compared NN NN O
the NN NN O
enzyme-based NN NN O
test NN NN O
widely NN NN O
used NN NN O
in NN NN O
screening NN NN O
for NN NN O
Tay-Sachs NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
with NN NN O
a NN NN O
test NN NN O
based NN NN O
on NN NN O
analysis NN NN O
of NN NN O
DNA NN NN O
. NN NN O

We NN NN O
developed NN NN O
methods NN NN O
to NN NN O
detect NN NN O
the NN NN O
three NN NN O
mutations NN NN O
in NN NN O
the NN NN O
HEXA NN NN O
gene NN NN O
that NN NN O
occur NN NN O
with NN NN O
high NN NN O
frequency NN NN O
among NN NN O
Ashkenazi NN NN O
Jews NN NN O
two NN NN O
mutations NN NN O
cause NN NN O
infantile NN NN O
Tay-Sachs NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
, NN NN O
and NN NN O
the NN NN O
third NN NN O
causes NN NN O
the NN NN O
adult-onset NN NN O
form NN NN O
of NN NN O
the NN NN O
disease NN NN O
. NN NN O

DNA NN NN O
segments NN NN O
containing NN NN O
these NN NN O
mutation NN NN O
sites NN NN O
were NN NN O
amplified NN NN O
with NN NN O
the NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
and NN NN O
analyzed NN NN O
for NN NN O
the NN NN O
presence NN NN O
of NN NN O
the NN NN O
mutations NN NN O
. NN NN O

RESULTS NN NN O
. NN NN O

Among NN NN O
62 NN NN O
Ashkenazi NN NN O
obligate NN NN O
carriers NN NN O
of NN NN O
Tay-Sachs NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
, NN NN O
the NN NN O
three NN NN O
specific NN NN O
mutations NN NN O
accounted NN NN O
for NN NN O
all NN NN O
but NN NN O
one NN NN O
of NN NN O
the NN NN O
mutant NN NN O
alleles NN NN O
( NN NN O
98 NN NN O
percent NN NN O
) NN NN O
. NN NN O

In NN NN O
216 NN NN O
Ashkenazi NN NN O
carriers NN NN O
identified NN NN O
by NN NN O
the NN NN O
enzyme NN NN O
test NN NN O
, NN NN O
DNA NN NN O
analysis NN NN O
showed NN NN O
that NN NN O
177 NN NN O
( NN NN O
82 NN NN O
percent NN NN O
) NN NN O
had NN NN O
one NN NN O
of NN NN O
the NN NN O
identified NN NN O
mutations NN NN O
. NN NN O

Of NN NN O
the NN NN O
177 NN NN O
, NN NN O
79 NN NN O
percent NN NN O
had NN NN O
the NN NN O
exon NN NN O
11 NN NN O
insertion NN NN O
mutation NN NN O
, NN NN O
18 NN NN O
percent NN NN O
had NN NN O
the NN NN O
intron NN NN O
12 NN NN O
splice-junction NN NN O
mutation NN NN O
, NN NN O
and NN NN O
3 NN NN O
percent NN NN O
had NN NN O
the NN NN O
less NN NN O
severe NN NN O
exon NN NN O
7 NN NN O
mutation NN NN O
associated NN NN O
with NN NN O
adult-onset NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
. NN NN O

The NN NN O
results NN NN O
of NN NN O
the NN NN O
enzyme NN NN O
tests NN NN O
in NN NN O
the NN NN O
39 NN NN O
subjects NN NN O
( NN NN O
18 NN NN O
percent NN NN O
) NN NN O
who NN NN O
were NN NN O
defined NN NN O
as NN NN O
carriers NN NN O
but NN NN O
in NN NN O
whom NN NN O
DNA NN NN O
analysis NN NN O
did NN NN O
not NN NN O
identify NN NN O
a NN NN O
mutant NN NN O
allele NN NN O
were NN NN O
probably NN NN O
false NN NN O
positive NN NN O
( NN NN O
although NN NN O
there NN NN O
remains NN NN O
some NN NN O
possibility NN NN O
of NN NN O
unidentified NN NN O
mutations NN NN O
) NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
of NN NN O
152 NN NN O
persons NN NN O
defined NN NN O
as NN NN O
noncarriers NN NN O
by NN NN O
the NN NN O
enzyme-based NN NN O
test NN NN O
, NN NN O
1 NN NN O
was NN NN O
identified NN NN O
as NN NN O
a NN NN O
carrier NN NN O
by NN NN O
DNA NN NN O
analysis NN NN O
( NN NN O
i NN NN O
. NN NN O

e NN NN O
e NN NN O
. NN NN O

, NN NN O
a NN NN O
false NN NN O
negative NN NN O
enzyme-test NN NN O
result NN NN O
) NN NN O
. NN NN O

CONCLUSIONS NN NN O
. NN NN O

The NN NN O
increased NN NN O
specificity NN NN O
and NN NN O
predictive NN NN O
value NN NN O
of NN NN O
the NN NN O
DNA-based NN NN O
test NN NN O
make NN NN O
it NN NN O
a NN NN O
useful NN NN O
adjunct NN NN O
to NN NN O
the NN NN O
diagnostic NN NN O
tests NN NN O
currently NN NN O
used NN NN O
to NN NN O
screen NN NN O
for NN NN O
carriers NN NN O
of NN NN O
Tay-Sachs NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

2390095 NN NN O
Total NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
of NN NN I-SpecificDisease
plasma NN NN I-SpecificDisease
cholesteryl NN NN I-SpecificDisease
ester NN NN I-SpecificDisease
transfer NN NN I-SpecificDisease
protein NN NN I-SpecificDisease
in NN NN O
subjects NN NN O
homozygous NN NN O
and NN NN O
heterozygous NN NN O
for NN NN O
the NN NN O
intron NN NN O
14 NN NN O
splicing NN NN O
defect NN NN O
. NN NN O

The NN NN O
molecular NN NN O
basis NN NN O
of NN NN O
cholesteryl NN NN B-SpecificDisease
ester NN NN I-SpecificDisease
transfer NN NN I-SpecificDisease
protein NN NN I-SpecificDisease
( NN NN I-SpecificDisease
CETP NN NN I-SpecificDisease
) NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
was NN NN O
investigated NN NN O
in NN NN O
4 NN NN O
unrelated NN NN O
CETP-deficient NN NN B-Modifier
families NN NN O
. NN NN O

The NN NN O
high NN NN O
density NN NN O
lipoprotein-cholesterol NN NN O
levels NN NN O
of NN NN O
the NN NN O
probands NN NN O
exceeded NN NN O
150 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
. NN NN O

The NN NN O
plasma NN NN O
of NN NN O
the NN NN O
probands NN NN O
was NN NN O
totally NN NN O
deficient NN NN O
in NN NN O
CETP NN NN O
activity NN NN O
and NN NN O
mass NN NN O
. NN NN O

The NN NN O
genomic NN NN O
DNA NN NN O
of NN NN O
the NN NN O
patients NN NN O
was NN NN O
amplified NN NN O
by NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
, NN NN O
using NN NN O
two NN NN O
oligonucleotide NN NN O
primers NN NN O
located NN NN O
in NN NN O
the NN NN O
intron NN NN O
12 NN NN O
and NN NN O
14 NN NN O
of NN NN O
the NN NN O
CETP NN NN O
gene NN NN O
, NN NN O
and NN NN O
the NN NN O
amplified NN NN O
products NN NN O
were NN NN O
directly NN NN O
sequenced NN NN O
. NN NN O

Two NN NN O
patients NN NN O
were NN NN O
homozygous NN NN O
for NN NN O
a NN NN O
G-to-A NN NN O
change NN NN O
at NN NN O
the NN NN O
5-splice NN NN O
donor NN NN O
site NN NN O
of NN NN O
the NN NN O
intron NN NN O
14 NN NN O
. NN NN O

The NN NN O
G-to-A NN NN O
change NN NN O
would NN NN O
cause NN NN O
impaired NN NN O
splicing NN NN O
of NN NN O
pre-messenger NN NN O
RNA NN NN O
. NN NN O

The NN NN O
other NN NN O
two NN NN O
probands NN NN O
were NN NN O
heterozygous NN NN O
for NN NN O
the NN NN O
mutation NN NN O
, NN NN O
but NN NN O
totally NN NN O
lacked NN NN O
CETP NN NN O
. NN NN O

Their NN NN O
lipoprotein NN NN O
patterns NN NN O
were NN NN O
also NN NN O
similar NN NN O
to NN NN O
those NN NN O
of NN NN O
the NN NN O
two NN NN O
homozygotes NN NN O
. NN NN O

Thus NN NN O
, NN NN O
other NN NN O
genetic NN NN B-DiseaseClass
defects NN NN I-DiseaseClass
or NN NN O
metabolic NN NN O
factors NN NN O
influencing NN NN O
CETP NN NN O
expression NN NN O
are NN NN O
implicated NN NN O
. NN NN O

The NN NN O
data NN NN O
suggest NN NN O
that NN NN O
the NN NN O
G-to-A NN NN O
mutation NN NN O
may NN NN O
be NN NN O
common NN NN O
in NN NN O
human NN NN O
plasma NN NN O
CETP NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

Furthermore NN NN O
, NN NN O
there NN NN O
could NN NN O
be NN NN O
compound NN NN O
heterozygotes NN NN O
who NN NN O
totally NN NN O
lack NN NN O
plasma NN NN O
CETP NN NN O
and NN NN O
have NN NN O
lipoprotein NN NN O
profiles NN NN O
similar NN NN O
to NN NN O
those NN NN O
of NN NN O
homozygotes NN NN O
. NN NN O

. NN NN O

2393028 NN NN O
Molecular NN NN O
genetics NN NN O
of NN NN O
the NN NN O
glucose-6-phosphate NN NN O
dehydrogenase NN NN O
( NN NN O
G6PD NN NN O
) NN NN O
Mediterranean NN NN O
variant NN NN O
and NN NN O
description NN NN O
of NN NN O
a NN NN O
new NN NN O
G6PD NN NN O
mutant NN NN O
, NN NN O
G6PD NN NN O
Andalus1361A NN NN O
. NN NN O


C NN NN O
. NN NN O

1 NN NN O
. NN NN O

1 NN NN O
. NN NN O

1 NN NN O
. NN NN O

49 NN NN O
) NN NN O
deficiency NN NN O
is NN NN O
the NN NN O
most NN NN O
common NN NN O
human NN NN O
enzymopathy NN NN B-DiseaseClass
; NN NN O
more NN NN O
than NN NN O
300 NN NN O
different NN NN O
biochemical NN NN O
variants NN NN O
of NN NN O
the NN NN O
enzyme NN NN O
have NN NN O
been NN NN O
described NN NN O
. NN NN O

In NN NN O
many NN NN O
parts NN NN O
of NN NN O
the NN NN O
world NN NN O
the NN NN O
Mediterranean NN NN O
type NN NN O
of NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
is NN NN O
prevalent NN NN O
. NN NN O

However NN NN O
, NN NN O
G6PD NN NN O
Mediterranean NN NN O
has NN NN O
come NN NN O
to NN NN O
be NN NN O
regarded NN NN O
as NN NN O
a NN NN O
generic NN NN O
term NN NN O
applied NN NN O
to NN NN O
similar NN NN O
G6PD NN NN O
mutations NN NN O
thought NN NN O
, NN NN O
however NN NN O
, NN NN O
to NN NN O
represent NN NN O
a NN NN O
somewhat NN NN O
heterogeneous NN NN O
group NN NN O
. NN NN O

A NN NN O
C NN NN O
-- NN NN O
-- NN NN O
T NN NN O
mutation NN NN O
at NN NN O
nucleotide NN NN O
563 NN NN O
of NN NN O
G6PD NN NN O
Mediterranean NN NN O
has NN NN O
been NN NN O
identified NN NN O
by NN NN O
Vulliamy NN NN O
et NN NN O
al NN NN O
. NN NN O

, NN NN O
and NN NN O
the NN NN O
same NN NN O
mutation NN NN O
has NN NN O
been NN NN O
found NN NN O
by NN NN O
De NN NN O
Vita NN NN O
et NN NN O
al NN NN O
. NN NN O

in NN NN O
G6PD NN NN O
Mediterranean NN NN O
, NN NN O
G6PD NN NN O
Sassari NN NN O
, NN NN O
and NN NN O
G6PD NN NN O
Cagliari NN NN O
. NN NN O

The NN NN O
latter NN NN O
subjects NN NN O
had NN NN O
an NN NN O
additional NN NN O
mutation NN NN O
, NN NN O
at NN NN O
nucleotide NN NN O
1311 NN NN O
, NN NN O
that NN NN O
did NN NN O
not NN NN O
produce NN NN O
a NN NN O
coding NN NN O
change NN NN O
. NN NN O

We NN NN O
have NN NN O
examined NN NN O
genomic NN NN O
DNA NN NN O
of NN NN O
five NN NN O
patients NN NN O
-- NN NN O
four NN NN O
of NN NN O
Spanish NN NN O
origin NN NN O
and NN NN O
one NN NN O
of NN NN O
Jewish NN NN O
origin NN NN O
-- NN NN O
having NN NN O
enzymatically NN NN O
documented NN NN O
G6PD NN NN O
Mediterranean NN NN O
. NN NN O

All NN NN O
had NN NN O
both NN NN O
the NN NN O
mutation NN NN O
at NN NN O
nucleotide NN NN O
563 NN NN O
and NN NN O
that NN NN O
at NN NN O
nucleotide NN NN O
1311 NN NN O
. NN NN O

A NN NN O
sixth NN NN O
sample NN NN O
, NN NN O
resembling NN NN O
G6PD NN NN O
Mediterranean NN NN O
kinetically NN NN O
but NN NN O
with NN NN O
a NN NN O
slightly NN NN O
rapid NN NN O
electrophoretic NN NN O
mobility NN NN O
, NN NN O
was NN NN O
designated NN NN O
G6PD NN NN O
Andalus NN NN O
and NN NN O
was NN NN O
found NN NN O
to NN NN O
have NN NN O
a NN NN O
different NN NN O
mutation NN NN O
, NN NN O
a NN NN O
G NN NN O
-- NN NN O
-- NN NN O
A NN NN O
transition NN NN O
at NN NN O
nucleotide NN NN O
1361 NN NN O
, NN NN O
producing NN NN O
an NN NN O
arginine-to-histidine NN NN O
substitution NN NN O
. NN NN O

These NN NN O
studies NN NN O
suggest NN NN O
that NN NN O
G6PD NN NN O
Mediterranean NN NN O
is NN NN O
, NN NN O
after NN NN O
all NN NN O
, NN NN O
relatively NN NN O
homogeneous NN NN O
. NN NN O

2404853 NN NN O
A NN NN O
normal NN NN O
male NN NN O
with NN NN O
an NN NN O
inherited NN NN O
deletion NN NN O
of NN NN O
one NN NN O
exon NN NN O
within NN NN O
the NN NN O
DMD NN NN B-Modifier
gene NN NN O
. NN NN O

We NN NN O
describe NN NN O
two NN NN O
brothers NN NN O
with NN NN O
identical NN NN O
inherited NN NN O
deletions NN NN O
of NN NN O
one NN NN O
single NN NN O
exon NN NN O
within NN NN O
the NN NN O
middle NN NN O
of NN NN O
the NN NN O
DMD NN NN B-Modifier
gene NN NN O
; NN NN O
one NN NN O
brother NN NN O
has NN NN O
Becker NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
diagnosed NN NN O
at NN NN O
11 NN NN O
years NN NN O
of NN NN O
age NN NN O
, NN NN O
whereas NN NN O
the NN NN O
older NN NN O
brother NN NN O
is NN NN O
normal NN NN O
at NN NN O
18 NN NN O
. NN NN O

These NN NN O
results NN NN O
have NN NN O
implications NN NN O
for NN NN O
genetic NN NN O
counselling NN NN O
and NN NN O
prenatal NN NN O
diagnosis NN NN O
in NN NN O
families NN NN O
with NN NN O
Becker NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
. NN NN O

. NN NN O

2450401 NN NN O
Duchenne NN NN B-Modifier
muscular NN NN I-Modifier
dystrophy NN NN I-Modifier
gene NN NN O
expression NN NN O
in NN NN O
normal NN NN O
and NN NN O
diseased NN NN O
human NN NN O
muscle NN NN O
. NN NN O

A NN NN O
probe NN NN O
for NN NN O
the NN NN O
5 NN NN O
end NN NN O
of NN NN O
the NN NN O
Duchenne NN NN B-Modifier
muscular NN NN I-Modifier
dystrophy NN NN I-Modifier
( NN NN O
DMD NN NN B-Modifier
) NN NN O
gene NN NN O
was NN NN O
used NN NN O
to NN NN O
study NN NN O
expression NN NN O
of NN NN O
the NN NN O
gene NN NN O
in NN NN O
normal NN NN O
human NN NN O
muscle NN NN O
, NN NN O
myogenic NN NN O
cell NN NN O
cultures NN NN O
, NN NN O
and NN NN O
muscle NN NN O
from NN NN O
patients NN NN O
with NN NN O
DMD NN NN B-SpecificDisease
. NN NN O

Expression NN NN O
was NN NN O
found NN NN O
in NN NN O
RNA NN NN O
from NN NN O
normal NN NN O
fetal NN NN O
muscle NN NN O
, NN NN O
adult NN NN O
cardiac NN NN O
and NN NN O
skeletal NN NN O
muscle NN NN O
, NN NN O
and NN NN O
cultured NN NN O
muscle NN NN O
after NN NN O
myoblast NN NN O
fusion NN NN O
. NN NN O

In NN NN O
DMD NN NN B-Modifier
muscle NN NN O
, NN NN O
expression NN NN O
of NN NN O
this NN NN O
portion NN NN O
of NN NN O
the NN NN O
gene NN NN O
was NN NN O
also NN NN O
revealed NN NN O
by NN NN O
in NN NN O
situ NN NN O
RNA NN NN O
hybridization NN NN O
, NN NN O
particularly NN NN O
in NN NN O
regenerating NN NN O
muscle NN NN O
fibers NN NN O
. NN NN O

. NN NN O

2491010 NN NN O
Molecular NN NN O
and NN NN O
phenotypic NN NN O
analysis NN NN O
of NN NN O
patients NN NN O
with NN NN O
deletions NN NN O
within NN NN O
the NN NN O
deletion-rich NN NN O
region NN NN O
of NN NN O
the NN NN O
Duchenne NN NN B-Modifier
muscular NN NN I-Modifier
dystrophy NN NN I-Modifier
( NN NN O
DMD NN NN B-Modifier
) NN NN O
gene NN NN O
. NN NN O

Eighty NN NN O
unrelated NN NN O
individuals NN NN O
with NN NN O
Duchenne NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DMD NN NN B-SpecificDisease
) NN NN O
or NN NN O
Becker NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
BMD NN NN B-SpecificDisease
) NN NN O
were NN NN O
found NN NN O
to NN NN O
have NN NN O
deletions NN NN O
in NN NN O
the NN NN O
major NN NN O
deletion-rich NN NN O
region NN NN O
of NN NN O
the NN NN O
DMD NN NN B-Modifier
locus NN NN O
. NN NN O

This NN NN O
region NN NN O
includes NN NN O
the NN NN O
last NN NN O
five NN NN O
exons NN NN O
detected NN NN O
by NN NN O
cDNA5b-7 NN NN O
, NN NN O
all NN NN O
exons NN NN O
detected NN NN O
by NN NN O
cDNA8 NN NN O
, NN NN O
and NN NN O
the NN NN O
first NN NN O
two NN NN O
exons NN NN O
detected NN NN O
by NN NN O
cDNA9 NN NN O
. NN NN O

These NN NN O
80 NN NN O
individuals NN NN O
account NN NN O
for NN NN O
approximately NN NN O
75 NN NN O
% NN NN O
of NN NN O
109 NN NN O
deletions NN NN O
of NN NN O
the NN NN O
gene NN NN O
, NN NN O
detected NN NN O
among NN NN O
181 NN NN O
patients NN NN O
analyzed NN NN O
with NN NN O
the NN NN O
entire NN NN O
dystrophin NN NN O
cDNA NN NN O
. NN NN O

Endpoints NN NN O
for NN NN O
many NN NN O
of NN NN O
these NN NN O
deletions NN NN O
were NN NN O
further NN NN O
characterized NN NN O
using NN NN O
two NN NN O
genomic NN NN O
probes NN NN O
, NN NN O
p20 NN NN O
( NN NN O
DXS269 NN NN O
; NN NN O
Wapenaar NN NN O
et NN NN O
al NN NN O
. NN NN O
) NN NN O

and NN NN O
GMGX11 NN NN O
( NN NN O
DXS239 NN NN O
; NN NN O
present NN NN O
paper NN NN O
) NN NN O
. NN NN O

Clinical NN NN O
findings NN NN O
are NN NN O
presented NN NN O
for NN NN O
all NN NN O
80 NN NN O
patients NN NN O
allowing NN NN O
a NN NN O
correlation NN NN O
of NN NN O
phenotypic NN NN O
severity NN NN O
with NN NN O
the NN NN O
genotype NN NN O
. NN NN O

Thirty-eight NN NN O
independent NN NN O
patients NN NN O
were NN NN O
old NN NN O
enough NN NN O
to NN NN O
be NN NN O
classified NN NN O
as NN NN O
DMD NN NN B-SpecificDisease
, NN NN O
BMD NN NN B-SpecificDisease
, NN NN O
or NN NN O
intermediate NN NN O
phenotype NN NN O
and NN NN O
had NN NN O
deletions NN NN O
of NN NN O
exons NN NN O
with NN NN O
sequenced NN NN O
intron NN NN O
/ NN NN O
exon NN NN O
boundaries NN NN O
. NN NN O

Of NN NN O
these NN NN O
, NN NN O
eight NN NN O
BMD NN NN B-Modifier
patients NN NN O
and NN NN O
one NN NN O
intermediate NN NN O
patient NN NN O
had NN NN O
gene NN NN O
deletions NN NN O
predicted NN NN O
to NN NN O
leave NN NN O
the NN NN O
reading NN NN O
frame NN NN O
intact NN NN O
, NN NN O
while NN NN O
21 NN NN O
DMD NN NN B-Modifier
patients NN NN O
, NN NN O
7 NN NN O
intermediate NN NN O
patients NN NN O
, NN NN O
and NN NN O
1 NN NN O
BMD NN NN B-Modifier
patient NN NN O
had NN NN O
gene NN NN O
deletions NN NN O
predicted NN NN O
to NN NN O
disrupt NN NN O
the NN NN O
reading NN NN O
frame NN NN O
. NN NN O

Thus NN NN O
, NN NN O
with NN NN O
two NN NN O
exceptions NN NN O
, NN NN O
frameshift NN NN O
deletions NN NN O
of NN NN O
the NN NN O
gene NN NN O
resulted NN NN O
in NN NN O
more NN NN O
severe NN NN O
phenotype NN NN O
than NN NN O
did NN NN O
in-frame NN NN O
deletions NN NN O
. NN NN O

This NN NN O
is NN NN O
in NN NN O
agreement NN NN O
with NN NN O
recent NN NN O
findings NN NN O
by NN NN O
Baumbach NN NN O
et NN NN O
al NN NN O
. NN NN O

and NN NN O
Koenig NN NN O
et NN NN O
al NN NN O
. NN NN O

but NN NN O
is NN NN O
in NN NN O
contrast NN NN O
to NN NN O
findings NN NN O
, NN NN O
by NN NN O
Malhotra NN NN O
et NN NN O
al NN NN O
. NN NN O

at NN NN O
the NN NN O
5 NN NN O
' NN NN O
end NN NN O
of NN NN O
the NN NN O
gene NN NN O
. NN NN O

2544995 NN NN O
Cloning NN NN O
of NN NN O
breakpoints NN NN O
of NN NN O
a NN NN O
chromosome NN NN O
translocation NN NN O
identifies NN NN O
the NN NN O
AN2 NN NN O
locus NN NN O
. NN NN O

Chromosome NN NN O
translocations NN NN O
involving NN NN O
11p13 NN NN O
have NN NN O
been NN NN O
associated NN NN O
with NN NN O
familial NN NN B-SpecificDisease
aniridia NN NN I-SpecificDisease
in NN NN O
two NN NN O
kindreds NN NN O
highlighting NN NN O
the NN NN O
chromosomal NN NN O
localization NN NN O
of NN NN O
the NN NN O
AN2 NN NN O
locus NN NN O
. NN NN O

This NN NN O
locus NN NN O
is NN NN O
also NN NN O
part NN NN O
of NN NN O
the NN NN O
WAGR NN NN B-Modifier
complex NN NN O
( NN NN O
Wilms NN NN B-SpecificDisease
tumor NN NN I-SpecificDisease
, NN NN O
aniridia NN NN B-SpecificDisease
, NN NN O
genitourinary NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
, NN NN O
and NN NN O
mental NN NN B-DiseaseClass
retardation NN NN I-DiseaseClass
) NN NN O
. NN NN O

In NN NN O
one NN NN O
kindred NN NN O
, NN NN O
the NN NN O
translocation NN NN O
is NN NN O
associated NN NN O
with NN NN O
a NN NN O
deletion NN NN O
, NN NN O
and NN NN O
probes NN NN O
for NN NN O
this NN NN O
region NN NN O
were NN NN O
used NN NN O
to NN NN O
identify NN NN O
and NN NN O
clone NN NN O
the NN NN O
breakpoints NN NN O
of NN NN O
the NN NN O
translocation NN NN O
in NN NN O
the NN NN O
second NN NN O
kindred NN NN O
. NN NN O

Comparison NN NN O
of NN NN O
phage NN NN O
restriction NN NN O
maps NN NN O
exclude NN NN O
the NN NN O
presence NN NN O
of NN NN O
any NN NN O
sizable NN NN O
deletion NN NN O
in NN NN O
this NN NN O
case NN NN O
. NN NN O

Sequences NN NN O
at NN NN O
the NN NN O
chromosome NN NN O
11 NN NN O
breakpoint NN NN O
are NN NN O
conserved NN NN O
in NN NN O
multiple NN NN O
species NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
the NN NN O
translocation NN NN O
falls NN NN O
within NN NN O
the NN NN O
AN2 NN NN O
gene NN NN O
. NN NN O

. NN NN O

2562820 NN NN O
Linkage NN NN O
analysis NN NN O
of NN NN O
the NN NN O
apolipoprotein NN NN O
C2 NN NN O
gene NN NN O
and NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
on NN NN O
human NN NN O
chromosome NN NN O
19 NN NN O
reveals NN NN O
linkage NN NN O
disequilibrium NN NN O
in NN NN O
a NN NN O
French-Canadian NN NN O
population NN NN O
. NN NN O

The NN NN O
gene NN NN O
for NN NN O
human NN NN O
apolipoprotein NN NN O
C2 NN NN O
( NN NN O
APOC2 NN NN O
) NN NN O
, NN NN O
situated NN NN O
on NN NN O
the NN NN O
proximal NN NN O
long NN NN O
arm NN NN O
of NN NN O
chromosome NN NN O
19 NN NN O
, NN NN O
is NN NN O
closely NN NN O
linked NN NN O
to NN NN O
the NN NN O
gene NN NN O
for NN NN O
the NN NN O
most NN NN O
common NN NN O
form NN NN O
of NN NN O
adult NN NN O
muscular NN NN B-DiseaseClass
dystrophy NN NN I-DiseaseClass
, NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
. NN NN O

Six NN NN O
APOC2 NN NN O
RFLPs NN NN O
( NN NN O
TaqI NN NN O
, NN NN O
BglI NN NN O
, NN NN O
BanI NN NN O
, NN NN O
BamHI NN NN O
, NN NN O
NcoI NN NN O
, NN NN O
and NN NN O
AvaII NN NN O
) NN NN O
have NN NN O
been NN NN O
identified NN NN O
to NN NN O
date NN NN O
. NN NN O

We NN NN O
have NN NN O
conducted NN NN O
a NN NN O
comprehensive NN NN O
DM NN NN B-Modifier
linkage NN NN O
study NN NN O
utilizing NN NN O
all NN NN O
six NN NN O
RFLPs NN NN O
and NN NN O
involving NN NN O
50 NN NN O
families NN NN O
and NN NN O
372 NN NN O
individuals NN NN O
. NN NN O

The NN NN O
most NN NN O
informative NN NN O
RFLPs NN NN O
are NN NN O
, NN NN O
in NN NN O
descending NN NN O
order NN NN O
, NN NN O
NcoI NN NN O
( NN NN O
lod NN NN O
= NN NN O
6 NN NN O
. NN NN O

64 NN NN O
, NN NN O
theta NN NN O
= NN NN O
0 NN NN O
. NN NN O

05 NN NN O
) NN NN O
, NN NN O
BglI NN NN O
( NN NN O
lod NN NN O
= NN NN O
6 NN NN O
. NN NN O

12 NN NN O
, NN NN O
theta NN NN O
= NN NN O
0 NN NN O
. NN NN O

05 NN NN O
) NN NN O
, NN NN O
AvaII NN NN O
( NN NN O
lod NN NN O
= NN NN O
6 NN NN O
. NN NN O

02 NN NN O
, NN NN O
theta NN NN O
= NN NN O
0 NN NN O
. NN NN O

03 NN NN O
) NN NN O
, NN NN O
BanI NN NN O
( NN NN O
lod NN NN O
= NN NN O
5 NN NN O
. NN NN O

76 NN NN O
, NN NN O
theta NN NN O
= NN NN O
0 NN NN O
. NN NN O

04 NN NN O
) NN NN O
, NN NN O
TaqI NN NN O
( NN NN O
lod NN NN O
= NN NN O
4 NN NN O
. NN NN O

29 NN NN O
, NN NN O
theta NN NN O
= NN NN O
0 NN NN O
. NN NN O

06 NN NN O
) NN NN O
, NN NN O
and NN NN O
BamHI NN NN O
( NN NN O
lod NN NN O
= NN NN O
1 NN NN O
. NN NN O

75 NN NN O
, NN NN O
theta NN NN O
= NN NN O
0 NN NN O
. NN NN O

01 NN NN O
) NN NN O
. NN NN O

A NN NN O
substantial NN NN O
increase NN NN O
in NN NN O
the NN NN O
lod NN NN O
scores NN NN O
over NN NN O
those NN NN O
seen NN NN O
with NN NN O
the NN NN O
individual NN NN O
RFLPs NN NN O
was NN NN O
obtained NN NN O
when NN NN O
the NN NN O
linkage NN NN O
of NN NN O
the NN NN O
entire NN NN O
APOC2 NN NN O
haplotype NN NN O
( NN NN O
composed NN NN O
of NN NN O
the NN NN O
six NN NN O
RFLPs NN NN O
) NN NN O
was NN NN O
studied NN NN O
( NN NN O
lod NN NN O
= NN NN O
17 NN NN O
. NN NN O

87 NN NN O
, NN NN O
theta NN NN O
= NN NN O
0 NN NN O
. NN NN O

04 NN NN O
) NN NN O
. NN NN O

We NN NN O
have NN NN O
observed NN NN O
significant NN NN O
inter-APOC2 NN NN O
RFLP NN NN O
linkage NN NN O
disequilibrium NN NN O
. NN NN O

Consequently NN NN O
, NN NN O
the NN NN O
three NN NN O
most NN NN O
informative NN NN O
RFLPs NN NN O
have NN NN O
been NN NN O
found NN NN O
to NN NN O
be NN NN O
BanI NN NN O
, NN NN O
TaqI NN NN O
, NN NN O
and NN NN O
either NN NN O
BglI NN NN O
, NN NN O
AvaII NN NN O
, NN NN O
or NN NN O
NcoI NN NN O
polymorphisms NN NN O
. NN NN O

We NN NN O
also NN NN O
demonstrate NN NN O
linkage NN NN O
disequilibrium NN NN O
between NN NN O
DM NN NN O
and NN NN O
APOC2 NN NN O
in NN NN O
our NN NN O
French-Canadian NN NN O
population NN NN O
( NN NN O
standardized NN NN O
disequilibrium NN NN O
constant NN NN O
phi NN NN O
= NN NN O
. NN NN O

22 NN NN O
, NN NN O
chi NN NN O
2 NN NN O
= NN NN O
5 NN NN O
. NN NN O

12 NN NN O
, NN NN O
df NN NN O
= NN NN O
1 NN NN O
, NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O

04 NN NN O
) NN NN O
. NN NN O

This NN NN O
represents NN NN O
the NN NN O
first NN NN O
evidence NN NN O
of NN NN O
linkage NN NN O
disequilibrium NN NN O
between NN NN O
APOC2 NN NN O
and NN NN O
the NN NN O
DM NN NN B-Modifier
locus NN NN O
. NN NN O

2563633 NN NN O
Phenylalanine NN NN O
hydroxylase NN NN O
gene NN NN O
haplotypes NN NN O
in NN NN O
Polynesians NN NN O
: NN NN O
evolutionary NN NN O
origins NN NN O
and NN NN O
absence NN NN O
of NN NN O
alleles NN NN O
associated NN NN O
with NN NN O
severe NN NN O
phenylketonuria NN NN B-SpecificDisease
. NN NN O

A NN NN O
total NN NN O
of NN NN O
630 NN NN O
haplotypes NN NN O
for NN NN O
the NN NN O
phenylalanine NN NN O
hydroxylase NN NN O
( NN NN O
PAH NN NN O
) NN NN O
gene NN NN O
locus NN NN O
were NN NN O
established NN NN O
in NN NN O
five NN NN O
groups NN NN O
of NN NN O
Polynesians NN NN O
comprising NN NN O
Samoans NN NN O
, NN NN O
Tongans NN NN O
, NN NN O
Cook NN NN O
Islanders NN NN O
, NN NN O
Maori NN NN O
, NN NN O
and NN NN O
Niueans NN NN O
. NN NN O

Considerable NN NN O
genetic NN NN O
continuity NN NN O
was NN NN O
demonstrated NN NN O
between NN NN O
these NN NN O
widely NN NN O
dispersed NN NN O
populations NN NN O
, NN NN O
since NN NN O
three NN NN O
common NN NN O
haplotypes NN NN O
( NN NN O
4 NN NN O
, NN NN O
1 NN NN O
, NN NN O
and NN NN O
7 NN NN O
) NN NN O
constituted NN NN O
over NN NN O
95 NN NN O
% NN NN O
of NN NN O
alleles NN NN O
. NN NN O

A NN NN O
control NN NN O
group NN NN O
of NN NN O
individuals NN NN O
from NN NN O
Southeast NN NN O
Asia NN NN O
shared NN NN O
the NN NN O
same NN NN O
major NN NN O
haplotypes NN NN O
, NN NN O
4 NN NN O
, NN NN O
1 NN NN O
, NN NN O
and NN NN O
7 NN NN O
, NN NN O
with NN NN O
Polynesians NN NN O
. NN NN O

These NN NN O
data NN NN O
provide NN NN O
further NN NN O
support NN NN O
for NN NN O
the NN NN O
theories NN NN O
of NN NN O
genetic NN NN O
homogeneity NN NN O
and NN NN O
of NN NN O
Asian NN NN O
affinities NN NN O
of NN NN O
the NN NN O
Polynesian NN NN O
precursor NN NN O
populations NN NN O
. NN NN O

The NN NN O
absence NN NN O
of NN NN O
severe NN NN O
phenylketonuria NN NN B-SpecificDisease
( NN NN O
PKU NN NN B-SpecificDisease
) NN NN O
in NN NN O
both NN NN O
Polynesians NN NN O
and NN NN O
Southeast NN NN O
Asians NN NN O
is NN NN O
consistent NN NN O
with NN NN O
the NN NN O
lack NN NN O
of NN NN O
PAH NN NN O
haplotypes NN NN O
2 NN NN O
and NN NN O
3 NN NN O
, NN NN O
on NN NN O
which NN NN O
the NN NN O
severe NN NN O
PKU NN NN B-Modifier
mutants NN NN O
have NN NN O
arisen NN NN O
among NN NN O
Caucasians NN NN O
. NN NN O

. NN NN O

2568588 NN NN O
Preferential NN NN O
germline NN NN O
mutation NN NN O
of NN NN O
the NN NN O
paternal NN NN O
allele NN NN O
in NN NN O
retinoblastoma NN NN B-SpecificDisease
. NN NN O

The NN NN O
event NN NN O
triggering NN NN O
malignant NN NN O
proliferation NN NN O
in NN NN O
70 NN NN O
% NN NN O
of NN NN O
retinoblastoma NN NN B-SpecificDisease
tumours NN NN I-SpecificDisease
is NN NN O
loss NN NN O
of NN NN O
heterozygosity NN NN O
for NN NN O
chromosome NN NN O
13q14 NN NN O
, NN NN O
whereby NN NN O
the NN NN O
normal NN NN O
retinoblastoma NN NN B-Modifier
gene NN NN O
( NN NN O
RB1 NN NN O
) NN NN O
allele NN NN O
is NN NN O
lost NN NN O
and NN NN O
an NN NN O
already NN NN O
mutated NN NN O
RB1 NN NN O
allele NN NN O
remains NN NN O
in NN NN O
the NN NN O
tumour NN NN B-DiseaseClass
. NN NN O

The NN NN O
first NN NN O
allele NN NN O
suffers NN NN O
a NN NN O
mutational NN NN O
event NN NN O
-- NN NN O
deletion NN NN O
, NN NN O
duplication NN NN O
or NN NN O
point NN NN O
mutation NN NN O
( NN NN O
manuscript NN NN O
in NN NN O
preparation NN NN O
) NN NN O
-- NN NN O
either NN NN O
in NN NN O
the NN NN O
germ NN NN O
line NN NN O
( NN NN O
all NN NN O
bilateral NN NN O
patients NN NN O
) NN NN O
or NN NN O
in NN NN O
a NN NN O
somatic NN NN O
retinal NN NN O
cell NN NN O
( NN NN O
most NN NN O
unilateral NN NN O
patients NN NN O
) NN NN O
. NN NN O

Most NN NN O
bilateral NN NN O
patients NN NN O
have NN NN O
no NN NN O
family NN NN O
history NN NN O
of NN NN O
retinoblastoma NN NN B-SpecificDisease
and NN NN O
are NN NN O
presumed NN NN O
to NN NN O
have NN NN O
new NN NN O
germline NN NN O
mutations NN NN O
which NN NN O
arose NN NN O
in NN NN O
the NN NN O
egg NN NN O
, NN NN O
sperm NN NN O
or NN NN O
early NN NN O
embryo NN NN O
. NN NN O

We NN NN O
have NN NN O
determined NN NN O
the NN NN O
parental NN NN O
origin NN NN O
of NN NN O
the NN NN O
retained NN NN O
allele NN NN O
in NN NN O
nine NN NN O
retinoblastoma NN NN B-SpecificDisease
tumours NN NN I-SpecificDisease
from NN NN O
eight NN NN O
unrelated NN NN O
non-familial NN NN O
cases NN NN O
by NN NN O
using NN NN O
RB1-linked NN NN O
genetic NN NN O
markers NN NN O
. NN NN O

Six NN NN O
tumours NN NN B-DiseaseClass
retained NN NN O
the NN NN O
paternal NN NN O
allele NN NN O
and NN NN O
three NN NN O
retained NN NN O
the NN NN O
maternal NN NN O
allele NN NN O
. NN NN O

Of NN NN O
the NN NN O
three NN NN O
unilateral NN NN B-DiseaseClass
tumours NN NN I-DiseaseClass
, NN NN O
only NN NN O
one NN NN O
retained NN NN O
the NN NN O
paternal NN NN O
RB1 NN NN O
allele NN NN O
. NN NN O

Thus NN NN O
, NN NN O
there NN NN O
is NN NN O
no NN NN O
evidence NN NN O
that NN NN O
the NN NN O
paternal NN NN O
RB1 NN NN O
allele NN NN O
is NN NN O
preferentially NN NN O
retained NN NN O
in NN NN O
retinoblastoma NN NN B-SpecificDisease
, NN NN O
as NN NN O
has NN NN O
been NN NN O
suggested NN NN O
to NN NN O
be NN NN O
the NN NN O
case NN NN O
in NN NN O
osteosarcoma NN NN B-SpecificDisease
. NN NN O

By NN NN O
contrast NN NN O
, NN NN O
tumours NN NN B-DiseaseClass
from NN NN O
four NN NN O
of NN NN O
the NN NN O
five NN NN O
bilateral NN NN O
patients NN NN O
retained NN NN O
the NN NN O
paternal NN NN O
RB1 NN NN O
allele NN NN O
. NN NN O

This NN NN O
suggests NN NN O
either NN NN O
that NN NN O
new NN NN O
germline NN NN O
RB1 NN NN O
mutations NN NN O
arise NN NN O
more NN NN O
frequently NN NN O
during NN NN O
spermatogenesis NN NN O
than NN NN O
during NN NN O
oogenesis NN NN O
, NN NN O
or NN NN O
that NN NN O
imprinting NN NN O
in NN NN O
the NN NN O
early NN NN O
embryo NN NN O
affects NN NN O
chromosomal NN NN O
susceptibility NN NN O
to NN NN O
mutation NN NN O
. NN NN O

. NN NN O

2569949 NN NN O
Haplotype NN NN O
analysis NN NN O
of NN NN O
the NN NN O
phenylalanine NN NN O
hydroxylase NN NN O
gene NN NN O
in NN NN O
Turkish NN NN O
phenylketonuria NN NN B-Modifier
families NN NN O
. NN NN O

We NN NN O
have NN NN O
estimated NN NN O
the NN NN O
haplotype NN NN O
distribution NN NN O
of NN NN O
mutant NN NN O
and NN NN O
normal NN NN O
phenylalanine NN NN O
hydroxylase NN NN O
( NN NN O
PAH NN NN O
) NN NN O
alleles NN NN O
for NN NN O
17 NN NN O
Turkish NN NN O
phenylketonuria NN NN B-Modifier
( NN NN O
PKU NN NN B-Modifier
) NN NN O
families NN NN O
20 NN NN O
normal NN NN O
and NN NN O
27 NN NN O
mutated NN NN O
PAH NN NN O
alleles NN NN O
could NN NN O
be NN NN O
identified NN NN O
. NN NN O

Of NN NN O
the NN NN O
latter NN NN O
, NN NN O
the NN NN O
most NN NN O
prevalent NN NN O
were NN NN O
associated NN NN O
with NN NN O
haplotype NN NN O
6 NN NN O
( NN NN O
29 NN NN O
. NN NN O

6 NN NN O
% NN NN O
) NN NN O
, NN NN O
1 NN NN O
( NN NN O
18 NN NN O
. NN NN O

5 NN NN O
% NN NN O
) NN NN O
and NN NN O
36 NN NN O
( NN NN O
11 NN NN O
. NN NN O

1 NN NN O
% NN NN O
) NN NN O
, NN NN O
while NN NN O
the NN NN O
normal NN NN O
alleles NN NN O
were NN NN O
preferentially NN NN O
associated NN NN O
with NN NN O
haplotype NN NN O
1 NN NN O
( NN NN O
20 NN NN O
% NN NN O
) NN NN O
. NN NN O

Of NN NN O
the NN NN O
19 NN NN O
different NN NN O
haplotypes NN NN O
observed NN NN O
, NN NN O
5 NN NN O
have NN NN O
not NN NN O
been NN NN O
described NN NN O
previously NN NN O
. NN NN O

The NN NN O
haplotype NN NN O
distribution NN NN O
differed NN NN O
significantly NN NN O
from NN NN O
that NN NN O
of NN NN O
the NN NN O
Northern NN NN O
European NN NN O
population NN NN O
. NN NN O

Two NN NN O
of NN NN O
the NN NN O
eight NN NN O
polymorphic NN NN O
sites NN NN O
were NN NN O
in NN NN O
association NN NN O
with NN NN O
PKU NN NN B-SpecificDisease
. NN NN O

No NN NN O
deletions NN NN O
of NN NN O
exon NN NN O
sequences NN NN O
were NN NN O
found NN NN O
in NN NN O
the NN NN O
families NN NN O
analysed NN NN O
. NN NN O

2571579 NN NN O
Huntington NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
: NN NN O
no NN NN O
evidence NN NN O
for NN NN O
locus NN NN O
heterogeneity NN NN O
. NN NN O

A NN NN O
total NN NN O
of NN NN O
63 NN NN O
families NN NN O
with NN NN O
Huntington NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
HD NN NN B-SpecificDisease
) NN NN O
were NN NN O
examined NN NN O
for NN NN O
linkage NN NN O
between NN NN O
HD NN NN B-SpecificDisease
and NN NN O
G8 NN NN O
( NN NN O
D4S10 NN NN O
) NN NN O
. NN NN O

The NN NN O
families NN NN O
included NN NN O
57 NN NN O
Caucasian NN NN O
, NN NN O
four NN NN O
Black NN NN O
American NN NN O
, NN NN O
and NN NN O
two NN NN O
Japanese NN NN O
. NN NN O

The NN NN O
combined NN NN O
maximum NN NN O
lod NN NN O
score NN NN O
was NN NN O
87 NN NN O
. NN NN O

69 NN NN O
at NN NN O
theta NN NN O
= NN NN O
0 NN NN O
. NN NN O

04 NN NN O
( NN NN O
99 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
0 NN NN O
. NN NN O

018-0 NN NN O
. NN NN O

071 NN NN O
) NN NN O
. NN NN O

The NN NN O
maximum NN NN O
frequency NN NN O
of NN NN O
recombination NN NN O
was NN NN O
0 NN NN O
. NN NN O

03 NN NN O
in NN NN O
males NN NN O
and NN NN O
0 NN NN O
. NN NN O

05 NN NN O
in NN NN O
females NN NN O
. NN NN O

Fifty-seven NN NN O
families NN NN O
gave NN NN O
positive NN NN O
lod NN NN O
scores NN NN O
; NN NN O
five NN NN O
small NN NN O
families NN NN O
gave NN NN O
mildly NN NN O
negative NN NN O
lod NN NN O
scores NN NN O
. NN NN O

The NN NN O
maximum NN NN O
likelihood NN NN O
estimate NN NN O
of NN NN O
alpha NN NN O
, NN NN O
the NN NN O
proportion NN NN O
of NN NN O
linked NN NN O
loci NN NN O
, NN NN O
was NN NN O
1 NN NN O
. NN NN O

0 NN NN O
with NN NN O
a NN NN O
lower NN NN O
99 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
of NN NN O
0 NN NN O
. NN NN O

88 NN NN O
. NN NN O

These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
there NN NN O
is NN NN O
only NN NN O
one NN NN O
HD NN NN B-Modifier
locus NN NN O
, NN NN O
although NN NN O
a NN NN O
second NN NN O
rare NN NN O
locus NN NN O
can NN NN O
not NN NN O
be NN NN O
ruled NN NN O
out NN NN O
. NN NN O

2575071 NN NN O
Haplotype NN NN O
and NN NN O
multipoint NN NN O
linkage NN NN O
analysis NN NN O
in NN NN O
Finnish NN NN O
choroideremia NN NN B-Modifier
families NN NN O
. NN NN O

Multipoint NN NN O
linkage NN NN O
analysis NN NN O
of NN NN O
choroideremia NN NN B-SpecificDisease
( NN NN O
TCD NN NN B-SpecificDisease
) NN NN O
and NN NN O
seven NN NN O
X NN NN O
chromosomal NN NN O
restriction NN NN O
fragment NN NN O
length NN NN O
polymorphisms NN NN O
( NN NN O
RFLPs NN NN O
) NN NN O
was NN NN O
carried NN NN O
out NN NN O
in NN NN O
18 NN NN O
Finnish NN NN O
TCD NN NN B-Modifier
families NN NN O
. NN NN O

The NN NN O
data NN NN O
place NN NN O
TCD NN NN B-SpecificDisease
distal NN NN O
to NN NN O
PGK NN NN O
and NN NN O
DXS72 NN NN O
, NN NN O
very NN NN O
close NN NN O
to NN NN O
DXYS1 NN NN O
and NN NN O
DXYS5 NN NN O
( NN NN O
Zmax NN NN O
= NN NN O
24 NN NN O
at NN NN O
theta NN NN O
= NN NN O
0 NN NN O
) NN NN O
and NN NN O
proximal NN NN O
to NN NN O
DXYS4 NN NN O
and NN NN O
DXYS12 NN NN O
. NN NN O

This NN NN O
agrees NN NN O
with NN NN O
the NN NN O
data NN NN O
obtained NN NN O
from NN NN O
other NN NN O
linkage NN NN O
studies NN NN O
and NN NN O
from NN NN O
physical NN NN O
mapping NN NN O
. NN NN O

All NN NN O
the NN NN O
TCD NN NN B-Modifier
males NN NN O
and NN NN O
carrier NN NN O
females NN NN O
studied NN NN O
have NN NN O
the NN NN O
same NN NN O
DXYS1 NN NN O
allele NN NN O
in NN NN O
coupling NN NN O
with NN NN O
TCD NN NN B-SpecificDisease
. NN NN O

In NN NN O
Northeastern NN NN O
Finland NN NN O
, NN NN O
66 NN NN O
/ NN NN O
69 NN NN O
chromosomes NN NN O
carrying NN NN O
TCD NN NN B-SpecificDisease
had NN NN O
the NN NN O
same NN NN O
haplotype NN NN O
at NN NN O
loci NN NN O
DXS72 NN NN O
, NN NN O
DXYS1 NN NN O
, NN NN O
DXYS4 NN NN O
, NN NN O
and NN NN O
DXYS12 NN NN O
. NN NN O

The NN NN O
same NN NN O
haplotype NN NN O
is NN NN O
seen NN NN O
in NN NN O
only NN NN O
15 NN NN O
/ NN NN O
99 NN NN O
chromosomes NN NN O
not NN NN O
carrying NN NN O
TCD NN NN B-SpecificDisease
. NN NN O

Moreover NN NN O
, NN NN O
in NN NN O
71 NN NN O
/ NN NN O
104 NN NN O
non-TCD NN NN O
chromosomes NN NN O
, NN NN O
the NN NN O
haplotype NN NN O
at NN NN O
six NN NN O
marker NN NN O
loci NN NN O
is NN NN O
different NN NN O
from NN NN O
those NN NN O
seen NN NN O
in NN NN O
any NN NN O
of NN NN O
the NN NN O
76 NN NN O
TCD NN NN B-Modifier
chromosomes NN NN O
. NN NN O

This NN NN O
supports NN NN O
the NN NN O
previously NN NN O
described NN NN O
hypothesis NN NN O
that NN NN O
the NN NN O
large NN NN O
Northern NN NN O
Finnish NN NN O
choroideremia NN NN B-Modifier
pedigrees NN NN O
, NN NN O
comprising NN NN O
a NN NN O
total NN NN O
of NN NN O
over NN NN O
80 NN NN O
living NN NN O
patients NN NN O
representing NN NN O
more NN NN O
than NN NN O
a NN NN O
fifth NN NN O
of NN NN O
all NN NN O
TCD NN NN B-Modifier
patients NN NN O
described NN NN O
worldwide NN NN O
, NN NN O
carry NN NN O
the NN NN O
same NN NN O
mutation NN NN O
. NN NN O

These NN NN O
linkage NN NN O
and NN NN O
haplotype NN NN O
data NN NN O
provide NN NN O
improved NN NN O
opportunities NN NN O
for NN NN O
prenatal NN NN O
diagnosis NN NN O
based NN NN O
on NN NN O
RFLP NN NN O
studies NN NN O
. NN NN O

. NN NN O

2575483 NN NN O
Autosomal NN NN O
dominant NN NN O
aniridia NN NN B-SpecificDisease
linked NN NN O
to NN NN O
the NN NN O
chromosome NN NN O
11p13 NN NN O
markers NN NN O
catalase NN NN O
and NN NN O
D11S151 NN NN O
in NN NN O
a NN NN O
large NN NN O
Dutch NN NN O
family NN NN O
. NN NN O

In NN NN O
a NN NN O
large NN NN O
pedigree NN NN O
with NN NN O
autosomal NN NN O
dominant NN NN O
aniridia NN NN B-SpecificDisease
, NN NN O
we NN NN O
found NN NN O
close NN NN O
linkage NN NN O
between NN NN O
the NN NN O
aniridia NN NN B-Modifier
locus NN NN O
AN2 NN NN O
and NN NN O
the NN NN O
markers NN NN O
catalase NN NN O
( NN NN O
CAT NN NN O
) NN NN O
( NN NN O
zeta NN NN O
= NN NN O
7 NN NN O
. NN NN O

27 NN NN O
at NN NN O
theta NN NN O
= NN NN O
0 NN NN O
. NN NN O

00 NN NN O
) NN NN O
and NN NN O
D11S151 NN NN O
( NN NN O
zeta NN NN O
= NN NN O
3 NN NN O
. NN NN O

86 NN NN O
at NN NN O
theta NN NN O
= NN NN O
0 NN NN O
. NN NN O

10 NN NN O
) NN NN O
flanking NN NN O
the NN NN O
AN2 NN NN O
locus NN NN O
on NN NN O
11p13 NN NN O
. NN NN O

Positive NN NN O
lod NN NN O
scores NN NN O
were NN NN O
also NN NN O
obtained NN NN O
for NN NN O
the NN NN O
11p13 NN NN O
-- NN NN O
-- NN NN O
11p14 NN NN O
markers NN NN O
D11S16 NN NN O
and NN NN O
FSHB NN NN O
with NN NN O
the NN NN O
linkage NN NN O
group NN NN O
CAT NN NN O
/ NN NN O
AN2 NN NN O
/ NN NN O
D11S151 NN NN O
. NN NN O

We NN NN O
conclude NN NN O
that NN NN O
the NN NN O
autosomal NN NN O
dominant NN NN O
aniridia NN NN B-SpecificDisease
in NN NN O
this NN NN O
family NN NN O
is NN NN O
due NN NN O
to NN NN O
a NN NN O
mutation NN NN O
at NN NN O
the NN NN O
AN2 NN NN O
locus NN NN O
on NN NN O
11p13 NN NN O
. NN NN O

We NN NN O
have NN NN O
excluded NN NN O
linkage NN NN O
( NN NN O
zeta NN NN O
less NN NN O
than NN NN O
-2 NN NN O
at NN NN O
theta NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O

18 NN NN O
) NN NN O
between NN NN O
the NN NN O
aniridia NN NN B-SpecificDisease
and NN NN O
the NN NN O
chromosome NN NN O
2p25 NN NN O
marker NN NN O
D2S1 NN NN O
( NN NN O
linked NN NN O
to NN NN O
ACP1 NN NN O
) NN NN O
. NN NN O

2591962 NN NN O
Recombination NN NN O
events NN NN O
that NN NN O
locate NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
distal NN NN O
to NN NN O
APOC2 NN NN O
on NN NN O
19q NN NN O
. NN NN O

We NN NN O
previously NN NN O
reported NN NN O
a NN NN O
recombination NN NN O
in NN NN O
an NN NN O
individual NN NN O
with NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
which NN NN O
placed NN NN O
the NN NN O
markers NN NN O
D19S19 NN NN O
and NN NN O
APOC2 NN NN O
on NN NN O
the NN NN O
same NN NN O
side NN NN O
of NN NN O
the NN NN O
DM NN NN B-Modifier
locus NN NN O
. NN NN O

Haplotyping NN NN O
of NN NN O
this NN NN O
family NN NN O
with NN NN O
more NN NN O
recently NN NN O
characterized NN NN O
probes NN NN O
which NN NN O
are NN NN O
either NN NN O
tightly NN NN O
linked NN NN O
to NN NN O
DM NN NN B-SpecificDisease
or NN NN O
distal NN NN O
to NN NN O
the NN NN O
linkage NN NN O
group NN NN O
at NN NN O
q13 NN NN O
. NN NN O

2 NN NN O
shows NN NN O
that NN NN O
the NN NN O
DM NN NN B-Modifier
locus NN NN O
is NN NN O
distal NN NN O
to NN NN O
APOC2 NN NN O
. NN NN O

This NN NN O
is NN NN O
confirmed NN NN O
by NN NN O
other NN NN O
recombinants NN NN O
where NN NN O
DM NN NN B-SpecificDisease
segregates NN NN O
with NN NN O
distal NN NN O
probes NN NN O
. NN NN O

Additional NN NN O
marker NN NN O
to NN NN O
marker NN NN O
recombinations NN NN O
in NN NN O
unaffected NN NN O
individuals NN NN O
are NN NN O
reported NN NN O
and NN NN O
support NN NN O
the NN NN O
order NN NN O
and NN NN O
orientation NN NN O
of NN NN O
the NN NN O
DM NN NN B-Modifier
linkage NN NN O
group NN NN O
as NN NN O
pter- NN NN O
( NN NN O
INSR NN NN O
, NN NN O
LDLR NN NN O
, NN NN O
S9 NN NN O
) NN NN O
- NN NN O
( NN NN O
S19 NN NN O
, NN NN O
BCL3 NN NN O
, NN NN O
APOC2 NN NN O
) NN NN O
- NN NN O
( NN NN O
CKMM NN NN O
, NN NN O
DM NN NN O
) NN NN O
- NN NN O
( NN NN O
S22 NN NN O
, NN NN O
+ NN NN O
+ NN NN O
+ NN NN O
PRKCG NN NN O
) NN NN O
-qter NN NN O
. NN NN O

The NN NN O
data NN NN O
presented NN NN O
here NN NN O
can NN NN O
not NN NN O
determine NN NN O
whether NN NN O
DM NN NN B-SpecificDisease
is NN NN O
proximal NN NN O
or NN NN O
distal NN NN O
to NN NN O
CKMM NN NN O
. NN NN O

The NN NN O
consequences NN NN O
of NN NN O
this NN NN O
probe NN NN O
order NN NN O
for NN NN O
antenatal NN NN O
diagnosis NN NN O
and NN NN O
future NN NN O
research NN NN O
aiming NN NN O
to NN NN O
isolate NN NN O
the NN NN O
gene NN NN O
which NN NN O
is NN NN O
affected NN NN O
in NN NN O
DM NN NN B-SpecificDisease
are NN NN O
discussed NN NN O
. NN NN O

2601691 NN NN O
Mutations NN NN O
in NN NN O
the NN NN O
RB1 NN NN O
gene NN NN O
and NN NN O
their NN NN O
effects NN NN O
on NN NN O
transcription NN NN O
. NN NN O

Inactivation NN NN O
of NN NN O
both NN NN O
alleles NN NN O
of NN NN O
the NN NN O
RB1 NN NN O
gene NN NN O
during NN NN O
normal NN NN O
retinal NN NN O
development NN NN O
initiates NN NN O
the NN NN O
formation NN NN O
of NN NN O
a NN NN O
retinoblastoma NN NN B-SpecificDisease
( NN NN I-SpecificDisease
RB NN NN I-SpecificDisease
) NN NN I-SpecificDisease
tumor NN NN I-SpecificDisease
. NN NN O

To NN NN O
identify NN NN O
the NN NN O
mutations NN NN O
which NN NN O
inactivate NN NN O
RB1 NN NN O
, NN NN O
21 NN NN O
RB NN NN B-SpecificDisease
tumors NN NN I-SpecificDisease
isolated NN NN O
from NN NN O
19 NN NN O
patients NN NN O
were NN NN O
analyzed NN NN O
with NN NN O
the NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
or NN NN O
an NN NN O
RNase NN NN O
protection NN NN O
assay NN NN O
or NN NN O
both NN NN O
. NN NN O

Mutations NN NN O
were NN NN O
identified NN NN O
in NN NN O
13 NN NN O
of NN NN O
21 NN NN O
RB NN NN B-SpecificDisease
tumors NN NN I-SpecificDisease
; NN NN O
in NN NN O
8 NN NN O
tumors NN NN B-DiseaseClass
, NN NN O
the NN NN O
precise NN NN O
errors NN NN O
in NN NN O
nucleotide NN NN O
sequence NN NN O
were NN NN O
characterized NN NN O
. NN NN O

Each NN NN O
of NN NN O
four NN NN O
germ NN NN O
line NN NN O
mutations NN NN O
involved NN NN O
a NN NN O
small NN NN O
deletion NN NN O
or NN NN O
duplication NN NN O
, NN NN O
while NN NN O
three NN NN O
somatic NN NN O
mutations NN NN O
were NN NN O
point NN NN O
mutations NN NN O
leading NN NN O
to NN NN O
splice NN NN O
alterations NN NN O
and NN NN O
loss NN NN O
of NN NN O
an NN NN O
exon NN NN O
from NN NN O
the NN NN O
mature NN NN O
RB1 NN NN O
mRNA NN NN O
. NN NN O

We NN NN O
were NN NN O
unable NN NN O
to NN NN O
detect NN NN O
expression NN NN O
of NN NN O
the NN NN O
mutant NN NN O
allele NN NN O
in NN NN O
lymphoblasts NN NN O
of NN NN O
three NN NN O
bilaterally NN NN O
affected NN NN O
patients NN NN O
, NN NN O
although NN NN O
the NN NN O
mutation NN NN O
was NN NN O
present NN NN O
in NN NN O
the NN NN O
genomic NN NN O
DNA NN NN O
and NN NN O
transcripts NN NN O
containing NN NN O
the NN NN O
mutations NN NN O
were NN NN O
obvious NN NN O
in NN NN O
the NN NN O
RB NN NN B-SpecificDisease
tumors NN NN I-SpecificDisease
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
a NN NN O
normal NN NN O
RB1 NN NN O
allele NN NN O
. NN NN O

The NN NN O
variations NN NN O
in NN NN O
the NN NN O
level NN NN O
of NN NN O
expression NN NN O
of NN NN O
mutant NN NN O
transcripts NN NN O
suggest NN NN O
deregulation NN NN O
of NN NN O
RB1 NN NN O
transcription NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
a NN NN O
functional NN NN O
RB1 NN NN O
gene NN NN O
product NN NN O
. NN NN O

. NN NN O

2651669 NN NN O
Partial NN NN O
deletion NN NN O
8q NN NN O
without NN NN O
Langer-Giedion NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
: NN NN O
a NN NN O
recognisable NN NN O
syndrome NN NN O
. NN NN O

We NN NN O
report NN NN O
two NN NN O
de NN NN O
novo NN NN O
cases NN NN O
of NN NN O
del NN NN O
( NN NN O
8 NN NN O
) NN NN O
( NN NN O
pter NN NN O
-- NN NN O
-- NN NN O
q24 NN NN O
. NN NN O

1 NN NN O
) NN NN O
with NN NN O
breakpoints NN NN O
involving NN NN O
the NN NN O
distal NN NN O
part NN NN O
of NN NN O
band NN NN O
8q24 NN NN O
. NN NN O

1 NN NN O
1 NN NN O
. NN NN O

The NN NN O
clinical NN NN O
features NN NN O
were NN NN O
similar NN NN O
and NN NN O
there NN NN O
were NN NN O
no NN NN O
obvious NN NN O
stigmata NN NN O
of NN NN O
Langer-Giedion NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
LGS NN NN B-SpecificDisease
) NN NN O
. NN NN O

There NN NN O
are NN NN O
three NN NN O
other NN NN O
cases NN NN O
reported NN NN O
with NN NN O
a NN NN O
deletion NN NN O
of NN NN O
chromosome NN NN O
8 NN NN O
at NN NN O
approximately NN NN O
the NN NN O
same NN NN O
breakpoint NN NN O
, NN NN O
one NN NN O
without NN NN O
LGS NN NN B-SpecificDisease
and NN NN O
some NN NN O
similarities NN NN O
to NN NN O
our NN NN O
cases NN NN O
, NN NN O
the NN NN O
other NN NN O
two NN NN O
with NN NN O
LGS NN NN B-SpecificDisease
. NN NN O

Our NN NN O
findings NN NN O
would NN NN O
support NN NN O
the NN NN O
observation NN NN O
that NN NN O
the NN NN O
critical NN NN O
segment NN NN O
for NN NN O
the NN NN O
assignment NN NN O
of NN NN O
LGS NN NN B-SpecificDisease
is NN NN O
proximal NN NN O
to NN NN O
or NN NN O
involves NN NN O
the NN NN O
proximal NN NN O
part NN NN O
of NN NN O
8q24 NN NN O
. NN NN O

1 NN NN O
, NN NN O
but NN NN O
a NN NN O
review NN NN O
of NN NN O
published NN NN O
reports NN NN O
suggests NN NN O
that NN NN O
the NN NN O
aetiology NN NN O
of NN NN O
LGS NN NN B-SpecificDisease
may NN NN O
be NN NN O
a NN NN O
more NN NN O
complex NN NN O
issue NN NN O

2703233 NN NN O
Myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
is NN NN O
closely NN NN O
linked NN NN O
to NN NN O
the NN NN O
gene NN NN O
for NN NN O
muscle-type NN NN O
creatine NN NN O
kinase NN NN O
( NN NN O
CKMM NN NN O
) NN NN O
. NN NN O

We NN NN O
have NN NN O
studied NN NN O
genetic NN NN O
linkage NN NN O
between NN NN O
the NN NN O
gene NN NN O
for NN NN O
creatine NN NN O
kinase NN NN O
muscle NN NN O
type NN NN O
( NN NN O
CKMM NN NN O
) NN NN O
and NN NN O
the NN NN O
gene NN NN O
for NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
. NN NN O

In NN NN O
a NN NN O
panel NN NN O
of NN NN O
65 NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
families NN NN O
from NN NN O
Canada NN NN O
and NN NN O
the NN NN O
Netherlands NN NN O
, NN NN O
a NN NN O
maximum NN NN O
lod NN NN O
score NN NN O
( NN NN O
Zmax NN NN O
) NN NN O
of NN NN O
22 NN NN O
. NN NN O

8 NN NN O
at NN NN O
a NN NN O
recombination NN NN O
frequency NN NN O
( NN NN O
theta NN NN O
) NN NN O
of NN NN O
0 NN NN O
. NN NN O

03 NN NN O
was NN NN O
obtained NN NN O
. NN NN O

Tight NN NN O
linkage NN NN O
was NN NN O
also NN NN O
demonstrated NN NN O
for NN NN O
CKMM NN NN O
and NN NN O
the NN NN O
gene NN NN O
for NN NN O
apolipoprotein NN NN O
C2 NN NN O
( NN NN O
ApoC2 NN NN O
) NN NN O
. NN NN O

This NN NN O
establishes NN NN O
CKMM NN NN O
as NN NN O
a NN NN O
useful NN NN O
marker NN NN O
for NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease

2729274 NN NN O
Color NN NN B-DiseaseClass
vision NN NN I-DiseaseClass
defects NN NN I-DiseaseClass
in NN NN O
adrenomyeloneuropathy NN NN B-SpecificDisease
. NN NN O

The NN NN O
relationship NN NN O
between NN NN O
abnormal NN NN B-DiseaseClass
color NN NN I-DiseaseClass
vision NN NN I-DiseaseClass
and NN NN O
adrenomyeloneuropathy NN NN B-SpecificDisease
( NN NN O
AMN NN NN B-SpecificDisease
) NN NN O
was NN NN O
investigated NN NN O
in NN NN O
27 NN NN O
AMN NN NN B-Modifier
patients NN NN O
and NN NN O
31 NN NN O
age-matched NN NN O
controls NN NN O
by NN NN O
using NN NN O
the NN NN O
Farnsworth-Munsell NN NN O
100 NN NN O
Hue NN NN O
test NN NN O
. NN NN O

Twelve NN NN O
( NN NN O
44 NN NN O
% NN NN O
) NN NN O
of NN NN O
27 NN NN O
patients NN NN O
showed NN NN O
test NN NN O
scores NN NN O
significantly NN NN O
above NN NN O
normal NN NN O
. NN NN O

The NN NN O
axes NN NN O
of NN NN O
bipolarity NN NN O
determined NN NN O
by NN NN O
the NN NN O
testing NN NN O
differed NN NN O
widely NN NN O
between NN NN O
the NN NN O
patients NN NN O
with NN NN O
abnormal NN NN O
scores NN NN O
, NN NN O
compatible NN NN O
with NN NN O
the NN NN O
notion NN NN O
that NN NN O
different NN NN O
alterations NN NN O
in NN NN O
visual NN NN O
pigment NN NN O
genes NN NN O
occur NN NN O
in NN NN O
different NN NN O
AMN NN NN B-Modifier
kindreds NN NN O
. NN NN O

These NN NN O
observations NN NN O
confirm NN NN O
our NN NN O
earlier NN NN O
impression NN NN O
that NN NN O
the NN NN O
frequency NN NN O
of NN NN O
abnormal NN NN B-DiseaseClass
color NN NN I-DiseaseClass
vision NN NN I-DiseaseClass
is NN NN O
increased NN NN O
in NN NN O
these NN NN O
kindreds NN NN O
, NN NN O
and NN NN O
it NN NN O
supports NN NN O
our NN NN O
contentions NN NN O
that NN NN O
( NN NN O
1 NN NN O
) NN NN O
AMN NN NN B-SpecificDisease
( NN NN O
and NN NN O
its NN NN O
companion NN NN O
, NN NN O
adrenoleukodystrophy NN NN B-DiseaseClass
) NN NN O
are NN NN O
very NN NN O
closely NN NN O
linked NN NN O
to NN NN O
the NN NN O
visual NN NN O
pigment NN NN O
loci NN NN O
at NN NN O
Xq28 NN NN O
and NN NN O
( NN NN O
2 NN NN O
) NN NN O
this NN NN O
proximity NN NN O
might NN NN O
provide NN NN O
the NN NN O
opportunity NN NN O
to NN NN O
observe NN NN O
contiguous NN NN B-DiseaseClass
gene NN NN I-DiseaseClass
defects NN NN I-DiseaseClass
. NN NN O

. NN NN O

2760209 NN NN O
Molecular NN NN O
analysis NN NN O
of NN NN O
a NN NN O
female NN NN O
Lesch-Nyhan NN NN B-Modifier
patient NN NN O
. NN NN O

We NN NN O
report NN NN O
the NN NN O
identification NN NN O
of NN NN O
a NN NN O
female NN NN O
patient NN NN O
with NN NN O
the NN NN O
X-linked NN NN O
recessive NN NN O
Lesch-Nyhan NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
hypoxanthine NN NN B-SpecificDisease
phosphoribosyltransferase NN NN I-SpecificDisease
[ NN NN I-SpecificDisease
HPRT NN NN I-SpecificDisease
] NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
) NN NN O
. NN NN O

Cytogenetic NN NN O
and NN NN O
carrier NN NN O
studies NN NN O
revealed NN NN O
structurally NN NN O
normal NN NN O
chromosomes NN NN O
for NN NN O
this NN NN O
patient NN NN O
and NN NN O
her NN NN O
parents NN NN O
and NN NN O
demonstrated NN NN O
that NN NN O
this NN NN O
mutation NN NN O
arose NN NN O
through NN NN O
a NN NN O
de NN NN O
novo NN NN O
gametic NN NN O
event NN NN O
. NN NN O

Comparison NN NN O
of NN NN O
this NN NN O
patients NN NN O
DNA NN NN O
with NN NN O
the NN NN O
DNA NN NN O
of NN NN O
her NN NN O
parents NN NN O
revealed NN NN O
that NN NN O
a NN NN O
microdeletion NN NN O
, NN NN O
which NN NN O
occurred NN NN O
within NN NN O
a NN NN O
maternal NN NN O
gamete NN NN O
and NN NN O
involved NN NN O
the NN NN O
entire NN NN O
HPRT NN NN O
gene NN NN O
, NN NN O
was NN NN O
partially NN NN O
responsible NN NN O
for NN NN O
the NN NN O
disease NN NN O
in NN NN O
this NN NN O
patient NN NN O
. NN NN O

Somatic NN NN O
cell NN NN O
hybrids NN NN O
, NN NN O
generated NN NN O
to NN NN O
separate NN NN O
maternal NN NN O
and NN NN O
paternal NN NN O
X NN NN O
chromosomes NN NN O
, NN NN O
showed NN NN O
that NN NN O
expression NN NN O
of NN NN O
two NN NN O
additional NN NN O
X-linked NN NN O
enzymes NN NN O
, NN NN O
phosphoglycerate NN NN O
kinase NN NN O
and NN NN O
glucose-6-phosphate NN NN O
dehydrogenase NN NN O
, NN NN O
were NN NN O
expressed NN NN O
only NN NN O
in NN NN O
cells NN NN O
that NN NN O
contained NN NN O
the NN NN O
maternal NN NN O
X NN NN O
chromosome NN NN O
, NN NN O
suggesting NN NN O
the NN NN O
presence NN NN O
of NN NN O
a NN NN O
functionally NN NN O
inactive NN NN O
paternal NN NN O
X NN NN O
chromosome NN NN O
. NN NN O

Furthermore NN NN O
, NN NN O
comparison NN NN O
of NN NN O
methylation NN NN O
patterns NN NN O
within NN NN O
a NN NN O
region NN NN O
of NN NN O
the NN NN O
HPRT NN NN O
gene NN NN O
known NN NN O
to NN NN O
be NN NN O
important NN NN O
in NN NN O
gene NN NN O
regulation NN NN O
revealed NN NN O
differences NN NN O
between NN NN O
DNA NN NN O
from NN NN O
the NN NN O
father NN NN O
and NN NN O
the NN NN O
patient NN NN O
, NN NN O
in NN NN O
keeping NN NN O
with NN NN O
an NN NN O
active NN NN O
HPRT NN NN O
locus NN NN O
in NN NN O
the NN NN O
father NN NN O
and NN NN O
an NN NN O
inactive NN NN O
HPRT NN NN O
locus NN NN O
in NN NN O
the NN NN O
patient NN NN O
. NN NN O

Together NN NN O
these NN NN O
data NN NN O
indicate NN NN O
that NN NN O
nonrandom NN NN O
inactivation NN NN O
of NN NN O
the NN NN O
cytogenetically NN NN O
normal NN NN O
paternal NN NN O
X NN NN O
chromosome NN NN O
and NN NN O
a NN NN O
microdeletion NN NN O
of NN NN O
the NN NN O
HPRT NN NN O
gene NN NN O
on NN NN O
an NN NN O
active NN NN O
maternal NN NN O
X NN NN O
chromosome NN NN O
were NN NN O
responsible NN NN O
for NN NN O
the NN NN O
absence NN NN O
of NN NN O
HPRT NN NN O
in NN NN O
this NN NN O
patient NN NN O
. NN NN O

. NN NN O

2773936 NN NN O
Pelizaeus-Merzbacher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
: NN NN O
an NN NN O
X-linked NN NN B-DiseaseClass
neurologic NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
of NN NN I-DiseaseClass
myelin NN NN I-DiseaseClass
metabolism NN NN I-DiseaseClass
with NN NN O
a NN NN O
novel NN NN O
mutation NN NN O
in NN NN O
the NN NN O
gene NN NN O
encoding NN NN O
proteolipid NN NN O
protein NN NN O
. NN NN O

The NN NN O
nosology NN NN O
of NN NN O
the NN NN O
inborn NN NN B-DiseaseClass
errors NN NN I-DiseaseClass
of NN NN I-DiseaseClass
myelin NN NN I-DiseaseClass
metabolism NN NN I-DiseaseClass
has NN NN O
been NN NN O
stymied NN NN O
by NN NN O
the NN NN O
lack NN NN O
of NN NN O
molecular NN NN O
genetic NN NN O
analysis NN NN O
. NN NN O

Historically NN NN O
, NN NN O
Pelizaeus-Merzbacher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
has NN NN O
encompassed NN NN O
a NN NN O
host NN NN O
of NN NN O
neurologic NN NN B-DiseaseClass
disorders NN NN I-DiseaseClass
that NN NN O
present NN NN O
with NN NN O
a NN NN O
deficit NN NN B-DiseaseClass
of NN NN I-DiseaseClass
myelin NN NN I-DiseaseClass
, NN NN O
the NN NN O
membrane NN NN O
elaborated NN NN O
by NN NN O
glial NN NN O
cells NN NN O
that NN NN O
encircles NN NN O
and NN NN O
successively NN NN O
enwraps NN NN O
axons NN NN O
. NN NN O

We NN NN O
describe NN NN O
here NN NN O
a NN NN O
Pelizaeus-Merzbacher NN NN B-Modifier
pedigree NN NN O
of NN NN O
the NN NN O
classical NN NN O
type NN NN O
, NN NN O
with NN NN O
X-linked NN NN O
inheritance NN NN O
, NN NN O
a NN NN O
typical NN NN O
clinical NN NN O
progression NN NN O
, NN NN O
and NN NN O
a NN NN O
pathologic NN NN O
loss NN NN O
of NN NN O
myelinating NN NN O
cells NN NN O
and NN NN O
myelin NN NN O
in NN NN O
the NN NN O
central NN NN O
nervous NN NN O
system NN NN O
. NN NN O

To NN NN O
discriminate NN NN O
variants NN NN O
of NN NN O
Pelizaeus-Merzbacher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
, NN NN O
a NN NN O
set NN NN O
of NN NN O
oligonucleotide NN NN O
primers NN NN O
was NN NN O
constructed NN NN O
to NN NN O
polymerase-chain-reaction NN NN O
( NN NN O
PCR NN NN O
) NN NN O
amplify NN NN O
and NN NN O
sequence NN NN O
the NN NN O
gene NN NN O
encoding NN NN O
proteolipid NN NN O
protein NN NN O
( NN NN O
PLP NN NN O
) NN NN O
, NN NN O
a NN NN O
structural NN NN O
protein NN NN O
that NN NN O
comprises NN NN O
half NN NN O
of NN NN O
the NN NN O
protein NN NN O
of NN NN O
the NN NN O
myelin NN NN O
sheath NN NN O
. NN NN O

The NN NN O
PLP NN NN O
gene NN NN O
in NN NN O
one NN NN O
of NN NN O
two NN NN O
affected NN NN O
males NN NN O
and NN NN O
the NN NN O
carrier NN NN O
mother NN NN O
of NN NN O
this NN NN O
family NN NN O
exhibited NN NN O
a NN NN O
single NN NN O
base NN NN O
difference NN NN O
in NN NN O
the NN NN O
more NN NN O
than NN NN O
2 NN NN O
kb NN NN O
of NN NN O
the NN NN O
PLP NN NN O
gene NN NN O
sequenced NN NN O
, NN NN O
a NN NN O
C NN NN O
-- NN NN O
-- NN NN O
T NN NN O
transition NN NN O
that NN NN O
would NN NN O
create NN NN O
a NN NN O
serine NN NN O
substitution NN NN O
for NN NN O
proline NN NN O
at NN NN O
the NN NN O
carboxy NN NN O
end NN NN O
of NN NN O
the NN NN O
protein NN NN O
. NN NN O

Our NN NN O
results NN NN O
delineate NN NN O
the NN NN O
clinical NN NN O
features NN NN O
of NN NN O
Pelizaeus-Merzbacher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
, NN NN O
define NN NN O
the NN NN O
possible NN NN O
molecular NN NN O
pathology NN NN O
of NN NN O
this NN NN O
dysmyelinating NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
, NN NN O
and NN NN O
address NN NN O
the NN NN O
molecular NN NN O
classification NN NN O
of NN NN O
inborn NN NN B-DiseaseClass
errors NN NN I-DiseaseClass
of NN NN I-DiseaseClass
myelin NN NN I-DiseaseClass
metabolism NN NN I-DiseaseClass
. NN NN O

Patients NN NN O
with NN NN O
the NN NN O
classical NN NN O
form NN NN O
( NN NN O
type NN NN O
I NN NN O
) NN NN O
and NN NN O
the NN NN O
more NN NN O
severely NN NN O
affected NN NN O
, NN NN O
connatal NN NN O
variant NN NN O
of NN NN O
Pelizaeus-Merzbacher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN I-SpecificDisease
type NN NN I-SpecificDisease
II NN NN I-SpecificDisease
) NN NN I-SpecificDisease
would NN NN O
be NN NN O
predicted NN NN O
to NN NN O
display NN NN O
mutation NN NN O
at NN NN O
the NN NN O
PLP NN NN O
locus NN NN O
. NN NN O

The NN NN O
other NN NN O
variants NN NN O
( NN NN O
types NN NN O
III-VI NN NN O
) NN NN O
, NN NN O
which NN NN O
have NN NN O
sometimes NN NN O
been NN NN O
categorized NN NN O
as NN NN O
Pelizaeus-Merzbacher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
, NN NN O
may NN NN O
represent NN NN O
mutations NN NN O
in NN NN O
genes NN NN O
encoding NN NN O
other NN NN O
structural NN NN O
myelin NN NN O
proteins NN NN O
or NN NN O
proteins NN NN O
critical NN NN O
to NN NN O
myelination NN NN O
. NN NN O

. NN NN O

2786201 NN NN O
Molecular NN NN O
basis NN NN O
of NN NN O
human NN NN O
von NN NN B-SpecificDisease
Willebrand NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
: NN NN O
analysis NN NN O
of NN NN O
platelet NN NN O
von NN NN B-Modifier
Willebrand NN NN I-Modifier
factor NN NN O
mRNA NN NN O
. NN NN O

von NN NN B-SpecificDisease
Willebrand NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
vWD NN NN B-SpecificDisease
) NN NN O
, NN NN O
the NN NN O
most NN NN O
common NN NN O
inherited NN NN B-DiseaseClass
bleeding NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
in NN NN O
humans NN NN O
, NN NN O
can NN NN O
result NN NN O
from NN NN O
either NN NN O
a NN NN O
quantitative NN NN O
or NN NN O
a NN NN O
qualitative NN NN O
defect NN NN O
in NN NN O
the NN NN O
adhesive NN NN O
glycoprotein NN NN O
, NN NN O
von NN NN B-Modifier
Willebrand NN NN I-Modifier
factor NN NN O
( NN NN O
vWF NN NN O
) NN NN O
. NN NN O

Molecular NN NN O
studies NN NN O
of NN NN O
vWD NN NN B-SpecificDisease
have NN NN O
been NN NN O
limited NN NN O
by NN NN O
the NN NN O
large NN NN O
size NN NN O
of NN NN O
the NN NN O
vWF NN NN O
gene NN NN O
and NN NN O
difficulty NN NN O
in NN NN O
obtaining NN NN O
the NN NN O
vWF NN NN O
mRNA NN NN O
from NN NN O
patients NN NN O
. NN NN O

By NN NN O
use NN NN O
of NN NN O
an NN NN O
adaptation NN NN O
of NN NN O
the NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
, NN NN O
vWF NN NN O
mRNA NN NN O
was NN NN O
amplified NN NN O
and NN NN O
sequenced NN NN O
from NN NN O
peripheral NN NN O
blood NN NN O
platelets NN NN O
. NN NN O

A NN NN O
silent NN NN O
vWF NN NN O
allele NN NN O
was NN NN O
identified NN NN O
, NN NN O
resulting NN NN O
from NN NN O
a NN NN O
cis NN NN O
defect NN NN O
in NN NN O
vWF NN NN O
mRNA NN NN O
transcription NN NN O
or NN NN O
processing NN NN O
. NN NN O

In NN NN O
two NN NN O
type NN NN B-Modifier
IIA NN NN I-Modifier
vWD NN NN I-Modifier
patients NN NN O
, NN NN O
two NN NN O
different NN NN O
but NN NN O
adjacent NN NN O
missense NN NN O
mutations NN NN O
were NN NN O
identified NN NN O
, NN NN O
the NN NN O
locations NN NN O
of NN NN O
which NN NN O
may NN NN O
identify NN NN O
an NN NN O
important NN NN O
vWF NN NN O
functional NN NN O
domain NN NN O
. NN NN O

Expression NN NN O
in NN NN O
heterologous NN NN O
cells NN NN O
of NN NN O
recombinant NN NN O
vWF NN NN O
containing NN NN O
one NN NN O
of NN NN O
these NN NN O
latter NN NN O
mutations NN NN O
reproduced NN NN O
the NN NN O
characteristic NN NN O
structural NN NN B-DiseaseClass
abnormality NN NN I-DiseaseClass
seen NN NN O
in NN NN O
type NN NN B-Modifier
IIA NN NN I-Modifier
vWD NN NN I-Modifier
plasma NN NN O
. NN NN O

. NN NN O

2792129 NN NN O
Familial NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
seventh NN NN I-SpecificDisease
component NN NN I-SpecificDisease
of NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
associated NN NN O
with NN NN O
recurrent NN NN O
meningococcal NN NN B-SpecificDisease
infections NN NN I-SpecificDisease
. NN NN O

We NN NN O
describe NN NN O
an NN NN O
11-year-old NN NN O
girl NN NN O
suffering NN NN O
from NN NN O
recurrent NN NN B-SpecificDisease
meningitis NN NN I-SpecificDisease
with NN NN O
a NN NN O
complete NN NN O
absence NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
seventh NN NN I-SpecificDisease
component NN NN I-SpecificDisease
of NN NN I-SpecificDisease
complemen NN NN I-SpecificDisease
t NN NN O
( NN NN O
C7 NN NN O
) NN NN O
. NN NN O

Diagnosis NN NN O
was NN NN O
established NN NN O
by NN NN O
haemolytic NN NN O
titration NN NN O
and NN NN O
western NN NN O
blotting NN NN O
. NN NN O

The NN NN O
patients NN NN O
serum NN NN O
lacked NN NN O
the NN NN O
85 NN NN O
kDa NN NN O
C7 NN NN O
chain NN NN O
. NN NN O

Haemolytic NN NN O
activity NN NN O
of NN NN O
serum NN NN O
was NN NN O
reconstituted NN NN O
with NN NN O
either NN NN O
pooled NN NN O
normal NN NN O
human NN NN O
serum NN NN O
or NN NN O
with NN NN O
purified NN NN O
C7 NN NN O
. NN NN O

The NN NN O
relatives NN NN O
( NN NN O
parents NN NN O
and NN NN O
one NN NN O
sister NN NN O
) NN NN O
had NN NN O
half-normal NN NN O
levels NN NN O
of NN NN O
both NN NN O
immunochemically NN NN O
and NN NN O
functionally NN NN O
determined NN NN O
C7 NN NN O
, NN NN O
indicating NN NN O
a NN NN O
heterozygous NN NN O
state NN NN O
for NN NN O
C7 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

. NN NN O

2817003 NN NN O
Translocation NN NN O
t NN NN O
( NN NN O
5 NN NN O
; NN NN O
11 NN NN O
) NN NN O
( NN NN O
q13.1 NN NN O
; NN NN O
p13 NN NN O
) NN NN O
associated NN NN O
with NN NN O
familial NN NN O
isolated NN NN B-SpecificDisease
aniridia NN NN I-SpecificDisease
. NN NN O

A NN NN O
father NN NN O
and NN NN O
daughter NN NN O
with NN NN O
isolated NN NN B-SpecificDisease
aniridia NN NN I-SpecificDisease
were NN NN O
observed NN NN O
to NN NN O
have NN NN O
an NN NN O
apparently NN NN O
balanced NN NN O
, NN NN O
reciprocal NN NN O
translocation NN NN O
involving NN NN O
chromosomes NN NN O
5 NN NN O
and NN NN O
11 NN NN O
[ NN NN O
t NN NN O
( NN NN O
5 NN NN O
; NN NN O
11 NN NN O
) NN NN O
( NN NN O
q13 NN NN O
. NN NN O

1 NN NN O
; NN NN O
p13 NN NN O
) NN NN O
] NN NN O
. NN NN O

No NN NN O
other NN NN O
clinical NN NN O
characteristics NN NN O
often NN NN O
associated NN NN O
with NN NN O
the NN NN O
deletion NN NN O
of NN NN O
11p13 NN NN O
were NN NN O
observed NN NN O
in NN NN O
this NN NN O
family NN NN O
. NN NN O

This NN NN O
finding NN NN O
, NN NN O
in NN NN O
association NN NN O
with NN NN O
3 NN NN O
other NN NN O
instances NN NN O
of NN NN O
single NN NN O
breaks NN NN O
at NN NN O
11p13 NN NN O
and NN NN O
aniridia NN NN B-SpecificDisease
, NN NN O
supports NN NN O
the NN NN O
assignment NN NN O
of NN NN O
AN2 NN NN O
to NN NN O
11p13 NN NN O
. NN NN O

2828430 NN NN O
Homozygous NN NN B-SpecificDisease
hypobetalipoproteinemia NN NN I-SpecificDisease
: NN NN O
a NN NN O
disease NN NN O
distinct NN NN O
from NN NN O
abetalipoproproteinemia NN NN B-SpecificDisease
at NN NN O
the NN NN O
molecular NN NN O
level NN NN O
. NN NN O

apoB NN NN O
DNA NN NN O
, NN NN O
RNA NN NN O
, NN NN O
and NN NN O
protein NN NN O
from NN NN O
two NN NN O
patients NN NN O
with NN NN O
homozygous NN NN B-SpecificDisease
hypobetalipoproteinemia NN NN I-SpecificDisease
( NN NN O
HBL NN NN B-SpecificDisease
) NN NN O
were NN NN O
evaluated NN NN O
and NN NN O
compared NN NN O
with NN NN O
normal NN NN O
individuals NN NN O
. NN NN O

Southern NN NN O
blot NN NN O
analysis NN NN O
with NN NN O
10 NN NN O
different NN NN O
cDNA NN NN O
probes NN NN O
revealed NN NN O
a NN NN O
normal NN NN O
gene NN NN O
without NN NN O
major NN NN O
insertions NN NN O
, NN NN O
deletions NN NN O
, NN NN O
or NN NN O
rearrangements NN NN O
. NN NN O

Northern NN NN O
and NN NN O
slot NN NN O
blot NN NN O
analyses NN NN O
of NN NN O
total NN NN O
liver NN NN O
mRNA NN NN O
from NN NN O
HBL NN NN B-Modifier
patients NN NN O
documented NN NN O
a NN NN O
normal NN NN O
size NN NN O
apoB NN NN O
mRNA NN NN O
that NN NN O
was NN NN O
present NN NN O
in NN NN O
greatly NN NN O
reduced NN NN O
quantities NN NN O
. NN NN O

ApoB NN NN O
protein NN NN O
was NN NN O
detected NN NN O
within NN NN O
HBL NN NN B-Modifier
hepatocytes NN NN O
utilizing NN NN O
immunohistochemical NN NN O
techniques NN NN O
; NN NN O
however NN NN O
, NN NN O
it NN NN O
was NN NN O
markedly NN NN O
reduced NN NN O
in NN NN O
quantity NN NN O
when NN NN O
compared NN NN O
with NN NN O
control NN NN O
samples NN NN O
. NN NN O

No NN NN O
apoB NN NN O
was NN NN O
detectable NN NN O
in NN NN O
the NN NN O
plasma NN NN O
of NN NN O
HBL NN NN B-Modifier
individuals NN NN O
with NN NN O
an NN NN O
ELISA NN NN O
assay NN NN O
. NN NN O

These NN NN O
data NN NN O
are NN NN O
most NN NN O
consistent NN NN O
with NN NN O
a NN NN O
mutation NN NN O
in NN NN O
the NN NN O
coding NN NN O
portion NN NN O
of NN NN O
the NN NN O
apoB NN NN O
gene NN NN O
in NN NN O
HBL NN NN B-Modifier
patients NN NN O
, NN NN O
leading NN NN O
to NN NN O
an NN NN O
abnormal NN NN O
apoB NN NN O
protein NN NN O
and NN NN O
apoB NN NN O
mRNA NN NN O
instability NN NN O
. NN NN O

These NN NN O
results NN NN O
are NN NN O
distinct NN NN O
from NN NN O
those NN NN O
previously NN NN O
noted NN NN O
in NN NN O
abetalipoproteinemia NN NN B-SpecificDisease
, NN NN O
which NN NN O
was NN NN O
characterized NN NN O
by NN NN O
an NN NN O
elevated NN NN O
level NN NN O
of NN NN O
hepatic NN NN O
apoB NN NN O
mRNA NN NN O
and NN NN O
accumulation NN NN O
of NN NN O
intracellular NN NN O
hepatic NN NN O
apoB NN NN O
protein NN NN O
. NN NN O

. NN NN O

2835825 NN NN O
Spontaneous NN NN O
reversion NN NN O
of NN NN O
novel NN NN O
Lesch-Nyhan NN NN B-Modifier
mutation NN NN O
by NN NN O
HPRT NN NN O
gene NN NN O
rearrangement NN NN O
. NN NN O

Molecular NN NN O
analysis NN NN O
of NN NN O
an NN NN O
unusual NN NN O
patient NN NN O
with NN NN O
the NN NN O
Lesch-Nyhan NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
has NN NN O
suggested NN NN O
that NN NN O
the NN NN O
mutation NN NN O
is NN NN O
due NN NN O
to NN NN O
a NN NN O
partial NN NN O
HPRT NN NN O
gene NN NN O
duplication NN NN O
. NN NN O

We NN NN O
now NN NN O
report NN NN O
the NN NN O
cloning NN NN O
and NN NN O
sequencing NN NN O
of NN NN O
the NN NN O
mutant NN NN O
HPRT NN NN O
cDNA NN NN O
which NN NN O
shows NN NN O
the NN NN O
precise NN NN O
duplication NN NN O
of NN NN O
exons NN NN O
2 NN NN O
and NN NN O
3 NN NN O
. NN NN O

This NN NN O
mutation NN NN O
is NN NN O
the NN NN O
result NN NN O
of NN NN O
an NN NN O
internal NN NN O
duplication NN NN O
of NN NN O
16-20 NN NN O
kilobases NN NN O
of NN NN O
the NN NN O
gene NN NN O
. NN NN O

The NN NN O
structure NN NN O
of NN NN O
the NN NN O
mutant NN NN O
gene NN NN O
suggests NN NN O
that NN NN O
the NN NN O
duplication NN NN O
was NN NN O
not NN NN O
generated NN NN O
by NN NN O
a NN NN O
single NN NN O
unequal NN NN O
crossing-over NN NN O
event NN NN O
between NN NN O
two NN NN O
normal NN NN O
HPRT NN NN O
alleles NN NN O
. NN NN O

Growth NN NN O
of NN NN O
Epstein-Barr NN NN B-Modifier
virus-transformed NN NN O
lymphoblasts NN NN O
from NN NN O
this NN NN O
patient NN NN O
in NN NN O
selective NN NN O
medium NN NN O
has NN NN O
permitted NN NN O
isolation NN NN O
of NN NN O
spontaneous NN NN O
HPRT NN NN O
+ NN NN O
revertants NN NN O
of NN NN O
this NN NN O
mutation NN NN O
. NN NN O

The NN NN O
reversion NN NN O
event NN NN O
involves NN NN O
a NN NN O
second NN NN O
major NN NN O
HPRT NN NN O
gene NN NN O
rearrangement NN NN O
where NN NN O
most NN NN O
or NN NN O
all NN NN O
of NN NN O
the NN NN O
duplicated NN NN O
portion NN NN O
of NN NN O
the NN NN O
mutant NN NN O
gene NN NN O
is NN NN O
deleted NN NN O
. NN NN O

The NN NN O
original NN NN O
mutation NN NN O
therefore NN NN O
has NN NN O
the NN NN O
potential NN NN O
for NN NN O
spontaneous NN NN O
somatic NN NN O
reversion NN NN O
. NN NN O

This NN NN O
may NN NN O
explain NN NN O
the NN NN O
relatively NN NN O
mild NN NN O
symptoms NN NN O
of NN NN O
the NN NN O
Lesch-Nyhan NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
exhibited NN NN O
by NN NN O
this NN NN O
patient NN NN O
. NN NN O

. NN NN O

2852474 NN NN O
Complex NN NN B-SpecificDisease
glycerol NN NN I-SpecificDisease
kinase NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
: NN NN O
molecular-genetic NN NN O
, NN NN O
cytogenetic NN NN O
, NN NN O
and NN NN O
clinical NN NN O
studies NN NN O
of NN NN O
five NN NN O
Japanese NN NN O
patients NN NN O
. NN NN O

Five NN NN O
male NN NN O
Japanese NN NN O
patients NN NN O
with NN NN O
complex NN NN B-SpecificDisease
glycerol NN NN I-SpecificDisease
kinase NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
( NN NN O
CGKD NN NN B-SpecificDisease
) NN NN O
and NN NN O
their NN NN O
relatives NN NN O
were NN NN O
studied NN NN O
clinically NN NN O
, NN NN O
cytogenetically NN NN O
, NN NN O
and NN NN O
molecular-genetically NN NN O
. NN NN O

All NN NN O
patients NN NN O
had NN NN O
muscular NN NN B-DiseaseClass
dystrophy NN NN I-DiseaseClass
or NN NN O
muscle NN NN B-DiseaseClass
weakness NN NN I-DiseaseClass
, NN NN O
mental NN NN B-DiseaseClass
retardation NN NN I-DiseaseClass
, NN NN O
congenital NN NN B-SpecificDisease
adrenal NN NN I-SpecificDisease
hypoplasia NN NN I-SpecificDisease
, NN NN O
and NN NN O
glycerol NN NN B-DiseaseClass
kinase NN NN I-DiseaseClass
deficiency NN NN I-DiseaseClass
. NN NN O

High-resolution NN NN O
GTG-banded NN NN O
chromosomes NN NN O
showed NN NN O
a NN NN O
microdeletion NN NN O
in NN NN O
the NN NN O
Xp21 NN NN O
region NN NN O
in NN NN O
all NN NN O
four NN NN O
patients NN NN O
examined NN NN O
and NN NN O
in NN NN O
all NN NN O
five NN NN O
mothers NN NN O
. NN NN O

Southern NN NN O
hybridizations NN NN O
, NN NN O
after NN NN O
digestions NN NN O
by NN NN O
restriction NN NN O
endonucleases NN NN O
, NN NN O
with NN NN O
various NN NN O
cloned NN NN O
DNAs NN NN O
( NN NN O
D2 NN NN O
, NN NN O
99-6 NN NN O
, NN NN O
B24 NN NN O
, NN NN O
C7 NN NN O
, NN NN O
L1-4 NN NN O
, NN NN O
cDMD13-14 NN NN O
, NN NN O
J66-HI NN NN O
, NN NN O
P20 NN NN O
, NN NN O
J-Bir NN NN O
, NN NN O
ERT87-30 NN NN O
, NN NN O
ERT87-15 NN NN O
, NN NN O
ERT87-8 NN NN O
, NN NN O
ERT87-1 NN NN O
, NN NN O
XJ-1 NN NN O
. NN NN O

1 NN NN O
, NN NN O
754 NN NN O
, NN NN O
cx5 NN NN O
. NN NN O

7 NN NN O
, NN NN O
and NN NN O
OTC-1 NN NN O
) NN NN O
that NN NN O
are NN NN O
located NN NN O
around NN NN O
Xp21 NN NN O
also NN NN O
showed NN NN O
a NN NN O
deletion NN NN O
in NN NN O
the NN NN O
genome NN NN O
of NN NN O
all NN NN O
patients NN NN O
and NN NN O
mothers NN NN O
. NN NN O

Although NN NN O
the NN NN O
deletion NN NN O
differed NN NN O
in NN NN O
size NN NN O
among NN NN O
patients NN NN O
, NN NN O
a NN NN O
segment NN NN O
commonly NN NN O
absent NN NN O
was NN NN O
located NN NN O
between NN NN O
the NN NN O
genomic NN NN O
sequences NN NN O
corresponding NN NN O
to NN NN O
L1-4 NN NN O
and NN NN O
cDMD13-14 NN NN O
. NN NN O

This NN NN O
finding NN NN O
indicated NN NN O
that NN NN O
the NN NN O
gene NN NN O
coding NN NN O
for NN NN O
glycerol NN NN O
kinase NN NN O
( NN NN O
GK NN NN O
) NN NN O
is NN NN O
located NN NN O
within NN NN O
this NN NN O
segment NN NN O
. NN NN O

A NN NN O
comparison NN NN O
of NN NN O
the NN NN O
clinical NN NN O
manifestations NN NN O
of NN NN O
the NN NN O
present NN NN O
five NN NN O
patients NN NN O
and NN NN O
reported NN NN O
CGKD NN NN B-Modifier
or NN NN O
Duchenne NN NN B-Modifier
muscular NN NN I-Modifier
dystrophy NN NN I-Modifier
( NN NN O
DMD NN NN B-Modifier
) NN NN O
patients NN NN O
with NN NN O
DNA NN NN O
deletion NN NN O
suggests NN NN O
the NN NN O
existence NN NN O
of NN NN O
a NN NN O
certain NN NN O
gene NN NN O
responsible NN NN O
for NN NN O
gonadotropin NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
( NN NN O
GTD NN NN B-SpecificDisease
) NN NN O
. NN NN O

The NN NN O
result NN NN O
of NN NN O
the NN NN O
present NN NN O
study NN NN O
and NN NN O
results NN NN O
of NN NN O
previous NN NN O
studies NN NN O
suggest NN NN O
that NN NN O
genes NN NN O
for NN NN O
ornithine NN NN O
transcarbamylase NN NN O
( NN NN O
OTC NN NN O
) NN NN O
, NN NN O
DMD NN NN B-SpecificDisease
, NN NN O
and NN NN O
GK NN NN O
and NN NN O
putative NN NN O
genes NN NN O
responsible NN NN O
for NN NN O
congenital NN NN B-SpecificDisease
adrenal NN NN I-SpecificDisease
hypoplasia NN NN I-SpecificDisease
( NN NN O
AHC NN NN B-SpecificDisease
) NN NN O
and NN NN O
GTD NN NN B-SpecificDisease
are NN NN O
arranged NN NN O
from NN NN O
telomere NN NN O
to NN NN O
centromere NN NN O
as NN NN O
pter NN NN O
-- NN NN O
GTD NN NN O
-- NN NN O
AHC NN NN O
-- NN NN O
GK NN NN O
-- NN NN O
DMD NN NN O
-- NN NN O
OTC NN NN O
-- NN NN O
cen NN NN O

2862466 NN NN O
Genetically NN NN O
determined NN NN O
low NN NN O
C4 NN NN O
: NN NN O
a NN NN O
predisposing NN NN O
factor NN NN O
to NN NN O
autoimmune NN NN B-SpecificDisease
chronic NN NN I-SpecificDisease
active NN NN I-SpecificDisease
hepatitis NN NN I-SpecificDisease
. NN NN O

Of NN NN O
26 NN NN O
patients NN NN O
with NN NN O
autoimmune NN NN B-SpecificDisease
chronic NN NN I-SpecificDisease
active NN NN I-SpecificDisease
hepatitis NN NN I-SpecificDisease
( NN NN O
CAH NN NN B-SpecificDisease
) NN NN O
starting NN NN O
in NN NN O
childhood NN NN O
18 NN NN O
( NN NN O
69 NN NN O
% NN NN O
) NN NN O
had NN NN O
low NN NN O
C4 NN NN O
and NN NN O
5 NN NN O
( NN NN O
19 NN NN O
% NN NN O
) NN NN O
had NN NN O
low NN NN O
C3 NN NN O
serum NN NN O
levels NN NN O
. NN NN O

Impaired NN NN O
hepatic NN NN O
synthesis NN NN O
and NN NN O
immune-consumption NN NN O
were NN NN O
unlikely NN NN O
since NN NN O
transferrin NN NN O
levels NN NN O
were NN NN O
normal NN NN O
in NN NN O
all NN NN O
patients NN NN O
, NN NN O
albumin NN NN O
levels NN NN O
were NN NN O
persistently NN NN O
low NN NN O
in NN NN O
only NN NN O
3 NN NN O
, NN NN O
and NN NN O
only NN NN O
3 NN NN O
had NN NN O
raised NN NN O
levels NN NN O
of NN NN O
activation NN NN O
fragment NN NN O
C3d NN NN O
. NN NN O

C4d NN NN O
was NN NN O
normal NN NN O
in NN NN O
all NN NN O
patients NN NN O
studied NN NN O
. NN NN O

In NN NN O
the NN NN O
families NN NN O
of NN NN O
12 NN NN O
probands NN NN O
with NN NN O
low NN NN O
C4 NN NN O
, NN NN O
7 NN NN O
parents NN NN O
had NN NN O
low NN NN O
C4 NN NN O
and NN NN O
2 NN NN O
had NN NN O
levels NN NN O
which NN NN O
were NN NN O
at NN NN O
the NN NN O
lower NN NN O
limit NN NN O
of NN NN O
normal NN NN O
. NN NN O

5 NN NN O
of NN NN O
10 NN NN O
siblings NN NN O
from NN NN O
5 NN NN O
families NN NN O
had NN NN O
low NN NN O
C4 NN NN O
. NN NN O

These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
low NN NN O
C4 NN NN O
levels NN NN O
in NN NN O
CAH NN NN B-SpecificDisease
are NN NN O
genetically NN NN O
determined NN NN O
. NN NN O

C4 NN NN O
phenotyping NN NN O
in NN NN O
20 NN NN O
patients NN NN O
and NN NN O
in NN NN O
26 NN NN O
parents NN NN O
showed NN NN O
that NN NN O
90 NN NN O
% NN NN O
and NN NN O
81 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
, NN NN O
had NN NN O
null NN NN O
allotypes NN NN O
at NN NN O
either NN NN O
the NN NN O
C4A NN NN O
or NN NN O
C4B NN NN O
locus NN NN O
compared NN NN O
with NN NN O
59 NN NN O
% NN NN O
in NN NN O
controls NN NN O
, NN NN O
indicating NN NN O
that NN NN O
defective NN NN O
expression NN NN O
of NN NN O
structural NN NN O
genes NN NN O
may NN NN O
contribute NN NN O
to NN NN O
the NN NN O
observed NN NN O
C4 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

. NN NN O

2884570 NN NN O
An NN NN O
amino-acid NN NN O
substitution NN NN O
involved NN NN O
in NN NN O
phenylketonuria NN NN B-SpecificDisease
is NN NN O
in NN NN O
linkage NN NN O
disequilibrium NN NN O
with NN NN O
DNA NN NN O
haplotype NN NN O
2 NN NN O
. NN NN O

Phenylketonuria NN NN B-SpecificDisease
( NN NN O
PKU NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
human NN NN I-DiseaseClass
genetic NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
caused NN NN O
by NN NN O
a NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
hepatic NN NN I-SpecificDisease
phenylalanine NN NN I-SpecificDisease
hydroxylase NN NN I-SpecificDisease
( NN NN O
PAH NN NN O
, NN NN O
phenylalanine NN NN O
4-monooxygenase NN NN O
, NN NN O
EC NN NN O
1 NN NN O
. NN NN O

14 NN NN O
. NN NN O

16 NN NN O
. NN NN O

1 NN NN O
) NN NN O
. NN NN O

PKU NN NN B-SpecificDisease
is NN NN O
a NN NN O
common NN NN O
inborn NN NN B-DiseaseClass
error NN NN I-DiseaseClass
of NN NN I-DiseaseClass
amino-acid NN NN I-DiseaseClass
metabolism NN NN I-DiseaseClass
in NN NN O
caucasian NN NN O
populations NN NN O
and NN NN O
approximately NN NN O
1 NN NN O
in NN NN O
50 NN NN O
individuals NN NN O
are NN NN O
carriers NN NN O
of NN NN O
a NN NN O
PKU NN NN B-Modifier
allele NN NN O
. NN NN O

To NN NN O
define NN NN O
the NN NN O
molecular NN NN O
basis NN NN O
of NN NN O
PKU NN NN B-SpecificDisease
, NN NN O
we NN NN O
characterized NN NN O
twelve NN NN O
restriction NN NN O
fragment-length NN NN O
polymorphism NN NN O
( NN NN O
RFLP NN NN O
) NN NN O
haplotypes NN NN O
of NN NN O
the NN NN O
PAH NN NN O
locus NN NN O
in NN NN O
the NN NN O
northern NN NN O
European NN NN O
population NN NN O
and NN NN O
observed NN NN O
that NN NN O
90 NN NN O
% NN NN O
of NN NN O
the NN NN O
PKU NN NN B-Modifier
alleles NN NN O
in NN NN O
this NN NN O
population NN NN O
are NN NN O
confined NN NN O
to NN NN O
four NN NN O
common NN NN O
RFLP NN NN O
haplotypes NN NN O
. NN NN O

We NN NN O
have NN NN O
recently NN NN O
reported NN NN O
a NN NN O
splicing NN NN O
mutation NN NN O
in NN NN O
the NN NN O
PAH NN NN O
gene NN NN O
that NN NN O
is NN NN O
associated NN NN O
with NN NN O
RFLP NN NN O
haplotype NN NN O
3 NN NN O
which NN NN O
is NN NN O
present NN NN O
at NN NN O
about NN NN O
40 NN NN O
% NN NN O
of NN NN O
mutant NN NN O
alleles NN NN O
. NN NN O

We NN NN O
now NN NN O
report NN NN O
the NN NN O
molecular NN NN B-DiseaseClass
lesion NN NN I-DiseaseClass
associated NN NN O
with NN NN O
the NN NN O
RFLP NN NN O
haplotype NN NN O
2 NN NN O
mutant NN NN O
allele NN NN O
. NN NN O

This NN NN O
defect NN NN O
is NN NN O
caused NN NN O
by NN NN O
a NN NN O
C-to-T NN NN O
transition NN NN O
in NN NN O
exon NN NN O
12 NN NN O
resulting NN NN O
in NN NN O
an NN NN O
amino-acid NN NN O
substitution NN NN O
( NN NN O
Arg NN NN O
to NN NN O
Trp NN NN O
) NN NN O
at NN NN O
residue NN NN O
408 NN NN O
of NN NN O
PAH NN NN O
. NN NN O

Direct NN NN O
hybridization NN NN O
analysis NN NN O
of NN NN O
the NN NN O
point NN NN O
mutation NN NN O
using NN NN O
a NN NN O
specific NN NN O
oligonucleotide NN NN O
probe NN NN O
demonstrated NN NN O
that NN NN O
this NN NN O
mutation NN NN O
is NN NN O
also NN NN O
in NN NN O
linkage NN NN O
disequilibrium NN NN O
with NN NN O
RFLP NN NN O
haplotype NN NN O
2 NN NN O
alleles NN NN O
that NN NN O
make NN NN O
up NN NN O
about NN NN O
20 NN NN O
% NN NN O
of NN NN O
mutant NN NN O
PAH NN NN O
genes NN NN O

2886237 NN NN O
Choroideremia NN NN B-SpecificDisease
: NN NN O
close NN NN O
linkage NN NN O
to NN NN O
DXYS1 NN NN O
and NN NN O
DXYS12 NN NN O
demonstrated NN NN O
by NN NN O
segregation NN NN O
analysis NN NN O
and NN NN O
historical-genealogical NN NN O
evidence NN NN O
. NN NN O

Linkage NN NN O
studies NN NN O
using NN NN O
restriction NN NN O
fragment NN NN O
length NN NN O
polymorphisms NN NN O
were NN NN O
conducted NN NN O
in NN NN O
the NN NN O
X-linked NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
, NN NN O
choroideremia NN NN B-SpecificDisease
, NN NN O
designated NN NN O
TCD NN NN B-SpecificDisease
for NN NN O
Progressive NN NN B-SpecificDisease
Tapeto-Choroidal NN NN I-SpecificDisease
Dystrophy NN NN I-SpecificDisease
. NN NN O

Previously NN NN O
demonstrated NN NN O
close NN NN O
linkage NN NN O
with NN NN O
locus NN NN O
DXYS1 NN NN O
was NN NN O
confirmed NN NN O
( NN NN O
lod NN NN O
11 NN NN O
. NN NN O

44 NN NN O
at NN NN O
0 NN NN O
recombination NN NN O
distance NN NN O
) NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
locus NN NN O
DXYS12 NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
closely NN NN O
linked NN NN O
with NN NN O
TCD NN NN B-SpecificDisease
( NN NN O
lod NN NN O
3 NN NN O
. NN NN O

31 NN NN O
at NN NN O
0 NN NN O
recombination NN NN O
distance NN NN O
) NN NN O
. NN NN O

The NN NN O
disease NN NN O
mainly NN NN O
occurs NN NN O
in NN NN O
three NN NN O
large NN NN O
kindreds NN NN O
in NN NN O
remote NN NN O
Northern NN NN O
Finland NN NN O
. NN NN O

While NN NN O
formal NN NN O
genealogical NN NN O
proof NN NN O
is NN NN O
lacking NN NN O
, NN NN O
all NN NN O
presently NN NN O
living NN NN O
( NN NN O
more NN NN O
than NN NN O
80 NN NN O
affected NN NN O
males NN NN O
and NN NN O
120 NN NN O
carrier NN NN O
females NN NN O
) NN NN O
probably NN NN O
originate NN NN O
from NN NN O
a NN NN O
common NN NN O
founder NN NN O
couple NN NN O
born NN NN O
in NN NN O
1644 NN NN O
and NN NN O
1646 NN NN O
, NN NN O
twelve NN NN O
generations NN NN O
ago NN NN O
. NN NN O

All NN NN O
36 NN NN O
patients NN NN O
and NN NN O
48 NN NN O
carriers NN NN O
tested NN NN O
from NN NN O
the NN NN O
three NN NN O
kindreds NN NN O
had NN NN O
the NN NN O
same NN NN O
haplotype NN NN O
( NN NN O
TCD NN NN B-SpecificDisease
/ NN NN O
DXYS1 NN NN O
, NN NN O
11kb NN NN O
/ NN NN O
DXYS12 NN NN O
, NN NN O
1 NN NN O
. NN NN O

6kb NN NN O
) NN NN O
. NN NN O

Given NN NN O
that NN NN O
at NN NN O
least NN NN O
105 NN NN O
female NN NN O
meioses NN NN O
transmitting NN NN O
TCD NN NN B-SpecificDisease
have NN NN O
occurred NN NN O
since NN NN O
1650 NN NN O
in NN NN O
these NN NN O
kindreds NN NN O
, NN NN O
extremely NN NN O
close NN NN O
linkage NN NN O
between NN NN O
TCD NN NN B-SpecificDisease
, NN NN O
DXYS1 NN NN O
and NN NN O
DXYS12 NN NN O
is NN NN O
suggested NN NN O
. NN NN O

The NN NN O
above NN NN O
haplotype NN NN O
is NN NN O
a NN NN O
very NN NN O
useful NN NN O
diagnostic NN NN O
tool NN NN O
in NN NN O
these NN NN O
TCD NN NN B-Modifier
families NN NN O
. NN NN O

We NN NN O
suggest NN NN O
that NN NN O
our NN NN O
historical-genealogical NN NN O
approach NN NN O
to NN NN O
linkage NN NN O
analysis NN NN O
may NN NN O
be NN NN O
possible NN NN O
elsewhere NN NN O
in NN NN O
similar NN NN O
isolated NN NN O
populations NN NN O

2894613 NN NN O
Von NN NN B-SpecificDisease
Hippel-Lindau NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
maps NN NN O
to NN NN O
the NN NN O
region NN NN O
of NN NN O
chromosome NN NN O
3 NN NN O
associated NN NN O
with NN NN O
renal NN NN B-SpecificDisease
cell NN NN I-SpecificDisease
carcinoma NN NN I-SpecificDisease
. NN NN O

Von NN NN B-SpecificDisease
Hippel-Lindau NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
VHL NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
dominant NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
with NN NN O
inherited NN NN O
susceptibility NN NN O
to NN NN O
various NN NN O
forms NN NN O
of NN NN O
cancer NN NN B-DiseaseClass
, NN NN O
including NN NN O
hemangioblastomas NN NN B-SpecificDisease
of NN NN O
the NN NN O
central NN NN O
nervous NN NN O
system NN NN O
, NN NN O
phaeochromocytomas NN NN B-SpecificDisease
, NN NN O
pancreatic NN NN B-SpecificDisease
malignancies NN NN I-SpecificDisease
, NN NN O
and NN NN O
renal NN NN B-SpecificDisease
cell NN NN I-SpecificDisease
carcinomas NN NN I-SpecificDisease
. NN NN O

Renal NN NN B-SpecificDisease
cell NN NN I-SpecificDisease
carcinomas NN NN I-SpecificDisease
constitute NN NN O
a NN NN O
particularly NN NN O
frequent NN NN O
cause NN NN O
of NN NN O
death NN NN O
in NN NN O
this NN NN O
disorder NN NN O
, NN NN O
occurring NN NN O
as NN NN O
bilateral NN NN B-CompositeMention
and NN NN I-CompositeMention
multifocal NN NN I-CompositeMention
tumours NN NN I-CompositeMention
, NN NN O
and NN NN O
presenting NN NN O
at NN NN O
an NN NN O
earlier NN NN O
age NN NN O
than NN NN O
in NN NN O
sporadic NN NN O
, NN NN O
non-familial NN NN O
cases NN NN O
of NN NN O
this NN NN O
tumour NN NN B-Modifier
type NN NN O
. NN NN O

We NN NN O
report NN NN O
here NN NN O
that NN NN O
the NN NN O
VHL NN NN B-Modifier
gene NN NN O
is NN NN O
linked NN NN O
to NN NN O
the NN NN O
locus NN NN O
encoding NN NN O
the NN NN O
human NN NN O
homologoue NN NN O
of NN NN O
the NN NN O
RAF1 NN NN O
oncogene NN NN O
, NN NN O
which NN NN O
maps NN NN O
to NN NN O
chromosome NN NN O
3p25 NN NN O
( NN NN O
ref NN NN O
. NN NN O

4 NN NN O
) NN NN O
. NN NN O

Crossovers NN NN O
with NN NN O
the NN NN O
VHL NN NN B-Modifier
locus NN NN O
suggest NN NN O
that NN NN O
the NN NN O
defect NN NN O
responsible NN NN O
for NN NN O
the NN NN O
VHL NN NN B-Modifier
phenotype NN NN O
is NN NN O
not NN NN O
a NN NN O
mutation NN NN O
in NN NN O
the NN NN O
RAF1 NN NN O
gene NN NN O
itself NN NN O
. NN NN O

An NN NN O
alternative NN NN O
or NN NN O
prior NN NN O
event NN NN O
to NN NN O
oncogene NN NN O
activation NN NN O
in NN NN O
tumour NN NN B-Modifier
formation NN NN O
may NN NN O
be NN NN O
the NN NN O
inactivation NN NN O
of NN NN O
a NN NN O
putative NN NN O
tumour NN NN B-Modifier
suppressor NN NN O
which NN NN O
can NN NN O
be NN NN O
associated NN NN O
with NN NN O
both NN NN O
the NN NN O
inherited NN NN B-CompositeMention
and NN NN I-CompositeMention
sporadic NN NN I-CompositeMention
forms NN NN I-CompositeMention
of NN NN I-CompositeMention
the NN NN I-CompositeMention
cancer NN NN I-CompositeMention
. NN NN O

Sporadic NN NN B-SpecificDisease
renal NN NN I-SpecificDisease
cell NN NN I-SpecificDisease
carcinomas NN NN I-SpecificDisease
have NN NN O
previously NN NN O
been NN NN O
associated NN NN O
with NN NN O
the NN NN O
loss NN NN O
of NN NN O
regions NN NN O
on NN NN O
chromosome NN NN O
3p NN NN O
( NN NN O
refs NN NN O
5 NN NN O
, NN NN O
6 NN NN O
) NN NN O
. NN NN O

Consequently NN NN O
, NN NN O
sporadic NN NN O
and NN NN O
VHL-associated NN NN O
forms NN NN O
of NN NN O
renal NN NN B-SpecificDisease
cell NN NN I-SpecificDisease
carcinoma NN NN I-SpecificDisease
might NN NN O
both NN NN O
result NN NN O
from NN NN O
alterations NN NN O
causing NN NN O
loss NN NN O
of NN NN O
function NN NN O
of NN NN O
the NN NN O
same NN NN O
tumour NN NN B-Modifier
suppressor NN NN O
gene NN NN O
on NN NN O
this NN NN O
chromosome NN NN O
. NN NN O

. NN NN O

2895982 NN NN O
Tightly NN NN O
linked NN NN O
flanking NN NN O
markers NN NN O
for NN NN O
the NN NN O
Lowe NN NN B-SpecificDisease
oculocerebrorenal NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
, NN NN O
with NN NN O
application NN NN O
to NN NN O
carrier NN NN O
assessment NN NN O
. NN NN O

The NN NN O
Lowe NN NN B-SpecificDisease
oculocerebrorenal NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
OCRL NN NN B-SpecificDisease
) NN NN O
is NN NN O
characterized NN NN O
by NN NN O
congenital NN NN O
cataract NN NN B-SpecificDisease
, NN NN O
mental NN NN B-DiseaseClass
retardation NN NN I-DiseaseClass
, NN NN O
and NN NN O
defective NN NN B-DiseaseClass
renal NN NN I-DiseaseClass
tubular NN NN I-DiseaseClass
function NN NN I-DiseaseClass
. NN NN O

A NN NN O
map NN NN O
assignment NN NN O
of NN NN O
OCRL NN NN B-SpecificDisease
to NN NN O
Xq24-q26 NN NN O
has NN NN O
been NN NN O
made NN NN O
previously NN NN O
by NN NN O
linkage NN NN O
analysis NN NN O
with NN NN O
DXS42 NN NN O
at NN NN O
Xq24-q26 NN NN O
( NN NN O
theta NN NN O
= NN NN O
0 NN NN O
, NN NN O
z NN NN O
= NN NN O
5 NN NN O
. NN NN O

09 NN NN O
) NN NN O
and NN NN O
with NN NN O
DXS10 NN NN O
at NN NN O
Xq26 NN NN O
( NN NN O
theta NN NN O
= NN NN O
0 NN NN O
, NN NN O
z NN NN O
= NN NN O
6 NN NN O
. NN NN O

45 NN NN O
) NN NN O
. NN NN O

Two NN NN O
additional NN NN O
families NN NN O
were NN NN O
studied NN NN O
and NN NN O
three NN NN O
additional NN NN O
polymorphisms NN NN O
were NN NN O
identified NN NN O
at NN NN O
DXS42 NN NN O
by NN NN O
using NN NN O
a NN NN O
35-kb NN NN O
sequence NN NN O
isolated NN NN O
with NN NN O
the NN NN O
probe NN NN O
detecting NN NN O
the NN NN O
original NN NN O
polymorphism NN NN O
at NN NN O
DXS42 NN NN O
. NN NN O

With NN NN O
additional NN NN O
OCRL NN NN B-Modifier
families NN NN O
made NN NN O
informative NN NN O
for NN NN O
DXS42 NN NN O
, NN NN O
theta NN NN O
remained NN NN O
0 NN NN O
with NN NN O
z NN NN O
= NN NN O
6 NN NN O
. NN NN O

63 NN NN O
; NN NN O
and NN NN O
for NN NN O
DXS10 NN NN O
theta NN NN O
= NN NN O
0 NN NN O
. NN NN O

03 NN NN O
and NN NN O
z NN NN O
= NN NN O
7 NN NN O
. NN NN O

07 NN NN O
. NN NN O

Evidence NN NN O
for NN NN O
placing NN NN O
OCRL NN NN O
at NN NN O
Xq25 NN NN O
also NN NN O
comes NN NN O
from NN NN O
a NN NN O
female NN NN O
with NN NN O
Lowe NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
and NN NN O
an NN NN O
X NN NN O
; NN NN O
3 NN NN O
translocation NN NN O
. NN NN O

We NN NN O
have NN NN O
used NN NN O
the NN NN O
Xq25 NN NN O
breakpoint NN NN O
in NN NN O
this NN NN O
patient NN NN O
to NN NN O
determine NN NN O
the NN NN O
position NN NN O
of NN NN O
OCRL NN NN O
relative NN NN O
to NN NN O
the NN NN O
two NN NN O
linked NN NN O
markers NN NN O
. NN NN O

Each NN NN O
derivative NN NN O
chromosome NN NN O
was NN NN O
isolated NN NN O
away NN NN O
from NN NN O
its NN NN O
normal NN NN O
counterpart NN NN O
in NN NN O
somatic NN NN O
cell NN NN O
hybrids NN NN O
. NN NN O

DXS42 NN NN O
was NN NN O
mapped NN NN O
to NN NN O
the NN NN O
derivative NN NN O
chromosome NN NN O
X NN NN O
containing NN NN O
Xpterq25 NN NN O
, NN NN O
and NN NN O
DXS10 NN NN O
was NN NN O
mapped NN NN O
to NN NN O
the NN NN O
derivative NN NN O
chromosome NN NN O
3 NN NN O
containing NN NN O
Xq25-qter NN NN O
. NN NN O

The NN NN O
markers NN NN O
DXS10 NN NN O
and NN NN O
DXS42 NN NN O
therefore NN NN O
show NN NN O
tight NN NN O
linkage NN NN O
with NN NN O
OCRL NN NN B-SpecificDisease
in NN NN O
six NN NN O
families NN NN O
and NN NN O
flank NN NN O
the NN NN O
Xq25 NN NN O
breakpoint NN NN O
in NN NN O
a NN NN O
female NN NN O
patient NN NN O
with NN NN O
an NN NN O
X NN NN O
; NN NN O
3 NN NN O
translocation NN NN O
. NN NN O

Linkage NN NN O
analysis NN NN O
with NN NN O
flanking NN NN O
markers NN NN O
was NN NN O
used NN NN O
to NN NN O
assess NN NN O
OCRL NN NN B-Modifier
carrier NN NN O
status NN NN O
in NN NN O
women NN NN O
at NN NN O
risk NN NN O
. NN NN O

Results NN NN O
, NN NN O
when NN NN O
compared NN NN O
with NN NN O
carrier NN NN O
determination NN NN O
by NN NN O
ophthalmologic NN NN O
examination NN NN O
, NN NN O
indicated NN NN O
that NN NN O
the NN NN O
slit-lamp NN NN O
exam NN NN O
can NN NN O
be NN NN O
a NN NN O
sensitive NN NN O
and NN NN O
specific NN NN O
method NN NN O
of NN NN O
carrier NN NN O
determination NN NN O
in NN NN O
many NN NN O
cases NN NN O

2910902 NN NN O
Identification NN NN O
of NN NN O
a NN NN O
single NN NN O
nucleotide NN NN O
change NN NN O
in NN NN O
the NN NN O
hypoxanthine-guanine NN NN O
phosphoribosyltransferase NN NN O
gene NN NN O
( NN NN O
HPRTYale NN NN O
) NN NN O
responsible NN NN O
for NN NN O
Lesch-Nyhan NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

Complete NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
hypoxanthine-guanine NN NN I-SpecificDisease
phosphoribosyltransferase NN NN I-SpecificDisease
( NN NN O
HPRT NN NN O
) NN NN O
causes NN NN O
the NN NN O
Lesch-Nyhan NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

Previous NN NN O
characterization NN NN O
of NN NN O
a NN NN O
mutant NN NN O
form NN NN O
of NN NN O
HPRT NN NN O
, NN NN O
HPRTYale NN NN O
, NN NN O
from NN NN O
a NN NN O
subject NN NN O
with NN NN O
the NN NN O
Lesch-Nyhan NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
revealed NN NN O
normal NN NN O
mRNA NN NN O
and NN NN O
protein NN NN O
concentrations NN NN O
, NN NN O
no NN NN O
residual NN NN O
catalytic NN NN O
activity NN NN O
, NN NN O
and NN NN O
cathodal NN NN O
migration NN NN O
upon NN NN O
PAGE NN NN O
. NN NN O

We NN NN O
have NN NN O
cloned NN NN O
and NN NN O
sequenced NN NN O
HPRTYale NN NN O
cDNA NN NN O
. NN NN O

The NN NN O
nucleotide NN NN O
sequence NN NN O
of NN NN O
full-length NN NN O
HPRTYale NN NN O
cDNA NN NN O
revealed NN NN O
a NN NN O
single NN NN O
nucleotide NN NN O
substitution NN NN O
compared NN NN O
with NN NN O
normal NN NN O
HPRT NN NN O
cDNA NN NN O
G NN NN O
-- NN NN O
-- NN NN O
C NN NN O
at NN NN O
nucleotide NN NN O
position NN NN O
211 NN NN O
. NN NN O

This NN NN O
transversion NN NN O
predicts NN NN O
substitution NN NN O
of NN NN O
arginine NN NN O
for NN NN O
glycine NN NN O
at NN NN O
amino NN NN O
acid NN NN O
position NN NN O
71 NN NN O
, NN NN O
explaining NN NN O
the NN NN O
cathodal NN NN O
migration NN NN O
of NN NN O
HPRTYale NN NN O
. NN NN O

Chou-Fasman NN NN O
secondary NN NN O
structure NN NN O
analysis NN NN O
predicts NN NN O
a NN NN O
change NN NN O
in NN NN O
the NN NN O
probability NN NN O
of NN NN O
beta-turn NN NN O
formation NN NN O
in NN NN O
the NN NN O
region NN NN O
containing NN NN O
the NN NN O
mutation NN NN O
. NN NN O

Inclusion NN NN O
of NN NN O
the NN NN O
bulky NN NN O
arginine NN NN O
side NN NN O
chain NN NN O
in NN NN O
place NN NN O
of NN NN O
glycine NN NN O
probably NN NN O
disrupts NN NN O
protein NN NN O
folding NN NN O
as NN NN O
well NN NN O
. NN NN O

Cloning NN NN O
mutant NN NN O
forms NN NN O
of NN NN O
cDNA NN NN O
allows NN NN O
identification NN NN O
of NN NN O
specific NN NN O
mutations NN NN O
, NN NN O
provides NN NN O
insight NN NN O
into NN NN O
mutational NN NN O
mechanisms NN NN O
, NN NN O
and NN NN O
facilitates NN NN O
structure-function NN NN O
analysis NN NN O
of NN NN O
mutant NN NN O
proteins NN NN O
. NN NN O

. NN NN O

2912069 NN NN O
Two NN NN O
point NN NN O
mutations NN NN O
are NN NN O
responsible NN NN O
for NN NN O
G6PD NN NN O
polymorphism NN NN O
in NN NN O
Sardinia NN NN O
. NN NN O

The NN NN O
human NN NN O
X-linked NN NN O
gene NN NN O
encoding NN NN O
glucose NN NN O
6-phosphate NN NN O
dehydrogenase NN NN O
( NN NN O
G6PD NN NN O
) NN NN O
is NN NN O
highly NN NN O
polymorphic NN NN O
; NN NN O
more NN NN O
than NN NN O
300 NN NN O
G6PD NN NN O
variants NN NN O
have NN NN O
been NN NN O
identified NN NN O
. NN NN O

G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
different NN NN O
geographical NN NN O
areas NN NN O
appears NN NN O
to NN NN O
have NN NN O
arisen NN NN O
through NN NN O
independent NN NN O
mutational NN NN O
events NN NN O
, NN NN O
but NN NN O
within NN NN O
the NN NN O
same NN NN O
population NN NN O
it NN NN O
may NN NN O
also NN NN O
be NN NN O
heterogeneous NN NN O
. NN NN O

One NN NN O
example NN NN O
is NN NN O
the NN NN O
island NN NN O
of NN NN O
Sardinia NN NN O
, NN NN O
where NN NN O
careful NN NN O
clinical NN NN O
and NN NN O
biochemical NN NN O
studies NN NN O
have NN NN O
identified NN NN O
four NN NN O
different NN NN O
G6PD NN NN O
variants NN NN O
. NN NN O

We NN NN O
cloned NN NN O
and NN NN O
sequenced NN NN O
the NN NN O
four NN NN O
G6PD NN NN O
variants NN NN O
from NN NN O
Sardinia NN NN O
and NN NN O
found NN NN O
that NN NN O
only NN NN O
two NN NN O
mutations NN NN O
are NN NN O
responsible NN NN O
for NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
this NN NN O
area NN NN O
one NN NN O
mutation NN NN O
is NN NN O
the NN NN O
cause NN NN O
of NN NN O
the NN NN O
G6PD NN NN B-SpecificDisease
Seattle-like NN NN I-SpecificDisease
phenotype NN NN I-SpecificDisease
, NN NN O
a NN NN O
milder NN NN O
form NN NN O
of NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
; NN NN O
the NN NN O
other NN NN O
mutation NN NN O
is NN NN O
responsible NN NN O
for NN NN O
all NN NN O
forms NN NN O
of NN NN O
very NN NN O
severe NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
Sardinia NN NN O
and NN NN O
, NN NN O
possibly NN NN O
, NN NN O
in NN NN O
the NN NN O
Mediterranean NN NN O
. NN NN O

. NN NN O

2912886 NN NN O
Chronic NN NN B-SpecificDisease
nonspherocytic NN NN I-SpecificDisease
hemolytic NN NN I-SpecificDisease
anemia NN NN I-SpecificDisease
( NN NN O
CNSHA NN NN B-SpecificDisease
) NN NN O
and NN NN O
glucose NN NN B-SpecificDisease
6 NN NN I-SpecificDisease
phosphate NN NN I-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
( NN NN I-SpecificDisease
G6PD NN NN I-SpecificDisease
) NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
familial NN NN B-SpecificDisease
amyloidotic NN NN I-SpecificDisease
polyneuropathy NN NN I-SpecificDisease
( NN NN O
FAP NN NN B-SpecificDisease
) NN NN O
. NN NN O

Molecular NN NN O
study NN NN O
of NN NN O
a NN NN O
new NN NN O
variant NN NN O
( NN NN O
G6PD NN NN O
Clinic NN NN O
) NN NN O
with NN NN O
markedly NN NN O
acidic NN NN O
pH NN NN O
optimum NN NN O
. NN NN O

A NN NN O
new NN NN O
glucose-6-phosphate NN NN O
dehydrogenase NN NN O
( NN NN O
G6PD NN NN O
) NN NN O
variant NN NN O
with NN NN O
severe NN NN O
erythrocytic NN NN B-SpecificDisease
G6PD NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
and NN NN O
a NN NN O
unique NN NN O
pH NN NN O
optimum NN NN O
is NN NN O
described NN NN O
in NN NN O
a NN NN O
young NN NN O
patient NN NN O
with NN NN O
chronic NN NN B-SpecificDisease
nonspherocytic NN NN I-SpecificDisease
hemolytic NN NN I-SpecificDisease
anemia NN NN I-SpecificDisease
( NN NN O
CNSHA NN NN B-SpecificDisease
) NN NN O
and NN NN O
familial NN NN B-SpecificDisease
amyloidotic NN NN I-SpecificDisease
polyneuropathy NN NN I-SpecificDisease
( NN NN O
FAP NN NN B-SpecificDisease
) NN NN O
. NN NN O

Chronic NN NN B-SpecificDisease
hemolysis NN NN I-SpecificDisease
was NN NN O
present NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
infections NN NN O
, NN NN O
oxidant NN NN O
drugs NN NN O
or NN NN O
ingestion NN NN O
of NN NN O
faba NN NN O
beans NN NN O
. NN NN O

Residual NN NN O
enzyme NN NN O
activity NN NN O
was NN NN O
about NN NN O
2 NN NN O
. NN NN O

6 NN NN O
% NN NN O
and NN NN O
63 NN NN O
% NN NN O
of NN NN O
normal NN NN O
activity NN NN O
in NN NN O
erythrocytes NN NN O
and NN NN O
leucocytes NN NN O
, NN NN O
respectively NN NN O
. NN NN O

A NN NN O
molecular NN NN O
study NN NN O
using NN NN O
standard NN NN O
methods NN NN O
showed NN NN O
G6PD NN NN O
in NN NN O
the NN NN O
patient NN NN O
to NN NN O
have NN NN O
normal NN NN O
electrophoretic NN NN O
mobility NN NN O
( NN NN O
at NN NN O
pH NN NN O
7 NN NN O
. NN NN O

0 NN NN O
, NN NN O
8 NN NN O
. NN NN O

0 NN NN O
and NN NN O
8 NN NN O
. NN NN O

8 NN NN O
) NN NN O
, NN NN O
normal NN NN O
apparent NN NN O
affinity NN NN O
for NN NN O
substrates NN NN O
( NN NN O
Km NN NN O
, NN NN O
G6P NN NN O
and NN NN O
NADP NN NN O
) NN NN O
and NN NN O
a NN NN O
slightly NN NN O
abnormal NN NN O
utilization NN NN O
of NN NN O
substrate NN NN O
analogues NN NN O
( NN NN O
decreased NN NN O
deamino-NADP NN NN O
and NN NN O
increased NN NN O
2-deoxyglucose-6-phosphate NN NN O
utilization NN NN O
) NN NN O
. NN NN O

Heat NN NN O
stability NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
markedly NN NN O
decreased NN NN O
( NN NN O
8 NN NN O
% NN NN O
of NN NN O
residual NN NN O
activity NN NN O
after NN NN O
20 NN NN O
min NN NN O
of NN NN O
incubation NN NN O
at NN NN O
46 NN NN O
degrees NN NN O
C NN NN O
) NN NN O
and NN NN O
a NN NN O
particular NN NN O
characteristic NN NN O
of NN NN O
this NN NN O
enzyme NN NN O
was NN NN O
a NN NN O
biphasic NN NN O
pH NN NN O
curve NN NN O
with NN NN O
a NN NN O
greatly NN NN O
increased NN NN O
activity NN NN O
at NN NN O
low NN NN O
pH NN NN O
. NN NN O

Although NN NN O
molecular NN NN O
characteristics NN NN O
of NN NN O
this NN NN O
variant NN NN O
closely NN NN O
resemble NN NN O
those NN NN O
of NN NN O
G6PD NN NN O
Bangkok NN NN O
and NN NN O
G6PD NN NN O
Duarte NN NN O
, NN NN O
it NN NN O
can NN NN O
be NN NN O
distinguished NN NN O
from NN NN O
these NN NN O
and NN NN O
all NN NN O
other NN NN O
previously NN NN O
reported NN NN O
variants NN NN O
by NN NN O
virtue NN NN O
of NN NN O
its NN NN O
unusual NN NN O
pH NN NN O
curve NN NN O
. NN NN O

Therefore NN NN O
the NN NN O
present NN NN O
variant NN NN O
has NN NN O
been NN NN O
designated NN NN O
G6PD NN NN O
Clinic NN NN O
to NN NN O
distinguish NN NN O
it NN NN O
from NN NN O
other NN NN O
G6PD NN NN O
variants NN NN O
previously NN NN O
described NN NN O

2927388 NN NN O
Molecular NN NN O
detection NN NN O
of NN NN O
chromosomal NN NN O
translocations NN NN O
that NN NN O
disrupt NN NN O
the NN NN O
putative NN NN O
retinoblastoma NN NN B-Modifier
susceptibility NN NN O
locus NN NN O
. NN NN O

A NN NN O
candidate NN NN O
DNA NN NN O
sequence NN NN O
with NN NN O
many NN NN O
of NN NN O
the NN NN O
properties NN NN O
predicted NN NN O
for NN NN O
the NN NN O
retinoblastoma NN NN B-Modifier
susceptibility NN NN O
( NN NN O
RB1 NN NN O
) NN NN O
locus NN NN O
has NN NN O
been NN NN O
cloned NN NN O
( NN NN O
S NN NN O
. NN NN O

H NN NN O
. NN NN O

Friend NN NN O
, NN NN O
R NN NN O
. NN NN O

Bernards NN NN O
, NN NN O
S NN NN O
. NN NN O

Rogelj NN NN O
, NN NN O
R NN NN O
. NN NN O

A NN NN O
. NN NN O

Weinberg NN NN O
, NN NN O
J NN NN O
. NN NN O

M NN NN O
. NN NN O

Rapaport NN NN O
, NN NN O
D NN NN O
. NN NN O

M NN NN O
. NN NN O

Albert NN NN O
, NN NN O
and NN NN O
T NN NN O
. NN NN O

P NN NN O
. NN NN O

Dryja NN NN O
, NN NN O
Nature NN NN O
[ NN NN O
London NN NN O
] NN NN O
323 NN NN O
643-645 NN NN O
, NN NN O
1986 NN NN O
) NN NN O
. NN NN O

The NN NN O
large NN NN O
size NN NN O
of NN NN O
this NN NN O
gene NN NN O
( NN NN O
ca NN NN O
. NN NN O

200 NN NN O
kilobases NN NN O
[ NN NN O
kb NN NN O
] NN NN O
) NN NN O
and NN NN O
its NN NN O
multiple NN NN O
dispersed NN NN O
exons NN NN O
( NN NN O
Wiggs NN NN O
et NN NN O
al NN NN O
. NN NN O

, NN NN O
N NN NN O
. NN NN O

Engl NN NN O
. NN NN O

J NN NN O
. NN NN O

Med NN NN O
. NN NN O

318 NN NN O
151-157 NN NN O
, NN NN O
1988 NN NN O
) NN NN O
complicate NN NN O
molecular NN NN O
screening NN NN O
strategies NN NN O
important NN NN O
in NN NN O
prenatal NN NN O
and NN NN O
presymptomatic NN NN O
diagnosis NN NN O
and NN NN O
in NN NN O
carrier NN NN O
detection NN NN O
. NN NN O

Here NN NN O
we NN NN O
used NN NN O
field NN NN O
inversion NN NN O
gel NN NN O
electrophoresis NN NN O
( NN NN O
FIGE NN NN O
) NN NN O
to NN NN O
construct NN NN O
a NN NN O
restriction NN NN O
map NN NN O
of NN NN O
approximately NN NN O
1 NN NN O
, NN NN O
000 NN NN O
kb NN NN O
of NN NN O
DNA NN NN O
surrounding NN NN O
the NN NN O
RB1 NN NN O
locus NN NN O
and NN NN O
to NN NN O
detect NN NN O
the NN NN O
translocation NN NN O
breakpoints NN NN O
in NN NN O
three NN NN O
retinoblastoma NN NN B-Modifier
patients NN NN O
. NN NN O

DNA NN NN O
probes NN NN O
from NN NN O
either NN NN O
the NN NN O
5 NN NN O
or NN NN O
3 NN NN O
end NN NN O
of NN NN O
the NN NN O
gene NN NN O
were NN NN O
used NN NN O
to NN NN O
detect NN NN O
a NN NN O
250-kb NN NN O
EagI NN NN O
restriction NN NN O
fragment NN NN O
in NN NN O
DNA NN NN O
from NN NN O
unaffected NN NN O
individuals NN NN O
. NN NN O

Both NN NN O
probes NN NN O
identified NN NN O
an NN NN O
additional NN NN O
hybridizing NN NN O
fragment NN NN O
in NN NN O
the NN NN O
DNA NN NN O
from NN NN O
each NN NN O
patient NN NN O
, NN NN O
permitting NN NN O
the NN NN O
breakpoints NN NN O
in NN NN O
all NN NN O
three NN NN O
to NN NN O
be NN NN O
mapped NN NN O
within NN NN O
the NN NN O
cloned NN NN O
RB1 NN NN O
gene NN NN O
. NN NN O

Analysis NN NN O
of NN NN O
the NN NN O
breakpoint NN NN O
in NN NN O
one NN NN O
translocation NN NN O
cell NN NN O
line NN NN O
allowed NN NN O
the NN NN O
RB1 NN NN O
gene NN NN O
to NN NN O
be NN NN O
oriented NN NN O
with NN NN O
its NN NN O
5 NN NN O
end NN NN O
toward NN NN O
the NN NN O
centromere NN NN O
. NN NN O

The NN NN O
5 NN NN O
end NN NN O
of NN NN O
the NN NN O
gene NN NN O
also NN NN O
appeared NN NN O
to NN NN O
be NN NN O
associated NN NN O
with NN NN O
a NN NN O
clustering NN NN O
of NN NN O
sites NN NN O
for NN NN O
several NN NN O
infrequently NN NN O
cleaving NN NN O
restriction NN NN O
enzymes NN NN O
, NN NN O
indicating NN NN O
the NN NN O
presence NN NN O
of NN NN O
an NN NN O
HpaII NN NN O
tiny NN NN O
fragment NN NN O
island NN NN O
. NN NN O

The NN NN O
detection NN NN O
and NN NN O
mapping NN NN O
of NN NN O
the NN NN O
translocation NN NN O
breakpoints NN NN O
of NN NN O
all NN NN O
three NN NN O
retinoblastoma NN NN B-Modifier
patients NN NN O
to NN NN O
within NN NN O
the NN NN O
putative NN NN O
RB1 NN NN O
gene NN NN O
substantiated NN NN O
the NN NN O
authenticity NN NN O
of NN NN O
this NN NN O
candidate NN NN O
sequence NN NN O
and NN NN O
demonstrated NN NN O
the NN NN O
utility NN NN O
of NN NN O
FIGE NN NN O
in NN NN O
detecting NN NN O
chromosomal NN NN O
rearrangements NN NN O
affecting NN NN O
this NN NN O
locus NN NN O
. NN NN O

2963536 NN NN O
Inherited NN NN O
C3 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
with NN NN O
recurrent NN NN O
infections NN NN O
and NN NN O
glomerulonephritis NN NN B-SpecificDisease
. NN NN O

A NN NN O
10-year-old NN NN O
Laotian NN NN O
boy NN NN O
had NN NN O
homozygous NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
third NN NN I-SpecificDisease
component NN NN I-SpecificDisease
of NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
and NN NN O
recurrent NN NN O
bacterial NN NN B-DiseaseClass
infections NN NN I-DiseaseClass
beginning NN NN O
at NN NN O
age NN NN O
5 NN NN O
months NN NN O
. NN NN O

Cellular NN NN O
and NN NN O
humoral NN NN O
immunity NN NN O
were NN NN O
normal NN NN O
, NN NN O
as NN NN O
were NN NN O
polymorphonuclear NN NN O
leukocyte NN NN O
chemotaxis NN NN O
and NN NN O
bactericidal NN NN O
activities NN NN O
. NN NN O

Serum NN NN O
complement-mediated NN NN O
hemolytic NN NN O
, NN NN O
chemotactic NN NN O
, NN NN O
and NN NN O
opsonic NN NN O
activities NN NN O
were NN NN O
deficient NN NN O
. NN NN O

In NN NN O
vitro NN NN O
addition NN NN O
of NN NN O
purified NN NN O
C3 NN NN O
to NN NN O
patient NN NN O
serum NN NN O
restored NN NN O
hemolytic NN NN O
complement NN NN O
to NN NN O
normal NN NN O
levels NN NN O
, NN NN O
and NN NN O
plasma NN NN O
infusion NN NN O
during NN NN O
each NN NN O
of NN NN O
four NN NN O
episodes NN NN O
of NN NN O
pneumonia NN NN B-SpecificDisease
significantly NN NN O
enhanced NN NN O
serum NN NN O
opsonic NN NN O
activity NN NN O
for NN NN O
as NN NN O
long NN NN O
as NN NN O
36 NN NN O
hours NN NN O
. NN NN O

A NN NN O
renal NN NN O
biopsy NN NN O
specimen NN NN O
revealed NN NN O
mesangiopathic NN NN B-SpecificDisease
glomerulonephritis NN NN I-SpecificDisease
, NN NN O
although NN NN O
significant NN NN O
levels NN NN O
of NN NN O
circulating NN NN O
IgG NN NN O
immune NN NN O
complexes NN NN O
were NN NN O
not NN NN O
detected NN NN O
. NN NN O

These NN NN O
findings NN NN O
further NN NN O
support NN NN O
the NN NN O
association NN NN O
of NN NN O
C3 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
with NN NN O
immune-complex NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
and NN NN O
suggest NN NN O
that NN NN O
plasma NN NN O
infusion NN NN O
may NN NN O
be NN NN O
an NN NN O
adjunct NN NN O
to NN NN O
antibiotic NN NN O
therapy NN NN O
in NN NN O
the NN NN O
management NN NN O
of NN NN O
severe NN NN O
pyogenic NN NN B-DiseaseClass
infections NN NN I-DiseaseClass
in NN NN O
patients NN NN O
with NN NN O
C3 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

. NN NN O

2989709 NN NN O
DNA NN NN O
restriction NN NN O
fragments NN NN O
associated NN NN O
with NN NN O
alpha NN NN O
1-antitrypsin NN NN O
indicate NN NN O
a NN NN O
single NN NN O
origin NN NN O
for NN NN O
deficiency NN NN O
allele NN NN O
PI NN NN O
Z NN NN O
. NN NN O

The NN NN O
alpha NN NN O
1-protease NN NN O
inhibitor NN NN O
, NN NN O
or NN NN O
alpha-antitrypsin NN NN O
( NN NN O
AAT NN NN O
) NN NN O
, NN NN O
a NN NN O
major NN NN O
plasma NN NN O
inhibitor NN NN O
of NN NN O
leukocyte NN NN O
elastase NN NN O
and NN NN O
bacterial NN NN O
proteases NN NN O
, NN NN O
is NN NN O
encoded NN NN O
at NN NN O
the NN NN O
PI NN NN O
locus NN NN O
on NN NN O
chromosome NN NN O
14 NN NN O
( NN NN O
14q24 NN NN O
. NN NN O

3-q32 NN NN O
. NN NN O

1 NN NN O
) NN NN O
. NN NN O

A NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
AAT NN NN I-SpecificDisease
in NN NN O
individuals NN NN O
homozygous NN NN O
for NN NN O
the NN NN O
PI NN NN O
Z NN NN O
allele NN NN O
occurs NN NN O
in NN NN O
about NN NN O
1 NN NN O
in NN NN O
2 NN NN O
, NN NN O
000-8 NN NN O
, NN NN O
000 NN NN O
caucasians NN NN O
and NN NN O
is NN NN O
associated NN NN O
with NN NN O
an NN NN O
increased NN NN O
risk NN NN O
of NN NN O
early NN NN O
adult NN NN O
onset NN NN O
emphysema NN NN B-DiseaseClass
and NN NN O
liver NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
in NN NN O
childhood NN NN O
. NN NN O

We NN NN O
have NN NN O
now NN NN O
used NN NN O
DNA NN NN O
polymorphisms NN NN O
associated NN NN O
with NN NN O
the NN NN O
AAT NN NN O
gene NN NN O
to NN NN O
investigate NN NN O
the NN NN O
origin NN NN O
of NN NN O
the NN NN O
PI NN NN O
Z NN NN O
allele NN NN O
. NN NN O

Using NN NN O
two NN NN O
genomic NN NN O
probes NN NN O
extending NN NN O
into NN NN O
the NN NN O
5 NN NN O
and NN NN O
3 NN NN O
flanking NN NN O
regions NN NN O
, NN NN O
respectively NN NN O
, NN NN O
we NN NN O
have NN NN O
identified NN NN O
eight NN NN O
polymorphic NN NN O
restriction NN NN O
sites NN NN O
. NN NN O

Extensive NN NN O
linkage NN NN O
disequilibrium NN NN O
occurs NN NN O
throughout NN NN O
the NN NN O
probed NN NN O
region NN NN O
with NN NN O
the NN NN O
PI NN NN O
Z NN NN O
allele NN NN O
, NN NN O
but NN NN O
not NN NN O
with NN NN O
normal NN NN O
PI NN NN O
M NN NN O
alleles NN NN O
. NN NN O

The NN NN O
Z NN NN O
allele NN NN O
occurs NN NN O
mainly NN NN O
with NN NN O
one NN NN O
haplotype NN NN O
, NN NN O
indicating NN NN O
a NN NN O
single NN NN O
, NN NN O
relatively NN NN O
recent NN NN O
, NN NN O
origin NN NN O
in NN NN O
caucasians NN NN O

2995231 NN NN O
Segregation NN NN O
analysis NN NN O
of NN NN O
a NN NN O
marker NN NN O
localised NN NN O
Xp21.2-Xp21.3 NN NN O
in NN NN O
Duchenne NN NN B-CompositeMention
and NN NN I-CompositeMention
Becker NN NN I-CompositeMention
muscular NN NN I-CompositeMention
dystrophy NN NN I-CompositeMention
families NN NN O
. NN NN O

A NN NN O
DNA NN NN O
marker NN NN O
C7 NN NN O
, NN NN O
localised NN NN O
Xp21 NN NN O
. NN NN O

1-Xp21 NN NN O
1-Xp21 NN NN O
. NN NN O

3 NN NN O
, NN NN O
has NN NN O
been NN NN O
studied NN NN O
in NN NN O
kindreds NN NN O
segregating NN NN O
for NN NN O
Duchenne NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DMD NN NN B-SpecificDisease
) NN NN O
and NN NN O
Becker NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
BMD NN NN B-SpecificDisease
) NN NN O
. NN NN O

In NN NN O
DMD NN NN B-Modifier
families NN NN O
four NN NN O
crossovers NN NN O
were NN NN O
observed NN NN O
in NN NN O
38 NN NN O
informative NN NN O
meioses NN NN O
between NN NN O
C7 NN NN O
and NN NN O
the NN NN O
DMD NN NN B-Modifier
locus NN NN O
( NN NN O
theta NN NN O
= NN NN O
0 NN NN O
. NN NN O

12 NN NN O
, NN NN O
z NN NN O
max NN NN O
= NN NN O
+ NN NN O
2 NN NN O
. NN NN O

72 NN NN O
) NN NN O
. NN NN O

In NN NN O
BMD NN NN B-Modifier
families NN NN O
no NN NN O
recombinants NN NN O
were NN NN O
observed NN NN O
in NN NN O
the NN NN O
16 NN NN O
informative NN NN O
meioses NN NN O
studied NN NN O
. NN NN O

These NN NN O
data NN NN O
are NN NN O
consistent NN NN O
with NN NN O
the NN NN O
localisation NN NN O
of NN NN O
the NN NN O
mutations NN NN O
in NN NN O
these NN NN O
disorders NN NN O
being NN NN O
in NN NN O
the NN NN O
same NN NN O
region NN NN O
of NN NN O
Xp21 NN NN O
. NN NN O

Studies NN NN O
in NN NN O
families NN NN O
also NN NN O
segregating NN NN O
for NN NN O
the NN NN O
DNA NN NN O
marker NN NN O
754 NN NN O
support NN NN O
the NN NN O
previously NN NN O
reported NN NN O
physical NN NN O
order NN NN O
of NN NN O
these NN NN O
loci NN NN O
as NN NN O
X NN NN O
centromere-754-DMD-BMD-C7-X NN NN O
telomere NN NN O
. NN NN O

A NN NN O
recombination NN NN O
fraction NN NN O
of NN NN O
0 NN NN O
. NN NN O

11 NN NN O
( NN NN O
z NN NN O
max NN NN O
= NN NN O
+ NN NN O
5 NN NN O
. NN NN O

58 NN NN O
) NN NN O
was NN NN O
found NN NN O
between NN NN O
DMD-754 NN NN O
by NN NN O
combining NN NN O
our NN NN O
previously NN NN O
published NN NN O
data NN NN O
with NN NN O
the NN NN O
data NN NN O
presented NN NN O
here NN NN O
. NN NN O

C7 NN NN O
and NN NN O
754 NN NN O
thus NN NN O
provide NN NN O
good NN NN O
bridging NN NN O
markers NN NN O
for NN NN O
the NN NN O
diagnosis NN NN O
of NN NN O
DMD NN NN B-SpecificDisease
and NN NN O
BMD NN NN B-SpecificDisease

3012567 NN NN O
Isolation NN NN O
of NN NN O
molecular NN NN O
probes NN NN O
associated NN NN O
with NN NN O
the NN NN O
chromosome NN NN O
15 NN NN O
instability NN NN O
in NN NN O
the NN NN O
Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

Flow NN NN O
cytometry NN NN O
and NN NN O
recombinant NN NN O
DNA NN NN O
techniques NN NN O
have NN NN O
been NN NN O
used NN NN O
to NN NN O
obtain NN NN O
reagents NN NN O
for NN NN O
a NN NN O
molecular NN NN O
analysis NN NN O
of NN NN O
the NN NN O
Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
PWS NN NN B-SpecificDisease
) NN NN O
. NN NN O

HindIII NN NN O
total-digest NN NN O
libraries NN NN O
were NN NN O
prepared NN NN O
in NN NN O
lambda NN NN O
phage NN NN O
Charon NN NN O
21A NN NN O
from NN NN O
flow-sorted NN NN O
inverted NN NN O
duplicated NN NN O
no NN NN O
. NN NN O

15 NN NN O
human NN NN O
chromosomes NN NN O
and NN NN O
propagated NN NN O
on NN NN O
recombination-proficient NN NN O
( NN NN O
LE392 NN NN O
) NN NN O
and NN NN O
recBC- NN NN O
, NN NN O
sbcB- NN NN O
( NN NN O
DB1257 NN NN O
) NN NN O
bacteria NN NN O
. NN NN O

Twelve NN NN O
distinct NN NN O
chromosome NN NN O
15-specific NN NN O
probes NN NN O
have NN NN O
been NN NN O
isolated NN NN O
. NN NN O

Eight NN NN O
localized NN NN O
to NN NN O
the NN NN O
region NN NN O
15q11 NN NN O
-- NN NN O
-- NN NN O
13 NN NN O
. NN NN O

Four NN NN O
of NN NN O
these NN NN O
eight NN NN O
sublocalized NN NN O
to NN NN O
band NN NN O
15q11 NN NN O
. NN NN O

2 NN NN O
and NN NN O
are NN NN O
shown NN NN O
to NN NN O
be NN NN O
deleted NN NN O
in NN NN O
DNA NN NN O
of NN NN O
one NN NN O
of NN NN O
two NN NN O
patients NN NN O
examined NN NN O
with NN NN O
the NN NN O
PWS NN NN B-SpecificDisease
. NN NN O

Heteroduplex NN NN O
analysis NN NN O
of NN NN O
two NN NN O
of NN NN O
these NN NN O
clones NN NN O
, NN NN O
which NN NN O
grew NN NN O
on NN NN O
DB1257 NN NN O
but NN NN O
not NN NN O
on NN NN O
LE392 NN NN O
, NN NN O
revealed NN NN O
stem-loop NN NN O
structures NN NN O
in NN NN O
the NN NN O
inserts NN NN O
, NN NN O
indicative NN NN O
of NN NN O
inverted NN NN O
, NN NN O
repeated NN NN O
DNA NN NN O
elements NN NN O
. NN NN O

Such NN NN O
DNA NN NN O
repeats NN NN O
might NN NN O
account NN NN O
for NN NN O
some NN NN O
of NN NN O
the NN NN O
cloning NN NN O
instability NN NN O
of NN NN O
DNA NN NN O
segments NN NN O
from NN NN O
proximal NN NN O
15q NN NN O
. NN NN O

Analysis NN NN O
of NN NN O
the NN NN O
genetic NN NN O
and NN NN O
physical NN NN O
instability NN NN O
associated NN NN O
with NN NN O
the NN NN O
repeated NN NN O
sequences NN NN O
we NN NN O
have NN NN O
isolated NN NN O
from NN NN O
band NN NN O
15q11 NN NN O
. NN NN O

2 NN NN O
may NN NN O
elucidate NN NN O
the NN NN O
molecular NN NN O
basis NN NN O
for NN NN O
the NN NN O
instability NN NN O
of NN NN O
this NN NN O
chromosomal NN NN O
region NN NN O
in NN NN O
patients NN NN O
with NN NN O
the NN NN O
PWS NN NN B-SpecificDisease
or NN NN O
other NN NN O
diseases NN NN O
associated NN NN O
with NN NN O
chromosomal NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
in NN NN O
the NN NN O
proximal NN NN O
long NN NN O
arm NN NN O
of NN NN O
human NN NN O
chromosome NN NN O
15 NN NN O

3014348 NN NN O
Analysis NN NN O
of NN NN O
deletions NN NN O
in NN NN O
DNA NN NN O
from NN NN O
patients NN NN O
with NN NN O
Becker NN NN B-CompositeMention
and NN NN I-CompositeMention
Duchenne NN NN I-CompositeMention
muscular NN NN I-CompositeMention
dystrophy NN NN I-CompositeMention
. NN NN O

Duchenne NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DMD NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
X-linked NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
genetic NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
for NN NN O
which NN NN O
the NN NN O
biochemical NN NN B-DiseaseClass
defect NN NN I-DiseaseClass
is NN NN O
as NN NN O
yet NN NN O
unknown NN NN O
. NN NN O

Recently NN NN O
, NN NN O
two NN NN O
cloned NN NN O
segments NN NN O
of NN NN O
human NN NN O
X-chromosome NN NN O
DNA NN NN O
have NN NN O
been NN NN O
described NN NN O
which NN NN O
detect NN NN O
structural NN NN O
alterations NN NN O
within NN NN O
or NN NN O
near NN NN O
the NN NN O
genetic NN NN O
locus NN NN O
responsible NN NN O
for NN NN O
the NN NN O
disorder NN NN O
. NN NN O

Both NN NN O
of NN NN O
these NN NN O
cloned NN NN O
segments NN NN O
were NN NN O
described NN NN O
as NN NN O
tightly NN NN O
linked NN NN O
to NN NN O
the NN NN O
locus NN NN O
and NN NN O
were NN NN O
capable NN NN O
of NN NN O
detecting NN NN O
deletions NN NN O
in NN NN O
the NN NN O
DNA NN NN O
of NN NN O
boys NN NN O
affected NN NN O
with NN NN O
DMD NN NN B-SpecificDisease
. NN NN O

In NN NN O
an NN NN O
attempt NN NN O
to NN NN O
determine NN NN O
more NN NN O
precisely NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
these NN NN O
deletions NN NN O
within NN NN O
a NN NN O
large NN NN O
population NN NN O
of NN NN O
DMD NN NN B-Modifier
patients NN NN O
and NN NN O
the NN NN O
accuracy NN NN O
of NN NN O
one NN NN O
of NN NN O
the NN NN O
segments NN NN O
, NN NN O
DXS164 NN NN O
( NN NN O
pERT87 NN NN O
) NN NN O
, NN NN O
in NN NN O
determining NN NN O
the NN NN O
inheritance NN NN O
of NN NN O
the NN NN O
DMD NN NN B-Modifier
X NN NN O
chromosome NN NN O
, NN NN O
the NN NN O
subclones NN NN O
1 NN NN O
, NN NN O
8 NN NN O
and NN NN O
15 NN NN O
were NN NN O
made NN NN O
available NN NN O
to NN NN O
many NN NN O
investigators NN NN O
throughout NN NN O
the NN NN O
world NN NN O
. NN NN O

Here NN NN O
we NN NN O
describe NN NN O
the NN NN O
combined NN NN O
results NN NN O
of NN NN O
more NN NN O
than NN NN O
20 NN NN O
research NN NN O
laboratories NN NN O
with NN NN O
respect NN NN O
to NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
deletions NN NN O
at NN NN O
the NN NN O
DXS164 NN NN O
locus NN NN O
in NN NN O
DNA NN NN O
samples NN NN O
isolated NN NN O
from NN NN O
patients NN NN O
with NN NN O
DMD NN NN B-SpecificDisease
and NN NN O
Becker NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
BMD NN NN B-SpecificDisease
) NN NN O
. NN NN O

The NN NN O
results NN NN O
indicate NN NN O
that NN NN O
the NN NN O
DXS164 NN NN O
locus NN NN O
apparently NN NN O
recombines NN NN O
with NN NN O
DMD NN NN B-SpecificDisease
5 NN NN O
% NN NN O
of NN NN O
the NN NN O
time NN NN O
, NN NN O
but NN NN O
is NN NN O
probably NN NN O
located NN NN O
between NN NN O
independent NN NN O
sites NN NN O
of NN NN O
mutation NN NN O
which NN NN O
yield NN NN O
DMD NN NN B-SpecificDisease
. NN NN O

The NN NN O
breakpoints NN NN O
of NN NN O
some NN NN O
deletions NN NN O
are NN NN O
delineated NN NN O
within NN NN O
the NN NN O
DXS164 NN NN O
locus NN NN O
, NN NN O
and NN NN O
it NN NN O
is NN NN O
evident NN NN O
that NN NN O
the NN NN O
deletions NN NN O
at NN NN O
the NN NN O
DMD NN NN B-Modifier
locus NN NN O
are NN NN O
frequent NN NN O
and NN NN O
extremely NN NN O
large NN NN O
. NN NN O

. NN NN O

3029599 NN NN O
A NN NN O
potential NN NN O
animal NN NN O
model NN NN O
for NN NN O
Lesch-Nyhan NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
through NN NN O
introduction NN NN O
of NN NN O
HPRT NN NN O
mutations NN NN O
into NN NN O
mice NN NN O
. NN NN O

The NN NN O
human NN NN O
Lesch-Nyhan NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
is NN NN O
a NN NN O
rare NN NN O
neurological NN NN B-DiseaseClass
and NN NN I-DiseaseClass
behavioural NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
, NN NN O
affecting NN NN O
only NN NN O
males NN NN O
, NN NN O
which NN NN O
is NN NN O
caused NN NN O
by NN NN O
an NN NN O
inherited NN NN B-DiseaseClass
deficiency NN NN I-DiseaseClass
in NN NN O
the NN NN O
level NN NN O
of NN NN O
activity NN NN O
of NN NN O
the NN NN O
purine NN NN O
salvage NN NN O
enzyme NN NN O
hypoxanthine-guanosine NN NN O
phosphoribosyl NN NN O
transferase NN NN O
( NN NN O
HPRT NN NN O
) NN NN O
. NN NN O

How NN NN O
the NN NN O
resulting NN NN O
alterations NN NN O
in NN NN O
purine NN NN O
metabolism NN NN O
lead NN NN O
to NN NN O
the NN NN O
severe NN NN O
symptoms NN NN O
characteristic NN NN O
of NN NN O
Lesch-Nyhan NN NN B-Modifier
patients NN NN O
is NN NN O
still NN NN O
not NN NN O
understood NN NN O
. NN NN O

No NN NN O
mutations NN NN O
at NN NN O
the NN NN O
Hprt NN NN O
locus NN NN O
leading NN NN O
to NN NN O
loss NN NN O
of NN NN O
activity NN NN O
have NN NN O
been NN NN O
described NN NN O
in NN NN O
laboratory NN NN O
animals NN NN O
. NN NN O

To NN NN O
derive NN NN O
an NN NN O
animal NN NN O
model NN NN O
for NN NN O
the NN NN O
Lesch-Nyhan NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
, NN NN O
we NN NN O
have NN NN O
used NN NN O
cultured NN NN O
mouse NN NN O
embryonic NN NN O
stem NN NN O
cells NN NN O
, NN NN O
mutagenized NN NN O
by NN NN O
retroviral NN NN O
insertion NN NN O
and NN NN O
selected NN NN O
for NN NN O
loss NN NN O
of NN NN O
HPRT NN NN O
activity NN NN O
, NN NN O
to NN NN O
construct NN NN O
chimaeric NN NN O
mice NN NN O
. NN NN O

Two NN NN O
clonal NN NN O
lines NN NN O
carrying NN NN O
different NN NN O
mutant NN NN O
Hprt NN NN O
alleles NN NN O
have NN NN O
given NN NN O
rise NN NN O
to NN NN O
germ NN NN O
cells NN NN O
in NN NN O
chimaeras NN NN O
, NN NN O
allowing NN NN O
the NN NN O
derivation NN NN O
of NN NN O
strains NN NN O
of NN NN O
mutant NN NN O
mice NN NN O
having NN NN O
the NN NN O
same NN NN O
biochemical NN NN O
defect NN NN O
as NN NN O
Lesch-Nyhan NN NN B-Modifier
patients NN NN O
. NN NN O

Male NN NN O
mice NN NN O
carrying NN NN O
the NN NN O
mutant NN NN O
alleles NN NN O
are NN NN O
viable NN NN O
and NN NN O
analysis NN NN O
of NN NN O
their NN NN O
cells NN NN O
shows NN NN O
a NN NN O
total NN NN O
lack NN NN O
of NN NN O
HPRT NN NN O
activity NN NN O
. NN NN O

. NN NN O

3032521 NN NN O
Re-evaluation NN NN O
of NN NN O
the NN NN O
sublocalization NN NN O
of NN NN O
esterase NN NN O
D NN NN O
and NN NN O
its NN NN O
relation NN NN O
to NN NN O
the NN NN O
retinoblastoma NN NN B-Modifier
locus NN NN O
by NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
. NN NN O

In NN NN O
situ NN NN O
hybridization NN NN O
of NN NN O
a NN NN O
cDNA NN NN O
probe NN NN O
for NN NN O
the NN NN O
esterase NN NN O
D NN NN O
gene NN NN O
( NN NN O
ESD NN NN O
) NN NN O
was NN NN O
carried NN NN O
out NN NN O
on NN NN O
human NN NN O
chromosomes NN NN O
. NN NN O

The NN NN O
probe NN NN O
hybridized NN NN O
most NN NN O
strongly NN NN O
to NN NN O
13q14 NN NN O
. NN NN O

2 NN NN O
and NN NN O
13q14 NN NN O
. NN NN O

3 NN NN O
3 NN NN O
. NN NN O

This NN NN O
observation NN NN O
raises NN NN O
doubts NN NN O
concerning NN NN O
the NN NN O
most NN NN O
recently NN NN O
published NN NN O
assignment NN NN O
of NN NN O
ESD NN NN O
to NN NN O
13q14 NN NN O
. NN NN O

1 NN NN O
1 NN NN O
. NN NN O

A NN NN O
deletion NN NN O
in NN NN O
an NN NN O
individual NN NN O
with NN NN O
retinoblastoma NN NN B-SpecificDisease
was NN NN O
reported NN NN O
to NN NN O
separate NN NN O
the NN NN O
closely NN NN O
linked NN NN O
ESD NN NN O
and NN NN O
retinoblastoma NN NN B-Modifier
( NN NN O
RB1 NN NN O
) NN NN O
loci NN NN O
, NN NN O
placing NN NN O
ESD NN NN O
proximal NN NN O
to NN NN O
RB1 NN NN O
. NN NN O

Quantitative NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
studies NN NN O
of NN NN O
this NN NN O
deletion NN NN O
do NN NN O
not NN NN O
confirm NN NN O
this NN NN O
interpretation NN NN O
. NN NN O

Rather NN NN O
, NN NN O
they NN NN O
suggest NN NN O
that NN NN O
ESD NN NN O
is NN NN O
missing NN NN O
from NN NN O
the NN NN O
deleted NN NN O
chromosome NN NN O
13 NN NN O
and NN NN O
duplicated NN NN O
on NN NN O
the NN NN O
normal NN NN O
homolog NN NN O
. NN NN O

From NN NN O
these NN NN O
findings NN NN O
, NN NN O
we NN NN O
conclude NN NN O
that NN NN O
the NN NN O
deletion NN NN O
in NN NN O
this NN NN O
individual NN NN O
can NN NN O
not NN NN O
be NN NN O
used NN NN O
to NN NN O
determine NN NN O
the NN NN O
orientation NN NN O
nor NN NN O
the NN NN O
sublocalization NN NN O
of NN NN O
ESD NN NN O
and NN NN O
RB1 NN NN O
within NN NN O
the NN NN O
13q14 NN NN O
region NN NN O
. NN NN O

313733 NN NN O
Hereditary NN NN B-SpecificDisease
C2 NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
associated NN NN O
with NN NN O
common NN NN O
variable NN NN O
immunodeficiency NN NN B-DiseaseClass
. NN NN O

Homozygous NN NN O
C2 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
a NN NN O
19-year-old NN NN O
boy NN NN O
was NN NN O
associated NN NN O
with NN NN O
variable NN NN O
immunodeficiency NN NN B-DiseaseClass
manifested NN NN O
by NN NN O
marked NN NN O
hypoimmunoglobulinemia NN NN B-DiseaseClass
and NN NN O
impaired NN NN O
antibody NN NN O
responses NN NN O
, NN NN O
normal NN NN O
circulating NN NN O
B NN NN O
lymphocytes NN NN O
, NN NN O
and NN NN O
subnormal NN NN O
T-cell NN NN O
functions NN NN O
. NN NN O

Neither NN NN O
antilymphocytic NN NN O
autoantibodies NN NN O
nor NN NN O
chromosomal NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
were NN NN O
found NN NN O
. NN NN O

Serum NN NN O
immunoglobulin NN NN O
levels NN NN O
were NN NN O
within NN NN O
normal NN NN O
limits NN NN O
in NN NN O
his NN NN O
parents NN NN O
and NN NN O
brother NN NN O
who NN NN O
were NN NN O
heterozygous NN NN O
for NN NN O
C2 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

The NN NN O
patients NN NN O
lymphocytes NN NN O
were NN NN O
homozygous NN NN O
at NN NN O
the NN NN O
HLA-D NN NN O
locus NN NN O
but NN NN O
expressed NN NN O
an NN NN O
antigen NN NN O
different NN NN O
from NN NN O
DW2 NN NN O
. NN NN O

. NN NN O

3162536 NN NN O
Mild NN NN O
and NN NN O
severe NN NN O
muscular NN NN B-DiseaseClass
dystrophy NN NN I-DiseaseClass
associated NN NN O
with NN NN O
deletions NN NN O
in NN NN O
Xp21 NN NN O
of NN NN O
the NN NN O
human NN NN O
X NN NN O
chromosome NN NN O
. NN NN O

We NN NN O
have NN NN O
analysed NN NN O
over NN NN O
300 NN NN O
patients NN NN O
suffering NN NN O
from NN NN O
Duchenne NN NN B-CompositeMention
or NN NN I-CompositeMention
Becker NN NN I-CompositeMention
muscular NN NN I-CompositeMention
dystrophy NN NN I-CompositeMention
( NN NN O
DMD NN NN B-SpecificDisease
or NN NN O
BMD NN NN B-SpecificDisease
) NN NN O
. NN NN O

Deletions NN NN O
have NN NN O
been NN NN O
characterised NN NN O
which NN NN O
encompass NN NN O
either NN NN O
the NN NN O
pERT87 NN NN O
( NN NN O
DXS164 NN NN O
) NN NN O
locus NN NN O
only NN NN O
, NN NN O
the NN NN O
XJ1 NN NN O
. NN NN O

1 NN NN O
( NN NN O
DXS206 NN NN O
) NN NN O
and NN NN O
HIP25 NN NN O
loci NN NN O
only NN NN O
, NN NN O
or NN NN O
all NN NN O
three NN NN O
loci NN NN O
. NN NN O

These NN NN O
loci NN NN O
have NN NN O
been NN NN O
shown NN NN O
to NN NN O
lie NN NN O
within NN NN O
the NN NN O
DMD NN NN B-Modifier
region NN NN O
covering NN NN O
several NN NN O
hundred NN NN O
kilobases NN NN O
( NN NN O
kb NN NN O
) NN NN O
of NN NN O
DNA NN NN O
. NN NN O

One NN NN O
mildly NN NN O
affected NN NN O
BMD NN NN B-Modifier
patient NN NN O
possesses NN NN O
a NN NN O
deletion NN NN O
of NN NN O
at NN NN O
least NN NN O
110 NN NN O
kb NN NN O
including NN NN O
exons NN NN O
of NN NN O
the NN NN O
DMD NN NN B-Modifier
gene NN NN O
. NN NN O

Other NN NN O
patients NN NN O
with NN NN O
similar NN NN O
exon NN NN O
deletions NN NN O
, NN NN O
or NN NN O
smaller NN NN O
deletions NN NN O
, NN NN O
show NN NN O
the NN NN O
more NN NN O
severe NN NN O
phenotype NN NN O
typical NN NN O
of NN NN O
DMD NN NN B-SpecificDisease
. NN NN O

We NN NN O
conclude NN NN O
from NN NN O
these NN NN O
studies NN NN O
that NN NN O
the NN NN O
severity NN NN O
of NN NN O
the NN NN O
clinical NN NN O
phenotype NN NN O
can NN NN O
not NN NN O
be NN NN O
explained NN NN O
on NN NN O
the NN NN O
basis NN NN O
of NN NN O
the NN NN O
size NN NN O
of NN NN O
the NN NN O
deletion NN NN O
. NN NN O

We NN NN O
discuss NN NN O
this NN NN O
in NN NN O
the NN NN O
context NN NN O
of NN NN O
candidate NN NN O
gene NN NN O
sequences NN NN O
. NN NN O

3169738 NN NN O
Patterns NN NN O
of NN NN O
exon NN NN O
deletions NN NN O
in NN NN O
Duchenne NN NN B-CompositeMention
and NN NN I-CompositeMention
Becker NN NN I-CompositeMention
muscular NN NN I-CompositeMention
dystrophy NN NN I-CompositeMention
. NN NN O

A NN NN O
panel NN NN O
of NN NN O
patients NN NN O
with NN NN O
Duchenne NN NN B-CompositeMention
and NN NN I-CompositeMention
Becker NN NN I-CompositeMention
muscular NN NN I-CompositeMention
dystrophy NN NN I-CompositeMention
( NN NN O
DMD NN NN B-SpecificDisease
and NN NN O
BMD NN NN B-SpecificDisease
) NN NN O
has NN NN O
been NN NN O
screened NN NN O
with NN NN O
the NN NN O
cDNA NN NN O
probes NN NN O
Cf56a NN NN O
and NN NN O
Cf23a NN NN O
, NN NN O
which NN NN O
detect NN NN O
exons NN NN O
in NN NN O
the NN NN O
central NN NN O
part NN NN O
of NN NN O
the NN NN O
DMD NN NN B-Modifier
gene NN NN O
. NN NN O

One NN NN O
or NN NN O
more NN NN O
exons NN NN O
were NN NN O
deleted NN NN O
in NN NN O
60 NN NN O
% NN NN O
of NN NN O
patients NN NN O
. NN NN O

The NN NN O
deletions NN NN O
were NN NN O
mapped NN NN O
and NN NN O
prove NN NN O
to NN NN O
be NN NN O
heterogeneous NN NN O
in NN NN O
size NN NN O
and NN NN O
extent NN NN O
, NN NN O
particularly NN NN O
in NN NN O
DMD NN NN B-SpecificDisease
. NN NN O

Deletions NN NN O
specific NN NN O
to NN NN O
DMD NN NN B-SpecificDisease
and NN NN O
to NN NN O
BMD NN NN B-SpecificDisease
are NN NN O
described NN NN O
. NN NN O

Half NN NN O
of NN NN O
all NN NN O
BMD NN NN B-Modifier
patients NN NN O
have NN NN O
a NN NN O
deletion NN NN O
of NN NN O
one NN NN O
particular NN NN O
small NN NN O
group NN NN O
of NN NN O
exons NN NN O
; NN NN O
smaller NN NN O
deletions NN NN O
within NN NN O
this NN NN O
same NN NN O
group NN NN O
produce NN NN O
the NN NN O
more NN NN O
severe NN NN O
DMD NN NN B-SpecificDisease
. NN NN O

. NN NN O

318684 NN NN O
Hereditary NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
third NN NN I-SpecificDisease
component NN NN I-SpecificDisease
of NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
in NN NN O
a NN NN O
child NN NN O
with NN NN O
fever NN NN B-DiseaseClass
, NN NN O
skin NN NN B-DiseaseClass
rash NN NN I-DiseaseClass
, NN NN O
and NN NN O
arthralgias NN NN B-DiseaseClass
: NN NN O
response NN NN O
to NN NN O
transfusion NN NN O
of NN NN O
whole NN NN O
blood NN NN O
. NN NN O

A NN NN O
previously NN NN O
well NN NN O
34-month-old NN NN O
male NN NN O
presenting NN NN O
with NN NN O
fever NN NN B-DiseaseClass
, NN NN O
skin NN NN B-DiseaseClass
rash NN NN I-DiseaseClass
, NN NN O
and NN NN O
arthralgias NN NN B-DiseaseClass
was NN NN O
found NN NN O
to NN NN O
lack NN NN O
C3 NN NN O
by NN NN O
immunochemical NN NN O
( NN NN O
undetectable NN NN O
) NN NN O
and NN NN O
hemolytic NN NN O
( NN NN O
1 NN NN O
% NN NN O
normal NN NN O
) NN NN O
assays NN NN O
. NN NN O

No NN NN O
infectious NN NN O
agent NN NN O
could NN NN O
be NN NN O
demonstrated NN NN O
. NN NN O

Protein NN NN O
levels NN NN O
of NN NN O
Clq NN NN O
. NN NN O

C4 NN NN O
, NN NN O
C5 NN NN O
, NN NN O
properdin NN NN O
, NN NN O
and NN NN O
C3b-INA NN NN O
and NN NN O
hemolytic NN NN O
activities NN NN O
of NN NN O
complement NN NN O
components NN NN O
C1 NN NN O
to NN NN O
C9 NN NN O
except NN NN O
C3 NN NN O
were NN NN O
normal NN NN O
or NN NN O
elevated NN NN O
; NN NN O
total NN NN O
hemolytic NN NN O
complement NN NN O
activity NN NN O
was NN NN O
13 NN NN O
% NN NN O
of NN NN O
normal NN NN O
and NN NN O
was NN NN O
reconstituted NN NN O
by NN NN O
purified NN NN O
C3 NN NN O
. NN NN O

Properdin NN NN O
factor NN NN O
B NN NN O
was NN NN O
702 NN NN O
( NN NN O
normal NN NN O
175 NN NN O
to NN NN O
275 NN NN O
) NN NN O
mug NN NN O
/ NN NN O
ml NN NN O
, NN NN O
and NN NN O
was NN NN O
not NN NN O
cleaver NN NN O
upon NN NN O
addition NN NN O
of NN NN O
zymosan NN NN O
or NN NN O
cobra NN NN O
venom NN NN O
factor NN NN O
. NN NN O

The NN NN O
serum NN NN O
had NN NN O
normal NN NN O
immune NN NN O
adherence NN NN O
activity NN NN O
, NN NN O
but NN NN O
was NN NN O
deficient NN NN O
in NN NN O
ability NN NN O
to NN NN O
opsonize NN NN O
Candida NN NN O
albicans NN NN O
for NN NN O
uptake NN NN O
and NN NN O
Escherichia NN NN O
coli NN NN O
for NN NN O
killing NN NN O
by NN NN O
neurophils NN NN O
, NN NN O
generate NN NN O
neutrophil NN NN O
chemotactic NN NN O
factors NN NN O
and NN NN O
inhibit NN NN O
the NN NN O
growth NN NN O
of NN NN O
E NN NN O
. NN NN O

coli NN NN O
; NN NN O
these NN NN O
activities NN NN O
were NN NN O
restored NN NN O
by NN NN O
purified NN NN O
C3 NN NN O
. NN NN O

A NN NN O
transfusion NN NN O
of NN NN O
320 NN NN O
ml NN NN O
1-hour-old NN NN O
normal NN NN O
whole NN NN O
blood NN NN O
on NN NN O
the NN NN O
fifty-second NN NN O
day NN NN O
resulted NN NN O
in NN NN O
transitory NN NN O
elevation NN NN O
of NN NN O
the NN NN O
C3 NN NN O
level NN NN O
to NN NN O
25 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
with NN NN O
a NN NN O
fall-off NN NN O
( NN NN O
approximately NN NN O
2 NN NN O
1 NN NN O
/ NN NN O
2 NN NN O
% NN NN O
per NN NN O
hour NN NN O
) NN NN O
to NN NN O
undetectable NN NN O
levels NN NN O
by NN NN O
69 NN NN O
hours NN NN O
; NN NN O
it NN NN O
was NN NN O
followed NN NN O
by NN NN O
disappearance NN NN O
of NN NN O
the NN NN O
skin NN NN B-DiseaseClass
rash NN NN I-DiseaseClass
and NN NN O
arthralgias NN NN B-DiseaseClass
and NN NN O
return NN NN O
to NN NN O
normal NN NN O
of NN NN O
the NN NN O
previously NN NN O
elevated NN NN O
temperature NN NN O
and NN NN O
CRP NN NN O
levels NN NN O
. NN NN O

C3 NN NN O
levels NN NN O
in NN NN O
family NN NN O
members NN NN O
( NN NN O
seven NN NN O
of NN NN O
24 NN NN O
half-normal NN NN O
) NN NN O
, NN NN O
lack NN NN O
of NN NN O
anti-C3 NN NN O
activity NN NN O
, NN NN O
normal NN NN O
C3b-INA NN NN O
levels NN NN O
and NN NN O
a NN NN O
normal NN NN O
rate NN NN O
of NN NN O
catabolism NN NN O
of NN NN O
transfused NN NN O
C3 NN NN O
indicated NN NN O
that NN NN O
the NN NN O
deficiency NN NN O
was NN NN O
inherited NN NN O
with NN NN O
autosomal NN NN O
codominance NN NN O
and NN NN O
involved NN NN O
decreased NN NN B-DiseaseClass
synthesis NN NN I-DiseaseClass
of NN NN I-DiseaseClass
C3 NN NN I-DiseaseClass
. NN NN O

Thus NN NN O
, NN NN O
this NN NN O
child NN NN O
is NN NN O
a NN NN O
unique NN NN O
individual NN NN O
with NN NN O
inherited NN NN B-SpecificDisease
C3 NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
presenting NN NN O
with NN NN O
absence NN NN O
of NN NN O
repeated NN NN O
infections NN NN O
, NN NN O
whose NN NN O
symptoms NN NN O
of NN NN O
fever NN NN B-DiseaseClass
, NN NN O
skin NN NN B-DiseaseClass
rash NN NN I-DiseaseClass
, NN NN O
and NN NN O
arthralgia NN NN B-DiseaseClass
were NN NN O
abated NN NN O
by NN NN O
whole NN NN O
blood NN NN O
transfusion NN NN O
. NN NN O

. NN NN O

3198117 NN NN O
Glucose-6-phosphate NN NN O
dehydrogenase NN NN O
variants NN NN O
and NN NN O
their NN NN O
frequency NN NN O
in NN NN O
Guangdong NN NN O
, NN NN O
China NN NN O
. NN NN O

Erythrocyte NN NN O
glucose-6-phosphate NN NN O
dehydrogenase NN NN O
( NN NN O
G6PD NN NN O
) NN NN O
was NN NN O
characterized NN NN O
in NN NN O
blood NN NN O
samples NN NN O
obtained NN NN O
from NN NN O
97 NN NN O
randomly NN NN O
selected NN NN O
males NN NN O
with NN NN O
enzyme NN NN B-DiseaseClass
deficiency NN NN I-DiseaseClass
from NN NN O
various NN NN O
regions NN NN O
of NN NN O
Guangdong NN NN O
Province NN NN O
, NN NN O
China NN NN O
. NN NN O

Nine NN NN O
new NN NN O
variants NN NN O
( NN NN O
Gd NN NN O
Kaiping NN NN O
, NN NN O
Gd NN NN O
Boluo NN NN O
, NN NN O
Gd NN NN O
Huiyang NN NN O
, NN NN O
Gd NN NN O
Gaomin NN NN O
, NN NN O
Gd NN NN O
Qing-Baijiang NN NN O
, NN NN O
Gd NN NN O
Gaozhou NN NN O
, NN NN O
Gd NN NN O
Huazhou NN NN O
, NN NN O
Gd NN NN O
Nanhai NN NN O
, NN NN O
and NN NN O
Gd NN NN O
Guangzhou NN NN O
) NN NN O
were NN NN O
identified NN NN O
. NN NN O

Of NN NN O
the NN NN O
31 NN NN O
variants NN NN O
found NN NN O
in NN NN O
this NN NN O
province NN NN O
, NN NN O
Gd NN NN O
Kaiping NN NN O
, NN NN O
Gd NN NN O
Taiwan-Hakka NN NN O
, NN NN O
Gd NN NN O
Haad NN NN O
Yai NN NN O
, NN NN O
Gd NN NN O
Haad NN NN O
Yai-like NN NN O
and NN NN O
Gd NN NN O
Huiyang NN NN O
occurred NN NN O
most NN NN O
frequently NN NN O
. NN NN O

The NN NN O
frequency NN NN O
of NN NN O
each NN NN O
variant NN NN O
was NN NN O
calculated NN NN O
. NN NN O

The NN NN O
results NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
genetic NN NN O
heterogeneity NN NN O
of NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
was NN NN O
high NN NN O
in NN NN O
this NN NN O
area NN NN O
. NN NN O

. NN NN O

3258663 NN NN O
Homozygous NN NN O
and NN NN O
heterozygous NN NN O
deletions NN NN O
of NN NN O
the NN NN O
von NN NN B-Modifier
Willebrand NN NN I-Modifier
factor NN NN O
gene NN NN O
in NN NN O
patients NN NN O
and NN NN O
carriers NN NN O
of NN NN O
severe NN NN O
von NN NN B-SpecificDisease
Willebrand NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

Severe NN NN O
von NN NN B-SpecificDisease
Willebrand NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
is NN NN O
characterized NN NN O
by NN NN O
undetectable NN NN O
or NN NN O
trace NN NN O
quantities NN NN O
of NN NN O
von NN NN B-Modifier
Willebrand NN NN I-Modifier
factor NN NN O
in NN NN O
plasma NN NN O
and NN NN O
tissue NN NN O
stores NN NN O
. NN NN O

We NN NN O
have NN NN O
studied NN NN O
the NN NN O
genomic NN NN O
DNA NN NN O
of NN NN O
10 NN NN O
affected NN NN O
individuals NN NN O
from NN NN O
six NN NN O
families NN NN O
with NN NN O
this NN NN O
disorder NN NN O
using NN NN O
probes NN NN O
from NN NN O
the NN NN O
5 NN NN O
and NN NN O
3 NN NN O
ends NN NN O
of NN NN O
the NN NN O
vWF NN NN O
cDNA NN NN O
and NN NN O
with NN NN O
a NN NN O
probe NN NN O
extending NN NN O
from NN NN O
the NN NN O
5 NN NN O
end NN NN O
into NN NN O
the NN NN O
central NN NN O
region NN NN O
. NN NN O

Southern NN NN O
blots NN NN O
of NN NN O
restriction NN NN O
endonuclease NN NN O
digests NN NN O
and NN NN O
gene NN NN O
dosage NN NN O
analysis NN NN O
measurements NN NN O
carried NN NN O
out NN NN O
with NN NN O
quantitative NN NN O
slot NN NN O
blots NN NN O
of NN NN O
undigested NN NN O
genomic NN NN O
DNA NN NN O
separated NN NN O
these NN NN O
patients NN NN O
into NN NN O
three NN NN O
groups NN NN O
. NN NN O

The NN NN O
first NN NN O
group NN NN O
consisted NN NN O
of NN NN O
a NN NN O
family NN NN O
with NN NN O
complete NN NN O
homozygous NN NN O
deletions NN NN O
of NN NN O
the NN NN O
vWF NN NN O
gene NN NN O
in NN NN O
the NN NN O
four NN NN O
probands NN NN O
. NN NN O

Gene NN NN O
dosage NN NN O
analysis NN NN O
was NN NN O
consistent NN NN O
with NN NN O
heterozygous NN NN O
deletions NN NN O
in NN NN O
both NN NN O
of NN NN O
the NN NN O
asymptomatic NN NN O
parents NN NN O
and NN NN O
four NN NN O
asymptomatic NN NN O
siblings NN NN O
of NN NN O
this NN NN O
kindred NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
0 NN NN O
. NN NN O

01 NN NN O
) NN NN O
. NN NN O

The NN NN O
second NN NN O
group NN NN O
was NN NN O
comprised NN NN O
of NN NN O
a NN NN O
family NN NN O
in NN NN O
which NN NN O
there NN NN O
was NN NN O
a NN NN O
complete NN NN O
heterozygous NN NN O
deletion NN NN O
of NN NN O
the NN NN O
vWF NN NN O
gene NN NN O
in NN NN O
the NN NN O
proband NN NN O
and NN NN O
one NN NN O
asymptomatic NN NN O
parent NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
a NN NN O
different NN NN O
type NN NN O
of NN NN O
genetic NN NN B-DiseaseClass
abnormality NN NN I-DiseaseClass
was NN NN O
inherited NN NN O
from NN NN O
the NN NN O
other NN NN O
parent NN NN O
. NN NN O

Thus NN NN O
, NN NN O
the NN NN O
patient NN NN O
appeared NN NN O
to NN NN O
be NN NN O
doubly NN NN O
heterozygous NN NN O
for NN NN O
interacting NN NN O
genetic NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
affecting NN NN O
vWF NN NN O
expression NN NN O
. NN NN O

In NN NN O
the NN NN O
third NN NN O
group NN NN O
, NN NN O
no NN NN O
gene NN NN O
deletions NN NN O
could NN NN O
be NN NN O
detected NN NN O
. NN NN O

Alloantibodies NN NN O
developed NN NN O
only NN NN O
in NN NN O
the NN NN O
kindred NN NN O
with NN NN O
homozygous NN NN O
deletions NN NN O
. NN NN O

These NN NN O
techniques NN NN O
should NN NN O
prove NN NN O
useful NN NN O
in NN NN O
identifying NN NN O
carriers NN NN O
of NN NN O
severe NN NN O
von NN NN B-SpecificDisease
Willebrand NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
and NN NN O
also NN NN O
in NN NN O
defining NN NN O
patients NN NN O
predictably NN NN O
at NN NN O
risk NN NN O
of NN NN O
developing NN NN O
alloantibodies NN NN O
to NN NN O
vWF NN NN O
. NN NN O

3343337 NN NN O
Sjogren-Larsson NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

Impaired NN NN O
fatty NN NN O
alcohol NN NN O
oxidation NN NN O
in NN NN O
cultured NN NN O
fibroblasts NN NN O
due NN NN O
to NN NN O
deficient NN NN O
fatty NN NN O
alcohol NN NN O
: NN NN O
nicotinamide NN NN O
adenine NN NN O
dinucleotide NN NN O
oxidoreductase NN NN O
activity NN NN O
. NN NN O

Lipid NN NN O
metabolism NN NN O
was NN NN O
studied NN NN O
in NN NN O
cultured NN NN O
skin NN NN O
fibroblasts NN NN O
from NN NN O
patients NN NN O
with NN NN O
the NN NN O
inherited NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
, NN NN O
Sjogren-Larsson NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
SLS NN NN B-SpecificDisease
) NN NN O
. NN NN O

Intact NN NN O
SLS NN NN B-Modifier
fibroblasts NN NN O
incubated NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
[ NN NN O
1-14C NN NN O
] NN NN O
palmitate NN NN O
accumulated NN NN O
more NN NN O
radioactive NN NN O
hexadecanol NN NN O
than NN NN O
did NN NN O
normal NN NN O
cells NN NN O
, NN NN O
whereas NN NN O
incorporation NN NN O
of NN NN O
radioactivity NN NN O
into NN NN O
other NN NN O
cellular NN NN O
lipids NN NN O
was NN NN O
unaltered NN NN O
. NN NN O

The NN NN O
hexadecanol NN NN O
content NN NN O
of NN NN O
SLS NN NN B-Modifier
fibroblasts NN NN O
was NN NN O
abnormally NN NN O
elevated NN NN O
. NN NN O

Hexadecanol NN NN O
accumulation NN NN O
was NN NN O
not NN NN O
due NN NN O
to NN NN O
increased NN NN O
fatty NN NN O
alcohol NN NN O
synthesis NN NN O
nor NN NN O
its NN NN O
deficient NN NN O
utilization NN NN O
for NN NN O
glycerol NN NN O
ether NN NN O
synthesis NN NN O
. NN NN O

The NN NN O
half-life NN NN O
of NN NN O
intracellular NN NN O
hexadecanol NN NN O
loaded NN NN O
into NN NN O
SLS NN NN B-Modifier
fibroblasts NN NN O
was NN NN O
increased NN NN O
( NN NN O
70 NN NN O
min NN NN O
) NN NN O
compared NN NN O
with NN NN O
normal NN NN O
( NN NN O
15 NN NN O
min NN NN O
) NN NN O
, NN NN O
and NN NN O
intact NN NN O
SLS NN NN B-Modifier
fibroblasts NN NN O
showed NN NN O
impaired NN NN O
oxidation NN NN O
of NN NN O
[ NN NN O
14C NN NN O
] NN NN O
-hexadecanol NN NN O
to NN NN O
fatty NN NN O
acid NN NN O
. NN NN O

Fatty NN NN O
alcohol NN NN O
NAD NN NN O
+ NN NN O
oxidoreductase NN NN O
, NN NN O
the NN NN O
enzyme NN NN O
catalyzing NN NN O
this NN NN O
reaction NN NN O
, NN NN O
was NN NN O
deficient NN NN O
in NN NN O
SLS NN NN B-Modifier
fibroblasts NN NN O
. NN NN O

Mean NN NN O
total NN NN O
activity NN NN O
in NN NN O
SLS NN NN B-Modifier
fibroblasts NN NN O
( NN NN O
n NN NN O
= NN NN O
5 NN NN O
) NN NN O
was NN NN O
13 NN NN O
% NN NN O
of NN NN O
that NN NN O
in NN NN O
normal NN NN O
fibroblasts NN NN O
, NN NN O
and NN NN O
palmitoyl NN NN O
CoA-inhibitable NN NN O
activity NN NN O
was NN NN O
1 NN NN O
% NN NN O
of NN NN O
normal NN NN O
. NN NN O

Fibroblasts NN NN O
from NN NN O
two NN NN O
obligate NN NN O
SLS NN NN B-Modifier
heterozygotes NN NN O
had NN NN O
enzyme NN NN O
activities NN NN O
intermediate NN NN O
between NN NN O
that NN NN O
in NN NN O
normal NN NN O
fibroblasts NN NN O
and NN NN O
individuals NN NN O
with NN NN O
SLS NN NN B-SpecificDisease
. NN NN O

These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
the NN NN O
primary NN NN O
defect NN NN O
in NN NN O
SLS NN NN B-SpecificDisease
is NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
fatty NN NN I-SpecificDisease
alcohol NN NN I-SpecificDisease
NAD NN NN I-SpecificDisease
+ NN NN I-SpecificDisease
oxidoreductase NN NN I-SpecificDisease
. NN NN O

SLS NN NN B-SpecificDisease
represents NN NN O
the NN NN O
first NN NN O
inherited NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
in NN NN O
man NN NN O
associated NN NN O
with NN NN O
an NN NN O
isolated NN NN O
abnormality NN NN B-DiseaseClass
in NN NN I-DiseaseClass
fatty NN NN I-DiseaseClass
alcohol NN NN I-DiseaseClass
metabolism NN NN I-DiseaseClass
. NN NN O

. NN NN O

3346017 NN NN O
Germinal NN NN B-DiseaseClass
mosaicism NN NN I-DiseaseClass
in NN NN O
Duchenne NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
. NN NN O

We NN NN O
have NN NN O
identified NN NN O
a NN NN O
Duchenne NN NN B-Modifier
muscular NN NN I-Modifier
dystrophy NN NN I-Modifier
( NN NN O
DMD NN NN B-Modifier
) NN NN O
pedigree NN NN O
where NN NN O
the NN NN O
disease NN NN O
is NN NN O
associated NN NN O
with NN NN O
a NN NN O
molecular NN NN O
deletion NN NN O
within NN NN O
the NN NN O
DMD NN NN B-Modifier
locus NN NN O
. NN NN O

We NN NN O
have NN NN O
examined NN NN O
the NN NN O
meiotic NN NN O
segregation NN NN O
products NN NN O
of NN NN O
the NN NN O
common NN NN O
female NN NN O
ancestor NN NN O
using NN NN O
marker NN NN O
restriction NN NN O
fragment NN NN O
length NN NN O
polymorphisms NN NN O
( NN NN O
RFLPs NN NN O
) NN NN O
detected NN NN O
by NN NN O
probes NN NN O
that NN NN O
lie NN NN O
within NN NN O
this NN NN O
deletion NN NN O
. NN NN O

These NN NN O
studies NN NN O
show NN NN O
that NN NN O
this NN NN O
female NN NN O
has NN NN O
transmitted NN NN O
three NN NN O
distinct NN NN O
types NN NN O
of NN NN O
X NN NN O
chromosome NN NN O
to NN NN O
her NN NN O
offspring NN NN O
. NN NN O

This NN NN O
observation NN NN O
may NN NN O
be NN NN O
explained NN NN O
by NN NN O
postulating NN NN O
that NN NN O
the NN NN O
mutation NN NN O
arose NN NN O
as NN NN O
a NN NN O
postzygotic NN NN O
deletion NN NN O
within NN NN O
this NN NN O
common NN NN O
ancestor NN NN O
, NN NN O
who NN NN O
was NN NN O
consequently NN NN O
germinally NN NN O
mosaic NN NN O
. NN NN O

. NN NN O

3346018 NN NN O
Nebulin NN NN O
seen NN NN O
in NN NN O
DMD NN NN B-Modifier
males NN NN O
including NN NN O
one NN NN O
patient NN NN O
with NN NN O
a NN NN O
large NN NN O
DNA NN NN O
deletion NN NN O
encompassing NN NN O
the NN NN O
DMD NN NN B-Modifier
gene NN NN O
. NN NN O

The NN NN O
presence NN NN O
of NN NN O
nebulin NN NN O
in NN NN O
a NN NN O
muscle NN NN O
specimen NN NN O
from NN NN O
a NN NN O
patient NN NN O
with NN NN O
Duchenne NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DMD NN NN B-SpecificDisease
) NN NN O
due NN NN O
to NN NN O
a NN NN O
large NN NN O
deletion NN NN O
precludes NN NN O
the NN NN O
possibility NN NN O
that NN NN O
this NN NN O
protein NN NN O
is NN NN O
the NN NN O
DMD NN NN B-Modifier
gene NN NN O
product NN NN O
. NN NN O

. NN NN O

3347839 NN NN O
Expression NN NN O
of NN NN O
the NN NN O
murine NN NN O
Duchenne NN NN B-Modifier
muscular NN NN I-Modifier
dystrophy NN NN I-Modifier
gene NN NN O
in NN NN O
muscle NN NN O
and NN NN O
brain NN NN O
. NN NN O

Complementary NN NN O
DNA NN NN O
clones NN NN O
were NN NN O
isolated NN NN O
that NN NN O
represent NN NN O
the NN NN O
5 NN NN O
terminal NN NN O
2 NN NN O
. NN NN O

5 NN NN O
kilobases NN NN O
of NN NN O
the NN NN O
murine NN NN O
Duchenne NN NN B-Modifier
muscular NN NN I-Modifier
dystrophy NN NN I-Modifier
( NN NN O
Dmd NN NN O
) NN NN O
messenger NN NN O
RNA NN NN O
( NN NN O
mRNA NN NN O
) NN NN O
. NN NN O

Mouse NN NN O
Dmd NN NN O
mRNA NN NN O
was NN NN O
detectable NN NN O
in NN NN O
skeletal NN NN O
and NN NN O
cardiac NN NN O
muscle NN NN O
and NN NN O
at NN NN O
a NN NN O
level NN NN O
approximately NN NN O
90 NN NN O
percent NN NN O
lower NN NN O
in NN NN O
brain NN NN O
. NN NN O

Dmd NN NN O
mRNA NN NN O
is NN NN O
also NN NN O
present NN NN O
, NN NN O
but NN NN O
at NN NN O
much NN NN O
lower NN NN O
than NN NN O
normal NN NN O
levels NN NN O
, NN NN O
in NN NN O
both NN NN O
the NN NN O
muscle NN NN O
and NN NN O
brain NN NN O
of NN NN O
three NN NN O
different NN NN O
strains NN NN O
of NN NN O
dystrophic NN NN B-Modifier
mdx NN NN O
mice NN NN O
. NN NN O

The NN NN O
identification NN NN O
of NN NN O
Dmd NN NN O
mRNA NN NN O
in NN NN O
brain NN NN O
raises NN NN O
the NN NN O
possibility NN NN O
of NN NN O
a NN NN O
relation NN NN O
between NN NN O
human NN NN O
Duchenne NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DMD NN NN B-SpecificDisease
) NN NN O
gene NN NN O
expression NN NN O
and NN NN O
the NN NN O
mental NN NN B-DiseaseClass
retardation NN NN I-DiseaseClass
found NN NN O
in NN NN O
some NN NN O
DMD NN NN B-Modifier
males NN NN O
. NN NN O

These NN NN O
results NN NN O
also NN NN O
provide NN NN O
evidence NN NN O
that NN NN O
the NN NN O
mdx NN NN O
mutations NN NN O
are NN NN O
allelic NN NN O
variants NN NN O
of NN NN O
mouse NN NN O
Dmd NN NN O
gene NN NN O
mutations NN NN O
. NN NN O

3348216 NN NN O
Glucose NN NN B-SpecificDisease
6-phosphate NN NN I-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
and NN NN O
incidence NN NN O
of NN NN O
hematologic NN NN B-DiseaseClass
malignancy NN NN I-DiseaseClass
. NN NN O

We NN NN O
have NN NN O
evaluated NN NN O
the NN NN O
hypothesis NN NN O
of NN NN O
a NN NN O
negative NN NN O
association NN NN O
between NN NN O
glucose NN NN B-SpecificDisease
6-phosphate NN NN I-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
( NN NN I-SpecificDisease
G6PD NN NN I-SpecificDisease
) NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
and NN NN O
cancer NN NN B-DiseaseClass
in NN NN O
a NN NN O
cohort NN NN O
of NN NN O
481 NN NN O
Sardinian NN NN O
males NN NN O
with NN NN O
hematological NN NN B-DiseaseClass
malignancies NN NN I-DiseaseClass
. NN NN O

The NN NN O
frequency NN NN O
of NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
the NN NN O
patients NN NN O
was NN NN O
not NN NN O
different NN NN O
from NN NN O
the NN NN O
incidence NN NN O
in NN NN O
a NN NN O
group NN NN O
of NN NN O
16 NN NN O
, NN NN O
219 NN NN O
controls NN NN O
. NN NN O

The NN NN O
same NN NN O
conclusion NN NN O
resulted NN NN O
from NN NN O
the NN NN O
comparison NN NN O
of NN NN O
the NN NN O
frequency NN NN O
of NN NN O
expression NN NN O
of NN NN O
the NN NN O
GdB NN NN O
gene NN NN O
in NN NN O
23 NN NN O
heterozygous NN NN O
women NN NN O
having NN NN O
a NN NN O
clonal NN NN O
hematologic NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
and NN NN O
a NN NN O
control NN NN O
group NN NN O
of NN NN O
37 NN NN O
healthy NN NN O
heterozygotes NN NN O
. NN NN O

Therefore NN NN O
at NN NN O
present NN NN O
there NN NN O
is NN NN O
no NN NN O
evidence NN NN O
that NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
has NN NN O
a NN NN O
protective NN NN O
effect NN NN O
against NN NN O
development NN NN O
of NN NN O
hematologic NN NN B-DiseaseClass
neoplasms NN NN I-DiseaseClass
. NN NN O

. NN NN O

3354603 NN NN O
Hepatoblastoma NN NN B-SpecificDisease
, NN NN O
pigmented NN NN B-DiseaseClass
ocular NN NN I-DiseaseClass
fundus NN NN I-DiseaseClass
lesions NN NN I-DiseaseClass
and NN NN O
jaw NN NN B-DiseaseClass
lesions NN NN I-DiseaseClass
in NN NN O
Gardner NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

Hepatoblastoma NN NN B-SpecificDisease
is NN NN O
a NN NN O
rare NN NN O
neoplasm NN NN B-DiseaseClass
of NN NN O
infants NN NN O
and NN NN O
children NN NN O
only NN NN O
recently NN NN O
documented NN NN O
in NN NN O
association NN NN O
with NN NN O
hereditary NN NN B-SpecificDisease
adenomatous NN NN I-SpecificDisease
polyposis NN NN I-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
colon NN NN I-SpecificDisease
[ NN NN O
Kingston NN NN O
et NN NN O
al NN NN O
. NN NN O

, NN NN O
1983 NN NN O
] NN NN O
. NN NN O

We NN NN O
report NN NN O
four NN NN O
children NN NN O
with NN NN O
hepatoblastoma NN NN B-SpecificDisease
from NN NN O
four NN NN O
unrelated NN NN O
families NN NN O
with NN NN O
Gardner NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
GS NN NN B-SpecificDisease
) NN NN O
. NN NN O

One NN NN O
child NN NN O
, NN NN O
now NN NN O
19 NN NN O
years NN NN O
old NN NN O
, NN NN O
survived NN NN O
after NN NN O
a NN NN O
resection NN NN O
of NN NN O
a NN NN O
hepatoblastoma NN NN B-SpecificDisease
in NN NN O
infancy NN NN O
and NN NN O
recently NN NN O
was NN NN O
found NN NN O
to NN NN O
have NN NN O
GS NN NN B-SpecificDisease
. NN NN O

He NN NN O
has NN NN O
an NN NN O
associated NN NN O
odontoma NN NN B-SpecificDisease
and NN NN O
pigmented NN NN B-DiseaseClass
ocular NN NN I-DiseaseClass
fundus NN NN I-DiseaseClass
lesions NN NN I-DiseaseClass
, NN NN O
both NN NN O
of NN NN O
which NN NN O
have NN NN O
been NN NN O
shown NN NN O
to NN NN O
be NN NN O
clinical NN NN O
markers NN NN O
of NN NN O
GS NN NN B-SpecificDisease
. NN NN O

Many NN NN O
individuals NN NN O
in NN NN O
these NN NN O
four NN NN O
GS NN NN B-Modifier
families NN NN O
, NN NN O
both NN NN O
affected NN NN O
and NN NN O
at NN NN O
risk NN NN O
, NN NN O
have NN NN O
osteomatous NN NN B-DiseaseClass
jaw NN NN I-DiseaseClass
lesions NN NN I-DiseaseClass
and NN NN O
pigmented NN NN B-DiseaseClass
ocular NN NN I-DiseaseClass
fundus NN NN I-DiseaseClass
lesions NN NN I-DiseaseClass
. NN NN O

A NN NN O
search NN NN O
for NN NN O
colonic NN NN B-DiseaseClass
polyps NN NN I-DiseaseClass
should NN NN O
be NN NN O
made NN NN O
in NN NN O
families NN NN O
of NN NN O
infants NN NN O
and NN NN O
children NN NN O
with NN NN O
hepatoblastoma NN NN B-SpecificDisease
. NN NN O

If NN NN O
the NN NN O
child NN NN O
survives NN NN O
, NN NN O
he NN NN O
or NN NN O
she NN NN O
should NN NN O
be NN NN O
monitored NN NN O
for NN NN O
the NN NN O
later NN NN O
appearance NN NN O
of NN NN O
colonic NN NN B-DiseaseClass
polyps NN NN I-DiseaseClass
. NN NN O

The NN NN O
finding NN NN O
of NN NN O
jaw NN NN B-DiseaseClass
lesions NN NN I-DiseaseClass
and NN NN O
/ NN NN O
or NN NN O
pigmented NN NN B-DiseaseClass
ocular NN NN I-DiseaseClass
fundus NN NN I-DiseaseClass
lesions NN NN I-DiseaseClass
in NN NN O
relatives NN NN O
at NN NN O
risk NN NN O
are NN NN O
indications NN NN O
of NN NN O
the NN NN O
possible NN NN O
presence NN NN O
of NN NN O
the NN NN O
GS NN NN B-Modifier
gene NN NN O
. NN NN O

3362213 NN NN O
Identification NN NN O
of NN NN O
an NN NN O
altered NN NN O
splice NN NN O
site NN NN O
in NN NN O
Ashkenazi NN NN O
Tay-Sachs NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

Tay-Sachs NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
genetic NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
resulting NN NN O
from NN NN O
mutation NN NN O
of NN NN O
the NN NN O
HEXA NN NN O
gene NN NN O
encoding NN NN O
the NN NN O
alpha-subunit NN NN O
of NN NN O
the NN NN O
lysosomal NN NN O
enzyme NN NN O
, NN NN O
beta-N-acetylhexosaminidase NN NN O
A NN NN O
( NN NN O
ref NN NN O
. NN NN O

1 NN NN O
) NN NN O
. NN NN O

A NN NN O
relatively NN NN O
high NN NN O
frequency NN NN O
of NN NN O
carriers NN NN O
( NN NN O
1 NN NN O
/ NN NN O
27 NN NN O
) NN NN O
of NN NN O
a NN NN O
lethal NN NN O
, NN NN O
infantile NN NN O
form NN NN O
of NN NN O
the NN NN O
disease NN NN O
is NN NN O
found NN NN O
in NN NN O
the NN NN O
Ashkenazi NN NN O
Jewish NN NN O
population NN NN O
, NN NN O
but NN NN O
it NN NN O
is NN NN O
not NN NN O
yet NN NN O
evident NN NN O
whether NN NN O
this NN NN O
has NN NN O
resulted NN NN O
from NN NN O
a NN NN O
founder NN NN O
effect NN NN O
and NN NN O
random NN NN O
genetic NN NN O
drift NN NN O
or NN NN O
from NN NN O
a NN NN O
selective NN NN O
advantage NN NN O
of NN NN O
heterozygotes NN NN O
. NN NN O

We NN NN O
have NN NN O
identified NN NN O
a NN NN O
single-base NN NN O
mutation NN NN O
in NN NN O
a NN NN O
cloned NN NN O
fragment NN NN O
of NN NN O
the NN NN O
HEXA NN NN O
gene NN NN O
from NN NN O
an NN NN O
Ashkenazi NN NN O
Jewish NN NN O
patient NN NN O
. NN NN O

This NN NN O
change NN NN O
, NN NN O
the NN NN O
substitution NN NN O
of NN NN O
a NN NN O
C NN NN O
for NN NN O
G NN NN O
in NN NN O
the NN NN O
first NN NN O
nucleotide NN NN O
of NN NN O
intron NN NN O
12 NN NN O
is NN NN O
expected NN NN O
to NN NN O
result NN NN O
in NN NN O
defective NN NN O
splicing NN NN O
of NN NN O
the NN NN O
messenger NN NN O
RNA NN NN O
. NN NN O

A NN NN O
test NN NN O
for NN NN O
the NN NN O
mutant NN NN O
allele NN NN O
based NN NN O
on NN NN O
amplification NN NN O
of NN NN O
DNA NN NN O
by NN NN O
the NN NN O
polymerase NN NN O
chain NN NN O
rection NN NN O
and NN NN O
cleavage NN NN O
of NN NN O
a NN NN O
DdeI NN NN O
restriction NN NN O
site NN NN O
generated NN NN O
by NN NN O
the NN NN O
mutation NN NN O
revealed NN NN O
that NN NN O
this NN NN O
case NN NN O
and NN NN O
two NN NN O
other NN NN O
cases NN NN O
of NN NN O
the NN NN O
Ashkenazi NN NN O
, NN NN O
infantile NN NN O
form NN NN O
of NN NN O
Tay-Sachs NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
are NN NN O
heterozygous NN NN O
for NN NN O
two NN NN O
different NN NN O
mutations NN NN O
. NN NN O

The NN NN O
occurrence NN NN O
of NN NN O
multiple NN NN O
mutant NN NN O
alleles NN NN O
warrants NN NN O
further NN NN O
examination NN NN O
of NN NN O
the NN NN O
selective NN NN O
advantage NN NN O
hypothesis NN NN O
. NN NN O

. NN NN O

3377761 NN NN O
X-linked NN NN B-SpecificDisease
glucose-6-phosphate NN NN I-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
Mus NN NN O
musculus NN NN O
. NN NN O

A NN NN O
mouse NN NN O
with NN NN O
X-linked NN NN B-SpecificDisease
glucose-6-phosphate NN NN I-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
( NN NN I-SpecificDisease
G6PD NN NN I-SpecificDisease
) NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
has NN NN O
been NN NN O
recovered NN NN O
in NN NN O
offspring NN NN O
of NN NN O
1-ethyl-1-nitrosourea-treated NN NN O
male NN NN O
mice NN NN O
. NN NN O

The NN NN O
activity NN NN O
alteration NN NN O
was NN NN O
detected NN NN O
in NN NN O
blood NN NN O
but NN NN O
can NN NN O
also NN NN O
be NN NN O
observed NN NN O
in NN NN O
other NN NN O
tissue NN NN O
extracts NN NN O
. NN NN O

Hemizygous NN NN O
, NN NN O
heterozygous NN NN O
, NN NN O
and NN NN O
homozygous NN NN O
mutants NN NN O
have NN NN O
, NN NN O
respectively NN NN O
, NN NN O
about NN NN O
15 NN NN O
, NN NN O
60 NN NN O
, NN NN O
and NN NN O
15 NN NN O
% NN NN O
G6PD NN NN O
remaining NN NN O
activity NN NN O
in NN NN O
the NN NN O
blood NN NN O
as NN NN O
compared NN NN O
to NN NN O
the NN NN O
wild NN NN O
type NN NN O
. NN NN O

Erythrocyte NN NN O
indices NN NN O
did NN NN O
not NN NN O
show NN NN O
differences NN NN O
between NN NN O
mutants NN NN O
and NN NN O
wild NN NN O
types NN NN O
. NN NN O

The NN NN O
mutation NN NN O
does NN NN O
not NN NN O
affect NN NN O
the NN NN O
electrophoretic NN NN O
migration NN NN O
, NN NN O
the NN NN O
isoelectric NN NN O
point NN NN O
, NN NN O
or NN NN O
the NN NN O
thermal NN NN O
stability NN NN O
. NN NN O

Kinetic NN NN O
properties NN NN O
, NN NN O
such NN NN O
as NN NN O
the NN NN O
Km NN NN O
for NN NN O
glucose-6-phosphate NN NN O
or NN NN O
for NN NN O
NADP NN NN O
and NN NN O
the NN NN O
relative NN NN O
utilization NN NN O
of NN NN O
substrate NN NN O
analogues NN NN O
, NN NN O
showed NN NN O
no NN NN O
differences NN NN O
between NN NN O
wild NN NN O
types NN NN O
and NN NN O
mutants NN NN O
with NN NN O
the NN NN O
exception NN NN O
of NN NN O
the NN NN O
relative NN NN O
utilization NN NN O
of NN NN O
deamino-NADP NN NN O
which NN NN O
was NN NN O
significantly NN NN O
lower NN NN O
in NN NN O
mutants NN NN O
. NN NN O

This NN NN O
is NN NN O
presently NN NN O
the NN NN O
only NN NN O
animal NN NN O
model NN NN O
for NN NN O
X-linked NN NN B-SpecificDisease
G6PD NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
humans NN NN O
. NN NN O

. NN NN O

3393536 NN NN O
Diverse NN NN O
point NN NN O
mutations NN NN O
in NN NN O
the NN NN O
human NN NN O
glucose-6-phosphate NN NN O
dehydrogenase NN NN O
gene NN NN O
cause NN NN O
enzyme NN NN B-DiseaseClass
deficiency NN NN I-DiseaseClass
and NN NN O
mild NN NN O
or NN NN O
severe NN NN O
hemolytic NN NN B-SpecificDisease
anemia NN NN I-SpecificDisease
. NN NN O


1 NN NN O
. NN NN O

1 NN NN O
. NN NN O

49 NN NN O
) NN NN O
deficiency NN NN O
is NN NN O
a NN NN O
common NN NN O
genetic NN NN B-DiseaseClass
abnormality NN NN I-DiseaseClass
affecting NN NN O
an NN NN O
estimated NN NN O
400 NN NN O
million NN NN O
people NN NN O
worldwide NN NN O
. NN NN O

Clinical NN NN O
and NN NN O
biochemical NN NN O
analyses NN NN O
have NN NN O
identified NN NN O
many NN NN O
variants NN NN O
exhibiting NN NN O
a NN NN O
range NN NN O
of NN NN O
phenotypes NN NN O
, NN NN O
which NN NN O
have NN NN O
been NN NN O
well NN NN O
characterized NN NN O
from NN NN O
the NN NN O
hematological NN NN O
point NN NN O
of NN NN O
view NN NN O
. NN NN O

However NN NN O
, NN NN O
until NN NN O
now NN NN O
, NN NN O
their NN NN O
precise NN NN O
molecular NN NN O
basis NN NN O
has NN NN O
remained NN NN O
unknown NN NN O
. NN NN O

We NN NN O
have NN NN O
cloned NN NN O
and NN NN O
sequenced NN NN O
seven NN NN O
mutant NN NN O
G6PD NN NN O
alleles NN NN O
. NN NN O

In NN NN O
the NN NN O
nondeficient NN NN O
polymorphic NN NN O
African NN NN O
variant NN NN O
G6PD NN NN O
A NN NN O
we NN NN O
have NN NN O
found NN NN O
a NN NN O
single NN NN O
point NN NN O
mutation NN NN O
. NN NN O

The NN NN O
other NN NN O
six NN NN O
mutants NN NN O
investigated NN NN O
were NN NN O
all NN NN O
associated NN NN O
with NN NN O
enzyme NN NN B-DiseaseClass
deficiency NN NN I-DiseaseClass
. NN NN O

In NN NN O
one NN NN O
of NN NN O
the NN NN O
commonest NN NN O
, NN NN O
G6PD NN NN O
Mediterranean NN NN O
, NN NN O
which NN NN O
is NN NN O
associated NN NN O
with NN NN O
favism NN NN B-DiseaseClass
among NN NN O
other NN NN O
clinical NN NN O
manifestations NN NN O
, NN NN O
a NN NN O
single NN NN O
amino NN NN O
acid NN NN O
replacement NN NN O
was NN NN O
found NN NN O
( NN NN O
serine NN NN O
-- NN NN O
-- NN NN O
phenylalanine NN NN O
) NN NN O
it NN NN O
must NN NN O
be NN NN O
responsible NN NN O
for NN NN O
the NN NN O
decreased NN NN O
stability NN NN O
and NN NN O
the NN NN O
reduced NN NN O
catalytic NN NN O
efficiency NN NN O
of NN NN O
this NN NN O
enzyme NN NN O
. NN NN O

Single NN NN O
point NN NN O
mutations NN NN O
were NN NN O
also NN NN O
found NN NN O
in NN NN O
G6PD NN NN O
Metaponto NN NN O
( NN NN O
Southern NN NN O
Italy NN NN O
) NN NN O
and NN NN O
in NN NN O
G6PD NN NN O
Ilesha NN NN O
( NN NN O
Nigeria NN NN O
) NN NN O
, NN NN O
which NN NN O
are NN NN O
asymptomatic NN NN O
, NN NN O
and NN NN O
in NN NN O
G6PD NN NN O
Chatham NN NN O
, NN NN O
which NN NN O
was NN NN O
observed NN NN O
in NN NN O
an NN NN O
Indian NN NN O
boy NN NN O
with NN NN O
neonatal NN NN B-DiseaseClass
jaundice NN NN I-DiseaseClass
. NN NN O

In NN NN O
G6PD NN NN O
`` NN NN O
Matera NN NN O
, NN NN O
`` NN NN O
which NN NN O
is NN NN O
now NN NN O
known NN NN O
to NN NN O
be NN NN O
the NN NN O
same NN NN O
as NN NN O
G6PD NN NN O
A- NN NN O
, NN NN O
two NN NN O
separate NN NN O
point NN NN O
mutations NN NN O
were NN NN O
found NN NN O
, NN NN O
one NN NN O
of NN NN O
which NN NN O
is NN NN O
the NN NN O
same NN NN O
as NN NN O
in NN NN O
G6PD NN NN O
A NN NN O
. NN NN O

In NN NN O
G6PD NN NN O
Santiago NN NN O
, NN NN O
a NN NN O
de NN NN O
novo NN NN O
mutation NN NN O
( NN NN O
glycine NN NN O
-- NN NN O
-- NN NN O
arginine NN NN O
) NN NN O
is NN NN O
associated NN NN O
with NN NN O
severe NN NN O
chronic NN NN O
hemolytic NN NN B-SpecificDisease
anemia NN NN I-SpecificDisease
. NN NN O

The NN NN O
mutations NN NN O
observed NN NN O
show NN NN O
a NN NN O
striking NN NN O
predominance NN NN O
of NN NN O
C NN NN O
-- NN NN O
-- NN NN O
T NN NN O
transitions NN NN O
, NN NN O
with NN NN O
CG NN NN O
doublets NN NN O
involved NN NN O
in NN NN O
four NN NN O
of NN NN O
seven NN NN O
cases NN NN O
. NN NN O

Thus NN NN O
, NN NN O
diverse NN NN O
point NN NN O
mutations NN NN O
may NN NN O
account NN NN O
largely NN NN O
for NN NN O
the NN NN O
phenotypic NN NN O
heterogeneity NN NN O
of NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

3417303 NN NN O
Tight NN NN O
linkage NN NN O
between NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
and NN NN O
apolipoprotein NN NN O
E NN NN O
genes NN NN O
revealed NN NN O
with NN NN O
allele-specific NN NN O
oligonucleotides NN NN O
. NN NN O

In NN NN O
16 NN NN O
families NN NN O
with NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
a NN NN O
novel NN NN O
approach NN NN O
based NN NN O
on NN NN O
use NN NN O
of NN NN O
allele-specific NN NN O
oligonucleotides NN NN O
has NN NN O
been NN NN O
employed NN NN O
to NN NN O
study NN NN O
the NN NN O
linkage NN NN O
relationship NN NN O
between NN NN O
the NN NN O
apolipoprotein NN NN O
E NN NN O
( NN NN O
APOE NN NN O
) NN NN O
gene NN NN O
and NN NN O
DM NN NN B-SpecificDisease
. NN NN O

Synthetic NN NN O
oligonucleotides NN NN O
, NN NN O
designed NN NN O
to NN NN O
discriminate NN NN O
between NN NN O
APOE NN NN O
alleles NN NN O
epsilon NN NN O
3 NN NN O
and NN NN O
epsilon NN NN O
4 NN NN O
, NN NN O
enabled NN NN O
us NN NN O
to NN NN O
distinguish NN NN O
heterozygous NN NN O
carriers NN NN O
in NN NN O
a NN NN O
hybridization NN NN O
assay NN NN O
. NN NN O

In NN NN O
a NN NN O
subset NN NN O
of NN NN O
families NN NN O
, NN NN O
the NN NN O
relevant NN NN O
segment NN NN O
of NN NN O
the NN NN O
APOE NN NN O
gene NN NN O
was NN NN O
enzymatically NN NN O
amplified NN NN O
to NN NN O
increase NN NN O
the NN NN O
sensitivity NN NN O
of NN NN O
the NN NN O
method NN NN O
. NN NN O

For NN NN O
DM NN NN O
and NN NN O
APOE NN NN O
, NN NN O
a NN NN O
maximum NN NN O
lod NN NN O
score NN NN O
( NN NN O
zmax NN NN O
of NN NN O
7 NN NN O
. NN NN O

47 NN NN O
was NN NN O
obtained NN NN O
at NN NN O
a NN NN O
recombination NN NN O
frequency NN NN O
( NN NN O
theta NN NN O
) NN NN O
of NN NN O
0 NN NN O
. NN NN O

047 NN NN O
( NN NN O
male NN NN O
theta NN NN O
= NN NN O
female NN NN O
theta NN NN O
) NN NN O
. NN NN O

No NN NN O
recombination NN NN O
( NN NN O
maximum NN NN O
lod NN NN O
score NN NN O
of NN NN O
5 NN NN O
. NN NN O

61 NN NN O
at NN NN O
theta NN NN O
= NN NN O
0 NN NN O
. NN NN O

0 NN NN O
) NN NN O
was NN NN O
found NN NN O
between NN NN O
APOE NN NN O
and NN NN O
the NN NN O
apolipoprotein NN NN O
CII NN NN O
( NN NN O
APOC2 NN NN O
) NN NN O
gene NN NN O
. NN NN O

These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
, NN NN O
in NN NN O
addition NN NN O
to NN NN O
APOC2 NN NN O
, NN NN O
APOE NN NN O
is NN NN O
a NN NN O
useful NN NN O
marker NN NN O
for NN NN O
presymptomatic NN NN O
DM NN NN B-Modifier
diagnosis NN NN O
. NN NN O

3422216 NN NN O
Regional NN NN O
localization NN NN O
of NN NN O
polymorphic NN NN O
DNA NN NN O
loci NN NN O
on NN NN O
the NN NN O
proximal NN NN O
long NN NN O
arm NN NN O
of NN NN O
the NN NN O
X NN NN O
chromosome NN NN O
using NN NN O
deletions NN NN O
associated NN NN O
with NN NN O
choroideremia NN NN B-SpecificDisease
. NN NN O

In NN NN O
two NN NN O
unrelated NN NN O
families NN NN O
, NN NN O
males NN NN O
have NN NN O
been NN NN O
identified NN NN O
who NN NN O
suffer NN NN O
from NN NN O
choroideremia NN NN B-SpecificDisease
and NN NN O
at NN NN O
the NN NN O
same NN NN O
time NN NN O
have NN NN O
an NN NN O
interstitial NN NN O
deletion NN NN O
on NN NN O
the NN NN O
proximal NN NN O
long NN NN O
arm NN NN O
of NN NN O
the NN NN O
X NN NN O
chromosome NN NN O
. NN NN O

By NN NN O
high-resolution NN NN O
banding NN NN O
we NN NN O
have NN NN O
characterized NN NN O
the NN NN O
deletion NN NN O
chromosomes NN NN O
as NN NN O
del NN NN O
( NN NN O
X NN NN O
) NN NN O
( NN NN O
q21 NN NN O
. NN NN O

1-q21 NN NN O
1-q21 NN NN O
. NN NN O

33 NN NN O
) NN NN O
and NN NN O
del NN NN O
( NN NN O
X NN NN O
) NN NN O
( NN NN O
q21 NN NN O
. NN NN O

2-q21 NN NN O
2-q21 NN NN O
. NN NN O

31 NN NN O
) NN NN O
respectively NN NN O
. NN NN O

By NN NN O
Southern NN NN O
blot NN NN O
analysis NN NN O
we NN NN O
have NN NN O
mapped NN NN O
ten NN NN O
different NN NN O
polymorphic NN NN O
DNA NN NN O
loci NN NN O
relative NN NN O
to NN NN O
the NN NN O
position NN NN O
of NN NN O
the NN NN O
deletion NN NN O
and NN NN O
the NN NN O
choroideremia NN NN B-Modifier
locus NN NN O
TCD NN NN O
. NN NN O

One NN NN O
probe NN NN O
, NN NN O
p31 NN NN O
, NN NN O
was NN NN O
shown NN NN O
to NN NN O
cover NN NN O
one NN NN O
of NN NN O
the NN NN O
breakpoints NN NN O
of NN NN O
the NN NN O
smallest NN NN O
deletion NN NN O
. NN NN O

The NN NN O
following NN NN O
order NN NN O
of NN NN O
the NN NN O
loci NN NN O
was NN NN O
suggested NN NN O
by NN NN O
deletion NN NN O
mapping NN NN O
cen-DXS106-DXS72-TCD- NN NN O
( NN NN O
DXYS1 NN NN O
/ NN NN O
DXYS23 NN NN O
/ NN NN O
DXYS5 NN NN O
) NN NN O
- NN NN O
DXYS2- NN NN O
( NN NN O
DXYS12 NN NN O
/ NN NN O
DXS3 NN NN O
) NN NN O
- NN NN O
( NN NN O
DXS17 NN NN O
/ NN NN O
DXS101 NN NN O
) NN NN O
- NN NN O
Xqter NN NN O
. NN NN O

3455778 NN NN O
Retroviral-mediated NN NN O
gene NN NN O
transfer NN NN O
of NN NN O
human NN NN O
phenylalanine NN NN O
hydroxylase NN NN O
into NN NN O
NIH NN NN O
3T3 NN NN O
and NN NN O
hepatoma NN NN B-Modifier
cells NN NN O
. NN NN O

Phenylketonuria NN NN B-SpecificDisease
( NN NN O
PKU NN NN B-SpecificDisease
) NN NN O
is NN NN O
caused NN NN O
by NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
hepatic NN NN I-SpecificDisease
enzyme NN NN I-SpecificDisease
phenylalanine NN NN I-SpecificDisease
hydroxylase NN NN I-SpecificDisease
( NN NN O
PAH NN NN O
) NN NN O
. NN NN O

A NN NN O
full-length NN NN O
human NN NN O
PAH NN NN O
cDNA NN NN O
sequence NN NN O
has NN NN O
been NN NN O
inserted NN NN O
into NN NN O
pzip-neoSV NN NN O
( NN NN O
X NN NN O
) NN NN O
, NN NN O
which NN NN O
is NN NN O
a NN NN O
retroviral NN NN O
vector NN NN O
containing NN NN O
the NN NN O
bacterial NN NN O
neo NN NN O
gene NN NN O
. NN NN O

The NN NN O
recombinant NN NN O
has NN NN O
been NN NN O
transfected NN NN O
into NN NN O
psi NN NN O
2 NN NN O
cells NN NN O
, NN NN O
which NN NN O
provide NN NN O
synthesis NN NN O
of NN NN O
the NN NN O
retroviral NN NN O
capsid NN NN O
. NN NN O

Recombinant NN NN O
virus NN NN O
was NN NN O
detected NN NN O
in NN NN O
the NN NN O
culture NN NN O
medium NN NN O
of NN NN O
the NN NN O
transfected NN NN O
psi NN NN O
2 NN NN O
cells NN NN O
, NN NN O
which NN NN O
is NN NN O
capable NN NN O
of NN NN O
transmitting NN NN O
the NN NN O
human NN NN O
PAH NN NN O
gene NN NN O
into NN NN O
mouse NN NN O
NIH NN NN O
3T3 NN NN O
cells NN NN O
by NN NN O
infection NN NN O
leading NN NN O
to NN NN O
stable NN NN O
incorporation NN NN O
of NN NN O
the NN NN O
recombinant NN NN O
provirus NN NN O
. NN NN O

Infected NN NN O
cells NN NN O
express NN NN O
PAH NN NN O
mRNA NN NN O
, NN NN O
immunoreactive NN NN O
PAH NN NN O
protein NN NN O
, NN NN O
and NN NN O
exhibit NN NN O
pterin-dependent NN NN O
phenylalanine NN NN O
hydroxylase NN NN O
activity NN NN O
. NN NN O

The NN NN O
recombinant NN NN O
virus NN NN O
is NN NN O
also NN NN O
capable NN NN O
of NN NN O
infecting NN NN O
a NN NN O
mouse NN NN O
hepatoma NN NN B-Modifier
cell NN NN O
line NN NN O
that NN NN O
does NN NN O
not NN NN O
normally NN NN O
synthesize NN NN O
PAH NN NN O
. NN NN O

PAH NN NN O
activity NN NN O
is NN NN O
present NN NN O
in NN NN O
the NN NN O
cellular NN NN O
extracts NN NN O
and NN NN O
the NN NN O
entire NN NN O
hydroxylation NN NN O
system NN NN O
is NN NN O
reconstituted NN NN O
in NN NN O
the NN NN O
hepatoma NN NN B-Modifier
cells NN NN O
infected NN NN O
with NN NN O
the NN NN O
recombinant NN NN O
viruses NN NN O
. NN NN O

Thus NN NN O
, NN NN O
recombinant NN NN O
viruses NN NN O
containing NN NN O
human NN NN O
PAH NN NN O
cDNA NN NN O
provide NN NN O
a NN NN O
means NN NN O
for NN NN O
introducing NN NN O
functional NN NN O
PAH NN NN O
into NN NN O
mammalian NN NN O
cells NN NN O
of NN NN O
hepatic NN NN O
origin NN NN O
and NN NN O
can NN NN O
potentially NN NN O
be NN NN O
introduced NN NN O
into NN NN O
whole NN NN O
animals NN NN O
as NN NN O
a NN NN O
model NN NN O
for NN NN O
somatic NN NN O
gene NN NN O
therapy NN NN O
for NN NN O
PKU NN NN B-SpecificDisease
. NN NN O

. NN NN O

3464560 NN NN O
Estimation NN NN O
of NN NN O
the NN NN O
male NN NN O
to NN NN O
female NN NN O
ratio NN NN O
of NN NN O
mutation NN NN O
rates NN NN O
from NN NN O
the NN NN O
segregation NN NN O
of NN NN O
X-chromosomal NN NN O
DNA NN NN O
haplotypes NN NN O
in NN NN O
Duchenne NN NN B-Modifier
muscular NN NN I-Modifier
dystrophy NN NN I-Modifier
families NN NN O
. NN NN O

A NN NN O
novel NN NN O
procedure NN NN O
is NN NN O
presented NN NN O
to NN NN O
estimate NN NN O
the NN NN O
ratio NN NN O
of NN NN O
male NN NN O
to NN NN O
female NN NN O
mutation NN NN O
rates NN NN O
for NN NN O
Duchenne NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DMD NN NN B-SpecificDisease
) NN NN O
. NN NN O

X-specific NN NN O
restriction NN NN O
fragment NN NN O
length NN NN O
polymorphisms NN NN O
are NN NN O
used NN NN O
to NN NN O
establish NN NN O
DNA NN NN O
haplotypes NN NN O
in NN NN O
three-generation NN NN O
DMD NN NN B-Modifier
families NN NN O
. NN NN O

From NN NN O
the NN NN O
proportion NN NN O
of NN NN O
DMD NN NN B-Modifier
patients NN NN O
who NN NN O
have NN NN O
inherited NN NN O
their NN NN O
maternal NN NN O
grandfathers NN NN O
X NN NN O
chromosome NN NN O
, NN NN O
the NN NN O
ratio NN NN O
of NN NN O
mutation NN NN O
rates NN NN O
can NN NN O
be NN NN O
calculated NN NN O
. NN NN O

In NN NN O
contrast NN NN O
to NN NN O
classical NN NN O
methods NN NN O
, NN NN O
the NN NN O
proposed NN NN O
procedure NN NN O
is NN NN O
not NN NN O
restricted NN NN O
to NN NN O
sporadic NN NN O
or NN NN O
familiar NN NN O
cases NN NN O
nor NN NN O
is NN NN O
any NN NN O
information NN NN O
on NN NN O
the NN NN O
carrier NN NN O
status NN NN O
of NN NN O
female NN NN O
relatives NN NN O
required NN NN O
. NN NN O

. NN NN O

3480530 NN NN O
Deletions NN NN O
of NN NN O
a NN NN O
DNA NN NN O
sequence NN NN O
in NN NN O
retinoblastomas NN NN B-SpecificDisease
and NN NN O
mesenchymal NN NN B-DiseaseClass
tumors NN NN I-DiseaseClass
: NN NN O
organization NN NN O
of NN NN O
the NN NN O
sequence NN NN O
and NN NN O
its NN NN O
encoded NN NN O
protein NN NN O
. NN NN O

Retinoblastoma NN NN B-SpecificDisease
is NN NN O
a NN NN O
childhood NN NN B-DiseaseClass
tumor NN NN I-DiseaseClass
that NN NN O
can NN NN O
arise NN NN O
because NN NN O
of NN NN O
mutant NN NN O
alleles NN NN O
acquired NN NN O
as NN NN O
somatic NN NN O
or NN NN O
germinal NN NN O
mutations NN NN O
. NN NN O

The NN NN O
mutant NN NN O
allele NN NN O
can NN NN O
be NN NN O
carried NN NN O
in NN NN O
the NN NN O
germ NN NN O
line NN NN O
. NN NN O

The NN NN O
mutations NN NN O
creating NN NN O
these NN NN O
alleles NN NN O
act NN NN O
by NN NN O
inactivating NN NN O
copies NN NN O
of NN NN O
a NN NN O
recessive NN NN O
oncogene NN NN O
located NN NN O
within NN NN O
band NN NN O
q14 NN NN O
of NN NN O
chromosome NN NN O
13 NN NN O
and NN NN O
termed NN NN O
the NN NN O
RB1 NN NN O
locus NN NN O
. NN NN O

We NN NN O
have NN NN O
reported NN NN O
isolation NN NN O
of NN NN O
a NN NN O
cDNA NN NN O
fragment NN NN O
that NN NN O
recognizes NN NN O
chromosomal NN NN O
sequences NN NN O
possessing NN NN O
many NN NN O
of NN NN O
the NN NN O
attributes NN NN O
of NN NN O
the NN NN O
retinoblastoma NN NN B-Modifier
gene NN NN O
associated NN NN O
with NN NN O
the NN NN O
RB1 NN NN O
locus NN NN O
. NN NN O

We NN NN O
now NN NN O
report NN NN O
that NN NN O
this NN NN O
segment NN NN O
is NN NN O
additionally NN NN O
the NN NN O
target NN NN O
of NN NN O
somatic NN NN O
mutations NN NN O
in NN NN O
mesenchymal NN NN B-DiseaseClass
tumors NN NN I-DiseaseClass
among NN NN O
patients NN NN O
having NN NN O
no NN NN O
apparent NN NN O
predisposition NN NN O
to NN NN O
retinoblastoma NN NN B-SpecificDisease
and NN NN O
no NN NN O
previous NN NN O
evidence NN NN O
of NN NN O
retinoblastoma NN NN B-SpecificDisease
. NN NN O

These NN NN O
tumors NN NN B-DiseaseClass
provide NN NN O
additional NN NN O
evidence NN NN O
that NN NN O
the NN NN O
cloned NN NN O
sequences NN NN O
are NN NN O
representative NN NN O
of NN NN O
a NN NN O
gene NN NN O
that NN NN O
is NN NN O
a NN NN O
frequent NN NN O
target NN NN O
of NN NN O
inactivation NN NN O
during NN NN O
tumorigenesis NN NN O
. NN NN O

Sequence NN NN O
analysis NN NN O
of NN NN O
this NN NN O
cDNA NN NN O
provides NN NN O
little NN NN O
insight NN NN O
into NN NN O
its NN NN O
normal NN NN O
functional NN NN O
role NN NN O
. NN NN O

. NN NN O

3524231 NN NN O
Treatment NN NN O
of NN NN O
Duchenne NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
with NN NN O
growth NN NN O
hormone NN NN O
inhibitors NN NN O
. NN NN O

A NN NN O
controlled NN NN O
, NN NN O
double-blind NN NN O
therapeutic NN NN O
trial NN NN O
with NN NN O
the NN NN O
drug NN NN O
mazindol NN NN O
, NN NN O
a NN NN O
growth NN NN O
hormone NN NN O
inhibitor NN NN O
, NN NN O
was NN NN O
performed NN NN O
in NN NN O
a NN NN O
pair NN NN O
of NN NN O
7 NN NN O
1 NN NN O
/ NN NN O
2 NN NN O
year-old NN NN O
monozygotic NN NN O
twins NN NN O
, NN NN O
with NN NN O
Duchenne NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DMD NN NN B-SpecificDisease
) NN NN O
. NN NN O

The NN NN O
rationale NN NN O
for NN NN O
this NN NN O
trial NN NN O
was NN NN O
based NN NN O
on NN NN O
a NN NN O
patient NN NN O
( NN NN O
reported NN NN O
previously NN NN O
) NN NN O
affected NN NN O
simultaneously NN NN O
with NN NN O
DMD NN NN B-SpecificDisease
and NN NN O
growth NN NN B-SpecificDisease
hormone NN NN I-SpecificDisease
( NN NN I-SpecificDisease
GH NN NN I-SpecificDisease
) NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
, NN NN O
who NN NN O
is NN NN O
showing NN NN O
a NN NN O
benign NN NN O
course NN NN O
of NN NN O
the NN NN O
dystrophic NN NN B-DiseaseClass
process NN NN I-DiseaseClass
and NN NN O
is NN NN O
still NN NN O
walking NN NN O
at NN NN O
18 NN NN O
years NN NN O
. NN NN O

One NN NN O
of NN NN O
the NN NN O
twins NN NN O
received NN NN O
2 NN NN O
mg NN NN O
of NN NN O
mazindol NN NN O
daily NN NN O
, NN NN O
while NN NN O
the NN NN O
other NN NN O
received NN NN O
a NN NN O
placebo NN NN O
. NN NN O

The NN NN O
assessment NN NN O
, NN NN O
repeated NN NN O
every NN NN O
2 NN NN O
months NN NN O
, NN NN O
included NN NN O
weight NN NN O
and NN NN O
height NN NN O
measurements NN NN O
, NN NN O
functional NN NN O
and NN NN O
motor NN NN O
ability NN NN O
tests NN NN O
, NN NN O
ergometry NN NN O
and NN NN O
determinations NN NN O
of NN NN O
serum NN NN O
enzymes NN NN O
and NN NN O
GH NN NN O
levels NN NN O
. NN NN O

After NN NN O
one NN NN O
year NN NN O
of NN NN O
trial NN NN O
the NN NN O
code NN NN O
was NN NN O
broken NN NN O
and NN NN O
it NN NN O
was NN NN O
seen NN NN O
that NN NN O
the NN NN O
twin NN NN O
under NN NN O
placebo NN NN O
treatment NN NN O
was NN NN O
strikingly NN NN O
worse NN NN O
than NN NN O
his NN NN O
brother NN NN O
, NN NN O
the NN NN O
progression NN NN O
of NN NN O
whose NN NN O
condition NN NN O
was NN NN O
practically NN NN O
arrested NN NN O
. NN NN O

These NN NN O
results NN NN O
strongly NN NN O
suggest NN NN O
that NN NN O
treatment NN NN O
with NN NN O
a NN NN O
GH NN NN O
inhibitor NN NN O
is NN NN O
beneficial NN NN O
for NN NN O
DMD NN NN B-Modifier
patients NN NN O
. NN NN O

. NN NN O

3563511 NN NN O
Identification NN NN O
and NN NN O
localization NN NN O
of NN NN O
mutations NN NN O
at NN NN O
the NN NN O
Lesch-Nyhan NN NN B-Modifier
locus NN NN O
by NN NN O
ribonuclease NN NN O
A NN NN O
cleavage NN NN O
. NN NN O

Many NN NN O
mutations NN NN O
leading NN NN O
to NN NN O
human NN NN O
disease NN NN O
are NN NN O
the NN NN O
result NN NN O
of NN NN O
single NN NN O
DNA NN NN O
base NN NN O
pair NN NN O
changes NN NN O
that NN NN O
can NN NN O
not NN NN O
be NN NN O
identified NN NN O
by NN NN O
Southern NN NN O
analysis NN NN O
. NN NN O

This NN NN O
has NN NN O
prompted NN NN O
the NN NN O
development NN NN O
of NN NN O
alternative NN NN O
assays NN NN O
for NN NN O
point NN NN O
mutation NN NN O
detection NN NN O
. NN NN O

The NN NN O
recently NN NN O
described NN NN O
ribonuclease NN NN O
A NN NN O
cleavage NN NN O
procedure NN NN O
, NN NN O
with NN NN O
a NN NN O
polyuridylic NN NN O
acid-paper NN NN O
affinity NN NN O
chromatography NN NN O
step NN NN O
, NN NN O
has NN NN O
been NN NN O
used NN NN O
to NN NN O
identify NN NN O
the NN NN O
mutational NN NN B-DiseaseClass
lesions NN NN I-DiseaseClass
in NN NN O
the NN NN O
hypoxanthine NN NN O
phosphoribosyltransferase NN NN O
( NN NN O
HPRT NN NN O
) NN NN O
messenger NN NN O
RNAs NN NN O
of NN NN O
patients NN NN O
with NN NN O
Lesch-Nyhan NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

Distinctive NN NN O
ribonuclease NN NN O
A NN NN O
cleavage NN NN O
patterns NN NN O
were NN NN O
identified NN NN O
in NN NN O
messenger NN NN O
RNA NN NN O
from NN NN O
5 NN NN O
of NN NN O
14 NN NN O
Lesch-Nyhan NN NN B-Modifier
patients NN NN O
who NN NN O
were NN NN O
chosen NN NN O
because NN NN O
no NN NN O
HPRT NN NN O
Southern NN NN O
or NN NN O
Northern NN NN O
blotting NN NN O
pattern NN NN O
changes NN NN O
had NN NN O
been NN NN O
found NN NN O
. NN NN O

This NN NN O
approach NN NN O
now NN NN O
allows NN NN O
HPRT NN NN O
mutation NN NN O
detection NN NN O
in NN NN O
50 NN NN O
percent NN NN O
of NN NN O
the NN NN O
cases NN NN O
of NN NN O
Lesch-Nyhan NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

The NN NN O
polyuridylic NN NN O
acid-paper NN NN O
affinity NN NN O
procedure NN NN O
provides NN NN O
a NN NN O
general NN NN O
method NN NN O
for NN NN O
analysis NN NN O
of NN NN O
low NN NN O
abundance NN NN O
messenger NN NN O
RNAs NN NN O
. NN NN O

. NN NN O

3565372 NN NN O
Two NN NN O
new NN NN O
variants NN NN O
of NN NN O
glucose-6-phosphate NN NN O
dehydrogenase NN NN O
associated NN NN O
with NN NN O
hereditary NN NN B-SpecificDisease
non-spherocytic NN NN I-SpecificDisease
hemolytic NN NN I-SpecificDisease
anemia NN NN I-SpecificDisease
: NN NN O
G6PD NN NN O
Wayne NN NN O
and NN NN O
G6PD NN NN O
Huron NN NN O
. NN NN O

Two NN NN O
new NN NN O
deficient NN NN O
variants NN NN O
of NN NN O
glucose-6-phosphate NN NN O
dehydrogenase NN NN O
( NN NN O
G6PD NN NN O
) NN NN O
causing NN NN O
hereditary NN NN B-SpecificDisease
nonspherocytic NN NN I-SpecificDisease
hemolytic NN NN I-SpecificDisease
anemia NN NN I-SpecificDisease
( NN NN O
HNSHA NN NN B-SpecificDisease
) NN NN O
are NN NN O
described NN NN O
. NN NN O

Both NN NN O
of NN NN O
these NN NN O
are NN NN O
unique NN NN O
and NN NN O
they NN NN O
have NN NN O
been NN NN O
named NN NN O
G6PD NN NN O
Wayne NN NN O
and NN NN O
G6PD NN NN O
Huron NN NN O
. NN NN O

Patients NN NN O
with NN NN O
G6PD NN NN O
Wayne NN NN O
underwent NN NN O
splenectomy NN NN O
and NN NN O
no NN NN O
objective NN NN O
improvement NN NN O
was NN NN O
noted NN NN O
. NN NN O

The NN NN O
patients NN NN O
with NN NN O
G6PD NN NN O
Huron NN NN O
were NN NN O
under NN NN O
medical NN NN O
observation NN NN O
for NN NN O
a NN NN O
considerable NN NN O
period NN NN O
of NN NN O
time NN NN O
without NN NN O
the NN NN O
diagnosis NN NN O
of NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
being NN NN O
entertained NN NN O
because NN NN O
the NN NN O
family NN NN O
was NN NN O
of NN NN O
Northern NN NN O
European NN NN O
origin NN NN O
. NN NN O

Since NN NN O
sporadic NN NN O
variants NN NN O
of NN NN O
G6PD NN NN O
causing NN NN O
HNSHA NN NN B-SpecificDisease
show NN NN O
no NN NN O
special NN NN O
racial NN NN O
predilection NN NN O
, NN NN O
the NN NN O
diagnosis NN NN O
of NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
should NN NN O
always NN NN O
be NN NN O
considered NN NN O
in NN NN O
patients NN NN O
with NN NN O
this NN NN O
syndrome NN NN O
. NN NN O

. NN NN O

3572301 NN NN O
Sialophorin NN NN O
, NN NN O
a NN NN O
surface NN NN O
sialoglycoprotein NN NN O
defective NN NN O
in NN NN O
the NN NN O
Wiskott-Aldrich NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
, NN NN O
is NN NN O
involved NN NN O
in NN NN O
human NN NN O
T NN NN O
lymphocyte NN NN O
proliferation NN NN O
. NN NN O

The NN NN O
mAb NN NN O
L10 NN NN O
was NN NN O
used NN NN O
to NN NN O
determine NN NN O
the NN NN O
distribution NN NN O
and NN NN O
the NN NN O
function NN NN O
of NN NN O
sialophorin NN NN O
, NN NN O
the NN NN O
heavily NN NN O
glycosylated NN NN O
surface NN NN O
molecule NN NN O
that NN NN O
is NN NN O
deficient NN NN O
/ NN NN O
defective NN NN O
in NN NN O
lymphocytes NN NN O
of NN NN O
patients NN NN O
with NN NN O
the NN NN O
X-linked NN NN B-SpecificDisease
immunodeficiency NN NN I-SpecificDisease
Wiskott-Aldrich NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

Dual-parameter NN NN O
FACS NN NN O
analysis NN NN O
indicated NN NN O
that NN NN O
sialophorin NN NN O
is NN NN O
expressed NN NN O
on NN NN O
CD4 NN NN O
+ NN NN O
and NN NN O
CD8 NN NN O
+ NN NN O
lymphocytes NN NN O
, NN NN O
on NN NN O
a NN NN O
subpopulation NN NN O
of NN NN O
peripheral NN NN O
blood NN NN O
B NN NN O
lymphocytes NN NN O
, NN NN O
on NN NN O
all NN NN O
thymocytes NN NN O
, NN NN O
and NN NN O
on NN NN O
a NN NN O
subpopulation NN NN O
of NN NN O
bone NN NN O
marrow NN NN O
cells NN NN O
. NN NN O

Functional NN NN O
studies NN NN O
demonstrated NN NN O
that NN NN O
L10 NN NN O
mAb NN NN O
stimulates NN NN O
the NN NN O
proliferation NN NN O
of NN NN O
peripheral NN NN O
blood NN NN O
T NN NN O
lymphocytes NN NN O
as NN NN O
measured NN NN O
by NN NN O
stimulation NN NN O
of NN NN O
[ NN NN O
3H NN NN O
] NN NN O
thymidine NN NN O
incorporation NN NN O
. NN NN O

The NN NN O
time NN NN O
course NN NN O
and NN NN O
magnitude NN NN O
of NN NN O
increased NN NN O
[ NN NN O
3H NN NN O
] NN NN O
thymidine NN NN O
incorporation NN NN O
by NN NN O
T NN NN O
lymphocytes NN NN O
in NN NN O
response NN NN O
to NN NN O
L10 NN NN O
mAb NN NN O
paralleled NN NN O
that NN NN O
induced NN NN O
by NN NN O
anti-CD3 NN NN O
mAb NN NN O
. NN NN O

Effective NN NN O
stimulation NN NN O
was NN NN O
dependent NN NN O
on NN NN O
the NN NN O
presence NN NN O
of NN NN O
monocytes NN NN O
and NN NN O
the NN NN O
Fc NN NN O
portion NN NN O
of NN NN O
L10 NN NN O
mAb NN NN O
. NN NN O

Stimulation NN NN O
of NN NN O
lymphocytes NN NN O
by NN NN O
L10 NN NN O
, NN NN O
like NN NN O
stimulation NN NN O
by NN NN O
anti-CD3 NN NN O
mAb NN NN O
, NN NN O
involves NN NN O
increased NN NN O
expression NN NN O
of NN NN O
4F2 NN NN O
, NN NN O
HLA-DR NN NN O
, NN NN O
and NN NN O
IL-2-R NN NN O
. NN NN O

These NN NN O
observations NN NN O
suggest NN NN O
that NN NN O
sialophorin NN NN O
functions NN NN O
in NN NN O
T NN NN O
cell NN NN O
activation NN NN O
. NN NN O

. NN NN O

3578281 NN NN O
Hypopigmentation NN NN B-DiseaseClass
in NN NN O
the NN NN O
Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

Cutaneous NN NN B-CompositeMention
and NN NN I-CompositeMention
ocular NN NN I-CompositeMention
pigmentation NN NN I-CompositeMention
were NN NN O
evaluated NN NN O
in NN NN O
29 NN NN O
individuals NN NN O
with NN NN O
the NN NN O
Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
PWS NN NN B-SpecificDisease
) NN NN O
. NN NN O

Criteria NN NN O
for NN NN O
hypopigmentation NN NN B-DiseaseClass
included NN NN O
the NN NN O
presence NN NN O
of NN NN O
type NN NN O
I NN NN O
or NN NN O
II NN NN O
skin NN NN O
, NN NN O
the NN NN O
lightest NN NN O
skin NN NN O
type NN NN O
in NN NN O
the NN NN O
family NN NN O
by NN NN O
history NN NN O
, NN NN O
and NN NN O
iris NN NN O
translucency NN NN O
on NN NN O
globe NN NN O
transillumination NN NN O
. NN NN O

On NN NN O
the NN NN O
basis NN NN O
of NN NN O
these NN NN O
criteria NN NN O
, NN NN O
48 NN NN O
% NN NN O
of NN NN O
the NN NN O
PWS NN NN B-Modifier
individuals NN NN O
were NN NN O
hypopigmented NN NN B-Modifier
. NN NN O

The NN NN O
presence NN NN O
of NN NN O
hypopigmentation NN NN B-DiseaseClass
correlated NN NN O
with NN NN O
a NN NN O
small NN NN O
interstitial NN NN O
deletion NN NN O
on NN NN O
the NN NN O
proximal NN NN O
long NN NN O
arm NN NN O
of NN NN O
chromosome NN NN O
15 NN NN O
; NN NN O
however NN NN O
, NN NN O
this NN NN O
deletion NN NN O
was NN NN O
also NN NN O
found NN NN O
in NN NN O
individuals NN NN O
who NN NN O
did NN NN O
not NN NN O
meet NN NN O
the NN NN O
full NN NN O
criteria NN NN O
for NN NN O
hypopigmentation NN NN B-DiseaseClass
. NN NN O

Hairbulb NN NN O
tyrosinase NN NN O
activity NN NN O
and NN NN O
glutathione NN NN O
content NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
urine NN NN O
cysteinyldopa NN NN O
excretion NN NN O
, NN NN O
were NN NN O
low NN NN O
in NN NN O
PWS NN NN B-Modifier
individuals NN NN O
with NN NN O
and NN NN O
without NN NN O
hypopigmentation NN NN B-DiseaseClass
and NN NN O
did NN NN O
not NN NN O
separate NN NN O
these NN NN O
two NN NN O
groups NN NN O
. NN NN O

We NN NN O
conclude NN NN O
that NN NN O
hypopigmentation NN NN B-DiseaseClass
is NN NN O
found NN NN O
in NN NN O
a NN NN O
significant NN NN O
proportion NN NN O
of NN NN O
individuals NN NN O
with NN NN O
PWS NN NN B-SpecificDisease
and NN NN O
that NN NN O
the NN NN O
hypopigmentation NN NN B-DiseaseClass
may NN NN O
be NN NN O
associated NN NN O
with NN NN O
a NN NN O
deletion NN NN O
of NN NN O
the NN NN O
long NN NN O
arm NN NN O
of NN NN O
chromosome NN NN O
15 NN NN O
. NN NN O

The NN NN O
mechanism NN NN O
for NN NN O
the NN NN O
hypopigmentation NN NN B-DiseaseClass
is NN NN O
unknown NN NN O
. NN NN O

. NN NN O

3591825 NN NN O
Phenotype NN NN O
heterogeneity NN NN O
among NN NN O
hemizygotes NN NN O
in NN NN O
a NN NN O
family NN NN O
biochemically NN NN O
screened NN NN O
for NN NN O
adrenoleukodystrophy NN NN B-SpecificDisease
. NN NN O

We NN NN O
report NN NN O
on NN NN O
two NN NN O
clinically NN NN O
, NN NN O
neurologically NN NN O
normal NN NN O
relatives NN NN O
of NN NN O
a NN NN O
boy NN NN O
affected NN NN O
by NN NN O
adrenoleukodystrophy NN NN B-SpecificDisease
( NN NN O
ALD NN NN B-SpecificDisease
) NN NN O
; NN NN O
they NN NN O
were NN NN O
found NN NN O
repeatedly NN NN O
to NN NN O
have NN NN O
the NN NN O
biochemical NN NN O
defect NN NN O
of NN NN O
an NN NN O
ALD NN NN B-Modifier
hemizygote NN NN O
. NN NN O

The NN NN O
assay NN NN O
consisted NN NN O
in NN NN O
the NN NN O
determination NN NN O
of NN NN O
very-long-chain NN NN O
fatty NN NN O
acids NN NN O
in NN NN O
lyophilized NN NN O
and NN NN O
reconstituted NN NN O
plasma NN NN O
. NN NN O

While NN NN O
no NN NN O
evidence NN NN O
of NN NN O
neurologic NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
( NN NN O
leukodystrophy NN NN B-SpecificDisease
or NN NN O
myeloneuropathy NN NN B-SpecificDisease
) NN NN O
was NN NN O
present NN NN O
in NN NN O
these NN NN O
hemizygotes NN NN O
, NN NN O
adrenocortical NN NN B-DiseaseClass
insufficiency NN NN I-DiseaseClass
provoking NN NN O
compensatory NN NN O
high NN NN O
ACTH NN NN O
release NN NN O
was NN NN O
found NN NN O
in NN NN O
both NN NN O
. NN NN O

These NN NN O
findings NN NN O
should NN NN O
be NN NN O
taken NN NN O
into NN NN O
consideration NN NN O
when NN NN O
counseling NN NN O
families NN NN O
in NN NN O
which NN NN O
cases NN NN O
with NN NN O
clinically NN NN O
expressed NN NN O
ALD NN NN B-SpecificDisease
are NN NN O
represented NN NN O
in NN NN O
several NN NN O
generations NN NN O
. NN NN O

. NN NN O

3600793 NN NN O
The NN NN O
mapping NN NN O
of NN NN O
a NN NN O
cDNA NN NN O
from NN NN O
the NN NN O
human NN NN O
X-linked NN NN B-Modifier
Duchenne NN NN I-Modifier
muscular NN NN I-Modifier
dystrophy NN NN I-Modifier
gene NN NN O
to NN NN O
the NN NN O
mouse NN NN O
X NN NN O
chromosome NN NN O
. NN NN O

The NN NN O
recent NN NN O
discovery NN NN O
of NN NN O
sequences NN NN O
at NN NN O
the NN NN O
site NN NN O
of NN NN O
the NN NN O
Duchenne NN NN B-Modifier
muscular NN NN I-Modifier
dystrophy NN NN I-Modifier
( NN NN O
DMD NN NN B-Modifier
) NN NN O
gene NN NN O
in NN NN O
humans NN NN O
has NN NN O
opened NN NN O
up NN NN O
the NN NN O
possibility NN NN O
of NN NN O
a NN NN O
detailed NN NN O
molecular NN NN O
analysis NN NN O
of NN NN O
the NN NN O
genes NN NN O
in NN NN O
humans NN NN O
and NN NN O
in NN NN O
related NN NN O
mammalian NN NN O
species NN NN O
. NN NN O

Until NN NN O
relatively NN NN O
recently NN NN O
, NN NN O
there NN NN O
was NN NN O
no NN NN O
obvious NN NN O
mouse NN NN O
model NN NN O
of NN NN O
this NN NN O
genetic NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
for NN NN O
the NN NN O
development NN NN O
of NN NN O
therapeutic NN NN O
strategies NN NN O
. NN NN O

The NN NN O
identification NN NN O
of NN NN O
a NN NN O
mouse NN NN O
X-linked NN NN O
mutant NN NN O
showing NN NN O
muscular NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
, NN NN O
mdx NN NN O
, NN NN O
has NN NN O
provided NN NN O
a NN NN O
candidate NN NN O
mouse NN NN O
genetic NN NN O
homologue NN NN O
to NN NN O
the NN NN O
DMD NN NN B-Modifier
locus NN NN O
; NN NN O
the NN NN O
relatively NN NN O
mild NN NN O
pathological NN NN O
features NN NN O
of NN NN O
mdx NN NN O
suggest NN NN O
it NN NN O
may NN NN O
have NN NN O
more NN NN O
in NN NN O
common NN NN O
with NN NN O
mutations NN NN O
of NN NN O
the NN NN O
Becker NN NN B-Modifier
muscular NN NN I-Modifier
dystrophy NN NN I-Modifier
type NN NN O
at NN NN O
the NN NN O
same NN NN O
human NN NN O
locus NN NN O
, NN NN O
however NN NN O
. NN NN O

But NN NN O
the NN NN O
close NN NN O
genetic NN NN O
linkage NN NN O
of NN NN O
mdx NN NN O
to NN NN O
G6PD NN NN O
and NN NN O
Hprt NN NN O
on NN NN O
the NN NN O
mouse NN NN O
X NN NN O
chromosome NN NN O
, NN NN O
coupled NN NN O
with NN NN O
its NN NN O
comparatively NN NN O
mild NN NN O
pathology NN NN O
, NN NN O
have NN NN O
suggested NN NN O
that NN NN O
the NN NN O
mdx NN NN O
mutation NN NN O
may NN NN O
instead NN NN O
correspond NN NN O
to NN NN O
Emery NN NN B-SpecificDisease
Dreifuss NN NN I-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
which NN NN O
itself NN NN O
is NN NN O
closely NN NN O
linked NN NN O
to NN NN O
DNA NN NN O
markers NN NN O
at NN NN O
Xq28-qter NN NN O
in NN NN O
the NN NN O
region NN NN O
of NN NN O
G6PD NN NN O
on NN NN O
the NN NN O
human NN NN O
X NN NN O
chromosome NN NN O
. NN NN O

Using NN NN O
an NN NN O
interspecific NN NN O
mouse NN NN O
domesticus NN NN O
/ NN NN O
spretus NN NN O
cross NN NN O
, NN NN O
segregating NN NN O
for NN NN O
a NN NN O
variety NN NN O
of NN NN O
markers NN NN O
on NN NN O
the NN NN O
mouse NN NN O
X NN NN O
chromosome NN NN O
, NN NN O
we NN NN O
have NN NN O
positioned NN NN O
on NN NN O
the NN NN O
mouse NN NN O
X NN NN O
chromosome NN NN O
sequences NN NN O
homologous NN NN O
to NN NN O
a NN NN O
DMD NN NN B-Modifier
cDNA NN NN O
clone NN NN O
. NN NN O

These NN NN O
sequences NN NN O
map NN NN O
provocatively NN NN O
close NN NN O
to NN NN O
the NN NN O
mdx NN NN O
mutation NN NN O
and NN NN O
unexpectedly NN NN O
distant NN NN O
from NN NN O
sparse NN NN O
fur NN NN O
, NN NN O
spf NN NN O
, NN NN O
the NN NN O
mouse NN NN O
homologue NN NN O
of NN NN O
OTC NN NN O
( NN NN O
ornithine NN NN O
transcarbamylase NN NN O
) NN NN O
which NN NN O
is NN NN O
closely NN NN O
linked NN NN O
to NN NN O
DMD NN NN B-SpecificDisease
on NN NN O
the NN NN O
human NN NN O
X NN NN O
chromosome NN NN O
. NN NN O

. NN NN O

3600794 NN NN O
Localization NN NN O
of NN NN O
the NN NN O
region NN NN O
homologous NN NN O
to NN NN O
the NN NN O
Duchenne NN NN B-Modifier
muscular NN NN I-Modifier
dystrophy NN NN I-Modifier
locus NN NN O
on NN NN O
the NN NN O
mouse NN NN O
X NN NN O
chromosome NN NN O
. NN NN O

Recent NN NN O
progress NN NN O
has NN NN O
resulted NN NN O
in NN NN O
part NN NN O
of NN NN O
the NN NN O
gene NN NN O
mutated NN NN O
in NN NN O
Duchenne NN NN B-CompositeMention
and NN NN I-CompositeMention
the NN NN I-CompositeMention
milder NN NN I-CompositeMention
Becker NN NN I-CompositeMention
muscular NN NN I-CompositeMention
dystrophies NN NN I-CompositeMention
being NN NN O
cloned NN NN O
and NN NN O
has NN NN O
suggested NN NN O
that NN NN O
the NN NN O
gene NN NN O
itself NN NN O
extends NN NN O
over NN NN O
1 NN NN O
, NN NN O
000 NN NN O
to NN NN O
2 NN NN O
, NN NN O
000 NN NN O
kilobases NN NN O
( NN NN O
kb NN NN O
) NN NN O
. NN NN O

To NN NN O
study NN NN O
how NN NN O
mutations NN NN O
in NN NN O
this NN NN O
gene NN NN O
affect NN NN O
muscle NN NN O
development NN NN O
and NN NN O
integrity NN NN O
, NN NN O
it NN NN O
would NN NN O
be NN NN O
of NN NN O
interest NN NN O
to NN NN O
have NN NN O
available NN NN O
a NN NN O
mouse NN NN O
model NN NN O
of NN NN O
the NN NN O
human NN NN O
disease NN NN O
. NN NN O

The NN NN O
mouse NN NN O
mdx NN NN O
mutation NN NN O
affects NN NN O
muscle NN NN O
and NN NN O
confers NN NN O
a NN NN O
mild NN NN O
dystrophic NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
, NN NN O
but NN NN O
it NN NN O
is NN NN O
not NN NN O
clear NN NN O
whether NN NN O
this NN NN O
mutation NN NN O
is NN NN O
equivalent NN NN O
to NN NN O
Duchenne NN NN B-CompositeMention
/ NN NN I-CompositeMention
Becker NN NN I-CompositeMention
muscular NN NN I-CompositeMention
dystrophy NN NN I-CompositeMention
in NN NN O
man NN NN O
. NN NN O

Here NN NN O
we NN NN O
describe NN NN O
the NN NN O
use NN NN O
of NN NN O
two NN NN O
sequences NN NN O
from NN NN O
the NN NN O
human NN NN O
Duchenne NN NN B-Modifier
muscular NN NN I-Modifier
dystrophy NN NN I-Modifier
( NN NN O
DMD NN NN B-Modifier
) NN NN O
gene NN NN O
that NN NN O
cross-hybridize NN NN O
to NN NN O
mouse NN NN O
X-linked NN NN O
sequences NN NN O
to NN NN O
localize NN NN O
the NN NN O
gene NN NN O
homologous NN NN O
to NN NN O
DMD NN NN B-SpecificDisease
in NN NN O
the NN NN O
mouse NN NN O
. NN NN O

Both NN NN O
sequences NN NN O
map NN NN O
to NN NN O
the NN NN O
region NN NN O
of NN NN O
10 NN NN O
centimorgan NN NN O
lying NN NN O
between NN NN O
the NN NN O
Tabby NN NN O
( NN NN O
Ta NN NN O
) NN NN O
and NN NN O
St14-1 NN NN O
( NN NN O
DxPas8 NN NN O
) NN NN O
loci NN NN O
, NN NN O
close NN NN O
to NN NN O
the NN NN O
phosphorylase NN NN O
b NN NN O
kinase NN NN O
locus NN NN O
( NN NN O
Phk NN NN O
) NN NN O
. NN NN O

By NN NN O
analogy NN NN O
with NN NN O
the NN NN O
human NN NN O
X-chromosome NN NN O
, NN NN O
we NN NN O
conclude NN NN O
that NN NN O
the NN NN O
region NN NN O
in NN NN O
the NN NN O
mouse NN NN O
around NN NN O
the NN NN O
G6pd NN NN O
and NN NN O
St14-1 NN NN O
loci NN NN O
may NN NN O
contain NN NN O
two NN NN O
genes NN NN O
corresponding NN NN O
to NN NN O
distinct NN NN O
human NN NN O
myopathies NN NN B-DiseaseClass
Emery NN NN B-SpecificDisease
Dreifuss NN NN I-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
which NN NN O
is NN NN O
known NN NN O
to NN NN O
be NN NN O
closely NN NN O
linked NN NN O
to NN NN O
St14-1 NN NN O
in NN NN O
man NN NN O
and NN NN O
the NN NN O
DMD NN NN B-Modifier
homologue NN NN O
described NN NN O
here NN NN O
. NN NN O

. NN NN O

3615198 NN NN O
GT NN NN O
to NN NN O
AT NN NN O
transition NN NN O
at NN NN O
a NN NN O
splice NN NN O
donor NN NN O
site NN NN O
causes NN NN O
skipping NN NN O
of NN NN O
the NN NN O
preceding NN NN O
exon NN NN O
in NN NN O
phenylketonuria NN NN B-SpecificDisease
. NN NN O

Classical NN NN B-SpecificDisease
Phenylketonuria NN NN I-SpecificDisease
( NN NN O
PKU NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
human NN NN I-DiseaseClass
genetic NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
caused NN NN O
by NN NN O
a NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
hepatic NN NN I-SpecificDisease
phenylalanine NN NN I-SpecificDisease
hydroxylase NN NN I-SpecificDisease
( NN NN O
PAH NN NN O
) NN NN O
. NN NN O

We NN NN O
isolated NN NN O
several NN NN O
mutant NN NN O
PAH NN NN O
cDNA NN NN O
clones NN NN O
from NN NN O
a NN NN O
PKU NN NN B-Modifier
carrier NN NN O
individual NN NN O
and NN NN O
showed NN NN O
that NN NN O
they NN NN O
contained NN NN O
an NN NN O
internal NN NN O
116 NN NN O
base NN NN O
pair NN NN O
deletion NN NN O
, NN NN O
corresponding NN NN O
precisely NN NN O
to NN NN O
exon NN NN O
12 NN NN O
of NN NN O
the NN NN O
human NN NN O
chromosomal NN NN O
PAH NN NN O
gene NN NN O
. NN NN O

The NN NN O
deletion NN NN O
causes NN NN O
the NN NN O
synthesis NN NN O
of NN NN O
a NN NN O
truncated NN NN O
protein NN NN O
lacking NN NN O
the NN NN O
C-terminal NN NN O
52 NN NN O
amino NN NN O
acids NN NN O
. NN NN O

Gene NN NN O
transfer NN NN O
and NN NN O
expression NN NN O
studies NN NN O
using NN NN O
the NN NN O
mutant NN NN O
PAH NN NN O
cDNA NN NN O
indicated NN NN O
that NN NN O
the NN NN O
deletion NN NN O
abolishes NN NN O
PAH NN NN O
activity NN NN O
in NN NN O
the NN NN O
cell NN NN O
as NN NN O
a NN NN O
result NN NN O
of NN NN O
protein NN NN O
instability NN NN O
. NN NN O

To NN NN O
determine NN NN O
the NN NN O
molecular NN NN O
basis NN NN O
of NN NN O
the NN NN O
deletion NN NN O
, NN NN O
the NN NN O
mutant NN NN O
chromosomal NN NN O
PAH NN NN O
gene NN NN O
was NN NN O
isolated NN NN O
from NN NN O
this NN NN O
individual NN NN O
and NN NN O
shown NN NN O
to NN NN O
contain NN NN O
a NN NN O
GT NN NN O
-- NN NN O
greater NN NN O
than NN NN O
AT NN NN O
substitution NN NN O
at NN NN O
the NN NN O
5 NN NN O
splice NN NN O
donor NN NN O
site NN NN O
of NN NN O
intron NN NN O
12 NN NN O
. NN NN O

Thus NN NN O
, NN NN O
the NN NN O
consequence NN NN O
of NN NN O
the NN NN O
splice NN NN O
donor NN NN O
site NN NN O
mutation NN NN O
in NN NN O
the NN NN O
human NN NN O
liver NN NN O
is NN NN O
the NN NN O
skipping NN NN O
of NN NN O
the NN NN O
preceding NN NN O
exon NN NN O
during NN NN O
RNA NN NN O
splicing NN NN O
. NN NN O

. NN NN O

3659917 NN NN O
Conservation NN NN O
of NN NN O
the NN NN O
Duchenne NN NN B-Modifier
muscular NN NN I-Modifier
dystrophy NN NN I-Modifier
gene NN NN O
in NN NN O
mice NN NN O
and NN NN O
humans NN NN O
. NN NN O

A NN NN O
portion NN NN O
of NN NN O
the NN NN O
Duchenne NN NN B-Modifier
muscular NN NN I-Modifier
dystrophy NN NN I-Modifier
( NN NN O
DMD NN NN B-Modifier
) NN NN O
gene NN NN O
transcript NN NN O
from NN NN O
human NN NN O
fetal NN NN O
skeletal NN NN O
muscle NN NN O
and NN NN O
mouse NN NN O
adult NN NN O
heart NN NN O
was NN NN O
sequenced NN NN O
, NN NN O
representing NN NN O
approximately NN NN O
25 NN NN O
percent NN NN O
of NN NN O
the NN NN O
total NN NN O
, NN NN O
14-kb NN NN O
DMD NN NN B-Modifier
transcript NN NN O
. NN NN O

The NN NN O
nucleic NN NN O
acid NN NN O
and NN NN O
predicted NN NN O
amino NN NN O
acid NN NN O
sequences NN NN O
from NN NN O
the NN NN O
two NN NN O
species NN NN O
are NN NN O
nearly NN NN O
90 NN NN O
percent NN NN O
homologous NN NN O
. NN NN O

The NN NN O
amino NN NN O
acid NN NN O
sequence NN NN O
that NN NN O
is NN NN O
predicted NN NN O
from NN NN O
this NN NN O
portion NN NN O
of NN NN O
the NN NN O
DMD NN NN B-Modifier
gene NN NN O
indicates NN NN O
that NN NN O
the NN NN O
protein NN NN O
product NN NN O
might NN NN O
serve NN NN O
a NN NN O
structural NN NN O
role NN NN O
in NN NN O
muscle NN NN O
, NN NN O
but NN NN O
the NN NN O
abundance NN NN O
and NN NN O
tissue NN NN O
distribution NN NN O
of NN NN O
the NN NN O
messenger NN NN O
RNA NN NN O
suggests NN NN O
that NN NN O
the NN NN O
DMD NN NN B-Modifier
protein NN NN O
is NN NN O
not NN NN O
nebulin NN NN O
. NN NN O

. NN NN O

3674116 NN NN O
Familial NN NN O
Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
with NN NN O
apparently NN NN O
normal NN NN O
chromosomes NN NN O
. NN NN O

We NN NN O
report NN NN O
on NN NN O
4 NN NN O
sibs NN NN O
( NN NN O
2F NN NN O
, NN NN O
2M NN NN O
) NN NN O
with NN NN O
Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
PWS NN NN B-SpecificDisease
) NN NN O
. NN NN O

Diagnosis NN NN O
was NN NN O
made NN NN O
clinically NN NN O
on NN NN O
the NN NN O
basis NN NN O
of NN NN O
history NN NN O
, NN NN O
behavior NN NN O
, NN NN O
and NN NN O
physical NN NN O
findings NN NN O
in NN NN O
3 NN NN O
of NN NN O
the NN NN O
sibs NN NN O
. NN NN O

The NN NN O
other NN NN O
child NN NN O
had NN NN O
died NN NN O
at NN NN O
age NN NN O
10 NN NN O
months NN NN O
with NN NN O
a NN NN O
history NN NN O
and NN NN O
clinical NN NN O
findings NN NN O
typical NN NN O
of NN NN O
first NN NN O
phase NN NN O
of NN NN O
PWS NN NN B-SpecificDisease
. NN NN O

Results NN NN O
of NN NN O
chromosome NN NN O
studies NN NN O
on NN NN O
the NN NN O
parents NN NN O
and NN NN O
surviving NN NN O
sibs NN NN O
were NN NN O
normal NN NN O
. NN NN O

The NN NN O
implications NN NN O
of NN NN O
this NN NN O
unusual NN NN O
familial NN NN O
occurrence NN NN O
for NN NN O
our NN NN O
understanding NN NN O
of NN NN O
PWS NN NN B-SpecificDisease
are NN NN O
discussed NN NN O
. NN NN O

. NN NN O

3678494 NN NN O
Nebulin NN NN O
and NN NN O
titin NN NN O
expression NN NN O
in NN NN O
Duchenne NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
appears NN NN O
normal NN NN O
. NN NN O

Monoclonal NN NN O
antibodies NN NN O
which NN NN O
recognize NN NN O
different NN NN O
epitopes NN NN O
on NN NN O
either NN NN O
titin NN NN O
or NN NN O
nebulin NN NN O
show NN NN O
normal NN NN O
staining NN NN O
patterns NN NN O
on NN NN O
frozen NN NN O
sections NN NN O
of NN NN O
three NN NN O
muscle NN NN O
biopsies NN NN O
of NN NN O
Duchenne NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DMD NN NN B-SpecificDisease
) NN NN O
. NN NN O

Gel NN NN O
electrophoresis NN NN O
and NN NN O
immunoblotting NN NN O
performed NN NN O
on NN NN O
two NN NN O
of NN NN O
these NN NN O
muscle NN NN O
biopsies NN NN O
show NN NN O
the NN NN O
normal NN NN O
pattern NN NN O
of NN NN O
titin NN NN O
and NN NN O
nebulin NN NN O
polypeptides NN NN O
. NN NN O

Since NN NN O
the NN NN O
donor NN NN O
of NN NN O
one NN NN O
of NN NN O
these NN NN O
biopsies NN NN O
has NN NN O
a NN NN O
large NN NN O
deletion NN NN O
of NN NN O
the NN NN O
5-region NN NN O
of NN NN O
the NN NN O
DMD NN NN B-Modifier
gene NN NN O
, NN NN O
our NN NN O
results NN NN O
argue NN NN O
against NN NN O
the NN NN O
recent NN NN O
proposal NN NN O
that NN NN O
nebulin NN NN O
is NN NN O
the NN NN O
gene NN NN O
mutated NN NN O
in NN NN O
DMD NN NN B-SpecificDisease
. NN NN O

. NN NN O

3718019 NN NN O
Heterozygous NN NN B-SpecificDisease
C2 NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
associated NN NN O
with NN NN O
angioedema NN NN B-SpecificDisease
, NN NN O
myasthenia NN NN B-SpecificDisease
gravis NN NN I-SpecificDisease
, NN NN O
and NN NN O
systemic NN NN B-SpecificDisease
lupus NN NN I-SpecificDisease
erythematosus NN NN I-SpecificDisease
. NN NN O

We NN NN O
describe NN NN O
a NN NN O
patient NN NN O
with NN NN O
myasthenia NN NN B-SpecificDisease
gravis NN NN I-SpecificDisease
, NN NN O
systemic NN NN B-SpecificDisease
lupus NN NN I-SpecificDisease
erythematosus NN NN I-SpecificDisease
, NN NN O
and NN NN O
angioedema NN NN B-SpecificDisease
associated NN NN O
with NN NN O
heterozygous NN NN O
complement NN NN B-SpecificDisease
factor NN NN I-SpecificDisease
2 NN NN I-SpecificDisease
( NN NN I-SpecificDisease
C2 NN NN I-SpecificDisease
) NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

The NN NN O
significance NN NN O
of NN NN O
this NN NN O
association NN NN O
is NN NN O
controversial NN NN O
, NN NN O
though NN NN O
the NN NN O
association NN NN O
of NN NN O
C2 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
with NN NN O
certain NN NN O
histocompatibility NN NN O
antigens NN NN O
suggests NN NN O
possible NN NN O
linkage NN NN O
to NN NN O
immune NN NN O
response NN NN O
genes NN NN O
. NN NN O

To NN NN O
our NN NN O
knowledge NN NN O
this NN NN O
is NN NN O
the NN NN O
first NN NN O
report NN NN O
of NN NN O
heterozygous NN NN O
C2 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
association NN NN O
with NN NN O
this NN NN O
combination NN NN O
of NN NN O
autoimmune NN NN B-DiseaseClass
disorders NN NN I-DiseaseClass
, NN NN O
and NN NN O
we NN NN O
discuss NN NN O
the NN NN O
aetiological NN NN O
implications NN NN O
. NN NN O

. NN NN O

3789016 NN NN O
Genetic NN NN O
analysis NN NN O
of NN NN O
an NN NN O
inherited NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
third NN NN I-SpecificDisease
component NN NN I-SpecificDisease
of NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
in NN NN O
Brittany NN NN O
spaniel NN NN O
dogs NN NN O
. NN NN O

Genetically NN NN O
determined NN NN O
C3 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
Brittany NN NN O
spaniel NN NN O
dogs NN NN O
shares NN NN O
a NN NN O
number NN NN O
of NN NN O
biochemical NN NN O
and NN NN O
clinical NN NN O
characteristics NN NN O
with NN NN O
the NN NN O
human NN NN O
disorder NN NN O
. NN NN O

In NN NN O
humans NN NN O
, NN NN O
the NN NN O
gene NN NN O
for NN NN O
C3 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
is NN NN O
a NN NN O
null NN NN O
gene NN NN O
that NN NN O
is NN NN O
allelic NN NN O
to NN NN O
the NN NN O
structural NN NN O
gene NN NN O
for NN NN O
C3 NN NN O
and NN NN O
is NN NN O
not NN NN O
linked NN NN O
to NN NN O
the NN NN O
major NN NN O
histocompatibility NN NN O
locus NN NN O
. NN NN O

The NN NN O
current NN NN O
study NN NN O
used NN NN O
allotype NN NN O
analysis NN NN O
of NN NN O
canine NN NN O
C3 NN NN O
in NN NN O
order NN NN O
to NN NN O
demonstrate NN NN O
that NN NN O
the NN NN O
gene NN NN O
for NN NN O
C3 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
these NN NN O
dogs NN NN O
is NN NN O
also NN NN O
a NN NN O
null NN NN O
gene NN NN O
allelic NN NN O
to NN NN O
the NN NN O
structural NN NN O
gene NN NN O
for NN NN O
C3 NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
preliminary NN NN O
pedigree NN NN O
analysis NN NN O
suggests NN NN O
that NN NN O
the NN NN O
gene NN NN O
for NN NN O
canine NN NN O
C3 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
is NN NN O
apparently NN NN O
not NN NN O
closely NN NN O
linked NN NN O
to NN NN O
the NN NN O
major NN NN O
histocompatibility NN NN O
complex NN NN O
of NN NN O
the NN NN O
dog NN NN O
. NN NN O

Thus NN NN O
, NN NN O
it NN NN O
appears NN NN O
that NN NN O
C3 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
Brittany NN NN O
spaniel NN NN O
dogs NN NN O
not NN NN O
only NN NN O
shares NN NN O
biochemical NN NN O
and NN NN O
clinical NN NN O
features NN NN O
with NN NN O
C3 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
humans NN NN O
, NN NN O
but NN NN O
also NN NN O
shares NN NN O
some NN NN O
genetic NN NN O
characteristics NN NN O
with NN NN O
the NN NN O
human NN NN O
disorder NN NN O
. NN NN O

. NN NN O

3856322 NN NN O
Gene NN NN O
transfer NN NN O
and NN NN O
expression NN NN O
of NN NN O
human NN NN O
phenylalanine NN NN O
hydroxylase NN NN O
. NN NN O

Phenylketonuria NN NN B-SpecificDisease
( NN NN O
PKU NN NN B-SpecificDisease
) NN NN O
is NN NN O
caused NN NN O
by NN NN O
a NN NN O
genetic NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
enzyme NN NN I-SpecificDisease
phenylalanine NN NN I-SpecificDisease
hydroxylase NN NN I-SpecificDisease
( NN NN O
PAH NN NN O
) NN NN O
. NN NN O

A NN NN O
full-length NN NN O
complementary NN NN O
DNA NN NN O
clone NN NN O
of NN NN O
human NN NN O
PAH NN NN O
was NN NN O
inserted NN NN O
into NN NN O
a NN NN O
eukaryotic NN NN O
expression NN NN O
vector NN NN O
and NN NN O
transferred NN NN O
into NN NN O
mouse NN NN O
NIH3T3 NN NN O
cells NN NN O
which NN NN O
do NN NN O
not NN NN O
normally NN NN O
express NN NN O
PAH NN NN O
. NN NN O

The NN NN O
transformed NN NN O
mouse NN NN O
cells NN NN O
expressed NN NN O
PAH NN NN O
messenger NN NN O
RNA NN NN O
, NN NN O
immunoreactive NN NN O
protein NN NN O
, NN NN O
and NN NN O
enzymatic NN NN O
activity NN NN O
that NN NN O
are NN NN O
characteristic NN NN O
of NN NN O
the NN NN O
normal NN NN O
human NN NN O
liver NN NN O
products NN NN O
, NN NN O
demonstrating NN NN O
that NN NN O
a NN NN O
single NN NN O
gene NN NN O
contains NN NN O
all NN NN O
of NN NN O
the NN NN O
necessary NN NN O
genetic NN NN O
information NN NN O
to NN NN O
code NN NN O
for NN NN O
functional NN NN O
PAH NN NN O
. NN NN O

These NN NN O
results NN NN O
support NN NN O
the NN NN O
use NN NN O
of NN NN O
the NN NN O
human NN NN O
PAH NN NN O
probe NN NN O
in NN NN O
prenatal NN NN O
diagnosis NN NN O
and NN NN O
detection NN NN O
of NN NN O
carriers NN NN O
, NN NN O
to NN NN O
provide NN NN O
new NN NN O
opportunities NN NN O
for NN NN O
the NN NN O
biochemical NN NN O
characterization NN NN O
of NN NN O
normal NN NN O
and NN NN O
mutant NN NN O
enzymes NN NN O
, NN NN O
and NN NN O
in NN NN O
the NN NN O
investigation NN NN O
of NN NN O
alternative NN NN O
genetic NN NN O
therapies NN NN O
for NN NN O
PKU NN NN B-SpecificDisease
. NN NN O

. NN NN O

3862128 NN NN O
Regional NN NN O
mapping NN NN O
of NN NN O
the NN NN O
phenylalanine NN NN O
hydroxylase NN NN O
gene NN NN O
and NN NN O
the NN NN O
phenylketonuria NN NN B-Modifier
locus NN NN O
in NN NN O
the NN NN O
human NN NN O
genome NN NN O
. NN NN O

Phenylketonuria NN NN B-SpecificDisease
( NN NN O
PKU NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
of NN NN O
amino NN NN O
acid NN NN O
metabolism NN NN O
caused NN NN O
by NN NN O
a NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
hepatic NN NN I-SpecificDisease
enzyme NN NN I-SpecificDisease
phenylalanine NN NN I-SpecificDisease
hydroxylase NN NN I-SpecificDisease
( NN NN O
PAH NN NN O
; NN NN O
phenylalanine NN NN O
4-monooxygenase NN NN O
, NN NN O
EC NN NN O
1 NN NN O
. NN NN O

14 NN NN O
. NN NN O

16 NN NN O
. NN NN O

1 NN NN O
) NN NN O
. NN NN O

A NN NN O
cDNA NN NN O
clone NN NN O
for NN NN O
human NN NN O
PAH NN NN O
has NN NN O
previously NN NN O
been NN NN O
used NN NN O
to NN NN O
assign NN NN O
the NN NN O
corresponding NN NN O
gene NN NN O
to NN NN O
human NN NN O
chromosome NN NN O
12 NN NN O
. NN NN O

To NN NN O
define NN NN O
the NN NN O
regional NN NN O
map NN NN O
position NN NN O
of NN NN O
the NN NN O
disease NN NN O
locus NN NN O
and NN NN O
the NN NN O
PAH NN NN O
gene NN NN O
on NN NN O
human NN NN O
chromosome NN NN O
12 NN NN O
, NN NN O
DNA NN NN O
was NN NN O
isolated NN NN O
from NN NN O
human-hamster NN NN O
somatic NN NN O
cell NN NN O
hybrids NN NN O
with NN NN O
various NN NN O
deletions NN NN O
of NN NN O
human NN NN O
chromosome NN NN O
12 NN NN O
and NN NN O
was NN NN O
analyzed NN NN O
by NN NN O
Southern NN NN O
blot NN NN O
analysis NN NN O
using NN NN O
the NN NN O
human NN NN O
cDNA NN NN O
PAH NN NN O
clone NN NN O
as NN NN O
a NN NN O
hybridization NN NN O
probe NN NN O
. NN NN O

From NN NN O
these NN NN O
results NN NN O
, NN NN O
together NN NN O
with NN NN O
detailed NN NN O
biochemical NN NN O
and NN NN O
cytogenetic NN NN O
characterization NN NN O
of NN NN O
the NN NN O
hybrid NN NN O
cells NN NN O
, NN NN O
the NN NN O
region NN NN O
on NN NN O
chromosome NN NN O
12 NN NN O
containing NN NN O
the NN NN O
human NN NN O
PAH NN NN O
gene NN NN O
has NN NN O
been NN NN O
defined NN NN O
as NN NN O
12q14 NN NN O
. NN NN O

3 NN NN O
-- NN NN O
-- NN NN O
qter NN NN O
3 NN NN O
-- NN NN O
-- NN NN O
qter NN NN O
. NN NN O

The NN NN O
PAH NN NN O
map NN NN O
position NN NN O
on NN NN O
chromosome NN NN O
12 NN NN O
was NN NN O
further NN NN O
localized NN NN O
by NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
of NN NN O
125I-labeled NN NN O
human NN NN O
PAH NN NN O
cDNA NN NN O
to NN NN O
chromosomes NN NN O
prepared NN NN O
from NN NN O
a NN NN O
human NN NN O
lymphoblastoid NN NN O
cell NN NN O
line NN NN O
. NN NN O

Results NN NN O
of NN NN O
these NN NN O
experiments NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
region NN NN O
on NN NN O
chromosome NN NN O
12 NN NN O
containing NN NN O
the NN NN O
PAH NN NN O
gene NN NN O
and NN NN O
the NN NN O
PKU NN NN B-Modifier
locus NN NN O
in NN NN O
man NN NN O
is NN NN O
12q22 NN NN O
-- NN NN O
-- NN NN O
12q24 NN NN O
. NN NN O

1 NN NN O
. NN NN O

These NN NN O
results NN NN O
not NN NN O
only NN NN O
provide NN NN O
a NN NN O
regionalized NN NN O
map NN NN O
position NN NN O
for NN NN O
a NN NN O
major NN NN O
human NN NN O
disease NN NN O
locus NN NN O
but NN NN O
also NN NN O
can NN NN O
serve NN NN O
as NN NN O
a NN NN O
reference NN NN O
point NN NN O
for NN NN O
linkage NN NN O
analysis NN NN O
with NN NN O
other NN NN O
DNA NN NN O
markers NN NN O
on NN NN O
human NN NN O
chromosome NN NN O
12 NN NN O

3876122 NN NN O
Heterogeneity NN NN O
of NN NN O
type NN NN B-SpecificDisease
I NN NN I-SpecificDisease
von NN NN I-SpecificDisease
Willebrand NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
: NN NN O
evidence NN NN O
for NN NN O
a NN NN O
subgroup NN NN O
with NN NN O
an NN NN O
abnormal NN NN O
von NN NN B-Modifier
Willebrand NN NN I-Modifier
factor NN NN O
. NN NN O

Type NN NN B-SpecificDisease
I NN NN I-SpecificDisease
von NN NN I-SpecificDisease
Willebrand NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
vWD NN NN B-SpecificDisease
) NN NN O
is NN NN O
characterized NN NN O
by NN NN O
equally NN NN O
low NN NN O
plasma NN NN O
concentrations NN NN O
of NN NN O
von NN NN B-Modifier
Willebrand NN NN I-Modifier
factor NN NN O
antigen NN NN O
( NN NN O
vWF NN NN O
Ag NN NN O
) NN NN O
and NN NN O
ristocetin NN NN O
cofactor NN NN O
( NN NN O
RiCof NN NN O
) NN NN O
and NN NN O
by NN NN O
the NN NN O
presence NN NN O
of NN NN O
all NN NN O
vWF NN NN O
multimers NN NN O
in NN NN O
sodium NN NN O
dodecyl NN NN O
sulfate NN NN O
( NN NN O
SDS NN NN O
) NN NN O
-agarose NN NN O
gel NN NN O
electrophoresis NN NN O
. NN NN O

For NN NN O
17 NN NN O
patients NN NN O
( NN NN O
13 NN NN O
kindreds NN NN O
) NN NN O
diagnosed NN NN O
with NN NN O
these NN NN O
criteria NN NN O
, NN NN O
we NN NN O
have NN NN O
studied NN NN O
the NN NN O
platelet NN NN O
contents NN NN O
of NN NN O
vWF NN NN O
Ag NN NN O
and NN NN O
RiCof NN NN O
and NN NN O
the NN NN O
changes NN NN O
of NN NN O
these NN NN O
in NN NN O
plasma NN NN O
after NN NN O
DDAVP NN NN O
infusion NN NN O
. NN NN O

Platelet NN NN O
vWF NN NN O
Ag NN NN O
and NN NN O
RiCof NN NN O
were NN NN O
normal NN NN O
in NN NN O
four NN NN O
kindreds NN NN O
( NN NN O
called NN NN O
`` NN NN O
platelet NN NN O
normal NN NN O
`` NN NN O
subgroup NN NN O
) NN NN O
; NN NN O
following NN NN O
1-deamino-8-D-arginine NN NN O
vasopressin NN NN O
; NN NN O
plasma NN NN O
vWF NN NN O
Ag NN NN O
, NN NN O
RiCof NN NN O
and NN NN O
the NN NN O
bleeding NN NN O
time NN NN O
( NN NN O
BT NN NN O
) NN NN O
became NN NN O
normal NN NN O
. NN NN O

In NN NN O
six NN NN O
kindreds NN NN O
, NN NN O
platelet NN NN O
vWF NN NN O
Ag NN NN O
and NN NN O
RiCof NN NN O
were NN NN O
equally NN NN O
low NN NN O
( NN NN O
platelet NN NN O
low NN NN O
) NN NN O
; NN NN O
after NN NN O
DDAVP NN NN O
, NN NN O
plasma NN NN O
vWF NN NN O
Ag NN NN O
and NN NN O
RiCof NN NN O
remained NN NN O
low NN NN O
, NN NN O
and NN NN O
the NN NN O
BT NN NN O
was NN NN O
prolonged NN NN O
. NN NN O

In NN NN O
three NN NN O
additional NN NN O
kindreds NN NN O
, NN NN O
platelets NN NN O
contained NN NN O
normal NN NN O
concentrations NN NN O
of NN NN O
vWF NN NN O
Ag NN NN O
, NN NN O
but NN NN O
RiCof NN NN O
was NN NN O
very NN NN O
low NN NN O
( NN NN O
platelet NN NN O
discordant NN NN O
) NN NN O
; NN NN O
even NN NN O
though NN NN O
a NN NN O
complete NN NN O
set NN NN O
of NN NN O
multimers NN NN O
was NN NN O
found NN NN O
in NN NN O
plasma NN NN O
and NN NN O
platelets NN NN O
, NN NN O
there NN NN O
was NN NN O
a NN NN O
relatively NN NN O
small NN NN O
amount NN NN O
of NN NN O
large NN NN O
multimers NN NN O
. NN NN O

After NN NN O
DDAVP NN NN O
, NN NN O
plasma NN NN O
vWF NN NN O
Ag NN NN O
became NN NN O
normal NN NN O
, NN NN O
but NN NN O
RiCof NN NN O
remained NN NN O
low NN NN O
and NN NN O
the NN NN O
BT NN NN O
was NN NN O
very NN NN O
prolonged NN NN O
. NN NN O

These NN NN O
findings NN NN O
demonstrated NN NN O
that NN NN O
there NN NN O
can NN NN O
be NN NN O
an NN NN O
abnormal NN NN O
vWF NN NN O
( NN NN O
RiCof NN NN O
less NN NN O
than NN NN O
vWF NN NN O
Ag NN NN O
) NN NN O
even NN NN O
in NN NN O
type NN NN B-SpecificDisease
I NN NN I-SpecificDisease
vWD NN NN I-SpecificDisease
, NN NN O
coexisting NN NN O
with NN NN O
a NN NN O
complete NN NN O
set NN NN O
of NN NN O
vWF NN NN O
multimers NN NN O
( NN NN O
platelet NN NN O
discordant NN NN O
) NN NN O
; NN NN O
that NN NN O
the NN NN O
abnormal NN NN O
vWF NN NN O
can NN NN O
be NN NN O
shown NN NN O
more NN NN O
clearly NN NN O
in NN NN O
platelets NN NN O
than NN NN O
in NN NN O
plasma NN NN O
or NN NN O
else NN NN O
in NN NN O
plasma NN NN O
after NN NN O
DDAVP NN NN O
infusion NN NN O
; NN NN O
and NN NN O
that NN NN O
DDAVP NN NN O
normalizes NN NN O
the NN NN O
BT NN NN O
only NN NN O
in NN NN O
those NN NN O
patients NN NN O
with NN NN O
normal NN NN O
platelet NN NN O
levels NN NN O
of NN NN O
both NN NN O
vWF NN NN O
Ag NN NN O
and NN NN O
RiCof NN NN O
( NN NN O
platelet NN NN O
normal NN NN O
) NN NN O
. NN NN O

. NN NN O

4019732 NN NN O
Genetic NN NN O
analysis NN NN O
in NN NN O
families NN NN O
with NN NN O
van NN NN B-SpecificDisease
der NN NN I-SpecificDisease
Woude NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

We NN NN O
have NN NN O
brought NN NN O
together NN NN O
information NN NN O
on NN NN O
864 NN NN O
affected NN NN O
individuals NN NN O
in NN NN O
164 NN NN O
families NN NN O
( NN NN O
including NN NN O
three NN NN O
new NN NN O
pedigrees NN NN O
) NN NN O
reported NN NN O
in NN NN O
the NN NN O
137 NN NN O
year NN NN O
period NN NN O
since NN NN O
1845 NN NN O
when NN NN O
Demarquay NN NN O
first NN NN O
described NN NN O
a NN NN O
family NN NN O
with NN NN O
what NN NN O
was NN NN O
later NN NN O
called NN NN O
van NN NN B-SpecificDisease
der NN NN I-SpecificDisease
Woude NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
VWS NN NN B-SpecificDisease
) NN NN O
. NN NN O

Both NN NN O
types NN NN O
of NN NN O
oral NN NN B-SpecificDisease
cleft NN NN I-SpecificDisease
, NN NN O
cleft NN NN B-SpecificDisease
palate NN NN I-SpecificDisease
( NN NN O
CP NN NN B-SpecificDisease
) NN NN O
and NN NN O
cleft NN NN B-SpecificDisease
lip NN NN I-SpecificDisease
with NN NN O
or NN NN O
without NN NN O
CP NN NN B-SpecificDisease
( NN NN O
CLP NN NN B-SpecificDisease
) NN NN O
, NN NN O
segregate NN NN O
in NN NN O
these NN NN O
families NN NN O
together NN NN O
with NN NN O
lower NN NN O
lip NN NN B-SpecificDisease
pits NN NN I-SpecificDisease
or NN NN O
fistulae NN NN B-SpecificDisease
in NN NN O
an NN NN O
autosomal NN NN O
dominant NN NN O
mode NN NN O
with NN NN O
high NN NN O
penetrance NN NN O
estimated NN NN O
to NN NN O
be NN NN O
K NN NN O
= NN NN O
. NN NN O

89 NN NN O
and NN NN O
. NN NN O

99 NN NN O
by NN NN O
different NN NN O
methods NN NN O
. NN NN O

Cleft NN NN O
types NN NN O
( NN NN O
CLP NN NN B-SpecificDisease
and NN NN O
CP NN NN B-SpecificDisease
) NN NN O
occur NN NN O
in NN NN O
VWS NN NN B-SpecificDisease
in NN NN O
the NN NN O
same NN NN O
proportions NN NN O
as NN NN O
in NN NN O
the NN NN O
general NN NN O
non-VWS NN NN O
population NN NN O
, NN NN O
ie NN NN O
, NN NN O
about NN NN O
twice NN NN O
as NN NN O
many NN NN O
cleft-bearing NN NN O
individuals NN NN O
have NN NN O
CLP NN NN B-SpecificDisease
as NN NN O
have NN NN O
CP NN NN B-SpecificDisease
. NN NN O

On NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
we NN NN O
do NN NN O
not NN NN O
find NN NN O
the NN NN O
usually NN NN O
observed NN NN O
excess NN NN O
of NN NN O
females NN NN O
with NN NN O
CP NN NN B-SpecificDisease
and NN NN O
excess NN NN O
of NN NN O
males NN NN O
with NN NN O
CLP NN NN B-SpecificDisease
; NN NN O
in NN NN O
VWS NN NN B-SpecificDisease
the NN NN O
sex NN NN O
ratios NN NN O
are NN NN O
more NN NN O
nearly NN NN O
equal NN NN O
. NN NN O

Lip NN NN B-SpecificDisease
pits NN NN I-SpecificDisease
also NN NN O
are NN NN O
equally NN NN O
distributed NN NN O
between NN NN O
the NN NN O
sexes NN NN O
. NN NN O

Affected NN NN O
males NN NN O
and NN NN O
females NN NN O
are NN NN O
equally NN NN O
likely NN NN O
to NN NN O
transmit NN NN O
VWS NN NN B-SpecificDisease
. NN NN O

However NN NN O
, NN NN O
there NN NN O
is NN NN O
an NN NN O
excess NN NN O
of NN NN O
less NN NN O
severely NN NN O
affected NN NN O
individuals NN NN O
among NN NN O
transmitters NN NN O
and NN NN O
a NN NN O
deficiency NN NN O
of NN NN O
more NN NN O
severely NN NN O
affected NN NN O
, NN NN O
brought NN NN O
about NN NN O
by NN NN O
a NN NN O
proband NN NN O
bias NN NN O
and NN NN O
differential NN NN O
fecundity NN NN O
. NN NN O

The NN NN O
expression NN NN O
of NN NN O
VWS NN NN B-SpecificDisease
is NN NN O
significantly NN NN O
modified NN NN O
by NN NN O
the NN NN O
genetic NN NN O
background NN NN O
More NN NN O
extreme NN NN O
phenotypes NN NN O
in NN NN O
parents NN NN O
tend NN NN O
to NN NN O
produce NN NN O
more NN NN O
extreme NN NN O
expression NN NN O
in NN NN O
their NN NN O
children NN NN O
. NN NN O

For NN NN O
a NN NN O
VWS NN NN B-Modifier
gene NN NN O
carrier NN NN O
the NN NN O
relative NN NN O
risk NN NN O
of NN NN O
transmitting NN NN O
a NN NN O
cleft NN NN O
is NN NN O
26 NN NN O
. NN NN O

45 NN NN O
% NN NN O
; NN NN O
that NN NN O
of NN NN O
transmitting NN NN O
lower NN NN O
lip NN NN B-SpecificDisease
pits NN NN I-SpecificDisease
is NN NN O
23 NN NN O
. NN NN O

55 NN NN O
% NN NN O
. NN NN O

Three NN NN O
pedigrees NN NN O
of NN NN O
lip NN NN B-SpecificDisease
pits NN NN I-SpecificDisease
in NN NN O
the NN NN O
literature NN NN O
show NN NN O
no NN NN O
clefts NN NN O
among NN NN O
a NN NN O
significant NN NN O
number NN NN O
of NN NN O
affected NN NN O
individuals NN NN O
. NN NN O

Control NN NN O
of NN NN O
gene NN NN O
expression NN NN O
in NN NN O
VWS NN NN B-SpecificDisease
in NN NN O
the NN NN O
three NN NN O
target NN NN O
tissues NN NN O
appears NN NN O
to NN NN O
be NN NN O
independent NN NN O
and NN NN O
separately NN NN O
designated NN NN O
. NN NN O

Mutation NN NN O
rate NN NN O
of NN NN O
the NN NN O
VWS NN NN B-Modifier
gene NN NN O
is NN NN O
calculated NN NN O
to NN NN O
be NN NN O
1 NN NN O
. NN NN O

8 NN NN O
X NN NN O
10 NN NN O
( NN NN O
-5 NN NN O
) NN NN O

409732 NN NN O
Hereditary NN NN B-SpecificDisease
C7 NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

Diagnosis NN NN O
and NN NN O
HLA NN NN O
studies NN NN O
in NN NN O
a NN NN O
French-Canadian NN NN O
family NN NN O
. NN NN O

The NN NN O
serum NN NN O
of NN NN O
a NN NN O
44-yr-old NN NN O
woman NN NN O
of NN NN O
French-Canadian NN NN O
descent NN NN O
having NN NN O
a NN NN O
B-27 NN NN O
positive NN NN O
ankylosing NN NN B-SpecificDisease
spondylitis NN NN I-SpecificDisease
was NN NN O
deficient NN NN B-SpecificDisease
in NN NN I-SpecificDisease
the NN NN I-SpecificDisease
seventh NN NN I-SpecificDisease
component NN NN I-SpecificDisease
of NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
( NN NN O
C7 NN NN O
) NN NN O
as NN NN O
determined NN NN O
by NN NN O
hemolytic NN NN O
and NN NN O
immunochemical NN NN O
methods NN NN O
. NN NN O

No NN NN O
inhibitor NN NN O
against NN NN O
C7 NN NN O
was NN NN O
detected NN NN O
, NN NN O
and NN NN O
the NN NN O
levels NN NN O
of NN NN O
all NN NN O
other NN NN O
complement NN NN O
components NN NN O
were NN NN O
normal NN NN O
. NN NN O

No NN NN O
deficiency NN NN O
in NN NN O
the NN NN O
opsonic NN NN O
activity NN NN O
of NN NN O
the NN NN O
serum NN NN O
was NN NN O
found NN NN O
, NN NN O
and NN NN O
the NN NN O
results NN NN O
of NN NN O
basic NN NN O
coagulation NN NN O
studies NN NN O
of NN NN O
the NN NN O
plasma NN NN O
were NN NN O
normal NN NN O
. NN NN O

On NN NN O
investigation NN NN O
of NN NN O
the NN NN O
patients NN NN O
family NN NN O
, NN NN O
two NN NN O
sisters NN NN O
were NN NN O
found NN NN O
to NN NN O
have NN NN O
the NN NN O
same NN NN O
deficiency NN NN O
but NN NN O
were NN NN O
otherwise NN NN O
in NN NN O
good NN NN O
health NN NN O
. NN NN O

The NN NN O
seven NN NN O
other NN NN O
siblings NN NN O
were NN NN O
heterozygous NN NN O
for NN NN O
C7 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
, NN NN O
while NN NN O
the NN NN O
paternal NN NN O
aunt NN NN O
had NN NN O
a NN NN O
normal NN NN O
C7 NN NN O
level NN NN O
. NN NN O

In NN NN O
the NN NN O
third NN NN O
generation NN NN O
, NN NN O
six NN NN O
children NN NN O
of NN NN O
the NN NN O
three NN NN O
homozygous NN NN O
sisters NN NN O
and NN NN O
five NN NN O
children NN NN O
of NN NN O
heterozygotes NN NN O
were NN NN O
available NN NN O
for NN NN O
testing NN NN O
. NN NN O

Studies NN NN O
of NN NN O
the NN NN O
HLA NN NN O
antigens NN NN O
in NN NN O
all NN NN O
the NN NN O
22 NN NN O
subjects NN NN O
and NN NN O
in NN NN O
three NN NN O
spouses NN NN O
indicated NN NN O
no NN NN O
close NN NN O
linkage NN NN O
between NN NN O
the NN NN O
CM NN NN B-SpecificDisease
deficienty NN NN I-SpecificDisease
and NN NN O
the NN NN O
HLA NN NN O
system NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
the NN NN O
simultaneous NN NN O
occurrence NN NN O
of NN NN O
two NN NN O
hereditary NN NN O
complement NN NN B-CompositeMention
deficiencies NN NN I-CompositeMention
( NN NN I-CompositeMention
C2 NN NN I-CompositeMention
and NN NN I-CompositeMention
C7 NN NN I-CompositeMention
) NN NN I-CompositeMention
was NN NN O
discovered NN NN O
in NN NN O
one NN NN O
family NN NN O
of NN NN O
this NN NN O
remarkable NN NN O
kindred NN NN O
. NN NN O

. NN NN O

492335 NN NN O
Genetic NN NN O
defect NN NN B-SpecificDisease
in NN NN I-SpecificDisease
secretion NN NN I-SpecificDisease
of NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
C5 NN NN I-SpecificDisease
in NN NN O
mice NN NN O
. NN NN O

A NN NN O
genetic NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
fifth NN NN I-SpecificDisease
( NN NN I-SpecificDisease
C5 NN NN I-SpecificDisease
) NN NN I-SpecificDisease
component NN NN I-SpecificDisease
of NN NN I-SpecificDisease
complement1-3 NN NN I-SpecificDisease
, NN NN O
a NN NN O
serum NN NN O
glycoprotein NN NN O
of NN NN O
molecular NN NN O
weight NN NN O
( NN NN O
MW NN NN O
) NN NN O
220 NN NN O
, NN NN O
000 NN NN O
( NN NN O
ref NN NN O
. NN NN O

4 NN NN O
) NN NN O
, NN NN O
has NN NN O
been NN NN O
found NN NN O
in NN NN O
39 NN NN O
% NN NN O
of NN NN O
inbred NN NN O
strains NN NN O
of NN NN O
mice3 NN NN O
. NN NN O

Sera NN NN O
of NN NN O
deficient NN NN O
mice NN NN O
lack NN NN O
detectable NN NN O
C5 NN NN O
activity NN NN O
and NN NN O
protein2 NN NN O
, NN NN O
3 NN NN O
. NN NN O

In NN NN O
addition NN NN O
deficient NN NN O
mice NN NN O
produce NN NN O
antibody NN NN O
to NN NN O
mouse NN NN O
C5 NN NN O
when NN NN O
injected NN NN O
with NN NN O
sera NN NN O
from NN NN O
C5 NN NN O
sufficient NN NN O
( NN NN O
normal NN NN O
) NN NN O
strains NN NN O
. NN NN O

Levy NN NN O
et NN NN O
al NN NN O
. NN NN O

5 NN NN O
showed NN NN O
that NN NN O
somatic NN NN O
cell NN NN O
hybrids NN NN O
between NN NN O
C5 NN NN O
deficient NN NN O
( NN NN O
B10 NN NN O
. NN NN O

D2 NN NN O
/ NN NN O
old NN NN O
line NN NN O
) NN NN O
macrophages NN NN O
and NN NN O
either NN NN O
C5 NN NN O
sufficient NN NN O
( NN NN O
B10 NN NN O
. NN NN O

D2 NN NN O
/ NN NN O
new NN NN O
line NN NN O
) NN NN O
mouse NN NN O
kidney NN NN O
or NN NN O
chicken NN NN O
erythroblasts NN NN O
secreted NN NN O
haemolytically NN NN O
active NN NN O
mouse NN NN O
C5 NN NN O
in NN NN O
vitro NN NN O
. NN NN O

Several NN NN O
possible NN NN O
molecular NN NN O
mechanisms NN NN O
to NN NN O
account NN NN O
for NN NN O
the NN NN O
findings NN NN O
were NN NN O
considered NN NN O
, NN NN O
but NN NN O
insufficient NN NN O
direct NN NN O
data NN NN O
were NN NN O
available NN NN O
to NN NN O
choose NN NN O
among NN NN O
them NN NN O
. NN NN O

We NN NN O
recently NN NN O
reported NN NN O
that NN NN O
mouse NN NN O
( NN NN O
CD NN NN O
. NN NN O

1 NN NN O
strain NN NN O
) NN NN O
peritoneal NN NN O
cells NN NN O
in NN NN O
culture NN NN O
synthesise NN NN O
and NN NN O
secrete NN NN O
a NN NN O
single NN NN O
chain NN NN O
precursor NN NN O
, NN NN O
pro-C5 NN NN O
( NN NN O
MW NN NN O
approximately NN NN O
210 NN NN O
, NN NN O
000 NN NN O
) NN NN O
, NN NN O
of NN NN O
the NN NN O
two-chain NN NN O
( NN NN O
alpha NN NN O
chain NN NN O
, NN NN O
125 NN NN O
, NN NN O
000 NN NN O
and NN NN O
beta NN NN O
chain NN NN O
83 NN NN O
, NN NN O
000 NN NN O
MW NN NN O
) NN NN O
C5 NN NN O
protein6 NN NN O
. NN NN O

Radiolabelled NN NN O
precursor NN NN O
C5 NN NN O
was NN NN O
contained NN NN O
within NN NN O
the NN NN O
cells NN NN O
and NN NN O
was NN NN O
secreted NN NN O
into NN NN O
the NN NN O
tissue NN NN O
culture NN NN O
media NN NN O
. NN NN O

Using NN NN O
similar NN NN O
methods NN NN O
, NN NN O
we NN NN O
now NN NN O
find NN NN O
that NN NN O
C5 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
each NN NN O
of NN NN O
five NN NN O
different NN NN O
mouse NN NN O
strains NN NN O
( NN NN O
AKR NN NN O
, NN NN O
SWR NN NN O
, NN NN O
DBA NN NN O
/ NN NN O
2J8 NN NN O
A NN NN O
/ NN NN O
HeJ NN NN O
and NN NN O
B10 NN NN O
. NN NN O

D2 NN NN O
/ NN NN O
old NN NN O
line NN NN O
) NN NN O
is NN NN O
due NN NN O
to NN NN O
a NN NN O
failure NN NN O
in NN NN O
secretion NN NN O
of NN NN O
C5 NN NN O
protein NN NN O
and NN NN O
not NN NN O
to NN NN O
a NN NN O
failure NN NN O
in NN NN O
biosynthesis NN NN O
of NN NN O
pro-C5 NN NN O

492812 NN NN O
Recurrent NN NN O
meningococcal NN NN B-SpecificDisease
meningitis NN NN I-SpecificDisease
with NN NN O
absence NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
sixth NN NN I-SpecificDisease
component NN NN I-SpecificDisease
of NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
: NN NN O
an NN NN O
evaluation NN NN O
of NN NN O
underlying NN NN O
immunologic NN NN O
mechanisms NN NN O
. NN NN O

A NN NN O
51 NN NN O
/ NN NN O
2-year-old NN NN O
black NN NN O
girl NN NN O
with NN NN O
recurrent NN NN O
meningococcal NN NN B-SpecificDisease
meningitis NN NN I-SpecificDisease
and NN NN O
absence NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
sixth NN NN I-SpecificDisease
component NN NN I-SpecificDisease
of NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
( NN NN O
C6 NN NN O
) NN NN O
is NN NN O
reported NN NN O
. NN NN O

To NN NN O
explore NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
recurrent NN NN O
neisserial NN NN B-SpecificDisease
infections NN NN I-SpecificDisease
in NN NN O
C6 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
, NN NN O
a NN NN O
detailed NN NN O
analysis NN NN O
of NN NN O
her NN NN O
immune NN NN O
competence NN NN O
was NN NN O
conducted NN NN O
. NN NN O

Her NN NN O
serum NN NN O
had NN NN O
normal NN NN O
chemotactic NN NN O
, NN NN O
opsonic NN NN O
, NN NN O
alternative NN NN O
complement NN NN O
pathway NN NN O
, NN NN O
and NN NN O
specific NN NN O
antibody NN NN O
activity NN NN O
, NN NN O
but NN NN O
lacked NN NN O
complement-mediated NN NN O
bacteriolytic NN NN O
activity NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
her NN NN O
C6-deficient NN NN B-Modifier
serum NN NN O
was NN NN O
indistinguishable NN NN O
from NN NN O
normal NN NN O
serum NN NN O
in NN NN O
a NN NN O
complement-dependent NN NN O
assay NN NN O
of NN NN O
phagocyte NN NN O
bactericidal NN NN O
activity NN NN O
. NN NN O

Absent NN NN O
bacteriolysis NN NN O
remains NN NN O
the NN NN O
only NN NN O
consistent NN NN O
defect NN NN O
associated NN NN O
with NN NN O
recurrent NN NN O
neisserial NN NN B-SpecificDisease
infections NN NN I-SpecificDisease
and NN NN O
absence NN NN O
of NN NN O
one NN NN O
of NN NN O
the NN NN O
late-acting NN NN O
complement NN NN O
components NN NN O
. NN NN O

. NN NN O

495634 NN NN O
Deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
fifth NN NN I-SpecificDisease
component NN NN I-SpecificDisease
of NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
in NN NN O
human NN NN O
subjects NN NN O
. NN NN O

Clinical NN NN O
, NN NN O
genetic NN NN O
and NN NN O
immunologic NN NN O
studies NN NN O
in NN NN O
a NN NN O
large NN NN O
kindred NN NN O
. NN NN O

The NN NN O
discovery NN NN O
of NN NN O
a NN NN O
large NN NN O
kindred NN NN O
with NN NN O
a NN NN O
heritable NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
fifth NN NN I-SpecificDisease
component NN NN I-SpecificDisease
of NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
( NN NN O
C5 NN NN O
) NN NN O
has NN NN O
permitted NN NN O
the NN NN O
accumulation NN NN O
of NN NN O
new NN NN O
clinical NN NN O
, NN NN O
genetic NN NN O
and NN NN O
immunologic NN NN O
data NN NN O
concerning NN NN O
the NN NN O
role NN NN O
of NN NN O
C5 NN NN O
in NN NN O
human NN NN O
subjects NN NN O
. NN NN O

The NN NN O
proband NN NN O
, NN NN O
who NN NN O
has NN NN O
had NN NN O
nine NN NN O
episodes NN NN O
of NN NN O
disseminated NN NN O
gonococcal NN NN B-SpecificDisease
infection NN NN I-SpecificDisease
, NN NN O
has NN NN O
a NN NN O
hemolytic NN NN O
C5 NN NN O
level NN NN O
of NN NN O
approximately NN NN O
0 NN NN O
. NN NN O

5 NN NN O
per NN NN O
cent NN NN O
of NN NN O
normal NN NN O
. NN NN O

No NN NN O
C5 NN NN O
protein NN NN O
was NN NN O
detectable NN NN O
, NN NN O
but NN NN O
low NN NN O
levels NN NN O
of NN NN O
functional NN NN O
C5 NN NN O
activity NN NN O
could NN NN O
be NN NN O
found NN NN O
using NN NN O
a NN NN O
sensitive NN NN O
bactericidal NN NN O
assay NN NN O
. NN NN O

The NN NN O
probands NN NN O
twin NN NN O
as NN NN O
well NN NN O
as NN NN O
another NN NN O
sister NN NN O
also NN NN O
had NN NN O
extremely NN NN O
low NN NN O
levels NN NN O
of NN NN O
hemolytic NN NN O
C5 NN NN O
( NN NN O
approximately NN NN O
0 NN NN O
. NN NN O

5 NN NN O
per NN NN O
cent NN NN O
normal NN NN O
) NN NN O
, NN NN O
but NN NN O
both NN NN O
these NN NN O
subjects NN NN O
have NN NN O
been NN NN O
healthy NN NN O
. NN NN O

Hemolytic NN NN O
complement NN NN O
and NN NN O
bacteriolytic NN NN O
activity NN NN O
could NN NN O
be NN NN O
restored NN NN O
by NN NN O
the NN NN O
addition NN NN O
of NN NN O
purified NN NN O
C5 NN NN O
. NN NN O

No NN NN O
chemotactic NN NN O
activity NN NN O
for NN NN O
polymorphonuclear NN NN O
leukocytes NN NN O
could NN NN O
be NN NN O
generated NN NN O
in NN NN O
the NN NN O
C5-deficient NN NN B-Modifier
serums NN NN O
upon NN NN O
activation NN NN O
of NN NN O
either NN NN O
the NN NN O
classic NN NN O
or NN NN O
alternative NN NN O
pathways NN NN O
, NN NN O
again NN NN O
demonstrating NN NN O
the NN NN O
importance NN NN O
of NN NN O
C5 NN NN O
in NN NN O
human NN NN O
subjects NN NN O
for NN NN O
the NN NN O
production NN NN O
of NN NN O
chemotactic NN NN O
factors NN NN O
. NN NN O

The NN NN O
chemotactic NN NN O
responsiveness NN NN O
of NN NN O
the NN NN O
patients NN NN O
polymorphonuclear NN NN O
leukocytes NN NN O
and NN NN O
monocytes NN NN O
to NN NN O
preformed NN NN O
chemotactic NN NN O
factors NN NN O
was NN NN O
not NN NN O
depressed NN NN O
. NN NN O

Twenty-two NN NN O
of NN NN O
32 NN NN O
other NN NN O
family NN NN O
members NN NN O
from NN NN O
three NN NN O
generations NN NN O
had NN NN O
depressed NN NN O
whole NN NN O
hemolytic NN NN O
complement NN NN O
levels NN NN O
. NN NN O

In NN NN O
19 NN NN O
of NN NN O
30 NN NN O
family NN NN O
members NN NN O
, NN NN O
levels NN NN O
of NN NN O
hemolytic NN NN O
C5 NN NN O
ranged NN NN O
from NN NN O
13 NN NN O
to NN NN O
64 NN NN O
per NN NN O
cent NN NN O
of NN NN O
normal NN NN O
. NN NN O

No NN NN O
linkage NN NN O
for NN NN O
C5 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
and NN NN O
the NN NN O
A NN NN O
or NN NN O
B NN NN O
loci NN NN O
of NN NN O
the NN NN O
major NN NN O
histocompatibility NN NN O
complex NN NN O
could NN NN O
be NN NN O
found NN NN O
. NN NN O

These NN NN O
data NN NN O
suggest NN NN O
an NN NN O
autosomal NN NN O
codominant NN NN O
mode NN NN O
of NN NN O
inheritance NN NN O
of NN NN O
C5 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

Deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
C5 NN NN I-SpecificDisease
is NN NN O
compatible NN NN O
with NN NN O
good NN NN O
health NN NN O
, NN NN O
but NN NN O
it NN NN O
can NN NN O
be NN NN O
associated NN NN O
with NN NN O
repeated NN NN O
disseminated NN NN O
gonococcal NN NN B-SpecificDisease
infection NN NN I-SpecificDisease

511159 NN NN O
Incidence NN NN O
and NN NN O
characteristics NN NN O
of NN NN O
glucose-6-phosphate NN NN O
dehydrogenase NN NN O
variants NN NN O
in NN NN O
Japan NN NN O
. NN NN O

A NN NN O
total NN NN O
of NN NN O
3000 NN NN O
men NN NN O
living NN NN O
in NN NN O
Yamaguchi NN NN O
were NN NN O
screened NN NN O
for NN NN O
glucose-6-phosphate NN NN B-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
( NN NN I-SpecificDisease
G6PD NN NN I-SpecificDisease
) NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
using NN NN O
Beutlers NN NN O
spot NN NN O
test NN NN O
and NN NN O
three NN NN O
types NN NN O
of NN NN O
starch NN NN O
gel NN NN O
electrophoresis NN NN O
. NN NN O

These NN NN O
electrophoresis NN NN O
used NN NN O
a NN NN O
phosphate NN NN O
buffer NN NN O
system NN NN O
at NN NN O
pH NN NN O
7 NN NN O
. NN NN O

0 NN NN O
, NN NN O
a NN NN O
TRIS-EDTA-borate NN NN O
buffer NN NN O
system NN NN O
at NN NN O
pH NN NN O
8 NN NN O
. NN NN O

6 NN NN O
, NN NN O
and NN NN O
a NN NN O
TRIS-hydrochloride NN NN O
buffer NN NN O
system NN NN O
at NN NN O
pH NN NN O
8 NN NN O
.. NN NN O
Fifteen NN NN O
G6PD-deficient NN NN B-Modifier
variants NN NN O
were NN NN O
found NN NN O
at NN NN O
the NN NN O
rate NN NN O
of NN NN O
0 NN NN O
. NN NN O

5 NN NN O
% NN NN O
and NN NN O
classified NN NN O
into NN NN O
four NN NN O
groups NN NN O
. NN NN O

As NN NN O
new NN NN O
variants NN NN O
, NN NN O
G6PD NN NN O
Konan NN NN O
, NN NN O
Kamiube NN NN O
, NN NN O
and NN NN O
Kiwa NN NN O
were NN NN O
identified NN NN O
. NN NN O

These NN NN O
three NN NN O
variants NN NN O
had NN NN O
a NN NN O
mild NN NN O
to NN NN O
moderate NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
and NN NN O
were NN NN O
not NN NN O
associated NN NN O
with NN NN O
any NN NN O
clinical NN NN O
signs NN NN O
. NN NN O

G6PD NN NN O
Konan NN NN O
had NN NN O
fast NN NN O
electrophoretic NN NN O
mobility NN NN O
as NN NN O
compared NN NN O
with NN NN O
normal NN NN O
levels NN NN O
, NN NN O
G6PD NN NN O
Kiwa NN NN O
had NN NN O
slightly NN NN O
elevated NN NN O
electrophoretic NN NN O
mobility NN NN O
, NN NN O
and NN NN O
G6PD NN NN O
Kamiube NN NN O
had NN NN O
normal NN NN O
electrophoretic NN NN O
mobility NN NN O
. NN NN O

These NN NN O
three NN NN O
variants NN NN O
had NN NN O
normal NN NN O
levels NN NN O
of NN NN O
Km NN NN O
G6P NN NN O
, NN NN O
Km NN NN O
NADP NN NN O
, NN NN O
and NN NN O
Ki NN NN O
NADPH NN NN O
, NN NN O
normal NN NN O
utilizations NN NN O
of NN NN O
both NN NN O
2-deoxy-G6P NN NN O
and NN NN O
deamino-NAPD NN NN O
, NN NN O
normal NN NN O
heat NN NN O
stability NN NN O
, NN NN O
and NN NN O
a NN NN O
normal NN NN O
pH NN NN O
curve NN NN O
. NN NN O

The NN NN O
other NN NN O
variant NN NN O
was NN NN O
G6PD NN NN O
Ube NN NN O
, NN NN O
which NN NN O
we NN NN O
had NN NN O
previously NN NN O
found NN NN O
in NN NN O
Yamaguchi NN NN O
( NN NN O
Nakashima NN NN O
et NN NN O
al NN NN O
. NN NN O

, NN NN O
1977 NN NN O
) NN NN O
. NN NN O

One NN NN O
boy NN NN O
with NN NN O
G6PD NN NN O
Ube NN NN O
was NN NN O
Korean NN NN O

523196 NN NN O
Utilization NN NN O
of NN NN O
purines NN NN O
by NN NN O
an NN NN O
HPRT NN NN O
variant NN NN O
in NN NN O
an NN NN O
intelligent NN NN O
, NN NN O
nonmutilative NN NN O
patient NN NN O
with NN NN O
features NN NN O
of NN NN O
the NN NN O
Lesch-Nyhan NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

The NN NN O
patient NN NN O
, NN NN O
H NN NN O
. NN NN O

Chr NN NN O
. NN NN O

B NN NN O
. NN NN O

, NN NN O
was NN NN O
among NN NN O
the NN NN O
first NN NN O
reported NN NN O
with NN NN O
hyperuricemia NN NN B-SpecificDisease
and NN NN O
central NN NN B-DiseaseClass
nervous NN NN I-DiseaseClass
system NN NN I-DiseaseClass
symptoms NN NN I-DiseaseClass
. NN NN O

He NN NN O
has NN NN O
been NN NN O
found NN NN O
to NN NN O
have NN NN O
a NN NN O
variant NN NN O
of NN NN O
hypoxanthine NN NN O
guanine NN NN O
phosphoribosyl NN NN O
transferase NN NN O
( NN NN O
HPRT NN NN O
; NN NN O
E NN NN O
. NN NN O

C NN NN O
. NN NN O

2 NN NN O
. NN NN O

4 NN NN O
. NN NN O

2 NN NN O
. NN NN O

8 NN NN O
) NN NN O
distinct NN NN O
from NN NN O
the NN NN O
enzyme NN NN O
present NN NN O
in NN NN O
patients NN NN O
with NN NN O
the NN NN O
Lesch-Nyhan NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

The NN NN O
patient NN NN O
had NN NN O
chroeoathetosis NN NN B-SpecificDisease
, NN NN O
spasticity NN NN B-SpecificDisease
, NN NN O
dysarthric NN NN B-SpecificDisease
speech NN NN I-SpecificDisease
, NN NN O
and NN NN O
hyperuricemia NN NN B-SpecificDisease
. NN NN O

However NN NN O
, NN NN O
his NN NN O
intelligence NN NN O
was NN NN O
normal NN NN O
and NN NN O
he NN NN O
had NN NN O
no NN NN O
evidence NN NN O
of NN NN O
self-mutilation NN NN O
. NN NN O

There NN NN O
was NN NN O
no NN NN O
activity NN NN O
of NN NN O
HPRT NN NN O
in NN NN O
the NN NN O
lysates NN NN O
of NN NN O
erythrocytes NN NN O
and NN NN O
cultured NN NN O
fibroblasts NN NN O
when NN NN O
analyzed NN NN O
in NN NN O
the NN NN O
usual NN NN O
manner NN NN O
. NN NN O

Using NN NN O
a NN NN O
newly NN NN O
developed NN NN O
method NN NN O
for NN NN O
the NN NN O
study NN NN O
of NN NN O
purine NN NN O
metabolism NN NN O
in NN NN O
intact NN NN O
cultured NN NN O
cells NN NN O
, NN NN O
this NN NN O
patient NN NN O
was NN NN O
found NN NN O
to NN NN O
metabolize NN NN O
some NN NN O
9 NN NN O
% NN NN O
of NN NN O
8-14C-hypoxanthine NN NN O
, NN NN O
and NN NN O
90 NN NN O
% NN NN O
of NN NN O
the NN NN O
isotope NN NN O
utilized NN NN O
was NN NN O
converted NN NN O
to NN NN O
adenine NN NN O
and NN NN O
guanine NN NN O
nucleotides NN NN O
. NN NN O

In NN NN O
contrast NN NN O
, NN NN O
cells NN NN O
from NN NN O
patients NN NN O
with NN NN O
the NN NN O
Lesch-Nyhan NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
were NN NN O
virtually NN NN O
completely NN NN O
unable NN NN O
to NN NN O
convert NN NN O
hypoxanthine NN NN O
to NN NN O
nucleotides NN NN O
. NN NN O

The NN NN O
patients NN NN O
fibroblasts NN NN O
were NN NN O
even NN NN O
more NN NN O
efficient NN NN O
in NN NN O
the NN NN O
metabolism NN NN O
of NN NN O
8-14C-guanine NN NN O
, NN NN O
which NN NN O
was NN NN O
utilized NN NN O
to NN NN O
the NN NN O
extent NN NN O
of NN NN O
27 NN NN O
% NN NN O
, NN NN O
over NN NN O
80 NN NN O
% NN NN O
of NN NN O
which NN NN O
was NN NN O
converted NN NN O
to NN NN O
guanine NN NN O
and NN NN O
adenine NN NN O
nucleotides NN NN O
. NN NN O

The NN NN O
growth NN NN O
of NN NN O
the NN NN O
cultured NN NN O
fibroblasts NN NN O
of NN NN O
this NN NN O
patient NN NN O
was NN NN O
intermediate NN NN O
in NN NN O
media NN NN O
containing NN NN O
hypoxanthine NN NN O
aminopterin NN NN O
thymidine NN NN O
( NN NN O
HAT NN NN O
) NN NN O
, NN NN O
whereas NN NN O
the NN NN O
growth NN NN O
of NN NN O
Lesch-Nyhan NN NN B-Modifier
cells NN NN O
was NN NN O
inhibited NN NN O
and NN NN O
normal NN NN O
cells NN NN O
grew NN NN O
normally NN NN O
. NN NN O

Similarly NN NN O
in NN NN O
8-azaguanine NN NN O
, NN NN O
6-thioguanine NN NN O
, NN NN O
and NN NN O
8-azahypoxanthine NN NN O
, NN NN O
the NN NN O
growth NN NN O
of NN NN O
the NN NN O
patients NN NN O
cells NN NN O
was NN NN O
intermediate NN NN O
between NN NN O
normal NN NN O
and NN NN O
Lesch-Nyhan NN NN B-Modifier
cells NN NN O
. NN NN O

These NN NN O
observations NN NN O
provide NN NN O
further NN NN O
evidence NN NN O
for NN NN O
genetic NN NN O
heterogeneity NN NN O
among NN NN O
patients NN NN O
with NN NN O
disorders NN NN O
in NN NN O
purine NN NN O
metabolism NN NN O
involving NN NN O
the NN NN O
HPRT NN NN O
gene NN NN O
. NN NN O

They NN NN O
document NN NN O
that NN NN O
this NN NN O
famous NN NN O
patient NN NN O
did NN NN O
not NN NN O
have NN NN O
the NN NN O
Lesch-Nyhan NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease

6086495 NN NN O
Localisation NN NN O
of NN NN O
the NN NN O
Becker NN NN B-Modifier
muscular NN NN I-Modifier
dystrophy NN NN I-Modifier
gene NN NN O
on NN NN O
the NN NN O
short NN NN O
arm NN NN O
of NN NN O
the NN NN O
X NN NN O
chromosome NN NN O
by NN NN O
linkage NN NN O
to NN NN O
cloned NN NN O
DNA NN NN O
sequences NN NN O
. NN NN O

A NN NN O
linkage NN NN O
study NN NN O
in NN NN O
30 NN NN O
Becker NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
BMD NN NN B-SpecificDisease
) NN NN O
kindreds NN NN O
using NN NN O
three NN NN O
cloned NN NN O
DNA NN NN O
sequences NN NN O
from NN NN O
the NN NN O
X NN NN O
chromosome NN NN O
which NN NN O
demonstrate NN NN O
restriction NN NN O
fragment NN NN O
length NN NN O
polymorphisms NN NN O
( NN NN O
RFLPs NN NN O
) NN NN O
, NN NN O
suggests NN NN O
that NN NN O
the NN NN O
BMD NN NN B-Modifier
gene NN NN O
is NN NN O
located NN NN O
on NN NN O
the NN NN O
short NN NN O
arm NN NN O
of NN NN O
the NN NN O
X NN NN O
chromosome NN NN O
, NN NN O
in NN NN O
the NN NN O
p21 NN NN O
region NN NN O
. NN NN O

The NN NN O
genes NN NN O
for NN NN O
Becker NN NN B-CompositeMention
and NN NN I-CompositeMention
Duchenne NN NN I-CompositeMention
dystrophies NN NN I-CompositeMention
must NN NN O
therefore NN NN O
be NN NN O
closely NN NN O
linked NN NN O
, NN NN O
if NN NN O
not NN NN O
allelic NN NN O
, NN NN O
and NN NN O
any NN NN O
future NN NN O
DNA NN NN O
probes NN NN O
found NN NN O
to NN NN O
be NN NN O
of NN NN O
practical NN NN O
use NN NN O
in NN NN O
one NN NN O
disorder NN NN O
should NN NN O
be NN NN O
equally NN NN O
applicable NN NN O
to NN NN O
the NN NN O
other NN NN O
. NN NN O

The NN NN O
linkage NN NN O
analysis NN NN O
also NN NN O
provides NN NN O
data NN NN O
on NN NN O
the NN NN O
frequency NN NN O
of NN NN O
recombination NN NN O
along NN NN O
the NN NN O
short NN NN O
arm NN NN O
of NN NN O
the NN NN O
X NN NN O
chromosome NN NN O
, NN NN O
and NN NN O
across NN NN O
the NN NN O
centromeric NN NN O
region NN NN O
. NN NN O

. NN NN O

6087154 NN NN O
Molecular NN NN O
evidence NN NN O
for NN NN O
new NN NN O
mutation NN NN O
at NN NN O
the NN NN O
hprt NN NN O
locus NN NN O
in NN NN O
Lesch-Nyhan NN NN B-Modifier
patients NN NN O
. NN NN O

Hypoxanthine-guanine NN NN O
phosphoribosyltransferase NN NN O
( NN NN O
HPRT NN NN O
; NN NN O
EC2 NN NN O
. NN NN O

4 NN NN O
. NN NN O

2 NN NN O
. NN NN O

8 NN NN O
) NN NN O
, NN NN O
which NN NN O
functions NN NN O
in NN NN O
the NN NN O
metabolic NN NN O
salvage NN NN O
of NN NN O
purines NN NN O
, NN NN O
is NN NN O
encoded NN NN O
by NN NN O
an NN NN O
X-linked NN NN O
gene NN NN O
in NN NN O
man NN NN O
. NN NN O

Partial NN NN O
HPRT NN NN B-DiseaseClass
deficiencies NN NN I-DiseaseClass
are NN NN O
associated NN NN O
with NN NN O
gouty NN NN B-SpecificDisease
arthritis NN NN I-SpecificDisease
, NN NN O
while NN NN O
absence NN NN O
of NN NN O
activity NN NN O
results NN NN O
in NN NN O
Lesch-Nyhan NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
L-N NN NN B-SpecificDisease
) NN NN O
. NN NN O

L-N NN NN B-Modifier
patients NN NN O
fail NN NN O
to NN NN O
reproduce NN NN O
and NN NN O
the NN NN O
heterozygous NN NN O
state NN NN O
appears NN NN O
to NN NN O
confer NN NN O
no NN NN O
selective NN NN O
advantage NN NN O
. NN NN O

Thus NN NN O
, NN NN O
Haldanes NN NN O
principle NN NN O
predicts NN NN O
that NN NN O
new NN NN O
mutations NN NN O
at NN NN O
the NN NN O
hprt NN NN O
locus NN NN O
must NN NN O
occur NN NN O
frequently NN NN O
in NN NN O
order NN NN O
for NN NN O
L-N NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
to NN NN O
be NN NN O
maintained NN NN O
in NN NN O
the NN NN O
population NN NN O
. NN NN O

This NN NN O
constant NN NN O
introduction NN NN O
of NN NN O
new NN NN O
mutations NN NN O
would NN NN O
be NN NN O
expected NN NN O
to NN NN O
result NN NN O
in NN NN O
a NN NN O
heterogeneous NN NN O
collection NN NN O
of NN NN O
genetic NN NN B-DiseaseClass
lesions NN NN I-DiseaseClass
, NN NN O
some NN NN O
of NN NN O
which NN NN O
may NN NN O
be NN NN O
novel NN NN O
. NN NN O

As NN NN O
we NN NN O
report NN NN O
here NN NN O
, NN NN O
the NN NN O
mutations NN NN O
in NN NN O
the NN NN O
hprt NN NN O
gene NN NN O
of NN NN O
seven NN NN O
L-N NN NN B-Modifier
patients NN NN O
, NN NN O
selected NN NN O
from NN NN O
an NN NN O
initial NN NN O
survey NN NN O
of NN NN O
28 NN NN O
patients NN NN O
, NN NN O
have NN NN O
been NN NN O
characterized NN NN O
and NN NN O
all NN NN O
were NN NN O
found NN NN O
to NN NN O
be NN NN O
distinctly NN NN O
different NN NN O
, NN NN O
as NN NN O
predicted NN NN O
. NN NN O

The NN NN O
origin NN NN O
of NN NN O
one NN NN O
unusual NN NN O
mutation NN NN O
has NN NN O
been NN NN O
identified NN NN O
by NN NN O
analysis NN NN O
of NN NN O
DNA NN NN O
from NN NN O
four NN NN O
generations NN NN O
of NN NN O
family NN NN O
members NN NN O
. NN NN O

Further NN NN O
molecular NN NN O
analysis NN NN O
of NN NN O
the NN NN O
origin NN NN O
of NN NN O
new NN NN O
mutations NN NN O
at NN NN O
the NN NN O
hprt NN NN O
locus NN NN O
should NN NN O
aid NN NN O
in NN NN O
resolving NN NN O
the NN NN O
issue NN NN O
of NN NN O
an NN NN O
apparent NN NN O
difference NN NN O
in NN NN O
the NN NN O
frequency NN NN O
of NN NN O
hprt NN NN O
mutations NN NN O
in NN NN O
males NN NN O
and NN NN O
females NN NN O

6101415 NN NN O
Allelic NN NN O
exclusion NN NN O
of NN NN O
glucose-6-phosphate NN NN O
dehydrogenase NN NN O
in NN NN O
platelets NN NN O
and NN NN O
T NN NN O
lymphocytes NN NN O
from NN NN O
a NN NN O
Wiskott-Aldrich NN NN B-Modifier
syndrome NN NN I-Modifier
carrier NN NN O
. NN NN O

An NN NN O
obligate NN NN O
carrier NN NN O
of NN NN O
the NN NN O
Wiskott-Aldrich NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
WAS NN NN B-SpecificDisease
) NN NN O
who NN NN O
was NN NN O
also NN NN O
heterozygous NN NN O
for NN NN O
the NN NN O
A NN NN O
and NN NN O
B NN NN O
types NN NN O
of NN NN O
X-linked NN NN O
glucose-6-phosphate NN NN O
dehydrogenase NN NN O
was NN NN O
found NN NN O
. NN NN O

With NN NN O
her NN NN O
it NN NN O
became NN NN O
possible NN NN O
to NN NN O
determine NN NN O
whether NN NN O
allelic NN NN O
exclusion NN NN O
occurs NN NN O
in NN NN O
particular NN NN O
cell-types NN NN O
of NN NN O
the NN NN O
WAS NN NN B-Modifier
carrier NN NN O
. NN NN O

If NN NN O
so NN NN O
, NN NN O
the NN NN O
remaining NN NN O
cells NN NN O
of NN NN O
a NN NN O
particular NN NN O
cell-type NN NN O
would NN NN O
express NN NN O
only NN NN O
the NN NN O
normal NN NN O
X NN NN O
chromosome NN NN O
and NN NN O
only NN NN O
one NN NN O
glucose-6-phosphate NN NN O
dehydrogenase NN NN O
isoenzyme NN NN O
would NN NN O
be NN NN O
demonstrable NN NN O
. NN NN O

This NN NN O
carrier NN NN O
had NN NN O
only NN NN O
the NN NN O
B NN NN O
isoenzyme NN NN O
of NN NN O
glucose-6-phosphate NN NN O
dehydrogenase NN NN O
in NN NN O
platelets NN NN O
and NN NN O
thymus-derived NN NN O
T NN NN O
lymphocytes NN NN O
, NN NN O
although NN NN O
both NN NN O
isoenzymes NN NN O
A NN NN O
and NN NN O
B NN NN O
were NN NN O
present NN NN O
in NN NN O
erythrocytes NN NN O
and NN NN O
neutrophils NN NN O
. NN NN O

These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
selection NN NN O
against NN NN O
the NN NN O
WAS NN NN B-Modifier
gene NN NN O
occurs NN NN O
in NN NN O
platelets NN NN O
and NN NN O
thymus-derived NN NN O
T NN NN O
lymphocytes NN NN O
and NN NN O
that NN NN O
the NN NN O
defects NN NN O
associated NN NN O
with NN NN O
WAS NN NN B-SpecificDisease
expressed NN NN O
in NN NN O
these NN NN O
cell-types NN NN O
may NN NN O
be NN NN O
implicated NN NN O
in NN NN O
the NN NN O
genesis NN NN O
of NN NN O
the NN NN O
Wiskott-Aldrich NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

. NN NN O

6103091 NN NN O
Complement NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
and NN NN O
nephritis NN NN B-SpecificDisease
. NN NN O

A NN NN O
report NN NN O
of NN NN O
a NN NN O
family NN NN O
. NN NN O

A NN NN O
family NN NN O
is NN NN O
described NN NN O
in NN NN O
which NN NN O
three NN NN O
children NN NN O
had NN NN O
homozygous NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
C3 NN NN I-SpecificDisease
and NN NN O
in NN NN O
which NN NN O
both NN NN O
parents NN NN O
and NN NN O
two NN NN O
other NN NN O
children NN NN O
were NN NN O
heterozygous NN NN O
for NN NN O
the NN NN O
C3 NN NN O
null NN NN O
gene NN NN O
. NN NN O

One NN NN O
child NN NN O
with NN NN O
heterozygous NN NN O
C3 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
was NN NN O
found NN NN O
to NN NN O
have NN NN O
membranoproliferative NN NN O
glomerulonephritis NN NN B-SpecificDisease
; NN NN O
proteinuria NN NN B-SpecificDisease
and NN NN O
/ NN NN O
or NN NN O
microscopical NN NN O
haematuria NN NN B-SpecificDisease
was NN NN O
present NN NN O
in NN NN O
all NN NN O
three NN NN O
homozygous NN NN O
C3-deficient NN NN B-Modifier
children NN NN O
. NN NN O

All NN NN O
children NN NN O
with NN NN O
homozygous NN NN O
or NN NN O
heterozygous NN NN O
C3 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
were NN NN O
, NN NN O
to NN NN O
a NN NN O
varying NN NN O
degree NN NN O
, NN NN O
susceptible NN NN O
to NN NN O
infection NN NN O
. NN NN O

The NN NN O
only NN NN O
child NN NN O
of NN NN O
the NN NN O
family NN NN O
with NN NN O
normal NN NN O
complement NN NN O
had NN NN O
no NN NN O
increased NN NN O
risk NN NN O
of NN NN O
infection NN NN O
and NN NN O
no NN NN O
renal NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
. NN NN O

This NN NN O
family NN NN O
study NN NN O
provides NN NN O
further NN NN O
support NN NN O
for NN NN O
the NN NN O
proposal NN NN O
that NN NN O
C3 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
predisposes NN NN O
to NN NN O
nephritis NN NN B-SpecificDisease
. NN NN O

. NN NN O

624546 NN NN O
Heterogeneity NN NN O
of NN NN O
glucose-6-phosphate NN NN B-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
Algeria NN NN O
. NN NN O

Study NN NN O
in NN NN O
Northern NN NN O
Algeria NN NN O
with NN NN O
description NN NN O
of NN NN O
five NN NN O
new NN NN O
variants NN NN O
. NN NN O

Glucose-6-phosphate NN NN B-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
( NN NN I-SpecificDisease
G6PD NN NN I-SpecificDisease
) NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
was NN NN O
found NN NN O
in NN NN O
3 NN NN O
. NN NN O

2 NN NN O
% NN NN O
of NN NN O
the NN NN O
male NN NN O
population NN NN O
living NN NN O
in NN NN O
the NN NN O
urban NN NN O
area NN NN O
of NN NN O
Algiers NN NN O
. NN NN O

The NN NN O
deficient NN NN O
subjects NN NN O
originated NN NN O
from NN NN O
multiple NN NN O
geographic NN NN O
regions NN NN O
of NN NN O
Northern NN NN O
Algeria NN NN O
, NN NN O
with NN NN O
prevalence NN NN O
of NN NN O
individuals NN NN O
of NN NN O
Berber-Kabyle NN NN O
origin NN NN O
. NN NN O

Red NN NN O
blood NN NN O
cell NN NN O
G6PD NN NN O
was NN NN O
partially NN NN O
purified NN NN O
and NN NN O
characterized NN NN O
in NN NN O
deficient NN NN O
males NN NN O
from NN NN O
17 NN NN O
families NN NN O
, NN NN O
and NN NN O
six NN NN O
different NN NN O
variants NN NN O
were NN NN O
found NN NN O
. NN NN O

Among NN NN O
them NN NN O
, NN NN O
only NN NN O
one NN NN O
, NN NN O
the NN NN O
Gd NN NN O
( NN NN O
- NN NN O
) NN NN O
Kabyle NN NN O
variant NN NN O
, NN NN O
had NN NN O
been NN NN O
previously NN NN O
described NN NN O
. NN NN O

It NN NN O
was NN NN O
detected NN NN O
in NN NN O
nine NN NN O
families NN NN O
. NN NN O

The NN NN O
other NN NN O
five NN NN O
variants NN NN O
were NN NN O
new NN NN O
Gd NN NN O
( NN NN O
- NN NN O
) NN NN O
Laghouat NN NN O
( NN NN O
four NN NN O
cases NN NN O
) NN NN O
, NN NN O
Gd NN NN O
( NN NN O
- NN NN O
) NN NN O
Blida NN NN O
( NN NN O
one NN NN O
case NN NN O
) NN NN O
, NN NN O
Gd NN NN O
( NN NN O
- NN NN O
) NN NN O
Thenia NN NN O
( NN NN O
one NN NN O
case NN NN O
) NN NN O
, NN NN O
Gd NN NN O
( NN NN O
- NN NN O
) NN NN O
Titteri NN NN O
( NN NN O
one NN NN O
case NN NN O
) NN NN O
, NN NN O
and NN NN O
Gd NN NN O
( NN NN O
- NN NN O
) NN NN O
Alger NN NN O
( NN NN O
two NN NN O
brothers NN NN O
) NN NN O
. NN NN O

Strikingly NN NN O
, NN NN O
the NN NN O
common NN NN O
Mediterranean NN NN O
variant NN NN O
was NN NN O
not NN NN O
found NN NN O
. NN NN O

G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
is NN NN O
heterogeneous NN NN O
in NN NN O
northern NN NN O
Algeria NN NN O
where NN NN O
autochtonous NN NN O
variants NN NN O
seem NN NN O
to NN NN O
prevail NN NN O
. NN NN O

The NN NN O
Kabyle NN NN O
variant NN NN O
may NN NN O
be NN NN O
common NN NN O
in NN NN O
this NN NN O
country NN NN O
. NN NN O

6337374 NN NN O
Glucose-6-phosphate NN NN B-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
inhibits NN NN O
in NN NN O
vitro NN NN O
growth NN NN O
of NN NN O
Plasmodium NN NN O
falciparum NN NN O
. NN NN O


1 NN NN O
. NN NN O

1 NN NN O
. NN NN O

49 NN NN O
) NN NN O
-deficient NN NN O
red NN NN O
blood NN NN O
cells NN NN O
from NN NN O
male NN NN O
hemizygotes NN NN O
and NN NN O
female NN NN O
heterozygotes NN NN O
from NN NN O
the NN NN O
island NN NN O
of NN NN O
Sardinia NN NN O
were NN NN O
studied NN NN O
for NN NN O
their NN NN O
ability NN NN O
to NN NN O
support NN NN O
growth NN NN O
in NN NN O
vitro NN NN O
of NN NN O
the NN NN O
malaria NN NN B-Modifier
-causing NN NN O
organism NN NN O
Plasmodium NN NN O
falciparum NN NN O
. NN NN O

Parasite NN NN O
growth NN NN O
was NN NN O
approximately NN NN O
one-third NN NN O
of NN NN O
normal NN NN O
in NN NN O
both NN NN O
hemi- NN NN O
and NN NN O
heterozygotes NN NN O
for NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

In NN NN O
Sardinians NN NN O
with NN NN O
the NN NN O
beta NN NN O
0-thalassemia NN NN O
trait NN NN O
, NN NN O
parasite NN NN O
growth NN NN O
was NN NN O
normal NN NN O
except NN NN O
when NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
occurred NN NN O
together NN NN O
with NN NN O
the NN NN O
thalassemia NN NN B-Modifier
trait NN NN O
. NN NN O

The NN NN O
data NN NN O
support NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
may NN NN O
confer NN NN O
a NN NN O
selective NN NN O
advantage NN NN O
in NN NN O
a NN NN O
malarious NN NN B-Modifier
area NN NN O
; NN NN O
the NN NN O
female NN NN O
heterozygote NN NN O
may NN NN O
be NN NN O
at NN NN O
a NN NN O
particular NN NN O
advantage NN NN O
because NN NN O
resistance NN NN O
to NN NN O
malaria NN NN B-SpecificDisease
equals NN NN O
that NN NN O
of NN NN O
male NN NN O
hemizygotes NN NN O
, NN NN O
but NN NN O
the NN NN O
risk NN NN O
of NN NN O
fatal NN NN B-SpecificDisease
hemolysis NN NN I-SpecificDisease
may NN NN O
be NN NN O
less NN NN O
. NN NN O

However NN NN O
, NN NN O
more NN NN O
female NN NN O
heterozygotes NN NN O
must NN NN O
be NN NN O
studied NN NN O
to NN NN O
confirm NN NN O
this NN NN O
hypothesis NN NN O
. NN NN O

No NN NN O
protective NN NN O
effect NN NN O
of NN NN O
beta NN NN O
0-thalassemia NN NN O
trait NN NN O
could NN NN O
be NN NN O
demonstrated NN NN O
in NN NN O
vitro NN NN O
. NN NN O

6387532 NN NN O
Bone NN NN O
marrow NN NN O
transplant NN NN O
in NN NN O
adrenoleukodystrophy NN NN B-SpecificDisease
. NN NN O

An NN NN O
allogeneic NN NN O
bone NN NN O
marrow NN NN O
transplant NN NN O
( NN NN O
BMT NN NN O
) NN NN O
from NN NN O
a NN NN O
normal NN NN O
HLA NN NN O
identical NN NN O
sibling NN NN O
donor NN NN O
was NN NN O
performed NN NN O
in NN NN O
a NN NN O
13-year-old NN NN O
boy NN NN O
with NN NN O
rapidly NN NN O
progressive NN NN O
adrenoleukodystrophy NN NN B-SpecificDisease
( NN NN O
ALD NN NN B-SpecificDisease
) NN NN O
. NN NN O

Engraftment NN NN O
and NN NN O
complete NN NN O
hematologic NN NN O
recovery NN NN O
occurred NN NN O
within NN NN O
4 NN NN O
weeks NN NN O
, NN NN O
but NN NN O
neurologic NN NN B-DiseaseClass
deterioration NN NN I-DiseaseClass
continued NN NN O
. NN NN O

The NN NN O
patient NN NN O
died NN NN O
of NN NN O
an NN NN O
adenovirus NN NN B-SpecificDisease
infection NN NN I-SpecificDisease
141 NN NN O
days NN NN O
after NN NN O
BMT NN NN O
. NN NN O

ALD NN NN B-SpecificDisease
is NN NN O
characterized NN NN O
by NN NN O
abnormally NN NN O
high NN NN O
plasma NN NN O
levels NN NN O
of NN NN O
very NN NN O
long NN NN O
chain NN NN O
fatty NN NN O
acids NN NN O
( NN NN O
VLCFA NN NN O
) NN NN O
as NN NN O
a NN NN O
result NN NN O
of NN NN O
impaired NN NN O
capacity NN NN O
to NN NN O
degrade NN NN O
them NN NN O
. NN NN O

Ten NN NN O
days NN NN O
after NN NN O
BMT NN NN O
, NN NN O
the NN NN O
white NN NN O
blood NN NN O
cell NN NN O
VLCFA NN NN O
levels NN NN O
and NN NN O
enzyme NN NN O
activity NN NN O
became NN NN O
normal NN NN O
; NN NN O
after NN NN O
3 NN NN O
months NN NN O
, NN NN O
there NN NN O
was NN NN O
progressive NN NN O
reduction NN NN O
of NN NN O
plasma NN NN O
VLCFA NN NN O
to NN NN O
levels NN NN O
only NN NN O
slightly NN NN O
above NN NN O
normal NN NN O
. NN NN O

. NN NN O

6453040 NN NN O
[ NN NN O
Gd- NN NN O
allele NN NN O
distribution NN NN O
patterns NN NN O
in NN NN O
Azerbaijan NN NN O
. NN NN O

III NN NN O
. NN NN O

The NN NN O
identification NN NN O
of NN NN O
mutant NN NN O
forms NN NN O
of NN NN O
glucose-6-phosphate NN NN O
dehydrogenase NN NN O
] NN NN O
In NN NN O
28 NN NN O
families NN NN O
with NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
living NN NN O
in NN NN O
3 NN NN O
settlements NN NN O
of NN NN O
Shekii NN NN O
district NN NN O
of NN NN O
Azerbaijan NN NN O
11 NN NN O
G6PD NN NN O
variants NN NN O
of NN NN O
II NN NN O
and NN NN O
III NN NN O
classes NN NN O
differing NN NN O
by NN NN O
kinetic NN NN O
properties NN NN O
were NN NN O
identified NN NN O
according NN NN O
WHO NN NN O
program NN NN O
. NN NN O

9 NN NN O
of NN NN O
them NN NN O
are NN NN O
characterized NN NN O
with NN NN O
the NN NN O
same NN NN O
electrophoretic NN NN O
mobility NN NN O
. NN NN O

Comparison NN NN O
of NN NN O
G6PD NN NN O
spectra NN NN O
in NN NN O
two NN NN O
subpopulations NN NN O
and NN NN O
in NN NN O
a NN NN O
mixed NN NN O
group NN NN O
permits NN NN O
to NN NN O
make NN NN O
a NN NN O
conclusion NN NN O
about NN NN O
existence NN NN O
of NN NN O
common NN NN O
and NN NN O
rare NN NN O
G6PD NN NN O
alleles NN NN O
in NN NN O
examined NN NN O
population NN NN O
. NN NN O

They NN NN O
distribute NN NN O
by NN NN O
gene NN NN O
drift NN NN O
supported NN NN O
by NN NN O
natural NN NN O
selection NN NN O
. NN NN O

Among NN NN O
7 NN NN O
samples NN NN O
of NN NN O
G6PD NN NN O
with NN NN O
normal NN NN O
and NN NN O
increased NN NN O
activity NN NN O
two NN NN O
new NN NN O
variants NN NN O
of NN NN O
IV NN NN O
class NN NN O
-- NN NN O
Nukha NN NN O
and NN NN O
Bash-Kungut NN NN O
-- NN NN O
were NN NN O
found NN NN O
. NN NN O

. NN NN O

6524872 NN NN O
Adrenoleukodystrophy NN NN B-SpecificDisease
: NN NN O
survey NN NN O
of NN NN O
303 NN NN O
cases NN NN O
: NN NN O
biochemistry NN NN O
, NN NN O
diagnosis NN NN O
, NN NN O
and NN NN O
therapy NN NN O
. NN NN O

Adrenoleukodystrophy NN NN B-SpecificDisease
( NN NN O
ALD NN NN B-SpecificDisease
) NN NN O
is NN NN O
a NN NN O
genetically NN NN O
determined NN NN O
disorder NN NN O
associated NN NN O
with NN NN O
progressive NN NN B-DiseaseClass
central NN NN I-DiseaseClass
demyelination NN NN I-DiseaseClass
and NN NN O
adrenal NN NN B-DiseaseClass
cortical NN NN I-DiseaseClass
insufficiency NN NN I-DiseaseClass
. NN NN O

All NN NN O
affected NN NN O
persons NN NN O
show NN NN O
increased NN NN O
levels NN NN O
of NN NN O
saturated NN NN O
unbranched NN NN O
very-long-chain NN NN O
fatty NN NN O
acids NN NN O
, NN NN O
particularly NN NN O
hexacosanoate NN NN O
( NN NN O
C26 NN NN O
0 NN NN O
) NN NN O
, NN NN O
because NN NN O
of NN NN O
impaired NN NN O
capacity NN NN O
to NN NN O
degrade NN NN O
these NN NN O
acids NN NN O
. NN NN O

This NN NN O
degradation NN NN O
normally NN NN O
takes NN NN O
place NN NN O
in NN NN O
a NN NN O
subcellular NN NN O
organelle NN NN O
called NN NN O
the NN NN O
peroxisome NN NN O
, NN NN O
and NN NN O
ALD NN NN B-SpecificDisease
, NN NN O
together NN NN O
with NN NN O
Zellwegers NN NN B-SpecificDisease
cerebrohepatorenal NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
, NN NN O
is NN NN O
now NN NN O
considered NN NN O
to NN NN O
belong NN NN O
to NN NN O
the NN NN O
newly NN NN O
formed NN NN O
category NN NN O
of NN NN O
peroxisomal NN NN B-DiseaseClass
disorders NN NN I-DiseaseClass
. NN NN O

Biochemical NN NN O
assays NN NN O
permit NN NN O
prenatal NN NN O
diagnosis NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
identification NN NN O
of NN NN O
most NN NN O
heterozygotes NN NN O
. NN NN O

We NN NN O
have NN NN O
identified NN NN O
303 NN NN O
patients NN NN O
with NN NN O
ALD NN NN B-SpecificDisease
in NN NN O
217 NN NN O
kindreds NN NN O
. NN NN O

These NN NN O
patients NN NN O
show NN NN O
a NN NN O
wide NN NN O
phenotypic NN NN O
variation NN NN O
. NN NN O

Sixty NN NN O
percent NN NN O
of NN NN O
patients NN NN O
had NN NN O
childhood NN NN O
ALD NN NN B-SpecificDisease
and NN NN O
17 NN NN O
% NN NN O
adrenomyeloneuropathy NN NN B-SpecificDisease
, NN NN O
both NN NN O
of NN NN O
which NN NN O
are NN NN O
X-linked NN NN O
, NN NN O
with NN NN O
the NN NN O
gene NN NN O
mapped NN NN O
to NN NN O
Xq28 NN NN O
. NN NN O

Neonatal NN NN B-SpecificDisease
ALD NN NN I-SpecificDisease
, NN NN O
a NN NN O
distinct NN NN O
entity NN NN O
with NN NN O
autosomal NN NN O
recessive NN NN O
inheritance NN NN O
and NN NN O
points NN NN O
of NN NN O
resemblance NN NN O
to NN NN O
Zellwegers NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
, NN NN O
accounted NN NN O
for NN NN O
7 NN NN O
% NN NN O
of NN NN O
the NN NN O
cases NN NN O
. NN NN O

Although NN NN O
excess NN NN O
C26 NN NN O
0 NN NN O
in NN NN O
the NN NN O
brain NN NN O
of NN NN O
patients NN NN O
with NN NN O
ALD NN NN B-SpecificDisease
is NN NN O
partially NN NN O
of NN NN O
dietary NN NN O
origin NN NN O
, NN NN O
dietary NN NN O
C26 NN NN O
0 NN NN O
restriction NN NN O
did NN NN O
not NN NN O
produce NN NN O
clear NN NN O
benefit NN NN O
. NN NN O

Bone NN NN O
marrow NN NN O
transplant NN NN O
lowered NN NN O
the NN NN O
plasma NN NN O
C26 NN NN O
0 NN NN O
level NN NN O
but NN NN O
failed NN NN O
to NN NN O
arrest NN NN O
neurological NN NN O
progression NN NN O
. NN NN O

. NN NN O

6540752 NN NN O
Genetic NN NN O
polymorphism NN NN O
of NN NN O
G6PD NN NN O
in NN NN O
a NN NN O
Bulgarian NN NN O
population NN NN O
. NN NN O

Considerable NN NN O
genetic NN NN O
heterogeneity NN NN O
in NN NN O
G6PD NN NN O
was NN NN O
found NN NN O
in NN NN O
the NN NN O
Bulgarian NN NN O
population-14 NN NN O
G6PD NN NN O
variants NN NN O
isolated NN NN O
from NN NN O
117 NN NN O
hemizygous NN NN O
carriers NN NN O
of NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

Of NN NN O
these NN NN O
, NN NN O
G6PD NN NN O
Mediterranean NN NN O
type NN NN O
was NN NN O
a NN NN O
polymorphic NN NN O
variant NN NN O
and NN NN O
G6PD NN NN O
Corinth NN NN O
occurred NN NN O
with NN NN O
high NN NN O
frequency NN NN O
. NN NN O

Two NN NN O
new NN NN O
variants NN NN O
were NN NN O
identified-G6PD NN NN O
Rudosem NN NN O
and NN NN O
G6PD NN NN O
Nedelino NN NN O
. NN NN O

In NN NN O
a NN NN O
selected NN NN O
group NN NN O
of NN NN O
78 NN NN O
subjects NN NN O
with NN NN O
clinical NN NN O
manifestations NN NN O
, NN NN O
four NN NN O
variants NN NN O
were NN NN O
established NN NN O
G6PD NN NN O
Mediterranian NN NN O
, NN NN O
G6PD NN NN O
Corinth NN NN O
, NN NN O
G6PD NN NN O
Seattle NN NN O
and NN NN O
G6PD NN NN O
Ohut NN NN O
II NN NN O
. NN NN O

. NN NN O

6585184 NN NN O
Clinical NN NN O
use NN NN O
of NN NN O
DNA NN NN O
markers NN NN O
linked NN NN O
to NN NN O
the NN NN O
gene NN NN O
for NN NN O
Duchenne NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
. NN NN O

Seventy NN NN O
families NN NN O
with NN NN O
Duchenne NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DMD NN NN B-SpecificDisease
) NN NN O
known NN NN O
to NN NN O
the NN NN O
Institute NN NN O
of NN NN O
Child NN NN O
Health NN NN O
fall NN NN O
into NN NN O
three NN NN O
categories NN NN O
with NN NN O
respect NN NN O
to NN NN O
potential NN NN O
linkage NN NN O
analysis NN NN O
with NN NN O
the NN NN O
X NN NN O
chromosome NN NN O
DNA NN NN O
markers NN NN O
RC8 NN NN O
and NN NN O
L1 NN NN O
. NN NN O

28 NN NN O
that NN NN O
bridge NN NN O
the NN NN O
DMD NN NN B-Modifier
gene NN NN O
. NN NN O

Families NN NN O
in NN NN O
which NN NN O
there NN NN O
is NN NN O
at NN NN O
least NN NN O
one NN NN O
obligatory NN NN O
female NN NN O
heterozygote NN NN O
( NN NN O
n NN NN O
= NN NN O
13 NN NN O
) NN NN O
. NN NN O

Here NN NN O
prediction NN NN O
and NN NN O
exclusion NN NN O
of NN NN O
DMD NN NN B-Modifier
gene NN NN O
transmission NN NN O
may NN NN O
be NN NN O
possible NN NN O
, NN NN O
the NN NN O
accuracy NN NN O
being NN NN O
dependent NN NN O
on NN NN O
the NN NN O
closeness NN NN O
of NN NN O
the NN NN O
linkage NN NN O
of NN NN O
the NN NN O
DNA NN NN O
marker NN NN O
( NN NN O
s NN NN O
) NN NN O
to NN NN O
the NN NN O
DMD NN NN B-Modifier
gene NN NN O
; NN NN O
an NN NN O
illustrative NN NN O
case NN NN O
is NN NN O
reported NN NN O
. NN NN O

Families NN NN O
in NN NN O
which NN NN O
there NN NN O
is NN NN O
a NN NN O
single NN NN O
affected NN NN O
boy NN NN O
, NN NN O
who NN NN O
also NN NN O
has NN NN O
one NN NN O
or NN NN O
more NN NN O
healthy NN NN O
brothers NN NN O
( NN NN O
n NN NN O
= NN NN O
26 NN NN O
) NN NN O
. NN NN O

Given NN NN O
an NN NN O
informative NN NN O
restriction NN NN O
fragment NN NN O
length NN NN O
polymorphism NN NN O
( NN NN O
RFLP NN NN O
) NN NN O
, NN NN O
the NN NN O
probability NN NN O
that NN NN O
the NN NN O
boy NN NN O
represents NN NN O
a NN NN O
new NN NN O
mutation NN NN O
can NN NN O
be NN NN O
reassessed NN NN O
; NN NN O
it NN NN O
is NN NN O
also NN NN O
possible NN NN O
to NN NN O
exclude NN NN O
the NN NN O
DMD NN NN B-Modifier
gene NN NN O
in NN NN O
a NN NN O
sister NN NN O
. NN NN O

Families NN NN O
with NN NN O
a NN NN O
single NN NN O
affected NN NN O
boy NN NN O
with NN NN O
no NN NN O
brother NN NN O
( NN NN O
n NN NN O
= NN NN O
30 NN NN O
) NN NN O
. NN NN O

Here NN NN O
exclusion NN NN O
of NN NN O
the NN NN O
DMD NN NN B-Modifier
gene NN NN O
in NN NN O
a NN NN O
sister NN NN O
may NN NN O
be NN NN O
possible NN NN O
. NN NN O

Only NN NN O
in NN NN O
one NN NN O
family NN NN O
was NN NN O
there NN NN O
no NN NN O
possibility NN NN O
of NN NN O
useful NN NN O
linkage NN NN O
analysis NN NN O
. NN NN O

The NN NN O
linkage NN NN O
analysis NN NN O
required NN NN O
is NN NN O
described NN NN O
, NN NN O
and NN NN O
the NN NN O
need NN NN O
to NN NN O
check NN NN O
DMD NN NN B-Modifier
families NN NN O
for NN NN O
informative NN NN O
RFLPs NN NN O
is NN NN O
stressed NN NN O
. NN NN O

6604602 NN NN O
Family NN NN O
studies NN NN O
in NN NN O
Bechterew NN NN B-SpecificDisease
's NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
ankylosing NN NN B-SpecificDisease
spondylitis NN NN I-SpecificDisease
) NN NN O
III NN NN O
. NN NN O

Genetics NN NN O
. NN NN O

The NN NN O
results NN NN O
of NN NN O
segregation NN NN O
analyses NN NN O
in NN NN O
75 NN NN O
families NN NN O
where NN NN O
the NN NN O
proband NN NN O
had NN NN O
ankylosing NN NN B-SpecificDisease
spondylitis NN NN I-SpecificDisease
, NN NN O
are NN NN O
presented NN NN O
. NN NN O

Of NN NN O
the NN NN O
278 NN NN O
adult NN NN O
, NN NN O
living NN NN O
first NN NN O
degree NN NN O
relatives NN NN O
, NN NN O
approximately NN NN O
85 NN NN O
% NN NN O
cooperated NN NN O
in NN NN O
the NN NN O
study NN NN O
. NN NN O

Clinical NN NN O
and NN NN O
radiographical NN NN O
examinations NN NN O
were NN NN O
performed NN NN O
and NN NN O
HLA NN NN O
typing NN NN O
was NN NN O
conducted NN NN O
. NN NN O

The NN NN O
results NN NN O
were NN NN O
in NN NN O
agreement NN NN O
with NN NN O
our NN NN O
hypothesis NN NN O
that NN NN O
ankylosing NN NN B-SpecificDisease
spondylitis NN NN I-SpecificDisease
is NN NN O
part NN NN O
of NN NN O
a NN NN O
syndrome NN NN O
where NN NN O
different NN NN O
genetic NN NN O
factors NN NN O
interact NN NN O
. NN NN O

Such NN NN O
known NN NN O
factors NN NN O
are NN NN O
HLA NN NN O
B27 NN NN O
associated NN NN O
disease NN NN O
susceptibility NN NN O
, NN NN O
susceptibility NN NN O
to NN NN O
psoriatic NN NN B-SpecificDisease
arthropathy NN NN I-SpecificDisease
and NN NN O
susceptibility NN NN O
to NN NN O
entero-arthropathy NN NN B-SpecificDisease
. NN NN O

Radiographical NN NN O
sacro-iliitis NN NN B-SpecificDisease
was NN NN O
restricted NN NN O
to NN NN O
HLA NN NN O
B27 NN NN O
positive NN NN O
relatives NN NN O
, NN NN O
and NN NN O
was NN NN O
more NN NN O
frequently NN NN O
found NN NN O
in NN NN O
relatives NN NN O
to NN NN O
probands NN NN O
with NN NN O
psoriasis NN NN B-SpecificDisease
than NN NN O
in NN NN O
relatives NN NN O
to NN NN O
probands NN NN O
without NN NN O
psoriasis NN NN B-SpecificDisease
. NN NN O

Environmental NN NN O
factors NN NN O
( NN NN O
intestinal NN NN O
bacteria NN NN O
) NN NN O
are NN NN O
known NN NN O
to NN NN O
trigger NN NN O
the NN NN O
disease NN NN O
at NN NN O
least NN NN O
in NN NN O
some NN NN O
persons NN NN O
, NN NN O
and NN NN O
we NN NN O
have NN NN O
postulated NN NN O
that NN NN O
all NN NN O
or NN NN O
most NN NN O
of NN NN O
them NN NN O
have NN NN O
the NN NN O
predisposition NN NN O
to NN NN O
develop NN NN O
disease NN NN O
. NN NN O

Thus NN NN O
, NN NN O
the NN NN O
syndrome NN NN O
has NN NN O
a NN NN O
multifactorial NN NN O
etiology NN NN O
. NN NN O

The NN NN O
phenotypic NN NN O
expressions NN NN O
of NN NN O
the NN NN O
different NN NN O
genetic NN NN O
predispositions NN NN O
involved NN NN O
, NN NN O
include NN NN O
sacro-iliitis NN NN B-SpecificDisease
, NN NN O
psoriasis NN NN B-SpecificDisease
, NN NN O
acute NN NN B-SpecificDisease
anterior NN NN I-SpecificDisease
uveitis NN NN I-SpecificDisease
, NN NN O
peripheral NN NN O
arthropathy NN NN B-SpecificDisease
and NN NN O
inflammatory NN NN B-SpecificDisease
bowel NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

We NN NN O
suggest NN NN O
the NN NN O
descriptive NN NN O
name NN NN O
HEREDITARY NN NN B-SpecificDisease
MULTIFOCAL NN NN I-SpecificDisease
RELAPSING NN NN I-SpecificDisease
INFLAMMATION NN NN I-SpecificDisease
( NN NN O
HEMRI NN NN B-SpecificDisease
) NN NN O
for NN NN O
this NN NN O
syndrome NN NN O
. NN NN O

Ankylosing NN NN B-SpecificDisease
spondylitis NN NN I-SpecificDisease
, NN NN O
psoriatic NN NN B-SpecificDisease
arthropathy NN NN I-SpecificDisease
and NN NN O
entero-arthropathy NN NN B-SpecificDisease
may NN NN O
be NN NN O
regarded NN NN O
as NN NN O
clinical NN NN O
sub-types NN NN O
of NN NN O
the NN NN O
syndrome NN NN O
. NN NN O

. NN NN O

6618488 NN NN O
Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
and NN NN O
chromosome NN NN O
15 NN NN O
. NN NN O

A NN NN O
clinical NN NN O
discussion NN NN O
of NN NN O
20 NN NN O
cases NN NN O
. NN NN O

A NN NN O
chromosome NN NN B-SpecificDisease
15 NN NN I-SpecificDisease
anomaly NN NN I-SpecificDisease
was NN NN O
observed NN NN O
in NN NN O
12 NN NN O
of NN NN O
20 NN NN O
patients NN NN O
, NN NN O
17 NN NN O
of NN NN O
whom NN NN O
were NN NN O
clinically NN NN O
suspected NN NN O
of NN NN O
having NN NN O
Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
PWS NN NN B-SpecificDisease
) NN NN O
. NN NN O

The NN NN O
clinical NN NN O
features NN NN O
of NN NN O
eight NN NN O
cases NN NN O
with NN NN O
15q11-12 NN NN O
deletion NN NN O
were NN NN O
very NN NN O
similar NN NN O
to NN NN O
those NN NN O
originally NN NN O
described NN NN O
in NN NN O
PWS NN NN B-SpecificDisease
. NN NN O

On NN NN O
the NN NN O
other NN NN O
hand NN NN O
, NN NN O
the NN NN O
group NN NN O
of NN NN O
normal NN NN O
karyotype NN NN O
patients NN NN O
is NN NN O
heterogeneous NN NN O
, NN NN O
and NN NN O
their NN NN O
features NN NN O
do NN NN O
not NN NN O
strictly NN NN O
correspond NN NN O
to NN NN O
the NN NN O
clinical NN NN O
definition NN NN O
of NN NN O
PWS NN NN B-SpecificDisease
. NN NN O

However NN NN O
, NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
PWS NN NN B-SpecificDisease
is NN NN O
associated NN NN O
with NN NN O
deletion NN NN O
of NN NN O
15q11-12 NN NN O
can NN NN O
neither NN NN O
explain NN NN O
the NN NN O
apparently NN NN O
balanced NN NN O
translocations NN NN O
of NN NN O
chromosome NN NN O
15 NN NN O
nor NN NN O
account NN NN O
for NN NN O
the NN NN O
small NN NN O
supernumerary NN NN O
metacentric NN NN O
chromosomes NN NN O
corresponding NN NN O
to NN NN O
an NN NN O
isochromosome NN NN O
15 NN NN O
for NN NN O
band NN NN O
15q11 NN NN O
observed NN NN O
in NN NN O
some NN NN O
cases NN NN O
. NN NN O

. NN NN O

6650504 NN NN O
The NN NN O
Tay-Sachs NN NN B-Modifier
disease NN NN I-Modifier
gene NN NN O
in NN NN O
North NN NN O
American NN NN O
Jewish NN NN O
populations NN NN O
: NN NN O
geographic NN NN O
variations NN NN O
and NN NN O
origin NN NN O
. NN NN O

From NN NN O
data NN NN O
collected NN NN O
in NN NN O
a NN NN O
North NN NN O
American NN NN O
Tay-Sachs NN NN B-Modifier
disease NN NN I-Modifier
( NN NN O
TSD NN NN B-Modifier
) NN NN O
heterozygote NN NN O
screening NN NN O
program NN NN O
, NN NN O
the NN NN O
TSD NN NN B-Modifier
carrier NN NN O
frequency NN NN O
among NN NN O
46 NN NN O
, NN NN O
304 NN NN O
Jewish NN NN O
individuals NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
. NN NN O

0324 NN NN O
( NN NN O
1 NN NN O
in NN NN O
31 NN NN O
individuals NN NN O
) NN NN O
. NN NN O

This NN NN O
frequency NN NN O
is NN NN O
consistent NN NN O
with NN NN O
earlier NN NN O
estimates NN NN O
based NN NN O
on NN NN O
TSD NN NN B-Modifier
incidence NN NN O
data NN NN O
. NN NN O

TSD NN NN B-Modifier
carrier NN NN O
frequencies NN NN O
were NN NN O
then NN NN O
examined NN NN O
by NN NN O
single NN NN O
country NN NN O
and NN NN O
single NN NN O
region NN NN O
of NN NN O
origin NN NN O
in NN NN O
28 NN NN O
, NN NN O
029 NN NN O
Jews NN NN O
within NN NN O
this NN NN O
sample NN NN O
for NN NN O
whom NN NN O
such NN NN O
data NN NN O
were NN NN O
available NN NN O
for NN NN O
analysis NN NN O
. NN NN O

Jews NN NN O
with NN NN O
Polish NN NN O
and NN NN O
/ NN NN O
or NN NN O
Russian NN NN O
ancestry NN NN O
constituted NN NN O
88 NN NN O
% NN NN O
of NN NN O
this NN NN O
sample NN NN O
and NN NN O
had NN NN O
a NN NN O
TSD NN NN B-Modifier
carrier NN NN O
frequency NN NN O
of NN NN O
. NN NN O

0327 NN NN O
. NN NN O

No NN NN O
TSD NN NN B-Modifier
carriers NN NN O
were NN NN O
observed NN NN O
among NN NN O
the NN NN O
166 NN NN O
Jews NN NN O
of NN NN O
Near NN NN O
Eastern NN NN O
origins NN NN O
. NN NN O

Relative NN NN O
to NN NN O
Jews NN NN O
of NN NN O
Polish NN NN O
and NN NN O
Russian NN NN O
origins NN NN O
, NN NN O
there NN NN O
was NN NN O
at NN NN O
least NN NN O
a NN NN O
twofold NN NN O
increase NN NN O
in NN NN O
the NN NN O
TSD NN NN B-Modifier
carrier NN NN O
frequency NN NN O
in NN NN O
Jews NN NN O
of NN NN O
Austrian NN NN O
, NN NN O
Hungarian NN NN O
, NN NN O
and NN NN O
Czechoslovakian NN NN O
origins NN NN O
( NN NN O
P NN NN O
less NN NN O
than NN NN O
. NN NN O

005 NN NN O
) NN NN O
. NN NN O

These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
the NN NN O
TSD NN NN B-Modifier
gene NN NN O
proliferated NN NN O
among NN NN O
the NN NN O
antecedents NN NN O
of NN NN O
modern NN NN O
Ashkenazi NN NN O
Jewry NN NN O
after NN NN O
the NN NN O
Second NN NN O
Diaspora NN NN O
( NN NN O
70 NN NN O
A NN NN O
. NN NN O

D NN NN O
. NN NN O
) NN NN O

and NN NN O
before NN NN O
their NN NN O
major NN NN O
migrations NN NN O
to NN NN O
regions NN NN O
of NN NN O
Poland NN NN O
and NN NN O
Russia NN NN O
( NN NN O
before NN NN O
1100 NN NN O
A NN NN O
. NN NN O

D NN NN O
. NN NN O
) NN NN O

. NN NN O

6783144 NN NN O
Human NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
sixth NN NN I-SpecificDisease
component NN NN I-SpecificDisease
of NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
meningococcal NN NN B-SpecificDisease
meningitis NN NN I-SpecificDisease
and NN NN O
no NN NN O
haemostasis NN NN B-DiseaseClass
abnormality NN NN I-DiseaseClass
. NN NN O

A NN NN O
case NN NN O
of NN NN O
human NN NN O
complete NN NN O
C6 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
is NN NN O
reported NN NN O
. NN NN O

The NN NN O
patient NN NN O
, NN NN O
a NN NN O
31 NN NN O
year NN NN O
old NN NN O
white NN NN O
male NN NN O
, NN NN O
was NN NN O
seen NN NN O
on NN NN O
the NN NN O
occasion NN NN O
of NN NN O
an NN NN O
isolated NN NN O
episode NN NN O
of NN NN O
meningococcal NN NN B-SpecificDisease
meningitis NN NN I-SpecificDisease
. NN NN O

Serum NN NN O
complement NN NN O
hemolytic NN NN O
and NN NN O
bactericidal NN NN O
activities NN NN O
were NN NN O
lacking NN NN O
and NN NN O
could NN NN O
be NN NN O
restored NN NN O
to NN NN O
normal NN NN O
by NN NN O
addition NN NN O
of NN NN O
appropriate NN NN O
amounts NN NN O
of NN NN O
purified NN NN O
C6 NN NN O
. NN NN O

No NN NN O
hemostatic NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
were NN NN O
observed NN NN O
. NN NN O

. NN NN O

6859721 NN NN O
Absence NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
seventh NN NN I-SpecificDisease
component NN NN I-SpecificDisease
of NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
chronic NN NN B-SpecificDisease
meningococcemia NN NN I-SpecificDisease
presenting NN NN O
as NN NN O
vasculitis NN NN B-SpecificDisease
. NN NN O

A NN NN O
previously NN NN O
healthy NN NN O
40-year-old NN NN O
man NN NN O
presenting NN NN O
with NN NN O
fever NN NN B-SpecificDisease
, NN NN O
arthritis NN NN B-SpecificDisease
, NN NN O
and NN NN O
cutaneous NN NN B-SpecificDisease
vasculitis NN NN I-SpecificDisease
was NN NN O
found NN NN O
to NN NN O
have NN NN O
chronic NN NN B-SpecificDisease
meningococcemia NN NN I-SpecificDisease
. NN NN O

Evaluation NN NN O
of NN NN O
his NN NN O
complement NN NN O
system NN NN O
showed NN NN O
an NN NN O
absence NN NN O
of NN NN O
functional NN NN O
and NN NN O
antigenic NN NN O
C7 NN NN O
, NN NN O
compatible NN NN O
with NN NN O
a NN NN O
complete NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
seventh NN NN I-SpecificDisease
component NN NN I-SpecificDisease
of NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
. NN NN O

Study NN NN O
of NN NN O
the NN NN O
patients NN NN O
family NN NN O
spanning NN NN O
four NN NN O
generations NN NN O
showed NN NN O
heterozygous NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
C7 NN NN I-SpecificDisease
in NN NN O
five NN NN O
members NN NN O
. NN NN O

Chronic NN NN B-SpecificDisease
neisserial NN NN I-SpecificDisease
infection NN NN I-SpecificDisease
can NN NN O
be NN NN O
associated NN NN O
with NN NN O
C7 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
and NN NN O
must NN NN O
be NN NN O
distinguished NN NN O
from NN NN O
other NN NN O
causes NN NN O
of NN NN O
cutaneous NN NN B-SpecificDisease
vasculitis NN NN I-SpecificDisease
. NN NN O

. NN NN O

6902670 NN NN O
Familial NN NN B-SpecificDisease
discoid NN NN I-SpecificDisease
lupus NN NN I-SpecificDisease
erythematosus NN NN I-SpecificDisease
associated NN NN O
with NN NN O
heterozygote NN NN O
C2 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

Two NN NN O
siblings NN NN O
with NN NN O
chronic NN NN B-SpecificDisease
discoid NN NN I-SpecificDisease
lupus NN NN I-SpecificDisease
erythematosus NN NN I-SpecificDisease
and NN NN O
several NN NN O
family NN NN O
members NN NN O
were NN NN O
found NN NN O
with NN NN O
heterozygous NN NN O
C2 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

An NN NN O
association NN NN O
with NN NN O
histocompatibility NN NN O
markers NN NN O
HLA-B18 NN NN O
and NN NN O
HLA-Dw2 NN NN O
was NN NN O
demonstrated NN NN O
, NN NN O
and NN NN O
the NN NN O
slow NN NN O
allotype NN NN O
of NN NN O
factor NN NN O
B NN NN O
was NN NN O
present NN NN O
. NN NN O

Linkage NN NN O
studies NN NN O
in NN NN O
this NN NN O
family NN NN O
suggested NN NN O
a NN NN O
close NN NN O
linkage NN NN O
between NN NN O
the NN NN O
C2 NN NN B-Modifier
deficiency NN NN I-Modifier
gene NN NN O
and NN NN O
genes NN NN O
coding NN NN O
for NN NN O
B18 NN NN O
, NN NN O
Dw2 NN NN O
, NN NN O
and NN NN O
BfS NN NN O
antigens NN NN O
. NN NN O

One NN NN O
HLA-ACB NN NN O
/ NN NN O
DBf NN NN O
recombinant NN NN O
was NN NN O
observed NN NN O
showing NN NN O
closer NN NN O
linkage NN NN O
between NN NN O
HLA-D NN NN O
and NN NN O
Bf NN NN O
than NN NN O
between NN NN O
HLA-B NN NN O
and NN NN O
Bf NN NN O
. NN NN O

. NN NN O

7055648 NN NN O
Severe-glucose-6-phosphate NN NN B-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
( NN NN I-SpecificDisease
G6PD NN NN I-SpecificDisease
) NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
associated NN NN O
with NN NN O
chronic NN NN O
hemolytic NN NN B-SpecificDisease
anemia NN NN I-SpecificDisease
, NN NN O
granulocyte NN NN B-DiseaseClass
dysfunction NN NN I-DiseaseClass
, NN NN O
and NN NN O
increased NN NN O
susceptibility NN NN O
to NN NN O
infections NN NN O
: NN NN O
description NN NN O
of NN NN O
a NN NN O
new NN NN O
molecular NN NN O
variant NN NN O
( NN NN O
G6PD NN NN O
Barcelona NN NN O
) NN NN O
. NN NN O

Molecular NN NN O
, NN NN O
kinetic NN NN O
, NN NN O
and NN NN O
functional NN NN O
studies NN NN O
were NN NN O
carried NN NN O
out NN NN O
on NN NN O
erythrocytes NN NN O
and NN NN O
leukocytes NN NN O
in NN NN O
a NN NN O
Spanish NN NN O
male NN NN O
with NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
, NN NN O
congenital NN NN B-SpecificDisease
nonspherocytic NN NN I-SpecificDisease
hemolytic NN NN I-SpecificDisease
anemia NN NN I-SpecificDisease
( NN NN O
CNSHA NN NN B-SpecificDisease
) NN NN O
, NN NN O
and NN NN O
increased NN NN O
susceptibility NN NN O
to NN NN O
infections NN NN O
. NN NN O

G6PD NN NN O
activity NN NN O
was NN NN O
absent NN NN O
in NN NN O
patients NN NN O
red NN NN O
cells NN NN O
and NN NN O
was NN NN O
about NN NN O
2 NN NN O
% NN NN O
of NN NN O
normal NN NN O
in NN NN O
leukocytes NN NN O
. NN NN O

Molecular NN NN O
studies NN NN O
using NN NN O
standard NN NN O
methods NN NN O
( NN NN O
WHO NN NN O
, NN NN O
1967 NN NN O
) NN NN O
showed NN NN O
G6PD NN NN O
in NN NN O
the NN NN O
patient NN NN O
to NN NN O
have NN NN O
a NN NN O
slightly NN NN O
fast NN NN O
electrophoretic NN NN O
mobility NN NN O
at NN NN O
pH NN NN O
8 NN NN O
. NN NN O

0 NN NN O
with NN NN O
otherwise NN NN O
normal NN NN O
properties NN NN O
( NN NN O
heat NN NN O
stability NN NN O
at NN NN O
46 NN NN O
degrees NN NN O
C NN NN O
, NN NN O
apparent NN NN O
affinity NN NN O
for NN NN O
substrates NN NN O
, NN NN O
optimum NN NN O
pH NN NN O
, NN NN O
and NN NN O
utilization NN NN O
of NN NN O
substrate NN NN O
analogues NN NN O
) NN NN O
. NN NN O

Other NN NN O
tests NN NN O
showed NN NN O
the NN NN O
patients NN NN O
granulocytes NN NN O
to NN NN O
engulf NN NN O
latex NN NN O
particles NN NN O
normally NN NN O
, NN NN O
but NN NN O
to NN NN O
have NN NN O
impaired NN NN O
reduction NN NN O
of NN NN O
nitroblue NN NN O
tetrazolium NN NN O
and NN NN O
ferricytochrome-c NN NN O
as NN NN O
well NN NN O
as NN NN O
reduced NN NN O
iodination NN NN O
. NN NN O

Chemotaxis NN NN O
and NN NN O
random NN NN O
migration NN NN O
of NN NN O
the NN NN O
patients NN NN O
granulocytes NN NN O
were NN NN O
normal NN NN O
as NN NN O
were NN NN O
myeloperoxidase NN NN O
, NN NN O
leukocyte NN NN O
alkaline NN NN O
phosphatase NN NN O
( NN NN O
LAP NN NN O
) NN NN O
, NN NN O
and NN NN O
ultrastructural NN NN O
features NN NN O
. NN NN O

The NN NN O
molecular NN NN O
characteristics NN NN O
of NN NN O
G6PD NN NN O
in NN NN O
the NN NN O
patient NN NN O
differed NN NN O
from NN NN O
those NN NN O
of NN NN O
all NN NN O
previously NN NN O
reported NN NN O
variants NN NN O
associated NN NN O
with NN NN O
CNSHA NN NN B-SpecificDisease
, NN NN O
so NN NN O
the NN NN O
present NN NN O
variant NN NN O
was NN NN O
provisionally NN NN O
called NN NN O
G6PD NN NN O
Barcelona NN NN O
to NN NN O
distinguish NN NN O
it NN NN O
from NN NN O
other NN NN O
G6PD NN NN O
variants NN NN O
previously NN NN O
described NN NN O
. NN NN O

Possible NN NN O
mechanisms NN NN O
for NN NN O
the NN NN O
severe NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
G6PD NN NN I-SpecificDisease
in NN NN O
erythrocytes NN NN O
and NN NN O
granulocytes NN NN O
was NN NN O
investigated NN NN O
by NN NN O
studies NN NN O
on NN NN O
the NN NN O
immunologic NN NN O
specific NN NN O
activity NN NN O
of NN NN O
the NN NN O
mutant NN NN O
enzyme NN NN O
. NN NN O

7076260 NN NN O
Glucose-6-phosphate NN NN B-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
Papua NN NN O
New NN NN O
Guinea NN NN O
. NN NN O

The NN NN O
description NN NN O
of NN NN O
13 NN NN O
new NN NN O
variants NN NN O
. NN NN O

A NN NN O
total NN NN O
of NN NN O
362 NN NN O
males NN NN O
from NN NN O
various NN NN O
regions NN NN O
of NN NN O
Papua NN NN O
New NN NN O
Guinea NN NN O
were NN NN O
screened NN NN O
for NN NN O
red NN NN O
cell NN NN O
glucose-6-phosphate NN NN O
dehydrogenase NN NN O
( NN NN O
G6PD NN NN O
) NN NN O
activity NN NN O
. NN NN O

Twenty-six NN NN O
G6PD NN NN B-Modifier
deficient NN NN I-Modifier
individuals NN NN O
were NN NN O
identified NN NN O
. NN NN O

Biochemical NN NN O
characterization NN NN O
of NN NN O
G6PD NN NN O
purified NN NN O
from NN NN O
these NN NN O
subjects NN NN O
has NN NN O
revealed NN NN O
13 NN NN O
new NN NN O
variants NN NN O
and NN NN O
several NN NN O
copies NN NN O
of NN NN O
previously NN NN O
described NN NN O
forms NN NN O
of NN NN O
G6PD NN NN O
. NN NN O

This NN NN O
study NN NN O
illustrates NN NN O
the NN NN O
extreme NN NN O
heterogeneity NN NN O
of NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
among NN NN O
the NN NN O
people NN NN O
of NN NN O
Papua NN NN O
New NN NN O
Guinea NN NN O
. NN NN O

. NN NN O

7106752 NN NN O
Heterogeneity NN NN O
of NN NN O
`` NN NN O
Mediterranean NN NN O
type NN NN O
'' NN NN O
glucose-6-phosphate NN NN B-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
( NN NN I-SpecificDisease
G6PD NN NN I-SpecificDisease
) NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
Spain NN NN O
and NN NN O
description NN NN O
of NN NN O
two NN NN O
new NN NN O
variants NN NN O
associated NN NN O
with NN NN O
favism NN NN B-SpecificDisease
. NN NN O

Glucose-6-phosphate NN NN O
dehydrogenase NN NN O
( NN NN O
G6PD NN NN O
) NN NN O
; NN NN O
EC NN NN O
1 NN NN O
. NN NN O

1 NN NN O
. NN NN O

1 NN NN O
. NN NN O

49 NN NN O
from NN NN O
thirty-six NN NN O
unrelated NN NN O
Spanish NN NN O
males NN NN O
was NN NN O
partially NN NN O
purified NN NN O
from NN NN O
blood NN NN O
, NN NN O
and NN NN O
the NN NN O
variants NN NN O
were NN NN O
characterized NN NN O
biochemically NN NN O
and NN NN O
electrophoretically NN NN O
according NN NN O
to NN NN O
the NN NN O
methods NN NN O
recommended NN NN O
by NN NN O
the NN NN O
world NN NN O
Health NN NN O
Organization NN NN O
. NN NN O

Subjects NN NN O
were NN NN O
from NN NN O
multiple NN NN O
geographic NN NN O
regions NN NN O
within NN NN O
Spain NN NN O
, NN NN O
and NN NN O
all NN NN O
suffered NN NN O
from NN NN O
hemolytic NN NN B-SpecificDisease
anemia NN NN I-SpecificDisease
, NN NN O
either NN NN O
acute NN NN O
( NN NN O
34 NN NN O
cases NN NN O
) NN NN O
or NN NN O
chronic NN NN O
nonspherocytic NN NN O
( NN NN O
2 NN NN O
cases NN NN O
) NN NN O
. NN NN O

Almost NN NN O
all NN NN O
the NN NN O
variants NN NN O
studied NN NN O
presented NN NN O
residual NN NN O
erythrocyte NN NN O
G6PD NN NN O
activity NN NN O
ranging NN NN O
from NN NN O
0 NN NN O
to NN NN O
10 NN NN O
% NN NN O
of NN NN O
normal NN NN O
, NN NN O
and NN NN O
five NN NN O
different NN NN O
mutants NN NN O
were NN NN O
responsible NN NN O
for NN NN O
the NN NN O
deficient NN NN O
phenotype NN NN O
. NN NN O

Three NN NN O
variants NN NN O
were NN NN O
similar NN NN O
to NN NN O
others NN NN O
previously NN NN O
described NN NN O
G6PD NN NN O
Mediterranean NN NN O
( NN NN O
11 NN NN O
cases NN NN O
) NN NN O
, NN NN O
G6PD NN NN O
Athens-like NN NN O
( NN NN O
3 NN NN O
cases NN NN O
) NN NN O
, NN NN O
and NN NN O
G6PD NN NN O
Union NN NN O
( NN NN O
2 NN NN O
cases NN NN O
) NN NN O
. NN NN O

The NN NN O
remaining NN NN O
variants NN NN O
were NN NN O
different NN NN O
from NN NN O
the NN NN O
numerous NN NN O
variants NN NN O
already NN NN O
reported NN NN O
and NN NN O
have NN NN O
been NN NN O
considered NN NN O
as NN NN O
new NN NN O
mutants NN NN O
. NN NN O

Provisionally NN NN O
they NN NN O
are NN NN O
called NN NN O
G6PD NN NN O
Betica NN NN O
( NN NN O
19 NN NN O
cases NN NN O
) NN NN O
and NN NN O
G6PD NN NN O
Menorca NN NN O
( NN NN O
1 NN NN O
case NN NN O
) NN NN O
. NN NN O

The NN NN O
present NN NN O
study NN NN O
constitutes NN NN O
the NN NN O
first NN NN O
attempt NN NN O
to NN NN O
characterize NN NN O
the NN NN O
deficient NN NN B-Modifier
G6PD NN NN I-Modifier
variants NN NN O
found NN NN O
in NN NN O
Spain NN NN O
and NN NN O
supplies NN NN O
new NN NN O
data NN NN O
on NN NN O
the NN NN O
relationship NN NN O
between NN NN O
molecular NN NN O
characteristics NN NN O
of NN NN O
deficient NN NN O
variants NN NN O
and NN NN O
their NN NN O
clinical NN NN O
manifestations NN NN O
. NN NN O

The NN NN O
most NN NN O
important NN NN O
findings NN NN O
can NN NN O
be NN NN O
summarized NN NN O
as NN NN O
follows NN NN O
( NN NN O
1 NN NN O
) NN NN O
The NN NN O
Spanish NN NN O
population NN NN O
is NN NN O
characterized NN NN O
by NN NN O
an NN NN O
important NN NN O
heterogeneity NN NN O
in NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

( NN NN O
2 NN NN O
) NN NN O
Although NN NN O
G6PD NN NN O
Mediterranean NN NN O
is NN NN O
very NN NN O
frequent NN NN O
, NN NN O
it NN NN O
presents NN NN O
a NN NN O
relatively NN NN O
high NN NN O
degree NN NN O
of NN NN O
polymorphism NN NN O
. NN NN O

( NN NN O
3 NN NN O
) NN NN O
Favism NN NN B-SpecificDisease
has NN NN O
been NN NN O
observed NN NN O
associated NN NN O
with NN NN O
all NN NN O
kinds NN NN O
of NN NN O
variants NN NN O
described NN NN O
here NN NN O
. NN NN O

( NN NN O
4 NN NN O
) NN NN O
G6PD NN NN O
Betica NN NN O
, NN NN O
which NN NN O
is NN NN O
the NN NN O
most NN NN O
frequent NN NN O
variant NN NN O
found NN NN O
in NN NN O
subjects NN NN O
of NN NN O
Southern NN NN O
Spanish NN NN O
origin NN NN O
, NN NN O
has NN NN O
been NN NN O
observed NN NN O
associated NN NN O
with NN NN O
favism NN NN B-SpecificDisease
in NN NN O
all NN NN O
cases NN NN O
except NN NN O
one NN NN O
. NN NN O

7166314 NN NN O
A NN NN O
new NN NN O
glucose-6-phosphate NN NN O
dehydrogenase NN NN O
variant NN NN O
( NN NN O
G6PD NN NN O
Nagano NN NN O
) NN NN O
associated NN NN O
with NN NN O
congenital NN NN B-SpecificDisease
hemolytic NN NN I-SpecificDisease
anemia NN NN I-SpecificDisease
. NN NN O

A NN NN O
new NN NN O
glucose-6-phosphate NN NN O
dehydrogenase NN NN O
( NN NN O
G6PD NN NN O
) NN NN O
variant NN NN O
associated NN NN O
with NN NN O
chronic NN NN B-SpecificDisease
nonspherocytic NN NN I-SpecificDisease
hemolytic NN NN I-SpecificDisease
anemia NN NN I-SpecificDisease
was NN NN O
reported NN NN O
. NN NN O

The NN NN O
patient NN NN O
, NN NN O
a NN NN O
6-year-old NN NN O
Japanese NN NN O
male NN NN O
, NN NN O
was NN NN O
noticed NN NN O
to NN NN O
have NN NN O
hemolytic NN NN B-SpecificDisease
anemia NN NN I-SpecificDisease
soon NN NN O
after NN NN O
birth NN NN O
, NN NN O
and NN NN O
a NN NN O
diagnosis NN NN O
of NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
was NN NN O
made NN NN O
at NN NN O
the NN NN O
age NN NN O
of NN NN O
2 NN NN O
. NN NN O

He NN NN O
had NN NN O
episodes NN NN O
of NN NN O
hemolytic NN NN B-DiseaseClass
crisis NN NN I-DiseaseClass
several NN NN O
times NN NN O
after NN NN O
upper NN NN B-SpecificDisease
respiratory NN NN I-SpecificDisease
infection NN NN I-SpecificDisease
. NN NN O

G6PD NN NN O
activity NN NN O
of NN NN O
the NN NN O
patient NN NN O
was NN NN O
5 NN NN O
. NN NN O

5 NN NN O
% NN NN O
of NN NN O
normal NN NN O
. NN NN O

The NN NN O
enzymatic NN NN O
characteristics NN NN O
were NN NN O
examined NN NN O
when NN NN O
he NN NN O
was NN NN O
5 NN NN O
years NN NN O
old NN NN O
, NN NN O
and NN NN O
his NN NN O
G6PD NN NN O
showed NN NN O
faster-than-normal NN NN O
electrophoretic NN NN O
mobility NN NN O
, NN NN O
low NN NN O
Km NN NN O
G6P NN NN O
, NN NN O
high NN NN O
Km NN NN O
NADP NN NN O
, NN NN O
low NN NN O
Ki NN NN O
NADPH NN NN O
, NN NN O
normal NN NN O
utilization NN NN O
of NN NN O
substrate NN NN O
analogues NN NN O
, NN NN O
heat NN NN O
instability NN NN O
, NN NN O
and NN NN O
a NN NN O
normal NN NN O
pH NN NN O
optimum NN NN O
curve NN NN O
. NN NN O

From NN NN O
these NN NN O
results NN NN O
, NN NN O
this NN NN O
was NN NN O
considered NN NN O
to NN NN O
be NN NN O
a NN NN O
new NN NN O
variant NN NN O
and NN NN O
was NN NN O
designated NN NN O
G6PD NN NN O
Nagano NN NN O
. NN NN O

Infection-induced NN NN O
hemolysis NN NN B-SpecificDisease
and NN NN O
chronic NN NN B-SpecificDisease
hemolytic NN NN I-SpecificDisease
anemia NN NN I-SpecificDisease
seem NN NN O
to NN NN O
be NN NN O
due NN NN O
to NN NN O
markedly NN NN O
impaired NN NN O
enzyme NN NN O
activity NN NN O
and NN NN O
thermal NN NN O
instability NN NN O
. NN NN O

7191069 NN NN O
Heterozygous NN NN O
C2-deficiency NN NN B-SpecificDisease
and NN NN O
myasthenia NN NN B-SpecificDisease
gravis NN NN I-SpecificDisease
. NN NN O

Complement NN NN B-Modifier
deficiency NN NN I-Modifier
states NN NN O
in NN NN O
myasthenia NN NN B-SpecificDisease
gravis NN NN I-SpecificDisease
( NN NN O
MG NN NN B-SpecificDisease
) NN NN O
have NN NN O
not NN NN O
been NN NN O
reported NN NN O
previously NN NN O
. NN NN O

We NN NN O
describe NN NN O
a NN NN O
19-year-old NN NN O
woman NN NN O
with NN NN O
typical NN NN O
MG NN NN B-SpecificDisease
and NN NN O
heterozygous NN NN O
C2 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
, NN NN O
along NN NN O
with NN NN O
HLA NN NN O
typing NN NN O
of NN NN O
the NN NN O
patient NN NN O
and NN NN O
her NN NN O
immediate NN NN O
family NN NN O
. NN NN O

. NN NN O

7202134 NN NN O
Adrenoleukodystrophy NN NN B-SpecificDisease
: NN NN O
increased NN NN O
plasma NN NN O
content NN NN O
of NN NN O
saturated NN NN O
very NN NN O
long NN NN O
chain NN NN O
fatty NN NN O
acids NN NN O
. NN NN O

With NN NN O
a NN NN O
new NN NN O
method NN NN O
we NN NN O
measured NN NN O
the NN NN O
saturated NN NN O
very NN NN O
long NN NN O
chain NN NN O
fatty NN NN O
acids NN NN O
in NN NN O
the NN NN O
plasma NN NN O
of NN NN O
adrenoleukodystrophy NN NN B-Modifier
( NN NN O
ALD NN NN B-Modifier
) NN NN O
hemizygotes NN NN O
, NN NN O
ALD NN NN B-Modifier
heterozygotes NN NN O
, NN NN O
and NN NN O
controls NN NN O
. NN NN O

ALD NN NN B-Modifier
hemizygotes NN NN O
showed NN NN O
increased NN NN O
levels NN NN O
of NN NN O
hexacosanoate NN NN O
( NN NN O
C26 NN NN O
fatty NN NN O
acid NN NN O
) NN NN O
which NN NN O
represented NN NN O
0 NN NN O
. NN NN O

081 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O

0066 NN NN O
% NN NN O
( NN NN O
SEM NN NN O
) NN NN O
of NN NN O
total NN NN O
fatty NN NN O
acids NN NN O
, NN NN O
compared NN NN O
to NN NN O
0 NN NN O
. NN NN O

015 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O

0032 NN NN O
% NN NN O
in NN NN O
the NN NN O
controls NN NN O
. NN NN O

C25 NN NN O
, NN NN O
C24 NN NN O
, NN NN O
and NN NN O
C23 NN NN O
fatty NN NN O
acids NN NN O
were NN NN O
also NN NN O
increased NN NN O
, NN NN O
but NN NN O
the NN NN O
C22 NN NN O
and NN NN O
C20 NN NN O
fatty NN NN O
acids NN NN O
were NN NN O
normal NN NN O
. NN NN O

C26 NN NN O
levels NN NN O
were NN NN O
also NN NN O
increased NN NN O
in NN NN O
most NN NN O
ALD NN NN B-Modifier
heterozygotes NN NN O
, NN NN O
with NN NN O
a NN NN O
mean NN NN O
level NN NN O
0 NN NN O
. NN NN O

057 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O

0063 NN NN O
% NN NN O
of NN NN O
total NN NN O
fatty NN NN O
acids NN NN O
. NN NN O

The NN NN O
technique NN NN O
can NN NN O
be NN NN O
used NN NN O
for NN NN O
diagnosis NN NN O
and NN NN O
carrier NN NN O
identification NN NN O
, NN NN O
and NN NN O
in NN NN O
the NN NN O
evaluation NN NN O
of NN NN O
therapy NN NN O
. NN NN O

7298854 NN NN O
Abnormal NN NN O
high NN NN O
density NN NN O
lipoproteins NN NN O
in NN NN O
cerebrotendinous NN NN B-SpecificDisease
xanthomatosis NN NN I-SpecificDisease
. NN NN O

The NN NN O
plasma NN NN O
lipoprotein NN NN O
profiles NN NN O
and NN NN O
high NN NN O
density NN NN O
lipoproteins NN NN O
( NN NN O
HDL NN NN O
) NN NN O
were NN NN O
characterized NN NN O
in NN NN O
patients NN NN O
with NN NN O
the NN NN O
genetic NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
cerebrotendinous NN NN B-SpecificDisease
xanthomatosis NN NN I-SpecificDisease
( NN NN O
CTX NN NN B-SpecificDisease
) NN NN O
. NN NN O

Abnormalities NN NN B-DiseaseClass
in NN NN I-DiseaseClass
the NN NN I-DiseaseClass
HDL NN NN I-DiseaseClass
may NN NN O
contribute NN NN O
to NN NN O
their NN NN O
increased NN NN O
atherogenesis NN NN O
and NN NN O
excessive NN NN O
deposits NN NN O
of NN NN O
tissue NN NN O
sterols NN NN O
in NN NN O
the NN NN O
presence NN NN O
of NN NN O
low NN NN O
or NN NN O
low-normal NN NN O
concentrations NN NN O
of NN NN O
plasma NN NN O
cholesterol NN NN O
( NN NN O
165 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
25 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
) NN NN O
and NN NN O
low NN NN O
density NN NN O
lipoproteins NN NN O
( NN NN O
LDL NN NN O
) NN NN O
. NN NN O

The NN NN O
mean NN NN O
HDL-cholesterol NN NN O
concentration NN NN O
in NN NN O
the NN NN O
CTX NN NN B-Modifier
plasmas NN NN O
was NN NN O
14 NN NN O
. NN NN O

5 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
3 NN NN O
. NN NN O

2 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
, NN NN O
about NN NN O
one-third NN NN O
the NN NN O
normal NN NN O
value NN NN O
. NN NN O

The NN NN O
low NN NN O
HDL-cholesterol NN NN O
reflects NN NN O
a NN NN O
low NN NN O
concentration NN NN O
and NN NN O
an NN NN O
abnormal NN NN O
lipid NN NN O
composition NN NN O
of NN NN O
the NN NN O
plasma NN NN O
HDL NN NN O
. NN NN O

Relative NN NN O
to NN NN O
normal NN NN O
HDL NN NN O
, NN NN O
the NN NN O
cholesteryl NN NN O
esters NN NN O
are NN NN O
low NN NN O
, NN NN O
free NN NN O
cholesterol NN NN O
and NN NN O
phospholipids NN NN O
essentially NN NN O
normal NN NN O
, NN NN O
and NN NN O
triglycerides NN NN O
increased NN NN O
. NN NN O

The NN NN O
ratio NN NN O
of NN NN O
apoprotein NN NN O
( NN NN O
apo NN NN O
) NN NN O
to NN NN O
total NN NN O
cholesterol NN NN O
in NN NN O
the NN NN O
HDL NN NN O
of NN NN O
CTX NN NN B-SpecificDisease
was NN NN O
two NN NN O
to NN NN O
three NN NN O
times NN NN O
greater NN NN O
than NN NN O
normal NN NN O
. NN NN O

In NN NN O
the NN NN O
CTX NN NN B-Modifier
HDL NN NN O
, NN NN O
the NN NN O
ratio NN NN O
of NN NN O
apoAI NN NN O
to NN NN O
apoAII NN NN O
was NN NN O
high NN NN O
, NN NN O
the NN NN O
proportion NN NN O
of NN NN O
apoC NN NN O
low NN NN O
, NN NN O
and NN NN O
a NN NN O
normally NN NN O
minor NN NN O
form NN NN O
of NN NN O
apoAI NN NN O
increased NN NN O
relative NN NN O
to NN NN O
other NN NN O
forms NN NN O
. NN NN O

The NN NN O
HDL NN NN O
in NN NN O
electron NN NN O
micrographs NN NN O
appeared NN NN O
normal NN NN O
morphologically NN NN O
and NN NN O
in NN NN O
particle NN NN O
size NN NN O
. NN NN O

The NN NN O
abnormalities NN NN O
in NN NN O
lipoprotein NN NN O
distribution NN NN O
profile NN NN O
and NN NN O
composition NN NN O
of NN NN O
the NN NN O
plasma NN NN O
HDL NN NN O
result NN NN O
from NN NN O
metabolic NN NN O
defects NN NN O
that NN NN O
are NN NN O
not NN NN O
understood NN NN O
but NN NN O
may NN NN O
be NN NN O
linked NN NN O
to NN NN O
the NN NN O
genetic NN NN B-DiseaseClass
defect NN NN I-DiseaseClass
in NN NN O
bile NN NN O
acid NN NN O
synthesis NN NN O
in NN NN O
CTX NN NN B-SpecificDisease
. NN NN O

As NN NN O
a NN NN O
consequence NN NN O
, NN NN O
it NN NN O
is NN NN O
probable NN NN O
that NN NN O
the NN NN O
normal NN NN O
functions NN NN O
of NN NN O
the NN NN O
HDL NN NN O
, NN NN O
possibly NN NN O
including NN NN O
modulation NN NN O
of NN NN O
LDL-cholesterol NN NN O
uptake NN NN O
and NN NN O
the NN NN O
removal NN NN O
of NN NN O
excess NN NN O
cholesterol NN NN O
from NN NN O
peripheral NN NN O
tissues NN NN O
, NN NN O
are NN NN O
perturbed NN NN O
significantly NN NN O
in NN NN O
this NN NN O
disease NN NN O
. NN NN O

7315872 NN NN O
Genetics NN NN O
of NN NN O
cerebrotendinous NN NN B-SpecificDisease
xanthomatosis NN NN I-SpecificDisease
( NN NN O
CTX NN NN B-SpecificDisease
) NN NN O
: NN NN O
an NN NN O
autosomal NN NN O
recessive NN NN O
trait NN NN O
with NN NN O
high NN NN O
gene NN NN O
frequency NN NN O
in NN NN O
Sephardim NN NN O
of NN NN O
Moroccan NN NN O
origin NN NN O
. NN NN O

We NN NN O
described NN NN O
6 NN NN O
patients NN NN O
( NN NN O
from NN NN O
3 NN NN O
families NN NN O
) NN NN O
affected NN NN O
with NN NN O
cerebrotendinous NN NN B-SpecificDisease
xanthomatosis NN NN I-SpecificDisease
( NN NN O
CTX NN NN B-SpecificDisease
) NN NN O
. NN NN O

All NN NN O
are NN NN O
Sephardic NN NN O
Jews NN NN O
of NN NN O
Moroccan NN NN O
extraction NN NN O
. NN NN O

In NN NN O
view NN NN O
of NN NN O
the NN NN O
small NN NN O
number NN NN O
of NN NN O
CTX NN NN B-Modifier
patients NN NN O
diagnosed NN NN O
in NN NN O
the NN NN O
world NN NN O
( NN NN O
a NN NN O
total NN NN O
of NN NN O
50 NN NN O
including NN NN O
our NN NN O
6 NN NN O
patients NN NN O
) NN NN O
, NN NN O
we NN NN O
are NN NN O
probably NN NN O
dealing NN NN O
with NN NN O
an NN NN O
ethnic NN NN O
subgroup NN NN O
with NN NN O
a NN NN O
high NN NN O
CTX NN NN O
gene NN NN O
frequency NN NN O
, NN NN O
which NN NN O
we NN NN O
have NN NN O
estimated NN NN O
to NN NN O
be NN NN O
1 NN NN O
/ NN NN O
108 NN NN O
. NN NN O

Since NN NN O
there NN NN O
are NN NN O
differences NN NN O
in NN NN O
expression NN NN O
in NN NN O
this NN NN O
disease NN NN O
, NN NN O
we NN NN O
recommend NN NN O
cholestanol NN NN O
study NN NN O
in NN NN O
cases NN NN O
of NN NN O
undiagnosed NN NN O
cataract NN NN B-SpecificDisease
or NN NN O
tendinous NN NN B-SpecificDisease
xanthomas NN NN I-SpecificDisease
in NN NN O
childhood NN NN O
or NN NN O
early NN NN O
adolescence NN NN O
. NN NN O

The NN NN O
diagnosis NN NN O
in NN NN O
CTX NN NN B-SpecificDisease
is NN NN O
important NN NN O
not NN NN O
only NN NN O
for NN NN O
genetic NN NN O
counseling NN NN O
, NN NN O
but NN NN O
also NN NN O
in NN NN O
veiw NN NN O
of NN NN O
possible NN NN O
treatment NN NN O
. NN NN O

. NN NN O

7316485 NN NN O
New NN NN O
genetic NN NN O
variants NN NN O
of NN NN O
glucose NN NN O
6-phosphate NN NN O
dehydrogenase NN NN O
( NN NN O
G6PD NN NN O
) NN NN O
in NN NN O
Italy NN NN O
. NN NN O

Six NN NN O
new NN NN O
variants NN NN O
of NN NN O
human NN NN O
erythrocyte NN NN O
G6PD NN NN O
have NN NN O
been NN NN O
characterized NN NN O
. NN NN O

All NN NN O
of NN NN O
them NN NN O
were NN NN O
found NN NN O
in NN NN O
Italian NN NN O
males NN NN O
and NN NN O
all NN NN O
were NN NN O
associated NN NN O
with NN NN O
enzyme NN NN B-DiseaseClass
deficiency NN NN I-DiseaseClass
, NN NN O
but NN NN O
only NN NN O
two NN NN O
with NN NN O
signs NN NN O
of NN NN O
haemolysis NN NN B-SpecificDisease
. NN NN O

These NN NN O
and NN NN O
other NN NN O
variants NN NN O
reported NN NN O
in NN NN O
the NN NN O
literature NN NN O
, NN NN O
which NN NN O
must NN NN O
thus NN NN O
far NN NN O
be NN NN O
regarded NN NN O
as NN NN O
sporadic NN NN O
, NN NN O
are NN NN O
found NN NN O
to NN NN O
map NN NN O
in NN NN O
parts NN NN O
of NN NN O
Italy NN NN O
where NN NN O
common NN NN O
types NN NN O
of NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
are NN NN O
also NN NN O
prevalent NN NN O
. NN NN O

. NN NN O

7390473 NN NN O
Variants NN NN O
of NN NN O
erythrocyte NN NN O
glucose-6-phosphate NN NN O
dehydrogenase NN NN O
( NN NN O
G6PD NN NN O
) NN NN O
in NN NN O
Bulgarian NN NN O
populations NN NN O
. NN NN O

Ten NN NN O
variants NN NN O
of NN NN O
erythrocyte NN NN O
glucose-6-phosphate NN NN O
dehydrogenase NN NN O
were NN NN O
identified NN NN O
in NN NN O
22 NN NN O
patients NN NN O
with NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
from NN NN O
three NN NN O
districts NN NN O
of NN NN O
Bulgaria NN NN O
. NN NN O

Corinth-like NN NN O
and NN NN O
Fayoum-like NN NN O
variants NN NN O
were NN NN O
the NN NN O
most NN NN O
frequent NN NN O
; NN NN O
Mediterranean NN NN O
, NN NN O
Ohut NN NN O
II NN NN O
, NN NN O
Kilgore NN NN O
, NN NN O
Boston NN NN O
, NN NN O
Poznan NN NN O
, NN NN O
and NN NN O
Panay NN NN O
variants NN NN O
and NN NN O
two NN NN O
new NN NN O
variants NN NN O
, NN NN O
Petrich NN NN O
and NN NN O
Gotze NN NN O
Delchev NN NN O
, NN NN O
were NN NN O
each NN NN O
found NN NN O
in NN NN O
one NN NN O
or NN NN O
two NN NN O
carriers NN NN O
. NN NN O

No NN NN O
correlation NN NN O
was NN NN O
revealed NN NN O
between NN NN O
clinical NN NN O
and NN NN O
biochemical NN NN O
polymorphism NN NN O
. NN NN O

. NN NN O

7422429 NN NN O
Nephropathy NN NN B-SpecificDisease
in NN NN O
the NN NN O
Wiskott-Aldrich NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

Nephropathy NN NN B-SpecificDisease
was NN NN O
detected NN NN O
in NN NN O
five NN NN O
of NN NN O
32 NN NN O
patients NN NN O
with NN NN O
the NN NN O
Wiskott-Aldrich NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
who NN NN O
were NN NN O
participating NN NN O
in NN NN O
a NN NN O
study NN NN O
of NN NN O
transfer NN NN O
factor NN NN O
( NN NN O
TF NN NN O
) NN NN O
therapy NN NN O
. NN NN O

In NN NN O
two NN NN O
patients NN NN O
, NN NN O
nephropathy NN NN B-SpecificDisease
was NN NN O
present NN NN O
before NN NN O
TF NN NN O
and NN NN O
did NN NN O
not NN NN O
appear NN NN O
changed NN NN O
by NN NN O
TF NN NN O
therapy NN NN O
. NN NN O

One NN NN O
of NN NN O
these NN NN O
patients NN NN O
subsequently NN NN O
developed NN NN O
progressive NN NN O
renal NN NN B-SpecificDisease
failure NN NN I-SpecificDisease
requiring NN NN O
dialysis NN NN O
beginning NN NN O
5 NN NN O
1 NN NN O
/ NN NN O
2 NN NN O
years NN NN O
after NN NN O
TF NN NN O
therapy NN NN O
. NN NN O

In NN NN O
two NN NN O
patients NN NN O
, NN NN O
decreased NN NN O
renal NN NN O
function NN NN O
appeared NN NN O
very NN NN O
soon NN NN O
after NN NN O
the NN NN O
administration NN NN O
of NN NN O
TF NN NN O
. NN NN O

One NN NN O
patient NN NN O
showed NN NN O
gradually NN NN O
decreasing NN NN O
renal NN NN O
function NN NN O
beginning NN NN O
after NN NN O
two NN NN O
years NN NN O
of NN NN O
TF NN NN O
therapy NN NN O
. NN NN O

An NN NN O
additional NN NN O
patient NN NN O
was NN NN O
identified NN NN O
who NN NN O
died NN NN O
with NN NN O
renal NN NN B-SpecificDisease
failure NN NN I-SpecificDisease
without NN NN O
having NN NN O
received NN NN O
TF NN NN O
. NN NN O

The NN NN O
results NN NN O
suggest NN NN O
that NN NN O
renal NN NN B-SpecificDisease
failure NN NN I-SpecificDisease
occurs NN NN O
in NN NN O
the NN NN O
Wiskott-Aldrich NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
more NN NN O
frequently NN NN O
than NN NN O
generally NN NN O
recognized NN NN O
and NN NN O
that NN NN O
administration NN NN O
of NN NN O
TF NN NN O
may NN NN O
precipitate NN NN O
or NN NN O
accelerate NN NN O
the NN NN O
renal NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
in NN NN O
patients NN NN O
with NN NN O
this NN NN O
syndrome NN NN O
. NN NN O

. NN NN O

7437512 NN NN O
Wiskott-Aldrich NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
: NN NN O
cellular NN NN B-DiseaseClass
impairments NN NN I-DiseaseClass
and NN NN O
their NN NN O
implication NN NN O
for NN NN O
carrier NN NN O
detection NN NN O
. NN NN O

A NN NN O
family NN NN O
in NN NN O
which NN NN O
two NN NN O
male NN NN O
siblings NN NN O
were NN NN O
affected NN NN O
with NN NN O
Wiskott-Aldrich NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
WAS NN NN B-SpecificDisease
) NN NN O
was NN NN O
studied NN NN O
using NN NN O
G-6-PD NN NN O
isoenzymes NN NN O
as NN NN O
an NN NN O
X-linked NN NN O
marker NN NN O
in NN NN O
order NN NN O
to NN NN O
investigate NN NN O
the NN NN O
nature NN NN O
of NN NN O
cellular NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
. NN NN O

Isolated NN NN O
peripheral NN NN O
blood NN NN O
cell NN NN O
types NN NN O
from NN NN O
the NN NN O
doubly NN NN O
heterozygous NN NN O
mother NN NN O
of NN NN O
the NN NN O
affected NN NN O
males NN NN O
seemingly NN NN O
failed NN NN O
to NN NN O
express NN NN O
the NN NN O
G-6-PD NN NN O
allele NN NN O
in NN NN O
cis NN NN O
position NN NN O
with NN NN O
the NN NN O
WAS NN NN B-Modifier
allele NN NN O
while NN NN O
her NN NN O
cultured NN NN O
skin NN NN O
fibroblasts NN NN O
expressed NN NN O
both NN NN O
G-6-PD NN NN O
alleles NN NN O
. NN NN O

Additionally NN NN O
, NN NN O
a NN NN O
histogram NN NN O
analysis NN NN O
of NN NN O
platelet NN NN O
size NN NN O
revealed NN NN O
a NN NN O
single NN NN O
population NN NN O
of NN NN O
abnormally NN NN O
small NN NN O
platelets NN NN O
in NN NN O
the NN NN O
affected NN NN O
propositus NN NN O
, NN NN O
whereas NN NN O
the NN NN O
heterozygous NN NN O
mother NN NN O
had NN NN O
no NN NN O
appreciable NN NN O
small NN NN O
platelet NN NN O
subpopulation NN NN O
. NN NN O

In NN NN O
vitro NN NN O
culture NN NN O
of NN NN O
hemopoietic NN NN O
progenitor NN NN O
cells NN NN O
of NN NN O
the NN NN O
heterozygous NN NN O
mother NN NN O
showed NN NN O
that NN NN O
the NN NN O
majority NN NN O
of NN NN O
progenitor NN NN O
cells NN NN O
did NN NN O
not NN NN O
express NN NN O
the NN NN O
WAS NN NN B-Modifier
allele NN NN O
. NN NN O

However NN NN O
, NN NN O
a NN NN O
small NN NN O
number NN NN O
of NN NN O
cells NN NN O
expressing NN NN O
the NN NN O
G-6-PD NN NN O
type NN NN O
linked NN NN O
with NN NN O
the NN NN O
WAS NN NN B-Modifier
allele NN NN O
were NN NN O
detected NN NN O
. NN NN O

The NN NN O
proportion NN NN O
of NN NN O
the NN NN O
latter NN NN O
progenitors NN NN O
was NN NN O
significantly NN NN O
higher NN NN O
among NN NN O
more NN NN O
primitive NN NN O
progenitors NN NN O
( NN NN O
those NN NN O
giving NN NN O
rise NN NN O
to NN NN O
later NN NN O
appearing NN NN O
colonies NN NN O
) NN NN O
. NN NN O

This NN NN O
observation NN NN O
suggests NN NN O
that NN NN O
selection NN NN O
against NN NN O
cells NN NN O
expressing NN NN O
the NN NN O
Wiskott-Aldrich NN NN B-SpecificDisease
defect NN NN I-SpecificDisease
takes NN NN O
place NN NN O
in NN NN O
the NN NN O
hemopoietic NN NN O
system NN NN O
of NN NN O
the NN NN O
heterozygous NN NN O
female NN NN O
and NN NN O
offers NN NN O
a NN NN O
possible NN NN O
means NN NN O
of NN NN O
carrier NN NN O
detection NN NN O
in NN NN O
some NN NN O
women NN NN O
. NN NN O

Linkage NN NN O
studies NN NN O
in NN NN O
this NN NN O
family NN NN O
revealed NN NN O
one NN NN O
example NN NN O
of NN NN O
probable NN NN O
recombination NN NN O
between NN NN O
the NN NN O
loci NN NN O
for NN NN O
WAS NN NN B-SpecificDisease
and NN NN O
G-6-PD NN NN O
among NN NN O
three NN NN O
informative NN NN O
subjects NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
these NN NN O
two NN NN O
loci NN NN O
may NN NN O
not NN NN O
be NN NN O
closely NN NN O
linked NN NN O
on NN NN O
the NN NN O
X-chromosome NN NN O
. NN NN O

. NN NN O

7444053 NN NN O
A NN NN O
new NN NN O
CT NN NN O
pattern NN NN O
in NN NN O
adrenoleukodystrophy NN NN B-SpecificDisease
. NN NN O

A NN NN O
new NN NN O
CT NN NN O
pattern NN NN O
was NN NN O
observed NN NN O
in NN NN O
2 NN NN O
patients NN NN O
with NN NN O
adrenoleukodystrophy NN NN B-SpecificDisease
( NN NN O
ALD NN NN B-SpecificDisease
) NN NN O
. NN NN O

This NN NN O
pattern NN NN O
, NN NN O
which NN NN O
the NN NN O
authors NN NN O
call NN NN O
Type NN NN O
II NN NN O
, NN NN O
is NN NN O
characterized NN NN O
by NN NN O
the NN NN O
absence NN NN O
of NN NN O
posterior NN NN O
periventricular NN NN O
areas NN NN O
of NN NN O
decreased NN NN O
attenuation NN NN O
around NN NN O
the NN NN O
trigone NN NN O
on NN NN O
non-contrast NN NN O
scans NN NN O
after NN NN O
contrast NN NN O
infusion NN NN O
, NN NN O
however NN NN O
, NN NN O
there NN NN O
is NN NN O
striking NN NN O
enhancement NN NN O
of NN NN O
various NN NN O
white-matter NN NN O
structures NN NN O
( NN NN O
tracts NN NN O
or NN NN O
fiber NN NN O
systems NN NN O
) NN NN O
such NN NN O
as NN NN O
the NN NN O
internal NN NN O
capsules NN NN O
, NN NN O
corpus NN NN O
callosum NN NN O
, NN NN O
corona NN NN O
radiata NN NN O
, NN NN O
forceps NN NN O
major NN NN O
, NN NN O
and NN NN O
cerebral NN NN O
peduncles NN NN O
. NN NN O

This NN NN O
is NN NN O
different NN NN O
from NN NN O
numerous NN NN O
previous NN NN O
descriptions NN NN O
of NN NN O
the NN NN O
CT NN NN O
pattern NN NN O
in NN NN O
ALD NN NN B-SpecificDisease
. NN NN O

Type NN NN B-SpecificDisease
II NN NN I-SpecificDisease
ALD NN NN I-SpecificDisease
does NN NN O
not NN NN O
appear NN NN O
to NN NN O
have NN NN O
been NN NN O
seen NN NN O
in NN NN O
any NN NN O
other NN NN O
leukoencephalopathy NN NN B-DiseaseClass
and NN NN O
is NN NN O
probably NN NN O
specific NN NN O
for NN NN O
a NN NN O
phenotypic NN NN O
variant NN NN O
or NN NN O
an NN NN O
evolving NN NN O
stage NN NN O
of NN NN O
ALD NN NN B-SpecificDisease
. NN NN O

. NN NN O

7450778 NN NN O
Further NN NN O
evidence NN NN O
for NN NN O
heterogeneity NN NN O
of NN NN O
glucose-6-phosphate NN NN B-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
Papua NN NN O
New NN NN O
Guinea NN NN O
. NN NN O

Four NN NN O
new NN NN O
G6PD NN NN O
variants NN NN O
have NN NN O
been NN NN O
characterized NN NN O
in NN NN O
individuals NN NN O
from NN NN O
Papua NN NN O
New NN NN O
Guinea NN NN O
. NN NN O

This NN NN O
study NN NN O
demonstrates NN NN O
that NN NN O
the NN NN O
previously NN NN O
reported NN NN O
Markham NN NN O
variant NN NN O
and NN NN O
the NN NN O
newly NN NN O
characterized NN NN O
Salata NN NN O
variant NN NN O
may NN NN O
be NN NN O
widely NN NN O
distributed NN NN O
in NN NN O
Papua NN NN O
New NN NN O
Guinea NN NN O
. NN NN O

Th NN NN O
data NN NN O
presented NN NN O
here NN NN O
together NN NN O
with NN NN O
those NN NN O
of NN NN O
previously NN NN O
published NN NN O
studies NN NN O
demonstrate NN NN O
a NN NN O
degree NN NN O
of NN NN O
heterogeneity NN NN O
of NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
that NN NN O
is NN NN O
much NN NN O
higher NN NN O
than NN NN O
that NN NN O
in NN NN O
other NN NN O
regions NN NN O
of NN NN O
the NN NN O
world NN NN O
where NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
is NN NN O
common NN NN O
. NN NN O

. NN NN O

7458742 NN NN O
Increased NN NN O
incidence NN NN O
of NN NN O
cataracts NN NN B-SpecificDisease
in NN NN O
male NN NN O
subjects NN NN O
deficient NN NN B-SpecificDisease
in NN NN I-SpecificDisease
glucose-6-phosphate NN NN I-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
. NN NN O

Glucose-6-phosphate NN NN B-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
( NN NN I-SpecificDisease
G6PD NN NN I-SpecificDisease
) NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
RBCs NN NN O
was NN NN O
found NN NN O
significantly NN NN O
more NN NN O
frequently NN NN O
in NN NN O
210 NN NN O
male NN NN O
cataractous NN NN B-Modifier
patients NN NN O
than NN NN O
in NN NN O
672 NN NN O
control NN NN O
subjects NN NN O
of NN NN O
Sardinian NN NN O
origin NN NN O
. NN NN O

The NN NN O
frequency NN NN O
of NN NN O
the NN NN O
deficiency NN NN O
was NN NN O
increasingly NN NN O
higher NN NN O
in NN NN O
presenile NN NN O
cataracts NN NN B-SpecificDisease
. NN NN O

In NN NN O
the NN NN O
G6PD-deficient NN NN B-Modifier
group NN NN O
, NN NN O
the NN NN O
incidence NN NN O
of NN NN O
cortical NN NN B-CompositeMention
and NN NN I-CompositeMention
total NN NN I-CompositeMention
cataracts NN NN I-CompositeMention
was NN NN O
also NN NN O
increased NN NN O
. NN NN O

It NN NN O
is NN NN O
suggested NN NN O
that NN NN O
decrease NN NN O
of NN NN O
the NN NN O
G6PD NN NN O
activity NN NN O
in NN NN O
the NN NN O
lens NN NN O
, NN NN O
which NN NN O
accompanies NN NN O
its NN NN O
deficiency NN NN O
in NN NN O
the NN NN O
erythrocyte NN NN O
, NN NN O
might NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
the NN NN O
cataracto-genesis NN NN O
of NN NN O
these NN NN O
patients NN NN O
. NN NN O

Moreover NN NN O
, NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
should NN NN O
be NN NN O
added NN NN O
to NN NN O
other NN NN O
conditions NN NN O
, NN NN O
such NN NN O
as NN NN O
the NN NN O
galactosemic NN NN B-Modifier
states NN NN O
and NN NN O
riboflavin NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
, NN NN O
where NN NN O
cataracts NN NN B-SpecificDisease
represent NN NN O
a NN NN O
sensitive NN NN O
indicator NN NN O
of NN NN O
metabolic NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
of NN NN O
the NN NN O
RBC NN NN O
. NN NN O

. NN NN O

7479827 NN NN O
Molecular NN NN O
basis NN NN O
of NN NN O
human NN NN O
mitochondrial NN NN O
very-long-chain NN NN B-SpecificDisease
acyl-CoA NN NN I-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
causing NN NN O
cardiomyopathy NN NN B-SpecificDisease
and NN NN O
sudden NN NN B-SpecificDisease
death NN NN I-SpecificDisease
in NN NN O
childhood NN NN O
. NN NN O

beta-Oxidation NN NN O
of NN NN O
long-chain NN NN O
fatty NN NN O
acids NN NN O
provides NN NN O
the NN NN O
major NN NN O
source NN NN O
of NN NN O
energy NN NN O
in NN NN O
the NN NN O
heart NN NN O
. NN NN O

Defects NN NN O
in NN NN O
enzymes NN NN O
of NN NN O
the NN NN O
beta-oxidation NN NN O
pathway NN NN O
cause NN NN O
sudden NN NN B-SpecificDisease
, NN NN I-SpecificDisease
unexplained NN NN I-SpecificDisease
death NN NN I-SpecificDisease
in NN NN O
childhood NN NN O
, NN NN O
acute NN NN O
hepatic NN NN B-SpecificDisease
encephalopathy NN NN I-SpecificDisease
or NN NN O
liver NN NN B-SpecificDisease
failure NN NN I-SpecificDisease
, NN NN O
skeletal NN NN B-SpecificDisease
myopathy NN NN I-SpecificDisease
, NN NN O
and NN NN O
cardiomyopathy NN NN B-SpecificDisease
. NN NN O

Very-long-chain NN NN O
acyl-CoA NN NN O
dehydrogenase NN NN O
[ NN NN O
VLCAD NN NN O
; NN NN O
very-long-chain-acyl-CoA NN NN O
( NN NN O
acceptor NN NN O
) NN NN O
2 NN NN O
, NN NN O
3-oxidoreductase NN NN O
, NN NN O
EC NN NN O
1 NN NN O
. NN NN O

3 NN NN O
3 NN NN O
. NN NN O

99 NN NN O
99 NN NN O
. NN NN O

13 NN NN O
] NN NN O
catalyzes NN NN O
the NN NN O
first NN NN O
step NN NN O
in NN NN O
beta-oxidation NN NN O
. NN NN O

We NN NN O
have NN NN O
isolated NN NN O
the NN NN O
human NN NN O
VLCAD NN NN O
cDNA NN NN O
and NN NN O
gene NN NN O
and NN NN O
determined NN NN O
the NN NN O
complete NN NN O
nucleotide NN NN O
sequences NN NN O
. NN NN O

Polymerase NN NN O
chain NN NN O
reaction NN NN O
amplification NN NN O
of NN NN O
VLCAD NN NN O
mRNA NN NN O
and NN NN O
genomic NN NN O
exons NN NN O
defined NN NN O
the NN NN O
molecular NN NN O
defects NN NN O
in NN NN O
two NN NN O
patients NN NN O
with NN NN O
VLCAD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
who NN NN O
presented NN NN O
with NN NN O
unexplained NN NN O
cardiac NN NN B-SpecificDisease
arrest NN NN I-SpecificDisease
and NN NN O
cardiomyopathy NN NN B-SpecificDisease
. NN NN O

In NN NN O
one NN NN O
, NN NN O
a NN NN O
homozygous NN NN O
mutation NN NN O
in NN NN O
the NN NN O
consensus NN NN O
dinucleotide NN NN O
of NN NN O
the NN NN O
donor NN NN O
splice NN NN O
site NN NN O
( NN NN O
g NN NN O
+ NN NN O
1 NN NN O
-- NN NN O
a NN NN O
) NN NN O
was NN NN O
associated NN NN O
with NN NN O
universal NN NN O
skipping NN NN O
of NN NN O
the NN NN O
prior NN NN O
exon NN NN O
( NN NN O
exon NN NN O
11 NN NN O
) NN NN O
. NN NN O

The NN NN O
second NN NN O
patient NN NN O
was NN NN O
a NN NN O
compound NN NN O
heterozygote NN NN O
, NN NN O
with NN NN O
a NN NN O
missense NN NN O
mutation NN NN O
, NN NN O
C1837 NN NN O
-- NN NN O
T NN NN O
, NN NN O
changing NN NN O
the NN NN O
arginine NN NN O
at NN NN O
residue NN NN O
613 NN NN O
to NN NN O
tryptophan NN NN O
on NN NN O
one NN NN O
allele NN NN O
and NN NN O
a NN NN O
single NN NN O
base NN NN O
deletion NN NN O
at NN NN O
the NN NN O
intron-exon NN NN O
6 NN NN O
boundary NN NN O
as NN NN O
the NN NN O
second NN NN O
mutation NN NN O
. NN NN O

This NN NN O
initial NN NN O
delineation NN NN O
of NN NN O
human NN NN O
mutations NN NN O
in NN NN O
VLCAD NN NN O
suggests NN NN O
that NN NN O
VLCAD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
reduces NN NN O
myocardial NN NN O
fatty NN NN O
acid NN NN O
beta-oxidation NN NN O
and NN NN O
energy NN NN O
production NN NN O
and NN NN O
is NN NN O
associated NN NN O
with NN NN O
cardiomyopathy NN NN B-SpecificDisease
and NN NN O
sudden NN NN B-SpecificDisease
death NN NN I-SpecificDisease
in NN NN O
childhood NN NN O
. NN NN O

7481765 NN NN O
Aberrant NN NN O
subcellular NN NN O
localization NN NN O
of NN NN O
BRCA1 NN NN O
in NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

The NN NN O
BRCA1 NN NN O
gene NN NN O
product NN NN O
was NN NN O
identified NN NN O
as NN NN O
a NN NN O
220-kilodalton NN NN O
nuclear NN NN O
phosphoprotein NN NN O
in NN NN O
normal NN NN O
cells NN NN O
, NN NN O
including NN NN O
breast NN NN O
ductal NN NN O
epithelial NN NN O
cells NN NN O
, NN NN O
and NN NN O
in NN NN O
18 NN NN O
of NN NN O
20 NN NN O
tumor NN NN B-Modifier
cell NN NN O
lines NN NN O
derived NN NN O
from NN NN O
tissues NN NN O
other NN NN O
than NN NN O
breast NN NN O
and NN NN O
ovary NN NN O
. NN NN O

In NN NN O
16 NN NN O
of NN NN O
17 NN NN O
breast NN NN B-Modifier
and NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
lines NN NN O
and NN NN O
17 NN NN O
of NN NN O
17 NN NN O
samples NN NN O
of NN NN O
cells NN NN O
obtained NN NN O
from NN NN O
malignant NN NN O
effusions NN NN O
, NN NN O
however NN NN O
, NN NN O
BRCA1 NN NN O
localized NN NN O
mainly NN NN O
in NN NN O
cytoplasm NN NN O
. NN NN O

Absence NN NN O
of NN NN O
BRCA1 NN NN O
or NN NN O
aberrant NN NN O
subcellular NN NN O
location NN NN O
was NN NN O
also NN NN O
observed NN NN O
to NN NN O
a NN NN O
variable NN NN O
extent NN NN O
in NN NN O
histological NN NN O
sections NN NN O
of NN NN O
many NN NN O
breast NN NN B-Modifier
cancer NN NN I-Modifier
biopsies NN NN O
. NN NN O

These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
BRCA1 NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
may NN NN O
be NN NN O
involved NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
many NN NN O
breast NN NN B-SpecificDisease
cancers NN NN I-SpecificDisease
, NN NN O
sporadic NN NN O
as NN NN O
well NN NN O
as NN NN O
familial NN NN O
. NN NN O

. NN NN O

7490097 NN NN O
Mapping NN NN O
of NN NN O
the NN NN O
mouse NN NN O
homologue NN NN O
of NN NN O
the NN NN O
Wilson NN NN B-Modifier
disease NN NN I-Modifier
gene NN NN O
to NN NN O
mouse NN NN O
chromosome NN NN O
8 NN NN O
. NN NN O

ATP7B NN NN O
, NN NN O
the NN NN O
gene NN NN O
altered NN NN O
in NN NN O
Wilson NN NN B-Modifier
disease NN NN I-Modifier
( NN NN O
WD NN NN B-Modifier
) NN NN O
patients NN NN O
, NN NN O
lies NN NN O
in NN NN O
a NN NN O
block NN NN O
of NN NN O
homology NN NN O
shared NN NN O
between NN NN O
human NN NN O
chromosome NN NN O
13q14 NN NN O
and NN NN O
the NN NN O
central NN NN O
region NN NN O
of NN NN O
mouse NN NN O
chromosome NN NN O
14 NN NN O
. NN NN O

However NN NN O
, NN NN O
we NN NN O
have NN NN O
mapped NN NN O
the NN NN O
murine NN NN O
homologue NN NN O
of NN NN O
ATP7B NN NN O
( NN NN O
Atp7b NN NN O
) NN NN O
to NN NN O
mouse NN NN O
chromosome NN NN O
8 NN NN O
by NN NN O
somatic NN NN O
cell NN NN O
hybrid NN NN O
analysis NN NN O
. NN NN O

Analysis NN NN O
of NN NN O
80 NN NN O
interspecific NN NN O
backcross NN NN O
offspring NN NN O
was NN NN O
used NN NN O
to NN NN O
position NN NN O
Atp7b NN NN O
close NN NN O
to NN NN O
D8Mit3 NN NN O
and NN NN O
another NN NN O
ATPase NN NN O
locus NN NN O
, NN NN O
Atp4b NN NN O
, NN NN O
on NN NN O
mouse NN NN O
chromosome NN NN O
8 NN NN O
. NN NN O

ATP4B NN NN O
lies NN NN O
in NN NN O
13q34 NN NN O
and NN NN O
is NN NN O
separated NN NN O
from NN NN O
ATP7B NN NN O
by NN NN O
several NN NN O
loci NN NN O
whose NN NN O
mouse NN NN O
homologues NN NN O
map NN NN O
to NN NN O
mouse NN NN O
chromosome NN NN O
14 NN NN O
. NN NN O

The NN NN O
assignment NN NN O
of NN NN O
Atp7b NN NN O
to NN NN O
mouse NN NN O
chromosome NN NN O
8 NN NN O
identifies NN NN O
a NN NN O
previously NN NN O
unrecognized NN NN O
region NN NN O
of NN NN O
homology NN NN O
between NN NN O
this NN NN O
chromosome NN NN O
and NN NN O
human NN NN O
chromosome NN NN O
13 NN NN O
. NN NN O

This NN NN O
assignment NN NN O
suggests NN NN O
a NN NN O
possible NN NN O
location NN NN O
for NN NN O
the NN NN O
toxic NN NN O
milk NN NN O
mutation NN NN O
in NN NN O
the NN NN O
mouse NN NN O
, NN NN O
which NN NN O
has NN NN O
been NN NN O
proposed NN NN O
as NN NN O
a NN NN O
homologue NN NN O
of NN NN O
WD NN NN B-SpecificDisease
. NN NN O

. NN NN O

7493024 NN NN O
Germline NN NN O
mutations NN NN O
of NN NN O
the NN NN O
BRCA1 NN NN O
gene NN NN O
in NN NN O
breast NN NN B-Modifier
and NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
families NN NN O
provide NN NN O
evidence NN NN O
for NN NN O
a NN NN O
genotype-phenotype NN NN O
correlation NN NN O
. NN NN O

Mutations NN NN O
in NN NN O
the NN NN O
BRCA1 NN NN O
gene NN NN O
, NN NN O
discovered NN NN O
in NN NN O
1994 NN NN O
, NN NN O
are NN NN O
associated NN NN O
with NN NN O
an NN NN O
80-90 NN NN O
% NN NN O
lifetime NN NN O
risk NN NN O
of NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

We NN NN O
have NN NN O
analysed NN NN O
60 NN NN O
families NN NN O
with NN NN O
a NN NN O
history NN NN O
of NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
/ NN NN I-CompositeMention
or NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
for NN NN O
germline NN NN O
mutations NN NN O
in NN NN O
BRCA1 NN NN O
. NN NN O

Twenty-two NN NN O
different NN NN O
mutations NN NN O
were NN NN O
detected NN NN O
in NN NN O
32 NN NN O
families NN NN O
( NN NN O
53 NN NN O
% NN NN O
) NN NN O
, NN NN O
of NN NN O
which NN NN O
14 NN NN O
are NN NN O
previously NN NN O
unreported NN NN O
. NN NN O

We NN NN O
observed NN NN O
a NN NN O
significant NN NN O
correlation NN NN O
between NN NN O
the NN NN O
location NN NN O
of NN NN O
the NN NN O
mutation NN NN O
in NN NN O
the NN NN O
gene NN NN O
and NN NN O
the NN NN O
ratio NN NN O
of NN NN O
breast NN NN B-Modifier
to NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
incidence NN NN O
within NN NN O
each NN NN O
family NN NN O
. NN NN O

Our NN NN O
data NN NN O
suggest NN NN O
a NN NN O
transition NN NN O
in NN NN O
risk NN NN O
such NN NN O
that NN NN O
mutations NN NN O
in NN NN O
the NN NN O
3 NN NN O
third NN NN O
of NN NN O
the NN NN O
gene NN NN O
are NN NN O
associated NN NN O
with NN NN O
a NN NN O
lower NN NN O
proportion NN NN O
of NN NN O
ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

Haplotype NN NN O
analysis NN NN O
supports NN NN O
previous NN NN O
data NN NN O
which NN NN O
suggest NN NN O
some NN NN O
BRCA1 NN NN O
mutation NN NN O
carriers NN NN O
have NN NN O
common NN NN O
ancestors NN NN O
; NN NN O
however NN NN O
, NN NN O
we NN NN O
have NN NN O
found NN NN O
at NN NN O
least NN NN O
two NN NN O
examples NN NN O
where NN NN O
recurrent NN NN O
mutations NN NN O
appear NN NN O
to NN NN O
have NN NN O
arisen NN NN O
independently NN NN O
. NN NN O

. NN NN O

7523157 NN NN O
Hereditary NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
seventh NN NN I-SpecificDisease
component NN NN I-SpecificDisease
of NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
and NN NN O
recurrent NN NN O
meningococcal NN NN B-SpecificDisease
infection NN NN I-SpecificDisease
: NN NN O
investigations NN NN O
of NN NN O
an NN NN O
Irish NN NN O
family NN NN O
using NN NN O
a NN NN O
novel NN NN O
haemolytic NN NN O
screening NN NN O
assay NN NN O
for NN NN O
complement NN NN O
activity NN NN O
and NN NN O
C7 NN NN O
M/N NN NN O
allotyping NN NN O
. NN NN O

Terminal NN NN B-SpecificDisease
complement NN NN I-SpecificDisease
component NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
predisposes NN NN O
to NN NN O
meningococcal NN NN B-SpecificDisease
infection NN NN I-SpecificDisease
and NN NN O
is NN NN O
inherited NN NN O
in NN NN O
an NN NN O
autosomal NN NN O
co-dominant NN NN O
manner NN NN O
. NN NN O

An NN NN O
Irish NN NN O
family NN NN O
is NN NN O
described NN NN O
, NN NN O
in NN NN O
which NN NN O
2 NN NN O
of NN NN O
3 NN NN O
brothers NN NN O
had NN NN O
recurrent NN NN O
meningococcal NN NN B-SpecificDisease
infection NN NN I-SpecificDisease
. NN NN O

A NN NN O
novel NN NN O
screening NN NN O
assay NN NN O
was NN NN O
used NN NN O
to NN NN O
investigate NN NN O
for NN NN O
terminal NN NN B-SpecificDisease
complement NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
and NN NN O
the NN NN O
2 NN NN O
affected NN NN O
brothers NN NN O
were NN NN O
found NN NN O
to NN NN O
be NN NN O
completely NN NN B-SpecificDisease
deficient NN NN I-SpecificDisease
in NN NN I-SpecificDisease
the NN NN I-SpecificDisease
seventh NN NN I-SpecificDisease
component NN NN I-SpecificDisease
of NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
( NN NN O
C7 NN NN O
) NN NN O
. NN NN O

Enzyme-linked NN NN O
immunosorbent NN NN O
assay NN NN O
for NN NN O
C7 NN NN O
revealed NN NN O
lower NN NN O
than NN NN O
normal NN NN O
levels NN NN O
in NN NN O
the NN NN O
remaining NN NN O
brother NN NN O
and NN NN O
parents NN NN O
. NN NN O

C7 NN NN O
M NN NN O
/ NN NN O
N NN NN O
protein NN NN O
polymorphism NN NN O
allotyping NN NN O
, NN NN O
used NN NN O
to NN NN O
investigate NN NN O
the NN NN O
segregation NN NN O
of NN NN O
the NN NN O
C7 NN NN B-Modifier
deficiency NN NN I-Modifier
genes NN NN O
, NN NN O
showed NN NN O
that NN NN O
the NN NN O
apparently NN NN O
complement NN NN O
sufficient NN NN O
brother NN NN O
was NN NN O
heterozygous NN NN O
C7 NN NN B-SpecificDisease
deficient NN NN I-SpecificDisease
and NN NN O
a NN NN O
carrier NN NN O
of NN NN O
one NN NN O
of NN NN O
the NN NN O
deficiency NN NN O
genes NN NN O
. NN NN O

Complement NN NN O
screening NN NN O
should NN NN O
be NN NN O
carried NN NN O
out NN NN O
in NN NN O
any NN NN O
individual NN NN O
suffering NN NN O
recurrent NN NN O
meningococcal NN NN B-SpecificDisease
infection NN NN I-SpecificDisease
or NN NN O
infection NN NN O
with NN NN O
an NN NN O
uncommon NN NN O
meningococcal NN NN B-Modifier
serogroup NN NN O
. NN NN O

Identification NN NN O
of NN NN O
complement NN NN B-Modifier
deficient NN NN I-Modifier
patients NN NN O
allows NN NN O
the NN NN O
implementation NN NN O
of NN NN O
strategies NN NN O
to NN NN O
prevent NN NN O
recurrent NN NN O
infection NN NN O
. NN NN O

. NN NN O

7535801 NN NN O
Molecular NN NN O
basis NN NN O
of NN NN O
subtotal NN NN B-SpecificDisease
complement NN NN I-SpecificDisease
C6 NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

A NN NN O
carboxy-terminally NN NN O
truncated NN NN O
but NN NN O
functionally NN NN O
active NN NN O
C6 NN NN O
. NN NN O

Individuals NN NN O
with NN NN O
subtotal NN NN B-SpecificDisease
complement NN NN I-SpecificDisease
C6 NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
possess NN NN O
a NN NN O
C6 NN NN O
molecule NN NN O
that NN NN O
is NN NN O
14 NN NN O
% NN NN O
shorter NN NN O
than NN NN O
normal NN NN O
C6 NN NN O
and NN NN O
present NN NN O
in NN NN O
low NN NN O
but NN NN O
detectable NN NN O
concentrations NN NN O
( NN NN O
1-2 NN NN O
% NN NN O
of NN NN O
the NN NN O
normal NN NN O
mean NN NN O
) NN NN O
. NN NN O

We NN NN O
now NN NN O
show NN NN O
that NN NN O
this NN NN O
dysmorphic NN NN O
C6 NN NN O
is NN NN O
bactericidally NN NN O
active NN NN O
and NN NN O
lacks NN NN O
an NN NN O
epitope NN NN O
that NN NN O
was NN NN O
mapped NN NN O
to NN NN O
the NN NN O
most NN NN O
carboxy-terminal NN NN O
part NN NN O
of NN NN O
C6 NN NN O
using NN NN O
C6 NN NN O
cDNA NN NN O
fragments NN NN O
expressed NN NN O
as NN NN O
fusion NN NN O
proteins NN NN O
in NN NN O
the NN NN O
pUEX NN NN O
expression NN NN O
system NN NN O
. NN NN O

We NN NN O
thus NN NN O
predicted NN NN O
that NN NN O
the NN NN O
abnormal NN NN O
C6 NN NN O
molecule NN NN O
might NN NN O
be NN NN O
carboxy-terminally NN NN O
truncated NN NN O
and NN NN O
sought NN NN O
a NN NN O
mutation NN NN O
in NN NN O
an NN NN O
area NN NN O
approximately NN NN O
14 NN NN O
% NN NN O
from NN NN O
the NN NN O
carboxy-terminal NN NN O
end NN NN O
of NN NN O
the NN NN O
coding NN NN O
sequence NN NN O
. NN NN O

By NN NN O
sequencing NN NN O
PCR-amplified NN NN O
products NN NN O
from NN NN O
this NN NN O
region NN NN O
, NN NN O
we NN NN O
found NN NN O
, NN NN O
in NN NN O
three NN NN O
individuals NN NN O
from NN NN O
two NN NN O
families NN NN O
, NN NN O
a NN NN O
mutation NN NN O
that NN NN O
might NN NN O
plausibly NN NN O
be NN NN O
responsible NN NN O
for NN NN O
the NN NN O
defect NN NN O
. NN NN O

All NN NN O
three NN NN O
have NN NN O
an NN NN O
abnormal NN NN O
5 NN NN O
splice NN NN O
donor NN NN O
site NN NN O
of NN NN O
intron NN NN O
15 NN NN O
, NN NN O
which NN NN O
would NN NN O
probably NN NN O
prevent NN NN O
splicing NN NN O
. NN NN O

An NN NN O
in-frame NN NN O
stop NN NN O
codon NN NN O
is NN NN O
found NN NN O
17 NN NN O
codons NN NN O
downstream NN NN O
from NN NN O
the NN NN O
intron NN NN O
boundary NN NN O
, NN NN O
which NN NN O
would NN NN O
lead NN NN O
to NN NN O
a NN NN O
truncated NN NN O
polypeptide NN NN O
13 NN NN O
. NN NN O

5 NN NN O
% NN NN O
smaller NN NN O
than NN NN O
normal NN NN O
C6 NN NN O
. NN NN O

This NN NN O
result NN NN O
was NN NN O
unexpected NN NN O
, NN NN O
as NN NN O
earlier NN NN O
studies NN NN O
mapped NN NN O
the NN NN O
C5b NN NN O
binding NN NN O
site NN NN O
, NN NN O
or NN NN O
a NN NN O
putative NN NN O
enzymatic NN NN O
region NN NN O
, NN NN O
to NN NN O
this NN NN O
part NN NN O
of NN NN O
C6 NN NN O
. NN NN O

Interestingly NN NN O
, NN NN O
all NN NN O
three NN NN O
subjects NN NN O
were NN NN O
probably NN NN O
heterozygous NN NN O
for NN NN O
both NN NN O
subtotal NN NN B-CompositeMention
C6 NN NN I-CompositeMention
and NN NN I-CompositeMention
complete NN NN I-CompositeMention
C6 NN NN I-CompositeMention
deficiency NN NN I-CompositeMention
. NN NN O

7543316 NN NN O
Myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
: NN NN O
evidence NN NN O
for NN NN O
a NN NN O
possible NN NN O
dominant-negative NN NN O
RNA NN NN O
mutation NN NN O
. NN NN O

The NN NN O
trinucleotide NN NN O
expansion NN NN O
mutation NN NN O
causing NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
is NN NN O
in NN NN O
the NN NN O
3 NN NN O
untranslated NN NN O
region NN NN O
of NN NN O
a NN NN O
protein NN NN O
kinase NN NN O
gene NN NN O
. NN NN O

The NN NN O
molecular NN NN O
mechanisms NN NN O
by NN NN O
which NN NN O
the NN NN O
expanded NN NN O
repeat NN NN O
causes NN NN O
the NN NN O
clinically NN NN O
variable NN NN O
and NN NN O
multisystemic NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
, NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
, NN NN O
are NN NN O
not NN NN O
understood NN NN O
. NN NN O

It NN NN O
has NN NN O
been NN NN O
particularly NN NN O
difficult NN NN O
to NN NN O
rationalize NN NN O
the NN NN O
dominant NN NN O
inheritance NN NN O
with NN NN O
the NN NN O
fact NN NN O
that NN NN O
the NN NN O
expansion NN NN O
mutation NN NN O
lies NN NN O
outside NN NN O
of NN NN O
the NN NN O
protein-encoding NN NN O
gene NN NN O
elements NN NN O
, NN NN O
and NN NN O
should NN NN O
not NN NN O
be NN NN O
translated NN NN O
into NN NN O
protein NN NN O
. NN NN O

Here NN NN O
we NN NN O
use NN NN O
muscle NN NN O
biopsies NN NN O
from NN NN O
classical NN NN O
adult-onset NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
patients NN NN O
to NN NN O
study NN NN O
the NN NN O
accumulation NN NN O
of NN NN O
transcripts NN NN O
from NN NN O
both NN NN O
the NN NN O
normal NN NN O
and NN NN O
expanded NN NN O
DM NN NN B-Modifier
kinase NN NN O
genes NN NN O
in NN NN O
patient NN NN O
muscle NN NN O
, NN NN O
and NN NN O
compare NN NN O
the NN NN O
results NN NN O
to NN NN O
normal NN NN O
and NN NN O
myopathic NN NN B-Modifier
controls NN NN O
. NN NN O

We NN NN O
found NN NN O
relatively NN NN O
small NN NN O
decreases NN NN O
of NN NN O
DM NN NN B-Modifier
kinase NN NN O
RNA NN NN O
in NN NN O
the NN NN O
total NN NN O
RNA NN NN O
pool NN NN O
from NN NN O
muscle NN NN O
; NN NN O
however NN NN O
, NN NN O
these NN NN O
reductions NN NN O
were NN NN O
not NN NN O
disease NN NN O
specific NN NN O
. NN NN O

Analysis NN NN O
of NN NN O
poly NN NN O
( NN NN O
A NN NN O
) NN NN O
+ NN NN O
RNA NN NN O
showed NN NN O
dramatic NN NN O
decreases NN NN O
of NN NN O
both NN NN O
the NN NN O
mutant NN NN O
and NN NN O
normal NN NN O
DM NN NN B-Modifier
kinase NN NN O
RNAs NN NN O
, NN NN O
and NN NN O
these NN NN O
changes NN NN O
were NN NN O
disease-specific NN NN O
. NN NN O

Our NN NN O
findings NN NN O
are NN NN O
consistent NN NN O
with NN NN O
a NN NN O
novel NN NN O
molecular NN NN O
pathogenetic NN NN O
mechanism NN NN O
for NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
both NN NN O
the NN NN O
normal NN NN O
and NN NN O
expanded NN NN O
DM NN NN B-Modifier
kinase NN NN O
genes NN NN O
are NN NN O
transcribed NN NN O
in NN NN O
patient NN NN O
muscle NN NN O
, NN NN O
but NN NN O
the NN NN O
abnormal NN NN O
expansion-containing NN NN O
RNA NN NN O
has NN NN O
a NN NN O
dominant NN NN O
effect NN NN O
on NN NN O
RNA NN NN O
metabolism NN NN O
by NN NN O
preventing NN NN O
the NN NN O
accumulation NN NN O
of NN NN O
poly NN NN O
( NN NN O
A NN NN O
) NN NN O
+ NN NN O
RNA NN NN O
. NN NN O

The NN NN O
ability NN NN O
of NN NN O
the NN NN O
expansion NN NN O
mutation NN NN O
to NN NN O
alter NN NN O
accumulation NN NN O
of NN NN O
poly NN NN O
( NN NN O
A NN NN O
) NN NN O
+ NN NN O
RNA NN NN O
in NN NN O
trans NN NN O
suggests NN NN O
that NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
may NN NN O
be NN NN O
the NN NN O
first NN NN O
example NN NN O
of NN NN O
a NN NN O
dominant-negative NN NN O
mutation NN NN O
manifested NN NN O
at NN NN O
the NN NN O
RNA NN NN O
level NN NN O
. NN NN O

. NN NN O

7545954 NN NN O
A NN NN O
strong NN NN O
candidate NN NN O
for NN NN O
the NN NN O
breast NN NN B-Modifier
and NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
susceptibility NN NN O
gene NN NN O
BRCA1 NN NN O
. NN NN O

A NN NN O
strong NN NN O
candidate NN NN O
for NN NN O
the NN NN O
17q-linked NN NN O
BRCA1 NN NN O
gene NN NN O
, NN NN O
which NN NN O
influences NN NN O
susceptibility NN NN O
to NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
, NN NN O
has NN NN O
been NN NN O
identified NN NN O
by NN NN O
positional NN NN O
cloning NN NN O
methods NN NN O
. NN NN O

Probable NN NN O
predisposing NN NN O
mutations NN NN O
have NN NN O
been NN NN O
detected NN NN O
in NN NN O
five NN NN O
of NN NN O
eight NN NN O
kindreds NN NN O
presumed NN NN O
to NN NN O
segregate NN NN O
BRCA1 NN NN O
susceptibility NN NN O
alleles NN NN O
. NN NN O

The NN NN O
mutations NN NN O
include NN NN O
an NN NN O
11-base NN NN O
pair NN NN O
deletion NN NN O
, NN NN O
a NN NN O
1-base NN NN O
pair NN NN O
insertion NN NN O
, NN NN O
a NN NN O
stop NN NN O
codon NN NN O
, NN NN O
a NN NN O
missense NN NN O
substitution NN NN O
, NN NN O
and NN NN O
an NN NN O
inferred NN NN O
regulatory NN NN O
mutation NN NN O
. NN NN O

The NN NN O
BRCA1 NN NN O
gene NN NN O
is NN NN O
expressed NN NN O
in NN NN O
numerous NN NN O
tissues NN NN O
, NN NN O
including NN NN O
breast NN NN O
and NN NN O
ovary NN NN O
, NN NN O
and NN NN O
encodes NN NN O
a NN NN O
predicted NN NN O
protein NN NN O
of NN NN O
1863 NN NN O
amino NN NN O
acids NN NN O
. NN NN O

This NN NN O
protein NN NN O
contains NN NN O
a NN NN O
zinc NN NN O
finger NN NN O
domain NN NN O
in NN NN O
its NN NN O
amino-terminal NN NN O
region NN NN O
, NN NN O
but NN NN O
is NN NN O
otherwise NN NN O
unrelated NN NN O
to NN NN O
previously NN NN O
described NN NN O
proteins NN NN O
. NN NN O

Identification NN NN O
of NN NN O
BRCA1 NN NN O
should NN NN O
facilitate NN NN O
early NN NN O
diagnosis NN NN O
of NN NN O
breast NN NN B-Modifier
and NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
susceptibility NN NN O
in NN NN O
some NN NN O
individuals NN NN O
as NN NN O
well NN NN O
as NN NN O
a NN NN O
better NN NN O
understanding NN NN O
of NN NN O
breast NN NN B-Modifier
cancer NN NN I-Modifier
biology NN NN O
. NN NN O

. NN NN O

7550229 NN NN O
Molecular NN NN O
characterization NN NN O
of NN NN O
galactosemia NN NN B-Modifier
( NN NN O
type NN NN O
1 NN NN O
) NN NN O
mutations NN NN O
in NN NN O
Japanese NN NN O
. NN NN O

We NN NN O
characterized NN NN O
two NN NN O
novel NN NN O
mutations NN NN O
of NN NN O
the NN NN O
galactose-1-phosphate NN NN O
uridyltransferase NN NN O
( NN NN O
GALT NN NN O
) NN NN O
gene NN NN O
in NN NN O
two NN NN O
Japanese NN NN O
patients NN NN O
with NN NN O
GALT NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
and NN NN O
identified NN NN O
N314D NN NN O
and NN NN O
R333W NN NN O
mutations NN NN O
, NN NN O
previously NN NN O
found NN NN O
in NN NN O
Caucasians NN NN O
. NN NN O

One NN NN O
novel NN NN O
missense NN NN O
mutation NN NN O
was NN NN O
an NN NN O
G-to-A NN NN O
transition NN NN O
in NN NN O
exon NN NN O
8 NN NN O
, NN NN O
resulting NN NN O
in NN NN O
the NN NN O
substitution NN NN O
of NN NN O
arginine NN NN O
by NN NN O
histidine NN NN O
at NN NN O
the NN NN O
codon NN NN O
231 NN NN O
( NN NN O
R231H NN NN O
) NN NN O
. NN NN O

GALT NN NN O
activity NN NN O
of NN NN O
the NN NN O
R231H NN NN O
mutant NN NN O
construct NN NN O
was NN NN O
reduced NN NN O
to NN NN O
15 NN NN O
% NN NN O
of NN NN O
normal NN NN O
controls NN NN O
in NN NN O
a NN NN O
COS NN NN O
cell NN NN O
expression NN NN O
system NN NN O
. NN NN O

The NN NN O
other NN NN O
was NN NN O
a NN NN O
splicing NN NN O
mutation NN NN O
, NN NN O
an NN NN O
A-to-G NN NN O
transition NN NN O
at NN NN O
the NN NN O
38th NN NN O
nucleotide NN NN O
in NN NN O
exon NN NN O
3 NN NN O
( NN NN O
318A NN NN O
-- NN NN O
G NN NN O
) NN NN O
, NN NN O
resulting NN NN O
in NN NN O
a NN NN O
38-bp NN NN O
deletion NN NN O
in NN NN O
the NN NN O
GALT NN NN O
cDNA NN NN O
by NN NN O
activating NN NN O
a NN NN O
cryptic NN NN O
splice NN NN O
acceptor NN NN O
site NN NN O
. NN NN O

In NN NN O
seven NN NN O
Japanese NN NN O
families NN NN O
( NN NN O
14 NN NN O
alleles NN NN O
for NN NN O
classic NN NN O
form NN NN O
and NN NN O
one NN NN O
allele NN NN O
for NN NN O
Duarte NN NN O
variant NN NN O
) NN NN O
with NN NN O
GALT NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
, NN NN O
the NN NN O
R231H NN NN O
and NN NN O
318A NN NN O
-- NN NN O
G NN NN O
mutations NN NN O
were NN NN O
found NN NN O
only NN NN O
on NN NN O
both NN NN O
alleles NN NN O
of NN NN O
the NN NN O
proband NN NN O
. NN NN O

The NN NN O
N314D NN NN O
and NN NN O
R333W NN NN O
mutations NN NN O
were NN NN O
found NN NN O
on NN NN O
one NN NN O
allele NN NN O
each NN NN O
. NN NN O

The NN NN O
Q188R NN NN O
was NN NN O
prevalent NN NN O
in NN NN O
the NN NN O
United NN NN O
States NN NN O
but NN NN O
not NN NN O
in NN NN O
Japanese NN NN O
patients NN NN O
. NN NN O

The NN NN O
N314D NN NN O
mutation NN NN O
was NN NN O
associated NN NN O
with NN NN O
the NN NN O
Duarte NN NN O
variant NN NN O
in NN NN O
Japanese NN NN O
persons NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
in NN NN O
the NN NN O
United NN NN O
States NN NN O
. NN NN O

We NN NN O
speculate NN NN O
that NN NN O
classic NN NN B-Modifier
galactosemia NN NN I-Modifier
mutations NN NN O
appear NN NN O
to NN NN O
differ NN NN O
between NN NN O
Japanese NN NN O
and NN NN O
Caucasian NN NN O
patients NN NN O
. NN NN O

Our NN NN O
limited NN NN O
data NN NN O
set NN NN O
on NN NN O
galactosemia NN NN B-Modifier
mutations NN NN O
in NN NN O
Japanese NN NN O
suggests NN NN O
that NN NN O
the NN NN O
N314D NN NN O
GALT NN NN O
mutation NN NN O
encoding NN NN O
the NN NN O
Duarte NN NN O
variant NN NN O
arose NN NN O
before NN NN O
Asian NN NN O
and NN NN O
Caucasian NN NN O
people NN NN O
diverged NN NN O
and NN NN O
that NN NN O
classic NN NN B-Modifier
galactosemia NN NN I-Modifier
mutations NN NN O
arose NN NN O
and NN NN O
/ NN NN O
or NN NN O
accumulated NN NN O
after NN NN O
the NN NN O
divergence NN NN O
of NN NN O
Asian NN NN O
and NN NN O
Caucasian NN NN O
populations NN NN O
. NN NN O

. NN NN O

7550230 NN NN O
Three NN NN O
novel NN NN O
aniridia NN NN B-Modifier
mutations NN NN O
in NN NN O
the NN NN O
human NN NN O
PAX6 NN NN O
gene NN NN O
. NN NN O

Aniridia NN NN B-SpecificDisease
( NN NN O
iris NN NN B-SpecificDisease
hypoplasia NN NN I-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
dominant NN NN I-DiseaseClass
congenital NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
of NN NN I-DiseaseClass
the NN NN I-DiseaseClass
eye NN NN I-DiseaseClass
. NN NN O

Mutations NN NN O
in NN NN O
the NN NN O
human NN NN O
aniridia NN NN B-Modifier
( NN NN O
PAX6 NN NN O
) NN NN O
gene NN NN O
have NN NN O
now NN NN O
been NN NN O
identified NN NN O
in NN NN O
many NN NN O
patients NN NN O
from NN NN O
various NN NN O
ethnic NN NN O
groups NN NN O
. NN NN O

In NN NN O
the NN NN O
study NN NN O
reported NN NN O
here NN NN O
we NN NN O
describe NN NN O
PAX6 NN NN O
mutations NN NN O
in NN NN O
one NN NN O
sporadic NN NN O
and NN NN O
five NN NN O
familial NN NN O
cases NN NN O
with NN NN O
aniridia NN NN B-SpecificDisease
. NN NN O

Of NN NN O
the NN NN O
four NN NN O
different NN NN O
mutations NN NN O
identified NN NN O
, NN NN O
one NN NN O
was NN NN O
identical NN NN O
to NN NN O
a NN NN O
previously NN NN O
reported NN NN O
mutation NN NN O
( NN NN O
C NN NN O
-- NN NN O
T NN NN O
transition NN NN O
at NN NN O
codon NN NN O
240 NN NN O
) NN NN O
, NN NN O
and NN NN O
three NN NN O
were NN NN O
novel NN NN O
two NN NN O
in NN NN O
the NN NN O
glycine-rich NN NN O
region NN NN O
and NN NN O
one NN NN O
in NN NN O
the NN NN O
proline NN NN O
/ NN NN O
serine NN NN O
/ NN NN O
threonine-rich NN NN O
( NN NN O
PST NN NN O
) NN NN O
region NN NN O
. NN NN O

One NN NN O
PAX6 NN NN O
mutation NN NN O
found NN NN O
in NN NN O
the NN NN O
PST NN NN O
region NN NN O
was NN NN O
associated NN NN O
with NN NN O
cataracts NN NN B-SpecificDisease
in NN NN O
an NN NN O
aniridia NN NN B-Modifier
family NN NN O
. NN NN O

Another NN NN O
splice NN NN O
mutation NN NN O
in NN NN O
the NN NN O
PST NN NN O
domain NN NN O
occurred NN NN O
in NN NN O
an NN NN O
aniridia NN NN B-Modifier
patient NN NN O
with NN NN O
anosmia NN NN B-SpecificDisease
( NN NN O
inability NN NN O
to NN NN O
smell NN NN O
) NN NN O
. NN NN O

The NN NN O
six NN NN O
new NN NN O
aniridia NN NN B-Modifier
cases NN NN O
reported NN NN O
here NN NN O
have NN NN O
mutations NN NN O
predicted NN NN O
to NN NN O
generate NN NN O
incomplete NN NN O
PAX6 NN NN O
proteins NN NN O
. NN NN O

These NN NN O
results NN NN O
support NN NN O
the NN NN O
theory NN NN O
that NN NN O
human NN NN O
aniridia NN NN B-SpecificDisease
is NN NN O
caused NN NN O
by NN NN O
haploinsufficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
PAX6 NN NN I-SpecificDisease
. NN NN O

. NN NN O

7550349 NN NN O
The NN NN O
carrier NN NN O
frequency NN NN O
of NN NN O
the NN NN O
BRCA1 NN NN O
185delAG NN NN O
mutation NN NN O
is NN NN O
approximately NN NN O
1 NN NN O
percent NN NN O
in NN NN O
Ashkenazi NN NN O
Jewish NN NN O
individuals NN NN O
. NN NN O

Since NN NN O
BRCA1 NN NN O
, NN NN O
the NN NN O
first NN NN O
major NN NN O
gene NN NN O
responsible NN NN O
for NN NN O
inherited NN NN B-SpecificDisease
breast NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
, NN NN O
was NN NN O
cloned NN NN O
, NN NN O
more NN NN O
than NN NN O
50 NN NN O
unique NN NN O
mutations NN NN O
have NN NN O
been NN NN O
detected NN NN O
in NN NN O
the NN NN O
germline NN NN O
of NN NN O
individuals NN NN O
with NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
. NN NN O

In NN NN O
high-risk NN NN O
pedigrees NN NN O
, NN NN O
female NN NN O
carriers NN NN O
of NN NN O
BRCA1 NN NN O
mutations NN NN O
have NN NN O
an NN NN O
80-90 NN NN O
% NN NN O
lifetime NN NN O
risk NN NN O
of NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
, NN NN O
and NN NN O
a NN NN O
40-50 NN NN O
% NN NN O
risk NN NN O
of NN NN O
ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

However NN NN O
, NN NN O
the NN NN O
mutation NN NN O
stats NN NN O
of NN NN O
individuals NN NN O
unselected NN NN O
for NN NN O
breast NN NN B-CompositeMention
or NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
has NN NN O
not NN NN O
been NN NN O
determined NN NN O
, NN NN O
and NN NN O
it NN NN O
is NN NN O
not NN NN O
known NN NN O
whether NN NN O
mutations NN NN O
in NN NN O
such NN NN O
individuals NN NN O
confer NN NN O
the NN NN O
same NN NN O
risk NN NN O
of NN NN O
cancer NN NN B-DiseaseClass
as NN NN O
in NN NN O
individuals NN NN O
from NN NN O
the NN NN O
high-risk NN NN O
families NN NN O
studied NN NN O
so NN NN O
far NN NN O
. NN NN O

Following NN NN O
the NN NN O
finding NN NN O
of NN NN O
a NN NN O
185delAG NN NN O
frameshift NN NN O
mutation NN NN O
in NN NN O
several NN NN O
Ashkenazi NN NN O
Jewish NN NN O
breast NN NN O
/ NN NN O
ovarian NN NN O
families NN NN O
, NN NN O
we NN NN O
have NN NN O
determined NN NN O
the NN NN O
frequency NN NN O
of NN NN O
this NN NN O
mutation NN NN O
in NN NN O
858 NN NN O
Ashkenazim NN NN O
seeking NN NN O
genetic NN NN O
testing NN NN O
for NN NN O
conditions NN NN O
unrelated NN NN O
to NN NN O
cancer NN NN B-DiseaseClass
, NN NN O
and NN NN O
in NN NN O
815 NN NN O
reference NN NN O
individuals NN NN O
not NN NN O
selected NN NN O
for NN NN O
ethnic NN NN O
origin NN NN O
. NN NN O

We NN NN O
observed NN NN O
the NN NN O
185delAG NN NN O
mutation NN NN O
in NN NN O
0 NN NN O
. NN NN O

9 NN NN O
% NN NN O
of NN NN O
Ashkenazim NN NN O
( NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
limit NN NN O
, NN NN O
0 NN NN O
. NN NN O

4-1 NN NN O
. NN NN O

8 NN NN O
% NN NN O
) NN NN O
and NN NN O
in NN NN O
none NN NN O
of NN NN O
the NN NN O
reference NN NN O
samples NN NN O
. NN NN O

Our NN NN O
results NN NN O
suggest NN NN O
that NN NN O
one NN NN O
in NN NN O
a NN NN O
hundred NN NN O
women NN NN O
of NN NN O
Ashkenazi NN NN O
descent NN NN O
may NN NN O
be NN NN O
at NN NN O
especially NN NN O
high NN NN O
risk NN NN O
of NN NN O
developing NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
/ NN NN I-CompositeMention
or NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
. NN NN O

7568002 NN NN O
Identification NN NN O
and NN NN O
localization NN NN O
of NN NN O
huntingtin NN NN O
in NN NN O
brain NN NN O
and NN NN O
human NN NN O
lymphoblastoid NN NN O
cell NN NN O
lines NN NN O
with NN NN O
anti-fusion NN NN O
protein NN NN O
antibodies NN NN O
. NN NN O

The NN NN O
Huntington NN NN B-Modifier
disease NN NN I-Modifier
( NN NN O
HD NN NN B-Modifier
) NN NN O
phenotype NN NN O
is NN NN O
associated NN NN O
with NN NN O
expansion NN NN O
of NN NN O
a NN NN O
trinucleotide NN NN O
repeat NN NN O
in NN NN O
the NN NN O
IT15 NN NN O
gene NN NN O
, NN NN O
which NN NN O
is NN NN O
predicted NN NN O
to NN NN O
encode NN NN O
a NN NN O
348-kDa NN NN O
protein NN NN O
named NN NN O
huntington NN NN O
. NN NN O

We NN NN O
used NN NN O
polyclonal NN NN O
and NN NN O
monoclonal NN NN O
anti-fusion NN NN O
protein NN NN O
antibodies NN NN O
to NN NN O
identify NN NN O
native NN NN O
huntingtin NN NN O
in NN NN O
rat NN NN O
, NN NN O
monkey NN NN O
, NN NN O
and NN NN O
human NN NN O
. NN NN O

Western NN NN O
blots NN NN O
revealed NN NN O
a NN NN O
protein NN NN O
with NN NN O
the NN NN O
expected NN NN O
molecular NN NN O
weight NN NN O
which NN NN O
is NN NN O
present NN NN O
in NN NN O
the NN NN O
soluble NN NN O
fraction NN NN O
of NN NN O
rat NN NN O
and NN NN O
monkey NN NN O
brain NN NN O
tissues NN NN O
and NN NN O
lymphoblastoid NN NN O
cells NN NN O
from NN NN O
control NN NN O
cases NN NN O
. NN NN O

In NN NN O
lymphoblastoid NN NN O
cell NN NN O
lines NN NN O
from NN NN O
juvenile-onset NN NN O
heterozygote NN NN O
HD NN NN B-Modifier
cases NN NN O
, NN NN O
both NN NN O
normal NN NN O
and NN NN O
mutant NN NN O
huntingtin NN NN O
are NN NN O
expressed NN NN O
, NN NN O
and NN NN O
increasing NN NN O
repeat NN NN O
expansion NN NN O
leads NN NN O
to NN NN O
lower NN NN O
levels NN NN O
of NN NN O
the NN NN O
mutant NN NN O
protein NN NN O
. NN NN O

Immunocytochemistry NN NN O
indicates NN NN O
that NN NN O
huntingtin NN NN O
is NN NN O
located NN NN O
in NN NN O
neurons NN NN O
throughout NN NN O
the NN NN O
brain NN NN O
, NN NN O
with NN NN O
the NN NN O
highest NN NN O
levels NN NN O
evident NN NN O
in NN NN O
larger NN NN O
neurons NN NN O
. NN NN O

In NN NN O
the NN NN O
human NN NN O
striatum NN NN O
, NN NN O
huntingtin NN NN O
is NN NN O
enriched NN NN O
in NN NN O
a NN NN O
patch-like NN NN O
distribution NN NN O
, NN NN O
potentially NN NN O
corresponding NN NN O
to NN NN O
the NN NN O
first NN NN O
areas NN NN O
affected NN NN O
in NN NN O
HD NN NN B-SpecificDisease
. NN NN O

Subcellular NN NN O
localization NN NN O
of NN NN O
huntingtin NN NN O
is NN NN O
consistent NN NN O
with NN NN O
a NN NN O
cytosolic NN NN O
protein NN NN O
primarily NN NN O
found NN NN O
in NN NN O
somatodendritic NN NN O
regions NN NN O
. NN NN O

Huntingtin NN NN O
appears NN NN O
to NN NN O
particularly NN NN O
associate NN NN O
with NN NN O
microtubules NN NN O
, NN NN O
although NN NN O
some NN NN O
is NN NN O
also NN NN O
associated NN NN O
with NN NN O
synaptic NN NN O
vesicles NN NN O
. NN NN O

On NN NN O
the NN NN O
basis NN NN O
of NN NN O
the NN NN O
localization NN NN O
of NN NN O
huntingtin NN NN O
in NN NN O
association NN NN O
with NN NN O
microtubules NN NN O
, NN NN O
we NN NN O
speculate NN NN O
that NN NN O
the NN NN O
mutation NN NN O
impairs NN NN O
the NN NN O
cytoskeletal NN NN O
anchoring NN NN O
or NN NN O
transport NN NN O
of NN NN O
mitochondria NN NN O
, NN NN O
vesicles NN NN O
, NN NN O
or NN NN O
other NN NN O
organelles NN NN O
or NN NN O
molecules NN NN O
. NN NN O

. NN NN O

7573040 NN NN O
Marked NN NN O
phenotypic NN NN O
heterogeneity NN NN O
associated NN NN O
with NN NN O
expansion NN NN O
of NN NN O
a NN NN O
CAG NN NN O
repeat NN NN O
sequence NN NN O
at NN NN O
the NN NN O
spinocerebellar NN NN B-Modifier
ataxia NN NN I-Modifier
3/Machado-Joseph NN NN I-Modifier
disease NN NN I-Modifier
locus NN NN O
. NN NN O

The NN NN O
spinocerebellar NN NN B-Modifier
ataxia NN NN I-Modifier
3 NN NN I-Modifier
locus NN NN O
( NN NN O
SCA3 NN NN B-SpecificDisease
) NN NN O
for NN NN O
type NN NN B-SpecificDisease
I NN NN I-SpecificDisease
autosomal NN NN I-SpecificDisease
dominant NN NN I-SpecificDisease
cerebellar NN NN I-SpecificDisease
ataxia NN NN I-SpecificDisease
( NN NN O
ADCA NN NN B-SpecificDisease
type NN NN I-SpecificDisease
I NN NN I-SpecificDisease
) NN NN O
, NN NN O
a NN NN O
clinically NN NN O
and NN NN O
genetically NN NN O
heterogeneous NN NN O
group NN NN O
of NN NN O
neurodegenerative NN NN B-DiseaseClass
disorders NN NN I-DiseaseClass
, NN NN O
has NN NN O
been NN NN O
mapped NN NN O
to NN NN O
chromosome NN NN O
14q32 NN NN O
. NN NN O

1 NN NN O
1 NN NN O
. NN NN O

ADCA NN NN B-Modifier
type NN NN I-Modifier
I NN NN I-Modifier
patients NN NN O
from NN NN O
families NN NN O
segregating NN NN O
SCA3 NN NN B-SpecificDisease
share NN NN O
clinical NN NN O
features NN NN O
in NN NN O
common NN NN O
with NN NN O
those NN NN O
with NN NN O
Machado-Joseph NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
MJD NN NN B-SpecificDisease
) NN NN O
, NN NN O
the NN NN O
gene NN NN O
of NN NN O
which NN NN O
maps NN NN O
to NN NN O
the NN NN O
same NN NN O
region NN NN O
. NN NN O

We NN NN O
show NN NN O
here NN NN O
that NN NN O
the NN NN O
disease NN NN O
gene NN NN O
segregating NN NN O
in NN NN O
each NN NN O
of NN NN O
three NN NN O
French NN NN O
ADCA NN NN B-Modifier
type NN NN I-Modifier
I NN NN I-Modifier
kindreds NN NN O
and NN NN O
in NN NN O
a NN NN O
French NN NN O
family NN NN O
with NN NN O
neuropathological NN NN O
findings NN NN O
suggesting NN NN O
the NN NN O
ataxochoreic NN NN O
form NN NN O
of NN NN O
dentatorubropallidoluysian NN NN B-SpecificDisease
atrophy NN NN I-SpecificDisease
carries NN NN O
an NN NN O
expanded NN NN O
CAG NN NN O
repeat NN NN O
sequence NN NN O
located NN NN O
at NN NN O
the NN NN O
same NN NN O
locus NN NN O
as NN NN O
that NN NN O
for NN NN O
MJD NN NN B-SpecificDisease
. NN NN O

Analysis NN NN O
of NN NN O
the NN NN O
mutation NN NN O
in NN NN O
these NN NN O
families NN NN O
shows NN NN O
a NN NN O
strong NN NN O
negative NN NN O
correlation NN NN O
between NN NN O
size NN NN O
of NN NN O
the NN NN O
expanded NN NN O
CAG NN NN O
repeat NN NN O
and NN NN O
age NN NN O
at NN NN O
onset NN NN O
of NN NN O
clinical NN NN O
disease NN NN O
. NN NN O

Instability NN NN O
of NN NN O
the NN NN O
expanded NN NN O
triplet NN NN O
repeat NN NN O
was NN NN O
not NN NN O
found NN NN O
to NN NN O
be NN NN O
affected NN NN O
by NN NN O
sex NN NN O
of NN NN O
the NN NN O
parent NN NN O
transmitting NN NN O
the NN NN O
mutation NN NN O
. NN NN O

Evidence NN NN O
was NN NN O
found NN NN O
for NN NN O
somatic NN NN O
and NN NN O
gonadal NN NN O
mosaicism NN NN O
for NN NN O
alleles NN NN O
carrying NN NN O
expanded NN NN O
trinucleotide NN NN O
repeats NN NN O
. NN NN O

7574457 NN NN O
Overexpression NN NN O
of NN NN O
DM20 NN NN O
messenger NN NN O
RNA NN NN O
in NN NN O
two NN NN O
brothers NN NN O
with NN NN O
Pelizaeus-Merzbacher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

Pelizaeus-Merzbacher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
is NN NN O
a NN NN O
rare NN NN B-DiseaseClass
, NN NN I-DiseaseClass
sex-linked NN NN I-DiseaseClass
recessive NN NN I-DiseaseClass
, NN NN I-DiseaseClass
dysmyelinating NN NN I-DiseaseClass
disease NN NN I-DiseaseClass
of NN NN I-DiseaseClass
the NN NN I-DiseaseClass
central NN NN I-DiseaseClass
nervous NN NN I-DiseaseClass
system NN NN I-DiseaseClass
that NN NN O
has NN NN O
been NN NN O
associated NN NN O
with NN NN O
mutations NN NN O
in NN NN O
the NN NN O
myelin NN NN O
proteolipid NN NN O
protein NN NN O
( NN NN O
PLP NN NN O
) NN NN O
gene NN NN O
. NN NN O

Only NN NN O
25 NN NN O
% NN NN O
of NN NN O
patients NN NN O
studied NN NN O
with NN NN O
Pelizaeus-Merzbacher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
have NN NN O
exonic NN NN O
mutations NN NN O
in NN NN O
this NN NN O
gene NN NN O
, NN NN O
the NN NN O
underlying NN NN O
cause NN NN O
of NN NN O
the NN NN O
disease NN NN O
in NN NN O
the NN NN O
remaining NN NN O
patients NN NN O
is NN NN O
unknown NN NN O
. NN NN O

The NN NN O
PLP NN NN O
gene NN NN O
encodes NN NN O
two NN NN O
major NN NN O
alternatively NN NN O
spliced NN NN O
transcripts NN NN O
called NN NN O
PLP NN NN O
and NN NN O
DM20 NN NN O
. NN NN O

PLP NN NN O
messenger NN NN O
RNA NN NN O
is NN NN O
specifically NN NN O
expressed NN NN O
in NN NN O
central NN NN O
nervous NN NN O
system NN NN O
tissue NN NN O
, NN NN O
whereas NN NN O
DM20 NN NN O
messenger NN NN O
RNA NN NN O
is NN NN O
found NN NN O
in NN NN O
central NN NN O
nervous NN NN O
system NN NN O
, NN NN O
cardiac NN NN O
, NN NN O
and NN NN O
other NN NN O
tissues NN NN O
. NN NN O

We NN NN O
studied NN NN O
cultured NN NN O
skin NN NN O
fibroblasts NN NN O
from NN NN O
2 NN NN O
brothers NN NN O
with NN NN O
Pelizaeus-Merzbacher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
who NN NN O
exhibited NN NN O
no NN NN O
detectable NN NN O
exonic NN NN O
mutation NN NN O
of NN NN O
the NN NN O
PLP NN NN O
gene NN NN O
. NN NN O

Examination NN NN O
of NN NN O
RNA NN NN O
from NN NN O
these NN NN O
cells NN NN O
showed NN NN O
that NN NN O
the NN NN O
level NN NN O
of NN NN O
DM20 NN NN O
messenger NN NN O
RNA NN NN O
is NN NN O
elevated NN NN O
sixfold NN NN O
relative NN NN O
to NN NN O
male NN NN O
control NN NN O
skin NN NN O
fibroblasts NN NN O
. NN NN O

An NN NN O
unrelated NN NN O
female NN NN O
carrier NN NN O
, NN NN O
also NN NN O
with NN NN O
no NN NN O
detectable NN NN O
exonic NN NN O
mutation NN NN O
, NN NN O
showed NN NN O
a NN NN O
threefold NN NN O
increase NN NN O
in NN NN O
DM20 NN NN O
messenger NN NN O
RNA NN NN O
in NN NN O
cultured NN NN O
skin NN NN O
fibroblasts NN NN O
. NN NN O

Our NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
in NN NN O
some NN NN O
patients NN NN O
, NN NN O
Pelizaeus-Merzbacher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
is NN NN O
caused NN NN O
by NN NN O
overexpression NN NN O
of NN NN O
PLP NN NN O
gene NN NN O
transcripts NN NN O
, NN NN O
and NN NN O
that NN NN O
in NN NN O
these NN NN O
families NN NN O
a NN NN O
50 NN NN O
% NN NN O
increase NN NN O
of NN NN O
DM20 NN NN O
messenger NN NN O
RNA NN NN O
in NN NN O
females NN NN O
, NN NN O
relative NN NN O
to NN NN O
the NN NN O
increase NN NN O
in NN NN O
affected NN NN O
males NN NN O
, NN NN O
can NN NN O
identify NN NN O
a NN NN O
female NN NN O
carrier NN NN O
. NN NN O

. NN NN O

7579347 NN NN O
The NN NN O
Wiskott-Aldrich NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
and NN NN O
X-linked NN NN B-SpecificDisease
congenital NN NN I-SpecificDisease
thrombocytopenia NN NN I-SpecificDisease
are NN NN O
caused NN NN O
by NN NN O
mutations NN NN O
of NN NN O
the NN NN O
same NN NN O
gene NN NN O
. NN NN O

The NN NN O
Wiskott-Aldrich NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
WAS NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
X-linked NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
characterized NN NN O
by NN NN O
thrombocytopenia NN NN B-SpecificDisease
, NN NN O
small NN NN O
platelets NN NN O
, NN NN O
eczema NN NN B-SpecificDisease
, NN NN O
recurrent NN NN O
infections NN NN O
, NN NN O
and NN NN O
immunodeficiency NN NN B-DiseaseClass
. NN NN O

Besides NN NN O
the NN NN O
classic NN NN O
WAS NN NN B-Modifier
phenotype NN NN O
, NN NN O
there NN NN O
is NN NN O
a NN NN O
group NN NN O
of NN NN O
patients NN NN O
with NN NN O
congenital NN NN B-SpecificDisease
X-linked NN NN I-SpecificDisease
thrombocytopenia NN NN I-SpecificDisease
( NN NN O
XLT NN NN B-SpecificDisease
) NN NN O
who NN NN O
have NN NN O
small NN NN O
platelets NN NN O
but NN NN O
only NN NN O
transient NN NN O
eczema NN NN B-SpecificDisease
, NN NN O
if NN NN O
any NN NN O
, NN NN O
and NN NN O
minimal NN NN O
immune NN NN B-DiseaseClass
deficiency NN NN I-DiseaseClass
. NN NN O

Because NN NN O
the NN NN O
gene NN NN O
responsible NN NN O
for NN NN O
WAS NN NN B-SpecificDisease
has NN NN O
been NN NN O
sequenced NN NN O
, NN NN O
it NN NN O
was NN NN O
possible NN NN O
to NN NN O
correlate NN NN O
the NN NN O
WAS NN NN B-Modifier
phenotypes NN NN O
with NN NN O
WAS NN NN B-Modifier
gene NN NN O
mutations NN NN O
. NN NN O

Using NN NN O
a NN NN O
fingerprinting NN NN O
screening NN NN O
technique NN NN O
, NN NN O
we NN NN O
determined NN NN O
the NN NN O
approximate NN NN O
location NN NN O
of NN NN O
the NN NN O
mutation NN NN O
in NN NN O
13 NN NN O
unrelated NN NN O
WAS NN NN B-Modifier
patients NN NN O
with NN NN O
mild NN NN O
to NN NN O
severe NN NN O
clinical NN NN O
symptoms NN NN O
. NN NN O

Direct NN NN O
sequence NN NN O
analysis NN NN O
of NN NN O
cDNA NN NN O
and NN NN O
genomic NN NN O
DNA NN NN O
obtained NN NN O
from NN NN O
patient-derived NN NN O
cell NN NN O
lines NN NN O
showed NN NN O
12 NN NN O
unique NN NN O
mutations NN NN O
distributed NN NN O
throughout NN NN O
the NN NN O
WAS NN NN B-Modifier
gene NN NN O
, NN NN O
including NN NN O
insertions NN NN O
, NN NN O
deletions NN NN O
, NN NN O
and NN NN O
point NN NN O
mutations NN NN O
resulting NN NN O
in NN NN O
amino NN NN O
acid NN NN O
substitutions NN NN O
, NN NN O
termination NN NN O
, NN NN O
exon NN NN O
skipping NN NN O
, NN NN O
or NN NN O
splicing NN NN O
defects NN NN O
. NN NN O

Of NN NN O
4 NN NN O
unrelated NN NN O
patients NN NN O
with NN NN O
the NN NN O
XLT NN NN B-Modifier
phenotype NN NN O
, NN NN O
3 NN NN O
had NN NN O
missense NN NN O
mutations NN NN O
affecting NN NN O
exon NN NN O
2 NN NN O
and NN NN O
1 NN NN O
had NN NN O
a NN NN O
splice-site NN NN O
mutation NN NN O
affecting NN NN O
exon NN NN O
9 NN NN O
. NN NN O

Patients NN NN O
with NN NN O
classic NN NN O
WAS NN NN B-SpecificDisease
had NN NN O
more NN NN O
complex NN NN O
mutations NN NN O
, NN NN O
resulting NN NN O
in NN NN O
termination NN NN O
codons NN NN O
, NN NN O
frameshift NN NN O
, NN NN O
and NN NN O
early NN NN O
termination NN NN O
. NN NN O

These NN NN O
findings NN NN O
provide NN NN O
direct NN NN O
evidence NN NN O
that NN NN O
XLT NN NN B-SpecificDisease
and NN NN O
WAS NN NN B-SpecificDisease
are NN NN O
caused NN NN O
by NN NN O
mutations NN NN O
of NN NN O
the NN NN O
same NN NN O
gene NN NN O
and NN NN O
suggest NN NN O
that NN NN O
severe NN NN O
clinical NN NN O
phenotypes NN NN O
are NN NN O
associated NN NN O
with NN NN O
complex NN NN O
mutations NN NN O
. NN NN O

. NN NN O

7581380 NN NN O
Myotonia NN NN B-SpecificDisease
levior NN NN I-SpecificDisease
is NN NN O
a NN NN O
chloride NN NN B-DiseaseClass
channel NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
. NN NN O

The NN NN O
group NN NN O
of NN NN O
dominant NN NN B-DiseaseClass
non-dystrophic NN NN I-DiseaseClass
myotonias NN NN I-DiseaseClass
, NN NN O
comprising NN NN O
disorders NN NN O
characterized NN NN O
by NN NN O
clinically NN NN O
similar NN NN O
forms NN NN O
of NN NN O
myogenic NN NN O
muscle NN NN O
stiffness NN NN O
, NN NN O
is NN NN O
genetically NN NN O
inhomogeneous NN NN O
. NN NN O

Dominant NN NN B-SpecificDisease
myotonia NN NN I-SpecificDisease
congenita NN NN I-SpecificDisease
( NN NN O
Thomsens NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
) NN NN O
is NN NN O
linked NN NN O
to NN NN O
CLCN1 NN NN O
, NN NN O
the NN NN O
gene NN NN O
encoding NN NN O
the NN NN O
major NN NN O
muscle NN NN O
chloride NN NN O
channel NN NN O
, NN NN O
localized NN NN O
on NN NN O
chromosome NN NN O
7q35 NN NN O
. NN NN O

In NN NN O
contrast NN NN O
, NN NN O
dominant NN NN B-DiseaseClass
myotonias NN NN I-DiseaseClass
sensitive NN NN O
to NN NN O
potassium NN NN O
are NN NN O
caused NN NN O
by NN NN O
point NN NN O
mutations NN NN O
in NN NN O
SCN4A NN NN O
on NN NN O
chromosome NN NN O
17q NN NN O
, NN NN O
the NN NN O
gene NN NN O
for NN NN O
the NN NN O
alpha NN NN O
subunit NN NN O
of NN NN O
the NN NN O
adult NN NN O
skeletal NN NN O
muscle NN NN O
sodium NN NN O
channel NN NN O
. NN NN O

No NN NN O
linkage NN NN O
or NN NN O
molecular NN NN O
genetic NN NN O
data NN NN O
are NN NN O
as NN NN O
yet NN NN O
available NN NN O
on NN NN O
myotonia NN NN B-SpecificDisease
levior NN NN I-SpecificDisease
characterized NN NN O
by NN NN O
milder NN NN O
symptoms NN NN O
and NN NN O
later NN NN O
onset NN NN O
of NN NN O
myotonia NN NN B-DiseaseClass
than NN NN O
in NN NN O
Thomsens NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
, NN NN O
and NN NN O
absence NN NN O
of NN NN O
muscle NN NN B-SpecificDisease
hypertrophy NN NN I-SpecificDisease
. NN NN O

We NN NN O
report NN NN O
a NN NN O
CLCN1 NN NN O
Gln-552-Arg NN NN O
substitution NN NN O
for NN NN O
a NN NN O
family NN NN O
with NN NN O
dominant NN NN O
inheritance NN NN O
previously NN NN O
diagnosed NN NN O
to NN NN O
have NN NN O
myotonia NN NN B-SpecificDisease
levior NN NN I-SpecificDisease
. NN NN O

Thus NN NN O
, NN NN O
this NN NN O
disorder NN NN O
appears NN NN O
as NN NN O
a NN NN O
variant NN NN O
of NN NN O
Thomsens NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
due NN NN O
to NN NN O
mutations NN NN O
leading NN NN O
to NN NN O
low NN NN O
clinical NN NN O
expressivity NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
we NN NN O
report NN NN O
a NN NN O
novel NN NN O
Ile-290-Met NN NN O
CLCN1 NN NN O
mutation NN NN O
for NN NN O
a NN NN O
typical NN NN O
Thomsen NN NN O
pedigree NN NN O
. NN NN O

In NN NN O
another NN NN O
family NN NN O
previously NN NN O
diagnosed NN NN O
as NN NN O
having NN NN O
Thomsens NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
, NN NN O
we NN NN O
unexpectedly NN NN O
found NN NN O
a NN NN O
CLCN1 NN NN O
14 NN NN O
bp NN NN O
deletion NN NN O
known NN NN O
to NN NN O
cause NN NN O
recessive NN NN B-DiseaseClass
myotonia NN NN I-DiseaseClass
, NN NN O
and NN NN O
a NN NN O
rare NN NN O
Trp-118-Gly NN NN O
polymorphism NN NN O
. NN NN O

. NN NN O

7586656 NN NN O
Southern NN NN O
analysis NN NN O
reveals NN NN O
a NN NN O
large NN NN O
deletion NN NN O
at NN NN O
the NN NN O
hypoxanthine NN NN O
phosphoribosyltransferase NN NN O
locus NN NN O
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
Lesch-Nyhan NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

Whole NN NN O
genomic NN NN O
hprt NN NN O
clones NN NN O
were NN NN O
used NN NN O
in NN NN O
Southern NN NN O
analysis NN NN O
to NN NN O
screen NN NN O
the NN NN O
integrity NN NN O
of NN NN O
the NN NN O
hprt NN NN O
gene NN NN O
in NN NN O
a NN NN O
family NN NN O
that NN NN O
includes NN NN O
a NN NN O
patient NN NN O
with NN NN O
HPRT NN NN B-SpecificDisease
enzyme NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
causal NN NN O
to NN NN O
Lesch-Nyhan NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

A NN NN O
5 NN NN O
kb NN NN O
DNA NN NN O
sequence NN NN O
deletion NN NN O
was NN NN O
found NN NN O
to NN NN O
have NN NN O
its NN NN O
endpoints NN NN O
in NN NN O
the NN NN O
first NN NN O
and NN NN O
third NN NN O
introns NN NN O
. NN NN O

The NN NN O
probes NN NN O
identified NN NN O
the NN NN O
carrier NN NN O
status NN NN O
of NN NN O
female NN NN O
family NN NN O
members NN NN O
, NN NN O
aided NN NN O
by NN NN O
an NN NN O
RFLP NN NN O
carried NN NN O
by NN NN O
the NN NN O
mothers NN NN O
normal NN NN O
X-chromosome NN NN O
. NN NN O

. NN NN O

7599636 NN NN O
Characterisation NN NN O
of NN NN O
molecular NN NN O
defects NN NN O
in NN NN O
X-linked NN NN B-SpecificDisease
amelogenesis NN NN I-SpecificDisease
imperfecta NN NN I-SpecificDisease
( NN NN O
AIH1 NN NN O
) NN NN O
. NN NN O

Amelogenins NN NN O
are NN NN O
an NN NN O
heterogenous NN NN O
family NN NN O
of NN NN O
proteins NN NN O
produced NN NN O
by NN NN O
ameloblasts NN NN O
of NN NN O
the NN NN O
enamel NN NN O
organ NN NN O
during NN NN O
tooth NN NN O
development NN NN O
. NN NN O

Disturbances NN NN O
of NN NN O
enamel NN NN O
formation NN NN O
occur NN NN O
in NN NN O
amelogenesis NN NN B-DiseaseClass
imperfecta NN NN I-DiseaseClass
, NN NN O
a NN NN O
clinically NN NN O
heterogenous NN NN O
group NN NN O
of NN NN O
inherited NN NN B-DiseaseClass
disorders NN NN I-DiseaseClass
characterised NN NN O
by NN NN O
defective NN NN O
enamel NN NN O
biomineralisation NN NN O
. NN NN O

An NN NN O
amelogenin NN NN O
gene NN NN O
, NN NN O
AMGX NN NN O
, NN NN O
has NN NN O
been NN NN O
mapped NN NN O
to NN NN O
the NN NN O
short NN NN O
of NN NN O
the NN NN O
X NN NN O
chromosome NN NN O
( NN NN O
Xp22 NN NN O
. NN NN O

1-p22 NN NN O
. NN NN O

3 NN NN O
) NN NN O
and NN NN O
has NN NN O
been NN NN O
implicated NN NN O
in NN NN O
the NN NN O
molecular NN NN O
pathology NN NN O
of NN NN O
X-linked NN NN B-SpecificDisease
amelogenesis NN NN I-SpecificDisease
imperfecta NN NN I-SpecificDisease
( NN NN O
AIH1 NN NN B-SpecificDisease
) NN NN O
. NN NN O

We NN NN O
have NN NN O
identified NN NN O
three NN NN O
families NN NN O
exhibiting NN NN O
AIH1 NN NN B-SpecificDisease
and NN NN O
screened NN NN O
the NN NN O
AMGX NN NN O
gene NN NN O
for NN NN O
mutations NN NN O
using NN NN O
single-strand NN NN O
conformational NN NN O
polymorphism NN NN O
analysis NN NN O
and NN NN O
DNA NN NN O
sequencing NN NN O
. NN NN O

Three NN NN O
novel NN NN O
mutations NN NN O
were NN NN O
identified NN NN O
a NN NN O
C-T NN NN O
substitution NN NN O
in NN NN O
exon NN NN O
5 NN NN O
, NN NN O
and NN NN O
a NN NN O
G-T NN NN O
substitution NN NN O
and NN NN O
single NN NN O
cytosine NN NN O
deletion NN NN O
in NN NN O
exon NN NN O
6 NN NN O
, NN NN O
confirming NN NN O
the NN NN O
existence NN NN O
of NN NN O
extensive NN NN O
allelic NN NN O
heterogeneity NN NN O
in NN NN O
this NN NN O
condition NN NN O
. NN NN O

The NN NN O
identification NN NN O
of NN NN O
family-specific NN NN O
mutations NN NN O
will NN NN O
enable NN NN O
early NN NN O
identification NN NN O
of NN NN O
affected NN NN O
individuals NN NN O
and NN NN O
correlation NN NN O
of NN NN O
clinical NN NN O
phenotype NN NN O
with NN NN O
genotype NN NN O
will NN NN O
facilitate NN NN O
an NN NN O
objective NN NN O
system NN NN O
of NN NN O
disease NN NN O
classification NN NN O
. NN NN O

7605382 NN NN O
Frequency NN NN O
of NN NN O
exon NN NN O
15 NN NN O
missense NN NN O
mutation NN NN O
( NN NN O
442D NN NN O
: NN NN O
G NN NN O
) NN NN O
in NN NN O
cholesteryl NN NN O
ester NN NN O
transfer NN NN O
protein NN NN O
gene NN NN O
in NN NN O
hyperalphalipoproteinemic NN NN B-Modifier
Japanese NN NN O
subjects NN NN O
. NN NN O

Cholesteryl NN NN O
ester NN NN O
transfer NN NN O
protein NN NN O
( NN NN O
CETP NN NN O
) NN NN O
transfers NN NN O
cholesteryl NN NN O
ester NN NN O
from NN NN O
high NN NN O
density NN NN O
lipoprotein NN NN O
( NN NN O
HDL NN NN O
) NN NN O
to NN NN O
apo NN NN O
B-containing NN NN O
lipoproteins NN NN O
. NN NN O

The NN NN O
hyperalphalipoproteinemia NN NN B-SpecificDisease
caused NN NN O
by NN NN O
CETP NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
is NN NN O
fairly NN NN O
common NN NN O
in NN NN O
Japan NN NN O
and NN NN O
one NN NN O
of NN NN O
the NN NN O
most NN NN O
common NN NN O
mutations NN NN O
in NN NN O
the NN NN O
CETP NN NN O
gene NN NN O
is NN NN O
the NN NN O
splicing NN NN O
defect NN NN O
of NN NN O
the NN NN O
intron NN NN O
14 NN NN O
, NN NN O
the NN NN O
allelic NN NN O
frequency NN NN O
of NN NN O
which NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
be NN NN O
0 NN NN O
. NN NN O

0049 NN NN O
in NN NN O
the NN NN O
Japanese NN NN O
general NN NN O
population NN NN O
. NN NN O

Recently NN NN O
, NN NN O
we NN NN O
have NN NN O
reported NN NN O
a NN NN O
missense NN NN O
mutation NN NN O
in NN NN O
exon NN NN O
15 NN NN O
of NN NN O
the NN NN O
CETP NN NN O
gene NN NN O
( NN NN O
442D NN NN O
G NN NN O
) NN NN O
, NN NN O
showing NN NN O
a NN NN O
dominant NN NN O
effect NN NN O
on NN NN O
the NN NN O
CETP NN NN O
activity NN NN O
and NN NN O
HDL-cholesterol NN NN O
level NN NN O
. NN NN O

In NN NN O
the NN NN O
current NN NN O
study NN NN O
, NN NN O
we NN NN O
determined NN NN O
the NN NN O
frequency NN NN O
of NN NN O
this NN NN O
new NN NN O
mutation NN NN O
in NN NN O
Japanese NN NN O
hyperalphalipoproteinemic NN NN B-Modifier
( NN NN O
HDL-cholesterol NN NN O
or NN NN O
= NN NN O
100 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
) NN NN O
subjects NN NN O
. NN NN O

A NN NN O
rapid NN NN O
and NN NN O
easy NN NN O
screening NN NN O
method NN NN O
for NN NN O
this NN NN O
new NN NN O
mutation NN NN O
was NN NN O
developed NN NN O
using NN NN O
a NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
( NN NN O
PCR NN NN O
) NN NN O
-mediated NN NN O
site-directed NN NN O
mutagenesis NN NN O
. NN NN O

Among NN NN O
117 NN NN O
Japanese NN NN O
hyperalphalipoproteinemic NN NN B-Modifier
subjects NN NN O
( NN NN O
HDL-cholesterol NN NN O
; NN NN O
116 NN NN O
. NN NN O

7 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
16 NN NN O
. NN NN O

5 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
, NN NN O
mean NN NN O
+ NN NN O
/ NN NN O
- NN NN O
S NN NN O
. NN NN O

D NN NN O
. NN NN O
) NN NN O

without NN NN O
the NN NN O
intron NN NN O
14 NN NN O
splice NN NN O
defect NN NN O
, NN NN O
three NN NN O
homozygotes NN NN O
( NN NN O
2 NN NN O
. NN NN O

5 NN NN O
% NN NN O
) NN NN O
and NN NN O
34 NN NN O
heterozygotes NN NN O
( NN NN O
29 NN NN O
. NN NN O

1 NN NN O
% NN NN O
) NN NN O
were NN NN O
found NN NN O
to NN NN O
have NN NN O
the NN NN O
442D NN NN O
G NN NN O
mutation NN NN O
. NN NN O

The NN NN O
relative NN NN O
allelic NN NN O
frequency NN NN O
of NN NN O
this NN NN O
mutation NN NN O
was NN NN O
calculated NN NN O
to NN NN O
be NN NN O
0 NN NN O
. NN NN O

17 NN NN O
. NN NN O

One NN NN O
of NN NN O
the NN NN O
homozygotes NN NN O
for NN NN O
the NN NN O
442D NN NN O
G NN NN O
mutation NN NN O
was NN NN O
the NN NN O
patient NN NN O
previously NN NN O
described NN NN O
by NN NN O
us NN NN O
as NN NN O
having NN NN O
hyperalphalipoproteinemia NN NN B-SpecificDisease
with NN NN O
corneal NN NN B-SpecificDisease
opacity NN NN I-SpecificDisease
and NN NN O
coronary NN NN B-SpecificDisease
heart NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

This NN NN O
was NN NN O
the NN NN O
first NN NN O
reported NN NN O
subject NN NN O
homozygous NN NN O
for NN NN O
the NN NN O
CETP NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
who NN NN O
also NN NN O
demonstrated NN NN O
atherosclerotic NN NN B-DiseaseClass
symptoms NN NN I-DiseaseClass
. NN NN O

In NN NN O
homozygous NN NN O
subjects NN NN O
, NN NN O
CETP NN NN O
activity NN NN O
ranged NN NN O
from NN NN O
37 NN NN O
% NN NN O
to NN NN O
62 NN NN O
% NN NN O
of NN NN O
the NN NN O
normal NN NN O
value NN NN O
, NN NN O
which NN NN O
was NN NN O
consistent NN NN O
with NN NN O
the NN NN O
results NN NN O
obtained NN NN O
from NN NN O
the NN NN O
transient NN NN O
expression NN NN O
experiment NN NN O
previously NN NN O
reported NN NN O
; NN NN O
however NN NN O
, NN NN O
the NN NN O
specific NN NN O
activity NN NN O
of NN NN O
CETP NN NN O
was NN NN O
not NN NN O
as NN NN O
low NN NN O
as NN NN O
expected NN NN O
. NN NN O

( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O

7607677 NN NN O
Mucopolysaccharidosis NN NN B-SpecificDisease
type NN NN I-SpecificDisease
IVA NN NN I-SpecificDisease
: NN NN O
common NN NN O
double NN NN O
deletion NN NN O
in NN NN O
the NN NN O
N-acetylgalactosamine-6-sulfatase NN NN O
gene NN NN O
( NN NN O
GALNS NN NN O
) NN NN O
. NN NN O

Mucopolysaccharidosis NN NN B-SpecificDisease
IVA NN NN I-SpecificDisease
( NN NN O
MPS NN NN B-SpecificDisease
IVA NN NN I-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
caused NN NN O
by NN NN O
a NN NN O
deficiency NN NN B-SpecificDisease
in NN NN I-SpecificDisease
N-acetylgalactosamine-6-sulfatase NN NN I-SpecificDisease
( NN NN O
GALNS NN NN O
) NN NN O
. NN NN O

We NN NN O
found NN NN O
two NN NN O
separate NN NN O
deletions NN NN O
of NN NN O
nearly NN NN O
8 NN NN O
. NN NN O

0 NN NN O
and NN NN O
6 NN NN O
. NN NN O

0 NN NN O
kb NN NN O
in NN NN O
the NN NN O
GALNS NN NN O
gene NN NN O
, NN NN O
including NN NN O
some NN NN O
exons NN NN O
. NN NN O

There NN NN O
are NN NN O
Alu NN NN O
repetitive NN NN O
elements NN NN O
near NN NN O
the NN NN O
breakpoints NN NN O
of NN NN O
the NN NN O
8 NN NN O
. NN NN O

0-kb NN NN O
deletion NN NN O
, NN NN O
and NN NN O
this NN NN O
deletion NN NN O
resulted NN NN O
from NN NN O
an NN NN O
Alu-Alu NN NN O
recombination NN NN O
. NN NN O

The NN NN O
other NN NN O
6 NN NN O
. NN NN O

0-kb NN NN O
deletion NN NN O
involved NN NN O
illegitimate NN NN O
recombinational NN NN O
events NN NN O
between NN NN O
incomplete NN NN O
short NN NN O
direct NN NN O
repeats NN NN O
of NN NN O
8 NN NN O
bp NN NN O
at NN NN O
deletion NN NN O
breakpoints NN NN O
. NN NN O

The NN NN O
same NN NN O
rearrangement NN NN O
has NN NN O
been NN NN O
observed NN NN O
in NN NN O
a NN NN O
heteroallelic NN NN O
state NN NN O
in NN NN O
four NN NN O
unrelated NN NN O
patients NN NN O
. NN NN O

This NN NN O
is NN NN O
the NN NN O
first NN NN O
documentation NN NN O
of NN NN O
a NN NN O
common NN NN O
double NN NN O
deletion NN NN O
a NN NN O
gene NN NN O
that NN NN O
is NN NN O
not NN NN O
a NN NN O
member NN NN O
of NN NN O
a NN NN O
gene NN NN O
cluster NN NN O
. NN NN O

7611277 NN NN O
Detection NN NN O
of NN NN O
eight NN NN O
BRCA1 NN NN O
mutations NN NN O
in NN NN O
10 NN NN O
breast/ovarian NN NN B-Modifier
cancer NN NN I-Modifier
families NN NN O
, NN NN O
including NN NN O
1 NN NN O
family NN NN O
with NN NN O
male NN NN B-SpecificDisease
breast NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

Genetic NN NN O
epidemiological NN NN O
evidence NN NN O
suggests NN NN O
that NN NN O
mutations NN NN O
in NN NN O
BRCA1 NN NN O
may NN NN O
be NN NN O
responsible NN NN O
for NN NN O
approximately NN NN O
one NN NN O
half NN NN O
of NN NN O
early NN NN O
onset NN NN O
familial NN NN B-SpecificDisease
breast NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
and NN NN O
the NN NN O
majority NN NN O
of NN NN O
familial NN NN B-CompositeMention
breast NN NN I-CompositeMention
/ NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
. NN NN O

The NN NN O
recent NN NN O
cloning NN NN O
of NN NN O
BRCA1 NN NN O
allows NN NN O
for NN NN O
the NN NN O
direct NN NN O
detection NN NN O
of NN NN O
mutations NN NN O
, NN NN O
but NN NN O
the NN NN O
feasibility NN NN O
of NN NN O
presymptomatic NN NN O
screening NN NN O
for NN NN O
cancer NN NN B-Modifier
susceptibility NN NN O
is NN NN O
unknown NN NN O
. NN NN O

We NN NN O
analyzed NN NN O
genomic NN NN O
DNA NN NN O
from NN NN O
one NN NN O
affected NN NN O
individual NN NN O
from NN NN O
each NN NN O
of NN NN O
24 NN NN O
families NN NN O
with NN NN O
at NN NN O
least NN NN O
three NN NN O
cases NN NN O
of NN NN O
ovarian NN NN B-CompositeMention
or NN NN I-CompositeMention
breast NN NN I-CompositeMention
cancer NN NN I-CompositeMention
, NN NN O
using NN NN O
SSCP NN NN O
assays NN NN O
. NN NN O

Variant NN NN O
SSCP NN NN O
bands NN NN O
were NN NN O
subcloned NN NN O
and NN NN O
sequenced NN NN O
. NN NN O

Allele-specific NN NN O
oligonucleotide NN NN O
hybridization NN NN O
was NN NN O
used NN NN O
to NN NN O
verify NN NN O
sequence NN NN O
changes NN NN O
and NN NN O
to NN NN O
screen NN NN O
DNA NN NN O
from NN NN O
control NN NN O
individuals NN NN O
. NN NN O

Six NN NN O
frameshift NN NN O
and NN NN O
two NN NN O
missense NN NN O
mutations NN NN O
were NN NN O
detected NN NN O
in NN NN O
10 NN NN O
different NN NN O
families NN NN O
. NN NN O

A NN NN O
frameshift NN NN O
mutation NN NN O
was NN NN O
detected NN NN O
in NN NN O
a NN NN O
male NN NN O
proband NN NN O
affected NN NN O
with NN NN O
both NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
prostate NN NN I-CompositeMention
cancer NN NN I-CompositeMention
. NN NN O

A NN NN O
40-bp NN NN O
deletion NN NN O
was NN NN O
detected NN NN O
in NN NN O
a NN NN O
patient NN NN O
who NN NN O
developed NN NN O
intra-abdominal NN NN B-DiseaseClass
carcinomatosis NN NN I-DiseaseClass
1 NN NN O
year NN NN O
after NN NN O
prophylactic NN NN O
oophorectomy NN NN O
. NN NN O

Mutations NN NN O
were NN NN O
detected NN NN O
throughout NN NN O
the NN NN O
gene NN NN O
, NN NN O
and NN NN O
only NN NN O
one NN NN O
was NN NN O
detected NN NN O
in NN NN O
more NN NN O
than NN NN O
a NN NN O
single NN NN O
family NN NN O
. NN NN O

These NN NN O
results NN NN O
provide NN NN O
further NN NN O
evidence NN NN O
that NN NN O
inherited NN NN B-CompositeMention
breast NN NN I-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
can NN NN O
occur NN NN O
as NN NN O
a NN NN O
consequence NN NN O
of NN NN O
a NN NN O
wide NN NN O
array NN NN O
of NN NN O
BRCA1 NN NN O
mutations NN NN O
. NN NN O

These NN NN O
results NN NN O
suggests NN NN O
that NN NN O
development NN NN O
of NN NN O
a NN NN O
screening NN NN O
test NN NN O
for NN NN O
BRCA1 NN NN O
mutations NN NN O
will NN NN O
be NN NN O
technically NN NN O
challenging NN NN O
. NN NN O

The NN NN O
finding NN NN O
of NN NN O
a NN NN O
mutation NN NN O
in NN NN O
a NN NN O
family NN NN O
with NN NN O
male NN NN B-SpecificDisease
breast NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
, NN NN O
not NN NN O
previously NN NN O
thought NN NN O
to NN NN O
be NN NN O
related NN NN O
to NN NN O
BRCA1 NN NN O
, NN NN O
also NN NN O
illustrates NN NN O
the NN NN O
potential NN NN O
difficulties NN NN O
of NN NN O
genetic NN NN O
counseling NN NN O
for NN NN O
individuals NN NN O
known NN NN O
to NN NN O
carry NN NN O
mutations NN NN O
. NN NN O

. NN NN O

7617034 NN NN O
Natural NN NN O
selection NN NN O
of NN NN O
hemi- NN NN O
and NN NN O
heterozygotes NN NN O
for NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
Africa NN NN O
by NN NN O
resistance NN NN O
to NN NN O
severe NN NN O
malaria NN NN B-SpecificDisease
. NN NN O

Glucose-6-phosphate NN NN B-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
( NN NN I-SpecificDisease
G6PD NN NN I-SpecificDisease
) NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
, NN NN O
the NN NN O
most NN NN O
common NN NN O
enzymopathy NN NN B-DiseaseClass
of NN NN O
humans NN NN O
, NN NN O
affects NN NN O
over NN NN O
400 NN NN O
million NN NN O
people NN NN O
. NN NN O

The NN NN O
geographical NN NN O
correlation NN NN O
of NN NN O
its NN NN O
distribution NN NN O
with NN NN O
the NN NN O
historical NN NN O
endemicity NN NN O
of NN NN O
malaria NN NN B-SpecificDisease
suggests NN NN O
that NN NN O
this NN NN O
disorder NN NN O
has NN NN O
risen NN NN O
in NN NN O
frequency NN NN O
through NN NN O
natural NN NN O
selection NN NN O
by NN NN O
malaria NN NN B-SpecificDisease
. NN NN O

However NN NN O
, NN NN O
attempts NN NN O
to NN NN O
confirm NN NN O
that NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
is NN NN O
protective NN NN O
in NN NN O
case-control NN NN O
studies NN NN O
of NN NN O
malaria NN NN B-SpecificDisease
have NN NN O
yielded NN NN O
conflicting NN NN O
results NN NN O
. NN NN O

Hence NN NN O
, NN NN O
for NN NN O
this NN NN O
X-linked NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
, NN NN O
it NN NN O
is NN NN O
unclear NN NN O
whether NN NN O
both NN NN O
male NN NN O
hemizygotes NN NN O
and NN NN O
female NN NN O
heterozygotes NN NN O
are NN NN O
protected NN NN O
or NN NN O
, NN NN O
as NN NN O
frequently NN NN O
suggested NN NN O
, NN NN O
only NN NN O
females NN NN O
. NN NN O

Furthermore NN NN O
, NN NN O
how NN NN O
much NN NN O
protection NN NN O
may NN NN O
be NN NN O
afforded NN NN O
is NN NN O
unknown NN NN O
. NN NN O

Here NN NN O
we NN NN O
report NN NN O
that NN NN O
, NN NN O
in NN NN O
two NN NN O
large NN NN O
case-control NN NN O
studies NN NN O
of NN NN O
over NN NN O
2 NN NN O
, NN NN O
000 NN NN O
African NN NN O
children NN NN O
, NN NN O
the NN NN O
common NN NN O
African NN NN O
form NN NN O
of NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
( NN NN O
G6PD NN NN B-SpecificDisease
A- NN NN I-SpecificDisease
) NN NN O
is NN NN O
associated NN NN O
with NN NN O
a NN NN O
46-58 NN NN O
% NN NN O
reduction NN NN O
in NN NN O
risk NN NN O
of NN NN O
severe NN NN O
malaria NN NN B-SpecificDisease
for NN NN O
both NN NN O
female NN NN O
heterozygotes NN NN O
and NN NN O
male NN NN O
hemizygotes NN NN O
. NN NN O

A NN NN O
mathematical NN NN O
model NN NN O
incorporating NN NN O
the NN NN O
measured NN NN O
selective NN NN O
advantage NN NN O
against NN NN O
malaria NN NN B-SpecificDisease
suggests NN NN O
that NN NN O
a NN NN O
counterbalancing NN NN O
selective NN NN O
disadvantage NN NN O
, NN NN O
associated NN NN O
with NN NN O
this NN NN O
enzyme NN NN B-DiseaseClass
deficiency NN NN I-DiseaseClass
, NN NN O
has NN NN O
retarded NN NN O
its NN NN O
rise NN NN O
in NN NN O
frequency NN NN O
in NN NN O
malaria NN NN B-Modifier
-endemic NN NN O
regions NN NN O
. NN NN O

Although NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
is NN NN O
now NN NN O
regarded NN NN O
as NN NN O
a NN NN O
generally NN NN O
benign NN NN O
disorder NN NN O
, NN NN O
in NN NN O
earlier NN NN O
environmental NN NN O
conditions NN NN O
it NN NN O
could NN NN O
have NN NN O
been NN NN O
significantly NN NN O
disadvantageous NN NN O
. NN NN O

. NN NN O

7630639 NN NN O
The NN NN O
alveolar NN NN B-Modifier
rhabdomyosarcoma NN NN I-Modifier
PAX3/FKHR NN NN O
fusion NN NN O
protein NN NN O
is NN NN O
a NN NN O
transcriptional NN NN O
activator NN NN O
. NN NN O

Chimeric NN NN O
transcription NN NN O
factors NN NN O
, NN NN O
created NN NN O
by NN NN O
gene NN NN O
fusions NN NN O
as NN NN O
the NN NN O
result NN NN O
of NN NN O
chromosomal NN NN O
translocations NN NN O
, NN NN O
have NN NN O
been NN NN O
implicated NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
several NN NN O
pathologically NN NN O
disparate NN NN O
solid NN NN B-DiseaseClass
tumors NN NN I-DiseaseClass
. NN NN O

The NN NN O
PAX3 NN NN O
/ NN NN O
FKHR NN NN O
fusion NN NN O
gene NN NN O
, NN NN O
formed NN NN O
by NN NN O
a NN NN O
t NN NN O
( NN NN O
2 NN NN O
; NN NN O
13 NN NN O
) NN NN O
( NN NN O
q35 NN NN O
; NN NN O
q14 NN NN O
) NN NN O
in NN NN O
alveolar NN NN B-SpecificDisease
rhabdomyosarcoma NN NN I-SpecificDisease
, NN NN O
encodes NN NN O
a NN NN O
hybrid NN NN O
protein NN NN O
that NN NN O
contains NN NN O
both NN NN O
PAX3 NN NN O
DNA NN NN O
binding NN NN O
domains NN NN O
, NN NN O
the NN NN O
paired NN NN O
box NN NN O
and NN NN O
homeodomain NN NN O
, NN NN O
linked NN NN O
to NN NN O
the NN NN O
bisected NN NN O
DNA NN NN O
binding NN NN O
domain NN NN O
of NN NN O
FKHR NN NN O
, NN NN O
a NN NN O
member NN NN O
of NN NN O
the NN NN O
forkhead NN NN O
family NN NN O
of NN NN O
transcription NN NN O
factors NN NN O
. NN NN O

Here NN NN O
we NN NN O
report NN NN O
that NN NN O
PAX3 NN NN O
and NN NN O
PAX3 NN NN O
/ NN NN O
FKHR NN NN O
display NN NN O
similar NN NN O
, NN NN O
but NN NN O
not NN NN O
identical NN NN O
transactivation NN NN O
activities NN NN O
when NN NN O
tested NN NN O
with NN NN O
model NN NN O
Pax NN NN O
recognition NN NN O
sequences NN NN O
. NN NN O

No NN NN O
functional NN NN O
role NN NN O
could NN NN O
be NN NN O
ascribed NN NN O
solely NN NN O
to NN NN O
the NN NN O
residual NN NN O
FKHR NN NN O
binding NN NN O
domain NN NN O
present NN NN O
in NN NN O
the NN NN O
fusion NN NN O
protein NN NN O
, NN NN O
but NN NN O
FKHR NN NN O
was NN NN O
found NN NN O
to NN NN O
contribute NN NN O
a NN NN O
strong NN NN O
carboxyl NN NN O
terminal NN NN O
activation NN NN O
domain NN NN O
replacing NN NN O
the NN NN O
one NN NN O
located NN NN O
in NN NN O
the NN NN O
unrearranged NN NN O
PAX3 NN NN O
gene NN NN O
. NN NN O

We NN NN O
show NN NN O
that NN NN O
the NN NN O
native NN NN O
PAX3 NN NN O
/ NN NN O
FKHR NN NN O
protein NN NN O
present NN NN O
in NN NN O
tumor NN NN B-Modifier
cells NN NN O
with NN NN O
this NN NN O
translocation NN NN O
has NN NN O
transcriptional NN NN O
characteristics NN NN O
similar NN NN O
to NN NN O
the NN NN O
in NN NN O
vitro NN NN O
expressed NN NN O
protein NN NN O
. NN NN O

The NN NN O
ability NN NN O
of NN NN O
the NN NN O
PAX3 NN NN O
/ NN NN O
FKHR NN NN O
hybrid NN NN O
protein NN NN O
to NN NN O
bind NN NN O
DNA NN NN O
in NN NN O
a NN NN O
sequence NN NN O
specific NN NN O
manner NN NN O
and NN NN O
to NN NN O
transactivate NN NN O
the NN NN O
expression NN NN O
of NN NN O
artificial NN NN O
reporter NN NN O
genes NN NN O
suggests NN NN O
that NN NN O
its NN NN O
aberrant NN NN O
expression NN NN O
could NN NN O
subvert NN NN O
the NN NN O
transcriptional NN NN O
programs NN NN O
that NN NN O
normally NN NN O
control NN NN O
the NN NN O
growth NN NN O
, NN NN O
differentiation NN NN O
, NN NN O
and NN NN O
survival NN NN O
of NN NN O
primitive NN NN O
myogenic NN NN O
precursors NN NN O
in NN NN O
vivo NN NN O
. NN NN O

. NN NN O

7652577 NN NN O
A NN NN O
p16INK4a-insensitive NN NN O
CDK4 NN NN O
mutant NN NN O
targeted NN NN O
by NN NN O
cytolytic NN NN O
T NN NN O
lymphocytes NN NN O
in NN NN O
a NN NN O
human NN NN O
melanoma NN NN B-SpecificDisease
. NN NN O

A NN NN O
mutated NN NN O
cyclin-dependent NN NN O
kinase NN NN O
4 NN NN O
( NN NN O
CDK4 NN NN O
) NN NN O
was NN NN O
identified NN NN O
as NN NN O
a NN NN O
tumor NN NN B-Modifier
-specific NN NN O
antigen NN NN O
recognized NN NN O
by NN NN O
HLA-A2 NN NN O
. NN NN O

1-restricted NN NN O
autologous NN NN O
cytolytic NN NN O
T NN NN O
lymphocytes NN NN O
( NN NN O
CTLs NN NN O
) NN NN O
in NN NN O
a NN NN O
human NN NN O
melanoma NN NN B-SpecificDisease
. NN NN O

The NN NN O
mutated NN NN O
CDK4 NN NN O
allele NN NN O
was NN NN O
present NN NN O
in NN NN O
autologous NN NN O
cultured NN NN O
melanoma NN NN B-Modifier
cells NN NN O
and NN NN O
metastasis NN NN O
tissue NN NN O
, NN NN O
but NN NN O
not NN NN O
in NN NN O
the NN NN O
patients NN NN O
lymphocytes NN NN O
. NN NN O

The NN NN O
mutation NN NN O
, NN NN O
an NN NN O
arginine-to-cysteine NN NN O
exchange NN NN O
at NN NN O
residue NN NN O
24 NN NN O
, NN NN O
was NN NN O
part NN NN O
of NN NN O
the NN NN O
CDK4 NN NN O
peptide NN NN O
recognized NN NN O
by NN NN O
CTLs NN NN O
and NN NN O
prevented NN NN O
binding NN NN O
of NN NN O
the NN NN O
CDK4 NN NN O
inhibitor NN NN O
p16INK4a NN NN O
, NN NN O
but NN NN O
not NN NN O
of NN NN O
p21 NN NN O
or NN NN O
of NN NN O
p27KIP1 NN NN O
. NN NN O

The NN NN O
same NN NN O
mutation NN NN O
was NN NN O
found NN NN O
in NN NN O
one NN NN O
additional NN NN O
melanoma NN NN B-SpecificDisease
among NN NN O
28 NN NN O
melanomas NN NN B-SpecificDisease
analyzed NN NN O
. NN NN O

These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
mutation NN NN O
of NN NN O
CDK4 NN NN O
can NN NN O
create NN NN O
a NN NN O
tumor NN NN B-Modifier
-specific NN NN O
antigen NN NN O
and NN NN O
can NN NN O
disrupt NN NN O
the NN NN O
cell-cycle NN NN O
regulation NN NN O
exerted NN NN O
by NN NN O
the NN NN O
tumor NN NN B-Modifier
suppressor NN NN O
p16INK4a NN NN O
. NN NN O

. NN NN O

7663517 NN NN O
Rapid NN NN O
detection NN NN O
of NN NN O
BRCA1 NN NN O
mutations NN NN O
by NN NN O
the NN NN O
protein NN NN O
truncation NN NN O
test NN NN O
. NN NN O

More NN NN O
than NN NN O
75 NN NN O
% NN NN O
of NN NN O
the NN NN O
reported NN NN O
mutations NN NN O
in NN NN O
the NN NN O
hereditary NN NN B-Modifier
breast NN NN I-Modifier
and NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
gene NN NN O
, NN NN O
BRCA1 NN NN O
, NN NN O
result NN NN O
in NN NN O
truncated NN NN O
proteins NN NN O
. NN NN O

We NN NN O
have NN NN O
used NN NN O
the NN NN O
protein NN NN O
truncation NN NN O
test NN NN O
( NN NN O
PTT NN NN O
) NN NN O
to NN NN O
screen NN NN O
for NN NN O
mutations NN NN O
in NN NN O
exon NN NN O
11 NN NN O
, NN NN O
which NN NN O
encodes NN NN O
61 NN NN O
% NN NN O
of NN NN O
BRCA1 NN NN O
. NN NN O

In NN NN O
45 NN NN O
patients NN NN O
from NN NN O
breast NN NN B-Modifier
and NN NN I-Modifier
/ NN NN I-Modifier
or NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
families NN NN O
we NN NN O
found NN NN O
six NN NN O
novel NN NN O
mutations NN NN O
two NN NN O
single NN NN O
nucleotide NN NN O
insertions NN NN O
, NN NN O
three NN NN O
small NN NN O
deletions NN NN O
( NN NN O
1-5 NN NN O
bp NN NN O
) NN NN O
and NN NN O
a NN NN O
nonsense NN NN O
mutation NN NN O
identified NN NN O
two NN NN O
unrelated NN NN O
families NN NN O
. NN NN O

Furthermore NN NN O
, NN NN O
we NN NN O
were NN NN O
able NN NN O
to NN NN O
amplify NN NN O
the NN NN O
remaining NN NN O
coding NN NN O
region NN NN O
by NN NN O
RT-PCR NN NN O
using NN NN O
lymphocyte NN NN O
RNA NN NN O
. NN NN O

Combined NN NN O
with NN NN O
PTT NN NN O
, NN NN O
we NN NN O
detected NN NN O
aberrantly NN NN O
spliced NN NN O
products NN NN O
affecting NN NN O
exons NN NN O
5 NN NN O
and NN NN O
6 NN NN O
in NN NN O
one NN NN O
of NN NN O
two NN NN O
BRCA1-linked NN NN O
families NN NN O
examined NN NN O
. NN NN O

The NN NN O
protein NN NN O
truncation NN NN O
test NN NN O
promises NN NN O
to NN NN O
become NN NN O
a NN NN O
valuable NN NN O
technique NN NN O
in NN NN O
detecting NN NN O
BRCA1 NN NN O
mutations NN NN O
. NN NN O

. NN NN O

7668252 NN NN O
Cloning NN NN O
of NN NN O
human NN NN O
very-long-chain NN NN O
acyl-coenzyme NN NN O
A NN NN O
dehydrogenase NN NN O
and NN NN O
molecular NN NN O
characterization NN NN O
of NN NN O
its NN NN O
deficiency NN NN O
in NN NN O
two NN NN O
patients NN NN O
. NN NN O

Two NN NN O
overlapping NN NN O
cDNA NN NN O
clones NN NN O
( NN NN O
1 NN NN O
, NN NN O
991 NN NN O
bp NN NN O
and NN NN O
736 NN NN O
bp NN NN O
, NN NN O
respectively NN NN O
) NN NN O
encoding NN NN O
the NN NN O
precursor NN NN O
of NN NN O
human NN NN O
mitochondrial NN NN O
very-long-chain NN NN O
acyl-coenzyme NN NN O
A NN NN O
dehydrogenase NN NN O
( NN NN O
VLCAD NN NN O
) NN NN O
were NN NN O
cloned NN NN O
and NN NN O
sequenced NN NN O
. NN NN O

The NN NN O
cDNA NN NN O
inserts NN NN O
of NN NN O
these NN NN O
clones NN NN O
together NN NN O
encompass NN NN O
a NN NN O
region NN NN O
of NN NN O
2 NN NN O
, NN NN O
177 NN NN O
bases NN NN O
, NN NN O
encoding NN NN O
the NN NN O
entire NN NN O
protein NN NN O
of NN NN O
655 NN NN O
amino NN NN O
acids NN NN O
, NN NN O
including NN NN O
a NN NN O
40-amino NN NN O
acid NN NN O
leader NN NN O
peptide NN NN O
and NN NN O
a NN NN O
615-amino NN NN O
acid NN NN O
mature NN NN O
polypeptide NN NN O
. NN NN O

PCR-amplified NN NN O
VLCAD NN NN O
cDNAs NN NN O
were NN NN O
sequenced NN NN O
in NN NN O
cultured NN NN O
fibroblasts NN NN O
from NN NN O
two NN NN O
VLCAD-deficient NN NN B-Modifier
patients NN NN O
. NN NN O

In NN NN O
both NN NN O
patients NN NN O
, NN NN O
a NN NN O
105-bp NN NN O
deletion NN NN O
encompassing NN NN O
bases NN NN O
1078-1182 NN NN O
in NN NN O
VLCAD NN NN O
cDNA NN NN O
was NN NN O
identified NN NN O
. NN NN O

The NN NN O
deletion NN NN O
seems NN NN O
to NN NN O
occur NN NN O
due NN NN O
to NN NN O
exon NN NN O
skipping NN NN O
during NN NN O
processing NN NN O
of NN NN O
VLCAD NN NN O
pre-mRNA NN NN O
. NN NN O

This NN NN O
is NN NN O
the NN NN O
first NN NN O
demonstration NN NN O
of NN NN O
a NN NN O
mutation NN NN O
causing NN NN O
VLCAD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

Quantitative NN NN O
cDNA NN NN O
expression NN NN O
of NN NN O
normal NN NN O
human NN NN O
VLCAD NN NN O
was NN NN O
performed NN NN O
in NN NN O
the NN NN O
patients NN NN O
fibroblasts NN NN O
, NN NN O
using NN NN O
vaccinia NN NN O
viral NN NN O
system NN NN O
, NN NN O
which NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
normal NN NN I-SpecificDisease
VLCAD NN NN I-SpecificDisease
protein NN NN I-SpecificDisease
causes NN NN O
impaired NN NN O
long-chain NN NN O
fatty NN NN O
acid NN NN O
beta-oxidation NN NN O
activity NN NN O
in NN NN O
the NN NN O
patients NN NN O
fibroblasts NN NN O
. NN NN O

In NN NN O
patient NN NN O
fibroblasts NN NN O
, NN NN O
raising NN NN O
VLCAD NN NN O
activity NN NN O
to NN NN O
approximately NN NN O
20 NN NN O
% NN NN O
of NN NN O
normal NN NN O
control NN NN O
fibroblast NN NN O
activity NN NN O
raised NN NN O
palmitic NN NN O
acid NN NN O
beta-oxidation NN NN O
flux NN NN O
to NN NN O
the NN NN O
level NN NN O
found NN NN O
in NN NN O
control NN NN O
fibroblasts NN NN O
, NN NN O
which NN NN O
may NN NN O
offer NN NN O
important NN NN O
information NN NN O
for NN NN O
the NN NN O
rational NN NN O
design NN NN O
of NN NN O
future NN NN O
somatic NN NN O
gene NN NN O
therapy NN NN O
for NN NN O
VLCAD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

. NN NN O

7696601 NN NN O
Brain NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
and NN NN O
molecular NN NN O
analysis NN NN O
in NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
. NN NN O

Abnormal NN NN O
amplification NN NN O
of NN NN O
a NN NN O
CTG NN NN O
repeat NN NN O
on NN NN O
chromosome NN NN O
19 NN NN O
is NN NN O
the NN NN O
molecular NN NN O
basis NN NN O
of NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
. NN NN O

Expansion NN NN O
of NN NN O
the NN NN O
repeat NN NN O
has NN NN O
been NN NN O
correlated NN NN O
with NN NN O
severity NN NN O
of NN NN O
several NN NN O
clinical NN NN O
features NN NN O
of NN NN O
the NN NN O
disease NN NN O
. NN NN O

We NN NN O
performed NN NN O
extensive NN NN O
cognitive NN NN O
testing NN NN O
, NN NN O
cerebral NN NN O
magnetic NN NN O
resonance NN NN O
imaging NN NN O
( NN NN O
MRI NN NN O
) NN NN O
and NN NN O
a NN NN O
molecular NN NN O
analysis NN NN O
in NN NN O
28 NN NN O
cases NN NN O
of NN NN O
DM NN NN B-SpecificDisease
to NN NN O
determine NN NN O
the NN NN O
relationship NN NN O
between NN NN O
the NN NN O
molecular NN NN O
defect NN NN O
and NN NN O
brain NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
. NN NN O

Performance NN NN O
in NN NN O
two NN NN O
or NN NN O
more NN NN O
cognitive NN NN O
tests NN NN O
was NN NN O
pathological NN NN O
in NN NN O
10 NN NN O
cases NN NN O
. NN NN O

Fourteen NN NN O
patients NN NN O
had NN NN O
subcortical NN NN O
white NN NN B-DiseaseClass
matter NN NN I-DiseaseClass
lesions NN NN I-DiseaseClass
on NN NN O
MRI NN NN O
, NN NN O
14 NN NN O
had NN NN O
cerebral NN NN B-SpecificDisease
atrophy NN NN I-SpecificDisease
. NN NN O

Amplification NN NN O
of NN NN O
the NN NN O
CTG NN NN O
repeat NN NN O
showed NN NN O
a NN NN O
strong NN NN O
correlation NN NN O
with NN NN O
cognitive NN NN O
test NN NN O
deficits NN NN O
when NN NN O
exceeding NN NN O
a NN NN O
length NN NN O
of NN NN O
over NN NN O
1000 NN NN O
trinucleotides NN NN O
. NN NN O

MRI NN NN O
lesions NN NN O
were NN NN O
associated NN NN O
with NN NN O
impaired NN NN O
psychometric NN NN O
performance NN NN O
, NN NN O
but NN NN O
MRI NN NN O
and NN NN O
molecular NN NN O
findings NN NN O
were NN NN O
only NN NN O
weakly NN NN O
related NN NN O
. NN NN O

Disease NN NN O
duration NN NN O
influenced NN NN O
the NN NN O
appearance NN NN O
and NN NN O
amount NN NN O
of NN NN O
white NN NN B-DiseaseClass
matter NN NN I-DiseaseClass
lesions NN NN I-DiseaseClass
on NN NN O
MRI NN NN O
. NN NN O

Quantification NN NN O
of NN NN O
CTG NN NN O
repeat NN NN O
size NN NN O
may NN NN O
allow NN NN O
an NN NN O
early NN NN O
estimate NN NN O
on NN NN O
the NN NN O
probability NN NN O
of NN NN O
brain NN NN O
involvement NN NN O
in NN NN O
DM NN NN B-SpecificDisease
; NN NN O
cognitive NN NN B-DiseaseClass
dysfunction NN NN I-DiseaseClass
is NN NN O
associated NN NN O
with NN NN O
white NN NN B-DiseaseClass
matter NN NN I-DiseaseClass
lesions NN NN I-DiseaseClass
and NN NN O
cerebral NN NN B-SpecificDisease
atrophy NN NN I-SpecificDisease
later NN NN O
on NN NN O
in NN NN O
the NN NN O
course NN NN O
. NN NN O

. NN NN O

7717396 NN NN O
Mutations NN NN O
in NN NN O
the NN NN O
gene NN NN O
for NN NN O
X-linked NN NN B-SpecificDisease
adrenoleukodystrophy NN NN I-SpecificDisease
in NN NN O
patients NN NN O
with NN NN O
different NN NN O
clinical NN NN O
phenotypes NN NN O
. NN NN O

Recently NN NN O
, NN NN O
the NN NN O
gene NN NN O
for NN NN O
the NN NN O
most NN NN O
common NN NN O
peroxisomal NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
, NN NN O
X-linked NN NN B-SpecificDisease
adrenoleukodystrophy NN NN I-SpecificDisease
( NN NN O
X-ALD NN NN B-SpecificDisease
) NN NN O
, NN NN O
has NN NN O
been NN NN O
described NN NN O
encoding NN NN O
a NN NN O
peroxisomal NN NN O
membrane NN NN O
transporter NN NN O
protein NN NN O
. NN NN O

We NN NN O
analyzed NN NN O
the NN NN O
entire NN NN O
protein-coding NN NN O
sequence NN NN O
of NN NN O
this NN NN O
gene NN NN O
by NN NN O
reverse-transcription NN NN O
PCR NN NN O
, NN NN O
SSCP NN NN O
, NN NN O
and NN NN O
DNA NN NN O
sequencing NN NN O
in NN NN O
five NN NN O
patients NN NN O
with NN NN O
different NN NN O
clinical NN NN O
expression NN NN O
of NN NN O
X-ALD NN NN B-SpecificDisease
and NN NN O
in NN NN O
their NN NN O
female NN NN O
relatives NN NN O
; NN NN O
these NN NN O
clinical NN NN O
expressions NN NN O
were NN NN O
cerebral NN NN O
childhood NN NN O
ALD NN NN B-SpecificDisease
, NN NN O
adrenomyeloneuropathy NN NN B-SpecificDisease
( NN NN O
AMN NN NN B-SpecificDisease
) NN NN O
, NN NN O
and NN NN O
`` NN NN O
Addison NN NN B-Modifier
disease NN NN I-Modifier
only NN NN I-Modifier
`` NN NN O
( NN NN O
ADO NN NN B-Modifier
) NN NN O
phenotype NN NN O
. NN NN O

In NN NN O
the NN NN O
three NN NN O
patients NN NN O
exhibiting NN NN O
the NN NN O
classical NN NN O
picture NN NN O
of NN NN O
severe NN NN O
childhood NN NN O
ALD NN NN B-SpecificDisease
we NN NN O
identified NN NN O
in NN NN O
the NN NN O
5 NN NN O
portion NN NN O
of NN NN O
the NN NN O
X-ALD NN NN B-Modifier
gene NN NN O
a NN NN O
38-bp NN NN O
deletion NN NN O
that NN NN O
causes NN NN O
a NN NN O
frameshift NN NN O
mutation NN NN O
, NN NN O
a NN NN O
3-bp NN NN O
deletion NN NN O
leading NN NN O
to NN NN O
a NN NN O
deletion NN NN O
of NN NN O
an NN NN O
amino NN NN O
acid NN NN O
in NN NN O
the NN NN O
ATP-binding NN NN O
domain NN NN O
of NN NN O
the NN NN O
ALD NN NN B-Modifier
protein NN NN O
, NN NN O
and NN NN O
a NN NN O
missense NN NN O
mutation NN NN O
. NN NN O

In NN NN O
the NN NN O
patient NN NN O
with NN NN O
the NN NN O
clinical NN NN O
phenotype NN NN O
of NN NN O
AMN NN NN B-SpecificDisease
, NN NN O
a NN NN O
nonsense NN NN O
mutation NN NN O
in NN NN O
codon NN NN O
212 NN NN O
, NN NN O
along NN NN O
with NN NN O
a NN NN O
second NN NN O
site NN NN O
mutation NN NN O
at NN NN O
codon NN NN O
178 NN NN O
, NN NN O
was NN NN O
observed NN NN O
. NN NN O

Analysis NN NN O
of NN NN O
the NN NN O
patient NN NN O
with NN NN O
the NN NN O
ADO NN NN B-Modifier
phenotype NN NN O
revealed NN NN O
a NN NN O
further NN NN O
missense NN NN O
mutation NN NN O
at NN NN O
a NN NN O
highly NN NN O
conserved NN NN O
position NN NN O
in NN NN O
the NN NN O
ALDP NN NN O
/ NN NN O
PMP70 NN NN O
comparison NN NN O
. NN NN O

The NN NN O
disruptive NN NN O
nature NN NN O
of NN NN O
two NN NN O
mutations NN NN O
( NN NN O
i NN NN O
. NN NN O

e NN NN O
. NN NN O

, NN NN O
the NN NN O
frameshift NN NN O
and NN NN O
the NN NN O
nonsense NN NN O
mutation NN NN O
) NN NN O
in NN NN O
patients NN NN O
with NN NN O
biochemically NN NN O
proved NN NN O
childhood NN NN O
ALD NN NN B-SpecificDisease
and NN NN O
AMN NN NN B-SpecificDisease
further NN NN O
strongly NN NN O
supports NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
alterations NN NN O
in NN NN O
this NN NN O
gene NN NN O
play NN NN O
a NN NN O
crucial NN NN O
role NN NN O
in NN NN O
the NN NN O
pathogenesis NN NN O
of NN NN O
X-ALD NN NN B-SpecificDisease
. NN NN O

Since NN NN O
the NN NN O
current NN NN O
biochemical NN NN O
techniques NN NN O
for NN NN O
X-ALD NN NN B-Modifier
carrier NN NN O
detection NN NN O
in NN NN O
affected NN NN O
families NN NN O
lack NN NN O
sufficient NN NN O
reliability NN NN O
, NN NN O
our NN NN O
procedure NN NN O
described NN NN O
for NN NN O
systematic NN NN O
mutation NN NN O
scanning NN NN O
is NN NN O
also NN NN O
capable NN NN O
of NN NN O
improving NN NN O
genetic NN NN O
counseling NN NN O
and NN NN O
prenatal NN NN O
diagnosis NN NN O

7726234 NN NN O
Duchenne NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
and NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
in NN NN O
the NN NN O
same NN NN O
patient NN NN O
. NN NN O

We NN NN O
report NN NN O
on NN NN O
the NN NN O
first NN NN O
patient NN NN O
identified NN NN O
with NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
and NN NN O
Duchenne NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DMD NN NN B-SpecificDisease
) NN NN O
. NN NN O

The NN NN O
family NN NN O
of NN NN O
the NN NN O
propositus NN NN O
had NN NN O
a NN NN O
strong NN NN O
history NN NN O
of NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
, NN NN O
and NN NN O
there NN NN O
was NN NN O
an NN NN O
intrafamilial NN NN O
pathological NN NN O
expansion NN NN O
of NN NN O
the NN NN O
responsible NN NN O
CTG NN NN O
repeat NN NN O
between NN NN O
the NN NN O
mildly NN NN O
affected NN NN O
mother NN NN O
( NN NN O
160 NN NN O
repeats NN NN O
; NN NN O
normal NN NN O
27 NN NN O
repeats NN NN O
) NN NN O
and NN NN O
her NN NN O
more NN NN O
severely NN NN O
affected NN NN O
son NN NN O
( NN NN O
650 NN NN O
repeats NN NN O
) NN NN O
, NN NN O
and NN NN O
his NN NN O
sister NN NN O
( NN NN O
650 NN NN O
repeats NN NN O
) NN NN O
. NN NN O

The NN NN O
propositus NN NN O
was NN NN O
an NN NN O
isolated NN NN O
case NN NN O
of NN NN O
Duchenne NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
with NN NN O
marked NN NN O
dystrophin NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
muscle NN NN O
biopsy NN NN O
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
still NN NN O
ambulatory NN NN O
post NN NN O
age NN NN O
16 NN NN O
. NN NN O

Myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
could NN NN O
interfere NN NN O
to NN NN O
some NN NN O
extent NN NN O
with NN NN O
the NN NN O
progression NN NN O
of NN NN O
Duchenne NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
. NN NN O

However NN NN O
, NN NN O
other NN NN O
interpretations NN NN O
are NN NN O
possible NN NN O
. NN NN O

Twelve NN NN O
percent NN NN O
of NN NN O
dystrophin NN NN O
revertant NN NN O
fibers NN NN O
as NN NN O
observed NN NN O
by NN NN O
immunohistochemistry NN NN O
could NN NN O
be NN NN O
sufficient NN NN O
to NN NN O
ameliorate NN NN O
typical NN NN O
DMD NN NN B-Modifier
clinical NN NN O
severity NN NN O
, NN NN O
or NN NN O
the NN NN O
patient NN NN O
may NN NN O
present NN NN O
a NN NN O
somatic NN NN O
mosaic NN NN O
. NN NN O

The NN NN O
pathophysiological NN NN O
interactions NN NN O
of NN NN O
these NN NN O
two NN NN O
unlinked NN NN O
disorders NN NN O
are NN NN O
discussed NN NN O
at NN NN O
the NN NN O
clinical NN NN O
and NN NN O
histopathological NN NN O
levels NN NN O
. NN NN O

. NN NN O

7759075 NN NN O
Age NN NN O
at NN NN O
diagnosis NN NN O
as NN NN O
an NN NN O
indicator NN NN O
of NN NN O
eligibility NN NN O
for NN NN O
BRCA1 NN NN O
DNA NN NN O
testing NN NN O
in NN NN O
familial NN NN B-SpecificDisease
breast NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

We NN NN O
searched NN NN O
for NN NN O
criteria NN NN O
that NN NN O
could NN NN O
indicate NN NN O
breast NN NN B-Modifier
cancer NN NN I-Modifier
families NN NN O
with NN NN O
a NN NN O
high NN NN O
prior NN NN O
probability NN NN O
of NN NN O
being NN NN O
caused NN NN O
by NN NN O
the NN NN O
breast NN NN B-Modifier
/ NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
susceptibility NN NN O
locus NN NN O
BRCA1 NN NN O
on NN NN O
chromosome NN NN O
17 NN NN O
. NN NN O

To NN NN O
this NN NN O
end NN NN O
, NN NN O
we NN NN O
performed NN NN O
a NN NN O
linkage NN NN O
study NN NN O
with NN NN O
59 NN NN O
consecutively NN NN O
collected NN NN O
Dutch NN NN O
breast NN NN B-Modifier
cancer NN NN I-Modifier
families NN NN O
, NN NN O
including NN NN O
16 NN NN O
with NN NN O
at NN NN O
least NN NN O
one NN NN O
case NN NN O
of NN NN O
ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

We NN NN O
used NN NN O
an NN NN O
intake NN NN O
cut-off NN NN O
of NN NN O
at NN NN O
least NN NN O
three NN NN O
first-degree NN NN O
relatives NN NN O
with NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
/ NN NN I-CompositeMention
or NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
at NN NN O
any NN NN O
age NN NN O
. NN NN O

Significant NN NN O
evidence NN NN O
for NN NN O
linkage NN NN O
was NN NN O
found NN NN O
only NN NN O
among NN NN O
the NN NN O
13 NN NN O
breast NN NN B-Modifier
cancer NN NN I-Modifier
families NN NN O
with NN NN O
a NN NN O
mean NN NN O
age NN NN O
at NN NN O
diagnosis NN NN O
of NN NN O
less NN NN O
than NN NN O
45 NN NN O
years NN NN O
. NN NN O

An NN NN O
unexpectedly NN NN O
low NN NN O
proportion NN NN O
of NN NN O
the NN NN O
breast-ovarian NN NN B-Modifier
cancer NN NN I-Modifier
families NN NN O
were NN NN O
estimated NN NN O
to NN NN O
be NN NN O
linked NN NN O
to NN NN O
BRCA1 NN NN O
, NN NN O
which NN NN O
could NN NN O
be NN NN O
due NN NN O
to NN NN O
a NN NN O
founder NN NN O
effect NN NN O
in NN NN O
the NN NN O
Dutch NN NN O
population NN NN O
. NN NN O

Given NN NN O
the NN NN O
expected NN NN O
logistical NN NN O
problems NN NN O
in NN NN O
clinical NN NN O
management NN NN O
now NN NN O
that NN NN O
BRCA1 NN NN O
has NN NN O
been NN NN O
identified NN NN O
, NN NN O
we NN NN O
propose NN NN O
an NN NN O
interim NN NN O
period NN NN O
in NN NN O
which NN NN O
only NN NN O
families NN NN O
with NN NN O
a NN NN O
strong NN NN O
positive NN NN O
family NN NN O
history NN NN O
for NN NN O
early NN NN O
onset NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
/ NN NN I-CompositeMention
or NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
will NN NN O
be NN NN O
offered NN NN O
BRCA1 NN NN O
mutation NN NN O
testing NN NN O
. NN NN O

. NN NN O

7759076 NN NN O
Linkage NN NN O
analysis NN NN O
of NN NN O
26 NN NN O
Canadian NN NN O
breast NN NN B-Modifier
and NN NN I-Modifier
breast-ovarian NN NN I-Modifier
cancer NN NN I-Modifier
families NN NN O
. NN NN O

We NN NN O
have NN NN O
examined NN NN O
26 NN NN O
Canadian NN NN O
families NN NN O
with NN NN O
hereditary NN NN B-CompositeMention
breast NN NN I-CompositeMention
or NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
for NN NN O
linkage NN NN O
to NN NN O
markers NN NN O
flanking NN NN O
the NN NN O
BRCA1 NN NN O
gene NN NN O
on NN NN O
chromosome NN NN O
17q12-q21 NN NN O
. NN NN O

Of NN NN O
the NN NN O
15 NN NN O
families NN NN O
that NN NN O
contain NN NN O
cases NN NN O
of NN NN O
ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
, NN NN O
94 NN NN O
% NN NN O
were NN NN O
estimated NN NN O
to NN NN O
be NN NN O
linked NN NN O
to NN NN O
BRCA1 NN NN O
. NN NN O

In NN NN O
contrast NN NN O
, NN NN O
there NN NN O
was NN NN O
no NN NN O
overall NN NN O
evidence NN NN O
of NN NN O
linkage NN NN O
in NN NN O
the NN NN O
group NN NN O
of NN NN O
10 NN NN O
families NN NN O
with NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
without NN NN O
ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

A NN NN O
genetic NN NN O
recombinant NN NN O
in NN NN O
a NN NN O
breast-ovarian NN NN B-Modifier
cancer NN NN I-Modifier
family NN NN O
indicates NN NN O
a NN NN O
placement NN NN O
of NN NN O
BRCA1 NN NN O
telomeric NN NN O
to NN NN O
D17S776 NN NN O
, NN NN O
and NN NN O
helps NN NN O
to NN NN O
define NN NN O
the NN NN O
region NN NN O
of NN NN O
assignment NN NN O
of NN NN O
the NN NN O
cancer NN NN B-Modifier
susceptibility NN NN O
gene NN NN O
. NN NN O

Other NN NN O
cancers NN NN B-DiseaseClass
of NN NN O
interest NN NN O
that NN NN O
appeared NN NN O
in NN NN O
the NN NN O
BRCA1-linked NN NN O
families NN NN O
included NN NN O
primary NN NN B-SpecificDisease
peritoneal NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
, NN NN O
cancer NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
fallopian NN NN I-SpecificDisease
tube NN NN I-SpecificDisease
, NN NN O
and NN NN O
malignant NN NN B-SpecificDisease
melanoma NN NN I-SpecificDisease
. NN NN O

. NN NN O

7759106 NN NN O
Structural NN NN O
analysis NN NN O
of NN NN O
the NN NN O
5 NN NN O
' NN NN O
region NN NN O
of NN NN O
mouse NN NN O
and NN NN O
human NN NN O
Huntington NN NN B-Modifier
disease NN NN I-Modifier
genes NN NN O
reveals NN NN O
conservation NN NN O
of NN NN O
putative NN NN O
promoter NN NN O
region NN NN O
and NN NN O
di- NN NN O
and NN NN O
trinucleotide NN NN O
polymorphisms NN NN O
. NN NN O

We NN NN O
have NN NN O
previously NN NN O
cloned NN NN O
and NN NN O
characterized NN NN O
the NN NN O
murine NN NN O
homologue NN NN O
of NN NN O
the NN NN O
Huntington NN NN B-Modifier
disease NN NN I-Modifier
( NN NN O
HD NN NN B-Modifier
) NN NN O
gene NN NN O
and NN NN O
shown NN NN O
that NN NN O
it NN NN O
maps NN NN O
to NN NN O
mouse NN NN O
chromosome NN NN O
5 NN NN O
within NN NN O
a NN NN O
region NN NN O
of NN NN O
conserved NN NN O
synteny NN NN O
with NN NN O
human NN NN O
chromosome NN NN O
4p16 NN NN O
. NN NN O

3 NN NN O
3 NN NN O
. NN NN O

Here NN NN O
we NN NN O
present NN NN O
a NN NN O
detailed NN NN O
comparison NN NN O
of NN NN O
the NN NN O
sequence NN NN O
of NN NN O
the NN NN O
putative NN NN O
promoter NN NN O
and NN NN O
the NN NN O
organization NN NN O
of NN NN O
the NN NN O
5 NN NN O
genomic NN NN O
region NN NN O
of NN NN O
the NN NN O
murine NN NN O
( NN NN O
Hdh NN NN O
) NN NN O
and NN NN O
human NN NN O
HD NN NN B-Modifier
genes NN NN O
encompassing NN NN O
the NN NN O
first NN NN O
five NN NN O
exons NN NN O
. NN NN O

We NN NN O
show NN NN O
that NN NN O
in NN NN O
this NN NN O
region NN NN O
these NN NN O
two NN NN O
genes NN NN O
share NN NN O
identical NN NN O
exon NN NN O
boundaries NN NN O
, NN NN O
but NN NN O
have NN NN O
different-size NN NN O
introns NN NN O
. NN NN O

Two NN NN O
dinucleotide NN NN O
( NN NN O
CT NN NN O
) NN NN O
and NN NN O
one NN NN O
trinucleotide NN NN O
intronic NN NN O
polymorphism NN NN O
in NN NN O
Hdh NN NN O
and NN NN O
an NN NN O
intronic NN NN O
CA NN NN O
polymorphism NN NN O
in NN NN O
the NN NN O
HD NN NN B-Modifier
gene NN NN O
were NN NN O
identified NN NN O
. NN NN O

Comparison NN NN O
of NN NN O
940-bp NN NN O
sequence NN NN O
5 NN NN O
to NN NN O
the NN NN O
putative NN NN O
translation NN NN O
start NN NN O
site NN NN O
reveals NN NN O
a NN NN O
highly NN NN O
conserved NN NN O
region NN NN O
( NN NN O
78 NN NN O
. NN NN O

8 NN NN O
% NN NN O
nucleotide NN NN O
identity NN NN O
) NN NN O
between NN NN O
Hdh NN NN O
and NN NN O
the NN NN O
HD NN NN B-Modifier
gene NN NN O
from NN NN O
nucleotide NN NN O
-56 NN NN O
to NN NN O
-206 NN NN O
( NN NN O
of NN NN O
Hdh NN NN O
) NN NN O
. NN NN O

Neither NN NN O
Hdh NN NN O
nor NN NN O
the NN NN O
HD NN NN B-Modifier
gene NN NN O
have NN NN O
typical NN NN O
TATA NN NN O
or NN NN O
CCAAT NN NN O
elements NN NN O
, NN NN O
but NN NN O
both NN NN O
show NN NN O
one NN NN O
putative NN NN O
AP2 NN NN O
binding NN NN O
site NN NN O
and NN NN O
numerous NN NN O
potential NN NN O
Sp1 NN NN O
binding NN NN O
sites NN NN O
. NN NN O

The NN NN O
high NN NN O
sequence NN NN O
identity NN NN O
between NN NN O
Hdh NN NN O
and NN NN O
the NN NN O
HD NN NN B-Modifier
gene NN NN O
for NN NN O
approximately NN NN O
200 NN NN O
bp NN NN O
5 NN NN O
to NN NN O
the NN NN O
putative NN NN O
translation NN NN O
start NN NN O
site NN NN O
indicates NN NN O
that NN NN O
these NN NN O
sequences NN NN O
may NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
regulating NN NN O
expression NN NN O
of NN NN O
the NN NN O
Huntington NN NN B-Modifier
disease NN NN I-Modifier
gene NN NN O

7761412 NN NN O
The NN NN O
protein NN NN O
deficient NN NN O
in NN NN O
Lowe NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
is NN NN O
a NN NN O
phosphatidylinositol-4,5-bisphosphate NN NN O
5-phosphatase NN NN O
. NN NN O

Lowe NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
, NN NN O
also NN NN O
known NN NN O
as NN NN O
oculocerebrorenal NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
, NN NN O
is NN NN O
caused NN NN O
by NN NN O
mutations NN NN O
in NN NN O
the NN NN O
X NN NN O
chromosome-encoded NN NN O
OCRL NN NN O
gene NN NN O
. NN NN O

The NN NN O
OCRL NN NN O
protein NN NN O
is NN NN O
51 NN NN O
% NN NN O
identical NN NN O
to NN NN O
inositol NN NN O
polyphosphate NN NN O
5-phosphatase NN NN O
II NN NN O
( NN NN O
5-phosphatase NN NN O
II NN NN O
) NN NN O
from NN NN O
human NN NN O
platelets NN NN O
over NN NN O
a NN NN O
span NN NN O
of NN NN O
744 NN NN O
aa NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
OCRL NN NN O
may NN NN O
be NN NN O
a NN NN O
similar NN NN O
enzyme NN NN O
. NN NN O

We NN NN O
engineered NN NN O
a NN NN O
construct NN NN O
of NN NN O
the NN NN O
OCRL NN NN O
cDNA NN NN O
that NN NN O
encodes NN NN O
amino NN NN O
acids NN NN O
homologous NN NN O
to NN NN O
the NN NN O
platelet NN NN O
5-phosphatase NN NN O
for NN NN O
expression NN NN O
in NN NN O
baculovirus-infected NN NN O
Sf9 NN NN O
insect NN NN O
cells NN NN O
. NN NN O

This NN NN O
cDNA NN NN O
encodes NN NN O
aa NN NN O
264-968 NN NN O
of NN NN O
the NN NN O
OCRL NN NN O
protein NN NN O
. NN NN O

The NN NN O
recombinant NN NN O
protein NN NN O
was NN NN O
found NN NN O
to NN NN O
catalyze NN NN O
the NN NN O
reactions NN NN O
also NN NN O
carried NN NN O
out NN NN O
by NN NN O
platelet NN NN O
5-phosphatase NN NN O
II NN NN O
. NN NN O

Thus NN NN O
OCRL NN NN O
converts NN NN O
inositol NN NN O
1 NN NN O
, NN NN O
4 NN NN O
, NN NN O
5-trisphosphate NN NN O
to NN NN O
inositol NN NN O
1 NN NN O
, NN NN O
4-bisphosphate NN NN O
, NN NN O
and NN NN O
it NN NN O
converts NN NN O
inositol NN NN O
1 NN NN O
, NN NN O
3 NN NN O
, NN NN O
4 NN NN O
, NN NN O
5-tetrakisphosphate NN NN O
to NN NN O
inositol NN NN O
1 NN NN O
, NN NN O
3 NN NN O
, NN NN O
4-trisphosphate NN NN O
. NN NN O

Most NN NN O
important NN NN O
, NN NN O
the NN NN O
enzyme NN NN O
converts NN NN O
phosphatidylinositol NN NN O
4 NN NN O
, NN NN O
5-bisphosphate NN NN O
to NN NN O
phosphatidylinositol NN NN O
4-phosphate NN NN O
. NN NN O

The NN NN O
relative NN NN O
ability NN NN O
of NN NN O
OCRL NN NN O
to NN NN O
catalyze NN NN O
the NN NN O
three NN NN O
reactions NN NN O
is NN NN O
different NN NN O
from NN NN O
that NN NN O
of NN NN O
5-phosphatase NN NN O
II NN NN O
and NN NN O
from NN NN O
that NN NN O
of NN NN O
another NN NN O
5-phosphatase NN NN O
isoenzyme NN NN O
from NN NN O
platelets NN NN O
, NN NN O
5-phosphatase NN NN O
I NN NN O
. NN NN O

The NN NN O
recombinant NN NN O
OCRL NN NN O
protein NN NN O
hydrolyzes NN NN O
the NN NN O
phospholipid NN NN O
substrate NN NN O
10- NN NN O
to NN NN O
30-fold NN NN O
better NN NN O
than NN NN O
5-phosphatase NN NN O
II NN NN O
, NN NN O
and NN NN O
5-phosphatase NN NN O
I NN NN O
does NN NN O
not NN NN O
cleave NN NN O
the NN NN O
lipid NN NN O
at NN NN O
all NN NN O
. NN NN O

We NN NN O
also NN NN O
show NN NN O
that NN NN O
OCRL NN NN O
functions NN NN O
as NN NN O
a NN NN O
phosphatidylinositol NN NN O
4 NN NN O
, NN NN O
5-bisphosphate NN NN O
5-phosphatase NN NN O
in NN NN O
OCRL-expressing NN NN O
Sf9 NN NN O
cells NN NN O
. NN NN O

These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
OCRL NN NN O
is NN NN O
mainly NN NN O
a NN NN O
lipid NN NN O
phosphatase NN NN O
that NN NN O
may NN NN O
control NN NN O
cellular NN NN O
levels NN NN O
of NN NN O
a NN NN O
critical NN NN O
metabolite NN NN O
, NN NN O
phosphatidylinositol NN NN O
4 NN NN O
, NN NN O
5-bisphosphate NN NN O
. NN NN O

Deficiency NN NN O
of NN NN O
this NN NN O
enzyme NN NN O
apparently NN NN O
causes NN NN O
the NN NN O
protean NN NN O
manifestations NN NN O
of NN NN O
Lowe NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

. NN NN O

7762560 NN NN O
New NN NN O
founder NN NN O
haplotypes NN NN O
at NN NN O
the NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
locus NN NN O
in NN NN O
southern NN NN O
Africa NN NN O
. NN NN O

The NN NN O
association NN NN O
between NN NN O
normal NN NN O
alleles NN NN O
at NN NN O
the NN NN O
CTG NN NN O
repeat NN NN O
and NN NN O
two NN NN O
nearby NN NN O
polymorphisms NN NN O
in NN NN O
the NN NN O
myotonin NN NN O
protein NN NN O
kinase NN NN O
gene NN NN O
, NN NN O
the NN NN O
Alu NN NN O
insertion NN NN O
/ NN NN O
deletion NN NN O
polymorphism NN NN O
and NN NN O
the NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
kinase NN NN O
( NN NN O
DMK NN NN O
) NN NN O
( NN NN O
G NN NN O
/ NN NN O
T NN NN O
) NN NN O
intron NN NN O
9 NN NN O
/ NN NN O
HinfI NN NN O
polymorphism NN NN O
, NN NN O
has NN NN O
been NN NN O
analyzed NN NN O
in NN NN O
South NN NN O
African NN NN O
Negroids NN NN O
, NN NN O
a NN NN O
population NN NN O
in NN NN O
which NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
has NN NN O
not NN NN O
been NN NN O
described NN NN O
. NN NN O

South NN NN O
African NN NN O
Negroids NN NN O
have NN NN O
a NN NN O
CTG NN NN O
allelic NN NN O
distribution NN NN O
that NN NN O
is NN NN O
significantly NN NN O
different NN NN O
from NN NN O
that NN NN O
in NN NN O
Caucasoids NN NN O
and NN NN O
Japanese NN NN O
the NN NN O
CTG NN NN O
repeat NN NN O
lengths NN NN O
of NN NN O
or NN NN O
= NN NN O
19 NN NN O
are NN NN O
very NN NN O
rare NN NN O
. NN NN O

The NN NN O
striking NN NN O
linkage NN NN O
disequilibrium NN NN O
between NN NN O
specific NN NN O
alleles NN NN O
at NN NN O
the NN NN O
Alu NN NN O
polymorphism NN NN O
( NN NN O
Alu NN NN O
( NN NN O
ins NN NN O
) NN NN O
and NN NN O
Alu NN NN O
( NN NN O
del NN NN O
) NN NN O
) NN NN O
, NN NN O
the NN NN O
HinfI NN NN O
polymorphism NN NN O
( NN NN O
HinfI-1 NN NN O
and NN NN O
HinfI-2 NN NN O
) NN NN O
, NN NN O
and NN NN O
the NN NN O
CTG NN NN O
repeat NN NN O
polymorphism NN NN O
seen NN NN O
in NN NN O
Caucasoid NN NN O
( NN NN O
Europeans NN NN O
and NN NN O
Canadians NN NN O
) NN NN O
populations NN NN O
was NN NN O
also NN NN O
found NN NN O
in NN NN O
the NN NN O
South NN NN O
African NN NN O
Negroid NN NN O
population NN NN O
. NN NN O

Numerous NN NN O
haplotypes NN NN O
, NN NN O
not NN NN O
previously NN NN O
described NN NN O
in NN NN O
Europeans NN NN O
, NN NN O
were NN NN O
, NN NN O
however NN NN O
, NN NN O
found NN NN O
. NN NN O

It NN NN O
thus NN NN O
seems NN NN O
likely NN NN O
that NN NN O
only NN NN O
a NN NN O
small NN NN O
number NN NN O
of NN NN O
these NN NN O
`` NN NN O
African NN NN O
`` NN NN O
chromosomes NN NN O
were NN NN O
present NN NN O
in NN NN O
the NN NN O
progenitors NN NN O
of NN NN O
all NN NN O
non-African NN NN O
peoples NN NN O
. NN NN O

These NN NN O
data NN NN O
provide NN NN O
support NN NN O
for NN NN O
the NN NN O
`` NN NN O
out NN NN O
of NN NN O
Africa NN NN O
`` NN NN O
model NN NN O
for NN NN O
the NN NN O
origin NN NN O
of NN NN O
modern NN NN O
humans NN NN O
and NN NN O
suggest NN NN O
that NN NN O
the NN NN O
rare NN NN O
ancestral NN NN O
DM NN NN B-Modifier
mutation NN NN O
event NN NN O
may NN NN O
have NN NN O
occurred NN NN O
after NN NN O
the NN NN O
migration NN NN O
from NN NN O
Africa NN NN O
, NN NN O
hence NN NN O
the NN NN O
absence NN NN O
of NN NN O
DM NN NN B-SpecificDisease
in NN NN O
sub-Saharan NN NN O
Negroid NN NN O
peoples NN NN O
. NN NN O

. NN NN O

7767095 NN NN O
Discordant NN NN O
clinical NN NN O
outcome NN NN O
in NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
relatives NN NN O
showing NN NN O
( NN NN O
CTG NN NN O
) NN NN O
n NN NN O
700 NN NN O
repeats NN NN O
. NN NN O

A NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
( NN NN O
DM NN NN B-Modifier
) NN NN O
family NN NN O
is NN NN O
described NN NN O
in NN NN O
which NN NN O
discordant NN NN O
DM NN NN B-Modifier
phenotypes NN NN O
were NN NN O
found NN NN O
in NN NN O
the NN NN O
children NN NN O
of NN NN O
two NN NN O
affected NN NN O
sisters NN NN O
with NN NN O
similar NN NN O
CTG NN NN O
expansion NN NN O
and NN NN O
clinical NN NN O
manifestations NN NN O
. NN NN O

In NN NN O
this NN NN O
family NN NN O
, NN NN O
congenital NN NN O
as NN NN O
well NN NN O
as NN NN O
early NN NN O
severe NN NN O
childhood NN NN O
and NN NN O
later NN NN O
childhood NN NN O
onset NN NN O
DM NN NN B-SpecificDisease
coexist NN NN O
. NN NN O

This NN NN O
observation NN NN O
strengthens NN NN O
the NN NN O
limited NN NN O
ability NN NN O
of NN NN O
lymphocytes NN NN O
CTG NN NN O
repeat NN NN O
number NN NN O
analysis NN NN O
in NN NN O
predicting NN NN O
genotype-phenotype NN NN O
correlations NN NN O
in NN NN O
DM NN NN B-Modifier
patients NN NN O
. NN NN O

. NN NN O

7769092 NN NN O
Purification NN NN O
of NN NN O
human NN NN O
very-long-chain NN NN O
acyl-coenzyme NN NN O
A NN NN O
dehydrogenase NN NN O
and NN NN O
characterization NN NN O
of NN NN O
its NN NN O
deficiency NN NN O
in NN NN O
seven NN NN O
patients NN NN O
. NN NN O

Mitochondrial NN NN O
very-long-chain NN NN O
acyl-coenzyme NN NN O
A NN NN O
dehydrogenase NN NN O
( NN NN O
VLCAD NN NN O
) NN NN O
was NN NN O
purified NN NN O
from NN NN O
human NN NN O
liver NN NN O
. NN NN O

The NN NN O
molecular NN NN O
masses NN NN O
of NN NN O
the NN NN O
native NN NN O
enzyme NN NN O
and NN NN O
the NN NN O
subunit NN NN O
were NN NN O
estimated NN NN O
to NN NN O
be NN NN O
154 NN NN O
and NN NN O
70 NN NN O
kD NN NN O
, NN NN O
respectively NN NN O
. NN NN O

The NN NN O
enzyme NN NN O
was NN NN O
found NN NN O
to NN NN O
catalyze NN NN O
the NN NN O
major NN NN O
part NN NN O
of NN NN O
mitochondrial NN NN O
palmitoylcoenzyme NN NN O
A NN NN O
dehydrogenation NN NN O
in NN NN O
liver NN NN O
, NN NN O
heart NN NN O
, NN NN O
skeletal NN NN O
muscle NN NN O
, NN NN O
and NN NN O
skin NN NN O
fibroblasts NN NN O
( NN NN O
89-97 NN NN O
, NN NN O
86-99 NN NN O
, NN NN O
96-99 NN NN O
, NN NN O
and NN NN O
78-87 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
) NN NN O
. NN NN O

Skin NN NN O
fibroblasts NN NN O
from NN NN O
26 NN NN O
patients NN NN O
suspected NN NN O
of NN NN O
having NN NN O
a NN NN O
disorder NN NN O
of NN NN O
mitochondrial NN NN O
beta-oxidation NN NN O
were NN NN O
analyzed NN NN O
for NN NN O
VLCAD NN NN O
protein NN NN O
using NN NN O
immunoblotting NN NN O
, NN NN O
and NN NN O
7 NN NN O
of NN NN O
them NN NN O
contained NN NN O
undetectable NN NN O
or NN NN O
trace NN NN O
levels NN NN O
of NN NN O
the NN NN O
enzyme NN NN O
. NN NN O

The NN NN O
seven NN NN O
deficient NN NN O
fibroblast NN NN O
lines NN NN O
were NN NN O
characterized NN NN O
by NN NN O
measuring NN NN O
acyl-coenzyme NN NN O
A NN NN O
dehydrogenation NN NN O
activities NN NN O
, NN NN O
overall NN NN O
palmitic NN NN O
acid NN NN O
oxidation NN NN O
, NN NN O
and NN NN O
VLCAD NN NN O
protein NN NN O
synthesis NN NN O
using NN NN O
pulse-chase NN NN O
, NN NN O
further NN NN O
confirming NN NN O
the NN NN O
diagnosis NN NN O
of NN NN O
VLCAD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

These NN NN O
results NN NN O
suggested NN NN O
the NN NN O
heterogenous NN NN O
nature NN NN O
of NN NN O
the NN NN O
mutations NN NN O
causing NN NN O
the NN NN O
deficiency NN NN O
in NN NN O
the NN NN O
seven NN NN O
patients NN NN O
. NN NN O

Clinically NN NN O
, NN NN O
all NN NN O
patients NN NN O
with NN NN O
VLCAD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
exhibited NN NN O
cardiac NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
. NN NN O

At NN NN O
least NN NN O
four NN NN O
of NN NN O
them NN NN O
presented NN NN O
with NN NN O
hypertrophic NN NN B-SpecificDisease
cardiomyopathy NN NN I-SpecificDisease
. NN NN O

This NN NN O
frequency NN NN O
( NN NN O
57 NN NN O
% NN NN O
) NN NN O
was NN NN O
much NN NN O
higher NN NN O
than NN NN O
that NN NN O
observed NN NN O
in NN NN O
patients NN NN O
with NN NN O
other NN NN O
disorders NN NN O
of NN NN O
mitochondrial NN NN O
long-chain NN NN O
fatty NN NN O
acid NN NN O
oxidation NN NN O
that NN NN O
may NN NN O
be NN NN O
accompanied NN NN O
by NN NN O
cardiac NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
in NN NN O
infants NN NN O
. NN NN O

. NN NN O

777027 NN NN O
Hereditary NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
fifth NN NN I-SpecificDisease
component NN NN I-SpecificDisease
of NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
in NN NN O
man NN NN O
. NN NN O

II NN NN O
. NN NN O

Biological NN NN O
properties NN NN O
of NN NN O
C5-deficient NN NN B-Modifier
human NN NN O
serum NN NN O
. NN NN O

The NN NN O
first NN NN O
known NN NN O
human NN NN O
kindred NN NN O
with NN NN O
hereditary NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
fifth NN NN I-SpecificDisease
component NN NN I-SpecificDisease
of NN NN I-SpecificDisease
complement NN NN I-SpecificDisease
( NN NN O
C5 NN NN O
) NN NN O
was NN NN O
documented NN NN O
in NN NN O
the NN NN O
accompanying NN NN O
report NN NN O
. NN NN O

This NN NN O
study NN NN O
examines NN NN O
several NN NN O
biological NN NN O
properties NN NN O
of NN NN O
C5-deficient NN NN B-Modifier
( NN NN O
C5D NN NN B-Modifier
) NN NN O
human NN NN O
serum NN NN O
, NN NN O
particularly NN NN O
sera NN NN O
obtained NN NN O
from NN NN O
two NN NN O
C5D NN NN B-Modifier
homozygotes NN NN O
. NN NN O

The NN NN O
proband NN NN O
, NN NN O
who NN NN O
has NN NN O
inactive NN NN O
systemic NN NN B-SpecificDisease
lupus NN NN I-SpecificDisease
erythematosus NN NN I-SpecificDisease
is NN NN O
completely NN NN O
lacking NN NN O
C5 NN NN O
, NN NN O
while NN NN O
her NN NN O
healthy NN NN O
half-sister NN NN O
has NN NN O
1-2 NN NN O
% NN NN O
of NN NN O
normal NN NN O
levels NN NN O
. NN NN O

Both NN NN O
sera NN NN O
were NN NN O
severely NN NN O
impaired NN NN O
in NN NN O
their NN NN O
ability NN NN O
to NN NN O
generate NN NN O
chemotactic NN NN O
activity NN NN O
for NN NN O
normal NN NN O
human NN NN O
neutrophils NN NN O
upon NN NN O
incubation NN NN O
with NN NN O
aggregated NN NN O
human NN NN O
gamma-globulin NN NN O
or NN NN O
Escherichia NN NN O
coli NN NN O
endotoxin NN NN O
. NN NN O

This NN NN O
function NN NN O
was NN NN O
fully NN NN O
restored NN NN O
in NN NN O
the NN NN O
siblings NN NN O
serum NN NN O
, NN NN O
and NN NN O
substantially NN NN O
improved NN NN O
in NN NN O
the NN NN O
probands NN NN O
serum NN NN O
, NN NN O
by NN NN O
addition NN NN O
of NN NN O
highly NN NN O
purified NN NN O
human NN NN O
C5 NN NN O
to NN NN O
normal NN NN O
serum NN NN O
concentrations NN NN O
. NN NN O

Sera NN NN O
from NN NN O
eight NN NN O
family NN NN O
members NN NN O
who NN NN O
were NN NN O
apparently NN NN O
heterozygous NN NN O
for NN NN O
C5 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
gave NN NN O
normal NN NN O
chemotactic NN NN O
scores NN NN O
. NN NN O

The NN NN O
ability NN NN O
of NN NN O
C5D NN NN B-Modifier
serum NN NN O
to NN NN O
opsonize NN NN O
Saccharomyces NN NN O
cerevisiae NN NN O
( NN NN O
bakers NN NN O
yeast NN NN O
) NN NN O
or NN NN O
Candida NN NN O
albicans NN NN O
for NN NN O
ingestion NN NN O
by NN NN O
normal NN NN O
neutrophils NN NN O
was NN NN O
completely NN NN O
normal NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
C5D NN NN B-Modifier
serum NN NN O
was NN NN O
capable NN NN O
of NN NN O
promoting NN NN O
normal NN NN O
phagocytosis NN NN O
and NN NN O
intracellular NN NN O
killing NN NN O
of NN NN O
Staphylococcus NN NN O
aureus NN NN O
. NN NN O

The NN NN O
probands NN NN O
serum NN NN O
was NN NN O
incapable NN NN O
of NN NN O
mediating NN NN O
lysis NN NN O
of NN NN O
erythrocytes NN NN O
from NN NN O
a NN NN O
patient NN NN O
with NN NN O
paroxysmal NN NN B-SpecificDisease
nocturnal NN NN I-SpecificDisease
hemoglobinuria NN NN I-SpecificDisease
in NN NN O
both NN NN O
the NN NN O
sucrose NN NN O
hemolysia NN NN O
and NN NN O
acid NN NN O
hemolysis NN NN O
tests NN NN O
, NN NN O
and NN NN O
also NN NN O
lacked NN NN O
bactericidal NN NN O
activity NN NN O
against NN NN O
sensitized NN NN O
or NN NN O
unsensitized NN NN O
Salmonella NN NN O
typhi NN NN O
. NN NN O

The NN NN O
siblings NN NN O
serum NN NN O
, NN NN O
containing NN NN O
only NN NN O
1-2 NN NN O
% NN NN O
of NN NN O
normal NN NN O
C5 NN NN O
, NN NN O
effectively NN NN O
lysed NN NN O
S NN NN O
. NN NN O

typhi NN NN O
, NN NN O
but NN NN O
only NN NN O
at NN NN O
eightfold NN NN O
lower NN NN O
serum NN NN O
dilutions NN NN O
as NN NN O
compared NN NN O
to NN NN O
normals NN NN O
. NN NN O

These NN NN O
findings NN NN O
underscore NN NN O
the NN NN O
critical NN NN O
role NN NN O
of NN NN O
C5 NN NN O
in NN NN O
the NN NN O
generation NN NN O
of NN NN O
chemotactic NN NN O
activity NN NN O
and NN NN O
in NN NN O
cytolytic NN NN O
reactions NN NN O
, NN NN O
as NN NN O
opposed NN NN O
to NN NN O
a NN NN O
nonobligatory NN NN O
or NN NN O
minimal NN NN O
role NN NN O
in NN NN O
opsonization NN NN O
, NN NN O
at NN NN O
least NN NN O
for NN NN O
the NN NN O
organisms NN NN O
under NN NN O
study NN NN O
. NN NN O

. NN NN O

7790377 NN NN O
Human NN NN O
peroxisomal NN NN O
targeting NN NN O
signal-1 NN NN O
receptor NN NN O
restores NN NN O
peroxisomal NN NN O
protein NN NN O
import NN NN O
in NN NN O
cells NN NN O
from NN NN O
patients NN NN O
with NN NN O
fatal NN NN O
peroxisomal NN NN B-DiseaseClass
disorders NN NN I-DiseaseClass
. NN NN O

Two NN NN O
peroxisomal NN NN O
targeting NN NN O
signals NN NN O
, NN NN O
PTS1 NN NN O
and NN NN O
PTS2 NN NN O
, NN NN O
are NN NN O
involved NN NN O
in NN NN O
the NN NN O
import NN NN O
of NN NN O
proteins NN NN O
into NN NN O
the NN NN O
peroxisome NN NN O
matrix NN NN O
. NN NN O

Human NN NN O
patients NN NN O
with NN NN O
fatal NN NN O
generalized NN NN O
peroxisomal NN NN B-DiseaseClass
deficiency NN NN I-DiseaseClass
disorders NN NN I-DiseaseClass
fall NN NN O
into NN NN O
at NN NN O
least NN NN O
nine NN NN O
genetic NN NN O
complementation NN NN O
groups NN NN O
. NN NN O

Cells NN NN O
from NN NN O
many NN NN O
of NN NN O
these NN NN O
patients NN NN O
are NN NN O
deficient NN NN O
in NN NN O
the NN NN O
import NN NN O
of NN NN O
PTS1-containing NN NN O
proteins NN NN O
, NN NN O
but NN NN O
the NN NN O
causes NN NN O
of NN NN O
the NN NN O
protein-import NN NN O
defect NN NN O
in NN NN O
these NN NN O
patients NN NN O
are NN NN O
unknown NN NN O
. NN NN O

We NN NN O
have NN NN O
cloned NN NN O
and NN NN O
sequenced NN NN O
the NN NN O
human NN NN O
cDNA NN NN O
homologue NN NN O
( NN NN O
PTS1R NN NN O
) NN NN O
of NN NN O
the NN NN O
Pichia NN NN O
pastoris NN NN O
PAS8 NN NN O
gene NN NN O
, NN NN O
the NN NN O
PTS1 NN NN O
receptor NN NN O
( NN NN O
McCollum NN NN O
, NN NN O
D NN NN O
. NN NN O

, NN NN O
E NN NN O
. NN NN O

Monosov NN NN O
, NN NN O
and NN NN O
S NN NN O
. NN NN O

Subramani NN NN O
. NN NN O

1993 NN NN O
. NN NN O

J NN NN O
. NN NN O

Cell NN NN O
Biol NN NN O
. NN NN O

121 NN NN O
761-774 NN NN O
) NN NN O
. NN NN O

The NN NN O
PTS1R NN NN O
mRNA NN NN O
is NN NN O
expressed NN NN O
in NN NN O
all NN NN O
human NN NN O
tissues NN NN O
examined NN NN O
. NN NN O

Antibodies NN NN O
to NN NN O
the NN NN O
human NN NN O
PTS1R NN NN O
recognize NN NN O
this NN NN O
protein NN NN O
in NN NN O
human NN NN O
, NN NN O
monkey NN NN O
, NN NN O
rat NN NN O
, NN NN O
and NN NN O
hamster NN NN O
cells NN NN O
. NN NN O

The NN NN O
protein NN NN O
is NN NN O
localized NN NN O
mainly NN NN O
in NN NN O
the NN NN O
cytosol NN NN O
but NN NN O
is NN NN O
also NN NN O
found NN NN O
to NN NN O
be NN NN O
associated NN NN O
with NN NN O
peroxisomes NN NN O
. NN NN O

Part NN NN O
of NN NN O
the NN NN O
peroxisomal NN NN O
PTS1R NN NN O
protein NN NN O
is NN NN O
tightly NN NN O
bound NN NN O
to NN NN O
the NN NN O
peroxisomal NN NN O
membrane NN NN O
. NN NN O

Antibodies NN NN O
to NN NN O
PTS1R NN NN O
inhibit NN NN O
peroxisomal NN NN O
protein-import NN NN O
of NN NN O
PTS1-containing NN NN O
proteins NN NN O
in NN NN O
a NN NN O
permeabilized NN NN O
CHO NN NN O
cell NN NN O
system NN NN O
. NN NN O

In NN NN O
vitro-translated NN NN O
PTS1R NN NN O
protein NN NN O
specifically NN NN O
binds NN NN O
a NN NN O
serine-lysine-leucine-peptide NN NN O
. NN NN O

A NN NN O
PAS8-PTS1R NN NN O
fusion NN NN O
protein NN NN O
complements NN NN O
the NN NN O
P NN NN O
. NN NN O

pastoris NN NN O
pas8 NN NN O
mutant NN NN O
. NN NN O

The NN NN O
PTS1R NN NN O
cDNA NN NN O
also NN NN O
complements NN NN O
the NN NN O
PTS1 NN NN B-SpecificDisease
protein-import NN NN I-SpecificDisease
defect NN NN I-SpecificDisease
in NN NN O
skin NN NN O
fibroblasts NN NN O
from NN NN O
patients NN NN O
-- NN NN O
belonging NN NN O
to NN NN O
complementation NN NN O
group NN NN O
two NN NN O
-- NN NN O
diagnosed NN NN O
as NN NN O
having NN NN O
neonatal NN NN B-SpecificDisease
adrenoleukodystrophy NN NN I-SpecificDisease
or NN NN O
Zellweger NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

The NN NN O
PTS1R NN NN O
gene NN NN O
has NN NN O
been NN NN O
localized NN NN O
to NN NN O
a NN NN O
chromosomal NN NN O
location NN NN O
where NN NN O
no NN NN O
other NN NN O
peroxisomal NN NN B-Modifier
disorder NN NN I-Modifier
genes NN NN O
are NN NN O
known NN NN O
to NN NN O
map NN NN O
. NN NN O

Our NN NN O
findings NN NN O
represent NN NN O
the NN NN O
only NN NN O
case NN NN O
in NN NN O
which NN NN O
the NN NN O
molecular NN NN O
basis NN NN O
of NN NN O
the NN NN O
protein-import NN NN B-DiseaseClass
deficiency NN NN I-DiseaseClass
in NN NN O
human NN NN O
peroxisomal NN NN B-DiseaseClass
disorders NN NN I-DiseaseClass
is NN NN O
understood NN NN O
. NN NN O

7795591 NN NN O
Spectrum NN NN O
of NN NN O
germline NN NN O
mutations NN NN O
in NN NN O
the NN NN O
RB1 NN NN O
gene NN NN O
: NN NN O
a NN NN O
study NN NN O
of NN NN O
232 NN NN O
patients NN NN O
with NN NN O
hereditary NN NN B-CompositeMention
and NN NN I-CompositeMention
non NN NN I-CompositeMention
hereditary NN NN I-CompositeMention
retinoblastoma NN NN I-CompositeMention
. NN NN O

Germline NN NN O
mutations NN NN O
in NN NN O
the NN NN O
RB1 NN NN O
gene NN NN O
confer NN NN O
hereditary NN NN O
predisposition NN NN O
to NN NN O
retinoblastoma NN NN B-SpecificDisease
. NN NN O

We NN NN O
have NN NN O
performed NN NN O
a NN NN O
mutation NN NN O
survey NN NN O
of NN NN O
the NN NN O
RB1 NN NN O
gene NN NN O
in NN NN O
232 NN NN O
patients NN NN O
with NN NN O
hereditary NN NN B-CompositeMention
or NN NN I-CompositeMention
non NN NN I-CompositeMention
hereditary NN NN I-CompositeMention
retinoblastoma NN NN I-CompositeMention
. NN NN O

We NN NN O
systematically NN NN O
explored NN NN O
all NN NN O
27 NN NN O
exons NN NN O
and NN NN O
flanking NN NN O
sequences NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
promotor NN NN O
. NN NN O

All NN NN O
types NN NN O
of NN NN O
point NN NN O
mutations NN NN O
are NN NN O
represented NN NN O
and NN NN O
are NN NN O
found NN NN O
unequally NN NN O
distributed NN NN O
along NN NN O
the NN NN O
RB1 NN NN O
gene NN NN O
sequence NN NN O
. NN NN O

In NN NN O
the NN NN O
population NN NN O
we NN NN O
studied NN NN O
, NN NN O
exons NN NN O
3 NN NN O
, NN NN O
8 NN NN O
, NN NN O
18 NN NN O
and NN NN O
19 NN NN O
are NN NN O
preferentially NN NN O
altered NN NN O
. NN NN O

The NN NN O
range NN NN O
of NN NN O
frequency NN NN O
of NN NN O
detection NN NN O
of NN NN O
germline NN NN O
mutations NN NN O
is NN NN O
about NN NN O
20 NN NN O
% NN NN O
, NN NN O
indicating NN NN O
that NN NN O
other NN NN O
mechanisms NN NN O
of NN NN O
inactivation NN NN O
of NN NN O
RB1 NN NN O
should NN NN O
be NN NN O
involved NN NN O
. NN NN O

The NN NN O
spectrum NN NN O
of NN NN O
mutations NN NN O
presented NN NN O
here NN NN O
should NN NN O
help NN NN O
to NN NN O
improve NN NN O
the NN NN O
clinical NN NN O
management NN NN O
of NN NN O
retinoblastoma NN NN B-SpecificDisease
and NN NN O
to NN NN O
understand NN NN O
the NN NN O
molecular NN NN O
mechanisms NN NN O
leading NN NN O
to NN NN O
tumorigenesis NN NN O
. NN NN O

. NN NN O

7795596 NN NN O
Aniridia NN NN B-Modifier
-associated NN NN O
cytogenetic NN NN O
rearrangements NN NN O
suggest NN NN O
that NN NN O
a NN NN O
position NN NN O
effect NN NN O
may NN NN O
cause NN NN O
the NN NN O
mutant NN NN O
phenotype NN NN O
. NN NN O

Current NN NN O
evidence NN NN O
suggests NN NN O
that NN NN O
aniridia NN NN B-SpecificDisease
( NN NN O
absence NN NN B-SpecificDisease
of NN NN I-SpecificDisease
iris NN NN I-SpecificDisease
) NN NN O
is NN NN O
caused NN NN O
by NN NN O
loss NN NN O
of NN NN O
function NN NN O
of NN NN O
one NN NN O
copy NN NN O
of NN NN O
the NN NN O
PAX6 NN NN O
gene NN NN O
, NN NN O
which NN NN O
maps NN NN O
to NN NN O
11p13 NN NN O
. NN NN O

We NN NN O
present NN NN O
the NN NN O
further NN NN O
characterisation NN NN O
of NN NN O
two NN NN O
aniridia NN NN B-Modifier
pedigrees NN NN O
in NN NN O
which NN NN O
the NN NN O
disease NN NN O
segregates NN NN O
with NN NN O
chromosomal NN NN O
rearrangements NN NN O
which NN NN O
involve NN NN O
11p13 NN NN O
but NN NN O
do NN NN O
not NN NN O
disrupt NN NN O
the NN NN O
PAX6 NN NN O
gene NN NN O
. NN NN O

We NN NN O
have NN NN O
isolated NN NN O
three NN NN O
human NN NN O
YAC NN NN O
clones NN NN O
which NN NN O
encompass NN NN O
the NN NN O
PAX6 NN NN O
locus NN NN O
and NN NN O
we NN NN O
have NN NN O
used NN NN O
these NN NN O
to NN NN O
show NN NN O
that NN NN O
in NN NN O
both NN NN O
cases NN NN O
the NN NN O
chromosomal NN NN O
breakpoint NN NN O
is NN NN O
at NN NN O
least NN NN O
85 NN NN O
kb NN NN O
distal NN NN O
of NN NN O
the NN NN O
3 NN NN O
end NN NN O
of NN NN O
PAX6 NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
the NN NN O
open NN NN O
reading NN NN O
frame NN NN O
of NN NN O
PAX6 NN NN O
is NN NN O
apparently NN NN O
free NN NN O
of NN NN O
mutations NN NN O
. NN NN O

We NN NN O
propose NN NN O
that NN NN O
the NN NN O
PAX6 NN NN O
gene NN NN O
on NN NN O
the NN NN O
rearranged NN NN O
chromosome NN NN O
11 NN NN O
is NN NN O
in NN NN O
an NN NN O
inappropriate NN NN O
chromatin NN NN O
environment NN NN O
for NN NN O
normal NN NN O
expression NN NN O
and NN NN O
therefore NN NN O
that NN NN O
a NN NN O
position NN NN O
effect NN NN O
is NN NN O
the NN NN O
underlying NN NN O
mechanism NN NN O
of NN NN O
disease NN NN O
in NN NN O
these NN NN O
families NN NN O
. NN NN O

. NN NN O

7795652 NN NN O
Somatic NN NN O
mutations NN NN O
in NN NN O
the NN NN O
BRCA1 NN NN O
gene NN NN O
in NN NN O
sporadic NN NN B-SpecificDisease
ovarian NN NN I-SpecificDisease
tumours NN NN I-SpecificDisease
. NN NN O

The NN NN O
BRCA1 NN NN O
gene NN NN O
on NN NN O
chromosome NN NN O
17q21 NN NN O
is NN NN O
responsible NN NN O
for NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
dominant NN NN I-DiseaseClass
syndrome NN NN I-DiseaseClass
of NN NN O
increased NN NN O
susceptibility NN NN O
to NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
but NN NN O
no NN NN O
somatic NN NN O
mutations NN NN O
in NN NN O
tumours NN NN B-DiseaseClass
have NN NN O
yet NN NN O
been NN NN O
described NN NN O
. NN NN O

To NN NN O
study NN NN O
the NN NN O
potential NN NN O
role NN NN O
of NN NN O
BRCA1 NN NN O
in NN NN O
sporadic NN NN O
carcinogenesis NN NN O
, NN NN O
we NN NN O
analysed NN NN O
the NN NN O
genomic NN NN O
DNA NN NN O
of NN NN O
tumour NN NN B-DiseaseClass
and NN NN O
normal NN NN O
fractions NN NN O
of NN NN O
47 NN NN O
ovarian NN NN B-SpecificDisease
cancers NN NN I-SpecificDisease
for NN NN O
mutations NN NN O
in NN NN O
BRCA1 NN NN O
using NN NN O
the NN NN O
single-strand NN NN O
conformation NN NN O
polymorphism NN NN O
technique NN NN O
. NN NN O

We NN NN O
now NN NN O
describe NN NN O
somatic NN NN O
mutations NN NN O
in NN NN O
the NN NN O
DNA NN NN O
of NN NN O
four NN NN O
tumours NN NN B-DiseaseClass
which NN NN O
also NN NN O
had NN NN O
loss NN NN O
of NN NN O
heterozygosity NN NN O
( NN NN O
LOH NN NN O
) NN NN O
at NN NN O
a NN NN O
BRCA1 NN NN O
intragenic NN NN O
marker NN NN O
. NN NN O

Our NN NN O
data NN NN O
support NN NN O
a NN NN O
tumour NN NN B-Modifier
suppressor NN NN O
mechanism NN NN O
for NN NN O
BRCA1 NN NN O
; NN NN O
somatic NN NN O
mutations NN NN O
and NN NN O
LOH NN NN O
may NN NN O
result NN NN O
in NN NN O
inactivation NN NN O
of NN NN O
BRCA1 NN NN O
in NN NN O
at NN NN O
least NN NN O
a NN NN O
small NN NN O
number NN NN O
of NN NN O
ovarian NN NN B-SpecificDisease
cancers NN NN I-SpecificDisease
. NN NN O

. NN NN O

7795653 NN NN O
Decreased NN NN O
expression NN NN O
of NN NN O
BRCA1 NN NN O
accelerates NN NN O
growth NN NN O
and NN NN O
is NN NN O
often NN NN O
present NN NN O
during NN NN O
sporadic NN NN B-Modifier
breast NN NN I-Modifier
cancer NN NN I-Modifier
progression NN NN O
. NN NN O

We NN NN O
have NN NN O
characterized NN NN O
expression NN NN O
of NN NN O
the NN NN O
familial NN NN B-Modifier
breast NN NN I-Modifier
and NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
gene NN NN O
, NN NN O
BRCA1 NN NN O
, NN NN O
in NN NN O
cases NN NN O
of NN NN O
non-hereditary NN NN B-SpecificDisease
( NN NN I-SpecificDisease
sporadic NN NN I-SpecificDisease
) NN NN I-SpecificDisease
breast NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
and NN NN O
analyzed NN NN O
the NN NN O
effect NN NN O
of NN NN O
antisense NN NN O
inhibition NN NN O
of NN NN O
BRCA1 NN NN O
on NN NN O
the NN NN O
proliferative NN NN O
rate NN NN O
of NN NN O
mammary NN NN O
epithelial NN NN O
cells NN NN O
. NN NN O

BRCA1 NN NN O
mRNA NN NN O
levels NN NN O
are NN NN O
markedly NN NN O
decreased NN NN O
during NN NN O
the NN NN O
transition NN NN O
from NN NN O
carcinoma NN NN B-DiseaseClass
in NN NN I-DiseaseClass
situ NN NN I-DiseaseClass
to NN NN O
invasive NN NN B-DiseaseClass
cancer NN NN I-DiseaseClass
. NN NN O

Experimental NN NN O
inhibition NN NN O
of NN NN O
BRCA1 NN NN O
expression NN NN O
with NN NN O
antisense NN NN O
oligonucleotides NN NN O
produced NN NN O
accelerated NN NN O
growth NN NN O
of NN NN O
normal NN NN O
and NN NN O
malignant NN NN O
mammary NN NN O
cells NN NN O
, NN NN O
but NN NN O
had NN NN O
no NN NN O
effect NN NN O
on NN NN O
non-mammary NN NN O
epithelial NN NN O
cells NN NN O
. NN NN O

These NN NN O
studies NN NN O
suggest NN NN O
that NN NN O
BRCA1 NN NN O
may NN NN O
normally NN NN O
serve NN NN O
as NN NN O
a NN NN O
negative NN NN O
regulator NN NN O
of NN NN O
mammary NN NN O
epithelial NN NN O
cell NN NN O
growth NN NN O
whose NN NN O
function NN NN O
is NN NN O
compromised NN NN O
in NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
either NN NN O
by NN NN O
direct NN NN O
mutation NN NN O
or NN NN O
alterations NN NN O
in NN NN O
gene NN NN O
expression NN NN O
. NN NN O

. NN NN O

7802009 NN NN O
Additional NN NN O
case NN NN O
of NN NN O
female NN NN O
monozygotic NN NN O
twins NN NN O
discordant NN NN O
for NN NN O
the NN NN O
clinical NN NN O
manifestations NN NN O
of NN NN O
Duchenne NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
due NN NN O
to NN NN O
opposite NN NN O
X-chromosome NN NN O
inactivation NN NN O
. NN NN O

A NN NN O
pair NN NN O
of NN NN O
female NN NN O
monozygotic NN NN O
( NN NN O
MZ NN NN O
) NN NN O
twins NN NN O
, NN NN O
heterozygous NN NN O
carriers NN NN O
for NN NN O
a NN NN O
deletion NN NN O
in NN NN O
the NN NN O
DMD NN NN B-Modifier
gene NN NN O
and NN NN O
discordant NN NN O
for NN NN O
the NN NN O
clinical NN NN O
manifestations NN NN O
of NN NN O
Duchenne NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
, NN NN O
were NN NN O
analyzed NN NN O
by NN NN O
molecular NN NN O
studies NN NN O
, NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
, NN NN O
and NN NN O
methylation NN NN O
pattern NN NN O
of NN NN O
X NN NN O
chromosomes NN NN O
to NN NN O
search NN NN O
for NN NN O
opposite NN NN O
X NN NN O
inactivation NN NN O
as NN NN O
an NN NN O
explanation NN NN O
of NN NN O
their NN NN O
clinical NN NN O
discordance NN NN O
. NN NN O

Results NN NN O
in NN NN O
lymphocytes NN NN O
and NN NN O
skin NN NN O
fibroblast NN NN O
cell NN NN O
lines NN NN O
suggest NN NN O
a NN NN O
partial NN NN O
mirror NN NN O
inactivation NN NN O
with NN NN O
the NN NN O
normal NN NN O
X NN NN O
chromosome NN NN O
preferentially NN NN O
active NN NN O
in NN NN O
the NN NN O
unaffected NN NN O
twin NN NN O
, NN NN O
and NN NN O
the NN NN O
maternal NN NN O
deleted NN NN O
X NN NN O
chromosome NN NN O
preferentially NN NN O
active NN NN O
in NN NN O
the NN NN O
affected NN NN O
twin NN NN O
. NN NN O

A NN NN O
review NN NN O
shows NN NN O
that NN NN O
MZ NN NN O
female NN NN O
twins NN NN O
discordant NN NN O
for NN NN O
X-linked NN NN B-DiseaseClass
diseases NN NN I-DiseaseClass
are NN NN O
not NN NN O
uncommon NN NN O
. NN NN O

Twinning NN NN O
and NN NN O
X NN NN O
inactivation NN NN O
may NN NN O
be NN NN O
interrelated NN NN O
and NN NN O
could NN NN O
explain NN NN O
the NN NN O
female NN NN O
twins NN NN O
discordant NN NN O
for NN NN O
X-linked NN NN O
traits NN NN O
. NN NN O

. NN NN O

7811247 NN NN O
X-linked NN NN B-SpecificDisease
adrenoleukodystrophy NN NN I-SpecificDisease
( NN NN O
ALD NN NN B-SpecificDisease
) NN NN O
: NN NN O
a NN NN O
novel NN NN O
mutation NN NN O
of NN NN O
the NN NN O
ALD NN NN B-Modifier
gene NN NN O
in NN NN O
6 NN NN O
members NN NN O
of NN NN O
a NN NN O
family NN NN O
presenting NN NN O
with NN NN O
5 NN NN O
different NN NN O
phenotypes NN NN O
. NN NN O

Fragments NN NN O
of NN NN O
the NN NN O
adrenoleukodystrophy NN NN B-Modifier
( NN NN O
ALD NN NN B-Modifier
) NN NN O
cDNA NN NN O
from NN NN O
a NN NN O
patient NN NN O
with NN NN O
adolescent NN NN B-SpecificDisease
ALD NN NN I-SpecificDisease
were NN NN O
amplified NN NN O
by NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
and NN NN O
subcloned NN NN O
. NN NN O

Bidirectional NN NN O
sequencing NN NN O
of NN NN O
the NN NN O
entire NN NN O
coding NN NN O
ALD NN NN B-Modifier
gene NN NN O
disclosed NN NN O
a NN NN O
cytosine NN NN O
to NN NN O
guanine NN NN O
transversion NN NN O
at NN NN O
nucleotide NN NN O
1451 NN NN O
in NN NN O
exon NN NN O
five NN NN O
, NN NN O
resulting NN NN O
in NN NN O
substitution NN NN O
of NN NN O
proline NN NN O
484 NN NN O
by NN NN O
arginine NN NN O
. NN NN O

Five NN NN O
of NN NN O
nine NN NN O
siblings NN NN O
of NN NN O
the NN NN O
patient NN NN O
, NN NN O
comprising NN NN O
two NN NN O
cerebral NN NN B-SpecificDisease
ALD NN NN I-SpecificDisease
, NN NN O
one NN NN O
adrenomyeloneuropathy NN NN B-SpecificDisease
, NN NN O
one NN NN O
Addison NN NN B-SpecificDisease
only NN NN I-SpecificDisease
as NN NN O
well NN NN O
as NN NN O
the NN NN O
symptomatic NN NN O
mother NN NN O
( NN NN O
all NN NN O
accumulating NN NN O
very NN NN O
long NN NN O
chain NN NN O
fatty NN NN O
acids NN NN O
) NN NN O
carried NN NN O
this NN NN O
mutation NN NN O
, NN NN O
which NN NN O
was NN NN O
not NN NN O
found NN NN O
in NN NN O
the NN NN O
unaffected NN NN O
persons NN NN O
, NN NN O
in NN NN O
five NN NN O
unrelated NN NN O
ALD NN NN B-Modifier
patients NN NN O
, NN NN O
and NN NN O
in NN NN O
twenty NN NN O
controls NN NN O
. NN NN O

We NN NN O
propose NN NN O
that NN NN O
this NN NN O
missense NN NN O
mutation NN NN O
generated NN NN O
the NN NN O
disease NN NN O
per NN NN O
se NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
metabolic NN NN O
defect NN NN O
; NN NN O
the NN NN O
different NN NN O
phenotypes NN NN O
, NN NN O
however NN NN O
, NN NN O
must NN NN O
have NN NN O
originated NN NN O
by NN NN O
means NN NN O
of NN NN O
additional NN NN O
pathogenetic NN NN O
factors NN NN O
. NN NN O

. NN NN O

7814011 NN NN O
Novel NN NN O
mutation NN NN O
at NN NN O
the NN NN O
initiation NN NN O
codon NN NN O
in NN NN O
the NN NN O
Norrie NN NN B-Modifier
disease NN NN I-Modifier
gene NN NN O
in NN NN O
two NN NN O
Japanese NN NN O
families NN NN O
. NN NN O

We NN NN O
have NN NN O
identified NN NN O
a NN NN O
new NN NN O
mutation NN NN O
of NN NN O
Norrie NN NN B-Modifier
disease NN NN I-Modifier
( NN NN O
ND NN NN B-Modifier
) NN NN O
gene NN NN O
in NN NN O
two NN NN O
Japanese NN NN O
males NN NN O
from NN NN O
unrelated NN NN O
families NN NN O
; NN NN O
they NN NN O
showed NN NN O
typical NN NN O
ocular NN NN O
features NN NN O
of NN NN O
ND NN NN B-SpecificDisease
but NN NN O
no NN NN O
mental NN NN B-DiseaseClass
retardation NN NN I-DiseaseClass
or NN NN O
hearing NN NN B-DiseaseClass
impairment NN NN I-DiseaseClass
. NN NN O

A NN NN O
mutation NN NN O
was NN NN O
found NN NN O
in NN NN O
both NN NN O
patients NN NN O
at NN NN O
the NN NN O
initiation NN NN O
codon NN NN O
of NN NN O
exon NN NN O
2 NN NN O
of NN NN O
the NN NN O
ND NN NN B-Modifier
gene NN NN O
( NN NN O
ATG NN NN O
to NN NN O
GTG NN NN O
) NN NN O
, NN NN O
with NN NN O
otherwise NN NN O
normal NN NN O
nucleotide NN NN O
sequences NN NN O
. NN NN O

Their NN NN O
mothers NN NN O
had NN NN O
the NN NN O
normal NN NN O
and NN NN O
mutant NN NN O
types NN NN O
of NN NN O
the NN NN O
gene NN NN O
, NN NN O
which NN NN O
was NN NN O
expected NN NN O
for NN NN O
heterozygotes NN NN O
of NN NN O
the NN NN O
disease NN NN O
. NN NN O

The NN NN O
mutation NN NN O
of NN NN O
the NN NN O
initiation NN NN O
codon NN NN O
would NN NN O
cause NN NN O
the NN NN O
failure NN NN O
of NN NN O
ND NN NN B-Modifier
gene NN NN O
expression NN NN O
or NN NN O
a NN NN O
defect NN NN O
in NN NN O
translation NN NN O
thereby NN NN O
truncating NN NN O
the NN NN O
amino NN NN O
terminus NN NN O
of NN NN O
ND NN NN B-Modifier
protein NN NN O
. NN NN O

In NN NN O
view NN NN O
of NN NN O
the NN NN O
rarity NN NN O
and NN NN O
marked NN NN O
heterogeneity NN NN O
of NN NN O
mutations NN NN O
in NN NN O
the NN NN O
ND NN NN B-Modifier
gene NN NN O
, NN NN O
the NN NN O
present NN NN O
apparently NN NN O
unrelated NN NN O
Japanese NN NN O
families NN NN O
who NN NN O
have NN NN O
lived NN NN O
in NN NN O
the NN NN O
same NN NN O
area NN NN O
for NN NN O
over NN NN O
two NN NN O
centuries NN NN O
presumably NN NN O
share NN NN O
the NN NN O
origin NN NN O
of NN NN O
the NN NN O
mutation NN NN O
. NN NN O

. NN NN O

7815415 NN NN O
Anticipation NN NN O
resulting NN NN O
in NN NN O
elimination NN NN O
of NN NN O
the NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
gene NN NN O
: NN NN O
a NN NN O
follow NN NN O
up NN NN O
study NN NN O
of NN NN O
one NN NN O
extended NN NN O
family NN NN O
. NN NN O

We NN NN O
have NN NN O
re-examined NN NN O
an NN NN O
extended NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
( NN NN O
DM NN NN B-Modifier
) NN NN O
family NN NN O
, NN NN O
previously NN NN O
described NN NN O
in NN NN O
1955 NN NN O
, NN NN O
in NN NN O
order NN NN O
to NN NN O
study NN NN O
the NN NN O
long NN NN O
term NN NN O
effects NN NN O
of NN NN O
anticipation NN NN O
in NN NN O
DM NN NN B-SpecificDisease
and NN NN O
in NN NN O
particular NN NN O
the NN NN O
implications NN NN O
for NN NN O
families NN NN O
affected NN NN O
by NN NN O
this NN NN O
disease NN NN O
. NN NN O

This NN NN O
follow NN NN O
up NN NN O
study NN NN O
provides NN NN O
data NN NN O
on NN NN O
35 NN NN O
gene NN NN O
carriers NN NN O
and NN NN O
46 NN NN O
asymptomatic NN NN O
at NN NN O
risk NN NN O
family NN NN O
members NN NN O
in NN NN O
five NN NN O
generations NN NN O
. NN NN O

Clinical NN NN O
anticipation NN NN O
, NN NN O
defined NN NN O
as NN NN O
the NN NN O
cascade NN NN O
of NN NN O
mild NN NN O
, NN NN O
adult NN NN O
, NN NN O
childhood NN NN O
, NN NN O
or NN NN O
congenital NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
in NN NN O
subsequent NN NN O
generations NN NN O
, NN NN O
appeared NN NN O
to NN NN O
be NN NN O
a NN NN O
relentless NN NN O
process NN NN O
, NN NN O
occurring NN NN O
in NN NN O
all NN NN O
affected NN NN O
branches NN NN O
of NN NN O
the NN NN O
family NN NN O
. NN NN O

The NN NN O
cascade NN NN O
was NN NN O
found NN NN O
to NN NN O
proceed NN NN O
asynchronously NN NN O
in NN NN O
the NN NN O
different NN NN O
branches NN NN O
, NN NN O
mainly NN NN O
because NN NN O
of NN NN O
an NN NN O
unequal NN NN O
number NN NN O
of NN NN O
generations NN NN O
with NN NN O
mild NN NN O
disease NN NN O
. NN NN O

The NN NN O
transition NN NN O
from NN NN O
the NN NN O
mild NN NN O
to NN NN O
the NN NN O
adult NN NN O
type NN NN O
was NN NN O
associated NN NN O
with NN NN O
transmission NN NN O
through NN NN O
a NN NN O
male NN NN O
parent NN NN O
. NN NN O

Stable NN NN O
transmission NN NN O
of NN NN O
the NN NN O
asymptomatic NN NN O
/ NN NN O
mild NN NN O
phenotype NN NN O
showed NN NN O
a NN NN O
female NN NN O
transmission NN NN O
bias NN NN O
. NN NN O

We NN NN O
further NN NN O
examined NN NN O
the NN NN O
extent NN NN O
and NN NN O
causes NN NN O
of NN NN O
gene NN NN O
loss NN NN O
in NN NN O
this NN NN O
pedigree NN NN O
. NN NN O

Gene NN NN O
loss NN NN O
in NN NN O
the NN NN O
patient NN NN O
group NN NN O
was NN NN O
complete NN NN O
, NN NN O
owing NN NN O
to NN NN O
infertility NN NN B-DiseaseClass
of NN NN O
the NN NN O
male NN NN O
patients NN NN O
with NN NN O
adult NN NN O
onset NN NN O
disease NN NN O
and NN NN O
the NN NN O
fact NN NN O
that NN NN O
mentally NN NN B-DiseaseClass
retarded NN NN I-DiseaseClass
patients NN NN O
did NN NN O
not NN NN O
procreate NN NN O
. NN NN O

Out NN NN O
of NN NN O
the NN NN O
46 NN NN O
at NN NN O
risk NN NN O
subjects NN NN O
in NN NN O
the NN NN O
two NN NN O
youngest NN NN O
generations NN NN O
, NN NN O
only NN NN O
one NN NN O
was NN NN O
found NN NN O
to NN NN O
have NN NN O
a NN NN O
full NN NN O
mutation NN NN O
. NN NN O

This NN NN O
is NN NN O
the NN NN O
only NN NN O
subject NN NN O
who NN NN O
may NN NN O
transmit NN NN O
the NN NN O
gene NN NN O
to NN NN O
the NN NN O
sixth NN NN O
generation NN NN O
. NN NN O

No NN NN O
protomutation NN NN O
carriers NN NN O
were NN NN O
found NN NN O
in NN NN O
the NN NN O
fourth NN NN O
and NN NN O
fifth NN NN O
generations NN NN O
. NN NN O

Therefore NN NN O
it NN NN O
is NN NN O
highly NN NN O
probable NN NN O
that NN NN O
the NN NN O
DM NN NN B-Modifier
gene NN NN O
will NN NN O
be NN NN O
eliminated NN NN O
from NN NN O
this NN NN O
pedigree NN NN O
within NN NN O
one NN NN O
generation NN NN O
. NN NN O

The NN NN O
high NN NN O
population NN NN O
frequency NN NN O
of NN NN O
DM NN NN B-SpecificDisease
can NN NN O
at NN NN O
present NN NN O
not NN NN O
be NN NN O
explained NN NN O
by NN NN O
the NN NN O
contribution NN NN O
of NN NN O
asymptomatic NN NN O
cases NN NN O
in NN NN O
the NN NN O
younger NN NN O
generations NN NN O
of NN NN O
known NN NN O
families NN NN O
, NN NN O
but NN NN O
is NN NN O
probably NN NN O
caused NN NN O
by NN NN O
the NN NN O
events NN NN O
in NN NN O
the NN NN O
ancestral NN NN O
generations NN NN O
. NN NN O

. NN NN O

7825578 NN NN O
The NN NN O
gene NN NN O
for NN NN O
spinal NN NN B-Modifier
cerebellar NN NN I-Modifier
ataxia NN NN I-Modifier
3 NN NN O
( NN NN O
SCA3 NN NN O
) NN NN O
is NN NN O
located NN NN O
in NN NN O
a NN NN O
region NN NN O
of NN NN O
approximately NN NN O
3 NN NN O
cM NN NN O
on NN NN O
chromosome NN NN O
14q24.3-q32.2 NN NN O
. NN NN O

SCA3 NN NN O
, NN NN O
the NN NN O
gene NN NN O
for NN NN O
spinal NN NN B-Modifier
cerebellar NN NN I-Modifier
ataxia NN NN I-Modifier
3 NN NN O
, NN NN O
was NN NN O
recently NN NN O
mapped NN NN O
to NN NN O
a NN NN O
15-cM NN NN O
interval NN NN O
between NN NN O
D14S67 NN NN O
and NN NN O
D14S81 NN NN O
on NN NN O
chromosome NN NN O
14q NN NN O
, NN NN O
by NN NN O
linkage NN NN O
analysis NN NN O
in NN NN O
two NN NN O
families NN NN O
of NN NN O
French NN NN O
ancestry NN NN O
. NN NN O

The NN NN O
SCA3 NN NN O
candidate NN NN O
region NN NN O
has NN NN O
now NN NN O
been NN NN O
refined NN NN O
by NN NN O
linkage NN NN O
analysis NN NN O
with NN NN O
four NN NN O
new NN NN O
microsatellite NN NN O
markers NN NN O
( NN NN O
D14S256 NN NN O
, NN NN O
D14S291 NN NN O
, NN NN O
D14S280 NN NN O
, NN NN O
and NN NN O
AFM343vf1 NN NN O
) NN NN O
in NN NN O
the NN NN O
same NN NN O
two NN NN O
families NN NN O
, NN NN O
in NN NN O
which NN NN O
19 NN NN O
additional NN NN O
individuals NN NN O
were NN NN O
genotyped NN NN O
, NN NN O
and NN NN O
in NN NN O
a NN NN O
third NN NN O
French NN NN O
family NN NN O
. NN NN O

Combined NN NN O
two-point NN NN O
linkage NN NN O
analyses NN NN O
show NN NN O
that NN NN O
the NN NN O
new NN NN O
markers NN NN O
, NN NN O
D14S280 NN NN O
and NN NN O
AFM343vf1 NN NN O
, NN NN O
are NN NN O
tightly NN NN O
linked NN NN O
to NN NN O
the NN NN O
SCA3 NN NN O
locus NN NN O
, NN NN O
with NN NN O
maximal NN NN O
lod NN NN O
scores NN NN O
, NN NN O
at NN NN O
recombination NN NN O
fraction NN NN O
, NN NN O
( NN NN O
theta NN NN O
) NN NN O
= NN NN O
. NN NN O

00 NN NN O
, NN NN O
of NN NN O
7 NN NN O
. NN NN O

05 NN NN O
and NN NN O
13 NN NN O
. NN NN O

70 NN NN O
, NN NN O
respectively NN NN O
. NN NN O

Combined NN NN O
multipoint NN NN O
and NN NN O
recombinant NN NN O
haplotype NN NN O
analyses NN NN O
localize NN NN O
the NN NN O
SCA3 NN NN O
locus NN NN O
to NN NN O
a NN NN O
3-cM NN NN O
interval NN NN O
flanked NN NN O
by NN NN O
D14S291 NN NN O
and NN NN O
D14S81 NN NN O
. NN NN O

The NN NN O
same NN NN O
allele NN NN O
for NN NN O
D14S280 NN NN O
segregates NN NN O
with NN NN O
the NN NN O
disease NN NN O
locus NN NN O
in NN NN O
the NN NN O
three NN NN O
kindreds NN NN O
. NN NN O

This NN NN O
allele NN NN O
is NN NN O
frequent NN NN O
in NN NN O
the NN NN O
French NN NN O
population NN NN O
, NN NN O
however NN NN O
, NN NN O
and NN NN O
linkage NN NN O
disequilibrium NN NN O
is NN NN O
not NN NN O
clearly NN NN O
established NN NN O
. NN NN O

The NN NN O
SCA3 NN NN O
locus NN NN O
remains NN NN O
within NN NN O
the NN NN O
29-cM NN NN O
region NN NN O
on NN NN O
14q24 NN NN O
. NN NN O

3-q32 NN NN O
. NN NN O

2 NN NN O
containing NN NN O
the NN NN O
gene NN NN O
for NN NN O
the NN NN O
Machado-Joseph NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
, NN NN O
which NN NN O
is NN NN O
clinically NN NN O
related NN NN O
to NN NN O
the NN NN O
phenotype NN NN O
determined NN NN O
by NN NN O
SCA3 NN NN O
, NN NN O
but NN NN O
it NN NN O
can NN NN O
not NN NN O
yet NN NN O
be NN NN O
concluded NN NN O
that NN NN O
both NN NN O
diseases NN NN O
result NN NN O
from NN NN O
alterations NN NN O
of NN NN O
the NN NN O
same NN NN O
gene NN NN O

7825586 NN NN O
An NN NN O
evaluation NN NN O
of NN NN O
genetic NN NN O
heterogeneity NN NN O
in NN NN O
145 NN NN O
breast-ovarian NN NN B-Modifier
cancer NN NN I-Modifier
families NN NN O
. NN NN O

Breast NN NN B-Modifier
Cancer NN NN I-Modifier
Linkage NN NN O
Consortium NN NN O
. NN NN O

The NN NN O
breast-ovary NN NN B-SpecificDisease
cancer-family NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
is NN NN O
a NN NN O
dominant NN NN O
predisposition NN NN O
to NN NN O
cancer NN NN B-CompositeMention
of NN NN I-CompositeMention
the NN NN I-CompositeMention
breast NN NN I-CompositeMention
and NN NN I-CompositeMention
ovaries NN NN I-CompositeMention
which NN NN O
has NN NN O
been NN NN O
mapped NN NN O
to NN NN O
chromosome NN NN O
region NN NN O
17q12-q21 NN NN O
. NN NN O

The NN NN O
majority NN NN O
, NN NN O
but NN NN O
not NN NN O
all NN NN O
, NN NN O
of NN NN O
breast-ovary NN NN B-Modifier
cancer NN NN I-Modifier
families NN NN O
show NN NN O
linkage NN NN O
to NN NN O
this NN NN O
susceptibility NN NN O
locus NN NN O
, NN NN O
designated NN NN O
BRCA1 NN NN O
. NN NN O

We NN NN O
report NN NN O
here NN NN O
the NN NN O
results NN NN O
of NN NN O
a NN NN O
linkage NN NN O
analysis NN NN O
of NN NN O
145 NN NN O
families NN NN O
with NN NN O
both NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
. NN NN O

These NN NN O
families NN NN O
contain NN NN O
either NN NN O
a NN NN O
total NN NN O
of NN NN O
three NN NN O
or NN NN O
more NN NN O
cases NN NN O
of NN NN O
early-onset NN NN O
( NN NN O
before NN NN O
age NN NN O
60 NN NN O
years NN NN O
) NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
or NN NN O
ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

All NN NN O
families NN NN O
contained NN NN O
at NN NN O
least NN NN O
one NN NN O
case NN NN O
of NN NN O
ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

Overall NN NN O
, NN NN O
an NN NN O
estimated NN NN O
76 NN NN O
% NN NN O
of NN NN O
the NN NN O
145 NN NN O
families NN NN O
are NN NN O
linked NN NN O
to NN NN O
the NN NN O
BRCA1 NN NN O
locus NN NN O
. NN NN O

None NN NN O
of NN NN O
the NN NN O
13 NN NN O
families NN NN O
with NN NN O
cases NN NN O
of NN NN O
male NN NN B-SpecificDisease
breast NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
appear NN NN O
to NN NN O
be NN NN O
linked NN NN O
, NN NN O
but NN NN O
it NN NN O
is NN NN O
estimated NN NN O
that NN NN O
92 NN NN O
% NN NN O
( NN NN O
95 NN NN O
% NN NN O
confidence NN NN O
interval NN NN O
76 NN NN O
% NN NN O
-100 NN NN O
% NN NN O
) NN NN O
of NN NN O
families NN NN O
with NN NN O
no NN NN O
male NN NN B-SpecificDisease
breast NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
and NN NN O
with NN NN O
two NN NN O
or NN NN O
more NN NN O
ovarian NN NN B-SpecificDisease
cancers NN NN I-SpecificDisease
are NN NN O
linked NN NN O
to NN NN O
BRCA1 NN NN O
. NN NN O

These NN NN O
data NN NN O
suggest NN NN O
that NN NN O
the NN NN O
breast-ovarian NN NN B-SpecificDisease
cancer-family NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
is NN NN O
genetically NN NN O
heterogeneous NN NN O
. NN NN O

However NN NN O
, NN NN O
the NN NN O
large NN NN O
majority NN NN O
of NN NN O
families NN NN O
with NN NN O
early-onset NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
and NN NN O
with NN NN O
two NN NN O
or NN NN O
more NN NN O
cases NN NN O
of NN NN O
ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
are NN NN O
likely NN NN O
to NN NN O
be NN NN O
due NN NN O
to NN NN O
BRCA1 NN NN O
mutations NN NN O
. NN NN O

. NN NN O

7833921 NN NN O
Molecular NN NN O
basis NN NN O
of NN NN O
essential NN NN B-SpecificDisease
fructosuria NN NN I-SpecificDisease
: NN NN O
molecular NN NN O
cloning NN NN O
and NN NN O
mutational NN NN O
analysis NN NN O
of NN NN O
human NN NN O
ketohexokinase NN NN O
( NN NN O
fructokinase NN NN O
) NN NN O
. NN NN O

Essential NN NN B-SpecificDisease
fructosuria NN NN I-SpecificDisease
is NN NN O
one NN NN O
of NN NN O
the NN NN O
oldest NN NN O
known NN NN O
inborn NN NN B-DiseaseClass
errors NN NN I-DiseaseClass
of NN NN I-DiseaseClass
metabolism NN NN I-DiseaseClass
. NN NN O

It NN NN O
is NN NN O
a NN NN O
benign NN NN O
condition NN NN O
which NN NN O
is NN NN O
believed NN NN O
to NN NN O
result NN NN O
from NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
hepatic NN NN I-SpecificDisease
fructokinase NN NN I-SpecificDisease
( NN NN O
ketohexokinase NN NN O
, NN NN O
KHK NN NN O
, NN NN O
E NN NN O
. NN NN O

C NN NN O
. NN NN O

2 NN NN O
. NN NN O

7 NN NN O
. NN NN O

1 NN NN O
. NN NN O

3 NN NN O
) NN NN O
. NN NN O

This NN NN O
enzyme NN NN O
catalyses NN NN O
the NN NN O
first NN NN O
step NN NN O
of NN NN O
metabolism NN NN O
of NN NN O
dietary NN NN O
fructose NN NN O
, NN NN O
conversion NN NN O
of NN NN O
fructose NN NN O
to NN NN O
fructose-1-phosphate NN NN O
. NN NN O

Despite NN NN O
the NN NN O
early NN NN O
recognition NN NN O
of NN NN O
this NN NN O
disorder NN NN O
, NN NN O
the NN NN O
primary NN NN O
structure NN NN O
of NN NN O
human NN NN O
KHK NN NN O
and NN NN O
the NN NN O
molecular NN NN O
basis NN NN O
of NN NN O
essential NN NN B-SpecificDisease
fructosuria NN NN I-SpecificDisease
have NN NN O
not NN NN O
been NN NN O
previously NN NN O
defined NN NN O
. NN NN O

In NN NN O
this NN NN O
report NN NN O
, NN NN O
the NN NN O
isolation NN NN O
and NN NN O
sequencing NN NN O
of NN NN O
full-length NN NN O
cDNA NN NN O
clones NN NN O
encoding NN NN O
human NN NN O
ketohexokinase NN NN O
are NN NN O
described NN NN O
. NN NN O

Alternative NN NN O
mRNA NN NN O
species NN NN O
and NN NN O
alternative NN NN O
KHK NN NN O
isozymes NN NN O
are NN NN O
produced NN NN O
by NN NN O
alternative NN NN O
polyadenylation NN NN O
and NN NN O
splicing NN NN O
of NN NN O
the NN NN O
KHK NN NN O
gene NN NN O
. NN NN O

The NN NN O
KHK NN NN O
proteins NN NN O
show NN NN O
a NN NN O
high NN NN O
level NN NN O
of NN NN O
sequence NN NN O
conservation NN NN O
relative NN NN O
to NN NN O
rat NN NN O
KHK NN NN O
. NN NN O

Direct NN NN O
evidence NN NN O
that NN NN O
mutation NN NN O
of NN NN O
the NN NN O
KHK NN NN O
structural NN NN O
gene NN NN O
is NN NN O
the NN NN O
cause NN NN O
of NN NN O
essential NN NN B-SpecificDisease
fructosuria NN NN I-SpecificDisease
was NN NN O
also NN NN O
obtained NN NN O
. NN NN O

In NN NN O
a NN NN O
well-characterized NN NN O
family NN NN O
, NN NN O
in NN NN O
which NN NN O
three NN NN O
of NN NN O
eight NN NN O
siblings NN NN O
have NN NN O
fructosuria NN NN B-DiseaseClass
, NN NN O
all NN NN O
affected NN NN O
individuals NN NN O
are NN NN O
compound NN NN O
heterozygotes NN NN O
for NN NN O
two NN NN O
mutations NN NN O
Gly40Arg NN NN O
and NN NN O
Ala43Thr NN NN O
. NN NN O

Both NN NN O
mutations NN NN O
result NN NN O
from NN NN O
G NN NN O
-- NN NN O
A NN NN O
transitions NN NN O
, NN NN O
and NN NN O
each NN NN O
alters NN NN O
the NN NN O
same NN NN O
conserved NN NN O
region NN NN O
of NN NN O
the NN NN O
KHK NN NN O
protein NN NN O
. NN NN O

Neither NN NN O
mutation NN NN O
was NN NN O
seen NN NN O
in NN NN O
a NN NN O
sample NN NN O
of NN NN O
52 NN NN O
unrelated NN NN O
control NN NN O
individuals NN NN O
. NN NN O

An NN NN O
additional NN NN O
conservative NN NN O
amino NN NN O
acid NN NN O
change NN NN O
( NN NN O
Val49IIe NN NN O
) NN NN O
was NN NN O
present NN NN O
on NN NN O
the NN NN O
KHK NN NN O
allele NN NN O
bearing NN NN O
Ala43Thr NN NN O

7857677 NN NN O
Homozygous NN NN O
presence NN NN O
of NN NN O
the NN NN O
crossover NN NN O
( NN NN O
fusion NN NN O
gene NN NN O
) NN NN O
mutation NN NN O
identified NN NN O
in NN NN O
a NN NN O
type NN NN B-Modifier
II NN NN I-Modifier
Gaucher NN NN I-Modifier
disease NN NN I-Modifier
fetus NN NN O
: NN NN O
is NN NN O
this NN NN O
analogous NN NN O
to NN NN O
the NN NN O
Gaucher NN NN O
knock-out NN NN O
mouse NN NN O
model NN NN O
? NN NN O

Gaucher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
GD NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
inherited NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
beta-glucocerebrosidase NN NN I-SpecificDisease
( NN NN O
EC NN NN O
3 NN NN O
. NN NN O

1 NN NN O
. NN NN O

2 NN NN O
. NN NN O

45 NN NN O
, NN NN O
gene NN NN O
symbol NN NN O
GBA NN NN O
) NN NN O
. NN NN O

In NN NN O
type NN NN B-SpecificDisease
I NN NN I-SpecificDisease
GD NN NN I-SpecificDisease
, NN NN O
the NN NN O
CNS NN NN O
is NN NN O
not NN NN O
involved NN NN O
( NN NN O
nonneuronopathic NN NN O
) NN NN O
, NN NN O
whereas NN NN O
in NN NN O
type NN NN B-SpecificDisease
II NN NN I-SpecificDisease
GD NN NN I-SpecificDisease
( NN NN O
acute NN NN O
neuronopathic NN NN O
) NN NN O
CNS NN NN O
involvement NN NN O
is NN NN O
early NN NN O
and NN NN O
rapidly NN NN O
progressive NN NN O
, NN NN O
while NN NN O
in NN NN O
type NN NN B-SpecificDisease
III NN NN I-SpecificDisease
GD NN NN I-SpecificDisease
( NN NN O
subacute NN NN O
neuronopathic NN NN O
) NN NN O
CNS NN NN O
involvement NN NN O
occurs NN NN O
later NN NN O
and NN NN O
is NN NN O
slowly NN NN O
progressive NN NN O
. NN NN O

The NN NN O
T6433C NN NN O
( NN NN O
L444P NN NN O
) NN NN O
substitution NN NN O
is NN NN O
prevalent NN NN O
in NN NN O
type NN NN B-SpecificDisease
GD NN NN I-SpecificDisease
II NN NN I-SpecificDisease
. NN NN O

It NN NN O
may NN NN O
occur NN NN O
alone NN NN O
as NN NN O
a NN NN O
single NN NN O
base-pair NN NN O
mutation NN NN O
but NN NN O
often NN NN O
is NN NN O
found NN NN O
as NN NN O
part NN NN O
of NN NN O
a NN NN O
complex NN NN O
allele NN NN O
containing NN NN O
additional NN NN O
GBA NN NN O
nucleotide NN NN O
substitutions NN NN O
, NN NN O
G6468C NN NN O
( NN NN O
A456P NN NN O
) NN NN O
and NN NN O
G6482C NN NN O
( NN NN O
V460V NN NN O
) NN NN O
, NN NN O
without NN NN O
( NN NN O
recNciI NN NN O
) NN NN O
or NN NN O
with NN NN O
( NN NN O
recTL NN NN O
) NN NN O
G5957C NN NN O
( NN NN O
D409H NN NN O
) NN NN O
. NN NN O

This NN NN O
complex NN NN O
allele NN NN O
is NN NN O
presumed NN NN O
to NN NN O
have NN NN O
formed NN NN O
by NN NN O
recombination NN NN O
( NN NN O
crossover NN NN O
, NN NN O
fusion NN NN O
) NN NN O
of NN NN O
the NN NN O
structural NN NN O
gene NN NN O
with NN NN O
the NN NN O
pseudogene NN NN O
, NN NN O
which NN NN O
contains NN NN O
the NN NN O
mutated NN NN O
sequences NN NN O
. NN NN O

Two NN NN O
complex NN NN O
alleles NN NN O
have NN NN O
never NN NN O
been NN NN O
demonstrated NN NN O
to NN NN O
coexist NN NN O
in NN NN O
any NN NN O
individual NN NN O
. NN NN O

We NN NN O
devised NN NN O
a NN NN O
selective NN NN O
PCR NN NN O
method NN NN O
for NN NN O
the NN NN O
specific NN NN O
amplification NN NN O
of NN NN O
the NN NN O
normal NN NN O
and NN NN O
/ NN NN O
or NN NN O
fusion NN NN O
gene NN NN O
. NN NN O

Using NN NN O
this NN NN O
procedure NN NN O
we NN NN O
demonstrated NN NN O
the NN NN O
fusion NN NN O
gene NN NN O
in NN NN O
homozygous NN NN O
form NN NN O
for NN NN O
the NN NN O
first NN NN O
time NN NN O
, NN NN O
in NN NN O
a NN NN O
Macedonian NN NN O
/ NN NN O
Ashkenazi NN NN O
Jewish NN NN O
GD NN NN B-Modifier
type NN NN I-Modifier
II NN NN I-Modifier
fetus NN NN O
. NN NN O

Both NN NN O
parents NN NN O
were NN NN O
carriers NN NN O
of NN NN O
the NN NN O
recombination NN NN O
. NN NN O

This NN NN O
was NN NN O
confirmed NN NN O
by NN NN O
direct NN NN O
sequence NN NN O
analysis NN NN O
. NN NN O

A NN NN O
previous NN NN O
conceptus NN NN O
in NN NN O
this NN NN O
family NN NN O
was NN NN O
stillborn NN NN B-DiseaseClass
at NN NN O
36 NN NN O
weeks NN NN O
, NN NN O
with NN NN O
features NN NN O
of NN NN O
severe NN NN O
type NN NN B-SpecificDisease
II NN NN I-SpecificDisease
GD NN NN I-SpecificDisease
. NN NN O

Neonates NN NN O
showing NN NN O
a NN NN O
severe NN NN O
clinical NN NN O
phenotype NN NN O
, NN NN O
analogous NN NN O
to NN NN O
the NN NN O
early NN NN O
neonatal NN NN O
lethal NN NN O
disease NN NN O
occurring NN NN O
in NN NN O
mice NN NN O
homozygous NN NN O
for NN NN O
a NN NN O
null NN NN O
allele NN NN O
produced NN NN O
by NN NN O
targeted NN NN O
disruption NN NN O
of NN NN O
GBA NN NN O
, NN NN O
have NN NN O
been NN NN O
described NN NN O
elsewhere NN NN O
, NN NN O
but NN NN O
the NN NN O
specific NN NN O
mutations NN NN O
in NN NN O
these NN NN O
cases NN NN O
have NN NN O
not NN NN O
yet NN NN O
been NN NN O
characterized NN NN O
. NN NN O

( NN NN O
ABSTRACT NN NN O
TRUNCATED NN NN O
AT NN NN O
250 NN NN O
WORDS NN NN O
) NN NN O

7858169 NN NN O
Late NN NN O
infantile NN NN O
metachromatic NN NN B-SpecificDisease
leukodystrophy NN NN I-SpecificDisease
in NN NN O
Israel NN NN O
. NN NN O

Metachromatic NN NN B-SpecificDisease
Leukodystrophy NN NN I-SpecificDisease
( NN NN O
MLD NN NN B-SpecificDisease
) NN NN O
is NN NN O
a NN NN O
neurodegenerative NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
in NN NN O
which NN NN O
the NN NN O
lysosomal NN NN O
enzyme NN NN O
, NN NN O
Aryl NN NN O
sulfatase NN NN O
A NN NN O
( NN NN O
ARSA NN NN O
) NN NN O
is NN NN O
deficient NN NN O
. NN NN O

The NN NN O
disease NN NN O
is NN NN O
inherited NN NN O
as NN NN O
an NN NN O
autosomal NN NN O
recessive NN NN O
trait NN NN O
and NN NN O
its NN NN O
frequency NN NN O
is NN NN O
estimated NN NN O
to NN NN O
be NN NN O
1 NN NN O
/ NN NN O
40 NN NN O
, NN NN O
000 NN NN O
live NN NN O
births NN NN O
. NN NN O

The NN NN O
gene NN NN O
of NN NN O
ARSA NN NN O
has NN NN O
been NN NN O
cloned NN NN O
and NN NN O
up NN NN O
to NN NN O
now NN NN O
eight NN NN O
mutations NN NN O
causing NN NN O
MLD NN NN B-SpecificDisease
have NN NN O
been NN NN O
reported NN NN O
. NN NN O

Another NN NN O
mutation NN NN O
, NN NN O
PD NN NN O
, NN NN O
leads NN NN O
to NN NN O
the NN NN O
deficiency NN NN O
of NN NN O
the NN NN O
enzyme NN NN O
in NN NN O
vitro NN NN O
( NN NN O
pseudodeficiency NN NN O
) NN NN O
without NN NN O
any NN NN O
known NN NN O
clinical NN NN O
effect NN NN O
. NN NN O

The NN NN O
PD NN NN O
mutation NN NN O
is NN NN O
frequent NN NN O
in NN NN O
all NN NN O
populations NN NN O
. NN NN O

In NN NN O
Israel NN NN O
, NN NN O
late NN NN O
infantile NN NN O
MLD NN NN B-SpecificDisease
was NN NN O
found NN NN O
to NN NN O
be NN NN O
very NN NN O
frequent NN NN O
in NN NN O
a NN NN O
small NN NN O
Jewish NN NN O
isolate NN NN O
, NN NN O
the NN NN O
Habbanite NN NN O
Jews NN NN O
( NN NN O
1 NN NN O
/ NN NN O
75 NN NN O
live NN NN O
births NN NN O
) NN NN O
. NN NN O

The NN NN O
molecular NN NN O
analysis NN NN O
demonstrated NN NN O
that NN NN O
in NN NN O
the NN NN O
Habbanite NN NN O
population NN NN O
, NN NN O
the NN NN O
mutation NN NN O
occurred NN NN O
on NN NN O
an NN NN O
allele NN NN O
with NN NN O
the NN NN O
PD NN NN O
mutation NN NN O
. NN NN O

The NN NN O
loss NN NN O
of NN NN O
ARSA NN NN O
activity NN NN O
is NN NN O
due NN NN O
to NN NN O
a NN NN O
point NN NN O
mutation NN NN O
C NN NN O
T NN NN O
leading NN NN O
to NN NN O
a NN NN O
change NN NN O
of NN NN O
proline NN NN O
to NN NN O
leucine NN NN O
. NN NN O

MLD NN NN B-SpecificDisease
is NN NN O
also NN NN O
frequent NN NN O
among NN NN O
Moslem NN NN O
Arabs NN NN O
in NN NN O
Jerusalem NN NN O
. NN NN O

The NN NN O
mutation NN NN O
is NN NN O
a NN NN O
transition NN NN O
G NN NN O
A NN NN O
destroying NN NN O
the NN NN O
splice NN NN O
donor NN NN O
site NN NN O
of NN NN O
exon NN NN O
2 NN NN O
. NN NN O

This NN NN O
mutation NN NN O
has NN NN O
been NN NN O
reported NN NN O
in NN NN O
patients NN NN O
with NN NN O
the NN NN O
late NN NN O
infantile NN NN O
MLD NN NN B-SpecificDisease
from NN NN O
different NN NN O
ethnic NN NN O
groups NN NN O
. NN NN O

The NN NN O
Christian NN NN O
Arabs NN NN O
in NN NN O
Israel NN NN O
also NN NN O
have NN NN O
a NN NN O
high NN NN O
incidence NN NN O
of NN NN O
the NN NN O
disease NN NN O
( NN NN O
1 NN NN O
/ NN NN O
10 NN NN O
, NN NN O
000 NN NN O
live NN NN O
births NN NN O
) NN NN O
; NN NN O
the NN NN O
mutation NN NN O
in NN NN O
this NN NN O
population NN NN O
is NN NN O
still NN NN O
unknown NN NN O
. NN NN O

Knowledge NN NN O
of NN NN O
the NN NN O
different NN NN O
mutations NN NN O
causing NN NN O
MLD NN NN B-SpecificDisease
in NN NN O
these NN NN O
defined NN NN O
populations NN NN O
will NN NN O
allow NN NN O
a NN NN O
carrier NN NN O
screening NN NN O
program NN NN O
to NN NN O
be NN NN O
carried NN NN O
out NN NN O
and NN NN O
prevent NN NN O
the NN NN O
birth NN NN O
of NN NN O
additional NN NN O
affected NN NN O
children NN NN O
. NN NN O

. NN NN O

7874117 NN NN O
A NN NN O
single NN NN O
amino NN NN O
acid NN NN O
substitution NN NN O
( NN NN O
G103D NN NN O
) NN NN O
in NN NN O
the NN NN O
type NN NN O
II NN NN O
collagen NN NN O
triple NN NN O
helix NN NN O
produces NN NN O
Kniest NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
. NN NN O

Kniest NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
is NN NN O
a NN NN O
moderately NN NN O
severe NN NN O
chondrodysplasia NN NN B-Modifier
phenotype NN NN O
that NN NN O
results NN NN O
from NN NN O
mutations NN NN O
in NN NN O
the NN NN O
gene NN NN O
for NN NN O
type NN NN O
II NN NN O
collagen NN NN O
, NN NN O
COL2A1 NN NN O
. NN NN O

Characteristics NN NN O
of NN NN O
the NN NN O
disorder NN NN O
include NN NN O
a NN NN O
short NN NN O
trunk NN NN O
and NN NN O
extremities NN NN O
, NN NN O
mid-face NN NN B-DiseaseClass
hypoplasia NN NN I-DiseaseClass
, NN NN O
cleft NN NN B-DiseaseClass
palate NN NN I-DiseaseClass
, NN NN O
myopia NN NN B-DiseaseClass
, NN NN O
retinal NN NN B-SpecificDisease
detachment NN NN I-SpecificDisease
, NN NN O
and NN NN O
hearing NN NN B-DiseaseClass
loss NN NN I-DiseaseClass
. NN NN O

Recently NN NN O
, NN NN O
deletions NN NN O
of NN NN O
all NN NN O
or NN NN O
part NN NN O
of NN NN O
exon NN NN O
12 NN NN O
have NN NN O
been NN NN O
identified NN NN O
in NN NN O
individuals NN NN O
with NN NN O
Kniest NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
, NN NN O
suggesting NN NN O
that NN NN O
mutations NN NN O
within NN NN O
this NN NN O
region NN NN O
of NN NN O
the NN NN O
protein NN NN O
may NN NN O
primarily NN NN O
result NN NN O
in NN NN O
the NN NN O
Kniest NN NN B-Modifier
dysplasia NN NN I-Modifier
phenotype NN NN O
. NN NN O

We NN NN O
used NN NN O
SSCP NN NN O
to NN NN O
analyze NN NN O
an NN NN O
amplified NN NN O
genomic NN NN O
DNA NN NN O
fragment NN NN O
containing NN NN O
exon NN NN O
12 NN NN O
from NN NN O
seven NN NN O
individuals NN NN O
with NN NN O
Kniest NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
. NN NN O

An NN NN O
abnormality NN NN O
was NN NN O
identified NN NN O
in NN NN O
one NN NN O
patient NN NN O
. NN NN O

DNA NN NN O
sequence NN NN O
analysis NN NN O
demonstrated NN NN O
that NN NN O
the NN NN O
patient NN NN O
was NN NN O
heterozygous NN NN O
for NN NN O
a NN NN O
G NN NN O
to NN NN O
A NN NN O
transition NN NN O
that NN NN O
implied NN NN O
substitution NN NN O
of NN NN O
glycine103 NN NN O
of NN NN O
the NN NN O
triple NN NN O
helical NN NN O
domain NN NN O
by NN NN O
aspartate NN NN O
. NN NN O

The NN NN O
mutation NN NN O
was NN NN O
not NN NN O
observed NN NN O
in NN NN O
DNA NN NN O
from NN NN O
either NN NN O
of NN NN O
the NN NN O
clinically NN NN O
unaffected NN NN O
parents NN NN O
of NN NN O
the NN NN O
proband NN NN O
. NN NN O

Protein NN NN O
microsequencing NN NN O
demonstrated NN NN O
expression NN NN O
of NN NN O
the NN NN O
abnormal NN NN O
allele NN NN O
in NN NN O
cartilage NN NN O
. NN NN O

These NN NN O
data NN NN O
demonstrate NN NN O
that NN NN O
point NN NN O
mutations NN NN O
which NN NN O
result NN NN O
in NN NN O
single NN NN O
amino NN NN O
acid NN NN O
substitutions NN NN O
can NN NN O
produce NN NN O
Kniest NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
and NN NN O
further NN NN O
support NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
alteration NN NN O
of NN NN O
a NN NN O
domain NN NN O
, NN NN O
which NN NN O
includes NN NN O
the NN NN O
region NN NN O
encoded NN NN O
by NN NN O
exon NN NN O
12 NN NN O
, NN NN O
in NN NN O
the NN NN O
type NN NN O
II NN NN O
collagen NN NN O
protein NN NN O
leads NN NN O
to NN NN O
this NN NN O
disorder NN NN O
. NN NN O

. NN NN O

7874163 NN NN O
CAG NN NN O
expansions NN NN O
in NN NN O
a NN NN O
novel NN NN O
gene NN NN O
for NN NN O
Machado-Joseph NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
at NN NN O
chromosome NN NN O
14q32.1 NN NN O
. NN NN O

We NN NN O
have NN NN O
identified NN NN O
a NN NN O
novel NN NN O
gene NN NN O
containing NN NN O
CAG NN NN O
repeats NN NN O
and NN NN O
mapped NN NN O
it NN NN O
to NN NN O
chromosome NN NN O
14q32 NN NN O
. NN NN O

1 NN NN O
, NN NN O
the NN NN O
genetic NN NN O
locus NN NN O
for NN NN O
Machado-Joseph NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
MJD NN NN B-SpecificDisease
) NN NN O
. NN NN O

In NN NN O
normal NN NN O
individuals NN NN O
the NN NN O
gene NN NN O
contains NN NN O
between NN NN O
13 NN NN O
and NN NN O
36 NN NN O
CAG NN NN O
repeats NN NN O
, NN NN O
whereas NN NN O
most NN NN O
of NN NN O
the NN NN O
clinically NN NN O
diagnosed NN NN O
patients NN NN O
and NN NN O
all NN NN O
of NN NN O
the NN NN O
affected NN NN O
members NN NN O
of NN NN O
a NN NN O
family NN NN O
with NN NN O
the NN NN O
clinical NN NN O
and NN NN O
pathological NN NN O
diagnosis NN NN O
of NN NN O
MJD NN NN B-SpecificDisease
show NN NN O
expansion NN NN O
of NN NN O
the NN NN O
repeat-number NN NN O
( NN NN O
from NN NN O
68-79 NN NN O
) NN NN O
. NN NN O

Southern NN NN O
blot NN NN O
analyses NN NN O
and NN NN O
genomic NN NN O
cloning NN NN O
demonstrates NN NN O
the NN NN O
existence NN NN O
of NN NN O
related NN NN O
genes NN NN O
. NN NN O

These NN NN O
results NN NN O
raise NN NN O
the NN NN O
possibility NN NN O
that NN NN O
similar NN NN O
abnormalities NN NN O
in NN NN O
related NN NN O
genes NN NN O
may NN NN O
give NN NN O
rise NN NN O
to NN NN O
diseases NN NN O
similar NN NN O
to NN NN O
MJD NN NN B-SpecificDisease
. NN NN O

7894491 NN NN O
Mutations NN NN O
in NN NN O
the NN NN O
BRCA1 NN NN O
gene NN NN O
in NN NN O
families NN NN O
with NN NN O
early-onset NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
. NN NN O

We NN NN O
analysed NN NN O
50 NN NN O
probands NN NN O
with NN NN O
a NN NN O
family NN NN O
history NN NN O
of NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
/ NN NN I-CompositeMention
or NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
for NN NN O
germline NN NN O
mutations NN NN O
in NN NN O
the NN NN O
coding NN NN O
region NN NN O
of NN NN O
the NN NN O
BRCA1 NN NN O
candidate NN NN O
gene NN NN O
, NN NN O
using NN NN O
single-strand NN NN O
conformation NN NN O
polymorphism NN NN O
( NN NN O
SSCP NN NN O
) NN NN O
analysis NN NN O
on NN NN O
PCR-amplified NN NN O
genomic NN NN O
DNA NN NN O
. NN NN O

A NN NN O
total NN NN O
of NN NN O
eight NN NN O
putative NN NN O
disease-causing NN NN O
alterations NN NN O
were NN NN O
identified NN NN O
four NN NN O
of NN NN O
these NN NN O
are NN NN O
frameshifts NN NN O
and NN NN O
two NN NN O
are NN NN O
nonsense NN NN O
mutations NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
we NN NN O
found NN NN O
two NN NN O
missense NN NN O
mutations NN NN O
, NN NN O
one NN NN O
of NN NN O
which NN NN O
changes NN NN O
the NN NN O
final NN NN O
cysteine NN NN O
of NN NN O
the NN NN O
BRCA1 NN NN O
zinc NN NN O
finger NN NN O
motif NN NN O
to NN NN O
glycine NN NN O
. NN NN O

These NN NN O
data NN NN O
are NN NN O
consistent NN NN O
with NN NN O
a NN NN O
tumour NN NN B-Modifier
suppressor NN NN O
model NN NN O
, NN NN O
and NN NN O
support NN NN O
the NN NN O
notion NN NN O
that NN NN O
this NN NN O
candidate NN NN O
gene NN NN O
is NN NN O
in NN NN O
fact NN NN O
BRCA1 NN NN O
. NN NN O

The NN NN O
heterogeneity NN NN O
of NN NN O
mutations NN NN O
, NN NN O
coupled NN NN O
with NN NN O
the NN NN O
large NN NN O
size NN NN O
of NN NN O
the NN NN O
gene NN NN O
, NN NN O
indicates NN NN O
that NN NN O
clinical NN NN O
application NN NN O
of NN NN O
BRCA1 NN NN O
mutation NN NN O
testing NN NN O
will NN NN O
be NN NN O
technically NN NN O
challenging NN NN O
. NN NN O

. NN NN O

7894493 NN NN O
Confirmation NN NN O
of NN NN O
BRCA1 NN NN O
by NN NN O
analysis NN NN O
of NN NN O
germline NN NN O
mutations NN NN O
linked NN NN O
to NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
in NN NN O
ten NN NN O
families NN NN O
. NN NN O

We NN NN O
provide NN NN O
genetic NN NN O
evidence NN NN O
supporting NN NN O
the NN NN O
identity NN NN O
of NN NN O
the NN NN O
candidate NN NN O
gene NN NN O
for NN NN O
BRCA1 NN NN O
through NN NN O
the NN NN O
characterization NN NN O
of NN NN O
germline NN NN O
mutations NN NN O
in NN NN O
63 NN NN O
breast NN NN B-Modifier
cancer NN NN I-Modifier
patients NN NN O
and NN NN O
10 NN NN O
ovarian NN NN B-Modifier
cancer NN NN I-Modifier
patients NN NN O
in NN NN O
ten NN NN O
families NN NN O
with NN NN O
cancer NN NN B-DiseaseClass
linked NN NN O
to NN NN O
chromosome NN NN O
17q21 NN NN O
. NN NN O

Nine NN NN O
different NN NN O
mutations NN NN O
were NN NN O
detected NN NN O
by NN NN O
screening NN NN O
BRCA1 NN NN O
DNA NN NN O
and NN NN O
RNA NN NN O
by NN NN O
single-strand NN NN O
conformation NN NN O
polymorphism NN NN O
analysis NN NN O
and NN NN O
direct NN NN O
sequencing NN NN O
. NN NN O

Seven NN NN O
mutations NN NN O
lead NN NN O
to NN NN O
protein NN NN O
truncations NN NN O
at NN NN O
sites NN NN O
throughout NN NN O
the NN NN O
gene NN NN O
. NN NN O

One NN NN O
missense NN NN O
mutation NN NN O
( NN NN O
which NN NN O
occurred NN NN O
independently NN NN O
in NN NN O
two NN NN O
families NN NN O
) NN NN O
leads NN NN O
to NN NN O
loss NN NN O
of NN NN O
a NN NN O
cysteine NN NN O
in NN NN O
the NN NN O
zinc NN NN O
binding NN NN O
domain NN NN O
. NN NN O

An NN NN O
intronic NN NN O
single NN NN O
basepair NN NN O
substitution NN NN O
destroys NN NN O
an NN NN O
acceptor NN NN O
site NN NN O
and NN NN O
activates NN NN O
a NN NN O
cryptic NN NN O
splice NN NN O
site NN NN O
, NN NN O
leading NN NN O
to NN NN O
a NN NN O
59 NN NN O
basepair NN NN O
insertion NN NN O
and NN NN O
chain NN NN O
termination NN NN O
. NN NN O

The NN NN O
four NN NN O
families NN NN O
with NN NN O
both NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
had NN NN O
chain NN NN O
termination NN NN O
mutations NN NN O
in NN NN O
the NN NN O
N-terminal NN NN O
half NN NN O
of NN NN O
the NN NN O
protein NN NN O
. NN NN O

. NN NN O

7909252 NN NN O
High NN NN O
resolution NN NN O
genetic NN NN O
analysis NN NN O
suggests NN NN O
one NN NN O
ancestral NN NN O
predisposing NN NN O
haplotype NN NN O
for NN NN O
the NN NN O
origin NN NN O
of NN NN O
the NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
mutation NN NN O
. NN NN O

The NN NN O
mutation NN NN O
causing NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
has NN NN O
been NN NN O
identified NN NN O
as NN NN O
an NN NN O
amplification NN NN O
of NN NN O
an NN NN O
unstable NN NN O
trinucleotide NN NN O
( NN NN O
CTG NN NN O
) NN NN O
n NN NN O
repeat NN NN O
in NN NN O
over NN NN O
99 NN NN O
% NN NN O
of NN NN O
the NN NN O
global NN NN O
DM NN NN B-Modifier
population NN NN O
. NN NN O

It NN NN O
is NN NN O
in NN NN O
complete NN NN O
linkage NN NN O
disequilibrium NN NN O
with NN NN O
an NN NN O
Alu NN NN O
element NN NN O
polymorphism NN NN O
within NN NN O
the NN NN O
DM NN NN B-Modifier
kinase NN NN O
gene NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
DM NN NN B-SpecificDisease
is NN NN O
a NN NN O
consequence NN NN O
of NN NN O
one NN NN O
or NN NN O
few NN NN O
ancestral NN NN O
mutations NN NN O
. NN NN O

A NN NN O
recent NN NN O
analysis NN NN O
utilizing NN NN O
this NN NN O
polymorphism NN NN O
as NN NN O
well NN NN O
as NN NN O
a NN NN O
flanking NN NN O
dinucleotide NN NN O
marker NN NN O
, NN NN O
suggested NN NN O
that NN NN O
similar NN NN O
to NN NN O
Fragile NN NN B-SpecificDisease
X NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
, NN NN O
DM NN NN B-SpecificDisease
exhibited NN NN O
a NN NN O
founder NN NN O
effect NN NN O
( NN NN O
Imbert NN NN O
et NN NN O
al NN NN O
. NN NN O

, NN NN O
1993 NN NN O
Nature NN NN O
Genet NN NN O
. NN NN O

4 NN NN O
, NN NN O
72-76 NN NN O
) NN NN O
. NN NN O

In NN NN O
contrast NN NN O
, NN NN O
the NN NN O
low NN NN O
reproductive NN NN O
fitness NN NN O
of NN NN O
individuals NN NN O
with NN NN O
congenital NN NN O
DM NN NN B-SpecificDisease
( NN NN O
the NN NN O
endpoint NN NN O
of NN NN O
genetic NN NN O
anticipation NN NN O
in NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
) NN NN O
suggests NN NN O
a NN NN O
higher NN NN O
rate NN NN O
of NN NN O
new NN NN O
mutations NN NN O
. NN NN O

We NN NN O
present NN NN O
a NN NN O
high NN NN O
resolution NN NN O
genetic NN NN O
analysis NN NN O
of NN NN O
the NN NN O
DM NN NN B-Modifier
locus NN NN O
using NN NN O
PCR NN NN O
based NN NN O
assays NN NN O
of NN NN O
nine NN NN O
polymorphisms NN NN O
, NN NN O
spanning NN NN O
a NN NN O
physical NN NN O
distance NN NN O
of NN NN O
30 NN NN O
kb NN NN O
, NN NN O
within NN NN O
and NN NN O
immediately NN NN O
flanking NN NN O
the NN NN O
DM NN NN B-Modifier
kinase NN NN O
gene NN NN O
. NN NN O

The NN NN O
persistent NN NN O
complete NN NN O
allelic NN NN O
association NN NN O
of NN NN O
the NN NN O
DM NN NN B-Modifier
mutation NN NN O
with NN NN O
all NN NN O
these NN NN O
polymorphisms NN NN O
provides NN NN O
further NN NN O
support NN NN O
to NN NN O
previous NN NN O
observations NN NN O
and NN NN O
suggests NN NN O
more NN NN O
strongly NN NN O
that NN NN O
the NN NN O
DM NN NN B-Modifier
mutation NN NN O
occurred NN NN O
on NN NN O
the NN NN O
background NN NN O
of NN NN O
a NN NN O
particular NN NN O
haplotype NN NN O
in NN NN O
which NN NN O
the NN NN O
( NN NN O
CTG NN NN O
) NN NN O
n NN NN O
repeat NN NN O
became NN NN O
inherently NN NN O
unstable NN NN O
and NN NN O
therefore NN NN O
predisposed NN NN O
to NN NN O
amplification NN NN O
. NN NN O

7937795 NN NN O
Genetic NN NN O
instability NN NN O
in NN NN O
human NN NN O
ovarian NN NN B-Modifier
cancer NN NN I-Modifier
cell NN NN O
lines NN NN O
. NN NN O

We NN NN O
have NN NN O
analyzed NN NN O
the NN NN O
stability NN NN O
of NN NN O
microsatellites NN NN O
in NN NN O
cell NN NN O
lines NN NN O
derived NN NN O
from NN NN O
human NN NN O
ovarian NN NN B-SpecificDisease
cancers NN NN I-SpecificDisease
and NN NN O
found NN NN O
that NN NN O
5 NN NN O
out NN NN O
of NN NN O
10 NN NN O
of NN NN O
the NN NN O
ovarian NN NN B-Modifier
tumor NN NN I-Modifier
cell NN NN O
lines NN NN O
are NN NN O
genetically NN NN B-DiseaseClass
unstable NN NN I-DiseaseClass
at NN NN O
the NN NN O
majority NN NN O
of NN NN O
the NN NN O
loci NN NN O
analyzed NN NN O
. NN NN O

In NN NN O
clones NN NN O
and NN NN O
subclones NN NN O
derived NN NN O
serially NN NN O
from NN NN O
one NN NN O
of NN NN O
these NN NN O
cell NN NN O
lines NN NN O
( NN NN O
2774 NN NN O
; NN NN O
serous NN NN B-SpecificDisease
cystadenocarcinoma NN NN I-SpecificDisease
) NN NN O
, NN NN O
a NN NN O
very NN NN O
high NN NN O
proportion NN NN O
of NN NN O
microsatellites NN NN O
distributed NN NN O
in NN NN O
many NN NN O
different NN NN O
regions NN NN O
of NN NN O
the NN NN O
genome NN NN O
change NN NN O
their NN NN O
size NN NN O
in NN NN O
a NN NN O
mercurial NN NN O
fashion NN NN O
. NN NN O

We NN NN O
conclude NN NN O
that NN NN O
genomic NN NN O
instability NN NN O
in NN NN O
ovarian NN NN B-SpecificDisease
tumors NN NN I-SpecificDisease
is NN NN O
a NN NN O
dynamic NN NN O
and NN NN O
ongoing NN NN O
process NN NN O
whose NN NN O
high NN NN O
frequency NN NN O
may NN NN O
have NN NN O
been NN NN O
previously NN NN O
underestimated NN NN O
by NN NN O
PCR-based NN NN O
allelotyping NN NN O
of NN NN O
bulk NN NN O
tumor NN NN B-Modifier
tissue NN NN O
. NN NN O

We NN NN O
have NN NN O
identified NN NN O
the NN NN O
source NN NN O
of NN NN O
the NN NN O
genetic NN NN O
instability NN NN O
in NN NN O
one NN NN O
ovarian NN NN B-SpecificDisease
tumor NN NN I-SpecificDisease
as NN NN O
a NN NN O
point NN NN O
mutation NN NN O
( NN NN O
R524P NN NN O
) NN NN O
in NN NN O
the NN NN O
human NN NN O
mismatch-repair NN NN O
gene NN NN O
MSH2 NN NN O
( NN NN O
Salmonella NN NN O
MutS NN NN O
homologue NN NN O
) NN NN O
, NN NN O
which NN NN O
has NN NN O
recently NN NN O
been NN NN O
shown NN NN O
to NN NN O
be NN NN O
involved NN NN O
in NN NN O
hereditary NN NN B-SpecificDisease
nonpolyposis NN NN I-SpecificDisease
colorectal NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

Patient NN NN O
2774 NN NN O
was NN NN O
a NN NN O
38-year-old NN NN O
heterozygote NN NN O
, NN NN O
and NN NN O
her NN NN O
normal NN NN O
tissue NN NN O
carried NN NN O
both NN NN O
mutant NN NN O
and NN NN O
wild-type NN NN O
alleles NN NN O
of NN NN O
the NN NN O
human NN NN O
MSH2 NN NN O
gene NN NN O
. NN NN O

However NN NN O
the NN NN O
wild-type NN NN O
allele NN NN O
was NN NN O
lost NN NN O
at NN NN O
some NN NN O
point NN NN O
early NN NN O
during NN NN O
tumorigenesis NN NN O
so NN NN O
that NN NN O
DNA NN NN O
isolated NN NN O
either NN NN O
from NN NN O
the NN NN O
patients NN NN O
ovarian NN NN B-SpecificDisease
tumor NN NN I-SpecificDisease
or NN NN O
from NN NN O
the NN NN O
2774 NN NN O
cell NN NN O
line NN NN O
carries NN NN O
only NN NN O
the NN NN O
mutant NN NN O
allele NN NN O
of NN NN O
the NN NN O
human NN NN O
MSH2 NN NN O
gene NN NN O
. NN NN O

The NN NN O
genetic NN NN O
instability NN NN O
observed NN NN O
in NN NN O
the NN NN O
tumor NN NN B-DiseaseClass
and NN NN O
cell NN NN O
line NN NN O
DNA NN NN O
, NN NN O
together NN NN O
with NN NN O
the NN NN O
germ-line NN NN O
mutation NN NN O
in NN NN O
a NN NN O
mismatch-repair NN NN O
gene NN NN O
, NN NN O
suggest NN NN O
that NN NN O
the NN NN O
MSH2 NN NN O
gene NN NN O
is NN NN O
involved NN NN O
in NN NN O
the NN NN O
onset NN NN O
and NN NN O
/ NN NN O
or NN NN O
progression NN NN O
in NN NN O
a NN NN O
subset NN NN O
of NN NN O
ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

. NN NN O

7939630 NN NN O
BRCA1 NN NN O
mutations NN NN O
in NN NN O
primary NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
carcinomas NN NN I-CompositeMention
. NN NN O

Loss NN NN O
of NN NN O
heterozygosity NN NN O
data NN NN O
from NN NN O
familial NN NN B-DiseaseClass
tumors NN NN I-DiseaseClass
suggest NN NN O
that NN NN O
BRCA1 NN NN O
, NN NN O
a NN NN O
gene NN NN O
that NN NN O
confers NN NN O
susceptibility NN NN O
to NN NN O
ovarian NN NN B-CompositeMention
and NN NN I-CompositeMention
early-onset NN NN I-CompositeMention
breast NN NN B-CompositeMention
cancer NN NN I-CompositeMention
, NN NN O
encodes NN NN O
a NN NN O
tumor NN NN B-Modifier
suppressor NN NN O
. NN NN O

The NN NN O
BRCA1 NN NN O
region NN NN O
is NN NN O
also NN NN O
subject NN NN O
to NN NN O
allelic NN NN O
loss NN NN O
in NN NN O
sporadic NN NN B-SpecificDisease
breast NN NN I-SpecificDisease
and NN NN I-SpecificDisease
ovarian NN NN I-SpecificDisease
cancers NN NN I-SpecificDisease
, NN NN O
an NN NN O
indication NN NN O
that NN NN O
BRCA1 NN NN O
mutations NN NN O
may NN NN O
occur NN NN O
somatically NN NN O
in NN NN O
these NN NN O
tumors NN NN B-DiseaseClass
. NN NN O

The NN NN O
BRCA1 NN NN O
coding NN NN O
region NN NN O
was NN NN O
examined NN NN O
for NN NN O
mutations NN NN O
in NN NN O
primary NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
tumors NN NN I-CompositeMention
that NN NN O
show NN NN O
allele NN NN O
loss NN NN O
at NN NN O
the NN NN O
BRCA1 NN NN O
locus NN NN O
. NN NN O

Mutations NN NN O
were NN NN O
detected NN NN O
in NN NN O
3 NN NN O
of NN NN O
32 NN NN O
breast NN NN O
and NN NN O
1 NN NN O
of NN NN O
12 NN NN O
ovarian NN NN B-SpecificDisease
carcinomas NN NN I-SpecificDisease
; NN NN O
all NN NN O
four NN NN O
mutations NN NN O
were NN NN O
germline NN NN O
alterations NN NN O
and NN NN O
occurred NN NN O
in NN NN O
early-onset NN NN O
cancers NN NN B-DiseaseClass
. NN NN O

These NN NN O
results NN NN O
suggest NN NN O
that NN NN O
mutation NN NN O
of NN NN O
BRCA1 NN NN O
may NN NN O
not NN NN O
be NN NN O
critical NN NN O
in NN NN O
the NN NN O
development NN NN O
of NN NN O
the NN NN O
majority NN NN O
of NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancers NN NN I-CompositeMention
that NN NN O
arise NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
a NN NN O
mutant NN NN O
germline NN NN O
allele NN NN O
. NN NN O

. NN NN O

7951315 NN NN O
PAX6 NN NN O
gene NN NN O
dosage NN NN O
effect NN NN O
in NN NN O
a NN NN O
family NN NN O
with NN NN O
congenital NN NN B-SpecificDisease
cataracts NN NN I-SpecificDisease
, NN NN O
aniridia NN NN B-SpecificDisease
, NN NN O
anophthalmia NN NN B-SpecificDisease
and NN NN O
central NN NN B-DiseaseClass
nervous NN NN I-DiseaseClass
system NN NN I-DiseaseClass
defects NN NN I-DiseaseClass
. NN NN O

The NN NN O
human NN NN O
eye NN NN O
malformation NN NN O
aniridia NN NN B-SpecificDisease
results NN NN O
from NN NN O
haploinsufficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
PAX6 NN NN I-SpecificDisease
, NN NN O
a NN NN O
paired NN NN O
box NN NN O
DNA-binding NN NN O
protein NN NN O
. NN NN O

To NN NN O
study NN NN O
this NN NN O
dosage NN NN O
effect NN NN O
, NN NN O
we NN NN O
characterized NN NN O
two NN NN O
PAX6 NN NN O
mutations NN NN O
in NN NN O
a NN NN O
family NN NN O
segregating NN NN O
aniridia NN NN B-SpecificDisease
and NN NN O
a NN NN O
milder NN NN O
syndrome NN NN O
consisting NN NN O
of NN NN O
congenital NN NN B-SpecificDisease
cataracts NN NN I-SpecificDisease
and NN NN O
late NN NN O
onset NN NN O
corneal NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
. NN NN O

The NN NN O
nonsense NN NN O
mutations NN NN O
, NN NN O
at NN NN O
codons NN NN O
103 NN NN O
and NN NN O
353 NN NN O
, NN NN O
truncate NN NN O
PAX6 NN NN O
within NN NN O
the NN NN O
N-terminal NN NN O
paired NN NN O
and NN NN O
C-terminal NN NN O
PST NN NN O
domains NN NN O
, NN NN O
respectively NN NN O
. NN NN O

The NN NN O
wild-type NN NN O
PST NN NN O
domain NN NN O
activates NN NN O
transcription NN NN O
autonomously NN NN O
and NN NN O
the NN NN O
mutant NN NN O
form NN NN O
has NN NN O
partial NN NN O
activity NN NN O
. NN NN O

A NN NN O
compound NN NN O
heterozygote NN NN O
had NN NN O
severe NN NN O
craniofacial NN NN B-CompositeMention
and NN NN I-CompositeMention
central NN NN I-CompositeMention
nervous NN NN I-CompositeMention
system NN NN I-CompositeMention
defects NN NN I-CompositeMention
and NN NN O
no NN NN B-DiseaseClass
eyes NN NN I-DiseaseClass
. NN NN O

The NN NN O
pattern NN NN O
of NN NN O
malformations NN NN O
is NN NN O
similar NN NN O
to NN NN O
that NN NN O
in NN NN O
homozygous NN NN O
Sey NN NN O
mice NN NN O
and NN NN O
suggests NN NN O
a NN NN O
critical NN NN O
role NN NN O
for NN NN O
PAX6 NN NN O
in NN NN O
controlling NN NN O
the NN NN O
migration NN NN O
and NN NN O
differentiation NN NN O
of NN NN O
specific NN NN O
neuronal NN NN O
progenitor NN NN O
cells NN NN O
in NN NN O
the NN NN O
brain NN NN O
. NN NN O

. NN NN O

7951316 NN NN O
A NN NN O
physical NN NN O
map NN NN O
and NN NN O
candidate NN NN O
genes NN NN O
in NN NN O
the NN NN O
BRCA1 NN NN O
region NN NN O
on NN NN O
chromosome NN NN O
17q12-21 NN NN O
. NN NN O

We NN NN O
have NN NN O
constructed NN NN O
a NN NN O
physical NN NN O
map NN NN O
of NN NN O
a NN NN O
4 NN NN O
cM NN NN O
region NN NN O
on NN NN O
chromosome NN NN O
17q12-21 NN NN O
that NN NN O
contains NN NN O
the NN NN O
hereditary NN NN B-Modifier
breast NN NN I-Modifier
and NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
gene NN NN O
BRCA1 NN NN O
. NN NN O

The NN NN O
map NN NN O
comprises NN NN O
a NN NN O
contig NN NN O
of NN NN O
137 NN NN O
overlapping NN NN O
yeast NN NN O
artificial NN NN O
chromosomes NN NN O
and NN NN O
P1 NN NN O
clones NN NN O
, NN NN O
onto NN NN O
which NN NN O
we NN NN O
have NN NN O
placed NN NN O
112 NN NN O
PCR NN NN O
markers NN NN O
. NN NN O

We NN NN O
have NN NN O
localized NN NN O
more NN NN O
than NN NN O
20 NN NN O
genes NN NN O
on NN NN O
this NN NN O
map NN NN O
, NN NN O
ten NN NN O
of NN NN O
which NN NN O
had NN NN O
not NN NN O
been NN NN O
mapped NN NN O
to NN NN O
the NN NN O
region NN NN O
previously NN NN O
, NN NN O
and NN NN O
have NN NN O
isolated NN NN O
30 NN NN O
cDNA NN NN O
clones NN NN O
representing NN NN O
partial NN NN O
sequences NN NN O
of NN NN O
as NN NN O
yet NN NN O
unidentified NN NN O
genes NN NN O
. NN NN O

Two NN NN O
genes NN NN O
that NN NN O
lie NN NN O
within NN NN O
a NN NN O
narrow NN NN O
region NN NN O
defined NN NN O
by NN NN O
meiotic NN NN O
breakpoints NN NN O
in NN NN O
BRCA1 NN NN O
patients NN NN O
have NN NN O
been NN NN O
sequenced NN NN O
in NN NN O
breast NN NN B-Modifier
cancer NN NN I-Modifier
patients NN NN O
without NN NN O
revealing NN NN O
any NN NN O
deleterious NN NN O
mutations NN NN O
. NN NN O

These NN NN O
new NN NN O
reagents NN NN O
should NN NN O
facilitate NN NN O
the NN NN O
identification NN NN O
of NN NN O
BRCA1 NN NN O
. NN NN O

. NN NN O

7951327 NN NN O
The NN NN O
LEC NN NN O
rat NN NN O
has NN NN O
a NN NN O
deletion NN NN O
in NN NN O
the NN NN O
copper NN NN O
transporting NN NN O
ATPase NN NN O
gene NN NN O
homologous NN NN O
to NN NN O
the NN NN O
Wilson NN NN B-Modifier
disease NN NN I-Modifier
gene NN NN O
. NN NN O

The NN NN O
Long-Evans NN NN O
Cinnamon NN NN O
( NN NN O
LEC NN NN O
) NN NN O
rat NN NN O
shows NN NN O
similarity NN NN O
to NN NN O
Wilson NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
in NN NN O
many NN NN O
clinical NN NN O
and NN NN O
biochemical NN NN O
features NN NN O
. NN NN O

We NN NN O
have NN NN O
cloned NN NN O
cDNAs NN NN O
for NN NN O
the NN NN O
rat NN NN O
gene NN NN O
( NN NN O
Atp7b NN NN O
) NN NN O
homologous NN NN O
to NN NN O
the NN NN O
human NN NN O
Wilson NN NN B-Modifier
disease NN NN I-Modifier
gene NN NN O
( NN NN O
ATP7B NN NN O
) NN NN O
and NN NN O
have NN NN O
used NN NN O
them NN NN O
to NN NN O
identify NN NN O
a NN NN O
partial NN NN O
deletion NN NN O
in NN NN O
the NN NN O
Atp7b NN NN O
gene NN NN O
in NN NN O
the NN NN O
LEC NN NN O
rat NN NN O
. NN NN O

The NN NN O
deletion NN NN O
removes NN NN O
at NN NN O
least NN NN O
900 NN NN O
bp NN NN O
of NN NN O
the NN NN O
coding NN NN O
region NN NN O
at NN NN O
the NN NN O
3 NN NN O
end NN NN O
, NN NN O
includes NN NN O
the NN NN O
crucial NN NN O
ATP NN NN O
binding NN NN O
domain NN NN O
and NN NN O
extends NN NN O
downstream NN NN O
of NN NN O
the NN NN O
gene NN NN O
. NN NN O

Our NN NN O
results NN NN O
provide NN NN O
convincing NN NN O
evidence NN NN O
for NN NN O
defining NN NN O
the NN NN O
LEC NN NN O
rat NN NN O
as NN NN O
an NN NN O
animal NN NN O
model NN NN O
for NN NN O
Wilson NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

This NN NN O
model NN NN O
will NN NN O
be NN NN O
important NN NN O
for NN NN O
studying NN NN O
liver NN NN O
pathophysiology NN NN O
, NN NN O
for NN NN O
developing NN NN O
therapy NN NN O
for NN NN O
Wilson NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
and NN NN O
for NN NN O
studying NN NN O
the NN NN O
pathway NN NN O
of NN NN O
copper NN NN O
transport NN NN O
and NN NN O
its NN NN O
possible NN NN O
interaction NN NN O
with NN NN O
other NN NN O
heavy NN NN O
metals NN NN O
. NN NN O

. NN NN O

7959759 NN NN O
Genomic NN NN O
organization NN NN O
of NN NN O
the NN NN O
adrenoleukodystrophy NN NN B-Modifier
gene NN NN O
. NN NN O

Adrenoleukodystrophy NN NN B-SpecificDisease
( NN NN O
ALD NN NN B-SpecificDisease
) NN NN O
, NN NN O
the NN NN O
most NN NN O
frequent NN NN O
peroxisomal NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
, NN NN O
is NN NN O
a NN NN O
severe NN NN O
neurodegenerative NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
associated NN NN O
with NN NN O
an NN NN O
impairment NN NN B-DiseaseClass
of NN NN I-DiseaseClass
very NN NN I-DiseaseClass
long NN NN I-DiseaseClass
chain NN NN I-DiseaseClass
fatty NN NN I-DiseaseClass
acids NN NN I-DiseaseClass
beta-oxidation NN NN I-DiseaseClass
. NN NN O

We NN NN O
have NN NN O
recently NN NN O
identified NN NN O
by NN NN O
positional NN NN O
cloning NN NN O
the NN NN O
gene NN NN O
responsible NN NN O
for NN NN O
ALD NN NN B-SpecificDisease
, NN NN O
located NN NN O
in NN NN O
Xq28 NN NN O
. NN NN O

It NN NN O
encodes NN NN O
a NN NN O
new NN NN O
member NN NN O
of NN NN O
the NN NN O
`` NN NN O
ABC NN NN O
`` NN NN O
superfamily NN NN O
of NN NN O
membrane-associated NN NN O
transporters NN NN O
that NN NN O
shows NN NN O
, NN NN O
in NN NN O
particular NN NN O
, NN NN O
significant NN NN O
homology NN NN O
to NN NN O
the NN NN O
70-kDa NN NN O
peroxisomal NN NN O
membrane NN NN O
protein NN NN O
( NN NN O
PMP70 NN NN O
) NN NN O
. NN NN O

We NN NN O
report NN NN O
here NN NN O
a NN NN O
detailed NN NN O
characterization NN NN O
of NN NN O
the NN NN O
ALD NN NN B-Modifier
gene NN NN O
structure NN NN O
. NN NN O

It NN NN O
extends NN NN O
over NN NN O
21 NN NN O
kb NN NN O
and NN NN O
consists NN NN O
of NN NN O
10 NN NN O
exons NN NN O
. NN NN O

To NN NN O
facilitate NN NN O
the NN NN O
detection NN NN O
of NN NN O
mutations NN NN O
in NN NN O
ALD NN NN B-Modifier
patients NN NN O
, NN NN O
we NN NN O
have NN NN O
determined NN NN O
the NN NN O
intronic NN NN O
sequences NN NN O
flanking NN NN O
the NN NN O
exons NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
sequence NN NN O
of NN NN O
the NN NN O
3 NN NN O
untranslated NN NN O
region NN NN O
and NN NN O
of NN NN O
the NN NN O
immediate NN NN O
5 NN NN O
promoter NN NN O
region NN NN O
. NN NN O

Sequences NN NN O
present NN NN O
in NN NN O
distal NN NN O
exons NN NN O
cross-hybridize NN NN O
strongly NN NN O
to NN NN O
additional NN NN O
sequences NN NN O
in NN NN O
the NN NN O
human NN NN O
genome NN NN O
. NN NN O

The NN NN O
ALD NN NN B-Modifier
gene NN NN O
has NN NN O
been NN NN O
positioned NN NN O
on NN NN O
a NN NN O
pulsed-field NN NN O
map NN NN O
between NN NN O
DXS15 NN NN O
and NN NN O
the NN NN O
L1CAM NN NN O
gene NN NN O
, NN NN O
about NN NN O
650 NN NN O
kb NN NN O
upstream NN NN O
from NN NN O
the NN NN O
color NN NN O
pigment NN NN O
genes NN NN O
. NN NN O

The NN NN O
frequent NN NN O
occurrence NN NN O
of NN NN O
color NN NN O
vision NN NN O
anomalies NN NN O
observed NN NN O
in NN NN O
patients NN NN O
with NN NN O
adrenomyeloneuropathy NN NN B-SpecificDisease
( NN NN O
the NN NN O
adult NN NN O
onset NN NN O
form NN NN O
of NN NN O
ALD NN NN B-SpecificDisease
) NN NN O
thus NN NN O
does NN NN O
not NN NN O
represent NN NN O
a NN NN O
contiguous NN NN B-DiseaseClass
gene NN NN I-DiseaseClass
syndrome NN NN I-DiseaseClass
but NN NN O
a NN NN O
secondary NN NN O
manifestation NN NN O
of NN NN O
ALD NN NN B-SpecificDisease
. NN NN O

. NN NN O

7959767 NN NN O
The NN NN O
murine NN NN O
homologues NN NN O
of NN NN O
the NN NN O
Huntington NN NN B-Modifier
disease NN NN I-Modifier
gene NN NN O
( NN NN O
Hdh NN NN O
) NN NN O
and NN NN O
the NN NN O
alpha-adducin NN NN O
gene NN NN O
( NN NN O
Add1 NN NN O
) NN NN O
map NN NN O
to NN NN O
mouse NN NN O
chromosome NN NN O
5 NN NN O
within NN NN O
a NN NN O
region NN NN O
of NN NN O
conserved NN NN O
synteny NN NN O
with NN NN O
human NN NN O
chromosome NN NN O
4p16.3 NN NN O
. NN NN O

Huntington NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
HD NN NN B-SpecificDisease
) NN NN O
is NN NN O
a NN NN O
severe NN NN O
autosomal NN NN B-DiseaseClass
dominant NN NN I-DiseaseClass
neurodegenerative NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
associated NN NN O
with NN NN O
a NN NN O
novel NN NN O
gene NN NN O
( NN NN O
IT15 NN NN O
) NN NN O
. NN NN O

Recently NN NN O
, NN NN O
we NN NN O
reported NN NN O
the NN NN O
cloning NN NN O
of NN NN O
Hdh NN NN O
, NN NN O
the NN NN O
murine NN NN O
homologue NN NN O
of NN NN O
IT15 NN NN O
. NN NN O

Here NN NN O
, NN NN O
using NN NN O
an NN NN O
interspecific NN NN O
backcross NN NN O
, NN NN O
we NN NN O
have NN NN O
mapped NN NN O
both NN NN O
Hdh NN NN O
and NN NN O
the NN NN O
mouse NN NN O
homologue NN NN O
of NN NN O
human NN NN O
alpha-adducin NN NN O
( NN NN O
Add1 NN NN O
) NN NN O
, NN NN O
a NN NN O
membrane-associated NN NN O
cytoskeletal NN NN O
protein NN NN O
gene NN NN O
. NN NN O

Both NN NN O
of NN NN O
these NN NN O
genes NN NN O
map NN NN O
in NN NN O
the NN NN O
same NN NN O
position NN NN O
on NN NN O
mouse NN NN O
chromosome NN NN O
5 NN NN O
in NN NN O
a NN NN O
region NN NN O
associated NN NN O
with NN NN O
ancestral NN NN O
chromosomal NN NN O
rearrangements NN NN O
and NN NN O
show NN NN O
no NN NN O
recombination NN NN O
with NN NN O
D5H4S43 NN NN O
, NN NN O
D5H4S115 NN NN O
, NN NN O
and NN NN O
D5H4S62 NN NN O
, NN NN O
the NN NN O
murine NN NN O
homologues NN NN O
of NN NN O
D4S43 NN NN O
, NN NN O
D4S115 NN NN O
, NN NN O
and NN NN O
D4S62 NN NN O
, NN NN O
respectively NN NN O
. NN NN O

Further NN NN O
mapping NN NN O
studies NN NN O
of NN NN O
humans NN NN O
, NN NN O
mice NN NN O
, NN NN O
and NN NN O
other NN NN O
mammalian NN NN O
species NN NN O
should NN NN O
reveal NN NN O
the NN NN O
nature NN NN O
of NN NN O
the NN NN O
rearrangements NN NN O
affecting NN NN O
this NN NN O
chromosomal NN NN O
segment NN NN O
during NN NN O
mammalian NN NN O
evolution NN NN O
. NN NN O

. NN NN O

7962532 NN NN O
Genetic NN NN O
cholesteryl NN NN B-SpecificDisease
ester NN NN I-SpecificDisease
transfer NN NN I-SpecificDisease
protein NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
caused NN NN O
by NN NN O
two NN NN O
prevalent NN NN O
mutations NN NN O
as NN NN O
a NN NN O
major NN NN O
determinant NN NN O
of NN NN O
increased NN NN O
levels NN NN O
of NN NN O
high NN NN O
density NN NN O
lipoprotein NN NN O
cholesterol NN NN O
. NN NN O

Genetic NN NN O
determinants NN NN O
of NN NN O
HDL NN NN O
cholesterol NN NN O
( NN NN O
HDL-C NN NN O
) NN NN O
levels NN NN O
in NN NN O
the NN NN O
general NN NN O
population NN NN O
are NN NN O
poorly NN NN O
understood NN NN O
. NN NN O

We NN NN O
previously NN NN O
described NN NN O
plasma NN NN O
cholesteryl NN NN B-SpecificDisease
ester NN NN I-SpecificDisease
transfer NN NN I-SpecificDisease
protein NN NN I-SpecificDisease
( NN NN I-SpecificDisease
CETP NN NN I-SpecificDisease
) NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
due NN NN O
to NN NN O
an NN NN O
intron NN NN O
14 NN NN O
G NN NN O
( NN NN O
+ NN NN O
1 NN NN O
) NN NN O
-to-A NN NN O
mutation NN NN O
( NN NN O
Int14 NN NN O
A NN NN O
) NN NN O
in NN NN O
several NN NN O
families NN NN O
with NN NN O
very NN NN O
high NN NN O
HDL-C NN NN O
levels NN NN O
in NN NN O
Japan NN NN O
. NN NN O

Subjects NN NN O
with NN NN O
HDL-C NN NN O
or NN NN O
= NN NN O
100 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
( NN NN O
n NN NN O
= NN NN O
130 NN NN O
) NN NN O
were NN NN O
screened NN NN O
by NN NN O
PCR NN NN O
single NN NN O
strand NN NN O
conformational NN NN O
polymorphism NN NN O
analysis NN NN O
of NN NN O
the NN NN O
CETP NN NN O
gene NN NN O
. NN NN O

Two NN NN O
other NN NN O
mutations NN NN O
were NN NN O
identified NN NN O
by NN NN O
DNA NN NN O
sequencing NN NN O
or NN NN O
primer-mediated NN NN O
restriction NN NN O
map NN NN O
modification NN NN O
of NN NN O
PCR NN NN O
products NN NN O
a NN NN O
novel NN NN O
intron NN NN O
14 NN NN O
splice NN NN O
donor NN NN O
site NN NN O
mutation NN NN O
caused NN NN O
by NN NN O
a NN NN O
T NN NN O
insertion NN NN O
at NN NN O
position NN NN O
+ NN NN O
3 NN NN O
from NN NN O
the NN NN O
exon14 NN NN O
/ NN NN O
intron14 NN NN O
boundary NN NN O
( NN NN O
Int14 NN NN O
T NN NN O
) NN NN O
and NN NN O
a NN NN O
missense NN NN O
mutation NN NN O
( NN NN O
Asp442 NN NN O
to NN NN O
Gly NN NN O
) NN NN O
within NN NN O
exon NN NN O
15 NN NN O
( NN NN O
D442G NN NN O
) NN NN O
. NN NN O

The NN NN O
Int14 NN NN O
T NN NN O
mutation NN NN O
was NN NN O
only NN NN O
found NN NN O
in NN NN O
one NN NN O
family NN NN O
. NN NN O

However NN NN O
, NN NN O
the NN NN O
D442G NN NN O
and NN NN O
Int14 NN NN O
A NN NN O
mutations NN NN O
were NN NN O
highly NN NN O
prevalent NN NN O
in NN NN O
subjects NN NN O
with NN NN O
HDL-C NN NN O
or NN NN O
= NN NN O
60 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
, NN NN O
with NN NN O
combined NN NN O
allele NN NN O
frequencies NN NN O
of NN NN O
9 NN NN O
% NN NN O
, NN NN O
12 NN NN O
% NN NN O
, NN NN O
21 NN NN O
% NN NN O
and NN NN O
43 NN NN O
% NN NN O
for NN NN O
HDL-C NN NN O
60-79 NN NN O
, NN NN O
80-99 NN NN O
, NN NN O
100-119 NN NN O
, NN NN O
and NN NN O
or NN NN O
= NN NN O
120 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
, NN NN O
respectively NN NN O
. NN NN O

Furthermore NN NN O
, NN NN O
prevalences NN NN O
of NN NN O
the NN NN O
D442G NN NN O
and NN NN O
Int14 NN NN O
A NN NN O
mutations NN NN O
were NN NN O
extremely NN NN O
high NN NN O
in NN NN O
a NN NN O
general NN NN O
sample NN NN O
of NN NN O
Japanese NN NN O
men NN NN O
( NN NN O
n NN NN O
= NN NN O
236 NN NN O
) NN NN O
, NN NN O
with NN NN O
heterozygote NN NN O
frequencies NN NN O
of NN NN O
7 NN NN O
% NN NN O
and NN NN O
2 NN NN O
% NN NN O
, NN NN O
respectively NN NN O
. NN NN O

These NN NN O
two NN NN O
mutations NN NN O
accounted NN NN O
for NN NN O
about NN NN O
10 NN NN O
% NN NN O
of NN NN O
the NN NN O
total NN NN O
variance NN NN O
of NN NN O
HDL-C NN NN O
in NN NN O
this NN NN O
population NN NN O
. NN NN O

The NN NN O
phenotype NN NN O
in NN NN O
a NN NN O
genetic NN NN O
compound NN NN O
heterozygote NN NN O
( NN NN O
Int14 NN NN O
T NN NN O
and NN NN O
Int14 NN NN O
A NN NN O
) NN NN O
was NN NN O
similar NN NN O
to NN NN O
that NN NN O
of NN NN O
Int14 NN NN O
A NN NN O
homozygotes NN NN O
( NN NN O
no NN NN O
detectable NN NN O
CETP NN NN O
and NN NN O
markedly NN NN O
increased NN NN O
HDL-C NN NN O
) NN NN O
, NN NN O
indicating NN NN O
that NN NN O
the NN NN O
Int14 NN NN O
T NN NN O
produces NN NN O
a NN NN O
null NN NN O
allele NN NN O
. NN NN O

In NN NN O
four NN NN O
D442G NN NN O
homozygotes NN NN O
, NN NN O
mean NN NN O
HDL-C NN NN O
levels NN NN O
( NN NN O
86 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
26 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
) NN NN O
were NN NN O
lower NN NN O
than NN NN O
in NN NN O
Int14 NN NN O
A NN NN O
homozygotes NN NN O
( NN NN O
158 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
35 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
) NN NN O
, NN NN O
reflecting NN NN O
residual NN NN O
CETP NN NN O
activity NN NN O
in NN NN O
plasma NN NN O
. NN NN O

In NN NN O
47 NN NN O
D442G NN NN O
heterozygotes NN NN O
, NN NN O
mean NN NN O
HDL-C NN NN O
levels NN NN O
were NN NN O
91 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
23 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
, NN NN O
similar NN NN O
to NN NN O
the NN NN O
level NN NN O
in NN NN O
D442G NN NN O
homozygotes NN NN O
, NN NN O
and NN NN O
significantly NN NN O
greater NN NN O
than NN NN O
mean NN NN O
HDL-C NN NN O
levels NN NN O
in NN NN O
Int14 NN NN O
A NN NN O
heterozygotes NN NN O
( NN NN O
69 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
15 NN NN O
mg NN NN O
/ NN NN O
dl NN NN O
) NN NN O
. NN NN O

Thus NN NN O
, NN NN O
the NN NN O
D442G NN NN O
mutation NN NN O
acts NN NN O
differently NN NN O
to NN NN O
the NN NN O
null NN NN O
mutations NN NN O
with NN NN O
weaker NN NN O
effects NN NN O
on NN NN O
HDL NN NN O
in NN NN O
the NN NN O
homozygous NN NN O
state NN NN O
and NN NN O
stronger NN NN O
effects NN NN O
in NN NN O
the NN NN O
heterozygotes NN NN O
, NN NN O
suggesting NN NN O
dominant NN NN O
expression NN NN O
of NN NN O
a NN NN O
partially NN NN O
defective NN NN O
allele NN NN O
. NN NN O

CETP NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
, NN NN O
reflecting NN NN O
two NN NN O
prevalent NN NN O
mutations NN NN O
( NN NN O
D442G NN NN O
and NN NN O
Int14 NN NN O
A NN NN O
) NN NN O
, NN NN O
is NN NN O
the NN NN O
first NN NN O
example NN NN O
of NN NN O
a NN NN O
genetic NN NN B-Modifier
deficiency NN NN I-Modifier
state NN NN O
which NN NN O
is NN NN O
sufficiently NN NN O
common NN NN O
to NN NN O
explain NN NN O
a NN NN O
significant NN NN O
fraction NN NN O
of NN NN O
the NN NN O
variation NN NN O
in NN NN O
HDL-C NN NN O
in NN NN O
the NN NN O
general NN NN O
population NN NN O
. NN NN O

. NN NN O

7964884 NN NN O
Treatment NN NN O
of NN NN O
cerebrotendinous NN NN B-SpecificDisease
xanthomatosis NN NN I-SpecificDisease
: NN NN O
effects NN NN O
of NN NN O
chenodeoxycholic NN NN O
acid NN NN O
, NN NN O
pravastatin NN NN O
, NN NN O
and NN NN O
combined NN NN O
use NN NN O
. NN NN O

Treatments NN NN O
by NN NN O
oral NN NN O
administration NN NN O
of NN NN O
chenodeoxycholic NN NN O
acid NN NN O
( NN NN O
CDCA NN NN O
) NN NN O
alone NN NN O
, NN NN O
3-hydroxy-3-methylglutaryl NN NN O
( NN NN O
HMG NN NN O
) NN NN O
CoA NN NN O
reductase NN NN O
inhibitor NN NN O
( NN NN O
pravastatin NN NN O
) NN NN O
alone NN NN O
, NN NN O
and NN NN O
combination NN NN O
of NN NN O
the NN NN O
two NN NN O
drugs NN NN O
were NN NN O
attempted NN NN O
for NN NN O
7 NN NN O
patients NN NN O
with NN NN O
cerebrotendinous NN NN B-SpecificDisease
xanthomatosis NN NN I-SpecificDisease
( NN NN O
CTX NN NN B-SpecificDisease
) NN NN O
. NN NN O

CDCA NN NN O
treatment NN NN O
at NN NN O
a NN NN O
dose NN NN O
of NN NN O
300 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
reduced NN NN O
serum NN NN O
cholestanol NN NN O
( NN NN O
67 NN NN O
. NN NN O

3 NN NN O
% NN NN O
reduction NN NN O
) NN NN O
, NN NN O
lathosterol NN NN O
( NN NN O
50 NN NN O
. NN NN O

8 NN NN O
% NN NN O
) NN NN O
, NN NN O
campesterol NN NN O
( NN NN O
61 NN NN O
. NN NN O

7 NN NN O
% NN NN O
) NN NN O
and NN NN O
sitosterol NN NN O
( NN NN O
12 NN NN O
. NN NN O

7 NN NN O
% NN NN O
) NN NN O
. NN NN O

However NN NN O
, NN NN O
the NN NN O
sera NN NN O
of NN NN O
the NN NN O
patients NN NN O
changed NN NN O
to NN NN O
be NN NN O
`` NN NN O
atherogenic NN NN O
`` NN NN O
; NN NN O
total NN NN O
cholesterol NN NN O
, NN NN O
triglyceride NN NN O
and NN NN O
low-density NN NN O
lipoprotein NN NN O
( NN NN O
LDL NN NN O
) NN NN O
-cholesterol NN NN O
were NN NN O
increased NN NN O
, NN NN O
while NN NN O
high-density NN NN O
lipoprotein NN NN O
( NN NN O
HDL NN NN O
) NN NN O
-cholesterol NN NN O
was NN NN O
decreased NN NN O
. NN NN O

Contrarily NN NN O
, NN NN O
pravastatin NN NN O
at NN NN O
a NN NN O
dose NN NN O
of NN NN O
10 NN NN O
mg NN NN O
/ NN NN O
day NN NN O
improved NN NN O
the NN NN O
sera NN NN O
of NN NN O
the NN NN O
patients NN NN O
to NN NN O
be NN NN O
markedly NN NN O
`` NN NN O
anti-atherogenic NN NN O
`` NN NN O
, NN NN O
but NN NN O
the NN NN O
reductions NN NN O
of NN NN O
cholestanol NN NN O
( NN NN O
30 NN NN O
. NN NN O

4 NN NN O
% NN NN O
) NN NN O
, NN NN O
lathosterol NN NN O
( NN NN O
44 NN NN O
. NN NN O

0 NN NN O
% NN NN O
) NN NN O
, NN NN O
campesterol NN NN O
( NN NN O
22 NN NN O
. NN NN O

9 NN NN O
% NN NN O
) NN NN O
and NN NN O
sitosterol NN NN O
( NN NN O
9 NN NN O
. NN NN O

6 NN NN O
% NN NN O
) NN NN O
were NN NN O
inadequate NN NN O
. NN NN O

Combined NN NN O
treatment NN NN O
with NN NN O
CDCA NN NN O
and NN NN O
pravastatin NN NN O
showed NN NN O
good NN NN O
overlapping NN NN O
of NN NN O
the NN NN O
effects NN NN O
of NN NN O
each NN NN O
drug NN NN O
alone NN NN O
. NN NN O

The NN NN O
sera NN NN O
of NN NN O
the NN NN O
patients NN NN O
were NN NN O
apparently NN NN O
more NN NN O
`` NN NN O
anti-atherogenic NN NN O
`` NN NN O
than NN NN O
those NN NN O
after NN NN O
CDCA NN NN O
treatment NN NN O
. NN NN O

Serum NN NN O
cholestanol NN NN O
concentration NN NN O
was NN NN O
still NN NN O
2 NN NN O
. NN NN O

7 NN NN O
times NN NN O
higher NN NN O
than NN NN O
in NN NN O
controls NN NN O
, NN NN O
but NN NN O
the NN NN O
serum NN NN O
lathosterol NN NN O
level NN NN O
was NN NN O
within NN NN O
the NN NN O
normal NN NN O
range NN NN O
, NN NN O
indicating NN NN O
that NN NN O
the NN NN O
enhancement NN NN O
of NN NN O
overall NN NN O
cholesterol NN NN O
synthesis NN NN O
in NN NN O
the NN NN O
patients NN NN O
was NN NN O
sufficiently NN NN O
suppressed NN NN O
. NN NN O

Plant NN NN O
sterol NN NN O
levels NN NN O
were NN NN O
also NN NN O
within NN NN O
the NN NN O
normal NN NN O
range NN NN O
. NN NN O

The NN NN O
combination NN NN O
of NN NN O
CDCA NN NN O
and NN NN O
pravastatin NN NN O
was NN NN O
a NN NN O
good NN NN O
treatment NN NN O
for NN NN O
CTX NN NN B-SpecificDisease
, NN NN O
based NN NN O
on NN NN O
the NN NN O
improvement NN NN O
of NN NN O
serum NN NN O
lipoprotein NN NN O
metabolism NN NN O
, NN NN O
the NN NN O
suppression NN NN O
of NN NN O
cholesterol NN NN O
synthesis NN NN O
, NN NN O
and NN NN O
reductions NN NN O
of NN NN O
cholestanol NN NN O
and NN NN O
plant NN NN O
sterol NN NN O
levels NN NN O
. NN NN O

In NN NN O
all NN NN O
of NN NN O
7 NN NN O
patients NN NN O
, NN NN O
the NN NN O
progression NN NN O
of NN NN O
disease NN NN O
was NN NN O
arrested NN NN O
, NN NN O
but NN NN O
dramatic NN NN O
effects NN NN O
on NN NN O
clinical NN NN O
manifestations NN NN O
, NN NN O
xanthoma NN NN B-DiseaseClass
, NN NN O
and NN NN O
electrophysiological NN NN O
findings NN NN O
could NN NN O
not NN NN O
be NN NN O
found NN NN O
after NN NN O
the NN NN O
treatment NN NN O
of NN NN O
these NN NN O
drugs NN NN O

7981671 NN NN O
Mutation NN NN O
spectrum NN NN O
in NN NN O
the NN NN O
CHM NN NN B-Modifier
gene NN NN O
of NN NN O
Danish NN NN O
and NN NN O
Swedish NN NN O
choroideremia NN NN B-Modifier
patients NN NN O
. NN NN O

The NN NN O
recent NN NN O
isolation NN NN O
of NN NN O
the NN NN O
complete NN NN O
open NN NN O
reading NN NN O
frame NN NN O
of NN NN O
the NN NN O
choroideremia NN NN B-Modifier
( NN NN O
CHM NN NN B-Modifier
) NN NN O
gene NN NN O
and NN NN O
the NN NN O
characterization NN NN O
of NN NN O
the NN NN O
exon-intron NN NN O
boundaries NN NN O
has NN NN O
paved NN NN O
the NN NN O
way NN NN O
to NN NN O
mutation NN NN O
detection NN NN O
in NN NN O
patients NN NN O
with NN NN O
classical NN NN O
choroideremia NN NN B-SpecificDisease
. NN NN O

We NN NN O
have NN NN O
performed NN NN O
mutation NN NN O
screening NN NN O
in NN NN O
patients NN NN O
from NN NN O
15 NN NN O
Danish NN NN O
and NN NN O
Swedish NN NN O
families NN NN O
by NN NN O
using NN NN O
Southern NN NN O
blot NN NN O
hybridization NN NN O
and NN NN O
the NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
single-strand NN NN O
conformation NN NN O
polymorphism NN NN O
( NN NN O
PCR-SSCP NN NN O
) NN NN O
technique NN NN O
. NN NN O

Causative NN NN O
mutations NN NN O
in NN NN O
the NN NN O
CHM NN NN B-Modifier
gene NN NN O
were NN NN O
detected NN NN O
in NN NN O
at NN NN O
least NN NN O
12 NN NN O
families NN NN O
, NN NN O
indicating NN NN O
that NN NN O
a NN NN O
substantial NN NN O
part NN NN O
of NN NN O
the NN NN O
mutations NN NN O
can NN NN O
be NN NN O
identified NN NN O
by NN NN O
this NN NN O
approach NN NN O
. NN NN O

In NN NN O
four NN NN O
of NN NN O
these NN NN O
families NN NN O
deletions NN NN O
of NN NN O
different NN NN O
sizes NN NN O
were NN NN O
found NN NN O
. NN NN O

Thus NN NN O
, NN NN O
in NN NN O
one NN NN O
patient NN NN O
, NN NN O
the NN NN O
deletion NN NN O
resulted NN NN O
in NN NN O
the NN NN O
absence NN NN O
of NN NN O
only NN NN O
one NN NN O
exon NN NN O
, NN NN O
while NN NN O
in NN NN O
another NN NN O
the NN NN O
deletion NN NN O
comprised NN NN O
the NN NN O
entire NN NN O
CHM NN NN B-Modifier
gene NN NN O
. NN NN O

Mapping NN NN O
of NN NN O
the NN NN O
deletion NN NN O
endpoints NN NN O
in NN NN O
these NN NN O
four NN NN O
patients NN NN O
and NN NN O
in NN NN O
another NN NN O
11 NN NN O
male NN NN O
patients NN NN O
with NN NN O
sizeable NN NN O
deletions NN NN O
enabled NN NN O
us NN NN O
to NN NN O
construct NN NN O
a NN NN O
very NN NN O
detailed NN NN O
map NN NN O
of NN NN O
intervals NN NN O
2 NN NN O
and NN NN O
3 NN NN O
of NN NN O
Xq21 NN NN O
. NN NN O

In NN NN O
the NN NN O
remaining NN NN O
11 NN NN O
Danish NN NN O
and NN NN O
Swedish NN NN O
families NN NN O
at NN NN O
least NN NN O
8 NN NN O
causative NN NN O
mutations NN NN O
were NN NN O
found NN NN O
by NN NN O
PCR-SSCP NN NN O
analysis NN NN O
and NN NN O
direct NN NN O
sequencing NN NN O
. NN NN O

Interestingly NN NN O
, NN NN O
all NN NN O
CHM NN NN B-Modifier
gene NN NN O
mutations NN NN O
detected NN NN O
thus NN NN O
far NN NN O
in NN NN O
choroideremia NN NN B-Modifier
patients NN NN O
give NN NN O
rise NN NN O
to NN NN O
the NN NN O
introduction NN NN O
of NN NN O
a NN NN O
premature NN NN O
stop NN NN O
codon NN NN O
. NN NN O

. NN NN O

7991123 NN NN O
Predominance NN NN O
of NN NN O
the NN NN O
adrenomyeloneuropathy NN NN B-Modifier
phenotype NN NN O
of NN NN O
X-linked NN NN B-SpecificDisease
adrenoleukodystrophy NN NN I-SpecificDisease
in NN NN O
The NN NN O
Netherlands NN NN O
: NN NN O
a NN NN O
survey NN NN O
of NN NN O
30 NN NN O
kindreds NN NN O
. NN NN O

X-linked NN NN B-SpecificDisease
adrenoleukodystrophy NN NN I-SpecificDisease
( NN NN O
X-ALD NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
inherited NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
of NN NN O
peroxisomal NN NN O
beta-oxidation NN NN O
associated NN NN O
with NN NN O
accumulation NN NN O
of NN NN O
saturated NN NN O
very NN NN O
long-chain NN NN O
fatty NN NN O
acids NN NN O
, NN NN O
which NN NN O
results NN NN O
in NN NN O
central NN NN O
and NN NN O
peripheral NN NN O
demyelination NN NN B-DiseaseClass
and NN NN O
in NN NN O
impaired NN NN B-CompositeMention
function NN NN I-CompositeMention
of NN NN I-CompositeMention
adrenal NN NN I-CompositeMention
cortex NN NN I-CompositeMention
and NN NN I-CompositeMention
testes NN NN I-CompositeMention
. NN NN O

The NN NN O
phenotypic NN NN O
expression NN NN O
is NN NN O
highly NN NN O
variable NN NN O
, NN NN O
childhood NN NN B-SpecificDisease
cerebral NN NN I-SpecificDisease
ALD NN NN I-SpecificDisease
( NN NN O
CCALD NN NN B-SpecificDisease
) NN NN O
and NN NN O
adrenomyeloneuropathy NN NN B-SpecificDisease
( NN NN O
AMN NN NN B-SpecificDisease
) NN NN O
being NN NN O
the NN NN O
main NN NN O
variants NN NN O
. NN NN O

We NN NN O
explored NN NN O
the NN NN O
30 NN NN O
Dutch NN NN O
kindreds NN NN O
well NN NN O
known NN NN O
to NN NN O
the NN NN O
Dutch NN NN O
X-ALD NN NN B-Modifier
/ NN NN O
AMN NN NN B-Modifier
Study NN NN O
Group NN NN O
and NN NN O
phenotyped NN NN O
77 NN NN O
male NN NN O
patients NN NN O
35 NN NN O
( NN NN O
46 NN NN O
% NN NN O
) NN NN O
had NN NN O
AMN NN NN B-SpecificDisease
and NN NN O
24 NN NN O
( NN NN O
31 NN NN O
% NN NN O
) NN NN O
CCALD NN NN B-SpecificDisease
or NN NN O
adolescent NN NN B-SpecificDisease
cerebral NN NN I-SpecificDisease
ALD NN NN I-SpecificDisease
( NN NN O
AdolCALD NN NN B-SpecificDisease
) NN NN O
. NN NN O

These NN NN O
percentages NN NN O
differ NN NN O
significantly NN NN O
from NN NN O
previous NN NN O
reports NN NN O
, NN NN O
in NN NN O
which NN NN O
25 NN NN O
to NN NN O
28 NN NN O
% NN NN O
of NN NN O
the NN NN O
patients NN NN O
developed NN NN O
AMN NN NN B-SpecificDisease
and NN NN O
53 NN NN O
to NN NN O
57 NN NN O
% NN NN O
CCALD NN NN B-SpecificDisease
or NN NN O
AdolCALD NN NN B-SpecificDisease
. NN NN O

Our NN NN O
findings NN NN O
indicate NN NN O
that NN NN O
-- NN NN O
at NN NN O
least NN NN O
in NN NN O
the NN NN O
Netherlands NN NN O
-- NN NN O
AMN NN NN B-SpecificDisease
may NN NN O
be NN NN O
the NN NN O
most NN NN O
frequent NN NN O
phenotype NN NN O
of NN NN O
X-ALD NN NN B-SpecificDisease
. NN NN O

. NN NN O

8002973 NN NN O
Adrenoleukodystrophy NN NN B-Modifier
gene NN NN O
encodes NN NN O
an NN NN O
80 NN NN O
kDa NN NN O
membrane NN NN O
protein NN NN O
. NN NN O

An NN NN O
antibody NN NN O
against NN NN O
the NN NN O
synthetic NN NN O
C-terminal NN NN O
peptides NN NN O
deduced NN NN O
from NN NN O
the NN NN O
cDNA NN NN O
of NN NN O
the NN NN O
gene NN NN O
responsible NN NN O
for NN NN O
X-linked NN NN B-SpecificDisease
adrenoleukodystrophy NN NN I-SpecificDisease
( NN NN O
ALD NN NN B-SpecificDisease
) NN NN O
was NN NN O
produced NN NN O
to NN NN O
characterize NN NN O
the NN NN O
product NN NN O
of NN NN O
the NN NN O
ALD NN NN B-Modifier
gene NN NN O
. NN NN O

The NN NN O
antibody NN NN O
reacted NN NN O
with NN NN O
the NN NN O
80 NN NN O
kDa NN NN O
band NN NN O
protein NN NN O
in NN NN O
control NN NN O
fibroblasts NN NN O
, NN NN O
while NN NN O
no NN NN O
bands NN NN O
were NN NN O
detected NN NN O
in NN NN O
the NN NN O
fibroblasts NN NN O
from NN NN O
a NN NN O
patient NN NN O
with NN NN O
ALD NN NN B-SpecificDisease
( NN NN O
# NN NN O
163 NN NN O
) NN NN O
, NN NN O
in NN NN O
which NN NN O
mRNA NN NN O
of NN NN O
the NN NN O
ALD NN NN B-Modifier
gene NN NN O
was NN NN O
undetectable NN NN O
based NN NN O
on NN NN O
Northern NN NN O
blot NN NN O
analysis NN NN O
. NN NN O

The NN NN O
293T NN NN O
cells NN NN O
transfected NN NN O
with NN NN O
the NN NN O
full-coding NN NN O
cDNA NN NN O
inserted NN NN O
in NN NN O
the NN NN O
expression NN NN O
vector NN NN O
produced NN NN O
a NN NN O
new NN NN O
80 NN NN O
kDa NN NN O
protein NN NN O
, NN NN O
as NN NN O
detected NN NN O
by NN NN O
Western NN NN O
blot NN NN O
. NN NN O

In NN NN O
an NN NN O
immunocytological NN NN O
study NN NN O
, NN NN O
the NN NN O
staining NN NN O
was NN NN O
in NN NN O
a NN NN O
punctate NN NN O
pattern NN NN O
, NN NN O
in NN NN O
the NN NN O
normal NN NN O
fibroblasts NN NN O
. NN NN O

However NN NN O
, NN NN O
there NN NN O
was NN NN O
no NN NN O
punctate NN NN O
staining NN NN O
in NN NN O
the NN NN O
# NN NN O
163 NN NN O
cells NN NN O
. NN NN O

These NN NN O
data NN NN O
thus NN NN O
indicate NN NN O
that NN NN O
the NN NN O
ALD NN NN B-Modifier
gene NN NN O
encodes NN NN O
an NN NN O
80 NN NN O
kDa NN NN O
membrane NN NN O
protein NN NN O
. NN NN O

. NN NN O

8004674 NN NN O
Isolation NN NN O
of NN NN O
the NN NN O
gene NN NN O
for NN NN O
McLeod NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
that NN NN O
encodes NN NN O
a NN NN O
novel NN NN O
membrane NN NN O
transport NN NN O
protein NN NN O
. NN NN O

McLeod NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
is NN NN O
an NN NN O
X-linked NN NN B-DiseaseClass
multisystem NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
characterized NN NN O
by NN NN O
abnormalities NN NN O
in NN NN O
the NN NN O
neuromuscular NN NN O
and NN NN O
hematopoietic NN NN O
systems NN NN O
. NN NN O

We NN NN O
have NN NN O
assembled NN NN O
a NN NN O
cosmid NN NN O
contig NN NN O
of NN NN O
360 NN NN O
kb NN NN O
that NN NN O
encompasses NN NN O
the NN NN O
McLeod NN NN B-Modifier
gene NN NN O
locus NN NN O
. NN NN O

A NN NN O
50 NN NN O
kb NN NN O
deletion NN NN O
was NN NN O
detected NN NN O
by NN NN O
screening NN NN O
DNA NN NN O
from NN NN O
patients NN NN O
with NN NN O
radiolabeled NN NN O
whole NN NN O
cosmids NN NN O
, NN NN O
and NN NN O
two NN NN O
transcription NN NN O
units NN NN O
were NN NN O
identified NN NN O
within NN NN O
this NN NN O
deletion NN NN O
. NN NN O

The NN NN O
mRNA NN NN O
expression NN NN O
pattern NN NN O
of NN NN O
one NN NN O
of NN NN O
them NN NN O
, NN NN O
designated NN NN O
as NN NN O
XK NN NN O
, NN NN O
correlates NN NN O
closely NN NN O
to NN NN O
the NN NN O
McLeod NN NN B-Modifier
phenotype NN NN O
. NN NN O

XK NN NN O
encodes NN NN O
a NN NN O
novel NN NN O
protein NN NN O
with NN NN O
structural NN NN O
characteristics NN NN O
of NN NN O
prokaryotic NN NN O
and NN NN O
eukaryotic NN NN O
membrane NN NN O
transport NN NN O
proteins NN NN O
. NN NN O

Nucleotide NN NN O
sequence NN NN O
analysis NN NN O
of NN NN O
XK NN NN O
from NN NN O
two NN NN O
unrelated NN NN O
McLeod NN NN B-Modifier
patients NN NN O
has NN NN O
identified NN NN O
point NN NN O
mutations NN NN O
at NN NN O
conserved NN NN O
splice NN NN O
donor NN NN O
and NN NN O
acceptor NN NN O
sites NN NN O
. NN NN O

These NN NN O
findings NN NN O
provide NN NN O
direct NN NN O
evidence NN NN O
that NN NN O
XK NN NN O
is NN NN O
responsible NN NN O
for NN NN O
McLeod NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

. NN NN O

8012387 NN NN O
X-linked NN NN B-SpecificDisease
spastic NN NN I-SpecificDisease
paraplegia NN NN I-SpecificDisease
and NN NN O
Pelizaeus-Merzbacher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
are NN NN O
allelic NN NN B-DiseaseClass
disorders NN NN I-DiseaseClass
at NN NN O
the NN NN O
proteolipid NN NN O
protein NN NN O
locus NN NN O
. NN NN O

Three NN NN O
forms NN NN O
of NN NN O
X-linked NN NN B-SpecificDisease
spastic NN NN I-SpecificDisease
paraplegia NN NN I-SpecificDisease
( NN NN O
SPG NN NN B-SpecificDisease
) NN NN O
have NN NN O
been NN NN O
defined NN NN O
. NN NN O

One NN NN O
locus NN NN O
( NN NN O
SPG NN NN O
1 NN NN O
) NN NN O
maps NN NN O
to NN NN O
Xq28 NN NN O
while NN NN O
two NN NN O
clinically NN NN O
distinct NN NN O
forms NN NN O
map NN NN O
to NN NN O
Xq22 NN NN O
( NN NN O
SPG2 NN NN O
) NN NN O
. NN NN O

A NN NN O
rare NN NN O
X-linked NN NN B-DiseaseClass
dysmyelinating NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
of NN NN O
the NN NN O
central NN NN O
nervous NN NN O
system NN NN O
, NN NN O
Pelizaeus-Merzbacher NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
PMD NN NN B-SpecificDisease
) NN NN O
, NN NN O
has NN NN O
also NN NN O
been NN NN O
mapped NN NN O
to NN NN O
Xq21-q22 NN NN O
, NN NN O
and NN NN O
is NN NN O
caused NN NN O
by NN NN O
mutations NN NN O
in NN NN O
the NN NN O
proteolipid NN NN O
protein NN NN O
gene NN NN O
( NN NN O
PLP NN NN O
) NN NN O
which NN NN O
encodes NN NN O
two NN NN O
myelin NN NN O
proteins NN NN O
, NN NN O
PLP NN NN O
and NN NN O
DM20 NN NN O
. NN NN O

While NN NN O
narrowing NN NN O
the NN NN O
genetic NN NN O
interval NN NN O
containing NN NN O
SPG2 NN NN O
in NN NN O
a NN NN O
large NN NN O
pedigree NN NN O
, NN NN O
we NN NN O
found NN NN O
that NN NN O
PLP NN NN O
was NN NN O
the NN NN O
closest NN NN O
marker NN NN O
to NN NN O
the NN NN O
disease NN NN O
locus NN NN O
, NN NN O
implicating NN NN O
PLP NN NN O
as NN NN O
a NN NN O
possible NN NN O
candidate NN NN O
gene NN NN O
. NN NN O

We NN NN O
have NN NN O
found NN NN O
that NN NN O
a NN NN O
point NN NN O
mutation NN NN O
( NN NN O
His139Tyr NN NN O
) NN NN O
in NN NN O
exon NN NN O
3B NN NN O
of NN NN O
an NN NN O
affected NN NN O
male NN NN O
produces NN NN O
a NN NN O
mutant NN NN O
PLP NN NN O
but NN NN O
a NN NN O
normal NN NN O
DM20 NN NN O
, NN NN O
and NN NN O
segregates NN NN O
with NN NN O
the NN NN O
disease NN NN O
( NN NN O
Zmax NN NN O
= NN NN O
6 NN NN O
. NN NN O

63 NN NN O
, NN NN O
theta NN NN O
= NN NN O
0 NN NN O
. NN NN O

00 NN NN O
) NN NN O
. NN NN O

It NN NN O
appears NN NN O
, NN NN O
therefore NN NN O
, NN NN O
that NN NN O
SPG2 NN NN O
and NN NN O
PMD NN NN B-SpecificDisease
are NN NN O
allelic NN NN B-DiseaseClass
disorders NN NN I-DiseaseClass

8023850 NN NN O
Canavan NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
: NN NN O
mutations NN NN O
among NN NN O
Jewish NN NN O
and NN NN O
non-Jewish NN NN O
patients NN NN O
. NN NN O

Canavan NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
leukodystrophy NN NN I-DiseaseClass
caused NN NN O
by NN NN O
the NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
aspartoacylase NN NN I-SpecificDisease
( NN NN O
ASPA NN NN O
) NN NN O
. NN NN O

Sixty-four NN NN O
probands NN NN O
were NN NN O
analyzed NN NN O
for NN NN O
mutations NN NN O
in NN NN O
the NN NN O
ASPA NN NN O
gene NN NN O
. NN NN O

Three NN NN O
point NN NN O
mutations NN NN O
-- NN NN O
693C NN NN O
-- NN NN O
A NN NN O
, NN NN O
854A NN NN O
-- NN NN O
C NN NN O
, NN NN O
and NN NN O
914C NN NN O
-- NN NN O
A NN NN O
-- NN NN O
were NN NN O
identified NN NN O
in NN NN O
the NN NN O
coding NN NN O
sequence NN NN O
. NN NN O

The NN NN O
693C NN NN O
-- NN NN O
A NN NN O
and NN NN O
914C NN NN O
-- NN NN O
A NN NN O
base NN NN O
changes NN NN O
, NN NN O
resulting NN NN O
in NN NN O
nonsense NN NN O
tyr231 NN NN O
-- NN NN O
ter NN NN O
and NN NN O
missense NN NN O
ala305 NN NN O
-- NN NN O
glu NN NN O
mutations NN NN O
, NN NN O
respectively NN NN O
, NN NN O
lead NN NN O
to NN NN O
complete NN NN O
loss NN NN O
of NN NN O
ASPA NN NN O
activity NN NN O
in NN NN O
in NN NN O
vitro NN NN O
expression NN NN O
studies NN NN O
. NN NN O

The NN NN O
854A NN NN O
-- NN NN O
C NN NN O
transversion NN NN O
converted NN NN O
glu NN NN O
to NN NN O
ala NN NN O
in NN NN O
codon NN NN O
285 NN NN O
. NN NN O

The NN NN O
glu285 NN NN O
-- NN NN O
ala NN NN O
mutant NN NN O
ASPA NN NN O
has NN NN O
2 NN NN O
. NN NN O

5 NN NN O
% NN NN O
of NN NN O
the NN NN O
activity NN NN O
expressed NN NN O
by NN NN O
the NN NN O
wild-type NN NN O
enzyme NN NN O
. NN NN O

A NN NN O
fourth NN NN O
mutation NN NN O
, NN NN O
433 NN NN O
-- NN NN O
2 NN NN O
( NN NN O
A NN NN O
-- NN NN O
G NN NN O
) NN NN O
transition NN NN O
, NN NN O
was NN NN O
identified NN NN O
at NN NN O
the NN NN O
splice-acceptor NN NN O
site NN NN O
in NN NN O
intron NN NN O
2 NN NN O
. NN NN O

The NN NN O
splice-site NN NN O
mutation NN NN O
would NN NN O
lead NN NN O
to NN NN O
skipping NN NN O
of NN NN O
exon NN NN O
3 NN NN O
, NN NN O
accompanied NN NN O
by NN NN O
a NN NN O
frameshift NN NN O
, NN NN O
and NN NN O
thus NN NN O
would NN NN O
produce NN NN O
aberrant NN NN O
ASPA NN NN O
. NN NN O

Of NN NN O
the NN NN O
128 NN NN O
unrelated NN NN O
Canavan NN NN B-Modifier
chromosomes NN NN O
analyzed NN NN O
, NN NN O
88 NN NN O
were NN NN O
from NN NN O
probands NN NN O
of NN NN O
Ashkenazi NN NN O
Jewish NN NN O
descent NN NN O
. NN NN O

The NN NN O
glu285 NN NN O
-- NN NN O
ala NN NN O
mutation NN NN O
was NN NN O
predominant NN NN O
( NN NN O
82 NN NN O
. NN NN O

9 NN NN O
% NN NN O
) NN NN O
in NN NN O
this NN NN O
population NN NN O
, NN NN O
followed NN NN O
by NN NN O
the NN NN O
tyr231 NN NN O
-- NN NN O
ter NN NN O
( NN NN O
14 NN NN O
. NN NN O

8 NN NN O
% NN NN O
) NN NN O
and NN NN O
433 NN NN O
-- NN NN O
2 NN NN O
( NN NN O
A NN NN O
-- NN NN O
G NN NN O
) NN NN O
( NN NN O
1 NN NN O
. NN NN O

1 NN NN O
% NN NN O
) NN NN O
mutations NN NN O
. NN NN O

The NN NN O
three NN NN O
mutations NN NN O
account NN NN O
for NN NN O
98 NN NN O
. NN NN O

8 NN NN O
% NN NN O
of NN NN O
the NN NN O
Canavan NN NN B-Modifier
chromosomes NN NN O
of NN NN O
Ashkenazi NN NN O
Jewish NN NN O
origin NN NN O
. NN NN O

The NN NN O
ala305 NN NN O
-- NN NN O
glu NN NN O
mutation NN NN O
was NN NN O
found NN NN O
exclusively NN NN O
in NN NN O
non-Jewish NN NN O
probands NN NN O
of NN NN O
European NN NN O
descent NN NN O
and NN NN O
constituted NN NN O
60 NN NN O
% NN NN O
of NN NN O
the NN NN O
40 NN NN O
mutant NN NN O
chromosomes NN NN O
. NN NN O

Predominant NN NN O
occurrence NN NN O
of NN NN O
certain NN NN O
mutations NN NN O
among NN NN O
Ashkenazi NN NN O
Jewish NN NN O
and NN NN O
non-Jewish NN NN O
patients NN NN O
with NN NN O
Canavan NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
would NN NN O
suggest NN NN O
a NN NN O
founding-father NN NN O
effect NN NN O
in NN NN O
propagation NN NN O
of NN NN O
these NN NN O
mutant NN NN O
chromosomes NN NN O

8071955 NN NN O
Intelligence NN NN O
quotient NN NN O
profile NN NN O
in NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
, NN NN O
intergenerational NN NN O
deficit NN NN O
, NN NN O
and NN NN O
correlation NN NN O
with NN NN O
CTG NN NN O
amplification NN NN O
. NN NN O

An NN NN O
abbreviated NN NN O
Wechsler NN NN O
Adult NN NN O
Intelligence NN NN O
Scale NN NN O
Revised NN NN O
( NN NN O
WAIS-R NN NN O
) NN NN O
was NN NN O
used NN NN O
to NN NN O
assess NN NN O
verbal NN NN O
and NN NN O
arithmetical NN NN O
cognitive NN NN O
performance NN NN O
in NN NN O
55 NN NN O
subjects NN NN O
with NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
, NN NN O
covering NN NN O
all NN NN O
grades NN NN O
of NN NN O
disease NN NN O
severity NN NN O
, NN NN O
and NN NN O
31 NN NN O
controls NN NN O
at NN NN O
50 NN NN O
% NN NN O
risk NN NN O
of NN NN O
inheriting NN NN O
DM NN NN B-SpecificDisease
. NN NN O

Scaled NN NN O
scores NN NN O
from NN NN O
the NN NN O
assessment NN NN O
were NN NN O
converted NN NN O
into NN NN O
an NN NN O
intelligence NN NN O
quotient NN NN O
( NN NN O
IQ NN NN O
) NN NN O
estimation NN NN O
on NN NN O
each NN NN O
person NN NN O
. NN NN O

Significant NN NN O
IQ NN NN O
differences NN NN O
were NN NN O
found NN NN O
between NN NN O
( NN NN O
1 NN NN O
) NN NN O
all NN NN O
55 NN NN O
DM NN NN B-Modifier
subjects NN NN O
( NN NN O
mean NN NN O
90 NN NN O
. NN NN O

2 NN NN O
, NN NN O
SD NN NN O
16 NN NN O
. NN NN O

1 NN NN O
) NN NN O
and NN NN O
31 NN NN O
controls NN NN O
( NN NN O
102 NN NN O
. NN NN O

6 NN NN O
, NN NN O
SD NN NN O
9 NN NN O
. NN NN O

4 NN NN O
) NN NN O
, NN NN O
with NN NN O
no NN NN O
sex NN NN O
differences NN NN O
in NN NN O
either NN NN O
group NN NN O
; NN NN O
( NN NN O
2 NN NN O
) NN NN O
15 NN NN O
affected NN NN O
parents NN NN O
( NN NN O
99 NN NN O
. NN NN O

3 NN NN O
, NN NN O
SD NN NN O
12 NN NN O
. NN NN O

2 NN NN O
) NN NN O
and NN NN O
their NN NN O
affected NN NN O
children NN NN O
( NN NN O
88 NN NN O
. NN NN O

1 NN NN O
, NN NN O
SD NN NN O
17 NN NN O
. NN NN O

2 NN NN O
) NN NN O
, NN NN O
where NN NN O
significance NN NN O
was NN NN O
dependent NN NN O
on NN NN O
parental NN NN O
sex NN NN O
being NN NN O
female NN NN O
; NN NN O
and NN NN O
( NN NN O
3 NN NN O
) NN NN O
15 NN NN O
pairs NN NN O
of NN NN O
affected NN NN O
sibs NN NN O
( NN NN O
89 NN NN O
. NN NN O

6 NN NN O
, NN NN O
SD NN NN O
13 NN NN O
. NN NN O

2 NN NN O
) NN NN O
and NN NN O
their NN NN O
normal NN NN O
sibs NN NN O
( NN NN O
100 NN NN O
. NN NN O

2 NN NN O
, NN NN O
SD NN NN O
7 NN NN O
. NN NN O

6 NN NN O
) NN NN O
. NN NN O

IQ NN NN O
steadily NN NN O
declined NN NN O
as NN NN O
( NN NN O
1 NN NN O
) NN NN O
the NN NN O
age NN NN O
of NN NN O
onset NN NN O
of NN NN O
signs NN NN O
and NN NN O
symptoms NN NN O
decreased NN NN O
, NN NN O
and NN NN O
( NN NN O
2 NN NN O
) NN NN O
the NN NN O
CTG NN NN O
expansion NN NN O
size NN NN O
increased NN NN O
. NN NN O

The NN NN O
correlation NN NN O
appeared NN NN O
to NN NN O
be NN NN O
more NN NN O
linear NN NN O
with NN NN O
age NN NN O
of NN NN O
onset NN NN O
. NN NN O

The NN NN O
correlation NN NN O
of NN NN O
IQ NN NN O
difference NN NN O
and NN NN O
CTG NN NN O
expansion NN NN O
difference NN NN O
in NN NN O
both NN NN O
the NN NN O
DM NN NN B-Modifier
parent-child NN NN O
pairs NN NN O
and NN NN O
normal NN NN O
sib-affected NN NN O
sib NN NN O
pairs NN NN O
was NN NN O
poor NN NN O
, NN NN O
indicating NN NN O
that NN NN O
CTG NN NN O
expansion NN NN O
is NN NN O
not NN NN O
a NN NN O
reliable NN NN O
predictor NN NN O
of NN NN O
IQ NN NN O
either NN NN O
in NN NN O
individual NN NN O
persons NN NN O
or NN NN O
families NN NN O
. NN NN O

Further NN NN O
analysis NN NN O
of NN NN O
cognitive NN NN O
function NN NN O
in NN NN O
DM NN NN B-SpecificDisease
is NN NN O
required NN NN O
to NN NN O
clarify NN NN O
specific NN NN O
deficits NN NN O
characteristic NN NN O
of NN NN O
this NN NN O
patient NN NN O
group NN NN O

8071957 NN NN O
Adenomatous NN NN B-SpecificDisease
polyposis NN NN I-SpecificDisease
coli NN NN I-SpecificDisease
and NN NN O
a NN NN O
cytogenetic NN NN O
deletion NN NN O
of NN NN O
chromosome NN NN O
5 NN NN O
resulting NN NN O
from NN NN O
a NN NN O
maternal NN NN O
intrachromosomal NN NN O
insertion NN NN O
. NN NN O

We NN NN O
present NN NN O
the NN NN O
clinical NN NN O
and NN NN O
laboratory NN NN O
findings NN NN O
in NN NN O
an NN NN O
institutionalised NN NN O
adult NN NN O
patient NN NN O
originally NN NN O
referred NN NN O
for NN NN O
autism NN NN B-SpecificDisease
. NN NN O

A NN NN O
high NN NN O
risk NN NN O
of NN NN O
colorectal NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
was NN NN O
predicted NN NN O
when NN NN O
an NN NN O
interstitial NN NN O
deletion NN NN O
of NN NN O
the NN NN O
long NN NN O
arm NN NN O
of NN NN O
chromosome NN NN O
5 NN NN O
, NN NN O
del NN NN O
( NN NN O
5 NN NN O
) NN NN O
( NN NN O
q15q22 NN NN O
. NN NN O

3 NN NN O
) NN NN O
, NN NN O
was NN NN O
detected NN NN O
in NN NN O
her NN NN O
lymphocytes NN NN O
and NN NN O
deletion NN NN O
of NN NN O
the NN NN O
MCC NN NN O
and NN NN O
APC NN NN B-Modifier
genes NN NN O
confirmed NN NN O
by NN NN O
molecular NN NN O
analysis NN NN O
. NN NN O

Adenomatous NN NN B-SpecificDisease
polyposis NN NN I-SpecificDisease
coli NN NN I-SpecificDisease
and NN NN O
carcinoma NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
rectum NN NN I-SpecificDisease
were NN NN O
subsequently NN NN O
diagnosed NN NN O
in NN NN O
the NN NN O
patient NN NN O
. NN NN O

She NN NN O
was NN NN O
profoundly NN NN O
mentally NN NN B-Modifier
retarded NN NN I-Modifier
, NN NN O
autistic NN NN B-Modifier
, NN NN O
and NN NN O
had NN NN O
minor NN NN O
dysmorphic NN NN B-SpecificDisease
features NN NN I-SpecificDisease
consistent NN NN O
with NN NN O
those NN NN O
of NN NN O
previous NN NN O
patients NN NN O
with NN NN O
similar NN NN O
deletions NN NN O
. NN NN O

The NN NN O
deletion NN NN O
arose NN NN O
as NN NN O
a NN NN O
result NN NN O
of NN NN O
recombination NN NN O
within NN NN O
the NN NN O
small NN NN O
insertion NN NN O
loop NN NN O
formed NN NN O
at NN NN O
meiosis NN NN O
by NN NN O
the NN NN O
direct NN NN O
insertion NN NN O
( NN NN O
dir NN NN O
ins NN NN O
( NN NN O
5 NN NN O
) NN NN O
( NN NN O
q22 NN NN O
. NN NN O

3q14 NN NN O
. NN NN O

2q15 NN NN O
) NN NN O
) NN NN O
found NN NN O
in NN NN O
the NN NN O
patients NN NN O
mother NN NN O
. NN NN O

This NN NN O
family NN NN O
further NN NN O
confirms NN NN O
the NN NN O
cytogenetic NN NN O
mapping NN NN O
of NN NN O
both NN NN O
MCC NN NN O
and NN NN O
APC NN NN B-Modifier
genes NN NN O
to NN NN O
5q22 NN NN O
and NN NN O
comparison NN NN O
with NN NN O
other NN NN O
recent NN NN O
cases NN NN O
suggests NN NN O
that NN NN O
both NN NN O
genes NN NN O
and NN NN O
their NN NN O
closely NN NN O
linked NN NN O
markers NN NN O
lie NN NN O
within NN NN O
the NN NN O
5q22 NN NN O
. NN NN O

1 NN NN O
subband NN NN O

8075631 NN NN O
Familial NN NN B-SpecificDisease
male NN NN I-SpecificDisease
breast NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
is NN NN O
not NN NN O
linked NN NN O
to NN NN O
the NN NN O
BRCA1 NN NN O
locus NN NN O
on NN NN O
chromosome NN NN O
17q NN NN O
. NN NN O

Breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
in NN NN O
men NN NN O
is NN NN O
about NN NN O
a NN NN O
hundredfold NN NN O
less NN NN O
common NN NN O
than NN NN O
in NN NN O
women NN NN O
and NN NN O
this NN NN O
has NN NN O
hindered NN NN O
research NN NN O
into NN NN O
its NN NN O
genetic NN NN O
basis NN NN O
. NN NN O

We NN NN O
have NN NN O
examined NN NN O
22 NN NN O
families NN NN O
with NN NN O
at NN NN O
least NN NN O
one NN NN O
case NN NN O
of NN NN O
male NN NN B-SpecificDisease
breast NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
for NN NN O
linkage NN NN O
to NN NN O
the NN NN O
hereditary NN NN B-Modifier
breast NN NN I-Modifier
and NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
locus NN NN O
, NN NN O
BRCA1 NN NN O
, NN NN O
on NN NN O
chromosome NN NN O
17q NN NN O
. NN NN O

We NN NN O
found NN NN O
strong NN NN O
evidence NN NN O
against NN NN O
linkage NN NN O
to NN NN O
BRCA1 NN NN O
( NN NN O
lod NN NN O
score-16 NN NN O
. NN NN O

63 NN NN O
) NN NN O
and NN NN O
the NN NN O
best NN NN O
estimate NN NN O
of NN NN O
the NN NN O
proportion NN NN O
of NN NN O
linked NN NN O
families NN NN O
was NN NN O
0 NN NN O
% NN NN O
( NN NN O
95 NN NN O
% NN NN O
CI NN NN O
0-18 NN NN O
% NN NN O
) NN NN O
. NN NN O

Our NN NN O
results NN NN O
indicate NN NN O
that NN NN O
there NN NN O
is NN NN O
a NN NN O
gene NN NN O
( NN NN O
s NN NN O
) NN NN O
other NN NN O
than NN NN O
BRCA1 NN NN O
which NN NN O
predisposes NN NN O
to NN NN O
early-onset NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
in NN NN O
women NN NN O
and NN NN O
which NN NN O
confers NN NN O
a NN NN O
higher NN NN O
risk NN NN O
of NN NN O
male NN NN B-SpecificDisease
breast NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

Identification NN NN O
of NN NN O
additional NN NN O
pedigrees NN NN O
that NN NN O
include NN NN O
cases NN NN O
of NN NN O
male NN NN B-SpecificDisease
breast NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
may NN NN O
therefore NN NN O
facilitate NN NN O
the NN NN O
mapping NN NN O
and NN NN O
isolation NN NN O
of NN NN O
this NN NN O
gene NN NN O
. NN NN O

8084618 NN NN O
The NN NN O
EWS NN NN O
gene NN NN O
, NN NN O
involved NN NN O
in NN NN O
Ewing NN NN B-DiseaseClass
family NN NN I-DiseaseClass
of NN NN I-DiseaseClass
tumors NN NN I-DiseaseClass
, NN NN O
malignant NN NN B-DiseaseClass
melanoma NN NN I-DiseaseClass
of NN NN I-DiseaseClass
soft NN NN I-DiseaseClass
parts NN NN I-DiseaseClass
and NN NN O
desmoplastic NN NN B-SpecificDisease
small NN NN I-SpecificDisease
round NN NN I-SpecificDisease
cell NN NN I-SpecificDisease
tumors NN NN I-SpecificDisease
, NN NN O
codes NN NN O
for NN NN O
an NN NN O
RNA NN NN O
binding NN NN O
protein NN NN O
with NN NN O
novel NN NN O
regulatory NN NN O
domains NN NN O
. NN NN O

The NN NN O
EWS NN NN O
gene NN NN O
, NN NN O
which NN NN O
maps NN NN O
to NN NN O
band NN NN O
q12 NN NN O
of NN NN O
human NN NN O
chromosome NN NN O
22 NN NN O
, NN NN O
is NN NN O
involved NN NN O
in NN NN O
a NN NN O
wide NN NN O
variety NN NN O
of NN NN O
human NN NN O
solid NN NN B-DiseaseClass
tumors NN NN I-DiseaseClass
including NN NN O
Ewing NN NN B-SpecificDisease
sarcoma NN NN I-SpecificDisease
, NN NN O
related NN NN O
primitive NN NN O
neuroectodermal NN NN B-DiseaseClass
tumors NN NN I-DiseaseClass
, NN NN O
malignant NN NN B-DiseaseClass
melanoma NN NN I-DiseaseClass
of NN NN I-DiseaseClass
soft NN NN I-DiseaseClass
parts NN NN I-DiseaseClass
and NN NN O
desmoplastic NN NN B-DiseaseClass
small NN NN I-DiseaseClass
round NN NN I-DiseaseClass
cell NN NN I-DiseaseClass
tumors NN NN I-DiseaseClass
. NN NN O

In NN NN O
these NN NN O
tumors NN NN B-DiseaseClass
, NN NN O
the NN NN O
EWS NN NN O
is NN NN O
fused NN NN O
to NN NN O
genes NN NN O
encoding NN NN O
transcriptional NN NN O
activators NN NN O
/ NN NN O
repressors NN NN O
, NN NN O
like NN NN O
Fli-1 NN NN O
or NN NN O
erg NN NN O
or NN NN O
ATF NN NN O
1 NN NN O
or NN NN O
wt1 NN NN O
. NN NN O

To NN NN O
better NN NN O
understand NN NN O
the NN NN O
function NN NN O
of NN NN O
the NN NN O
EWS NN NN O
protein NN NN O
, NN NN O
we NN NN O
cloned NN NN O
the NN NN O
EWS NN NN O
cDNA NN NN O
. NN NN O

Sequence NN NN O
analysis NN NN O
of NN NN O
this NN NN O
cDNA NN NN O
revealed NN NN O
differential NN NN O
splicing NN NN O
involving NN NN O
two NN NN O
exons NN NN O
encoding NN NN O
72 NN NN O
amino NN NN O
acids NN NN O
. NN NN O

Both NN NN O
alternatively NN NN O
spliced NN NN O
transcripts NN NN O
, NN NN O
EWS NN NN O
and NN NN O
EWS-b NN NN O
, NN NN O
are NN NN O
expressed NN NN O
in NN NN O
a NN NN O
variety NN NN O
of NN NN O
cells NN NN O
. NN NN O

Because NN NN O
EWS NN NN O
proteins NN NN O
contain NN NN O
putative NN NN O
conserved NN NN O
RNA NN NN O
binding NN NN O
motifs NN NN O
, NN NN O
we NN NN O
studied NN NN O
the NN NN O
RNA NN NN O
binding NN NN O
properties NN NN O
of NN NN O
the NN NN O
EWS NN NN O
protein NN NN O
. NN NN O

The NN NN O
EWS-b NN NN O
protein NN NN O
binds NN NN O
to NN NN O
RNA NN NN O
in NN NN O
vitro NN NN O
and NN NN O
, NN NN O
specifically NN NN O
, NN NN O
to NN NN O
poly NN NN O
G NN NN O
and NN NN O
poly NN NN O
U NN NN O
. NN NN O

The NN NN O
RNA NN NN O
binding NN NN O
activity NN NN O
was NN NN O
localized NN NN O
to NN NN O
the NN NN O
carboxy NN NN O
terminal NN NN O
86 NN NN O
amino NN NN O
acids NN NN O
, NN NN O
which NN NN O
constitute NN NN O
RGG NN NN O
box NN NN O
. NN NN O

Thus NN NN O
the NN NN O
amino NN NN O
terminal NN NN O
domain NN NN O
of NN NN O
EWS NN NN O
( NN NN O
NTD-EWS NN NN O
) NN NN O
, NN NN O
which NN NN O
is NN NN O
involved NN NN O
in NN NN O
chromosome NN NN O
translocation NN NN O
may NN NN O
regulate NN NN O
the NN NN O
specificity NN NN O
of NN NN O
RNA NN NN O
binding NN NN O
activity NN NN O
of NN NN O
EWS NN NN O
. NN NN O

An NN NN O
EWS-erg NN NN O
chimeric NN NN O
protein NN NN O
, NN NN O
which NN NN O
is NN NN O
found NN NN O
in NN NN O
Ewings NN NN B-Modifier
sarcoma NN NN I-Modifier
cells NN NN O
, NN NN O
functions NN NN O
as NN NN O
a NN NN O
transcriptional NN NN O
activator NN NN O
. NN NN O

Mutational NN NN O
analysis NN NN O
of NN NN O
EWS-erg NN NN O
chimeric NN NN O
protein NN NN O
revealed NN NN O
that NN NN O
NTD-EWS NN NN O
functions NN NN O
as NN NN O
a NN NN O
regulatory NN NN O
domain NN NN O
for NN NN O
the NN NN O
transcriptional NN NN O
activation NN NN O
properties NN NN O
of NN NN O
EWS-erg NN NN O
chimeric NN NN O
protein NN NN O
. NN NN O

. NN NN O

8088831 NN NN O
Canavan NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
: NN NN O
genomic NN NN O
organization NN NN O
and NN NN O
localization NN NN O
of NN NN O
human NN NN O
ASPA NN NN O
to NN NN O
17p13-ter NN NN O
and NN NN O
conservation NN NN O
of NN NN O
the NN NN O
ASPA NN NN O
gene NN NN O
during NN NN O
evolution NN NN O
. NN NN O

Canavan NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
, NN NN O
or NN NN O
spongy NN NN B-SpecificDisease
degeneration NN NN I-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
brain NN NN I-SpecificDisease
, NN NN O
is NN NN O
a NN NN O
severe NN NN O
leukodystrophy NN NN B-SpecificDisease
caused NN NN O
by NN NN O
the NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
aspartoacylase NN NN I-SpecificDisease
( NN NN O
ASPA NN NN O
) NN NN O
. NN NN O

Recently NN NN O
, NN NN O
a NN NN O
missense NN NN O
mutation NN NN O
was NN NN O
identified NN NN O
in NN NN O
human NN NN O
ASPA NN NN O
coding NN NN O
sequence NN NN O
from NN NN O
patients NN NN O
with NN NN O
Canavan NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

The NN NN O
human NN NN O
ASPA NN NN O
gene NN NN O
has NN NN O
been NN NN O
cloned NN NN O
and NN NN O
found NN NN O
to NN NN O
span NN NN O
29 NN NN O
kb NN NN O
of NN NN O
the NN NN O
genome NN NN O
. NN NN O

Human NN NN O
aspartoacylase NN NN O
is NN NN O
coded NN NN O
by NN NN O
six NN NN O
exons NN NN O
intervened NN NN O
by NN NN O
five NN NN O
introns NN NN O
. NN NN O

The NN NN O
exons NN NN O
vary NN NN O
from NN NN O
94 NN NN O
( NN NN O
exon NN NN O
III NN NN O
) NN NN O
to NN NN O
514 NN NN O
( NN NN O
exon NN NN O
VI NN NN O
) NN NN O
bases NN NN O
. NN NN O

The NN NN O
exon NN NN O
/ NN NN O
intron NN NN O
splice NN NN O
junction NN NN O
sites NN NN O
follow NN NN O
the NN NN O
gt NN NN O
/ NN NN O
ag NN NN O
consensus NN NN O
sequence NN NN O
rule NN NN O
. NN NN O

Southern NN NN O
blot NN NN O
analysis NN NN O
of NN NN O
genomic NN NN O
DNA NN NN O
from NN NN O
human NN NN O
/ NN NN O
mouse NN NN O
somatic NN NN O
cell NN NN O
hybrid NN NN O
cell NN NN O
lines NN NN O
localized NN NN O
ASPA NN NN O
to NN NN O
human NN NN O
chromosome NN NN O
17 NN NN O
. NN NN O

The NN NN O
human NN NN O
ASPA NN NN O
locus NN NN O
was NN NN O
further NN NN O
mapped NN NN O
in NN NN O
the NN NN O
17p13-ter NN NN O
region NN NN O
by NN NN O
fluorescence NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
. NN NN O

The NN NN O
bovine NN NN O
aspa NN NN O
gene NN NN O
has NN NN O
also NN NN O
been NN NN O
cloned NN NN O
, NN NN O
and NN NN O
its NN NN O
exon NN NN O
/ NN NN O
intron NN NN O
organization NN NN O
is NN NN O
identical NN NN O
to NN NN O
that NN NN O
of NN NN O
the NN NN O
human NN NN O
gene NN NN O
. NN NN O

The NN NN O
500-base NN NN O
sequence NN NN O
upstream NN NN O
of NN NN O
the NN NN O
initiator NN NN O
ATG NN NN O
codon NN NN O
in NN NN O
the NN NN O
human NN NN O
gene NN NN O
and NN NN O
that NN NN O
in NN NN O
the NN NN O
bovine NN NN O
gene NN NN O
are NN NN O
77 NN NN O
% NN NN O
identical NN NN O
. NN NN O

Human NN NN O
ASPA NN NN O
coding NN NN O
sequences NN NN O
cross-hybridize NN NN O
with NN NN O
genomic NN NN O
DNA NN NN O
from NN NN O
yeast NN NN O
, NN NN O
chicken NN NN O
, NN NN O
rabbit NN NN O
, NN NN O
cow NN NN O
, NN NN O
dog NN NN O
, NN NN O
mouse NN NN O
, NN NN O
rat NN NN O
, NN NN O
and NN NN O
monkey NN NN O
. NN NN O

The NN NN O
specificity NN NN O
of NN NN O
cross-species NN NN O
hybridization NN NN O
of NN NN O
coding NN NN O
sequences NN NN O
suggests NN NN O
that NN NN O
aspartoacylase NN NN O
has NN NN O
been NN NN O
conserved NN NN O
during NN NN O
evolution NN NN O
. NN NN O

It NN NN O
should NN NN O
now NN NN O
be NN NN O
possible NN NN O
to NN NN O
identify NN NN O
mutations NN NN O
in NN NN O
the NN NN O
noncoding NN NN O
genomic NN NN O
sequences NN NN O
that NN NN O
lead NN NN O
to NN NN O
Canavan NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
and NN NN O
to NN NN O
study NN NN O
the NN NN O
regulation NN NN O
of NN NN O
ASPA NN NN O
. NN NN O

. NN NN O

8098180 NN NN O
Myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
: NN NN O
size- NN NN O
and NN NN O
sex-dependent NN NN O
dynamics NN NN O
of NN NN O
CTG NN NN O
meiotic NN NN O
instability NN NN O
, NN NN O
and NN NN O
somatic NN NN O
mosaicism NN NN O
. NN NN O

Myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
is NN NN O
a NN NN O
progressive NN NN O
neuromuscular NN NN B-DiseaseClass
disorder NN NN I-DiseaseClass
which NN NN O
results NN NN O
from NN NN O
elongations NN NN O
of NN NN O
an NN NN O
unstable NN NN O
( NN NN O
CTG NN NN O
) NN NN O
n NN NN O
repeat NN NN O
, NN NN O
located NN NN O
in NN NN O
the NN NN O
3 NN NN O
untranslated NN NN O
region NN NN O
of NN NN O
the NN NN O
DM NN NN B-Modifier
gene NN NN O
. NN NN O

A NN NN O
correlation NN NN O
has NN NN O
been NN NN O
demonstrated NN NN O
between NN NN O
the NN NN O
increase NN NN O
in NN NN O
the NN NN O
repeat NN NN O
number NN NN O
of NN NN O
this NN NN O
sequence NN NN O
and NN NN O
the NN NN O
severity NN NN O
of NN NN O
the NN NN O
disease NN NN O
. NN NN O

However NN NN O
, NN NN O
the NN NN O
clinical NN NN O
status NN NN O
of NN NN O
patients NN NN O
can NN NN O
not NN NN O
be NN NN O
unambiguously NN NN O
ascertained NN NN O
solely NN NN O
on NN NN O
the NN NN O
basis NN NN O
of NN NN O
the NN NN O
number NN NN O
of NN NN O
CTG NN NN O
repeats NN NN O
. NN NN O

Moreover NN NN O
, NN NN O
the NN NN O
exclusive NN NN O
maternal NN NN O
inheritance NN NN O
of NN NN O
the NN NN O
congenital NN NN O
form NN NN O
remains NN NN O
unexplained NN NN O
. NN NN O

Our NN NN O
observation NN NN O
of NN NN O
differently NN NN O
sized NN NN O
repeats NN NN O
in NN NN O
various NN NN O
DM NN NN B-Modifier
tissues NN NN O
from NN NN O
the NN NN O
same NN NN O
individual NN NN O
may NN NN O
explain NN NN O
why NN NN O
the NN NN O
size NN NN O
of NN NN O
the NN NN O
mutation NN NN O
observed NN NN O
in NN NN O
lymphocytes NN NN O
does NN NN O
not NN NN O
necessarily NN NN O
correlate NN NN O
with NN NN O
the NN NN O
severity NN NN O
and NN NN O
nature NN NN O
of NN NN O
symptoms NN NN O
. NN NN O

Through NN NN O
a NN NN O
molecular NN NN O
and NN NN O
genetic NN NN O
study NN NN O
of NN NN O
142 NN NN O
families NN NN O
including NN NN O
418 NN NN O
DM NN NN B-Modifier
patients NN NN O
, NN NN O
we NN NN O
have NN NN O
investigated NN NN O
the NN NN O
dynamics NN NN O
of NN NN O
the NN NN O
CTG NN NN O
repeat NN NN O
meiotic NN NN O
instability NN NN O
. NN NN O

A NN NN O
positive NN NN O
correlation NN NN O
between NN NN O
the NN NN O
size NN NN O
of NN NN O
the NN NN O
repeat NN NN O
and NN NN O
the NN NN O
intergenerational NN NN O
enlargement NN NN O
was NN NN O
observed NN NN O
similarly NN NN O
through NN NN O
male NN NN O
and NN NN O
female NN NN O
meioses NN NN O
for NN NN O
or NN NN O
= NN NN O
0 NN NN O
. NN NN O

5-kb NN NN O
CTG NN NN O
sequences NN NN O
. NN NN O

Beyond NN NN O
0 NN NN O
. NN NN O

5 NN NN O
kb NN NN O
, NN NN O
the NN NN O
intergenerational NN NN O
variation NN NN O
was NN NN O
more NN NN O
important NN NN O
through NN NN O
female NN NN O
meioses NN NN O
, NN NN O
whereas NN NN O
a NN NN O
tendency NN NN O
to NN NN O
compression NN NN O
was NN NN O
observed NN NN O
almost NN NN O
exclusively NN NN O
in NN NN O
male NN NN O
meioses NN NN O
, NN NN O
for NN NN O
or NN NN O
= NN NN O
1 NN NN O
. NN NN O

5-kb NN NN O
fragments NN NN O
. NN NN O

This NN NN O
implies NN NN O
a NN NN O
size- NN NN O
and NN NN O
sex-dependent NN NN O
meiotic NN NN O
instability NN NN O
. NN NN O

Moreover NN NN O
, NN NN O
segregation NN NN O
analysis NN NN O
supports NN NN O
the NN NN O
hypothesis NN NN O
of NN NN O
a NN NN O
maternal NN NN O
as NN NN O
well NN NN O
as NN NN O
a NN NN O
familial NN NN O
predisposition NN NN O
for NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
the NN NN O
congenital NN NN O
form NN NN O
. NN NN O

Finally NN NN O
, NN NN O
this NN NN O
analysis NN NN O
reveals NN NN O
a NN NN O
significant NN NN O
excess NN NN O
of NN NN O
transmitting NN NN O
grandfathers NN NN O
partially NN NN O
accounted NN NN O
for NN NN O
by NN NN O
increased NN NN O
fertility NN NN O
in NN NN O
affected NN NN O
males NN NN O

8098245 NN NN O
Illegitimate NN NN O
transcription NN NN O
of NN NN O
the NN NN O
phenylalanine NN NN O
hydroxylase NN NN O
gene NN NN O
in NN NN O
lymphocytes NN NN O
for NN NN O
identification NN NN O
of NN NN O
mutations NN NN O
in NN NN O
phenylketonuria NN NN B-SpecificDisease
. NN NN O

Taking NN NN O
advantage NN NN O
of NN NN O
the NN NN O
illegitimate NN NN O
transcription NN NN O
of NN NN O
the NN NN O
phenylalanine NN NN O
hydroxylase NN NN O
( NN NN O
PAH NN NN O
) NN NN O
gene NN NN O
, NN NN O
we NN NN O
have NN NN O
been NN NN O
able NN NN O
to NN NN O
analyse NN NN O
the NN NN O
PAH NN NN O
cDNA NN NN O
sequence NN NN O
of NN NN O
hyperphenylalaninemic NN NN B-Modifier
children NN NN O
in NN NN O
circulating NN NN O
lymphocytes NN NN O
. NN NN O

Using NN NN O
this NN NN O
approach NN NN O
, NN NN O
we NN NN O
have NN NN O
also NN NN O
identified NN NN O
3 NN NN O
novel NN NN O
mutations NN NN O
in NN NN O
cDNA NN NN O
from NN NN O
liver NN NN O
and NN NN O
lymphocytes NN NN O
of NN NN O
two NN NN O
patients NN NN O
. NN NN O

One NN NN O
mutation NN NN O
, NN NN O
detected NN NN O
by NN NN O
the NN NN O
abnormal NN NN O
pattern NN NN O
of NN NN O
migration NN NN O
of NN NN O
an NN NN O
amplified NN NN O
fragment NN NN O
, NN NN O
is NN NN O
a NN NN O
C NN NN O
to NN NN O
T NN NN O
transition NN NN O
in NN NN O
the NN NN O
splice NN NN O
acceptor NN NN O
site NN NN O
of NN NN O
intron NN NN O
10 NN NN O
, NN NN O
which NN NN O
resulted NN NN O
in NN NN O
the NN NN O
skipping NN NN O
of NN NN O
exon NN NN O
11 NN NN O
with NN NN O
the NN NN O
premature NN NN O
termination NN NN O
of NN NN O
RNA NN NN O
translation NN NN O
downstream NN NN O
from NN NN O
exon NN NN O
12 NN NN O
( NN NN O
-3 NN NN O
IVS10 NN NN O
) NN NN O
. NN NN O

The NN NN O
other NN NN O
two NN NN O
mutations NN NN O
are NN NN O
missense NN NN O
mutations NN NN O
in NN NN O
exons NN NN O
10 NN NN O
and NN NN O
11 NN NN O
( NN NN O
respectively NN NN O
, NN NN O
L333F NN NN O
and NN NN O
E390G NN NN O
) NN NN O
. NN NN O

The NN NN O
present NN NN O
study NN NN O
supports NN NN O
the NN NN O
view NN NN O
that NN NN O
circulating NN NN O
lymphocytes NN NN O
give NN NN O
easy NN NN O
access NN NN O
to NN NN O
PAH NN NN O
gene NN NN O
transcripts NN NN O
whose NN NN O
nucleotide NN NN O
sequence NN NN O
is NN NN O
identical NN NN O
to NN NN O
that NN NN O
reported NN NN O
in NN NN O
liver NN NN O
and NN NN O
therefore NN NN O
represent NN NN O
a NN NN O
useful NN NN O
tool NN NN O
for NN NN O
molecular NN NN O
genetic NN NN O
studies NN NN O
in NN NN O
phenylketonuria NN NN B-SpecificDisease
. NN NN O

. NN NN O

8101038 NN NN O
High NN NN O
residual NN NN O
arylsulfatase NN NN O
A NN NN O
( NN NN O
ARSA NN NN O
) NN NN O
activity NN NN O
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
late-infantile NN NN B-SpecificDisease
metachromatic NN NN I-SpecificDisease
leukodystrophy NN NN I-SpecificDisease
. NN NN O

We NN NN O
identified NN NN O
a NN NN O
patient NN NN O
suffering NN NN O
from NN NN O
late-infantile NN NN B-SpecificDisease
metachromatic NN NN I-SpecificDisease
leukodystrophy NN NN I-SpecificDisease
( NN NN O
MLD NN NN B-SpecificDisease
) NN NN O
who NN NN O
has NN NN O
a NN NN O
residual NN NN O
arylsulfatase NN NN O
A NN NN O
( NN NN O
ARSA NN NN O
) NN NN O
activity NN NN O
of NN NN O
about NN NN O
10 NN NN O
% NN NN O
. NN NN O

Fibroblasts NN NN O
of NN NN O
the NN NN O
patient NN NN O
show NN NN O
significant NN NN O
sulfatide NN NN O
degradation NN NN O
activity NN NN O
exceeding NN NN O
that NN NN O
of NN NN O
adult NN NN B-Modifier
MLD NN NN I-Modifier
patients NN NN O
. NN NN O

Analysis NN NN O
of NN NN O
the NN NN O
ARSA NN NN O
gene NN NN O
in NN NN O
this NN NN O
patient NN NN O
revealed NN NN O
heterozygosity NN NN O
for NN NN O
two NN NN O
new NN NN O
mutant NN NN O
alleles NN NN O
in NN NN O
one NN NN O
allele NN NN O
, NN NN O
deletion NN NN O
of NN NN O
C NN NN O
447 NN NN O
in NN NN O
exon NN NN O
2 NN NN O
leads NN NN O
to NN NN O
a NN NN O
frameshift NN NN O
and NN NN O
to NN NN O
a NN NN O
premature NN NN O
stop NN NN O
codon NN NN O
at NN NN O
amino NN NN O
acid NN NN O
position NN NN O
105 NN NN O
; NN NN O
in NN NN O
the NN NN O
second NN NN O
allele NN NN O
, NN NN O
a NN NN O
G NN NN O
-- NN NN O
A NN NN O
transition NN NN O
in NN NN O
exon NN NN O
5 NN NN O
causes NN NN O
a NN NN O
Gly309 NN NN O
-- NN NN O
Ser NN NN O
substitution NN NN O
. NN NN O

Transient NN NN O
expression NN NN O
of NN NN O
the NN NN O
mutant NN NN O
Ser309-ARSA NN NN O
resulted NN NN O
in NN NN O
only NN NN O
13 NN NN O
% NN NN O
enzyme NN NN O
activity NN NN O
of NN NN O
that NN NN O
observed NN NN O
in NN NN O
cells NN NN O
expressing NN NN O
normal NN NN O
ARSA NN NN O
. NN NN O

The NN NN O
mutant NN NN O
ARSA NN NN O
is NN NN O
correctly NN NN O
targeted NN NN O
to NN NN O
the NN NN O
lysosomes NN NN O
but NN NN O
is NN NN O
unstable NN NN O
. NN NN O

These NN NN O
findings NN NN O
are NN NN O
in NN NN O
contrast NN NN O
to NN NN O
previous NN NN O
results NN NN O
showing NN NN O
that NN NN O
the NN NN O
late-infantile NN NN B-SpecificDisease
type NN NN I-SpecificDisease
of NN NN I-SpecificDisease
MLD NN NN I-SpecificDisease
is NN NN O
always NN NN O
associated NN NN O
with NN NN O
the NN NN O
complete NN NN O
absence NN NN O
of NN NN O
ARSA NN NN O
activity NN NN O
. NN NN O

The NN NN O
expression NN NN O
of NN NN O
the NN NN O
mutant NN NN O
ARSA NN NN O
protein NN NN O
may NN NN O
be NN NN O
influenced NN NN O
by NN NN O
particular NN NN O
features NN NN O
of NN NN O
oligodendrocytes NN NN O
, NN NN O
such NN NN O
that NN NN O
the NN NN O
level NN NN O
of NN NN O
mutant NN NN O
enzyme NN NN O
is NN NN O
lower NN NN O
in NN NN O
these NN NN O
cells NN NN O
than NN NN O
in NN NN O
others NN NN O
. NN NN O

. NN NN O

8104633 NN NN O
An NN NN O
arylsulfatase NN NN O
A NN NN O
( NN NN O
ARSA NN NN O
) NN NN O
missense NN NN O
mutation NN NN O
( NN NN O
T274M NN NN O
) NN NN O
causing NN NN O
late-infantile NN NN B-SpecificDisease
metachromatic NN NN I-SpecificDisease
leukodystrophy NN NN I-SpecificDisease
. NN NN O

Metachromatic NN NN B-SpecificDisease
leukodystrophy NN NN I-SpecificDisease
( NN NN O
MLD NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
lysosomal NN NN I-DiseaseClass
storage NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
caused NN NN O
by NN NN O
a NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
arylsulfatase NN NN I-SpecificDisease
A NN NN I-SpecificDisease
( NN NN O
ARSA NN NN O
; NN NN O
EC NN NN O
3 NN NN O
. NN NN O

1 NN NN O
1 NN NN O
. NN NN O

6 NN NN O
6 NN NN O
. NN NN O

8 NN NN O
) NN NN O
. NN NN O

The NN NN O
8 NN NN O
ARSA NN NN O
exons NN NN O
and NN NN O
adjacent NN NN O
intron NN NN O
boundaries NN NN O
from NN NN O
a NN NN O
patient NN NN O
with NN NN O
late-infantile NN NN B-SpecificDisease
metachromatic NN NN I-SpecificDisease
leukodystrophy NN NN I-SpecificDisease
were NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
( NN NN O
PCR NN NN O
) NN NN O
amplified NN NN O
in NN NN O
seven NN NN O
discrete NN NN O
reactions NN NN O
. NN NN O

Amplified NN NN O
ARSA NN NN O
exons NN NN O
were NN NN O
analysed NN NN O
for NN NN O
the NN NN O
presence NN NN O
of NN NN O
sequence NN NN O
alterations NN NN O
by NN NN O
single-strand NN NN O
conformation NN NN O
polymorphism NN NN O
analysis NN NN O
, NN NN O
followed NN NN O
by NN NN O
direct NN NN O
sequencing NN NN O
of NN NN O
PCR NN NN O
products NN NN O
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
homozygous NN NN O
for NN NN O
a NN NN O
C NN NN O
-- NN NN O
T NN NN O
transition NN NN O
in NN NN O
exon NN NN O
IV NN NN O
that NN NN O
results NN NN O
in NN NN O
the NN NN O
substitution NN NN O
of NN NN O
a NN NN O
highly NN NN O
conserved NN NN O
threonine NN NN O
residue NN NN O
at NN NN O
amino NN NN O
acid NN NN O
274 NN NN O
with NN NN O
a NN NN O
methionine NN NN O
( NN NN O
T274M NN NN O
) NN NN O
. NN NN O

Analysis NN NN O
of NN NN O
a NN NN O
further NN NN O
29 NN NN O
MLD NN NN B-Modifier
patients NN NN O
revealed NN NN O
the NN NN O
presence NN NN O
of NN NN O
five NN NN O
additional NN NN O
homozygotes NN NN O
for NN NN O
T274M NN NN O
. NN NN O

All NN NN O
6 NN NN O
T274M NN NN O
homozygotes NN NN O
( NN NN O
representing NN NN O
four NN NN O
families NN NN O
) NN NN O
were NN NN O
of NN NN O
Lebanese NN NN O
descent NN NN O
, NN NN O
and NN NN O
all NN NN O
were NN NN O
known NN NN O
to NN NN O
be NN NN O
the NN NN O
result NN NN O
of NN NN O
consanguineous NN NN O
marriages NN NN O
. NN NN O

The NN NN O
altered NN NN O
amino NN NN O
acid NN NN O
is NN NN O
rigidly NN NN O
conserved NN NN O
among NN NN O
10 NN NN O
sulfatases NN NN O
from NN NN O
Escherichia NN NN O
coli NN NN O
to NN NN O
humans NN NN O
; NN NN O
therefore NN NN O
, NN NN O
it NN NN O
is NN NN O
most NN NN O
likely NN NN O
that NN NN O
the NN NN O
resultant NN NN O
mutant NN NN O
protein NN NN O
will NN NN O
have NN NN O
little NN NN O
or NN NN O
no NN NN O
enzyme NN NN O
activity NN NN O
. NN NN O

This NN NN O
is NN NN O
consistent NN NN O
with NN NN O
the NN NN O
very NN NN O
low NN NN O
ARSA NN NN O
activity NN NN O
measured NN NN O
in NN NN O
these NN NN O
patients NN NN O
and NN NN O
their NN NN O
uniformly NN NN O
severe NN NN O
clinical NN NN O
presentation NN NN O

8111379 NN NN O
Mutations NN NN O
in NN NN O
the NN NN O
PAX6 NN NN O
gene NN NN O
in NN NN O
patients NN NN O
with NN NN O
hereditary NN NN O
aniridia NN NN B-SpecificDisease
. NN NN O

The NN NN O
14 NN NN O
exons NN NN O
of NN NN O
the NN NN O
PAX6 NN NN O
gene NN NN O
have NN NN O
been NN NN O
analysed NN NN O
exon-by-exon NN NN O
using NN NN O
SSCP NN NN O
in NN NN O
6 NN NN O
aniridia NN NN B-Modifier
families NN NN O
. NN NN O

In NN NN O
each NN NN O
family NN NN O
band NN NN O
shifts NN NN O
were NN NN O
observed NN NN O
on NN NN O
the NN NN O
SSCP NN NN O
gels NN NN O
for NN NN O
only NN NN O
one NN NN O
exon NN NN O
and NN NN O
direct NN NN O
PCR-sequencing NN NN O
revealed NN NN O
mutations NN NN O
in NN NN O
each NN NN O
case NN NN O
. NN NN O

Two NN NN O
mutations NN NN O
involved NN NN O
C NN NN O
-- NN NN O
T NN NN O
transitions NN NN O
in NN NN O
CGAarg NN NN O
codons NN NN O
in NN NN O
exons NN NN O
9 NN NN O
and NN NN O
11 NN NN O
. NN NN O

Another NN NN O
C NN NN O
-- NN NN O
T NN NN O
transition NN NN O
converted NN NN O
a NN NN O
CAG-glutamine NN NN O
to NN NN O
a NN NN O
TAG-stop NN NN O
in NN NN O
exon NN NN O
7 NN NN O
. NN NN O

Small NN NN O
insertions NN NN O
created NN NN O
frameshifts NN NN O
which NN NN O
produced NN NN O
downstream NN NN O
stop NN NN O
codons NN NN O
in NN NN O
another NN NN O
two NN NN O
patients NN NN O
and NN NN O
an NN NN O
A NN NN O
-- NN NN O
T NN NN O
mutation NN NN O
disrupted NN NN O
the NN NN O
splice NN NN O
donor NN NN O
site NN NN O
of NN NN O
exon NN NN O
5 NN NN O
in NN NN O
the NN NN O
remaining NN NN O
family NN NN O
. NN NN O

Thus NN NN O
, NN NN O
complete NN NN O
inactivation NN NN O
of NN NN O
the NN NN O
PAX6 NN NN O
gene NN NN O
is NN NN O
predicted NN NN O
in NN NN O
all NN NN O
cases NN NN O
. NN NN O

Analysis NN NN O
of NN NN O
other NN NN O
affected NN NN O
members NN NN O
of NN NN O
the NN NN O
families NN NN O
showed NN NN O
that NN NN O
, NN NN O
in NN NN O
each NN NN O
case NN NN O
, NN NN O
all NN NN O
affected NN NN O
individuals NN NN O
carried NN NN O
the NN NN O
same NN NN O
family-specific NN NN O
mutation NN NN O
. NN NN O

One NN NN O
polymorphism NN NN O
was NN NN O
found NN NN O
in NN NN O
exon NN NN O
7 NN NN O
. NN NN O

This NN NN O
data NN NN O
strongly NN NN O
supports NN NN O
the NN NN O
candidature NN NN O
of NN NN O
PAX6 NN NN O
as NN NN O
the NN NN O
gene NN NN O
responsible NN NN O
for NN NN O
hereditary NN NN O
aniridia NN NN B-SpecificDisease
. NN NN O

. NN NN O

8113388 NN NN O
Three NN NN O
novel NN NN O
mutations NN NN O
in NN NN O
five NN NN O
unrelated NN NN O
subjects NN NN O
with NN NN O
hereditary NN NN O
protein NN NN B-SpecificDisease
S NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
type NN NN I-SpecificDisease
I NN NN I-SpecificDisease
. NN NN O

A NN NN O
panel NN NN O
of NN NN O
eight NN NN O
unrelated NN NN O
subjects NN NN O
with NN NN O
inherited NN NN O
type NN NN B-SpecificDisease
I NN NN I-SpecificDisease
protein NN NN I-SpecificDisease
S NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
was NN NN O
screened NN NN O
for NN NN O
mutations NN NN O
in NN NN O
the NN NN O
PROS1 NN NN O
gene NN NN O
. NN NN O

In NN NN O
five NN NN O
subjects NN NN O
an NN NN O
abnormality NN NN O
was NN NN O
found NN NN O
but NN NN O
mutations NN NN O
were NN NN O
not NN NN O
detected NN NN O
in NN NN O
the NN NN O
remaining NN NN O
three NN NN O
subjects NN NN O
. NN NN O

Two NN NN O
subjects NN NN O
shared NN NN O
a NN NN O
G NN NN O
-- NN NN O
A NN NN O
transition NN NN O
at NN NN O
position NN NN O
+ NN NN O
5 NN NN O
of NN NN O
the NN NN O
donor NN NN O
splice NN NN O
site NN NN O
consensus NN NN O
sequence NN NN O
of NN NN O
intron NN NN O
10 NN NN O
. NN NN O

Also NN NN O
in NN NN O
two NN NN O
subjects NN NN O
an NN NN O
A NN NN O
-- NN NN O
T NN NN O
transversion NN NN O
was NN NN O
detected NN NN O
in NN NN O
the NN NN O
stopcodon NN NN O
of NN NN O
the NN NN O
PROS1 NN NN O
gene NN NN O
; NN NN O
this NN NN O
transversion NN NN O
predicts NN NN O
a NN NN O
protein NN NN O
S NN NN O
molecule NN NN O
that NN NN O
is NN NN O
extended NN NN O
by NN NN O
14 NN NN O
amino NN NN O
acids NN NN O
. NN NN O

The NN NN O
fifth NN NN O
subject NN NN O
was NN NN O
found NN NN O
to NN NN O
possess NN NN O
two NN NN O
sequence NN NN O
abnormalities NN NN O
. NN NN O

One NN NN O
allele NN NN O
carried NN NN O
a NN NN O
G NN NN O
-- NN NN O
A NN NN O
transition NN NN O
near NN NN O
the NN NN O
donor NN NN O
splice NN NN O
junction NN NN O
of NN NN O
intron NN NN O
2 NN NN O
, NN NN O
but NN NN O
this NN NN O
abnormality NN NN O
is NN NN O
probably NN NN O
neutral NN NN O
, NN NN O
since NN NN O
it NN NN O
was NN NN O
inherited NN NN O
from NN NN O
the NN NN O
parent NN NN O
with NN NN O
normal NN NN O
protein NN NN O
S NN NN O
antigen NN NN O
levels NN NN O
. NN NN O

In NN NN O
the NN NN O
other NN NN O
allele NN NN O
a NN NN O
single NN NN O
T NN NN O
insertion NN NN O
in NN NN O
codon NN NN O
-25 NN NN O
was NN NN O
found NN NN O
. NN NN O

Analysis NN NN O
of NN NN O
platelet NN NN O
RNA NN NN O
showed NN NN O
that NN NN O
only NN NN O
the NN NN O
mRNA NN NN O
with NN NN O
the NN NN O
A NN NN O
-- NN NN O
T NN NN O
mutation NN NN O
in NN NN O
the NN NN O
stopcodon NN NN O
is NN NN O
present NN NN O
in NN NN O
amounts NN NN O
comparable NN NN O
to NN NN O
wildtype NN NN O
RNA NN NN O
. NN NN O

mRNA NN NN O
from NN NN O
the NN NN O
alleles NN NN O
with NN NN O
the NN NN O
other NN NN O
two NN NN O
mutations NN NN O
was NN NN O
either NN NN O
undetectable NN NN O
or NN NN O
present NN NN O
in NN NN O
greatly NN NN O
reduced NN NN O
amounts NN NN O
. NN NN O

The NN NN O
latter NN NN O
indicates NN NN O
that NN NN O
a NN NN O
mRNA NN NN O
based NN NN O
approach NN NN O
is NN NN O
not NN NN O
feasible NN NN O
for NN NN O
the NN NN O
genetic NN NN O
analysis NN NN O
of NN NN O
protein NN NN B-SpecificDisease
S NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
type NN NN I-SpecificDisease
I NN NN I-SpecificDisease
. NN NN O

. NN NN O

8116611 NN NN O
Characteristics NN NN O
of NN NN O
intergenerational NN NN O
contractions NN NN O
of NN NN O
the NN NN O
CTG NN NN O
repeat NN NN O
in NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
. NN NN O

In NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
, NN NN O
the NN NN O
size NN NN O
of NN NN O
a NN NN O
CTG NN NN O
repeat NN NN O
in NN NN O
the NN NN O
DM NN NN B-Modifier
kinase NN NN O
gene NN NN O
generally NN NN O
increases NN NN O
in NN NN O
successive NN NN O
generations NN NN O
with NN NN O
clinical NN NN O
evidence NN NN O
of NN NN O
anticipation NN NN O
. NN NN O

However NN NN O
, NN NN O
there NN NN O
have NN NN O
also NN NN O
been NN NN O
cases NN NN O
with NN NN O
an NN NN O
intergenerational NN NN O
contraction NN NN O
of NN NN O
the NN NN O
repeat NN NN O
. NN NN O

We NN NN O
examined NN NN O
1 NN NN O
, NN NN O
489 NN NN O
DM NN NN B-Modifier
parent-offspring NN NN O
pairs NN NN O
, NN NN O
of NN NN O
which NN NN O
95 NN NN O
( NN NN O
6 NN NN O
. NN NN O

4 NN NN O
% NN NN O
) NN NN O
showed NN NN O
such NN NN O
contractions NN NN O
in NN NN O
peripheral NN NN O
blood NN NN O
leukocytes NN NN O
( NN NN O
PBL NN NN O
) NN NN O
. NN NN O

In NN NN O
56 NN NN O
of NN NN O
the NN NN O
95 NN NN O
pairs NN NN O
, NN NN O
clinical NN NN O
data NN NN O
allowed NN NN O
an NN NN O
analysis NN NN O
of NN NN O
their NN NN O
anticipation NN NN O
status NN NN O
. NN NN O

It NN NN O
is NN NN O
surprising NN NN O
that NN NN O
anticipation NN NN O
occurred NN NN O
in NN NN O
27 NN NN O
( NN NN O
48 NN NN O
% NN NN O
) NN NN O
of NN NN O
these NN NN O
56 NN NN O
pairs NN NN O
, NN NN O
while NN NN O
none NN NN O
clearly NN NN O
showed NN NN O
a NN NN O
later NN NN O
onset NN NN O
of NN NN O
DM NN NN B-SpecificDisease
in NN NN O
the NN NN O
symptomatic NN NN O
offspring NN NN O
. NN NN O

The NN NN O
contraction NN NN O
occurred NN NN O
in NN NN O
76 NN NN O
( NN NN O
10 NN NN O
% NN NN O
) NN NN O
of NN NN O
753 NN NN O
paternal NN NN O
transmissions NN NN O
and NN NN O
in NN NN O
19 NN NN O
( NN NN O
3 NN NN O
% NN NN O
) NN NN O
of NN NN O
736 NN NN O
maternal NN NN O
transmissions NN NN O
. NN NN O

Anticipation NN NN O
was NN NN O
observed NN NN O
more NN NN O
frequently NN NN O
in NN NN O
maternal NN NN O
( NN NN O
85 NN NN O
% NN NN O
) NN NN O
than NN NN O
in NN NN O
paternal NN NN O
( NN NN O
37 NN NN O
% NN NN O
) NN NN O
transmissions NN NN O
( NN NN O
P NN NN O
. NN NN O

001 NN NN O
) NN NN O
. NN NN O

The NN NN O
parental NN NN O
repeat NN NN O
size NN NN O
correlated NN NN O
with NN NN O
the NN NN O
size NN NN O
of NN NN O
intergenerational NN NN O
contraction NN NN O
( NN NN O
r2 NN NN O
= NN NN O
. NN NN O

50 NN NN O
, NN NN O
P NN NN O
. NN NN O

001 NN NN O
) NN NN O
, NN NN O
and NN NN O
the NN NN O
slope NN NN O
of NN NN O
linear NN NN O
regression NN NN O
was NN NN O
steeper NN NN O
in NN NN O
paternal NN NN O
( NN NN O
- NN NN O
. NN NN O

62 NN NN O
) NN NN O
than NN NN O
in NN NN O
maternal NN NN O
( NN NN O
- NN NN O
. NN NN O

30 NN NN O
) NN NN O
transmissions NN NN O
( NN NN O
P NN NN O
. NN NN O

001 NN NN O
) NN NN O
. NN NN O

Sixteen NN NN O
DM NN NN B-Modifier
parents NN NN O
had NN NN O
multiple NN NN O
DM NN NN B-Modifier
offspring NN NN O
with NN NN O
the NN NN O
CTG NN NN O
repeat NN NN O
contractions NN NN O
. NN NN O

This NN NN O
frequency NN NN O
was NN NN O
higher NN NN O
than NN NN O
the NN NN O
frequency NN NN O
expected NN NN O
from NN NN O
the NN NN O
probability NN NN O
of NN NN O
the NN NN O
repeat NN NN O
contractions NN NN O
( NN NN O
6 NN NN O
. NN NN O

4 NN NN O
% NN NN O
) NN NN O
and NN NN O
the NN NN O
size NN NN O
of NN NN O
DM NN NN B-Modifier
sib NN NN O
population NN NN O
( NN NN O
1 NN NN O
. NN NN O

54 NN NN O
DM NN NN B-Modifier
offspring NN NN O
per NN NN O
DM NN NN B-Modifier
parent NN NN O
, NN NN O
in NN NN O
968 NN NN O
DM NN NN B-Modifier
parents NN NN O
) NN NN O
. NN NN O

We NN NN O
conclude NN NN O
that NN NN O
( NN NN O
1 NN NN O
) NN NN O
intergenerational NN NN O
contractions NN NN O
of NN NN O
the NN NN O
CTG NN NN O
repeat NN NN O
in NN NN O
leukocyte NN NN O
DNA NN NN O
frequently NN NN O
accompanies NN NN O
apparent NN NN O
anticipation NN NN O
, NN NN O
especially NN NN O
when NN NN O
DM NN NN B-SpecificDisease
is NN NN O
maternally NN NN O
transmitted NN NN O
, NN NN O
and NN NN O
( NN NN O
2 NN NN O
) NN NN O
the NN NN O
paternal NN NN O
origin NN NN O
of NN NN O
the NN NN O
repeat NN NN O
and NN NN O
the NN NN O
presence NN NN O
of NN NN O
the NN NN O
repeat NN NN O
contraction NN NN O
in NN NN O
a NN NN O
sibling NN NN O
increase NN NN O
the NN NN O
probability NN NN O
of NN NN O
the NN NN O
CTG NN NN O
repeat NN NN O
contraction NN NN O

8128954 NN NN O
Gonosomal NN NN O
mosaicism NN NN O
in NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
patients NN NN O
: NN NN O
involvement NN NN O
of NN NN O
mitotic NN NN O
events NN NN O
in NN NN O
( NN NN O
CTG NN NN O
) NN NN O
n NN NN O
repeat NN NN O
variation NN NN O
and NN NN O
selection NN NN O
against NN NN O
extreme NN NN O
expansion NN NN O
in NN NN O
sperm NN NN O
. NN NN O

Myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
is NN NN O
caused NN NN O
by NN NN O
abnormal NN NN O
expansion NN NN O
of NN NN O
a NN NN O
polymorphic NN NN O
( NN NN O
CTG NN NN O
) NN NN O
n NN NN O
repeat NN NN O
, NN NN O
located NN NN O
in NN NN O
the NN NN O
DM NN NN B-Modifier
protein NN NN O
kinase NN NN O
gene NN NN O
. NN NN O

We NN NN O
determined NN NN O
the NN NN O
( NN NN O
CTG NN NN O
) NN NN O
n NN NN O
repeat NN NN O
lengths NN NN O
in NN NN O
a NN NN O
broad NN NN O
range NN NN O
of NN NN O
tissue NN NN O
DNAs NN NN O
from NN NN O
patients NN NN O
with NN NN O
mild NN NN O
, NN NN O
classical NN NN O
, NN NN O
or NN NN O
congenital NN NN O
manifestation NN NN O
of NN NN O
DM NN NN B-Modifier
. NN NN O

Differences NN NN O
in NN NN O
the NN NN O
repeat NN NN O
length NN NN O
were NN NN O
seen NN NN O
in NN NN O
somatic NN NN O
tissues NN NN O
from NN NN O
single NN NN O
DM NN NN B-Modifier
individuals NN NN O
and NN NN O
twins NN NN O
. NN NN O

Repeats NN NN O
appeared NN NN O
to NN NN O
expand NN NN O
to NN NN O
a NN NN O
similar NN NN O
extent NN NN O
in NN NN O
tissues NN NN O
originating NN NN O
from NN NN O
the NN NN O
same NN NN O
embryonal NN NN O
origin NN NN O
. NN NN O

In NN NN O
most NN NN O
male NN NN O
patients NN NN O
carrying NN NN O
intermediate- NN NN O
or NN NN O
small-sized NN NN O
expansions NN NN O
in NN NN O
blood NN NN O
, NN NN O
the NN NN O
repeat NN NN O
lengths NN NN O
covered NN NN O
a NN NN O
markedly NN NN O
wider NN NN O
range NN NN O
in NN NN O
sperm NN NN O
. NN NN O

In NN NN O
contrast NN NN O
, NN NN O
male NN NN O
patients NN NN O
with NN NN O
large NN NN O
allele NN NN O
expansions NN NN O
in NN NN O
blood NN NN O
( NN NN O
700 NN NN O
CTGs NN NN O
) NN NN O
had NN NN O
similar NN NN O
or NN NN O
smaller NN NN O
repeats NN NN O
in NN NN O
sperm NN NN O
, NN NN O
when NN NN O
detectable NN NN O
. NN NN O

Sperm NN NN O
alleles NN NN O
with NN NN O
1 NN NN O
, NN NN O
000 NN NN O
CTGs NN NN O
were NN NN O
not NN NN O
seen NN NN O
. NN NN O

We NN NN O
conclude NN NN O
that NN NN O
DM NN NN B-Modifier
patients NN NN O
can NN NN O
be NN NN O
considered NN NN O
gonosomal NN NN O
mosaics NN NN O
, NN NN O
i NN NN O
. NN NN O

e NN NN O
e NN NN O
. NN NN O

, NN NN O
combined NN NN O
somatic NN NN O
and NN NN O
germ-line NN NN O
tissue NN NN O
mosaics NN NN O
. NN NN O

Most NN NN O
remarkably NN NN O
, NN NN O
we NN NN O
observed NN NN O
multiple NN NN O
cases NN NN O
where NN NN O
the NN NN O
length NN NN O
distributions NN NN O
of NN NN O
intermediate- NN NN O
or NN NN O
small-sized NN NN O
alleles NN NN O
in NN NN O
fathers NN NN O
sperm NN NN O
were NN NN O
significantly NN NN O
different NN NN O
from NN NN O
that NN NN O
in NN NN O
their NN NN O
offsprings NN NN O
blood NN NN O
. NN NN O

Our NN NN O
combined NN NN O
findings NN NN O
indicate NN NN O
that NN NN O
intergenerational NN NN O
length NN NN O
changes NN NN O
in NN NN O
the NN NN O
unstable NN NN O
CTG NN NN O
repeat NN NN O
are NN NN O
most NN NN O
likely NN NN O
to NN NN O
occur NN NN O
during NN NN O
early NN NN O
embryonic NN NN O
mitotic NN NN O
divisions NN NN O
in NN NN O
both NN NN O
somatic NN NN O
and NN NN O
germ-line NN NN O
tissue NN NN O
formation NN NN O
. NN NN O

Both NN NN O
the NN NN O
initial NN NN O
CTG NN NN O
length NN NN O
, NN NN O
the NN NN O
overall NN NN O
number NN NN O
of NN NN O
cell NN NN O
divisions NN NN O
involved NN NN O
in NN NN O
tissue NN NN O
formation NN NN O
, NN NN O
and NN NN O
perhaps NN NN O
a NN NN O
specific NN NN O
selection NN NN O
process NN NN O
in NN NN O
spermatogenesis NN NN O
may NN NN O
influence NN NN O
the NN NN O
dynamics NN NN O
of NN NN O
this NN NN O
process NN NN O
. NN NN O

A NN NN O
model NN NN O
explaining NN NN O
mitotic NN NN O
instability NN NN O
and NN NN O
sex-dependent NN NN O
segregation NN NN O
phenomena NN NN O
in NN NN O
DM NN NN B-Modifier
manifestation NN NN O
is NN NN O
discussed NN NN O

8162051 NN NN O
Regionally NN NN O
clustered NN NN O
APC NN NN B-Modifier
mutations NN NN O
are NN NN O
associated NN NN O
with NN NN O
a NN NN O
severe NN NN O
phenotype NN NN O
and NN NN O
occur NN NN O
at NN NN O
a NN NN O
high NN NN O
frequency NN NN O
in NN NN O
new NN NN O
mutation NN NN O
cases NN NN O
of NN NN O
adenomatous NN NN B-SpecificDisease
polyposis NN NN I-SpecificDisease
coli NN NN I-SpecificDisease
. NN NN O

Germline NN NN O
mutation NN NN O
in NN NN O
APC NN NN O
at NN NN O
5q21-22 NN NN O
results NN NN O
in NN NN O
the NN NN O
dominantly NN NN O
inherited NN NN O
syndrome NN NN O
adenomatous NN NN B-SpecificDisease
polyposis NN NN I-SpecificDisease
coli NN NN I-SpecificDisease
( NN NN O
APC NN NN B-SpecificDisease
) NN NN O
. NN NN O

Somatic NN NN O
mutation NN NN O
in NN NN O
this NN NN O
gene NN NN O
is NN NN O
an NN NN O
early NN NN O
event NN NN O
in NN NN O
colorectal NN NN O
tumourigenesis NN NN O
. NN NN O

Both NN NN O
types NN NN O
of NN NN O
mutation NN NN O
are NN NN O
concentrated NN NN O
in NN NN O
the NN NN O
5 NN NN O
half NN NN O
of NN NN O
exon NN NN O
15 NN NN O
. NN NN O

We NN NN O
have NN NN O
used NN NN O
single NN NN O
strand NN NN O
conformational NN NN O
polymorphism NN NN O
( NN NN O
SSCP NN NN O
) NN NN O
and NN NN O
heteroduplex NN NN O
analysis NN NN O
to NN NN O
screen NN NN O
for NN NN O
variants NN NN O
in NN NN O
this NN NN O
region NN NN O
of NN NN O
the NN NN O
gene NN NN O
in NN NN O
a NN NN O
total NN NN O
of NN NN O
45 NN NN O
affected NN NN O
but NN NN O
unrelated NN NN O
individuals NN NN O
. NN NN O

Eighteen NN NN O
patients NN NN O
had NN NN O
no NN NN O
family NN NN O
history NN NN O
of NN NN O
the NN NN O
disease NN NN O
; NN NN O
of NN NN O
these NN NN O
11 NN NN O
were NN NN O
classified NN NN O
as NN NN O
having NN NN O
a NN NN O
severe NN NN O
phenotype NN NN O
, NN NN O
based NN NN O
on NN NN O
an NN NN O
early NN NN O
age NN NN O
at NN NN O
presentation NN NN O
or NN NN O
cancer NN NN B-Modifier
development NN NN O
. NN NN O

This NN NN O
compared NN NN O
with NN NN O
6 NN NN O
of NN NN O
27 NN NN O
familial NN NN O
cases NN NN O
. NN NN O

A NN NN O
5 NN NN O
bp NN NN O
deletion NN NN O
at NN NN O
codon NN NN O
1309 NN NN O
reported NN NN O
to NN NN O
occur NN NN O
in NN NN O
10-15 NN NN O
% NN NN O
of NN NN O
unselected NN NN O
APC NN NN B-Modifier
patients NN NN O
worldwide NN NN O
, NN NN O
was NN NN O
found NN NN O
in NN NN O
5 NN NN O
of NN NN O
the NN NN O
18 NN NN O
new NN NN O
mutation NN NN O
cases NN NN O
and NN NN O
4 NN NN O
of NN NN O
the NN NN O
27 NN NN O
familial NN NN O
cases NN NN O
all NN NN O
nine NN NN O
were NN NN O
classed NN NN O
as NN NN O
severe NN NN O
. NN NN O

A NN NN O
further NN NN O
3 NN NN O
new NN NN O
mutations NN NN O
and NN NN O
1 NN NN O
familial NN NN O
mutation NN NN O
were NN NN O
located NN NN O
downstream NN NN O
from NN NN O
codon NN NN O
1309 NN NN O
, NN NN O
these NN NN O
individuals NN NN O
similarly NN NN O
being NN NN O
classed NN NN O
as NN NN O
phenotypically NN NN O
severe NN NN O
. NN NN O

In NN NN O
contrast NN NN O
all NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
mutations NN NN O
detected NN NN O
in NN NN O
affected NN NN O
individuals NN NN O
with NN NN O
an NN NN O
average NN NN O
phenotype NN NN O
were NN NN O
located NN NN O
prior NN NN O
to NN NN O
codon NN NN O
1309 NN NN O
. NN NN O

The NN NN O
frequent NN NN O
association NN NN O
of NN NN O
a NN NN O
severe NN NN O
phenotype NN NN O
with NN NN O
fresh NN NN O
mutation NN NN O
may NN NN O
explain NN NN O
the NN NN O
apparent NN NN O
conflict NN NN O
of NN NN O
a NN NN O
high NN NN O
mutation NN NN O
rate NN NN O
( NN NN O
20-30 NN NN O
% NN NN O
) NN NN O
in NN NN O
a NN NN O
condition NN NN O
, NN NN O
which NN NN O
on NN NN O
average NN NN O
, NN NN O
is NN NN O
lethal NN NN O
at NN NN O
a NN NN O
post-reproductive NN NN O
age NN NN O
. NN NN O

. NN NN O

8162071 NN NN O
Mutations NN NN O
at NN NN O
the NN NN O
PAX6 NN NN O
locus NN NN O
are NN NN O
found NN NN O
in NN NN O
heterogeneous NN NN O
anterior NN NN B-DiseaseClass
segment NN NN I-DiseaseClass
malformations NN NN I-DiseaseClass
including NN NN O
Peters NN NN B-SpecificDisease
' NN NN I-SpecificDisease
anomaly NN NN I-SpecificDisease
. NN NN O

Mutation NN NN O
or NN NN O
deletion NN NN O
of NN NN O
the NN NN O
PAX6 NN NN O
gene NN NN O
underlies NN NN O
many NN NN O
cases NN NN O
of NN NN O
aniridia NN NN B-SpecificDisease
. NN NN O

Three NN NN O
lines NN NN O
of NN NN O
evidence NN NN O
now NN NN O
converge NN NN O
to NN NN O
implicate NN NN O
PAX6 NN NN O
more NN NN O
widely NN NN O
in NN NN O
anterior NN NN B-DiseaseClass
segment NN NN I-DiseaseClass
malformations NN NN I-DiseaseClass
including NN NN O
Peters NN NN B-SpecificDisease
anomaly NN NN I-SpecificDisease
. NN NN O

First NN NN O
, NN NN O
a NN NN O
child NN NN O
with NN NN O
Peters NN NN B-SpecificDisease
anomaly NN NN I-SpecificDisease
is NN NN O
deleted NN NN O
for NN NN O
one NN NN O
copy NN NN O
of NN NN O
PAX6 NN NN O
. NN NN O

Second NN NN O
, NN NN O
affected NN NN O
members NN NN O
of NN NN O
a NN NN O
family NN NN O
with NN NN O
dominantly NN NN O
inherited NN NN O
anterior NN NN B-DiseaseClass
segment NN NN I-DiseaseClass
malformations NN NN I-DiseaseClass
, NN NN O
including NN NN O
Peters NN NN B-SpecificDisease
anomaly NN NN I-SpecificDisease
are NN NN O
heterozygous NN NN O
for NN NN O
an NN NN O
R26G NN NN O
mutation NN NN O
in NN NN O
the NN NN O
PAX6 NN NN O
paired NN NN O
box NN NN O
. NN NN O

Third NN NN O
, NN NN O
a NN NN O
proportion NN NN O
of NN NN O
Sey NN NN O
/ NN NN O
+ NN NN O
Smalleye NN NN O
mice NN NN O
, NN NN O
heterozygous NN NN O
for NN NN O
a NN NN O
nonsense NN NN O
mutation NN NN O
in NN NN O
murine NN NN O
Pax-6 NN NN O
, NN NN O
have NN NN O
an NN NN O
ocular NN NN O
phenotype NN NN O
resembling NN NN O
Peters NN NN B-SpecificDisease
anomaly NN NN I-SpecificDisease
. NN NN O

We NN NN O
therefore NN NN O
propose NN NN O
that NN NN O
a NN NN O
variety NN NN O
of NN NN O
anterior NN NN B-DiseaseClass
segment NN NN I-DiseaseClass
anomalies NN NN I-DiseaseClass
may NN NN O
be NN NN O
associated NN NN O
with NN NN O
PAX6 NN NN O
mutations NN NN O
. NN NN O

. NN NN O

8178825 NN NN O
Huntington NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
without NN NN O
CAG NN NN O
expansion NN NN O
: NN NN O
phenocopies NN NN O
or NN NN O
errors NN NN O
in NN NN O
assignment NN NN O
? NN NN O

Huntington NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
HD NN NN B-SpecificDisease
) NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
be NN NN O
associated NN NN O
with NN NN O
an NN NN O
expanded NN NN O
CAG NN NN O
repeat NN NN O
within NN NN O
a NN NN O
novel NN NN O
gene NN NN O
on NN NN O
4p16 NN NN O
. NN NN O

3 NN NN O
( NN NN O
IT15 NN NN O
) NN NN O
. NN NN O

A NN NN O
total NN NN O
of NN NN O
30 NN NN O
of NN NN O
1 NN NN O
, NN NN O
022 NN NN O
affected NN NN O
persons NN NN O
( NN NN O
2 NN NN O
. NN NN O

9 NN NN O
% NN NN O
of NN NN O
our NN NN O
cohort NN NN O
) NN NN O
did NN NN O
not NN NN O
have NN NN O
an NN NN O
expanded NN NN O
CAG NN NN O
in NN NN O
the NN NN O
disease NN NN O
range NN NN O
. NN NN O

The NN NN O
reasons NN NN O
for NN NN O
not NN NN O
observing NN NN O
expansion NN NN O
in NN NN O
affected NN NN O
individuals NN NN O
are NN NN O
important NN NN O
for NN NN O
determining NN NN O
the NN NN O
sensitivity NN NN O
of NN NN O
using NN NN O
repeat NN NN O
length NN NN O
both NN NN O
for NN NN O
diagnosis NN NN O
of NN NN O
affected NN NN O
patients NN NN O
and NN NN O
for NN NN O
predictive NN NN O
testing NN NN O
programs NN NN O
and NN NN O
may NN NN O
have NN NN O
biological NN NN O
relevance NN NN O
for NN NN O
the NN NN O
understanding NN NN O
of NN NN O
the NN NN O
molecular NN NN O
mechanism NN NN O
underlying NN NN O
HD NN NN B-SpecificDisease
. NN NN O

Here NN NN O
we NN NN O
show NN NN O
that NN NN O
the NN NN O
majority NN NN O
( NN NN O
18 NN NN O
) NN NN O
of NN NN O
the NN NN O
individuals NN NN O
with NN NN O
normal NN NN O
sized NN NN O
alleles NN NN O
represent NN NN O
misdiagnosis NN NN O
, NN NN O
sample NN NN O
mix-up NN NN O
, NN NN O
or NN NN O
clerical NN NN O
error NN NN O
. NN NN O

The NN NN O
remaining NN NN O
12 NN NN O
patients NN NN O
represent NN NN O
possible NN NN O
phenocopies NN NN O
for NN NN O
HD NN NN B-SpecificDisease
. NN NN O

In NN NN O
at NN NN O
least NN NN O
four NN NN O
cases NN NN O
, NN NN O
family NN NN O
studies NN NN O
of NN NN O
these NN NN O
phenocopies NN NN O
excluded NN NN O
4p16 NN NN O
. NN NN O

3 NN NN O
as NN NN O
the NN NN O
region NN NN O
responsible NN NN O
for NN NN O
the NN NN O
phenotype NN NN O
. NN NN O

Mutations NN NN O
in NN NN O
the NN NN O
HD NN NN B-Modifier
gene NN NN O
that NN NN O
are NN NN O
other NN NN O
than NN NN O
CAG NN NN O
expansion NN NN O
have NN NN O
not NN NN O
been NN NN O
excluded NN NN O
for NN NN O
the NN NN O
remaining NN NN O
eight NN NN O
cases NN NN O
; NN NN O
however NN NN O
, NN NN O
in NN NN O
as NN NN O
many NN NN O
as NN NN O
seven NN NN O
of NN NN O
these NN NN O
persons NN NN O
, NN NN O
retrospective NN NN O
review NN NN O
of NN NN O
these NN NN O
patients NN NN O
clinical NN NN O
features NN NN O
identified NN NN O
characteristics NN NN O
not NN NN O
typical NN NN O
for NN NN O
HD NN NN B-SpecificDisease
. NN NN O

This NN NN O
study NN NN O
shows NN NN O
that NN NN O
on NN NN O
rare NN NN O
occasions NN NN O
mutations NN NN O
in NN NN O
other NN NN O
, NN NN O
as-yet-undefined NN NN O
genes NN NN O
can NN NN O
present NN NN O
with NN NN O
a NN NN O
clinical NN NN O
phenotype NN NN O
very NN NN O
similar NN NN O
to NN NN O
that NN NN O
of NN NN O
HD NN NN B-SpecificDisease

8187068 NN NN O
Frequent NN NN O
detection NN NN O
of NN NN O
codon NN NN O
877 NN NN O
mutation NN NN O
in NN NN O
the NN NN O
androgen NN NN O
receptor NN NN O
gene NN NN O
in NN NN O
advanced NN NN B-SpecificDisease
prostate NN NN I-SpecificDisease
cancers NN NN I-SpecificDisease
. NN NN O

Prostatic NN NN O
tissue NN NN O
specimens NN NN O
derived NN NN O
from NN NN O
transurethral NN NN O
resections NN NN O
of NN NN O
patients NN NN O
with NN NN O
metastatic NN NN B-SpecificDisease
prostate NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
were NN NN O
analyzed NN NN O
for NN NN O
genetic NN NN O
alterations NN NN O
in NN NN O
the NN NN O
hormone-binding NN NN O
domain NN NN O
of NN NN O
the NN NN O
androgen NN NN O
receptor NN NN O
( NN NN O
AR NN NN O
) NN NN O
gene NN NN O
. NN NN O

Direct NN NN O
sequencing NN NN O
of NN NN O
the NN NN O
polymerase NN NN O
chain NN NN O
reaction-derived NN NN O
DNAs NN NN O
of NN NN O
6 NN NN O
of NN NN O
24 NN NN O
specimens NN NN O
revealed NN NN O
a NN NN O
codon NN NN O
877 NN NN O
mutation NN NN O
( NN NN O
ACT NN NN O
-- NN NN O
GCT NN NN O
, NN NN O
Thr NN NN O
-- NN NN O
Ala NN NN O
) NN NN O
in NN NN O
the NN NN O
hormone-binding NN NN O
domain NN NN O
of NN NN O
the NN NN O
AR NN NN O
gene NN NN O
. NN NN O

This NN NN O
same NN NN O
AR NN NN O
mutation NN NN O
has NN NN O
been NN NN O
reported NN NN O
previously NN NN O
in NN NN O
a NN NN O
metastatic NN NN B-Modifier
prostate NN NN I-Modifier
cancer NN NN I-Modifier
cell NN NN O
line NN NN O
, NN NN O
LNCaP NN NN O
, NN NN O
where NN NN O
this NN NN O
mutation NN NN O
confers NN NN O
upon NN NN O
the NN NN O
AR NN NN O
an NN NN O
altered NN NN O
ligand-binding NN NN O
specificity NN NN O
which NN NN O
is NN NN O
stimulated NN NN O
by NN NN O
estrogens NN NN O
, NN NN O
progestagens NN NN O
, NN NN O
and NN NN O
antiandrogens NN NN O
. NN NN O

It NN NN O
is NN NN O
possible NN NN O
that NN NN O
analogous NN NN O
to NN NN O
an NN NN O
activated NN NN O
/ NN NN O
altered NN NN O
growth NN NN O
factor NN NN O
receptor NN NN O
oncogene NN NN O
, NN NN O
codon NN NN O
877 NN NN O
mutant NN NN O
AR NN NN O
with NN NN O
altered NN NN O
ligand NN NN O
binding NN NN O
may NN NN O
provide NN NN O
a NN NN O
selective NN NN O
growth NN NN O
advantage NN NN O
in NN NN O
the NN NN O
genesis NN NN O
of NN NN O
a NN NN O
subset NN NN O
of NN NN O
advanced NN NN B-SpecificDisease
prostate NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

Although NN NN O
estrogens NN NN O
are NN NN O
used NN NN O
infrequently NN NN O
, NN NN O
antiandrogens NN NN O
are NN NN O
used NN NN O
increasingly NN NN O
in NN NN O
hormonal NN NN O
therapy NN NN O
for NN NN O
patients NN NN O
with NN NN O
advanced NN NN B-SpecificDisease
prostate NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

The NN NN O
stimulatory NN NN O
effect NN NN O
of NN NN O
these NN NN O
therapeutic NN NN O
agents NN NN O
on NN NN O
the NN NN O
codon NN NN O
877 NN NN O
mutant NN NN O
AR NN NN O
further NN NN O
suggests NN NN O
that NN NN O
this NN NN O
frequently NN NN O
observed NN NN O
AR NN NN O
mutation NN NN O
may NN NN O
contribute NN NN O
to NN NN O
the NN NN O
treatment NN NN O
refractory NN NN O
disease NN NN O
. NN NN O

. NN NN O

8188241 NN NN O
The NN NN O
human NN NN O
gene NN NN O
for NN NN O
alkaptonuria NN NN B-SpecificDisease
( NN NN O
AKU NN NN B-SpecificDisease
) NN NN O
maps NN NN O
to NN NN O
chromosome NN NN O
3q NN NN O
. NN NN O

Alkaptonuria NN NN B-SpecificDisease
( NN NN O
AKU NN NN B-SpecificDisease
; NN NN O
McKusick NN NN O
no NN NN O
. NN NN O

203500 NN NN O
) NN NN O
is NN NN O
a NN NN O
rare NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
caused NN NN O
by NN NN O
the NN NN O
lack NN NN O
of NN NN O
homogentisic NN NN O
acid NN NN O
oxidase NN NN O
activity NN NN O
. NN NN O

Patients NN NN O
excrete NN NN O
large NN NN O
amounts NN NN O
of NN NN O
homogentisic NN NN O
acid NN NN O
in NN NN O
their NN NN O
urine NN NN O
and NN NN O
a NN NN O
black NN NN O
ochronotic NN NN O
pigment NN NN O
is NN NN O
deposited NN NN O
in NN NN O
their NN NN O
cartilage NN NN O
and NN NN O
collagenous NN NN O
tissues NN NN O
. NN NN O

Ochronosis NN NN B-SpecificDisease
is NN NN O
the NN NN O
predominant NN NN O
clinical NN NN O
complication NN NN O
of NN NN O
the NN NN O
disease NN NN O
leading NN NN O
to NN NN O
ochronotic NN NN B-SpecificDisease
arthropathy NN NN I-SpecificDisease
, NN NN O
dark NN NN O
urine NN NN O
, NN NN O
pigment NN NN O
changes NN NN O
of NN NN O
the NN NN O
skin NN NN O
, NN NN O
and NN NN O
other NN NN O
clinical NN NN O
features NN NN O
. NN NN O

A NN NN O
mutation NN NN O
causing NN NN O
alkaptonuria NN NN B-SpecificDisease
in NN NN O
the NN NN O
mouse NN NN O
has NN NN O
mapped NN NN O
to NN NN O
chromosome NN NN O
16 NN NN O
. NN NN O

Considering NN NN O
conserved NN NN O
synteny NN NN O
, NN NN O
we NN NN O
were NN NN O
able NN NN O
to NN NN O
map NN NN O
the NN NN O
human NN NN O
gene NN NN O
to NN NN O
chromosome NN NN O
3q NN NN O
in NN NN O
six NN NN O
alkaptonuria NN NN B-Modifier
pedigrees NN NN O
of NN NN O
Slovak NN NN O
origin NN NN O
. NN NN O

. NN NN O

8195156 NN NN O
Structure NN NN O
of NN NN O
the NN NN O
human NN NN O
Na+/glucose NN NN O
cotransporter NN NN O
gene NN NN O
SGLT1 NN NN O
. NN NN O

Intestinal NN NN O
uptake NN NN O
of NN NN O
dietary NN NN O
glucose NN NN O
and NN NN O
galactose NN NN O
is NN NN O
mediated NN NN O
by NN NN O
the NN NN O
SGLT1 NN NN O
Na NN NN O
+ NN NN O
/ NN NN O
glucose NN NN O
cotransporter NN NN O
of NN NN O
the NN NN O
brush NN NN O
border NN NN O
. NN NN O

An NN NN O
SGLT1 NN NN O
missense NN NN O
mutation NN NN O
underlies NN NN O
hereditary NN NN B-SpecificDisease
glucose NN NN I-SpecificDisease
/ NN NN I-SpecificDisease
galactose NN NN I-SpecificDisease
malabsorption NN NN I-SpecificDisease
, NN NN O
characterized NN NN O
by NN NN O
potentially NN NN O
fatal NN NN O
diarrhea NN NN B-SpecificDisease
; NN NN O
conversely NN NN O
, NN NN O
oral NN NN O
rehydration NN NN O
therapy NN NN O
exploits NN NN O
normal NN NN O
transport NN NN O
to NN NN O
alleviate NN NN O
life-threatening NN NN O
diarrhea NN NN B-SpecificDisease
of NN NN O
infectious NN NN O
origin NN NN O
. NN NN O

We NN NN O
have NN NN O
mapped NN NN O
the NN NN O
entire NN NN O
human NN NN O
SGLT1 NN NN O
Na NN NN O
+ NN NN O
/ NN NN O
glucose NN NN O
cotransporter NN NN O
gene NN NN O
from NN NN O
cosmid NN NN O
and NN NN O
lambda NN NN O
phage NN NN O
clones NN NN O
representing NN NN O
a NN NN O
genomic NN NN O
region NN NN O
of NN NN O
112 NN NN O
kilobases NN NN O
. NN NN O

Transcription NN NN O
initiation NN NN O
occurred NN NN O
from NN NN O
a NN NN O
site NN NN O
27 NN NN O
base NN NN O
pairs NN NN O
3 NN NN O
of NN NN O
a NN NN O
TATAA NN NN O
sequence NN NN O
. NN NN O

All NN NN O
exon-flanking NN NN O
regions NN NN O
were NN NN O
sequenced NN NN O
, NN NN O
and NN NN O
the NN NN O
entire NN NN O
112-kilobase NN NN O
region NN NN O
mapped NN NN O
with NN NN O
four NN NN O
restriction NN NN O
enzymes NN NN O
. NN NN O

SGLT1 NN NN O
is NN NN O
comprised NN NN O
of NN NN O
15 NN NN O
exons NN NN O
( NN NN O
spanning NN NN O
72 NN NN O
kilobases NN NN O
) NN NN O
; NN NN O
a NN NN O
possible NN NN O
evolutionary NN NN O
origin NN NN O
from NN NN O
a NN NN O
six-membrane-span NN NN O
ancestral NN NN O
precursor NN NN O
via NN NN O
a NN NN O
gene NN NN O
duplication NN NN O
event NN NN O
is NN NN O
suggested NN NN O
from NN NN O
comparison NN NN O
of NN NN O
exons NN NN O
against NN NN O
protein NN NN O
secondary NN NN O
structure NN NN O
and NN NN O
from NN NN O
sequence NN NN O
considerations NN NN O
. NN NN O

A NN NN O
new NN NN O
missense NN NN O
mutation NN NN O
in NN NN O
exon NN NN O
1 NN NN O
causing NN NN O
glucose NN NN B-SpecificDisease
/ NN NN I-SpecificDisease
galactose NN NN I-SpecificDisease
malabsorption NN NN I-SpecificDisease
is NN NN O
also NN NN O
described NN NN O
. NN NN O

This NN NN O
is NN NN O
the NN NN O
first NN NN O
Na NN NN O
( NN NN O
+ NN NN O
) NN NN O
-dependent NN NN O
cotransporter NN NN O
gene NN NN O
structure NN NN O
reported NN NN O
. NN NN O

These NN NN O
data NN NN O
facilitate NN NN O
the NN NN O
search NN NN O
for NN NN O
new NN NN O
glucose NN NN B-Modifier
/ NN NN I-Modifier
galactose NN NN I-Modifier
malabsorption NN NN I-Modifier
-related NN NN O
mutations NN NN O
in NN NN O
this NN NN O
important NN NN O
gene NN NN O
and NN NN O
provide NN NN O
a NN NN O
basis NN NN O
for NN NN O
future NN NN O
evolutionary NN NN O
comparisons NN NN O
with NN NN O
other NN NN O
Na NN NN O
( NN NN O
+ NN NN O
) NN NN O
-dependent NN NN O
cotransporters NN NN O
. NN NN O

. NN NN O

8198124 NN NN O
Four NN NN O
novel NN NN O
PEPD NN NN O
alleles NN NN O
causing NN NN O
prolidase NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

Mutations NN NN O
at NN NN O
the NN NN O
PEPD NN NN O
locus NN NN O
cause NN NN O
prolidase NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
( NN NN O
McKusick NN NN O
170100 NN NN O
) NN NN O
, NN NN O
a NN NN O
rare NN NN O
autosomal NN NN B-DiseaseClass
recessive NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
characterized NN NN O
by NN NN O
iminodipeptiduria NN NN B-SpecificDisease
, NN NN O
skin NN NN B-SpecificDisease
ulcers NN NN I-SpecificDisease
, NN NN O
mental NN NN B-DiseaseClass
retardation NN NN I-DiseaseClass
, NN NN O
and NN NN O
recurrent NN NN B-DiseaseClass
infections NN NN I-DiseaseClass
. NN NN O

Four NN NN O
PEPD NN NN O
mutations NN NN O
from NN NN O
five NN NN O
severely NN NN O
affected NN NN O
individuals NN NN O
were NN NN O
characterized NN NN O
by NN NN O
analysis NN NN O
of NN NN O
reverse-transcribed NN NN O
, NN NN O
PCR-amplified NN NN O
( NN NN O
RT-PCR NN NN O
) NN NN O
cDNA NN NN O
. NN NN O

We NN NN O
used NN NN O
SSCP NN NN O
analysis NN NN O
on NN NN O
four NN NN O
overlapping NN NN O
cDNA NN NN O
fragments NN NN O
covering NN NN O
the NN NN O
entire NN NN O
coding NN NN O
region NN NN O
of NN NN O
the NN NN O
PEPD NN NN O
gene NN NN O
and NN NN O
detected NN NN O
abnormal NN NN O
SSCP NN NN O
bands NN NN O
for NN NN O
the NN NN O
fragment NN NN O
spanning NN NN O
all NN NN O
or NN NN O
part NN NN O
of NN NN O
exons NN NN O
13-15 NN NN O
in NN NN O
three NN NN O
of NN NN O
the NN NN O
probands NN NN O
. NN NN O

Direct NN NN O
sequencing NN NN O
of NN NN O
the NN NN O
mutant NN NN O
cDNAs NN NN O
showed NN NN O
a NN NN O
G NN NN O
-- NN NN O
A NN NN O
, NN NN O
1342 NN NN O
substitution NN NN O
( NN NN O
G448R NN NN O
) NN NN O
in NN NN O
two NN NN O
patients NN NN O
and NN NN O
a NN NN O
3-bp NN NN O
deletion NN NN O
( NN NN O
delta NN NN O
E452 NN NN O
or NN NN O
delta NN NN O
E453 NN NN O
) NN NN O
in NN NN O
another NN NN O
. NN NN O

In NN NN O
the NN NN O
other NN NN O
two NN NN O
probands NN NN O
the NN NN O
amplified NN NN O
products NN NN O
were NN NN O
of NN NN O
reduced NN NN O
size NN NN O
. NN NN O

Direct NN NN O
sequencing NN NN O
of NN NN O
these NN NN O
mutant NN NN O
cDNAs NN NN O
revealed NN NN O
a NN NN O
deletion NN NN O
of NN NN O
exon NN NN O
5 NN NN O
in NN NN O
one NN NN O
patient NN NN O
and NN NN O
of NN NN O
exon NN NN O
7 NN NN O
in NN NN O
the NN NN O
other NN NN O
. NN NN O

Intronic NN NN O
sequences NN NN O
flanking NN NN O
exons NN NN O
5 NN NN O
and NN NN O
7 NN NN O
were NN NN O
identified NN NN O
using NN NN O
inverse NN NN O
PCR NN NN O
followed NN NN O
by NN NN O
direct NN NN O
sequencing NN NN O
. NN NN O

Conventional NN NN O
PCR NN NN O
and NN NN O
direct NN NN O
sequencing NN NN O
then NN NN O
established NN NN O
the NN NN O
intron-exon NN NN O
borders NN NN O
of NN NN O
the NN NN O
mutant NN NN O
genomic NN NN O
DNA NN NN O
revealing NN NN O
two NN NN O
splice NN NN O
acceptor NN NN O
mutations NN NN O
a NN NN O
G NN NN O
-- NN NN O
C NN NN O
substitution NN NN O
at NN NN O
position NN NN O
-1 NN NN O
of NN NN O
intron NN NN O
4 NN NN O
and NN NN O
an NN NN O
A NN NN O
-- NN NN O
G NN NN O
substitution NN NN O
at NN NN O
position NN NN O
-2 NN NN O
of NN NN O
intron NN NN O
6 NN NN O
. NN NN O

Our NN NN O
results NN NN O
indicate NN NN O
that NN NN O
the NN NN O
severe NN NN O
form NN NN O
of NN NN O
prolidase NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
is NN NN O
caused NN NN O
by NN NN O
multiple NN NN O
PEPD NN NN O
alleles NN NN O
. NN NN O

In NN NN O
this NN NN O
report NN NN O
we NN NN O
attempt NN NN O
to NN NN O
begin NN NN O
the NN NN O
process NN NN O
of NN NN O
describing NN NN O
these NN NN O
alleles NN NN O
and NN NN O
cataloging NN NN O
their NN NN O
phenotypic NN NN O
expression NN NN O
. NN NN O

. NN NN O

8198128 NN NN O
Recombinations NN NN O
in NN NN O
individuals NN NN O
homozygous NN NN O
by NN NN O
descent NN NN O
localize NN NN O
the NN NN O
Friedreich NN NN B-SpecificDisease
ataxia NN NN I-SpecificDisease
locus NN NN O
in NN NN O
a NN NN O
cloned NN NN O
450-kb NN NN O
interval NN NN O
. NN NN O

The NN NN O
locus NN NN O
for NN NN O
Friedreich NN NN B-SpecificDisease
ataxia NN NN I-SpecificDisease
( NN NN O
FRDA NN NN B-SpecificDisease
) NN NN O
, NN NN O
a NN NN O
severe NN NN O
neurodegenerative NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
, NN NN O
is NN NN O
tightly NN NN O
linked NN NN O
to NN NN O
markers NN NN O
D9S5 NN NN O
and NN NN O
D9S15 NN NN O
, NN NN O
and NN NN O
analysis NN NN O
of NN NN O
rare NN NN O
recombination NN NN O
events NN NN O
has NN NN O
suggested NN NN O
the NN NN O
order NN NN O
cen-FRDA-D9S5-D9S15-qter NN NN O
. NN NN O

We NN NN O
report NN NN O
here NN NN O
the NN NN O
construction NN NN O
of NN NN O
a NN NN O
YAC NN NN O
contig NN NN O
extending NN NN O
800 NN NN O
kb NN NN O
centromeric NN NN O
to NN NN O
D9S5 NN NN O
and NN NN O
the NN NN O
isolation NN NN O
of NN NN O
five NN NN O
new NN NN O
microsatellite NN NN O
markers NN NN O
from NN NN O
this NN NN O
region NN NN O
. NN NN O

In NN NN O
order NN NN O
to NN NN O
map NN NN O
these NN NN O
markers NN NN O
with NN NN O
respect NN NN O
to NN NN O
the NN NN O
FRDA NN NN B-Modifier
locus NN NN O
, NN NN O
all NN NN O
within NN NN O
a NN NN O
1-cM NN NN O
confidence NN NN O
interval NN NN O
, NN NN O
we NN NN O
sought NN NN O
to NN NN O
increase NN NN O
the NN NN O
genetic NN NN O
information NN NN O
of NN NN O
available NN NN O
FRDA NN NN B-Modifier
families NN NN O
by NN NN O
considering NN NN O
homozygosity NN NN O
by NN NN O
descent NN NN O
and NN NN O
association NN NN O
with NN NN O
founder NN NN O
haplotypes NN NN O
in NN NN O
isolated NN NN O
populations NN NN O
. NN NN O

This NN NN O
approach NN NN O
allowed NN NN O
us NN NN O
to NN NN O
identify NN NN O
one NN NN O
phase-known NN NN O
recombination NN NN O
and NN NN O
one NN NN O
probable NN NN O
historic NN NN O
recombination NN NN O
on NN NN O
haplotypes NN NN O
from NN NN O
Reunion NN NN O
Island NN NN O
patients NN NN O
, NN NN O
both NN NN O
of NN NN O
which NN NN O
place NN NN O
three NN NN O
of NN NN O
the NN NN O
five NN NN O
markers NN NN O
proximal NN NN O
to NN NN O
FRDA NN NN B-SpecificDisease
. NN NN O

This NN NN O
represents NN NN O
the NN NN O
first NN NN O
identification NN NN O
of NN NN O
close NN NN O
FRDA NN NN B-Modifier
flanking NN NN O
markers NN NN O
on NN NN O
the NN NN O
centromeric NN NN O
side NN NN O
. NN NN O

The NN NN O
two NN NN O
other NN NN O
markers NN NN O
allowed NN NN O
us NN NN O
to NN NN O
narrow NN NN O
the NN NN O
breakpoint NN NN O
of NN NN O
a NN NN O
previously NN NN O
identified NN NN O
distal NN NN O
recombination NN NN O
that NN NN O
is NN NN O
180 NN NN O
kb NN NN O
from NN NN O
D9S5 NN NN O
( NN NN O
26P NN NN O
) NN NN O
. NN NN O

Taken NN NN O
together NN NN O
, NN NN O
the NN NN O
results NN NN O
place NN NN O
the NN NN O
FRDA NN NN B-Modifier
locus NN NN O
in NN NN O
a NN NN O
450-kb NN NN O
interval NN NN O
, NN NN O
which NN NN O
is NN NN O
small NN NN O
enough NN NN O
for NN NN O
direct NN NN O
search NN NN O
of NN NN O
candidate NN NN O
genes NN NN O
. NN NN O

A NN NN O
detailed NN NN O
rare NN NN O
cutter NN NN O
restriction NN NN O
map NN NN O
and NN NN O
a NN NN O
cosmid NN NN O
contig NN NN O
covering NN NN O
this NN NN O
interval NN NN O
were NN NN O
constructed NN NN O
and NN NN O
should NN NN O
facilitate NN NN O
the NN NN O
search NN NN O
of NN NN O
genes NN NN O
in NN NN O
this NN NN O
region NN NN O
. NN NN O

. NN NN O

8209890 NN NN O
Investigation NN NN O
of NN NN O
thermoregulatory NN NN O
characteristics NN NN O
in NN NN O
patients NN NN O
with NN NN O
Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

A NN NN O
survey NN NN O
instrument NN NN O
is NN NN O
used NN NN O
to NN NN O
assess NN NN O
temperature NN NN O
regulation NN NN O
characteristics NN NN O
in NN NN O
children NN NN O
with NN NN O
Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
PWS NN NN B-SpecificDisease
) NN NN O
compared NN NN O
to NN NN O
3 NN NN O
control NN NN O
groups NN NN O
sibs NN NN O
of NN NN O
PWS NN NN B-Modifier
patients NN NN O
( NN NN O
SIB NN NN O
) NN NN O
, NN NN O
neurodevelopmentally NN NN B-Modifier
handicapped NN NN I-Modifier
children NN NN O
( NN NN O
ND NN NN O
) NN NN O
, NN NN O
and NN NN O
age NN NN O
and NN NN O
gender NN NN O
matched NN NN O
well NN NN O
children NN NN O
( NN NN O
WC NN NN O
) NN NN O
. NN NN O

Significant NN NN O
differences NN NN O
were NN NN O
found NN NN O
between NN NN O
PWS NN NN B-Modifier
patients NN NN O
, NN NN O
SIB NN NN O
controls NN NN O
, NN NN O
and NN NN O
WC NN NN O
controls NN NN O
in NN NN O
the NN NN O
prevalence NN NN O
of NN NN O
febrile NN NN O
convulsions NN NN O
, NN NN O
fever-associated NN NN O
symptoms NN NN O
, NN NN O
and NN NN O
temperature NN NN O
less NN NN O
than NN NN O
94 NN NN O
degrees NN NN O
F NN NN O
. NN NN O

No NN NN O
differences NN NN O
were NN NN O
noted NN NN O
in NN NN O
any NN NN O
variable NN NN O
between NN NN O
the NN NN O
PWS NN NN B-Modifier
patients NN NN O
and NN NN O
the NN NN O
ND NN NN O
controls NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
these NN NN O
abnormalities NN NN O
are NN NN O
not NN NN O
unique NN NN O
to NN NN O
PWS NN NN B-SpecificDisease
, NN NN O
but NN NN O
can NN NN O
occur NN NN O
in NN NN O
any NN NN O
neurodevelopmentally NN NN B-Modifier
handicapped NN NN I-Modifier
individual NN NN O
, NN NN O
further NN NN O
suggesting NN NN O
these NN NN O
do NN NN O
not NN NN O
necessarily NN NN O
reflect NN NN O
syndrome-specific NN NN O
hypothalamic NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
. NN NN O

. NN NN O

8240110 NN NN O
Phenotypic NN NN O
variation NN NN O
including NN NN O
retinitis NN NN B-SpecificDisease
pigmentosa NN NN I-SpecificDisease
, NN NN O
pattern NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
, NN NN O
and NN NN O
fundus NN NN B-SpecificDisease
flavimaculatus NN NN I-SpecificDisease
in NN NN O
a NN NN O
single NN NN O
family NN NN O
with NN NN O
a NN NN O
deletion NN NN O
of NN NN O
codon NN NN O
153 NN NN O
or NN NN O
154 NN NN O
of NN NN O
the NN NN O
peripherin/RDS NN NN O
gene NN NN O
. NN NN O

BACKGROUND NN NN O
AND NN NN O
OBJECTIVES NN NN O
Mutations NN NN O
of NN NN O
the NN NN O
peripherin NN NN O
/ NN NN O
RDS NN NN O
gene NN NN O
have NN NN O
been NN NN O
reported NN NN O
in NN NN O
autosomal NN NN B-SpecificDisease
dominant NN NN I-SpecificDisease
retinitis NN NN I-SpecificDisease
pigmentosa NN NN I-SpecificDisease
, NN NN O
pattern NN NN O
macular NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
, NN NN O
and NN NN O
retinitis NN NN B-SpecificDisease
punctata NN NN I-SpecificDisease
albescens NN NN I-SpecificDisease
. NN NN O

We NN NN O
report NN NN O
herein NN NN O
the NN NN O
occurrence NN NN O
of NN NN O
three NN NN O
separate NN NN O
phenotypes NN NN O
within NN NN O
a NN NN O
single NN NN O
family NN NN O
with NN NN O
a NN NN O
novel NN NN O
3-base NN NN O
pair NN NN O
deletion NN NN O
of NN NN O
codon NN NN O
153 NN NN O
or NN NN O
154 NN NN O
of NN NN O
the NN NN O
peripherin NN NN O
/ NN NN O
RDS NN NN O
gene NN NN O
. NN NN O

DESIGN NN NN O
Case NN NN O
reports NN NN O
with NN NN O
clinical NN NN O
features NN NN O
, NN NN O
fluorescein NN NN O
angiography NN NN O
, NN NN O
kinetic NN NN O
perimetry NN NN O
, NN NN O
electrophysiological NN NN O
studies NN NN O
, NN NN O
and NN NN O
molecular NN NN O
genetics NN NN O
. NN NN O

SETTING NN NN O
University NN NN O
medical NN NN O
centers NN NN O
. NN NN O

PATIENTS NN NN O
A NN NN O
75-year-old NN NN O
woman NN NN O
, NN NN O
her NN NN O
two NN NN O
daughters NN NN O
( NN NN O
aged NN NN O
44 NN NN O
and NN NN O
50 NN NN O
years NN NN O
) NN NN O
, NN NN O
and NN NN O
her NN NN O
49-year-old NN NN O
son NN NN O
were NN NN O
screened NN NN O
for NN NN O
peripherin NN NN O
/ NN NN O
RDS NN NN O
mutations NN NN O
because NN NN O
of NN NN O
the NN NN O
presence NN NN O
of NN NN O
multiple NN NN O
phenotypes NN NN O
within NN NN O
the NN NN O
same NN NN O
family NN NN O
. NN NN O

RESULTS NN NN O
The NN NN O
mother NN NN O
presented NN NN O
at NN NN O
age NN NN O
63 NN NN O
years NN NN O
with NN NN O
a NN NN O
profoundly NN NN O
abnormal NN NN O
electroretinogram NN NN O
( NN NN O
ERG NN NN O
) NN NN O
and NN NN O
adult-onset NN NN O
retinitis NN NN B-SpecificDisease
pigmentosa NN NN I-SpecificDisease
that NN NN O
progressed NN NN O
dramatically NN NN O
over NN NN O
12 NN NN O
years NN NN O
, NN NN O
with NN NN O
marked NN NN O
loss NN NN O
of NN NN O
peripheral NN NN O
visual NN NN O
field NN NN O
. NN NN O

One NN NN O
daughter NN NN O
developed NN NN O
pattern NN NN B-SpecificDisease
macular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
at NN NN O
age NN NN O
31 NN NN O
years NN NN O
. NN NN O

At NN NN O
age NN NN O
44 NN NN O
years NN NN O
, NN NN O
her NN NN O
ERG NN NN O
was NN NN O
moderately NN NN O
abnormal NN NN O
but NN NN O
her NN NN O
clinical NN NN O
disease NN NN O
was NN NN O
limited NN NN O
to NN NN O
the NN NN O
macula NN NN O
. NN NN O

Another NN NN O
daughter NN NN O
presented NN NN O
at NN NN O
age NN NN O
42 NN NN O
years NN NN O
with NN NN O
macular NN NN B-SpecificDisease
degeneration NN NN I-SpecificDisease
and NN NN O
over NN NN O
10 NN NN O
years NN NN O
developed NN NN O
the NN NN O
clinical NN NN O
picture NN NN O
of NN NN O
fundus NN NN B-SpecificDisease
flavimaculatus NN NN I-SpecificDisease
. NN NN O

Her NN NN O
peripheral NN NN O
visual NN NN O
field NN NN O
was NN NN O
preserved NN NN O
but NN NN O
her NN NN O
ERG NN NN O
was NN NN O
moderately NN NN O
abnormal NN NN O
. NN NN O

The NN NN O
son NN NN O
had NN NN O
onset NN NN O
of NN NN O
macular NN NN B-SpecificDisease
degeneration NN NN I-SpecificDisease
at NN NN O
age NN NN O
44 NN NN O
years NN NN O
. NN NN O

Pericentral NN NN B-SpecificDisease
scotomas NN NN I-SpecificDisease
were NN NN O
present NN NN O
and NN NN O
the NN NN O
ERG NN NN O
was NN NN O
markedly NN NN O
abnormal NN NN O
. NN NN O

Fluorescein NN NN O
angiography NN NN O
revealed NN NN O
punctate NN NN O
pigment NN NN O
epithelial NN NN O
transmission NN NN O
defects NN NN O
. NN NN O

CONCLUSIONS NN NN O
A NN NN O
3-base NN NN O
pair NN NN O
deletion NN NN O
of NN NN O
codon NN NN O
153 NN NN O
or NN NN O
154 NN NN O
of NN NN O
the NN NN O
peripherin NN NN O
/ NN NN O
RDS NN NN O
gene NN NN O
can NN NN O
produce NN NN O
clinically NN NN O
disparate NN NN O
phenotypes NN NN O
even NN NN O
within NN NN O
the NN NN O
same NN NN O
family NN NN O
. NN NN O

. NN NN O

8244393 NN NN O
Assignment NN NN O
of NN NN O
the NN NN O
human NN NN O
Na+/glucose NN NN O
cotransporter NN NN O
gene NN NN O
SGLT1 NN NN O
to NN NN O
chromosome NN NN O
22q13.1 NN NN O
. NN NN O

The NN NN O
Na NN NN O
+ NN NN O
/ NN NN O
glucose NN NN O
cotransporter NN NN O
gene NN NN O
SGLT1 NN NN O
encodes NN NN O
the NN NN O
primary NN NN O
carrier NN NN O
protein NN NN O
responsible NN NN O
for NN NN O
the NN NN O
uptake NN NN O
of NN NN O
the NN NN O
dietary NN NN O
sugars NN NN O
glucose NN NN O
and NN NN O
galactose NN NN O
from NN NN O
the NN NN O
intestinal NN NN O
lumen NN NN O
. NN NN O

SGLT1 NN NN O
transport NN NN O
activity NN NN O
is NN NN O
currently NN NN O
exploited NN NN O
in NN NN O
oral NN NN O
rehydration NN NN O
therapy NN NN O
. NN NN O

The NN NN O
75-kDa NN NN O
glycoprotein NN NN O
is NN NN O
localized NN NN O
in NN NN O
the NN NN O
brush NN NN O
border NN NN O
of NN NN O
the NN NN O
intestinal NN NN O
epithelium NN NN O
and NN NN O
is NN NN O
predicted NN NN O
to NN NN O
comprise NN NN O
12 NN NN O
membrane NN NN O
spans NN NN O
. NN NN O

In NN NN O
two NN NN O
patients NN NN O
with NN NN O
the NN NN O
autosomal NN NN B-SpecificDisease
recessive NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
glucose NN NN I-SpecificDisease
/ NN NN I-SpecificDisease
galactose NN NN I-SpecificDisease
malabsorption NN NN I-SpecificDisease
, NN NN O
the NN NN O
underlying NN NN O
cause NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
a NN NN O
missense NN NN O
mutation NN NN O
in NN NN O
SGLT1 NN NN O
, NN NN O
and NN NN O
the NN NN O
Asp28 NN NN O
-- NN NN O
Asn NN NN O
change NN NN O
was NN NN O
demonstrated NN NN O
in NN NN O
vitro NN NN O
to NN NN O
eliminate NN NN O
SGLT1 NN NN O
transport NN NN O
activity NN NN O
. NN NN O

The NN NN O
SGLT1 NN NN O
gene NN NN O
was NN NN O
previously NN NN O
shown NN NN O
to NN NN O
reside NN NN O
on NN NN O
the NN NN O
distal NN NN O
q NN NN O
arm NN NN O
of NN NN O
chromosome NN NN O
22 NN NN O
( NN NN O
11 NN NN O
. NN NN O

2 NN NN O
-- NN NN O
qter NN NN O
) NN NN O
. NN NN O

We NN NN O
have NN NN O
used NN NN O
a NN NN O
cosmid NN NN O
probe NN NN O
for NN NN O
fluorescence NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
, NN NN O
which NN NN O
refines NN NN O
the NN NN O
localization NN NN O
to NN NN O
22q13 NN NN O
. NN NN O

1 NN NN O
, NN NN O
and NN NN O
provide NN NN O
an NN NN O
example NN NN O
of NN NN O
the NN NN O
utility NN NN O
of NN NN O
the NN NN O
SGLT1 NN NN O
probe NN NN O
as NN NN O
a NN NN O
diagnostic NN NN O
for NN NN O
genetic NN NN B-DiseaseClass
diseases NN NN I-DiseaseClass
associated NN NN O
with NN NN O
translocations NN NN O
of NN NN O
chromosome NN NN O
22 NN NN O
. NN NN O

8252631 NN NN O
Restriction NN NN O
of NN NN O
ocular NN NN O
fundus NN NN O
lesions NN NN O
to NN NN O
a NN NN O
specific NN NN O
subgroup NN NN O
of NN NN O
APC NN NN B-Modifier
mutations NN NN O
in NN NN O
adenomatous NN NN B-Modifier
polyposis NN NN I-Modifier
coli NN NN I-Modifier
patients NN NN O
. NN NN O

In NN NN O
humans NN NN O
, NN NN O
alteration NN NN O
of NN NN O
the NN NN O
tumor NN NN B-Modifier
suppressor NN NN O
gene NN NN O
, NN NN O
APC NN NN B-Modifier
, NN NN O
causes NN NN O
adenomatous NN NN B-SpecificDisease
polyposis NN NN I-SpecificDisease
coli NN NN I-SpecificDisease
, NN NN O
a NN NN O
condition NN NN O
causing NN NN O
predisposition NN NN O
to NN NN O
colorectal NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

The NN NN O
syndrome NN NN O
inconsistently NN NN O
associates NN NN O
characteristic NN NN O
patches NN NN O
of NN NN O
congenital NN NN B-SpecificDisease
hypertrophy NN NN I-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
retinal NN NN I-SpecificDisease
pigment NN NN I-SpecificDisease
epithelium NN NN I-SpecificDisease
( NN NN O
CHRPE NN NN B-SpecificDisease
) NN NN O
. NN NN O

Ocular NN NN O
examination NN NN O
revealed NN NN O
that NN NN O
patients NN NN O
expressing NN NN O
CHRPE NN NN B-SpecificDisease
tend NN NN O
to NN NN O
cluster NN NN O
within NN NN O
specific NN NN O
families NN NN O
. NN NN O

The NN NN O
exact NN NN O
APC NN NN B-Modifier
mutation NN NN O
was NN NN O
identified NN NN O
in NN NN O
42 NN NN O
unrelated NN NN O
patients NN NN O
. NN NN O

In NN NN O
all NN NN O
cases NN NN O
these NN NN O
mutations NN NN O
were NN NN O
predicted NN NN O
to NN NN O
lead NN NN O
to NN NN O
the NN NN O
synthesis NN NN O
of NN NN O
a NN NN O
truncated NN NN O
protein NN NN O
. NN NN O

The NN NN O
extent NN NN O
of NN NN O
CHRPE NN NN B-SpecificDisease
was NN NN O
found NN NN O
to NN NN O
be NN NN O
dependent NN NN O
on NN NN O
the NN NN O
position NN NN O
of NN NN O
the NN NN O
mutation NN NN O
along NN NN O
the NN NN O
coding NN NN O
sequence NN NN O
. NN NN O

CHRPE NN NN B-Modifier
lesions NN NN O
are NN NN O
almost NN NN O
always NN NN O
absent NN NN O
if NN NN O
the NN NN O
mutation NN NN O
occurs NN NN O
before NN NN O
exon NN NN O
9 NN NN O
, NN NN O
but NN NN O
are NN NN O
systematically NN NN O
present NN NN O
if NN NN O
it NN NN O
occurs NN NN O
after NN NN O
this NN NN O
exon NN NN O
. NN NN O

Thus NN NN O
, NN NN O
the NN NN O
range NN NN O
of NN NN O
phenotypic NN NN O
expression NN NN O
observed NN NN O
among NN NN O
affected NN NN O
patients NN NN O
may NN NN O
result NN NN O
in NN NN O
part NN NN O
from NN NN O
different NN NN O
allelic NN NN O
manifestations NN NN O
of NN NN O
APC NN NN B-Modifier
mutations NN NN O
. NN NN O

. NN NN O

8258524 NN NN O
The NN NN O
effects NN NN O
of NN NN O
dystrophin NN NN O
gene NN NN O
mutations NN NN O
on NN NN O
the NN NN O
ERG NN NN O
in NN NN O
mice NN NN O
and NN NN O
humans NN NN O
. NN NN O

PURPOSE NN NN O
. NN NN O

The NN NN O
authors NN NN O
earlier NN NN O
findings NN NN O
of NN NN O
a NN NN O
negative NN NN O
electroretinogram NN NN O
( NN NN O
ERG NN NN O
) NN NN O
in NN NN O
a NN NN O
boy NN NN O
with NN NN O
Duchenne NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DMD NN NN B-SpecificDisease
) NN NN O
led NN NN O
them NN NN O
to NN NN O
investigate NN NN O
dystrophin NN NN O
gene NN NN O
deletions NN NN O
and NN NN O
ERGs NN NN O
in NN NN O
five NN NN O
boys NN NN O
with NN NN O
DMD NN NN B-SpecificDisease
. NN NN O

The NN NN O
authors NN NN O
wanted NN NN O
to NN NN O
determined NN NN O
whether NN NN O
there NN NN O
were NN NN O
similar NN NN O
ERG NN NN O
findings NN NN O
in NN NN O
an NN NN O
animal NN NN O
model NN NN O
for NN NN O
DMD NN NN B-SpecificDisease
, NN NN O
the NN NN O
mdx NN NN O
mouse NN NN O
. NN NN O

METHODS NN NN O
. NN NN O

Ganzfeld NN NN O
ERGs NN NN O
were NN NN O
recorded NN NN O
in NN NN O
five NN NN O
boys NN NN O
with NN NN O
DMD NN NN B-SpecificDisease
after NN NN O
a NN NN O
complete NN NN O
ophthalmic NN NN O
examination NN NN O
. NN NN O

The NN NN O
dystrophin NN NN O
gene NN NN O
was NN NN O
analyzed NN NN O
by NN NN O
Southern NN NN O
blot NN NN O
hybridization NN NN O
. NN NN O

ERGs NN NN O
were NN NN O
recorded NN NN O
in NN NN O
anesthetized NN NN O
mdx NN NN O
and NN NN O
control NN NN O
mice NN NN O
with NN NN O
a NN NN O
modified NN NN O
Grass NN NN O
photostimulator NN NN O
( NN NN O
Grass NN NN O
Instrument NN NN O
Company NN NN O
, NN NN O
Quincy NN NN O
, NN NN O
MA NN NN O
) NN NN O
. NN NN O

RESULTS NN NN O
. NN NN O

Ophthalmic NN NN O
examinations NN NN O
in NN NN O
all NN NN O
five NN NN O
boys NN NN O
had NN NN O
normal NN NN O
findings NN NN O
, NN NN O
yet NN NN O
an NN NN O
abnormal NN NN O
negative NN NN O
ERG NN NN O
was NN NN O
recorded NN NN O
for NN NN O
each NN NN O
subject NN NN O
. NN NN O

The NN NN O
subjects NN NN O
gene NN NN O
deletions NN NN O
were NN NN O
variable NN NN O
, NN NN O
ranging NN NN O
from NN NN O
large NN NN O
deletions NN NN O
to NN NN O
no NN NN O
detectable NN NN O
deletions NN NN O
. NN NN O

The NN NN O
ERGs NN NN O
of NN NN O
the NN NN O
mdx NN NN O
mice NN NN O
were NN NN O
normal NN NN O
and NN NN O
did NN NN O
not NN NN O
differ NN NN O
significantly NN NN O
from NN NN O
those NN NN O
of NN NN O
the NN NN O
control NN NN O
mice NN NN O
. NN NN O

CONCLUSIONS NN NN O
. NN NN O

The NN NN O
authors NN NN O
believe NN NN O
the NN NN O
unique NN NN O
ERG NN NN O
recorded NN NN O
for NN NN O
the NN NN O
human NN NN O
subjects NN NN O
is NN NN O
a NN NN O
manifestation NN NN O
of NN NN O
DMD NN NN B-SpecificDisease
associated NN NN O
with NN NN O
defects NN NN O
at NN NN O
the NN NN O
dystrophin NN NN O
gene NN NN O
locus NN NN O
and NN NN O
represents NN NN O
a NN NN O
new NN NN O
clinical NN NN O
entity NN NN O
. NN NN O

The NN NN O
ERG NN NN O
of NN NN O
the NN NN O
mdx NN NN O
mouse NN NN O
may NN NN O
be NN NN O
spared NN NN O
for NN NN O
several NN NN O
reasons NN NN O
, NN NN O
including NN NN O
milder NN NN O
effects NN NN O
of NN NN O
the NN NN O
mouse NN NN O
gene NN NN O
defect NN NN O
, NN NN O
differences NN NN O
in NN NN O
muscle NN NN O
and NN NN O
retinal NN NN O
gene NN NN O
product NN NN O
, NN NN O
or NN NN O
species NN NN O
differences NN NN O
in NN NN O
the NN NN O
biochemical NN NN O
role NN NN O
of NN NN O
dystrophin NN NN O
. NN NN O

The NN NN O
ERG NN NN O
shows NN NN O
promise NN NN O
of NN NN O
becoming NN NN O
a NN NN O
noninvasive NN NN O
diagnostic NN NN O
tool NN NN O
for NN NN O
DMD NN NN B-SpecificDisease
and NN NN O
its NN NN O
milder NN NN O
allelic NN NN O
forms NN NN O
. NN NN O

. NN NN O

8259519 NN NN O
Association NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
tumor NN NN I-Modifier
suppressor NN NN O
protein NN NN O
with NN NN O
catenins NN NN O
. NN NN O

Mutations NN NN O
of NN NN O
APC NN NN O
appear NN NN O
to NN NN O
initiate NN NN O
sporadic NN NN O
and NN NN O
inherited NN NN O
forms NN NN O
of NN NN O
human NN NN O
colorectal NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

Although NN NN O
these NN NN O
mutations NN NN O
have NN NN O
been NN NN O
well NN NN O
characterized NN NN O
, NN NN O
little NN NN O
is NN NN O
known NN NN O
about NN NN O
the NN NN O
function NN NN O
of NN NN O
the NN NN O
APC NN NN B-Modifier
gene NN NN O
product NN NN O
. NN NN O

Two NN NN O
cellular NN NN O
proteins NN NN O
that NN NN O
associate NN NN O
with NN NN O
APC NN NN B-SpecificDisease
were NN NN O
identified NN NN O
by NN NN O
nucleotide NN NN O
sequence NN NN O
analysis NN NN O
and NN NN O
peptide NN NN O
mapping NN NN O
as NN NN O
the NN NN O
E-cadherin-associated NN NN O
proteins NN NN O
alpha- NN NN O
and NN NN O
beta-catenin NN NN O
. NN NN O

A NN NN O
27-residue NN NN O
fragment NN NN O
of NN NN O
APC NN NN O
containing NN NN O
a NN NN O
15-amino NN NN O
acid NN NN O
repeat NN NN O
was NN NN O
sufficient NN NN O
for NN NN O
the NN NN O
interaction NN NN O
with NN NN O
the NN NN O
catenins NN NN O
. NN NN O

These NN NN O
results NN NN O
suggest NN NN O
an NN NN O
important NN NN O
link NN NN O
between NN NN O
tumor NN NN B-Modifier
initiation NN NN O
and NN NN O
cell NN NN O
adhesion NN NN O
. NN NN O

. NN NN O

8266996 NN NN O
Difference NN NN O
in NN NN O
methylation NN NN O
patterns NN NN O
within NN NN O
the NN NN O
D15S9 NN NN O
region NN NN O
of NN NN O
chromosome NN NN O
15q11-13 NN NN O
in NN NN O
first NN NN O
cousins NN NN O
with NN NN O
Angelman NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
and NN NN O
Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

Abnormalities NN NN O
of NN NN O
chromosome NN NN O
region NN NN O
15q11-13 NN NN O
are NN NN O
associated NN NN O
with NN NN O
Angelman NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
AS NN NN B-SpecificDisease
) NN NN O
and NN NN O
Prader-Willi NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
PWS NN NN B-SpecificDisease
) NN NN O
. NN NN O

Differences NN NN O
between NN NN O
the NN NN O
methylation NN NN O
patterns NN NN O
of NN NN O
the NN NN O
region NN NN O
of NN NN O
chromosome NN NN O
15q11-13 NN NN O
which NN NN O
hybridizes NN NN O
to NN NN O
the NN NN O
highly NN NN O
conserved NN NN O
DNA NN NN O
, NN NN O
DN34 NN NN O
, NN NN O
in NN NN O
normal NN NN O
individuals NN NN O
and NN NN O
in NN NN O
patients NN NN O
with NN NN O
AS NN NN B-SpecificDisease
and NN NN O
PWS NN NN B-SpecificDisease
have NN NN O
been NN NN O
described NN NN O
. NN NN O

We NN NN O
report NN NN O
on NN NN O
a NN NN O
family NN NN O
in NN NN O
which NN NN O
first NN NN O
cousins NN NN O
are NN NN O
affected NN NN O
by NN NN O
AS NN NN B-SpecificDisease
and NN NN O
PWS NN NN B-SpecificDisease
as NN NN O
a NN NN O
result NN NN O
of NN NN O
a NN NN O
familial NN NN O
paracentric NN NN O
inversion NN NN O
of NN NN O
15q11-q13 NN NN O
. NN NN O

The NN NN O
results NN NN O
of NN NN O
the NN NN O
studies NN NN O
on NN NN O
this NN NN O
family NN NN O
demonstrate NN NN O
the NN NN O
differences NN NN O
in NN NN O
the NN NN O
methylation NN NN O
patterns NN NN O
in NN NN O
the NN NN O
2 NN NN O
conditions NN NN O
and NN NN O
the NN NN O
phenomenon NN NN O
of NN NN O
genomic NN NN O
imprinting NN NN O
, NN NN O
whereby NN NN O
genetic NN NN O
information NN NN O
is NN NN O
expressed NN NN O
differently NN NN O
dependent NN NN O
on NN NN O
the NN NN O
parent NN NN O
of NN NN O
origin NN NN O
. NN NN O

. NN NN O

8279472 NN NN O
Haplotype NN NN O
studies NN NN O
in NN NN O
Wilson NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

In NN NN O
51 NN NN O
families NN NN O
with NN NN O
Wilson NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
, NN NN O
we NN NN O
have NN NN O
studied NN NN O
DNA NN NN O
haplotypes NN NN O
of NN NN O
dinucleotide NN NN O
repeat NN NN O
polymorphisms NN NN O
( NN NN O
CA NN NN O
repeats NN NN O
) NN NN O
in NN NN O
the NN NN O
13q14 NN NN O
. NN NN O

3 NN NN O
region NN NN O
, NN NN O
to NN NN O
examine NN NN O
these NN NN O
markers NN NN O
for NN NN O
association NN NN O
with NN NN O
the NN NN O
Wilson NN NN B-Modifier
disease NN NN I-Modifier
gene NN NN O
( NN NN O
WND NN NN O
) NN NN O
. NN NN O

In NN NN O
addition NN NN O
to NN NN O
a NN NN O
marker NN NN O
( NN NN O
D13S133 NN NN O
) NN NN O
described NN NN O
elsewhere NN NN O
, NN NN O
we NN NN O
have NN NN O
developed NN NN O
three NN NN O
new NN NN O
highly NN NN O
polymorphic NN NN O
markers NN NN O
( NN NN O
D13S314 NN NN O
, NN NN O
D13S315 NN NN O
, NN NN O
and NN NN O
D13S316 NN NN O
) NN NN O
close NN NN O
to NN NN O
the NN NN O
WND NN NN O
locus NN NN O
. NN NN O

We NN NN O
have NN NN O
examined NN NN O
the NN NN O
distribution NN NN O
of NN NN O
marker NN NN O
alleles NN NN O
at NN NN O
the NN NN O
loci NN NN O
studied NN NN O
and NN NN O
have NN NN O
found NN NN O
that NN NN O
D13S314 NN NN O
, NN NN O
D13S133 NN NN O
, NN NN O
and NN NN O
D13S316 NN NN O
each NN NN O
show NN NN O
nonrandom NN NN O
distribution NN NN O
on NN NN O
chromosomes NN NN O
carrying NN NN O
the NN NN O
WND NN NN O
mutation NN NN O
. NN NN O

We NN NN O
have NN NN O
studied NN NN O
haplotypes NN NN O
of NN NN O
these NN NN O
three NN NN O
markers NN NN O
and NN NN O
have NN NN O
found NN NN O
that NN NN O
there NN NN O
are NN NN O
highly NN NN O
significant NN NN O
differences NN NN O
between NN NN O
WND NN NN O
and NN NN O
normal NN NN O
haplotypes NN NN O
in NN NN O
northern NN NN O
European NN NN O
families NN NN O
. NN NN O

These NN NN O
findings NN NN O
have NN NN O
important NN NN O
implications NN NN O
for NN NN O
mutation NN NN O
detection NN NN O
and NN NN O
molecular NN NN O
diagnosis NN NN O
in NN NN O
families NN NN O
with NN NN O
Wilson NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

8281142 NN NN O
Genetic NN NN O
analysis NN NN O
of NN NN O
the NN NN O
BRCA1 NN NN O
region NN NN O
in NN NN O
a NN NN O
large NN NN O
breast/ovarian NN NN O
family NN NN O
: NN NN O
refinement NN NN O
of NN NN O
the NN NN O
minimal NN NN O
region NN NN O
containing NN NN O
BRCA1 NN NN O
. NN NN O

We NN NN O
have NN NN O
analyzed NN NN O
a NN NN O
single NN NN O
multi-affected NN NN O
breast NN NN B-Modifier
/ NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
pedigree NN NN O
( NN NN O
BOV3 NN NN O
) NN NN O
and NN NN O
have NN NN O
shown NN NN O
consistent NN NN O
inheritance NN NN O
of NN NN O
markers NN NN O
on NN NN O
chromosome NN NN O
17q NN NN O
with NN NN O
the NN NN O
disease NN NN O
confirming NN NN O
that NN NN O
this NN NN O
family NN NN O
is NN NN O
due NN NN O
to NN NN O
the NN NN O
BRCA1 NN NN O
gene NN NN O
. NN NN O

Analysis NN NN O
of NN NN O
17q NN NN O
haplotypes NN NN O
shows NN NN O
a NN NN O
recombination NN NN O
event NN NN O
in NN NN O
a NN NN O
bilateral NN NN O
breast NN NN B-Modifier
cancer NN NN I-Modifier
case NN NN O
which NN NN O
suggests NN NN O
that NN NN O
the NN NN O
BRCA1 NN NN O
gene NN NN O
lies NN NN O
distal NN NN O
to NN NN O
D17S857 NN NN O
; NN NN O
D17S857 NN NN O
is NN NN O
thus NN NN O
the NN NN O
new NN NN O
proximal NN NN O
boundary NN NN O
for NN NN O
the NN NN O
region NN NN O
containing NN NN O
BRCA1 NN NN O
. NN NN O

Combining NN NN O
this NN NN O
information NN NN O
with NN NN O
previously NN NN O
published NN NN O
mapping NN NN O
information NN NN O
suggests NN NN O
that NN NN O
BRCA1 NN NN O
is NN NN O
contained NN NN O
in NN NN O
a NN NN O
region NN NN O
estimated NN NN O
at NN NN O
1-1 NN NN O
. NN NN O

5 NN NN O
Mb NN NN O
in NN NN O
length NN NN O
. NN NN O

All NN NN O
seven NN NN O
breast NN NN B-Modifier
tumour NN NN I-Modifier
/ NN NN O
blood NN NN O
pairs NN NN O
examined NN NN O
from NN NN O
this NN NN O
family NN NN O
show NN NN O
loss NN NN O
of NN NN O
heterozygosity NN NN O
in NN NN O
the NN NN O
tumours NN NN B-DiseaseClass
. NN NN O

The NN NN O
allel NN NN O
retained NN NN O
in NN NN O
each NN NN O
tumour NN NN B-DiseaseClass
was NN NN O
from NN NN O
the NN NN O
disease-bearing NN NN O
chromosome NN NN O
implicating NN NN O
BRCA1 NN NN O
as NN NN O
a NN NN O
tumour NN NN B-Modifier
suppressor NN NN O
gene NN NN O
. NN NN O

We NN NN O
have NN NN O
sequenced NN NN O
the NN NN O
17 NN NN O
beta-oestradiol NN NN O
dehydrogenase NN NN O
genes NN NN O
( NN NN O
EDH17B1 NN NN O
and NN NN O
EDH17B2 NN NN O
) NN NN O
which NN NN O
have NN NN O
been NN NN O
suggested NN NN O
as NN NN O
candidate NN NN O
genes NN NN O
for NN NN O
BRCA1 NN NN O
in NN NN O
four NN NN O
members NN NN O
of NN NN O
this NN NN O
family NN NN O
. NN NN O

No NN NN O
germline NN NN O
mutations NN NN O
were NN NN O
detected NN NN O
. NN NN O

8281152 NN NN O
Myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
kinase NN NN O
is NN NN O
a NN NN O
component NN NN O
of NN NN O
neuromuscular NN NN O
junctions NN NN O
. NN NN O

The NN NN O
clinical NN NN O
manifestation NN NN O
of NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
is NN NN O
correlated NN NN O
to NN NN O
the NN NN O
extent NN NN O
of NN NN O
expansion NN NN O
of NN NN O
an NN NN O
unstable NN NN O
[ NN NN O
CTG NN NN O
] NN NN O
n NN NN O
DNA NN NN O
motif NN NN O
. NN NN O

Recent NN NN O
studies NN NN O
have NN NN O
demonstrated NN NN O
that NN NN O
this NN NN O
trinucleotide NN NN O
motif NN NN O
forms NN NN O
part NN NN O
of NN NN O
the NN NN O
last NN NN O
, NN NN O
3 NN NN O
untranslated NN NN O
exon NN NN O
of NN NN O
a NN NN O
gene NN NN O
which NN NN O
potentially NN NN O
encodes NN NN O
multiple NN NN O
protein NN NN O
isoforms NN NN O
of NN NN O
a NN NN O
serine NN NN O
/ NN NN O
threonine NN NN O
protein NN NN O
kinase NN NN O
( NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
protein NN NN O
kinase NN NN O
, NN NN O
DM-PK NN NN O
) NN NN O
. NN NN O

We NN NN O
report NN NN O
here NN NN O
on NN NN O
the NN NN O
development NN NN O
of NN NN O
antisera NN NN O
against NN NN O
synthetic NN NN O
DM-PK NN NN O
peptide NN NN O
antigens NN NN O
and NN NN O
their NN NN O
use NN NN O
in NN NN O
biochemical NN NN O
and NN NN O
histochemical NN NN O
studies NN NN O
. NN NN O

Immunoreactive NN NN O
DM-kinase NN NN O
protein NN NN O
of NN NN O
53 NN NN O
kD NN NN O
is NN NN O
present NN NN O
at NN NN O
low NN NN O
levels NN NN O
in NN NN O
skeletal NN NN O
and NN NN O
cardiac NN NN O
muscle NN NN O
extracts NN NN O
of NN NN O
DM NN NN B-Modifier
patients NN NN O
and NN NN O
normal NN NN O
controls NN NN O
. NN NN O

Immunohistochemical NN NN O
staining NN NN O
revealed NN NN O
that NN NN O
DM-PK NN NN O
is NN NN O
localised NN NN O
prominently NN NN O
at NN NN O
sites NN NN O
of NN NN O
neuromuscular NN NN O
and NN NN O
myotendinous NN NN O
junctions NN NN O
( NN NN O
NMJs NN NN O
and NN NN O
MTJs NN NN O
) NN NN O
of NN NN O
human NN NN O
and NN NN O
rodent NN NN O
skeletal NN NN O
muscles NN NN O
. NN NN O

Furthermore NN NN O
, NN NN O
very NN NN O
low NN NN O
levels NN NN O
of NN NN O
immunoreactive NN NN O
DM-PK NN NN O
protein NN NN O
are NN NN O
present NN NN O
in NN NN O
the NN NN O
sarcoplasm NN NN O
of NN NN O
predominantly NN NN O
type NN NN O
I NN NN O
fibres NN NN O
in NN NN O
various NN NN O
muscles NN NN O
. NN NN O

Strikingly NN NN O
, NN NN O
presence NN NN O
of NN NN O
the NN NN O
protein NN NN O
can NN NN O
also NN NN O
be NN NN O
demonstrated NN NN O
for NN NN O
NMJs NN NN O
of NN NN O
muscular NN NN O
tissues NN NN O
of NN NN O
adult NN NN O
and NN NN O
congenital NN NN O
cases NN NN O
of NN NN O
DM NN NN B-SpecificDisease
, NN NN O
with NN NN O
no NN NN O
gross NN NN O
changes NN NN O
in NN NN O
structural NN NN O
organisation NN NN O
. NN NN O

Our NN NN O
findings NN NN O
provide NN NN O
a NN NN O
basis NN NN O
for NN NN O
further NN NN O
characterisation NN NN O
of NN NN O
the NN NN O
role NN NN O
of NN NN O
the NN NN O
kinase NN NN O
in NN NN O
protein NN NN O
assembly NN NN O
processes NN NN O
or NN NN O
signal NN NN O
mediation NN NN O
at NN NN O
synaptic NN NN O
sites NN NN O
and NN NN O
ultimately NN NN O
for NN NN O
the NN NN O
understanding NN NN O
of NN NN O
the NN NN O
complex NN NN O
pathophysiology NN NN O
of NN NN O
DM NN NN B-SpecificDisease
. NN NN O

. NN NN O

8282802 NN NN O
Markedly NN NN O
accelerated NN NN O
catabolism NN NN O
of NN NN O
apolipoprotein NN NN O
A-II NN NN O
( NN NN O
ApoA-II NN NN O
) NN NN O
and NN NN O
high NN NN O
density NN NN O
lipoproteins NN NN O
containing NN NN O
ApoA-II NN NN O
in NN NN O
classic NN NN O
lecithin NN NN O
: NN NN O
cholesterol NN NN B-SpecificDisease
acyltransferase NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
and NN NN O
fish-eye NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

Classic NN NN B-CompositeMention
( NN NN I-CompositeMention
complete NN NN I-CompositeMention
) NN NN I-CompositeMention
lecithin NN NN I-CompositeMention
cholesterol NN NN I-CompositeMention
acyltransferase NN NN I-CompositeMention
( NN NN I-CompositeMention
LCAT NN NN I-CompositeMention
) NN NN I-CompositeMention
deficiency NN NN I-CompositeMention
and NN NN O
Fish-eye NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
partial NN NN B-SpecificDisease
LCAT NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
) NN NN O
are NN NN O
genetic NN NN O
syndromes NN NN O
associated NN NN O
with NN NN O
markedly NN NN O
decreased NN NN O
plasma NN NN O
levels NN NN O
of NN NN O
high NN NN O
density NN NN O
lipoprotein NN NN O
( NN NN O
HDL NN NN O
) NN NN O
cholesterol NN NN O
but NN NN O
not NN NN O
with NN NN O
an NN NN O
increased NN NN O
risk NN NN O
of NN NN O
atherosclerotic NN NN B-SpecificDisease
cardiovascular NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

We NN NN O
investigated NN NN O
the NN NN O
metabolism NN NN O
of NN NN O
the NN NN O
HDL NN NN O
apolipoproteins NN NN O
( NN NN O
apo NN NN O
) NN NN O
apoA-I NN NN O
and NN NN O
apoA-II NN NN O
in NN NN O
a NN NN O
total NN NN O
of NN NN O
five NN NN O
patients NN NN O
with NN NN O
LCAT NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
, NN NN I-SpecificDisease
one NN NN O
with NN NN O
classic NN NN B-SpecificDisease
LCAT NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
and NN NN O
four NN NN O
with NN NN O
Fish-eye NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

Plasma NN NN O
levels NN NN O
of NN NN O
apoA-II NN NN O
were NN NN O
decreased NN NN O
to NN NN O
a NN NN O
proportionately NN NN O
greater NN NN O
extent NN NN O
( NN NN O
23 NN NN O
% NN NN O
of NN NN O
normal NN NN O
) NN NN O
than NN NN O
apoA-I NN NN O
( NN NN O
30 NN NN O
% NN NN O
of NN NN O
normal NN NN O
) NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
plasma NN NN O
concentrations NN NN O
of NN NN O
HDL NN NN O
particles NN NN O
containing NN NN O
both NN NN O
apoA-I NN NN O
and NN NN O
apoA-II NN NN O
( NN NN O
LpA-I NN NN O
A-II NN NN O
) NN NN O
were NN NN O
much NN NN O
lower NN NN O
( NN NN O
18 NN NN O
% NN NN O
of NN NN O
normal NN NN O
) NN NN O
than NN NN O
those NN NN O
of NN NN O
particles NN NN O
containing NN NN O
only NN NN O
apoA-I NN NN O
( NN NN O
LpA-I NN NN O
) NN NN O
( NN NN O
51 NN NN O
% NN NN O
of NN NN O
normal NN NN O
) NN NN O
. NN NN O

The NN NN O
metabolic NN NN O
basis NN NN O
for NN NN O
the NN NN O
low NN NN O
levels NN NN O
of NN NN O
apoA-II NN NN O
and NN NN O
LpA-I NN NN O
A-II NN NN O
was NN NN O
investigated NN NN O
in NN NN O
all NN NN O
five NN NN O
patients NN NN O
using NN NN O
both NN NN O
exogenous NN NN O
radiotracer NN NN O
and NN NN O
endogenous NN NN O
stable NN NN O
isotope NN NN O
labeling NN NN O
techniques NN NN O
. NN NN O

The NN NN O
mean NN NN O
plasma NN NN O
residence NN NN O
time NN NN O
of NN NN O
apoA-I NN NN O
was NN NN O
decreased NN NN O
at NN NN O
2 NN NN O
. NN NN O

08 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O

27 NN NN O
d NN NN O
( NN NN O
controls NN NN O
4 NN NN O
. NN NN O

74 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O

65 NN NN O
days NN NN O
) NN NN O
; NN NN O
however NN NN O
, NN NN O
the NN NN O
residence NN NN O
time NN NN O
of NN NN O
apoA-II NN NN O
was NN NN O
even NN NN O
shorter NN NN O
at NN NN O
1 NN NN O
. NN NN O

66 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O

24 NN NN O
d NN NN O
( NN NN O
controls NN NN O
5 NN NN O
. NN NN O

25 NN NN O
+ NN NN O
/ NN NN O
- NN NN O
0 NN NN O
. NN NN O

61 NN NN O
d NN NN O
) NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
the NN NN O
catabolism NN NN O
of NN NN O
apoA-I NN NN O
in NN NN O
LpA-I NN NN O
A-II NN NN O
was NN NN O
substantially NN NN O
faster NN NN O
than NN NN O
that NN NN O
of NN NN O
apoA-I NN NN O
in NN NN O
LpA-I NN NN O
. NN NN O

In NN NN O
summary NN NN O
, NN NN O
genetic NN NN O
syndromes NN NN O
of NN NN O
either NN NN O
complete NN NN B-CompositeMention
or NN NN I-CompositeMention
partial NN NN I-CompositeMention
LCAT NN NN I-CompositeMention
deficiency NN NN I-CompositeMention
result NN NN O
in NN NN O
low NN NN O
levels NN NN O
of NN NN O
HDL NN NN O
through NN NN O
preferential NN NN O
hypercatabolism NN NN O
of NN NN O
apoA-II NN NN O
and NN NN O
HDL NN NN O
particles NN NN O
containing NN NN O
apoA-II NN NN O
. NN NN O

Because NN NN O
LpA-I NN NN O
has NN NN O
been NN NN O
proposed NN NN O
to NN NN O
be NN NN O
more NN NN O
protective NN NN O
than NN NN O
LpA-I NN NN O
A-II NN NN O
against NN NN O
atherosclerosis NN NN B-SpecificDisease
, NN NN O
this NN NN O
selective NN NN O
effect NN NN O
on NN NN O
the NN NN O
metabolism NN NN O
of NN NN O
LpA-I NN NN O
A-II NN NN O
may NN NN O
provide NN NN O
a NN NN O
potential NN NN O
explanation NN NN O
why NN NN O
patients NN NN O
with NN NN O
classic NN NN B-SpecificDisease
LCAT NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
and NN NN O
Fish-eye NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
are NN NN O
not NN NN O
at NN NN O
increased NN NN O
risk NN NN O
for NN NN O
premature NN NN O
atherosclerosis NN NN B-SpecificDisease
despite NN NN O
markedly NN NN O
decreased NN NN O
levels NN NN O
of NN NN O
HDL NN NN O
cholesterol NN NN O
and NN NN O
apoA-I NN NN O

8301658 NN NN O
X NN NN B-SpecificDisease
linked NN NN I-SpecificDisease
recessive NN NN I-SpecificDisease
thrombocytopenia NN NN I-SpecificDisease
. NN NN O

A NN NN O
Saudi NN NN O
Arab NN NN O
boy NN NN O
presented NN NN O
in NN NN O
early NN NN O
childhood NN NN O
with NN NN O
thrombocytopenia NN NN B-SpecificDisease
, NN NN O
morphologically NN NN O
large NN NN O
and NN NN O
normal NN NN O
sized NN NN O
platelets NN NN O
, NN NN O
increased NN NN O
mean NN NN O
platelet NN NN O
volume NN NN O
, NN NN O
and NN NN O
a NN NN O
hypermegakaryocytic NN NN O
bone NN NN O
marrow NN NN O
. NN NN O

There NN NN O
was NN NN O
no NN NN O
clinical NN NN O
and NN NN O
laboratory NN NN O
evidence NN NN O
of NN NN O
any NN NN O
significant NN NN O
immunological NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
. NN NN O

Similar NN NN O
findings NN NN O
in NN NN O
two NN NN O
other NN NN O
brothers NN NN O
suggested NN NN O
strongly NN NN O
that NN NN O
they NN NN O
were NN NN O
all NN NN O
suffering NN NN O
from NN NN O
an NN NN O
X NN NN B-SpecificDisease
linked NN NN I-SpecificDisease
recessive NN NN I-SpecificDisease
thrombocytopenic NN NN I-SpecificDisease
disorder NN NN I-SpecificDisease
. NN NN O

Results NN NN O
of NN NN O
DNA NN NN O
analysis NN NN O
with NN NN O
the NN NN O
probe NN NN O
M27 NN NN O
beta NN NN O
are NN NN O
consistent NN NN O
with NN NN O
X NN NN O
linkage NN NN O
and NN NN O
indicate NN NN O
also NN NN O
that NN NN O
the NN NN O
locus NN NN O
of NN NN O
the NN NN O
relevant NN NN O
gene NN NN O
lies NN NN O
close NN NN O
to NN NN O
or NN NN O
is NN NN O
identical NN NN O
to NN NN O
the NN NN O
locus NN NN O
of NN NN O
the NN NN O
gene NN NN O
for NN NN O
the NN NN O
Wiskott-Aldrich NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
WAS NN NN B-SpecificDisease
) NN NN O
. NN NN O

Because NN NN O
of NN NN O
various NN NN O
features NN NN O
which NN NN O
include NN NN O
the NN NN O
presence NN NN O
of NN NN O
large NN NN O
and NN NN O
normal NN NN O
sized NN NN O
platelets NN NN O
( NN NN O
rather NN NN O
than NN NN O
small NN NN O
platelets NN NN O
) NN NN O
and NN NN O
freedom NN NN O
from NN NN O
significant NN NN O
immune NN NN B-DiseaseClass
deficiencies NN NN I-DiseaseClass
, NN NN O
it NN NN O
is NN NN O
likely NN NN O
that NN NN O
the NN NN O
X NN NN B-SpecificDisease
linked NN NN I-SpecificDisease
recessive NN NN I-SpecificDisease
thrombocytopenia NN NN I-SpecificDisease
in NN NN O
this NN NN O
family NN NN O
is NN NN O
an NN NN O
isolated NN NN O
entity NN NN O
quite NN NN O
distinct NN NN O
from NN NN O
the NN NN O
classical NN NN O
WAS NN NN B-Modifier
phenotype NN NN O
. NN NN O

However NN NN O
, NN NN O
a NN NN O
modified NN NN O
expression NN NN O
of NN NN O
the NN NN O
WAS NN NN B-Modifier
gene NN NN O
producing NN NN O
a NN NN O
mild NN NN O
phenotypic NN NN O
variant NN NN O
can NN NN O
not NN NN O
be NN NN O
excluded NN NN O
entirely NN NN O
. NN NN O

. NN NN O

8302543 NN NN O
Macular NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
associated NN NN O
with NN NN O
mutations NN NN O
at NN NN O
codon NN NN O
172 NN NN O
in NN NN O
the NN NN O
human NN NN O
retinal NN NN B-Modifier
degeneration NN NN I-Modifier
slow NN NN O
gene NN NN O
. NN NN O

BACKGROUND NN NN O
Recently NN NN O
, NN NN O
mutations NN NN O
in NN NN O
the NN NN O
retinal NN NN B-Modifier
degeneration NN NN I-Modifier
slow NN NN O
( NN NN O
rds NN NN O
) NN NN O
gene NN NN O
which NN NN O
codes NN NN O
for NN NN O
peripherin-rds NN NN O
have NN NN O
been NN NN O
implicated NN NN O
as NN NN O
a NN NN O
cause NN NN O
of NN NN O
autosomal NN NN B-SpecificDisease
dominant NN NN I-SpecificDisease
retinitis NN NN I-SpecificDisease
pigmentosa NN NN I-SpecificDisease
. NN NN O

Because NN NN O
this NN NN O
gene NN NN O
is NN NN O
expressed NN NN O
in NN NN O
both NN NN O
rods NN NN O
and NN NN O
cones NN NN O
, NN NN O
mutations NN NN O
in NN NN O
the NN NN O
rds NN NN O
gene NN NN O
might NN NN O
be NN NN O
expected NN NN O
to NN NN O
cause NN NN O
degeneration NN NN O
affecting NN NN O
either NN NN O
the NN NN O
scotopic NN NN O
or NN NN O
photopic NN NN O
systems NN NN O
. NN NN O

Mutations NN NN O
at NN NN O
codon NN NN O
172 NN NN O
of NN NN O
the NN NN O
rds NN NN O
gene NN NN O
have NN NN O
been NN NN O
identified NN NN O
in NN NN O
three NN NN O
families NN NN O
with NN NN O
autosomal NN NN O
dominantly NN NN O
inherited NN NN O
, NN NN O
progressive NN NN O
macular NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
. NN NN O

METHODS NN NN O
Affected NN NN O
individuals NN NN O
underwent NN NN O
ophthalmic NN NN O
examination NN NN O
, NN NN O
scotopic NN NN O
perimetry NN NN O
, NN NN O
dark NN NN O
adaptometry NN NN O
, NN NN O
measurement NN NN O
of NN NN O
color-contrast NN NN O
sensitivity NN NN O
, NN NN O
and NN NN O
electroretinography NN NN O
to NN NN O
characterize NN NN O
the NN NN O
photoreceptor NN NN O
dysfunction NN NN O
. NN NN O

RESULTS NN NN O
In NN NN O
all NN NN O
but NN NN O
one NN NN O
affected NN NN O
member NN NN O
, NN NN O
symptoms NN NN O
of NN NN O
progressive NN NN O
central NN NN O
visual NN NN B-SpecificDisease
loss NN NN I-SpecificDisease
developed NN NN O
in NN NN O
the NN NN O
third NN NN O
or NN NN O
fourth NN NN O
decade NN NN O
of NN NN O
life NN NN O
accompanied NN NN O
by NN NN O
central NN NN B-SpecificDisease
scotoma NN NN I-SpecificDisease
and NN NN O
well-demarcated NN NN O
atrophy NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
retinal NN NN I-SpecificDisease
pigment NN NN I-SpecificDisease
epithelium NN NN I-SpecificDisease
and NN NN O
choriocapillaris NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
macula NN NN I-SpecificDisease
. NN NN O

In NN NN O
general NN NN O
, NN NN O
cone NN NN O
and NN NN O
rod NN NN O
thresholds NN NN O
were NN NN O
elevated NN NN O
, NN NN O
and NN NN O
color-contrast NN NN O
sensitivity NN NN O
was NN NN O
absent NN NN O
in NN NN O
the NN NN O
central NN NN O
visual NN NN O
field NN NN O
. NN NN O

Peripherally NN NN O
, NN NN O
the NN NN O
scotopic NN NN O
sensitivities NN NN O
were NN NN O
normal NN NN O
, NN NN O
as NN NN O
was NN NN O
the NN NN O
recovery NN NN O
from NN NN O
bleach NN NN O
. NN NN O

Cone NN NN O
electroretinograms NN NN O
were NN NN O
diminished NN NN O
in NN NN O
amplitude NN NN O
, NN NN O
and NN NN O
delayed NN NN O
in NN NN O
all NN NN O
affected NN NN O
adults NN NN O
except NN NN O
one NN NN O
. NN NN O

Rod NN NN O
electroretinograms NN NN O
were NN NN O
normal NN NN O
or NN NN O
near NN NN O
normal NN NN O
in NN NN O
amplitude NN NN O
, NN NN O
and NN NN O
had NN NN O
normal NN NN O
implicit NN NN O
times NN NN O
. NN NN O

Affected NN NN O
asymptomatic NN NN O
children NN NN O
had NN NN O
macular NN NN O
changes NN NN O
, NN NN O
abnormal NN NN O
color-contrast NN NN O
sensitivity NN NN O
, NN NN O
and NN NN O
reduced NN NN O
pattern NN NN O
and NN NN O
cone NN NN O
electroretinograms NN NN O
. NN NN O

CONCLUSION NN NN O
These NN NN O
results NN NN O
indicate NN NN O
that NN NN O
mutations NN NN O
in NN NN O
the NN NN O
rds NN NN O
gene NN NN O
can NN NN O
be NN NN O
expressed NN NN O
as NN NN O
a NN NN O
macular NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
, NN NN O
with NN NN O
evidence NN NN O
of NN NN O
primary NN NN O
cone NN NN B-DiseaseClass
dysfunction NN NN I-DiseaseClass
and NN NN O
preservation NN NN O
of NN NN O
peripheral NN NN O
rod NN NN O
function NN NN O
. NN NN O

. NN NN O

8304342 NN NN O
Anonymous NN NN O
marker NN NN O
loci NN NN O
within NN NN O
400 NN NN O
kb NN NN O
of NN NN O
HLA-A NN NN O
generate NN NN O
haplotypes NN NN O
in NN NN O
linkage NN NN O
disequilibrium NN NN O
with NN NN O
the NN NN O
hemochromatosis NN NN B-Modifier
gene NN NN O
( NN NN O
HFE NN NN O
) NN NN O
The NN NN O
hemochromatosis NN NN B-Modifier
gene NN NN O
( NN NN O
HFE NN NN O
) NN NN O
maps NN NN O
to NN NN O
6p21 NN NN O
. NN NN O

3 NN NN O
and NN NN O
is NN NN O
less NN NN O
than NN NN O
1 NN NN O
cM NN NN O
from NN NN O
the NN NN O
HLA NN NN O
class NN NN O
I NN NN O
genes NN NN O
; NN NN O
however NN NN O
, NN NN O
the NN NN O
precise NN NN O
physical NN NN O
location NN NN O
of NN NN O
the NN NN O
gene NN NN O
has NN NN O
remained NN NN O
elusive NN NN O
and NN NN O
controversial NN NN O
. NN NN O

The NN NN O
unambiguous NN NN O
identification NN NN O
of NN NN O
a NN NN O
crossover NN NN O
event NN NN O
within NN NN O
hemochromatosis NN NN B-Modifier
families NN NN O
is NN NN O
very NN NN O
difficult NN NN O
; NN NN O
it NN NN O
is NN NN O
particularly NN NN O
hampered NN NN O
by NN NN O
the NN NN O
variability NN NN O
of NN NN O
the NN NN O
phenotypic NN NN O
expression NN NN O
as NN NN O
well NN NN O
as NN NN O
by NN NN O
the NN NN O
sex- NN NN O
and NN NN O
age-related NN NN O
penetrance NN NN O
of NN NN O
the NN NN O
disease NN NN O
. NN NN O

For NN NN O
these NN NN O
practical NN NN O
considerations NN NN O
, NN NN O
traditional NN NN O
linkage NN NN O
analysis NN NN O
could NN NN O
prove NN NN O
of NN NN O
limited NN NN O
value NN NN O
in NN NN O
further NN NN O
refining NN NN O
the NN NN O
extrapolated NN NN O
physical NN NN O
position NN NN O
of NN NN O
HFE NN NN O
. NN NN O

We NN NN O
therefore NN NN O
embarked NN NN O
upon NN NN O
a NN NN O
linkage-disequilibrium NN NN O
analysis NN NN O
of NN NN O
HFE NN NN O
and NN NN O
normal NN NN O
chromosomes NN NN O
from NN NN O
the NN NN O
Brittany NN NN O
population NN NN O
. NN NN O

In NN NN O
the NN NN O
present NN NN O
report NN NN O
, NN NN O
66 NN NN O
hemochromatosis NN NN B-Modifier
families NN NN O
yielding NN NN O
151 NN NN O
hemochromatosis NN NN B-Modifier
chromosomes NN NN O
and NN NN O
182 NN NN O
normal NN NN O
chromosomes NN NN O
were NN NN O
RFLP-typed NN NN O
with NN NN O
a NN NN O
battery NN NN O
of NN NN O
probes NN NN O
, NN NN O
including NN NN O
two NN NN O
newly NN NN O
derived NN NN O
polymorphic NN NN O
markers NN NN O
from NN NN O
the NN NN O
6 NN NN O
. NN NN O

7 NN NN O
and NN NN O
HLA-F NN NN O
loci NN NN O
located NN NN O
150 NN NN O
and NN NN O
250 NN NN O
kb NN NN O
telomeric NN NN O
to NN NN O
HLA-A NN NN O
, NN NN O
respectively NN NN O
. NN NN O

The NN NN O
results NN NN O
suggest NN NN O
a NN NN O
strong NN NN O
peak NN NN O
of NN NN O
existing NN NN O
linkage NN NN O
disequilibrium NN NN O
focused NN NN O
within NN NN O
the NN NN O
i82-to-6 NN NN O
. NN NN O

7 NN NN O
interval NN NN O
( NN NN O
approximately NN NN O
250 NN NN O
kb NN NN O
) NN NN O
. NN NN O

The NN NN O
zone NN NN O
of NN NN O
linkage NN NN O
disequilibrium NN NN O
is NN NN O
flanked NN NN O
by NN NN O
the NN NN O
i97 NN NN O
locus NN NN O
, NN NN O
positioned NN NN O
30 NN NN O
kb NN NN O
proximal NN NN O
to NN NN O
i82 NN NN O
, NN NN O
and NN NN O
the NN NN O
HLA-F NN NN O
gene NN NN O
, NN NN O
found NN NN O
250 NN NN O
kb NN NN O
distal NN NN O
to NN NN O
HLA-A NN NN O
, NN NN O
markers NN NN O
of NN NN O
which NN NN O
display NN NN O
no NN NN O
significant NN NN O
association NN NN O
with NN NN O
HFE NN NN O
. NN NN O

These NN NN O
data NN NN O
support NN NN O
the NN NN O
possibility NN NN O
that NN NN O
HFE NN NN O
resides NN NN O
within NN NN O
the NN NN O
400-kb NN NN O
expanse NN NN O
of NN NN O
DNA NN NN O
between NN NN O
i97 NN NN O
and NN NN O
HLA-F NN NN O
. NN NN O

Alternatively NN NN O
, NN NN O
the NN NN O
very NN NN O
tight NN NN O
association NN NN O
of NN NN O
HLA-A3 NN NN O
and NN NN O
allele NN NN O
1 NN NN O
of NN NN O
the NN NN O
6 NN NN O
. NN NN O

7 NN NN O
locus NN NN O
, NN NN O
both NN NN O
of NN NN O
which NN NN O
are NN NN O
comprised NN NN O
by NN NN O
the NN NN O
major NN NN O
ancestral NN NN O
or NN NN O
founder NN NN O
HFE NN NN O
haplotype NN NN O
in NN NN O
Brittany NN NN O
, NN NN O
supports NN NN O
the NN NN O
possibility NN NN O
that NN NN O
the NN NN O
disease NN NN O
gene NN NN O
may NN NN O
reside NN NN O
immediately NN NN O
telomeric NN NN O
to NN NN O
the NN NN O
6 NN NN O
. NN NN O

7 NN NN O
locus NN NN O
within NN NN O
the NN NN O
linkage-disequilibrium NN NN O
zone NN NN O
. NN NN O

Additionally NN NN O
, NN NN O
hemochromatosis NN NN B-Modifier
haplotypes NN NN O
possessing NN NN O
HLA-A11 NN NN O
and NN NN O
the NN NN O
low-frequency NN NN O
HLA-F NN NN O
polymorphism NN NN O
( NN NN O
allele NN NN O
2 NN NN O
) NN NN O
are NN NN O
supportive NN NN O
of NN NN O
a NN NN O
separate NN NN O
founder NN NN O
chromosome NN NN O
containing NN NN O
a NN NN O
second NN NN O
, NN NN O
independently NN NN O
arising NN NN O
mutant NN NN O
allele NN NN O
. NN NN O

Overall NN NN O
, NN NN O
the NN NN O
establishment NN NN O
of NN NN O
a NN NN O
likely NN NN O
`` NN NN O
hemochromatosis NN NN B-Modifier
critical NN NN O
region NN NN O
`` NN NN O
centromeric NN NN O
boundary NN NN O
and NN NN O
the NN NN O
identification NN NN O
of NN NN O
a NN NN O
linkage-disequilibrium NN NN O
zone NN NN O
both NN NN O
significantly NN NN O
contribute NN NN O
to NN NN O
a NN NN O
reduction NN NN O
in NN NN O
the NN NN O
amount NN NN O
of NN NN O
DNA NN NN O
required NN NN O
to NN NN O
be NN NN O
searched NN NN O
for NN NN O
novel NN NN O
coding NN NN O
sequences NN NN O
constituting NN NN O
the NN NN O
HFE NN NN B-SpecificDisease
defect NN NN I-SpecificDisease

8307570 NN NN O
Genomic NN NN O
structure NN NN O
of NN NN O
the NN NN O
EWS NN NN O
gene NN NN O
and NN NN O
its NN NN O
relationship NN NN O
to NN NN O
EWSR1 NN NN O
, NN NN O
a NN NN O
site NN NN O
of NN NN O
tumor NN NN B-Modifier
-associated NN NN O
chromosome NN NN O
translocation NN NN O
. NN NN O

The NN NN O
EWS NN NN O
gene NN NN O
has NN NN O
been NN NN O
identified NN NN O
based NN NN O
on NN NN O
its NN NN O
location NN NN O
at NN NN O
the NN NN O
chromosome NN NN O
22 NN NN O
breakpoint NN NN O
of NN NN O
the NN NN O
t NN NN O
( NN NN O
11 NN NN O
; NN NN O
22 NN NN O
) NN NN O
( NN NN O
q24 NN NN O
; NN NN O
q12 NN NN O
) NN NN O
translocation NN NN O
that NN NN O
characterizes NN NN O
Ewing NN NN B-SpecificDisease
sarcoma NN NN I-SpecificDisease
and NN NN O
related NN NN O
neuroectodermal NN NN B-SpecificDisease
tumors NN NN I-SpecificDisease
. NN NN O

The NN NN O
EWS NN NN O
gene NN NN O
spans NN NN O
about NN NN O
40 NN NN O
kb NN NN O
of NN NN O
DNA NN NN O
and NN NN O
is NN NN O
encoded NN NN O
by NN NN O
17 NN NN O
exons NN NN O
. NN NN O

The NN NN O
nucleotide NN NN O
sequence NN NN O
of NN NN O
the NN NN O
exons NN NN O
is NN NN O
identical NN NN O
to NN NN O
that NN NN O
of NN NN O
the NN NN O
previously NN NN O
described NN NN O
cDNA NN NN O
. NN NN O

The NN NN O
first NN NN O
7 NN NN O
exons NN NN O
encode NN NN O
the NN NN O
N-terminal NN NN O
domain NN NN O
of NN NN O
EWS NN NN O
, NN NN O
which NN NN O
consists NN NN O
of NN NN O
a NN NN O
repeated NN NN O
degenerated NN NN O
polypeptide NN NN O
of NN NN O
7 NN NN O
to NN NN O
12 NN NN O
residues NN NN O
rich NN NN O
in NN NN O
tyrosine NN NN O
, NN NN O
serine NN NN O
, NN NN O
threonine NN NN O
, NN NN O
glycine NN NN O
, NN NN O
and NN NN O
glutamine NN NN O
. NN NN O

Exons NN NN O
11 NN NN O
, NN NN O
12 NN NN O
, NN NN O
and NN NN O
13 NN NN O
encode NN NN O
the NN NN O
putative NN NN O
RNA NN NN O
binding NN NN O
domain NN NN O
. NN NN O

The NN NN O
three NN NN O
glycine- NN NN O
and NN NN O
arginine-rich NN NN O
motifs NN NN O
of NN NN O
the NN NN O
gene NN NN O
are NN NN O
mainly NN NN O
encoded NN NN O
by NN NN O
exons NN NN O
8-9 NN NN O
, NN NN O
14 NN NN O
, NN NN O
and NN NN O
16 NN NN O
. NN NN O

The NN NN O
DNA NN NN O
sequence NN NN O
in NN NN O
the NN NN O
5 NN NN O
region NN NN O
of NN NN O
the NN NN O
gene NN NN O
has NN NN O
features NN NN O
of NN NN O
a NN NN O
CpG-rich NN NN O
island NN NN O
and NN NN O
lacks NN NN O
canonical NN NN O
promoter NN NN O
elements NN NN O
, NN NN O
such NN NN O
as NN NN O
TATA NN NN O
and NN NN O
CCAAT NN NN O
consensus NN NN O
sequences NN NN O
. NN NN O

Positions NN NN O
of NN NN O
the NN NN O
chromosome NN NN O
22 NN NN O
breakpoints NN NN O
were NN NN O
determined NN NN O
for NN NN O
19 NN NN O
Ewing NN NN B-DiseaseClass
tumors NN NN I-DiseaseClass
. NN NN O

They NN NN O
were NN NN O
localized NN NN O
in NN NN O
introns NN NN O
7 NN NN O
or NN NN O
8 NN NN O
in NN NN O
18 NN NN O
cases NN NN O
and NN NN O
in NN NN O
intron NN NN O
10 NN NN O
in NN NN O
1 NN NN O
case NN NN O
. NN NN O

. NN NN O

8314592 NN NN O
Norrie NN NN B-Modifier
disease NN NN I-Modifier
gene NN NN O
: NN NN O
characterization NN NN O
of NN NN O
deletions NN NN O
and NN NN O
possible NN NN O
function NN NN O
. NN NN O

Positional NN NN O
cloning NN NN O
experiments NN NN O
have NN NN O
resulted NN NN O
recently NN NN O
in NN NN O
the NN NN O
isolation NN NN O
of NN NN O
a NN NN O
candidate NN NN O
gene NN NN O
for NN NN O
Norrie NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
pseudoglioma NN NN B-SpecificDisease
; NN NN O
NDP NN NN B-SpecificDisease
) NN NN O
, NN NN O
a NN NN O
severe NN NN O
X-linked NN NN B-DiseaseClass
neurodevelopmental NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
. NN NN O

Here NN NN O
we NN NN O
report NN NN O
the NN NN O
isolation NN NN O
and NN NN O
analysis NN NN O
of NN NN O
human NN NN O
genomic NN NN O
DNA NN NN O
clones NN NN O
encompassing NN NN O
the NN NN O
NDP NN NN B-Modifier
gene NN NN O
. NN NN O

The NN NN O
gene NN NN O
spans NN NN O
28 NN NN O
kb NN NN O
and NN NN O
consists NN NN O
of NN NN O
3 NN NN O
exons NN NN O
, NN NN O
the NN NN O
first NN NN O
of NN NN O
which NN NN O
is NN NN O
entirely NN NN O
contained NN NN O
within NN NN O
the NN NN O
5 NN NN O
untranslated NN NN O
region NN NN O
. NN NN O

Detailed NN NN O
analysis NN NN O
of NN NN O
genomic NN NN O
deletions NN NN O
in NN NN O
Norrie NN NN B-Modifier
patients NN NN O
shows NN NN O
that NN NN O
they NN NN O
are NN NN O
heterogeneous NN NN O
, NN NN O
both NN NN O
in NN NN O
size NN NN O
and NN NN O
in NN NN O
position NN NN O
. NN NN O

By NN NN O
PCR NN NN O
analysis NN NN O
, NN NN O
we NN NN O
found NN NN O
that NN NN O
expression NN NN O
of NN NN O
the NN NN O
NDP NN NN B-Modifier
gene NN NN O
was NN NN O
not NN NN O
confined NN NN O
to NN NN O
the NN NN O
eye NN NN O
or NN NN O
to NN NN O
the NN NN O
brain NN NN O
. NN NN O

An NN NN O
extensive NN NN O
DNA NN NN O
and NN NN O
protein NN NN O
sequence NN NN O
comparison NN NN O
between NN NN O
the NN NN O
human NN NN O
NDP NN NN B-Modifier
gene NN NN O
and NN NN O
related NN NN O
genes NN NN O
from NN NN O
the NN NN O
database NN NN O
revealed NN NN O
homology NN NN O
with NN NN O
cysteine-rich NN NN O
protein-binding NN NN O
domains NN NN O
of NN NN O
immediate NN NN O
-- NN NN O
early NN NN O
genes NN NN O
implicated NN NN O
in NN NN O
the NN NN O
regulation NN NN O
of NN NN O
cell NN NN O
proliferation NN NN O
. NN NN O

We NN NN O
propose NN NN O
that NN NN O
NDP NN NN O
is NN NN O
a NN NN O
molecule NN NN O
related NN NN O
in NN NN O
function NN NN O
to NN NN O
these NN NN O
genes NN NN O
and NN NN O
may NN NN O
be NN NN O
involved NN NN O
in NN NN O
a NN NN O
pathway NN NN O
that NN NN O
regulates NN NN O
neural NN NN O
cell NN NN O
differentiation NN NN O
and NN NN O
proliferation NN NN O
. NN NN O

. NN NN O

8317477 NN NN O
The NN NN O
normal NN NN O
Huntington NN NN B-Modifier
disease NN NN I-Modifier
( NN NN O
HD NN NN B-Modifier
) NN NN O
allele NN NN O
, NN NN O
or NN NN O
a NN NN O
closely NN NN O
linked NN NN O
gene NN NN O
, NN NN O
influences NN NN O
age NN NN O
at NN NN O
onset NN NN O
of NN NN O
HD NN NN B-SpecificDisease
. NN NN O

We NN NN O
evaluated NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
Huntington NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
HD NN NN B-SpecificDisease
) NN NN O
is NN NN O
influenced NN NN O
by NN NN O
the NN NN O
normal NN NN O
HD NN NN B-Modifier
allele NN NN O
by NN NN O
comparing NN NN O
transmission NN NN O
patterns NN NN O
of NN NN O
genetically NN NN O
linked NN NN O
markers NN NN O
at NN NN O
the NN NN O
D4S10 NN NN O
locus NN NN O
in NN NN O
the NN NN O
normal NN NN O
parent NN NN O
against NN NN O
age NN NN O
at NN NN O
onset NN NN O
in NN NN O
the NN NN O
affected NN NN O
offspring NN NN O
. NN NN O

Analysis NN NN O
of NN NN O
information NN NN O
from NN NN O
21 NN NN O
sibships NN NN O
in NN NN O
14 NN NN O
kindreds NN NN O
showed NN NN O
a NN NN O
significant NN NN O
tendency NN NN O
for NN NN O
sibs NN NN O
who NN NN O
have NN NN O
similar NN NN O
onset NN NN O
ages NN NN O
to NN NN O
share NN NN O
the NN NN O
same NN NN O
D4S10 NN NN O
allele NN NN O
from NN NN O
the NN NN O
normal NN NN O
parent NN NN O
. NN NN O

Affected NN NN O
sibs NN NN O
who NN NN O
inherited NN NN O
different NN NN O
D4S10 NN NN O
alleles NN NN O
from NN NN O
the NN NN O
normal NN NN O
parent NN NN O
tended NN NN O
to NN NN O
have NN NN O
more NN NN O
variable NN NN O
ages NN NN O
at NN NN O
onset NN NN O
. NN NN O

These NN NN O
findings NN NN O
suggest NN NN O
that NN NN O
the NN NN O
expression NN NN O
of NN NN O
HD NN NN B-SpecificDisease
is NN NN O
modulated NN NN O
by NN NN O
the NN NN O
normal NN NN O
HD NN NN B-Modifier
allele NN NN O
or NN NN O
by NN NN O
a NN NN O
closely NN NN O
linked NN NN O
locus NN NN O
. NN NN O

. NN NN O

8326491 NN NN O
Further NN NN O
investigation NN NN O
of NN NN O
the NN NN O
HEXA NN NN O
gene NN NN O
intron NN NN O
9 NN NN O
donor NN NN O
splice NN NN O
site NN NN O
mutation NN NN O
frequently NN NN O
found NN NN O
in NN NN O
non-Jewish NN NN O
Tay-Sachs NN NN B-Modifier
disease NN NN I-Modifier
patients NN NN O
from NN NN O
the NN NN O
British NN NN O
Isles NN NN O
. NN NN O

In NN NN O
a NN NN O
previous NN NN O
study NN NN O
we NN NN O
found NN NN O
that NN NN O
a NN NN O
Tay-Sachs NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
TSD NN NN B-SpecificDisease
) NN NN O
causing NN NN O
mutation NN NN O
in NN NN O
the NN NN O
intron NN NN O
9 NN NN O
donor NN NN O
splice NN NN O
site NN NN O
of NN NN O
the NN NN O
HEXA NN NN O
gene NN NN O
occurs NN NN O
at NN NN O
high NN NN O
frequency NN NN O
in NN NN O
non-Jewish NN NN O
patients NN NN O
and NN NN O
carriers NN NN O
from NN NN O
the NN NN O
British NN NN O
Isles NN NN O
. NN NN O

It NN NN O
was NN NN O
found NN NN O
more NN NN O
frequently NN NN O
in NN NN O
subjects NN NN O
of NN NN O
Irish NN NN O
, NN NN O
Scottish NN NN O
, NN NN O
and NN NN O
Welsh NN NN O
origin NN NN O
compared NN NN O
with NN NN O
English NN NN O
origin NN NN O
( NN NN O
63 NN NN O
% NN NN O
and NN NN O
31 NN NN O
% NN NN O
respectively NN NN O
) NN NN O
. NN NN O

We NN NN O
have NN NN O
now NN NN O
tested NN NN O
, NN NN O
in NN NN O
a NN NN O
blind NN NN O
study NN NN O
, NN NN O
26 NN NN O
American NN NN O
TSD NN NN B-Modifier
carriers NN NN O
and NN NN O
28 NN NN O
non-carriers NN NN O
who NN NN O
have NN NN O
British NN NN O
ancestry NN NN O
for NN NN O
the NN NN O
intron NN NN O
9 NN NN O
splice NN NN O
site NN NN O
mutation NN NN O
. NN NN O

Six NN NN O
of NN NN O
the NN NN O
carriers NN NN O
and NN NN O
none NN NN O
of NN NN O
the NN NN O
controls NN NN O
were NN NN O
positive NN NN O
for NN NN O
the NN NN O
mutation NN NN O
. NN NN O

All NN NN O
six NN NN O
had NN NN O
Irish NN NN O
ancestry NN NN O
, NN NN O
compared NN NN O
with NN NN O
nine NN NN O
of NN NN O
the NN NN O
20 NN NN O
other NN NN O
( NN NN O
intron NN NN O
9 NN NN O
mutation NN NN O
negative NN NN O
) NN NN O
TSD NN NN B-Modifier
carriers NN NN O
( NN NN O
p NN NN O
0 NN NN O
. NN NN O

05 NN NN O
) NN NN O
. NN NN O

These NN NN O
results NN NN O
confirm NN NN O
the NN NN O
previously NN NN O
found NN NN O
high NN NN O
frequency NN NN O
of NN NN O
the NN NN O
intron NN NN O
9 NN NN O
mutation NN NN O
in NN NN O
non-Jewish NN NN O
TSD NN NN B-Modifier
families NN NN O
of NN NN O
British NN NN O
Isles NN NN O
, NN NN O
particularly NN NN O
Irish NN NN O
, NN NN O
origin NN NN O
, NN NN O
and NN NN O
reinforce NN NN O
the NN NN O
need NN NN O
to NN NN O
screen NN NN O
such NN NN O
families NN NN O
for NN NN O
this NN NN O
mutation NN NN O
. NN NN O

8346255 NN NN O
Molecular NN NN O
mechanisms NN NN O
of NN NN O
oncogenic NN NN O
mutations NN NN O
in NN NN O
tumors NN NN B-DiseaseClass
from NN NN O
patients NN NN O
with NN NN O
bilateral NN NN B-CompositeMention
and NN NN I-CompositeMention
unilateral NN NN I-CompositeMention
retinoblastoma NN NN I-CompositeMention
. NN NN O

The NN NN O
RB1 NN NN O
gene NN NN O
from NN NN O
12 NN NN O
human NN NN O
retinoblastoma NN NN B-SpecificDisease
tumors NN NN I-SpecificDisease
has NN NN O
been NN NN O
analyzed NN NN O
exon-by-exon NN NN O
with NN NN O
the NN NN O
single-strand NN NN O
conformation NN NN O
polymorphism NN NN O
technique NN NN O
. NN NN O

Mutations NN NN O
were NN NN O
found NN NN O
in NN NN O
all NN NN O
tumors NN NN B-DiseaseClass
, NN NN O
and NN NN O
one-third NN NN O
of NN NN O
the NN NN O
tumors NN NN B-DiseaseClass
had NN NN O
independent NN NN O
mutations NN NN O
in NN NN O
both NN NN O
alleles NN NN O
neither NN NN O
of NN NN O
which NN NN O
were NN NN O
found NN NN O
in NN NN O
the NN NN O
germ NN NN O
line NN NN O
, NN NN O
confirming NN NN O
their NN NN O
true NN NN O
sporadic NN NN O
nature NN NN O
. NN NN O

In NN NN O
the NN NN O
remaining NN NN O
two-thirds NN NN O
of NN NN O
the NN NN O
tumors NN NN B-DiseaseClass
only NN NN O
one NN NN O
mutation NN NN O
was NN NN O
found NN NN O
, NN NN O
consistent NN NN O
with NN NN O
the NN NN O
loss-of-heterozygosity NN NN O
theory NN NN O
of NN NN O
tumorigenesis NN NN O
. NN NN O

Point NN NN O
mutations NN NN O
, NN NN O
the NN NN O
majority NN NN O
of NN NN O
which NN NN O
were NN NN O
C NN NN O
-- NN NN O
T NN NN O
transitions NN NN O
, NN NN O
were NN NN O
the NN NN O
most NN NN O
common NN NN O
abnormality NN NN O
and NN NN O
usually NN NN O
resulted NN NN O
in NN NN O
the NN NN O
conversion NN NN O
of NN NN O
an NN NN O
arginine NN NN O
codon NN NN O
to NN NN O
a NN NN O
stop NN NN O
codon NN NN O
. NN NN O

Small NN NN O
deletions NN NN O
were NN NN O
the NN NN O
second NN NN O
most NN NN O
common NN NN O
abnormality NN NN O
and NN NN O
most NN NN O
often NN NN O
created NN NN O
a NN NN O
downstream NN NN O
stop NN NN O
codon NN NN O
as NN NN O
the NN NN O
result NN NN O
of NN NN O
a NN NN O
reading NN NN O
frameshift NN NN O
. NN NN O

Deletions NN NN O
and NN NN O
point NN NN O
mutations NN NN O
also NN NN O
affected NN NN O
splice NN NN O
junctions NN NN O
. NN NN O

Direct NN NN O
repeats NN NN O
were NN NN O
present NN NN O
at NN NN O
the NN NN O
breakpoint NN NN O
junctions NN NN O
in NN NN O
the NN NN O
majority NN NN O
of NN NN O
deletions NN NN O
, NN NN O
supporting NN NN O
a NN NN O
slipped-mispairing NN NN O
mechanism NN NN O
. NN NN O

Point NN NN O
mutations NN NN O
generally NN NN O
produced NN NN O
DNA NN NN O
sequences NN NN O
which NN NN O
resulted NN NN O
in NN NN O
perfect NN NN O
homology NN NN O
with NN NN O
endogenous NN NN O
sequences NN NN O
which NN NN O
lay NN NN O
within NN NN O
14 NN NN O
bp NN NN O
. NN NN O

. NN NN O

8364574 NN NN O
PAX6 NN NN O
mutations NN NN O
in NN NN O
aniridia NN NN B-SpecificDisease
. NN NN O

Aniridia NN NN B-SpecificDisease
is NN NN O
a NN NN O
congenital NN NN B-DiseaseClass
malformation NN NN I-DiseaseClass
of NN NN I-DiseaseClass
the NN NN I-DiseaseClass
eye NN NN I-DiseaseClass
, NN NN O
chiefly NN NN O
characterised NN NN O
by NN NN O
iris NN NN B-SpecificDisease
hypoplasia NN NN I-SpecificDisease
, NN NN O
which NN NN O
can NN NN O
cause NN NN O
blindness NN NN B-SpecificDisease
. NN NN O

The NN NN O
PAX6 NN NN O
gene NN NN O
was NN NN O
isolated NN NN O
as NN NN O
a NN NN O
candidate NN NN O
aniridia NN NN B-Modifier
gene NN NN O
by NN NN O
positional NN NN O
cloning NN NN O
from NN NN O
the NN NN O
smallest NN NN O
region NN NN O
of NN NN O
overlap NN NN O
of NN NN O
aniridia NN NN B-Modifier
-associated NN NN O
deletions NN NN O
. NN NN O

Subsequently NN NN O
PAX6 NN NN O
intragenic NN NN O
mutations NN NN O
were NN NN O
demonstrated NN NN O
in NN NN O
Smalleye NN NN O
, NN NN O
a NN NN O
mouse NN NN O
mutant NN NN O
which NN NN O
is NN NN O
an NN NN O
animal NN NN O
model NN NN O
for NN NN O
aniridia NN NN B-SpecificDisease
, NN NN O
and NN NN O
six NN NN O
human NN NN O
aniridia NN NN B-Modifier
patients NN NN O
. NN NN O

In NN NN O
this NN NN O
paper NN NN O
we NN NN O
describe NN NN O
four NN NN O
additional NN NN O
PAX6 NN NN O
point NN NN O
mutations NN NN O
in NN NN O
aniridia NN NN B-Modifier
patients NN NN O
, NN NN O
both NN NN O
sporadic NN NN O
and NN NN O
familial NN NN O
. NN NN O

These NN NN O
mutations NN NN O
highlight NN NN O
regions NN NN O
of NN NN O
the NN NN O
gene NN NN O
which NN NN O
are NN NN O
essential NN NN O
for NN NN O
normal NN NN O
PAX6 NN NN O
function NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
the NN NN O
frequency NN NN O
at NN NN O
which NN NN O
we NN NN O
have NN NN O
found NN NN O
PAX6 NN NN O
mutations NN NN O
suggests NN NN O
that NN NN O
lesions NN NN O
in NN NN O
PAX6 NN NN O
will NN NN O
account NN NN O
for NN NN O
most NN NN O
cases NN NN O
of NN NN O
aniridia NN NN B-SpecificDisease
. NN NN O

. NN NN O

8370681 NN NN O
Detection NN NN O
of NN NN O
a NN NN O
novel NN NN O
arginine NN NN O
vasopressin NN NN O
defect NN NN O
by NN NN O
dideoxy NN NN O
fingerprinting NN NN O
. NN NN O

Autosomal NN NN B-SpecificDisease
dominant NN NN I-SpecificDisease
neurohypophyseal NN NN I-SpecificDisease
diabetes NN NN I-SpecificDisease
insipidus NN NN I-SpecificDisease
is NN NN O
a NN NN O
familial NN NN O
form NN NN O
of NN NN O
diabetes NN NN B-DiseaseClass
insipidus NN NN I-DiseaseClass
. NN NN O

This NN NN O
disorder NN NN O
is NN NN O
associated NN NN O
with NN NN O
variable NN NN O
levels NN NN O
of NN NN O
arginine NN NN O
vasopressin NN NN O
( NN NN O
AVP NN NN O
) NN NN O
and NN NN O
diabetes NN NN B-DiseaseClass
insipidus NN NN I-DiseaseClass
of NN NN O
varying NN NN O
severity NN NN O
, NN NN O
which NN NN O
responds NN NN O
to NN NN O
exogenous NN NN O
AVP NN NN O
. NN NN O

To NN NN O
determine NN NN O
the NN NN O
molecular NN NN O
basis NN NN O
of NN NN O
autosomal NN NN B-SpecificDisease
dominant NN NN I-SpecificDisease
neurohypophyseal NN NN I-SpecificDisease
diabetes NN NN I-SpecificDisease
insipidus NN NN I-SpecificDisease
, NN NN O
the NN NN O
AVP NN NN O
genes NN NN O
of NN NN O
members NN NN O
of NN NN O
a NN NN O
large NN NN O
kindred NN NN O
were NN NN O
analyzed NN NN O
. NN NN O

A NN NN O
new NN NN O
method NN NN O
, NN NN O
called NN NN O
dideoxy NN NN O
fingerprinting NN NN O
, NN NN O
was NN NN O
used NN NN O
to NN NN O
detect NN NN O
an NN NN O
AVP NN NN O
mutation NN NN O
that NN NN O
was NN NN O
characterized NN NN O
by NN NN O
DNA NN NN O
sequencing NN NN O
. NN NN O

The NN NN O
novel NN NN O
defect NN NN O
found NN NN O
changes NN NN O
the NN NN O
last NN NN O
codon NN NN O
of NN NN O
the NN NN O
AVP NN NN O
signal NN NN O
peptide NN NN O
from NN NN O
alanine NN NN O
to NN NN O
threonine NN NN O
, NN NN O
which NN NN O
should NN NN O
perturb NN NN O
cleavage NN NN O
of NN NN O
mature NN NN O
AVP NN NN O
from NN NN O
its NN NN O
precursor NN NN O
protein NN NN O
and NN NN O
inhibit NN NN O
its NN NN O
secretion NN NN O
or NN NN O
action NN NN O
. NN NN O

. NN NN O

8375105 NN NN O
Germinal NN NN O
mosaicism NN NN O
in NN NN O
a NN NN O
Duchenne NN NN B-Modifier
muscular NN NN I-Modifier
dystrophy NN NN I-Modifier
family NN NN O
: NN NN O
implications NN NN O
for NN NN O
genetic NN NN O
counselling NN NN O
. NN NN O

In NN NN O
this NN NN O
study NN NN O
we NN NN O
describe NN NN O
a NN NN O
three-generation NN NN O
family NN NN O
in NN NN O
which NN NN O
two NN NN O
siblings NN NN O
were NN NN O
affected NN NN O
by NN NN O
Duchenne NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DMD NN NN B-SpecificDisease
) NN NN O
. NN NN O

Immunohistochemical NN NN O
analysis NN NN O
of NN NN O
muscle NN NN O
dystrophin NN NN O
and NN NN O
haplotype NN NN O
analysis NN NN O
of NN NN O
the NN NN O
DMD NN NN B-Modifier
locus NN NN O
revealed NN NN O
that NN NN O
the NN NN O
X NN NN O
chromosome NN NN O
carrying NN NN O
the NN NN O
DMD NN NN B-Modifier
gene NN NN O
was NN NN O
transmitted NN NN O
from NN NN O
the NN NN O
healthy NN NN O
maternal NN NN O
grandfather NN NN O
to NN NN O
his NN NN O
three NN NN O
daughters NN NN O
, NN NN O
including NN NN O
the NN NN O
probands NN NN O
mother NN NN O
. NN NN O

These NN NN O
findings NN NN O
indicate NN NN O
that NN NN O
the NN NN O
grandfather NN NN O
was NN NN O
a NN NN O
germinal NN NN O
mosaic NN NN O
for NN NN O
the NN NN O
DMD NN NN B-Modifier
gene NN NN O
. NN NN O

The NN NN O
definition NN NN O
of NN NN O
the NN NN O
carrier NN NN O
status NN NN O
in NN NN O
two NN NN O
possible NN NN O
carriers NN NN O
led NN NN O
us NN NN O
to NN NN O
give NN NN O
accurate NN NN O
genetic NN NN O
counselling NN NN O
and NN NN O
to NN NN O
prevent NN NN O
the NN NN O
birth NN NN O
of NN NN O
an NN NN O
affected NN NN O
boy NN NN O
. NN NN O

The NN NN O
results NN NN O
of NN NN O
this NN NN O
study NN NN O
demonstrate NN NN O
the NN NN O
usefulness NN NN O
of NN NN O
haplotype NN NN O
analysis NN NN O
and NN NN O
immunohistochemical NN NN O
muscle NN NN O
dystrophin NN NN O
studies NN NN O
to NN NN O
detect NN NN O
hidden NN NN O
germinal NN NN O
mosaicism NN NN O
and NN NN O
to NN NN O
improve NN NN O
genetic NN NN O
counselling NN NN O
. NN NN O

. NN NN O

8401501 NN NN O
Genetic NN NN O
mapping NN NN O
of NN NN O
the NN NN O
breast-ovarian NN NN B-DiseaseClass
cancer NN NN I-DiseaseClass
syndrome NN NN I-DiseaseClass
to NN NN O
a NN NN O
small NN NN O
interval NN NN O
on NN NN O
chromosome NN NN O
17q12-21 NN NN O
: NN NN O
exclusion NN NN O
of NN NN O
candidate NN NN O
genes NN NN O
EDH17B2 NN NN O
and NN NN O
RARA NN NN O
. NN NN O

A NN NN O
susceptibility NN NN O
gene NN NN O
for NN NN O
hereditary NN NN B-DiseaseClass
breast-ovarian NN NN I-DiseaseClass
cancer NN NN I-DiseaseClass
, NN NN O
BRCA1 NN NN O
, NN NN O
has NN NN O
been NN NN O
assigned NN NN O
by NN NN O
linkage NN NN O
analysis NN NN O
to NN NN O
chromosome NN NN O
17q21 NN NN O
. NN NN O

Candidate NN NN O
genes NN NN O
in NN NN O
this NN NN O
region NN NN O
include NN NN O
EDH17B2 NN NN O
, NN NN O
which NN NN O
encodes NN NN O
estradiol NN NN O
17 NN NN O
beta-hydroxysteroid NN NN O
dehydrogenase NN NN O
II NN NN O
( NN NN O
17 NN NN O
beta-HSD NN NN O
II NN NN O
) NN NN O
, NN NN O
and NN NN O
RARA NN NN O
, NN NN O
the NN NN O
gene NN NN O
for NN NN O
retinoic NN NN O
acid NN NN O
receptor NN NN O
alpha NN NN O
. NN NN O

We NN NN O
have NN NN O
typed NN NN O
22 NN NN O
breast NN NN B-Modifier
and NN NN I-Modifier
breast-ovarian NN NN I-Modifier
cancer NN NN I-Modifier
families NN NN O
with NN NN O
eight NN NN O
polymorphisms NN NN O
from NN NN O
the NN NN O
chromosome NN NN O
17q12-21 NN NN O
region NN NN O
, NN NN O
including NN NN O
two NN NN O
in NN NN O
the NN NN O
EDH17B2 NN NN O
gene NN NN O
. NN NN O

Genetic NN NN O
recombination NN NN O
with NN NN O
the NN NN O
breast NN NN B-Modifier
cancer NN NN I-Modifier
trait NN NN O
excludes NN NN O
RARA NN NN O
from NN NN O
further NN NN O
consideration NN NN O
as NN NN O
a NN NN O
candidate NN NN O
gene NN NN O
for NN NN O
BRCA1 NN NN O
. NN NN O

Both NN NN O
BRCA1 NN NN O
and NN NN O
EDH17B2 NN NN O
map NN NN O
to NN NN O
a NN NN O
6 NN NN O
cM NN NN O
interval NN NN O
( NN NN O
between NN NN O
THRA1 NN NN O
and NN NN O
D17S579 NN NN O
) NN NN O
and NN NN O
no NN NN O
recombination NN NN O
was NN NN O
observed NN NN O
between NN NN O
the NN NN O
two NN NN O
genes NN NN O
. NN NN O

However NN NN O
, NN NN O
direct NN NN O
sequencing NN NN O
of NN NN O
overlapping NN NN O
PCR NN NN O
products NN NN O
containing NN NN O
the NN NN O
entire NN NN O
EDH17B2 NN NN O
gene NN NN O
in NN NN O
four NN NN O
unrelated NN NN O
affected NN NN O
women NN NN O
did NN NN O
not NN NN O
uncover NN NN O
any NN NN O
sequence NN NN O
variation NN NN O
, NN NN O
other NN NN O
than NN NN O
previously NN NN O
described NN NN O
polymorphisms NN NN O
. NN NN O

Mutations NN NN O
in NN NN O
the NN NN O
EDH17B2 NN NN O
gene NN NN O
, NN NN O
therefore NN NN O
do NN NN O
not NN NN O
appear NN NN O
to NN NN O
be NN NN O
responsible NN NN O
for NN NN O
the NN NN O
hereditary NN NN B-DiseaseClass
breast-ovarian NN NN I-DiseaseClass
cancer NN NN I-DiseaseClass
syndrome NN NN I-DiseaseClass
. NN NN O

Single NN NN O
meiotic NN NN O
crossovers NN NN O
in NN NN O
affected NN NN O
women NN NN O
suggest NN NN O
that NN NN O
BRCA1 NN NN O
is NN NN O
flanked NN NN O
by NN NN O
the NN NN O
loci NN NN O
RARA NN NN O
and NN NN O
D17S78 NN NN O
. NN NN O

. NN NN O

8408659 NN NN O
A NN NN O
missense NN NN O
mutation NN NN O
in NN NN O
the NN NN O
cholesteryl NN NN O
ester NN NN O
transfer NN NN O
protein NN NN O
gene NN NN O
with NN NN O
possible NN NN O
dominant NN NN O
effects NN NN O
on NN NN O
plasma NN NN O
high NN NN O
density NN NN O
lipoproteins NN NN O
. NN NN O

Plasma NN NN O
HDL NN NN O
are NN NN O
a NN NN O
negative NN NN O
risk NN NN O
factor NN NN O
for NN NN O
atherosclerosis NN NN B-SpecificDisease
. NN NN O

Cholesteryl NN NN O
ester NN NN O
transfer NN NN O
protein NN NN O
( NN NN O
CETP NN NN O
; NN NN O
476 NN NN O
amino NN NN O
acids NN NN O
) NN NN O
transfers NN NN O
cholesteryl NN NN O
ester NN NN O
from NN NN O
HDL NN NN O
to NN NN O
other NN NN O
lipoproteins NN NN O
. NN NN O

Subjects NN NN O
with NN NN O
homozygous NN NN O
CETP NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
caused NN NN O
by NN NN O
a NN NN O
gene NN NN O
splicing NN NN O
defect NN NN O
have NN NN O
markedly NN NN O
elevated NN NN O
HDL NN NN O
; NN NN O
however NN NN O
, NN NN O
heterozygotes NN NN O
have NN NN O
only NN NN O
mild NN NN O
increases NN NN O
in NN NN O
HDL NN NN O
. NN NN O

We NN NN O
describe NN NN O
two NN NN O
probands NN NN O
with NN NN O
a NN NN O
CETP NN NN O
missense NN NN O
mutation NN NN O
( NN NN O
442 NN NN O
D NN NN O
G NN NN O
) NN NN O
. NN NN O

Although NN NN O
heterozygous NN NN O
, NN NN O
they NN NN O
have NN NN O
threefold NN NN O
increases NN NN O
in NN NN O
HDL NN NN O
concentration NN NN O
and NN NN O
markedly NN NN O
decreased NN NN O
plasma NN NN O
CETP NN NN O
mass NN NN O
and NN NN O
activity NN NN O
, NN NN O
suggesting NN NN O
that NN NN O
the NN NN O
mutation NN NN O
has NN NN O
dominant NN NN O
effects NN NN O
on NN NN O
CETP NN NN O
and NN NN O
HDL NN NN O
in NN NN O
vivo NN NN O
. NN NN O

Cellular NN NN O
expression NN NN O
of NN NN O
mutant NN NN O
cDNA NN NN O
results NN NN O
in NN NN O
secretion NN NN O
of NN NN O
only NN NN O
30 NN NN O
% NN NN O
of NN NN O
wild NN NN O
type NN NN O
CETP NN NN O
activity NN NN O
. NN NN O

Moreover NN NN O
, NN NN O
coexpression NN NN O
of NN NN O
wild NN NN O
type NN NN O
and NN NN O
mutant NN NN O
cDNAs NN NN O
leads NN NN O
to NN NN O
inhibition NN NN O
of NN NN O
wild NN NN O
type NN NN O
secretion NN NN O
and NN NN O
activity NN NN O
. NN NN O

The NN NN O
dominant NN NN O
effects NN NN O
of NN NN O
the NN NN O
CETP NN NN O
missense NN NN O
mutation NN NN O
during NN NN O
cellular NN NN O
expression NN NN O
probably NN NN O
explains NN NN O
why NN NN O
the NN NN O
probands NN NN O
have NN NN O
markedly NN NN O
increased NN NN O
HDL NN NN O
in NN NN O
the NN NN O
heterozygous NN NN O
state NN NN O
, NN NN O
and NN NN O
suggests NN NN O
that NN NN O
the NN NN O
active NN NN O
molecular NN NN O
species NN NN O
of NN NN O
CETP NN NN O
may NN NN O
be NN NN O
multimeric NN NN O
. NN NN O

. NN NN O

8434621 NN NN O
Familial NN NN B-SpecificDisease
Mediterranean NN NN I-SpecificDisease
fever NN NN I-SpecificDisease
in NN NN O
the NN NN O
colchicine NN NN O
era NN NN O
: NN NN O
the NN NN O
fate NN NN O
of NN NN O
one NN NN O
family NN NN O
. NN NN O

In NN NN O
order NN NN O
to NN NN O
demonstrate NN NN O
the NN NN O
effect NN NN O
of NN NN O
prophylactic NN NN O
colchicine NN NN O
treatment NN NN O
on NN NN O
the NN NN O
natural NN NN O
history NN NN O
of NN NN O
familial NN NN B-SpecificDisease
Mediterranean NN NN I-SpecificDisease
fever NN NN I-SpecificDisease
( NN NN O
FMF NN NN B-SpecificDisease
) NN NN O
, NN NN O
a NN NN O
family NN NN O
is NN NN O
presented NN NN O
with NN NN O
6 NN NN O
out NN NN O
of NN NN O
9 NN NN O
siblings NN NN O
affected NN NN O
by NN NN O
FMF NN NN B-SpecificDisease
. NN NN O

Each NN NN O
patient NN NN O
represents NN NN O
a NN NN O
different NN NN O
stage NN NN O
of NN NN O
the NN NN O
amyloidotic NN NN B-SpecificDisease
kidney NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
of NN NN O
FMF NN NN B-SpecificDisease
and NN NN O
the NN NN O
effect NN NN O
of NN NN O
continuous NN NN O
colchicine NN NN O
treatment NN NN O
on NN NN O
its NN NN O
course NN NN O
. NN NN O

Considered NN NN O
together NN NN O
, NN NN O
the NN NN O
members NN NN O
of NN NN O
this NN NN O
family NN NN O
present NN NN O
an NN NN O
almost NN NN O
complete NN NN O
clinical NN NN O
, NN NN O
genetic NN NN O
, NN NN O
and NN NN O
behavioral NN NN O
picture NN NN O
of NN NN O
the NN NN O
disease NN NN O
. NN NN O

. NN NN O

8440142 NN NN O
Detection NN NN O
of NN NN O
a NN NN O
new NN NN O
submicroscopic NN NN O
Norrie NN NN B-Modifier
disease NN NN I-Modifier
deletion NN NN O
interval NN NN O
with NN NN O
a NN NN O
novel NN NN O
DNA NN NN O
probe NN NN O
isolated NN NN O
by NN NN O
differential NN NN O
Alu NN NN O
PCR NN NN O
fingerprint NN NN O
cloning NN NN O
. NN NN O

Differential NN NN O
Alu NN NN O
PCR NN NN O
fingerprint NN NN O
cloning NN NN O
was NN NN O
used NN NN O
to NN NN O
isolate NN NN O
a NN NN O
DNA NN NN O
probe NN NN O
from NN NN O
the NN NN O
Xp11 NN NN O
. NN NN O

4 NN NN O
-- NN NN O
p11 NN NN O
. NN NN O

21 NN NN O
region NN NN O
of NN NN O
the NN NN O
human NN NN O
X NN NN O
chromosome NN NN O
. NN NN O

This NN NN O
novel NN NN O
sequence NN NN O
, NN NN O
cpXr318 NN NN O
( NN NN O
DXS742 NN NN O
) NN NN O
, NN NN O
detects NN NN O
a NN NN O
new NN NN O
submicroscopic NN NN O
deletion NN NN O
interval NN NN O
at NN NN O
the NN NN O
Norrie NN NN B-Modifier
disease NN NN I-Modifier
locus NN NN O
( NN NN O
NDP NN NN O
) NN NN O
. NN NN O

Combining NN NN O
our NN NN O
data NN NN O
with NN NN O
the NN NN O
consensus NN NN O
genetic NN NN O
map NN NN O
of NN NN O
the NN NN O
proximal NN NN O
short NN NN O
arm NN NN O
of NN NN O
the NN NN O
X NN NN O
chromosome NN NN O
, NN NN O
we NN NN O
propose NN NN O
the NN NN O
physical NN NN O
order NN NN O
Xcen-DXS14-DXS255- NN NN O
( NN NN O
DXS426 NN NN O
, NN NN O
TIMP NN NN O
) NN NN O
- NN NN O
( NN NN O
DXS742- NN NN O
( NN NN O
[ NN NN O
MAOB-MAOA-DXS7 NN NN O
] NN NN O
, NN NN O
NDP NN NN O
) NN NN O
-DXS77-DXS228 NN NN O
) NN NN O
-DXS209-DXS148-DXS196- NN NN O
+ NN NN O
+ NN NN O
+ NN NN O
Xpter NN NN O
. NN NN O

The NN NN O
cpXr318 NN NN O
probe NN NN O
and NN NN O
a NN NN O
subclone NN NN O
from NN NN O
a NN NN O
cosmid NN NN O
corresponding NN NN O
to NN NN O
the NN NN O
DXS7 NN NN O
locus NN NN O
were NN NN O
converted NN NN O
into NN NN O
sequence-tagged NN NN O
sites NN NN O
. NN NN O

Finally NN NN O
, NN NN O
DXS742 NN NN O
, NN NN O
DSX7 NN NN O
, NN NN O
DXS77 NN NN O
, NN NN O
and NN NN O
MAOA NN NN O
were NN NN O
integrated NN NN O
into NN NN O
a NN NN O
physical NN NN O
map NN NN O
spanning NN NN O
the NN NN O
Norrie NN NN B-Modifier
disease NN NN I-Modifier
locus NN NN O

8441467 NN NN O
Putative NN NN O
X-linked NN NN B-Modifier
adrenoleukodystrophy NN NN I-Modifier
gene NN NN O
shares NN NN O
unexpected NN NN O
homology NN NN O
with NN NN O
ABC NN NN O
transporters NN NN O
. NN NN O

Adrenoleukodystrophy NN NN B-SpecificDisease
( NN NN O
ALD NN NN B-SpecificDisease
) NN NN O
is NN NN O
an NN NN O
X-linked NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
affecting NN NN O
1 NN NN O
/ NN NN O
20 NN NN O
, NN NN O
000 NN NN O
males NN NN O
either NN NN O
as NN NN O
cerebral NN NN B-SpecificDisease
ALD NN NN I-SpecificDisease
in NN NN O
childhood NN NN O
or NN NN O
as NN NN O
adrenomyeloneuropathy NN NN B-SpecificDisease
( NN NN O
AMN NN NN B-SpecificDisease
) NN NN O
in NN NN O
adults NN NN O
. NN NN O

Childhood NN NN O
ALD NN NN B-SpecificDisease
is NN NN O
the NN NN O
more NN NN O
severe NN NN O
form NN NN O
, NN NN O
with NN NN O
onset NN NN O
of NN NN O
neurological NN NN O
symptoms NN NN O
between NN NN O
5-12 NN NN O
years NN NN O
of NN NN O
age NN NN O
. NN NN O

Central NN NN B-DiseaseClass
nervous NN NN I-DiseaseClass
system NN NN I-DiseaseClass
demyelination NN NN I-DiseaseClass
progresses NN NN O
rapidly NN NN O
and NN NN O
death NN NN O
occurs NN NN O
within NN NN O
a NN NN O
few NN NN O
years NN NN O
. NN NN O

AMN NN NN B-SpecificDisease
is NN NN O
a NN NN O
milder NN NN O
form NN NN O
of NN NN O
the NN NN O
disease NN NN O
with NN NN O
onset NN NN O
at NN NN O
15-30 NN NN O
years NN NN O
of NN NN O
age NN NN O
and NN NN O
a NN NN O
more NN NN O
progressive NN NN O
course NN NN O
. NN NN O

Adrenal NN NN B-DiseaseClass
insufficiency NN NN I-DiseaseClass
( NN NN O
Addisons NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
) NN NN O
may NN NN O
remain NN NN O
the NN NN O
only NN NN O
clinical NN NN O
manifestation NN NN O
of NN NN O
ALD NN NN B-SpecificDisease
. NN NN O

The NN NN O
principal NN NN O
biochemical NN NN O
abnormality NN NN O
of NN NN O
ALD NN NN B-SpecificDisease
is NN NN O
the NN NN O
accumulation NN NN O
of NN NN O
very-long-chain NN NN O
fatty NN NN O
acids NN NN O
( NN NN O
VLCFA NN NN O
) NN NN O
because NN NN O
of NN NN O
impaired NN NN O
beta-oxidation NN NN O
in NN NN O
peroxisomes NN NN O
. NN NN O

The NN NN O
normal NN NN O
oxidation NN NN O
of NN NN O
VLCFA-CoA NN NN O
in NN NN O
patients NN NN O
fibroblasts NN NN O
suggested NN NN O
that NN NN O
the NN NN O
gene NN NN O
coding NN NN O
for NN NN O
the NN NN O
VLCFA-CoA NN NN O
synthetase NN NN O
could NN NN O
be NN NN O
a NN NN O
candidate NN NN O
gene NN NN O
for NN NN O
ALD NN NN B-SpecificDisease
. NN NN O

Here NN NN O
we NN NN O
use NN NN O
positional NN NN O
cloning NN NN O
to NN NN O
identify NN NN O
a NN NN O
gene NN NN O
partially NN NN O
deleted NN NN O
in NN NN O
6 NN NN O
of NN NN O
85 NN NN O
independent NN NN O
patients NN NN O
with NN NN O
ALD NN NN B-SpecificDisease
. NN NN O

In NN NN O
familial NN NN O
cases NN NN O
, NN NN O
the NN NN O
deletions NN NN O
segregated NN NN O
with NN NN O
the NN NN O
disease NN NN O
. NN NN O

An NN NN O
identical NN NN O
deletion NN NN O
was NN NN O
detected NN NN O
in NN NN O
two NN NN O
brothers NN NN O
presenting NN NN O
with NN NN O
different NN NN O
clinical NN NN O
ALD NN NN B-Modifier
phenotypes NN NN O
. NN NN O

Candidate NN NN O
exons NN NN O
were NN NN O
identified NN NN O
by NN NN O
computer NN NN O
analysis NN NN O
of NN NN O
genomic NN NN O
sequences NN NN O
and NN NN O
used NN NN O
to NN NN O
isolate NN NN O
complementary NN NN O
DNAs NN NN O
by NN NN O
exon NN NN O
connection NN NN O
and NN NN O
screening NN NN O
of NN NN O
cDNA NN NN O
libraries NN NN O
. NN NN O

The NN NN O
deduced NN NN O
protein NN NN O
sequence NN NN O
shows NN NN O
significant NN NN O
sequence NN NN O
identity NN NN O
to NN NN O
a NN NN O
peroxisomal NN NN O
membrane NN NN O
protein NN NN O
of NN NN O
M NN NN O
( NN NN O
r NN NN O
) NN NN O
70K NN NN O
that NN NN O
is NN NN O
involved NN NN O
in NN NN O
peroxisome NN NN O
biogenesis NN NN O
and NN NN O
belongs NN NN O
to NN NN O
the NN NN O
ATP-binding NN NN O
cassette NN NN O
superfamily NN NN O
of NN NN O
transporters NN NN O
. NN NN O

. NN NN O

8460149 NN NN O
Targeted NN NN O
modification NN NN O
of NN NN O
the NN NN O
apolipoprotein NN NN O
B NN NN O
gene NN NN O
results NN NN O
in NN NN O
hypobetalipoproteinemia NN NN B-SpecificDisease
and NN NN O
developmental NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
in NN NN O
mice NN NN O
. NN NN O

Familial NN NN B-SpecificDisease
hypobetalipoproteinemia NN NN I-SpecificDisease
is NN NN O
an NN NN O
autosomal NN NN B-DiseaseClass
codominant NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
resulting NN NN O
in NN NN O
a NN NN O
dramatic NN NN O
reduction NN NN O
in NN NN O
plasma NN NN O
concentrations NN NN O
of NN NN O
apolipoprotein NN NN O
( NN NN O
apo NN NN O
) NN NN O
B NN NN O
, NN NN O
cholesterol NN NN O
, NN NN O
and NN NN O
beta-migrating NN NN O
lipoproteins NN NN O
. NN NN O

A NN NN O
benefit NN NN O
of NN NN O
hypobetalipoproteinemia NN NN B-SpecificDisease
is NN NN O
that NN NN O
mildly NN NN O
affected NN NN O
individuals NN NN O
may NN NN O
be NN NN O
protected NN NN O
from NN NN O
coronary NN NN B-DiseaseClass
vascular NN NN I-DiseaseClass
disease NN NN I-DiseaseClass
. NN NN O

We NN NN O
have NN NN O
used NN NN O
gene NN NN O
targeting NN NN O
to NN NN O
generate NN NN O
mice NN NN O
with NN NN O
a NN NN O
modified NN NN O
Apob NN NN O
allele NN NN O
. NN NN O

Mice NN NN O
containing NN NN O
this NN NN O
allele NN NN O
display NN NN O
all NN NN O
of NN NN O
the NN NN O
hallmarks NN NN O
of NN NN O
human NN NN O
hypobetalipoproteinemia NN NN B-SpecificDisease
they NN NN O
produce NN NN O
a NN NN O
truncated NN NN O
apoB NN NN O
protein NN NN O
, NN NN O
apoB70 NN NN O
, NN NN O
and NN NN O
have NN NN O
markedly NN NN O
decreased NN NN O
plasma NN NN O
concentrations NN NN O
of NN NN O
apoB NN NN O
, NN NN O
beta-lipoproteins NN NN O
, NN NN O
and NN NN O
total NN NN O
cholesterol NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
the NN NN O
mice NN NN O
manifest NN NN O
several NN NN O
characteristics NN NN O
that NN NN O
are NN NN O
occasionally NN NN O
observed NN NN O
in NN NN O
human NN NN O
hypobetalipoproteinemia NN NN B-SpecificDisease
, NN NN O
including NN NN O
reduced NN NN O
plasma NN NN O
triglyceride NN NN O
concentrations NN NN O
, NN NN O
fasting NN NN O
chylomicronemia NN NN B-SpecificDisease
, NN NN O
and NN NN O
reduced NN NN O
high NN NN O
density NN NN O
lipoprotein NN NN O
cholesterol NN NN O
. NN NN O

An NN NN O
unexpected NN NN O
finding NN NN O
is NN NN O
that NN NN O
the NN NN O
modified NN NN O
Apob NN NN O
allele NN NN O
is NN NN O
strongly NN NN O
associated NN NN O
with NN NN O
exencephalus NN NN B-SpecificDisease
and NN NN O
hydrocephalus NN NN B-SpecificDisease
. NN NN O

These NN NN O
mice NN NN O
should NN NN O
help NN NN O
increase NN NN O
our NN NN O
understanding NN NN O
of NN NN O
hypobetalipoproteinemia NN NN B-SpecificDisease
, NN NN O
atherogenesis NN NN B-DiseaseClass
, NN NN O
and NN NN O
the NN NN O
etiology NN NN O
of NN NN O
exencephalus NN NN B-SpecificDisease
and NN NN O
hydrocephalus NN NN B-SpecificDisease
. NN NN O

. NN NN O

8466512 NN NN O
A NN NN O
novel NN NN O
disease NN NN O
with NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
mitochondrial NN NN I-SpecificDisease
very-long-chain NN NN I-SpecificDisease
acyl-CoA NN NN I-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
. NN NN O

Palmitoyl-CoA NN NN O
dehydrogenase NN NN O
activity NN NN O
in NN NN O
skin NN NN O
fibroblasts NN NN O
from NN NN O
seven NN NN O
patients NN NN O
with NN NN O
unidentified NN NN O
defects NN NN O
of NN NN O
fatty NN NN O
acid NN NN O
oxidation NN NN O
was NN NN O
measured NN NN O
in NN NN O
the NN NN O
presence NN NN O
and NN NN O
absence NN NN O
of NN NN O
antibodies NN NN O
against NN NN O
medium-chain NN NN O
, NN NN O
long-chain NN NN O
, NN NN O
and NN NN O
very-long-chain NN NN O
acyl-CoA NN NN O
dehydrogenases NN NN O
( NN NN O
VLCAD NN NN O
) NN NN O
. NN NN O

Two NN NN O
of NN NN O
the NN NN O
patients NN NN O
, NN NN O
4-5 NN NN O
month NN NN O
old NN NN O
boys NN NN O
, NN NN O
were NN NN O
found NN NN O
to NN NN O
have NN NN O
a NN NN O
novel NN NN O
disease NN NN O
, NN NN O
VLCAD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
, NN NN O
as NN NN O
judged NN NN O
from NN NN O
the NN NN O
results NN NN O
of NN NN O
very NN NN O
low NN NN O
palmitoyl-CoA NN NN O
dehydrogenase NN NN O
activity NN NN O
and NN NN O
the NN NN O
lack NN NN O
of NN NN O
immunoreactivity NN NN O
toward NN NN O
antibody NN NN O
raised NN NN O
to NN NN O
purified NN NN O
VLCAD NN NN O
. NN NN O

. NN NN O

8471773 NN NN O
Molecular NN NN O
characterization NN NN O
of NN NN O
glucose-6-phosphate NN NN B-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
( NN NN I-SpecificDisease
G6PD NN NN I-SpecificDisease
) NN NN I-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
patients NN NN O
of NN NN O
Chinese NN NN O
descent NN NN O
and NN NN O
identification NN NN O
of NN NN O
new NN NN O
base NN NN O
substitutions NN NN O
in NN NN O
the NN NN O
human NN NN O
G6PD NN NN O
gene NN NN O
. NN NN O

The NN NN O
underlying NN NN O
DNA NN NN O
changes NN NN O
associated NN NN O
with NN NN O
glucose-6-phosphate NN NN B-Modifier
dehydrogenase NN NN I-Modifier
( NN NN I-Modifier
G6PD NN NN I-Modifier
) NN NN I-Modifier
-deficient NN NN I-Modifier
Asians NN NN O
have NN NN O
not NN NN O
been NN NN O
extensively NN NN O
investigated NN NN O
. NN NN O

To NN NN O
fill NN NN O
this NN NN O
gap NN NN O
, NN NN O
we NN NN O
sequenced NN NN O
the NN NN O
G6PD NN NN O
gene NN NN O
of NN NN O
43 NN NN O
G6PD-deficient NN NN B-Modifier
Chinese NN NN O
whose NN NN O
G6PD NN NN O
was NN NN O
well NN NN O
characterized NN NN O
biochemically NN NN O
. NN NN O

DNA NN NN O
samples NN NN O
were NN NN O
obtained NN NN O
from NN NN O
peripheral NN NN O
blood NN NN O
of NN NN O
these NN NN O
individuals NN NN O
for NN NN O
sequencing NN NN O
using NN NN O
a NN NN O
direct NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
( NN NN O
PCR NN NN O
) NN NN O
sequencing NN NN O
procedure NN NN O
. NN NN O

From NN NN O
these NN NN O
43 NN NN O
samples NN NN O
, NN NN O
we NN NN O
have NN NN O
identified NN NN O
five NN NN O
different NN NN O
types NN NN O
of NN NN O
nucleotide NN NN O
substitutions NN NN O
in NN NN O
the NN NN O
G6PD NN NN O
gene NN NN O
at NN NN O
cDNA NN NN O
1388 NN NN O
from NN NN O
G NN NN O
to NN NN O
A NN NN O
( NN NN O
Arg NN NN O
to NN NN O
His NN NN O
) NN NN O
; NN NN O
at NN NN O
cDNA NN NN O
1376 NN NN O
from NN NN O
G NN NN O
to NN NN O
T NN NN O
( NN NN O
Arg NN NN O
to NN NN O
Leu NN NN O
) NN NN O
; NN NN O
at NN NN O
cDNA NN NN O
1024 NN NN O
from NN NN O
C NN NN O
to NN NN O
T NN NN O
( NN NN O
Leu NN NN O
to NN NN O
Phe NN NN O
) NN NN O
; NN NN O
at NN NN O
cDNA NN NN O
392 NN NN O
from NN NN O
G NN NN O
to NN NN O
T NN NN O
( NN NN O
Gly NN NN O
to NN NN O
Val NN NN O
) NN NN O
; NN NN O
at NN NN O
cDNA NN NN O
95 NN NN O
from NN NN O
A NN NN O
to NN NN O
G NN NN O
( NN NN O
His NN NN O
to NN NN O
Arg NN NN O
) NN NN O
. NN NN O

These NN NN O
five NN NN O
nucleotide NN NN O
substitutions NN NN O
account NN NN O
for NN NN O
over NN NN O
83 NN NN O
% NN NN O
of NN NN O
our NN NN O
43 NN NN O
G6PD-deficient NN NN B-Modifier
samples NN NN O
and NN NN O
these NN NN O
substitutions NN NN O
have NN NN O
not NN NN O
been NN NN O
reported NN NN O
in NN NN O
non-Asians NN NN O
. NN NN O

The NN NN O
substitutions NN NN O
found NN NN O
at NN NN O
cDNA NN NN O
392 NN NN O
and NN NN O
cDNA NN NN O
1024 NN NN O
are NN NN O
new NN NN O
findings NN NN O
. NN NN O

The NN NN O
substitutions NN NN O
at NN NN O
cDNA NN NN O
1376 NN NN O
and NN NN O
1388 NN NN O
account NN NN O
for NN NN O
over NN NN O
50 NN NN O
% NN NN O
of NN NN O
the NN NN O
43 NN NN O
samples NN NN O
examined NN NN O
indicating NN NN O
a NN NN O
high NN NN O
prevalence NN NN O
of NN NN O
these NN NN O
two NN NN O
alleles NN NN O
among NN NN O
G6PD-deficient NN NN B-Modifier
Chinese NN NN O
. NN NN O

Our NN NN O
findings NN NN O
add NN NN O
support NN NN O
to NN NN O
the NN NN O
notion NN NN O
that NN NN O
diverse NN NN O
point NN NN O
mutations NN NN O
may NN NN O
account NN NN O
largely NN NN O
for NN NN O
much NN NN O
of NN NN O
the NN NN O
phenotypic NN NN O
heterogeneity NN NN O
of NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
. NN NN O

. NN NN O

8477262 NN NN O
Identification NN NN O
of NN NN O
mutations NN NN O
in NN NN O
Danish NN NN O
choroideremia NN NN B-Modifier
families NN NN O
. NN NN O

We NN NN O
have NN NN O
searched NN NN O
for NN NN O
mutations NN NN O
in NN NN O
the NN NN O
choroideremia NN NN B-Modifier
gene NN NN O
( NN NN O
CHM NN NN B-Modifier
) NN NN O
in NN NN O
patients NN NN O
from NN NN O
12 NN NN O
Danish NN NN O
families NN NN O
in NN NN O
which NN NN O
CHM NN NN B-SpecificDisease
is NN NN O
segregating NN NN O
. NN NN O

Employing NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
( NN NN O
PCR NN NN O
) NN NN O
, NN NN O
single NN NN O
strand NN NN O
conformation NN NN O
polymorphism NN NN O
( NN NN O
SSCP NN NN O
) NN NN O
analysis NN NN O
, NN NN O
and NN NN O
direct NN NN O
DNA NN NN O
sequencing NN NN O
, NN NN O
different NN NN O
mutations NN NN O
have NN NN O
been NN NN O
identified NN NN O
in NN NN O
6 NN NN O
patients NN NN O
. NN NN O

All NN NN O
the NN NN O
mutations NN NN O
will NN NN O
interfere NN NN O
with NN NN O
the NN NN O
correct NN NN O
translation NN NN O
of NN NN O
the NN NN O
mRNA NN NN O
predicting NN NN O
a NN NN O
truncated NN NN O
protein NN NN O
or NN NN O
no NN NN O
gene NN NN O
product NN NN O
at NN NN O
all NN NN O
. NN NN O

. NN NN O

8499920 NN NN O
Structure NN NN O
and NN NN O
genomic NN NN O
sequence NN NN O
of NN NN O
the NN NN O
myotonic NN NN B-Modifier
dystrophy NN NN I-Modifier
( NN NN O
DM NN NN B-Modifier
kinase NN NN O
) NN NN O
gene NN NN O
. NN NN O

The NN NN O
mutation NN NN O
causing NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
DM NN NN B-SpecificDisease
) NN NN O
has NN NN O
recently NN NN O
been NN NN O
identified NN NN O
as NN NN O
an NN NN O
unstable NN NN O
CTG NN NN O
trinucleotide NN NN O
repeat NN NN O
located NN NN O
in NN NN O
the NN NN O
3 NN NN O
untranslated NN NN O
region NN NN O
of NN NN O
a NN NN O
gene NN NN O
encoding NN NN O
for NN NN O
a NN NN O
protein NN NN O
with NN NN O
putative NN NN O
serine-threonine NN NN O
protein NN NN O
kinase NN NN O
activity NN NN O
. NN NN O

In NN NN O
this NN NN O
report NN NN O
we NN NN O
present NN NN O
the NN NN O
genomic NN NN O
sequences NN NN O
of NN NN O
the NN NN O
human NN NN O
and NN NN O
murine NN NN O
DM NN NN B-Modifier
kinase NN NN O
gene NN NN O
. NN NN O

A NN NN O
comparison NN NN O
of NN NN O
these NN NN O
sequences NN NN O
with NN NN O
each NN NN O
other NN NN O
and NN NN O
with NN NN O
known NN NN O
cDNA NN NN O
sequences NN NN O
from NN NN O
both NN NN O
species NN NN O
, NN NN O
led NN NN O
us NN NN O
to NN NN O
predict NN NN O
a NN NN O
translation NN NN O
initiation NN NN O
codon NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
determine NN NN O
the NN NN O
organization NN NN O
of NN NN O
the NN NN O
DM NN NN B-Modifier
kinase NN NN O
gene NN NN O
. NN NN O

Several NN NN O
polymorphisms NN NN O
within NN NN O
the NN NN O
human NN NN O
DM NN NN B-Modifier
kinase NN NN O
gene NN NN O
have NN NN O
been NN NN O
identified NN NN O
, NN NN O
and NN NN O
PCR NN NN O
assays NN NN O
to NN NN O
detect NN NN O
two NN NN O
of NN NN O
these NN NN O
are NN NN O
described NN NN O
. NN NN O

The NN NN O
complete NN NN O
sequence NN NN O
and NN NN O
characterization NN NN O
of NN NN O
the NN NN O
structure NN NN O
of NN NN O
the NN NN O
DM NN NN B-Modifier
kinase NN NN O
gene NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
identification NN NN O
of NN NN O
novel NN NN O
polymorphisms NN NN O
within NN NN O
the NN NN O
gene NN NN O
, NN NN O
represent NN NN O
an NN NN O
important NN NN O
step NN NN O
in NN NN O
a NN NN O
further NN NN O
understanding NN NN O
of NN NN O
the NN NN O
genetics NN NN O
of NN NN O
myotonic NN NN B-SpecificDisease
dystrophy NN NN I-SpecificDisease
and NN NN O
the NN NN O
molecular NN NN O
biology NN NN O
of NN NN O
the NN NN O
gene NN NN O
. NN NN O

. NN NN O

8500791 NN NN O
Autosomal NN NN O
recessive NN NN O
transmission NN NN O
of NN NN O
hemophilia NN NN B-SpecificDisease
A NN NN I-SpecificDisease
due NN NN O
to NN NN O
a NN NN O
von NN NN B-Modifier
Willebrand NN NN I-Modifier
factor NN NN O
mutation NN NN O
. NN NN O

The NN NN O
differential NN NN O
diagnosis NN NN O
of NN NN O
the NN NN O
genetic NN NN B-DiseaseClass
bleeding NN NN I-DiseaseClass
disorders NN NN I-DiseaseClass
, NN NN O
hemophilia NN NN B-SpecificDisease
A NN NN I-SpecificDisease
and NN NN O
von NN NN B-SpecificDisease
Willebrand NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
, NN NN O
is NN NN O
occasionally NN NN O
confounded NN NN O
by NN NN O
the NN NN O
close NN NN O
molecular NN NN O
relationship NN NN O
of NN NN O
coagulation NN NN O
factor NN NN O
VIII NN NN O
and NN NN O
von NN NN B-Modifier
Willebrand NN NN I-Modifier
factor NN NN O
( NN NN O
vWF NN NN O
) NN NN O
. NN NN O

This NN NN O
report NN NN O
describes NN NN O
the NN NN O
autosomal NN NN O
inheritance NN NN O
of NN NN O
a NN NN O
hemophilia NN NN B-Modifier
A NN NN I-Modifier
phenotype NN NN O
due NN NN O
to NN NN O
a NN NN O
mutation NN NN O
of NN NN O
vWF NN NN O
that NN NN O
results NN NN O
in NN NN O
defective NN NN O
factor NN NN O
VIII NN NN O
binding NN NN O
. NN NN O

The NN NN O
proband NN NN O
was NN NN O
a NN NN O
female NN NN O
patient NN NN O
with NN NN O
low NN NN O
levels NN NN O
of NN NN O
factor NN NN O
VIII NN NN O
activity NN NN O
. NN NN O

Polymerase NN NN O
chain NN NN O
reaction NN NN O
( NN NN O
PCR NN NN O
) NN NN O
amplification NN NN O
and NN NN O
DNA NN NN O
sequencing NN NN O
were NN NN O
employed NN NN O
to NN NN O
examine NN NN O
exons NN NN O
encoding NN NN O
the NN NN O
putative NN NN O
factor NN NN O
VIII NN NN O
binding NN NN O
domain NN NN O
of NN NN O
vWF NN NN O
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
homozygous NN NN O
for NN NN O
a NN NN O
single NN NN O
point NN NN O
mutation NN NN O
causing NN NN O
a NN NN O
Thr NN NN O
-- NN NN O
Met NN NN O
substitution NN NN O
at NN NN O
amino NN NN O
acid NN NN O
position NN NN O
28 NN NN O
in NN NN O
the NN NN O
mature NN NN O
vWF NN NN O
subunit NN NN O
. NN NN O

The NN NN O
phenotypic NN NN O
expression NN NN O
of NN NN O
the NN NN O
mutation NN NN O
was NN NN O
determined NN NN O
to NN NN O
be NN NN O
recessive NN NN O
because NN NN O
heterozygous NN NN O
family NN NN O
members NN NN O
were NN NN O
clinically NN NN O
unaffected NN NN O
. NN NN O

Recombinant NN NN O
vWF NN NN O
containing NN NN O
the NN NN O
observed NN NN O
amino NN NN O
acid NN NN O
substitution NN NN O
was NN NN O
expressed NN NN O
in NN NN O
COS-1 NN NN O
cells NN NN O
. NN NN O

The NN NN O
mutant NN NN O
vWF NN NN O
was NN NN O
processed NN NN O
and NN NN O
secreted NN NN O
normally NN NN O
, NN NN O
and NN NN O
was NN NN O
functionally NN NN O
equivalent NN NN O
to NN NN O
wild-type NN NN O
vWF NN NN O
in NN NN O
its NN NN O
ability NN NN O
to NN NN O
bind NN NN O
to NN NN O
platelets NN NN O
. NN NN O

However NN NN O
, NN NN O
the NN NN O
mutant NN NN O
failed NN NN O
to NN NN O
bind NN NN O
factor NN NN O
VIII NN NN O
, NN NN O
demonstrating NN NN O
that NN NN O
the NN NN O
mutation NN NN O
was NN NN O
functionally NN NN O
related NN NN O
to NN NN O
the NN NN O
observed NN NN O
hemophilia NN NN B-Modifier
phenotype NN NN O
. NN NN O

The NN NN O
family NN NN O
we NN NN O
describe NN NN O
demonstrates NN NN O
the NN NN O
recessive NN NN O
inheritance NN NN O
of NN NN O
a NN NN O
recently NN NN O
recognized NN NN O
class NN NN O
of NN NN O
genetic NN NN O
bleeding NN NN O
disorders NN NN O
, NN NN O
we NN NN O
call NN NN O
`` NN NN O
autosomal NN NN O
hemophilia NN NN B-SpecificDisease
. NN NN O
`` NN NN O

We NN NN O
conclude NN NN O
that NN NN O
vWF NN NN O
mutation NN NN O
may NN NN O
be NN NN O
an NN NN O
under NN NN O
recognized NN NN O
cause NN NN O
of NN NN O
hemophilia NN NN B-SpecificDisease
, NN NN O
especially NN NN O
in NN NN O
cases NN NN O
where NN NN O
the NN NN O
inheritance NN NN O
pattern NN NN O
is NN NN O
not NN NN O
consistent NN NN O
with NN NN O
X-linked NN NN O
transmission NN NN O
. NN NN O

8522307 NN NN O
Somatic NN NN O
von NN NN B-Modifier
Hippel-Lindau NN NN I-Modifier
mutation NN NN O
in NN NN O
clear NN NN O
cell NN NN O
papillary NN NN B-SpecificDisease
cystadenoma NN NN I-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
epididymis NN NN I-SpecificDisease
. NN NN O

Papillary NN NN B-SpecificDisease
cystadenoma NN NN I-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
epididymis NN NN I-SpecificDisease
is NN NN O
an NN NN O
uncommon NN NN O
benign NN NN O
lesion NN NN O
that NN NN O
may NN NN O
occur NN NN O
sporadically NN NN O
or NN NN O
as NN NN O
a NN NN O
manifestation NN NN O
of NN NN O
von NN NN B-SpecificDisease
Hippel-Lindau NN NN I-SpecificDisease
( NN NN I-SpecificDisease
VHL NN NN I-SpecificDisease
) NN NN I-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

Neither NN NN O
immunohistochemical NN NN O
studies NN NN O
nor NN NN O
molecular NN NN O
genetic NN NN O
analyses NN NN O
of NN NN O
the NN NN O
VHL NN NN B-Modifier
gene NN NN O
have NN NN O
been NN NN O
reported NN NN O
previously NN NN O
for NN NN O
this NN NN O
lesion NN NN O
. NN NN O

The NN NN O
authors NN NN O
describe NN NN O
two NN NN O
cases NN NN O
of NN NN O
clear NN NN O
cell NN NN O
papillary NN NN B-SpecificDisease
cystadenoma NN NN I-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
epididymis NN NN I-SpecificDisease
, NN NN O
both NN NN O
of NN NN O
which NN NN O
were NN NN O
initially NN NN O
confused NN NN O
with NN NN O
metastatic NN NN B-SpecificDisease
renal NN NN I-SpecificDisease
cell NN NN I-SpecificDisease
carcinoma NN NN I-SpecificDisease
. NN NN O

Both NN NN O
lesions NN NN O
showed NN NN O
positive NN NN O
immunohistochemical NN NN O
staining NN NN O
for NN NN O
low NN NN O
and NN NN O
intermediate NN NN O
molecular NN NN O
weight NN NN O
keratins NN NN O
( NN NN O
Cam NN NN O
5 NN NN O
. NN NN O

2 NN NN O
and NN NN O
AE1 NN NN O
/ NN NN O
AE3 NN NN O
) NN NN O
, NN NN O
EMA NN NN O
, NN NN O
vimentin NN NN O
, NN NN O
alpha NN NN O
1-antitrypsin NN NN O
, NN NN O
and NN NN O
alpha NN NN O
1-antichymotrypsin NN NN O
. NN NN O

Each NN NN O
was NN NN O
negative NN NN O
for NN NN O
CEA NN NN O
. NN NN O

Because NN NN O
clear NN NN O
cell NN NN O
papillary NN NN B-SpecificDisease
cystadenoma NN NN I-SpecificDisease
is NN NN O
similar NN NN O
to NN NN O
renal NN NN B-SpecificDisease
cell NN NN I-SpecificDisease
carcinoma NN NN I-SpecificDisease
histologically NN NN O
, NN NN O
and NN NN O
because NN NN O
both NN NN O
occur NN NN O
as NN NN O
components NN NN O
of NN NN O
the NN NN O
von NN NN B-Modifier
Hippel-Lindau NN NN I-Modifier
disease NN NN I-Modifier
complex NN NN O
, NN NN O
the NN NN O
authors NN NN O
analyzed NN NN O
both NN NN O
cases NN NN O
for NN NN O
the NN NN O
presence NN NN O
of NN NN O
mutations NN NN O
in NN NN O
the NN NN O
VHL NN NN B-Modifier
gene NN NN O
. NN NN O

A NN NN O
somatic NN NN O
VHL NN NN B-Modifier
gene NN NN O
mutation NN NN O
was NN NN O
detected NN NN O
in NN NN O
one NN NN O
of NN NN O
the NN NN O
two NN NN O
tumors NN NN B-DiseaseClass
by NN NN O
polymerase NN NN O
chain NN NN O
reaction NN NN O
followed NN NN O
by NN NN O
single-strand NN NN O
conformation NN NN O
polymorphism NN NN O
analysis NN NN O
. NN NN O

Direct NN NN O
sequencing NN NN O
revealed NN NN O
a NN NN O
cytosine NN NN O
to NN NN O
thymine NN NN O
transition NN NN O
at NN NN O
nucleotide NN NN O
694 NN NN O
, NN NN O
resulting NN NN O
in NN NN O
the NN NN O
replacement NN NN O
of NN NN O
an NN NN O
arginine NN NN O
with NN NN O
a NN NN O
stop NN NN O
codon NN NN O
after NN NN O
the NN NN O
sixth NN NN O
amino NN NN O
acid NN NN O
of NN NN O
exon NN NN O
3 NN NN O
. NN NN O

As NN NN O
the NN NN O
VHL NN NN B-Modifier
gene NN NN O
is NN NN O
believed NN NN O
to NN NN O
function NN NN O
as NN NN O
a NN NN O
tumor NN NN B-Modifier
suppressor NN NN O
gene NN NN O
, NN NN O
VHL NN NN B-Modifier
gene NN NN O
mutations NN NN O
may NN NN O
play NN NN O
a NN NN O
role NN NN O
in NN NN O
the NN NN O
initiation NN NN O
of NN NN O
tumorigenesis NN NN O
in NN NN O
sporadic NN NN O
cystadenomas NN NN B-SpecificDisease
of NN NN I-SpecificDisease
the NN NN I-SpecificDisease
epididymis NN NN I-SpecificDisease
. NN NN O

8528198 NN NN O
Identification NN NN O
of NN NN O
WASP NN NN O
mutations NN NN O
in NN NN O
patients NN NN O
with NN NN O
Wiskott-Aldrich NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
and NN NN O
isolated NN NN B-SpecificDisease
thrombocytopenia NN NN I-SpecificDisease
reveals NN NN O
allelic NN NN O
heterogeneity NN NN O
at NN NN O
the NN NN O
WAS NN NN B-Modifier
locus NN NN O
. NN NN O

Mutation NN NN O
in NN NN O
the NN NN O
gene NN NN O
encoding NN NN O
the NN NN O
recently NN NN O
isolated NN NN O
WASP NN NN O
protein NN NN O
has NN NN O
now NN NN O
been NN NN O
identified NN NN O
as NN NN O
the NN NN O
genetic NN NN B-DiseaseClass
defect NN NN I-DiseaseClass
responsible NN NN O
for NN NN O
the NN NN O
X-linked NN NN B-SpecificDisease
Wiskott-Aldrich NN NN I-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
WAS NN NN B-SpecificDisease
) NN NN O
, NN NN O
a NN NN O
primary NN NN O
immunodeficiency NN NN B-DiseaseClass
disease NN NN I-DiseaseClass
associated NN NN O
with NN NN O
extensive NN NN O
phenotypic NN NN O
variability NN NN O
. NN NN O

To NN NN O
elucidate NN NN O
the NN NN O
range NN NN O
of NN NN O
WASP NN NN O
mutations NN NN O
responsible NN NN O
for NN NN O
WAS NN NN B-SpecificDisease
, NN NN O
we NN NN O
used NN NN O
PCR-SSCP NN NN O
analysis NN NN O
to NN NN O
screen NN NN O
for NN NN O
WASP NN NN O
gene NN NN O
mutation NN NN O
in NN NN O
19 NN NN O
unrelated NN NN O
boys NN NN O
with NN NN O
the NN NN O
diagnosis NN NN O
of NN NN O
classical NN NN O
or NN NN O
attenuated NN NN O
WAS NN NN B-SpecificDisease
or NN NN O
isolated NN NN B-SpecificDisease
thrombocytopenia NN NN I-SpecificDisease
. NN NN O

All NN NN O
19 NN NN O
patients NN NN O
had NN NN O
WASP NN NN O
mutations NN NN O
, NN NN O
each NN NN O
of NN NN O
which NN NN O
localized NN NN O
to NN NN O
the NN NN O
initial NN NN O
three NN NN O
or NN NN O
terminal NN NN O
three NN NN O
exons NN NN O
of NN NN O
the NN NN O
gene NN NN O
, NN NN O
and NN NN O
the NN NN O
majority NN NN O
of NN NN O
which NN NN O
were NN NN O
unique NN NN O
in NN NN O
each NN NN O
case NN NN O
. NN NN O

However NN NN O
, NN NN O
a NN NN O
missense NN NN O
mutation NN NN O
which NN NN O
results NN NN O
in NN NN O
substitution NN NN O
of NN NN O
the NN NN O
arginine NN NN O
at NN NN O
WAS NN NN B-Modifier
codon NN NN O
86 NN NN O
was NN NN O
identified NN NN O
in NN NN O
three NN NN O
boys NN NN O
with NN NN O
severe NN NN O
WAS NN NN B-SpecificDisease
as NN NN O
well NN NN O
as NN NN O
in NN NN O
one NN NN O
boy NN NN O
presenting NN NN O
with NN NN O
thrombocytopenia NN NN B-SpecificDisease
alone NN NN O
. NN NN O

While NN NN O
the NN NN O
three NN NN O
mutations NN NN O
found NN NN O
in NN NN O
the NN NN O
isolated NN NN B-Modifier
thrombocytopenia NN NN I-Modifier
patients NN NN O
leave NN NN O
the NN NN O
reading NN NN O
frame NN NN O
intact NN NN O
, NN NN O
about NN NN O
one-half NN NN O
of NN NN O
the NN NN O
gene NN NN O
alterations NN NN O
detected NN NN O
in NN NN O
both NN NN O
severe NN NN O
and NN NN O
attenuated NN NN O
WAS NN NN B-SpecificDisease
patients NN NN O
result NN NN O
in NN NN O
frameshifted NN NN O
transcript NN NN O
and NN NN O
premature NN NN O
translation NN NN O
termination NN NN O
. NN NN O

These NN NN O
findings NN NN O
therefore NN NN O
confirm NN NN O
the NN NN O
association NN NN O
of NN NN O
WAS NN NN B-SpecificDisease
with NN NN O
WASP NN NN O
mutation NN NN O
and NN NN O
identify NN NN O
WASP NN NN O
mutation NN NN O
as NN NN O
a NN NN O
cause NN NN O
for NN NN O
isolated NN NN O
congenital NN NN B-SpecificDisease
thrombocytopenia NN NN I-SpecificDisease
in NN NN O
males NN NN O
. NN NN O

While NN NN O
the NN NN O
WASP NN NN O
gene NN NN O
defects NN NN O
responsible NN NN O
for NN NN O
isolated NN NN B-SpecificDisease
thrombocytopenia NN NN I-SpecificDisease
and NN NN O
other NN NN O
mild NN NN O
presentations NN NN O
of NN NN O
WAS NN NN B-SpecificDisease
do NN NN O
not NN NN O
appear NN NN O
distinct NN NN O
from NN NN O
those NN NN O
resulting NN NN O
in NN NN O
severe NN NN O
WAS NN NN B-SpecificDisease
, NN NN O
these NN NN O
data NN NN O
indicate NN NN O
that NN NN O
analysis NN NN O
of NN NN O
WASP NN NN O
gene NN NN O
mutation NN NN O
provides NN NN O
a NN NN O
valuable NN NN O
tool NN NN O
for NN NN O
distinguishing NN NN O
the NN NN O
spectrum NN NN O
of NN NN O
WAS NN NN B-Modifier
patients NN NN O
and NN NN O
the NN NN O
subset NN NN O
of NN NN O
males NN NN O
with NN NN O
isolated NN NN B-SpecificDisease
thrombocytopenia NN NN I-SpecificDisease
who NN NN O
represent NN NN O
mild NN NN O
cases NN NN O
of NN NN O
WAS NN NN B-SpecificDisease
. NN NN O

. NN NN O

8528199 NN NN O
WASP NN NN O
gene NN NN O
mutations NN NN O
in NN NN O
Wiskott-Aldrich NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
and NN NN O
X-linked NN NN B-SpecificDisease
thrombocytopenia NN NN I-SpecificDisease
. NN NN O

The NN NN O
WASP NN NN O
gene NN NN O
has NN NN O
been NN NN O
recently NN NN O
cloned NN NN O
from NN NN O
Xp11 NN NN O
. NN NN O

23 NN NN O
and NN NN O
shown NN NN O
to NN NN O
be NN NN O
mutated NN NN O
in NN NN O
three NN NN O
patients NN NN O
with NN NN O
the NN NN O
Wiskott-Aldrich NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
WAS NN NN B-SpecificDisease
) NN NN O
. NN NN O

We NN NN O
have NN NN O
developed NN NN O
a NN NN O
screening NN NN O
protocol NN NN O
for NN NN O
identifying NN NN O
WASP NN NN O
gene NN NN O
alterations NN NN O
in NN NN O
genomic NN NN O
DNA NN NN O
and NN NN O
have NN NN O
identified NN NN O
a NN NN O
spectrum NN NN O
of NN NN O
novel NN NN O
mutations NN NN O
in NN NN O
12 NN NN O
additional NN NN O
unrelated NN NN O
families NN NN O
. NN NN O

These NN NN O
missense NN NN O
, NN NN O
nonsense NN NN O
and NN NN O
frameshift NN NN O
mutations NN NN O
involve NN NN O
eight NN NN O
of NN NN O
the NN NN O
12 NN NN O
exons NN NN O
of NN NN O
the NN NN O
gene NN NN O
. NN NN O

Two NN NN O
mutations NN NN O
creating NN NN O
premature NN NN O
termination NN NN O
codons NN NN O
were NN NN O
associated NN NN O
with NN NN O
lack NN NN O
of NN NN O
detectable NN NN O
mRNA NN NN O
on NN NN O
Northern NN NN O
blots NN NN O
. NN NN O

Four NN NN O
amino NN NN O
acid NN NN O
substitutions NN NN O
, NN NN O
Leu27Phe NN NN O
, NN NN O
Thr48Ile NN NN O
, NN NN O
Val75Met NN NN O
and NN NN O
Arg477Lys NN NN O
, NN NN O
were NN NN O
found NN NN O
in NN NN O
patients NN NN O
with NN NN O
congenital NN NN B-SpecificDisease
thrombocytopenia NN NN I-SpecificDisease
and NN NN O
no NN NN O
clinically NN NN O
evident NN NN O
immune NN NN O
defect NN NN O
indicating NN NN O
that NN NN O
the NN NN O
WASP NN NN O
gene NN NN O
is NN NN O
the NN NN O
site NN NN O
for NN NN O
mutations NN NN O
in NN NN O
X-linked NN NN B-SpecificDisease
thrombocytopenia NN NN I-SpecificDisease
as NN NN O
well NN NN O
as NN NN O
in NN NN O
WAS NN NN B-SpecificDisease
. NN NN O

A NN NN O
T-cell NN NN O
line NN NN O
from NN NN O
a NN NN O
WAS NN NN B-Modifier
patient NN NN O
contained NN NN O
two NN NN O
independent NN NN O
DNA NN NN O
alterations NN NN O
, NN NN O
a NN NN O
constitutional NN NN O
frameshift NN NN O
mutation NN NN O
, NN NN O
also NN NN O
present NN NN O
in NN NN O
peripheral NN NN O
blood NN NN O
leukocytes NN NN O
from NN NN O
the NN NN O
patient NN NN O
, NN NN O
and NN NN O
compensatory NN NN O
splice NN NN O
site NN NN O
mutation NN NN O
unique NN NN O
to NN NN O
the NN NN O
cell NN NN O
line NN NN O
. NN NN O

The NN NN O
distribution NN NN O
of NN NN O
eight NN NN O
missense NN NN O
mutations NN NN O
provides NN NN O
valuable NN NN O
information NN NN O
on NN NN O
amino NN NN O
acids NN NN O
which NN NN O
are NN NN O
essential NN NN O
for NN NN O
normal NN NN O
protein NN NN O
function NN NN O
, NN NN O
and NN NN O
suggests NN NN O
that NN NN O
sites NN NN O
in NN NN O
the NN NN O
first NN NN O
two NN NN O
exons NN NN O
are NN NN O
hot-spots NN NN O
for NN NN O
mutation NN NN O
. NN NN O

8528200 NN NN O
Evidence NN NN O
for NN NN O
inter-generational NN NN O
instability NN NN O
in NN NN O
the NN NN O
CAG NN NN O
repeat NN NN O
in NN NN O
the NN NN O
MJD1 NN NN O
gene NN NN O
and NN NN O
for NN NN O
conserved NN NN O
haplotypes NN NN O
at NN NN O
flanking NN NN O
markers NN NN O
amongst NN NN O
Japanese NN NN O
and NN NN O
Caucasian NN NN O
subjects NN NN O
with NN NN O
Machado-Joseph NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
. NN NN O

The NN NN O
size NN NN O
of NN NN O
the NN NN O
( NN NN O
CAG NN NN O
) NN NN O
n NN NN O
repeat NN NN O
array NN NN O
in NN NN O
the NN NN O
3 NN NN O
end NN NN O
of NN NN O
the NN NN O
MJD1 NN NN O
gene NN NN O
and NN NN O
the NN NN O
haplotype NN NN O
at NN NN O
a NN NN O
series NN NN O
of NN NN O
microsatellite NN NN O
markers NN NN O
surrounding NN NN O
the NN NN O
MJD1 NN NN O
gene NN NN O
were NN NN O
examined NN NN O
in NN NN O
a NN NN O
large NN NN O
cohort NN NN O
of NN NN O
Japanese NN NN O
and NN NN O
Caucasian NN NN O
subjects NN NN O
affected NN NN O
with NN NN O
Machado-Joseph NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
( NN NN O
MJD NN NN B-SpecificDisease
) NN NN O
. NN NN O

Our NN NN O
data NN NN O
provide NN NN O
five NN NN O
novel NN NN O
observations NN NN O
. NN NN O

First NN NN O
, NN NN O
MJD NN NN B-SpecificDisease
is NN NN O
associated NN NN O
with NN NN O
expansion NN NN O
fo NN NN O
the NN NN O
array NN NN O
from NN NN O
the NN NN O
normal NN NN O
range NN NN O
of NN NN O
14-37 NN NN O
repeats NN NN O
to NN NN O
68-84 NN NN O
repeats NN NN O
in NN NN O
most NN NN O
Japanese NN NN O
and NN NN O
Caucasian NN NN O
subjects NN NN O
, NN NN O
but NN NN O
no NN NN O
subjects NN NN O
were NN NN O
observed NN NN O
with NN NN O
expansions NN NN O
intermediate NN NN O
in NN NN O
size NN NN O
between NN NN O
those NN NN O
of NN NN O
the NN NN O
normal NN NN O
and NN NN O
MJD NN NN B-Modifier
affected NN NN O
groups NN NN O
. NN NN O

Second NN NN O
, NN NN O
the NN NN O
expanded NN NN O
allele NN NN O
associated NN NN O
with NN NN O
MJD NN NN B-SpecificDisease
displays NN NN O
inter-generational NN NN O
instability NN NN O
, NN NN O
particularly NN NN O
in NN NN O
male NN NN O
meioses NN NN O
, NN NN O
and NN NN O
this NN NN O
instability NN NN O
was NN NN O
associated NN NN O
with NN NN O
the NN NN O
clinical NN NN O
phenomenon NN NN O
of NN NN O
anticipation NN NN O
. NN NN O

Third NN NN O
, NN NN O
the NN NN O
size NN NN O
of NN NN O
the NN NN O
expanded NN NN O
allele NN NN O
is NN NN O
not NN NN O
only NN NN O
inversely NN NN O
correlated NN NN O
with NN NN O
the NN NN O
age-of-onset NN NN O
of NN NN O
MJD NN NN B-SpecificDisease
( NN NN O
r NN NN O
= NN NN O
-0 NN NN O
. NN NN O

738 NN NN O
, NN NN O
p NN NN O
0 NN NN O
. NN NN O

001 NN NN O
) NN NN O
, NN NN O
but NN NN O
is NN NN O
also NN NN O
correlated NN NN O
with NN NN O
the NN NN O
frequency NN NN O
of NN NN O
other NN NN O
clinical NN NN O
features NN NN O
[ NN NN O
e NN NN O
. NN NN O

g NN NN O
g NN NN O
. NN NN O

pseudoexophthalmos NN NN O
and NN NN O
pyramidal NN NN O
signs NN NN O
were NN NN O
more NN NN O
frequent NN NN O
in NN NN O
subjects NN NN O
with NN NN O
large NN NN O
repeats NN NN O
( NN NN O
p NN NN O
0 NN NN O
. NN NN O

10 NN NN O
001 NN NN O
and NN NN O
p NN NN O
0 NN NN O
. NN NN O

05 NN NN O
respectively NN NN O
) NN NN O
] NN NN O
. NN NN O

Fourth NN NN O
, NN NN O
the NN NN O
disease NN NN O
phenotype NN NN O
is NN NN O
significantly NN NN O
more NN NN O
severe NN NN O
and NN NN O
had NN NN O
an NN NN O
early NN NN O
age NN NN O
of NN NN O
onset NN NN O
( NN NN O
16 NN NN O
years NN NN O
) NN NN O
in NN NN O
a NN NN O
subject NN NN O
homozygous NN NN O
for NN NN O
the NN NN O
expanded NN NN O
allele NN NN O
, NN NN O
which NN NN O
contrasts NN NN O
with NN NN O
Huntington NN NN B-SpecificDisease
disease NN NN I-SpecificDisease
and NN NN O
suggests NN NN O
that NN NN O
the NN NN O
expanded NN NN O
allele NN NN O
in NN NN O
the NN NN O
MJD1 NN NN O
gene NN NN O
could NN NN O
exert NN NN O
its NN NN O
effect NN NN O
either NN NN O
by NN NN O
a NN NN O
dominant NN NN O
negative NN NN O
effect NN NN O
( NN NN O
putatively NN NN O
excluded NN NN O
in NN NN O
HD NN NN B-SpecificDisease
) NN NN O
or NN NN O
by NN NN O
a NN NN O
gain NN NN O
of NN NN O
function NN NN O
effect NN NN O
as NN NN O
proposed NN NN O
for NN NN O
HD NN NN B-SpecificDisease
. NN NN O

Finally NN NN O
, NN NN O
Japanese NN NN O
and NN NN O
Caucasian NN NN O
subjects NN NN O
affected NN NN O
with NN NN O
MJD NN NN B-SpecificDisease
share NN NN O
haplotypes NN NN O
at NN NN O
several NN NN O
markers NN NN O
surrounding NN NN O
the NN NN O
MJD1 NN NN O
gene NN NN O
, NN NN O
which NN NN O
are NN NN O
uncommon NN NN O
in NN NN O
the NN NN O
normal NN NN O
Japanese NN NN O
and NN NN O
Caucasian NN NN O
population NN NN O
, NN NN O
and NN NN O
which NN NN O
suggests NN NN O
the NN NN O
existence NN NN O
either NN NN O
of NN NN O
common NN NN O
founders NN NN O
in NN NN O
these NN NN O
populations NN NN O
or NN NN O
of NN NN O
chromosomes NN NN O
susceptible NN NN O
to NN NN O
pathologic NN NN O
expansion NN NN O
of NN NN O
the NN NN O
CAG NN NN O
repeat NN NN O
in NN NN O
the NN NN O
MJD1 NN NN O
gene NN NN O

8530105 NN NN O
A NN NN O
4-megabase NN NN O
YAC NN NN O
contig NN NN O
that NN NN O
spans NN NN O
the NN NN O
Langer-Giedion NN NN B-Modifier
syndrome NN NN I-Modifier
region NN NN O
on NN NN O
human NN NN O
chromosome NN NN O
8q24.1 NN NN O
: NN NN O
use NN NN O
in NN NN O
refining NN NN O
the NN NN O
location NN NN O
of NN NN O
the NN NN O
trichorhinophalangeal NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
and NN NN O
multiple NN NN O
exostoses NN NN O
genes NN NN O
( NN NN O
TRPS1 NN NN O
and NN NN O
EXT1 NN NN O
) NN NN O
. NN NN O

We NN NN O
have NN NN O
constructed NN NN O
a NN NN O
physical NN NN O
map NN NN O
covering NN NN O
over NN NN O
4 NN NN O
Mb NN NN O
of NN NN O
human NN NN O
chromosome NN NN O
8q24 NN NN O
. NN NN O

1 NN NN O
and NN NN O
used NN NN O
this NN NN O
map NN NN O
to NN NN O
refine NN NN O
the NN NN O
locations NN NN O
of NN NN O
the NN NN O
genes NN NN O
responsible NN NN O
for NN NN O
Langer-Giedion NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
. NN NN O

The NN NN O
map NN NN O
is NN NN O
composed NN NN O
of NN NN O
overlapping NN NN O
YAC NN NN O
clones NN NN O
that NN NN O
were NN NN O
identified NN NN O
and NN NN O
ordered NN NN O
in NN NN O
relation NN NN O
to NN NN O
sequence NN NN O
tagged NN NN O
sites NN NN O
mapped NN NN O
to NN NN O
the NN NN O
Langer-Giedion NN NN O
chromosomal NN NN O
region NN NN O
on NN NN O
somatic NN NN O
cell NN NN O
hybrids NN NN O
. NN NN O

The NN NN O
minimal NN NN O
region NN NN O
of NN NN O
overlap NN NN O
of NN NN O
Langer-Giedion NN NN B-Modifier
syndrome NN NN I-Modifier
deletions NN NN O
, NN NN O
previously NN NN O
identified NN NN O
by NN NN O
analysis NN NN O
of NN NN O
15 NN NN O
patients NN NN O
, NN NN O
was NN NN O
placed NN NN O
on NN NN O
the NN NN O
map NN NN O
by NN NN O
analysis NN NN O
of NN NN O
2 NN NN O
patients NN NN O
whose NN NN O
deletions NN NN O
define NN NN O
the NN NN O
endpoints NN NN O
. NN NN O

The NN NN O
chromosome NN NN O
8 NN NN O
breakpoint NN NN O
of NN NN O
a NN NN O
balanced NN NN O
t NN NN O
( NN NN O
8 NN NN O
; NN NN O
9 NN NN O
) NN NN O
( NN NN O
q24 NN NN O
. NN NN O

11 NN NN O
; NN NN O
q33 NN NN O
. NN NN O

3 NN NN O
) NN NN O
translocation NN NN O
from NN NN O
a NN NN O
patient NN NN O
with NN NN O
trichorhinophalangeal NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
( NN NN O
TRPS NN NN B-SpecificDisease
I NN NN O
) NN NN O
was NN NN O
found NN NN O
to NN NN O
be NN NN O
located NN NN O
just NN NN O
within NN NN O
the NN NN O
proximal NN NN O
end NN NN O
of NN NN O
the NN NN O
minimal NN NN O
deletion NN NN O
region NN NN O
. NN NN O

A NN NN O
deletion NN NN O
of NN NN O
8q24 NN NN O
. NN NN O

11-q24 NN NN O
11-q24 NN NN O
. NN NN O

3 NN NN O
in NN NN O
a NN NN O
patient NN NN O
with NN NN O
multiple NN NN O
exostoses NN NN O
was NN NN O
found NN NN O
to NN NN O
overlap NN NN O
the NN NN O
distal NN NN O
end NN NN O
of NN NN O
the NN NN O
LGS NN NN B-Modifier
deletion NN NN O
region NN NN O
, NN NN O
indicating NN NN O
that NN NN O
the NN NN O
EXT1 NN NN O
gene NN NN O
is NN NN O
distal NN NN O
to NN NN O
the NN NN O
TRPS1 NN NN O
gene NN NN O
and NN NN O
supporting NN NN O
the NN NN O
hypothesis NN NN O
that NN NN O
Langer-Giedion NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
is NN NN O
due NN NN O
to NN NN O
loss NN NN O
of NN NN O
functional NN NN O
copies NN NN O
of NN NN O
both NN NN O
the NN NN O
TRPS1 NN NN O
and NN NN O
the NN NN O
EXT1 NN NN O
genes NN NN O

8531967 NN NN O
BRCA1 NN NN O
mutations NN NN O
in NN NN O
a NN NN O
population-based NN NN O
sample NN NN O
of NN NN O
young NN NN O
women NN NN O
with NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

BACKGROUND NN NN O
. NN NN O

Inherited NN NN O
mutations NN NN O
in NN NN O
the NN NN O
BRCA1 NN NN O
gene NN NN O
are NN NN O
associated NN NN O
with NN NN O
a NN NN O
high NN NN O
risk NN NN O
of NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
in NN NN O
some NN NN O
families NN NN O
. NN NN O

However NN NN O
, NN NN O
little NN NN O
is NN NN O
known NN NN O
about NN NN O
the NN NN O
contribution NN NN O
of NN NN O
BRCA1 NN NN O
mutations NN NN O
to NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
in NN NN O
the NN NN O
general NN NN O
population NN NN O
. NN NN O

We NN NN O
analyzed NN NN O
DNA NN NN O
samples NN NN O
from NN NN O
women NN NN O
enrolled NN NN O
in NN NN O
a NN NN O
population-based NN NN O
study NN NN O
of NN NN O
early-onset NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
to NN NN O
assess NN NN O
the NN NN O
spectrum NN NN O
and NN NN O
frequency NN NN O
of NN NN O
germ-line NN NN O
BRCA1 NN NN O
mutations NN NN O
in NN NN O
young NN NN O
women NN NN O
with NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

METHODS NN NN O
. NN NN O

We NN NN O
studied NN NN O
80 NN NN O
women NN NN O
in NN NN O
whom NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
was NN NN O
diagnosed NN NN O
before NN NN O
the NN NN O
age NN NN O
of NN NN O
35 NN NN O
, NN NN O
and NN NN O
who NN NN O
were NN NN O
not NN NN O
selected NN NN O
on NN NN O
the NN NN O
basis NN NN O
of NN NN O
family NN NN O
history NN NN O
. NN NN O

Genomic NN NN O
DNA NN NN O
was NN NN O
studied NN NN O
for NN NN O
BRCA1 NN NN O
mutations NN NN O
by NN NN O
analysis NN NN O
involving NN NN O
single-strand NN NN O
conformation NN NN O
polymorphisms NN NN O
and NN NN O
with NN NN O
allele-specific NN NN O
assays NN NN O
. NN NN O

Alterations NN NN O
were NN NN O
defined NN NN O
by NN NN O
DNA NN NN O
sequencing NN NN O
. NN NN O

RESULTS NN NN O
. NN NN O

Germ-line NN NN O
BRCA1 NN NN O
mutations NN NN O
were NN NN O
identified NN NN O
in NN NN O
6 NN NN O
of NN NN O
the NN NN O
80 NN NN O
women NN NN O
. NN NN O

Four NN NN O
additional NN NN O
rare NN NN O
sequence NN NN O
variants NN NN O
of NN NN O
unknown NN NN O
functional NN NN O
importance NN NN O
were NN NN O
also NN NN O
identified NN NN O
. NN NN O

Two NN NN O
of NN NN O
the NN NN O
mutations NN NN O
and NN NN O
three NN NN O
of NN NN O
the NN NN O
rare NN NN O
sequence NN NN O
variants NN NN O
were NN NN O
found NN NN O
among NN NN O
the NN NN O
39 NN NN O
women NN NN O
who NN NN O
reported NN NN O
no NN NN O
family NN NN O
history NN NN O
of NN NN O
breast NN NN B-CompositeMention
or NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
. NN NN O

None NN NN O
of NN NN O
the NN NN O
mutations NN NN O
and NN NN O
only NN NN O
one NN NN O
of NN NN O
the NN NN O
rare NN NN O
variants NN NN O
was NN NN O
identified NN NN O
in NN NN O
a NN NN O
reference NN NN O
population NN NN O
of NN NN O
73 NN NN O
unrelated NN NN O
subjects NN NN O
. NN NN O

CONCLUSIONS NN NN O
. NN NN O

Alterations NN NN O
in NN NN O
BRCA1 NN NN O
were NN NN O
identified NN NN O
in NN NN O
approximately NN NN O
10 NN NN O
percent NN NN O
of NN NN O
this NN NN O
cohort NN NN O
of NN NN O
young NN NN O
women NN NN O
with NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

The NN NN O
risk NN NN O
of NN NN O
harboring NN NN O
a NN NN O
mutation NN NN O
was NN NN O
not NN NN O
limited NN NN O
to NN NN O
women NN NN O
with NN NN O
family NN NN O
histories NN NN O
of NN NN O
breast NN NN B-CompositeMention
or NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
. NN NN O

These NN NN O
results NN NN O
represent NN NN O
a NN NN O
minimal NN NN O
estimate NN NN O
of NN NN O
the NN NN O
frequency NN NN O
of NN NN O
BRCA1 NN NN O
mutations NN NN O
in NN NN O
this NN NN O
population NN NN O
. NN NN O

Comprehensive NN NN O
methods NN NN O
of NN NN O
identifying NN NN O
BRCA1 NN NN O
mutations NN NN O
and NN NN O
understanding NN NN O
their NN NN O
importance NN NN O
will NN NN O
be NN NN O
needed NN NN O
before NN NN O
testing NN NN O
of NN NN O
women NN NN O
in NN NN O
the NN NN O
general NN NN O
population NN NN O
can NN NN O
be NN NN O
undertaken NN NN O
. NN NN O

. NN NN O

8533757 NN NN O
Novel NN NN O
inherited NN NN O
mutations NN NN O
and NN NN O
variable NN NN O
expressivity NN NN O
of NN NN O
BRCA1 NN NN O
alleles NN NN O
, NN NN O
including NN NN O
the NN NN O
founder NN NN O
mutation NN NN O
185delAG NN NN O
in NN NN O
Ashkenazi NN NN O
Jewish NN NN O
families NN NN O
. NN NN O

Thirty-seven NN NN O
families NN NN O
with NN NN O
four NN NN O
or NN NN O
more NN NN O
cases NN NN O
of NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
or NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
were NN NN O
analyzed NN NN O
for NN NN O
mutations NN NN O
in NN NN O
BRCA1 NN NN O
. NN NN O

Twelve NN NN O
different NN NN O
germ-line NN NN O
mutations NN NN O
, NN NN O
four NN NN O
novel NN NN O
and NN NN O
eight NN NN O
previously NN NN O
observed NN NN O
, NN NN O
were NN NN O
detected NN NN O
in NN NN O
16 NN NN O
families NN NN O
. NN NN O

Five NN NN O
families NN NN O
of NN NN O
Ashkenazi NN NN O
Jewish NN NN O
descent NN NN O
carried NN NN O
the NN NN O
185delAG NN NN O
mutation NN NN O
and NN NN O
shared NN NN O
the NN NN O
same NN NN O
haplotype NN NN O
at NN NN O
eight NN NN O
polymorphic NN NN O
markers NN NN O
spanning NN NN O
approximately NN NN O
850 NN NN O
kb NN NN O
at NN NN O
BRCA1 NN NN O
. NN NN O

Expressivity NN NN O
of NN NN O
185delAG NN NN O
in NN NN O
these NN NN O
families NN NN O
varied NN NN O
, NN NN O
from NN NN O
early-onset NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
without NN NN O
ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

Mutation NN NN O
4184delTCAA NN NN O
occurred NN NN O
independently NN NN O
in NN NN O
two NN NN O
families NN NN O
. NN NN O

In NN NN O
one NN NN O
family NN NN O
, NN NN O
penetrance NN NN O
was NN NN O
complete NN NN O
, NN NN O
with NN NN O
females NN NN O
developing NN NN O
early-onset NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
or NN NN O
ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
and NN NN O
the NN NN O
male NN NN O
carrier NN NN O
developing NN NN O
prostatic NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
, NN NN O
whereas NN NN O
, NN NN O
in NN NN O
the NN NN O
other NN NN O
family NN NN O
, NN NN O
penetrance NN NN O
was NN NN O
incomplete NN NN O
and NN NN O
only NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
occurred NN NN O
, NN NN O
diagnosed NN NN O
at NN NN O
ages NN NN O
38-81 NN NN O
years NN NN O
. NN NN O

Two NN NN O
novel NN NN O
nonsense NN NN O
mutations NN NN O
led NN NN O
to NN NN O
the NN NN O
loss NN NN O
of NN NN O
mutant NN NN O
BRCA1 NN NN O
transcript NN NN O
in NN NN O
families NN NN O
with NN NN O
10 NN NN O
and NN NN O
6 NN NN O
cases NN NN O
of NN NN O
early-onset NN NN O
breast NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
and NN NN O
ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

A NN NN O
665-nt NN NN O
segment NN NN O
of NN NN O
the NN NN O
BRCA1 NN NN O
3-UTR NN NN O
and NN NN O
1 NN NN O
. NN NN O

3 NN NN O
kb NN NN O
of NN NN O
genomic NN NN O
sequence NN NN O
including NN NN O
the NN NN O
putative NN NN O
promoter NN NN O
region NN NN O
were NN NN O
invariant NN NN O
by NN NN O
single-strand NN NN O
conformation NN NN O
analysis NN NN O
in NN NN O
13 NN NN O
families NN NN O
without NN NN O
coding-sequence NN NN O
mutations NN NN O
. NN NN O

Overall NN NN O
in NN NN O
our NN NN O
series NN NN O
, NN NN O
BRCA1 NN NN O
mutations NN NN O
have NN NN O
been NN NN O
detected NN NN O
in NN NN O
26 NN NN O
families NN NN O
16 NN NN O
with NN NN O
positive NN NN O
BRCA1 NN NN O
lod NN NN O
scores NN NN O
, NN NN O
7 NN NN O
with NN NN O
negative NN NN O
lod NN NN O
scores NN NN O
( NN NN O
reflecting NN NN O
multiple NN NN O
sporadic NN NN O
breast NN NN B-SpecificDisease
cancers NN NN I-SpecificDisease
) NN NN O
, NN NN O
and NN NN O
3 NN NN O
not NN NN O
tested NN NN O
for NN NN O
linkage NN NN O
. NN NN O

Three NN NN O
other NN NN O
families NN NN O
have NN NN O
positive NN NN O
lod NN NN O
scores NN NN O
for NN NN O
linkage NN NN O
to NN NN O
BRCA2 NN NN O
, NN NN O
but NN NN O
13 NN NN O
families NN NN O
without NN NN O
detected NN NN O
BRCA1 NN NN O
mutations NN NN O
have NN NN O
negative NN NN O
lod NN NN O
scores NN NN O
for NN NN O
both NN NN O
BRCA1 NN NN O
and NN NN O
BRCA2 NN NN O
. NN NN O

8533762 NN NN O
A NN NN O
new NN NN O
glucose-6-phosphate NN NN O
dehydrogenase NN NN O
variant NN NN O
, NN NN O
G6PD NN NN O
Orissa NN NN O
( NN NN O
44 NN NN O
Ala NN NN O
-- NN NN O
Gly NN NN O
) NN NN O
, NN NN O
is NN NN O
the NN NN O
major NN NN O
polymorphic NN NN O
variant NN NN O
in NN NN O
tribal NN NN O
populations NN NN O
in NN NN O
India NN NN O
. NN NN O

Deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
glucose-6-phosphate NN NN I-SpecificDisease
dehydrogenase NN NN I-SpecificDisease
( NN NN O
G6PD NN NN O
) NN NN O
is NN NN O
usually NN NN O
found NN NN O
at NN NN O
high NN NN O
frequencies NN NN O
in NN NN O
areas NN NN O
of NN NN O
the NN NN O
world NN NN O
where NN NN O
malaria NN NN B-SpecificDisease
has NN NN O
been NN NN O
endemic NN NN O
. NN NN O

The NN NN O
frequency NN NN O
and NN NN O
genetic NN NN O
basis NN NN O
of NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
have NN NN O
been NN NN O
studied NN NN O
in NN NN O
Africa NN NN O
, NN NN O
around NN NN O
the NN NN O
Mediterranean NN NN O
, NN NN O
and NN NN O
in NN NN O
the NN NN O
Far NN NN O
East NN NN O
, NN NN O
but NN NN O
little NN NN O
such NN NN O
information NN NN O
is NN NN O
available NN NN O
about NN NN O
the NN NN O
situation NN NN O
in NN NN O
India NN NN O
. NN NN O

To NN NN O
determine NN NN O
the NN NN O
extent NN NN O
of NN NN O
heterogeneity NN NN O
of NN NN O
G6PD NN NN O
, NN NN O
we NN NN O
have NN NN O
studied NN NN O
several NN NN O
different NN NN O
Indian NN NN O
populations NN NN O
by NN NN O
screening NN NN O
for NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
, NN NN O
followed NN NN O
by NN NN O
molecular NN NN O
analysis NN NN O
of NN NN O
deficient NN NN O
alleles NN NN O
. NN NN O

The NN NN O
frequency NN NN O
of NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
varies NN NN O
between NN NN O
3 NN NN O
% NN NN O
and NN NN O
15 NN NN O
% NN NN O
in NN NN O
different NN NN O
tribal NN NN O
and NN NN O
urban NN NN O
groups NN NN O
. NN NN O

Remarkably NN NN O
, NN NN O
a NN NN O
previously NN NN O
unreported NN NN O
deficient NN NN O
variant NN NN O
, NN NN O
G6PD NN NN O
Orissa NN NN O
( NN NN O
44 NN NN O
Ala NN NN O
-- NN NN O
Gly NN NN O
) NN NN O
, NN NN O
is NN NN O
responsible NN NN O
for NN NN O
most NN NN O
of NN NN O
the NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
in NN NN O
tribal NN NN O
Indian NN NN O
populations NN NN O
but NN NN O
is NN NN O
not NN NN O
found NN NN O
in NN NN O
urban NN NN O
populations NN NN O
, NN NN O
where NN NN O
most NN NN O
of NN NN O
the NN NN O
G6PD NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
is NN NN O
due NN NN O
to NN NN O
the NN NN O
G6PD NN NN O
Mediterranean NN NN O
( NN NN O
188 NN NN O
Ser NN NN O
-- NN NN O
Phe NN NN O
) NN NN O
variant NN NN O
. NN NN O

The NN NN O
KmNADP NN NN O
of NN NN O
G6PD NN NN O
Orissa NN NN O
is NN NN O
fivefold NN NN O
higher NN NN O
than NN NN O
that NN NN O
of NN NN O
the NN NN O
normal NN NN O
enzyme NN NN O
. NN NN O

This NN NN O
may NN NN O
be NN NN O
due NN NN O
to NN NN O
the NN NN O
fact NN NN O
that NN NN O
the NN NN O
alanine NN NN O
residue NN NN O
that NN NN O
is NN NN O
replaced NN NN O
by NN NN O
glycine NN NN O
is NN NN O
part NN NN O
of NN NN O
a NN NN O
putative NN NN O
coenzyme-binding NN NN O
site NN NN O
. NN NN O

. NN NN O

8533768 NN NN O
Evidence NN NN O
for NN NN O
linkage NN NN O
of NN NN O
bipolar NN NN B-SpecificDisease
disorder NN NN I-SpecificDisease
to NN NN O
chromosome NN NN O
18 NN NN O
with NN NN O
a NN NN O
parent-of-origin NN NN O
effect NN NN O
. NN NN O

A NN NN O
susceptibility NN NN O
gene NN NN O
on NN NN O
chromosome NN NN O
18 NN NN O
and NN NN O
a NN NN O
parent-of-origin NN NN O
effect NN NN O
have NN NN O
been NN NN O
suggested NN NN O
for NN NN O
bipolar NN NN B-SpecificDisease
affective NN NN I-SpecificDisease
disorder NN NN I-SpecificDisease
( NN NN O
BPAD NN NN B-SpecificDisease
) NN NN O
. NN NN O

We NN NN O
have NN NN O
studied NN NN O
28 NN NN O
nuclear NN NN O
families NN NN O
selected NN NN O
for NN NN O
apparent NN NN O
unilineal NN NN O
transmission NN NN O
of NN NN O
the NN NN O
BPAD NN NN B-Modifier
phenotype NN NN O
, NN NN O
by NN NN O
using NN NN O
31 NN NN O
polymorphic NN NN O
markers NN NN O
spanning NN NN O
chromosome NN NN O
18 NN NN O
. NN NN O

Evidence NN NN O
for NN NN O
linkage NN NN O
was NN NN O
tested NN NN O
with NN NN O
affected-sib-pair NN NN O
and NN NN O
LOD NN NN O
score NN NN O
methods NN NN O
under NN NN O
two NN NN O
definitions NN NN O
of NN NN O
the NN NN O
affected NN NN O
phenotype NN NN O
. NN NN O

The NN NN O
affected-sibpair NN NN O
analyses NN NN O
indicated NN NN O
excess NN NN O
allele NN NN O
sharing NN NN O
for NN NN O
markers NN NN O
on NN NN O
18p NN NN O
within NN NN O
the NN NN O
region NN NN O
reported NN NN O
previously NN NN O
. NN NN O

The NN NN O
greatest NN NN O
sharing NN NN O
was NN NN O
at NN NN O
D18S37 NN NN O
64 NN NN O
% NN NN O
in NN NN O
bipolar NN NN O
and NN NN O
recurrent NN NN O
unipolar NN NN O
( NN NN O
RUP NN NN O
) NN NN O
sib NN NN O
pairs NN NN O
( NN NN O
P NN NN O
= NN NN O
. NN NN O

0006 NN NN O
) NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
excess NN NN O
sharing NN NN O
of NN NN O
the NN NN O
paternally NN NN O
, NN NN O
but NN NN O
not NN NN O
maternally NN NN O
, NN NN O
transmitted NN NN O
alleles NN NN O
was NN NN O
observed NN NN O
at NN NN O
three NN NN O
markers NN NN O
on NN NN O
18q NN NN O
at NN NN O
D18S41 NN NN O
, NN NN O
51 NN NN O
bipolar NN NN O
and NN NN O
RUP NN NN O
sib NN NN O
pairs NN NN O
were NN NN O
concordant NN NN O
for NN NN O
paternally NN NN O
transmitted NN NN O
alleles NN NN O
, NN NN O
and NN NN O
21 NN NN O
pairs NN NN O
were NN NN O
discordant NN NN O
( NN NN O
P NN NN O
= NN NN O
0004 NN NN O
) NN NN O
. NN NN O

The NN NN O
evidence NN NN O
for NN NN O
linkage NN NN O
to NN NN O
loci NN NN O
on NN NN O
both NN NN O
18p NN NN O
and NN NN O
18q NN NN O
was NN NN O
strongest NN NN O
in NN NN O
the NN NN O
11 NN NN O
paternal NN NN O
pedigrees NN NN O
, NN NN O
i NN NN O
. NN NN O

e NN NN O
e NN NN O
. NN NN O

, NN NN O
those NN NN O
in NN NN O
which NN NN O
the NN NN O
father NN NN O
or NN NN O
one NN NN O
of NN NN O
the NN NN O
fathers NN NN O
sibs NN NN O
is NN NN O
affected NN NN O
. NN NN O

In NN NN O
these NN NN O
pedigrees NN NN O
, NN NN O
the NN NN O
greatest NN NN O
allele NN NN O
sharing NN NN O
( NN NN O
81 NN NN O
% NN NN O
; NN NN O
P NN NN O
= NN NN O
. NN NN O

00002 NN NN O
) NN NN O
and NN NN O
the NN NN O
highest NN NN O
LOD NN NN O
score NN NN O
( NN NN O
3 NN NN O
. NN NN O

51 NN NN O
; NN NN O
phi NN NN O
= NN NN O
0 NN NN O
. NN NN O

0 NN NN O
) NN NN O
were NN NN O
observed NN NN O
at NN NN O
D18S41 NN NN O
. NN NN O

Our NN NN O
results NN NN O
provide NN NN O
further NN NN O
support NN NN O
for NN NN O
linkage NN NN O
of NN NN O
BPAD NN NN B-SpecificDisease
to NN NN O
chromosome NN NN O
18 NN NN O
and NN NN O
the NN NN O
first NN NN O
molecular NN NN O
evidence NN NN O
for NN NN O
a NN NN O
parent-of-origin NN NN O
effect NN NN O
operating NN NN O
in NN NN O
this NN NN O
disorder NN NN O
. NN NN O

The NN NN O
number NN NN O
of NN NN O
loci NN NN O
involved NN NN O
, NN NN O
and NN NN O
their NN NN O
precise NN NN O
location NN NN O
, NN NN O
require NN NN O
further NN NN O
study NN NN O

8551426 NN NN O
A NN NN O
prevalent NN NN O
mutation NN NN O
for NN NN O
galactosemia NN NN B-SpecificDisease
among NN NN O
black NN NN O
Americans NN NN O
. NN NN O

OBJECTIVE NN NN O
To NN NN O
define NN NN O
the NN NN O
mutation NN NN O
causing NN NN O
galactosemia NN NN B-SpecificDisease
in NN NN O
patients NN NN O
of NN NN O
black NN NN O
American NN NN O
origin NN NN O
who NN NN O
have NN NN O
no NN NN O
galactose-1-phosphate NN NN O
uridyltransferase NN NN O
( NN NN O
GALT NN NN O
) NN NN O
activity NN NN O
in NN NN O
erythrocytes NN NN O
but NN NN O
good NN NN O
clinical NN NN O
outcome NN NN O
. NN NN O

METHODS NN NN O
We NN NN O
discovered NN NN O
a NN NN O
mutation NN NN O
caused NN NN O
by NN NN O
a NN NN O
C NN NN O
-- NN NN O
T NN NN O
transition NN NN O
at NN NN O
base-pair NN NN O
1158 NN NN O
of NN NN O
the NN NN O
GALT NN NN O
gene NN NN O
that NN NN O
results NN NN O
in NN NN O
a NN NN O
serine-to-leucine NN NN O
substitution NN NN O
at NN NN O
codon NN NN O
135 NN NN O
( NN NN O
S135L NN NN O
) NN NN O
. NN NN O

We NN NN O
developed NN NN O
a NN NN O
method NN NN O
with NN NN O
which NN NN O
to NN NN O
screen NN NN O
populations NN NN O
for NN NN O
its NN NN O
prevalence NN NN O
. NN NN O

We NN NN O
compared NN NN O
galactose-1-phosphate NN NN O
uridyltransferase NN NN O
among NN NN O
erythrocytes NN NN O
, NN NN O
leukocytes NN NN O
, NN NN O
and NN NN O
transformed NN NN O
lymphoblasts NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
total NN NN O
body NN NN O
oxidation NN NN O
of NN NN O
D- NN NN O
( NN NN O
13C NN NN O
) NN NN O
-galactose NN NN O
to NN NN O
13CO2 NN NN O
among NN NN O
three NN NN O
genotypes NN NN O
for NN NN O
GALT NN NN O
( NN NN O
S135L NN NN O
/ NN NN O
S135L NN NN O
, NN NN O
Q188R NN NN O
/ NN NN O
Q188R NN NN O
, NN NN O
and NN NN O
Normal NN NN O
/ NN NN O
Normal NN NN O
) NN NN O
. NN NN O

RESULTS NN NN O
We NN NN O
found NN NN O
a NN NN O
48 NN NN O
% NN NN O
prevalence NN NN O
of NN NN O
the NN NN O
S135L NN NN O
mutation NN NN O
among NN NN O
17 NN NN O
black NN NN O
American NN NN O
patients NN NN O
with NN NN O
classic NN NN B-SpecificDisease
galactosemia NN NN I-SpecificDisease
and NN NN O
a NN NN O
1 NN NN O
% NN NN O
prevalence NN NN O
in NN NN O
a NN NN O
population NN NN O
of NN NN O
50 NN NN O
black NN NN O
Americans NN NN O
without NN NN O
galactosemia NN NN B-SpecificDisease
. NN NN O

The NN NN O
S135L NN NN O
mutation NN NN O
was NN NN O
not NN NN O
found NN NN O
in NN NN O
84 NN NN O
white NN NN O
patients NN NN O
with NN NN O
G NN NN O
/ NN NN O
G NN NN O
galactosemia NN NN B-SpecificDisease
nor NN NN O
in NN NN O
87 NN NN O
white NN NN O
control NN NN O
subjects NN NN O
without NN NN O
galactosemia NN NN B-SpecificDisease
. NN NN O

We NN NN O
found NN NN O
normal NN NN O
whole NN NN O
body NN NN O
oxidation NN NN O
of NN NN O
D- NN NN O
( NN NN O
13C NN NN O
) NN NN O
-galactose NN NN O
by NN NN O
the NN NN O
patient NN NN O
homozygous NN NN O
for NN NN O
S135L NN NN O
and NN NN O
various NN NN O
degrees NN NN O
of NN NN O
enzyme NN NN O
impairment NN NN O
among NN NN O
different NN NN O
tissues NN NN O
. NN NN O

CONCLUSIONS NN NN O
The NN NN O
S135L NN NN O
mutation NN NN O
in NN NN O
the NN NN O
GALT NN NN O
gene NN NN O
is NN NN O
a NN NN O
prevalent NN NN O
cause NN NN O
of NN NN O
galactosemia NN NN B-SpecificDisease
among NN NN O
black NN NN O
patients NN NN O
. NN NN O

Because NN NN O
GALT NN NN O
activity NN NN O
varies NN NN O
in NN NN O
different NN NN O
tissues NN NN O
of NN NN O
patients NN NN O
homozygous NN NN O
for NN NN O
S135L NN NN O
, NN NN O
they NN NN O
may NN NN O
have NN NN O
a NN NN O
better NN NN O
clinical NN NN O
outcome NN NN O
than NN NN O
patients NN NN O
who NN NN O
are NN NN O
homozygous NN NN O
for NN NN O
Q188R NN NN O
when NN NN O
both NN NN O
are NN NN O
treated NN NN O
from NN NN O
infancy NN NN O
. NN NN O

. NN NN O

8554067 NN NN O
A NN NN O
high NN NN O
incidence NN NN O
of NN NN O
BRCA1 NN NN O
mutations NN NN O
in NN NN O
20 NN NN O
breast-ovarian NN NN B-Modifier
cancer NN NN I-Modifier
families NN NN O
. NN NN O

We NN NN O
have NN NN O
analyzed NN NN O
20 NN NN O
breast-ovarian NN NN B-Modifier
cancer NN NN I-Modifier
families NN NN O
, NN NN O
the NN NN O
majority NN NN O
of NN NN O
which NN NN O
show NN NN O
positive NN NN O
evidence NN NN O
of NN NN O
linkage NN NN O
to NN NN O
chromosome NN NN O
17q12 NN NN O
for NN NN O
germ-line NN NN O
mutations NN NN O
in NN NN O
the NN NN O
BRCA1 NN NN O
gene NN NN O
. NN NN O

BRCA1 NN NN O
mutations NN NN O
cosegregating NN NN O
with NN NN O
breast NN NN B-Modifier
and NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
susceptibility NN NN O
were NN NN O
identified NN NN O
in NN NN O
16 NN NN O
families NN NN O
, NN NN O
including NN NN O
1 NN NN O
family NN NN O
with NN NN O
a NN NN O
case NN NN O
of NN NN O
male NN NN B-SpecificDisease
breast NN NN I-SpecificDisease
cancer NN NN I-SpecificDisease
. NN NN O

Nine NN NN O
of NN NN O
these NN NN O
mutations NN NN O
have NN NN O
not NN NN O
been NN NN O
reported NN NN O
previously NN NN O
. NN NN O

The NN NN O
majority NN NN O
of NN NN O
mutations NN NN O
were NN NN O
found NN NN O
to NN NN O
generate NN NN O
a NN NN O
premature NN NN O
stop NN NN O
codon NN NN O
leading NN NN O
to NN NN O
the NN NN O
formation NN NN O
of NN NN O
a NN NN O
truncated NN NN O
BRCA1 NN NN O
protein NN NN O
of NN NN O
2 NN NN O
% NN NN O
-88 NN NN O
% NN NN O
of NN NN O
the NN NN O
expected NN NN O
normal NN NN O
length NN NN O
. NN NN O

Two NN NN O
mutations NN NN O
altered NN NN O
the NN NN O
RING NN NN O
finger NN NN O
domain NN NN O
. NN NN O

Sequencing NN NN O
of NN NN O
genomic NN NN O
DNA NN NN O
led NN NN O
to NN NN O
the NN NN O
identification NN NN O
of NN NN O
a NN NN O
mutation NN NN O
in NN NN O
the NN NN O
coding NN NN O
region NN NN O
of NN NN O
BRCA1 NN NN O
in NN NN O
12 NN NN O
families NN NN O
, NN NN O
and NN NN O
cDNA NN NN O
analysis NN NN O
revealed NN NN O
an NN NN O
abnormal NN NN O
or NN NN O
missing NN NN O
BRCA1 NN NN O
transcript NN NN O
in NN NN O
4 NN NN O
of NN NN O
the NN NN O
8 NN NN O
remaining NN NN O
families NN NN O
. NN NN O

A NN NN O
total NN NN O
of NN NN O
eight NN NN O
mutations NN NN O
were NN NN O
associated NN NN O
with NN NN O
a NN NN O
reduced NN NN O
quantity NN NN O
of NN NN O
BRCA1 NN NN O
transcript NN NN O
. NN NN O

We NN NN O
were NN NN O
unable NN NN O
to NN NN O
detect NN NN O
BRCA1 NN NN O
mutations NN NN O
in NN NN O
4 NN NN O
of NN NN O
the NN NN O
20 NN NN O
families NN NN O
, NN NN O
but NN NN O
only NN NN O
1 NN NN O
of NN NN O
these NN NN O
was NN NN O
clearly NN NN O
linked NN NN O
to NN NN O
BRCA1 NN NN O
. NN NN O

It NN NN O
is NN NN O
expected NN NN O
that NN NN O
the NN NN O
majority NN NN O
of NN NN O
clear NN NN O
examples NN NN O
of NN NN O
the NN NN O
breast-ovarian NN NN B-SpecificDisease
syndrome NN NN I-SpecificDisease
will NN NN O
be NN NN O
associated NN NN O
with NN NN O
germ-line NN NN O
mutations NN NN O
in NN NN O
the NN NN O
coding NN NN O
region NN NN O
of NN NN O
BRCA1 NN NN O
. NN NN O

. NN NN O

8563759 NN NN O
Brca1 NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
results NN NN O
in NN NN O
early NN NN O
embryonic NN NN B-DiseaseClass
lethality NN NN I-DiseaseClass
characterized NN NN O
by NN NN O
neuroepithelial NN NN B-DiseaseClass
abnormalities NN NN I-DiseaseClass
. NN NN O

The NN NN O
breast NN NN B-Modifier
and NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
susceptibility NN NN O
gene NN NN O
, NN NN O
BRCA1 NN NN O
, NN NN O
has NN NN O
been NN NN O
cloned NN NN O
and NN NN O
shown NN NN O
to NN NN O
encode NN NN O
a NN NN O
zinc-finger NN NN O
protein NN NN O
of NN NN O
unknown NN NN O
function NN NN O
. NN NN O

Mutations NN NN O
in NN NN O
BRCA1 NN NN O
account NN NN O
for NN NN O
at NN NN O
least NN NN O
80 NN NN O
% NN NN O
of NN NN O
families NN NN O
with NN NN O
both NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
, NN NN O
as NN NN O
well NN NN O
as NN NN O
some NN NN O
non-familial NN NN O
sporadic NN NN O
ovarian NN NN B-SpecificDisease
cancers NN NN I-SpecificDisease
. NN NN O

The NN NN O
loss NN NN O
of NN NN O
wild-type NN NN O
BRCA1 NN NN O
in NN NN O
tumours NN NN B-DiseaseClass
of NN NN O
individuals NN NN O
carrying NN NN O
one NN NN O
nonfunctional NN NN O
BRCA1 NN NN O
allele NN NN O
suggests NN NN O
that NN NN O
BRCA1 NN NN O
encodes NN NN O
a NN NN O
tumour NN NN B-Modifier
suppressor NN NN O
that NN NN O
may NN NN O
inhibit NN NN O
the NN NN O
proliferation NN NN O
of NN NN O
mammary NN NN O
epithelial NN NN O
cells NN NN O
. NN NN O

To NN NN O
examine NN NN O
the NN NN O
role NN NN O
of NN NN O
BRCA1 NN NN O
in NN NN O
normal NN NN O
tissue NN NN O
growth NN NN O
and NN NN O
differentiation NN NN O
, NN NN O
and NN NN O
to NN NN O
generate NN NN O
a NN NN O
potential NN NN O
model NN NN O
for NN NN O
the NN NN O
cancer NN NN B-Modifier
susceptibility NN NN O
associated NN NN O
with NN NN O
loss NN NN O
of NN NN O
BRCA1 NN NN O
function NN NN O
, NN NN O
we NN NN O
have NN NN O
created NN NN O
a NN NN O
mouse NN NN O
line NN NN O
carrying NN NN O
a NN NN O
mutation NN NN O
in NN NN O
one NN NN O
Brca1 NN NN O
allele NN NN O
. NN NN O

Analysis NN NN O
of NN NN O
mice NN NN O
homozygous NN NN O
for NN NN O
the NN NN O
mutant NN NN O
allele NN NN O
indicate NN NN O
that NN NN O
Brca1 NN NN O
is NN NN O
critical NN NN O
for NN NN O
normal NN NN O
development NN NN O
, NN NN O
as NN NN O
these NN NN O
mice NN NN O
died NN NN O
in NN NN O
utero NN NN O
between NN NN O
10 NN NN O
and NN NN O
13 NN NN O
days NN NN O
of NN NN O
gestation NN NN O
( NN NN O
E10-E13 NN NN O
) NN NN O
. NN NN O

Abnormalities NN NN O
in NN NN O
Brca1-deficient NN NN B-Modifier
embryos NN NN O
were NN NN O
most NN NN O
evident NN NN O
in NN NN O
the NN NN O
neural NN NN O
tube NN NN O
, NN NN O
with NN NN O
40 NN NN O
% NN NN O
of NN NN O
the NN NN O
embryos NN NN O
presenting NN NN O
with NN NN O
varying NN NN O
degrees NN NN O
of NN NN O
spina NN NN B-SpecificDisease
bifida NN NN I-SpecificDisease
and NN NN O
anencephaly NN NN B-SpecificDisease
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
the NN NN O
neuroepithelium NN NN O
in NN NN O
Brca1-deficient NN NN B-Modifier
embryos NN NN O
appeared NN NN O
disorganized NN NN O
, NN NN O
with NN NN O
signs NN NN O
of NN NN O
both NN NN O
rapid NN NN O
proliferation NN NN O
and NN NN O
excessive NN NN O
cell NN NN O
death NN NN O
. NN NN O

. NN NN O

8566952 NN NN O
Identification NN NN O
of NN NN O
mutations NN NN O
in NN NN O
the NN NN O
ALD-gene NN NN O
of NN NN O
20 NN NN O
families NN NN O
with NN NN O
adrenoleukodystrophy NN NN B-SpecificDisease
/ NN NN O
adrenomyeloneuropathy NN NN B-SpecificDisease
. NN NN O

Adrenoleukodystrophy NN NN B-SpecificDisease
( NN NN O
ALD NN NN B-SpecificDisease
) NN NN O
, NN NN O
an NN NN O
X-linked NN NN B-DiseaseClass
inherited NN NN I-DiseaseClass
metabolic NN NN I-DiseaseClass
disorder NN NN I-DiseaseClass
, NN NN O
is NN NN O
the NN NN O
most NN NN O
frequent NN NN O
inborn NN NN B-DiseaseClass
peroxisomal NN NN I-DiseaseClass
disease NN NN I-DiseaseClass
. NN NN O

It NN NN O
leads NN NN O
to NN NN O
demyelination NN NN B-DiseaseClass
in NN NN I-DiseaseClass
the NN NN I-DiseaseClass
central NN NN I-DiseaseClass
and NN NN I-DiseaseClass
peripheral NN NN I-DiseaseClass
nervous NN NN I-DiseaseClass
system NN NN I-DiseaseClass
. NN NN O

Defective NN NN O
beta-oxidation NN NN O
of NN NN O
saturated NN NN O
very NN NN O
long NN NN O
chain NN NN O
fatty NN NN O
acids NN NN O
( NN NN O
VLCFAs NN NN O
; NN NN O
C22 NN NN O
0-C26 NN NN O
0 NN NN O
) NN NN O
in NN NN O
peroxisomes NN NN O
has NN NN O
been NN NN O
shown NN NN O
to NN NN O
lead NN NN O
to NN NN O
an NN NN O
accumulation NN NN O
of NN NN O
VLCFAs NN NN O
in NN NN O
leukoid NN NN O
areas NN NN O
of NN NN O
the NN NN O
central NN NN O
nervous NN NN O
system NN NN O
, NN NN O
peripheral NN NN O
nerves NN NN O
, NN NN O
adrenal NN NN O
gland NN NN O
, NN NN O
and NN NN O
blood NN NN O
. NN NN O

The NN NN O
ALD NN NN B-Modifier
gene NN NN O
has NN NN O
been NN NN O
recently NN NN O
identified NN NN O
and NN NN O
encodes NN NN O
a NN NN O
745-amino-acid NN NN O
protein NN NN O
. NN NN O

We NN NN O
screened NN NN O
patients NN NN O
with NN NN O
adrenoleukodystrophy NN NN B-SpecificDisease
/ NN NN O
adrenomyeloneuropathy NN NN B-SpecificDisease
( NN NN O
ALD NN NN B-SpecificDisease
/ NN NN O
AMN NN NN B-SpecificDisease
) NN NN O
from NN NN O
20 NN NN O
kindreds NN NN O
for NN NN O
mutations NN NN O
in NN NN O
the NN NN O
ALD NN NN B-Modifier
gene NN NN O
. NN NN O

Eleven NN NN O
missense NN NN O
and NN NN O
two NN NN O
nonsense NN NN O
mutations NN NN O
, NN NN O
five NN NN O
deletions NN NN O
, NN NN O
and NN NN O
one NN NN O
insertion NN NN O
were NN NN O
detected NN NN O
by NN NN O
direct NN NN O
sequencing NN NN O
of NN NN O
eight NN NN O
reverse NN NN O
transcribed NN NN O
fragments NN NN O
of NN NN O
the NN NN O
ALD NN NN B-Modifier
-gene NN NN O
mRNA NN NN O
. NN NN O

Four NN NN O
mutations NN NN O
could NN NN O
be NN NN O
shown NN NN O
to NN NN O
be NN NN O
de NN NN O
novo NN NN O
. NN NN O

All NN NN O
mutations NN NN O
could NN NN O
be NN NN O
confirmed NN NN O
in NN NN O
carriers NN NN O
by NN NN O
sequencing NN NN O
genomic NN NN O
DNA NN NN O
. NN NN O

No NN NN O
correlation NN NN O
between NN NN O
the NN NN O
type NN NN O
of NN NN O
mutation NN NN O
and NN NN O
the NN NN O
severity NN NN O
of NN NN O
the NN NN O
phenotype NN NN O
could NN NN O
be NN NN O
observed NN NN O
. NN NN O

The NN NN O
mutations NN NN O
were NN NN O
not NN NN O
detected NN NN O
in NN NN O
the NN NN O
ALD NN NN B-Modifier
gene NN NN O
of NN NN O
30 NN NN O
healthy NN NN O
persons NN NN O
. NN NN O

. NN NN O

8566965 NN NN O
The NN NN O
murine NN NN O
homolog NN NN O
of NN NN O
the NN NN O
human NN NN O
breast NN NN B-Modifier
and NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
susceptibility NN NN O
gene NN NN O
Brca1 NN NN O
maps NN NN O
to NN NN O
mouse NN NN O
chromosome NN NN O
11D NN NN O
. NN NN O

The NN NN O
recently NN NN O
cloned NN NN O
human NN NN O
breast NN NN B-Modifier
and NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
susceptibility NN NN O
gene NN NN O
, NN NN O
BRCA1 NN NN O
, NN NN O
is NN NN O
located NN NN O
on NN NN O
human NN NN O
chromosome NN NN O
17q21 NN NN O
. NN NN O

We NN NN O
have NN NN O
isolated NN NN O
murine NN NN O
genomic NN NN O
clones NN NN O
containing NN NN O
Brca1 NN NN O
as NN NN O
a NN NN O
first NN NN O
step NN NN O
in NN NN O
generating NN NN O
a NN NN O
mouse NN NN O
model NN NN O
for NN NN O
the NN NN O
loss NN NN O
of NN NN O
BRCA1 NN NN O
function NN NN O
. NN NN O

A NN NN O
mouse NN NN O
genomic NN NN O
library NN NN O
was NN NN O
screened NN NN O
using NN NN O
probes NN NN O
corresponding NN NN O
to NN NN O
exon NN NN O
11 NN NN O
of NN NN O
the NN NN O
human NN NN O
BRCA1 NN NN O
gene NN NN O
. NN NN O

Two NN NN O
overlapping NN NN O
mouse NN NN O
clones NN NN O
were NN NN O
identified NN NN O
that NN NN O
hybridized NN NN O
to NN NN O
human NN NN O
BRCA1 NN NN O
exons NN NN O
9-12 NN NN O
. NN NN O

Sequence NN NN O
analysis NN NN O
of NN NN O
1 NN NN O
. NN NN O

4 NN NN O
kb NN NN O
of NN NN O
the NN NN O
region NN NN O
of NN NN O
these NN NN O
clones NN NN O
corresponding NN NN O
to NN NN O
part NN NN O
of NN NN O
human NN NN O
exon NN NN O
11 NN NN O
revealed NN NN O
72 NN NN O
% NN NN O
nucleic NN NN O
acid NN NN O
identity NN NN O
but NN NN O
only NN NN O
50 NN NN O
% NN NN O
amino NN NN O
acid NN NN O
identity NN NN O
with NN NN O
the NN NN O
human NN NN O
gene NN NN O
. NN NN O

The NN NN O
longest NN NN O
of NN NN O
the NN NN O
mouse NN NN O
Brca1 NN NN O
genomic NN NN O
clones NN NN O
maps NN NN O
to NN NN O
chromosome NN NN O
11D NN NN O
, NN NN O
as NN NN O
determined NN NN O
by NN NN O
two-color NN NN O
fluorescence NN NN O
in NN NN O
situ NN NN O
hybridization NN NN O
. NN NN O

The NN NN O
synteny NN NN O
to NN NN O
human NN NN O
chromosome NN NN O
17 NN NN O
was NN NN O
confirmed NN NN O
by NN NN O
cohybridization NN NN O
with NN NN O
the NN NN O
mouse NN NN O
probe NN NN O
for NN NN O
the NN NN O
NF1-gene NN NN O
. NN NN O

This NN NN O
comparative NN NN O
study NN NN O
confirms NN NN O
that NN NN O
the NN NN O
relative NN NN O
location NN NN O
of NN NN O
the NN NN O
BRCA1 NN NN O
gene NN NN O
has NN NN O
been NN NN O
conserved NN NN O
between NN NN O
mice NN NN O
and NN NN O
humans NN NN O
. NN NN O

8571951 NN NN O
Atelosteogenesis NN NN B-SpecificDisease
type NN NN I-SpecificDisease
II NN NN I-SpecificDisease
is NN NN O
caused NN NN O
by NN NN O
mutations NN NN O
in NN NN O
the NN NN O
diastrophic NN NN B-Modifier
dysplasia NN NN I-Modifier
sulfate-transporter NN NN O
gene NN NN O
( NN NN O
DTDST NN NN O
) NN NN O
: NN NN O
evidence NN NN O
for NN NN O
a NN NN O
phenotypic NN NN O
series NN NN O
involving NN NN O
three NN NN O
chondrodysplasias NN NN B-DiseaseClass
. NN NN O

Atelosteogenesis NN NN B-SpecificDisease
type NN NN I-SpecificDisease
II NN NN I-SpecificDisease
( NN NN O
AO NN NN B-SpecificDisease
II NN NN I-SpecificDisease
) NN NN O
is NN NN O
a NN NN O
neonatally NN NN O
lethal NN NN O
chondrodysplasia NN NN B-DiseaseClass
whose NN NN O
clinical NN NN O
and NN NN O
histological NN NN O
characteristics NN NN O
resemble NN NN O
those NN NN O
of NN NN O
another NN NN O
chondrodysplasia NN NN B-DiseaseClass
, NN NN O
the NN NN O
much NN NN O
less NN NN O
severe NN NN O
diastrophic NN NN B-SpecificDisease
dysplasia NN NN I-SpecificDisease
( NN NN O
DTD NN NN B-SpecificDisease
) NN NN O
. NN NN O

The NN NN O
similarity NN NN O
suggests NN NN O
a NN NN O
shared NN NN O
pathogenesis NN NN O
involving NN NN O
lesions NN NN O
in NN NN O
the NN NN O
same NN NN O
biochemical NN NN O
pathway NN NN O
and NN NN O
perhaps NN NN O
the NN NN O
same NN NN O
gene NN NN O
. NN NN O

DTD NN NN B-SpecificDisease
is NN NN O
caused NN NN O
by NN NN O
mutations NN NN O
in NN NN O
the NN NN O
recently NN NN O
identified NN NN O
diastrophic NN NN B-Modifier
dysplasia NN NN I-Modifier
sulfate-transporter NN NN O
gene NN NN O
( NN NN O
DTDST NN NN O
) NN NN O
. NN NN O

Here NN NN O
, NN NN O
we NN NN O
report NN NN O
that NN NN O
AOII NN NN B-Modifier
patients NN NN O
also NN NN O
have NN NN O
DTDST NN NN O
mutations NN NN O
, NN NN O
which NN NN O
lead NN NN O
to NN NN O
defective NN NN O
uptake NN NN O
of NN NN O
inorganic NN NN O
sulfate NN NN O
and NN NN O
insufficient NN NN O
sulfation NN NN O
of NN NN O
macromolecules NN NN O
by NN NN O
patient NN NN O
mesenchymal NN NN O
cells NN NN O
in NN NN O
vitro NN NN O
. NN NN O

Together NN NN O
with NN NN O
our NN NN O
recent NN NN O
observation NN NN O
that NN NN O
a NN NN O
third NN NN O
even NN NN O
more NN NN O
severe NN NN O
chondrodysplasia NN NN B-DiseaseClass
, NN NN O
achondrogenesis NN NN O
type NN NN O
IB NN NN O
, NN NN O
is NN NN O
also NN NN O
caused NN NN O
by NN NN O
mutations NN NN O
in NN NN O
DTDST NN NN O
, NN NN O
these NN NN O
results NN NN O
demonstrate NN NN O
a NN NN O
phenotypic NN NN O
series NN NN O
of NN NN O
three NN NN O
chondrodysplasias NN NN B-DiseaseClass
of NN NN O
increasing NN NN O
severity NN NN O
caused NN NN O
by NN NN O
lesions NN NN O
in NN NN O
a NN NN O
single NN NN O
sulfate-transporter NN NN O
gene NN NN O
. NN NN O

The NN NN O
severity NN NN O
of NN NN O
the NN NN O
phenotype NN NN O
appears NN NN O
to NN NN O
be NN NN O
correlated NN NN O
with NN NN O
the NN NN O
predicted NN NN O
effect NN NN O
of NN NN O
the NN NN O
mutations NN NN O
on NN NN O
the NN NN O
residual NN NN O
activity NN NN O
of NN NN O
the NN NN O
DTDST NN NN O
protein NN NN O
. NN NN O

. NN NN O

8571953 NN NN O
Haplotype NN NN O
and NN NN O
phenotype NN NN O
analysis NN NN O
of NN NN O
six NN NN O
recurrent NN NN O
BRCA1 NN NN O
mutations NN NN O
in NN NN O
61 NN NN O
families NN NN O
: NN NN O
results NN NN O
of NN NN O
an NN NN O
international NN NN O
study NN NN O
. NN NN O

Several NN NN O
BRCA1 NN NN O
mutations NN NN O
have NN NN O
now NN NN O
been NN NN O
found NN NN O
to NN NN O
occur NN NN O
in NN NN O
geographically NN NN O
diverse NN NN O
breast NN NN B-Modifier
and NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
families NN NN O
. NN NN O

To NN NN O
investigate NN NN O
mutation NN NN O
origin NN NN O
and NN NN O
mutation-specific NN NN O
phenotypes NN NN O
due NN NN O
to NN NN O
BRCA1 NN NN O
, NN NN O
we NN NN O
constructed NN NN O
a NN NN O
haplotype NN NN O
of NN NN O
nine NN NN O
polymorphic NN NN O
markers NN NN O
within NN NN O
or NN NN O
immediately NN NN O
flanking NN NN O
the NN NN O
BRCA1 NN NN O
locus NN NN O
in NN NN O
a NN NN O
set NN NN O
of NN NN O
61 NN NN O
breast NN NN B-Modifier
/ NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
families NN NN O
selected NN NN O
for NN NN O
having NN NN O
one NN NN O
of NN NN O
six NN NN O
recurrent NN NN O
BRCA1 NN NN O
mutations NN NN O
. NN NN O

Tests NN NN O
of NN NN O
both NN NN O
mutations NN NN O
and NN NN O
family-specific NN NN O
differences NN NN O
in NN NN O
age NN NN O
at NN NN O
diagnosis NN NN O
were NN NN O
not NN NN O
significant NN NN O
. NN NN O

A NN NN O
comparison NN NN O
of NN NN O
the NN NN O
six NN NN O
mutations NN NN O
in NN NN O
the NN NN O
relative NN NN O
proportions NN NN O
of NN NN O
cases NN NN O
of NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
was NN NN O
suggestive NN NN O
of NN NN O
an NN NN O
effect NN NN O
( NN NN O
P NN NN O
= NN NN O
. NN NN O

069 NN NN O
) NN NN O
, NN NN O
with NN NN O
57 NN NN O
% NN NN O
of NN NN O
women NN NN O
presumed NN NN O
affected NN NN O
because NN NN O
of NN NN O
the NN NN O
1294 NN NN O
del NN NN O
40 NN NN O
BRCA1 NN NN O
mutation NN NN O
having NN NN O
ovarian NN NN B-SpecificDisease
cancer NN NN I-SpecificDisease
, NN NN O
compared NN NN O
with NN NN O
14 NN NN O
% NN NN O
of NN NN O
affected NN NN O
women NN NN O
with NN NN O
the NN NN O
splice-site NN NN O
mutation NN NN O
in NN NN O
intron NN NN O
5 NN NN O
of NN NN O
BRCA1 NN NN O
. NN NN O

For NN NN O
the NN NN O
BRCA1 NN NN O
mutations NN NN O
studied NN NN O
here NN NN O
, NN NN O
the NN NN O
individual NN NN O
mutations NN NN O
are NN NN O
estimated NN NN O
to NN NN O
have NN NN O
arisen NN NN O
9-170 NN NN O
generations NN NN O
ago NN NN O
. NN NN O

In NN NN O
general NN NN O
, NN NN O
a NN NN O
high NN NN O
degree NN NN O
of NN NN O
haplotype NN NN O
conservation NN NN O
across NN NN O
the NN NN O
region NN NN O
was NN NN O
observed NN NN O
, NN NN O
with NN NN O
haplotype NN NN O
differences NN NN O
most NN NN O
often NN NN O
due NN NN O
to NN NN O
mutations NN NN O
in NN NN O
the NN NN O
short-tandem-repeat NN NN O
markers NN NN O
, NN NN O
although NN NN O
some NN NN O
likely NN NN O
instances NN NN O
of NN NN O
recombination NN NN O
also NN NN O
were NN NN O
observed NN NN O
. NN NN O

For NN NN O
several NN NN O
of NN NN O
the NN NN O
instances NN NN O
, NN NN O
there NN NN O
was NN NN O
evidence NN NN O
for NN NN O
multiple NN NN O
, NN NN O
independent NN NN O
, NN NN O
BRCA1 NN NN O
mutational NN NN O
events NN NN O
. NN NN O

8575748 NN NN O
Isolation NN NN O
of NN NN O
the NN NN O
mouse NN NN O
homologue NN NN O
of NN NN O
BRCA1 NN NN O
and NN NN O
genetic NN NN O
mapping NN NN O
to NN NN O
mouse NN NN O
chromosome NN NN O
11 NN NN O
. NN NN O

The NN NN O
BRCA1 NN NN O
gene NN NN O
is NN NN O
in NN NN O
large NN NN O
part NN NN O
responsible NN NN O
for NN NN O
hereditary NN NN O
human NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
. NN NN O

Here NN NN O
we NN NN O
report NN NN O
the NN NN O
isolation NN NN O
of NN NN O
the NN NN O
murine NN NN O
Brca1 NN NN O
homologue NN NN O
cDNA NN NN O
clones NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
we NN NN O
identified NN NN O
genomic NN NN O
P1 NN NN O
clones NN NN O
that NN NN O
contain NN NN O
most NN NN O
, NN NN O
if NN NN O
not NN NN O
all NN NN O
, NN NN O
of NN NN O
the NN NN O
mouse NN NN O
Brca1 NN NN O
locus NN NN O
. NN NN O

DNA NN NN O
sequence NN NN O
analysis NN NN O
revealed NN NN O
that NN NN O
the NN NN O
mouse NN NN O
and NN NN O
human NN NN O
coding NN NN O
regions NN NN O
are NN NN O
75 NN NN O
% NN NN O
identical NN NN O
at NN NN O
the NN NN O
nucleotide NN NN O
level NN NN O
while NN NN O
the NN NN O
predicted NN NN O
amino NN NN O
acid NN NN O
identity NN NN O
is NN NN O
only NN NN O
58 NN NN O
% NN NN O
. NN NN O

A NN NN O
DNA NN NN O
sequence NN NN O
variant NN NN O
in NN NN O
the NN NN O
Brca1 NN NN O
locus NN NN O
was NN NN O
identified NN NN O
and NN NN O
used NN NN O
to NN NN O
map NN NN O
this NN NN O
gene NN NN O
on NN NN O
a NN NN O
( NN NN O
Mus NN NN O
m NN NN O
. NN NN O

musculus NN NN O
Czech NN NN O
II NN NN O
x NN NN O
C57BL NN NN O
/ NN NN O
KsJ NN NN O
) NN NN O
F1 NN NN O
x NN NN O
C57BL NN NN O
/ NN NN O
KsJ NN NN O
intersubspecific NN NN O
backcross NN NN O
to NN NN O
distal NN NN O
mouse NN NN O
chromosome NN NN O
11 NN NN O
. NN NN O

The NN NN O
mapping NN NN O
of NN NN O
this NN NN O
gene NN NN O
to NN NN O
a NN NN O
region NN NN O
highly NN NN O
syntenic NN NN O
with NN NN O
human NN NN O
chromosome NN NN O
17 NN NN O
, NN NN O
coupled NN NN O
with NN NN O
Southern NN NN O
and NN NN O
Northern NN NN O
analyses NN NN O
, NN NN O
confirms NN NN O
that NN NN O
we NN NN O
isolated NN NN O
the NN NN O
murine NN NN O
Brca1 NN NN O
homologue NN NN O
rather NN NN O
than NN NN O
a NN NN O
related NN NN O
RING NN NN O
finger NN NN O
gene NN NN O
. NN NN O

The NN NN O
isolation NN NN O
of NN NN O
the NN NN O
mouse NN NN O
Brca1 NN NN O
homologue NN NN O
will NN NN O
facilitate NN NN O
the NN NN O
creation NN NN O
of NN NN O
mouse NN NN O
models NN NN O
for NN NN O
germline NN NN O
BRCA1 NN NN B-SpecificDisease
defects NN NN I-SpecificDisease
. NN NN O

. NN NN O

8589715 NN NN O
Emerin NN NN B-SpecificDisease
deficiency NN NN I-SpecificDisease
at NN NN O
the NN NN O
nuclear NN NN O
membrane NN NN O
in NN NN O
patients NN NN O
with NN NN O
Emery-Dreifuss NN NN B-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
. NN NN O

Mutations NN NN O
in NN NN O
the NN NN O
STA NN NN O
gene NN NN O
at NN NN O
the NN NN O
Xq28 NN NN O
locus NN NN O
have NN NN O
been NN NN O
found NN NN O
in NN NN O
patients NN NN O
with NN NN O
X-linked NN NN B-SpecificDisease
Emery-Dreifuss NN NN I-SpecificDisease
muscular NN NN I-SpecificDisease
dystrophy NN NN I-SpecificDisease
( NN NN O
EDMD NN NN B-SpecificDisease
) NN NN O
. NN NN O

This NN NN O
gene NN NN O
encodes NN NN O
a NN NN O
hitherto NN NN O
unknown NN NN O
protein NN NN O
named NN NN O
emerin NN NN O
. NN NN O

To NN NN O
elucidate NN NN O
the NN NN O
subcellular NN NN O
localization NN NN O
of NN NN O
emerin NN NN O
, NN NN O
we NN NN O
raised NN NN O
two NN NN O
antisera NN NN O
against NN NN O
synthetic NN NN O
peptide NN NN O
fragments NN NN O
predicted NN NN O
from NN NN O
emerin NN NN O
cDNA NN NN O
. NN NN O

Using NN NN O
both NN NN O
antisera NN NN O
, NN NN O
we NN NN O
found NN NN O
positive NN NN O
nuclear NN NN O
membrane NN NN O
staining NN NN O
in NN NN O
skeletal NN NN O
, NN NN O
cardiac NN NN O
and NN NN O
smooth NN NN O
muscles NN NN O
in NN NN O
the NN NN O
normal NN NN O
controls NN NN O
and NN NN O
in NN NN O
patients NN NN O
with NN NN O
neuromuscular NN NN B-DiseaseClass
diseases NN NN I-DiseaseClass
other NN NN O
than NN NN O
EDMD NN NN B-SpecificDisease
. NN NN O

In NN NN O
contrast NN NN O
, NN NN O
a NN NN O
deficiency NN NN O
in NN NN O
immunofluorescent NN NN O
staining NN NN O
of NN NN O
skeletal NN NN O
and NN NN O
cardiac NN NN O
muscle NN NN O
from NN NN O
EDMD NN NN B-Modifier
patients NN NN O
was NN NN O
observed NN NN O
. NN NN O

A NN NN O
34 NN NN O
kD NN NN O
protein NN NN O
is NN NN O
immunoreactive NN NN O
with NN NN O
the NN NN O
antisera NN NN O
-- NN NN O
the NN NN O
protein NN NN O
is NN NN O
equivalent NN NN O
to NN NN O
that NN NN O
predicted NN NN O
for NN NN O
emerin NN NN O
. NN NN O

Together NN NN O
, NN NN O
our NN NN O
findings NN NN O
suggest NN NN O
the NN NN O
specific NN NN O
deficiency NN NN B-SpecificDisease
of NN NN I-SpecificDisease
emerin NN NN I-SpecificDisease
in NN NN O
the NN NN O
nuclear NN NN O
membrane NN NN O
of NN NN O
muscle NN NN O
cells NN NN O
in NN NN O
patients NN NN O
with NN NN O
EDMD NN NN B-SpecificDisease
. NN NN O

. NN NN O

8589721 NN NN O
Growth NN NN B-DiseaseClass
retardation NN NN I-DiseaseClass
and NN NN O
tumour NN NN B-Modifier
inhibition NN NN O
by NN NN O
BRCA1 NN NN O
. NN NN O

Inherited NN NN O
mutations NN NN O
in NN NN O
BRCA1 NN NN O
predispose NN NN O
to NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
, NN NN O
but NN NN O
the NN NN O
role NN NN O
of NN NN O
BRCA1 NN NN O
in NN NN O
sporadic NN NN O
breast NN NN B-CompositeMention
and NN NN I-CompositeMention
ovarian NN NN I-CompositeMention
cancer NN NN I-CompositeMention
has NN NN O
previously NN NN O
been NN NN O
elusive NN NN O
. NN NN O

Here NN NN O
, NN NN O
we NN NN O
show NN NN O
that NN NN O
retroviral NN NN O
transfer NN NN O
of NN NN O
the NN NN O
wild-type NN NN O
BRCA1 NN NN O
gene NN NN O
inhibits NN NN O
growth NN NN O
in NN NN O
vitro NN NN O
of NN NN O
all NN NN O
breast NN NN B-Modifier
and NN NN I-Modifier
ovarian NN NN I-Modifier
cancer NN NN I-Modifier
cell NN NN O
lines NN NN O
tested NN NN O
, NN NN O
but NN NN O
not NN NN O
colon NN NN B-Modifier
or NN NN I-Modifier
lung NN NN I-Modifier
cancer NN NN I-Modifier
cells NN NN O
or NN NN O
fibroblasts NN NN O
. NN NN O

Mutant NN NN O
BRCA1 NN NN O
has NN NN O
no NN NN O
effect NN NN O
on NN NN O
growth NN NN O
of NN NN O
breast NN NN B-Modifier
cancer NN NN I-Modifier
cells NN NN O
; NN NN O
ovarian NN NN B-Modifier
cancer NN NN I-Modifier
cell NN NN O
growth NN NN O
is NN NN O
not NN NN O
affected NN NN O
by NN NN O
BRCA1 NN NN O
mutations NN NN O
in NN NN O
the NN NN O
5 NN NN O
portion NN NN O
of NN NN O
the NN NN O
gene NN NN O
, NN NN O
but NN NN O
is NN NN O
inhibited NN NN O
by NN NN O
3 NN NN O
BRCA1 NN NN O
mutations NN NN O
. NN NN O

Development NN NN O
of NN NN O
MCF-7 NN NN B-DiseaseClass
tumours NN NN I-DiseaseClass
in NN NN O
nude NN NN O
mice NN NN O
is NN NN O
inhibited NN NN O
when NN NN O
MCF-7 NN NN O
cells NN NN O
are NN NN O
transfected NN NN O
with NN NN O
wild-type NN NN O
, NN NN O
but NN NN O
not NN NN O
mutant NN NN O
, NN NN O
BRCA1 NN NN O
. NN NN O

Most NN NN O
importantly NN NN O
, NN NN O
among NN NN O
mice NN NN O
with NN NN O
established NN NN O
MCF-7 NN NN B-DiseaseClass
tumours NN NN I-DiseaseClass
, NN NN O
peritoneal NN NN O
treatment NN NN O
with NN NN O
a NN NN O
retroviral NN NN O
vector NN NN O
expressing NN NN O
wild-type NN NN O
BRCA1 NN NN O
significantly NN NN O
inhibits NN NN O
tumour NN NN B-Modifier
growth NN NN O
and NN NN O
increased NN NN O
survival NN NN O
. NN NN O

. NN NN O

